U.S. patent application number 10/247310 was filed with the patent office on 2004-05-13 for benzopiperidine derivatives.
This patent application is currently assigned to Eisai Co., Ltd.. Invention is credited to Arai, Tohru, Clark, Richard, Kamada, Atsushi, Kaneko, Toshihiko, Kawahara, Tetsuya, Muramoto, Kenzo, Ohi, Norihito, Ohkuro, Masayoshi, Okano, Kazuo, Ozaki, Fumihiro, Sonoda, Jiro, Takenaka, Osamu, Yokohama, Hiromitsu.
Application Number | 20040092737 10/247310 |
Document ID | / |
Family ID | 16587858 |
Filed Date | 2004-05-13 |
United States Patent
Application |
20040092737 |
Kind Code |
A1 |
Kaneko, Toshihiko ; et
al. |
May 13, 2004 |
Benzopiperidine derivatives
Abstract
Benzopiperidine derivatives represented by formula (I), salts
thereof or hydrates thereof, processes for producing the same and
drugs comprising the same: 1 wherein the variables are as described
in the specification. These compounds are useful as drugs
efficacious in the prevention and treatment of these various
inflammatory diseases and immunologic diseases, such as rheumatoid
arthritis, atopic dermatitis, psoriasis, asthma, and rejection
reaction accompanying organ transplantation.
Inventors: |
Kaneko, Toshihiko; (Ibaraki,
JP) ; Clark, Richard; (Ibaraki, JP) ; Ohi,
Norihito; (Ibaraki, JP) ; Ozaki, Fumihiro;
(Ibaraki, JP) ; Kawahara, Tetsuya; (Ibaraki,
JP) ; Kamada, Atsushi; (Ibaraki, JP) ; Okano,
Kazuo; (Ibaraki, JP) ; Yokohama, Hiromitsu;
(Ibaraki, JP) ; Muramoto, Kenzo; (Ibaraki, JP)
; Arai, Tohru; (Tokyo, JP) ; Ohkuro,
Masayoshi; (Ibaraki, JP) ; Takenaka, Osamu;
(Ibaraki, JP) ; Sonoda, Jiro; (Ibaraki,
JP) |
Correspondence
Address: |
BIRCH STEWART KOLASCH & BIRCH
PO BOX 747
FALLS CHURCH
VA
22040-0747
US
|
Assignee: |
Eisai Co., Ltd.
|
Family ID: |
16587858 |
Appl. No.: |
10/247310 |
Filed: |
September 20, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10247310 |
Sep 20, 2002 |
|
|
|
09230852 |
Apr 5, 1999 |
|
|
|
09230852 |
Apr 5, 1999 |
|
|
|
PCT/JP97/02787 |
Aug 8, 1997 |
|
|
|
Current U.S.
Class: |
544/34 ; 544/101;
544/102; 544/345; 544/347; 544/35 |
Current CPC
Class: |
C07D 513/04 20130101;
C07D 487/04 20130101 |
Class at
Publication: |
544/034 ;
544/035; 544/101; 544/102; 544/345; 544/347 |
International
Class: |
C07D 513/02; C07D
498/02 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 9, 1996 |
JP |
8-210344 |
Claims
1. A benzopiperidine derivative represented by the following
general formula (I), its salt or hydrates thereof: 2092wherein
R.sup.1 to R.sup.3 may be the same or different and each
represents: 1) hydrogen, 2) optionally substituted lower alkyl; 3)
optionally substituted lower alkenyl; 4) optionally substituted
lower alkynyl; 5) optionally substituted lower cycloalkyl; 6)
optionally substituted lower cycloalkenyl; 7) optionally
substituted C.sub.2-6 alkoxy; 8) a group represented by the
following formula: 2093wherein X and Y represent each optionally
substituted lower alkylene optionally having a heteroatom,
optionally substituted lower alkenylene optionally having a
heteroatom or optionally substituted lower alkynylene optionally
having a heteroatom; l and m may be the same or different and each
represents 0 or 1; the ring A represents an optionally substituted
cycloalkyl ring optionally having one or more heteroatoms; the ring
B represents a ring optionally having one or more double bonds in
the ring selected from the following ones: a) an optionally
substituted cycloalkyl ring optionally having a heteroatom; b) an
optionally substituted bicycloalkyl ring optionally having a
heteroatom, wherein the different atoms (bridgehead carbon atoms)
in the ring B are bonded to each other via an optionally
substituted C.sub.1 or higher alkylene group optionally having a
heteroatom; or c) an optionally substituted spiro-hydrocarbon ring
optionally having a heteroatom, wherein both ends of an optionally
substituted C.sub.1 or higher alkylene group optionally having a
heteroatom are bonded to a carbon atom (bridgehead carbon atom) in
the ring B; 9) a group represented by the following formula:
2094wherein X.sup.1 represents optionally substituted lower
alkylene optionally having a heteroatom, optionally substituted
lower alkenylene optionally having a heteroatom or optionally
substituted lower alkynylene optionally having a heteroatom;
l.sup.1 is 0 or 1; the ring A.sup.1 represents: a) an optionally
substituted cycloalkyl ring optionally having one or more
heteroatoms; b) an optionally substituted cycloalkenyl ring
optionally having one or more heteroatoms; or c) an optionally
substituted spiro-hydrocarbon ring optionally having a heteroatom,
wherein both ends of an optionally substituted C.sub.1 or higher
alkylene group optionally having a heteroatom are bonded to a
carbon atom (bridgehead carbon atom) in the ring A.sup.1; or 10) a
group represented by the following formula:
--(X.sup.2).sub.l.sub..sup.2--Q wherein X.sup.2 represents
optionally substituted lower alkylene optionally having a
heteroatom, optionally substituted lower alkenylene optionally
having a heteroatom or optionally substituted lower alkynylene
optionally having a heteroatom; l.sup.2 is 0 or 1; Q represents: a)
heteroaryl consisting of one or more optionally substituted rings
or aryl consisting of one or more optionally substituted rings; b)
optionally substituted quaternary ammonio; c) a group represented
by the formula: 2095wherein R.sup.5 and R.sup.6 may be the same or
different and each represents hydrogen or lower alkyl; d) lower
acyl; e) lower acyloxy; f) carbamoyl; g) a group represented by the
following formula: 2096wherein R.sup.7 and R.sup.8 may be the same
or different and each represents hydrogen, lower alkyl, a group
represented by the formula: 2097wherein R.sup.71 represents lower
alkyl, trifluoromethyl, aryl or a group represented by the formula:
2098wherein R.sup.72 and R.sup.73 may be the same or different and
each represents hydrogen, lower alkyl, lower cycloalkyl or aryl; a
group represented by the following formula: 2099wherein R.sup.81
represents hydrogen, lower alkyl or aryl; a group represented by
the formula: 2100wherein R.sup.74 and R.sup.75 may be the same or
different and each represents hydrogen or lower alkyl; a group
represented by the formula: 2101wherein R.sup.76 represents
hydrogen, lower alkyl, cyano, pyridyl or lower alkylsulfonyl;
R.sup.77 represents hydrogen or lower alkyl, or an amino protecting
group; h) protected hydroxy; i) a group represented by the formula:
--S--R.sup.82 wherein R.sup.82 represents hydrogen, lower alkyl or
a mercapto protecting group; j) carboxy; k) protected carboxy; l) a
group represented by the formula: 2102wherein W represents oxygen
or sulfur; R.sup.83 and R.sup.84 may be the same or different and
each represents hydrogen, lower alkyl, lower cycloalkyl, cyano,
aryl or a group represented by the formula: --SO.sub.2R.sup.85
wherein R.sup.85 represents hydrogen, hydroxy, lower alkyl or aryl;
or R.sup.83 and R.sup.84 may together form optionally substituted
lower cycloalkyl optionally having one or more heteroatoms; m)
sulfonyl; n) sulfonylamido; o) azido; p) formyl; q) a group
represented by the formula: 2103wherein R.sup.86, R.sup.87 and
R.sup.88 may be the same or different and each represents hydrogen,
aryl, heteroaryl, optionally substituted lower alkyl, hydroxy(lower
alkyl), cyano, amino, nitro, acetyl or a group represented by the
formula: --SO.sub.2R.sup.89 wherein R.sup.89 represents aryl,
hydroxy, optionally substituted lower alkyl, trifluoromethyl or
amino; or R.sup.86 and R.sup.87 may together form an optionally
substituted lower cycloalkyl optionally having one or more
heteroatoms; r) guanidino; s) hydrazino; t) isocyano; u) cyanate;
v) isocyanate; w) thiocyanate; x) isothiocyanate; y) nitroso; or z)
a group represented by the formula: 2104wherein R.sup.90 and
R.sup.91 represent each hydrogen or lower alkyl, provided that the
case where R.sup.1 to R.sup.3 each represents methyl in the case 2)
of the above definition thereof is excluded; R represents: 1)
hydrogen; 2) lower alkyl; 3) optionally substituted arylalkyl; 4)
optionally substituted heteroarylalkyl; 5) an amino protective
group; 6) a group represented by the following formula: 2105wherein
X.sup.3 represents optionally substituted lower alkylene optionally
having a heteroatom, optionally substituted lower alkenylene
optionally having a heteroatom or optionally substituted lower
alkynylene optionally having a heteroatom; R.sup.9 and R.sup.10 may
be the same or different and each represents hydrogen, lower alkyl
or an amino protective group; or 7) a group represented by the
formula: --X.sup.4--CO.sub.2R.sup.11 wherein X.sup.4 represents
optionally substituted lower alkylene optionally having a
heteroatom, optionally substituted lower alkenylene optionally
having a heteroatom or optionally substituted lower alkynylene
optionally having a heteroatom; R.sup.11 represents hydrogen, lower
alkyl or a carboxy protecting group; E represents N or a group
represented by the formula: C--R.sup.4 wherein R.sup.4 has the same
meaning as 1 to 10) as defined above with respect to R.sup.1 to
R.sup.3; Z represents O, S, SO, SO.sub.2 or a group represented by
the following general formula: N--R.sup.12 wherein R.sup.12
represents hydrogen, lower alkyl or an amino protecting group; the
ring G represents an optionally substituted heteroaryl ring having
one or more nitrogen atoms; provided that the following cases are
excluded: a) that in which R.sup.1 to R.sup.3 are each hydrogen, E
is CH, Z is O, S, or SO.sub.2 and the ring G is an unsubstituted
(i.e., all of the substituents being hydrogen atoms) heteroaryl
ring having one or more nitrogen atoms; b) that in which R.sup.1 to
R.sup.3 are each hydrogen, E is CH, Z is O, S, SO.sub.2 or NH and
the substituent(s) of the ring G is optionally substituted phenyl,
pyridinyl, thienyl, nitro, cyano, halogeno, acetyl, methyl, ethyl,
t-butyl, ethoxy, N-methylpiperazyl, naphthyl, optionally protected
carboxyalkyl or amino; c) that in which R.sup.1 to R.sup.3 are each
hydrogen, E is CH, Z is NH and the ring G is unsubstituted (i.e.,
all of the substituents being hydrogen atoms) pyridazine; and d)
that in which R.sup.1 to R.sup.3 are each all hydrogen, E is CH, R
is a group other than hydrogen, Z is NR.sup.12 (R.sup.12 being
lower alkyl or an amino protective group) and the ring G is an
optionally substituted heteroaryl ring optionally having one or
more nitrogen atoms.
2. The benzopiperidine derivative as set forth in claim 1, its salt
or hydrates thereof, wherein Z in the formula (I) is S.
3. The benzopiperidine derivative as set forth in claim 1 its salt
or hydrates thereof, wherein the ring G in the formula (I) is an
optionally substituted pyrazine ring.
4. A benzopiperidine derivative represented by the following
general formula (II), its salt or hydrates thereof: 2106wherein R,
E, Z and the ring G are each as defined above; U represents: 1) a
group represented by the formula: 2107wherein X, Y, l, m and the
rings A and B are each as defined above; or 2) a group represented
by the formula: 2108wherein X.sup.1, l.sup.1 and the ring A.sup.1
are each as defined above.
5. The benzopiperidine derivative as set forth in claim 4, its salt
or hydrates thereof, wherein U in the general formula (II)
represents: 1) a group represented by the formula: 2109wherein X,
Y, l, m and the ring B are each as defined above; and the ring
A.sup.2 represents an optionally substituted cycloalkyl ring having
one or more heteroatoms; or 2) a group represented by the formula:
2110wherein X.sup.1 and l.sup.1 are each as defined above; and the
ring A.sup.3 represents: a) an optionally substituted cycloalkyl
ring having one or more heteroatoms; b) an optionally substituted
cycloalkenyl ring having one or more heteroatoms; or c) an
optionally substituted spiro-hydrocarbon ring having one or more
heteroatoms, wherein the both ends of an optionally substituted
C.sub.1 or higher alkylene group optionally having a heteroatom are
bonded to a carbon atom (bridgehead carbon atom) in the ring
A.sup.3.
6. A benzopiperidine derivative represented by the formula (III),
its salt or hydrates thereof: 2111wherein R, E, Z and the ring G
are each as defined above; U.sup.1 represents: 1) a group
represented by the formula: 2112wherein Y, m and the rings A.sup.2
and B are each as defined above; or 2) a group represented by the
following formula: 2113wherein the ring A.sup.3 is as defined
above.
7. The benzopiperidine derivative as set forth in claim 1 its salt
or hydrates thereof, wherein the ring G in the formula (II) or
(III) is an optionally substituted pyrazine ring.
8. A process for producing a derivative represented by the formula
(VI), its salt or hydrates thereof: 2114wherein R, E, Z, the ring
G, X, Y, l, m, the ring A.sup.2 and the ring B are each as defined
above, which comprises reacting a compound represented by the
following general formula (IV) or (IV'): 2115wherein R, E, Z, the
ring G, X and l are each as defined above, and Lev. represents a
leaving group, with a compound represented by the following formula
(V): 2116wherein Y, m, the ring A.sup.2 and the ring B are each as
defined above, provided that the ring B is optionally protected,
optionally followed by deblocking.
9. A 10H-pyrazino[2,3-b][1,4]benzothiazine derivative represented
by the formula (IV-1) or (IV'-1), its salt or hydrates thereof:
2117wherein Lev. is as defined above.
10. A bicycloalkyl derivative represented by the formula (VII), its
salt or hydrates thereof: 2118wherein Y, m and the rings A.sup.2
and B are each as defined above; R.sup.13 represents hydrogen,
lower alkyl or an amino protective group; and R.sup.14 and R.sup.15
may be the same or different and each represents hydrogen or lower
alkyl.
11. A bicycloalkyl derivative represented by the formula (X), its
salt or hydrates thereof: 2119wherein Y, m, the rings A.sup.2 and B
and R.sup.13 are each as defined above; X.sup.5 represents
optionally substituted lower alkylene optionally having a
heteroatom, optionally substituted lower alkenylene optionally
having a heteroatom or optionally substituted lower alkynylene
optionally having a heteroatom; l.sup.5 is 0 or 1; and Q.sup.1
represents carboxy, alkoxycarbonyl, sulfamoyl, amido, optionally
protected hydroxy or optionally protected amino.
12. A bicycloalkyl derivative represented by the following general
formula (XI), (XII), (XIII), (XIV), (XV) or (XVI), its salt or
hydrates thereof: 2120wherein R.sup.13, X.sup.5, l.sup.5 and
Q.sup.5 are each as defined above; and R.sup.14' and R.sup.15' may
be the same or different and each represents hydrogen or lower
alkyl, provided that the following cases are excluded: that in
which, in the formula (XI) or (XII), R.sup.15' and R.sup.14' are
each hydrogen, l.sup.5 is 0 and Q.sup.1 is carboxy or
ethoxycarbonyl; that in which, in the general formula (XI),
R.sup.13 is methyl, l.sup.5 is 1, X.sup.5 has one carbon atom and
forms a double bond together with a carbon atom on the ring to
which it is bonded and Q.sup.1 is ethoxycarbonyl,
4-methoxyphenylcarbonyl or formyl, or R.sup.13 is methyl, l.sup.5
is 1, X.sup.5 is unsubstituted methylene and Q.sup.1 is
ethoxycarbonyl; and that in which, in the formula (XIII), R.sup.13
is benzyl or benzoyl, l.sup.5 is 0 and Q.sup.1 is
ethoxycarbonyl.
13. A bicycloalkyl derivative selected from among those represented
by the formulae 1) to 3), its salt or hydrates thereof: 2121wherein
R.sup.13 is as defined above; and R.sup.18 represents hydrogen,
lower alkyl or a carboxy protective group, provided that the case
where, in the compound of the formula 1), R.sup.13 is methyl and
R.sup.14 is ethyl is excluded.
14. A piperidine derivative represented by the formula (XVII) or
(XVIII), its salt or hydrates thereof: 2122wherein R.sup.13,
X.sup.5, l.sup.5 and Q.sup.1 are each as defined above, provided
that the following cases are excluded: that in which, in the
general formula (XVII), X.sup.5 is unsubstituted C.sub.1-4
alkylene, l.sup.5 is 0 or 1 and Q.sup.1 is ethoxycarbonyl, or
X.sup.5 is unsubstituted C.sub.1-3 alkylene, l.sup.5 is 0 or 1 and
Q.sup.1 is amino protected by carbonyl; and that in which, in the
formula (XVIII), l.sup.1 is 0, Q.sup.1 is amino optionally
protected by tert-butoxycarbonyl or hydroxy optionally protected by
methanesulfonyl.
15. A piperidine derivative represented by the formula (XIX), (XX)
or (XXI), its salt or hydrates thereof: 2123wherein R.sup.13,
X.sup.5, l.sup.5 and R.sup.18 are each as defined above; and Me
represents methyl.
16. A piperidine derivative selected from among those represented
by the formulae 1) to 3), its salt or hydrates thereof: 2124wherein
R.sup.13 and R.sup.18 are each as defined above; and Me represents
methyl.
17. A drug comprising a benzopiperidine derivative represented by
the formula (I) as set forth in claim 1, its pharmacologically
acceptable salt or hydrates thereof.
18. A drug comprising a benzopiperidine derivative, its
pharmacologically acceptable salt or hydrates thereof as set forth
in claim 17, which is a preventive or remedy for inflammatory
immunologic diseases and autoimmune diseases.
19. A drug comprising a benzopiperidine derivative, its
pharmacologically acceptable salt or hydrates thereof as set forth
in claim 17 which is a preventive or remedy for rheumatism,
collagen disease, asthma, nephritis, ischemic reflow disorders,
psoriasis, atopic dermatitis or the rejection reaction accompanying
organ transplantation.
20. Use of a benzopiperidine compound as defined in claim 1, a
pharmacologically acceptable salt thereof or a pharmacologically
acceptable hydrate in manufacturing a pharmacological medicine.
21. A pharmaceutical composition comprising a pharmacologically
effective amount of a benzopiperidine compound as defined in claim
1, a pharmacologically acceptable salt thereof or a
pharmacologically acceptable hydrate and a pharmacologically
acceptable carrier.
22. A method for treating inflammatory immunologic diseases or
autoimmune diseases, which comprises the step of administering a
pharmacologically effective amount of a benzopiperidine compound as
defined in claim 1, a pharmacologically acceptable salt thereof or
a pharmacologically acceptable hydrate to a human patient suffering
from inflammatory immunologic diseases or autoimmune diseases.
Description
BACKGROUND OF THE INVENTION
[0001] 1. Field of the Invention
[0002] This invention relates to benzopiperidine derivatives, salts
thereof or hydrates thereof, which are useful in the prevention and
treatment of immunologic diseases, etc., drugs containing the same,
processes for producing the same and intermediates thereof.
[0003] 2. Prior Art
[0004] In recent years, the participation adhesion molecules such
as ICAM-1, VCAM-1 and E-selectin participate in the processes of
extravascular infiltration of leukocytes into inflammatory tissues,
metastasis of cancer cells, recognition of antigens by immunocytes
and proliferation of immunocytes has come to be regarded as highly
important. For example, rheumatoid arthritis is actually associated
with the promoted expression of adhesion molecules in joints, the
infiltration of lymphocytes into joint synovial membranes and
neutrophil infiltration into the synovial fluid. It has been also
reported that adhesion molecules participate in asthma, nephritis,
ischemic reflow disorders, psoriasis, atopic dermatitis, the
rejection reaction accompanying organ transplantation, and cancer
metastasis. Therefore, it is expected that the inflammatory
immunologic diseases such as asthma, nephritis, psoriasis, atopic
dermatitis, inflammation, ischemic reflow disorders and the
rejection reaction accompanying organ transplantation, autoimmune
diseases such as rheumatism and collagen disease, and cancer
metastasis can be inhibited by regulating the adhesion of
leukocytes, neutrophilis, cancer cells, etc. to intravascular
endothelial cells and controlling the antigen recognition
process.
[0005] When treating various inflammatory diseases and immune
diseases such as rheumatoid arthritis, it has been a common
practice to suppress the inflammation by the use of nonsteroidal
antiinflammatory drugs (NSAID) such as indomethacin and ibuprofen,
and steroids, i.e., "symptomatic treatments".
[0006] Recently, attempts have been also made to use
immunomodulators such as D-penicillamine which is a remedy for
rheumatism and Wilson's disease, and levamisole which is an
immunopotentiator activating T cells, in order to ameliorate
immunopathy at the early stage, i.e., "causal treatments".
[0007] However, NSAIDs such as indomethacin have serious side
effects such as gastric ulceration. Moreover, it is considered that
these drugs are not efficacious against tissue disorders or the
pathological progression associated with chronic inflammation. With
respect to steroids too, the problem of serious side effects
frequently arises.
[0008] On the other hand, hitherto no immunomodulator has been
known satisfactory both in its therapeutic effects and side
effects. Accordingly, the development of excellent drugs suitable
for both symptomatic and causal treatments has been urgently
required.
[0009] As compounds having similar structures to those of the
compounds of the present invention, it was disclosed in
JP-A-60-115524 that 1,4-diazaphenothiazine derivatives have
5-lipoxygenase inhibitory effects. However, this patent provides
few examples, despite its broad claims. That is to say, the claims
thereof are not clearly supported by the description in the
specification.
[0010] Furthermore, the above-mentioned patent neither states nor
suggests that these compounds are efficacious in the prevention and
treatment of various diseases owing to the cell adhesion inhibitory
effects thereof, as clarified in the present invention.
[0011] On the other hand, compounds analogous to the compounds of
the present invention are reported as nerve relaxants in J. Med.
Chem., 16 (4), 564 (1983) and as antibacterial agents, insecticides
and herbicides in U.S. Pat. No. 3663543, U.S. Pat. No. 3746707,
U.S. Pat. No. 3808208, U.S. Pat. No. 3.821213 and U.S. Pat. No.
3845044.
SUMMARY OF THE INVENTION
[0012] The present inventors have conducted extensive studies in
order to provide drugs efficacious in the prevention and treatment
of these various inflammatory diseases and immunologic diseases
such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma
and the rejection reaction accompanying organ transplantation. As a
result, they have succeeding in discovering that benzopiperidine
derivatives with novel structures have excellent antiinflammatory
and anti-immunologic disease effects, thus completing the present
invention.
[0013] Accordingly, the present invention relates to
benzopiperidine derivatives represented by the following formula
(I), salts thereof or hydrates thereof, processes for producing the
same and drugs comprising the same: 2
[0014] wherein R.sup.1 to R.sup.3 may be the same or different and
each represents:
[0015] 1) hydrogen,
[0016] 2) optionally substituted lower alkyl;
[0017] 3) optionally substituted lower alkenyl;
[0018] 4) optionally substituted lower alkynyl;
[0019] 5) optionally substituted lower cycloalkyl;
[0020] 6) optionally substituted lower cycloalkenyl;
[0021] 7) optionally substituted C.sub.2-6 alkoxy;
[0022] 8) a group represented by the following formula: 3
[0023] wherein X and Y represent each optionally substituted lower
alkylene optionally having a heteroatom, optionally substituted
lower alkenylene optionally having a heteroatom or optionally
substituted lower alkynylene optionally having a heteroatom; l and
m may be the same or different and each represents 0 or 1; the ring
A represents an optionally substituted cycloalkyl ring optionally
having one or more heteroatoms; the ring B represents a ring
optionally having one or more double bonds in the ring which is
selected from owing following:
[0024] a) an optionally substituted cycloalkyl ring optionally
having a heteroatom;
[0025] b) an optionally substituted bicycloalkyl ring optionally
having a heteroatom, wherein the different atoms (bridgehead atoms)
in the ring B are bonded to each other via an optionally
substituted C.sub.1 or higher alkylene group optionally having a
heteroatom; or
[0026] c) an optionally substituted spiro-hydrocarbon ring
optionally having a heteroatom, wherein the both ends of an
optionally substituted C.sub.1 or higher alkylene group optionally
having a heteroatom are bonded to a carbon atom (bridgehead carbon
atom) in the ring B;
[0027] 9) a group represented by the following formula: 4
[0028] wherein X.sup.1 represents an optionally substituted lower
alkylene optionally having a heteroatom, optionally substituted
lower alkenylene optionally having a heteroatom or optionally
substituted lower alkynylene optionally having a heteroatom;
[0029] l.sup.1 is 0 or 1; the ring A.sup.1 represents:
[0030] a) an optionally substituted cycloalkyl ring optionally
having one or more heteroatoms;
[0031] b) an optionally substituted cycloalkenyl ring optionally
having one or more heteroatoms; or
[0032] c) an optionally substituted spiro-hydrocarbon ring
optionally having a heteroatom, wherein the both ends of an
optionally substituted C.sub.1 or higher alkylene group optionally
having a heteroatom are bonded to a carbon atom (bridgehead carbon
atom) in the ring A.sup.1; or
[0033] 10) a group represented by the following formula:
--(X.sup.2).sub.l2-Q
[0034] wherein X.sup.2 represents an optionally substituted lower
alkylene optionally having a heteroatom, optionally substituted
lower alkenylene optionally having a heteroatom or optionally
substituted lower alkynylene optionally having a heteroatom;
[0035] l.sup.2 is 0 or 1;
[0036] Q represents:
[0037] a) heteroaryl consisting of one or more optionally
substituted rings or aryl consisting of one or more optionally
substituted rings;
[0038] b) optionally substituted quaternary ammonio;
[0039] c) a group represented by the following formula: 5
[0040] wherein R.sup.5 and R.sup.6 may be the same or different and
each represents hydrogen or lower alkyl;
[0041] d) lower acyl;
[0042] e) lower acyloxy;
[0043] f) carbamoyl;
[0044] g) a group represented by the following formula: 6
[0045] wherein R.sup.7 and R.sup.8 may be the same or different and
each represents hydrogen, lower alkyl, a group represented by the
formula: 7
[0046] wherein R.sup.71 represents lower alkyl, trifluoromethyl,
aryl or a group represented by the formula: 8
[0047] wherein R.sup.72 and R.sup.73 may be the same or different
and each represents hydrogen, lower alkyl, lower cycloalkyl or
aryl;
[0048] a group represented by the following formula: 9
[0049] wherein R.sup.81 represents hydrogen, lower alkyl or
aryl;
[0050] a group represented by the following formula: 10
[0051] wherein R.sup.74 and R.sup.75 may be the same or different
and each represents hydrogen or lower alkyl;
[0052] a group represented by the following formula: 11
[0053] wherein R.sup.76 represents hydrogen, lower alkyl, cyano,
pyridyl or lower alkylsulfonyl; R.sup.77 represents hydrogen or
lower alkyl, or an amino protecting group;
[0054] h) protected hydroxy;
[0055] i) a group represented by the following formula:
--S--R.sup.82
[0056] wherein R.sup.82 represents hydrogen, lower alkyl or a
mercapto protecting group;
[0057] j) carboxy;
[0058] k) protected carboxy;
[0059] l) a group represented by the following formula: 12
[0060] wherein W represents oxygen or sulfur; R.sup.83 and R.sup.84
may be the same or different and each represents hydrogen, lower
alkyl, lower cycloalkyl, cyano, aryl or a group represented by the
following formula:
--SO.sub.2R.sup.85
[0061] wherein R.sup.85 represents hydrogen, hydroxy, lower alkyl
or aryl; or R.sup.83 and R.sup.84 may together form an optionally
substituted lower cycloalkyl optionally having one or more
heteroatoms;
[0062] m) sulfonyl;
[0063] n) sulfonylamido;
[0064] o) azido;
[0065] p) formyl;
[0066] q) a group represented by the following formula: 13
[0067] wherein R.sup.86, R.sup.87 and R.sup.88 may be the same or
different and each represents hydrogen, aryl, heteroaryl,
optionally substituted lower alkyl, hydroxy(lower alkyl), cyano,
amino, nitro, acetyl or a group represented by the following
formula:
--SO.sub.2R.sup.89
[0068] wherein R.sup.89 represents aryl, hydroxy, optionally
substituted lower alkyl, trifluoromethyl or amino; or R.sup.86 and
R.sup.87 may together form an optionally substituted lower
cycloalkyl optionally having one or more heteroatoms;
[0069] r) guanidino;
[0070] s) hydrazino;
[0071] t) isocyano;
[0072] u) cyanate;
[0073] v) isocyanate;
[0074] w) thiocyanate;
[0075] x) isothiocyanate;
[0076] y) nitroso; or
[0077] z) a group represented by the following formula: 14
[0078] wherein R.sup.90 and R.sup.91 each represents hydrogen or
lower alkyl, provided that the case where R.sup.1 to R.sup.3 each
represents methyl in the case 2) of the above definition thereof is
excluded;
[0079] R represents:
[0080] 1) hydrogen;
[0081] 2) lower alkyl;
[0082] 3) optionally substituted arylalkyl;
[0083] 4) optionally substituted heteroarylalkyl;
[0084] 5) an amino protecting group;
[0085] 6) a group represented by the following formula: 15
[0086] wherein X.sup.3 represents an optionally substituted lower
alkylene optionally having a heteroatom, optionally substituted
lower alkenylene optionally having a heteroatom or optionally
substituted lower alkynylene optionally having a heteroatom;
R.sup.9 and R.sup.10 may be the same or different and each
represents hydrogen, lower alkyl or an amino protecting group;
or
[0087] 7) a group represented by the following formula:
--X.sup.4--CO.sub.2R.sup.11
[0088] wherein X.sup.4 represents optionally substituted lower
alkylene optionally having a heteroatom, optionally substituted
lower alkenylene optionally having a heteroatom or optionally
substituted lower alkynylene optionally having a heteroatom;
R.sup.11 represents hydrogen, lower alkyl or a carboxyl protecting
group;
[0089] E represents N or a group represented by the following
formula:
C--R.sup.4
[0090] wherein R.sup.4 has the same meaning as 1 to 11) as defined
above with respect to R.sup.1 to R.sup.3;
[0091] Z represents O, S, SO, SO.sub.2 or a group represented by
the following formula:
N--R.sup.12
[0092] wherein R.sup.12 represents hydrogen, lower alkyl or an
amino protecting group;
[0093] the ring G represents an optionally substituted heteroaryl
ring having one or more nitrogen atoms;
[0094] provided that the following cases are excluded:
[0095] a) that in which R.sup.1 to R.sup.3 are each hydrogen, E is
CH, Z is O, S, or SO.sub.2 and the ring G is an unsubstituted
(i.e., all of the substituents being hydrogen atoms) heteroaryl
ring having one or more nitrogen atoms;
[0096] b) that in which R.sup.1 to R.sup.3 are each hydrogen, E is
CH, Z is O, S, SO.sub.2 or NH and the substituent(s) of the ring G
is optionally substituted phenyl, pyridinyl, thienyl, nitro, cyano,
halogeno, acetyl, methyl, ethyl, t-butyl, ethoxy,
N-methylpiperazyl, naphthyl, optionally protected carboxyalkyl or
amino;
[0097] c) that in which R.sup.1 to R.sup.3 are each hydrogen, E is
CH, Z is NH and the ring G is unsubstituted (i.e., all of the
substituents are hydrogen atoms) pyridazine; and
[0098] d) that in which R.sup.1 to R.sup.3 are each hydrogen, E is
CH, R is a group other than hydrogen, Z is NR.sup.12' (R.sup.12'
being lower alkyl or an amino protecting group) and the ring G is
an optionally substituted heteroaryl ring optionally having one or
more nitrogen atoms.
[0099] Now, the contents of the present invention will be described
in detail.
[0100] Although the contents of the present invention are as has
been described above, the invention preferably relates to
benzopiperidine derivatives of the above formula (I), wherein Z is
S, salts thereof or hydrates thereof, processes for producing the
same and drugs comprising the same, and benzopiperidine derivatives
of the above formula (I), wherein the ring G is an optionally
substituted pyrazine ring, salts thereof or hydrates thereof,
processes for producing the same and drugs comprising the same.
Still more preferably, the invention relates to benzopiperidine
derivatives represented by the following formula (II), salts
thereof or hydrates thereof, processes for producing the same and
drugs comprising the same: 16
[0101] wherein R, E, Z and the ring G are each as defined
above;
[0102] U represents:
[0103] 1) a group represented by the following formula: 17
[0104] wherein X, Y, l, m and the rings A and B are each as defined
above; or
[0105] 2) a group represented by the following formula: 18
[0106] wherein X.sup.1, l.sup.1 and the ring A.sup.1 are each as
defined above.
[0107] Still more preferably, the invention relates to
benzopiperidine derivatives represented by the above formula (II),
salts thereof or hydrates thereof, processes for producing the same
and drugs comprising the same, wherein U in the formula (II)
represents:
[0108] 1) a group represented by the following formula: 19
[0109] wherein X, Y, l, m and the ring B are each as defined above;
and
[0110] the ring A.sup.2 represents an optionally substituted
cycloalkyl ring having one or more heteroatoms; or
[0111] 2) a group represented by the following formula: 20
[0112] wherein X.sup.1 and l.sup.1 are each as defined above;
and
[0113] the ring A.sup.3 represents:
[0114] a) an optionally substituted cycloalkyl ring having one or
more heteroatoms;
[0115] b) an optionally substituted cycloalkenyl ring having one or
more heteroatoms; or
[0116] c) an optionally substituted spiro-hydrocarbon ring having
one or more heteroatoms, wherein both ends of an optionally
substituted C.sub.1 or higher alkylene group optionally having a
heteroatom are bonded to a carbon atom (bridgehead carbon atom) in
the ring A.sup.3. Particularly preferably, it relates to
benzopiperidine derivatives represented by the following formula
(III), salts thereof or hydrates thereof, processes for producing
the same and drugs comprising the same: 21
[0117] wherein R, E, Z and the ring G are each as defined
above;
[0118] U.sup.1 represents:
[0119] 1) a group represented by the following formula: 22
[0120] wherein Y, m and the rings A.sup.2 and B are each as defined
above; or
[0121] 2) a group represented by the following formula: 23
[0122] wherein the ring A.sup.3 is as defined above. Still
preferably, the invention relates to benzopiperidine derivatives
represented by the following formula (II) or (III), wherein the
ring G is an optionally substituted pyrazine ring, salts thereof or
hydrates thereof, processes for producing the same and drugs
comprising the same. In the most desirable case, the present
invention relates to a benzopiperidine derivative selected from
among those represented by the following formulae 1) to 3), its
salt or hydrates thereof, a process for producing the same and
drugs comprising the same: 24
[0123] Although compounds are sometimes given as particular isomers
in structural formulae herein for the sake of convenience, the
compounds of the present invention are not restricted to the
structural formulae given for the sake of convenience but involve
all of the isomers and isomeric mixtures such as geometrical
isomers occurring structurally, optical isomers depending on
asymmetric carbon, stereoisomers and tautomers.
[0124] Next, the terms employed herein will be described in
detail.
[0125] First, the definition of the formula (I) will be
illustrated. R.sup.1 to R.sup.4 are each as defined above.
(R.sup.4, which is a group defined in E and having the same meaning
as those of R.sup.1 to R.sup.3, is illustrated together with
R.sup.1 to R.sup.3 herein).
[0126] The expression "optionally substituted" as used herein
particularly means that the corresponding group may be substituted
by substituent(s), for example, hydroxy; thiol; nitro; nitroso;
morpholino; thiomorpholino; halogeno such as fluoro, bromo and
iodo; nitrile; isocyano; cyanate; isocyanate; thiocyanate;
isothiocyanate; azido; formyl; thioformyl; alkyl such as methyl,
ethyl, propyl, isopropyl and butyl; alkenyl such as vinyl, allyl
and propenyl; alkynyl such as ethynyl, butynyl and propargyl;
alkoxy corresponding to lower alkyl such as methoxy, ethoxy,
propoxy and butoxy; halogenoalkyl such as fluoromethyl,
difluoromethyl, trifluoromethyl and fluoroethyl; hydroxyalkyl such
as hydroxymethyl, hydroxyethyl and hydroxypropyl; guanidino;
hydrazino; hydraozono; ureido; ureylene; amidino; formimidoyl;
acetimidoyl; carbamoyl; thiocarbamoyl; carbamoylalkyl such as
carbamoylmethyl and carbamoylethyl; alkylcarbamoyl such as
methylcarbamoyl and dimethylcarbamoyl; carbamido; sulfoamino;
sulfamoyl; sulfamoylalkyl such as sulfamoylmethyl and
sulfamoylethyl; alkylsulfamoyl such as methylsulfamoyl and
dimethylsulfamoyl; sulfamido; N-alkylsulfamido such as
N-methylsulfamido and N-ethylsulfamido; arylsulfamido such as
N-phenylsulfamido; alkanoyl such as acetyl, propionyl and butyryl;
thioacetyl; amino; hydroxyamino; alkylamino such as methylamino,
ethylamino and isopropylamino; dialkylamino such as dimethylamino,
methylethylamino and diethylamino; acylamino such as acetylamino
and benzoylamino; aminoalkyl such as aminomethyl, aminoethyl and
aminopropyl; carboxy; alkoxycarbonyl such as methoxycarbonyl,
ethoxycarbonyl and propoxycarbonyl; alkoxycarbonylalkyl such as
methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl,
methoxycarbonylethyl, ethoxycarbonylethyl and propoxycarbonylethyl;
alkyloxyalkyl such as methyloxymethyl, methyloxyethyl,
ethyloxymethyl and ethyloxyethyl; alkylthioalkyl such as
methylthiomethyl, methylthioethyl, ethylthiomethyl and
ethylthioethyl; aminoalkylaminoalkyl such as aminomethylaminomethyl
and aminoethylaminomethyl; alkylcarbonyloxy such as
methylcarbonyloxy, ethylcarbonyloxy and isopropylcarbonyloxy;
arylalkoxyalkoxyalkyl such as oxymethyl and benzyloxyethyloxyethyl;
hydroxyalkoxyalkyl such as hydroxyethyloxymethyl and
hydroxyethyloxyethyl; arylalkoxyalkyl such as benzyloxymethyl,
benzyloxyethyl and benzyloxypropyl; quaternary ammonio such as
trimethylammonio, methylethylmethylammonio and triethylammonio;
cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and
cyclohexyl; cycloalkenyl such as cyclopropenyl, cyclobutenyl,
cyclopentenyl and cyclohexenyl; aryl such as phenyl, pyridinyl,
thienyl, furyl and pyrrolyl; alkylthio such as methylthio,
ethylthio, propylthio and butylthio; arylthio such as phenylthio,
pyridinylthio, thienylthio, furylthio and pyrrolylthio; aryl(lower
alkyl) such as benzyl, trityl and dimethoxytrityl; sulfonyl and
substituted sulfonyl such as mesyl and p-toluenesulfonyl; sulfinyl
and substituted sulfinyl such as methylsulfinyl, ethylsulfinyl and
phenylsulfinyl; sulfenyl and substituted sulfenyl such as
methylsulfenyl, ethylsulfenyl and phenylsulfenyl; aryloyl such as
benzoyl, toluoyl and cinnamoyl; halogenoaryl such as fluorophenyl
and bromophenyl; and oxyalkoxy such as methylenedioxy.
[0127] The expression "having one or more substituents" means that
the corresponding group may have an arbitrary combination of these
substituents. For example, the present invention involves alkyl,
alkenyl, alkynyl, alkoxy, etc. substituted by hydroxy, thiol,
nitro, morpholino, thiomorpholino, halogeno, nitrile, azido,
formyl, ammonio, alkylamino, dialkylamino, carbamoyl, sulfonyl,
etc.
[0128] The expression "optionally substituted" as used herein below
has the meaning as defined above.
[0129] The term "lower alkyl group" means a linear or branched
C.sub.1-6 alkyl group. Particular examples thereof include methyl
[methyl being excluded from the definition 2) of R.sup.1 to
R.sup.4], ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl,
t-butyl, n-pentyl, i-pentyl, sec-pentyl, t-pentyl, neopentyl,
1-methylbutyl, 2-methylbutyl, 1,1-dimethylpropyl,
1,2-dimethylpropyl, n-hexyl, i-hexyl, 1-methylpentyl,
2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl,
1,2-dimethylbutyl, 2,2,-dimethylbutyl, 1,3-dimethylbutyl,
2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl,
1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl,
1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl groups.
Preferable examples thereof include methyl, ethyl, n-propyl,
i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, i-pentyl,
sec-pentyl, t-pentyl, neopentyl, 1-methylbutyl, 2-methylbutyl,
1,1-dimethylpropyl, 1,2-dimethylpropyl, n-hexyl and i-hexyl groups.
Still more preferable ones are methyl, ethyl, n-propyl, i-propyl,
n-butyl, i-butyl, sec-butyl and t-butyl groups and the most
desirable ones are methyl, ethyl, n-propyl and i-propyl groups.
[0130] The term "lower alkenyl group" means a linear or branched
C.sub.1-6 alkenyl group which is the residue of a compound having a
double bond in the above-mentioned alkyl group. Particular examples
thereof include ethenyl, 1-propen-1-yl, 2-propen-1-yl,
3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 1-buten-3-yl,
1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl, 1-methyl-1-propen-1-yl,
2-methyl-1-propen-1-yl, 1-methyl-2-propen-1-yl,
2-methyl-2-propen-1-yl, 1-methyl-1-buten-1-yl,
2-methyl-1-buten-1-yl, 3-methyl-1-buten-1-yl,
1-methyl-2-buten-1-yl, 2-methyl-2-buten-1-yl,
3-methyl-2-buten-1-yl, 1-methyl-3-buten-1-yl,
2-methyl-3-buten-1-yl, 3-methyl-3-buten-1-yl, 1-ethyl-1-buten-1-yl,
2-ethyl-1-buten-1-yl, 3-ethyl-1-buten-1-yl, 1-ethyl-2-buten-1-yl,
2-ethyl-2-buten-1-yl, 3-ethyl-2-buten-1-yl, 1-ethyl-3-buten-1-yl,
2-ethyl-3-buten-1-yl, 3-ethyl-3-buten-1-yl,
1,1-dimethyl-1-buten-1-yl, 1,2-dimethyl-1-buten-1-y- l,
1,3-dimethyl-1-buten-1-yl, 2,2-dimethyl-1-buten-1-yl,
3,3-dimethyl-1-buten-1-yl, 1,1-dimethyl-2-buten-1-yl,
1,2-dimethyl-2-buten-1-yl, 1,3-dimethyl-2-buten-1-yl,
2,2-dimethyl-2-buten-1-yl, 3,3-dimethyl-2-buten-1-yl,
1,1-dimethyl-3-buten-1-yl, 1,2-dimethyl-3-buten-1-yl,
1,3-dimethyl-3-buten-1-yl, 2,2-dimethyl-3-buten-1-yl,
3,3-dimethyl-3-buten-1-yl, 1-penten-1-yl, 2-penten-1-yl,
3-penten-1-yl, 4-penten-1-yl, 1-penten-2-yl, 2-penten-2-yl,
3-penten-2-yl, 4-penten-2-yl, 1-penten-3-yl, 2-penten-3-yl,
1-penten-1-yl, 2-penten-1-yl, 3-penten-1-yl, 4-penten-1-yl,
4-penten-2-yl, 2-penten-2-yl, 3-penten-2-yl, 4-penten-2-yl,
1-penten-3-yl, 2-penten-3-yl, 1-methyl-1-penten-1-yl,
2-methyl-1-penten-1-yl, 3-methyl-1-penten-1-yl,
4-methyl-1-penten-1-yl, 1-methyl-2-penten-1-yl,
2-methyl-2-penten-1-yl, 3-methyl-2-penten-1-yl,
4-methyl-2-penten-1-yl, 1-methyl-3-penten-1-yl,
2-methyl-3-penten-1-yl, 3-methyl-3-penten-1-yl,
4-methyl-3-penten-1-yl, 1-methyl-4-penten-1-yl,
2-methyl-4-penten-1-yl, 3-methyl-4-penten-1-yl,
4-methyl-4-penten-1-yl, 1-methyl-1-penten-2-yl,
2-methyl-1-penten-2-yl, 3-methyl-2-penten-2-yl,
4-methyl-1-penten-2-yl, 1-methyl-2-penten-2-yl,
2-methyl-2-penten-2-yl, 3-methyl-2-penten-2-yl,
4-methyl-2-penten-2-yl, 1-methyl-3-penten-2-yl,
2-methyl-3-penten-2-yl, 3-methyl-3-penten-2-yl,
4-methyl-3-penten-2-yl, 1-methyl-4-penten-2-yl,
2-methyl-4-penten-2-yl, 3-methyl-4-penten-2-yl,
4-methyl-4-penten-2-yl, 1-methyl-1-penten-3-yl,
2-methyl-1-penten-3-yl, 3-methyl-1-penten-3-yl,
4-methyl-1-penten-3-yl, 1-methyl-2-penten-3-yl,
2-methyl-2-penten-3-yl, 3-methyl-2-penten-3-yl,
4-methyl-2-penten-3-yl, 1-hexen-1-yl, 1-hexen-2-yl, 1-hexen-3-yl,
1-hexen-4-yl, 1-hexen-5-yl, 1-hexen-6-yl, 2-hexen-1-yl,
2-hexen-2-yl, 2-hexen-3-yl, 2-hexen-4-yl, 2-hexen-5-yl,
2-hexen-6-yl, 3-hexen-1-yl, 3-hexen-2-yl and 3-hexen-3-yl groups.
Preferable examples thereof include ethenyl, 1-propen-1-yl,
2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl,
1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl,
1-methyl-1-propen-1-yl, 2-methyl-1-propen-1-yl,
1-methyl-2-propen-1-yl, 2-methyl-2-propen-1-yl,
1-methyl-1-buten-1-yl, 2-methyl-1-buten-1-yl,
3-methyl-1-buten-1-yl, 1-methyl-2-buten-1-yl,
2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl,
1-methyl-3-buten-1-yl, 2-methyl-3-buten-1-yl,
3-methyl-3-buten-1-yl, 1-ethyl-1-buten-1-yl, 2-ethyl-1-buten-1-yl,
3-ethyl-1-buten-1-yl, 1-ethyl-2-buten-1-yl, 2-ethyl-2-buten-1-yl,
3-ethyl-2-buten-1-yl, 1-ethyl-3-buten-1-yl, 2-ethyl-3-buten-1-yl,
3-ethyl-3-buten-1-yl, 1,1-dimethyl-1-buten-1-yl,
1,2-dimethyl-1-buten-1-yl, 1,3-dimethyl-1-buten-1-yl,
2,2-dimethyl-1-buten-1-yl, 3,3-dimethyl-1-buten-1-yl,
1,1-dimethyl-2-buten-1-yl, 1,2-dimethyl-2-buten-1-yl,
1,3-dimethyl-2-buten-1-yl, 2,2-dimethyl-2-buten-1-yl,
3,3-dimethyl-2-buten-1-yl, 1,1-dimethyl-3-buten-1-yl,
1,2-dimethyl-3-buten-1-yl, 1,3-dimethyl-3-buten-1-yl,
2,2-dimethyl-3-buten-1-yl and 3,3-dimethyl-3-buten-1-yl groups.
Still more preferable ones are ethenyl, 1-propen-1-yl,
2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl,
1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl, 2-buten-2-yl,
1-methyl-1-propen-1-yl, 2-methyl-1-propen-1-yl,
1-methyl-2-propen-1-yl, 2-methyl-2-propen-1-yl,
1-methyl-1-buten-1-yl, 2-methyl-1-buten-1-yl,
3-methyl-1-buten-1-yl, 1-methyl-2-buten-1-yl,
2-methyl-2-buten-1-yl, 3-methyl-2-buten-1-yl,
1-methyl-3-buten-1-yl, 2-methyl-3-buten-1-yl and
3-methyl-3-buten-1-yl groups. The most desirable ones are ethenyl,
1-propen-1-yl, 2-propen-1-yl, 3-propen-1-yl, 1-buten-1-yl,
1-buten-2-yl, 1-buten-3-yl, 1-buten-4-yl, 2-buten-1-yl and
2-buten-2-yl groups.
[0131] The term "lower alkynyl group" means a linear or branched
C.sub.1-6 alkynyl group which is the residue of a compound having a
triple bond in the above-mentioned alkyl group. Particular examples
thereof include ethynyl, 1-propyn-1-yl, 2-propyn-1-yl,
3-propyn-1-yl, 1-butyn-1-yl, 1-butyn-2-yl, 1-butyn-3-yl,
1-butyn-4-yl, 2-butyn-1-yl, 2-butyn-2-yl, 1-methyl-1-propyn-1-yl,
2-methyl-1-propyn-1-yl, 1-methyl-2-propyn-1-yl,
2-methyl-2-propyn-1-yl, 1-methyl-1-butyn-1-yl,
2-methyl-1-butyn-1-yl, 3-methyl-1-butyn-1-yl,
1-methyl-2-butyn-1-yl, 2-methyl-2-butyn-1-yl,
3-methyl-2-butyn-1-yl, 1-methyl-3-butyn-1-yl,
2-methyl-3-butyn-1-yl, 3-methyl-3-butyn-1-yl, 1-ethyl-1-butyn-1-yl,
2-ethyl-1-butyn-1-yl, 3-ethyl-1-butyn-1-yl, 1-ethyl-2-butyn-1-yl,
2-ethyl-2-butyn-1-yl, 3-ethyl-2-butyn-1-yl, 1-ethyl-3-butyn-1-yl,
2-ethyl-3-butyn-1-yl, 3-ethyl-3-butyn-1-yl,
1,1-dimethyl-1-butyn-1-yl, 1,2-dimethyl-1-butyn-1-y- l,
1,3-dimethyl-1-butyn-1-yl, 2,2-dimethyl-1-butyn-1-yl,
3,3-dimethyl-1-butyn-1-yl, 1,1-dimethyl-2-butyn-1-yl,
1,2-dimethyl-2-butyn-1-yl, 1,3-dimethyl-2-butyn-1-yl,
2,2-dimethyl-2-butyn-1-yl, 3,3-dimethyl-2-butyn-1-yl,
1,1-dimethyl-3-butyn-1-yl, 1,2-dimethyl-3-butyn-1-yl,
1,3-dimethyl-3-butyn-1-yl, 2,2-dimethyl-3-butyn-1-yl,
3,3-dimethyl-3-butyn-1-yl, 1-pentyn-1-yl, 2-pentyn-1-yl,
3-pentyn-1-yl, 4-pentyn-1-yl, 1-pentyn-2-yl, 2-pentyn-2-yl,
3-pentyn-2-yl, 4-pentyn-2-yl, 1-pentyn-3-yl, 2-pentyn-3-yl,
1-pentyn-1-yl, 2-pentyn-1-yl, 3-pentyn-1-yl, 4-pentyn-1-yl,
1-pentyn-2-yl, 2-pentyn-2-yl, 3-pentyn-2-yl, 4-pentyn-2-yl,
1-pentyn-3-yl, 2-pentyn-3-yl, 1-methyl-1-pentyn-1-yl,
2-methyl-1-pentyn-1-yl, 3-methyl-1-pentyn-1-yl,
4-methyl-1-pentyn-1-yl, 1-methyl-2-pentyn-1-yl,
2-methyl-2-pentyn-1-yl, 3-methyl-2-pentyn-1-yl,
4-methyl-2-pentyn-1-yl, 1-methyl-3-pentyn-1-yl,
2-methyl-3-pentyn-1-yl, 3-methyl-3-pentyn-1-yl,
4-methyl-3-pentyn-1-yl, 1-methyl-4-pentyn-1-yl,
2-methyl-4-pentyn-1-yl, 3-methyl-4-pentyn-1-yl,
4-methyl-4-pentyn-1-yl, 1-methyl-1-pentyn-2-yl,
2-methyl-1-pentyn-2-yl, 3-methyl-1-pentyn-2-yl,
4-methyl-1-pentyn-2-yl, 1-methyl-2-pentyn-2-yl,
2-methyl-2-pentyn-2-yl, 3-methyl-2-pentyn-2-yl,
4-methyl-2-pentyn-2-yl, 1-methyl-3-pentyn-2-yl,
2-methyl-3-pentyn-2-yl, 3-methyl-3-pentyn-2-yl,
4-methyl-3-pentyn-2-yl, 1-methyl-4-pentyn-2-yl,
2-methyl-4-pentyn-2-yl, 3-methyl-4-pentyn-2-yl,
4-methyl-4-pentyn-2-yl, 1-methyl-1-pentyn-3-yl,
2-methyl-1-pentyn-3-yl, 3-methyl-1-pentyn-3-yl,
4-methyl-1-pentyn-3-yl, 1-methyl-2-pentyn-3-yl,
2-methyl-2-pentyn-3-yl, 3-methyl-2-pentyn-3-yl,
4-methyl-2-pentyn-3-yl, 1-hexyn-1-yl, 1-hexyn-2-yl, 1-hexyn-3-yl,
1-hexyn-4-yl, 1-hexyn-5-yl, 1-hexyn-6-yl, 2-hexyn-1-yl,
2-hexyn-2-yl, 2-hexyn-3-yl, 2-hexyn-4-yl, 2-hexyn-5-yl,
2-hexyn-6-yl, 3-hexyn-1-yl, 3-hexyn-2-yl and 3-hexyn-3-yl groups.
Preferable examples thereof include ethynyl, 1-propyn-1-yl,
2-propyn-1-yl, 3-propyn-1-yl, 1-butyn-1-yl, 1-butyn-2-yl,
1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl, 2-butyn-2-yl,
1-methyl-1-propyn-1-yl,2-methyl- -1-propyn-1-yl,
1-methyl-2-propyn-1-yl, 2-methyl-2-propyn-1-yl,
1-methyl-1-butyn-1-yl, 2-methyl-1-butyn-1-yl,
3-methyl-1-butyn-1-yl, 1-methyl-2-butyn-1-yl,
2-methyl-2-butyn-1-yl, 3-methyl-2-butyn-1-yl,
1-methyl-3-butyn-1-yl, 2-methyl-3-butyn-1-yl,
3-methyl-3-butyn-1-yl, 1-ethyl-1-butyn-1-yl, 2-ethyl-1-butyn-1-yl,
3-ethyl-1-butyn-1-yl, 1-ethyl-2-butyn-1-yl, 2-ethyl-2-butyn-1-yl,
3-ethyl-2-butyn-1-yl, 1-ethyl-3-butyn-1-yl, 2-ethyl-3-butyn-1-yl,
3-ethyl-3-butyn-1-yl, 1,1-dimethyl-1-butyn-1-yl,
1,2-dimethyl-1-butyn-1-yl, 1,3-dimethyl-1-butyn-1-yl,
2,2-dimethyl-1-butyn-1-yl, 3,3-dimethyl-1-butyn-1-yl,
1,1-dimethyl-2-butyn-1-yl, 1,2-dimethyl-2-butyn-1-yl,
1,3-dimethyl-2-butyn-1-yl, 2,2-dimethyl-2-butyn-1-yl,
3,3-dimethyl-2-butyn-1-yl, 1,1-dimethyl-3-butyn-1-yl,
1,2-dimethyl-3-butyn-1-yl, 1,3-dimethyl-3-butyn-1-yl,
2,2-dimethyl-3-butyn-1-yl and 3,3-dimethyl-3-butyn-1-yl groups.
Still preferable ones are ethynyl, 1-propyn-1-yl, 2-propyn-1-yl,
3-propyn-1-yl, 1-butyn-1-yl, 1-butyn-2-yl, 1-butyn-3-yl,
1-butyn-4-yl, 2-butyn-1-yl, 2-butyn-2-yl, 1-methyl-1-propyn-1-yl,
2-methyl-1-propyn-1-yl, 1-methyl-2-propyn-1-yl,
2-methyl-2-propyn-1-yl, 1-methyl-1-butyn-1-yl,
2-methyl-1-butyn-1-yl, 3-methyl-1-butyn-1-yl,
1-methyl-2-butyn-1-yl, 2-methyl-2-butyn-1-yl,
3-methyl-2-butyn-1-yl, 1-methyl-3-butyn-1-yl, 2-methyl-3-butyn-1-yl
and 3-methyl-3-butyn-1-yl groups. The most desirable ones are
ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 3-propyn-1-yl, 1-butyn-1-yl,
1-butyn-2-yl, 1-butyn-3-yl, 1-butyn-4-yl, 2-butyn-1-yl and
2-butyn-2-yl groups.
[0132] Examples of the lower cycloalkyl group include cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl groups.
[0133] Examples of the lower cycloalkenyl group include
cyclopropenyl, cyclobutenyl, cyclopentenyl and cyclohexenyl
groups.
[0134] The term "C.sub.2-6 alkoxy group" means groups corresponding
to C.sub.2-6 residues of the above-mentioned lower alkyl groups.
Particular examples thereof include ethoxy, n-propoxy, i-propoxy,
n-butoxy, i-butoxy, sec-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy,
sec-pentyloxy, t-pentyloxy, neopentyloxy, 1-methylbutoxy,
2-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy,
n-hexyloxy, 1-hexyloxy, 1-methylpentyloxy, 2-methylpentyloxy,
3-methylpentyloxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy,
2,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy,
3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy,
1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy,
1-ethyl-1-methylpropoxy and 1-ethyl-2-methylpropoxy groups.
Preferable examples thereof include ethoxy, n-propoxy, i-propoxy,
n-butoxy, i-butoxy, sec-butoxy, t-butoxy, n-pentyloxy, i-pentyloxy,
sec-pentyloxy, t-pentyloxy, neopentyloxy, 1-methylbutoxy,
2-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy,
n-hexyloxy and i-hexyloxy groups. Still more preferable examples
are ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy
and t-butoxy groups.
[0135] The term "lower alkylene group" in the definition of X and Y
means a divalent group formed by eliminating one hydrogen atom from
each of the carbon atoms at both ends of a linear saturated
C.sub.1-6 hydrocarbon. Particular examples thereof include
methylene, ethylene, propylene, butylene, pentylene and hexylene
groups. Preferable examples thereof include methylene, ethylene,
propylene, butylene and pentylene groups. Methylene, ethylene,
propylene and butylene groups are still more preferable and
methylene, ethylene and propylene groups are further preferable
therefor. Among them all, a methylene group is the most
desirable.
[0136] Similarly, the term "lower alkenylene group" means a
divalent group formed by eliminating one hydrogen atom from each of
the carbon atoms at both ends of a linear unsaturated C.sub.2-6
hydrocarbon. Particular examples thereof include vinylene,
propenylene, butenylene, pentenylene and hexenylene groups.
Preferable examples thereof include vinylene, propenylene,
butenylene and pentenylene groups and vinylene, propenylene and
butenylene groups are still preferable. Vinylene and propenylene
groups are more preferable and a vinylene group is the most
desirable.
[0137] Similarly, the term "lower alkynylene group" means a
divalent group formed by eliminating one hydrogen atom from each of
the carbon atoms at both ends of a linear unsaturated C.sub.2-6
hydrocarbon. Particular examples thereof include ethynyl, propynyl,
butynyl, pentynyl and hexynyl groups. Preferable examples thereof
include ethynyl, propynyl, butynyl and pentynyl groups. Ethynyl,
propynyl and, butynyl groups are still more preferable and ethynyl
and propynyl groups are further preferable therefor. An ethynyl
group is the most desirable.
[0138] l and m may be the same or different and each represents 0
or 1.
[0139] The fact that 1 is 0 means a compound of the following
formula wherein the ring A is bonded not via "optionally
substituted lower alkylene optionally having a heteroatom,
optionally substituted lower alkenylene optionally having a
heteroatom or optionally substituted lower alkynylene optionally
having a heteroatom" represented by X but directly: 25
[0140] wherein Y, m and the rings A and B are each as defined
above.
[0141] Similarly, the fact that m is 0 means a compound of the
following formula wherein the bridgehead carbon atom of the ring A
is bonded not via "optionally substituted lower alkylene optionally
having a heteroatom, optionally substituted lower alkenylene
optionally having a heteroatom or optionally substituted lower
alkynylene optionally having a heteroatom" represented by Y but
directly to the bridgehead carbon atom of the ring B: 26
[0142] wherein X, l and the rings A and B are each as defined
above.
[0143] Therefore, the fact that l and m are the same and each
represents 0 means a compound of the following formula wherein the
ring A is bonded not via "optionally substituted lower alkylene
optionally having a heteroatom, optionally substituted lower
alkenylene optionally having a heteroatom or optionally substituted
lower alkynylene optionally having a heteroatom" represented by X
but directly and the bridgehead carbon atom of the ring A is bonded
not via "optionally substituted lower alkylene optionally having a
heteroatom, optionally substituted lower alkenylene optionally
having a heteroatom or optionally substituted lower alkynylene
optionally having a heteroatom" represented by Y but directly to
the bridgehead carbon atom of the ring B. 27
[0144] wherein the rings A and B are each as defined above.
[0145] The ring A represents an optionally substituted cycloalkyl
ring optionally having one or more heteroatoms.
[0146] The term "heteroatom" as used herein means in particular
oxygen, sulfur, nitrogen, phosphorus, arsenic, antimony, silicon,
germanium, tin, lead, boron, mercury, etc. Preferable examples
thereof include oxygen, sulfur and nitrogen atoms and a nitrogen
atom is Still more preferable.
[0147] In the expression "having a heteroatom" or "optionally
having a heteroatom" as used herein, the heteroatom has the meaning
as defined above.
[0148] A cycloalkyl ring means a saturated monocyclic hydrocarbon.
Namely, particular examples of the ring A are those represented by
the following structural formulae optionally having a substituent
and optionally having one or more heteroatoms: 28
[0149] Preferable examples thereof include those represented by the
following structural formulae optionally having a substituent and
optionally having one or more heteroatoms: 29
[0150] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having one or more heteroatoms: 30
[0151] Still more preferable examples thereof include those
represented by the following structural formula optionally having a
substituent and optionally having one or more heteroatoms: 31
[0152] The most desirable one is an optionally substituted
piperidine ring optionally having one or more heteroatoms.
[0153] The ring B represents a ring optionally having one or more
double bonds in the ring selected from the following ones: a) an
optionally substituted cycloalkyl ring optionally having a
heteroatom; b) an optionally substituted bicycloalkyl ring
optionally having a heteroatom wherein the different atoms
(bridgehead carbon atoms) in the ring B are bonded to each other
via an optionally substituted C.sub.1 or higher alkylene group
optionally having a heteroatom; and c) an optionally substituted
spiro-hydrocarbon ring optionally having a heteroatom wherein both
ends of an optionally substituted C.sub.1 or higher alkylene group
optionally having a heteroatom are bonded to a carbon atom
(bridgehead carbon atom) in the ring B. Thus, particular examples
of the ring B are those represented by the following structural
formulae optionally having one or more double bond in the ring,
optionally having a substituent and optionally having a heteroatom:
32333435
[0154] Preferable examples thereof include those represented by the
following structural formulae optionally having a substituent and
optionally having a heteroatom: 363738
[0155] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having a heteroatom: 3940
[0156] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having a heteroatom: 41
[0157] Particularly preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having a heteroatom: 42
[0158] The most desirable ones are those represented by the
following structural formulae optionally having a substituent and
optionally having a heteroatom: 43
[0159] X.sup.1 represents an optionally substituted lower alkylene
optionally having a heteroatom, optionally substituted lower
alkenylene optionally having a heteroatom or optionally substituted
lower alkylene optionally having a heteroatom. Thus, it has the
same meaning as that of X as defined above. The heteroatom in the
definition of X.sup.1 is preferably a nitrogen atom, though it is
not restricted thereto.
[0160] l.sup.1 is 0 or 1.
[0161] When l.sup.1 is 0, therefore, the following formula: 44
[0162] wherein X, l.sup.1 and the ring A.sup.1 are each as defined
above;
[0163] means the following formula: 45
[0164] wherein the ring A.sup.1 is as defined above.
[0165] The ring A.sup.1 represents: a) an optionally substituted
cycloalkyl ring optionally having one or more heteroatoms; b) an
optionally substituted cycloalkenyl ring optionally having one or
more heteroatoms; or c) an optionally substituted spiro-hydrocarbon
ring optionally having a heteroatom, wherein both ends of an
optionally substituted C.sub.1 or higher alkylene group optionally
having a heteroatom are bonded to a carbon atom (bridgehead carbon
atom) in the ring A.sup.1. Thus, particular examples of the ring
A.sup.1 include those represented by the following structural
formulae optionally having a substituent, optionally having a
heteroatom and optionally having a double bond in the ring:
4647
[0166] Preferable examples thereof include those represented by the
following structural formulae optionally having a substituent,
optionally having a heteroatom and optionally having a double bond
in the ring: 48
[0167] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent, optionally having a heteroatom and optionally having
a double bond in the ring: 49
[0168] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent, optionally having a heteroatom and optionally having
a double bond in the ring: 50
[0169] Particularly preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent, optionally having a heteroatom and optionally having
a double bond in the ring: 51
[0170] The most desirable examples thereof are those represented by
the following structural formulae optionally having a substituent,
optionally having a heteroatom and optionally having a double bond
in the ring: 52
[0171] and piperidine and pyrrolidine rings optionally having a
substituent, optionally having a heteroatom and optionally having a
double bond in the ring.
[0172] X.sup.2 represents an optionally substituted lower alkylene
optionally having a heteroatom, optionally substituted lower
alkenylene optionally having a heteroatom or optionally substituted
lower alkynylene optionally having a heteroatom.
[0173] l.sup.2 is 0 or 1.
[0174] When l.sup.2 is 0, therefore, the following formula:
--(X.sup.2).sub.l2-Q
[0175] wherein X.sup.2, l.sup.2 and Q are each as defined
above;
[0176] means the following formula:
-Q
[0177] wherein Q is as defined above.
[0178] Q is as defined above. In the definition of Q, particular
examples of a) heteroaryl consisting of one or more optionally
substituted rings include rings represented by the following
structural formulae optionally having a substituent: 53
[0179] Preferable examples are those represented by the following
structural formulae: 54
[0180] Still more preferable examples are those represented by the
following structural formulae: 55
[0181] Still further preferable examples are those represented by
the following structural formulae: 56
[0182] Particularly preferable examples are those represented by
the following structural formulae: 57
[0183] The most desirable ones are those represented by the
following structural formulae: 58
[0184] Particular examples of aryl consisting of one or more
optionally substituted rings include phenyl, tolyl, xylyl, cumenyl,
mesityl and naphthyl groups.
[0185] The expression "b) optionally substituted quaternary
ammonio" means those having optionally substituted tetravalent
nitrogen. Such a quaternary ammonio group may be an acyclic one, a
cyclic one or a combination thereof. It may have one or more
heteroatoms selected from among nitrogen, sulfur and oxygen.
Examples of the acyclic quaternary ammonio group include those
represented by the following formula: 59
[0186] wherein R.sup.23 to R.sup.25 may be the same or different
and each represents lower alkyl, lower alkoxy(lower alkyl),
hydroxy(lower alkyl), carboxy(lower alkyl), amino(lower alkyl),
carbamoyl(lower alkyl), lower alkenyl, lower alkynyl,
halogeno(lower alkyl), halogeno(lower alkenyl), halogeno(lower
alkynyl) or aryl. Particular examples thereof include those
represented by the following formulae optionally having a
substituent: 60
[0187] wherein Me represents methyl; Et represents ethyl; Pr
represents propyl; and Bu represents butyl; the same will apply
hereinafter.
[0188] Preferable examples thereof include those represented by the
following formulae optionally having a substituent: 61
[0189] Still more preferable examples thereof include those
represented by the following formulae optionally having a
substituent: 62
[0190] The most preferable examples thereof are those represented
by the following formulae: 63
[0191] Examples of the cyclic quaternary ammonio group include
those represented by the following formula: 64
[0192] wherein R.sup.26 represents lower alkyl, lower alkoxy(lower
alkyl), hydroxy(lower alkyl), carboxy(lower alkyl), amino(lower
alkyl), carbamoyl(lower alkyl), lower alkenyl, lower alkynyl,
halogeno(lower alkyl), halogeno(lower alkenyl), halogeno(lower
alkynyl) or aryl; and the ring A.sup.4 represents an optionally
substituted cycloalkyl ring optionally having a double bond in the
ring;
[0193] those represented by the following formula: 65
[0194] wherein R.sup.27 represents lower alkyl, lower alkoxy(lower
alkyl), hydroxy(lower alkyl), carboxy(lower alkyl), amino(lower
alkyl), carbamoyl(lower alkyl), lower alkenyl, lower alkynyl,
halogeno(lower alkyl), halogeno(lower alkenyl), halogeno(lower
alkynyl) or aryl; and the ring A.sup.5 represents an optionally
substituted heteroaryl ring optionally having one or more
heteroatoms;
[0195] or those represented by the following formula: 66
[0196] wherein the ring A.sup.6 represents an optionally
substituted heteroaryl ring optionally having one or more
heteroatoms.
[0197] Particular examples thereof include those represented by the
following structural formulae optionally having a substituent and
optionally having one or more heteroatoms: 67
[0198] wherein R.sup.26 and R.sup.27 are each as defined above.
[0199] Preferable examples thereof include those represented by the
following structural formulae optionally having a substituent and
optionally having one or more heteroatoms: 68
[0200] wherein R.sup.26 and R.sup.27 are each as defined above.
[0201] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having one or more heteroatoms: 69
[0202] wherein R.sup.26 is as defined above.
[0203] Still more preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having one or more heteroatoms: 70
[0204] wherein R.sup.26 is as defined above.
[0205] Particularly preferable examples thereof include those
represented by the following structural formulae optionally having
a substituent and optionally having one or more heteroatoms: 71
[0206] wherein R.sup.26 is as defined above.
[0207] The most desirable ones are those represented by the
following structural formulae optionally having a substituent and
optionally having one or more heteroatoms: 72
[0208] wherein R.sup.26 is as defined above.
[0209] R.sup.5 and R.sup.6 may be the same or different and each
represents hydrogen or lower alkyl. The term "lower alkyl" as used
herein has the same meaning as the one defined above.
[0210] Thus, particular examples of c) the group represented by the
following formula: 73
[0211] wherein R.sup.5 and R.sup.6 are each as defined above,
include those represented by the following structural formulae:
74
[0212] Preferable examples thereof include those represented by the
following structural formulae: 75
[0213] Still more preferable examples thereof include those
represented by the following structural formulae: 76
[0214] The most desirable ones are those represented by the
following structural formulae: 77
[0215] Particular examples of the lower acyl group include formyl,
acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl,
pivaloyl, hexanoyl, acryloyl, methacryloyl, crotonyl, chloroformyl,
pyruvoyl, oxalo, methoxalyl, ethoxalyl and benzoyl groups.
[0216] The lower acyloxy group means those corresponding to the
above-mentioned lower acyl groups. Particular examples thereof
include formyloxy, acetyloxy, propionyloxy, butyryloxy,
isobutyryloxy, valeryloxy, isovaleryloxy, pivaloyloxy, hexanoyloxy,
acryloyloxy, methacryloyloxy, crotonyloxy, chloroformyloxy,
pyruvoyloxy, oxaloxy, methoxalyloxy, ethoxalyloxy and benzoyloxy
groups.
[0217] R.sup.7 and R.sup.8 are each as defined above. In the
definition of R.sup.7 and R.sup.8, the lower alkyl and lower
cycloalkyl groups are each as defined above.
[0218] Also, the lower alkyl groups in the definition of R.sup.71,
R.sup.72, R.sup.73, R.sup.74, R.sup.75, R.sup.76, R.sup.77 and
R.sup.81 and the lower cycloalkyl groups in the definition of
R.sup.72 and R.sup.73 have each the same meaning as the one defined
above.
[0219] The aryl groups in the definition of R.sup.71, R.sup.72,
R.sup.73, R.sup.81, R.sup.83, R.sup.84 and R.sup.85 means aromatic
ring groups. Particular examples thereof include phenyl, tolyl,
xylyl, cumenyl, mesityl and naphthyl groups.
[0220] The amino protecting group is not restricted but may be an
arbitrary one known as an amino protecting group in organic
synthesis. Examples thereof include optionally substituted lower
alkanoyl groups such as formyl, acetyl, chloroacetyl,
dichloroacetyl, propionyl, phenylacetyl, phenoxyacetyl and
thienylacetyl groups; optionally substituted lower alkoxycarbonyl
groups such as benzyloxycarbonyl, t-butoxycarbonyl and
p-nitrobenzyloxycarbonyl groups; substituted lower alkyl groups
such as methyl, t-butyl, 2,2,2-trichloroethyl, trityl,
p-methoxybenzyl, p-nitrobenzyl, diphenylmethyl, pivaloyloxymethyl,
methoxymethyl and ethoxymethyl groups; substituted silyl groups
such as trimethylsilyl and t-butyldimethylsilyl groups; substituted
silylalkoxyalkyl groups such as trimethylsilylmethoxymethyl,
trimethylsilylethoxymethyl, t-butyldimethylsilylmethoxymethyl and
t-butyldimethylsilylethoxymethyl groups; and optionally substituted
benzylidene groups such as benzylidene, salicylidene,
p-nitrobenzylidene, m-chlorobenzylidene,
3,5-di(t-butyl)-4-hydroxybenzylidene and 3,5-di(t-butyl)benzylidene
groups.
[0221] Such a protective group can be eliminated by conventional
methods such as hydrolysis or reduction selected depending on the
type thereof.
[0222] The term "protected hydroxy" means a hydroxyl group
protected by a hydroxyl protecting group. Examples thereof are not
restricted, so long as they are protected by protecting groups
commonly known as a hydroxyl protecting group in organic synthesis.
Examples of the hydroxyl protecting group include lower alkylsilyl
groups such as trimethylsilyl and t-butyldimethylsilyl groups;
lower alkoxymethyl groups such as methoxymethyl and 2-methoxymethyl
groups; a tetrahydropyranyl group; aralkyl groups such as benzyl,
p-methoxybenzyl, 2,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl
and trityl groups; acyl groups such as formyl and acetyl groups;
lower alkoxycarbonyl groups such as t-butoxycarbonyl,
2-iodoethoxycarbonyl and 2,2,2-trichloroethoxycarbonyl groups;
alkenyloxycarbonyl groups such as 2-propenyloxycarbonyl,
2-chloro-2-propenyloxycarbonyl,
3-methoxycarbonyl-2-propenyloxycarbonyl,
2-methyl-2-propenyloxycarbonyl, 2-butenyloxycarbonyl and
cinnamyloxycarbonyl groups; and aralkyloxycarbonyl groups such as
benzyloxycarbonyl, p-methoxybenzyloxycarbonyl,
o-nitrobenzyloxycarbonyl and p-nitrobenzyloxycarbonyl groups.
[0223] R.sup.82 represents hydrogen, lower alkyl or a mercapto
protective group. The lower alkyl as used herein has the same
meaning as the one defined above. The mercapto protective group may
be an arbitrary one without restriction so long as it is commonly
known as a mercapto protective group in organic synthesis. More
particularly speaking, use can be made of the above-mentioned
hydroxy protective groups or disulfide derivatives as the mercapto
protective group.
[0224] The term "protected carboxy" means a carboxyl group
protected by a carboxyl protecting group. The carboxyl protective
group may be an arbitrary one without restriction so long as it is
commonly known as a carboxyl protecting group in organic synthesis.
Particular examples of the carboxyl protective group include linear
and branched C.sub.1-4 lower alkyl groups such as methyl, ethyl,
isopropyl and t-butyl groups; halogeno(lower alkyl) groups such as
2-iodoethyl and 2,2,2-trichloroethyl groups; lower alkoxymethyl
groups such as methoxymethyl, ethoxymethyl and isobutoxymethyl
groups; lower aliphatic acyloxymethyl groups such as
butyryloxymethyl and pivaloyloxymethyl groups; 1-(lower
alkoxy)carbonyloxyethyl groups such as 1-methoxycarbonyloxyethyl
and 1-ethoxycarbonyloxyethyl groups; aralkyl groups such as benzyl,
p-methoxybenzyl, o-nitrobenzyl and p-nitrobenzyl groups; and
benzhydryl and phthalidyl groups.
[0225] W represents oxygen or sulfur. When W is oxygen, therefore,
the group represented by the following formula: 78
[0226] wherein W, R.sup.83 and R.sup.84 are each as defined
above,
[0227] represents a group represented by the following formula:
79
[0228] wherein W, R.sup.83 and R.sup.84 are each as defined
above.
[0229] When W is sulfur, therefore, the group represented by the
following formula: 80
[0230] wherein W, R.sup.83 and R.sup.84 are each as defined
above,
[0231] represents a group represented by the following formula:
81
[0232] wherein W, R.sup.83 and R.sup.84 are each as defined
above.
[0233] R.sup.83 and R.sup.84 may be the same or different and each
represents hydrogen, lower alkyl, lower cycloalkyl, cyano or a
group represented by the following formula:
--SO.sub.2R.sup.85
[0234] wherein R.sup.85 represents hydrogen, hydroxy or lower
alkyl.
[0235] Alternatively, R.sup.83 and R.sup.84 together form an
optionally substituted lower cycloalkyl optionally having one or
more heteroatoms.
[0236] The lower alkyl groups in R.sup.83, R.sup.84 and R.sup.85
and the lower cycloalkyl groups in R.sup.83 and R.sup.84 are each
as defined above.
[0237] Particular examples of the optionally substituted lower
cycloalkyl optionally having one or more heteroatoms formed by
R.sup.83 and R.sup.84 together include optionally substituted
pyrrolidyl, imidazolidyl, piperazolidyl, piperidyl, piperazyl and
morpholino groups optionally having one or more heteroatoms.
[0238] R.sup.86, R.sup.87 and R.sup.88 are as defined above. Also,
the lower alkyl groups in R.sup.86, R.sup.87 and R.sup.88 have the
same meaning as the one defined above. The term "hydroxy(lower
alkyl)" means a lower alkyl group substituted with hydroxy. The
optionally substituted lower cycloalkyl group optionally having one
or more heteroatoms formed by R.sup.86 and R.sup.87 together has
the same meaning as the one defined above with respect to R.sup.83
and R.sup.84.
[0239] R.sup.90 and R.sup.91 each represents hydrogen or lower
alkyl. The lower alkyl has the same meaning as the one defined
above.
[0240] Next, the definition of R will be illustrated.
[0241] R is as defined above and the lower alkyl groups in the
definition of R also have the same meaning as the one defined
above.
[0242] The term "optionally substituted arylalkyl" means an
optionally substituted alkyl group substituted by an optionally
substituted aryl group. Particular examples of the aryl group
include benzene, pentalene, indene, naphthalene, azulene,
heptalene, biphenylene, indacene, acenaphthylene, fluorene,
phenalene, phenanthrene and anthracene. Preferable examples thereof
include benzene, pentalene, indene, naphthalene and azulene.
Particular examples of the alkyl group include the optionally
substituted lower alkyl groups as cited above.
[0243] The term "optionally substituted heteroarylalkyl" means an
optionally substituted alkyl group substituted by an optionally
substituted heteroaryl group. Particular examples of the heteroaryl
group include pyridine, thiophene, furan, pyrrole, oxazole,
isoxazole, thiazole, isothiazole, imidazole, triazole, pyrazole,
furazan, thiadiazole, oxadiazole, pyridazine, pyrimidine, pyrazine,
indole, isoindole, indazole, chromene, quinoline, isoquinoline,
cinnoline, quinazoline, quinoxaline, naphthyridine, phthalazine,
purine, pteridine, thienofuran, imidazothiazole, benzofuran,
benzothiophene, benzoxazole, benzothiazole, benzothiadiazole,
benzimidazole, imidazopyridine, pyrrolopyridine, pyrrolopyrimidine
and pyridopyrimidine. Preferable examples thereof include pyridine,
thiophene, thiazole, thiadiazole, imidazole, pyrimidine,
benzimidazole, imidazopyridine and purine. Particular examples of
the alkyl group include the optionally substituted lower alkyl
groups as cited above.
[0244] The amino protecting group is as defined above.
[0245] The lower alkylene, lower alkenylene and lower alkynylene
groups in X.sup.3 are each as defined above.
[0246] The lower alkyl group and the amino protecting group in
R.sup.9 and R.sup.10 are each as defined above.
[0247] The lower alkylene, lower alkenylene and lower alkynylene
groups in X.sup.4 are each as defined above.
[0248] The lower alkyl group and the carboxy protecting group in
R.sup.11 are each as defined above.
[0249] Next, the definition of E will be illustrated.
[0250] E is as defined above and R.sup.4 in the definition of E
also has the same meaning as the one described with respect to
R.sup.1 to R.sup.3.
[0251] Next, the definition of Z will be illustrated.
[0252] Z is as defined above and the lower alkyl group and the
amino protective group in R.sup.12 in the definition of Z also have
each the same meaning as the one defined above.
[0253] Next, the definition of the ring G will be illustrated.
[0254] The ring G represents an optionally substituted heteroaryl
ring having one or more nitrogen atoms. Particular examples of the
heteroaryl group having one or more nitrogen atoms include
pyridine, pyrrole, oxazole, isoxazole, thiazole, isothiazole,
imidazole, triazole, pyrazole, furazan, thiadiazole, oxadiazole,
pyridazine, pyrimidine, pyrazine, indole, isoindole, indazole,
quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline,
naphthyridine, phthalazine, purine, pteridine, imidazothiazole,
benzoxazole, benzothiazole, benzothiadiazole, benzimidazole,
imidazopyridine, pyrrolopyridine, pyrrolopyrimidine and
pyridopyrimidine. Preferable examples thereof include pyridine,
pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole,
triazole, pyrazole, furazan, thiadiazole, oxadiazole, pyridazine,
pyrimidine and pyridine. Particularly preferable examples thereof
include pyridine, pyrrole, imidazole, triazole, pyrazole,
pyridazine, pyrimidine and pyrazine. Still preferable examples are
imidazole, triazole, pyridazine, pyrimidine and pyrazine.
Particularly preferable ones are pyridine, pyridazine, pyrimidine
and pyrazine. The most desirable ones are pyrimidine and
pyrazine.
[0255] Thus the compounds represented by the formula (I) have been
defined, provided that the benzopiperidine derivatives as will be
specified below are excluded from the present invention: a) that in
which R.sup.1 to R.sup.3 are each hydrogen, E is CH, Z is O, S, or
SO.sub.2 and the ring G is an unsubstituted (i.e., all of the
substituents being hydrogen atoms) heteroaryl ring having one or
more nitrogen atoms; b) that in which R.sup.1 to R.sup.3 are each
hydrogen, E is CH, Z is O, S, SO.sub.2 or NH and the substituent(s)
of the ring G is optionally substituted phenyl, pyridinyl, thienyl,
nitro, cyano, halogeno, acetyl, methyl, ethyl, t-butyl, ethoxy,
N-methylpiperazyl, naphthyl, optionally protected carboxyalkyl or
amino; c) that in which R.sup.1 to R.sup.3 are each hydrogen, E is
CH, Z is NH and the ring G is unsubstituted (i.e., all of the
substituents being hydrogen atoms) pyridazine; and d) that in which
R.sup.1 to R.sup.3 are each hydrogen, E is CH, R is a group other
than hydrogen, Z is NR.sup.12' (R.sup.12' being lower alkyl or an
amino protective group) and the ring G is an optionally substituted
heteroaryl ring optionally having one or more nitrogen atoms. The
term "optionally substituted phenyl" as used herein means a phenyl
group optionally substituted by methoxy or halogeno. The term
"optionally protected carboxyalkyl" means a carboxyalkyl group
which may have a protecting group commonly employed as a carboxy
protecting group in organic synthesis.
[0256] In particular, benzopiperidine derivatives of the formula
(I) wherein Z is S, their salts or hydrates thereof are useful.
[0257] In particular, benzopiperidine derivatives of the formula
(I) wherein the ring G is an optionally substituted pyrazine ring,
their salts or hydrates thereof are useful.
[0258] In particular, benzopiperidine derivatives of the formula
(I) wherein Z is S and the ring G is an optionally substituted
pyrazine ring, their salts or hydrates thereof are useful.
[0259] In the definition of the compounds represented by the above
formula (II), R, Z, E and the ring G have each the same meaning as
the one defined above. Now, the definition of U will be
illustrated.
[0260] U is as defined above and X, Y, l, m, the rings A and B,
X.sup.1, l.sup.1 and the ring A.sup.1 employed in the definition of
U also have each the same meaning as the one defined with respect
to the formula (I).
[0261] In the definition of the compounds represented by the above
formula (III), R, Z, E and the ring G have each the same meaning as
the one defined above. Now, the definition of U.sup.1 will be
illustrated.
[0262] U.sup.1 is as defined above and X, Y, l, m, the rings A and
B, X.sup.1, l.sup.1 and the ring A.sup.1 employed in the definition
of U.sup.1 also have each the same meaning as the one defined with
respect to the formula (I).
[0263] In the present invention, the type of salt is not
particularly restricted. Examples thereof include inorganic acid
addition salts such as hydrofluoride, hydrochloride, sulfate,
nitrate, perchlorate, phosphate, carbonate, bicarbonate,
hydrobromide and hydriodide; organic carboxylic acid addition salts
such as acetate, maleate, fumarate, oxalate, lactate, tartrate and
trifluoroacetate; organic sulfonic acid addition salts such as
methanesulfonate, trifluoromethanesulfonate, ethanesulfonate,
hydroxymethanesulfonate, hydroxyethanesulfonate, benzenesulfonate,
toluenesulfonate and taurine salt; amine addition salts such as
trimethylamine salt, triethylamine salt, pyridine salt, procaine
salt, picoline salt, dicyclohexylamine salt,
N,N'-dibenzylethylenediamine salt, N-methylglucamine salt,
diethanolamine salt, triethanolamine salt,
tris(hydroxymethylamino)methane salt and phenethylbenzylamine salt;
alkali metal addition salts such as sodium salt and potassium salt;
alkaline earth metal addition salts such as magnesium salt and
calcium salt; and amino acid addition salts such as argininate,
lysinate, serinate, glycinate, aspartate and glutamate.
[0264] The compounds of the present invention are benzopiperidine
derivatives represented by the above formula (I), their salts or
hydrates thereof. Preferable ones are the above compounds wherein
at least one of R.sup.1 to R.sup.3 is a group represented by the
following formula while other group(s) are hydrogen, their salts
and hydrates thereof: 82
[0265] wherein X, Y, l, m and the rings A and B are each as defined
above.
[0266] Still more preferable ones are benzopiperidine derivatives
represented by the above formula (II), their salts or hydrates
thereof. Still preferable ones are benzopiperidine derivatives
represented by the above formula (III), their salts or hydrates
thereof. Particularly preferable ones are those wherein Z is S and,
still more preferably, the ring G is pyrazine, their salts or
hydrates thereof. The most desirable ones are benzopiperidine
derivatives represented by the following formula, their salts or
hydrates thereof: 83
[0267] Among all, 10H-pyrazino[2,3-b][1,4]bentothiazine derivatives
represented by the following formula are particularly preferable:
84
[0268] wherein R.sup.1 to R.sup.4 are each as defined above.
[0269] Moreover, the benzopiperidine derivatives represented by the
above formula (I), i.e., the compounds of the present invention,
their pharmacologically acceptable salts or hydrates thereof are
useful as a drug.
[0270] Particularly preferable drugs containing these
benzopiperidine derivatives represented by the above formula (I),
their pharmacologically acceptable salts or hydrates thereof are
preventives and remedies for inflammatory diseases or autoimmune
diseases, more particularly inflammatory immune diseases, for
example, asthma, nephritis, ischemic reflow disorders, psoriasis,
atopic dermatitis and the rejection reaction accompanying organ
transplantation and autoimmune diseases such as arthritis and
collagen disease. Still more preferable drugs are preventives and
remedies for arthritis which contain the benzopiperidine
derivatives represented by the above formula (I), their salts or
hydrates thereof.
[0271] In addition, it is highly worthwhile to use the
benzopiperidine derivatives represented by the above formula (I),
their salts or hydrates thereof in the production of drugs and to
use the benzopiperidine derivatives represented by the above
formula (I), their salts or hydrates thereof in the treatment of
immune diseases. Furthermore, the benzopiperidine derivatives
represented by the above formula (I), their salts or hydrates
thereof are highly useful as remedies ensuring the efficacious
administration of these compounds.
[0272] The dose of the drugs according to the present invention
varies depending on the severity of the symptoms, the age, sex and
body weight of the patient, the administration method, the disease,
etc. In usual, such a drug may be administered in a daily dose of
10 .mu.g to 50 g to an adult one to several times per day.
[0273] The drugs according to the present invention may be
administered by an arbitrary method without restriction. Namely,
they can be orally or parenterally administered in a conventional
manner.
[0274] To produce pharmaceutical preparations thereof, use can be
made of fillers, binders, lubricants, coloring agents, corrigents,
etc. commonly-employed in the art optionally together with
stabilizers, emulsifiers, sorbefacients, surfactants, etc. These
preparations are produced by blending components commonly employed
in pharmaceutical preparations in a conventional manner.
[0275] Examples of these components include animal and vegetable
oils (soybean oil, beef tallow, synthetic glycerides, etc.),
hydrocarbons (liquid paraffin, squalane, solid paraffin, etc.),
ester oils (octyldodecyl myristate, isopropyl myristate, etc.),
higher alcohols (cetostearyl alcohol, behenyl alcohol, etc.),
silicone resins, silicone oils, surfactants (polyoxyethylene fatty
acid esters, sorbitan fatty acid esters, glycerol fatty acid
esters, polyoxyethylene sorbitan fatty acid esters,
polyoxyethylene-hardened castor oil, polyoxyethylene/polyoxypropy-
lene block copolymer, etc.), water-soluble polymers
(hydroxyethylcellulose, polyacrylic acid, carboxyvinyl polymer,
polyethylene glycol, polyvinylpyrrolidone, methylcellulose, etc.),
alcohols (ethanol, isopropanol, etc.), polyhydric alcohols
(glycerol, propylene glycol, dipropylene glycol, sorbitol, etc.),
saccharides (glucose, sucrose, etc.), inorganic powders (silicic
acid anhydride, aluminum magnesium silicate, aluminum silicate,
etc.) and purified water. To regulate the pH value, use can be made
of inorganic acids (hydrochloric acid, phosphoric acid, etc.),
alkali metal salts of inorganic acids (sodium phosphate, etc.),
inorganic bases (sodium hydroxide, etc.), organic acids (lower
fatty acids, citric acid, lactic acid, etc.), metal salts of
organic acids (sodium citrate, sodium lactate, etc.) and organic
bases (arginine, ethanolamine, etc.). If needed, preservatives,
antioxidants, etc. may be further added thereto.
[0276] The pharmacologically acceptable salts are not particularly
restricted in type. Examples thereof include inorganic acid
addition salts such as hydrochloride, sulfate, carbonate,
bicarbonate, hydrobromide and hydriodide; organic carboxylic acid
addition salts such as acetate, maleate, lactate, tartrate and
trifluoroacetate; organic sulfonic acid addition salts such as
methanesulfonate, hydroxymethanesulfonate, hydroxyethanesulfonate,
benzenesulfonate, toluenesulfonate and taurine salt; amine addition
salts such as trimethylamine salt, triethylamine salt, pyridine
salt, procaine salt, picoline salt, dicyclohexylamine salt,
N,N'-dibenzylethylenediamine salt, N-methylglucamine salt,
diethanolamine salt, triethanolamine salt,
tris(hydroxymethylamino)methane salt and phenethylbenzylamine salt;
and amino acid addition salts such as argininate, lysinate,
serinate, glycinate, aspartate and glutamate.
[0277] The compounds of the present invention can be produced by,
for example, the following method. Namely, a compound represented
by the formula (IV) or (IV'): 85
[0278] wherein R, E, Z, the ring G, X and l are each as defined
above, and Lev. represents a leaving group, is reacted with a
compound represented by the formula (V): 86
[0279] wherein Y, m and the rings A.sup.2 and B are each as defined
above, and the ring B is optionally protected,
[0280] followed by, if required, deblocking and thus a
benzopiperidine derivative represented by the formula (VI), its
salt or hydrates thereof can be produced: 87
[0281] wherein R, E, Z, the ring G, X, Y, l, m and the rings
A.sup.2 and B are each as defined above.
[0282] In the production of the compounds of the present invention,
therefore, 10H-pyrazino[2,3-b][1,4]benzothiazine derivatives
represented by the following formula (IV-1) or (IV'-1), their salts
or hydrates thereof: 88
[0283] wherein Lev. is as defined above, and bicycloalkyl
derivatives represented by the following formula (VII), their salts
or hydrates thereof: 89
[0284] wherein Y, m, the rings A.sup.2 and B are each as defined
above, R.sup.13 represents hydrogen, lower alkyl or an amino
protective group, and R.sup.14 and R.sup.15 may be the same or
different and each represents hydrogen or lower alkyl, are useful
as the production intermediates.
[0285] The term "Lev." as used herein means a leaving group which
may be an arbitrary one commonly known as a leaving group in
organic synthesis without restriction. Examples thereof include
halogen atoms such as chlorine, bromine and iodine atoms; alkylthio
groups such as methylthio, ethylthio and propylthio groups;
arylthio groups such as phenylthio, toluylthio and 2-pyridylthio
groups; alkylsulfonyloxy groups such as methanesulfonyloxy,
trifluoromethanesulfonyloxy, ethanesulfonyloxy and
propanesulfonyloxy groups; arylsulfonyloxy groups such as
benzenesulfonyloxy and p-toluenesulfonyloxy groups; alkanoyloxy
groups such as acetoxy and trifluoroacetoxy groups; alkoxy groups
such as methoxy, ethoxy and propoxy groups; alkylamino groups such
as methylamino, ethylamino, propylamino and butylamino groups;
dialkylamino groups such as dimethylamino, diethylamino,
dipropylamino, methylethylamino, ethylpropylamino and
methylpropylamino groups; and substituted phosphoryloxy groups such
as a diphenoxyphosphoryloxy group.
[0286] In the formula (VII), the lower alkyl and the amino
protective group in the definition of R.sup.13 have each the same
meaning as the one defined above. Similarly, the lower alkyl in
R.sup.14 and R.sup.15 has the same meaning as the one defined
above. Also, Y, m and the rings A.sup.2 and B are each as defined
above.
[0287] Among the intermediates represented by the formula (VII) in
the production of the compounds of the present invention,
bicycloalkyl derivatives represented by the following formula (X),
their salts and hydrates thereof are useful: 90
[0288] wherein Y, m, the rings A.sup.2 and B and R.sup.13 are each
as defined above; X.sup.5 represents an optionally substituted
lower alkylene optionally having a heteroatom, optionally
substituted lower alkenylene optionally having a heteroatom or
optionally substituted lower alkynylene optionally having a
heteroatom; l.sup.5 is 0 or 1; and Q.sup.1 represents carboxy,
alkoxycarbonyl, sulfamoyl, amido, optionally protected hydroxy or
optionally protected amino.
[0289] In particular, bicycloalkyl derivatives represented by the
following formula (XI), (XII), (XIII), (XIV), (XV) or (XVI), their
salts and hydrates thereof are useful: 91
[0290] wherein R.sup.13, X.sup.5, l.sup.5 and Q.sup.1 are each as
defined above; and R.sup.14' and R.sup.15' may be the same or
different and each represents hydrogen or lower alkyl, provided
that the following cases are excluded: that in which, in the
formula (XI) or (XII), R.sup.15' and R.sup.14' are each hydrogen,
l.sup.5 is 0 and Q.sup.1 is carboxy or ethoxycarbonyl; that in
which, in the formula (XI), R.sup.13 is methyl, l.sup.5 is 1,
X.sup.5 has one carbon atom and forms a double bond with a carbon
on the ring bonded thereto and Q.sup.1 is ethoxycarbonyl,
4-methoxy-phenylcarbonyl or formyl, or R.sup.13 is methyl, l.sup.5
is 1, X.sup.5 is unsubstituted methylene and Q.sup.1 is
ethoxycarbonyl; and that in which, in the formula (XIII), R.sup.13
is benzyl or benzoyl, l.sup.5 is 0 and Q.sup.1 is
ethoxycarbonyl.
[0291] Further, bicycloalkyl derivatives selected from among
compounds represented by the following formulae 1) to 3), their
salts and hydrates thereof are still more useful: 92
[0292] wherein R.sup.13 is as defined above; and R.sup.18
represents hydrogen, lower alkyl or a carboxy protecting group,
provided that the case where, in a compound of formula 1), R.sup.13
is methyl and R.sup.18 is ethyl is excluded. The lower alkyl and
the amino protecting group in the definition of R.sup.13 have each
the same meaning as the one defined above. Similarly, the lower
alkyl and the carboxy protecting group in the definition of
R.sup.18 have each the same meaning as the one defined above.
[0293] Furthermore, piperidine derivatives represented by the
formula (XVII) or (XVIII), their salts or hydrates thereof are also
novel compounds and useful as the intermediates in the synthesis of
the compounds of the present invention: 93
[0294] wherein R.sup.13, X.sup.5, l.sup.5 and Q.sup.1 are each as
defined above, provided that the following cases are excluded: that
in which, in the formula (XVII), X.sup.5 is unsubstituted C.sub.1-4
alkylene, l.sup.5 is 0 or 1 and Q.sup.1 is ethoxycarbonyl, or
X.sup.5 is unsubstituted C.sub.1-3 alkylene, l.sup.5 is 0 or 1 and
Q.sup.1 is amino protected by carbonyl; and that in which, in the
formula (XVIII), l.sup.1 is 0 and Q.sup.1 is amino optionally
protected by tert-butoxycarbonyl or hydroxy optionally protected by
methanesulfonyl; in particular, piperidine derivatives represented
by the formula (XIX), (XX) or (XXI), their salts or hydrates
thereof are useful therefor: 94
[0295] wherein R.sup.13, X.sup.5, l.sup.5 and R.sup.18 are each as
defined above;
[0296] and, in particular, piperidine derivatives selected from
among the compounds represented by the formulae. 1), 2) or 3):
95
[0297] wherein R.sup.13 and R.sup.18 are each as defined above.
[0298] Now, general processes for synthesizing the compounds of the
present invention will be illustrated.
[0299] Production process 1: 96
[0300] wherein Ra and Ra' represent each a carboxy protecting
group; Hal. represents halogeno; Za represents a substituent of the
ring G which is a pyrazine ring herein; and R' represents:
[0301] 1) lower alkyl;
[0302] 2) optionally substituted arylalkyl;
[0303] 3) optionally substituted heteroarylalkyl;
[0304] 4) an amino protecting group;
[0305] 5) a group represented by the formula: 97
[0306] wherein X.sup.3, R.sup.9 and R.sup.10 are each as defined
above; or
[0307] 6) a group represented by the formula:
--X.sup.4--CO.sub.2R.sup.11
[0308] wherein X.sup.4 and R.sup.11 are each as defined above.
[0309] Step I
[0310] A compound represented by the formula (1) is treated with a
sulfurizing agent in a solvent such as ethanol in the presence of
an alkali such as sodium hydroxide to thereby give a compound of
the formula (2). As the sulfurizing agent, use can be made of
disodium disulfide, dilithium disulfide, etc. The reaction
temperature preferably ranges from 25 to 120.degree. C., though it
is not restricted thereto.
[0311] Step II
[0312] Next, the intermediate represented by the formula (2) is
treated with a metal such as tin in a solvent such as ethanol in
the presence of an acid such as hydrochloric acid to thereby give a
compound of the formula (3).
[0313] Step III
[0314] Subsequently, the compound of the formula (3) is reacted
with an appropriate alcohol or orthoester in the presence of an
acid such as hydrochloric acid or sulfuric acid to thereby give a
compound represented by the formula (4).
[0315] Step IV
[0316] In a solvent such as dry N,N-dimethylformamide, the compound
of the formula (4) is reacted with a dihalogenated pyrazine such as
2,3-dichloropyrazine [formula (5)] to thereby give a compound
represented by the formula (6).
[0317] Step V
[0318] The compound represented by the formula (6) or (9) is
treated with a reducing agent such as diisobutylaluminum hydride or
aluminum lithium hydride in a solvent to thereby give a compound
represented by the formula (7) or (10). As the solvent, use can be
made of:dry ethers such as dry tetrahydrofuran. The reaction is
preferably effected at a temperature of -50 to 50.degree. C.
[0319] Step VI
[0320] The compound represented by the formula (7) or (10) is
treated with a halogenating agent such as methanesulfonyl chloride
in a solvent such as dry N,N-dimethylformamide in the presence of
an appropriate base such as pyridine to thereby give a compound
represented by the formula (8) or (11).
[0321] Step VII
[0322] The compound represented by the formula (6) is treated with
a base such as sodium hydride and a protecting group reagent such
as methoxymethyl chloride in a solvent to thereby give a compound
represented by the formula (9).
[0323] Step VIII
[0324] The compound represented by, the formula (11) is treated
with an acid such as hydrochloric acid or trifluoroacetic acid in a
solvent to thereby give a compound represented by the formula
(8).
[0325] Production process 2: 98
[0326] wherein the rings A.sup.2 and B, Y, m, the ring G, R', Z, E,
X, l and Hal. are each as defined above; and R.sup.13a represents a
lower alkyl or an amino protective group.
[0327] Step IX
[0328] A compound represented by the formula (12) is reacted with
an acid chloride such as 1-chloroethyl chloroformate or vinyl
chloroformate optionally in a solvent. Next, an appropriate
alcoholic solvent is added thereto and reacted therewith.
Alternatively, it is treated with an appropriate solvent containing
hydrochloric acid or hydrobromic acid and then heated in an
alcoholic solvent. Alternatively, it is subjected to a reduction
reaction in a solvent such as methanol/ethanol/tetrahydrofuran/-
ethyl acetate by using a metal catalyst under normal hydrogen
pressure to elevated pressure. Thus, a compound represented by the
formula (13) can be obtained.
[0329] Step X
[0330] The compound represented by the formula (13) is treated with
the compound represented by the formula (8) or (11) obtained by the
production process 1 in a solvent in the presence of an appropriate
base such as anhydrous potassium carbonate or diisopropylamine to
leave as it is give a compound represented by the formula (14). As
the solvent, it is preferable to use a dry solvent such as dry
N,N-dimethylformamide. The reaction is effected preferably at a
temperature of 25 to 150.degree. C. If necessary, the compound
represented by the formula (14) may be subjected to optical
resolution with the use of a chiral column, etc. to thereby
separate enantiomers from each other.
[0331] Step XI
[0332] When the compound represented by the formula (14) has an
ester group as a substituent, this compound is hydrolyzed by
reacting with an appropriate base in an aqueous solvent to thereby
give a compound of the formula (16) having a carboxyl group.
[0333] In the above reaction, it is also possible to synthesize the
compound of the formula (14) by using a protecting group of the
functional group commonly employed in organic synthesis, then
purifying the product by an appropriate operation commonly employed
in the art such as silica gel column chromatography and then
deblocking the same.
[0334] Step XXIV
[0335] When the compound represented by the formula (14) has a
carboxyl group or an ester group as a substituent, the ester of the
formula (14) may be treated with a reducing agent such as aluminum
lithium hydride in a dry solvent such as tetrahydrofuran, diethyl
ether or dimethoxyethane at 0.degree. C. to room temperature to
thereby give a compound having a terminal alcohol group represented
by the formula (15).
[0336] Production process 3-1: 99
[0337] wherein R.sup.13a and the rings A.sup.2 and B are each as
defined above; R.sup.c represents lower alkyl or a carboxy
protecting group; R.sup.d and R.sup.e may be the same or different
and each represents lower alkyl; and T represents optionally
substituted lower alkylene, optionally substituted lower
alkenylene, optionally substituted lower alkynylene or optionally
substituted arylene.
[0338] In the definition of T, the optionally substituted lower
alkylene, optionally substituted lower alkenylene and optionally
substituted lower alkynylene have each the same meaning as the one
as will be defined below. On the other hand, the optionally
substituted arylene means a divalent aromatic ring group optionally
having substituent(s). Particular examples thereof include
o-phenylene, m-phenylene, p-phenylene, methylphenylene and
naphthylene groups.
[0339] Step XII
[0340] A compound of the formula (17), which is a commercially
available product or one obtained in accordance with, for example,
the method described in Bull. Soc. Chim. Fr., 2981 (1989), is
subjected to the Mannich reaction described in J.A.C.S., 84, 3139
(1962); Chem. Pharm. Bull., 11 (3), 333 (1963), etc. with an
appropriate amine and an appropriate aldehyde in a solvent to
thereby give a compound represented by the formula (18). As the
solvent, use can be made of ethanol, methanol, acetic acid, etc.
The reaction is effected preferably at from 25.degree. C. to the
reflux temperature.
[0341] Step XIII
[0342] The compound represented by the formula (18) is reacted with
an appropriate Wittig-Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (19). As the solvent, use can be made of
dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, etc. The reaction can be
effected at from -100.degree. C. to the boiling point of the
solvent.
[0343] Step XIV
[0344] The compound represented by the formula (19) is reduced with
the use of an appropriate metal or an appropriate metal catalyst in
a solvent to thereby give a compound represented by the formula
(20). The compound of the formula (20) can be obtained by, for
example, using a catalyst such as palladium in a solvent such as
methanol, ethanol or ethyl acetate under normal to elevated
hydrogen pressure, or treating the compound (19) with magnesium in
a solvent such as methanol.
[0345] Step XV
[0346] Compounds represented by the formula (20), (24), etc. are
reacted with a base such as lithium diisopropylamide in a dry
solvent such as diethyl ether or tetrahydrofuran and then reacted
with an alkyl halide to thereby give compounds represented by the
formula (21), (25), etc. respectively. The reaction temperature
preferably ranges from -100 to 25.degree. C.
[0347] Step XVI
[0348] The compound represented by the formula (18) is treated with
a cyanidation reagent such as tosylmethyl isocyanide (TosMic) in a
mixture of a solvent such as dimethoxyethane, tetrahydrofuran or
diethyl ether with an alcoholic solvent such as tert-butanol in the
presence of a base such as potassium tert-butoxide to thereby give
a cyano compound represented by the formula (22). It is preferable
to effect this reaction at a temperature of 0 to 100.degree. C.
[0349] Step XVII
[0350] The cyano compound of the formula (22), etc. is treated with
a base such as sodium hydroxide or potassium hydroxide in an
alcoholic solvent such as ethanol, propanol, ethylene glycol or
diethylene glycol and heated under reflux to thereby give a
carboxylic acid represented by the formula (23), etc.
[0351] Step XVIII
[0352] The compound of the formula (23), etc. is treated with an
activator such as thionyl chloride in an alcoholic solvent such as
methanol or ethanol to thereby give an ester of the formula (24),
etc. The reaction temperature preferably ranges from 0.degree. C.
to room temperature.
[0353] Step XIX
[0354] A dihalomethane such as dibromomethane or diiodomethane is
treated successively with a lithium amide such as lithium
2,2,6,6-tetramethylpipe- ridine and the ester of the formula (24),
etc. After further treating with a base, the obtained product is
hydrolyzed to thereby give an ester represented by the formula
(26), etc. As a solvent, it is preferable to use tetrahydrofuran,
diethyl ether, etc. The reaction temperature ranges from
-90.degree. C. to room temperature.
[0355] Step XXI
[0356] An alcohol represented by the formula (33) is treated with a
base such as sodium hydride or sodium methoxide and then reacted
with a halogenated acetate such as an alkyl iodoacetate such as
ethyl iodoacetate to thereby give an ether represented by the
formula (34). When a phenol derivative is employed as an alkylating
agent, an ether represented by the formula (34) can be obtained by
the so-called Mitsunobu reaction with the use of a condensing agent
such as diethyl azadicarboxylate and triphenylphosphine.
[0357] Production process 3-2: 100
[0358] wherein the rings A.sup.2 and B, R.sup.13a, R.sup.c, R.sup.d
and R.sup.e are each as defined above.
[0359] Step XX
[0360] An ester such as methyl acetate or ethyl acetate is treated
with a base such as lithium diisopropylamide and reacted with a
ketone represented by the formula (18). Thus a
.beta.-hydroxyacetate represented by the formula (27) can be
obtained. As the solvent, it is appropriate to use diethyl ether,
tetrahydrofuran, etc. The reaction temperature ranges from
-78.degree. C. to room temperature.
[0361] Step XXI
[0362] The alcohol represented by the formula (27) is treated with
a base such as sodium hydride or sodium methoxide and then reacted
with an alkyl halide such as methyl iodide or ethyl iodide in a
solvent such as dimethoxyethane, tetrahydrofuran or
N,N-dimethylformamide to thereby give an ether represented by the
formula (28). When a phenol derivative is employed as an alkylating
agent, an ether represented by the formula (28) can be obtained by
the so-called Mitsunobu reaction with the use of a condensing agent
such as diethyl azadicarboxylate and triphenylphosphine.
[0363] Step XXII
[0364] (Methoxymethyl)trimethylsilane, methoxymethyl
dimethylphosphonate, etc. is treated with a strong base such as
butyllithium in a dry solvent such as tetrahydrofuran,
dimethoxyethane or diethyl ether to thereby give an enol ether.
Next, this product is hydrolyzed with an acid such as hydrochloric
acid, sulfuric acid or acetic acid in an alcoholic solvent such as
methanol or ethanol to thereby give an aldehyde having one more
carbon atom as represented by the formula (29), etc.
[0365] Step XXIII
[0366] A dithiane such as 2-trimethyl-1,3-dithiane is reacted with
a strong base such as butyllithium and the anion thus obtained is
reacted with the aldehyde represented by the formula (29). The
crude dithiane thus obtained is then treated with a metal salt such
as mercury chloride to thereby give an ester represented by the
formula (32).
[0367] Step XIII
[0368] The compound represented by the formula (29) is reacted with
an appropriate Wittig-Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (30). As the solvent, use can be made of
dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, etc. The reaction can be
effected at from -10.degree. C. to the boiling point of the
solvent.
[0369] Step XIV
[0370] The compound represented by the formula (30) is reduced with
the use of an appropriate metal or an appropriate metal catalyst in
a solvent to thereby give a compound represented by the formula
(31). The compound of the formula (31) can be obtained by, for
example, using a catalyst such as palladium in a solvent such as
methanol, ethanol or ethyl acetate under normal to elevated
hydrogen pressure, or treating the compound (30) with magnesium in
a solvent such as methanol.
[0371] Production process 4: 101
[0372] wherein the rings A.sup.2 and B, R.sup.13a, R.sup.c and
R.sup.d are each as defined above; R.sup.13b represents lower alkyl
or an amino protective group; and Ac represents acetyl.
[0373] Step XXV
[0374] An amine represented by the formula (20) is treated with an
amino protecting group such as vinyl chloroformate optionally in an
appropriate solvent such as 1,2-dichloroethane at 0.degree. C. to
the reflux temperature to thereby give an amine protected with
vinylformate represented by the formula (38). It is preferable that
R.sup.13b is a carbamate-type amino protecting group, still more
preferably vinyloxycarbonyl.
[0375] Step XI
[0376] A compound represented by the formula (38) is reacted with
an appropriate base in an aqueous solvent and then hydrolyzed to
thereby give a compound of the formula (39) having a carboxyl
group.
[0377] Step XXVI
[0378] The carboxylic acid represented by the formula (39) is
reacted with active esterifying agents such as N-hydroxysuccinimide
with N,N-dicyclohexylcarbodiimide or a base such as triethylamine
with ethyl chloroformate to thereby give an active acid anhydride.
This is then treated with an appropriate reducing agent such as
sodium borohydride to thereby give an alcohol represented by the
formula (37).
[0379] Step XXIV
[0380] Similarly to the above-mentioned procedure, the ester
represented by the formula (20) is treated with a reducing agent
such as aluminum lithium hydride in a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane to thereby give
an alcohol represented by the formula (33).
[0381] Step XXVII
[0382] The alcohol represented by the formula (33) is treated with
acetic anhydride or acetyl chloride in an appropriate solvent in
the presence of pyridine as a base to thereby give an ester
represented by the formula (35).
[0383] Step XXV
[0384] Similarly to the above-mentioned procedure, the amine
compound represented by the formula (35) is treated with an amino
protecting group such as vinyl chloroformate optionally in an
appropriate solvent such as 1,2-dichloroethane at 0.degree. C. to
the reflux temperature to thereby give an amine protected by
vinylformate represented by the formula (36). R.sup.13b is
preferably a carbamate-type protecting group, though it is not
restricted to such.
[0385] Step XI
[0386] Similarly to the above-mentioned procedure, the compound
represented by the formula (36) is reacted with an appropriate base
in an aqueous solvent and then hydrolyzed to thereby give a
compound of the formula (37) having a hydroxyl group.
[0387] Step XXVIII
[0388] The alcohol represented by the formula (37) is reacted with
an activating reagent such as methanesulfonyl chloride or
p-toluenesulfonyl chloride in the presence of an appropriate base
such as pyridine. Next, it is treated with a cyaniding agent such
as sodium cyanide or potassium cyanide in an aprotic polar solvent
such as dimethyl sulfoxide to thereby give a cyano compound
represented by the formula (40). This reaction can be effected from
room temperature to the boiling point of the solvent.
[0389] Step XVII
[0390] Similarly to the above-mentioned procedure, the cyano
compound of the formula (40) is treated with a base such as sodium
hydroxide or potassium hydroxide in an alcoholic solvent such as
ethanol, propanol, ethylene glycol or diethylene glycol and heated
under reflux to thereby give a carboxylic acid of the formula
(41).
[0391] Step XVIII
[0392] Similarly to the above-mentioned procedure, the compound of
the formula (41) is treated with an activator such as thionyl
chloride in an alcoholic solvent such as methanol or ethanol to
thereby give an ester of the formula (42). The reaction temperature
preferably ranges from 0.degree. C. to room temperature.
[0393] Step XXIX
[0394] A solution of the alcohol represented by the formula (37)
in, for example, methylene chloride is added to a reaction mixture
obtained from oxalyl chloride and dimethyl sulfoxide and treated
with a base such as triethylamine, i.e., the so-called Swern
oxidation. Thus, an aldehyde represented by the formula (43) can be
obtained.
[0395] Step XIII
[0396] The compound represented by the formula (43) is reacted with
an appropriate Wittig-Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (44). As the solvent, use can be made of
dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyl lithium, etc. The reaction can be
effected at from -10.degree. C. to the boiling point of the
solvent.
[0397] Step IX
[0398] The compound represented by the formula (44) is treated with
an appropriate solvent containing hydrobromic acid and then heated
in an alcoholic solvent to thereby give a compound represented by
the formula (45).
[0399] Step XIV
[0400] Similarly to the above-mentioned procedure, the compound
represented by the formula (45) is reduced by the use of an
appropriate metal or an appropriate metal catalyst in a solvent to
thereby give a compound represented by the formula (46). The
compound of the formula (46) can be obtained by, for example, using
a catalyst such as palladium in a solvent such as methanol, ethanol
or ethyl acetate under normal to elevated hydrogen pressure, or
treating the compound (45) with magnesium in a solvent such as
methanol.
[0401] Production process 5-1: 102
[0402] wherein the rings A.sup.2 and B, R.sup.13a, R.sup.c, R.sup.d
and l are each as defined above; and M represents an optionally
substituted lower alkylene optionally having a heteroatom,
optionally substituted lower alkenylene optionally having a
heteroatom, optionally substituted lower alkynylene optionally
having a heteroatom or optionally substituted arylene optionally
having a heteroatom.
[0403] In the definition of M, the optionally substituted lower
alkylene optionally having a heteroatom, the optionally substituted
lower alkenylene optionally having a heteroatom and the optionally
substituted lower alkynylene optionally having a heteroatom have
each the same meaning as the one defined above, while the
optionally substituted arylene optionally having a heteroatom means
an optionally substituted divalent aromatic ring group optionally
having a heteroatom. Particular examples of the divalent aromatic
ring group include o-phenylene, m-phenylene, p-phenylene,
methylphenylene and naphthylene groups.
[0404] Step XXX
[0405] A ketone represented by the formula (47) is reacted with a
thioalcohol such as ethanedithiol in the presence of a boron
trifluoride complex in a solvent such as dichloromethane to thereby
give a thioketal represented by the formula (48).
[0406] Step XXXI
[0407] The thioketal represented by the formula (48) is treated
with a reducing reagent such as Raney nickel to thereby give a
compound represented by the formula (49). As a solvent, use can be
made of ethanol, methanol etc. The reaction is preferably effected
at the reflux temperature of the solvent.
[0408] Step XIX
[0409] Similarly to the above-mentioned procedure, a dihalomethane
such as dibromomethane or diiodomethane is treated successively
with a lithium amide such as lithium 2,2,6,6-tetramethylpiperidine
and the ester of the formula (49). After further treating with
base, the obtained product is hydrolyzed with an acid to thereby
give an ester represented by the formula (50). As a solvent, it is
preferable to use tetrahydrofuran, diethyl ether, etc. The reaction
temperature ranges from -90.degree. C. to room temperature.
[0410] Production process 5-2: 103
[0411] wherein the rings A.sup.2 and B, R.sup.13a, R.sup.13b,
R.sup.c and n are each as defined above.
[0412] Step XXXII
[0413] Methyltriphenylphosphonium bromide is treated with an
appropriate base such as potassium tert-butoxide or butyllithium in
a solvent such as toluene, xylene or tetrahydrofuran. Next, ketones
represented by the formulae (18) and (54) are reacted therewith to
thereby give compounds represented by the formulae (51) and (55).
The reaction temperature preferably ranges from -78.degree. C. to
room temperature.
[0414] Step IX
[0415] Similarly to the above-mentioned procedure, the compound
represented by the formula (51) is reacted with an acid chloride
such as 1-chloroethyl chloroformate or vinyl chloroformate
optionally in a solvent. Next, an appropriate alcoholic solvent is
added thereto and reacted therewith. Alternatively, it is treated
with an appropriate solvent containing hydrochloric acid or
hydrobromic acid and then heated in an alcoholic solvent.
Alternatively, it is subjected to a reduction reaction in a solvent
such as methanol/ethanol/tetrahydrofuran/ethyl acetate by using a
metal catalyst under normal to elevated hydrogen pressure. Thus, a
compound represented by the formula (52) can be obtained.
[0416] Step XXXIII
[0417] The compound represented by the formula (52) is reacted
with, for example, di-tert-butyl dicarbonate as an amino protecting
group preferably at 0.degree. C. to room temperature in the
presence of a base such as pyridine, diisopropylethylamine or
triethylamine in an appropriate solvent such as methanol to thereby
give a compound represented by the formula (53). R.sup.13b may be
arbitrary, so long as it is a lower alkyl or an amino protecting
group. Preferable examples of the amino protecting group as
R.sup.13b are those which can be converted into carbamate, amide,
sulfonamide, etc. after the introduction of the protecting group.
For example, butoxycarbonyl is preferable therefor.
[0418] Step XXXIV
[0419] The compound represented by the formula (53) is treated with
zinc/copper alloy and trichloroacetyl chloride in a dry solvent
such as diethyl ether, dimethoxyethane or tetrahydrofuran to
thereby give a crude dichlorobutanone compound. Then the crude
product thus obtained is treated with a reducing agent such as
ammonium chloride/zinc in methanol to thereby give a spiroketone
compound represented by the formula (54). The reaction temperature
preferably ranges from 0 to 50.degree. C.
[0420] Step XXXV
[0421] An exo-methylene compound represented by the formula (55) is
treated with an appropriate borane compound such as a
borane/tetrahydrofuran complex in an appropriate solvent such as
dry tetrahydrofuran or dimethoxyethane followed by treatment with
an oxidizing agent such as hydrogen peroxide in an alkaline
solution. Thus, an alcohol compound represented by the formula (56)
can be obtained.
[0422] Step XXIX
[0423] Similarly to the above-mentioned procedure, a solution of
the alcohol represented by the formula (56) in, for example,
methylene chloride is added to a reaction mixture obtained from
oxalyl chloride and dimethyl sulfoxide and treated with a base such
as triethylamine, i.e., the so-called Swern oxidation. Thus, an
aldehyde represented by the formula (57) can be obtained.
[0424] Step XXXVI
[0425] The compound represented by the formula (57) is treated with
bromine preferably at 0.degree. C. to room temperature in an
appropriate alcoholic solvent such as methanol or ethanol in the
presence of an alkaline base such as sodium hydrogencarbonate or
potassium carbonate to thereby give an ester compound represented
by the formula (58).
[0426] Step XIII
[0427] Similarly to the above-mentioned procedure, the compound
represented by the formula (54) is reacted with an appropriate
Wittig-Horner-Emmons reagent in a solvent in the presence of an
appropriate base to thereby give a compound represented by the
formula (59). As the solvent, use can be made of dry solvents such
as N,N-dimethylformamide, tetrahydrofuran or diethyl ether. As the
base, use can be made of sodium hydride, potassium tert-butoxide,
n-butyllithium, etc. The reaction can be effected at -100.degree.
C. to the boiling point of the solvent.
[0428] Step XIV
[0429] Similarly to the above-mentioned procedure, the compound
represented by the formula (59) is reduced by the use of an
appropriate metal or an appropriate metal catalyst in a solvent to
thereby give a compound represented by the formula (60). The
compound of the formula (60) can be obtained by, for example, using
a catalyst such as palladium in a solvent such as methanol, ethanol
or ethyl acetate under normal to elevated hydrogen pressure, or
treating the compound (59) with magnesium in a solvent such as
methanol.
[0430] Production process 5-3: 104
[0431] wherein the rings A.sup.2 and B and R.sup.13a are each as
defined above.
[0432] Step XXI
[0433] A compound represented by the formula (61) is treated with a
base such as sodium hydride or sodium methoxide and then reacted
with a compound of the formula (62) in a solvent such as
dimethoxyethane, tetrahydrofuran or N,N-dimethylformamide to
thereby give a compound represented by the formula (63).
[0434] Step XXXVII
[0435] The compound represented by the formula (63) is treated in
1,2-dichloroethane employed as a solvent successively with
trifluoromethanesulfonic anhydride and a base such as collidine to
thereby give a cyclized product represented by the formula
(64).
[0436] Production process 6: 105
[0437] wherein the rings A.sup.2 and B, R.sup.13a, R.sup.c, Y and m
are each as defined above.
[0438] Step XXXVIII
[0439] A coumarate derivative represented by the formula (65) is
reacted with a compound represented by the formula (66) under
heating preferably at 80 to 150.degree. C. to thereby give cyclized
products represented by the formulae (67) and (67').
[0440] Step XXXIX
[0441] A compound represented by the formula (67) is cyclized by
heating, optionally in an appropriate solvent, to thereby give a
tricyclic compound represented by the formula (68). The compound of
the formula (69) can be synthesized from the compound (67') also
under the same conditions too. The reaction is preferably effected
at 100 to 200.degree. C.
[0442] Step XXXX
[0443] The amide compounds represented by the formulae (68), (71)
and (72) are treated with a thioamidation agent such as a Lawson
reagent in a solvent such as benzene, toluene or xylene to thereby
give crude thioamide compounds. These crude products are treated
with an alkylating agent such as methyl iodide in a solvent such as
tetrahydrofuran, dimethoxyethane or diethyl ether preferably at
room temperature to thereby give reduced compounds represented by
the formulae (70), (73) and (74) respectively.
[0444] Step XIV
[0445] Similar to the above-mentioned procedure, the compounds
represented by the formulae (68) and (69) are reduced by the use of
an appropriate metal or an appropriate metal catalyst in a solvent
to thereby give compounds represented by the formulae (71) and
(72). These products can be obtained by, for example, using a
catalyst such as palladium in a solvent such as methanol, ethanol
or ethyl acetate under normal to elevated hydrogen pressure, or
treating the starting compounds with magnesium in a solvent such as
methanol.
[0446] Production process 7-1 106
[0447] wherein the rings A.sup.2, B and G, R, R.sup.13a, R.sup.13b,
R.sup.c, R.sup.e, Z, E, X and l are each as defined above.
[0448] Step XXXXI
[0449] A compound represented by the formula (20) is treated with
an alkyllithium such as methyllithium or ethyllithium or a Grignard
reagent such as a methylmagnesium halide in a solvent such as dry
tetrahydrofuran, diethyl ether or dimethoxyethane at -78.degree. C.
to the boiling point of the solvent to thereby give an alcohol
represented by the formula (75)
[0450] Step IX
[0451] Similarly to the above-mentioned procedure, a compound
represented by the formula (37) is reacted with an acid chloride
such as 1-chloroethyl chloroformate or vinyl chloroformate
optionally in a solvent. Next, an appropriate solvent is added
thereto and reacted therewith. Alternatively, it is treated with an
appropriate solvent containing hydrochloric acid or hydrobromic
acid and then heated in an alcoholic solvent. Thus, a compound
represented by the formula (78) can be obtained.
[0452] Step XXVI
[0453] Similarly to the above-mentioned procedure, an acid
represented by the formula (16) is reacted with a reducing agent
such as aluminum lithium hydride in a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane to thereby give
an alcohol represented by the formula (84).
[0454] Production process 7-2 107
[0455] wherein the rings A.sup.2 and B, R.sup.13a and R.sup.c are
each as defined above; and R.sup.e' represents lower alkyl.
[0456] Step IX
[0457] Similarly to the above-mentioned procedure, a compound
represented by the formula (20) or (21) is reacted with an acid
chloride such as 1-chloroethyl chloroformate or vinyl chloroformate
optionally in a solvent. Next, an appropriate alcoholic solvent is
added thereto and reacted therewith. Alternatively, it is treated
with an appropriate solvent containing hydrochloric acid or
hydrobromic acid and then heated in an alcoholic solvent. Thus, a
compound represented by the formula (76) can be obtained.
[0458] Step XXIV
[0459] Similarly to the above-mentioned procedure, an ester
represented by the formula (76) is treated with a reducing agent
such as aluminum lithium hydride in a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane at 0.degree. C.
to room temperature to thereby give an alcohol represented by the
formula (77).
[0460] Production process 7-3: 108
[0461] wherein the rings A.sup.2 and B, R.sup.13a and R.sup.13b are
each as defined above; and R.sup.p represents a hydroxy protective
group.
[0462] The term "hydroxy protective group" as used in the
definition of R.sup.p has the same meaning as the one defined
above.
[0463] Step XXIV
[0464] Similarly to the above-mentioned procedure, an aldehyde
represented by the formula (29) is treated with a reducing agent
such as aluminum lithium hydride in a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane at 0.degree. C.
to room temperature to thereby give an alcohol represented by the
formula (79).
[0465] Step XXVII
[0466] Similarly to the above-mentioned procedure, the alcohol
represented by the formula (79) is treated with, for example,
acetic anhydride or acetyl chloride as a hydroxy protective group
in an appropriate solvent in the presence of pyridine as a base to
thereby give an ester represented by the formula (80).
[0467] Step XXV
[0468] Similarly to the above-mentioned procedure, the amine
represented by the formula (80) is treated with an amino protecting
group such as vinyl chloroformate optionally in an appropriate
solvent such as 1,2-dichloroethane at 0.degree. C. to the reflux
temperature to thereby give an amine protected by vinylformate
represented by the formula (81). R.sup.13b is preferably a
carbamate type amino protecting group, in particular,
vinyloxycarbonyl.
[0469] Step XI
[0470] Similarly to the above-mentioned procedure, the compound
represented by the formula (81) is reacted with an appropriate base
in an aqueous solvent and then hydrolyzed to thereby give a
compound of the formula (82) having a hydroxyl group.
[0471] Step IX
[0472] The compound represented by the formula (82) is reacted with
an appropriate solvent containing hydrochloric acid or hydrobromic
acid and then heated in an alcoholic solvent to thereby give a
compound represented by the formula (83),
[0473] Production process 8:
[0474] The compounds of the present invention can be synthesized by
using the above-mentioned methods or combining publicly known
organic synthesis methods. Now, particular methods for synthesizing
preferable compounds will be illustrated. 109
[0475] wherein R.sup.13a and R.sup.c and Hal. are each as defined
above; R.sup.f, R.sup.z and R.sup.h represent substitutents, having
the same meaning as that defined above, of the rings A and B which
are respectively a piperidine ring and a cyclohexyl ring having Qa;
and Za represents a substituent, containing the same meaning as the
one defined above, of the ring G which is a pyrazine ring.
[0476] This compound can be synthesized by combining the
above-mentioned procedures.
[0477] Step XII
[0478] A compound of the formula (17a), which is a commercially
available product or one obtained in accordance with, for example,
the method described in Bull. Soc. Chim. Fr., 2981 (1989), is
subjected to the Mannich reaction described in J.A.C.S., 84, 3139
(1962) and Chem. Pharm. Bull., 11 (3), 333 (1963) with an
appropriate amine and an appropriate aldehyde in a solvent to
thereby give a compound represented by the formula (18a). As the
solvent, use can be made of ethanol, methanol, acetic acid, etc.
The reaction is preferably effected at 25.degree. C. to the reflux
temperature.
[0479] Step XIII
[0480] The compound represented by the formula (18a) is reacted
with an appropriate Wittig-Horner-Emmons reagent in a solvent in
the presence of an appropriate base to thereby give a compound
represented by the formula (19a). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, etc. The reaction can be
effected at -100.degree. C. to the boiling point of the
solvent.
[0481] Step XIV
[0482] The compound represented by the formula (19a) is reduced by
the use of an appropriate metal or an appropriate metal catalyst in
a solvent to thereby give a compound represented by the formula
(20a). The compound of the formula (20a) can be obtained by, for
example, using a catalyst such as palladium in a solvent such as
methanol, ethanol or ethyl acetate under normal to elevated
hydrogen pressure, or treating the compound (19a) with magnesium in
a solvent such as methanol.
[0483] Step XV
[0484] The compound represented by the formula (20a) is reacted
with a base such as lithium diisopropylamide in a dry solvent such
as diethyl ether or tetrahydrofuran and then reacted with an alkyl
halide to thereby give a compound represented by the formula (21a).
The reaction temperature preferably ranges from -100 to 25.degree.
C.
[0485] Step IX
[0486] The compounds represented by the formulae (20a) and (21a)
are treated with an acid chloride such as 1-chloroethyl
chloroformate or vinyl chloroformate optionally in a solvent. Next,
an appropriate solvent such as an alcohol is added thereto and
reacted therewith. Alternatively, it is treated with an appropriate
solvent containing hydrochloric acid or hydrobromic acid and then
heated in an alcoholic solvent. Thus, a compound represented by the
formula (85) can be obtained.
[0487] Step X
[0488] The compound represented by the formula (85) is treated with
the compound represented by the formula (8) obtained by the
production process 1 in a solvent in the presence of an appropriate
base such as anhydrous potassium carbonate or diisopropylamine to
thereby give a compound represented by the formula (86). As the
solvent, it is preferable to use a dry solvent such as dry
N,N-dimethylformamide. The reaction is preferably effected at a
temperature of 25 to 150.degree. C. If necessary, the compound
represented by the formula (86) may be subjected to optical
resolution with the use of a chiral column, etc. to thereby
separate enantiomers from each other.
[0489] Step XI
[0490] The compound represented by the formula (86) is reacted with
an appropriate base in an aqueous solvent and then hydrolyzed to
thereby give a compound of the formula (87).
[0491] In the above reaction, it is also possible to synthesize the
product by using a protecting group of the functional group
commonly employed in organic synthesis, then purifying the product
by an appropriate operation commonly employed in the art such as
silica gel column chromatography and then deblocking the same.
110
[0492] wherein G, Z, E, X.sup.2, I.sup.2 Q and Hal are each as
defined above; and B.sup.1 represents hydroxymethyl, halide,
methoxy, methoxymethyl, lower alkyl or alkoxycarbonyl.
[0493] Step XXXXII
[0494] The compounds represented by the formulae (90) and (92) are
treated with a base such as sodium hydride and then reacted with a
halogen compound of the formula (89) in a solvent such as dry
N,N-dimethylformamide or tetrahydrofuran to thereby give the
compounds of the formulae (91) and (93) respectively. Similarly, a
compound represented by the formula (96) can be obtained from the
compounds (92) and (95).
[0495] Step IV
[0496] The compound of the formula (92) is reacted with a
dihalogenated heteroaryl compound as the one represented by the
formula (89) in a solvent such as dry N,N-dimethylformamide to
thereby give a compound represented by the formula (94).
[0497] Step XXXXIII
[0498] The compound represented by the formula (91) is treated with
a reducing agent such as iron in a solvent mixture of an alcohol,
tetrahydrofuran and water in the presence of ammonium chloride.
Alternatively, it is treated with hydrosulfite sodium in a solvent
mixture of tetrahydrofuran with water. Thus, an amine represented
by the formula (93) can be produced. As the alcohol, use can be
made of methanol, ethanol and isopropanol. In some cases, the
intermediate (93) undergoes ring closure and thus a
tricycloheteroaryl derivative represented by the formula (94) can
be directly obtained.
[0499] Step XXXXIV
[0500] The amine represented by the formula (93) is heated in an
appropriate solvent to thereby give a tricycloheteroaryl derivative
represented by the formula (94). As the solvent, use can be made of
alcohols such as methanol or ethanol, dry N,N-dimethylformamide,
etc. It is also possible to use an acid such as hydrochloric acid,
acetic acid or p-toluenesulfonic acid as a catalyst. The reaction
is effected preferably at 50.degree. C. to the reflux
temperature.
[0501] Step XXXXV
[0502] The compound represented by the formula (96) is heated in an
appropriate solvent in the presence of an oxidizing agent and an
acid. Alternatively, it is reacted with a base in an appropriate
solvent in the presence of an oxidizing agent. Thus a
tricycloheteroaryl derivative represented by the formula (94) can
be obtained. As the oxidizing agent, use can be made of iodine,
sulfur, etc. As the acid, use can be made of acetic acid, etc. As
the base, use can be made of sodium hydride. As the solvent, use
can be made of diphenyl ether, dry N,N-dimethylformamide, etc. The
reaction can be carried out at 0 to 200.degree. C. 111
[0503] wherein G, Z, E, X.sup.2, I.sup.2, Q and B.sup.1 are each as
defined above; and .alpha. is 0 or 1.
[0504] Step XXXXII
[0505] The compound represented by the formula (92) is treated with
a base such as sodium hydride and then reacted with a halogen
compound (97) in a solvent such as dry N,N-dimethylformamide or
tetrahydrofuran to thereby give a compound represented by the
formula (98).
[0506] Step XXXXVII
[0507] When .alpha. is 1, the amine represented by the formula (98)
is reacted with a carboxylic anhydride, phosphoric anhydride and an
acid halide optionally in an appropriate solvent in the presence of
an appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to. thereby give an amide represented by
the formula (99). As the solvent, use can be made of dry
dichloromethane, etc. The reaction can be carried out at 0.degree.
C. to the reflux temperature.
[0508] Step XXXXV
[0509] The compound represented by the formula (99) is heated in an
appropriate solvent in the presence of an oxidizing agent and an
acid. Alternatively, it is reacted with a base in an appropriate
solvent in the presence of an oxidizing agent. Thus a
tricycloheteroaryl derivative represented by the formula (100) can
be obtained. As the oxidizing agent, use can be made of iodine,
sulfur, etc. As the acid, use can be made of acetic acid, etc. As
the base, use can be made of sodium hydride. As the solvent, use
can be made of diphenyl ether, dry N,N-dimethylformamide, etc. The
reaction can be carried out at 0 to 200.degree. C. 112
[0510] wherein G, Z, E, X.sup.2, I.sup.2, Q, R, R' and R.sup.a are
each as defined above.
[0511] Step VII
[0512] An amine represented by the formula (101) is treated with a
base such as sodium hydride and a protective reagent such as
methoxymethyl chloride in a solvent to thereby give a compound
represented by the formula (105).
[0513] Step V
[0514] The compound represented by the formula (101) or (105) is
treated with a reducing agent such as diisobutylaluminum hydride or
aluminum lithium hydride in a solvent to thereby give a compound
represented by the formula (102) or (106). As the solvent, use can
be made of dry tetrahydrofuran, dry diethyl ether, etc. The
reaction is preferably effected at a temperature of -50.degree. C.
to the reflux temperature.
[0515] Step VI
[0516] The compound represented by the formula (102) or (106) is
treated with a halogenating agent such as methanesulfonyl chloride
in a solvent such as dry N,N-dimethylformamide in the presence of
an appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give a compound represented by
the formula (103) or (107).
[0517] Step XXIX
[0518] Similar to the above-mentioned procedure, a solution of the
compound represented by the formula (102) or (106) in, for example,
methylene chloride is added to a reaction mixture obtained from
oxalyl chloride and dimethyl sulfoxide and treated with a base such
as triethylamine. Alternatively, it is treated with pyridinium
dichromate in a solvent such as dichloromethane or
N,N-dimethylformamide or treated with manganese dioxide in a
solvent such as dichloromethane. Thus, an aldehyde represented by
the formula (104) or (108) can be obtained. 113
[0519] wherein the rings A.sup.1 and A.sup.3, G, Z, E, X.sup.1,
I.sup.1, M, R, R', R.sup.13a and Hal are each as defined above.
[0520] Step IX
[0521] A compound represented by the (110) or (117) is treated in
the following manner. 1) When R.sup.13a is alkyl, etc., the
starting compound is reacted with an acid chloride such as
1-chloroethyl chloroformate or vinyl chloroformate optionally in a
solvent. Next, an appropriate alcoholic solvent is added thereto
and reacted therewith. Alternatively, it is treated with an
appropriate solvent containing hydrochloric acid or hydrobromic
acid and then heated in an alcoholic solvent. 2) When R.sup.13a is
tert-butoxycarbonyl, etc., the starting compound is reacted with an
appropriate acid such as acetic acid, trifluoroacetic acid or
hydrochloric acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran. 3) When R.sup.13a is a
protective group which can be eliminated, such as benzyl, the
starting compound is hydrogenated in an appropriate solvent such as
methanol, ethanol, ethyl acetate or tetrahydrofuran by using a
metal catalyst such as palladium or platinum (IV) oxide under
normal to elevated hydrogen pressure. Thus, a compound represented
by the formula (111) or (118) can be obtained.
[0522] Step X
[0523] The compound represented by the formula (111) or (118) is
treated with a halide represented by the formula (112) in a solvent
in the presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylethylamine to thereby give a compound
represented by the formula (113) or (119). As the solvent, use can
be made of N,N-dimethylformamide, etc. The reaction can be effected
at a temperature of 0 to 150.degree. C.
[0524] Step VIII
[0525] When R in the compounds represented by the formulae (113),
(116), (119) and (122) is methoxymethyl, these compounds are
treated with an appropriate acid such as acetic acid,
trifluoroacetic acid or hydrochloric acid optionally in a solvent
such as dichloromethane or tetrahydrofuran/water to thereby give
compounds represented by the formulae (114), (115), (120) and
(121). The reaction can be effected at 0.degree. C. to the reflux
temperature ofthe solvent.
[0526] Step XI
[0527] When the compounds represented by the formulae. (113),
(114), (119) and (120) have an ester group in the molecule, these
compounds are treated with an appropriate base in an aqueous
solvent to thereby give compounds represented by the formulae
(116), (115), (122) and (121) respectively. As the solvent, use can
be made of alcoholic solvents such as methanol or ethanol or
solvent mixtures such as alcohol/tetrahydrofuran/water. As the
base, use can be made of sodium hydroxide or potassium hydroxide.
The reaction can be carried out at room temperature to the reflux
temperature of the solvent. 114
[0528] wherein the ring A.sup.3, M and R.sup.13a are each as
defined above; R.sup.j represents hydrogen, fluorine or optionally
substituted lower alkyl; EWG represents ester, nitrile, optionally
substituted phenyl, etc.; A.sup.7 represents: 1) the same group as
A.sup.3; or 2) a bicyclic ring AB wherein the bridgehead carbon
atoms are directly bonded to each other; R.sup.s represents
optionally substituted C.sub.0-6 alkylene; and R.sup.t represents
hydrogen or lower alkyl, or, in some cases, neither R.sup.s nor
R.sup.t exists and the carbon atom in the side chain to which
R.sup.s and R.sup.t are bonded in the formula is one of the members
of the ring A.sup.7.
[0529] Step XIII
[0530] The compound represented by the formula (124) is reacted
with an appropriate Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (125). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, lithium diisopropylamide,
etc. The reaction can be effected at -100.degree. C. to the reflux
temperature of the solvent.
[0531] Step XIV
[0532] The compound represented by the formula (125) is subjected
to a reduction reaction in a solvent with the use of an appropriate
metal catalyst to thereby give a compound represented by the
formula (126). The reaction can be effected in a solvent such as
methanol, ethanol, ethyl acetate or tetrahydrofuran with the use of
palladium, platinum (IV) oxide, etc. under normal to elevated
hydrogen pressure. 115
[0533] wherein M, R.sup.13a, A.sup.3, R.sup.5 and R.sup.t are each
as defined above.
[0534] Step XXIV
[0535] A compound represented by the formula (127) or (129) is
treated with a reducing agent such as aluminum lithium hydride in a
solvent to thereby give a compound represented by the formula (128)
or (130). As the solvent, use can be made of dry solvents such as
tetrahydrofuran, diethyl ether or dimethoxyethane. The reaction can
be effected at -50.degree. C. to the reflux temperature. 116
[0536] wherein G, Z, E, X.sup.1, l.sup.1, R' and Hal are each as
defined above.
[0537] Step X
[0538] A compound represented by the formula (131) is treated with
an appropriately protected 3-aminomethylpyridine derivative in a
solvent in the presence of an appropriate base such as anhydrous
potassium carbonate or N,N-diisopropylamine to thereby give a
compound represented by the formula (132). As the solvent, use can
be made of ethanol, dry N,N-dimethylformamide, etc. The reaction
can be effected at a temperature of 0 to 150.degree. C.
[0539] Step XXIV
[0540] The compound represented by the formula (132) is treated
with a reducing agent such as aluminum lithium hydride in a solvent
to thereby give a compound represented by the formula (133). As the
solvent, use can be made of methanol, ethanol, etc. The reaction
can be effected at 0.degree. C. to the reflux temperature.
[0541] Step XXIV
[0542] The compound represented by the formula (133) is treated
with a reducing agent such as aluminum lithium hydride in a solvent
to thereby give a compound represented by the formula (134). As the
solvent, it is preferable to use isopropyl alcohol. It is
preferable to effect the reaction at 50.degree. C. to the reflux
temperature.
[0543] Step VIII
[0544] The compound represented by the formula (134) is treated
with an appropriate acid such as acetic acid, trifluoroacetic acid
or hydrochloric acid optionally in a solvent such as,
dichloromethane or tetrahydrofuran/water to thereby give a compound
represented by the formula (135). Although the reaction can be
effected at 0.degree. C. to the reflux temperature of the solvent,
it is carried out in acetic acid at 80.degree. C. in the most
desirable case.
[0545] Step XXXXVII
[0546] The amine represented by the formula (135) is reacted with
methanesulfonic anhydride or the acid halide optionally in an
appropriate solvent such as dichloromethane In the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylamine to thereby give a compound represented by the
formula (136). 117
[0547] wherein G, Z, E, X.sup.1, l.sup.1, M, R.sup.13a R.sup.13b,
A.sup.3 and Hal are each as defined above.
[0548] Step XXXIII
[0549] A compound represented by the formula (137) is reacted with,
for example, di-tert-butyl dicarbonate as an amino protective group
preferably at 0.degree. C. to room temperature in the presence of a
base such as pyridine, triethylamine or N,N-diisopropylethylamine
in an appropriate solvent such as methanol or dichloromethane to
thereby give a compound represented by the formula (138). R.sup.13b
may be an arbitrary one, so long as it is lower alkyl or an amino
protective group. The most desirable example of R.sup.13b is an
alkyl carbamate.
[0550] Step IX
[0551] The compound represented by the (138) is treated in the
following manner 1) When R.sup.13a is alkyl, etc., the starting
compound is reacted with an acid chloride such as 1-chloroethyl
chloroformate or vinyl chloroformate optionally in a solvent. Next,
an appropriate alcoholic solvent is added thereto and reacted
therewith. Alternatively, it is treated with an appropriate solvent
containing hydrochloric acid or hydrobromic acid and then heated in
an alcoholic solvent. 2) When R.sup.13a is tert-butoxycarbonyl,
etc., the starting compound is reacted with an appropriate acid
such as acetic acid, trifluoroacetic acid or hydrochloric acid
optionally in an appropriate solvent such as dichloromethane or
tetrahydrofuran. 3) When R.sup.13a is a protective group which can
be eliminated, such as benzyl, the starting compound is
hydrogenated in an appropriate solvent such as methanol, ethanol,
ethyl acetate or tetrahydrofuran by using a metal catalyst such as
palladium or platinum (IV) oxide under normal to elevated hydrogen
pressure. Thus, a compound represented by the formula (139) can be
obtained.
[0552] Step X
[0553] The compound represented by the formula (139) is treated
with a halide represented by the formula (140) in a solvent in the
presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylamine to thereby give a compound
represented by the formula (141). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction can be effected at
a temperature of 50 to 150.degree. C.
[0554] Step IX
[0555] The compound represented by the formula (141) is treated in
the following manner. 1) When R.sup.13b is alkyl, etc., the
starting compound is reacted with an acid chloride such as
1-chloroethyl chloroformate or vinyl chloroformate optionally in a
solvent. Next, an appropriate alcoholic solvent is added thereto
and reacted therewith. Alternatively, it is treated with an
appropriate solvent containing hydrochloric acid or hydrobromic
acid and then heated in an alcoholic solvent. 2) When R.sup.13a is
tert-butoxycarbonyl, etc., the starting compound is reacted with an
appropriate acid such as acetic acid, trifluoroacetic acid or
hydrochloric acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran. 3) When R.sup.13a is a
protective group which can be eliminated, such as benzyl, the
starting compound is hydrogenated in an appropriate solvent such as
methanol, ethanol, ethyl acetate or tetrahydrofuran by using a
metal catalyst such as palladium or platinum (IV) oxide under
normal to elevated hydrogen pressure. Thus, a compound represented
by the formula (142) can be obtained. 118
[0556] wherein R.sup.13a, A.sup.3 and M are each as defined above;
L.sup.1 represents optionally substituted lower alkyl,
trifluoromethyl, optionally substituted aryl or optionally
substituted heteroaryl; R.sup.k and R.sup.1 may be the same or
different and each represents hydrogen or optionally substituted
lower C.sub.1-10 alkyl optionally having a heteroatom ; R.sup.j
represents hydrogen, lower alkyl, amino or protected carboxy; and
V.sup.1 represents nitrile or methanesulfonyl.
[0557] Step XXXXVI
[0558] An amine represented by the formula (137) is reacted with a
carboxylic anhydride, a carboxylic phosphoric anhydride or an acid
halide optionally in an appropriate solvent in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give an amide represented by
the formula (146). As the solvent, use can be made of dry
dichloromethane, etc. The reaction can be carried out at 0.degree.
C. to the reflux temperature.
[0559] Step XXXXVII
[0560] The amine represented by the formula (137) is reacted with
methanesulfonic anhydride or an acid halide optionally in an
appropriate solvent such as dichloromethane in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-duisopropylamine to thereby give a compound represented by the
formula (145).
[0561] Step XXXXVIII
[0562] The amine represented by the formula (137) is treated with
an appropriate sulfamic acid halide optionally in an appropriate
solvent such as dichloromethane in the presence of an appropriate
base such as pyridine, triethylamine or N,N-diisopropyl-ethylamine.
Alternatively, it is treated with an activated sulfamic acid ester
under reflux in a solvent such as 1,4-dioxane. Alternatively, it is
reacted with sulfamide in dimethoxyethane at 100.degree. C. Thus,
the compound represented by the formula (144) can be obtained.
[0563] Step XXXXIX
[0564] The amine represented by the formula (137) is reacted with
an appropriate imidate or thioimidate in a solvent such as
acetonitrile or methanol to thereby give a compound represented by
the formula (143). It is preferable that the reaction is carried
out at 0 to 40.degree. C. 119
[0565] wherein M, R.sup.13a, A.sup.3 and R.sup.4 are each as
defined above.
[0566] Step L
[0567] A compound represented by the formula (137) is treated with
ethyl isocyanatoacetate in an appropriate solvent to thereby give a
compound represented by the formula (148). As the solvent, use can
be made of tetrahydrofuran, etc. The reaction can be effected at
room temperature to the reflux temperature of the solvent. 120
[0568] wherein M, T, L.sup.1, R.sup.13a, A.sup.3 and R.sup.a are
each as defined above.
[0569] Step XXXXVI
[0570] An amine represented by the formula (149) is reacted with an
activated ester such as a carboxylic anhydride, a carboxylic
phosphoric anhydride or an acid halide optionally in an appropriate
solvent in the presence of an appropriate base such as pyridine,
triethylamine or N,N-diisopropylethylamine to thereby give an amide
represented by the formula (150). As the solvent, use can be made
of dry dichloromethane, etc. The reaction can be carried out at
0.degree. C. to the reflux temperature.
[0571] Step XXI
[0572] The compound represented by the formula (149) is treated
with an appropriate alkyl halide having a carboxyl group or an
ester group in the presence of an appropriate base such as
pyridine, triethylamine or N,N-diisopropylamine in a solvent such
as dichloromethane, tetrahydrofuran or N,N-dimetyl formamide to
thereby give an amine compound represented by the formula
(151).
[0573] Step XXXXVII
[0574] The amine represented by the formula (149) is reacted with
an appropriate sulfonic anhydride or an acid halide optionally in
an appropriate solvent such as dichloromethane in the presence of
an appropriate base such as pyridine, triethylamine or
N,N-diisopropylamine to thereby give a compound represented by the
formula (152). 121
[0575] wherein T, L.sup.1, R.sup.13a, A.sup.3, V.sup.1, R.sup.j and
R.sup.a are each as defined above.
[0576] Step XXXXVI
[0577] An amine represented by the formula (153) is reacted with a
carboxylic anhydride, a carboxylic phosphoric anhydride or an acid
halide optionally in an appropriate solvent in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give an amide represented by
the formula (154). As the solvent, use can be made of dry
dichloromethane, etc. The reaction can be carried out at 0.degree.
C. to the reflux temperature.
[0578] Step XXI
[0579] The compound represented by the formula (153) is treated
with an appropriate alkyl halide having a carboxyl group or an
ester group in the presence of an appropriate base such as
pyridine, triethylamine or N,N-diisopropylamine in a solvent such
as dichloromethane, tetrahydrofuran or N,N-dimetylformamide to
thereby give an amine compound represented by the formula
(155).
[0580] Step XXXXVII
[0581] The amine represented by the formula (153) is reacted with
an appropriate sulfonic anhydride or an acid halide optionally in
an appropriate solvent such as dichloromethane in the presence of
an appropriate base such as pyridine, triethylamine or
N,N-diisopropylamine to thereby give a compound represented by the
formula (156).
[0582] Step XXXXIX
[0583] The amine represented by the formula (153) is reacted with
an appropriate imidate or thioimidate in a solvent such as
acetonitrile or methanol to thereby give a compound represented by
the formula (157). It is preferable that the reaction is carried
out at 0 to 40.degree. C. 122
[0584] wherein G, Z, E, X.sup.1, l.sup.1, M, R.sup.13a, A.sup.3 and
Hal are each as defined above.
[0585] Step XXXXVII
[0586] An amine represented by the formula (137) is reacted with an
appropriate sulfonic acid halide derivative in an appropriate dry
solvent such as dichloromethane or diethyl ether to thereby give a
compound represented by the formula (158). The reaction is effected
preferably at 0.degree. C. to room temperature.
[0587] Step IX
[0588] The compound represented by the formula (158) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (159). For example, the reaction may be effected in a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium or platinum (IV) oxide as a catalyst
under normal to elevated hydrogen pressure.
[0589] Step X
[0590] The compound represented by the formula (159) is treated
with a halide represented by the formula (133) in a solvent in the
presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylamine to thereby give a compound
represented by the formula (160). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction can be effected at
a temperature of 50 to 150.degree. C.
[0591] Step LI
[0592] The compound represented by the formula (160) is treated
with a reagent such as tetra-n-butylammonium fluoride or caesium
fluoride in a dry solvent such as tetrahydrofuran to thereby give a
carboxylic acid represented by the formula (161). The reaction is
effected preferably at 0.degree. C. to room temperature. 123
[0593] wherein M, T, R.sup.13a, A.sup.3 and R.sup.a are each as
defined above; and Nu represents a nucleophilic atom such as
oxygen, nitrogen or sulfur.
[0594] Step XXI
[0595] A compound represented by the formula (162) is treated with
an appropriate alkyl halide having a carboxyl group or an ester
group either in a solvent such as dichloromethane, tetrahydrofuran
or N,N-dimethylformamide in the presence of an appropriate base
such as pyridine, triethylamine or N,N-diisopropylamine, or after
being treated with a base such as sodium hydride or sodium
methoxide in a solvent such as dimethoxyethane, tetrahydrofuran or
N,N-dimethylformamide to thereby give a derivative represented by
the formula (163). When Nu is oxygen and a phenol derivative is
employed as a substitute for the alkyl halide, an ether represented
by the formula (163) can be obtained by the Mitsunobu reaction with
the use of a condensing agent such as diethyl azadicarboxylate or
triphenylphosphine.
[0596] Step LII
[0597] The compound represented by the formula (162) is reacted
with sodium isocyanate, potassium isocyanate, etc. in a solvent
such as water or ethanol to thereby give a compound represented by
the formula (164). 124
[0598] wherein M, R.sup.13a, A.sup.7, R.sup.s and R.sup.t are each
as defined above.
[0599] Step XXIX
[0600] A solution of a compound represented by the formula (165)
in., for example, methylene chloride is added to a reaction mixture
obtained from oxalyl chloride and dimethyl sulfoxide and treated
with a base such as triethylamine. Alternatively, it is treated
with pyridinium dichromate in a solvent such as dichloromethane or
treated with manganese dioxide in a solvent such as
dichloromethane. Thus, a carbonyl compound represented by the
formula (166) can be obtained.
[0601] Step XXIV
[0602] A compound represented by the formula (171) is treated with
a reducing agent such as diisobutylaluminum hydride, aluminum
lithium hydride or lithium borohydride in a solvent such as dry
tetrahydrofuran or dry diethyl ether, or treated with a reducing
agent such as sodium borohydride in an alcoholic solvent to thereby
give an alcohol represented by the formula (172).
[0603] Step XXXVI
[0604] The compound represented by the formula (169) is treated
with bromine in an appropriate alcoholic solvent such as methanol
or ethanol in the presence of a base such as sodium
hydrogencarbonate or potassium carbonate preferably at 0.degree. C.
to room temperature. Alternatively, the starting compound is
treated with pyridinium chromate in an appropriate alcoholic
solvent such as methanol or ethanol. Alternatively, it is treated
with manganese dioxide in an appropriate alcoholic solvent such as
methanol or ethanol in the presence of sodium cyanide and acetic
acid and then treated with sulfuric acid, hydrochloric acid,
thionyl chloride, etc. in an appropriate alcoholic solvent such as
methanol or ethanol. Alternatively, it is treated with sodium
chlorite in a solvent mixture of water and dimethyl sulfoxide in
the presence of sodium dihydrogenphosphate and then reacted with
trimethylsilyl-diazomethane in a solvent such as methanol.
Alternatively, it is treated with an activating agent such as
thionyl chloride in an appropriate alcoholic solvent such as
methanol or ethanol. Thus, an ester compound represented by the
formula (170) can be obtained.
[0605] Step XXIV
[0606] A compound represented by the formula (167) is treated with
a reducing agent such as diisobutylaluminum hydride, aluminum
lithium hydride or lithium borohydride in a solvent such as dry
tetrahydrofuran or dry diethyl ether to thereby give an alcohol
represented by the formula (168).
[0607] Step XVII
[0608] A cyano compound of the formula (173) is treated with a base
such as sodium hydroxide or potassium hydroxide in an alcoholic
solvent such as ethanol, propanol, ethylene glycol or diethylene
glycol and heated under reflux to thereby give a carboxylic acid of
the formula (174).
[0609] Step XVIII
[0610] The compound of the formula (174) is treated with an
activator such as thionyl chloride in an alcoholic solvent such as
methanol or ethanol to thereby give an ester of the formula (175).
The reaction temperature preferably ranges from 0.degree. C. to
room temperature. 125
[0611] wherein Hal, R.sup.13a, A.sup.3 and R.sup.d are each as
defined above.
[0612] Step X
[0613] A compound represented by the formula (177) is heated with a
amine protecting reagent such as benzyl chloride in a solvent to
thereby give a compound represented by the formula (178). As the
solvent, use can be made of dry N,N-dimethylformamide, acetone,
ethanol, etc. The reaction can be effected at a temperature of
50.degree. C. to the reflux temperature.
[0614] Step XXIV
[0615] The compound represented by the formula (178) is treated
with a reducing agent such as lithium borohydride in a solvent to
thereby give a compound represented by the formula (179). As the
solvent, use can be made of dry N,N-dimethylformamide, acetone,
ethanol, etc. The reaction can be effected at 50.degree. C. to the
reflux temperature.
[0616] Step VIII
[0617] The compound represented by the formula (179) is treated
optionally in an appropriate solvent such as dichloromethane or
tetrahydrofuran/water in the presence of an appropriate acid such
as acetic acid, trifluoroacetic acid or hydrochloric acid to
thereby give a compound represented by the formula (180). The
reaction can be effected at 0.degree. C. to the reflux temperature
of the solvent. 126
[0618] wherein M, R.sup.13a, A.sup.3 and R.sup.a are each as
defined above.
[0619] Step LIII
[0620] A ketone represented by the formula (176) is reacted with an
anion obtained by treating an alkyne with a strong base such as
n-butyllithium or lithium diisopropylamine in a dry solvent such as
tetrahydrofuran or diethyl ether to thereby give a compound
represented by the formula (181). The reaction can be effected at
-100.degree. C. to room temperature.
[0621] Step XIV
[0622] The compound represented by the formula (181) is subjected
to a reduction reaction in a solvent with the use of an appropriate
metal catalyst to thereby give a compound represented by the
formula (182). For example, use can be made of a hydrogenation
reaction effected in a solvent such as methanol, ethanol, ethyl
acetate or tetrahydrofuran with the use of palladium, platinum (IV)
oxide, etc. under normal to elevated hydrogen pressure.
[0623] Step XXXXI
[0624] A compound represented by the formula (147) is treated with
methyllithium or methylmagnesium halide in a solvent such as dry
tetrahydrofuran, diethyl ether or dimethoxyethane at -78.degree. C.
to the boiling point of the solvent to thereby give an alcohol
represented by the formula (183). 127
[0625] wherein M, R.sup.13a, A.sup.3 and R.sup.6 are each as
defined above; and X.sub.n means an alkylene side chain having n
carbon atoms which is directly bonded to the ring when n is 0.
[0626] Step LIV
[0627] A compound of the formula (184) is reacted with dimethyl
malonate in a solvent such as pyridine at room temperature to the
boiling point of the solvent. Then the intermediate thus obtained
is treated with diazomethane in a solvent to thereby give a
compound represented by the formula (185). 128
[0628] wherein M, R.sup.13a, A.sup.3, X.sub.n and R.sup.a are each
as defined above.
[0629] Step LV
[0630] An aldehyde represented by the formula (184) is treated with
carbon tetrabromide and a phosphine such as triphenylphosphine in a
solvent such as dry dichloromethane to thereby give a dibromoalkene
derivative represented by the formula (186).
[0631] Step LV
[0632] The compound represented by the formula (186) is treated
with a strong base such as n-butyllithium in a dry solvent such as
tetrahydrofuran or diethyl ether at -100 to 0.degree. C. Then the
intermediate thus obtained is treated with a reagent such as ethyl
chloroformate or diethyl carbonate to thereby give a compound
represented by the formula (187). 129
[0633] wherein M, R.sup.13a, A.sup.3, X.sub.n and R.sup.a are each
as defined above.
[0634] Step XV
[0635] The compound represented by the formula (188) is reacted
with a strong base such as lithium diisopropylamide in a dry
solvent such as tetrahydrofuran, diethyl ether or
hexamethyl-phosphorous triamide at -100 to 0.degree. C. and then
reacted with a dihalogenated ethane such as dibromoethane to
thereby give a derivative represented by the formula (189).
[0636] Step LVII
[0637] The compound represented by the formula (189) is treated
with potassium tert-butoxide in a dry solvent such as
tetrahydrofuran to thereby give a cyclopropyl derivative
represented by the formula (190). The reaction can be effected at
0.degree. C. to the reflux temperature of the solvent. 130
[0638] wherein M, R.sup.13a, A.sup.3 and R.sup.a are each as
defined above.
[0639] Step LVIII
[0640] A compound represented by the formula (188) is treated with
a strong base such as n-butyllithium or lithium diisopropylamide in
a dry solvent such as tetrahydrofuran, diethyl ether or
hexamethyl-phosphorous triamide at -100 to 0.degree. C. and then
treated with peroxymolybdeum (pyridine) hexamethylphosphorous
triamide to thereby give a compound represented by the formula
(191). 131
[0641] wherein M, R.sup.13a, A.sup.7, R.sup.d, R.sup.k and R.sup.a
are each as defined above.
[0642] Step XV
[0643] A compound represented by the formula (192) is treated with
a strong base such as lithium diisopropylamide in a dry solvent
such as tetrahydrofuran, diethyl ether or hexamethyl-phosphorous
triamide at -100 to 0.degree. C. and then reacted with an
alkylating agent such as methyl iodide to thereby give a derivative
represented by the formula (193).
[0644] Step XXIV
[0645] The compound represented by the formula (193) is treated
with a reducing agent such as diisobutylaluminum hydride, aluminum
lithium hydride or lithium borohydride in a solvent such as dry
tetrahydrofuran or dry diethyl ether to thereby give an alcohol
represented by the formula (194).
[0646] Step XXVIII
[0647] The alcohol represented by the formula (194) is reacted with
methanesulfonyl chloride, p-toluenesulfonyl chloride etc. in the
presence of an appropriate base such as pyridine. Next, it is
treated with a cyanidation agent such as sodium cyanide or
potassium cyanide in an aprotic polar solvent such as dimethyl
sulfoxide or N,N-dimethylformamide to thereby give a cyano compound
represented by the formula (195). This reaction can be effected at
room temperature to the boiling point of the solvent.
[0648] Step IX
[0649] The compound represented by the formula (195) is treated in
the following manner. 1) When R.sup.13a is alkyl, etc., the
starting compound is reacted with an acid chloride such as
1-chloroethyl chloroformate or vinyl chloroformate optionally in a
solvent. Next, an appropriate alcoholic solvent is added thereto
and reacted therewith. Alternatively, it is treated with an
appropriate solvent containing hydrochloric acid or hydrobromic
acid and then heated in an alcoholic solvent. 2) When R.sup.13a is
tert-butoxycarbonyl, etc., the starting compound is reacted with an
appropriate acid such as acetic acid, trifluoroacetic acid or
hydrochloric acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran. 3) When R.sup.13a is a
protective group which can be eliminated, such as benzyl, the
starting compound is hydrogenated in an appropriate solvent such as
methanol, ethanol, ethyl acetate or tetrahydrofuran by using a
metal catalyst such as palladium or platinum (IV) oxide under
normal to elevated hydrogen pressure. Thus, a compound represented
by the formula (196) can be obtained.
[0650] Step XXXIII
[0651] A compound represented by the formula (196) is reacted with,
for example, benzyl chloride as an amino protective group
preferably at 0.degree. C. to room temperature in the presence of a
base such as pyridine, triethylamine or N,N-diisopropyl-ethylamine
in an appropriate solvent such as methanol or dichloromethane to
thereby give a compound represented by the formula (197). R.sup.13b
may be an arbitrary one, so long as it is lower alkyl or an amino
protective group. The most desirable example of R.sup.13b is
benzyl. 132
[0652] wherein M, R.sup.13a, A.sup.3 and R.sup.a are each as
defined above.
[0653] Step LIX
[0654] The compound represented by the formula (198) is reacted
with ethyl vinyl ether preferably at 0.degree. C. to room
temperature without using any solvent in the presence of a mercuric
salt to thereby give an ether represented by the formula (199).
Mercuric trifluoroacetate is the most desirable catalyst.
[0655] Step LX
[0656] The compound represented by the formula (199) is heated in
an appropriate solvent to thereby give an aldehyde represented by
the formula (200). As the solvent, use can be made of benzonitrile,
decalin, nitrobenzene, etc. The reaction can be effected at
100.degree. C. to the reflux temperature.
[0657] Step XXXVI
[0658] The compound represented by the formula (200) is treated
with pyridinium dichromate in an appropriate alcoholic solvent such
as methanol or ethanol to thereby give an ester represented by the
formula (201).
[0659] Step XIV
[0660] The compound represented by the formula (201) is subjected
to a reduction reaction-in a solvent with the use of an appropriate
metal catalyst to thereby give a compound represented by the
formula (202). For example, use can be made of a hydrogenation
reaction effected in a solvent such as methanol, ethanol, ethyl
acetate or tetrahydrofuran with the use of palladium, platinum (IV)
oxide, etc. under nor 133
[0661] wherein M, R.sup.13a, A.sup.3, R.sup.d and R.sup.a are each
as defined above; and B.sup.2 represents hydrogen, lower alkyl,
lower alkoxy or halide.
[0662] Step LXI
[0663] A compound represented by the formula (176) is subjected in
an appropriate solvent to a halogen-metal exchange reaction or
reacted with an aryl-Grignard or aryllithium obtained by a
lithiation reaction to thereby give a compound represented by the
formula (203). As the solvent, use can be made of a dry solvent
such as tetrahydrofuran, diethyl ether or dimethoxyethane. The
reaction can be effected at -1000 C to the reflux temperature of
the solvent.
[0664] Step VIII
[0665] The compound represented by the formula (203) is treated
optionally in an appropriate solvent such as dichloromethane or
tetrahydrofuran/water with an appropriate acid such as acetic acid,
trifluoroacetic acid or hydrochloric acid to thereby give a
compound represented by the formula (204). The reaction can be
effected at 0.degree. C. to the reflux temperature of the
solvent.
[0666] Step XXIII
[0667] The aldehyde represented by the formula (204) is reacted
with an anion obtained by treating a dithiane such as
2-trimethyl-1,3-dithiane with a strong base such as butyllithium at
-100.degree. C. to room temperature in a dry solvent such as
tetrahydrofuran. The dithiane thus obtained is then treated with a
metal salt such as mercury chloride in a solvent such as
methanol/water. Alternatively, it is reacted with methyl
methylsulfinylmethyl sulfoxide in a solvent such as methanol at
room temperature to the reflux temperature in the presence of
benzyltrimethylammonium hydroxide and the intermediate thus
obtained is treated under acidic conditions with the use of, for
example, hydrogen chloride/methanol to thereby give an ester
represented by the formula (205). 134
[0668] wherein M, R.sup.13a, R.sup.13b, A.sup.3, B.sup.2 and
R.sup.a are each as defined above; and R.sup.pa represents a
hydroxy protective group such as benzyl or methoxymethyl, or
hydrogen.
[0669] Step LXI
[0670] The compound represented by the formula (176) is subjected
in an appropriate solvent to a halogen-metal exchange reaction or
reacted with an aryl-Grignard or aryllithium obtained by a
hydrogen-metal exchange reaction to thereby give compounds
represented by the formulae (207), (211) and (215). As the solvent,
use can be made of a dry solvent such as tetrahydrofuran, diethyl
ether or dimethoxyethane. The reaction can be effected at
-100.degree. C. to the reflux temperature of the solvent.
[0671] Step LXVII
[0672] The compounds represented by the formulae (207), (211) and
(215) are subjected to a dehydration reaction by heating under
reflux in the presence of an acid catalyst in an appropriate
solvent to thereby give compounds represented by the formulae
(208), (212) and (216) respectively. As the solvent, use can be
made of benzene, toluene, etc.
[0673] Step XIV
[0674] The compounds represented by the formulae (208), (213) and
(216) are subjected to a reduction reaction with the use of an
appropriate metal catalyst to thereby give compounds represented by
the formulae (209), (214) and (217) respectively. The reaction may
be carried out in, for example, a solvent such as methanol,
ethanol, ethyl acetate or tetrahydrofuran under normal to elevated
hydrogen pressure with the use of palladium, platinum (IV) oxide,
etc. as the catalyst.
[0675] Step XXXIII
[0676] The compounds represented by the formulae (209) and (217)
are reacted with, for example, di-tert-butyl dicarbonate as an
amino protective group preferably at 0.degree. C. to room
temperature in the presence of a base such as pyridine,
triethylamine or N,N-diisopropylethylamine in an appropriate
solvent such as methanol or dichloromethane to thereby give
compounds represented by the formulae (210) and (218). R.sup.13b
may be an arbitrary one, so long as it is lower alkyl or an amino
protective group. The most desirable example of R.sup.13b is alkyl
carbamate.
[0677] Step LXIII
[0678] The compound represented by the formula (212) is treated
with n-butyllithium in a dry solvent such as tetrahydrofuran at
-100 to 0.degree. C. and the anion thus obtained is treated with a
regent such as diethyl carbonate or ethyl chloroformate to thereby
give a compound represented by the formula (213). 135
[0679] wherein R.sup.13a, A.sup.7, B.sup.2, R.sup.s and R.sup.t are
each as defined above.
[0680] Step LXIV
[0681] A compound represented by the formula (219) is reacted with
an appropriate benzyl cyanide in the presence of an appropriate
phase transfer catalyst in a thick aqueous solution of an alkali to
thereby give a piperidine derivative represented by the formula
(220). This reaction can be effected at room temperature to
100.degree. C. 136
[0682] wherein R.sup.13a, A.sup.3, R.sup.k, R.sup.s and R.sup.t are
each as defined above.
[0683] Step LXV
[0684] A carbonyl derivative represented by the formula (221) is
reacted with an appropriate hydroxylamine in a solvent such as
ethanol in the presence of a catalyst such as sodium acetate to
thereby give an oxime represented by the formula (222). This
reaction can be effected at room temperature to the reflux
temperature.
[0685] Step XXI
[0686] The oxime represented by the formula (222) is treated with a
base such as sodium hydride or sodium methoxide and then reacted
with an alkyl halide in a solvent such as dimethoxyethane,
tetrahydrofuran or N,N-dimethylformamide to thereby give a
derivative represented by the formula (223). This reaction is
effected preferably at 0.degree. C. to room temperature.
[0687] Step LXVI
[0688] An .alpha.,.beta.-unsaturated ester represented by the
formula (224) is treated with a base such as
1,8-diazabicyclo[5.4.0]-7-undecene at room temperature to reflux
temperature in an appropriate solvent such as toluene to thereby
give a .beta.,.gamma.-derivative represented by the formula (225).
mal to elevated hydrogen pressure. 137
[0689] wherein M, R.sup.13a, A.sup.7, R.sup.a, R.sup.d, R.sup.k,
R.sup.s and R.sup.t are each as defined above.
[0690] Step XXXII
[0691] Methyltriphenylphosphonium bromide is treated with an
appropriate base such as potassium tert-butoxide or butyllithium in
a solvent such as toluene, xylene or tetrahydrofuran. Next, ketones
represented by the formulae (167) and (228) are reacted therewith
to thereby give compounds represented by the formulae (226) and
(229) respectively. The reaction temperature preferably ranges from
-78.degree. C. to room temperature.
[0692] Step XXXIV
[0693] The compound represented by the formula (226) is treated
with zinc/copper alloy and trichloroacetyl chloride in a dry
solvent such as diethyl ether, dimethoxyethane or tetrahydrofuran
to thereby give a crude dichlorobutyl ketone derivative represented
by the formula (227). The reaction temperature preferably ranges
from 0 to 50.degree. C.
[0694] Step LXVII
[0695] The dichloroketone represented by the formula (227) is
treated with a reducing agent such as zinc in an alcoholic solvent
such as methanol in the presence of ammonium chloride to thereby
give a ketone compound represented by the formula (228). The
reaction temperature preferably ranges from 0 to 50.degree. C.
[0696] Step XXXV
[0697] An exo-methylene compound represented by the formula (229)
is treated with an appropriate borane compound such as a
borane/tetrahydrofuran complex in an appropriate solvent such as
dry tetrahydrofuran or dimethoxyethane followed by the treatment
with an oxidizing agent such as hydrogen peroxide in an alkali
solution to thereby give an alcohol compound represented by the
formula (230).
[0698] Step XIII
[0699] The compound represented by the formula (228) is reacted
with an appropriate Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (231). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, lithium diisopropylamide,
etc. The reaction can be effected at -100.degree. C. to the reflux
temperature of the solvent.
[0700] Step LXVIII
[0701] The .alpha.,.beta.-unsaturated ester represented by the
formula (231) is reacted with an alkylcopper complex in a dry
solvent such as diethyl ether in the presence of an appropriate
activator such as chlorotrimethylsilane to thereby give a compound
represented by the formula (232). The reaction is effected
preferably at -80 to 0.degree. C.
[0702] Step XVI
[0703] The compound represented by the formula (228) is treated
with a cyanidation reagent such as tosylmethyl isocyanide in a
mixture of a solvent such as dimethoxyethane, tetrahydrofuran or
diethyl ether with an alcoholic solvent such as tert-butanol in the
presence of a base such as potassium tert-butoxide to thereby give
a cyano compound represented by the formula (233). It is preferable
to effect this reaction at a temperature of 0 to 100.degree. C.
[0704] Step IX
[0705] The compound represented by the formula (233) is treated in
the following manner. 1) When R.sup.13a is alkyl, etc., the
starting compound is reacted with an acid chloride such as
1-chloroethyl chloroformate or vinyl chloroformate optionally in a
solvent. Next, an appropriate alcoholic solvent is added thereto
and reacted therewith. Alternatively, it is treated with an
appropriate solvent containing hydrochloric acid or hydrobromic
acid and then heated in an alcoholic solvent. 2) When R.sup.13a is
tert-butoxycarbonyl, etc., the starting compound is reacted with an
appropriate acid such as acetic acid, trifluoroacetic acid or
hydrochloric acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran. 3) When R.sup.13a is a
protective group which can be eliminated, such as benzyl, the
starting compound is hydrogenated in an appropriate solvent such as
methanol, ethanol, ethyl acetate or tetrahydrofuran by using a
metal catalyst such as palladium or platinum (IV) oxide under
normal to elevated hydrogen pressure. Thus, a compound represented
by the formula (234) can be obtained.
[0706] Step XXXIII
[0707] The compound represented by the formula (234) is reacted
with, for example, benzyl chloride as an amino protective group
preferably at 0.degree. C. to room temperature in the presence of a
base such as pyridine, triethylamine or N,N-diisopropyl-ethylamine
in an appropriate solvent such as methanol or dichloromethane to
thereby give a compound represented by the formula (235). R.sup.13b
may be an arbitrary one, so long as it is lower alkyl or an amino
protective group. The most desirable example of R.sup.13b is
benzyl. 138
[0708] wherein M, R.sup.13a, A.sup.3, R.sup.a, R.sup.k, R.sup.s and
R.sup.t are each as defined above.
[0709] Step LXIX
[0710] A ketone compound represented by the formula (236) is
treated with a peroxide such as 3-chloroperbenzoic acid in an
appropriate solvent such as dichloromethane in the presence of
sodium carbonate, etc. to thereby give a lactone compound
represented by the formula (237). The reaction temperature
preferably ranges from -100 to 0.degree. C.
[0711] Step LXX
[0712] The lactone compound represented by the formula (237) is
treated with diisobutylaluminum hydride in an appropriate solvent
such as toluene or dichloromethane to thereby give a lactol
compound represented by the formula (238). The reaction temperature
preferably ranges from -100 to 0.degree. C.
[0713] Step XIII
[0714] The compound represented by the formula (238) is reacted
with an appropriate Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (239). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, lithium diisopropylamide,
etc. The reaction can be effected at -100.degree. C. to the reflux
temperature of the solvent.
[0715] Step XIV
[0716] The compound represented by the formula (239) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (240). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
under normal to elevated hydrogen pressure with the use of
palladium, platinum (IV) oxide, etc. as the catalyst. 139
[0717] wherein M, R.sup.13a, A.sup.3 and X.sub.n are each as
defined above.
[0718] Step LXXI
[0719] An alkene compound represented by the formula (241) is
reacted with diethylzinc and iodomethane in an appropriate solvent
such as dichloromethane to thereby give a cyclopropyl derivative
represented by the formula (242). The reaction temperature
preferably ranges from 0.degree. C. to room temperature. 140
[0720] wherein M, R.sup.13a and A.sup.3 are each as defined
above.
[0721] Step XXXXI
[0722] A compound represented by the formula (176) is treated with
allyllithium or allylmagnesium halide in a solvent such as dry
tetrahydrofuran, diethyl ether or dimethoxyethane at -78.degree. C.
to the boiling point of the solvent to thereby give an alcohol
represented by the formula (243).
[0723] Step LXXII
[0724] The alkene compound represented by the formula (243) is
treated with a peroxide such as 3-chloroperbenzoic acid in an
appropriate solvent such as dichloromethane in the presence of
sodium carbonate, etc to thereby give an epoxide represented by the
formula (244). The reaction temperature preferably ranges from room
temperature to 40.degree. C.
[0725] Step LXXIII
[0726] The compound represented by the formula (244) is treated
with a base such as lithium hydroxide in a solvent mixture of
dimethyl sulfoxide with water to thereby give a compound
represented by the formula (245). The reaction temperature
preferably ranges from 50 to 150.degree. C. 141
[0727] wherein G, Z, E, X.sup.1, l.sup.1, R.sup.13a, Hal and
R.sup.a are each as defined above.
[0728] Step LXXVI
[0729] A thiophene derivative represented by the formula (265) is
treated with a strong base such as n-butyllithium or lithium
diisopropylamide in a dry solvent such as tetrahydrofuran, diethyl
ether or hexamethylphosphorous triamide at from -100 to 0.degree.
C. Then the anion thus obtained is treated with a formulation agent
such as N,N-dimethylformamide to thereby give an aldehyde
represented by the formula (266).
[0730] Step LXXVII
[0731] The aldehyde represented by the formula (266) is reacted
with an anion obtained by treating a dithiane such as
2-trimethylsilyl-1,3-dithia- ne with a strong base such as
butyllithium in a dry solvent such as tetrahydrofuran at from
-100.degree. C. to room temperature to thereby give a
methylenethiazine represented by the formula (267).
[0732] Step IX
[0733] The compound represented by the formula (267) is treated
with an appropriate acid such as hydrochloric acid, trifluoroacetic
acid or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give an amine
represented by the formula (268).
[0734] Step X
[0735] The compound represented by the formula (267) is
treated-with a halide represented by the formula (140) in a solvent
in the presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylethylamine to thereby give a compound
represented by the formula (269). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction can be effected at
from 0 to 150.degree. C.
[0736] Step LXXVIII
[0737] The methylenethiazine represented by the formula (269) is
treated with a metal salt such as mercury chloride in a solvent
such as methanol/water to thereby give an ester compound
represented by the formula (270). 142
[0738] wherein G, Z, E, X.sup.1, l.sup.1, R', R.sup.a and Hal are
each as defined above.
[0739] Step X
[0740] A compound represented by the formula (131) is treated with
a protected 3-(hydroxymethyl)pyridine derivative in a solvent in
the presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylethylamine to thereby give a compound
represented by the formula (271). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction can be effected at
from 0 to 150.degree. C.
[0741] Step XXIV
[0742] The compound represented by the formula (271) is treated
with a reducing agent such as sodium borohydride in a solvent to
thereby give a compound represented by the formula (272). As the
solvent, use can be made of methanol, ethanol, etc. The reaction
can be effected at from 0.degree. C. to the reflux temperature.
[0743] Step LI
[0744] The compound represented by the formula (272) is treated
with a reagent such as tetra-n-butylammonium fluoride or caesium
fluoride in a dry solvent such as tetrahydrofuran to thereby give
an alcohol represented by the formula (273). The reaction is
effected preferably at from 0.degree. C. to room temperature.
[0745] Step XXIX
[0746] A solution of the alcohol represented by the formula (273)
in, for example, methylene chloride is added to a reaction mixture
obtained from oxalyl chloride and dimethyl sulfoxide and treated
with a base such as triethylamine. Alternatively, it is treated
with pyridinium dichromate in a solvent such as dichloromethane or
N,N-dimethylformamide or treated with manganese dioxide in a
solvent such as dichloromethane. Thus, an aldehyde represented by
the formula (274) can be obtained.
[0747] Step XXXVI
[0748] The compound represented by the formula (274) is treated
with bromine in an appropriate alcoholic solvent such as methanol
or ethanol in the presence of a base such as sodium
hydrogencarbonate or potassium carbonate preferably at from
0.degree. C. to room temperature. Alternatively, the starting
compound is treated with pyridinium chromate in an appropriate
alcoholic solvent such as methanol or ethanol. Alternatively, it is
treated with manganese dioxide in an appropriate alcoholic solvent
such as methanol or ethanol in the presence of sodium cyanide and
acetic acid and then treated with sulfuric acid, hydrochloric acid,
thionyl chloride, etc. in an appropriate alcoholic solvent such as
methanol or ethanol. Alternatively, it is treated with sodium
chlorite in a solvent mixture of water with dimethyl sulfoxide in
the presence of sodium dihydrogenphosphate and then reacted with
trimethylsilyl-diazometh- ane in a solvent such as methanol.
Alternatively, it is treated with an activating agent such as
thionyl chloride in an appropriate alcoholic solvent such as
methanol or ethanol. Thus, an ester compound represented by the
formula (275) can be obtained. 143
[0749] wherein G, Z, A.sup.1, E, X.sup.1, l.sup.1, Hal and R' are
each as defined above.
[0750] Step LXXIX
[0751] 4-Hydroxypyridine is treated with a strong base such as
sodium hydride or lithium diisopropylamide in a dry solvent such as
tetrahydrofuran or N,N-dimethylformamide. The anion thus obtained
is then treated with a halogen compound (131) at from 0to
100.degree. C. to thereby give a pyridone represented by the
formula (277).
[0752] Step XXIV
[0753] The pyridone represented by the formula (277) is treated
with a reducing agent such as aluminum lithium hydride in a dry
solvent such as dry diethyl ether at from 0 to 50.degree. C. to
thereby give an .alpha.,.beta.-unsaturated enone (278). 144
[0754] wherein G, Z, R.sup.a, E, X.sup.1, l.sup.1, Hal and R' are
each as defined above.
[0755] Step LXXIX
[0756] The compound represented by the formula (279) is treated
with a strong base such as sodium hydride or lithium
diisopropylamide in a dry solvent such as tetrahydrofuran or
N,N-dimethylformamide. The anion thus obtained is then treated with
a halogen compound (131) at from 0 to 100.degree. C. to thereby
give a compound represented by the formula (280).
[0757] Step VIII
[0758] The compound represented by the formula (280) is treated
with an appropriate acid such as hydrochloric acid, trifluoroacetic
acid or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give an amine
represented by the formula (281).
[0759] Step LXXX
[0760] The ester compound represented by the formula (281) is
treated with water and an excessive amount of a strong base such as
potassium tert-butoxide in a dry solvent such as dimethyl sulfoxide
to thereby give a carboxylic acid represented by the formula (282).
This reaction is effected preferably at from 0 to 50.degree. C.
145
[0761] wherein A.sup.3, G, Z, R.sup.a, E, X.sup.1, l.sup.1, Hal and
R' are each as defined above.
[0762] Step XI
[0763] A compound represented by the formula (283) is treated with
an appropriate base in an aqueous ethanol solvent followed by
hydrolysis to thereby give a compound having a carboxyl group
represented by the formula (284). As the base, use can be made of
sodium hydroxide, potassium hydroxide, etc. The reaction can be
effected at from room temperature to the reflux temperature of the
solvent. 146147
[0764] wherein G, Z, M, E, X.sup.1, l.sup.1, Hal, A.sup.3 and R'
are each as defined above.
[0765] Step XXXXVI
[0766] An amine represented by the formula (137) is reacted with
diketen in an appropriate solvent to thereby give an amdie
represented by the formula (285). As the solvent, use can be made
of toluene, etc. The reaction can be effected at from 0.degree. C.
to the reflux temperature.
[0767] Step IX
[0768] The compound represented by the formula (285) is subjected
to a reduction reaction in a solvent with the use of an appropriate
metal catalyst to thereby give a compound represented by the
formula (286). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
under normal to elevated hydrogen pressure with the use of
palladium, platinum (IV) oxide, etc. as the catalyst.
[0769] Step X
[0770] The compound represented by the formula (286) is treated
with a halide represented by the formula (131) in a solvent in the
presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylethylamine to thereby give a compound
represented by the formula (287). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction can be effected at
from 0 to 150.degree. C.
[0771] Step LXXXI
[0772] The dicarbonyl compound represented by the formula (287) is
treated with N,N-dimethylformamide dimethyl acetal in an
appropriate solvent at from 50 to 100.degree. C. to thereby give a
compound represented by the formula (288).
[0773] Step LXXXII
[0774] The compound represented by the formula (288) is reacted
with hydroxylamine hydrochloride in an alcoholic solvent such as
methanol at from room temperature to the reflux, temperature to
thereby give an oxazole represented by the formula (289).
[0775] Step VIII
[0776] The compound represented by the formula (289) is treated
with an appropriate acid such as hydrochloric acid, trifluoroacetic
acid or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give an amine
represented by the formula (290).
[0777] Step LXXXIII
[0778] The isoxazole represented by the formula (290) is treated
with N,N-dimethylformamide dimethyl acetal in a dry solvent such as
tetrahydrofuran at from room temperature to the reflux temperature
to thereby give a compound represented by the formula (291).
148
[0779] wherein G, Z, E, X.sup.1, l.sup.1, A.sup.1, R.sup.k and
R.sup.1 are each as defined above.
[0780] Step LXXXIV
[0781] An amine represented by the formula (292) is reacted with
3,4-dimethoxy-3-cyclobutene-1,2-dione in an appropriate solvent
such as N,N-dimethylformamide, ethanol, methanol or dichloromethane
optionally in the presence of a base such as triethylamine at from
room temperature to the reflux temperature to thereby give a
compound represented by the formula (293).
[0782] Step LXXXIV
[0783] The compound represented by the formula (293) is treated
with an appropriate amine or ammonia in an appropriate solvent such
as N,N-dimethylformamide, ethanol, methanol or dichloromethane
optionally in the presence of a base such as triethylamine at from
room temperature to the reflux temperature to thereby give a
compound represented by the formula (294). 149
[0784] wherein R.sup.13a, R.sup.k and R.sup.1 are each as defined
above.
[0785] Step LXXXIV
[0786] An amine represented by the formula (153) is reacted with
3,4-dimethoxy-3-cyclobutene-1,2-dione in an appropriate solvent
such as N,N-dimethylformamide, ethanol, methanol or dichloromethane
optionally in the presence of a base such as triethylamine at from
room temperature to the reflux temperature to thereby give a
compound represented by the formula (295).
[0787] Step LXXXIV
[0788] The compound represented by the formula (295) is treated
with an appropriate amine or ammonia in an appropriate solvent such
as N,N-dimethylformamide, ethanol, methanol or dichloromethane
optionally in the presence of a base such as triethylamine at from
room temperature to the reflux temperature to thereby give a
compound represented by the formula (296). 150
[0789] wherein G, Z, E, X.sup.1, l.sup.1, A.sup.3, R', R.sup.d,
X.sub.n and V.sup.1 are each as defined above.
[0790] Step X
[0791] A compound represented by the formula (297) is treated with
a halide represented by the formula (131) in a solvent in the
presence of an appropriate base such as anhydrous potassium
carbonate or N,N-diisopropylethylamine to thereby give a compound
represented by the formula (298). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction can be effected at
from 0 to 150.degree. C.
[0792] Step VIII
[0793] The compound represented by the formula (298) is treated
with an appropriate acid such as hydrochloric acid, trifluoroacetic
acid or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahyarofuran to thereby give an amine
represented by the formula (299).
[0794] Step LXXXV
[0795] The nitrile compound represented by the formula (299) is
treated with an appropriate acid in an alcoholic solvent to thereby
give an imidate represented by the formula (300) (i.e., the
so-called Pinner reaction). It is preferable to use hydrochloric
acid as the acid. The reaction is preferably effected in methanol
at from 0 to 10.degree. C.
[0796] Step LXXXVI
[0797] The imidate represented by the formula (300) is reacted with
an amine or an amide in an appropriate solvent to thereby give a
compound represented by the formula (301). The most desirable
solvent is acetonitrile. The reaction is effected preferably at
from room temperature to 40.degree. C.
[0798] Step LXXXVII
[0799] The nitrile represented by the formula (298) is treated with
an azidation agent such as sodium azide in a dry solvent such as
dimethyl sulfoxide, N,N-dimethylformamide or 1-methyl-2-pyrrolidone
at from 50.degree. C. to the reflux temperature in the presence of
a catalyst such as ammonium chloride to thereby give a tetrazole
derivative represented by the formula (302). 151
[0800] wherein G, Z, E, X.sup.1, l.sup.1, R.sup.k, R.sup.1 and Hal
are each as defined above; A.sup.8 represents heteroaryl having no
acidic proton group such as NH; and .psi. represents lower alkyl or
oxygen.
[0801] Step X
[0802] A halogen compound represented by the formula (140) is
treated with a heteroaryl compound having no acidic proton, such as
pyridine, an amine compound represented by the formula (305), a
tertiary amine or an N,N-dialkylhydroxylamine, to thereby give
compounds represented by the formulae (303), (306) and (307)
respectively. As the solvent, use can be made of ethanol, dry
N,N-dimethylformamide, etc. The reaction can be effected at from 50
to 150.degree. C.
[0803] Step LXXXVIII
[0804] A carboxylic acid represented by the formula (304) is
reacted with a silylation agent such as chlorotrimethylsilane,
trimethylsilyl trifluoroacetate or
N-methyl-N-(trimethylsilyl)trifluoroacetamide in an appropriate
solvent optionally in the presence of a base such as imidazole,
pyridine or N,N-diisopropylethylamine to thereby give an ester
compound represented by the formula (305). As the solvent, use can
be made of dry solvent such as N,N-dimethylformamide, acetonitrile
or dichloromethane. The reaction can be effected at from 0 to
40.degree. C. 152
[0805] wherein A.sup.3, M, R.sup.k and R.sup.1 are each as defined
above.
[0806] Step LXXXIX
[0807] An acid halide represented by the formula (308) is treated
with an appropriate amine optionally in an appropriate solvent such
dichloromethane or methanol in the presence of an appropriate base
such as pyridine, triethylamine or N,N-diisopropylethylamine to
thereby give a compound represented by the formula (309).
[0808] Step XIV
[0809] The compound represented by the formula (309) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (310). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 153
[0810] wherein M, R.sup.13a and A.sup.3 are each as defined
above.
[0811] Step LXVIII
[0812] A compound represented by the formula (311) is treated with
a strong base such as n-butyllithium or lithium diisopropylamide in
a dry solvent such as tetrahydrofuran, diethyl ether or
hexamethyl-phosphorous triamide at from -100 to 0.degree. C. The
anion thus obtained is then treated with a metal salt such as
cupric iodide to thereby effect a metal exchange reaction. The
copper complex thus obtained is treated with an appropriate acid
halide to thereby give a compound represented by the formula
(312).
[0813] Step XIII
[0814] An appropriately protected 4-piperidine-carbaldehyde is
reacted with a Horner-Emmons reagent represented by the formula
(312) in a solvent in the presence of an appropriate base to
thereby give a compound represented by the formula (313). As the
solvent, use can be made of dry solvents such as
N,N-dimethylformamide, tetrahydrofuran or diethyl ether. As the
base, use can be made of sodium hydride, potassium tert-butoxide,
n-butyllithium, lithium diisopropylamide, etc. The reaction can be
effected at from -100.degree. C. to the reflux temperature of the
solvent.
[0815] Step XIV
[0816] The compound represented by the formula (313) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (314). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 154
[0817] wherein M, R.sup.13a, R.sup.a and A.sup.3 are each as
defined above; and L.sup.2 represents a substituent such as
methylsulfonyl, nitryl, tetarzol-5-yl or
8-methyl-8-azabicyclo[3.2.1]octan-3-yl.
[0818] Step XI
[0819] A compound represented by the formula (147) is reacted with
an appropriate base in an aqueous solvent followed by hydrolysis to
thereby give a compound having a carboxyl group represented by the
formula (315). As the solvent, use can be made of alcoholic
solvents such as methanol or ethanol or solvent mixtures such as
alcohol/tetrahydrofuran/water. As the base, use can be made of
sodium hydroxide, potassium hydroxide, etc. The reaction can be
effected at from room temperature to the reflux temperature of the
solvent.
[0820] Step LXXXX
[0821] The carboxylic acid represented by the formula (315) is
reacted with an appropriate diimide, an appropriate chloroformate,
an appropriate dichlorophosphonate or carbonyldiimidazole at from 0
to 60.degree. C. in an appropriate dry solvent such as
N,N-dimethylformamide, tetrahydrofuran, acetonitrile or
dichloromethane optionally in the presence of an appropriate base
such as pyridine, triethylamine or N,N-diisopropylamine. The
activated ester thus obtained is then reacted with an appropriate
amine or amine derivative to thereby give an amide represented by
the formula (316). 155
[0822] wherein G, Z, E, X.sup.1, l.sup.1, R.sup.k, R.sup.1, R' and
Hal are each as defined above.
[0823] Step XXVIII
[0824] An alcohol represented by the formula (131) is treated with
a cyanidation reagent such as sodium cyanide or potassium cyanide
in an appropriate solvent such as dimethyl sulfoxide to thereby
give a nitrile represented by the formula (317). The reaction can
be effected at from room temperature to 100.degree. C.
[0825] Step XVII
[0826] The cyano compound of the formula (317) is treated with a
base such as sodium hydroxide or potassium hydroxide in an
alcoholic solvent such as ethanol, propanol, ethylene glycol or
diethylene glycol and heated under reflux to thereby give a
carboxylic acid of the formula (318).
[0827] Step LXXXXI
[0828] The carboxylic acid of the formula (318) is treated with
diphenyl phosphate azide in an appropriate dry solvent such as
tetrahydrofuran in the presence of an appropriate tertiary amine
base such as triethylamine. The intermediate thus obtained is then
treated with an appropriate secondary or primary amine to thereby
give a urea derivative represented by the formula (319). 156
[0829] wherein G, Z, E, X.sup.1, l.sup.1, A.sup.1, R.sup.k,
R.sup.1, R' and Hal are each as defined above.
[0830] Step XXXXVI
[0831] An amine represented by the formula (276) is reacted with
chloroacetyl chloride optionally in an appropriate solvent in the
presence of an appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give an amide represented by
the formula (320). As the solvent, use can be made of dry
N,N-dimethylformamide, dry dichloromethane, etc. The reaction can
be effected at from 0.degree. C. to room temperature.
[0832] Step LXXXIX
[0833] The halogen compound represented by the formula (320) is
treated with an appropriate amine optionally in an appropriate
solvent such as dichloromethane or dry N,N-dimethylformamide in the
presence of an appropriate base such as anhydrous potassium
carbonate, pyridine, triethylamine or N,N-diisopropylethylamine to
thereby give a compound represented by the formula (321). 157
[0834] wherein G, Z, E, X.sup.1, l.sup.1, A.sup.1, R.sup.k,
R.sup.1, R' and Hal are each as defined above.
[0835] Step LXXXX
[0836] A carboxylic acid represented by the formula (318) is
reacted with an appropriate diimide, an appropriate chloroformate,
an appropriate dichlorophosphonate or carbonyldiimidazole at from 0
to 60.degree. C. in an appropriate dry solvent such as
N,N-dimethylformamide, tetrahydrofuran, acetonitrile or
dichloromethane optionally in the presence of an appropriate base
such as pyridine, triethylamine or N,N-diisopropylethylamine. The
activated ester thus obtained is then reacted with an appropriate
amine or amine derivative to thereby give an amide represented by
the formula (322). 158
[0837] wherein G, Z, E, X.sup.1, l.sup.1, A.sup.1, R.sup.k,
R.sup.1, R' and Hal are each as defined above.
[0838] Step LXXXXII
[0839] A ketone represented by the formula (323) is treated with a
bromination agent such as tetra-n-butylammonium tribromide or
N-bromosuccinimide in a solvent mixture such as
methanol/dichloromethane or a solvent such as tetrahydrofuran to
thereby give a halogen compound represented by the formula
(324).
[0840] Step LXXXIX
[0841] The halogen compound of the formula (324) is treated with an
appropriate amine optionally in an appropriate solvent such as
dichloromethane or dry N,N-dimethylformamide in the presence of an
appropriate base such as anhydrous potassium carbonate, pyridine,
triethylamine or N,N-diisopropylethylamine to thereby give a
compound represented by the formula (325). 159
[0842] wherein G, Z, E, X.sup.1, l.sup.1 and A.sup.3 are each as
defined above.,
[0843] Step LXXXXIII
[0844] An .alpha.,.beta.-unsaturated ketone compound represented by
the formula (326) is treated with mercaptoacetic acid in an
appropriate dry solvent such as dichloromethane or tetrahydrofuran
in the presence of a strong base such as sodium hydride to thereby
give a compound represented by the formula (327). This reaction is
effected preferably at from 0.degree. C. to room temperature.
160
[0845] wherein G, Z, E, X.sup.2, l.sup.2 and R are each as defined
above.
[0846] Step LXXIX
[0847] A compound represented by the formula (258) having a
nucleophilic heteroatom is treated with a strong base such as
sodium hydride or lithium diisopropylamide in a dry solvent such as
tetrahydrofuran or N,N-dimethylformamide. The anion thus obtained
is then treated with a halogen compound (328) at from 0 to
100.degree. C. or reacted in an alcoholic solvent such as ethanol
or methanol optionally in the presence of a base such as
triethylamine at from room temperature to the reflux temperature.
Thus a compound represented by the formula (329) can be
obtained.
[0848] Step LXXXXIV
[0849] When the compound represented by the formula (258) is a
primary amine, it is treated with an aldehyde represented by the
formula (330) in an appropriate solvent such as toluene or benzene
at from room temperature to the reflux temperature. The
intermediate thus obtained is treated with an appropriate reducing
agent such as sodium borohydride or sodium borocyanohydride in an
appropriate alcoholic solvent such as ethanol or methanol or in an
appropriate solvent mixture such as thanol/tetrahydrofuran to
thereby give a compound represented by the formula (329).
[0850] Step VIII
[0851] The compounds represented by the formulae (329) and (333)
are treated with an appropriate acid such as hydrochloric acid,
trifluoroacetic acid or acetic acid optionally in an appropriate
solvent such as dichloromethane or tetrahydrofuran to thereby give
amines represented by the formulae (331) and (332).
[0852] Step XI
[0853] When the compounds represented by the formulae (329) and
(331) have an ester group in the molecule, these compounds are
reacted with an appropriate base in an aqueous solvent to thereby
give compounds having a carboxyl group represented by the formulae
(333) and (332) respectively. As the solvent, use can be made of
alcoholic solvents such as methanol or ethanol or solvent mixtures
such as alcohol/tetrahydrofuran/water. As the base, use can be made
of sodium hydroxide or potassium hydroxide. The reaction can be
carried out at from room temperature to the reflux temperature of
the solvent. 161
[0854] wherein G, Z, E, X.sup.2, l.sup.2, X.sub.n, Hal and R' are
each as defined above; DI represents a heteroaryl ring such as
pyridine or purine; l is 0 or 1; and R.sup.m represents hydrogen,
optionally substituted alkyl optionally having a heteroatom and
optionally having an optionally substituted aryl, heteroaryl or
heterocycloalkyl ring, optionally substituted aryl, optionally
substituted heteroaryl or optionally substituted
heterocycloalkyl.
[0855] Step LXXXXV
[0856] A halide represented by the formula (335) is *reacted with
an alkyne in a dry solvent such as N,N-dimethylformamide at from
room temperature to 120.degree. C. in the presence of a catalyst
such as dichlorobis(triphenylphosphine)palladium with
triphenylphosphine, an oxidizing agent such as cupric iodide and a
base such as triethylamine to thereby give compounds represented by
the formulae (336) and (338).
[0857] Step XIV
[0858] The compounds represented by the formulae (336) and (339)
are subjected to a reduction reaction with the use of an
appropriate metal catalyst in a solvent to thereby give compounds
represented by the formulae (337) and (342). The reaction may be
carried out in, for example, a solvent such as methanol, ethanol,
ethyl acetate or tetrahydrofuran with the use of palladium,
platinum (IV) oxide, etc. as the catalyst under normal to elevated
hydrogen pressure.
[0859] Step LI
[0860] The compound represented by the formula (338) is treated
with a reagent such as tetra-n-butylammonium fluoride or caesium
fluoride in a dry solvent such as tetrahydrofuran to thereby give a
carboxylic acid represented by the formula (339). The reaction is
effected preferably at from 0.degree. C. to room temperature.
[0861] Step LXXXXVI
[0862] The alkyne represented by the formula (339) is -reacted with
dimethylcarbamoyl chloride optionally in a dry solvent such as
N,N-dimethylformamide at from room temperature to 120.degree. C. in
the presence of a catalyst such as
dichlorobis(triphenylphosphine)palladium with triphenylphosphine,
an oxidizing agent such as cupric iodide and a base such as
triethylamine to thereby give an amide represented by the formula
(340).
[0863] Step LXXXXVII
[0864] The alkyne represented by the formula (339) is reacted with
a strong base such as n-butyllithium in a dry solvent such as
tetrahydrofuran at from -100 to 0.degree. C. and the anion thus
obtained is treated with dry ice to thereby give a compound
represented by the formula (341). 162
[0865] wherein L.sup.1 and R.sup.d are each as defined above; and
A.sup.9 represents heteroaryl having an acidic proton group such as
NH (for example, imidazole or purine).
[0866] Step LXXXXVIII
[0867] The compound represented by the formula (344) is reacted
with N,N'-disuccinimidyl carbonate, carbonyldiimidazole, etc. in a
dry solvent such as acetonitrile or N,N-dimethylformamide at from
0.degree. C. to the reflux temperature to thereby give a compound
represented by the formula (345).
[0868] Step LIL
[0869] The compound represented by the formula (344) is reacted
with an acid anhydride such as trifluoroacetic anhydride at from 50
to 150.degree. C. under elevated pressure to thereby give a purine
derivative represented by the formula (346). 163
[0870] wherein A.sup.9, Hal, R.sup.d and R.sup.e are each as
defined above; and R.sup.pb represents an alcohol protective group
having a silyl group.
[0871] Step C
[0872] A halide represented by the formula (347) is reacted with an
appropriate vinyl-tri-n-butyltin (IV) derivative in a dry solvent
such as N,N-dimethylformamide at from room temperature to
120.degree. C. in the presence of a catalyst such as
dichlorobis-(triphenylphosphine)palladium and triphenylphosphine to
thereby give an alkene represented by the formula (348).
[0873] Step VIII
[0874] The compound represented by the formula (348) is treated
with an appropriate acid such as hydrochloric acid, trifluoroacetic
acid or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give a ketone
represented by the formula (349).
[0875] Step XXIV
[0876] The compound represented by the formula (349) is treated
with a reducing agent such as sodium borohydride in a solvent to
thereby give a compound represented by the formula (350). As the
solvent, use can be made of methanol, ethanol, etc. The reaction
can be effected at from 0.degree. C. to the reflux temperature.
[0877] Step LXXXVIII
[0878] The alcohol represented by the formula (350) is reacted with
a silylation agent such as chloro-tert-butyldimethylsilane,
(tert-butyldimethylsilyl)trifluoroacetate or
N-methyl-N-(tert-butyldimeth- ylsilyl) trifluoroacetamide in an
appropriate solvent optionally in the presence of a base such as
imidazole, pyridine or N,N-diisopropylethylami- ne to thereby give
an ester compound represented by the formula (351). As the solvent,
use can be made of a dry solvent such as N,N-dimethylformamide,
acetonitrile or dichloromethane. The reaction can be effected at
from 0 to 40.degree. C. 164
[0879] wherein G, Z, E, X.sup.2, l.sup.2, Q, Hal, R.sup.k, R.sup.1
and R' are each as defined above.
[0880] Step LXXIX
[0881] An appropriate purine derivative is treated with a strong
base such as sodium hydride or lithium dilsopropylamide in a dry
solvent such as tetrahydrofuran or N,N-dimethylformamide. The anion
thus obtained is then treated with a halogen compound (352) at from
0 to 100.degree. C. to thereby give compounds represented by the
formulae (353) and (354).
[0882] Step LXXXIX
[0883] The halides represented by the formulae (353) and (354) are
treated with an appropriate amine optionally in an appropriate
solvent such as dichloromethane or methanol at from room
temperature to the reflux temperature to thereby give compounds
represented by the formulae (355) and (356) respectively. 165
[0884] wherein G, Z, E, X.sup.2, l.sup.2, Q, Hal, M, R.sup.a and R'
are each as defined above.
[0885] Step LXXIX
[0886] A purine derivative represented by the formula (357) is
treated with a strong base such as sodium hydride or lithium
diisopropylamide in a dry solvent such as tetrahydrofuran or
N,N-dimethylformamide. The anion thus obtained is then treated with
a halogen compound (352) at from 0 to 100.degree. C. to thereby
give compounds represented by the formulae (358) and (359).
[0887] Step CI
[0888] The compounds represented by the formulae (358) and (359)
are treated with boron tribromide in an appropriate dry solvent
such as dichloromethane at from 0.degree. C. to the reflux
temperature to thereby give compounds represented by the formulae
(360) and (361). 166
[0889] wherein G, Z, E, X.sup.2, l.sup.2, Q, Hal, R.sup.k and R'
are each as defined above.
[0890] Step C
[0891] A halide represented by the formula (354) is reacted with an
appropriate vinyl-tri-n-butyltin (IV) derivative in a dry solvent
such as N,N-dimethylformamide at from room temperature to
120.degree. C. in the presence of a catalyst such as
dichlorobis-(triphenylphosphine)palladium and triphenylphosphine to
thereby give an alkene represented by the formula (362).
[0892] Step XIV
[0893] The compound represented by the formula (362) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (363). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetra 167
[0894] wherein G, Z, E, X.sup.2, l.sup.2, Q, Hal, R.sup.d, R.sup.e
and R' are each as defined above.
[0895] Step C
[0896] Halides represented by the formulae (353) and (354) are
reacted with an appropriate vinyl-tri-n-butyltin (IV) derivative in
a dry solvent such as N,N-dimethylformamide at from room
temperature to 120.degree. C. in the presence of a catalyst such as
dichlorobis(triphenylphosphine)pall- adium and triphenylphosphine
to thereby give alkenes represented by the formulae (364) and (366)
respectively.
[0897] Step VIII
[0898] The compounds represented by the formulae (364) and (366)
are treated with an appropriate acid such as hydrochloric acid,
trifluoroacetic acid or acetic acid optionally in an appropriate
solvent such as dichloromethane or tetrahydrofuran to thereby give
ketones represented by the formulae (365) and (367)
respectively.
[0899] Step VII
[0900] The amine represented by the formula (367) is treated with a
base such as sodium hydride and a protecting reagent such as
methoxymethyl chloride in a solvent to thereby give a compound
represented by the formula (368).
[0901] Step XXIV
[0902] The compound represented by the formula (368) is treated
with a reducing agent such as sodium borohydride in a solvent to
thereby give a compound represented by the formula (369). As the
solvent, use can be made of methanol, ethanol, etc. The reaction
can be effected at from 0.degree. C. to the reflux temperature.
[0903] Step XXXXI
[0904] A compound represented by the formula (368) is treated with
methyllithium or a methylmagnesium halide in a solvent such as dry
tetrahydrofuran, diethyl ether or dimethoxyethane at from
-78.degree. C. to the boiling point of the solvent to thereby give
an alcohol represented by the formula (370). 168
[0905] drofuran with the use of palladium, platinum (IV) oxide,
etc. as the catalyst under normal to elevated hydrogen
pressure.
[0906] wherein G, Z, E, X.sup.2, l.sup.2, Q, Hal, R.sup.pb, R.sup.e
and R' are each as defined above.
[0907] Step LXXIX
[0908] A purine derivative represented by the formula (351) is
treated with a strong base such as sodium hydride or lithium
diisopropylamide in a dry solvent such as tetrahydrofuran or
N,N-dimethylformamide. The anion thus obtained is then treated with
a halogen compound (352) at from 0 to 100.degree. C. to thereby
give a compound represented by the formula (371).
[0909] Step VIII
[0910] The compound represented by the formula (371) is treated
with an appropriate acid such as hydrochloric acid, trifluoroacetic
acid or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give a compound
represented by the formula (372). Trifluoroacetic acid is the most
desirable acid. The reaction is effected preferably at from
0.degree. C. to room temperature.
[0911] Step LI
[0912] The compound represented by the formula (372) is treated
with a reagent such as tetra-n-butylammonium fluoride or caesium
fluoride in a dry solvent such as tetrahydrofuran to thereby give
an alcohol represented by the formula (373). The reaction is
effected preferably at from 0.degree. C. to room temperature.
169
[0913] wherein G, Z, E, X.sup.2, l.sup.2, Q, Hal, R.sup.k, R.sup.1
and R' are each as defined above.
[0914] Step LXXXIX
[0915] A halide represented by the formula (374) is treated with an
appropriate amine in an appropriate solvent such as methanol,
ethanol or tetrahydrofuran or a mixture thereof at from 50 to
150.degree. C. under elevated pressure to thereby give a compound
represented by the formula (375). 170
[0916] wherein G, Z, E, X.sup.2, l.sup.2, X.sub.n, Q, R.sup.d,
R.sup.e, R.sup.k, R.sup.m and R are each as defined above; V.sup.2
represents cyano, methylsulfonyl or 2-pyridyl; when X.sub.n.sup.1
is an alkylene side chain having n carbon atoms and n is 0, then
the substituent is bonded directly to D.sup.d or X.sub.n; D.sup.2
represents a heteroaryl ring such as imidazole, purine, or
4-phenylimidazole; and 1 is 0 or 1.
[0917] Step CII
[0918] An amine represented by the formula (376) is treated with
N,N-dimethylformamide dimethyl acetal in a solvent mixture of
tetrahydrofuran with methanol at from room temperature to the
reflux temperature to thereby give an amidine represented by the
formula (377).
[0919] Step XXXXIX
[0920] The amine represented by the formula (376) is reacted with
an appropriate imidate or thioimidate in a solvent such as
acetonitrile or methanol to thereby give a compound represented by
the formula (378). It is preferable that the reaction is carried
out at from 0 to 40.degree. C. 171
[0921] wherein G, Z, E, X.sup.2, l.sup.2, Q, R.sup.k, R.sup.1,
R.sup.m, Nu, X.sub.n, X.sub.n.sup.1, D.sup.2, l and R are each as
defined above.
[0922] Step CIII
[0923] A nitrile derivative represented by the formula (379) is
reacted with ammonium chloride, an appropriate primary amine
hydrochloride or an appropriate secondary amine hydrochloride in a
dry solvent such as toluene or benzene at from 50.degree. C. to the
reflux temperature in the presence of trimethylaluminum to thereby
give an amidine represented by the formula (380).
[0924] Step XXIV
[0925] The compound represented by the formula (379) is treated
with a reducing agent such as aluminum lithium hydride or lithium
borohydride in a solvent such as dry tetrahydrofuran or dry diethyl
ether to thereby give an amine of the formula (381). The reaction
can be effected at from 0.degree. C. to the reflux temperature.
[0926] Step LXXXV
[0927] The nitrile compound represented by the formula (379) is
treated with an appropriate acid in an alcoholic solvent to thereby
give an imidate represented by the formula (382) (i.e., the
so-called Pinner reaction). It is preferable to use hydrochloric
acid as the acid. The reaction is preferably effected in
methanol/dichloromethane at from -20 to 0.degree. C.
[0928] Step CIV
[0929] The imidate represented by the formula (382) is reacted with
cyanamide in an appropriate solvent in the presence of sodium
monohydrogenphosphate and sodium dihydrogenphosphate to thereby
give a derivative represented by the formula (383). As the solvent,
it is preferable to use acetonitrile. The reaction is effected
preferably at from 0.degree. C. to room temperature.
[0930] Step LXXXVI
[0931] The imidate represented by the formula (383) is reacted with
an amine or an amide in an appropriate solvent to thereby give
compounds represented by the formulae (384) and (385). As the
solvent, use can be made of acetonitrile, tetrahydrofuran, etc. The
reaction is effected preferably at from 0.degree. C. to reflux
temperature. 172
[0932] wherein G, Z, E, X.sup.2, l.sup.2, Q, R.sup.k, R.sup.1,
R.sup.m, Nu, X.sub.n, X.sub.n.sup.1, D.sup.2, l and R are each as
defined above; V.sup.3 represents nitryl, methyl, sulfonyl,
phenylsulfonyl, trifluoromethylsulfonyl, sulfamoyl or
N,N-dimethylcarbamoyl; and A.sup.5 represents optionally
substituted tetrahydropyrimidine.
[0933] Step CV
[0934] A nitrile represented by the formula (379) is reacted with
sodium hydrosulfide and hydrogen sulfide in an appropriate
alcoholic solvent such as methanol at from -30 to 100.degree. C.
under elevated pressure to thereby give a thioamide represented by
the formula (386).
[0935] Step CVI
[0936] The thioamide represented by the formula (386) is reacted
with an alkylating agent such as methyl iodide in an appropriate
solvent such as acetone. The thioimide thus obtained is then
reacted with an appropriate amine or a derivative of amide or
sulfonamide in an appropriate alcoholic solvent at from room
temperature to 60.degree. C. to thereby give derivatives
represented by the formulae (387), (388), (389) and (390). 173
[0937] wherein G, Z, E, X.sup.2, l.sup.2, Q and R' are each as
defined above.
[0938] Step VIII
[0939] A compound represented by the formula (334) is treated with
an appropriate acid such as hydrochloric acid, trifluoroacetic acid
or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give an amine
represented by the formula (88a). 174
[0940] wherein G, Z, E, X.sup.2, l.sup.2, Q, R.sup.d, R.sup.m and
R' are each as defined above; and Ar represents aryl having no
acidic proton or heteroaryl having no acidic proton.
[0941] Step XXXXI
[0942] A compound represented by the formula (108) is treated with
methyllithium or a methylmagnesium halide in a solvent such as dry
tetrahydrofuran, diethyl ether or dimethoxyethane at from
-78.degree. C. to the boiling point of the solvent to thereby give
an alcohol represented by the formula (391).
[0943] Step LXI
[0944] The compound represented by the formula (108) is reacted in
an appropriate solvent with an aryl-Grignard or aryllithium
obtained by a halogen-metal exchange reaction or a hydrogen-metal
exchange reaction or an aryl cerium complex obtained by treating
the former compound with cerium (III) chloride to thereby give a
compound represented by the formula (392). As the solvent, use can
be made of a dry solvent such as tetrahydrofuran, diethyl ether or
dimethoxyethane. The reaction can be effected at from -100.degree.
C. to the reflux temperature of the solvent.
[0945] Step LIII
[0946] A ketone represented by the formula (108) is reacted with an
anion obtained by treating an alkyne with a strong base such as
n-butyllithium or lithium diisopropylamine in a dry solvent such as
tetrahydrofuran or diethyl ether to thereby give a compound
represented by the formula (393). The reaction can be effected at
from -100.degree. C. to room temperature.
[0947] Step XIV
[0948] The compound represented by the formula (393) is subjected
to a reduction reaction in a solvent with the use of an appropriate
metal catalyst to thereby give a compound represented by the
formula (394). For example, use can be made of a hydrogenation
reaction effected in a solvent such as methanol, ethanol, ethyl
acetate or tetrahydrofuran with the use of palladium, platinum (IV)
oxide, etc. under normal to elevated hydrogen pressure. 175
[0949] wherein G, Z, E, X.sup.2, l.sup.2, Q, Ar, R.sup.e and R' are
each as defined above.
[0950] Step CVII
[0951] Compounds represented by the formulae (392) and (397) are
reacted with dimethylaminosulfur trifluoride optionally in a dry
solvent such as dichloromethane at from room temperature to
50.degree. C. to thereby give compounds represented by the formulae
(395) and (401) respectively.
[0952] Step XXI
[0953] The compound represented by the formula (392) is treated
with a base such as sodium hydride or sodium methoxide in a solvent
such as dimethoxyethane, tetrahydrofuran or N,N-dimethylformamide
and then reacted with an alkyl halide to thereby give a derivative
represented by the formula (396). This reaction is effected
preferably at from -100.degree. C. to room temperature.
[0954] Step XXIX
[0955] A solution of the alcohol represented by the formula (392)
in, for example, methylene chloride is added to a reaction mixture
obtained from oxalyl chloride and dimethyl sulfoxide and treated
with a base such as triethylamine. Alternatively, it is treated
with pyridinium dichromate in a solvent such as dichloromethane or
treated with manganese dioxide in a solvent such as
dichloromethane. Thus, a ketone represented by the formula (397)
can be obtained.
[0956] Step XXXXI
[0957] The compound represented by the formula (397) is treated
with methyllithium or a methylmagnesium halide in a solvent such as
dry tetrahydrofuran, diethyl ether or dimethoxyethane at from
-78.degree. C. to the boiling point of the solvent to thereby give
an alcohol represented by the formula (398).
[0958] Step CVIII
[0959] The compound represented by the formula (398) is reacted
with chloromethanesulfonyl chloride in an appropriate dry solvent
such as dichloromethane in the presence of an appropriate base such
as pyridine to thereby give a compound represented by the formula
(399). The reaction can be effected at from 0.degree. C. to the
reflux temperature.
[0960] Step XIV
[0961] The compound represented by the formula (399) is subjected
to a reduction reaction in a solvent with the use of an appropriate
metal catalyst to thereby give a compound represented by the
formula (400). For example, use can be made of a hydrogenation
reaction effected in a solvent such as methanol, ethanol, ethyl
acetate or tetrahydrofuran with the use of palladium, platinum (IV)
oxide, etc. under normal to elevated hydrogen pressure. 176
[0962] wherein G, Z, E, X.sup.2, l.sup.2, Q, A.sup.a, R.sup.pb and
R' are each as defined above.
[0963] Step LXXXXIII
[0964] A compound represented by the formula (482) is treated with
mercaptoacetic acid in an appropriate dry solvent such as
dichloromethane or tetrahydrofuran in the presence of a strong base
such as sodium hydride to thereby give a compound represented by
the formula (402). The reaction can be effected at from 0 to
100.degree. C.
[0965] Step XI
[0966] The compound represented by the formula (402) is reacted
with an appropriate base in an aqueous solvent to thereby give a
compound having a carboxyl group (403). As the solvent, use can be
made of alcoholic solvents such as methanol or ethanol or solvent
mixtures such as alcohol/tetrahydrofuran/water. As the base, use
can be made of sodium hydroxide, potassium hydroxide, etc. The
reaction can be effected at from room temperature to the reflux
temperature of the solvent.
[0967] Step LXXXVIII
[0968] The alcohol represented by the formula (482) is reacted with
a silylation agent such as chloro-tert-butyldimethylsilane,
(tert-butyldimethylsilyl) trifluoroacetate or
N-methyl-N-(tert-butyldimet- hyl-silyl)trifluoroacetamide in an
appropriate solvent optionally in the presence of a base such as
imidazole, pyridine or N,N-diisopropylethylami- ne to thereby give
an ester compound represented by the formula (404). As the solvent,
use can be made of a dry solvent such as N,N-dimethylformamide,
acetonitrile or dichloromethane. The reaction can be effected at
from 0 to 40.degree. C.
[0969] Step LXXXXV
[0970] A halide represented by the formula (404) is reacted with an
appropriate alkyne in a dry solvent such as N,N-dimethylformamide
at from room temperature to 120.degree. C. in the presence of a
catalyst such as palladium (II) acetate with triphenylphosphine and
a base such as triethylamine to thereby give a compound represented
by the formula (405).
[0971] Step XIV
[0972] The compound represented by the formula (405) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give compound represented by the
formula (406). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure.
[0973] Step LI
[0974] The compounds represented by the formulae (405) and (406)
are treated with a reagent such as tetra-n-butylammonium fluoride
or caesium fluoride in a dry solvent such as tetrahydrofuran to
thereby give compounds represented by the formulae (408) and (407)
respectively. The reaction is effected preferably at from 0.degree.
C. to room temperature. 177
[0975] wherein G, Z, E, X.sup.2, l.sup.2, Q, A.sup.8 and R' are
each as defined above; and A.sup.1a represents saturated
heterocycloalkyl.
[0976] Step XXXXVI
[0977] An alcohol represented by the formula (409) is reacted with
a carboxylic anhydride and an acid halide optionally in an
appropriate solvent in the presence of an appropriate base such as
pyridine, triethylamine or N,N-diisopropylethylamine to thereby
give an ester represented by the formula (410). As the solvent, use
can be made of dry dichloromethane, etc. The reaction can be
effected at from 0.degree. C. to reflux temperature.
[0978] Step XIV
[0979] The compound represented by the formula (410) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (411). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure.
[0980] Step CIX
[0981] The compound represented by the formula (410) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (412). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 178
[0982] wherein G, Z, E, X.sup.2, l.sup.2, Q, A.sup.9 and R' are
each as defined above; and R.sup.pc represents a protective group
such as trityl or dimethylsulfamoyl.
[0983] Step LXI
[0984] A compound represented by the formula (108) is reacted in an
appropriate solvent with an aryl-Grignard or aryllithium obtained
from the compound represented by the formula (413) by a
halogen-metal exchange reaction or a hydrogen-metal exchange
reaction or an arylcerium complex obtained by treating the former
compound with cerium (III) chloride to thereby give a compound
represented by the formula (414). As the solvent, use can be made
of a dry solvent such as tetrahydrofuran, diethyl ether or
dimethoxyethane. The reaction can be effected at from -100.degree.
C. to the reflux temperature of the solvent.
[0985] Step VIII
[0986] When R.sup.pc is a protective group which can be eliminated
by treating with an acid, such as trityl, a compound represented by
the formula (414) is treated with an appropriate acid such as
hydrochloric acid, trifluoroacetic acid or acetic acid optionally
in an appropriate solvent such as dichloromethane or
tetrahydrofuran to thereby give an amine represented by the formula
(415).
[0987] Step XXXXVI
[0988] An alcohol represented by the formula (414) is reacted with
phenyl chlorothioformate optionally in an appropriate solvent in
the presence of an appropriate base such as pyridine, triethylamine
or N,N-diisopropylethylamine to thereby give an ester represented
by the formula (416). As the solvent, use can be made of dry
acetonitrile, dry dichloromethane, etc. The reaction can be
effected at from 0.degree. C. to reflux temperature.
[0989] Step CX
[0990] The compound represented by the formula (416) is treated
with a reducing agent such as tri-n-butyltin (IV) hydride in an
appropriate solvent such as toluene or benzene at from room
temperature to the reflux temperature to thereby give a compound
represented by the formula (417).
[0991] Step XI
[0992] When R.sup.pc is a protective group which can be eliminated
by treating with an alkali, such as dimethylsulfamoyl, the
compounds represented by the formulae (414) and (417) are reacted
with an appropriate base in an aqueous solvent to thereby give
compounds represented by formulae (415) and (418) respectively. As
the solvent, use can be made of alcoholic solvents such as methanol
or ethanol or solvent mixtures such as
alcohol/tetrahydrofuran/water. As the base, use can be made of
sodium hydroxide, potassium hydroxide, etc. The reaction can be
effected at from room temperature to the reflux temperature of the
solvent. 179
[0993] wherein G, Z, E, X.sup.2, l.sup.2, Q, A.sup.8 and R' are
each as defined above.
[0994] Step LXI
[0995] A compound represented by the formula (108) is reacted in an
appropriate solvent with a lithium anion obtained from the compound
represented by the formula (419) by a hydrogen-metal exchange
reaction to thereby give a compound represented by the formula
(420). As the solvent, use can be made of a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane. The reaction can
be effected at from -100.degree. C. to the reflux temperature of
the solvent. 180
[0996] wherein G, Z, E, X.sup.2, l.sup.2, Q, R.sup.a, A.sup.8 and
R' are each as defined above.
[0997] Step LXI
[0998] A compound represented by the formula (105) is reacted in an
appropriate solvent with a lithium anion obtained from the compound
represented by the formula (419) by a hydrogen-metal exchange
reaction to thereby give a compound represented by the formula
(421). As the solvent, use can be made of a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane. The reaction can
be effected at from -100.degree. C. to the reflux temperature of
the solvent. 181
[0999] wherein G, Z, E, X.sup.2, l.sup.2, Q, Ar and R' are each as
defined above.
[1000] Step XXXII
[1001] An appropriate arylmethyltriphenylphosphonium bromide or
heteroarylmethyltriphenylphosphonium bromide is treated with an
appropriate base such as potassium tert-butoxide or butyllithium in
a solvent such as toluene, xylene or tetrahydrofuran followed by a
reaction with an aldehyde represented by the formula (108). Thus a
compound represented by the formula (422) can be obtained. The
reaction temperature preferably ranges from -78.degree. C. to the
reflux temperature of the solvent.
[1002] Step XIV
[1003] The compound represented by the formula (422) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (423). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 182
[1004] wherein G, Z, E, X.sup.2, l.sup.2, Q, X.sub.n,
X.sub.n.sup.1, D.sup.2, l and R' are each as defined above.
[1005] Step XIV
[1006] A compound represented by the formula (424) is subjected to
a reduction reaction with the use of an appropriate metal catalyst
in a solvent to thereby give a compound represented by the formula
(376). The reaction may be carried out in, for example, a solvent
such as methanol, ethanol, ethyl acetate or tetrahydrofuran with
the use of palladium, platinum (IV) oxide, etc. as the catalyst
under normal to elevated hydrogen pressure. 183
[1007] wherein G, Z, E, X.sup.2, l.sup.2, L, Q, X.sub.n,
X.sub.n.sup.1, D.sup.2, l and R' are each as defined above.
[1008] Step XXXXVI
[1009] An amine represented by the formula (376) is reacted with a
carboxylic anhydride and an acid halide optionally in an
appropriate solvent in the presence of an appropriate base such as
pyridine, triethylamine or N,N-diisopropylethylamine to thereby
give amides represented by the formulae (426) and (429). As the
solvent, use can be made of dry dichloromethane, etc. The reaction
can be effected at from 0.degree. C. to reflux temperature.
[1010] Step XXXXVII
[1011] The compound represented by the formula (376) is reacted
with an appropriate sulfonic anhydride or acid halide optionally in
an appropriate solvent such as dichloromethane in the presence of
an appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give a compound represented by
the formula (425).
[1012] Step XXXXVIII
[1013] The amine represented by the formula (376) is treated with
an acid halide of an appropriate sulfamic acid optionally in an
appropriate solvent such as dichloromethane in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine. Alternatively, it is treated with
chlorosulfonyl isocyanate in a dry solvent such as tetrahydrofuran
and the intermediate is treated with an appropriate acid such as
formic acid. Alternatively, it is reacted with sulfamide in
dimethoxyethane at 100.degree. C. Thus, a compound represented by
the formula (428) can be obtained.
[1014] Step LXXXIII
[1015] The isoxazole represented by the formula (426) is treated
with N,N-dimethylformamide dimethyl acetal in a dry solvent such as
tetrahydrofuran at from room temperature to the reflux temperature
to thereby give a compound represented by the formula (427).
184
[1016] wherein G, Z, E, X.sup.2, l.sup.2, M, Q, R.sup.a, R.sup.c,
R.sup.d, R.sup.k and R' are each as defined above; and D.sup.3
represents an imidazole or pyridine ring.
[1017] Step LXXXX
[1018] A carboxylic acid represented by the formula (431) is
reacted with an appropriate diimide, an appropriate chloroformate,
an appropriate dichlorophosphonate or carbonyldiimidazole at from 0
to 60.degree. C. in an appropriate dry solvent such as
N,N-dimethylformamide, tetrahydrofuran, acetonitrile or
dichloromethane optionally in the presence of an appropriate base
such as pyridine, triethylamine or N,N-diisopropylethylamine. The
activated ester thus obtained is then reacted with ammonia to
thereby give an amide represented by the formula (432).
[1019] Step XI
[1020] The compound represented by the formula (430) is reacted
with an appropriate base in an aqueous solvent to thereby give a
compound having a carboxyl group (431). As the solvent, use can be
made of alcoholic solvents such as methanol or ethanol or solvent
mixtures such as alcohol/tetrahydrofuran/water. As the base, use
can be made of sodium hydroxide, potassium hydroxide, etc. The
reaction can be effected at from room temperature to the reflux
temperature of the solvent.
[1021] Step LXXXIX
[1022] The ester represented by the formula (430) is treated with
an appropriate amine optionally in an appropriate solvent such as
methanol, ethanol or tetrahydrofuran at from room temperature to
150.degree. C. under atmospheric or elevated pressure to thereby
give a compound represented by the formula (432).
[1023] Step XXXXI
[1024] The compounds represented by the formulae (430) and (435)
are treated with methyllithium or a methylmagnesium halide in a
solvent such as dry tetrahydrofuran, diethyl ether or
dimethoxyethane at from -78.degree. C. to the boiling point of the
solvent to thereby give alcohols represented by the formulae (433)
and (436) respectively.
[1025] Step XXIV
[1026] The compound represented by the formula (430) is treated
with a reducing agent such as aluminum lithium hydride or lithium
borohydride in a solvent such as dry tetrahydrofuran or dry diethyl
ether to thereby give an amine of the formula (434). The reaction
can be effected at from 0.degree. C. to the reflux temperature.
[1027] Step XXIX
[1028] A solution of the alcohol represented by the formula (434)
in, for example, methylene chloride is added to a reaction mixture
obtained from oxalyl chloride and dimethyl sulfoxide and treated
with a base such as triethylamine. Alternatively, it is treated
with pyridinium dichromate in a solvent such as dichloromethane or
treated with manganese dioxide in a solvent such as dichloromethane
or N,N-dimethylformamide. Thus, a carbonyl compound represented by
the formula (435) can be obtained.
[1029] Step XIII
[1030] The compound represented by the formula (435) is reacted
with an appropriate Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (437). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, lithium diisopropylamide,
etc. The reaction can be effected at from -100.degree. C. to the
reflux temperature of the solvent. 185
[1031] wherein G, Z, E, X.sup.2, l.sup.2, R', Q and R.sup.m are
each as defined above.
[1032] Step XXIV
[1033] A compound represented by the formula (438) is treated with
a reducing agent such as aluminum lithium hydride or lithium
borohydride in a solvent such as dry tetrahydrofuran or dry diethyl
ether, or with a reducing agent such as sodium borohydride in an
alcoholic solvent such as methanol or ethanol to thereby give an
amine of the formula (439). The reaction can be effected at from
0.degree. C. to the reflux temperature. 186
[1034] wherein R.sup.a, A.sup.9 and R.sup.pc are each as defined
above.
[1035] Step LXI
[1036] An appropriate aldehyde is reacted in an appropriate solvent
with an aryl-Grignard obtained from the compound represented by the
formula (440) by a halogen-metal exchange reaction or a
hydrogen-metal exchange reaction or an arylcerium complex obtained
by treating the former compound with cerium (III) chloride to
thereby give compounds represented by the formulae (441) and (446).
As the solvent, use can be made of a dry solvent such as
tetrahydrofuran, diethyl ether or dimethoxyethane. The reaction can
be effected at from -100.degree. C. to the reflux temperature of
the solvent.
[1037] Step XXXXVI
[1038] Alcohols represented by the formulae (441) and (447) are
reacted with a carboxylic anhydride, a carboxylic phosphoric
anhydride and an acid halide optionally in an appropriate solvent
in the presence of an appropriate base such as pyridine,
triethylamine or N,N-diisopropylethylamine to thereby give esters
represented by the formulae (442) and (448) respectively. As the
solvent, use can be made of dry dichloromethane, etc. The reaction
can be effected at from 0.degree. C. to reflux temperature.
[1039] Step XIV
[1040] The compounds represented by the formulae (442) and (448)
are subjected to a reduction reaction with the use of an
appropriate metal catalyst in a solvent to thereby give compounds
represented by the formulae (443) and (449) respectively. The
reaction may be carried out in, for example, a solvent such as
methanol, ethanol, ethyl acetate or tetrahydrofuran with the use of
palladium, platinum (IV) oxide, etc. as the catalyst under normal
to elevated hydrogen pressure.
[1041] Step XI
[1042] The compounds represented by the formulae (441) and (443)
are reacted with an appropriate base in an aqueous solvent to
thereby give compounds represented by the formulae (445) and (444).
As the solvent, use can be made of alcoholic solvents such as
methanol or ethanol or solvent mixtures such as
alcohol/tetrahydrofuran/water. As the base, use can be made of
sodium hydroxide, potassium hydroxide, etc. The reaction can be
effected at from room temperature to the reflux temperature of the
solvent.
[1043] Step CXI
[1044] The compound represented by the formula (446) is reacted
with an appropriate base such as potassium hydroxide in an
appropriate solvent such as ethanol at from room temperature to the
reflux temperature. The intermediate thus obtained is then treated
with an acid such as sulfuric acid in an appropriate solvent such
as methanol or ethanol at from room temperature to the reflux
temperature to thereby give compounds represented by the formulae
(447) and (450). 187
[1045] wherein G, Z, E, X.sup.2, l.sup.2, R', Q, X.sub.n,
X.sub.n.sup.1, D.sup.2 and l are each as defined above.
[1046] Step CXII
[1047] An aldehyde represented by the formula (451) is treated with
3-hydroxy-3-methyl-2-butanone in a solvent such as methanol or
tetrahydrofuran or a mixture thereof in the presence of an
appropriate base such as lithium hydroxide to thereby give a
compound represented by the formula (452).
[1048] Step XIV
[1049] The compound represented by the formula (452) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (453). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 188
[1050] wherein R.sup.n represents methyl or tert-butyloxy.
[1051] Step XXXXVI
[1052] An amine represented by the formula (454) is reacted with
sodium hydride optionally in an appropriate solvent in the presence
of an appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine and the free compound thus obtained is
then reacted with a carboxylic anhydride and an acid halide to
thereby give an amide represented by the formula (455). As the
solvent, it is preferable to use dry N,N-dimethylformamide. The
reaction can be effected at from 0.degree. C. to the reflux
temperature.
[1053] Step VII
[1054] The amine represented by the formula (455) is treated with a
base such as sodium hydride and a protecting reagent such as
(2-trimethylsilyl)-ethoxymethyl chloride in a solvent such as dry
N,N-dimethylformamide at from 0.degree. C. to room temperature to
thereby give a compound represented by the formula (456). 189
[1055] wherein G, Z, E, X.sup.2, l.sup.2 and R' are each as defined
above.
[1056] Step VIII
[1057] A compound represented by the formula (457) is treated with
an appropriate acid such as hydrochloric acid, trifluoroacetic acid
or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give an amine
represented by the formula (458). 190
[1058] wherein Hal, R.sup.d and R.sup.m are each as defined
above.
[1059] Step XV
[1060] A compound represented by the formula (459) is reacted with
a base such as sodium hydride in a solvent such as dry
N,N-dimethylformamide. Then the anion thus obtained is reacted with
an appropriate halide at from room temperature to 100.degree. C. to
thereby give a compound represented by the formula (460).
[1061] Step LXXXXIII
[1062] The diester represented by the formula (460) is treated with
a base such as sodium hydride in a solvent such as dry
N,N-dimethylformamide at from 0.degree. C. to room temperature.
Then the anion thus obtained is reacted with a halide represented
by the formula (461) at from room temperature to 100.degree. C. to
thereby give a compound represented by the formula (462).
[1063] Step XI
[1064] The compound represented by the formula (462) is reacted
with an appropriate base such as sodium hydroxide or potassium
hydroxide in an alcoholic solvent such as methanol or ethanol or an
aqueous solvent such as a solvent mixture of alcohol,
tetrahydrofuran and water at from room temperature to the reflux
temperature the solvent. Alternatively, it is reacted with lithium
chloride in a solvent such as dry N,N-dimethylformamide. Thus
compounds represented by the formulae (463) and (465) can be
obtained.
[1065] Step XIV
[1066] The compounds represented by the formulae (463) and (465)
are subjected to a reduction reaction with the use of an
appropriate metal catalyst in a solvent to thereby give compounds
represented by the formulae (464) and (466). The reaction may be
carried out in, for example, a solvent such as methanol, ethanol,
ethyl acetate or tetrahydrofuran with the use of palladium,
platinum (IV) oxide, etc. as the catalyst under normal to elevated
hydrogen pressure. 191
[1067] wherein G, Z, E, X.sup.2, l.sup.2, Nu, M, R' and R.sup.a are
each as defined above.
[1068] Step LXXXXIV
[1069] A compound represented by the formula (460) is reacted with
an aldehyde represented by the formula (108) in an appropriate
solvent such as toluene or benzene at from room temperature to the
reflux temperature. The intermediate thus obtained is then treated
with an appropriate reducing agent such as sodium borohydride or
sodium borocyanohydride in an appropriate alcoholic solvent such as
ethanol or methanol or an appropriate solvent mixture such as
ethanol/tetrahydrofuran at from 50.degree. C. to the reflux
temperature to thereby give a compound represented by the formula
(468). 192
[1070] wherein G, Z, Q, E, X.sup.2, l.sup.2, R', L.sup.1, R.sup.k
and R.sup.m are each as defined above; and R.sup.m1 has the same
meaning as that of R.sup.m, provided that when R.sup.m and R.sup.m1
both exist in the molecule, then they may be the same or
different.
[1071] Step XXI
[1072] An amine represented by the formula (469) is reacted with an
appropriate alkyl halide in the presence of an appropriate amine
such as pyridine, triethylamine or N,N-diisopropylethylamine in a
solvent such as dichloromethane, tetrahydrofuran or
N,N-dimethylformamide to thereby give an amine represented by the
formula (470).
[1073] Step XXXXVI
[1074] An amine represented by the formula (469) is reacted with a
carboxylic anhydride and an acid halide optionally in an
appropriate solvent in the presence of an appropriate base such as
pyridine, triethylamine or N,N-diisopropylethylamine to thereby
give an amide represented by the formula (475). As the solvent, use
can be made of dry dichloromethane, etc. The reaction can be
effected at from 0.degree. C. to reflux temperature.
[1075] Step LXXXXIV
[1076] The compound represented by the formula (469) is reacted
with formalin in an appropriate solvent such as acetonitrile at
from room temperature to the reflux temperature in the presence of
an appropriate reducing agent such as sodium borohydride or sodium
borocyanohydride to thereby give a compound represented by the
formula (474).
[1077] Step XXXXVII
[1078] The amine represented by the formula (469) is reacted with
an appropriate sulfonic anhydride or acid halide optionally in an
appropriate solvent such as dichloromethane in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give a compound represented by
the formula (473).
[1079] Step LII
[1080] The compound represented by the formula (469) is reacted
with sodium isocyanate, potassium isocyanate, etc. in a solvent
such as water or ethanol optionally in the presence of an
appropriate acid such as acetic acid. Alternatively, it is reacted
with trimethylsilyl isocyanate in a dry solvent such as
tetrahydrofuran in the presence of a base such as triethylamine at
from room temperature to the reflux temperature to thereby give a
compound represented by the formula (471).
[1081] Step L
[1082] The compound represented by the formula (469) is reacted
with an appropriate isocyanate in an appropriate solvent to thereby
give a compound represented by the formula (472). As the solvent,
use can be made of tetrahydrofuran, toluene, etc. The reaction can
be effected at from room temperature to the reflux temperature of
the solvent. 193
[1083] wherein G, Z, Q, E, X.sup.2, l.sup.2, R and R.sup.m are each
as defined above.
[1084] Step CXIII
[1085] A compound represented by the formula (476) is reacted with
phthalimide in an appropriate dry solvent such as tetrahydrofuran
or dichloromethane in the presence of triphenylphosphine and
diethyl diazodicarboxylate to thereby give a compound represented
by the formula (477). The reaction can be effected at from
0.degree. C. to the reflux temperature.
[1086] Step CXIV
[1087] The compound represented by the formula (477) is reacted
with hydrazine in an alcoholic solvent such as ethanol to thereby
give an amine derivative represented by the formula (478). The
reaction is effected preferably at from 50.degree. C. to the reflux
temperature. 194
[1088] wherein G, Q, Z, E, X.sup.2, l.sup.2, R, R' and R.sup.d are
each as defined above.
[1089] Step XXXXVI
[1090] An amine represented by the formula (479) is reacted with a
carboxylic anhydride and an acid halide optionally in an
appropriate solvent in the presence of an appropriate base such as
pyridine, triethylamine or N,N-diisopropylethylamine to thereby
give amides represented by the formulae (480) and (483). As the
solvent, use can be made of dry dichloromethane, dry
tetrahydrofuran, etc. The reaction can be effected at from
0.degree. C. to the reflux temperature.
[1091] Step CXV
[1092] The amine represented by the formula (479) is heated under
reflux in ethyl formate to thereby give an amdie derivative
represented by the formula (481).
[1093] Step CXVI
[1094] Benzoyl chloride is treated with ammonium thiocyanate in
acetone. The reagent thus obtained is then reacted with the amine
represented by the formula (479) to thereby give a thiourea
derivative represented by the formula (484).
[1095] Step VIII
[1096] A compound represented by the formula (484) is treated with
an appropriate acid such as hydrochloric acid, trifluoroacetic acid
or acetic acid optionally in an appropriate solvent such as
dichloromethane or tetrahydrofuran to thereby give an amine
represented by the formula (485).
[1097] Step XI
[1098] The compound represented by the formula (485) is reacted
with an appropriate base such as sodium hydroxide or potassium
hydroxide in an alcoholic solvent such as methanol or ethanol or an
aqueous solvent such as a solvent mixture of alcohol,
tetrahydrofuran and water at from room temperature to the reflux
temperature of the solvent to thereby give a compound represented
by the formula (486). 195
[1099] wherein G, Q, Z, E, X.sup.2, l.sup.2, R', R.sup.m and
L.sup.1 are each as defined above.
[1100] Step XXI
[1101] A compound represented by the formula (487) is treated with
an appropriate base such as sodium hydride or sodium methoxide in a
solvent such as dimethoxyethane, tetrahydrofuran or
N,N-dimethylformamide and then reacted with an appropriate alkyl
halide to thereby give a derivative represented by the formula
(488). The reaction can be effected at from -100.degree. C. to room
temperature.
[1102] Step L
[1103] The compound represented by the formula (487) is reacted
with an isocyanate in an appropriate solvent to thereby give a
compound represented by the formula (489). As the solvent, use can
be made of tetrahydrofuran or toluene. The reaction can be effected
at from room temperature to the reflux temperature of the solvent.
It is sometimes preferable to effect the reaction in the presence
of a base such as pyridine or triethylamine. 196
[1104] wherein G, Z, Q, E, X.sup.2, l.sup.2, R', R.sup.a and
R.sup.c are each as defined above.
[1105] Step CXVII
[1106] An aldehyde represented by the formula (108) is reacted with
a trihalomethane such as tribromoethane in an aqueous solvent
mixture such as water/1,4-dioxane at from 0.degree. C. to room
temperature in the presence of a base such as potassium hydroxide
or sodium hydroxide and lithium chloride to thereby give a compound
represented by the formula (490).
[1107] Step III
[1108] The compound represented by the formula (490) is reacted
with an alkylating agent such as methyl iodide in a dry solvent
such as N,N-dimethylformamide or tetrahydrofuran at from 0 to
40.degree. C. in the presence of a base such as potassium carbonate
to thereby give an ester represented by the formula (491).
[1109] Step CXVIII
[1110] The aldehyde represented by the formula (108) is reacted
with a haloacetic acid derivative such as methyl bromoacetate in an
appropriate dry solvent such as dry tetrahydrofuran in the presence
of trimethyl borate and zinc dust to thereby give a compound
represented by the formula (492).
[1111] Step XXIV
[1112] The compound represented by the formula (492) is treated
with a reducing agent such as aluminum lithium hydride or lithium
borohydride in a solvent such as dry tetrahydrofuran or dry diethyl
ether to thereby give an amine of the formula (493). The reaction
can be effected at from 0.degree. C. to the reflux temperature.
197
[1113] wherein G, Q, Z, E, X.sup.2, l.sup.2, R' and R.sup.a are
each as defined above.
[1114] Step XIII
[1115] The compound represented by the formula (108) is reacted
with an appropriate Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (494). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, lithium diisopropylamide,
etc. The reaction can be effected at from -100.degree. C. to the
reflux temperature of the solvent.
[1116] Step XXIV
[1117] The compound represented by the formula (494) is treated
with a reducing agent such as aluminum lithium hydride or lithium
borohydride in a solvent such as dry tetrahydrofuran or dry diethyl
ether to thereby give an alcohol of the formula (495). The reaction
can be effected at from 0.degree. C. to the reflux temperature.
[1118] Step XIV
[1119] The compound represented by the formula (495) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (496). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 198
[1120] wherein G, Q, Z, E, X.sup.2, l.sup.2, R.sup.m, V.sup.1, R'
and R.sup.a are each as defined above.
[1121] Step XI
[1122] A compound represented by the formula (105) is reacted with
an appropriate base such as sodium hydroxide or potassium hydroxide
In an alcoholic solvent such as methanol or ethanol or an aqueous
solvent such as a solvent mixture of alcohol, tetrahydrofuran and
water at from room temperature to the reflux temperature of the
solvent to thereby give a compound represented by the formula
(499).
[1123] Step XVII
[1124] The compound represented by the formula (497) is treated
with hydrogen peroxide in a solvent such as ethanol or dimethyl
sulfoxide or a mixture thereof in the presence of a base such as
sodium hydroxide or potassium hydroxide at from 0.degree. C. to
room temperature. Alternatively, it is reacted with an alkali such
as sodium hydroxide or potassium hydroxide in a solvent such as
dimethyl sulfoxide at from 50 to 100.degree. C. to thereby give a
compound represented by the formula (498).
[1125] Step CXIX
[1126] The amide represented by the formula (498) is treated with
bromine in water in the presence of a base such as sodium hydroxide
or potassium hydroxide to thereby give an amine represented by the
formula (479).
[1127] Step LXXXIX
[1128] The ester represented by the formula (105) is treated with
hydroxylamine hydrochloride in a solvent mixture such as
tetrahydrofuran/water in the presence of a base such as sodium
hydroxide or potassium hydroxide to thereby give a compound
represented by the formula (500).
[1129] Step LXXXX
[1130] The carboxylic acid represented by the formula (499) is
reacted with an appropriate diimide, an appropriate chloroformate,
an appropriate dichlorophosphonate or carbonyldiimidazole at from 0
to 60.degree. C. in an appropriate dry solvent such as
N,N-dimethylformamide, tetrahydrofuran, acetonitrile or
dichloromethane optionally in the presence of an appropriate base
such as pyridine, triethylamine or N,N-diisopropylethylamine. The
activated ester thus obtained is then reacted with ammonia or an
appropriate amine or amine derivative to thereby give amides
represented by the formulae (498), (501) and (502). 199
[1131] wherein G, Z, Q, E, X.sup.2, l.sup.2 and R' are each as
defined above.
[1132] Step XIII
[1133] The compound represented by the formula (108) is reacted
with an appropriate Horner-Emmons reagent in a solvent in the
presence of an appropriate base to thereby give a compound
represented by the formula (503). As the solvent, use can be made
of dry solvents such as N,N-dimethylformamide, tetrahydrofuran or
diethyl ether. As the base, use can be made of sodium hydride,
potassium tert-butoxide, n-butyllithium, lithium diisopropylamide,
etc. The reaction can be effected at from -100.degree. C. to the
reflux temperature of the solvent.
[1134] Step LXXXVII
[1135] The nitrile represented by the formula (503) is treated with
an azidation agent such as sodium azide in a dry solvent such as
dimethyl sulfoxide, N,N-dimethylformamide or 1-methyl-2-pyrrolidone
at from 50.degree. C. to the reflux temperature to thereby give a
tetrazole derivative represented by the formula (504).
[1136] Step CXXI
[1137] In a dry solvent such as tetrahydrofuran,
(tirmethylsilyl)dizaometh- ane is treated with a strong base such
as n-butyllithium at from -100.degree. C. to room temperature. The
anion thus obtained is reacted with the compound of the formula
(503) to thereby give a pyrazole derivative represented by the
formula (505).
[1138] Step LI
[1139] The compound represented by the formula (505) is treated
with a reagent such as tetra-n-butylammonium fluoride or caesium
fluoride in a dry solvent such as tetrahydrofuran to thereby give a
compound represented by the formula (506).
[1140] Step LXV
[1141] An aldehyde derivative represented by the formula (108) is
reacted with hydroxylamine in a solvent such as ethanol or
tetrahydrofuran in the presence of a catalyst such as sodium
acetate or ammonium acetate to thereby give an oxime represented by
the formula (507). This reaction can be effected at from room
temperature to the reflux temperature.
[1142] Step CXX
[1143] The oxime represented by the formula (507) is heated under
reflux in trifluoroacetonitrile to thereby give a nitrile
represented by the formula (497).
[1144] Step LXXXVII
[1145] The nitrile represented by the formula (497) is treated with
an azidation agent such as sodium azide in a dry solvent such as
dimethyl sulfoxide, N,N-dimethylformamide or 1-methyl-2-pyrrolidone
at from 50.degree. C. to the reflux temperature in the presence of
a catalyst such as ammonium chloride to thereby give a tetrazole
derivative represented by the formula (508).
[1146] Step CXXII
[1147] The aldehyde represented by the formula (108) is reacted
with 2-aminoethanethiol in an alcoholic solvent such as methanol in
the presence of a base such as sodium methoxide at from room
temperature to the reflux temperature to thereby give a compound
represented by the formula (509). 200
[1148] wherein G, Z, Q, E, X.sup.2, l.sup.2, Hal, R.sup.m, R.sup.k
and R are each as defined above.
[1149] Step XXVIII
[1150] A halide represented by the formula (510) is treated with a
cyanidation reagent such as sodium cyanide or potassium cyanide in
an appropriate solvent such as dimethyl sulfoxide to thereby give a
nitrile compound represented by the formula (511). The reaction can
be effected at from room temperature to 100.degree. C.
[1151] Step CV
[1152] The nitrile represented by the formula (511) is reacted with
sodium hydrosulfide and hydrogen sulfide in an appropriate solvent
such as methanol at from -30 to 100.degree. C. under elevated
pressure to thereby give a thioamide represented by the formula
(512).
[1153] Step CXXIII
[1154] The thioamide represented by the formula (512) is reacted
with an appropriate .alpha.-halocarbonyl derivative in an
appropriate solvent mixture such as tetrahydrofuran/dimethoxyethane
or ethanol/N,N-dimethylformamide at from room temperature to
100.degree. C. optionally in the presence of an appropriate base
such as potassium hydrogencarboante or sodium hydrogencarbonate to
thereby give compounds represented by the formulae (513) and
(514).
[1155] Step CXXIV
[1156] The compound represented by the formula (513) is reacted
with an appropriate acid anhydride such as trifluoroacetic
anhydride, an acid halide, etc. in an appropriate solvent such as
dimethoxyethane in the presence of an appropriate base such as
pyridine to thereby give a thiazole represented by the formula
(514).
[1157] Step CXXV
[1158] The thioamide represented by the formula (512) is reacted
with hydrazine in an appropriate solvent such as tetrahydrofuran or
ethanol or a mixture thereof at from room temperature to the reflux
temperature. The intermediate thus obtained is treated with an
appropriate orthoester in an appropriate solvent such as
tetrahydrofuran or ethanol or a mixture thereof at from room
temperature to the reflux temperature to thereby give a compound
represented by the formula (515). 201
[1159] wherein G, Z, Q, E, X.sup.2, l.sup.2, Nu and R' are each as
defined above.
[1160] Step CXXVI
[1161] An aldehyde represented by the formula (108) is treated with
a tosylmethyl isocyanide in an appropriate alcoholic solvent such
as methanol or ethanol in the presence of an appropriate base such
as potassium carbonate or sodium carbonate to thereby give an
oxazole represented by the formula (516). The reaction can be
effected at from room temperature to the reflux temperature of the
solvent.
[1162] Step CXXVII
[1163] The aldehyde represented by the formula (108) is reacted
with an appropriate secondary amine in pyridine to thereby give a
compound represented by the formula (517). The reaction is effected
preferably at from 50.degree. C. to the reflux temperature.
[1164] Step XXXXIV
[1165] The imine represented by the formula (517) is heated under
reflux in pyridine in the presence of oxygen to thereby give a
cyclized product represented by the formula (518). 202
[1166] wherein G, Z, Q, E, X.sup.2, l.sup.2, Nu and R' are each as
defined above.
[1167] Step XVI
[1168] The ketone compound represented by the formula (519) is
treated with a strong base such as lithium diisopropylamide in a
dry solvent such as tetrahydrofuran or diethyl ether. Then the
anion thus obtained is treated with an acetylation agent such as
acetic anhydride or acetyl chloride to thereby give a diketone
compound represented by the formula (520).
[1169] Step CXIV
[1170] The compound represented by the formula (520) is reacted
with hydrazine or hydroxylamine in an alcoholic solvent such as
methanol or ethanol to thereby give a compound represented by the
formula (521). The reaction can be effected preferably at from
50.degree. C. to the reflux temperature. 203
[1171] wherein G, Z, Q, E, X.sup.2, l.sup.2, Hal and R' are each as
defined above.
[1172] Step LXXXIX
[1173] An acid halide represented by the formula (522) is treated
with 2-aminopyridine optionally in an appropriate solvent such as
dichloromethane, methanol or tetrahydrofuran or a solvent mixture
such as ethanol/tetrahydrofuran in the presence of an appropriate
base such as sodium hydrogencarbonate, pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give a compound represented by
the formula (523). The reaction can be effected at from 0.degree.
C. to the reflux temperature.
[1174] Step CXXVIII
[1175] The ketone compound represented by the formula (523) is
treated with thionyl chloride in an appropriate dry solvent such as
carbon tetrachloride at from room temperature to the reflux
temperature to thereby give a compound represented by the formula
(524).
[1176] Step CXXIII
[1177] The haloketone represented by the formula (522) is reacted
with an appropriate thioamide derivative or thioimidate in an
appropriate solvent mixture such as tetrahydrofuran/dimethoxyethane
or ethanol/N,N-dimethylformamide at from room temperature to
100.degree. C. optionally in the presence of an appropriate base
such as potassium hydrogencarbonate or sodium hydrogencarbonate to
thereby give compounds represented by the formulae (525) and (526).
204
[1178] wherein G, Z, Q, E, X.sup.2 and l.sup.2 are each as defined
above.
[1179] Step XXXXIV
[1180] An amine represented by the formula (527) is heated in an
appropriate: solvent to thereby give a triazole derivative
represented by the formula (528). As the solvent, use can be made
of dry N,N-dimethylformamide, etc. The reaction is effected
preferably at from 50 to 150.degree. C. 205
[1181] wherein B.sup.1 and R' are each as defined above.
[1182] Step XXXXII
[1183] A compound represented by the formula (530) is treated with
a base such as sodium hydride and then reacted with a halogen
compound (529) in a solvent such as dry N,N-dimethylformamide or
tetrahydrofuran to thereby give a compound represented by the
formula (531).
[1184] Step XXXXIII
[1185] The nitro compounds represented by the formulae (531) and
(535) are treated with a reducing agent such as iron in a solvent
mixture of an alcohol, tetrahydrofuran and water in the presence of
ammonium chloride. Alternatively, it is treated with sodium
hydrosulfite in a solvent mixture of tetrahydrofuran with water.
Thus, compounds represented by the formulae (532) and (536) can be
produced respectively. As the alcohol, use can be made of methanol,
ethanol, isopropanol etc.
[1186] Step VII
[1187] The amines represented by the formulae (532) and (534) are
treated with a base such as sodium hydride and a protecting reagent
such as methoxymethyl chloride in a solvent such as
N,N-dimethylformamide to thereby give compounds represented by the
formulae (533) and (535) respectively.
[1188] Step XXI
[1189] The compounds represented by the formulae (534) and (536)
are treated with a base such as sodium hydride and an appropriate
alkylating agent in a dry solvent such as N,N-dimethylformamide to
thereby give compounds represented by the formulae (531) and (537)
respectively. 206
[1190] wherein G, Z, Q, E, X.sup.2, l.sup.2 and R' are each as
defined above.
[1191] Step CXXIX
[1192] An alkene represented by the formula (538) is treated with
osmium tetraoxide in a solvent such as acetone or tert-butanol or a
mixture thereof in the presence of an oxidizing agent such as
N-methyl-morpholine to thereby give a diol represented by the
formula (539).
[1193] Step XXXXIII
[1194] The nitro compound represented by the formula (539) is
treated with a reducing agent such as iron in a solvent mixture of
an alcohol, tetrahydrofuran and water in the presence of ammonium
chloride. Alternatively, it is treated with sodium hydrosulfite in
a solvent mixture of tetrahydrofuran with water. Thus, a compound
represented by the formula (540) can be produced. As the alcohol,
use can be made of methanol, ethanol, isopropanol, etc. 207
[1195] wherein R.sup.k is as defined above.
[1196] Step XIV
[1197] The compound represented by the formula (541) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (542). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure. 208
[1198] wherein G, Z, Q, E, X.sup.2, l.sup.2, M, R.sup.a and R' are
each as defined above.
[1199] Step XXIV
[1200] A compound represented by the formula (543) is treated with
a reducing agent such as aluminum lithium hydride or lithium
borohydride in a solvent such as dry tetrahydrofuran or dry diethyl
ether to thereby give an alcohol of the formula (544). The reaction
can be effected at from 0.degree. C. to the reflux temperature.
209
[1201] wherein G, Z, Q, E, X.sup.2, l.sup.2, M, R.sup.k, R.sup.1
and R' are each as defined above.
[1202] Step LXXXIX
[1203] A halide represented by the formula (545) is treated with an
appropriate amine in an appropriate alcoholic solvent such as
methanol or ethanol to thereby give an amine derivative represented
by the formula (546). The reaction can be effected at from room
temperature to the reflux temperature.
[1204] Step XXXXIII
[1205] The nitro compound represented by the formula (546) is
treated with a reducing agent such as iron in a solvent mixture of
an alcohol, tetrahydrofuran and water in the presence of ammonium
chloride. Alternatively, it is treated with sodium hydrosulfite in
a solvent mixture of tetrahydrofuran with water. Thus, a compound
represented by the formula (547) can be produced. As the alcohol,
use can be made of methanol, ethanol, isopropanol, etc. 210
[1206] wherein G, Z, Q, E, X.sup.2, l.sup.2, M, L.sup.1 and R' are
each as defined above.
[1207] Step XXXXVII
[1208] An amine represented by the formula (548) is reacted with an
appropriate sulfonic anhydride or acid halide optionally in an
appropriate solvent such as dichloromethane in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give a compound represented by
the formula (549).
[1209] Step LXXIX
[1210] The sulfonic acid derivative represented by the formula
(549) is treated with an appropriate sulfonamide in a dry solvent
such as tetrahydrofuran or N,N-dimethylformamide in the presence of
a strong base such as sodium hydride or lithium diisopropylamide at
from 0 to 100.degree. C. to thereby give a compound represented by
the formula (550). 211
[1211] wherein G, Z, Q, E, X.sup.2, l.sup.2, M, Hal and R' are each
as defined above.
[1212] Step XXI
[1213] A compound represented by the formula (551) is treated with
a base such as sodium hydride and an appropriate alkylating agent
in a dry solvent such as N,N-dimethylformamide to thereby give a
compound represented by the formula (552).
[1214] Step LXXXVII
[1215] The nitrile represented by the formula (552) is treated with
an azidation agent such as sodium azide in a dry solvent such as
dimethyl sulfoxide, N,N-dimethylformamide or 1-methyl-2-pyrrolidone
at from 50.degree. C. to the reflux temperature to thereby give an
azide represented by the formula (553).
[1216] Step XIV
[1217] The compound represented by the formula (553) is subjected
to a reduction reaction with the use of an appropriate metal
catalyst in a solvent to thereby give a compound represented by the
formula (555). The reaction may be carried out in, for example, a
solvent such as methanol, ethanol, ethyl acetate or tetrahydrofuran
with the use of palladium, platinum (IV) oxide, etc. as the
catalyst under normal to elevated hydrogen pressure.
[1218] Step CXIII
[1219] The compound represented by the formula (552) is reacted
with phthalimide in an appropriate dry solvent such as
tetrahydrofuran or dichloromethane in the presence of
triphenylphosphine and diethyl diazodicarboxylate to thereby give a
compound represented by the formula (554). The reaction can be
effected at from 0.degree. C. to the reflux temperature.
[1220] Step CXIV
[1221] The compound represented by the formula (554) is reacted
with hydrazine in an alcoholic solvent such as ethanol to thereby
give an amine derivative represented by the formula (555). The
reaction is effected preferably at from 50.degree. C. to the reflux
temperature.
[1222] Step XXXXVII
[1223] The amine represented by the formula (555) is reacted with
an appropriate sulfonic anhydride or acid halide optionally in an
appropriate solvent such as dichloromethane or
N,N-dimethylformamide in the presence of an appropriate base such
as pyridine, triethylamine or N,N-diisopropylethylamine to thereby
give a compound represented by the formula (556).
[1224] Step CXXX
[1225] The amine represented by the formula (555) is reacted with
formamidinesulfonic acid or an appropriate methylisothiourea
derivative in an appropriate alcoholic solvent such as methanol at
from 0.degree. C. to the reflux temperature to thereby give a
compound represented by the formula (557).
[1226] Step LII
[1227] The compound represented by the formula (555) is reacted
with sodium isocyanate, potassium isocyanate, etc. in a solvent
such as water or ethanol optionally in the presence of an
appropriate acid such as acetic acid. Alternatively, it is reacted
with trimethylsilyl isocyanate in a dry solvent such as
tetrahydrofuran in the presence of a base such as triethylamine at
from room temperature to the reflux temperature to thereby give a
compound represented by the formula (558).
[1228] Step XXXXVI
[1229] An amine represented by the formula (555) is reacted with a
carboxylic anhydride, a carboxylic phosphoric anhydride or an acid
halide optionally in an appropriate solvent in the presence of an
appropriate base such as pyridine, triethylamine or
N,N-diisopropylethylamine to thereby give an amide represented by
the formula (559). As the solvent, use can be made of dry
N,N-dimethylformamide, dry dichloromethane, etc. The reaction can
be effected at from 0.degree. C. to the reflux temperature. 212
[1230] wherein G, Z, Q, E, X.sup.2, l.sup.2 and R' are each as
defined above.
[1231] Step LXX
[1232] The nitrile compound represented by the formula (497) is
treated with diisobutylaluminum hydride in an appropriate solvent
such as toluene or dichloromethane to thereby give an aldehyde
compound represented by the formula (108). The reaction temperature
preferably ranges from -100.degree. C. to room temperature. 213
[1233] wherein G, Z, Q, E, X.sup.2, l.sup.2 and R' are each as
defined above.
[1234] Step XXXII
[1235] Methyltriphenylphosphonium bromide is reacted with an
appropriate base such as potassium tert-butoxide or butyllithium in
a solvent such as N,N-dimethylformamide, toluene, xylene or
tetrahydrofuran followed by a reaction with an aldehyde represented
by the formula (108). Thus a compound represented by the formula
(560) can be obtained. The reaction temperature preferably ranges
from room temperature to 100.degree. C.
[1236] Step CXXIX
[1237] The alkene represented by the formula (560) is treated with
osmium tetraoxide in a solvent such as acetone or tert-butanol or a
mixture thereof in the presence of an oxidizing agent such as
N-methylmorpholine oxide to thereby give a diol represented by the
formula (561). 214
[1238] wherein G, Z, Q, E, X.sup.2, l.sup.2, Hal, Ar and R' are
each as defined above.
[1239] Step CXXXI
[1240] A halide represented by the formula (562) is reacted with an
appropriate arylcopper complex or heteroarylcopper complex in a dry
solvent such as toluene or N,N-dimethylformamide in the presence of
triphenylphosphine to thereby give a compound represented by the
formula (563). 215
[1241] wherein G, Z, Q, E, X.sup.2, l.sup.2, R.sup.a, R.sup.d and
R' are each as defined above.
[1242] Step LXXXIX
[1243] An alkyne compound represented by the formula (564) is
treated with an appropriate amine such as dimethylamine in an
appropriate alcoholic solvent such as methanol or ethanol to
thereby give a ketone compound represented by the formula (565).
The reaction can be effected at from room temperature to the reflux
temperature.
[1244] Step LXXXXIII
[1245] The .alpha.,.beta.-alkynyl ester compound represented by the
formula (564) is treated with sodium thiomethoxide in a solvent
mixture of N,N-dimethylformamide with methanol to thereby give a
compound represented by the formula (566). The reaction is effected
preferably at from 0.degree. C. to room temperature.
[1246] Step LXIX
[1247] A sulfide compound represented by the formula (566) is
treated with a peroxide such as 3-chloroperbenzoic acid in an
appropriate solvent such as dichloromethane in the presence of
sodium carbonate, etc. to thereby give a sulfoxide compound
represented by the formula (567). The reaction temperature
preferably ranges from room temperature to 40.degree. C. 216
[1248] wherein G, Z, Q, E, X.sup.2 and l.sup.2 are each as defined
above.
[1249] Step XXI
[1250] A thiourea compound represented by the formula (486) is
treated with an appropriate methylating agent such as methyl iodide
in a solvent such as acetone to thereby give a methyliosthiourea
derivative represented by the formula (568).
[1251] Step LXXXIX
[1252] The thiourea compound represented by the formula (568) is
treated with cyanamide in a dry solvent such as tetrahydrofuran or
N,N-dimethylformamide to thereby give a compound represented by the
formula (569). The reaction is effected preferably at from 50 to
100.degree. C. 217
[1253] wherein G, Z, Q, E, X.sup.2 and l.sup.2 are each as defined
above; and V.sup.4 represents nitro or methylsulfonyl.
[1254] Step CXXX
[1255] An amine represented by the formula (570) is reacted with
formamidinesulfonic acid or an appropriate methylisothiourea
derivative in an appropriate alcoholic solvent such as methanol at
from 0.degree. C. to the reflux temperature to thereby give
compounds represented by the formulae (571) and (572). 218
[1256] wherein G, Z, Q, E, X.sup.2 and l.sup.2 are each as defined
above.
[1257] Step CXXXII
[1258] An aldehyde represented by the formula (104) is reacted with
an appropriate cyanidation agent such as sodium cyanide or
potassium cyanide in a solvent mixture of ethanol with water at
from room temperature to the reflux temperature to thereby give an
amidine compound represented by the formula (573). 219
[1259] wherein G, Z, Q, E, R.sup.d, Hal, X.sup.2 and l.sup.2 are
each as defined above.
[1260] Step CXXXIII
[1261] A halide represented by the formula (574) is heated in an
appropriate trialkyl phosphite to thereby give a dialkyl
phosphonate represented by the formula (575). The reaction is
effected preferably at from 100 to 200.degree. C. 220
[1262] wherein G, Z, Q, E, R', Hal, X.sup.2 and l.sup.2 are each as
defined above.
[1263] Step CXXXIV
[1264] A halide represented by the formula (352) is reacted with
sodium sulfite in a solvent mixture of an appropriate alcohol such
as methanol with water at from room temperature to the reflux
temperature to thereby give a sulfonic acid derivative represented
by the formula (576). 221
[1265] wherein R.sup.d is as defined above.
[1266] Step LXXXV
[1267] A nitrile compound represented by the formula (577) is
treated with an appropriate acid in an alcoholic solvent to thereby
give an imidate represented by the formula (578) (i.e., the
so-called Pinner reaction). It is preferable to use hydrochloric
acid as the acid. The reaction is preferably effected in
methanol/dichloromethane at from 0 to 10.degree. C.
[1268] Step LXXXVI
[1269] The imidate represented by the formula (578) is reacted with
an amine or an amide in an appropriate solvent to thereby give a
compound represented by the formula (579). Acetonitrile or a
mixture of acetonitrile with methanol may be cited as the most
desirable solvent. The reaction is effected preferably at from room
temperature to 40.degree. C. 222
[1270] wherein G, Z, E, R', R.sup.a, X.sup.2, and l.sup.2 are each
as defined above.
[1271] Step XXIX
[1272] A compound represented by the formula (580) is reacted with
a reducing agent such as sodium borohydride in a solvent to thereby
give a compound represented by the formula (581). As the solvent,
use can be,made of methanol, ethanol, etc. The reaction can be
effected at from 0.degree. C. to the reflux temperature. 223
[1273] Step LXIX
[1274] A sulfide compound represented by the formula (582) is
treated with a peroxide such as 3-chloroperbenzoic acid in an
appropriate solvent such as dichloromethane in the presence of
sodium carbonate, etc. Alternatively, it is treated with hydrogen
peroxide in acetic acid. Thus, a sulfoxide compound represented by
the formula (583) can be obtained. The reaction temperature
preferably ranges from room temperature to 40.degree. C.
[1275] Production process 8: 224
[1276] wherein the ring G, E, Z, R' and U.sup.1 are as defined
above.
[1277] Step 1
[1278] This step comprises protecting the hydroxyl group of a
compound represented by the general formula (584) to thereby give a
compound represented by the general formula (585). Although the
protective group is nonlimitative and any arbitrary group may be
used so long as it is known as a hydroxyl protective group in
organic synthesis, preferable examples thereof are alkylsilyl
groups such as trimethylsilyl, isopropyldimethylsilyl,
tert-butyldimethylsilyl and tert-butyldiphenylsilyl. When the
protective group is an alkylsilyl group, the reaction is conducted
by treating a compound (584) with an alkylsilyl chloride such as
tert-butyldimethylsilyl chloride at a temperature of -50 to
50.degree. C. in a solvent such as N,N-dimethylformamide,
N,N-dimethylacetamide, tetrahydrofuran or dioxane in the presence
of a base such as imidazole, pyridine or dimethylpyridine.
[1279] Step 2
[1280] This step comprises introducing a lower alkyl group,
optionally substaituted arylalkyl gorup, optionally substituted
heteroaryl group, amino protective group, group represented by
--X.sup.3--NR.sup.9R.sup.10; wherein X.sup.3, R.sup.9 and R.sup.10
are as defined above, group represented by
--X.sup.4--CO.sub.2R.sup.11; wherein X.sup.4 and R.sup.11 are as
defined above, into the NH group of the compound represented by the
general formula (585). The reaction is conducted in the
conventional method.
[1281] Step 3
[1282] This step comprises eliminating the hydroxyl protective
group of the compound represented by the general formula (586).
When the protective group is an alkylsilyl group, this reaction is
conducted by using potassium carbonate/methanol, acetic acid/water,
boron trifluoride etherate/chloroform, tetra-n-butylammonium
chloride/potassium fluoride/acetonitrile, or tetra-n-butylammonium
fluoride/dioxane or tetrahydrofuran, among which preferred is
tetra-n-butylammonium fluoride/tetrahydrofuran. The reaction
temperature ranges from 0 to 50.degree. C.
[1283] Step 4
[1284] This step comprises oxidizing the hydroxymethyl group of the
compound represented by the general formula (587) to thereby give
an aldehyde represented by the general formula (588). The aldehyde
is obtained by adding a solution of the alcohol represented by the
formula (587) in a solvent such as methylene chloride to a liquid
reaction mixture prepared from oxalyl chloride and dimethyl
sulfoxide and treating the resultant mixture with a base such as
triethylamine, by treating the above solution of the alcohol with
pyridinium dichromate in a solvent such as dichloromethane or
N,N-dimethylformamide, or by treating the above solution with
manganese dioxide in a solvent such as dichloromethane.
[1285] Step 5
[1286] This step comprises conducting a reductive amination by
treating the compound represented by the formula (588) with a
secondary amine in the presence of a reducing agent.
[1287] The reaction of the aldehyde reprsented by the formula (588)
with the secondary amine is conducted in an appropriate solvent
such as toluene or benzene at room temperature to the solvent
reflux temperature and treating the intermediate thus obtained with
an appropriate reducing agent such as sodium borohydride or sodium
boron cyanohydride in an appropriate alcoholic solvent such as
ethanol or methanol or an appropriate solvent mixture such as
ethanol/tetrahydrofuran at a temperature of 50.degree. C. to the
solvent reflux temperature to thereby obtain the compound
represented by the formula (589).
[1288] The compounds of the present invention can be easily
produced by the above-mentioned production processes or publicly
known processes.
[1289] The solvent usable in the present invention described above
may be an arbitrary one without restriction so long as it doesn't
inhibit the reaction and has been employed commonly in organic
synthesis. Examples thereof include lower alcohols such as
methanol, ethanol, propanol and butanol; polyalcohols such as
ethylene glycol and glycerol; ketones such as acetone, methyl ethyl
ketone, diethyl ketone and cyclohexanone; ethers such as diethyl
ether, isopropyl ether, tetrahydrofuran, dioxane, 2-methoxyethanol
and 1,2-dimethoxyethane; nitriles such as acetonitrile and
propionitrile; esters such as methyl acetate, ethyl acetate,
isopropyl acetate, butyl acetate and diethyl phthalate; halogenated
hydrocarbons such as dichloromethane, chloroform, carbon
tetrachloride, 1,2-dichloroethane, trichloroethylene and
tetrachloroethylene; aromatic solvents such as benzene, toluene,
xylene, monochlorobenzene, nitrobenzene, indene, pyridine,
quinoline, collidine and phenol; hydrocarbons such as pentane,
cyclohexane, hexane, heptane, octane, isooctane, petroleum benzene
and petroleum ether; amines such as ethanolamine, diethylamine,
triethylamine, pyrrolidine, piperidine, piperazine, morpholine,
aniline, dimethylaniline, benzylamine and toluidine; amides such as
formamide, N-methylpyrrolidone, N,N-dimethylimidazolone,
N,N-dimethylacetamide and N,N-dimethylformamide; phosphoramides
such as hexamethylphosphoric triamide and hexamethylphosphorous
triamide; water, other solvents commonly employed in the art and
mixtures thereof. The mixing ratio is not particularly
restricted.
[1290] The base to be used in the present invention, partially
above described, may be an arbitrary one without restriction so
long as it has been well known as a base for organic synthesis and
as it doesn't inhibit the reaction. Examples thereof include sodium
carbonate, sodium hydrogencarbonate, potassium carbonate, sodium
hydride, potassium hydride, t-butoxypotassium, pyridine,
dimethylaminopyridine, trimethylamine, triethylamine,
N,N-diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine,
N-methylpiperidine, N,N-dimethylaniline,
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine,
4-dimethylaminopyridine, picoline, lutidine, quinoline,
isoquinoline, sodium hydroxide, potassium hydroxide, lithium
hydroxide, butyllithium and, sodium and potassium alcoholates such
as sodium methylate and potassium methylate.
[1291] As the halogenation agent, use can be made of an arbitrary
one commonly employed in the synthesis of acid halides. Examples
thereof include phosgene, diphosgene (phosgene dimer), triphosgene
(phosgene trimer), thionyl chloride, thionyl bromide, phosphorus
trichloride, phosphorus tribromide, phosphorus oxychloride,
phosphorus pentachloride, trichloromethyl chloroformate, oxalyl
chloride and Vilsmeier reagents obtained by treating acid amides or
phosphoramide with these halogenation agents.
[1292] The reducing agent is not particularly restricted but may be
an arbitrary one commonly employed in organic synthesis. Examples
thereof include NaBH.sub.4, LIBH.sub.4, Zn(BH.sub.4).sub.2,
Me.sub.4NBH(OAc).sub.3, NaBH.sub.3CN, Selctride, Super Hydride
(LiBHEt.sub.3), LiAlH.sub.4, DIBAL, LiAlH(t-BuO).sub.3, Red-al,
binap, and catalytic hydrogenation catalysts of platinum,
palladium, rhodium, ruthenium, nickel, etc.
[1293] After the completion of these reactions, the products may be
purified by conventional procedures, for example, column
chromatography with the use of silica gel, adsorbent resins, etc.
or recrystallization from appropriate solvents, if desired.
[1294] To illustrate the usefulness of the present invention, the
following pharmacological experimental examples will be given.
EXPERIMENTAL EXAMPLE 1
Effect on the Expression of ICAM-1 in Human Cultured Umbilical Cord
Endothelial Cells
[1295] Examination was made on the effect on the expression of
ICAM-1 which is one of adhesion molecules expressed on the surfaces
of cultured endothelia cells. The endotheliall cells were suspended
in an MCDB131 medium containing 10% of fetal calf serum and
pipetted into a 96-well culture plate (10,000 cells/well). After
culturing at 37.degree. C. in the presence of 5% of carbon dioxide
for 2 days, 1 ng/ml of a tumor necrosis factor (TNF) and a test
compound were added to the 96-well culture plate. After culturing
at 37.degree. C. in the presence of 5% of carbon dioxide for 4
hours and then washing with a phosphate buffer once, 0.05% of
glutaraldehyde was added thereto. Six minutes thereafter, the plate
was washed twice and 1 .mu.g/ml of a mouse antihuman ICAM-1
antibody was added thereto. After allowing to stand for 1 hour, it
was washed twice and a peroxidase-labeled sheep antimouse
immunoglobulin antibody was added thereto. After allowing to stand
for 1 hour, it was washed twice and a color developing substrate
for peroxidase (o-phenylenediamine) was added thereto. After
allowing to stand at room temperature for 10 minutes, a 1 N
solution of sulfuric acid was added thereto. Then the absorbance at
490 nm was measured with the use of an absorptiometer for 96-well
plate. The value thus obtained was employed as an indication of the
ICAM-1 expression.
[1296] The following Table 1 shows the 50% inhibitory
concentrations (IC.sub.50; .mu.M) calculated by taking the
expression dose under the addition of TNF as 100% and that under
the addition of no TNF as 0%.
1 TABLE 1 Compd. IC.sub.50 Compd. IC.sub.50 (Ex. No.) (.mu.M) (Ex.
No.) (.mu.M) 15 2.3 102 2.6 18 3.5 103 6.6 23 1.6 104 2.8 24 4.1
105 5.8 30 0.5 106 2.8 31 1.1 107 3.3 70 2.8 113 2.5 71 0.8 118 1.6
73 0.6 121 7.4 74 1.9 402 0.32 75 2.4 403 0.34 77 2.8 460 0.32 78
1.4 659 0.71 79 0.5 677 0.90 80 4.1 686 0.90 82 3.4 698 0.49 83 2.8
717 1.15 85 6.4 729 1.30 87 2.9 901 1.8 88 2.6 1145 0.77 89 2.8
1241 3.6 90 2.8 1409 0.67 91 2.9 1439 0.49 98 2.4 1487 0.67 100 3.8
1568 0.5 101 2.6
EXPERIMENTAL EXAMPLE 2
Effect on Carrageenin-Induced Rat Pleurisy
[1297] 200 .mu.l of a carrageenin solution (10 mg/ml in
physiological saline) was intrathoracically injected into rats.
Five hours thereafter, blood of the animals was collected from the
abdominal aorta under etherization so as to induce death from blood
loss. The exudate was taken up from the thoracic cavity and weighed
with a single-pan balance. Further, the exudate was diluted with
Turk's solution and the cells were counted by using a counting
chamber. Next the total cell count was calculated by multiplying
the cell count by the exudate volume. Thus the inhibitory ratio was
calculated by taking the total cell count with the administration
of carrageenin as 100% and that with the administration of
physiological saline as 0%. Each test compound was suspended in a
0.5% solution of methylcellulose and orally administered at a dose
of 5 ml/kg 30 minutes before the injection of carrageenin. Table 2
shows the results.
2TABLE 2 Compd. Dose Inhibitory (Ex. No.) (mg/kg) ratio (%) 15 10
64 18 10 67 23 10 52 24 10 54 30 10 85 31 10 38 71 10 94 73 10 74
79 10 44 83 10 34 88 10 65 89 10 83 91 10 76 98 10 30 101 10 48 106
10 46 121 10 70 402 10 57 403 10 35 460 10 57 659 10 20 677 10 76
686 10 71 698 10 26 717 10 32 729 10 64 901 30 38 1145 10 29 1241
100 28 1439 30 77 1487 30 32 1568 30 50
[1298] As described above, the compounds of the present invention
have excellent anti-immune effects and, therefore, are highly
useful as preventives and remedies for inflammatory immune diseases
or autoimmune diseases, in particular, as preventives and remedies
for rheumatism, atopic dermatitis, psoriasis, asthma and the
rejection reaction-accompanying organ transplantation.
[1299] As the above experimental examples show, the compounds of
the present invention inhibit the functions of adhesion molecules
and thus exhibit anti-immune and anti-inflammatory effects.
Accordingly, they are useful as preventives and remedies for
inflammatory immune diseases such as inflammation, ischemic reflow
disorders and the rejection reaction accompanying organ
transplantation, autoimmune diseases such as rheumatism and
collagen disease and cancer metastasis. More particularly, these
compounds are useful as preventives and remedies for asthma,
nephritis, ischemic reflow disorders, psoriasis, atopic dermatitis,
rheumatism, collagen disease, the rejection reaction accompanying
organ transplantation and cancer metastasis.
[1300] Of them, particularly useful compounds are as follows:
[1301] 1) (endo,
syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-
-3-azabicyclo[3.3.1]non-9-yl]acetic acid;
[1302] 2) (endo,
anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
)-3-azabicyclo[3.3.1]non-9-yl]acetic acid;
[1303] 3)
(+)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8--
ylmethyl) -6,7-dimethyl-3-azabicyclo:[3.2.1]oct-8-yl]acetic
acid;
[1304] 4)
(-)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8--
ylmethyl) -6,7-dimethyl-3-azabicyclo[3.2.1oct-8-yl]acetic acid;
[1305] 5)
(+)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin--
8-ylmethyl) -6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoic
acid; and
[1306] 6)
(-)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin--
8-ylmethyl) -6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoic
acid.
EXAMPLES
[1307] To further illustrate the present invention in greater
detail, and not by way of limitation, the following Examples will
be given.
EXAMPLE 1
Methyl10H-pyrazino[2,3-b][1,4]benzothiazine-8-carboxylate
[1308] 225
[1309] 600 g of sodium sulfide nonahydrate and 80 g of flower of
sulfur was heated to prepare a homogeneous solution of disodium
disulfide. To a suspension of 4-chloro-3-nitrobenzoic acid in
ethanol (2,250 ml) was added a solution of 67 g of sodium hydroxide
in water (125 ml). To the mixture obtained was added the solution
prepared above under stirring and the resulting mixture was heated
under reflux for 30 minutes. Next, the reaction mixture was brought
back to room temperature and the crystals formed were taken up by
filtration and air-dried to thereby give 450 g of dark green
powdery crystals. By repeating the same procedure, 4.67 kg of dark
green crystals were obtained from 5.20 kg of 4-chloro
-3-nitrobenzoic acid.
[1310] 500 g of the crystals thus obtained and 1220 g of tin dust
were suspended in 2,800 ml of ethanol and conc. hydrochloric acid
was added dropwise thereinto until the reaction was completed.
After completion of the reaction, the tin residue was eliminated
and the solvent was reduced to a small volume through distillation
under reduced pressure. After adding conc. hydrochloric acid and
ethanol to the residue, the crystals thus precipitated were taken
up by filtration and air-dried to thereby give 300 g of a pale
yellow powder. By repeating the same procedure, 2.79 kg of the
product was obtained from 4.67 kg of the starting material.
[1311] 2,400 ml of methanol was saturated with hydrogen chloride
gas and 800 g of the above-mentioned pale yellow powder was added
thereto. After heating under reflux for 7 hours, the solvent was
completely distilled off to dryness to thereby give 950 g of pale
yellow crystals. By repeating the same procedure, 3.70 kg of the
product was obtained from 2.79 kg of the starting material.
[1312] 1.0 kg of the crystals obtained were suspended in 1000 ml of
N,N-dimethylformamide and 800 g of 2,3-dichloropyrazine was added
dropwise thereinto with stirring. After the completion of the
addition, the mixture was further reacted at 100.degree. C. for 30
minutes and then brought back to room temperature. After adding 2 l
of water to the reaction system, the crystals thus precipitated
were taken up by filtration and washed successively with water and
diethyl ether to thereby give 400 g of the title compound as a
yellow powder.
[1313] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1314] 3.78(s, 3H), 7.02(d, J=8.2 Hz, 1H), 7.29(dd, J=1.9, 8.2 Hz,
1H), 7.31(d, J=1.9 Hz, 1H), 7.64(d, J=2.9 Hz, 1H), 7.65(d, J=2.9
Hz, 1H), 9.63(s, 1H)
[1315] m.p.: 265-268.degree. C.
[1316] MS: FAB(+)259(M.sup.+)
EXAMPLE 2
10H-Pyrazino[2,3-b][1,4]benzothiazine-8-methanol
[1317] 226
[1318] 259 g of methyl
10H-pyrazino[2,3-b][1,4]benzothiazine-8-carboxylate was dissolved
in a solvent mixture of 3 l of methylene chloride with 0.5 l of
tetrahydrofuran under a nitrogen atmosphere. Next, 2.5 l of a 1.01
M solution of diisobutylaluminum hydride in toluene was added
dropwise thereinto while cooling the mixture so as to maintain the
temperature in the system at 15.degree. C. or below. After the
completion of the reaction, the reaction mixture was poured into a
mixture of 5 kg of ice with 3 l of methylene chloride. After adding
5 l of tetrahydrofuran, the resulting mixture was stirred for 1
hour. Then it was filtered and the filtrate was washed with water.
After distilling off the solvent under reduced pressure, the
obtained crystals were washed with diisopropyl ether to thereby
give 125 g of the title compound as yellow crystals.
[1319] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1320] 4.30(d, J=6.0 Hz, 2H) 5.17(t, J=6.0 Hz, 1H), 6.70(d, J=7.9
Hz, 1H), 6.75(s, 1H), 6:83(d, J=7.9 Hz, 1H), 7.61(d, J=2.6 Hz, 1H),
7.63(d, J=2.6 Hz, 1H), 9.50(s, 1H)
[1321] m.p.: 187-189.degree. C.
EXAMPLE 3
10H-Pyrazino[2,3-b][1,4]benzothiazine-8-methanol
[1322] 227
[1323] Into a solution of 40 g of lithium aluminum lithium hydride
in tetrahydrofuran (1 l) was dropped a solution of 200 g of methyl
10H-pyrazino[2,3-b][1,4]benzothiazine-8-carboxylate in
tetrahydrofuran (2.5 l) while maintaining the mixture at a
temperature not exceeding 15.degree. C. After continuing the
reaction at 15.degree. C. or below for 1 hour, 40 ml of water, 40
ml of a 15% aqueous solution of sodium hydroxide and 120 ml of
water were successively added and the resulting mixture was stirred
for an additional 1 hour. After filtering off the insoluble matter,
the solvent was distilled off under reduced pressure to thereby
give 125 g of the title compound as yellow crystals.
[1324] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1325] 4.30(d, J=6.0 Hz, 2H), 5.17(t, J=6.0 Hz, 1H), 6.70(d, J=7.9
Hz, 1H), 6.75(s, 1H), 6.83(d, J=7.9 Hz, 1H), 7.61(d, J=2.6 Hz, 1H),
7.63(d, J=2.6 Hz, 1H), 9.50(s, 1H)
[1326] m.p.: 187-189.degree. C.
[1327] MS: FAB(+)231(M.sup.+)
EXAMPLE 4
8-Chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[1328] 228
[1329] Into a solution of 7 g of
10H-pyrazino[2,3-b][1,4]benzothiazine-8-m- ethanol and 6.1 ml of
pyridine in N,N-dimethylformamide (50 ml) was added dropwise 5.9 ml
of methanesulfonyl chloride at 0.degree. C. After stirring at room
temperature for 1 hour, the reaction mixture was poured into a
pre-cooled aqueous solution of methylene chloride/sodium
hydrogencarbonate, extracted with ethyl acetate, washed with water
and dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the crystals thus precipitated were
diluted with a small amount of ethyl acetate, taken up by
filtration and washed with diethyl ether. Thus 4.7 g of the title
compound was obtained as a yellow powder.
[1330] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1331] 4.58(s, 2H), 6.78-6.80(m, 1H), 6.80-6.84(m, 1H), 6.90(dd,
J=1.7, 7.9 Hz, 1H), 7.63-7.66(m, 2H), 9.58(s, 1H)
[1332] m.p. : 161-162.degree. C.
[1333] MS: FAB(+)249(M.sup.+)
EXAMPLE 5
Methyl10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine-8-carboxylate
[1334] 229
[1335] 415 g of methyl 10H-pyrazino[2,3-b
][1,4]benzothiazine-8-carboxylat- e was suspended in 2.5 1 of
N,N-dimethylformamide in a nitrogen atmosphere. Then 66 g of sodium
hydride (oily: 60% or more) was added in portions thereto while
maintaining the mixture at -10 to 0.degree. C. Then the resulting
mixture was stirred for 1 hour. Next, 110 g of chloromethyl methyl
ether was dropped thereinto while maintaining the mixture at a
temperature not exceeding 5.degree. C. After the completion of the
reaction, the reaction mixture was poured into ice, extracted with
methylene chloride twice, washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, diisopropyl ether was added to the residues and
the crystals thus precipitated were taken up by filtration to
thereby give 335 g of the title compound as yellow crystals.
[1336] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1337] 3.55(s, 3H), 3.91(s, 3H), 5.30(s, 2H), 7.55(d, J=8.5 Hz,
1H), 7.61(d, J=8.5 Hz, 1H), 7.74(s, 1H), 7.85(s, 2H)
[1338] m.p. : 151-152.degree. C.
[1339] MS: FAB(+)303(M.sup.+)
EXAMPLE 6
10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine-8-methanol
[1340] 230
[1341] Into a solution of 350 g of methyl 10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine-8-carboxylate in methylene
chloride (2.5 L) was added dropwise under a nitrogen atmosphere 3.2
l of a 1.01 M solution of diisobutylaluminum hydride in toluene
while maintaining the system at a temperature not exceeding
15.degree. C. Then the reaction mixture was poured into ice and
stirred for 1 hour. After filtering off the insoluble matter, the
filtrate was washed with water. After distilling off the solvent
under reduced pressure, the crude crystals thus obtained were
washed with diisopropyl ether to thereby give 250 g of the title
compound as pale yellow crystals.
[1342] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1343] 3.53(s, 3H), 4.63(s, 2H), 5.29(s, 2H), 6.97(dd, J=1.3, 7.9
Hz, 1H), 7.01(d, J=7.9 Hz, 1H), 7.15(d, J=1.3 Hz, 1H), 7.84(d,
J=2.9 Hz, 1H), 7.85(d, J=2.9 Hz, 1H)
EXAMPLE 7
8-Chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[1344] 231
[1345] Into a solution of 19 g of 10-methoxymethyl
-10H-pyrazino[2,3-b][1,- 4]benzothiazine-8-methanol and 13.9 ml of
pyridine in N,N-dimethylformamide (150 ml) was added dropwise under
a nitrogen atmosphere 13.3 ml of methanesulfonyl chloride at
0.degree. C. Then the reaction mixture was stirred at room
temperature for 1 hour and then poured into a pre-cooled aqueous
solution of methylene chloride/sodium hydrogen carbonate. Then it
was extracted with ethyl acetate, washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with methylene chloride) to thereby give
13.6 g of the title compound as pale yellow crystals.
[1346] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1347] 3.55(s, 3H), 4.52(s, 2H), 5.29(s, 2H), 6.99(d, J=7.6 Hz,
1H),. 7.00(d, J=7.6 Hz, 1H), 7.16(s, 1H), 7.84(d, J=2.9 Hz, 1H),
7.85(d, J=2.9 Hz, 1H)
[1348] m.p.: 125-126.degree. C.
[1349] MS: FAB(+)293(M.sup.+)
EXAMPLE 8
8-Chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[1350] 232
[1351] 6 g of 8-chloromethyl-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]ben- zothiazine was dissolved in 50 ml of
tetrahydrofuran and 20 ml of 6 N hydrochloric acid was added
thereto at 0.degree. C. After stirring at room temperature for 30
minutes, the reaction mixture was poured into ice-water and
extracted with ethyl acetate. The extract was washed with water,
dried over anhydrous magnesium sulfate, filtered and concentrated
under reduced pressure. The crystals precipitating in the course of
the concentration were taken up by filtration and washed with
diethyl ether to thereby give 4.8 g of the title compound as yellow
crystals.
[1352] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1353] 4.58(s, 2H), 6.78-6.80(m, 1H), 6.80-6.84(m, 1H), 6.90(dd,
J=1.7, 7.9 Hz, 1H), 7.63-7.66(m, 2H), 9.58(s, 1H)
[1354] m.p.: 161-162.degree. C.
[1355] MS: FAB(+)249(M.sup.+)
EXAMPLE 9
8-Chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[1356] 233
[1357] Into 250 ml of a solution of 26.9 g of 8-chloromethyl
-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine in
methylene chloride was dropped 50 ml of trifluoroacetic acid at
0.degree. C. After reacting at room temperature for 12 hours, the
reaction mixture was cooled to 0.degree. C. and neutralized by
adding an aqueous solution of sodium hydrogencarbonate. The
crystals thus precipitated were taken up by filtration and washed
successively with water and diethyl ether to thereby give 19.1 g of
the title compound as yellow crystals.
[1358] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1359] 4.58(s, 2H), 6.78-6.80(m, 1H), 6.80-6.84(m, 1H), 6.90(dd,
J=1.7, 7.9 Hz, 1H), 7.63-7.66(m, 2H), 9.58(s, 1H)
[1360] m.p.: 161-162.degree. C.
[1361] MS: FAB(+)249(M.sup.+)
EXAMPLE 10
Methyl(syn)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetate
oxalate
[1362] 234
[1363] 37.13 g of ethyl
(3-methyl-3-azabicyclo[3.3.1]non-9-ylidene)acetate was dissolved in
815 ml of methanol. After adding 20.24 g of magnesium, the
resulting mixture was stirred at room temperature for 18 hours.
Then a saturated aqueous solution of ammonium chloride was added to
the reaction mixture followed by extraction with ethyl acetate. The
ethyl acetate layer was washed successively with water and a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After concentrating the solvent under
reduced pressure, 34.32 g of crude methyl
(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetate was obtained.
[1364] 34.32 g of this oily substance was dissolved in 343 ml of
ethanol. After adding 19.58 g of oxalic acid dehydrate, the
resulting mixture was allowed to stand at room temperature. The
crystals thus precipitated were recrystallized from 550 ml of
ethanol to thereby give 17.76 g of the title compound as white
needles.
[1365] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1366] 1.51(m, 1H), 1.64-1.75(m, 2H), 1.78-1.86(m, 4H), 1.96(m,
1H), 2.07(m, 1H), 2.60(d, J=8.6 Hz, 2H), 2.61(s, 3H), 2.88-2.96(m,
2H), 3.16-3.24(m, 2H), 3.61(s, 3H)
[1367] m.p.: 181-185.degree. C. (decomp.)
EXAMPLE 11
Ethyl(syn)-(3-methyl-3-azabicyclo[3.3.1]non-9yl)acetate
[1368] 235
[1369] 67.36 g of
methyl(syn)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetat- e oxalate
was dissolved in water and the solution made basic by adding
aqueous ammonia. Then it was extracted with ethyl acetate. The
ethyl acetate layer was washed successively with water and a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After concentrating the solvent under
reduced pressure, 46.64 g of crude methyl (syn)-(3-methyl
-3-azabicyclo[3.3.1]non-9-yl)acetate was obtained.
[1370] 46.64 g of this oily substance was dissolved in 500 ml of
ethanol. After adding 100 ml of 4 N hydrogen chloride/dioxane, the
resulting mixture was heated under reflux for 8 hours. Then the
reaction mixture was concentrated under reduced pressure. After
adding water, the residue was made basic by adding aqueous ammonia
and then extracted with ethyl acetate. The ethyl acetate layer was
washed with water and a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
concentrating the solvent under reduced pressure, 45.50 g of the
title compound was obtained as a slightly yellow oily
substance.
[1371] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1372] 1.26(t, J=7.1 Hz, 3H), 1.46(m, 1H), 1.55-1.76(m, 4H),
1.78-1.88(m, 2H), 2.00(m, 1H), 2.13(s, 3H), 2.32-2.38(m, 2H),
2.41(d, J=7.9 Hz, 2H), 2.46(m, 1H), 2.57-2.65(m, 2H), 4.12(q, J=7.1
Hz, 2H)
EXAMPLE 12
Ethyl(syn)-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]acetate
[1373] 236
[1374] 45.50 g of
ethyl(syn)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetate was
dissolved in 155 ml of 1,2-dichloroethane. After adding 51.6 ml of
vinyl chloroformate, the resulting mixture was stirred at room
temperature for 45 minutes and then heated under reflux for 4
hours. Next, the reaction mixture was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography (eluted with toluene/ethyl acetate) to thereby give
37.63 g of the title compound as a slightly yellow oily
substance.
[1375] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1376] 1.26(t, J=7.1 Hz, 3H), 1.52(m, 1H), 1.66-1.82(m, 5H),
1.84-1.93(m, 2H), 2.16(m, 1H), 2.46(d, J=7.9 Hz, 2H), 3.23(m, 1H),
3.33(m, 1H), 3.88-3.96(m, 2H), 4.15(q, J=7.1 Hz, 2H), 4.45(dd,
J=1.6, 6.3 Hz, 1H), 4.79(dd, J=1.6, 13.9 Hz, 1H), 7.25(dd, J=6.3,
13.9 Hz, 1H)
EXAMPLE 13
Ethyl(syn)-(3-azabicyclo[3.3.1]non-9-yl)acetate
[1377] 237
[1378] To 37.63 g of ethyl(syn)-(3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]acetate was added 150 ml of 4
N-hydrogen chloride/dioxane and the resulting mixture was stirred
at room temperature for 1 hour. After adding 300 ml of ethanol, the
reaction mixture was heated under reflux for 30 minutes. Then the
reaction mixture was concentrated under reduced pressure and the
residue was made basic by adding ice-water and aqueous ammonia
followed by extraction with methylene chloride. After drying over
anhydrous sodium sulfate, the residue was concentrated under
reduced pressure to thereby give 27.34 g of the title compound as a
pale yellow oily substance.
[1379] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1380] 1.26(t, J=7.1 Hz, 3H), 1.54(br.s, 2H), 1.67(m, 1H),
1.76-1.94(m, 4H), 2.10-2.34(m, 3H), 2.55(d, J=7.9 Hz, 2H),
2.81-2.89(m, 2H), 3.14-3.24(m, 2H), 4.13(q, J=7.1 Hz, 2H)
EXAMPLE 14
Ethyl(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyc-
lo-[3.3.1]non-9-yl]acetate
[1381] 238
[1382] To 300 ml of N,N-dimethylformamide were added 30.79 g of
8-chloromethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine, 27.34 g of
ethyl(syn)-(3-azabicyclo[3.3.1]non-9-yl) acetate and 23.65 ml of
diisopropylethylamine and the resulting mixture was stirred at
80.degree. C. for 3 hours. Then the reaction mixture was poured
into ice/water and extracted with ethyl acetate. The ethyl acetate
layer was washed with water and a saturated aqueous solution of
sodium chloride, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (eluted with toluene/ethyl
acetate). Next, it was dissolved in 1 l of ethyl acetate and
extracted with 1 N hydrochloric acid. The aqueous layer was made
basic with aqueous ammonia and extracted with ethyl acetate. The
ethyl acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous magnesium sulfate
and concentrated under reduced pressure. After adding n-hexane, the
crystals thus precipitated were taken up by filtration and washed
with diisopropyl ether to thereby give 36.99 g of the title
compound as a yellow powder.
[1383] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1384] 1.25(t, J=7.1 Hz, 3H), 1.55(m, 1H), 1.60-1.86(m, 6H),
2.00-2.08(m, 1H), 2.36-2.47(m, 4H), 2.53-2.68(m, 3H), 3.23(s, 2H),
4.12(q, J=7.1 Hz, 2H), 6.41(br.s, 1H), 6.49(d, J=1.3 Hz, 1H),
6.76(dd, J=1.3, 8.1 Hz, 1H), 6.83(d, J=8.1 Hz, 1H), 7.57(d, J=2.9
Hz, 1H), 7.69(d, J=2.9 Hz, 1H)
[1385] m.p.: 114-116.degree. C.
EXAMPLE 15
(syn)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[3.-
3.1]non-9-yl]acetic acid
[1386] 239
[1387] 36.00 g of
ethyl(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
methyl)-3-azabicyclo[3.3.1]non-9-yl]acetate was dissolved in
tetrahydrofuran (380 ml) and ethanol (380 ml). After adding 187 ml
of 1 N sodium hydroxide, the resulting mixture was stirred at room
temperature for 15 hours. Then the reaction mixture was
concentrated under reduced pressure. After adding 200 ml of water,
the residue was concentrated under reduced pressure to thereby
reduce the volume by half. After adding 500 ml of water, it was
acidified (about pH 5) by adding a solution of sodium
dihydrogenphosphate. After adding 800 ml of ethyl acetate and
stirring, the crystals thus precipitated were taken up by
filtration, washed with water and dried at 50.degree. C. to thereby
give 31.2 g of the title compound as a yellow powder.
[1388] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1389] 1.46(m, 1H), 1.56-1.69(m, 4H), 1.73-1.82(m, 2H), 1.89(m,
1H), 2.30-2.37(m, 4H), 2.53-2.70(m, 3H), 3.18(s, 2H), 6.69(dd,
J=1.5, 7.9 Hz, 1H), 6.73(d, J=1.5 Hz, 1H), 6.84(d, J=7.9 Hz, 1H),
7.63(d, J=2.7 Hz, 1H), 7.64(d, J=2.7 Hz, 1H), 9.57(s, 1H)
[1390] m.p.: 235-239.degree. C.
[1391] MS: FAB(+)397(MH.sup.+)
EXAMPLE 16
Ethyl(anti)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetate
[1392] 240
[1393] 70 g of
ethyl(3-methyl-3-azabicyclo[3.3.1)non-9-ylidene)acetate was
dissolved in 700 ml of ethanol. After adding 42 ml of conc.
Hydrochloric acid and 21 g of 10% palladium-carbon (moisture
content: 50%), the mixture was hydrogenated for 12 hours under
atmospheric pressure at ordinary temperature. After filtering off
the palladium-carbon, the filtrate was concentrated under reduced
pressure. Next the residue was made basic by adding an aqueous
solution of sodium hydroxide and was extracted with ethyl acetate.
The extract was washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
filtering, the solvent was distilled off under reduced pressure to
thereby give 65 g of the title compound as a colorless oily
substance.
[1394] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1395] 1.25(t, J=7 Hz, 3H), 1.30-1.50(m, 1H), 1.40-1.70(m, 2H),
1.63(br.s, 2H), 1.60-1.93(m, 2H), 1.90-2.05(m, 1H), 2.13(s, 3H),
2.23(br.d, J=10 Hz, 2H), 2.30-2.58(m, 1H), 2.48(d, J=8 Hz, 2H),
2.88(br.d, J=10 Hz, 2H), 4.13(q, J=7 Hz, 2H)
EXAMPLE 17
Ethyl(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicy-
clo[3.3.1]non-9yl]acetate
[1396] 241
[1397] 61 g of
ethyl(anti)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetate was
cooled to 0.degree. C. and 85.2 g of 1-chloroethyl chloroformate
was added dropwise thereinto. After stirring at the same
temperature for 15 minutes, the reaction mixture was reacted at
100.degree. C. for 1 hour. Then it was brought back to room
temperature and the 1-chloroethyl chloroformate was distilled off
under reduced pressure. After adding 500 ml of ethanol, the residue
was heated under reflux for 1 hour. After distilling off the
solvent under reduced pressure, 71 g of crude
ethyl(anti)-(3-azabicyclo[3.3.1]non-9-yl)acetate hydrochloride was
obtained.
[1398] To 500 ml of a solution of this crude product in
N,N-dimethylformamide were added 52 g of
8-chloromethyl-10H-pyrazino[2,3-- b][1,4]benzothiazine and 115 g of
anhydrous potassium carbonate and the resulting mixture was reacted
at 100.degree. C. for 4 hours and 30 minutes. Then the reaction
mixture was cooled to 0.degree. C., added to a mixture of ice/water
with ethyl acetate and extracted with ethyl acetate. The extract
was washed with a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, the obtained residue was purified
by silica gel column chromatography (eluted with methylene
chloride/ethyl acetate) to thereby give 51 g of the title compound
as a yellow powder.
[1399] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1400] 1.14(t, J=7 Hz, 3H), 1.34-1.48(m, 3H), 1.56(br.s, 2H),
1.60-1.75(m, 2H), 1.82-1.92(m, 1H), 2.15(br.d, J=11 Hz, 2H),
2.43(d, J=8 Hz, 2H), 2.4-2.6(m, 1H), 2.85(br.d, J=9 Hz, 2H),
3.15(s, 2H), 4.02(q, J=7 Hz, 2H), 6.67(dd, J=2, 8 Hz, 1H), 6.71(d,
J=2 Hz, 1H), 6.82(d, J=8 Hz, 1H), 7.61(d, J=3 Hz, 1H), 7.62(d, J=3
Hz, 1H), 9.55(s, 1H)
[1401] m.p.: 142-143.degree. C.
[1402] MS: FAB(+)425(MH.sup.+)
EXAMPLE 18
(anti)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[3-
.3.1]non-9-yl]acetic acid
[1403] 242
[1404] 31 g of
ethyl(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylme-
thyl)-3-azabicyclo[3.3.1]non-9-yl]acetate was dissolved in ethanol
(150 ml) and tetrahydrofuran (150 ml). After adding 75 ml of an
aqueous solution of 8.8 g of sodium hydroxide, the resulting
mixture was heated under reflux in a nitrogen atmosphere for 1
hour. Then the reaction mixture was washed with a saturated aqueous
solution of sodium chloride, dried over anhydrous magnesium sulfate
and filtered. After distilling off the solvent under reduced
pressure, the crystals precipitated in the course of the
distillation were taken up by filtration to thereby give 18.6 g of
the title compound as a yellow powder.
[1405] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm;
[1406] 1.34-1.48(m, 3H), 1.58(br.s, 2H), 1.60-1.76(m, 2H),
1.80-1.90(m, 1H), 2.14(br.d, J=10 Hz, 2H), 2.33(d, J=8 Hz, 2H),
2.44-2.60(m, 1H), 2.85(br.d, J=10 Hz, 2H), 3.15(s, 2H), 6.67(d, J=8
Hz, 1H), 6.72(s, 1H), 6.82(d, J=8 Hz, 1H), 7.60(d, J=3 Hz, 1H),
7.62(d, J=3 Hz, 1H), 9.54(s, 1H)
[1407] m.p.: 215-217.degree. C.
[1408] MS: FAB(+)397(MH.sup.+)
EXAMPLE 19
Ethyl(.+-.)-(6R*,7R*)-(3,6,7-trimethyl
-3-azabicyclo[3.2.1]oct-8-ylidene)a- cetate
[1409] 243
[1410] To a solution of 8 g of paraformaldehyde in methanol (100
ml) were added 10 ml of a 40% solution of methylamine in methanol,
7.7 ml of acetic acid and 10 g of 3,4-dimethylcyclopentanone and
the resulting mixture was heated under reflux for 1.5 hours. After
distilling off the solvent under reduced pressure, the residue was
acidified by adding a dilute aqueous solution of hydrochloric acid
and then was extracted with ethyl acetate. The aqueous layer was
made basic with a dilute aqueous solution of sodium hydroxide and
then extracted with ethyl acetate. The organic layer was dried over
anhydrous magnesium sulfate and the solvent was distilled off under
reduced pressure. Then the obtained residue was distilled under
reduced pressure (70-75.degree. C./1 mmHg) to thereby give 2.7 g of
crude (6R*,7R*) -3,6,7-trimethyl-3-azabicyclo(3.2.1]octan-8- -one
as a pale yellow oily substance.
[1411] To a solution of 4.35 g of triethyl phosphonoacetate in
tetrahydrofuran (50 ml) was added 0.85 g of sodium hydride (oily:
60-72%) under ice-cooling and the resulting mixture was stirred at
0.degree. C. for 10 minutes. Then a solution of 2.7 g of the crude
(6R*,7R*)-3,6,7-trimethyl -3-azabicyclo[3.2.1]octan-8-one in
tetrahydrofuran (20 ml) was added thereto and the reaction mixture
was heated under reflux for 1 hour. After adding ethyl acetate, the
reaction mixture was washed with a saturated aqueous solution of
sodium chloride and the organic layer was dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
1.6 g of the title compound as a pale yellow oily substance.
[1412] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1413] 0.90(d, J=7.2 Hz, 3H), 1.17(d, J=7.2 Hz, 3H), 1.29(t, J=7.2
Hz, 3H), 1.40-1.50(m, 1H), 1.74-1.93(m, 1H), 2.08-2.30(m, 3H),
2.20(s, 3H), 2.80-2.90(m, 1H), 2.90-3.00(m, 1H), 3.35-3.44,
3.50-3.58(m, total 1H), 4.15(q, J=7.2 Hz, 2H), 5.58, 5.66(s, total
1H)
EXAMPLE 20
Ethyl(.+-.)-(anti)-(6R*,7R*)-(3,6,7-trimethyl
-3-azabicyclo[3.2.1]oct-8-yl- )acetate
[1414] 244
[1415] To a solution of 1.6 g of ethyl
(6R*,7R*)-(3,6,7-trimethyl-3-azabic-
yclo[3.2.1]oct-8-ylidene)acetate in methanol (100 ml) was added 0.4
g of 10% palladium-carbon (moisture content: 50%) and the resulting
mixture was stirred under a hydrogen gas stream at room temperature
overnight. Then the reaction mixture was filtered through celite.
After distilling off the solvent under reduced pressure, 1.6 g of
the title compound was obtained as a pale yellow oily
substance.
[1416] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1417] 1.06(d, J=7.2 Hz, 3H), 1.08(d, J=7.2 Hz, 3H), 1.26(t, J=6.4
Hz, 3H), 1.63-1.84(m, 4H), 1.92(t, J=8.0 Hz, 1H), 2.02(d, J=9.6 Hz,
1H), 2.08(d, J=9.6 Hz, 1H), 2.21(s, 3H), 2.37(d, J=8.0 Hz, 2H),
2.67(d, J=9.6 Hz, 1H), 2.85(d, J=9.6 Hz, 1H), 4.13(q, J=6.4 Hz,
2H)
EXAMPLE 21
Ethyl(.+-.)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
methyl) -6,7-dimethyl-3-azabicyclo[3.2.1]oct-8-yl]acetate
[1418] 245
[1419] To a solution of 1.6 g of ethyl(anti)
-(6R*,7R*)-(3,6,7-trimethyl-3- -azabicyclo[3.2.1]oct-8-yl)acetate
in 1,2-dichloroethane (70 ml) was added 2.2 ml of 1-chloroethyl
chloroformate and the resulting mixture was heated under reflux for
1.5 hours. After distilling off the solvent under reduced pressure,
500 ml of methanol was added to the residue and the mixture was
heated under reflux for 1 hour. After distilling off the solvent
under reduced pressure, a dilute aqueous solution of sodium
hydroxide was added to the residue followed by the extraction with
ethyl acetate. The organic layer was dried over anhydrous magnesium
sulfate and then the solvent was distilled off under reduced
pressure. To a solution of the residue in N,N-dimethylformamide (50
ml) were added 1.1 g of
8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine and 1.9 g of
potassium carbonate and the resulting mixture was stirred for 2
hours at 100.degree. C. After adding ethyl acetate, the reaction
mixture was washed with a saturated aqueous solution of sodium
chloride thrice and then the organic layer was dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with methylene chloride/methanol) to thereby
give 2.0 g of the title compound as a yellow oily substance.
[1420] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1421] 1.06(d, J=7.2 Hz, 3H), 1.09(d, J=7.2 Hz, 3H), 1.25(t, J=7.2
Hz, 3H), 1.60-1.82(m, 4H), 1.96(t, J=8.0 Hz, 1H), 2.05(d, J=9.2 Hz,
1H), 2.13(d, J=9.2 Hz, 1H)., 2.37(d, J=7.2 Hz, 2H), 2.64(dd, J=3.6,
9.2 Hz, 1H), 2.84(dd, J=3.6, 9.2 Hz, 1H), 3.24(d, J=13.2 Hz, 1H),
3.36(d, J=13.2 Hz, 1H), 4.13(q, J=7.2 Hz, 2H), 6.49(d, J=1.6 Hz,
1H), 6.52(s, 1H), 6.76(dd, J=1.6, 8.0 Hz, 1H), 6.81(d, J=8.0 Hz,
1H), 7.57(d, J=2.8 Hz, 1H), 7.69(d, J=2.8 Hz, 1H)
EXAMPLE 22
Ethyl(+)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmet-
hyl) -6,7-dimethyl-3-azabicyclo[3.2.1]oct-8-yl]acetate and
ethyl(-)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylme-
thyl) -6,7-dimethyl-3-azabicyclo[3.2.1]oct-8-yl]acetate
[1422] 0.2 g of
ethyl(.+-.)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]b-
enzothiazin-8-ylmethyl)
-6,7-dimethyl-3-azabicyclo-[3.2.1]oct-8-yl]acetate was dissolved in
ethanol (5 ml) and n-hexane (5 ml) and the enantiomers were
resolved by using CHIRALPAK AD [20 (diameter).times.250 mm; mfd. by
Daicel Chemical Industries, Ltd.; eluted with ethanol at 10
ml/min]. Thus the (+)-compound was eluted first followed by the
(-)-compound. From 1.4 g of the racemic modification, 0.59 g (99%
e.e. or above) and 0.52 g (98.7% e.e.) of the (+)- and
(-)-compounds were obtained respectively each as a yellow oily
substance.
[1423] (+)-compound: .alpha..sup.25.sub.D+20.6.degree. (c=1.02
THF)
[1424] (-)-compound: .alpha..sup.25.sub.D-19.7.degree. (c=1.01
THF)
EXAMPLE 23
(+)-(anti)-(6R*,7R*)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-6,7-dimethyl-3-azabicyclo[3.2.1]oct-8-yl]acetic acid
[1425] 246
[1426] To a solution of 0.575 g of ethyl(.+-.)-(anti)
-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-6,7-dimet-
hyl-3-azabicyclo[3.2.1]oct-8-yl]acetate in a solvent mixture of
tetrahydrofuran (10 ml) with methanol (10 ml) was added 2 ml of a 4
N aqueous solution of sodium hydroxide and the resulting mixture
was stirred at 60.degree. C. for 50 minutes. After further adding 1
ml of a 4 N aqueous solution of sodium hydroxide, the resulting
mixture was reacted at the same temperature for 30 minutes. After
the completion of the reaction, the solvent was distilled off under
reduced pressure and the residue was suspended in water. The pH
value thereof was regulated to 5 with a 1 N aqueous solution of
hydrochloric acid then the mixture was extracted with ethyl
acetate. The extract was dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. Then the residue was purified
by silica gel column chromatography (eluted with methylene
chloride/methanol) to thereby give 0.49 g of the title compound as
yellow crystals.
[1427] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1428] 1.01(d, J=7.2 Hz, 3H), 1.05(d, J=7.2 Hz, 3H), 1.60-1.80(m,
4H), 1.83(t, J=7.2 Hz, 1H), 1.97(d, J=10 Hz, 1H), 2.04(d, J=10 Hz,
1H), 2.27(d, J=7.6 Hz, 2H), 2.59(dd, J=4.0, 10 Hz, 1H), 2.78(dd,
J=2.8, 10 Hz, 1H), 3.21(d, J=13.2 Hz, 1H), 3.30(d, J=13.2 Hz, 1H),
6.70(d, J=8.0 Hz, 1H), 6.74(br.s, 1H), 6.84(d, J=8.0 Hz, 1H),
7.63(d, J=2.8 Hz, 1H), 7.65(d, J=2.8 Hz, 1H), 9.55(s, 1H)
[1429] .alpha..sup.25.sub.D+21.2.degree. (c=1.03 THF)
[1430] m.p.: 179-180.degree. C.
[1431] MS: FAB(+)411(MH.sup.+)
EXAMPLE 24
(-)-(anti)-(6R*,7R*)-[3-(10H-Pyrazino[2,3-b][1,4benzothiazin-8-ylmethyl)
-6,7-dimethyl-3-azabicyclo[3.2.1]oct-8-yl]acetic acid
[1432] 247
[1433] 0.277 g of the title compound was obtained as yellow
crystals by treating 0.509 g of ethyl
(-)-(anti)-(6R*,7R*)-[3-(10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl)
-6,7-dimethyl-3-azabicyclo[3.2.1]oct-8-yl]aceta- te in the same
manner as described in Example 23.
[1434] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1435] 1.01(d, J=7.2 Hz, 3H), 1.05(d, J=7.2 Hz, 3H), 1.60-1.80(m,
4H), 1.83(t, J=7.2 Hz, 1H), 1.97(d, J=10 Hz, 1H), 2.04(d, J=10 Hz,
1H), 2.27(d, J=7.6 Hz, 2H), 2.59(dd, J=4.0, 10 Hz, 1H), 2.78(dd,
J=2.8, 10 Hz, 1H), 3.21(d, J=13.2 Hz, 1H), 3.30(d, J=13.2 Hz, 1H),
6.70(d, J=8.0 Hz, 1H), 6.74(br.s, 1H), 6.84(d, J=8.0 Hz, 1H),
7.63(d, J=2.8 Hz, 1H), 7.65(d, J=2.8 Hz, 1H),. 9.55(s, 1H)
[1436] .alpha..sup.25.sub.D-21.3.degree. (c=1.01 THF)
[1437] m.p.: 179-180.degree. C.
[1438] MS: FAB(+)411(MH.sup.+)
EXAMPLE 25
Ethyl(.+-.)-(6R*,8R*)-(3,6,8-trimethyl
-3-azabicyclo[3.3.1]non-9-ylidene)a- cetate
[1439] 248
[1440] To a solution of 180 g of paraformaldehyde in methanol (500
ml) were slowly added under ice-cooling 230 ml of a 40% solution of
methylamine in methanol and 17 ml of acetic acid. After adding
dropwise a solution of 250 ml of 3,5-dimethylcyclohexanone in
methanol (1 l) thereinto, the resulting mixture was heated under
reflux for 5 hours. Then the reaction mixture was cooled to room
temperature and the solvent was distilled off under reduced
pressure. The residue was acidified by adding dilute hydrochloric
acid and then extracted with ethyl acetate. The aqueous layer was
made basic by adding sodium hydroxide and then extracted with ethyl
acetate. The organic layer was dried over anhydrous magnesium
sulfate and the solvent was distilled off under reduced pressure.
Then the residue was distilled under reduced pressure
(100-110.degree. C,/1 mmHg) to thereby give 79 g of crude
(6R*,8R*)-3,6,8-trimethyl-3-azabicyclo[3.3.1 ]nonan-9-one as a pale
yellow oily substance.
[1441] To a solution of 130 g of triethyl phosphono acetate in
tetrahydrofuran (600 ml) was added 25 g of sodium hydride (oily:
60% or above) under ice-cooling and the resulting mixture was
stirred at room temperature for 10 minutes. Then a solution of 70 g
of the crude
(6R*,8R*)-3,6,8-trimethyl-3-azabicyclo[3.3.1]nonan-9-one in
tetrahydrofuran (300 ml) was added thereto and the reaction mixture
was heated under reflux for 2 hours. After adding ethyl acetate,
the reaction mixture was washed twice with a saturated aqueous
solution of sodium chloride and the organic layer was dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
31.5 g of the title compound as a pale yellow oily substance.
[1442] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1443] 0.80-1.00(m, 1H), 0.96(d, J=6.8 Hz, 3H), 1.02(d, J=6.8 Hz,
3H), 1.28(t, J=6.8 Hz, 3H), 1.70-1.77(m, 1H), 1.81-1.86(m, 1H),
2.00-2.12(m, 4H), 2.20(s, 3H), 2.75(m, 2H), 3.58-3.62(m, 1H),
4.16(q, J=6.8 Hz, 2H), 5.66(s, 1H)
EXAMPLE 26
Ethyl(.+-.)-(anti)-(6R*,8R*)-(3,6,8-trimethyl
-3-azabicyclo[3.3.1]non-9-yl- )acetate
[1444] 249
[1445] To a solution of 31.5 g of ethyl (.+-.)
-(6R*,8R*)-(3,6,8-trimethyl-
-3-azabicyclo[3.3.1]non-9-ylidene)acetate in methanol (300 ml) was
added 6 g of 10% palladium-carbon (moisture content: 50%) and the
resulting mixture was stirred at room temperature for 12 hours
under a hydrogen gas stream. Then the reaction mixture was filtered
through celite and the solvent was distilled off under reduced
pressure. Thus 30.7 g of the title compound was obtained as a pale
yellow oily substance.
[1446] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1447] 0.80-1.00(m, 1H), 1.02(d, J=6.8 Hz, 6H), 1.28(t, J=6.8 Hz,
3H), 1.38-1.48(m, 2H), 1.70-1.90(m, 2H), 1.92-2.08(m, 2H),
2.10-2.15(m, 2H), 2.22(s, 3H), 2.45(d, J=6.8 Hz, 2H), 2.56-2.70(m,
2H), 4.41(q, J=6.8 Hz, 2H)
EXAMPLE 27
Ethyl(.+-.)-(anti)-(6R*,8R*)-2-(3,6,8-trimethyl-3-azabicyclo[3.3.1]non-9-y-
l)propanoate
[1448] 250
[1449] To a solution of 6 g of diisopropylamine in tetrahydrofuran
(60 ml) was added 33 ml of a 1.6 M solution of n-butyllithium in
hexane at -70.degree. C. and the resulting mixture was stirred at
0.degree. C. for 30 minutes. After recooling to -70.degree. C., a
solution of 10.1 g of
ethyl(anti)-(6R*,8R*)-2-(3,6,8-trimethyl-3-azabicyclo[3.3.1]non-9-yl)acet-
ate in tetrahydrofuran (40 ml) was added dropwise thereinto and the
resulting mixture was stirred at -70.degree. C. for 2 hours. Then 3
ml of methyl iodide was added dropwise into the reaction mixture
and the mixture was stirred at -70.degree. C. for 2 hours. After
adding a saturated aqueous solution of ammonium chloride, the
mixture was extracted with ethyl acetate twice. The organic layer
was dried over anhydrous magnesium sulfate and the solvent was
distilled off under reduced pressure. Thus 11.2 g of the title
compound was obtained as a pale yellow oily substance.
[1450] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1451] 0.80-1.00(m, 1H), 1.00(d, J=6.8 Hz, 3H), 1.02(d, J=6.8 Hz,
3H), 1.18(d, J=6.8 Hz, 3H), 1.30(t, J=6.8 Hz, 3H), 1.30-1.40(m,
2H), 1.70-1.85(m, 2H), 1.90-2.00(m, 2H), 2.05-2.16(m, 2H), 2.20(s,
3H), 2.52-2.78(m, 3H), 4.14(q, J=6.8 Hz, 2H)
EXAMPLE 28
Ethyl(.+-.)-(anti)-(6R*,8R*)-2-[3-10H-pyrazino[2,3-b][4]benzothiazin-8-ylm-
ethyl) -6,8-dimethy-3-azabicyclo[3.3.1]non-9-yl)propanoate
[1452] 251
[1453] To a solution of 18.2 g of ethyl(anti)
-(6R*,8R*)-2-(3,6,8-trimethy-
l-3-azabicyclo[3.3.1]non-9-yl)propanoate in 1,2-dichloroethane (180
ml) was added 9 ml of 1-chloroethyl chloroformate and the resulting
mixture was heated under reflux for 2 hours. After distilling off
the solvent under reduced pressure, 200 ml of methanol was added to
the residue and the mixture was heated under reflux for 1 hour.
After distilling off the solvent under reduced pressure, the
residue was made basic by adding a dilute aqueous solution of
sodium hydroxide and was then extracted with ethyl acetate. The
organic layer was dried over anhydrous magnesium sulfate and then
the solvent was distilled off under reduced pressure. To a solution
of the residue in N,N-dimethylformamide (100ml) were added 2 g of
8-chloromethyl -10H-pyrazino[2,3-b][1,4]benzothiazine and 3.3 g of
potassium carbonate and the resulting mixture was stirred at
80.degree. C. for 2 hours. After adding ethyl acetate, the reaction
mixture was washed with a saturated aqueous solution of sodium
chloride thrice and then the organic layer was dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluting with n-hexane/ethyl acetate) to thereby
give 3 g of the title compound as a yellow oily substance.
[1454] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1455] 0.80-1.00(m, 1H), 0.98(d, J=6.8 Hz, 3H), 1.00(d, J=6.8 Hz,
3H), 1.15(d, J=6.8 Hz, 3H), 1.26(t, J=6.8 Hz, 3H), 1.30-1.37(m,
1H), 1.42-1.50(m, 1H), 1.55-1.85(m, 4H), 1.98(d, J=7.2 Hz, 2H),
2.58(d, J=7.2 Hz, 1H), 2.64(d, J=7.2 Hz, 1H), 2.65-2.80(m, 1H),
3.26(s, 2H), 4.14(q, J=6.8 Hz, 2H), 6.40(br.s, 1H), 6.51(s, 1H),
6.76(d, J=8.0 Hz, 1H), 6.82(d, J=8.0 Hz, 1H), 7.56(d, J=2.8 Hz,
1H), 7.68(d, J=2.8 Hz, 1H)
EXAMPLE 29
Ethyl(.+-.)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8--
ylmethyl) -6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoate and
ethyl (-)-(anti)-(6R*,8R*)
-2-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth- yl)
-6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoate
[1456] 0.53 g of ethyl
(.+-.)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1-
,4]benzothiazin-8-ylmethyl)
-6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]prop- anoate was
dissolved in a solvent mixture of n-hexane with ethanol (97:3) and
the enantiomers were resolved by using CHIRALPAK AD (5
(diameter).times.50 cm; mfd. by Daicel Chemical Industries, Ltd.;
eluting with n-hexane/ethanol (97.5:2.5) at 150 ml/min]. Thus the
(+)-compound was eluted first followed by the (-)-compound. From
120 g of the racemic mixture, 41 g (100% e.e.) and 37 g (99% e.e.
or above) of the (+)- and (-)-compounds were obtained respectively
each as yellow crystals.
[1457] (+)-compound: .alpha..sup.25.sub.D+15.0.degree. (c=1.00
EtOH)
[1458] m.p.: 135-136.degree. C.
[1459] MS: FAB(+)467(MH.sup.+)
[1460] (-)-compound: .alpha..sup.25.sub.D-14.7.degree. (c=1.02
EtOH)
[1461] m.p.: 135-136.degree. C.
[1462] MS: FAB(+)467(MH.sup.+)
EXAMPLE 30
(+)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
) -6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoic acid
[1463] 252
[1464] 22.2 g of
ethyl(+)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,4]b-
enzothiazin-8-ylmethyl)
-6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoa- te was
dissolved in ethanol (530 ml) and water (130 ml). After adding 6.0
g of lithium hydroxide, the resulting mixture was heated under
reflux under a nitrogen gas stream for 24 hours. After distilling
off the solvent under reduced pressure, the residue was neutralized
by adding a dilute aqueous solution of hydrochloric acid and then
acidified by adding an aqueous solution of sodium
dihydrogenphosphate then the mixture was extracted with ethyl
acetate. The organic layer was dried over anhydrous magnesium
sulfate and the solvent was concentrated under reduced pressure to
thereby give yellow crystals. After recrystallizing from ethyl
acetate/diisopropyl ether, 18 g of the title compound was obtained
as yellow crystals.
[1465] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1466] 0.84-1.0(m, 1H), 0.95(d, J=6.8 Hz, 3H), 0.98(d, J=6.8 Hz,
3H), 1.06(d, J=6.8 Hz, 3H), 1.28-1.38(m, 2H), 1.54-1.82(m, 4H),
1.87(d, J=7.2 Hz, 1H), 1.89(d, J=7.2 Hz, 1H), 2.48-2.55(m, 1H),
2.55(d, J=7.2 Hz, 1H), 2.60(d, J=7.2 Hz, 1H), 3.24(s, 2H), 6.68(d,
J=8.0 Hz, 1H), 6.75(s, 1H), 6.84(d, J=8.0 Hz, 1H), 7.61(d, J=2.8
Hz, 1H), 7.63(d, J=2.8 Hz, 1H), 9.52(br.s, 1H), 12.0(br.s, 1H)
[1467] .alpha..sup.25.sub.D+6.31.degree. (c=1.03, THF)
[1468] m.p.: 205-210.degree. C.
[1469] MS: FAB(+)439(MH.sup.+)
EXAMPLE 31
(-)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
) -6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propanoic acid
[1470] 253
[1471] 0.3 g of the title compound was obtained as yellow crystals
by treating 0.5 g of ethyl
(-)-(anti)-(6R*,8R*)-2-[3-(10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl)-6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]propan-
oate in the same manner as described in Example 30.
[1472] .sup.1H-NMR(DMSO-d.sub.6).delta. ppm;
[1473] 0.84-1.00(m, 1H), 0.95(d, J=6.8 Hz, 3H), 0.98(d, J=6.8 Hz,
3H), 1.06(d, J=6.8 Hz, 3H), 1.28-1.38(m, 2H), 1.54-1.82(m, 4H),
1.87(d, J=7.2 Hz, 1H), 1.89(d, J=7.2 Hz, 1H), 2.48-2.55(m, 1H),
2.55(d, J=7.2 Hz, 1H), 2.60(d, J=7.2 Hz, 1H), 3.24(s, 2H), 6.68(d,
J=8.0 Hz, 1H), 6.75(s, 1H), 6.84(d, J=8.0 Hz, 1H), 7.61(d, J=2.8
Hz, 1H), 7.63(d, J=2.8 Hz, 1H), 9.52(br.s, 1H), 12.0(br.s, 1H)
[1474] .alpha..sup.25.sub.D-5.72.degree. (c=1.03, THF)
[1475] m.p.: 205-210.degree. C.
[1476] MS: FAB(+)439(MH.sup.+)
PRODUCTION EXAMPLE 1
[(anti)-2-(6R*,8R*)-3,6,8-Trimethyl
-3-azabicyclo[3.3.1]non-9-yl]ethyl acetate
[1477] 254
[1478] To a solution of 8.5 g of ethyl(anti)
-(6R*,8R*)-[3,6,8-trimethyl-3- -azabicyclo[3.3.1]non-9-yl]acetate
in tetrahydrofuran (100 ml) was slowly added 0.9 g of aluminum
hydride under ice-cooling and the resulting mixture was stirred at
0.degree. C. for 30 minutes. Next, a mixture of methanol with water
was slowly added to the reaction mixture. After being diluted with
ethyl acetate, the reaction mixture was filtered through celite.
After distilling off the solvent under reduced pressure, 7.6 g of a
pale yellow oily substance was obtained.
[1479] To a solution of 7.6 g of this pale yellow oily substance in
methylene chloride (100 ml) were added 5.5 g of acetic anhydride,
7.5 ml of triethylamine and 0.44 g of 4-dimethylaminopyridine and
the resulting mixture was stirred at room temperature for 2.5 days.
Then the reaction mixture was washed with water and the organic
layer was dried over anhydrous magnesium sulfate. After distilling
off the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluting with methylene
chloride/methanol) to thereby give 7.6 g of the title compound as a
pale yellow oily substance.
[1480] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1481] 0.70-1.08(m, 6H), 0.98(d, J=6.8 Hz, 3H), 1.02(d, J=6.8 Hz,
3H), 1.60-2.00(m, 5H), 2.05(s, 3H), 2.06(s, 3H), 2.60-2.70(m, 2H),
4.07(t, J=6.8 Hz, 2H)
PRODUCTION EXAMPLE 2
[(anti)-2-[(6R*,8R*)-3-(Vinyloxycarbonyl)
-6,8-dimethyl-3-azabicyclo[3.3.1- ]non-9-yl]ethyl]acetate
[1482] 255
[1483] To a solution of 7.6 g of
[(anti)-2-[(6R*,8R*)-3,6,8-trimethyl-3-az-
abicyclo[3.3.1]nonan-9-yl]ethyl]acetate in 1,2-dichloroethane (100
ml) was added 3.8 ml of vinyl chloroformate and the resulting
mixture was heated under reflux for 1 hour. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluting with n-hexane/ethyl
acetate) to thereby give 5.1 g of the title compound as a pale
yellow oily substance.
[1484] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1485] 0.90-1.0(m, 1H), 0.98(d, J=6.8 Hz, 3H), 1.02(d, J=6.8 Hz,
3H), 1.40-1.60(m, 4H), 1.74-1.90(m, 3H), 2.05(s, 3H), 2.70-2.90(m,
2H), 3.92-4.26(m, 4H), 4.43(m, 2H), 4.78(d, J=16 Hz, 1H),
7.12-7.25(m, 1H)
PRODUCTION EXAMPLE 3
(anti)-(6R*,8R*)-[3-(Vinyloxycarbonyl)
-6,8-dimethyl-3-azabicyclo[3.3.1]no- n-9-yl]acetaldehyde
[1486] 256
[1487] To a solution of 5.1 g of
[(anti)-2-[(6R*,8R*)-3-(vinyloxycarbnyl)--
6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]ethyl]acetate in methanol
(50 ml) was added 7 ml of a 5 N aqueous solution of sodium
hydroxide and the resulting mixture was stirred at room temperature
for 1 hour. After distilling off the solvent under reduced
pressure, the residue was neutralized by adding dilute hydrochloric
acid and then extracted with ethyl acetate. The organic layer was
dried over anhydrous magnesium sulfate and the solvent was
distilled off under reduced pressure to thereby give 4.3 g of
(anti)-(6R*,8R*)-2-[3-(vinyloxycarbonyl)
-6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]ethanol as a yellow oily
substance.
[1488] Into a solution of 3.6 g of oxalyl chloride in methylene
chloride (50 ml) was added dropwise 2.6 ml of dimethyl sulfoxide at
-70.degree. C. After stirring for 10 minutes, a solution of 2.5 g
of (anti)-(6R*,8R*)-2-[3-(vinyloxycarbonyl)-6,8-dimethyl
-3-azabicyclo[3.3.1]non-9-yl]ethanol in methylene chloride (30 ml)
was added dropwise thereinto. After stirring at -70.degree. C. for
3 hours, 7.8 ml of triethylamine was added thereto. Then the
reaction mixture was brought back to room temperature and washed
with water. The organic layer was dried over anhydrous magnesium
sulfate and the solvent was distilled off under reduced pressure.
The residue was purified by silica gel column chromatography
(eluting with n-hexane/ethyl acetate) to thereby give 2.1 g of the
title compound as a pale yellow oily substance.
[1489] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1490] 0.98(d, J=6.8 Hz, 3H), 1.02(d, J=6.8 Hz, 3H), 1.42-1.70(m,
5H), 1.85-1.95(m, 1H), 2.17-2.23(m, 1H), 2.64(d, J=6.8 Hz, 2H),
2.80-2.95(m, 2H), 3.94-4.08(m, 2H), 4.46(d, J=6.8 Hz, 1H), 4.78(d,
J=16 Hz, 1H), 7.20(dd, J=6.8, 16 Hz, 1H), 9.72(t, J=6.8 Hz, 1H)
PRODUCTION EXAMPLE 4
Ethyl(anti)-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]acetate
[1491] 257
[1492] 0.78 g of
ethyl(anti)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl]acetate was
dissolved in 10 ml of 1,2-dichloroethane. After adding 0.6 ml of
vinyl chloroformate, the resulting mixture was stirred at room
temperature for 1 hour and then heated under reflux for 2 hours.
The reaction mixture was concentrated and, after adding water,
extracted with ethyl acetate. The ethyl acetate layer was washed
with 1 N hydrochloric acid, a saturated aqueous solution of sodium
hydrogencarbonate and a saturated aqueous solution of sodium
chloride and dried over anhydrous sodium sulfate. After
concentrating the solvent under reduced pressure, 0.52 g of the
title compound was obtained as a pale brown oily substance.
[1493] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1494] 1.27(t, J=7.1 Hz, 3H), 1.48(m, 1H), 1.59-1.83(m, 7H),
2.21(m, 1H), 2.53(d, J=7.5 Hz, 2H), 3.15(m, 1H), 3.23(m, 1H),
4.15(q, J=7.1 Hz, 2H), 4.17-4.26(m, 2H), 4.45(dd, J=1.5, 6.3 Hz,
1H), 4.79(dd, J=1.5, 13.9 Hz, 1H), 7.25(dd, J=6.3, 13.9 Hz, 1H)
PRODUCTION EXAMPLE 5
(anti)-[3-(Vinyloxycarbonyl) -3-azabicyclo[3.3.1]non-9-yl]acetic
acid
[1495] 258
[1496] 3.01 g of ethyl(anti)-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non- -9-yl]acetate was dissolved in 30 ml of
ethanol. After adding 16.1 ml of1 N sodium hydroxide, the resulting
mixture was stirred at room temperature for 4 hours. Then the
reaction mixture was concentrated and water was added thereto. The
aqueous layer was washed with ether and acidified with 1 N
hydrochloric acid and then extracted with ethyl acetate. After
drying the extracts over anhydrous sodium sulfate and concentrating
the solvent under reduced pressure, 2.9 g of the title compound was
obtained as a pale yellow oily substance.
[1497] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1498] 1.50(m, 1H), 1.60-1.86(m, 7H), 2.22(m, 1H), 2.60(d, J=7.5
Hz, 2H), 3.15(m, 1H), 3.23(m, 1H), 4.17-4.28(m, 2H), 4.45(dd,
J=1.6, 6.4 Hz, 1H), 4.79(dd, J=1.6, 14.1 Hz, 1H), 7.24(dd, J=6.4,
14.1 Hz, 1H)
PRODUCTION EXAMPLE 6
(anti)-2-[3-(Vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]ethanol
[1499] 259
[1500] To a solution of 500 mg of (anti)-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid in tetrahydrofuran (10 ml)
were added 294 mg of N-hydroxysuccinimide and 449 mg of
N,N'-dicyclohexyl carbodiimide and the resulting mixture was
stirred at room temperature for 8 hours. Next, the reaction mixture
was ice-cooled and 187 mg of sodium borohydride was added thereto.
After stirring for 20 minutes, the reaction mixture was stirred at
room temperature for an additional 15 hours and then was extracted
with ethyl acetate containing ice/water. The ethyl acetate layer
was washed with water, 1 N sodium hydroxide and a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After concentrating under reduced pressure, the matters
insoluble in methylene chloride were filtered off. Then the residue
was purified by silica gel column chromatography (eluting with
methylene chloride/methanol) to thereby give 348 mg of the title
compound as a colorless oily substance.
[1501] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1502] 1.41-1.90(m, 12H), 3.12(m, 1H), 3.19(m, 1H), 3.73(t, J=6.4
Hz, 2H), 4.17-4.25(m, 2H), 4.44(dd, J=1.5, 6.2 Hz, 1H), 4.78(dd,
J=1.5, 14.1 Hz, 1H), 7.25(dd, J=6.2, 14.1 Hz, 1H)
PRODUCTION EXAMPLE 7
(anti)-[3-(Vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]acetaldehyde
[1503] 260
[1504] 0.32 ml of oxalyl chloride was dissolved in 8 ml of
methylene chloride, cooled to -60.degree. C. and stirred. 0.28 ml
of dimethyl sulfoxide was dissolved in 1 ml of methylene chloride
and then was added dropwise to the above solution while maintaining
the bulk temperature at -50.degree. C. or below. 5 minutes
thereafter, 580 mg of (anti)-2-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]ethanol was dissolved in 2 ml of
methylene chloride and added dropwise to the above mixture while
maintaining the bulk temperature at -50.degree. C. or below. After
15 minutes, 1.7 ml of triethylamine was added dropwise to while
maintaining the bulk temperature at -50.degree. C. or below. After
20 minutes, the reaction mixture was heated to room temperature and
stirred for 1 hour. After adding water, the reaction mixture was
extracted with ethyl acetate. The ethyl acetate layer was washed
with 1 N hydrochloric acid, a saturated aqueous solution of sodium
hydrogencarbonate and a saturated aqueous solution of sodium
chloride, dried over anhydrous sodium sulfate and concentrated
under reduced pressure. Then the residue was purified by silica gel
column chromatography (eluting with n-hexane/ethyl acetate) to
thereby give 451 mg of the title compound as a colorless oily
substance.
[1505] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1506] 1.48(m, 1H), 1.60-1.82(m, 7H), 2.33(m, 1H), 2.66-2.72(m,
2H), 3.18(m, 1H), 3.25(m, 1H), 4.08-4.13(m, 2H), 4.45(dd, J=1.6,
6.2 Hz, 1H), 4.79(dd, J=1.6, 14.0 Hz, 1H), 7.25(dd, J=6.2, 14.0 Hz,
1H), 9.83(t, J=1.6 Hz, 1H)
PRODUCTION EXAMPLE 8
1-[3-[N-(2-Cyclobutylidene)ethyl)-N-(p-tolylsulfonyl)aminol
-1-oxopropyl]pyrrolidine
[1507] 261
[1508] 5.84 g of
1-[3-(p-tolylsulfonylamino)-1-oxopropyl]pyrrolidine was dissolved
in 300 ml of dry N,N-dimethylformamide under a nitrogen atmosphere.
After adding 0.83 g of sodium hydride, the resulting mixture was
stirred for 30 minutes. Then 4.76 g of 2-bromoethylidenecyclobutane
was added thereto and the resulting mixture was stirred at
90.degree. C. for 3 hours. After adding 500 ml of water and 500 ml
of ethyl acetate, the organic layer was washed with water, dried
over anhydrous magnesium sulfate and filtered. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluting with methanol/methylene
chloride) to thereby give 6.78 g of the title compound as a yellow
oily substance.
[1509] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1510] 1.63(d, J=1 Hz, 3H), 1.65(d, J=1 Hz, 3H), 1.86(m, 2H),
1.96(m, 2H), 2.42(s, 3H), 2.68(t, J=8 Hz, 2H), 3.38(t, J=8 Hz, 2H),
3.44(t, J=7 Hz, 4H), 3.80(d, J=7 Hz, 2H), 4.98(t, sept, J=1, 7 Hz,
1H), 7.29(d, J=8 Hz, 2H), 7.69(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 9
3-(p-Tolylsulfonyl)-6-oxo-3-azabicyclo[3.3.1]heptane-7-spiro-cyclobutane
[1511] 262
[1512] 7.56 g of trifluoromethanesulfonic acid was dissolved in 180
ml of dry 1,2-dichloroethane in a nitrogen atmosphere. Into the
solution thus obtained was added dropwise 6.77 g of
1-[3-[N-(2-cyclobutylidene)ethyl)-N-
-(p-tolylsulfonyl)amino[-1-oxopropyl]pyrrolidine in 180 ml of
1,2-dichloroethane. Further,2.37 g of collidine in 180 ml of
1,2-dichloroethane was added dropwise thereinto and the resulting
mixture was heated under reflux at 90.degree. C. for 2 hours. After
distilling off the solvent under reduced pressure, the residue was
dissolved in 300 ml of water and 300 ml of carbon tetrachloride and
then heated to 100.degree. C. under a nitrogen atmosphere for 3
hours. The solvent was decanted and the organic layer was dried
over anhydrous magnesium sulfate and filtered. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluting with n-hexane/ethyl
acetate) to thereby give 3.41 g of the title compound as an orange
oily substance.
[1513] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1514] 1.89(m, 4H), 2.01(m, 2H), 2.44(s, 3H), 2.85(s, 2H), 3.77(dd,
J=2, 10 Hz, 2H), 3.89(dd, J=2, 10 Hz, 2H), 7.31(d, J=8 Hz, 2H),
7.69(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 10
1,3,5-Trimethyl-3-azabicyclo[3.3.1]nonan-9-one
[1515] 263
[1516] To 1 l of a solution of 25 g of 2,6-dimethylcyclohexanone in
acetic acid were added 13.5 g of methylamine hydrochloride and 32.4
g of formalin (37% aqueous solution) and the resulting mixture was
heated to 100.degree. C. for 2 hours. After removing the solvent
under reduced pressure, the obtained residue was distributed
between ethyl acetate and an aqueous solution of potassium
carbonate. The organic layer was extracted and dried over anhydrous
sodium sulfate. Then the residue was purified by silica gel column
chromatography (eluting with ethyl acetate/n-hexane) to thereby
give 19 g of the title compound as a colorless oily substance.
[1517] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1518] 0.92(s, 6H), 1.36-1.45(m, 1H), 1.66-1.76(m, 2H),
2.02-2.09(m, 2H), 2.16(s, 3H), 2.17-2.22(m, 2H), 2.92-2.98(m, 2H),
3.02-3.17(m, 1H)
PRODUCTION EXAMPLE 11
1,3,5-Trimethyl-9-methoxymethylene -3-azabicyclo[3.3.1]nonane
[1519] 264
[1520] 100 ml of a solution of 20.5 ml of
(methoxymethyl)trimethylsilane in dry tetrahydrofuran was cooled
under a nitrogen atmosphere. Then 92 ml of a 1.3 M solution of
s-butyllithium in cyclohexane was added dropwise thereinto at
-78.degree. C. After the completion of the addition, the mixture
was stirred at -35.degree. C. for 30 minutes. After adding 10.9 g
of 1,3,5-trimethyl-3-azabicyclo[3.3.1]nonan-9-one, the resulting
mixture was stirred at room temperature for 2 hours and then poured
into a cooled aqueous solution of ammonium chloride. Then it was
made alkaline by adding potassium carbonate and extracted with
ethyl acetate. The organic layer was washed with water and dried
over anhydrous sodium sulfate. After distilling off the solvent
under reduced pressure, 9.2 g of the title compound was obtained as
a pale-brown oily substance.
[1521] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1522] 0.83(s, 3H), 1.15(s, 3H), 1.20-1.37(m, 2H), 1.42-1.59(m,
2H), 1.62-1.68(m, 1H), 1.69(dd, J=3.3, 10.7 Hz, 1H), 1.86(dd,
J=3.3, 10.7 Hz, 1H), 1.99(s, 3H), 2.50(d, J=10.7 Hz, 1H), 2.61(d,
J=10.7 Hz, 1H), 2.67-2.83(m, 1H), 3.41(s, 3H), 5.59(s, 1H)
PRODUCTION EXAMPLE 12
(1,3,5-Trimethyl-3-azabicyclo[3.3.1]non-9 -yl) carbaldehyde
[1523] 265
[1524] 9.2 g of 1,3,5-trimethyl-9-methoxymethylene
-3-azabicyclo-[3.3.1]no- nane was slowly added dropwise to 30 ml of
formic acid at room temperature. After completion of the addition,
the formic acid was distilled off under reduced pressure. Then the
residue was distributed between ethyl acetate and an aqueous
solution of potassium carbonate. The organic layer was extracted
and dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluting with n-hexane/ethyl acetate) to
thereby give 7.3 g of the title compound as a colorless oily
substance.
[1525] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1526] 0.83(s, 6H), 1.55-1.64(m, 4H), 1.65-1.80(m, 3H), 1.73(d,
J=7.0 Hz, 1H), 2.08(s, 3H), 2.60(d, J=12.0 Hz, 2H), 2.74-2.91(m,
1H), 10.06(d, J=7.0 Hz, 1H)
PRODUCTION EXAMPLE 13
(6R*,8R*)-(3,6,8-Trimethyl
-3-azabicyclo[3.3.1]non-9-yl)carbaldehyde
[1527] 266
[1528] Into a solution of 19.2 g of
(methoxymethyl)triphenyl-phosphonium chloride in dry
tetrahydrofuran (200 ml) was added dropwise 32 ml of a 1.6 M
solution of n-butyllithium at -70.degree. C. and the resulting
mixture was stirred at 0.degree. C. for 30 minutes. Then a solution
of 6 g of (6R*,8R*) -3,6,8-trimethyl-3-azabicyclo[3.3.1]nonan-9-one
in dry tetrahydrofuran (30 ml) was dropped into the reaction
mixture and the mixture was stirred at room temperature overnight.
After adding ethyl acetate, the reaction mixture was washed with
water and the organic layer was dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure, a
yellow oily substance was obtained.
[1529] To a solution of this oily substance in acetone (50 ml) was
added 15 ml of a 6 N aqueous solution of hydrochloric acid and the
resulting mixture was stirred at room temperature for 4 hours. Then
the reaction mixture was made alkaline by adding a 1 N aqueous
solution of sodium hydroxide and extracted with ethyl acetate. The
organic layer was dried over anhydrous magnesium sulfate and the
solvent was distilled off under reduced pressure. Then the residue
was purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 2.0 g of the title compound
as a pale yellow oily substance.
[1530] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1531] 1.02(d, J=6.8 Hz, 6H), 1.50-2.00(m, 7H), 2.08-2.15(m, 2H),
2.24(br.s, 3H), 2.68-2.80(m, 2H), 9.85(s, 1H)
PRODUCTION EXAMPLE 14
3-Methyl-9-methylene-3-azabicyclo[3.3.1]nonane
[1532] 267
[1533] To a solution of 6.9 g of methyltriphenyl phosphonium
bromide in toluene (30 ml) was added 2.2 g of potassium
tert-butoxide at 0.degree. C. and the resulting mixture was stirred
for 30 minutes. Next, 3.0 g of
3-methyl-3-azabicyclo[3.3.1]nonan-9-one was added thereto and the
mixture was reacted for 1 hour. After adding ether, the reaction
mixture was washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
filtering and concentrating, the residue was purified by silica gel
column chromatography (eluted with ether/n-hexane) to thereby give
3.1 g of the title compound as a yellow oily substance.
[1534] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1535] 1.40-1.50(m, 1H), 1.65-1.80(m, 2H), 1.80-2.00(m, 2H),
2.13(s, 3H), 2.1-2.4(m, 4H), 2.45-2.65(m, 1H), 2.83-2.98(m, 2H),
4.58(s, 2H)
PRODUCTION EXAMPLE 15
3-(tert-Butoxycarbonyl)-9-methylene -3-azabicyclo[3.3.1]nonane
[1536] 268
[1537] 1.0 g of 3-methyl-9-methylene-3-azabicyclo (3.3.1]nonane was
dissolved in 1,2-dichloroethane (5 ml). After adding 1.37 g of
1-chloroethyl chloroformate, the resulting mixture was heated under
reflux at 110.degree. C. for 2 hours. After distilling off the
solvent under reduced pressure, methanol was added to the residue
and the mixture was heated under reflux for 1 hour. After
distilling off the solvent under reduced pressure, 1.0 g of brown
crude crystals were obtained. These crystals were dissolved in 30
ml of methanol and 1.8 ml of triethylamine and 1.7 g of
di-tert-butyl dicarbonate were added thereto. After reacting at
room temperature for 1 hour, water was added to the reaction
mixture. Then the mixture was extracted with ethyl acetate, washed
with dilute hydrochloric acid and a saturated aqueous solution of
potassium hydrogencarbonate and dried over anhydrous magnesium
sulfate. After concentrating under reduced pressure, the residue
was purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 0.8 g of the title compound as a
yellow oily substance.
[1538] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1539] 1.47(s, 9H), 1.6-2.0(m, 6H), 2.33(br.s, 1H), 2.39(br.s, 1H),
2.95(br.d, J=13 Hz, 1H), 3.04(br.d, J=13 Hz, 1H), 4.13(d, J=12 Hz,
1H), 4.27(d, J=12 Hz, 1H), 4.67(s, 2H)
PRODUCTION EXAMPLE 16
3-(tert-Butoxycarbonyl)-3-azabicyclo[3.3.1]nonane-9-spirocyclobutan-3'-one
[1540] 269
[1541] To 3.7 g of zinc/copper alloy was added a solution of 1.4 g
of 3-(tert-butoxycarbonyl)-9-methylene -3-azabicyclo[3.3.1]-nonane
in dry ether (30 ml). Subsequently, a solution of 2.6 ml of
trichloroacetyl chloride in dry dimethoxyethane (50 ml) was dropped
thereinto and the resulting mixture was reacted at room temperature
for 3 hours. Then a saturated aqueous solution of sodium
hydrogencarbonate was added to the reaction mixture while
maintaining the mixture at 0.degree. C. or below. After filtering
off the zinc/copper alloy, the filtrate was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
concentrating under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 1.5 g of a yellow oily substance.
This product was dissolved in 40 ml of a saturated solution of
ammonium chloride in methanol. After adding 1.7 g of zinc, the
resulting mixture was reacted at room temperature for 24 hours.
After filtering off the zinc, water was added to the residue. Next,
it was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After concentrating, the residue was purified by
silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 0.8 g of the title compound as a
colorless oily substance.
[1542] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1543] 1.47(s, 9H), 1.55-1.90(m, 8H), 2.8-2.95(m, 4H), 3.06(d, J=14
Hz, 1H), 3.15(d, J=14 Hz, 1H), 4.02(d, J=13 Hz, 1H), 4.15(d, J=13
Hz, 1H)
PRODUCTION EXAMPLE 16'
(6R*,8R*)-3-(tert-Butoxycarbonyl)
-6,8-dimethyl-3-azabicyclo[3.3.1]-nonane
-9-spirocyclobutan-3'-one
[1544] 270
[1545] The title compound was obtained by treating
(.+-.)-(6R*,8R*)-3,6,8-- trimethyl-3-azabicyclo[3.3.1]nonan-9-one
by the same methods as those of Production Examples 14, 15 and
16.
[1546] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1547] 1.01-1.13(m, 6H), 1.3-1.95(m, 5H), 1.45(s, 9H), 2.65-3.0(m,
3H), 2.89(s, 4H), 3.7-3.85(m, 1H), 3.9-4.0(m, 1H)
PRODUCTION EXAMPLE 17 to 24
[1548] The following unsaturated esters were obtained by the same
method as the one of Example 19.
3TABLE 3 Prodn. Ex. Structural formula NMR 17 271 .sup.1H-NMR
(CDCl.sub.3) .delta.ppm: 0.9, 0.95 (d, J=7 Hz, total 3H),1.0-1.2
(m, 1H), 1.26 (t, J=7 Hz 3H), 1.5-2.0 (m, 2H), 2.14 (s, 3H),
2.0-2.3 (m, 4H), 2.6-2.8 (m, 1H), 2.85-3.0 (m, 2H), 3.70-3.90 (s,
total 1H), 4.15 (q, J=7 Hz, 2H), 5.59, 5.74 (s, total 1H) 18 272
.sup.1H-NMR (CDCl.sub.3) .delta.ppm: 1.29 (t, J=7 Hz, 3H), 1.69 (m,
3H), 1.7-2.0 (m, 2H), 2.15-2.30 (m, 1H), 2.25 (s, 3H), 2.48 (m,
1H), 2.8-2.9 (m, 2H), 3.75 (m, 1H), 4.17 (q, J=7 Hz, 2H), 5.64 (s,
1H) 19 273 .sup.1H-NMR (CDCl.sub.3) .delta.ppm: 1.2-1.4 (m, 3H),
1.83 (s, 1H), 2.26 (s, 4H), 2.45 (d, J=8 Hz, 2H), 3.14-3.23 (m,
2H), 3.78 (d, J=8 Hz, 2H), 3.98 (s, 1H), 4.1-4.25 (m, 3H), 5.74 (s,
1H) 20 274 .sup.1H-NMR (CDCl.sub.3) .delta.ppm: 1.26 (t, J=6.8 Hz,
3H), 2.25 (s, 3H), 2.34-2.41 (m, 2H), 2.49-2.54 (m, 1H), 2.74-2.81
(m, 2H) 2.78 (d, J=4.2 Hz, 2H), 2.83-2.89 (m, 2H), 3.49 (d, J=14.2
Hz, 1H), 3.53 (d, J=14.2 Hz, 1H), 4.13 (q, J=6.8 Hz, 2H), 4.18-4.25
(m, 1H), 5.71 (s, 1H), 7.20-7.36 (m, 5H) 21 275 .sup.1H-NMR
(CDCl.sub.3) .delta.ppm: 1.28 (t, J=7.2 Hz, 3H), 1.32-1.43 (m, 2H),
1.60-1.72 (m, 3H), 1.78-1.94 (m, 3H), 1.99-2.05 (m, 1H), 2.05-2.10
(m, 1H), 2.17 (s, 3H), 2.51-2.58 (m, 1H), 2.60-2.66 (m, 2H),
3.93-4.00 (m, 1H), 4.14 (q, J=7.2 Hz, 2H), 5.65 (s, 1H)
[1549]
4TABLE 4 Prodn. Ex. Structural formula NMR 22 276 .sup.1H-NMR
(CDCl.sub.3) .delta.ppm: 0.78 (d, J=4.6 Hz, 3H), 1.28 (t, J=6.4 Hz,
3H), 1.30-1.43 (m, 2H), 1.90-2.10 (m, 2H), 2.14 (s, 3H), 2.18-2.32
(m, 4H), 2.93-3.10 (m, 3H), 4.15 (q, J=6.4 Hz, 2H), 5.62 (s, 1H) 23
277 .sup.1H-NMR (CDCl.sub.3) .delta.ppm: 0.89 (s. 3H), 0.95 (s,
3H), 1.28 (t, J=7.0 Hz, 3H), 1.69-1.81 (m, 2H), 1.84-1.91 (m, 2H),
2.00-2.09 (m, 2H), 2.21 (s, 3H), 2.35-2.43 (m, 1H), 2.71-2.81 (m,
2H), 4.00-4.07 (m, 1H), 4.16 (q, J=7.0 Hz, 2H), 5.73 (s, 1H) 24 278
.sup.1H-NMR (CDCl.sub.3) .delta.ppm: 0.8 & 0.84 (s, 9H(1:1)),
1.29 (t, J=7.2 Hz, 3H), 1.45-1.58 (m, 1H), 1.60-1.72 (m, 1H),
1.94-2.07 (1H, 3H), 2.13 & 2.20 (s, 3H(1:1)), 2.18-2.40 (m,
2H), 2.70-2.97 (m, 3H), 3.92-4.04 (m, 1H), 4.15 (q, J=7.2 Hz, 2H),
5.61 & 5.64 (s, 1H(1:1))
PRODUCTION EXAMPLE 25
Ethyl [[3-(p-tolylsulfonyl)
-3-azabicyclo[3.3.1]heptane-7-spiro-cyclobutan-
]-6-ylidene]acetate
[1550] 279
[1551] To a solution of 1.61 g of triethyl phosphonoacetate in dry
tetrahydrofuran (40 ml) was added 0.288 g of sodium hydride (oily:
60% or above) and the resulting mixture was stirred at room
temperature for 20 minutes. Then a solution of 1.83 g of
3-(p-tolylsulfonyl)-6-oxo-3-azabicy-
clo[3.3.1]heptane-7-spiro-cyclobutane in tetrahydrofuran (10 ml)
was added thereto and the resulting mixture was reacted for 2
hours. After distilling off the solvent under reduced pressure, the
residue was poured into a 0.1 N aqueous solution of sodium
hydroxide and extracted with ethyl acetate. The extract was dried
over anhydrous magnesium sulfate and distilled off under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with ethyl acetate/n-hexane) to thereby give
2.1 g of the title compound as a colorless oily substance.
[1552] .sup.1H-NMR(CDCl.sub.3).delta. ppm;
[1553] 1.26(t, J=7 Hz, 3H), 1.66(m, 2H), 1.77(m, 2H), 1.94(m, 2H),
2.42(s, 3H), 2.73(td, J=3, 6 Hz, 1H), 3.35(m, 1H), 3.62(dd, J=3, 10
Hz, 1H), 3.69(d, J=2 Hz, 1H), 3.71(t, J=2 Hz, 1H), 3.81(dd, J=3, 10
Hz, 1H), 4.12(q, J=7 Hz, 2H), 5.58(s, 1H), 7.26(d, J=8 Hz, 2H),
7.67(d, J=8 Hz, 2H)
PRODUCTION EXAMPLES 26 to 32
[1554] The following saturated esters were obtained by the same
method as the one of Example 20.
5TABLE 5 Prodn. Ex. Structural formula NMR 26 280 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.26 (t, J=7 Hz, anti), 1.26 (t, J=7 Hz,
3H, syn), 1.65-1.80 (m, 4H, anti and syn), 1.90-2.06 (m, 3H, anti
and syn), 2.09 (d, J=10 Hz, 2H, anti), 2.17 (d, J=8 Hz, 2H, anti),
2.22 (s, 3H, anti), 2.25 (s, 3H, syn), 2.34 (d, J=11 Hz, 2H, syn),
2.48 (dd, J=4, 11 Hz, 2H, # syn), 2.57 (d, J=8 Hz, 2H, syn), 2.72
(dd, J=4, 11 Hz, 2H, anti), 4.14 (q, J=7 Hz, 2H, syn and anti)
[1555]
6TABLE 6 Prodn. Ex. Structural formula NMR 27 281 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 0.81 (d, J=6.8 Hz, 3H), 1.25-1.36 (m,
2H), 1.26 (t, J=7.2 Hz, 3H), 1.62-1.70 (m, 2H), 1.90-2.04 (m, 2H),
2.14 (s, 3H), 2.12-2.24 (m, 2H). 2.41 (d, J=7.2 Hz, 2H), 2.54-2.74
(m. 2H), 2.83-2.92 (m, 2H), 4.13 (q, J=7.2 Hz, 2H) 28 282
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.21 (t, J=7 Hz, 3H), 1.40
(m, 1H), 1.52 (m, 1H), 1.66-1.80 (m, 2H), 2.04-2.06 (m, 4H), 2.22
(m, 2H), 2.42-2.52 (m, 4H), 3.42-3.55 (m, 4H), 4.26 (q, J=7 Hz,
2H), 7.30 (m, 2H), 7.71 (m, 2H) 29 283 .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 0.83 & 0.84 (s, J=7.2 Hz, 3H), 1.30-1.62 (m, 4H),
1.68-2.00 (m, 6H), 2.12 & 2.14 (s, 3H(1:1)), 2.36 (d, J=7.2 Hz,
1H), 2.47 (d, 7.2 Hz, 1H), 2.52-2.57 (m, 1H), 2.81-2.86 (m, 1H),
4.13 (q, J=7.2 Hz, 2H)
[1556]
7TABLE 7 Prodn. Ex. Structural formula NMR 30 284 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 0.98 (s, 3H), 1.25 (t, J=7.0 Hz, 3H),
1.32 (s, 3H), 1.32-1.40 (m, 2H), 1.64-1.72 (m, 4H), 1.81-1.88 (m,
1H), 2.12 (s, 3H), 2.12-2.18 (m, 2H), 2.35 (d, J=7.6 Hz, 2H),
2.68-2.73 (m, 2H), 4.12 (q, J=7.0 Hz, 2H) 31 285 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.03 (d, J=8 Hz, 3H), 1.25 (t, J=5 Hz,
3H), 1.1-1.3 (m, 1H), 1.4-1.7 (m, 3H), 1.8-2.0 (m, 3H), 2.0-2.30
(m, 5H), 2.35-2.43 (m, 3H), 2.6-2.9 (m, 2H), 4.0-4.1 (m, 2H) 32 286
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.2-1.3 (m, 3H), 1.56 (br.s,
1H), 2.06-2.16 (m, 1H), 2.24-2.30 (m, 3H), 2.30-2.38 (m, 2H),
2.42-2.52 (m, 1H), 2.6-2.68 (m, 2H), 3.12 (br.d, J=11 Hz, 2H), 3.81
(d, J=12 Hz, 2H), 3.9-3.98 (m, 2H), 4.1-4.2 (m, 2H)
PRODUCTION EXAMPLE 33
Ethyl(3-methyl-7-phenyl-3-azabicyclo[3.3.1]non-9-yl)acetate
[1557] 287
[1558] The title compound was obtained by treating
4-phenylcyclohexanone by the same methods as those of Examples 19
and 20.
[1559] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1560] 1.28(t, J=7.2 Hz, 3H), 1,70-2.34(m, 10H), 2.22(s, 3H),
2.59(d, J=7.2 Hz, 2H), 2.5-2.70(m, 1H), 2.92-3.04(m, 1H), 4.16(q,
J=7.2 Hz, 2H), 7.12-7.38(m, 5H)
PRODUCTION EXAMPLE 34
(3-Methyl-3-azabicyclo[3.3.1]nonan-9-yl )carbonitrile
[1561] 288
[1562] 6.2 g of 3-methyl-3-azabicyclo[3.3.1]nonan -9-one was
dissolved in 150 ml of dry dimethoxyethane and 40 ml of
tert-butanol. Then 46 g of potassium tert-butoxide and 15.8 g of
tosylmethyl isocyanide were added thereto at 0.degree. C. After
stirring for 30 minutes, the resulting mixture was heated under
reflux for 3 hours. Then the reaction mixture was brought back to
room temperature and water was added thereto. The resulting mixture
was extracted with ethyl acetate, washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After concentrating under reduced pressure, the obtained
residue was purified by silica gel column chromatography (eluted
with ethyl acetate/n-hexane) to thereby give 5.5 g of the title
compound as a yellow oily substance.
[1563] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1564] one isomer
[1565] 1.45-1.60(m, 1H), 1.55-1.70(m, 2H), 1.7-1.8(m, 2H),
1.95-2.1(m, 2H), 2.14(s, 3H), 2.18(d, J=10 Hz, 2H), 2.4-2.6(m, 1H),
2.64(s, 1H), 2.93(d, J=10 Hz, 2H)
[1566] other isomer
[1567] 1.4-1.5(m, 1H), 1.54-1.70(m, 2H), 1.84-1.94(m, 2H),
2.04-2.12(m, 2H), 2.18(s, 3H), 2.44-2.6(m, 1H), 2.58(d, J=12 Hz,
2H), 2.64-2.68(m, 1H), 2.80(d, J=12 Hz, 2H)
PRODUCTION EXAMPLE 35
Methyl(3-methyl-3-azabicyclo[3.3.1]non-9-yl )carboxylate
[1568] 289
[1569] To a solution of 5.5 g of
(3-methyl-3-azabicyclo[3.3.1]nonan-9-yl)c- arbonitrile in 20 ml of
ethylene glycol was added a solution of 48 g of potassium hydroxide
in 50 ml of water and the resulting mixture was reacted at
200.degree. C. for 6 hours. Then the reaction mixture was brought
back to room temperature and made weakly acidic by adding an
aqueous solution of sodium dihydrogenphosphate. After concentrating
under reduced pressure, the residue was washed with tetrahydrofuran
and ethanol and the washing liquor was concentrated. Next, 500 ml
of methanol was added thereto. After further adding 10 ml of
thionyl chloride, the resulting mixture was reacted at 70.degree.
C. for 3 hours. The reaction mixture was cooled to 0.degree. C. and
made alkaline by adding an aqueous solution of sodium hydroxide.
Then it was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After concentrating under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 3.4 g of the title
compound as a pale brown oily substance.
[1570] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1571] 1.3-1.5(m, total 1H), 1.55-1.92(m, total 4H), 2.08 and
2.15(s, total 3H), 2.16-2.38(m, total 5H), 2.38-2.58(m, total 1H),
2.93 and 2.67(d, J.=10 Hz, total 2H), 3.72 and 3.70(s, total
3H)
PRODUCTION EXAMPLE 36
[1572] The following compound was obtained by the same method as
the one of Production Example 35.
8TABLE 8 Prodn. Ex. Structural formula NMR 36 290 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.64-1.76 (m, 4H), 2.05 (s, 1H), 2.08 (s,
1H), 2.24 (s, 3H), 2.30 (s. 1H), 2.50 (br.s, 2H), 2.75 (dd, J=4, 11
Hz, 2H), 3.66 (s, 3H)
PRODUCTION EXAMPLES 37 to 39
[1573] The following compounds were obtained by the same method as
the one of Production Example 25.
9TABLE 9 Prodn. Ex. Structural formula NMR 37 291 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.03 (d, J=6.8 Hz, 3H), 1.05 (d, J=6.8
Hz, 3H), 1.31 (t, J=7.2 Hz, 3H), 1.44-1.63 (m, 7H), 1.85 (s, 3H),
2.35 (t, J=6.8 Hz, 2H), 2.75 (d, J=12.8 Hz, 1H), 2.83 (d, J=12.8
Hz, 1H), 3.98 (d, J=12.8 Hz, 1H), 4.03 (d, J=12.8 Hz, 1H), 4.21 (q,
J=7.2 Hz, 2H), 4.43 (d, J=6.4 # Hz, 1H), 4.78 (d, J=14.4 Hz, 1H),
6.73 (t, J=6.8 Hz, 1H), 7.21 (dd, J=6.4, 14.4 Hz, 1H) 38 292
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.00 (d, J=6.8 Hz, 3H), 1.04
(d, J=6.8 Hz, 3H), 1.30 (t, J=7.2 Hz, 3H), 1.64 (m, 4H), 1.88-2.40
(m, 1H), 2.38 (t, J=6.8 Hz, 2H), 2.72-2.86 (1H, 2H), 3.95-4.07 (m,
2H), 4.22 (q, J=7.2 Hz, 2H), 4.40-4.50 (m, 1H), 4.78 (d, J=14 Hz,
1H), 5.82 (d, J=15.6 Hz, 1H), 6.89 # (td, J=6.8, 15.6 Hz, 1H), 7.21
(dd, J=6.4, 14 Hz, 1H) 39 293 .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.31 (t, J=7.1 Hz, 3H), 1.49 (m, 1H), 1.58-1.85 (m, 8H), 1.89 (d,
J=1.3 Hz, 3H), 2.40 (t, J=7.1 Hz, 2H), 3.10 (m, 1H), 3.18 (m, 1H),
4.16-4.26 (m, 4H), 4.45 (dd, J=1.6, 6.2 Hz, 1H), 4.79 (dd, J=1.6,
13.9 Hz, 1H), 6.74 (m, 1H), 7.25 (dd, J=6.2, 13.9 Hz, 1H)
PRODUCTION EXAMPLES 40 to 43
[1574] The following compounds were obtained by the same methods as
those of Production Example 25 and Example 20.
10TABLE 10 Prodn. Ex. Structural formula NMR 40 294 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 0.80-1.00 (m, 4H), 1.01 (d, J=7.2 Hz,
6H), 1.26 (t, J=7.2 Hz, 3H), 1.40-1.48 (m, 2H), 1.78 (q, J=7.6 Hz,
2H), 1.78-1.95 (m, 2H), 2.04-2.12 (m, 1H), 2.19 (br.s, 3H), 2.31 (t
J=7.6 Hz, 2H), 2.55-2.67 (m, 2H), 4.13 (q, J=7.2 Hz, 2H) 41 295
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.80-1.05 (m. 4H), 1.00 (d,
J=7.2 Hz, 3H), 1.02 (d, J=7.2Hz, 3H), 1.13 (d, J=6.8 Hz, 3H), 1.26
(t, J=6.8 Hz, 3H), 1.20-1.95 (m, 7H), 2.19 (br.s, 3H), 2.40-2.68
(m, 3H), 4.13 (q, J=6.8 Hz, 2H) 42 296 .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.2-1.9 (m, 10H), 1.24 (t, J=7 Hz, 3H), 1.45 (s, 9H),
2.17-2.33 (m, 2H), 2.39 (d, J=7 Hz, 2H), 2.4-2.6 (m, 1H), 2.9-3.25
(m, 2H), 3.82 (t, J=14 Hz, 1H), 3.95 (t, 13 Hz, 1H), 4.11 (q, J=7
Hz, 2H) 43 297 .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.95-1.15 (m,
6H), 1.24 (t, J=5 Hz, 3H), 1.43 (s, 9H), 1.2-1.6 (m, 8H), 2.1-2.25
(m, 2H), 2.38 (d, J=8 Hz, 2H), 2.5-2.65 (m, 1H), 2.6-2.9 (m, 2H),
3.5-3.65 (m, 2H), 4.09 (q, J=5 Hz, 2H)
PRODUCTION EXAMPLE 44
[1575] The following compound was obtained by the same methods as
those of Examples 19 and 12.
11TABLE 11 Prodn. Ex. Structural formula NMR 44 298 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.35 (t, J=7.7 Hz, 3H), 1.50-1.58 (m,
1H), 1.74-1.98 (m, 3H), 2.00-2.09 (m, 2H), 3.07-3.23 (m, 3H),
3.81-3.88 (m, 1H), 4.30 (q, J=7.7 Hz, 2H), 4.31-4.38 (m, 2H), 4.48
(dd, J=1.7, 5.9 Hz, 1H), 4.82 (dd, J=1.7, 14.7 Hz, 1H), 7.25 (dd,
J=5.9, 14.7 Hz, 1H)
PRODUCTION EXAMPLE 45
Ethyl 3-[3-(vinyloxycarbonyl)
-1,5-dimethyl-3-azabicyclo[3.3.1]non-9-yl]-2- -methylpropenoate
[1576] 299
[1577] The title compound was obtained by treating
(1,3,5-trimethyl-3-azab- icyclo[3.3.1]-non-9-yl)carbaldehyde by the
same methods as those of Production Example 25 and Example 12.
[1578] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1579] 0.73(s, 6H), 1.32(t, J=7.0 Hz, 3H), 1.42-1.51(m, 2H),
1.54-1.70(m, 3H), 1.72-1.88(m, 1H), 1.90(d, J=1.9 Hz, 3H), 2.18(d,
J=11.4 Hz, 1H), 2.70(d, J=11.3 Hz, 1H), 2.78(d, J=11.3 Hz, 1H),
4.00(d, J=13.1 Hz, 1H), 4.07(d, J=13.1 Hz, 1H), 4.21(q, J=7.0 Hz,
2H), 4.46(dd, J=1.7, 5.9 Hz, 1H), 4.80(dd, J=1.7, 14.7 Hz, 1H),
6.93(qd, J=1.9, 11.4 Hz, 1H), 7.25(dd, J=5.9, 14.7 Hz, 1H)
PRODUCTION EXAMPLE 46
Ethyl[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]fluoroacetate
[1580] 300
[1581] The title compound was obtained by treating
3-methyl-3-azabicyclo[3- .3.1]nonan-9-one by the same methods as
those of Production Example 25 and Examples 20 and 12 with the use
of an appropriate Horner-Emmons reagent.
[1582] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1583] 1.32(t, J=7.4 Hz, 3H), 1.51-1.59(m, 1H), 1.64-1.94(m, 6H),
2.06-2.18(m, 2H), 3.05-3.12(m, 1H), 3.14-3.21(m, 1H), 4.16-4.33(m,
2H), 4.28(q, J=7.4 Hz, 2H), 4.46(dd, J=1.8, 6.3 Hz, 1H), 4.79(dd,
J=1.8, 14.0 Hz, 1H), 5.17(dd, J=10.4, 49.2 Hz, 1H), 7.25(dd, J=6.3,
14.0 Hz, 1H)
PRODUCTION EXAMPLE 47
Ethyl(syn)-(6R*,7R*)-[6.7-dimethyl
-3-(vinyloxycarbonyl)-3-azabicyclo[3.2.- 1]oct-8-yl]acetate
[1584] 301
[1585] The title compound was obtained by treating
ethyl(6R*,7R*)-[3,6,7-t-
rimethyl-3-azabicyclo[3.2.1]oct-8-ylidene]acetate by the same
methods as those of Examples 10, 11 and 12.
[1586] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1587] 0.98, 1.05(d, J=7.0 Hz, total 3H), 0.99, 1.06(d, J=7.1 Hz,
total 3H), 1.26(t, J=7.1 Hz, 3H), 1.37-1.45(m, 1H), 1.53-1.63(m,
1H), 1.67-1.74(m, 1H), 1.84-1.94(m, 1H), 2.29-2.37(m, 1H),
2.48-2.62(m, 2H), 3.06, 3.14(dd, J=2.4, 13.7 Hz, total 1H), 3.13,
3.22(dd, J=2.0, 13.0 Hz, total 1H), 3.60, 3.63(t, J=2.7 Hz, total
1H), 3.82, 3.86(br.m, total 1H), 4.15(q, J=7.1 Hz, 2H), 4.44,
4.45(dd, J=1.5, 6.2 Hz, total 1H), 4.76, 4.79(dd, J=1.5, 13.9 Hz,
total 1H), 7.23, 7.24(dd, J=6.2, 13.9 Hz, total 1H)
PRODUCTION EXAMPLE 48
Ethyl(3-methyl-9-oxo-3-azabicyclo[3.3.1]non-1-yl)carboxylate
ethylenedithioketal
[1588] 302
[1589] 5.0 g of
ethyl(3-methyl-9-oxo-3-azabicyclo[3.3.1]non-1-yl)carboxyla- te and
2.8 ml of 1,2-ethanedithiol were dissolved in methylene chloride
(45 ml) and ice-cooled. Then 4.1 ml of a boron trifluoride/diethyl
ether complex was dropped thereinto and the resulting mixture was
stirred at room temperature for 5 days. The reaction mixture was
concentrated and 1 N sodium hydroxide was added thereto. After
extracting with ethyl acetate, the ethyl acetate layer was washed
with 1 N sodium hydroxide, water and a saturated aqueous solution
of sodium chloride, dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The obtained residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 2.42 g of the title
compound as a colorless oily substance.
[1590] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1591] 1.26(t, J=7.1 Hz, 3H), 1.46(m, 1H), 1.82(m, 1H),
1.91-2.02(m, 2H), 2.18(s, 3H), 2.20(m, 1H), 2.48(m, 1H),
2.59-2.86(m, 4H), 3.05(dd, J=0.9, 12.1 Hz, 1H), 3.15-3.25(m, 4H),
4.13(m, 2H)
PRODUCTION EXAMPLE 49
Ethyl(3-methyl-3-azabicyclo[3.3.1]non-1-yl) carboxylate
[1592] 303
[1593] 2.42 g of
ethyl(3-methyl-9-oxo-3-azabicyclo[3.3.1]non-1-yl)carboxyl- ate
ethylenedithioketal was dissolved in ethanol (200 ml). After adding
40 g of Raney nickel, the resulting mixture was heated under reflux
for 2 hours. Then the reaction mixture was filtered and
concentrated under reduced pressure. The obtained residue was
purified by silica gel column chromatography (eluted with
toluene/ethyl acetate) to thereby give 0.95 g of the title compound
as a slightly yellow oily substance.
[1594] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1595] 1.24(t, J=7.1 Hz, 3H), 1.46-1.63(m, 3H), 1.64-1.78(m, 3H),
1.90-1.99(m, 2H), 2.06-2.18(m, 5H), 2.59(m, 1H), 2.78(m, 1H),
3.02(m, 1H), 4.10(q, J=7.1 Hz, 2H)
PRODUCTION EXAMPLE 50
Ethyl(3-methyl-3-azabicyclo[3.3.1]non-1-yl)acetate
[1596] 304
[1597] 1.1 ml of dibromomethane was dissolved in tetrahydrofuran
(20 ml) and cooled to -90.degree. C. Into the solution thus
obtained were dropped 9.77 ml of a 1.6 M solution of n-butyllithium
in hexane and 20 ml of a solution of lithium
2,2,6,6-tetramethylpiperidide, which had been prepared from 2.88 ml
of 2,2,6,6-tetramethylpiperidine, in tetrahydrofuran while
maintaining the bulk temperature at 10.degree. C. or below. 5
minutes thereafter, 10 ml of a solution of 1.0 g of ethyl
(3-methyl-3-azabicyclo[3.3.1]non-1-yl)carboxylate in
tetrahydrofuran was dropped thereinto. After 20 minutes, 0.8 ml of
2,2,6,6-tetramethylpiperid- ine was added thereto. 5 minutes
thereafter, 23.7 ml of a 1.6 M solution of n-butyllithium in hexane
was dropped thereinto and the resulting mixture was stirred. After
10 minutes, the reaction mixture was heated to 30.degree. C. and
stirred for 1 hour. Then the reaction mixture was quickly dropped
into a solution of hydrogen chloride prepared from 25 ml of acetyl
chloride and. 250 ml of ethanol and stirred at room temperature for
14 hours. The reaction mixture was concentrated and an aqueous
solution of potassium carbonate was added thereto followed by the
extraction with ethyl acetate. The ethyl acetate layer was washed
with water and a saturated aqueous solution of sodium chloride and
dried over anhydrous sodium sulfate. After concentrating under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.63 g of the title compound as a slightly yellow oily
substance.
[1598] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1599] 1.26(t, J=7.1 Hz, 3H), 1.34(m, 1H), 1.40-1.60(m, 4H),
1.68-1.78(m, 2H), 1.83-1.93(m, 2H), 2.06(m, 1H), 2.07(s, 2H),
2.11(s, 3H), 2.56(m, 1H), 2.76-2.86.(m, 2H), 4.11(q, J=7.1 Hz,
2H)
PRODUCTION EXAMPLE 51
Ethyl(syn)-(3-benzyl-3-azabicyclo[3.3.1]non-7-yl)acetate
[1600] 305
[1601] The title compound was obtained from ethyl
(3-benzyl-3-azabicyclo[3- .3.1]non-7-yl)carboxylate by the same
method as the one of Production Example 50.
[1602] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1603] 1.03(m, 1H), 1.23(m, 2H), 1.25(t, J=7.1 Hz, 3H), 1.77(m,
1H), 1.85-2.09(m, 7H), 2.24(d, J=7.0 Hz, 2H), 2.50-2.58(m, 2H),
3.43(s, 2H), 4.13(q, J=7.1 Hz, 2H), 7.20-7.35(m, 5H)
PRODUCTION EXAMPLE 52
[(anti)-2-[3-(Vinyloxycarbonyl)
-3-azabicyclo[3.3.11-non-9-yl]ethyl]methan- esulfonate]
[1604] 306
[1605] 290 mg of
(anti)-2-[3-(vinyloxycarbonyl)-3-azabicyclo-[3.3.1]non-9--
yl]ethanol was dissolved in 4 ml of methylene chloride and 0.23 ml
of pyridine was added thereto followed by ice-cooling. After adding
0.2 ml of methanesulfonyl chloride,.the resulting mixture was
stirred at room temperature for 14 hours. Then the reaction mixture
was concentrated and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
370 mg of the title compound as a colorless oily substance.
[1606] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1607] 1.48(m, 1H), 1.60-1.87(m, 8H), 1.95-2.03(m, 2H), 3.03(s,
3H), 3.12(m, 1H), 3.19(m, 1H), 4.18-4.27(m, 2H), 4.30(t, J=6.4 Hz,
2H), 4.45(dd, J=1.6, 6.2 Hz, 1H), 4.79(dd, J=1.6, 14.1 Hz, 1H),
7.25(dd, J=6.2, 14.1 H, 1H)
PRODUCTION EXAMPLE 53
(anti)-3-[3-(Vinyloxycarbonyl) -3-azabicyclo[3.3.1
]non-9-yl]propanenitril- e
[1608] 307
[1609] 370 mg of
[(anti)-2-[3-(vinyloxycarbonyl)-3-azabicyclo[3.3.1]non-9--
yl]ethyl] methanesulfonate was dissolved in dimethyl sulfoxide (3
ml). After adding 108 mg of sodium cyanide, the resulting mixture
was stirred at 80.degree. C. for 2 hours. After adding water, the
reaction mixture was extracted with ethyl acetate. Then the ethyl
acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous magnesium sulfate
and concentrated under reduced pressure. Then the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 167 mg of the title
compound as a colorless oily substance.
[1610] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1611] 1.48(m, 1H), 1.61-1.84(m, 8H), 1.87-1.95(m, 2H), 2.39(t,
J=7.3 Hz, 2H), 3.12(m, 1H), 3.20(m, 1H), 4.20-4.30(m, 2H), 4.46(dd,
J=1.6, 6.2 Hz, 1H), 4.79(dd, J=1.6, 14.1 Hz, 1H), 7.25(dd, J=6.2,
14.1 Hz, 1H)
PRODUCTION EXAMPLE 54
Methyl(anti)-3-(3-azabicyclo[3.3.1]non-9-yl)propanoate
[1612] 308
[1613] 167 mg of
(anti)-3-[3-(vinyloxycarbonyl)-3-azabicyclo-[3.3.1]non-9--
yl]propanenitrile was dissolved in ethanol (2 ml). After adding 2
ml of water and 107 mg of potassium hydroxide, the resulting
mixture was heated under reflux for 12 hours. After further adding
2 ml of ethanol and 107 mg of potassium hydroxide, the resulting
mixture was heated under reflux for additional 10 hours. Then the
reaction mixture was concentrated under reduced pressure. After
adding 10 ml of 10% hydrogen chloride/methanol, the reaction
mixture was heated under reflux for 3 hours and then concentrated
under reduced pressure. An aqueous solution of potassium carbonate
was added to the residue followed by the extraction with methylene
chloride. After drying over anhydrous potassium carbonate, it was
concentrated under reduced pressure. Then the residue was purified
by silica gel column chromatography (eluted with methylene
chloride/methanol/conc. aqueous ammonia) to thereby give 97 mg of
the title compound as a pale brown oily substance.
[1614] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1615] 1.49-1.67(m, 6H), 1.71-2.03(m, 5H), 2.12(m, 1H), 2.31(t,
J=7.7 Hz, 2H), 2.96-3.04(m, 2H), 3.12-3.18(m, 2H), 3.68(s, 3H)
PRODUCTION EXAMPLES 55 and 56
[1616] The following compounds were obtained by the same method as
the one of Example 27.
12TABLE 12 Prodn. Ex. Structural formula NMR 55 309 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.11 (s, J=7.0 Hz, 3H), 1.25 (t, J=7.1
Hz, 3H), 1.38-1.68 (m, 6H), 1.77 (br.s, 1H), 1.87 (m, 1H),
2.09-2.21 (m, 5H), 2.42 (m, 1H), 2.77-2.89 (m, 2H), 2.94 (m, 1H),
4.13 (q, J=7.1 Hz, 2H) 56 310 .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.24 and 1.25 (s, 3H), 1.30-1.38, 1.64-1.70, 1.76-1.92, 1.96-1.98,
2.08-2.12 (m, 8H), 2.07 and 2.18 (s, 3H), 2.30-2.35, 2.38-2.46,
2.58-2.70 (m, 4H), 3.67 and 3.72 (s, 3H)
PRODUCTION EXAMPLES 57 to 60
[1617] The following compounds were obtained by the same method as
the one of Example 12.
13TABLE 13 Prodn. Ex. Structural formula NMR 57 311 .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.15 (d, J=7 Hz, 3H), 1.26 (t, J=7 Hz,
3H), 1.45-1.52 (m, 1H), 1.58-1.72 (m, 5H), 1.78 (br.d, J=11 Hz,
1H), 1.84-1.91 (m, 2H), 2.84 (qd, J=7, 11 Hz, 1H), 3.05-3.20 (m,
2H), 4.15-4.18 (q, J=7Hz, 2H), 4.18-4.29 (s, 2H), 4.44 (dd, J=2, 6
Hz, 0.5H), 4.44 (dd, J=2, 6 Hz, # 0.5H), 4.77 (dd, J=2, 14 Hz,
0.5H), 4.78 (dd, J=2, 14 Hz, 0.5H), 7.22 (dd, J=6, 14 Hz, 1H) 58
312 .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.15 (d, J=7 Hz, 1.5H),
1.17 (d, J=7 Hz, 1.5H), 1.25 (t, J=7 Hz, 1.5H), 1.26 (t, J=7 Hz,
1.5H), 1.43-1.54 (m, 2H), 1.64-1.78 (m, 4H), 1.82-1.88 (m, 1H),
1.89-2.01 (m, 2H), 2.74 (dq, J=7, 9 Hz, 1H), 3.16 (ddd, J=15, 3, 1
Hz), 0.5H), 3.23 (ddd, J=1, 3, 14 Hz, 0.5H), 3.36 # (ddd, J=2, 5,
14 Hz, 0.5H), 3.43 (ddd, J=2, 4, 15 Hz, 0.5H), 3.88 (m, 2H), 4.14
(q, J=7 Hz, 2H), 4.44 (dd, J=1, 6 Hz, 1H), 4.78 (dd, J=1, 14 Hz,
1H), 7.25 (dd, J=6, 14 Hz, 1H) 59 313 .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.36-1.42 (m, 1H), 1.55 (s, 3H), 1.64-1.82 (m, 5H),
2.12 (br.s, 1H), 2.17 (br.s, 1H), 3.43 (ddd, J=2, 5, 14 Hz, 14 Hz,
1H), 3.74 (s, 3H), 3.92 (dd, J=2, 5 Hz, 1H), 3.95 (dd, J=2, 5 Hz,
1H), 4.46 (dd, J=2, 6 Hz, 1H), 4.80 (dd, J=2, 14 Hz, 1H), 7.25 (dd,
J=6, 14 Hz, 1H) 60 314 .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.45-1.52 (m, 1H), 1.55 (s, 3H), 1.64-1.76 (m, 3H), 1.95 (br.s,
2H), 2.12 (br.s, 1H), 2.16 (br.s, 1H), 3.33 (ddd. J=2, 4, 13 Hz,
1H), 3.35 (ddd, J=3, 4, 13 Hz, 1H), 3.72 (s, 3H), 3.99 (br.t, J=13
Hz, 2H), 4.43 (dd, J=2, 6 Hz, 1H), 4.77 (dd, J=2, 14 Hz, 1H), 7.22
(dd, J=6, 14 Hz, 1H)
PRODUCTION EXAMPLE 61
Ethyl(11-hydroxy-9-methyl
-9-azabicyclo[5.3.1]undec-11-yl)acetate
[1618] 315
[1619] A solution of 2.1 g of ethyl ethynyl ether (a 50% hexane
solution) in dry diethyl ether (25 ml) was cooled in a nitrogen
atmosphere to -78.degree. C. After dropping 6 ml of a 2.5 M
solution of n-butyllithium in hexane, the resulting mixture was
stirred for 10 minutes. Next, 10 ml of a solution of 78 g of
3-methyl-3-azabicyclo[5.3.1]undecan-11-one in dry diethyl ether (10
ml) was dropped into the reaction mixture. After stirring for 15
minutes, the mixture was brought back to room temperature and then
distributed into an aqueous solution of ammonium chloride and ethyl
acetate. The organic layer was extracted and dried over anhydrous
sodium sulfate. After distilling off the solvent, an oily component
was obtained. Then 100 ml of tetrahydrofuran was added thereto and
the resulting mixture was stirred. After dropping 10 mmol of conc.
sulfuric acid thereinto, the reaction mixture was distributed into
an aqueous solution of sodium bicarbonate and ethyl acetate and the
organic layer was extracted. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with ethyl acetate/n-hexane) to thereby give
1.29 g of the title compound as a colorless oily substance.
[1620] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1621] 1.14-1.26(m, 2H), 1.26(t, J=7.2 Hz, 3H), 1.50-1.65(m, 3H),
1.68-1.73(m, 2H), 1.77-1.90(m, 3H), 2.02-2.12(m, 2H), 2.15(s, 3H),
2.15-2.22(m, 2H), 2.64(d, J=12.6 Hz, 2H), 2.67(s, 2H), 3.92(s, 1H),
4.15(q, J=7.2 Hz, 2H)
PRODUCTION EXAMPLE 62
9-(1,3-Dithian-2-ylidenemethyl)
-1,3,5-trimethyl-3-azabicyclo[3.3.1nonane
[1622] 316
[1623] Into 50 ml of a solution of 2.85 ml of 2-trimethylsilyl
-1,3-dithiane in dry tetrahydrofuran was dropped 5.2 ml of a 2.5 M
solution of n-butyllithium in hexane at -30.degree. C. After
stirring for 30 minutes, 1.93 g of
(1,3,5-trimethyl-3-azabicyclo[3.3.1]non-9-yl)carbal- dehdye was
added thereto and the resulting mixture was stirred at room
temperature over day and night. Then the reaction mixture was
poured into an aqueous solution of ammonium chloride, made alkaline
with potassium carbonate and extracted with ethyl acetate. The
organic layer was washed with water and dried over anhydrous sodium
sulfate. After distilling off the solvent under reduced pressure,
the residue was recrystallized from n-hexane to thereby give 1.78 g
of the title compound as colorless needles.
[1624] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1625] 0.55(s, 6H), 1.14-1.24(m, 2H), 1.24-1,34(m, 3H),
1.65(dd,J=2.2, 11.8H, 2H), 1.91(s, 3H), 1.98-2.05(m, 2H), 2.10(d,
J=11.0 Hz, 1H), 2.42-2.55(m, 1H), 2.49(d, J=11.8Hz, 2H),
2.65-2.74(m, 4H), 6.03(d, J=11.0 Hz, 1H)
PRODUCTION EXAMPLE 63
Methyl(1.3.5-trimethyl-3-azabicyclo[3.3.1non-9-yl)acetate
[1626] 317
[1627] To a solution of 1.78 g of 9-(1,3-dithian-2-ylidenemethyl)
-1,3,5-trimethyl-3-azabicyclo[3.3.1]nonane in a solvent mixture of
methanol (27 ml) with water (3 ml) was added 3.53 g of mercuric
chloride under stirring and the resulting mixture was then refluxed
for 20 hours. Next, the reaction mixture was poured into ethyl
acetate/an aqueous solution of potassium carbonate and filtered
through celite. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.23 g of the title compound as a colorless oily substance.
[1628] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1629] 0.57(s, 6H), 1.09-1.24(m, 5H), 1.51(t, J=6.0 Hz, 1H),
1.70(dd, J=2.5, 11.6 Hz, 2H), 1.90(s, 3H), 2.17(d, J=6.0 Hz, 2H),
2.45(d, J=11.6 Hz, 2H), 2.42-2.49(m, 1H), 3.51(s, 3H)
PRODUCTION EXAMPLE 64
(anti)-2-(3-Methyl-3-azabicyclo[3.3.1]non-9-yl)ethanol
[1630] 318
[1631] To a solution of 2.8, g of ethyl(anti)-(3-methyl
-3-azabicyclo[3.3.1]non-9-yl)acetate in dry tetrahydrofuran (50 ml)
was added 0.47 g of lithium aluminum hydride at 0.degree. C. and
the resulting mixture was reacted for 20 minutes. After adding a
10% aqueous solution of sodium hydroxide to the reaction-mixture,
the insoluble matters were filtered off and the filtrate was
concentrated under reduced pressure to thereby give 2.5 g of the
title compound as a colorless oily substance.
[1632] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1633] 1.3-1.45(m, 1H), 1.45-1.65(m, 6H), 1.75(q, J=5 Hz, 4H),
2.14(s, 3H), 2.0-2.25(m, 2H), 2.3-2.50(m, 1H), 2.83-2.98(m, 2H),
3.68(q, J=5 Hz, 2H)
PRODUCTION EXAMPLE 65
Methyl 4-(2-((anti)-3-methyl
-3-azabicyclo[3.3.1]non-9-yl)ethyloxy]phenyla- cetate
[1634] 319
[1635] To a solution of 0.9 g of (anti)-2-(3-methyl
-3-azabicyclo[3.3.1]non-9-yl)ethanol, 1.2 g of methyl
4-hydroxyphenylacetate and 1.95 g of triphenylphosphine in dry
tetrahydrofuran (30 ml) was added 1.2 ml of diethyl
azodicarboxylate at 0.degree. C. The obtained mixture was reacted
for 10 minutes and then stirred at room temperature for 72 hours.
After adding water and dilute hydrochloric acid, the reaction
mixture was washed with ethyl acetate. Then aqueous ammonia was
added to the aqueous layer followed by the extraction with ethyl
acetate. The extract was washed with a saturated aqueous solution
of sodium chloride, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 1.0 g of the title compound as a
colorless oily substance.
[1636] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1637] 1.4-1.7(m, 7H), 1.7-1.9(m, 2H), 1.96(q, J=7 Hz, 2H),
2.1-2.25(m, 4H), 2.35-2.50(m, 1H), 2.85-2.95(m, 2H), 3.56(s, 2H),
3.68(s, 3H), 3.97(t, J=7 Hz, 2H), 6.85(d, J=8 Hz, 2H), 7.18(d, J=8
Hz, 2H)
PRODUCTION EXAMPLES 66 and 67
[1638] The following compounds were obtained by the same method as
the one of Production Example 65.
14TABLE 14 Prodn. Ex. Structural formula NMR 66 320methyl 3-[2-
[(anti)-3-methyl-3- azabicyclo[3.3.1]- non-9-yl]-ethyloxy]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.3-1.45(m, 1H), 1.4-1.6(m,
3H), 1.5-1.65(m, 3H), 1.67-1.8(m, 2H), 1.92(q, J=8Hz, 2H),
2.0-2.2(m, 4H), 2.3-2.5(m, 1H), 2.8-2.95(m, 2H), 3.85(s, 3H),
3.97(t, J=7 Hz, 2H), 7.03(ddd, J=1, 3, 8 Hz, 1H), # 7.27(t, J=8 Hz,
1H), 7.48(dd, J=1, 3 Hz, 1H), 7.55(ddd, J=1, 3, 8 Hz, 1H) 67
321ethyl 4-[2-[(anti)- 3-methyl-3- azabicyclo[3.3.1]- non-9-yl]-
ethyloxy]benzoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.36(t, J=5
Hz, 3H), 1.3-1.5(m, 1H), 1.5-1.6(m, 3H), 1.6-1.7(m, 2H), 1.7-1.9(m,
2H), 1.95-2.05(m, 2H), 2.13(s, 3H), 2.19(d, J=10 Hz, 2H),
2.35-2.50(m, 1H), 2.93(d, J=10 Hz, 2H), 4.04(t, J=5 Hz, 2H),
4.33(q, J=5 Hz, 2H), 6.90(d, # J=8 Hz, 2H), 8.00(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 68
tert-Butyl[2-((anti)-3-methyl
-3-azabicyclo[3.3.1]non-9-yl)ethyloxy]acetat- e
[1639] 322
[1640] To 17 ml of a 50% aqueous solution of sodium hydroxide and 5
ml of methylene chloride were added 0.7 g of
(anti)-2-[3-methyl-3-azabicyclo[3.- 3.1]non-9-yl]ethanol, 5.6 ml of
tert-butyl bromoacetate and 1.3 g of tetrabutylammonium
hydrogensulfate and the resulting mixture was vigorously stirred at
room temperature for 2 hours. After adding dilute hydrochloric
acid, the reaction mixture was washed with ether. Then aqueous
ammonia was added thereto and the mixture was extracted with ethyl
acetate. The extract was washed with a saturated aqueous solution
of sodium chloride, dried over anhydrous magnesium sulfate and
concentrated under reduced pressure. Thus, 1.3 g of the title
compound was obtained as a yellow oily substance.
[1641] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1642] 1.46(s, 9H), 1.40-1.90(m, 10H), 2.11(s, 3H), 2.1-2.2(m, 2H),
2.3-2.5(m, 1H), 2.83-2.95(m, 2H), 3.53(t, J=5 Hz, 2H), 3.94(s,
2H)
PRODUCTION EXAMPLE 69
Ethyl[2-((anti)-3-methyl-3-azabicyclo[3.3.1]non-9-yl)ethyloxy]acetate
[1643] 323
[1644] To a solution of 1.3 g of tert-butyl[2-((anti)
-3-methyl-3-azabicyclo[3.3.1]non-9-yl)ethyloxy]acetate in methylene
chloride (10 ml) was added 3.92 ml of trifluoroacetic acid and the
resulting mixture was reacted at 50.degree. C. for 30 minutes. Then
the reaction mixture was concentrated under reduced pressure to
thereby give 1.0 g of a crude carboxylic acid as a yellow oily
substance. To 1.0 g of this crude carboxylic acid was added 100 ml
of ethanol. Next, 3 ml of thionyl chloride was dropped thereinto
and the resulting mixture was heated under reflux for 1 hour. The
reaction mixture was concentrated and aqueous ammonia was added
thereto. Then it was extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After concentrating under reduced
pressure, 0.7 g of the title compound was obtained as a pale brown
oily substance.
[1645] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1646] 1.28(t, J=5 Hz, 3H), 1.25-1.70(m, 6H), 1.70-1.85(m, 4H),
2.13(s, 3H), 2.05-2.-25(m, 2H), 2.25-2.50(m, 1H), 2.80-3.00(m, 2H),
3.55(t, J=5 Hz, 2H); 4.05(s, 2H), 4.21(q, J=5 Hz, 2H)
PRODUCTION EXAMPLE 70
Ethyl(anti)-(3-methyl-(syn)
-9-methoxy-3-azabicyclo[3.3.1]non-9-yl)acetate and
ethyl(syn)-(3-methyl-(anti)-9-methoxy-3-azabicyclo[3.3.1]non-9-yl)ace-
tate
[1647] 324
[1648] To a solution of 2.5 ml of ethyl acetate in dry
tetrahydrofuran (100 ml) was added at -78.degree. C. 27.5 ml of a
1.0 M solution of lithium bis(trimethylsilyl)amide in hexane and
the resulting mixture was stirred for 1 hour. Next, 3.0 g of
3-methyl-3-azabicyclo[3.3.1]nonan-9-on- e was dropped thereinto and
the mixture was slowly heated from -78.degree. C. to room
temperature and reacted for 3 hours. After adding a cold saturated
aqueous solution of ammonium chloride, the reaction mixture was
extracted with ethyl acetate. The extract was washed with a
saturated aqueous solution of sodium chloride, dried over anhydrous
magnesium sulfate and concentrated under reduced pressure to
thereby give 5.3 g of a yellow oily substance.
[1649] To a solution of 1.0 g of this oily substance and 0.34 ml of
methyl iodide in dry N,N-dimethylformamide (20 ml) was added sodium
hydride (oily: 60% or above) at room temperature and the mixture
was reacted for 12 hours. After adding ice/water, the reaction
mixture was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After concentrating under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 0.3 g (anti) and 0.1 g
(syn) of the title compounds each as a yellow oily substance.
[1650] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1651] anti
[1652] 1.24(t, J=5 Hz, 3H), 1.30-1.45(m, 1H), 1.45-1.55(m, 2H),
1.55-1.65(m, 1H), 1.9-2.11(m, 3H), 2.19(s, 3H), 2.3-2.5(m, 1H),
2.50(br.d, J=13 Hz, 2H), 2.76(s, 2H), 2.84(br.d, J=13 Hz, 2H),
3.28(s, 3H), 4.13(q, J=5 Hz, 2H)
[1653] syn
[1654] 1.25(t, J=5 Hz, 3H), 1.35-1.50(m, 1H), 1.55(br.s, 2H),
1.74-1.90(m, 4H), 1.98(br.s, 2H), 2.13(br.s, 2H), 2.58(br.s, 3H),
2.4-2.6(m-1H), 2.76(s, 2H), 3.25(s, 3H), 4.14(q, J=5 Hz, 2H)
PRODUCTION EXAMPLE 71
3-(tert-Butoxycarbonyl)-3-azabicyclo[3.3.1]nonane-9-spiro-(3'-methylene)cy-
clobutane
[1655] 325
[1656] 7 g of the title compound was obtained as a colorless oily
substance from 9.7 g of 3-(tert-butoxycarbonyl)
-3-azabicyclo[3.3.1]nonan- e-9-spiro-cyclobutan -3'-one by the same
method as the one of
PRODUCTION EXAMPLE 14.
[1657] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1658] 1.46(s, 9H), 1.3-1.8(m, 8H), 2.52(s, 2H), 2.56(s, 2H),
3.03(d, J=12 Hz, 1H), 3.11(d, J=12 Hz, 1H), 3.88(d, J=13 Hz, 1H),
4.01(d, J=13 Hz, 1H), 4.81(m, 2H)
PRODUCTION EXAMPLE 72
[3-(tert-Butoxycarbonyl)-3-azabicyclo[3.3.1]nonane-9-spiro-cyclobut-3'-yl]-
methanol
[1659] 326
[1660] To a solution of 5 g of 3-(tert-butoxycarbonyl)
-3-azabicyclo[3.3.1]nonane-9-spiro -(3'-methylene)cyclobutane in
dry tetrahydrofuran (100 ml) was added 106 ml of a 1 M solution of
a borane/tetrahydrofuran complex in tetrahydrofuran at 0.degree. C.
and the resulting mixture was reacted for 12 hours. After adding 33
ml of 4 N sodium hydroxide at 0.degree. C., 49 ml of a 30% aqueous
solution of hydrogen peroxide was further added thereto and the
resulting mixture was stirred at room temperature for 3 hours.
After adding an aqueous solution of sodium thiosulfate, the
reaction mixture was extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After concentrating, the residue was
purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 4.7 g of the title compound as a
colorless oil.
[1661] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1662] 1.3-1.9(m, 10H), 1.45(s, 9H), 2.0-2.18(m, 2H), 2.28-2.44(m,
1H), 2.94-3.2(m, 2H), 3.58(d, J=6 Hz, 2H), 3.64(t, J=6 Hz, 1H),
3.83(br.t, J=15 Hz, 1H), 3.96(br.t, J=13 Hz, 1H)
PRODUCTION EXAMPLE 73
[3-(tert-Butoxycarbonyl)-3-azabicyclo[3.3.1]nonane-9-spiro-cyclobut-3'-yl]-
carbaldehyde
[1663] 327
[1664] Into a solution of 1.6 ml of oxalyl chloride in methylene
chloride (50 ml) was dropped 1.4 ml of dry dimethyl sulfoxide at
-78.degree. C. Next, a solution of 4.6 g of
[3-(tert-butoxy-carbonyl)-3-azabicyclo[3.3.1-
]nonane-9-spiro-cyclobut-3'-yl]-methanol in methylene chloride (20
ml) was added thereto. After reacting at -78.degree. C. for 40
minutes, 8.7 ml of triethylamine was dropped thereinto. Then the
reaction mixture was stirred from -78.degree. C. to room
temperature over 30 minutes. After adding water, the reaction
mixture was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After concentrating under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with ethyl acetate/n-hexane) to thereby give 3.4 g of the title
compound as a pale yellow oily substance.
[1665] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1666] 1.37((br.s, 1H), 1.4-1.85(m, 7H), 1.45(s, 9H), 2.0-2.25(m,
4H), 2.95-3.20(m, 2H), 3.83(d, J=13 Hz, 1H), 3.88(d, J=13 Hz, 1H),
3.99(t, J=14 Hz, 1H), 9.75(s, 1H)
PRODUCTION EXAMPLE 74
Methyl[3-(tert-butoxycarbonyl)
-3-azabicyclo[3.3.1]nonane-9-spiro-cyclobut -3'-yl]carboxylate
[1667] 328
[1668] To a solution of 3.4 g of [3-(tert-butoxycarbonyl)
-3-azabicyclo[3.3.1]nonane-9-spiro-cyclobut -3'-yl]carbaldehyde in
methanol (17 ml) was added 15.4 g of sodium hydrogencarbonate. Then
2 ml of bromine was dropped thereinto. After reacting at room
temperature for 1 hour, ice/water and an aqueous solution of sodium
thiosulfate were added thereto followed by the extraction with
ethyl acetate. The extract was washed with a saturated aqueous
solution of sodium chloride, dried over anhydrous magnesium sulfate
and concentrated under reduced pressure. The obtained residue was
purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 1.4 g of the title compound as a
colorless oily substance.
[1669] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1670] 1.1-1.2(m, 1H), 1.45(s, 9H), 1.5-1.8(m, 8H), 2.00-2.15(m,
2H), 2.15-2.33(m, 2H), 2.93-3.05(m, 1H), 3.08(br.d, J=13 Hz, 1H),
3.68(s, 3H), 3.85(br.t, J=11 Hz, 1H), 3.99(br.t, J=11 Hz, 1H)
PRODUCTION EXAMPLE 75
N-Allyl-N-methyl-6-methoxycarbonyl
-2-oxa-3-oxobicyclo[2.2.2]oct-5-ene -7-carboxamide and
N-allyl-N-methyl-6-methoxycarbonyl
-2-oxa-3-oxobicyclo[2.2.2]oct-5-ene -8-carboxamide
[1671] A mixture of 10.42 g of methyl coumalate with 10.56 g of
N-allyl-N-methylacrylamide was stirred at 100.degree. C. for 17
hours. Then the reaction mixture was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
two isomers. From the less polar fraction, 7.90 g of
N-allyl-N-methyl-6-metho- xycarbonyl
-2-oxa-3-oxobicyclo[2.2.2]oct-5-ene -8-carboxamide was obtained as
a slightly yellow powder. From the more polar fraction, on the
other hand, 4.19 g of N-allyl-N-methyl-6-methoxycarbonyl
-2-oxa-3-oxobicyclo[2.2.2]oct-5-ene-7-carboxamide was obtained as a
pale yellow oily substance. 329
[1672] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1673] 1.81, 1.90(m, total 1H), 2.28, 2.34(m, total 1H), 2.88,
3.05(s, total 3H), 3.49, 3.57(m, total 1H), 3.65-3.72(m, 1H), 3.82,
3.84(s, total 3H), 3.96-4.07(m, 2H), 5.12-5.32(m, 2H), 5.56-5.86(m,
2H), 7.32-7.38(m, 1H) 330
[1674] .sup.1H-NMR(CDCl.sub.33 ) .delta. ppm;
[1675] 1.74, 1.77(d, J=5.1 Hz, total 1H), 2.66, 2.75(ddd, J=4.2,
6.4, 10.4 Hz, total 1H), 2.89, 2.97(s, total 3H), 3.23, 3.31(m,
total 1H), 3,79(s, 3H), 3.82-4.00(m, 3H), 5.10-5.30(m, 2H),.
5.64-5.81(m, 2H), 7.51, 7.53(d, J=2.2 Hz, total 1H)
PRODUCTION EXAMPLE 76
Methyl
3-methyl-2-oxo-3-azatricyclo[5.3.1.0.sup.5,10]undec-8-ene-9-carboxy-
late
[1676] 331
[1677] 4.75 g of N-allyl-N-methyl-6-methoxycarbonyl
-2-oxa-3-oxobicyclo[2.2.2]oct-5-ene -7-carboxamide was stirred at
180.degree. C. for 6 hours. Then the reaction mixture was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 0.93 g of the title compound as a pale
yellow oily substance.
[1678] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1679] 1.33(ddd, J=2.0, 5.3, 12.6 Hz, 1H), 1.57(dt, J=3.1, 13.2 Hz,
1H), 1.69-1.84(m, 2H), 1.90(m, 1H), 2.38(m, 1H), 2.79(m, 1H),
2.98(br.s, 3H), 3.17(dd, J=1.5, 12.3 Hz, 1H), 3.32(m, 1H), 3.53(dd,
J=4.4, 12.3 Hz, 1H), 3.77(s, 3H), 7.44(dd, J=1.5, 7.0 Hz, 1H)
PRODUCTION EXAMPLE 77
Methyl
3-methyl-2-oxo-3-azatricyclo[5.3.1.0.sup.5,10]undec-8-ene-8-carboxy-
late
[1680] 332
[1681] The title compound was obtained as a pale yellow oily
substance from N-allyl-N-methyl-6-methoxycarbonyl
-2-oxa-3-oxobicyclo[2.2.2]oct-5-e- ne -8-carboxamide by the same
method as the one of Production Example 76.
[1682] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1683] 1.34(ddd, J=2.0, 5.1, 12.8 Hz, 1H), 1.59(dt, J=3.1, 13.2 Hz,
1H), 1.71-1.94(m, 3H), 2.38(m, 1H), 2.86(m, 1H), 2.98(s, 3H),
3.18-3.25(m, 2H), 3.49(dd, J=4.2, 12.3 Hz, 1H), 3.77(s, 3H),
7.29(dd, J=1.6, 7.0 Hz, 1H)
PRODUCTION EXAMPLE 78
Methyl
3-methyl-2-oxo-3-azatricyclo[5.3.1.0.sup.5,10]undecane-9-carboxylat-
e
[1684] 333
[1685] 0.7 g of methyl
3-methyl-2-oxo-3-azatricyclo-[5.3.1.0.sup.5,10]unde-
c-8-ene-9-carboxylate was dissolved in methanol (15 ml). After
adding 0.3 g of 10% palladium-carbon, the resulting mixture was
hydrogenated at ordinary temperature under atmospheric pressure for
19 hours. After filtering off the catalyst, the residue was
concentrated under reduced pressure. After adding ethyl acetate to
the residue, it was filtered and the filtrate was concentrated
under reduced pressure to thereby give 0.78 g of the title compound
as a slightly yellow oily substance.
[1686] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1687] 1.30(m, 1H), 1.46(m, 1H), 1.59(m, 1H), 1.76-2.14(m, 5H),
2.17(m, 1H), 2.54(m, 1H), 2.71(m, 1H), 2.94(br.s, 3H), 3.03(dd,
J=1.6, 12.1 Hz, 1H), 3.47(dd, J=1.6, 12.1 Hz, 1H), 3.68(s, 3H)
PRODUCTION EXAMPLE 79
Methyl
3-methyl-2-oxo-3-azatricyclo[5.3.1.0.sup.5,10]undecane-8-carboxylat-
e
[1688] 334
[1689] The title compound was obtained as a slightly yellow oily
substance from methyl 3-methyl
-2-oxo-3-azatricyclo-[5.3.1.0.sup.5,10]undec-8-ene -8-carboxylate
by the same method as the one of Production Example 78.
[1690] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1691] 1.36(m, 1H), 1.44(m, 1H), 1.78-1.91(m, 3H), 1.93-2.13(m,
4H), 2.49-2.62(m, 2H), 2.94(s, 3H), 3.02(dd, J=1.3, 11.9 Hz, 1H),
3.44(dd, J=3.7, 11.9 Hz, 1H), 3.70(s, 3H)
PRODUCTION EXAMPLE 80
Methyl
3-methyl-2-thioxo-3-azatricyclo[5.3.1.0.sup.5,10]undec-8-ene-9-carb-
oxylate
[1692] 335
[1693] 2.24 g of methyl
3-methyl-2-oxo-3-azatricyclo[5.3.1.0.sup.5,10]unde-
c-8-ene-9-carboxylate was dissolved in toluene (30 ml). After
adding 2.31 g of Lawson's reagent, the resulting mixture was heated
to 100.degree. C. for 1 hour. Then the reaction mixture was
purified as such by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 1.91 g of the title
compound as colorless needles.
[1694] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1695] 1.31(ddd, J=2.2, 5.1, 13.0 Hz, 1H), 1.59(dt, J=3.3, 13.4 Hz,
1H), 1.80(ddt, J=3.5, 11.7, 13.0 Hz, 1H), 1.98-2.08(m, 2H), 2.78(m,
1H), 3.14(ddd, J=3.3, 6.0, 12.7 Hz, 1H), 3.28(m, 1H), 3.46(dd,
J=1.3, 13.7 Hz, 1H), 3.49(s, 3H), 3.76(s, 3H), 3.80(ddd, J=0.4,
4.8, 13.7 Hz, 1H), 7.45(dd, J=1.5, 7.0 Hz, 1H)
PRODUCTION EXAMPLE 81
ethyl 3-methyl-3-azatricyclo
5.3.1.0.sup.5,10]undec-8-ene-9-carboxylate
[1696] 336
[1697] 1.0 g of methyl 3-methyl-2-oxo-3-azatricyclo
5.3.1.0.sup.5,10]undec-8-ene-9-carboxylate was dissolved in
tetrahydrofuran (32 ml). After adding 2.5 ml of methyl iodide, the
resulting mixture was stirred at room temperature for 19 hours.
After distilling off the solvent under reduced pressure, a yellow
amorphous product was obtained. Then it was dissolved in methanol
(26 ml). After adding 0.18 g of sodium borohydrie, the resulting
mixture was stirred under ice-cooling. After 30 minutes, 0.18 g of
sodium borohydride was added thereto and the resulting mixture was
stirred at room temperature for additional 1 hour. After adding
ice/water, the reaction mixture was extracted with ethyl acetate.
The organic layer was washed with water and a saturated aqueous
solution of sodium chloride and extracted with 1 N hydrochloric
acid. Then aqueous ammonia was added to the aqueous layer followed
by the extraction with ethyl acetate. The organic layer was washed
successively with water and a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, 0.88 g of the
title compound was obtained as a colorless oily substance.
[1698] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1699] 1.35-1.48(m, 2H), 1.50-1.72(m, 4H), 1.92-2.07(m, 2H),
2.28(br.s, 3H), 2.61-2.80(m, 4H), 3.75(s, 3H), 7.42(dd, J=1.3, 6.8
Hz, 1H)
PRODUCTION EXAMPLE 82
ethyl
3-methyl-3-azatricyclo[5.3.1.0.sup.5,10]undecane-9-carboxylate
[1700] 337
[1701] 632 g of the title compound was obtained as a slightly
yellow oily substance from 778 mg of 3-methyl -2-oxo-3-azatricyclo[
5.3.1.0.sup.5,10]undecane-9-carboxylate by the same methods as
those of Production Examples 80 and 81.
[1702] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1703] 1.46-2.06(m, 12H), 2.28(br.s, 3H), 2.50-2.70(m, 3H), 3.69(s,
3H)
PRODUCTION EXAMPLE 83
Methyl
3-methyl-3-azatricyclo[5.3.1.0.sup.5,10]undecane-8-carboxylate
[1704] 338
[1705] The title compound was obtained from 3-methyl
-2-oxo-3-azatricyclo[5.3.1.0.sup.5,10]undecane-8-carboxylate by the
same methods as those of Production Examples 80 and 81.
[1706] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1707] 1.21(br.s, 1H), 1.57-1.80(m, 7H), 1.84-2.14(m, 4H),
2.26(br.s, 3H), 2.44-2.74(m, 3H), 3.68(s, 3H)
EXAMPLES 32 to 43
[1708] The following compounds were obtained by the same methods as
those of Examples 12, 13 and 14 optionally using potassium
carbonate as a base.
15TABLE 15 Ex. Structural formula NMR 32 339ethyl [3-(10H-
pyrazino[2,3-b] [1,4]- benzothiazin-8-ylmethyl)-3-
azabicyclo[3.3.1]non-9-ylidene]acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.28(t, J=7 Hz, 3H), 1.47-1.65(m, 2H), 1.75-1.90(m,
2H), 1.95-2.05(m, 2H), 2.07(m, 1H), 2.25-2.35(m, 3H), 2.70-2.87 (m,
1H), 2.98-3.05(m, 2H), 3.95(m, 1H), 4.15(q, J=7 Hz, 2H), 5.63(s,
1H), 6.44(s, 1H), # 1H), 6.52(d, J=1 Hz, 1H), 6.79(dd, J=1, 8 Hz,
1H), 6.85(d, J=8 Hz, 1H), 7.58(d, J=2 Hz, 1H), 7.70(d, J=2 Hz, 1H)
33 340methyl [3-(10H-pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3-azabicyclo[3.3.1]non- 9-yl]carboxylate (syn: anti
.apprxeq. 1:1) .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.4-1.9(m,
total 7H), 2.20-2.28, 2.28-2.38(m, total 2H), 2.37(m, total 1H),
2.5-2.76(m, total 1H), 2.66-2.70, 2.94-3.00(m, total 2H), 3.17,
3.24(s, total 2H), 3.71, 3.72(s, total 3H), 6.40(br.s, # total 1H),
6.48, 6.52(m, total 1H), 6.76-6.80(m, total 1H), 6.82, 6.84(d, J=8
Hz, total 1H), 7.55-7.58(m, total 1H), 7.68-7.72(m, total 1H) 34
341ethyl [3-(10H-pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3-aza-7- oxabicyclo[3.3.1]non- 9-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.26(t, J=7 Hz, 3H),
1.58(br.s, 2H), 2.10-2.18(m, 1H), 2.41(d, J=11 Hz, 2H), 2.65(d, J=8
Hz, 2H). 3.0-3.15(m, 2H), 3.35(s, 2H), 3.77(d, J=12 Hz, 2H),
3.97(d, J=12Hz, 2H), 4.14(q, J=7 Hz, 2H), 6.75(d. J=8 Hz, 1H),
6.78(s, # 1H), 6.79(d, J=8 Hz, 1H), 7.14-7.18(m, 1H), 7.55(d, J=3
Hz, 1H), 7.65(d, J=3 Hz, 1H)
[1709]
16TABLE 16 Ex. Structural formula NMR 35 342methyl [3-(10H-
pyrazino[2,3-b] [1,4]- benzothiazin-8- ylmethyl)-7-methyl-3-
azabicyclo[3.3.1]non- 9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 0.86(d, J=6.4 Hz, 3H), 1.24-1.37(m, 2H), 1.60-1.70(m, 2H),
1.90-2.05(m, 2H), 2.15-2.27(m, 2H), 2.40-2.48(m, 1H), 2.43(d, J=7.2
Hz, 2H), 2.73-2.92 (m, 3H), 3.23(s, 2H), 3.67(s, 3H), 6.37(br.s,
1H), 6.46(s, 1H), 6.76(d, # J=8.0 Hz, 1H), 6.84(d, J=8.0 Hz, 1H),
7.57(d, J=7.2 Hz, 1H), 7.69(d, J=7.2 Hz, 1H) 36 343ethyl [3-(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-7,7- dimethyl-3-
azabicyclo[3.3.1]non- 9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 0.99(s, 3H), 1.24(t, J=7.0 Hz, 3H), 1.31-1.39(m, 2H), 1.42(s,
3H), 1.64-1.74(m, 4H), 1.85-1.93(m, 1H), 2.12-2.19(m, 2H), 2.35(d,
J=7.9 Hz, 2H), 2.74-2.81(m, 2H), 3.25(s, 2H), 4.12(q, # J=7.0 Hz,
2H), 6.38-6.43(br.s, 1H), 6.45(d, J=1.6 Hz, 1H), 6.74(dd, J=1.6,
7.9 Hz, 1H), 6.81(d, J=7.9 Hz, 1H), 7.56(d, J=3.0 Hz, 1H), 7.68(d,
J=3.0 Hz, 1H) 37 344methyl [3-(10H- pyrazino[2,3- b]
[1,4]benzothiazin- 8-ylmethyl)-7-phenyl-3- azabicyclo[3.3.1]non-
9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.73-1.94(m, 7H),
2.07-2.14(m, 1H), 2.30-2.38(m, 2H), 2.59(d, J=7.2 Hz, 2H),
2.96-3.05(m, 2H), 3.31(s, 2H), 3.69(s, 3H), 6.37(br.s, 1H), 6.49(s,
1H), 6.84-6.90 (m, 2H), 7.16-7.39(m, 5H), 7.57(d, J= #7.2 Hz, 1H),
7.69(d, J=7.2 Hz, 1H)
[1710]
17TABLE 17 Ex. Structural formula NMR 38 345ethyl [3-(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-6-methyl-3-
azabicyclo[3.3.1]non- 9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.06(d, J=8 Hz, 3H), 1.2-1.3(m, 3H), 1.4-2.1(m, 7H), 2.19(dd,
J=2, 10 Hz, 1H), 2.22-2.30(m, 1H), 2.40-2.70(m, 3H), 2.75-2.90(m,
2H), 3.19(d, J=14 Hz, 1H), 3.26(d, J=14 Hz, 1H), 4.05-4.20(m, 2H),
6.36- #6.40(m, 1H), 6.50(d, J=1 Hz, 1H), 6.76(dd, J=1, 8 Hz, 1H),
6.82(d, J=8 Hz, 1H), 7.56(d, J=3 Hz, 1H), 7.69(d, J=3 Hz, 1H) 39
346methyl [3-(10H- pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-1,5-dimethyl-3- azabicyclo[3.3.1]non- 9-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.71(s, 6H), 1.29-1.46(m, 5H),
1.73(t, J=5.9 Hz, 1H), 1.90(d, J=11.8 Hz, 2H), 2.33(d, J=5.9 Hz,
2H), 2.63(d, J=11.8 Hz, 2H), 2.66-2.83(m, 1H), 3.14(s, 2H), 3.66(S,
3H), 6.48(s, 1H), 6.75(d, #J=7.7 Hz, 1H), 6.80(s, 1H), 6.81(d,
J=7.7 Hz, 1H), 7.55(d, J=2.6 Hz, 1H), 7.68(d,m J=2.6 Hz, 1H) 40
347methyl 3-(10H- pyrazino[2,3-b][1,4]benzothi- azin-
8-ylmethyl)-3- azatricyclo[5.3.1.0.sup.5.10]undecane-9-carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.51-1.66(m, 6 Hz),
1.70-1.79(m, 3H), 1.84-2.00(m, 3H), 2.51-2.63(m, 3H), 3.27(d,
J=13.6 Hz, 1H), 3.32(d, J=13.6 Hz, 1H), 3.68(s, 3H), 5.57(br.s,
1H), 6.60(br.Ss 1H), 6.79(dd, J=1.5, 7.9 Hz, # 1H), 6.82(d, J=7.9
Hz, 1H), 7.57(d, J=2.9 Hz, 1H), 7.69(d, J=2.9 Hz, 1H)
[1711]
18TABLE 18 Ex. Structural formula NMR 41 348ethyl
(anti)-(6R*,8R*)-3-[3-(10H- pyrazino[2,3-b] [1,4]benzothiazin-
8-ylmethyl-6,8-dimethyl-3- azabicyclo[3.3.1]non- 9-yl]propanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.75-0.90(m, 2H), 0.99(d,
J=7.2 Hz, 6H), 1.15-1.24(m, 1H), 1.26(t, J=7.2 Hz, 3H),
1.35-1.44(m, 2H), 1.72-1.84(m, 3H), 1.93(d, J=10.4 Hz, 2H),
2.25-2.36(m, 1H), # 2.32(t, J=7.2 Hz, 2H), 2.59(d, J=10.4 Hz, 2H),
3.25(s, 2H), 4.12(q, J=7.2 Hz, 2H), 6.38(br.s, 1H), 6.51(s, 1H),
6.76(d, J=8.0 Hz, 1H), 6.82(d, J=8.0 Hz, 1H), 7.57(d, J=2.8 Hz,
1H), 7.69(d, J=2.8 Hz, 1H) 42 349methyl 3-(10H-pyrazino[2,3- b]
[1,4]benzothiazin- 8-ylmethyl)-3-
azatricyclo[5.3.1.0.sup.5.10]undecan- e-8-carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.23(m, 1H), 1.45(m, 1H),
1.55-1.76(m, 6H), 1.89-1.96(m, 2H), 2.00-2.08(m, 2H), 2.44-2.60(m,
3H), 3.30(s, 2H), 3.69(s, 3H), 6.49(br.s, 1H), 6.56(br.s, 1H),
6.80(dd, J=1.3, 8.2 Hz, # 1H), 6.83(d, J=8.2 Hz, 1H), 7.57(d, J=2.7
Hz, 1H), 7.69(d, J=2.7 Hz, 1H) 43 350methyl 3-(10H-pyrazino[2,3- b]
[1,4]benzothiazin- 8-ylmethyl)-3-
azatricyclo[5.3.1.0.sup.5.10]undec-8-ene-9-carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.34-1.44(m, 2H), 1.56-1.65(m,
4H), 2.01-2.08(m, 2H), 2.66-2.76(m, 4H), 3.35(s, 2H), 3.75(s, 3H),
6.58(br.s, 2H), 6.83(br.s, 2H), 7.41(dd, J=1.3, 7.0 Hz, 1H),
7.57(d, J=2.9 Hz, 1H), 7.69(d, J=2.9 Hz, 1H)
EXAMPLE 44
Ethyl[8-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-8-azabicyclo[4.3-
.1]dec-10-yl]acetate
[1712] 351
[1713] The title compound was obtained as a yellow oily substance
by treating
ethyl(8-methyl-8-azabicyclo[4.3.1]dec-10-ylidene)acetate by the
same methods as those of Examples 20, 12, 13 and 14 by using
potassium carbonate as a base.
[1714] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1715] 1.25(t, J=7.0 Hz, 3H), 1.50-1.62(m, 4H), 1.75-1.87(m, 2H),
1.87-1.95(m, 2H), 1.97-2.10(m, 4H), 2.17-2.26(m, 1H), 2.50(d, J=7.3
Hz, 2H), 2.62-2.68(m, 2H), 3.20(s, 2H), 4.12(q, J=7.0 Hz, 2H),
6.42-6.47(br.s, 1H), 6.51(d, J=1.5 Hz, 1H), 6.78(dd, J=1.5, 7.8 Hz,
1H), 6.82(d, J=7.8 Hz, 1H), 7.56(d, J=3.1 Hz, 1H), 7.68(d, J=3.1
Hz, 1H)
EXAMPLES 45 to 47
[1716] The following compounds were obtained by the same methods as
those of Examples 13 and 14 by using potassium carbonate as a
base.
19TABLE 19 Ex. Structural formula NMR 45 352ethyl (syn)-2-[3-
(10H-pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3-azabicyclo[3.3.1]non- 9-yl]propanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.10(d, J=7 Hz, 3H), 1.24(t,
J=7 Hz, 3H), 1.52-1.90(m, 9H), 2.29(br.d, J=12 Hz, 1H), 2.49(br.d,
J=12 Hz, 2H), 2.63(br.d, J=12 Hz, 1H), 2.80(dd, J=8, 12 Hz, 1H),
3.23(s, 2H), 4.13(q, J=7 Hz, 2H), 6.38(br.s, 1H), 6.50(d, # J=2 Hz,
1H), 6.76(dd, J=2, 8 Hz, 1H), 6.82(d, J=8 Hz, 1H), 7.56(d, J=3 Hz,
1H), 7.69(d, J=3 Hz, 1H) 46 353ethyl (anti)-2-]3-
(10H-pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3-azabicyclo[3.3.1]non- 9-yl]propanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.11(d, J=7 Hz, 3H), 1.24(t,
J=7 Hz, 3H), 1.46-1.55(m, 4H), 1.56-1.64(s, 2H), 1.77(br.s, 1H),
1.82-1.95(m, 1H), 2.20(m, 2H), 2.55(m, 1H), 2.82(dd, J=7, 11 Hz,
1H), 2.88(br.d, J= #11Hz, 1H), 2.96(br.d, J=11 Hz, 1H), 3.21(s,
2H), 4.12(q, J=7 Hz, 2H), 6.43(br.s, 1H), 6.50(d, J=2 Hz, 1H),
6.77(dd, J=2, 8 Hz, 1H), 6.82(d, J=8 Hz, 1H), 7.56(d, J=3 Hz, 1H),
7.68(d, J=3 Hz, 1H) 47 354ethyl (syn)-(6R*,7R*)-[3-(10H-
pyrazino[2,3-b] [1,4]benzothiazin- 8-ylmethyl)-6,7-dimethyl-3-
azabicyclo[3.2.1]oct- 8-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.01(d, J=7.1 Hz, 3H), 1.09(d, J=7.0 Hz, 3H), 1.25(t, J=7.1
Hz, 3H), 1.49-1.59(m, 2H), 1.64(m, 1H), 1.74(m, 1H), 2.22(m, 1H),
2.27(d, J=10.0 Hz, 1H), 2.36(d, J=12.5 Hz, 1H), 2.39(dd, J=3.9,
11.2 Hz, # 1H, 2.48(dd, J=7.1, 15.0 Hz, 1H), 2.53-2.60(m, 2H),
3.28(d, J=13.2 Hz, 1H), 3.38(d, J=13.2 Hz, 1H), 4.13(q, J=7.1 Hz,
2H), 6.49(d, J=1.3 Hz, 1H), 6.50(br.s, 1H), 6.76(dd, J=1.3, 7.9 Hz,
1H), 6.81(d, J=7.9 Hz, 1H), 7.57(d, J=2.9 Hz, 1H), 7.69(d, J=2.9
Hz, 1H)
EXAMPLES 48 to 59
[1717] The following compounds were obtained by the same method as
the one of Example 17.
20TABLE 20 Ex. Structural formula NMR 48 355ethyl
[3-(10H-pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3-azabicyclo [3.2.1]oct-8-yl]acetate (syn: anti
.apprxeq. 1:2) .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25(t, J=7 Hz,
3H, anti), 1.26(t, J=7 Hz, 3H, syn), 1.5-2.1(m, 7H), 2.08-2.15(m,
2H, anti), 2.16(d, J=8 Hz, 2H, anti), 2.35-2.45(m, 4H, # syn),
2.58(d, J=7 Hz, 2H, syn), 2.62-2.70(m, 2H, anti), 3.31(s, 2H,
anti), 3.34(s, 2H, syn), 4.13(q, J=7 Hz, 2H, anti), 4.14(q, J=7 Hz,
2H, syn), 6.42(br.s, 1H), 6.53(br.s, 1H), 6.77(d, J=8 Hz, 1H),
6.82(d, J=8 Hz, 1H), 7.57(d, J=3 Hz, 1H), 7.69(d, J=3 Hz, 1H) 49
356ethyl [3-(10H-pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.2.1]oct- 8-ylidene]acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.28(t, J=7 Hz, 3H), 1.50-1.75(m, 2H), 1.8-2.0(m, 2H),
2.21(d, J=10 Hz, 1H), 2.29(d, J=10 Hz, 1H), 2.47(m, 1H), 2.83(dd,
J=4, 10 Hz, 2H), 3.31(d, J=16 Hz, 1H), 3.37(d, J=16 Hz, 1H),
3.75(m, 1H), 4.16(q, J=7 Hz, 2H), # 5.63(s, H), 6.46-6.56(m, 1H),
6.54(s, 1H), 6.78(d, J=8 Hz, 1H), 6.83(d, J=8 Hz, 7.58(d, J=3 Hz,
1H), 7.70(d, J=3 Hz, 1H) 50 357methyl [3-(10H- pyrazino[2,3- b]
[ylmethyl)-3- azabicyclo[3.2.1]oct- 8-yl]carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.70(m, 4H), 2.10(d, J=10 Hz,
2H), 2.34(s, 1H), 2.50(br.s, 2H), 2.71(dd, J=4, 10 Hz, 2H), 3.33(s,
2H), 3.66(s, 3H), 6.44(br.s, 1H), 6.53(d, J=1 Hz, 1H), 6.77(dd,
J=1, 8 Hz, 1H), 6.83(d, J=8 Hz, 1H), 7.57(d, J=3 Hz, # 1H), 7.69(d,
J=3 Hz, 1H)
[1718]
21TABLE 21 Ex. Structural formula NMR 51 358methyl [3-(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-7-tert- butyl-3-
azabicyclo[3.2.1]non- 9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 0.89(s, 9H). 1.24-1.36(m, 3H), 1.76-1.92(m, 5H), 2.01-2.06(m,
2H), 2.50(d, J=7.2 Hz, 2H), 2.56-2.63(m, 2H), 3.23(s, 2H), 3.68(s,
3H), 6.22(br.s, 1H), 6.52(s, 1H), 6.78(d, J=8.0 Hz, # 1H), 6.82(d,
J=8.0Hz, 1H), 7.57(d, J=2.8 Hz, 1H), 7.69(d, J=2.8 Hz, 1H) 52
359methyl (anti)- (6R*,8R*)-[4-(10H- pyrazino[2,3- b]
[1,4]benzothiazin- 9-ylmethyl)-6,8- dimethyl-3-
azabicyclo[3.3.1]non- 9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 0.80-1.00(m, 1H), 0.99(d, J=6.8 Hz, 6H), 1.40-1.45(m, 2H),
1.68-1.90(m, 4H), 2.03(d, J=10 Hz, 2H), 2.46(d, J=7.6 Hz, 2H),
2.58(d, J=10 Hz, 2H), 3.26(s, 2H), 3.67(s, 3H), 6.38 #(br.s, 1H),
6.51(s, 1H), 6.76(d, J=8.0 Hz, 1H), 6.82(d, J=8.0 Hz, 1H), 7.56(d,
J=2.8 Hz, 1H), 7.69(d, J=2.8 Hz, 1H) 53 360ethyl 3-[(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]non- 9-yl]carboxylate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.23(t, J=7.1 Hz, 3H), 1.54-1.82(m, 6H), 1.88-1.98(m,
2H), 2.13(m, 1H), 2.13(m, 1H), 2.20(dd, J=2.0, 10.8 Hz, 1H),
2.70(m, 1H), 2.81(m, 1H), 3.06(m, 1H), 3.21(d, J=13.4 Hz, 1H),
3.27(d, J=13.4 Hz, 1H), 4.09(q, J= #7.1 Hz, 2H), 6.43(br.s, 1H),
6.49(d, J=1.3 Hz, 1H), 6.77(dd, J=1.3, 7.9 Hz, 1H), 6.84(d, J=7.9
Hz, 1H), 7.57(d, J=2.9 Hz, 1H), 7.69(d, J=2.9 Hz, 1H)
[1719]
22TABLE 22 Ex. Structural formula NMR 54 361ethyl (anti)-2-[3-
(10H-pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-6-methyl-3-
azabicyclo[3.3.1]non- 9-yl]ethoxyacetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.28(t, J=7 Hz, 3H), 1.4-1.55(m, 2H), 1.56-1.65(m,
3H), 1.7-1.85(m, 5H), 2.22(br.d, J=11 Hz, 2H), 2.45-2.6(m, 1H),
2.91(d, J=11 Hz, 2H), 3.21(s, 2H), 3.55(t, J=7 Hz, # 2H), 4.06(s,
2H), 4.21(q, J=7 Hz, 2H), 6.40(br.s, 1H), 6.51(s, 1H), 6.77(d, J=8
Hz, 1H), 6.82(d. J=8 Hz, 1H), 7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz,
1H) 55 362methyl (anti)-2-[2- [3-(10H-pyrazino[2,3- b]
[1,4]benzothiazin- 8-ylmethyl)-3- azabicyclo[3.3.1]non-9-
yl]ethyloxy]phenylacetic acid .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.45-1.55(m, 2H), 1.62-1.75(m, 4H), 1.75-1.90(m, 2H, 1.96(q, J=7
Hz, 2H), 2.20-2.25(m, 2H), 2.50-2.63(m, 1H), 2.90-2.95(m, 2H),
3.22(s, 2H), 3.56(s, 2H), 3.68 #(s, 3H), 3.97(t, J=6 Hz, 2H),
6.46-6.50(m, 1H), 6.51(d, J=1 Hz, 1H), 6.78(dd, J=1, 8 Hz, 1H),
6.83(d, J=8 Hz, 1H), 6.85(d, J=8 Hz, 2H), 7.18(d, J=8 Hz, 2H),
7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz, 1H) 56 363ethyl
(anti)-[3-(10H- pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-(syn)-9- methoxy-3- azabicyclo[3.3.1]non- 9-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24(t, J=7 Hz, 3H),
1.44-1.54(m, 2H), 1.59(d, J=5 Hz, 1H), 1.9-2.3(m, 4H), 2.53(br.d,
J=12 Hz, 3H), 2.77(s, 2H), 2.85(br.d, J=12 Hz, 2H), 3.28(s, 3H),
3.29(s, 2H), 4.13(q, J=7 Hz, 2H), 6.42(m, 1H), 6.49(d, J= #1 Hz,
1H), 6.76(dd, J=1, 8 Hz, 1H), 6.83(d, J=8 Hz, 1H), 7.57(d, J=3 Hz,
1H), 7.67(d, J=3 Hz, 1H)
[1720]
23TABLE 23 Ex. Structural formula NMR 57 364ethyl 3-[(10H-
pyrazino[2,3- b] [1,4-]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]non- 1-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.22(t, J=7.1 Hz, 3H), 1.36-1.61(m, 5H), 1.66-1.78(m, 2H).
1.88-1.97(m, 2H), 2.06(s, 2H), 2.10(m, 1H), 2.69(m, 1H),
2.78-2.88(m, 2H), 3.17(d, J=13.6 Hz, 1H), 3.23(d, J=13.6 Hz, 1H),
4.10(q, J= #7.1 Hz, 2H), 6.42(br.s, 1H). 6.49(d, J=1.6 Hz, 1H),
6.76(dd, J=1.6, 7.9 Hz, 1H), 6.83(d, J=7.9 Hz, 1H), 7.57(d, J=2.9
Hz, 1H), 7.69(d, J=2.9 Hz, 1H) 58 365ethyl (syn)-[3-(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-(anti)-9-methoxy-3-
azabicyclo[3.3.1]non- 9-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.25(t, J=7 Hz, 3H), 1.45-1.55(m, 1H), 1.72-1.80(m, 2H),
1.80-1.95(m, 2H), 1.99(br.s, 2H), 2.3-2.35(m, 1H), 2.5-2.65(m, 4H),
2.77(s, 2H), 3.22(s, 2H), 3.20(s, 3H), 4.14(q, J=7 Hz, 2H), 6.40(s,
1H), 6.49(d, #J=1 Hz, 1H), 6.77(dd, J=1, 8 Hz, 1H), 6.82(d, J=8 Hz,
1H), 7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz, 1H) 59 366methyl
(anti)-3-[2- [3-(10H-pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3- azabicyclo[3.3.1]non- 9-yl]- ethyloxy]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.2-2.2(m, 10H), 2.23(br.d,
J=10 Hz, 2H), 2.4-2.6(m, 1H), 2.94(br.d, J=10 Hz, 2H), 3.21(s, 2H),
3.90(s, 3H), 4.03(t, J=5 Hz, 2H), 6.35(s, 1H), 6.51(s, 1H), 6.78(d,
J=7 Hz, 1H), 6.84(d, # J=7Hz, 1H), 7.0-7.1(m, 1H), 7.3-7.4(m, 1H),
7.5-7.8(m, 4H)
EXAMPLE 60
Ethyl(anti)-(6R*,8R*)-4-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-6,8-dimethyl -3-azabicyclo[3.3.1]non-9-yl]butanoate
[1721] 367
[1722] To a solution of 1.0 g of
ethyl(6R*,8R*)-4-[3-(vinyloxycarbonyl)-6,-
8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]-2-butenoate in dioxane (10
ml) was added 30 ml of a 4 N solution of hydrochloric acid in
dioxane and the resulting mixture was stirred at room temperature.
After distilling off the solvent under reduced pressure, 10 ml of
methanol was added to the residue and the resulting mixture was
heated under reflux for 1 hour. After distilling off the solvent
under reduced pressure, the residue was made alkaline by adding a
dilute aqueous solution of sodium hydroxide and extracted with
ethyl acetate. The organic layer was dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
0.25 g of 10% palladium-carbon (moisture content: 50%) was added to
the residual methanolic solution and the resulting mixture was
stirred under a hydrogen gas stream at room temperature overnight.
Then the reaction mixture was filtered through celite. After
distilling off the solvent under reduced pressure, 0.9 g of a pale
yellow oily substance was obtained.
[1723] To a solution of 0.9 g of this yellow oily substance and
0.75 g of 8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine in
N,N-dimethylformamide was added 1.24 g of potassium carbonate and
the resulting mixture was stirred at 100.degree. C. for 3 hours.
After adding ethyl acetate, the reaction mixture was washed with a
saturated aqueous solution of sodium chloride. Then the organic
layer was dried over anhydrous magnesium sulfate. After distilling
off the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 1.0 g of the title compound as a yellow
oily substance.
[1724] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1725] 0.98(d, J=7.2 Hz, 6H), 1.18-1.80(m, 13H), 1.93(d, J=9.2 Hz,
2H), 2.28(t, J=7.2 Hz, 2H), 2.58(d, J=9.2 Hz, 2H), 3.02(d, J=9.2
Hz, 1H), 3.25(s, 2H), 4.13(q, J=7.2 Hz, 2H), 6.43(br.s, 1H),
6.52(s, 1H), 6.76(d, J=8.0 Hz, 1H), 6.82(d, J=8.0 Hz, 1H), 7.56(d,
J=2.8 Hz, 1H), 7.68(d, J=2.8 Hz, 1H)
EXAMPLES 61 and 62
[1726] The following compounds were obtained by the same method as
the one of Example 60.
24TABLE 24 Ex. Structural formula NMR 61 368ethyl (anti)-4-[3-
(10H-pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]non- 9-yl]-2- methylbutanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.16(d, J=7.0 Hz, 3H), 1.26(d,
J=7.1 Hz, 3H), 1.32-1.68(m, 10H), 1.68-1.83(m, 2H), 2.15-2.22(m,
2H), 2.41(m, 1H), 2.52(m, 1H), 2.88-2.95(m, 2H), 3.21(s, 2H),
4.14(q, J=7.1 Hz, 2H), #6.38(br.s, 1H), 6.52(d, J=1.5 Hz, 1H),
6.78(dd, J=1.5, 7.9 Hz, 1H), 6.83(d, J=7.9 Hz, 1H), 7.57(d, J=2.9
Hz, 1H), 7.69(d, J=2.9 Hz, 1H) 62 369ethyl (anti)-
(6R*,8R*)-4-[3-(10H- pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-6,8- dimethyl-3- azabicyclo[3.3.1]non- 9-yl]-2-
methylbutanoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.97(d, J=6.8
Hz, 6H), 1.14(d, J=6.8 Hz, 3H), 1.26(t, J=7.2 Hz, 3H), 1.30-1.80(m,
11H), 1.93(d, J=12.4 Hz, 2H), 2.34-2.45(m, 1H), 2.58(d, J=12.4Hz,
2H), 3.24(s, 2H), 4.12(d, # J=7.2 Hz, 2H), 6.36(br.s, 1H), 6.52(s,
1H), 6.76(d, J=8.0 Hz, 1H), 6.81(d, J=8.0 Hz, 1H), 7.57(d, J=2.8
Hz, 1H), 7.68(d, J=2.8 Hz, 1H)
EXAMPLE 63
Methyl(anti)-3-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azab-
icyclo[3.3.1]non-9-yl]propanoate
[1727] 370
[1728] The title compound was obtained by treating
methyl(anti)-3-(3-azabi- cyclo[3.3.1]non-9-yl)propanoate by the
same method as the one of Example 14 by using potassium carbonate
as a base.
[1729] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1730] 1.37-1.55(m, 4H), 1.58-1.90(m, 6H), 2.16-2.23(m, 2H),
2.30(t, J=7.2 Hz, 2H), 2.53(m, 1H), 2.88-2.96(m, 2H), 3.22(s, 2H),
3.68(s, 3H), 6.37(br.s, 1H), 6.51(d, J=1.3 Hz, 1H), 6.77(dd, J=1.3,
7.9 Hz, 1H), 6.83(d, J=7.9 Hz, 1H), 7.57(d, J=2.9 Hz, 1H), 7.69(d,
J=2.9 Hz, 1H)
EXAMPLE 64
Methyl(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicy-
clo[3.3.1]non-7-yl]carboxylate
[1731] 371
[1732] 360 mg of
methyl(syn)-[3-benzyl-3-azabicyclo[3.3.1]non-7-yl]carboxy- late was
dissolved in methanol (15 ml). After adding 0.5 g of 10%
palladium-carbon and 0.3 ml of conc. hydrochloric acid, the
resulting mixture was hydrogenated at 60.degree. C. under
atmospheric pressure for 2 hours. After filtering off the catalyst,
the residue was concentrated under reduced pressure to thereby give
a slightly yellow oily substance.
[1733] This oily substance was dissolved in 5 ml of
N,N-dimethylformamide. After adding 320 mg of
8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazi- ne and 0.68 ml
of N,N-diisopropylethylamine, the resulting mixture was stirred at
80.degree. C. for 3 hours. After adding water, the reaction mixture
was extracted with ethyl acetate. The ethyl acetate layer was
washed with water and a saturated aqueous solution of sodium
chloride, dried over anhydrous sodium sulfate and concentrated
under reduced pressure. Next, the residue was purified by silica
gel column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 111 mg of the title compound as a yellow solid.
[1734] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1735] 1.31(m, 1H), 1.51(m, 1H), 1.74-1.88(m, 4H), 2.16-2.26(m,
2H), 2.37-2.47(m, 2H), 2.53(m, 1H), 2.65-2.74(m, 2H), 3.30(s, 2H),
3.72(s, 3H), 6.48(br.s, 1H), 6.62(d, J=7.9 Hz, 1H), 6.63(br.s, 1H),
6.81(d, J=7.9 Hz, 1H), 7.53(d, J=2.9 Hz, 1H), 7.68(d, J=2.9 Hz,
1H)
EXAMPLE 65
[1736] The following compound was obtained by the same method as
the one of Example 64.
25TABLE 53 Ex. Structural formula NMR 65 372ethyl (syn)-[3-(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]non- 7-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.05(m, 1H), 1.28(t, J=7.1 Hz, 3H), 1.35-1.46(m, 2H),
1.72-1.80(m, 2H), 1.85-2.08(m, 6H), 2.33(d, J=6.0 Hz, 2H),
2.50-2.57(m, 2H), 3.28(s, 2H), 4.18(q, J=7.1 Hz, 2H), 6.70(d, J=7.9
Hz, # 1H), 6.79(d, J=7.9 Hz, 1H), 6.81(s, 1H), 7.19(br.s, 1H),
7.56(d, J=2.9 Hz, 1H), 7.65(d, J=2.9 Hz, 1H)
EXAMPLE 66
Ethyl[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[3.3-
.1]nonane-9-spiro-cyclobut-3'-yl]acetate
[1737] 373
[1738] To a solution of 4.7 g of ethyl[3-(tert-butoxycarbonyl)
-3-azabicyclo[3.3.1]nonane-9-spiro-cyclobut -3'-yl]acetate in
tetrahydrofuran (50 ml) was added 20 ml of conc. hydrochloric acid
and the resulting mixture was stirred at room temperature for 1
hour. After concentrating the reaction mixture under reduced
pressure, 3.7 g of crude
ethyl(3-azabicyclo[3.3.1]nonane-9-spiro-cyclobut -3'-yl)acetate was
obtained. To a solution of 2.0 g of this crude product in
N,N-dimethylformamide (30 ml) were added 1.3 g of
8-chloromethyl-10H-pyra- zino[2,3-b][1,4]benzothiazine and 3 g of
anhydrous potassium carbonate and the resulting mixture was stirred
at 100.degree. C. for 3 hours. Then the reaction mixture was
brought back to room temperature and ice/water was added thereto
followed by the extraction with ethyl acetate. Next, it was washed
with a saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with ethyl acetate/toluene) to thereby give
1.0 g of the title compound as a yellow oily substance.
[1739] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1740] 1.18(t, J=7 Hz, 3H), 1.2-1.90(m, 10H), 2.1-2.6(m, 7H),
2.29(d, J=12 Hz), 3.08(s, 2H), 4.04(q, J=2 Hz, 2H), 6.3-6.45(m,
1H), 6.43(d, J=2 Hz, 1H), 6.69(dd, J=2, 8 Hz, 1H), 6.75(d, J=8 Hz,
1H), 7.49(d, J=3 Hz, 1H), 7.62(d, J=3 Hz, 1H)
EXAMPLES 67 and 68
[1741] The following compounds were obtained by the same method as
the one of Example 66.
26TABLE 26 Ex. Structural formula NMR 67 374ethyl (6R*,8R*)-[3-
(10H-pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl)-6,8-
dimethyl-3- azabicyclo[3.3.1]nonane- 9-spiro-cyclobut-3'-
yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.70(q, J=10 Hz,
1H), 0.99(d, J=7 Hz, 3H), 1.04(d, J=7 Hz, 3H), 1.24(t, J=7 Hz, 3H),
1.4-1.55(m, 3H), 1.6-1.7(m, 2H), 1.7-1.9(m, 2H), 1.98(d, J=10 Hz,
1H), 2.10(d, J=10 Hz, 1H), # 2.15-2.25(m, 2H), 2.25-2.4(m, 2H),
2.36(d, J=8 Hz, 2H), 2.45-2.6(m, 1H), 3.18(s, 2H), 4.10(q, J=7 Hz,
2H), 6.49(s, 1H), 6.6-6.7(br.s, 1H), 6.74(d, J=8 Hz, 1H), 6.80(d,
J=8 Hz, 1H), 7.56(d, J=3 Hz, 1H), 7.66-7.69(m, 1H) 68 375methyl
[3-(10H- pyrazino[2,3- b] [1,4-]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]nonane-9- spiro-cyclobut-3'-yl]carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.3-1.4(m, 1H), 1.5-1.64(m,
5H), 1.7-1.86(m, 1H), 1.96-2.14(m, 2H), 2.12-2.38(m, 3H),
2.29(br.d, J=12 Hz, 1H), 2.44-2.60(m, 1H), 2.66(t, J=13 Hz, 2H),
2.92(quint, J=9 Hz, 1H), 3.13(d, J=14 Hz, # 1H), 3.17(d, J=14 Hz,
1H), 3.67(s, 3H), 6.49(s, 1H), 6.53(s, 1H), 6.75(d, J=8 Hz, 1H),
6.81(d, J=8 Hz, 1H), 7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz, 1H)
EXAMPLE 69
Ethyl(anti)-[[3-(10H-pyrazino[2,3-b][1,4benzothiazin-8-ylmethyl)-3-azabicy-
clo[3.1.1]heptane-7-spiro-cyclobutan]-6-yl]acetate and
ethyl(syn)-[[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabic-
yclo[3.1.1]heptane-7-spiro-cyclobutan]-6-yl]acetate
[1742] In a nitrogen atmosphere, 2.00 g of ethyl
[[3-(p-tolylsulfonyl)-3-a-
zabicyclo[3.3.1]heptane-7-spiro-cyclobutan]-6-yl]acetate was
dissolved in 90 ml of dry 1,2-dimethoxyethane and the obtained
solution was cooled to -70.degree. C. Into the above sulfonamide
solution was dropped in a nitrogen atmosphere a green solution of
sodium naphthalenide obtained by reacting 6.8 g of naphthalene with
0.97 g of sodium in 100 ml of dimethoxyethane. After adding 5 ml of
an aqueous solution of sodium hydrogencarbonate, 6 g of anhydrous
sodium carbonate and 150 ml of ethyl acetate, the organic layer was
dried over potassium carbonate and distilled off under reduced
pressure. To a solution of the crude product thus obtained in 35 ml
of N,N-dimethylformamide were added 1.99 g 8-chloromethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine and 0.89 g of anhydrous
potassium hydrogencarbonate and the resulting mixture was reacted
at 90.degree. C. in a nitrogen atmosphere for 2 hours. Then the
reaction mixture was cooled to room temperature and added to 350 ml
of water and 350 ml of ethyl acetate. The organic layer was washed
with water, dried over anhydrous magnesium sulfate, filtered and
distilled under reduced pressure. The residue was purified by
silica gel column chromatography (eluted with methylene
chloride/methanol) to thereby give 0.62 g of
ethyl(anti)-[[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.1.1]heptane-7-spiro-cyclobutan]-6-yl]acetate
and0.49 g of
ethyl(syn)-[(3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-aza-
bicyclo[3.1.1]heptane-7-spiro-cyclobutan]-6-yl]acetate each as a
yellow powder. 376
[1743] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1744] 1.25(t, J=7Hz, 3H), 1.80(m, 2H), 1.86(m, 2H), 2.14(m, 4H),
2.25(m, 1H), 2.62(d, J=7 Hz, 2H), 2.81(d, J=11 Hz, 2H), 2.87(d,
J=11 Hz, 2H), 3.45(s, 2H), 4.13(q, J=7 Hz, 2H), 6.44(s, 1H),
6.51(s, 1H), 6.74(d, J=(d, J=8 Hz, 1H), 6.82(d, J=8 Hz, 1H),
7.58(d, J=3 Hz, 1H), 7.68(d, J=3 Hz, 1H) 377
[1745] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1746] 1.25(t, J=7 Hz, 3H), 1.85(m, 3H), 1.93(br.s, 2H), 2.10(br.s,
2H), 2.30(t, J=8 Hz, 2H), 2.60(d, J=8 Hz, 2H), 2.98(br.s, 4H),
3.58(br.s, 2H), 4.12(q, J=7 Hz, 2H), 6.55(s, 1H), 6.75(d, J=8 Hz,
1H), 6.82(d, J=8 Hz, 1H), 7.57(d, J=3 Hz, 1H), 7.68(d, J=3 Hz,
1H)
EXAMPLES 70 to 111
[1747] The compounds listed in the following tables were obtained
by the same method as the one of Example 18.
27TABLE 27 Ex. Structural formula MS M.p. NMR 70 378[3-(10H-
pyrazino[2,3- b] [1,4]benzothiazin- 8-ylmethyl-3-
azabicyclo[3.2.1]oct- 8-ylidene]acetic acid FAB(+) 381(MH.sup.+)
268-271.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.46-1.62(m, 2H), 1.74-1.90(m, 2H), 2.02-2.14(m, 2H), 2.68-2.80(m,
2H), 3.28(s, 2H), 3.20-3.40(m, 1H), 3.52-3.66(m, 1H), 5.53(s, #
1H), 6.68(dd, J=1, 8 Hz, 1H), 6.80(s, 1H), 6.82(d, J=8 Hz, 1H),
7.55-7.65(m, 1H), 7.62(d, J=3 Hz, 1H), 9.53(s, 1H) 71
379[3-(10H-pyrazino [2,3-b] [1,4]benzothiazin-8- ylmethyl)-3-
azabicyclo[3.2.1]oct- 8-yl]acetic acid FAB(+) 383(MH.sup.+)
244-245.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.50-2.10(m, 10H), 2.2-2.3(m, 1H), 2.4-2.65(m, 2H), 3.25 and
3.28(s, 2H), 6.68(d, J=8 Hz, 1H), 6.78(s, 1H), 6.81(d, J=8 Hz, 1H),
7.55- #7.65(m, 2H), 9.53(s, 1H) 72 380[3-(10H-pyrazino [2,3-b]
[1,4]benzothiazin-8- ylmethyl)-3- azabicyclo[3.3.1]non-
9-ylidene]acetic acid FAB(+) 395(MH.sup.+) 253-255.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.36-1.48(m, 1H),
1.60-1.76(m, 2H), 1.86-1.98(m, 2H), 2.08-2.20(m, 2H), 2.26-2.34(m,
1H), 2.68-2.86(m, 1H), 2.90-3.00(m, 2H), 3.14(d, J=13 Hz, # 1H),
3.18(d, J=13 Hz, 1H), 3.80-3.86(m, 1H), 5.55(s, 1H), 6.70(dd, J=1.8
Hz, 1H), 6.74(s, 1H), 6.85(d, J=8 Hz, 1H), 7.61(d, J=3 Hz, 1H),
7.63(d, J=3 Hz, 1H), 9.57(s, 1H), 11.9-12.1(m, 1H)
[1748]
28TABLE 28 Ex. Structural formula MS M.p. NMR 73
381[3-(10H-pyrazino [2,3-b] [1,4]benzothiazin-8- ylmethyl)-3-
azabicyclo[3.2.1]oct- 8-yl]carboxylic acid FAB(+) 369(MH.sup.+)
261-264.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.52-1.68(m, 4H), 1.98-2.08(m, 2H), 2.25(s, 1H), 2.32-2.40(m, 2H),
2.54-2.66(m, 2H), 3.26(s, 2H), 6.68(d, J=8 Hz, 1H), 6.79(s, 1H),
6.81(d, J= #8 Hz, 1H), 7.61(d, J=3 Hz, 1H), 7.63(d, J=3 Hz, 1H),
9.54(s, 1H), 1.20-12.2(m, 1H) 74 382(anti)-[3-(10H- pyrazino[2,3-
b] [1,4]benzothiazin- 8-ylmethyl)-3- azabicylo[3.3.1]non-
9-yl]carboxylic acid FAB(+) 383(MH.sup.+) 272-275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.38-1.40(m, 1H),
1.48-1.56(m, 2H), 1.64-1.76(m, 2H), 2.08(br.s, 2H), 2.16(br.d, J=10
Hz, 2H), 2.28(br.s, 1H), 2.46-2.64(m, 1H), 2.82- #2.90(m, 2H),
3.16(s, 2H), 6.69(dd, J=1, 8 Hz, 1H), 6.73(d, J=1 Hz, 1H), 6.84(d,
J=8 Hz, 1H), 7.61(d, J=3 Hz, 1H), 7.63(d, J=3 Hz, 1H), 9.56(s, 1H)
75 383(syn)-[3-(10H- pyrazino[2,3- b] [1,4]benzothiazin-
8-ylmethyl)-3- azabicyclo[3.3.1]non- 9-yl]carboxylic acid FAB(+)
383(MH.sup.+) 278-281.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.36-1.46(m, 1H), 1.56-1.68(m, 2H), 1.70-1.80(m, 2H),
2.15(br.s, 2H), 2.22(br.d, J=11 Hz, 2H), 2.28(br.s, 1H),
2.50-2.70(m, 1H), 2.62(br.d, # J=10 Hz, 2H), 3.08(s, 2H), 6.67(dd,
J=1, 8 Hz, 1H), 6.70(d, J=1 Hz, 1H), 6.82(d, J=8 Hz, 1H), 7.61(d,
J=3 Hz, 1H), 7.63(d, J=3 Hz, 1H), 9.54(s, 1H)
[1749]
29TABLE 29 Ex. Structural formula MS M.p. NMR 76 384 FAB (+) 399
(MH.sup.+) oily substance .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.54 (br.s, 2H), 1.86-1.96 (m, 1H), 2.18-2.28 (m, 2H), 2.53 (br.d,
J = 8 Hz, 2H), 2.84-2.94 (m, 2H), 3.23 (s, 2H), 3.57 (br.d, J = 8
Hz, 2H), 3.72-3.84 (m, 2H), 6.74 (s, 1H), 6.70-6.80 (m, 1H), 6.83
(d, J = 8 Hz, 1H), 7.61 (d, J = 2 Hz, 1H), 7.62 (d, J = 2 Hz, 1H),
9.52 (s, 1H) 77 385 FAB (+) 453 (MH.sup.+) 138-140.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 0.80 (s, 9H), 1.10-1.25 (m,
3H), 1.60-2.00 (m, 7H), 2.34 (d, J = 6.8 Hz, 2H), 2.54 (d, J = 10.4
Hz, 2H), 3.17 (s, 2H), 6.58 (s, 1H), 6.78 (d, J = 8.0 Hz, 1H), 6.82
(d, J = 8.0 Hz, 1H), 7.61 (d, J = 2.8 Hz, 1H), 7.62 (d, J = 2.8 Hz,
1H), 9.42 (s, 1H) 78 386 FAB (+) 411 (MH.sup.+) 142-146.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 0.86 (d, J = 6.8 Hz, 3H),
1.32-1.43 (m, 2H), 1.53-1.62 (m, 2H), 1.64-1.76 (m. 2H), 1.93-2.02
(m,2 H), 2.27 (d, J = 9.6 Hz, 2H), 2.38 (d, J = 7.2 Hz, 2H), 2.94
(d, J = 9.6 Hz, 2H), 3.26 (s, 2H), 6.63 (s, 1H), 6.76 (d, J = 8.0
Hz, 1H), 6.79 (d, J = 8.0 Hz, 1H), 7.55 (d, J = 2.8 Hz, 1H), 7.56 #
(d, J = 2.8 Hz, 1H)
[1750]
30TABLE 30 Ex. Structural formula MS M.p. NMR 79 387 FAB (+) 425
(MH.sup.+) 200-212.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 0.77-0.90 (m, 1H), 0.92 (d, J = 6.8 Hz, 6H), 1.35 (br.s, 2H),
1.60-1.80 (m, 4H), 1.91 (d, J = 10.4 Hz, 2H), 2.32 (d, J = 6.8 Hz,
2H), 2.53 (d, J = 10.4 Hz, 2H), 3.20 (s, 2H), 6.67 (d, J = 8.0 Hz,
1H), 6.74 (s, 1H), 6.81 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 2.8 Hz,
1H), 7.62 (d, J = 2.8 Hz, 1H), 9.25 (s, 1H) 80 388 FAB (+) 411
(MH.sup.+) 217-218.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.41-1.54 (m, 4H), 1.67-1.77 (m, 2H), 1.82-1.89 (m, 2H),
1.92-2.09 (m, 5H), 2.37 (d, J = 7.4 Hz, 2H), 2.56 -2.62 (m, 2H),
3.14 (s, 2H), 6.68-6.72 (m, 2H), 6.83 (dd, J = 1.8, 7.7 Hz, 1H),
7.61 (d, J = 2.8 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 9.55 (s, 1H) 81
389 FAB (+) 381 (MH.sup.+) 211-214.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 0.93 (s, 3H), 1.23-1.29 (m, 2H), 1.38
(s, 3H), 1.56-1.68 (m, 4H), 1.68-1.77 (m, 1H), 2.03-2.10 (m, 2H),
2.22 (d, J = 8.0 HZ, 2H), 2.68-2.74 (m, 2H), 3.20 (s, 2H), 6.64 (d,
J = 1.5 Hz, 1H), 6.67 (dd, J = 1.5, 7.7 Hz, 1H), 6.83 (d, J = 7.7
hz, 1H), 7.61 (d, J = 2.8 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 9.50 #
(s, 1H)
[1751]
31TABLE 31 Ex. Structural formula MS M.p. NMR 82 390 FAB (+) 411
(MH.sup.+) 126-128.degree. C. .sup.1H-NMR (CD.sub.3OD) .delta. ppm:
1.11 (d, J = 7 Hz, 3H), 1.49-1.56 (m, 1H), 1.58-1.62 (d, J = 11 Hz,
1H), 1.63-1.74 (m, 3H), 1.81-1.83 (dd, J = 4, 9 Hz, 1H), 1.86-1.94
(m, 2H), 2.38-2.42 (br.d, J = 11 Hz, 1H), 2.57-2.62 (br.d, J = 11
Hz, 1H), 2.64-2.80 (m, 4H), 3.27 (s, 2H), 6.67 (s, 1H), 6.79 (s,
2H), 7.55 (d, J = 3 Hz, 1H), 7.57 # (d, J = 3 Hz, 1H) 83 391 FAB
(+) 411 (MH.sup.+) 233-234.degree. C. .sup.1H-NMR (CD.sub.3OD)
.delta. ppm: 1.11 (d, J = 7 Hz, 3H), 1.46-1.58 (m, 4H), 1.65 (br.s,
1H), 1.64-1.74 (m, 1H), 1.83 (br.s, 1H), 1.89-2.00 (m, 1H), 2.27
(t, J = 10 Hz, 2H), 2.56-2.66 (m, 1H), 2/76-2.83 (dt, J = 7, 11 Hz,
1H), 2.96 (d, J = 11 Hz, 1H), 3.04 (d, J = 11 Hz, 1H), 3.26 (s,
2H), 6.67 (s, 1H), 6.79 (s, 2H), 7.55 (d, J = 3 Hz, 1H), 7.57 # (d,
J =3 Hz, 1H) 84 392 FAB (+) 439 (MH.sup.+) 104-108.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.24 (d, J = 7.0 Hz, 3H),
1.34-1.83 (m, 12H), 2.13-2.23 (m, 2H), 2.46 (m, 1H), 2.59 (m, 1H),
2.88-2.98 (br.s, 2H), 3.22 (br.s, 2H), 6.65 (br.s, 1H), 6.69-6.83
(m, 2H), 7.35 (d, J = 2.7 Hz, 1H), 7.60 (d, J = 2.7 Hz, 1H), 8.97
(br.s, 1H)
[1752]
32TABLE 32 Ex. Structural formula MS M.p. NMR 85 393 FAB (+) 409
(MH.sup.+) 175-180.degree. C. .sup.1H-NMR (CD.sub.3OD) .delta. ppm:
1.88 (m, 2H), 1.99 (m, 2H), 2.26 (s, 2H), 2.38 (t, J = 8 Hz, 2H),
2.54-2.60 (m, 1H), 2.68 (d, J = 8 Hz, 2H), 3.46 (d, J = 12 Hz, 2H),
3.63 (d, J = 12 Hz, 2H), 4.08 (s, 2H), 6.84(s, 1H), 6.95 (d, J = 8
Hz, 1H), 6.99 (d, J = 8 Hz, 1H), 7.61 9s, 2H) 86 394 FAB (+) 409
(MH.sup.+) 90-92.degree. C. .sup.1H-NMR (CD.sub.3OD) .delta. ppm:
1.78-1.85 (m, 2H, 1.90-1.94 (m, 2H), 2.14-2.18 (m, 4H), 2.46-2.52
(m, 1H), 2.59 (d, J = 7 Hz, 2H), 2.89 (d, J = 11 Hz, 2H), 2.97 (d,
J = 11 Hz, 2H), 3.49 (s, 2H), 6.67 (d, J = 2 Hz, 1H), 6.76 (dd, J =
2, 8 Hz, 1H), 6.79 (d, J = 8 Hz, 1H), 7.55 (d, J = 3 Hz, 1H), 7.57
(d, J = 3 Hz, 1H) 87 395 FAB (+) 473 (MH.sup.+) 128-131.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.59.varies.1.96 (m, 10H),
2.21 (d, J = 10 Hz, 2H), 2.93 (d, J = 10 Hz, 2H), 3.23 (s, 2H),
6.73 (s, 1H), 6.77 (d, J + 8.0 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H),
7.10-7.20 (m, 2H), 7.25-7.35 (m, 3H), 7.61 (d, J = 2.8 Hz, 1H),
7.63 (d, J = 2.8 Hz, 1H), 9.56 (s, 1H)
[1753]
33TABLE 33 Ex. Structural formula MS M.p. NMR 88 396 FAB (+) 409
(MH.sup.+) 254-159.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.16 (m, 1H), 1.41-1.70 (m, 7H), 1.84-1.98 (m, 4H), 2.37 (m,
1H), 2.43-2.56 (m, 2H), 3.26 (s, 2H), 6.72 (dd, J = 1.5, 7.9 Hz,
1H), 6.83 (d, J = 7.9 Hz, 1H), 6.84 (d, J = 1.5 Hz, 1H), 7.63 (d, J
= 2.9 Hz, 1H), 7.64 (d, J = 2.9 Hz, 1H), 9.55 (s, 1H), 12.02 (br.s,
1H) 89 397 FAB (+) 411 (MH.sup.+) .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 0.99 (d, J = 7.2 Hz, 3H), 1.03 (d, J = 7.2 Hz, 3H),
1.57-1.74 (m, 5H), 1.80 (t, J = 8.0 Hz, 1H), 1.95 (d, J = 8.0 Hz,
1H), 2.02 (d, J = 8.0 Hz, 1H), 2.24 (d, J = 7.6 Hz, 1H), 2.57 (d, J
= 10 Hz, 1H), 2.75 (d, J = 10 Hz, 1H), 3.18 (d, J = 12.8 hz, 1H),
3.29 (d, J = 12.8 Hz, 1H), 6.67 (d, J = 8.0 Hz, 1H), 6.72 # (s,
1H), 6.81 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 2.8 Hz, 1H), 7.62 (d, J
= 2.8 Hz, 1H), 9.53 (s, 1H), 12.0 (br.s, 1H) 90 398 FAB (+) 383
(MH.sup.+) 186-188.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.46-1.72 (m, 6 H), 1.82 (m, 1H), 1.91 (m, 1H), 2.02-2.13 (m,
2H), 2.71 (m, 1H), 2.79 (m, 1H), 2.93 (m, 1H), 3.12 (d, J = 13.4
Hz, 1H), 3.25 (d, J = 13.4 Hz, 1H), 6.70 (dd, J = 1.2, 7.9 Hz, 1H),
6.74 (d, J = 1.2 Hz, 1H), 6.86 (d, J = 7.9 Hz, 1H), 7.63 (d, J =
2.9 Hz, 1H), 7.64 (d, J = 2.9 Hz, 1H), 9.85 (s, 1H), 12.20 # (br.s,
1H)
[1754]
34TABLE 34 Ex. Structural formula MS M.p. NMR 91 399 FAB (+) 411
(MH.sup.+) 125-130.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta.ppm: 1.00 (d, J = 7 Hz, 3H), 1.10-1.20 (m, 1H), 1.30-1.45
(m, 1H), 1.50 (br.s, 1H), 1.60 (br.s, 1H), 1.70-1.90 (m, 3H), 2.08
(d, J = 8 Hz, 1H), 2.14 (d, J = 8 Hz, 1H), 2.3-2.5 (m, 2H), 2.68
(m, 1H), 2.73 (d, J = 10 Hz, 1H), 2.82 (d, J = 10 Hz, 1H), 2.82 (d,
J = 10 Hz, 1H), 3.13 (d, J = Hz, 1H), # 3.20 (d, J = 13 Hz, 1H),
6.67 (d, J = 13 Hz, 1H), 6.72 (s, 1H), 6.82 (d, J = 8 Hz, 1H), 7.06
(d, J = 3 Hz, 1H), 7.62 (d, J = 3 Hz, 1H), 9.54 (s, 1H), 12.3
(br.s, 1H) 92 400 FAB (+) 411 (MH.sup.+) 233-225.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.33-1.48 (m, 4H),
1.54-1.78 (m, 6H), 2.08-2.21 (m, 4H), 2.54 (m, 1H), 2.84-2.91 (m,
2H), 3.17 (s, 2H), 6.70 (dd, J - 1.5, 7.9 Hz, 1H), 6.73 (d, J = 1.5
Hz, 1H), 6.84 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 2.7 Hz, 1H), 7.64
(d, J = 2.7 Hz, 1H), 9.56 (s, 1H) 93 401 FAB (+) 439 (MH.sup.+)
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 0.84-1.00 (m, 1H), 0.95 (d,
J = 6.8 Hz, 3H), 0.98 (d, J = 6.8 hz, 3H), 1.06 (d, J = 6.8 Hz,
3H), 1.28-1.38 (m, 2H), 1.54-1.82 (m, 4H), 1.87 (d, J = 7.2 Hz,
1H), 1.89 (d, J = 7.2 Hz, 1H), 2.48-2.55 (m, 1H), 2.55 (d, J = 7.2
Hz, 1H), 2.60 (d, J = 7.2 Hz, 1H), 3.24 (s, 2H), 6.68 (d, J = 8.0
Hz, 1H), 6.75 (s, 1H), # 6.84 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 2.8
Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 9.52 (br.s, 1H), 12.0 (br.s,
1H)
[1755]
35TABLE 35 Ex. Structural formula MS M.p. NMR 94 402 FAB (+) 503
(MH.sup.+) 234-236.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.30-1.50 (m, 3H), 1.55-1.30-1.50 (m, 3H), 1.55-1.60 (br.s,
3H), 1.70-1.85 (m, 2H), 1.80-1.95 (m, 2H), 2.15 (br.d, J = 10 Hz,
2H), 2H), 2.50-2.60 (m, 1H), 2.87 (br.d, J = 11 Hz, 2H), 3.15 (s,
2H), 3.95-4.05 (m, 2H), 6.68 (d, J = 8 Hz, 1H), 6.72 (s, 1H), 6.83
(d, J = 8 Hz, 1H), 7.16 (dd, J = 2.8 # Hz, 1H), 7.37 (t, J = 8 Hz,
1H), 7.40 (s, 1H), 7.49 (d, J = 8 Hz, 1H), 7.60 (d, J = 3 Hz, 1H),
7.62 (d, J = 3 Hz, 1H), 9.56 (s, 1H), 12.97 (br.s, 1H) 95 403 FAB
(+) 441 (MH.sup.+) 108-113.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.30-1.45 (m, 3H), 1.45-1.60 (m, 3H), 1.60-1.80 (m,
4H), 2.06-2.20 (m, 2H), 2.50 (m, 1H), 2.80-2.90 (m, 2H), 3.15 (s,
2H), 3.43 (t, J = 6 Hz, 2H), 3.93 (s, 2H), 6.68 (d, J = 8 Hz, 1H),
6.72 (s, 1H), 6.83 (d, J = 8 Hz, 1H), 7.61 (d, J = 3 Hz, 1H), 7.62
(d, J = 3 Hz, 1H), 9.55 (s, 1H) 96 404 FAB (+) 517 (MH.sup.+)
208-210.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.36-1.50 (m, 3H), 1.63 (br.s, 3H), 1.7-1.86 (m, 2H), 1.80-1.92 (m,
2H), 2.15 (br.d, J = 11 Hz, 2H), 2.46-2.64 (m, 1H), 2.87 (br.d, J =
10 Hz, 2H), 3.16 (s, 2H), 3.45 (s, 2H), 3.95 (t, J = 7 Hz, 2H),
6.69 (d, J = 7 Hz, 1H), 6.73 (s, 1H), 6.83 (d, J = 7 Hz, 1H), 6.84
(d, J = 8 Hz, 2H), 7.12 (d, J = 8 Hz, # 2H), 7.61 (d, J = 3 Hz,
1H), 7.62 (d, J = 3 Hz, 1H), 9.55 (s, 1H), 12.21 (s, 1H)
[1756]
36TABLE 36 Ex. Structural formula MS M.p. NMR 97 405 0.97 (d, J =
7.1 Hz, 3H), 1.06 (d, J = 7.1 Hz, 3H), 1.44 (m, 1H), 1.52 (m, 1H),
1.63 (m, 1H), 1.69 (m, 1H), 2.09 (m, 1H), 2.23 (d, J = 10.6 Hz,
1H), 2.26-2.34 (m, 2H), 2.38 (dd, J = 7.5, 15.6 Hz, 1H), 2.42-2.52
(m, 2H), 3.23 (d, J = 13.0 Hz, 1H), 3.32 (d, H = 13.0 Hz, 1H), 6.69
(dd, J = 13.0 Hz, 1H), 6.69 (dd, J = 1.5, 7.7 Hz, 1H), 6.73 (d, J =
1.5 Hz, 1H), 6.83 # (d, J = 7.7 Hz, 1H), 7.62 (d, J = 2.9 Hz, 1H),
7.63 (d, J = 2.9 Hz, 1H), 9.54 (s, 1H), 12.02 (s, 1H) 98 406 FAB
(+) 383 (MH.sup.+) .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.28 (m,
1H), 1.46 (m, 1H), 1.68-1.78 (m, 4H), 2.11-2.18 (m, 2H), 2.24-2.33
(m, 2H), 2.41 (m, 1H), 2.59-2.66 (m, 2H), 3.18 (s, 2H), 6.58 (d, J
= 1.6 Hz, 1H), 6.65 (d, J = 7.9 Hz, 1H), 6.83 (dd, J = 1.6, 7.9 Hz,
1H), 7.63 (d, J = 2.9 Hz, 1H), 7.64 (d, J = 2.9 Hz, 1H), 9.37 (s,
1H), 11.54 (br.s, 1H) 99 407 FAB (+) 425 (MH.sup.+) 226-229.degree.
C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 0.66 (s, 6H), 1.21-1.39
(m, 6H), 1.57 (t, J = 5.9 hz, 1H), 1.78 (d, J - 11.8 Hz, 2H), 2.20
(d, J = 5.9 Hz, 2H), 2.40 (d, J = 11.8 Hz, 2H), 3.08 (s, 2H), 6.67
(dd, J = 1.0, 7.7 Hz, 1H), 6.70 (d, J = 1.0 Hz, 1H), 6.83 (d, J =
7.7 Hz, 1H), 7.61 (d, J = 2.6 Hz, 1H), 7.62 (d, J = 2.6 Hz, 1H),
9.54 # (s, 1H), 12.00 (ss, 1H)
[1757]
37TABLE 37 Ex. Structural MS M.p. NMR 100 408 110-115.degree. C.
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.97 (d, J = 7.6 Hz, 3H),
0.99 (d, J = 7.6 Hz, 3H), 1.21 (d, J = 6.8 Hz, 3H), 1.30-2.00 (m,
12H), 2.38-2.64 (m, 4H), 3.25 (s, 2H), 6.56 (s, 1H), 6.66-6.82 (m,
2H), 7.24 (d, J = 2.8 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H), 8.03 (s,
1H) 101 409 FAB (+) 439 (MH.sup.+) 110-115.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta.ppm: 0.76-0.87 (m, 1H), 0.93 (d, J = 6.4 Hz,
6H), 1.50-1.90 (m, 1H), 1.32-1.39 (m, 2H), 1.56-1.78 (m, 5H), 1.84
(d, J = 9.6 Hz, 2H), 2.17 (t, J = 7.2 Hz, 2H), 2.52 (d, J = 10 Hz,
2H), 3.19 (s, 2H), 6.67 (d, J = 8 Hz, 1H), 6.74 (s, 1H), # 6.81 (d,
J = 8 Hz, 1H), 7.61 (d, J = 2.8 Hz, 1H), 7.62 (d, J = 2.8 Hz, 1H),
9.52 (s, 1H) 102 410 98-105.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 0.92 (d, J = 6.8 Hz, 6H), 1.38-1.92 (m, 13H), 2.01 (t,
J = 6.4 Hz, 2H), 2.52 (d, J = 10.8 Hz, 2H), 3.18 (s, 2H), 6.67 (d,
J = 8.4 Hz, 1H), 6.74 (s, 1H), 6.82 (d, J = 8.4 Hz, 1H), 7.60 (d, J
= 2.4 Hz, 1H), 7.62 (d, J = 2.4 Hz, 1H), 9.53 (s, 1H)
[1758]
38TABLE 38 Ex. Structural formula MS M.p. NMR 103 411 FAB (+) 427
(MH.sup.+) 217-219.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.30-1.46 (m, 3H), 1.84-2.00 (m, 4H), 2.40-2.60 (m, 3H), 2.66
(s, 2H), 2.68-2.78 (m, 2H), 3.15 (s, 3H), 3.22 (s, 2H), 6.68 (dd, J
= 1, 8 hz, 1H), 6.71 (s, 1H), 6.83 9d, J = 8 hz, 1H), 7.61 (d, J =
3 hz, 1H), 7.63 (d, J = 3 hz, 1H), 9.56 9s, 1H) 104 412 FAB (+) 397
(MH.sup.+) 215-217.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.32-1.54 (m, 5H), 1.62-1.74 (m, 2H), 1.83-1.90 (m, 2H), 1.96
(s, 2H), 2.06 (m, 1H), 2.64-2.85 (m, 3H), 3.12 (d, J = 13.7 hz,
1H), 3.16 (d, J = 13.7 Hz, 1H), 6.69 (dd, J = 1.5, 7.9 Hz, 1H),
6.73 (d, J = 1.5 Hz, 1H), 6.85 (d, J = 7.9 Hz, 1H), 7.63 9d, J =
2.9 Hz, 1H), 7.64 9d, J = 2.9 Hz, 1H), 9.57 (s, 1H) 105 413 FAB (+)
427 (MH.sup.+) 225-228.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta.ppm: 1.30-1.45 (m, 1H), 1.56-1.68 (m, 2H), 1.70-1.90 (m,
3H), 1.99 (br.s, 1H), 2.16 (s, 2H), 2.34-2.70 (m, 5H), 3.13 (s,
2H), 3.15 (s, 3H), 6.70 (d, J = 8 hz, 1H), 6.72 (s, 1H), 6.83 (d, J
= 8 Hz, 1H), 7.61 (d, J = 3 Hz, 1H), 7.63 (d, J = 3 Hz, 1H), 9.56
(s, 1H)
[1759]
39TABLE 39 Ex. Structural formula MS M.p. NMR 106 414 FAB (+) 409
(MH.sup.+) 263-266.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.44-1.60 (m, 6H), 1.64-1.79 (m, 4H), 1.84 (m, 1H), 1.93 (m,
1H), 2.45- 2.57 (m, 3H), 3.26 (s, 2H), 6.46 (dd, J = 1.6, 7.9 Hz,
1H), 6.83 (d, J = 1.6 hz, 1H), 6.84 (d, J = 7.9 Hz, 1H), 7.63 (d, J
= 2.7 Hz, 1H), 7.64 (d, J = 2.7 Hz, 1H), 9.56 (s, 1H), 12.06 (br.s,
1H) 107 415 ESI397.1 (MH.sup.+) 206-209.degree. C. (dec)
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 0.96 (m, 1H), 1.07-1.18
(m,2 2H), 1.70 (m, 1H), 1.79-1.94 (m, 7H), 2.15 (d, J = 6.0 Hz,
2H), 2.42-2.50 (m, 2H), 3.23 (s, 2H), 6.73 (dd, J = 1.5, 7.9 Hz,
1H), 6.77 (d, J = 1.5 Hz, 1H), 6.84 (d, J = 7.9 Hz, 1H), 7.63 (d, J
= 2.9 hz, 1H), 7.64 (d, J = 2.9 Hz, 1H), 9.58 (s, 1H), 11.97 (br.s,
1H) 108 416 FAB (+) 437 (MH.sup.+) 199-201.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.22-1.82 (m, 9H), 2.02-2.38 (m, 3H),
2.26 (d, J = 8Hz, 2H), 2.22-2.38 (m, 2H), 2.44-2.66 (m, 3H), 3.08
(s, 2H), 6.67 (d, J = 8Hz, 1H), 6.70 (d, J = 8 Hz, 1H), 6.82 (d, J
= 8 Hz, 1H), 7.61 (d, J = 3 Hz, 1H), 7.62 (d, J = 3 Hz, 1H), 9.54
(s, 1H), 11.93 (s, 1H)
[1760]
40TABLE 40 Ex. Structural formula MS M.p. NMR 109 417 FAB (+) 465
(MH.sup.+) 205-206.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 0.68 (q, J = 12 Hz, 1H), 0.95 (d, J = 7 Hz, 3H), 0.99 (d, J =
7 Hz, 3H), 1.21 (m, 1H), 1.34-1.50 (m,3H), 1.58 (m, 1H), 1.80 (m,
2H), 1.90 (d, J = 9 Hz, 1H), 2.00-2.16 (m, 3H), 2.16-2.30 (m, 2H),
2.26 (d, J = 8 hz, 2H), 2.39 (m, J = 8 Hz, 1H), 3.13 (s, 2H), 6.66
(d, J = 8 Hz, 1H), 6.72 (s, 1H), # 6.80 (d, J = 8 Hz, 1H), 7.60 (d,
J = 3 Hz, 1H), 7.62 (d, J = 3 Hz, 1H), 9.51 (s, 1H), 11.9 (s, 1H)
110 418 FAB (+) 409 (MH.sup.+) 263-266.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.26-1.36 (m, 2H), 1.46-1.55 (m, 2H),
1.56-1.65 (m, 2H), 1.93-2.01 (m, 2H), 2.58 (s, 1H), 2.62-2.74 (m,
3H), 3.13 (s, 2H), 6.77 (d, J = 7.9 Hz, 1H), 6.84 (d, J = 7.9 Hz,
1H), 6.78 (s, 1H), 7.29 (dd, J = 1.1, 6.8 Hz, 1H), 7.63 (d, J = 2.9
Hz, 1H), 7.64 (d, J = 2.9 Hz, 1H), 9.56 (s, 1H), 12.11 (s, 1H) 111
419 FAB (+) 423 (MH.sup.+) 98-101.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.22-1.32 (m, 1H), 1.42-1.80 (m, 6H),
1.86 (dd, J = 8, 12 Hz, 1H), 1.93 (dd, J = 8, 12 Hz, 1H), 2.04-2.18
(m, 3H), 2.23 (br.d, J = 11 Hz, 1H), 2.42-2.66 (m, 1H), 2.59 (br.t,
J = 12 Hz, 2H), 2.83 (m, 1H), 3.09 (s, 2H), 6.66 (dd, J = 2, 8 Hz,
1H), 6.70 (s, 1H), 6.82 (d, J = 8 Hz, 1H), 7.61 (d, J = 2 Hz, 1H),
# 7.62 (d, J = 2 Hz, 1H), 9.55 (s, 1H), 12.0 (s, 1H)
EXAMPLES 112 to 116
[1761] The following compounds were obtained by the same methods as
those of Examples 13 and 14 (optionally using anhydrous potassium
carbonate as a substitute for diisopropylamine) and that of Example
18.
41TABLE 41 Ex. Structural formula MS M.p. NMR 112 420 FAB (+) 449
(MH.sup.-), 451 (MH.sup.+) 249-251.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 0.58 (s, 6H), 1.28-1.38 (m, 2H),
1.38-1.55 (m, 3H), 1.76 (d, J = 1.7 Hz, 3H), 1.82 (br.d, J = 11.5
Hz, 2H), 2.00 (br.d, J = 11.9 Hz, 1H), 2.67 (br.d, J = 11.5 Hz,
2H), 2.74-2.89 (m, 1H), 3.13 (s, 2H), 6.68 (d, J = 8.1 Hz, 1H),
6.73 (d, J = 1.1 Hz, 1H), 6.84 (dd, J = 1.1, 8.1 Hz, 1H), # 6.85
(dd, J = 1.7, 11.9 Hz, 1H), 7.60-7.65 (m, 2H), 9.56 (s, 1H),
12.18-12.25 (br.s, 1H) 113 421 FAB (+) 397 (MH.sup.+)
264-265.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.18 (s,
3H), 1.27-1.35 (m, 1H), 1.53-1.61 (m, 2H), 1.75-1.88 (m, 5H),
2.53-2.64 (m, 4H), 3.23 (s, 2H), 6.68 (dd, J = 1.8 Hz, 1H), 6.72
(d, J = 1Hz, 1H), 6.83 (d, J = 8 hz, # 1H), 7.61 (d, J = 3 Hz, 1H),
7.62 (d, J = 3 hz, 1H), 9.44 (br.s, 1H) 114 422 FAB (+) 413
(MH.sup.+) 223-226.degree. C. (dec) .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.39-1.49 (m, 1H), 1.60-1.72 (m, 2H), 1.88-1.96 (m,
2H), 2.10-2.19 (m, 2H), 2.69-2.84 (m, 1H), 2.88-2.99 (m, 3H), 3.14
(d, J = 12.3 hz, 1H), 3.20 9d, J - 12.3 hz, 1H), 3.61-3.67 (m, 1H),
6.70 (d, J = 7.6 Hz, 1H), 6.74 (d, J = 1.0 Hz, 1H), 6.85 (dd, J =
1.0, 7.6 hz, 1H), 7.61 9d, # J = 2.8 Hz, 1H), 7.63 (d, J = 2.8 Hz,
1H), 9.57 (s, 1H)
[1762]
42TABLE 42 Ex. Structural formula MS M.p. NMR 115 423 FAB (+) 415
(MH.sup.+) 185-187.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.40-1.55 (m, 3H), 1.58-1.90 (m, 4H), 2.08-2.18 (m, 2H),
2.50-2.68 (m, 1H), 2.83-2.95 (m, 2H), 3.13-3.18 (m, 1H), 3.17 (s,
2H), 5.18 9dd, J = 10.6, 49.6 Hz, 1H), 6.68 (d, J = 8.2 hz, 1H),
6.73 9s, 1H), 6.84 (d, J = 8.2 hz, 1H), 7.60-7.64 (m, 2H), 9.57 (s,
1H) 116 424 FAB (+) 397 (MH.sup.+) 183-185.degree. C. .sup.1H-NMR
(CD.sub.3OD) .delta. ppm: 1.28 (s, 3H), 1.41-1.52 (m, 1H), 1.56
(dd, J = 6, 12 Hz, 2H), 1.98 (m, 3H0, 2.08 (s, 2H), 2.57 (m, 2H),
2.73 (m, 2H), 3.24 (s, 2H), 6.64 (d, J = 2 hz, 1H), 6.77 (dd, J =
2, 8 Hz, 1H), 6.79 (d, J = 8 hz, 1H), 7.55 9d, j = 3 hz, 1H), 7.57
9d, J = 3 hz, 1H)
EXAMPLES 117 to 119
[1763] The following compounds were obtained from known compounds
by the same methods as those of Examples 12, 13 and 14 (using
anhydrous potassium carbonate as a substitute for diisopropylamine)
and that of Example 18.
43TABLE 43 Ex. Structural formula MS M.p. NMR 117 425 FAB (+) 383
(MH.sup.+) 155-158.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.15-1.23 (m, 2H), 1.51-1.60 (m, 2H), 1.88-1.96 (m, 2H),
1.97-2.05 (m, 2H), 2.07-2.19 (m, 1H), 2.30 (d, J = 8.4 hz, 2H),
2.97-3.06 (m, 2 H), 3.26 (s, 2H), 6.72 (dd, J = 1.6, 8.2 hz, 1H),
6.80 (d, J = 8.2 hz, 1H), 6.84 (d, J = 1.6 hz, 1H), 7.61 (d, J =
2.6 Hz, 1H), 7.62 (d, J = 2.6 hz, 1H), 9.45 9s, 1H) 118 426 FAB (+)
381 (MH.sup.+) 206-208.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.27 (m, 2H), 1.77-1.88 (m, 2H), 1.88-1.98 (m, 1H),
2.12-2.23 (m, 1H), 2.49-2.57 (m, 1H), 3.12-3.22 (m, 2H), 3.34-3.51
(m, 3H), 5.60 (s, 1H), 6.75 9d, J = 8.6 Hz, 1H), 6.82 (d, J = 8.6
Hz, 1H), 6.87 (s, 1H), 7.60 (d, J = 2.7 Hz, 1H), 7.61 (d, J = 2.7
Hz, 1H), 9.46 (s, 1H) 119 427 FAB (+) 369 (MH.sup.+) 158.degree. C.
(dec) .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.49-1.58 (m, 4H),
1.65-1.74 (m, 2H), 1.86-1.94 (m, 2H), 2.44-2.55 (m, 1H), 3.05-3.11
(m, 2H), 3.29 (s, 2H), 6.71 9dd, J = 1.3, 8.0 Hz, 1H), 6.81 (d, J =
8.0 Hz, 1H), 6.87 (d, J = 1.3 Hz, 1H), 7.61 (d, J = 2.9 Hz, 1H),
7.62 9d, J = 2.9 Hz, 1H), 9.84 9s, 1H)
EXAMPLE 120
[1764] The following compound was obtained by treating
(6R*,8R*)-3-(3,6,8-trimethyl-3-azabicyclo[3.3.1]non-9-yl)-2-methylpropano-
ic acid by the same methods as those of Examples 12, 13 and 14
(using anhydrous potassium carbonate as a substitute for
diisopropylamine) and that of Example 18.
44TABLE 44 Ex. Structural formula MS M.p. NMR 120 428(6R*,
8R*)-3-[3-(10H-pyrazino[2,3-b][1,4]benz- othiazin-8-ylmethyl)-6,8-
dimethyl-3-azabicyclo[3.3.1]non-9-yl]-2-methylpr- opanoic acid
FAB(+) 453 (MH.sup.+) 110-115.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 0.75-0.90(m, 1H), # 0.94(d, J=6.8Hz, 6H), 1.00(d,
J=6.8Hz, 3H), 1.14-1.43(m, 4H), 1.55-1.78(m, 5H), 1.85(d, J=10.8Hz,
2H), 2.52(d, J=10.8Hz, 2H), 2H), 3.19(s, 2H), 6.67(d, J=7.6Hz, 1H),
6.73(s, 1H), 6.81(d, J=7.6Hz, 1H), 7.61(d, J=2.8Hz, 1H), 7.62(d,
J=2.8Hz, 1H), 9.51(s, 1H)
EXAMPLE 121
[1765] The following compound was obtained by treating ethyl
4-[2-[(anti)-3-methyl-3-azabicyclo[3.3.1]non-9-yl]ethyloxy]benzoate
by the same methods as those of Examples 17 and 18.
45TABLE 45 Ex. Structural formula MS M.p. NMR 121
429(anti)-4-[2-[3-(10H- pyrazino[2,3-b][1,4]benz- othiazin-8-
ylmethyl)-3- azabicyclo[3.3.1]non -9-yl]ethyloxy]benzoic acid
FAB(+) 503 (MH.sup.+) 239-242.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.35-1.50(m, 3H), 1.62(br.s, 3H), 1.65-1.75(m, 2H),
1.80- # 1.95(m, 2H), 2.14(br.d, J=10Hz, 2H), 2.45-2.65 (m, 1H),
2.87(br.d, J=10Hz, 2H), 3.15(s, 2H), 4.05(t, J=6Hz, 2H), 6.68(d,
J=8Hz, 1H), 6.72(s, 1H), 6.83(d, J=8Hz, 1H), 6.98(d, J=8Hz, 2H),
7.61(s, 2H), 7.85(d, J=8Hz, 2H), 9.55(s, 1H), 12.58(br.s, 1H)
EXAMPLE 122
[1766] The following compound was obtained by treating
ethyl(11-hydroxy-9-methyl-9-azabicyclo[5.3.1]undec-11-yl)acetate by
the same methods as those of Examples 12, 13, 14 and 18.
46TABLE 46 Ex. Structural formula MS M.p. NMR 122 430[9-(10H-
pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl-11- hydroxy-9-
azabicyclo[5.3.1]und ec-11-yl]acetic acid FAB(+) 441 (MH.sup.+)
217-218.degree. C. (dec) .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.10-1.25(m, 2H), 1.50-1.65(m, 4H), 1.77-1.93(m, 4H), 1.97- #
2.09(m, 2H), 2.23-2.32(m, 2H), 2.70-2.77(m, 2H), 2.79(s, 2H),
3.23(s, 2H), 6.45(d, J=1.6Hz, 1H), 6.74(s, 1H), 6.79(d, J=7.8Hz,
1H), 6.85(dd, J=1.6, 7.8Hz, 1H), 7.27(d, J=3.1Hz, 1H), 7.59(d,
J=3.1Hz, 1H), 8.85-9.04(br.s, 1H)
EXAMPLE 123
[1767] The following compound was obtained by treating
ethyl(3-benzyl-7-methyl-3,7-diazabicyclo[3.3.1]non-9-ylidene)acetate
by the same methods as those of Examples 64 and 18.
47TABLE 47 Ex. Structural formula MS M.p. NMR 123 431[3-(10H-
pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl)-7- methyl-3,7-
diazabicyclo[3.3.1]non-9-yl]acetic acid FAB(+) 412 (MH.sup.+)
220.degree. C. (dec) .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
2.00-2.04(m, 2H), 2.13-2.20 and 2.24-2.30(m, # 1H)(3:7)), 2.35 and
2.37(d, J=8.5Hz, 2H(7:3)), 2.80 and 2.82(s, 3H(7:3)), 2.50-2.56 and
2.73-2.79(m, 2H(3:7)), 2.89-2.95 and 3.18-3.23(m, 2H(7:3)),
3.16-3.21 and 3.28-3.48(m, 2H(7:3)), 3.35-3.41 and 3.55-3.60(m,
2H(3:7)), 3.47 and 3.49(s, 2H(3:7)), 6.59-6.62(m, 1H), 6.78- #
6.82(m, 1H), 6.87(d, J=7.9Hz, 1H), 7.58(d, J=3.0Hz, 1H), 7.59(d,
J=3.0Hz, 1H)
PRODUCTION EXAMPLE 84
(anti)-3-(Vinyloxycarbonyl)
-9-aminomethyl-3-azabicyclo[3.3.1]nonane
[1768] 432
[1769] To 10 ml of benzene were added 500 mg of
(anti)-[3-(vinyloxycarbony- l)-3-azabicyclo[3.3.1]non-9-yl]acetic
acid, 0.31 ml of triethylamine and 0.45 ml of diphenylphosphoryl
azide and the resulting mixture was stirred at 80.degree. C. for 3
hours. After concentrating the reaction mixture, a colorless oily
substance was obtained. This oily substance was dissolved in 10 ml
of tetrahydrofuran and 5.0 ml of 1 N sodium hydroxide was added
thereto. After stirring at room temperature for 30 minutes, water
was added to the reaction mixture followed by the extraction with
chloroform. Then it was dried over anhydrous sodium sulfate and
concentrated under reduced pressure. The obtained residue was
purified by silica gel column chromatography (eluted with methylene
chloride/methanol/conc. aqueous ammonia) to thereby give 342 mg of
the title compound as a colorless oily substance.
[1770] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1771] 1.46(m, 1H), 1.57-1.95(m, 10H), 2.91(d, J=7.5 Hz, 2H),
3.11(m, 1H), 3.18(m, H), 4.18-4.28(m, 2H), 4.45(dd, J=1.5, 6.2 Hz,
1H), 4.79(dd, J=1.5, 13.9 Hz, 1H), 7.25(dd, J=6.2, 13.9 Hz, 1H)
PRODUCTION EXAMPLE 85
N-[(anti)-3-(Vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]methyl-N',N'-d- imethylsulfamide
[1772] 433
[1773] 342 mg of (anti)-3-(vinyloxycarbonyl)-9-aminomethyl
-3-azabicyclo[3.3.1]nonane was dissolved in 10 ml of methylene
chloride. After adding 0.25 ml of triethylamine, the resulting
mixture was ice-cooled. Then 0.2 ml of dimethylsulfamoyl chloride
was dropped thereinto and the mixture was stirred at room
temperature for 14 hours. After further adding 0.25 ml of
triethylamine and 0.2 ml of dimethylsulfamoyl chloride, the
reaction mixture was stirred at room temperature for additional 4
hours. Then the reaction mixture was concentrated and the residue
was purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 406 mg of the title
compound as a colorless oily substance.
[1774] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1775] 1.46-1.89(m, 9H), 2.83(s, 6H), 3.10(m, 1H), 3.18(m, 1H),
3.23-3.30(m, 2H), 4.05(br.s, 1H), 4.20-4.29(m, 2H), 4.46(dd, J=1.6,
6.2 Hz, 1H), 4.79(dd, J=1.6, 14.1 Hz, 1H), 7.24(dd, J=6.2, 14.1 Hz,
1H)
PRODUCTION EXAMPLE 86
(anti)-1-(3-Methyl-3-azabicyclo[3.3.1]non-9-yl)-2-methyl-2-propanol
[1776] 434
[1777] To 5 ml of ether was added 13 ml of a solution of
methylmagnesium iodide in ether (ca 2M). Next, 10 ml of a solution
of 2.25 g of ethyl(anti)
-(3-methyl-3-azabicyclo-[3.3.1]non-9-yl)acetate in ether was
dropped at room temperature thereinto and the resulting mixture was
heated under reflux for 2 hours. After adding a saturated aqueous
solution of ammonium chloride, the reaction mixture was extracted
with ether. The ether layer was washed with water and saturated
aqueous solution of sodium chloride, dried over anhydrous sodium
sulfate and concentrated under reduced pressure. The obtained
residue was purified by alumina chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 1.01 g of the title
compound as a colorless oily substance.
[1778] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1779] 1.18(s, 1H), 1.24(s, 6H), 1.39(m, 1H), 1.48-1.66(m, 7H),
1.72-1.84(m, 2H), 2.13(s, 3H), 2.18-2.27(m, 2H) 2.42(m, 1H),
2.85-2.94(m, 2H)
PRODUCTION EXAMPLE 87
(anti)-1-(3-Azabicyclo[3.3.1]non-9-yl)-2-methyl-2-propanol
hydrochloride
[1780] 435
[1781] To 0.91 g of
(anti)-1-[3-methyl-3-azabicyclo[3.3.1]-non-9-yl]-2-met-
hyl-2-propanol was added 0.7 ml of 1-chloroethyl chloroformate and
the resulting mixture was stirred at room temperature for 30
minutes and then heated to 60.degree. C. for 1 hour. After
concentrating the reaction mixture under reduced pressure, 10 ml of
ethanol was added to the residue and the mixture was heated at
60.degree. C. for 1 hour. The reaction mixture was concentrated
under reduced pressure and the crystals thus obtained were washed
with ethyl acetate to thereby give 740 mg of the title compound as
a slightly yellow powder.
[1782] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm;
[1783] 1.17(s, 6H), 1.45-1.60(m, 6H), 1.70-1.92(m, 6H),
3.08-3.19(m, 2H), 3.21-3.28(m, 2H), 4.18(br.s, 1H)
PRODUCTION EXAMPLE 88
Ethyl(anti)-2-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl)-2-methyl- propionate
[1784] 436
[1785] To 40 ml of dry tetrahydrofuran was added 9.04 ml of
diisopropylamine and the resulting mixture was cooled to
-60.degree. C. Then 40.3 ml of a 1.6 M solution of n-butyllithium
in hexane was added thereto and the resulting mixture was stirred
for 50 minutes. After dropping 10 ml of a solution of 3.08 g of
ethyl(anti)-2-(3-methyl-azabicy- clo[3.3.1]non-9-yl)propionate in
tetrahydrofuran, the resulting mixture was stirred at 0.degree. C.
for 30 minutes. After cooling the mixture to -60.degree. C. again,
4.02 ml of methyl iodide was dropped thereinto and the reaction
mixture was stirred at room temperature for 3 days. After adding
ice/water, the reaction mixture was extracted with ethyl acetate.
Then the ethyl acetate layer was washed with water and a saturated
aqueous solution of sodium chloride, dried over anhydrous sodium
sulfate and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 2.82 g of a pale yellow
oily substance.
[1786] This oily substance was dissolved in 10 ml of
1,2-dichloroethane and 1.5 ml of vinyl chloroformate was added
thereto. The obtained mixture was stirred at room temperature for
35 minutes and then heated under reflux for 9.5 hours. The reaction
mixture was concentrated under reduced pressure and ice/water was
added thereto followed by the extraction with ethyl acetate. The
ethyl acetate layer was washed with 1 N hydrochloric acid, water, a
saturated aqueous solution of sodium hydrogencarbonate and a
saturated aqueous solution of sodium chloride, dried over anhydrous
sodium sulfate and concentrated under reduced pressure. The residue
was purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 1.03 g of the title
compound as a slightly yellow oily substance.
[1787] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1788] 1.26(t, J=7.1 Hz, 3H), 1.31(s, 6H), 1.45(m, 1H),
1.56-2.06(m, 8H), 3.12(m, 1H), 3.20(m, 1H), 4.10-4.20(m, 4H),
4.44(dd, J=1.6, 6.2 Hz, 1H), 4.78(dd, J=1.6, 14.1 Hz, 1H), 7.24(dd,
J=6.2, 14.1 Hz, 1H)
PRODUCTION EXAMPLE 89
Ethyl(anti)-2-(3-Azabicyclo[3.3.1]non-9-yl)-2-methylpropionate
[1789] 437
[1790] To 1.03 g of ethyl(anti)-2-[3-(vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]-2-methylpropionate was added 5 ml of
4 N hydrogenchloride in dioxane and,the resulting mixture was
stirred at room temperature for 30 minutes. The reaction mixture
was concentrated under reduced pressure and 20 ml of ethanol was
added to the residue. Then the resulting mixture was heated under
reflux for 25 minutes. After concentrating the reaction mixture
under reduced pressure, water and potassium carbonate were added to
the residue followed by the extraction with methylene chloride.
Next, it was dried over anhydrous sodium sulfate and concentrated
under reduced pressure to thereby give 802 mg of the title compound
as a slightly yellow oily substance.
[1791] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1792] 1.26(t, J=7.1 Hz, 3H), 1.28(s, 6H), 1.54-1.65(m, 3H),
1.76-2.22(m, 7H), 2.98-3.16(m, 4H), 4.11(q, J=7.1 Hz, 2H)
PRODUCTION EXAMPLE 90
(anti)-2-(3-Azabicyclo[3.3.1]non-9-yl)-2-methyl-1-propanol
[1793] 438
[1794] 250 mg of lithium aluminum hydride was suspended in
tetrahydrofuran (30 ml) and ice-cooled. Into this suspension was
dropped a solution of 802 mg of
ethyl(anti)-2-(3-azabicyclo[3.3.1]non-9-yl)-2-methylpropionate in
tetrahydrofuran (10 ml) and the resulting mixture was stirred for
30 minutes. By successively adding 0.25 ml of water, 0.25 ml of 15%
sodium hydroxide and 0.75 ml of water, the excessive reagent was
decomposed. After further adding anhydrous sodium sulfate and
celite, the reaction mixture was stirred at room temperature. Then
the reaction mixture was filtered and concentrated to thereby give
757 mg of the title compound as a slightly yellow oily
substance.
[1795] .sup.1H-NMR(CDCl.sup.3) .delta. ppm;
[1796] 1.01(s, 6H), 1.59-1.71(m, 4H), 1.82-2.06(m, 6H), 2.14(m,
1H), 3.01-3.07(m, 2H), 3.09-3.14(m, 2H), 3.42(s, 2H)
PRODUCTION EXAMPLE 91
(anti)-2-(3-Azabicyclo[3.3.1]non-9-yl)-1-propanol
[1797] 439
[1798] The title compound was obtained as a colorless oily
substance from
ethyl(anti)-2-(3-azabicyclo[3.3.1]non-9-yl)propionate by the same
methods as those of Example 12 and Production Examples 89 and
90.
[1799] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1800] 0.97(d, J=6.8 Hz, 3H), 1.36(m, 1H), 1.54-2.26(m, 11H),
2.95-3.03(m, 2H), 3.16(m, 2H), 3.46(dd, J=6.4, 10.6 Hz, 1H),
3.71(dd, J=3.3, 10.6 Hz, 1H)
PRODUCTION EXAMPLE 92
(syn)-2-(3-Azabicyclo[3.3.1]non-9-yl)ethanol
[1801] 440
[1802] The title compound was obtained as a colorless oily
substance from ethyl(syn)-(3-azabicyclo[3.3.1]non-9-yl)acetate by
the same method as the one of Production Example 90.
[1803] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1804] 01.50(br.s, 2H), 1.62-1.94(m, 9H), 2.19(m, 1H), 2.78-2.86(m,
2H), 3.18-3.25(m, 2H), 3.70(t, J=6.8 Hz, 2H), 3.75(m, 1H)
PRODUCTION EXAMPLE 93
[1805] 3-Methyl-9-methoxymethylene -3-azabicyclo[3.3.1]nonane
441
[1806] 3.67 ml of methoxytrimethylsilane was dissolved in 30 ml of
tetrahydrofuran and cooled to -60.degree. C. Next, 18.1 ml of a 1.3
M solution of sec-butyllithium in cyclohexane was dropped thereinto
while maintaining the bulk temperature at -50.degree. C. or below.
After the completion of the dropping, the resulting mixture was
stirred at -25 to -30.degree. C. for 30 minutes. Then it was cooled
to -35.degree. C. and a solution of 3.0 g of
3-methyl-3-azabicyclo[3.3.1]nonan-9-one in tetrahydrofuran (10 ml)
was dropped thereinto while maintaining the bulk temperature at
-25.degree. C. or below. Subsequently, the reaction mixture was
slowly heated to room temperature. After stirring for 6 hours, a
saturated aqueous solution of ammonium chloride was added to the
reaction mixture followed by the extraction with ethyl acetate. The
ethyl acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous magnesium sulfate
and concentrated under reduced pressure. Thus 4.96 g of a pale
yellow oily substance was obtained.
[1807] 3.91 g of this oily substance was dissolved in
tetrahydrofuran (50 ml). After adding 3.01 g of 35% potassium
hydride, the resulting mixture was stirred at 60.degree. C. for 30
minutes. Then a saturated aqueous solution of ammonium chloride was
added to the reaction mixture followed by the extraction with ethyl
acetate. The ethyl acetate layer was washed with water and a
saturated aqueous solution of sodium chloride, dried over anhydrous
sodium sulfate and concentrated under reduced pressure. Then the
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 1.14 g of the title
compound as a colorless oily substance.
[1808] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1809] 1.46(m, 1H), 1.54-1.74(m, 3H), 1.79-1.91(m, 2H),
2.06-2.21(br.m, 5H), 2.58(m, 1H), 2.82-2.95(m, 3H), 3.54(s, 3H),
5.80(s, 1H)
PRODUCTION EXAMPLE 94
[(anti)-(3-Methyl-3-azabicyclo[3.3.1]non-9-yl)methyl]acetate
[1810] 442
[1811] To 1.14 g of
3-methyl-9-methoxymethylene-3-azabicyclo[3.3.1]nonane were added 10
ml of 1 N hydrochloric acid and 20 ml of methanol and the resulting
mixture was stirred at room temperature for 2 hours. After adding 5
ml of conc. hydrochloric acid, the resulting mixture was stirred
for additional 16 hours. After adding an aqueous solution of
potassium carbonate, the reaction mixture was extracted with ethyl
acetate. The ethyl acetate layer was washed with water and a
saturated aqueous solution of sodium chloride, dried over anhydrous
sodium sulfate and concentrated under reduced pressure. The residue
was purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 450 mg of a colorless oily
substance.
[1812] 150 mg of lithium aluminum hydride was suspended in
tetrahydrofuran (10 ml) and ice-cooled. Then 450 mg of the
above-mentioned oily substance dissolved in tetrahydrofuran (5 ml)
was dropped thereinto and the resulting mixture was stirred for 2
hours. Next, 0.15 ml of water, 0.15 ml of 15% sodium hydroxide and
0.45 ml of water were successively added thereto to thereby
decompose the excessive reagent. After further adding anhydrous
sodium sulfate and celite, the reaction mixture was stirred at room
temperature. Then the reaction mixture was filtered and
concentrated to thereby give 500 mg of a colorless oily
substance.
[1813] 500 mg of this oily substance was dissolved in methylene
chloride (10 ml) and 0.5 ml of triethylamine, 0.34 ml of acetic
anhydride and a catalytic amount of 4-dimethylaminopyridine were
added thereto. The obtained mixture was stirred at room temperature
for 2 hours. Then the reaction mixture was concentrated and a
saturated aqueous solution of sodium hydrogencarbonate was added
thereto followed by the extraction with ethyl acetate. The ethyl
acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous sodium sulfate
and concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 149 mg of the title compound as a
colorless oily substance.
[1814] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1815] 1.42(m, 1H), 1.51-1.61(m, 2H), 1.65-1.79(m, 5H), 2.06(s,
3H), 2.10-2.21(m, 5H), 2.44(m, 1H), 2.88-2.95(m, 2H), 4.23(d, J=7.3
Hz, 2H)
PRODUCTION EXAMPLE 95
[(anti)-[3-(Vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]methyl]acetate
[1816] 443
[1817] 168 mg of
[(anti)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)methyl]acet- ate was
dissolved in 1,2-dichloroethane (5 ml). After adding 1 ml of vinyl
chloroformate, the resulting mixture was stirred at room
temperature for 35 minutes and then heated under reflux for 5
hours. Then the reaction mixture was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
101 mg of the title compound as a white solid.
[1818] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1819] 1.49(m, 1H), 1.60-1.90(m, 7H), 2.00(m, 1H), 2.08(s, 3H),
3.11(m, 1H), 3.19(m, 1H), 4.18-4.30(m, 4H), 4.46(dd, J=1.5, 6.2 Hz,
1H), 4.79(dd, J=1.5, 14.1 Hz, 1H), 7.25(dd, J=6.2, 14.1 Hz, 1H)
PRODUCTION EXAMPLE 96
(anti)-3-(Vinyloxycarbonyl)
-3-azabicyclo[3.3.1]non-9-yl]methanol
[1820] 444
[1821] 101 mg of
[(anti)-[3-(vinyloxycarbonyl)-3-azabicyclo-[3.3.1]non-9-y-
l]methyl]acetate was dissolved in methanol (3 ml). After adding 1
ml of 1 N sodium hydroxide, the resulting mixture was stirred at
room temperature for 1 hour. Then the reaction mixture was
concentrated under reduced pressure and, after adding water,
extracted with ethyl acetate. The ethyl acetate layer was washed
with a saturated aqueous solution of sodium chloride, dried over
anhydrous sodium sulfate and concentrated under reduced pressure to
thereby give 91 mg of the title compound as a colorless oily
substance.
[1822] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1823] 1.36-1.96(m, 10H), 3.12(m, 1H), 3.19(m, 1H), 3.83(d, J=7.5
Hz, 2H), 4.19-4.27(m, 2H), 4.45(dd, J=1.5, 6.2 Hz, 1H), 4.79(dd,
J=1.5, 13.9 Hz, 1H), 7.25(dd, J=6.2, 13.9 Hz, 1H)
PRODUCTION EXAMPLE 97
(anti)-3-(Vinyloxycarbonyl) -3-azabicyclo[3.3.1]nonan-9-ol and
(syn)-3-(vinyloxycarbonyl) -3-azabicyclo[3.3.1]nonan-9-ol
[1824] The title compounds were obtained from (3-methyl
-3-azabicyclo[3.3.1]non-9-yl)acetate by the same methods as those
of Production Examples 95 and 96. 445
[1825] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1826] 1.46(m, 1H), 1.57-1.77(m, 4H), 1.84-1.92(m, 2H),
1.97-2.12(m, 2H), 3.14(m, 1H), 3.22(m, 1H), 3.93(t, J=3.5 Hz, 1H),
4.20-4.30(m, 2H), 4.46(dd, J=2.1, 6.2 Hz, 1H), 4.79(dd, J=2.1, 13.9
Hz, 1H), 7.23(dd, J=6.2, 13.9 Hz, 1H) 446
[1827] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1828] 1.42(m, 1H), 1.56-1.75(m, 4H), 1.80-1.99(m, 4H), 3.44(m,
1H), 3.53(m, 1H), 3.83(t, J=3.5 Hz, 1H), 3.88-3.98(m, 2H), 4.44(dd,
J-1.5, 6.3 Hz, 1H), 4.78(dd, J=1.5, 13.9 Hz, 1H), 7.25(dd, J=6.3,
13.9 Hz, 1H)
EXAMPLE 124
(anti)-2-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo-
[3.3.1]non-9-yl]ethanol
[1829] 447
[1830] To 348 mg of (anti)-2-[3-(vinyloxycarbonyl)
-3-azabicyclo-[3.3.1]no- n-9-yl]ethanol was added 5 ml of 4 N
hydrogen chloride in dioxane and the resulting mixture was stirred
at room temperature for 1 hour. Then it was concentrated under
reduced pressure and 20 ml of methanol was added to the residue.
After heating under reflux for 1 hour, the reaction mixture was
concentrated under reduced pressure to thereby give crude
(anti)-2-(3-azabicyclo[3.3.1]non-9-yl)ethanol hydrochloride as a
white solid. Next, 5 ml of N,N-dimethylformamide was added thereto.
After further adding 374 mg of
8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothia- zine and 622 mg
of anhydrous potassium carbonate, the resulting mixture was stirred
at 80.degree. C. for 4 hours. Then ice/water was added to the
reaction mixture followed by the extraction with ethyl acetate. The
ethyl acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous magnesium sulfate
and concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluted with methylene
chloride/methanol) to thereby give 341 mg of the title compound as
a dark yellow powder.
[1831] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1832] 1.33(m, 1H), 1.44-1.85(m, 10H), 2.18-2.26(m, 2H), 2.55(m,
1H), 2.89-2.95(m, 2H), 3.22(s, 2H), 3.69(q, J=6.8 Hz, 2H),
6.52(br.s 2H), 6.78(dd, J=1.5, 7.9 Hz, 1H), 6.83(d, J=7.9 Hz, 1H),
7.57(d, J=2.9 Hz, 1H), 7.69(d, J=2.9 Hz, 1H)
[1833] MS: FAB(+)383(MH.sup.+)
[1834] m.p.: 123-127.degree. C.
EXAMPLES 125 to 128
[1835] The following compounds were obtained by the same method as
the one of Example 124.
48TABLE 48 Ex. Structural formula MS M.p. NMR 125
448(anti)-[3-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-3- azabicyclo[3.3.1]non -9-yl]methyl-N',N'-
dimethylsulfamide FAB(+) 475 (MH.sup.+) 215-219.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.45-1.79(m, 8H), 2.16- #
2.23(m, 2H), 2.56(m, 1H), 2.82(s, 6H), 2.92-2.99(m, 2H),
3.19-3.26(m, 4H), 4.16(m, 1H), 6.51(d, J=1.5Hz, 1H), 6.57(br.s,
1H), 6.77(dd, J=1.5, 8.1Hz, 1H), 6.83(d, J=8.1Hz, 1H), 7.56(d,
J=2.9Hz, 1H), 7.69(d, J=2.9Hz, 1H) 126 449(anti)-3-(10H-
pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]non an-9-ol FAB(+) 355 (MH.sup.+) 215-219.degree.
C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.30-1.41(m, 3H),
1.60-1.66(m, 2H), 1.90-2.03(m, 2H), 2.13- # 2.20(m, 2H), 2.52(m,
1H), 2.79-2.88(m, 2H), 3.15(s, 2H), 3.53(m, 1H), 4.62(d, J=2.9Hz,
1H), 6.70(dd, J=1.3, 7.9Hz, 1H), 6.73(d, J=1.3Hz, 1H), 6.84(d,
J=7.9Hz, 1H), 7.63(d, J=2.9Hz, 1H), 7.64(d, J=2.9Hz, 1H), 9.56(s,
1H) 127 450(syn)-3-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-3- azabicyclo[3.3.1]non an-9-ol FAB(+) 355 (MH.sup.+)
189-192.degree. C. .sup.1NMR (DMSO-d.sub.6) .delta. ppm: 1.34(m,
1H), 1.52-1.68(m, 4H), 1.72-1.80(m, 2H), 2.43- # 2.62(m, 5H),
3.14(s, 2H), 3.49(m, 1H), 4.57(d, J=2.6Hz, 1H), 6.69(dd, J=1.3,
7.9Hz, 1H), 6.73(d, J=1.3Hz, 1H), 6.83(d, J=7.9Hz, 1H), 7.63(d,
J=2.9Hz, 1H), 7.64(d, J=2.9Hz, 1H), 9.55(s, 1H) 128
451(anti)-2-[3-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-3- azabicyclo[3.3.1]non -9-yl]methanol FAB(+) 368
(MH.sup.+) 233-236.degree. C. .sup.1NMR(DMSO-d.sub.6) .delta. ppm:
1.36-1.58(m, 4H), 1.60-1.75(m, 4H), 2.08- # 2.16(m, 2H), 2.56(m,
1H), 2.35-2.42(m, 2H), 3.18(s, 2H), 3.52(dd, J=5.7, 7.3Hz, 2H),
4.37(t, J=5.7Hz, 1H), 6.71(dd, J=1.5, 7.9Hz, 1H), 6.74(d, J=1.5Hz,
1H), 6.85(d, J=7.9Hz, 1H), 7.63(d, J=2.9Hz, 1H), 7.64(d, J=2.9Hz,
1H), 9.57(s, 1H)
EXAMPLE 129
(anti)-(6R*,8R*)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-6,8--
dimethyl-3-azabicyclo[3.3.1]non-9-yl]ethanol
[1836] 452
[1837] To a solution of 2.0 g of
(anti)-(6R*,8R*)-[3-(10H-pyrazino[2,3-b][-
1,4]benzothiazin-8-ylmethyl)-6,8-dimethyl-3-azabicyclo[3.3.1]non-9-yl]acet-
ate in tetrahydrofuran were added 0.08 ml of triethylamine and 0.05
ml of ethyl chloroformate and the resulting mixture was stirred at
room temperature for 30 minutes. After adding an aqueous solution
of 0.05 g of sodium borohydride, the reaction mixture was stirred
at room temperature for 30 minutes. Then the reaction mixture was
washed with water and the organic layer was dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with methylene chloride/methanol) to thereby
give 0.16 g of the title compound as a yellow amorphous
substance.
[1838] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1839] 100(d, J=7.2 Hz, 6H), 1.37-1.80(m, 10H), 1.97(d, J=8.0 Hz,
2H), 2.59(d, J=8.0 Hz, 2H), 3.26(s, 2H), 3.60-3.70(m, 2H),
6.38(br.s, 1H), 6.52(s, 1H), 6.77;(d, J=8.0 Hz, 1H), 6.82(d, J=8.0
Hz, 1H), 7.56(d, J=2.8 Hz, 1H), 7.68(d, J=2.8 Hz, 1H)
[1840] MS: FAB(+)411(MH.sup.+)
EXAMPLE 130
(anti)-1-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo-
[3.3.1]non-9-yl]-2-methyl-2-propanol
[1841] 453
[1842] To 10 ml of N,N-dimethylformamide were added 790 mg of
8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine, 740 mg of
(anti)-1-(3-azabicyclo[3.3.1]non-9-yl)-2-methyl-2-propanol
hydrochloride and 1.31 g of anhydrous potassium carbonate and the
resulting mixture was stirred at 80.degree. C. for 3.5 hours. After
adding ice/water, the reaction mixture was extracted with ethyl
acetate. The ethyl acetate layer was washed with water and a
saturated aqueous solution of sodium chloride, dried over anhydrous
sodium sulfate and concentrated under reduced pressure. Then the
residue was purified by silica gel column chromatography (eluted
with toluene/ethyl acetate) to thereby give 568 mg of the title
compound as a yellow powder.
[1843] .sup.1H-NMR(CDCl.sub.3) .delta. ppm;
[1844] 1.24(s, 6H), 1.38-1.56(m, 3H), 1.58-1.70(m, 6H),
1.74-1.86(m, 2H), 2.24-2.30(m, 2H), 2.55(m, 1H), 2.87-2.94(m, 2H),
3.22(s, 2H), 6.52(d, J=1.5 Hz, 1H), 6.59(br.s, 1H), 6.78(dd, J=1.5,
7.9 Hz, 1H), 6.83(d, J=7.9 Hz, 1H), 7.56(d, J=2.9 Hz, 1H), 7.69(d,
J=2.9 Hz, 1H)
[1845] MS: FAB(+)411(MH.sup.+)
[1846] m.p.: 182-185.degree. C.
EXAMPLES 131 to 133
[1847] The following compounds were obtained by the same method as
the one of Example 130.
49TABLE 49 Ex. Structural formula MS M.p. NMR 131
454(anti)-2-[3-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-3- azabicyclo[3.3.1]non -9-yl]-2-methyl-1- propanol
FAB(+) 411 (MH.sup.+) 181-183.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 0.91(s, 6H), 1.34-1.54(m, # 4H), 1.80-1.94(m, 4H),
2.12-2.20(m, 2H), 2.60(m, 1H), 2.79-2.86(m, 2H), 3.16(m, 4H),
4.49(t, J=5.1Hz, 1H), 6.70(dd, J=1.5, 7.9Hz, 1H), 6.73(d, J=1.5Hz,
1H), 6.84(d, J=7.9Hz, 1H), 7.63(d, J=2.7Hz, 1H), 7.64(d, J=2.7Hz,
1H), 9.56(s, 1H) 132 455(anti)-2-[3-(10H- pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl)-3- azabicyclo[3.3.1]non
-9-yl]-1-propanol FAB(+) 397 (MH.sup.+) 88-92.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.97(d, J=6.8Hz, 3H), 1.19(m,
1H), 1.35(t, # J=5.4Hz, 1H), 1.43-1.55(m, 3H), 1.66-1.84(m, 4H),
1.97(m, 1H), 2.13-2.22(m, 2H), 2.56(m, 1H), 2.88-2.99(m, 2H),
3.21(s, 2H), 3.48(m, 1H), 3.52(m, 1H), 6.52(br.2, 1H), 6.60(br.s,
1H), 6.78(dd, J=1.5, 7.9Hz, 1H), 6.83(d, J=7.9Hz, 1H), 7.56(d,
J=2.7Hz, 1H), # 7.69(d, J=2.7Hz, 1H) 133 456(syn-2-[3-(10H-
pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.1]non -9-yl]ethanol FAB(+) 368 (MH.sup.+)
171-173.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.40(br.t,
J=4.9Hz, 1H), 1.49-1.75(m, 8H), 1.76- # 1.86(m, 2H), 2.38-2.46(m,
2H), 2.55-2.69(m, 3H), 3.21(s, 2H), 3.68(q, J=6.8Hz, 2H),
6.50(br.s, 1H), 6.59(br.s, 1H), 6.77(br.d, J=7.7Hz, 1H), 7.82(d,
J=7.7Hz, 1H), 7.57(d, J=2.9Hz, 1H), 7.69(d, J=2.9Hz, 1H)
PRODUCTION EXAMPLE 98
4-[(3-Chloropyrazin-2-yl)thio]-3-nitrobenzyl alcohol
[1848] 1.876 g of 4-chloro-3-nitrobenzyl alcohol was dissolved in
20 ml of dimethyl sulfoxide. After adding 820 mg of anhydrous
sodium sulfide, the resulting mixture was stirred at room
temperature for 15 hours. After adding 1.19 g of
2,3-dichloropyrazine thereto, the reaction mixture was stirred at
100.degree. C. for 1 hour. After adding ice/water, the reaction
mixture was extracted with ethyl acetate, washed successively with
water, 1 N hydrochloric acid, water, 1 N sodium hydroxide, and a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
-chromatography (eluted with ethyl acetate/n-hexane) to thereby
give 1.60 g of the title compound as yellow crystals. 457
[1849] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1850] 4.46(d, J=5.9 Hz, 2H), 5.61(t, J=5.9 Hz, 1H), 7.70(dd,
J=1.8, 8.1 Hz, 1H), 7.76(d, J=8.1 Hz, 1H), 8.09(d, J=1.8 Hz, 1H),
8.33(d, J=2.6 Hz, 1H), 8.41(d, J=2.6 Hz, 1H)
[1851] m.p. 110-113.degree. C.
PRODUCTION EXAMPLE 99
3-Amino-4-[(3-chloropyrazin-2-yl)thio]benzyl alcohol
[1852] 1.60 g of 4-[(3-chloropyrazin-2-yl)thio]-3-nitrobenzyl
alcohol was dissolved in a solvent mixture of tetrahydrofuran (20
ml)/2-propanol (20 ml)/water (7 ml). After adding 0.16 g of
ammonium chloride and 1.50 g of iron powder, the resulting mixture
was heated under reflux for 30 minutes. Then the reaction mixture
was filtered through celite and concentrated under reduced
pressure. After adding ethanol, the reaction mixture was
concentrated under reduced pressure. Then tetrahydrofuran was added
to the residue and the insoluble matters were separated by
filtration. After distilling off the solvent under reduced
pressure, 1.47 g of the title compound was obtained as yellow
crystals. 458
[1853] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1854] 4.41(d, J=5.9 Hz, 2H), 5.16(t, J=5.9 Hz, 1H), 5.38(br.s,
2H), 6.51(dd, J=1.8, 7.9 Hz, 1H), 6.77(d, J=1.8 Hz, 1H), 7.18(d,
J=7.9 Hz, 1H), 8.17(d, J=2.6 Hz, 1H), 8.34(d, J=2.6 Hz, 1H)
[1855] m.p.: 148-150.degree. C. (decompose)
PRODUCTION EXAMPLE 100
Methyl 3-amino-4-(4-cyanopyridin-3-yl)thiobenzoate
[1856] To a solution of 34.8 g of methyl 3-amino-4-mercaptobenzoate
in degassed dimethylformamide (150 ml) was added 11.7 g of sodium
hydride at 10.degree. C. or below in a nitrogen atmosphere. After
stirring for 20 minutes, 16.86 g of 3-chloro-4-cyanopyridine was
added thereto and the resulting mixture was stirred for additional
20 minutes. After adding ethyl acetate, the mixture was washed with
water and the aqueous layer was extracted with ethyl acetate. The
organic layers were combined, washed with water and a saturated
aqueous solution of sodium chloride, dried over anhydrous magnesium
sulfate, filtered and concentrated under reduced pressure. The
solid matter precipitated during the above procedure was taken up
by filtration and washed with ether. Thus, 23.1 g of the title
compound was obtained as a yellow solid. 459
[1857] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1858] 3.92(s, 3H), 4.46(br.s, 2H), 7.41(dd, J=2,8 Hz, 1H),
7.46(dd, J=1,5 Hz, 1H), 7.49(d, J=2 Hz, 1H), 7.53(d, J=8 Hz, 1H),
8.20(d, J=1 Hz, 1H), 8.51(d, J=5 Hz, 1H)
PRODUCTION EXAMPLE 101
Methyl 3-amino-4-(1-oxo-4-cyano-3-pyridylthio)benzoate
[1859] To a solution of 9.33 g of methyl 3-amino-4-mercaptobenzoate
in dimethylformamide (50 ml) was added 2.04 g of sodium hydride at
0.degree. C. in a nitrogen atmosphere. After stirring for 30
minutes, a solution of 5.25 g of 3-chloro-4-cyanopyridine oxide in
N,N-dimethylformamide (20 ml) was added thereto and the resulting
mixture was stirred for additional 2 hours. After diluting with
ethyl acetate, the mixture was washed with water, dried over
anhydrous magnesium sulfate, filtered and concentrated under
reduced pressure. The residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.85 g of the title compound as a pale yellow solid. 460
[1860] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1861] 3.83(s, 3H), 6.07(br.s, 2H), 7.14(dd, J=2,8 Hz, 1H), 7.20(d,
J=2 Hz, 1H), 7.48(d, J=2 Hz, 1H), 7.49(d, J=8 Hz, 1H), 7.94(d, J=7
Hz, 1H), 8.16(d, J=2,7 Hz, 1H)
PRODUCTION EXAMPLE 102
4-Chloro-5-nitro-o-anisic acid
[1862] To a solution of 33 g of 4-chloro-o-anisic acid in sulfuric
acid (100 ml) was added 20 g of potassium nitrate under ice-cooling
and the resulting mixture was stirred for 2 hours. The reaction
mixture was added to ice/water and extracted with ethyl acetate and
the organic layer was dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, 41 g of the
title compound was obtained as pale yellow crystals. 461
[1863] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1864] 3.96(s, 3H), 7.49(s, 1H), 8.38(s, 1H)
PRODUCTION EXAMPLE 103
Methyl 4-mercapto-5-nitro-o-anisate
[1865] To a solution of 3.1 g of 4-chloro-5-nitro-o-anisic acid in
methanol (100 ml) was added a catalytic amount of sulfuric acid and
the resulting mixture was heated under reflux for 3 hours. Then the
reaction mixture was poured into ice/water and extracted with ethyl
acetate. The organic layer was washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
3.3 g of methyl 4-chloro-5-nitro-o-anisate was obtained as pale
yellow crystals.
[1866] To a solution of 3.3 g of the crystals obtained above in
methanol (50 ml) was added 3.2 g of sodium hydrogensulfide and the
resulting mixture was heated under reflux for 30 minutes. After
distilling off the solvent under reduced pressure, dilute
hydrochloric acid was added to the residue followed by extraction
with ethyl acetate and the organic layer was then dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, diethyl ether was added to the residue and the
crystals thus precipitated were taken up by filtration. Thus 2.1 g
of the title compound was obtained as yellow crystals. 462
[1867] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1868] 3.91(s, 3H), 4.00(s, 3H), 4.28(s, 1H), 6.89(s, 1H), 8.81(s,
1H) PRODUCTION EXAMPLE 104
Methyl 2-methoxy-4-(2-chloropyrazin-3-yl)thio-5-nitrobenzoate
[1869] To a solution of 6.45 g of methyl 4-mercapto
-5-nitro-o-anisate in N,N-dimethylformamide (100 ml) were added 4.4
g of potassium carbonate and 4.75 g of 2,3-dichloropyrazine. Then
the mixture was allowed to react at 80.degree. C. for 2 hours.
After adding ethyl acetate, the reaction mixture was washed with a
saturated aqueous solution of sodium chloride and the organic layer
was dried over anhydrous magnesium sulfate. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 3.14 g of the title compound as a brown
solid. 463
[1870] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1871] 3.93(s, 3H), 3.94(s, 3H), 7.16(s, 1H), 8.19(d, J=2.4 Hz,
1H), 8.23(d, J=2.4 Hz, 1H), 8.71(s,1H)
PRODUCTION EXAMPLE 105
Methyl 5-amino-6-mercaptonicotinate
[1872] To a solution of 6 g of methyl 6-chloro-5-nitronicotinate in
methanol (100 ml) was added 6.7 g of sodium hydrogensulfide and the
resulting mixture was heated under reflux for 2 hours. After
distilling off the solvent under reduced pressure, dilute
hydrochloric acid was added to the residue followed by extraction
with ethyl acetate. The organic layer was dried over anhydrous
magnesium sulfate and the solvent was distilled off under reduced
pressure. Diisopropyl ether was added to the residue and the
crystals thus precipitated were taken up by filtration to thereby
give 24.7 g of the title compound as yellow crystals. 464
[1873] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1874] 3.78(s, 3H),5.91-6.00(br.s, 2H), 7.12(d, J=2.0 Hz, 1H),
7.53(dd, J=2.0, 6.4 Hz, 1H)
PRODUCTION EXAMPLE 106
Diethyl 4-(methoxymethoxy)cyclohexane-1,1-dicarboxylate
[1875] 12.3 g of diethyl 4-hydroxycyclohexane-1,1-dicarboxylate was
dissolved in 160 ml of dichloromethane and 26.3 ml of
diisopropylethylamine was added thereto followed by ice-cooling.
Next, 9.6 ml of chloromethyl methyl ether was added thereto and the
reaction mixture was stirred at room temperature for 15 hours. Then
the reaction mixture was concentrated and the residue was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 11.10 g of the title compound as a
colorless oily substance. 465
[1876] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1877] 1.24(t, J=7.1 Hz, 3H), 1.26(t, J=7.1 Hz, 3H), 1.51-1.62(m,
2H), 1.81-1.90(m, 4H), 2.25-2.34(m, 2H), 3.36(s, 3H), 3.61(m, 1H),
4.17(q, J=7.1 Hz, 2H), 4.20(q, J=7.1 Hz, 2H), 4.66(s, 2H)
PRODUCTION EXAMPLE 107
4-(Methoxymethoxy)cyclohexane-1,1-dimethanol
[1878] 1.76 g of lithium aluminum hydride was suspended in 90 ml of
tetrahydrofuran and ice-cooled. Then 11.1 g of diethyl
4-(methoxymethoxy)cyclohexane -1,1-dicarboxylate dissolved in 30 ml
of tetrahydrofuran was dropped thereinto. After stirring for 40
minutes, 1.8 ml of water, 1.8 ml of 15% sodium hydroxide and 5.4 ml
of water were successively added thereto so as to decompose the
excessive reagent. After further adding anhydrous sodium sulfate
and celite, the reaction mixture was stirred at room temperature,
filtered and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluted with
dichlorometheane/methanol) to thereby give 6.84 g of the title
compound as a white solid. 466
[1879] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1880] 1.17-1.26(m, 2H), 1.44-1.54(m, 2H), 1.66-1.74(m, 2H),
1.75-1.84(m, 2H), 2.12(br.s, 2H), 3.37(s, 3H), 3.56(s, 2H), 3.59(m,
1H), 3.71(s, 2H), 4.68(s, 2H)
PRODUCTION EXAMPLE 108
4-(Methoxymethoxy)cyclohexane-1,1-dimethyl dimethanesulfonate
[1881] 6.84 g of 4-(methoxymethoxy)cyclohexane-1,1-dimethanol was
dissolved in 110 ml of dichloromethane and 13.56 g of pyridine was
added thereto and ice-cooled. 7.79 ml of methanesulfonyl chloride
was added thereto and the resulting mixture was stirred at room
temperature for 17 hours. Then the reaction mixture was
concentrated and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
11.91 g of the title compound as a colorless oily substance.
467
[1882] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1883] 1.37-1.46(m, 2H), 1.52-1.63(m, 2H), 1.71-1.84(m, 4H),
3.05(s, 6H), 3.37(s, 3H), 3.65(m, 1H), 4.10(s, 2H), 4.17(s, 2H),
4.66(s, 2H)
PRODUCTION EXAMPLE 109
N-Benzyl-cis-1,2,3,6-tetrahydrophthalimide
[1884] 30.2 g of cis-1,2,3,6-tetrahydrophthalimide was dissolved in
200 ml of N,N-dimethylformamide. After adding 38.7 g of potassium
carbonate and 30.4 g of benzyl chloride, the resulting mixture was
stirred at 50.degree. C. for 3 hours and further at room
temperature overnight. Then the reaction mixture was diluted with
ethyl acetate and washed with water. The aqueous layer was
extracted with ethyl acetate. The organic layer was washed
successively with water and a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
filtering, the solvent was distilled off under reduced pressure.
The crude crystals thus obtained were ground and washed with
diisopropyl ether and n-hexane followed by filtration. Thus 39.1 g
of the title compound was obtained as pale yellow crystals. 468
[1885] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1886] 2.16-2.29(m, 2H), 2.55-2.68(m, 2H), 3.04-3.15(m, 2H),
4.63(s, 2H), 5.83-5.92(m, 2H), 7.22-7.33(m, 5H)
PRODUCTION EXAMPLE 110
3-Benzyl-3-azabicyclo[4.3.0]-7-nonene
[1887] 11.6 g of N-benzyl-cis-1,2,3,6-tetrahydrophthalimide was
dissolved in 280 ml of tetrahydrofuran. Then 5.47 g of lithium
aluminum hydride was gradually added thereto under ice-cooling.
After the completion of the addition, the resulting mixture was
stirred at room temperature overnight. Into the reaction mixture
were successively dropped 6 ml of water, 6 ml of a 15% solution of
sodium hydroxide and 13 ml of water under ice-cooling. The
suspended matters thus formed were taken up by filtration and the
mother liquor was dried over anhydrous magnesium sulfate. After
filtration, the solvent was concentrated under reduced pressure and
the residue thus obtained was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
8.33 g of the title compound as a pale yellow oily substance.
469
[1888] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1889] 1.84-1.90(m, 2H), 2.10-2.30(m, 4H), 2.40(br.s, 2H),
2.92-2.98(m, 2H), 3.62(s, 2H), 5.81(m, 2H),7.22-7.40(m, 5H)
PRODUCTION EXAMPLE 111
N-Methyl-2-(pyridin-4-yl)ethanesulfonamide
[1890] To 50 ml of a 40% solution of methylamine in methanol was
added 3.0 g of 2-(pyridin-4-yl)ethanesulfonyl chloride
hydrochloride as such (i.e., as a solid). After stirring for a
while at room temperature, a solution of 2.1 g of sodium
hydrogencarbonate in 15 ml of water was carefully added thereto.
The reaction mixture was concentrated under reduced pressure and
the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol) to thereby give 1.3 g of the
title compound as brownish white scaly crystals. 470
[1891] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1892] 2.80(d, J=6 Hz, 3H), 3.12(m, 2H), 3.31(m, 2H), 4.49(q, J=6
Hz, 1H), 7.18(d, J=6 Hz, 2H), 8.47(d, J=6 Hz, 2H)
PRODUCTION EXAMPLES
[1893] The following compounds were obtained by the same procedure
as the one of Production Example 111.
50 Prodn . Ex. Structural formula NMR 112 471N,N-dimethyl-2-
(pyridin-4- yl)ethanesulfonamide .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.87(s, 6H), 3.09-3.19(m, 4H), 7.16(d, J=6Hz, 2H), 8.55(d,
J=6Hz, 2H) 113 472N,N-(3- oxapentamethylene)-2-
(pyridin-4-yl)ethane- sulfonamide .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.08-3.21(m, 4H), 3.27(t, J=5Hz, 4H), 3.75(t, J=5Hz, 4H),
7.16(d, J=6Hz, 2H), 8.55(d, J=6Hz, 2H)
PRODUCTION EXAMPLE 114
3-[4-(tert-Butoxycarbonyl)piperazino]-3-methoxy-3-cyclobutene
-1,2-dione
[1894] 10.05 g of 1-(tert-butoxycarbonyl)piperazine and 7.67 g of
3,4-dimethoxy-3-cyclobutene-1,2-dione were dissolved in 180 ml of
ethanol and stirred at room temperature for 18 hours. The
precipitate thus formed was taken up by filtration to thereby give
6.92 g of the title compound as white needles. 473
[1895] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1896] 1.48(s, 9H), 3.51-3.57(m, 6H), 3.87(m, 2H), 4.40(s, 3H)
PRODUCTION EXAMPLE 115
4-Amino-3-[4-(tert-butoxycarbonyl)piperazino]-3-cyclobutene
-1,2-dione
[1897] 2.00 g of
3-[4-(tert-butoxycarbonyl)piperazino]-3-methoxy-3-cyclobu- tene
-1,2-dione was dissolved in 25 ml of methanol. After adding 0.43 g
of ammonium chloride, the resulting mixture was stirred at room
temperature for 65 hours. The precipitate thus formed was taken up
by filtration and washed with ethanol to thereby give 1.83 g of the
title compound as a slightly yellow powder. 474
[1898] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1899] 1.42(s, 9H), 3.42(m, 4H), 3.63(m, 4H), 7.73(br.s, 2H)
PRODUCTION EXAMPLES
[1900] The following compounds were obtained by the same procedure
as the one of Production Example 115.
51 Prodn. Ex. Structural formula NMR 116 4753-[4-(tert-
butoxycarbonyl)piperazino ]-4-methylamino-3- cyclobutene-1,2-dione
.sup.1H-NMR(DMSO-D.sub.6) .delta. ppm: 1.41(s, 9H), 3.17(s, 3H),
3.39-3.44(m, 4H), 3.57-3.64(m, 4H), 7.65(m, 1H) 117 4763-[4-(tert-
butoxycarbonyl)piperazino ]-4-dimethylamino-3-
cyclobutene-1,2-dione .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.39(s, 9H), 3.14(s, 6H), 3.39-3.44(m, 4H), 3.52-3.57(m, 4H)
PRODUCTION EXAMPLE 118
(4-Diethylphosphono-3-oxo-2-methylbutan-2-yl) acetate
[1901] Into a solution of 3.04 g of diethyl methylphosphonate in
tetrahydrofuran (20 ml) was dropped a 1.6 M solution (12.5 ml) of
n-buthyllithium in hexane at -70.degree. C. in a nitrogen
atmosphere. After adding 4.00 g of anhydrous cuprous iodide, the
reaction mixture was heated to -35.degree. C. and stirred for 30
minutes. After cooling to -70.degree. C. again, the solution was
added to a solution of 4.93 g of 2-acetoxy-2-methylpropanoyl
chloride in tetrahydrofuran (30 ml) which had been cooled to
-70.degree. C. in a nitrogen atmosphere. Then the internal
temperature was elevated to room temperature and the mixture was
stirred for 15 hours. After adding ethyl acetate, the pH value of
the mixture was regulated to 6 with sodium dihydrogenphosphate. The
insoluble matters were separated by filtration and the organic
layer was dried over anhydrous magnesium sulfate, filtered and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (eluted with dichloromethane/ethyl
acetate) to thereby give 2.61 g of the title compound as a pale
yellow oily substance. 477
[1902] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1903] 1.33(t, J=7 Hz, 6H), 1.52(s, 6H), 2.08(s, 3H), 3.14(d, J=21
Hz, 2H), 4.16(m, 4H)
PRODUCTION EXAMPLE 119
Ethyl[4-(ethoxycabronyl)-1-(nitromethyl)cyclohex -1-yl]acetate
[1904] 1.28 g of anhydrous potassium carbonate was suspended in 9
ml of dimethyl sulfoxide and heated to 90.degree. C. Then 4.43 g of
ethyl [4-(ethoxycarbonyl)cyclohexylidene]acetate and 1.5 ml of
nitromethane dissolved in 5 ml of dimethyl sulfoxide were dropped
thereinto over 2 hours. After heating for 2 hours and 15 minutes,
the reaction mixture was ice-cooled and 3 ml of conc. hydrochloric
acid was dropped thereinto. After adding water, it was extracted
with ethyl acetate. The organic layer was washed successively with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous sodium sulfate. Then it was concentrated under
reduced pressure and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate). Thus 4.72 g of
the title compound was obtained as a slightly yellow oily
substance. 478
[1905] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1906] 1.23-1.30(m, 6H), 1.35-1.45(m, 2H), 1.61-1.76(m, 2H),
1.80-1.93(m, 4H), 2.25-2.38(m, 1H), 2.47 and 2.60(s, total 2H),
4.10-4.19(m, 4H), 4.64 and 4.80(s, total 2H)
EXAMPLE 134
(anti)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid methanesulfonate
[1907] 30.00 g of
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 900 ml
of tetrahydrofuran. After adding dropwise 5.16 ml of
methanesulfonic acid thereinto, the resulting mixture was stirred
at room temperature for 2 hours. The precipitate was cillected by
filtration, washed with tetrahydrofuran and hot-air dried at
80.degree. C. for 6 hours to thereby give 37.7 g of a yellow
powder.
[1908] This powder was dissolved in a mixture of 200 ml of water
with 0.49 ml of methanesulfonic acid and the insoluble matter was
separated by filtration. After concentrating under reduced
pressure, seed crystals were added and the mixture was allowed to
stand at room temperature for 4 days. After adding 50 ml of cold
water, the mixture was well ground and collected by filtration.
Then it was washed with 30 ml of cold water, hot-air dried at
80.degree. C. for 10 hours and ground in an agate mortar to thereby
give 32.30 g of the title compound as a yellow powder. 479
[1909] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1910] 1.65-1.82(m, 4H), 1.87-2.00(m, 2H), 2.07(br.m, 2H), 2.28(m,
1H), 2.57(d, J=7.5 Hz, 2H), 2.73(s, 3H), 3.29-3.37(m, 2H),
3.52-3.60(m, 2H), 4.17(s, 2H), 6.83(br.s, 1H), 6.95(d, J=8.0 Hz,
1H), 6.97(dd, J=1.5, 8.0 Hz, 1H), 7.60(d, J=2.9 Hz, 1H), 7.61(d,
J=2.9 Hz, 1H)
[1911] m.p.: 263-265.degree. C.
EXAMPLE 135
(anti)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid hydrochloride
[1912] 10.00 g of
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 300 ml
of tetrahydrofuran and the insoluble matter was separated by
filtration. After adding 27.8 ml of 1 N hydrochloric acid, the
resulting mixture was allowed to stand at room temperature for 2
hours. The precipitate thus formed was collected by filtration,
washed with tetrahydrofuran and hot-air dried at 80.degree. C. for
3 hours to thereby give 11.19 g of a yellow powder.
[1913] These crystals were added to a mixture of 1.7 l of water
with 25.8 ml of 1 N hydrochloric acid and dissolved therein by
heating. The insoluble matter was separated by filtration. After
adding seed crystals, the mixture was allowed to stand at 4.degree.
C. for 20 hours. The precipitate thus formed was collected by
filtration, washed with cold water and hot-air dried at 80.degree.
C. for 8 hours to thereby give 8.98 g of the title compound as
yellow needles. 480
[1914] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1915] 1.63-2.00(m, 6H), 2.06(br.m, 2H), 2.26(m, 1H), 2.57(d, J=7.7
Hz, 2H), 3.25-3.36(m, 2H), 3.48-3.58(m, 2H), 4.15(s, 2H), 6.83(s,
1H), 6.97(s, 2H), 7.61(s, 2H)
[1916] m.p.: 271-276.degree. C. (decomposes)
EXAMPLE 136
(anti)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid p-toluenesulfonate
[1917] 1.50 g of
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 45 ml
of tetrahydrofuran and 0.721 g of p-toluenesulfonic acid
monohydrate was added thereto. After stirring the resulting mixture
at room temperature for 1.5 hours, the precipitate thus formed was
collected by filtration, washed with tetrahydrofuran and hot-air
dried at 80.degree. C. for 6 hours to thereby give a yellow
powder.
[1918] These crystals were suspended in a solvent mixture of 60 ml
of water with 6 ml of ethanol and allowed to stand at room
temperature overnight. The precipitate thus formed was collected by
filtration, washed with water and hot-air dried at 80.degree. C.
for 10 hours to thereby give 1.70 g of the title compound as yellow
needles. 481
[1919] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1920] 1.42-1.78(m, 4H), 1.85-1.96(m, 2H), 2.05 (br.m, 2H), 2.25(m,
1H), 2.36(s, 3H), 2.56(d, J=7.5 Hz, 2H), 3.27-3.35(m, 2H),
3.50-3.58(m, 2H), 4.16(s, 2H), 6.82(s, 1H), 6.95(s, 2H),
7.21-7.25(m, 2H), 7.60(d, J=2.9 Hz, 1H), 7.61(d, J=2.9 Hz, 1H),
7.69-7.73(m, 2H)
[1921] m.p.: 265-268.degree. C.
EXAMPLE 137
(anti)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]nonan-9-yl]acetic acid
hemil,2-ethanedisulfonate
[1922] 1.00 g of
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 30 ml
of tetrahydrofuran and 0.571 g of 1,2-ethanedisulfonic acid
dihydrate and 60 ml of ethanol were added thereto. After stirring
the resulting mixture at room temperature for 4 hours, the
precipitate thus formed was collected by filtration, washed with
ethanol, and hot-air dried at 80.degree. C. for 6 hours to thereby
give 1.419 g of a yellow powder.
[1923] 2.815 g of these crystals were suspended in 90 ml of water
and allowed to stand at room temperature overnight. The precipitate
thus formed was collected by filtration, washed with water and
hot-air dried at 80.degree. C. for 10 hours to thereby give 2.202 g
of the title compound as yellow needles. 482
[1924] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1925] 1.50-1.64(m, 3H), 1.66-1.80(m, 3H), 1.95(br.m, 2H), 2.21(m,
1H), 2.45(d, J=7.5 Hz, 2H), 2.65(s, 2H), 3.22-3.31(m, 2H),
3.35-3.45(m, 2H), 4.13(s, 2H), 6.87(s, 1H), 7.01(s, 2H), 7.67(d,
J=2.7 Hz, 1H), 7.68(d, J=2.7 Hz, 1H)
[1926] m.p.: 272-279.degree. C. (decomposes)
EXAMPLE 138
Sodium
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabi-
cyclo[3.3.1]non-9-yl]acetate
[1927] 1.50 g of
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in a
solvent mixture of 45 ml of tetrahydrofuran with 45 ml of ethanol.
After adding 3.79 ml of 1 N sodium hydroxide, the resulting mixture
was filtered. After almost completely distilling off the solvent
under reduced pressure, ethyl acetate was added to the residue.
Then the precipitate thus formed was collected by filtration,
washed with ethyl acetate, hot-air dried at 80.degree. C. for 6
hours and air-dried at room temperature to thereby give 1.516 g of
the title compound as a yellow powder. 483
[1928] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1929] 1.42-1.53(m, 3H), 1.66(br.m, 2H), 1.83-1.95(m, 2H), 2.02(m,
1H), 2.25-2.31(m, 2H), 2.36(d, J=7.7 Hz, 2H), 2.66(m, 1H),
2.90-2.96(m, 2H), 3.21(s, 2H), 6.67(s, 1H), 6.78(s, 2H), 7.54(d,
J=2.9 Hz, 1H), 7.56(d, J=2.9 Hz, 1H)
[1930] m.p.: 270.degree. C. (decomposes)
EXAMPLE 139
Potassium(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-aza-
bicyclo[3.3.1]non-9-yl]acetate
[1931] 3.00 g of
(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in a
solvent mixture of 45 ml of tetrahydrofuran with 45 ml of ethanol.
After adding 7.58 ml of 1 N potassium hydroxide, the resulting
mixture was filtered. After distilling off the solvent under
reduced pressure, ethanol was added to the residue followed by
concentration again. After adding ethyl acetate, the precipitate
thus formed was collected by filtration and dried at room
temperature under reduced pressure to thereby give 3.26 g of a
yellow powder.
[1932] 3.60 g of these crystals were hot-recrystallized from 36 ml
of ethanol. The precipitate thus formed was collected by
filtration, washed with ethanol, hot-air dried at 50.degree. C. for
5 hours, ground in mortar and hot-air dried at 100.degree. C. for
10 hours. After allowing to stand at room temperature, 1.92 g of
the title compound was obtained as a yellow powder. 484
[1933] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1934] 1.42-1.54(m, 3H), 1.66(br.m, 2H), 1.83-1.95(m, 2H), 2.02(m,
1H), 2.24-2.32(m, 2H), 2.37(d, J=7.7 Hz, 2H), 2.66(m, 1H),
2.90-2.96(m, 2H), 3.21(s, 2H), 6.67(s, 1H), 6.78(s, 2H), 7.54(d,
J=2.7 Hz, 1H), 7.56(d, J=2.7 Hz, 1H)
[1935] m.p.: 280.degree. C. (decomposes)
EXAMPLE 140
(syn)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid hydrochloride
[1936] 1.5 g of
(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-
-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 80 ml of
tetrahydrofuran. After adding 0.35 ml of conc. hydrochloric acid
and 160 ml of acetone, the resulting mixture was stirred at room
temperature for 1 hour. Then about 200 ml of water was added and to
dissolve the precipitate. After concentrating the solution under
reduced pressure to about 30 ml, the precipitate was collected by
filtration and dried under reduced pressure at room temperature to
thereby give 1.5 g of the title compound as yellow crystals.
485
[1937] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1938] 1.76-2.02(m, 6H), 2.08(br.m, 2H), 2.18(m, 1H), 2.51(d, J=7.7
Hz, 2H), 3.25-3.40(m, 4H), 4.18(s, 2H), 6.86(d, J=1.3 Hz, 1H),
6.97(d, J=8.1 Hz, 1H), 6.99(dd, J=1.3, 8.1 Hz, 1H), 7.61(d, J=2.7
Hz, 1H), 7.62(d, J-2.7 Hz, 1H)
[1939] m.p. : 238-248.degree. C.
EXAMPLE 141
(syn)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid methanesulfonate
[1940] 10.00 g of
(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 400 ml
of tetrahydrofuran and the insoluble matter was filtered off. Then
1.64 ml of methanesulfonic acid was dropped thereinto and the
resulting mixture was stirred at room temperature. 30 minutes
thereafter, 800 ml of acetone was added and the resulting mixture
was stirred for additional 1 hour. The precipitate was collected by
filtration and washed with acetone to thereby give a yellow
powder.
[1941] This powder was dissolved in 1.3 l of water and the
insoluble matter was filtered off. The residue was concentrated
under reduced pressure to about 100 ml and the precipitate was
collected by filtration, washed with a small amount of water and
hot-air dried at 50.degree. C. for 2 hours. Then it was dried under
reduced pressure in a desiccator for 64 hours to thereby give 9.70
g of the title compound as a yellow powder. 486
[1942] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1943] 1.74-2.02(m, 6H), 2.07(br.m, 2H), 2.17(m, 1H), 2.51(d, J=7.7
Hz, 2H), 2.72(s, 3H), 3.25-3.39(m, 4H), 4.18(s, 2H), 6.84(br.s,
1H), 6.96(d, J=8.1 Hz, 1H), 6.98(dd, J=8.1 Hz, 1H), 7.61(s, 2H)
[1944] m.p.: 267-271.degree. C. (decompose)
EXAMPLE 142
(syn)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid p-toluenesulfonate
[1945] 1.3 g of (syn)-[3-(10
H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 80 ml of
tetrahydrofuran. After adding 0.62 g of p-toluenesulfonic acid
monohydrate, the mixture was stirred at room temperature for 30
minutes. The precipitate was collected by filtration and dried
under reduced pressure.
[1946] The crystals were suspended in 5 ml of ethanol and stirred
at room temperature for 3 hours. After collected by filtration, the
product was hot-air dried at 50.degree. C. for 8 hours and then
air-dried at room temperature for 11 hours. Thus 1.4 g of the title
compound was obtained as yellow needles. 487
[1947] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1948] 1.72-1.99(m, 6H), 2.06(br.m, 2H), 2.17(m, 1H), 2.37(s, 3H),
2.50(d, J=7.7 Hz, 2H), 3.24-3.38(m, 4H), 4.16(s, 2H), 6.82(br.s,
1H), 6.97(s, 2H), 7.21-7.25(m, 2H), 7.61(d, J=3.1 Hz, 1H), 7.62(d,
J=3.1 Hz, 1H), 7.69-7.73(m, 2H)
[1949] m.p.: 157.degree. C. (decomposes)
EXAMPLE 143
(syn)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azabicyclo[3.3.1]non-9-yl]acetic acid sulfate
[1950] 1.3 g of
(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-
-3-azabicyclo[3.3.1]non-9-yl]acetic acid was dissolved in 60 ml of
tetrahydrofuran. After adding 0.18 ml of conc. sulfuric acid and
120 ml of acetone, the resulting mixture was stirred at room
temperature for 1 hour. Then water (about 200 ml) was added thereto
to thereby dissolve the precipitate and the mixture was
concentrated to about 20 ml under reduced pressure. After adding
seed crystals, the precipitate was collected by filtration to
thereby give 1.1 g of the title compound as yellow crystals.
488
[1951] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1952] 1.73-2.04(m, 6H), 2.08(br.m, 2H), 2.18(m, 1H), 2.51(d, J=7.7
Hz, 2H), 3.25-3.40(m, 4H), 4.18(s, 2H), 6.85(d, J=1.3 Hz, 1H),
6.97(br.s, 2H), 7.61(s, 2H)
[1953] m.p.: 2256.degree. C. (decomposes)
EXAMPLE 144
Sodium
(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabic-
yclo[3.3.1]non-9-yl]acetate
[1954] 1.310 g of
(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was suspended in a
solvent mixture of 50 ml of tetrahydrofuran with 50 ml of ethanol.
After adding 3.31 ml of 1 N sodium hydroxide, the resulting mixture
was filtered. After distilling off the solvent under reduced
pressure, ethanol was added and the solvent was almost completely
distilled off under reduced pressure. Then the precipitate was
collected by filtration, washed with a small portion of ethanol and
hot-air dried at 90.degree. C. for 10 hours. Then it was allowed to
stand at room temperature to thereby give 1.408 g of the title
compound as a yellow powder. 489
[1955] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1956] 1.50(m, 1H), 1.65-1.86(m, 6H), 2.03(m, 1H), 2.31(d, J=7.7
Hz, 2H), 2.47-2.53(m, 2H), 2.59-2.64(m, 2H), 2.73(m, 1H), 3.22(s,
2H), 6.65(s, 1H), 6.77(s, 2H), 7.54(d, J=2.9 Hz, 1H), 7.56(d, J=2.9
Hz, 1H)
[1957] m.p.: 260.degree. C. (decomposes)
EXAMPLE 145
Potassium(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azab-
icyclo[3.3.1]non-9-yl]acetate
[1958] 1.310 g of
(syn)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)-3-azabicyclo[3.3.1]non-9-yl]acetic acid was suspended in a
solvent mixture of 50 ml of tetrahydrofuran with 50 ml of ethanol.
After adding 3.31 ml of 1 N potassium hydroxide, the resulting
mixture was filtered. After distilling off the solvent under
reduced pressure, ethanol was added and the mixture was
concentrated again. After adding ethyl acetate, the precipitate was
collected by filtration and hot-air dried at 90.degree. C. for 10
hours. Then it was allowed to stand at room temperature to thereby
give 1.566 g of the title compound as a yellow powder. 490
[1959] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[1960] 1.50(m, 1H), 1.65-1.86(m, 6H), 2.03(m, 1H), 2.31(d, J=7.9
Hz, 2H), 2.46-2.54(m, 2H), 2.58-2.65(m, 2H), 2.73(m, 1H), 3.22(s,
2H), 6.66(s, 1H), 6.77(s, 2H), 7.54(d, J=2.8 Hz, 1H), 7.56(d, J=2.8
Hz, 1H)
[1961] m.p.: 272.degree. C. (decomposes)
EXAMPLE 146
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)methanol
[1962] To 1.47 g of 3-amino-4-[(3-chloropyrazin-2-yl)thio]benzyl
alcohol were added 20 ml of methanol and 0.45 ml of conc.
hydrochloric acid and the resulting mixture was heated under reflux
for 30 minutes. Then the reaction mixture was made alkaline by
adding ice-water and aqueous ammonia. The precipitate was collected
by filtration and dried to thereby give 1.23 g of the title
compound as yellow crystals. 491
[1963] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1964] 4.30(d, J=6.0 Hz, 2H), 5.17(t, J=6.0 Hz, 1H), 6.70(d, J=7.9
Hz, 1H), 6.75(s, 1H), 6.83(d, J=7.9 Hz, 1H), 7.61(d, J=2.6 Hz, 1H),
7.63(d, J=2.6 Hz, 1H), 9.50(s, 1H)
EXAMPLE 147
Methyl 10H-pyrazino[2,3-b][1,4]benzoxazine-8-carboxylate
[1965] 21.3 g of methyl 3-amino-4-hydroxybenzoate and 23 g of
2,3-dichloropyrazine were added to 40 ml of dry
N,N-dimethylformamide and the resulting mixture was stirred under
heating to 160.degree. C. for 6 hours. Then the reaction mixture
was brought back to room temperature and the crystals thus
precipitated were taken up by filtration and washed with ethyl
acetate. Thus 23 g of the title compound was obtained as brown
crystals. 492
[1966] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1967] 3.80(s, 3H), 6.86(d, J=8 Hz, 1H), 7.20(d, J=2 Hz, 1H),
7.30(dd, J=2, 8 Hz, 1H), 7.30(d, J=3 Hz, 1H), 7.51(d, J=3 Hz, 1H),
9.81(s, 1H)
EXAMPLE 148
Methyl 10H-pyrido[3,2-b][1,4]benzothiazine-8-carboxylate
[1968] 150 g of methyl 3-amino-4-mercaptobenzoate hydrochloride was
suspended in 200 ml of diphenyl ether and heated to 100.degree. C.
After dropping 2-chloropyridine thereinto, 10.3 g of iodine was
further added and the resulting mixture was reacted at 200.degree.
C. for 3 hours. After adding 20 ml of sulfuric acid and 300 ml of
methanol at room temperature, the resulting mixture was heated
under reflux for 3 hours. Then the reaction mixture was brought
back to room temperature and poured into a cold saturated aqueous
solution of sodium bicarbonate. Next, it was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and then dried over anhydrous magnesium sulfate. The
extract was distilled off under reduced pressure and the residue
was purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 1.3 g of the title compound as
yellow crystals. 493
[1969] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1970] 3.88(s, 3H), 6.72(dd, J=5, 7 Hz, 1H), 6.84(br.s, 1H),
6.95(d, J=8 Hz, 1H), 7.15(dd, J=2, 8 Hz, 1H), 7.17(d, J=2 Hz, 1H),
7.47(dd, J=2, 8 Hz, 1H), 7.84(dd, J=2, 5 Hz, 1H)
EXAMPLE 149
Methyl 5H-pyrido[3,4-b][1,4]benzothiazine-7-carboxylate
[1971] To a solution of 18.43 g of methyl 3-amino
-4-(4-cyanopyridin-3-yl)- thiobenzoate in dimethylformamide (70 ml)
was added 22.2 g of p-toluenesulfonic acid in a nitrogen
atmosphere. Then the resulting mixture was stirred at 120.degree.
C. for 2 hours. Then the reaction mixture was cooled to room
temperature and the crystals thus precipitated in the course of
cooling were taken up by filtration and washed with ethyl acetate.
Thus 13.5 g of p-toluenesulfonate of the title compound was
obtained as yellow crystals. A 10.3 g portion of this salt was
suspended in a solution mixture of 50 ml of a saturated aqueous
solution of sodium hydrogencarbonate with 5 ml of tetrahydrofuran
and the suspension was stirred for 20 minutes. The suspended
matters were taken up by filtration, washed successively with water
and ether and dried under reduced pressure overnight. Thus, 6.48 g
of the title compound was obtained as yellow crystals. 494
[1972] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1973] 3.79(s, 3H), 6.48(d, J=6 Hz, 1H), 7.04(d, J=8 Hz, 1H),
7.21(d, J=1 Hz, 1H), 7.33(dd, J=1, 8 Hz, 1H), 7.87(s, 1H), 7.98(d,
J=6 Hz, 1H), 9.26(s, 1H)
EXAMPLE 150
Methyl
4-cyano-10-(methoxyethyl)-10H-pyrido[3,2-b][1,4]-benzothiazine-8-ca-
rboxylate
[1974] To a solution of methyl 3-amino-4-(1-oxo-4-cyano
-3-pyridylthio)benzoate in pyridine (20 ml) was added 5 ml of
acetic anhydride and the resulting mixture was stirred for 16
hours. Then the reaction mixture was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography (eluted with dichloromethane/ethyl acetate) to
thereby give 0.45 g of methyl
3-acetamido-4-(1-oxo-4-cyano-3-pyridylthio)benzoate as a colorless
solid. 0.079 g of sodium hydride was added in a nitrogen atmosphere
to a solution of 0.45 g of methyl 3-acetamido
-4-(1-oxo-4-cyano-3-pyridylthio)- benzoate in N,N-dimethylformamide
(15 ml) and the resulting mixture was stirred for 10 minutes. After
adding 0.503 g of sulfur, the resulting mixture was stirred at
130.degree. C. for 15 minutes. The reaction mixture was diluted
with water and the crystals thus precipitated were taken up by
filtration and washed with water. Thus 0.267 g of methyl 4-cyano
-10H-pyrido[3,2-b][1,4]-benzothiazine-8-carboxylate was obtained as
yellow crystals. To a solution of 0.267 g of methyl
4-cyano-10H-pyrido[3,2-b][1,4]-benzothiazine -8-carboxylate in
N,N-dimethylformamide (20 ml) were successively added in a nitrogen
atmosphere 0.045 g of sodium hydride and a solution of 0.12 ml of
chloromethyl methyl ether in N,N-dimethylformamide (9 ml) and the
resulting mixture was stirred for 1 hour. Then the reaction mixture
was diluted with water and eluted with ethyl acetate. The organic
layer was washed with water and a saturated aqueous solution of
sodium chloride, dried over anhydrous magnesium sulfate, filtered
and concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluted with
n-hexane/dichloromethane) to thereby give 0.152 g of the title
compound as pale yellow crystals. 495
[1975] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1976] 3.40(s, 3H), 3.95(s, 3H), 5.37(s, 2H), 7.22(d, J=8 Hz, 1H),
7.26(d, J=5 Hz, 1H), 7.76(dd, J=2, 8 Hz, 1H), 7.77(d, J=2 Hz, 1H),
8.19(d, J=5 Hz, 1H)
EXAMPLE 151
Methyl 10H-pyrazino[2,3-b][1,4]-benzothiazine-7-carboxylate
[1977] 40 g of methyl 3-(N,N-dimethylcarbamoylthio)
-4-nitrobenzoate was added to a solvent mixture of a 30% aqueous
solution of potassium hydroxide (50 ml) with methanol (20 ml) and
the resulting mixture was stirred under heating to 80.degree. C.
for 1.5 hours. Then the reaction mixture was brought back to room
temperature and acidified with dilute hydrochloric acid. The brown
crystals thus precipitated were taken up by filtration and dried.
Into a solution of 20 g of the crystals thus obtained and 40 g of a
tin powder (200-mesh) in ethanol (200 ml) was dropped 10 ml of
conc. hydrochloric acid in such a manner that the temperature in
the reaction system did not exceed 70.degree. C. After diluting
with methanol, the mixture was filtered through celite to thereby
eliminate the residual tin. After distilling off the solvent under
reduced pressure, ethyl acetate saturated with hydrogen chloride
gas was added to the oily substance thus obtained and the pale
yellow crystals thus precipitated were filtered. To 15 g of the
crystals thus obtained was added 200 ml of a 10% solution of
hydrochloric acid in methanol and the resulting mixture was heated
under reflux for 6 hours. After distilling off the solvent under
reduced pressure completely, 30 ml of N,N-dimethylformamide was
added thereto. Next, 15 g of dichloropyrazine was further added and
the resulting mixture was heated to 110.degree. C. for 1 hour.
After diluting with water, the crystals thus precipitated were
filtered and washed well with water and diethyl ether. Thus 13.5 g
of the title compound was obtained as yellow crystals. 496
[1978] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1979] 3.75(s, 3H), 6.77(d, J=8.4 Hz, 1H), 7.40(d, J=1.8 Hz, 1H),
7.53(dd, J=1.8, 8.4 Hz, 1H), 7.68(d, J=2.9 Hz, 1H), 7.69(d, J=2.9
Hz, 1H), 9.93(s, 1H)
EXAMPLE 152
Methyl 10H-pyrimido[5,4-b][1,4]-benzothiazine-8-carboxylate
[1980] 100 ml of a solution of 16.3 g of crude methyl
3-mercapto-4-aminobenzoate hydrochloride and 20 ml of triethylamine
in methanol was stirred under ice-cooling and 7.2 g of
4-chloro-5-bromopyrimidine was dropped thereinto. The colorless
precipitate thus formed was filtered to thereby give 9.0 g of crude
methyl 4-[5-bromopyrimidin -4-yl)thio]-3-aminobenzoate. 9.0 g of
methyl 4-[5-bromopyrimidin-4-yl)thio]-3-aminobenzoate, 200 mg of a
copper powder and 1.3 g of potassium carbonate were heated in 5 ml
of N,N-dimethylformamide to 110.degree. C. for 1 hour. Then the
mixture was hot-filtered to thereby eliminate the copper powder.
After recrystallization, the crystals thus precipitated were taken
up by filtration and washed with water to thereby give 6.2 g of the
title compound as a pale yellow crude product. 497
[1981] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[1982] 3.79(s, 3H), 7.06(d, J=8.5 Hz, 1H), 7.36(d, J=1.1 Hz, 1H),
7.37(dd, J=1.1, 8.5 Hz, 1H), 7.89-8.02(br.s, 1H), 8.18-8.28(br.s,
1H), 9.43(s, 1H)
EXAMPLE 153
Methyl 7-methoxy-10H-pyrazino[2,3-b][1,4]-benzothiazine
-8-carboxylate
[1983] To a solution of 2.7 g of methyl 2-methoxy
-4-(2-chloropyrazin-3-yl- )thio-5-nitrobenzoate in tetrahydrofuran
(100 ml) were added 50 ml of a saturated aqueous solution of sodium
hydrosufide and 30 ml of 27% aqueous ammonia and the resulting
mixture was vigorously stirred at room temperature for 1 hour. Then
the reaction mixture was extracted with ethyl acetate and the
organic layer was dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, a solution of
the residue in tetrahydrofuran was stirred at 70.degree. C. for 1
hour. After distilling off the solvent under reduced pressure,
dichloroemthane was added to the residue. The crystals thus
precipitated were filtered to thereby give 1.9 g of the title
compound as red crystals. 498
[1984] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1985] 3.83(s, 3H), 3.86(s, 3H), 6.36-6.43(br.s, 1H), 6.53(s, 1H),
7.00(s, 1H), 7.59(d, J=2.8 Hz, 1H), 7.69(d, J=2.8 Hz, 1H)
EXAMPLE 154
Methyl
10-(methoxymethyl)-10H-pyrazino[2,3-b]pyrido[3,2-e][1,4]thiazine-8--
carboxylate
[1986] To a solution of 1.0 g of methyl
5-amino-6-mercaptonicotinate in N,N-dimethylformamide (30 ml) were
added 0.52 g of sodium hydride (oily: 60% or more) and 0.97 g of
2,3-dichloropyrazine and the resulting mixture was reacted at
100.degree. C. for 2 hours. Then ethyl acetate was added to the
reaction mixture, which was then washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
diethyl ether was added to the residue and the crystals thus
precipitated were taken up by filtration to thereby give 0.43 g of
crude methyl
10H-pyrazino[2,3-b]pyrido[3,2-e][1,4]thiazin-8-carboxylate as a
brown solid. To a solution of 1.43 g of these crude crystals in
N,N-dimethylformamide (50 ml) were added 0.26 g of sodium hydride
(60% oily) and 0.5 g of chloromethyl methyl ether and the resulting
mixture was reacted under ice-cooling for 1 hour. After adding
ethyl acetate, the mixture was washed with a saturated aqueous
solution of sodium chloride. The organic layer was dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, diethyl ether was added to the residue and the
crystals thus precipitated were taken up by filtration to thereby
give 1.5 g of the title compound as red crystals. 499
[1987] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1988] 3.52(s, 3H), 3.93(s, 3H), 5.27(s, 2H), 7.78(d, J=1.6 Hz,
1H), 7.82(d, J=2.8 Hz, 1H), 7.85(d, J=2.8 Hz, 1H), 8.58(d, J=1.6
Hz, 1H)
EXAMPLES 155 to 157
[1989] The following compounds were obtained by the same procedure
as the one of Example 5.
52 Ex. Structural formula NMR 155 500methyl 10-
(methoxymethyl)-10H- pyrazino[2,3-b][1,4]- benzoxazine-8-
carboxylate .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.33(s, 3H),
3.81(s, 3H), 5.27(s, 2H), 6.97(d, J=8Hz, 1H), 7.41(d, J=2Hz, 1H),
7.46(dd, J=2, 8Hz, 1H), 7.48(d, J=4Hz, 1H), 7.69(d, J=4Hz, 1H) 156
501methyl 5- (methoxymethyl)-5H- pyrido[3,4-b][1,4]-
benzothiazine-7- carboxylate .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.56(s, 3H), 3.92(s, 3H), 5.03(s, 2H), 6.88 (d, J=6Hz, 1H), 7.15(d,
J=8Hz, 1H), 7.67(m, 2H), 8.18(s, 1H), 8.30(d, J=6Hz, 1H) 157
502methyl 7-methoxy-10- (methoxymethyl)-10H- pyrazino[2,3-b][1,4]-
benzothiazine-7- carboxylate .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.53(s, 3H), 3.87(s, 3H), 3.89(s, 3H), 5.28(s, 2H), 6.34(s, 1H),
7.60(s, 1H), 7.84(d, J=2.8Hz, 1H), 7.85(d, J=2.8Hz, 1H)
EXAMPLE 158
10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazine
-7-methanol
[1990] 100 ml of a solution of 7.0 g of ethyl
10H-pyrazino[2,3-b][1,4]benz- othiazine-7-carboxylate in
N,N-dimethylformamide was ice-cooled in a nitrogen atmosphere and
1.3 g of sodium hydride (60% oily) was added thereto. Then the
resulting mixture was brought back to room temperature and stirred
for 1 hour. Next, it was ice-cooled again and 2.5 ml of
chloromethyl ether was dropped thereinto. After the completion of
the reaction, the reaction mixture was distributed into water and
ethyl acetate. The organic layer was extracted, washed with water
and dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with ethyl acetate/hexane) to
thereby give 5.0 g of ethyl 10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazine-7-carb- oxylate as pale
yellow crystals.
[1991] 200 ml of a solution of 9.8 g of ethyl 10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazine-7-carboxylate in
dichloromethane was ice-cooled in a nitrogen atmosphere and 81 ml
of diisobutylaluminum hydride (1.01 M toluene solution) was dropped
thereinto. After the completion of the reaction, ice and celite
were added to the reaction mixture and stirred at room temperature
for 1 hour. Then the mixture was diluted with ethyl acetate and
filtered through celite to thereby separate the organic layer.
After distilling off the solvent under reduced pressure, 8.0 g of
the title compound was obtained as pale yellow crystals. 503
[1992] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1993] 1.78(t, J=6.0 Hz, 1H), 3.52(s, 3H), 4.57(d, J=6.0 Hz, 2H),
5.25(s, 2H), 7.03(s, 1H), 7.10(d, J=8.2 Hz, 1H), 7.12(d, J=8.2 Hz,
1H), 7.82(d, J=2.8 Hz, 1H), 7.83(d, J=2.8 Hz, 1H)
EXAMPLES 159 and 160
[1994] Starting with methyl
10H-pyrimido[5,4-b][1,4]-benzothiazine-8-carbo- xylate and methyl
5-(methoxymethyl) -5H-pyrido[3,4-b][1,4]benzothiazine
-7-carboxylate, the following compounds were obtained by the same
procedure as the one of
EXAMPLE 6.
[1995]
53 Ex. Structural formula NMR 159 50410H-pyrimido[5,4-
b][1,4]-benzothiazine- 8-methanol .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 4.30(d, J=6.5Hz, 2H), 5.17(t, J=6.5Hz, 1H), 6.76(d, J=7.4Hz,
1H), 6.80(s, 1H), 6.87(d, J=7.4Hz, 1H), 7.84-8.00(br.s, 1H),
8.22(s, 1H), 9.83(s, 1H) 160 5055-(methoxymethyl)-5H- pyrido[3,4-
b][1,4]benzothiazine- 7-methanol .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.54(s, 3H), 4.65(s, 2H), 5.03(s, 2H), 6.87(d, J=6Hz, 1H),
7.00(d, J=8Hz, 1H), 7.08(s, 1H), 7.09(d, J=8Hz, 1H), 8.18(s, 1H),
8.27(d, J=6Hz, 1H)
EXAMPLE 161
4-Cyano-10-(methoxymethyl)-10H-pyrido[3,2-b][1,4]-benzothiazine-8-methanol
[1996] To a solution of 0.19 g of methyl 4-cyano
-10-(methoxymethyl)-10H-p- yrido[3,2-b][1,4]-benzothiazine
-8-carboxylate in dry tetrahydrofuran (5 ml) was added in a
nitrogen atmosphere a solution of 0.026 g of lithium borohydride in
tetrahydrofuran (10 ml) and the resulting mixture was heated under
reflux for 20 minutes. After bringing back to room temperature, the
mixture was extracted with 15 ml of water and 15 ml of acetic acid
and dried over anhydrous magnesium sulfate. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.12 g of the title
compound as a pale yellow solid. 506
[1997] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[1998] 1.92(br.s, 1H), 3.39(s, 3H), 4.68(s, 2H), 5.34(s, 2H),
7.09(dd, J=2, 8 Hz, 1H), 7.14(d, J=8 Hz, 1H), 7.18(d, J=2 Hz, 1H),
7.22(d, J=5 Hz, 1H), 8.16(d, J=5 Hz, 1H)
EXAMPLES 162 to 165
[1999] The following compounds were obtained by the same procedure
as the one of EXAMPLE 3.
54 Ex. Structural formula NMR 162 50710-(methoxymethyl)-10H-
pyrazino[2,3-b][1,4]- benzoxazine-8-methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.74(br.s, 1H), 3.46(s, 3H),
4.58(s, 2H), 5.31(s, 2H), 6.82-6.86(m, 2H), 6.92-6.94(m, 1H),
7.43(d, J=3Hz, 1H), 7.78(d, J=3Hz, 1H) 163 50810H-pyrazino[2,3-
b][1,4]-benzoxazine-8- methanol .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 4.28(d, J=6Hz, 2H), 5.12(t, J=6Hz, 1H), 6.60(d, J=8Hz, 1H),
6.61(s, 1H), 6.69(d, J=8Hz, 1H), 7.24(d, J=3Hz, 1H), 7.44(d, J=3Hz,
1H), 9.63(s, 1H) 164 50910H-pyrido[3,2-b][1,4]- benzothiazine-8-
methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.56(s, 2H),
6.58-6.60(m, 1H), 6.64-6.70(m, 1H), 6.71(dd, J=5, 7Hz, 1H),
6.80-6.84(m, 1H), 6.98(m, 1H), 7.17(dd, J=1, 7Hz, 1H), 7.81(dd,
J=1, 5Hz, 1H) 165 5107-methoxy-10- (methoxymethyl)-10H-
pyrazino[2,3-b ][1,4]- benzoxyazine-8-methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.23(t, J=6Hz, 1H), 3.52(2,
3H), 3.82(s, 3H), 4.62(d, J=6Hz, 2H), 5.26(s, 2H), 6.54(s, 1H),
7.13(s, 1H), 7.82(s, 2H)
EXAMPLES 166 to 171
[2000] The following compounds were obtained by the same procedure
as the one of Example 4.
55 Ex. Structural formula NMR 166 5118-(chloromethyl)-10-
(methoxymethyl)-10H- pyrazino[2,3- b][1,4]benzoxazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.25(s, 3H), 4.48(s, 2H),
5.3(s, 2H), 6.81(d, J=8Hz, 1H), 6.88(d, J=8Hz, 1H), 6.93(s, 1H),
7.43(s, 1H), 7.58(s, 1H) 167 5128-(chloromethyl)-10H- -
pyrazino[2,3- ][1,4]benzoxazine .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 4.58(s, 2H), 6.65(s, 1H), 6.75(s, 2H), 7.26(s, 1H), 7.46(s,
1H), 9.73(s, 1H) 168 5138-(chloromehtyl)-10H- pyrido[3,2-
b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.41(s,
2H), 6.70(dd, J=2, 8Hz, 1H), 6.76(d, J=2Hz, 1H), 6.85(d, J=8Hz,
1H), 6.91(dd, J=2, 8Hz, 1H), 7.22(dd, J=2, 7Hz, 1H), 7.56(dd, J=1,
6Hz, 1H), 9.3-9.4(m, 1H) 169 5145-(methoxymethyl)-7-
(chloromethyl)-5H- pyrido[3,4-b-]- [1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.60(s, 3H), 4.55(s, 2H),
5.09(s, 2H), 7.09-7.13(m, 3H), 7.18(dd, J=2, 8Hz, 1H), 8.21(s, 1H),
8.33(d, J=6Hz, 1H) 170 5154-cycano-10- (methoxymethyl)-8-
(chloromethyl)-10H- pyrido[3,2- b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.40(s, 3H), 4.65(s, 2H),
5.33(s, 2H), 7.12(dd, J=2, 8Hz, 1H), 7.15(d, J=8Hz, 1H), 7.18(d,
J=2Hz, 1H), 7.25(d, J=5Hz, 1H), 8.18(d, J=5Hz, 1H) 171
5167-(chloromethyl)-10- (methoxymehtyl)-10H- pyrazino-[2,3-
b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.51(s,
3H), 4.47(s, 2H), 5.26(s, 2H), 7.04(d, J=1.8Hz, 1H), 7.12(d,
J=7.9Hz, 1H), 7.14(dd, J=1.8, 7.9Hz, 1H), 7.83(d, J=2.7Hz, 1H),
7.85(d, J=2.7Hz, 1H)
EXAMPLE 172
8-(Chloromethyl)-10-(methoxymethyl)-10H-pyrazino[2,3-b]pyrido[3,2-e][1,4]t-
hiazine
[2001] Methyl
10-(methoxymethyl)-10H-pyrazino[2,3-b]pyrido[3,2-e][1,4]thia-
zine-8-carboxylate was treated in the same manner as those of
Examples 6 and 4 to thereby give the title compound as yellow
crystals. 517
[2002] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2003] 3.52(s, 3H), 4.49(s, 2H), 5.26(s, 2H), 7.32(d, J=2.0 Hz,
1H), 7.81(d, J=2.6 Hz, 1H), 7.86(d, J=2.6 Hz, 1H), 8.02(d, J=2.0
Hz, 1H)
EXAMPLE 173
7-Methoxy-10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzoxazine-8-carbox-
aldehyde
[2004] To a solution of 1.17 g of 7-methoxy-10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]-benzoxazine -8-methanol in 50 ml of
1,2-dichloroethane was added 3.2 g of manganese dioxide and the
resulting mixture was heated under reflux for 2 hours. The reaction
mixture was filtered through celite. After distilling off the
solvent under reduced pressure, 0.75 g of the title compound was
obtained as a brown solid. 518
[2005] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2006] 3.53(s, 3H), 3.89(s, 3H), 5.26(s, 2H), 6.66(s, 1H), 7.53(s,
1H), 7.84(d, J=3 Hz, 1H), 7.87(d, J=3 Hz, 1H)10.34(s, 1H)
EXAMPLE 174
10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazine
-8-carboxaldehyde
[2007] To a solution of 20 g of 10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,- 4]-benzoxazine-8-methanol in 200 ml of
dichloromethane was added 132 g of manganese dioxide and the
resulting mixture was reacted at room temperature for 18 hours.
After filtering off the manganese dioxide, the filtrate was
concentrated to thereby give 16 g of the title compound as yellow
crystals. 519
[2008] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2009] 3.56(s, 3H), 5.32(s, 2H), 7.15(d, J=8.0 Hz, 1H), 7.45(dd,
J=1.6, 8.0 Hz, 1H), 7.58(d, J=1.6 Hz, 1H), 7.87(s, 2H), 9.90(s,
1H)
EXAMPLE 175
Ethyl
3-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl]pro-
panoate
[2010] 1.5 g of
10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazine--
8-carboxaldehyde was successively treated in the same manners as
those of Production Example 25 and Example 20 to thereby give 1.3 g
of the title compound as a yellow oily substance. 520
[2011] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2012] 1.15-1.20(m, 3H), 2.53(t, J=8 Hz, 2H), 2.83(t, J=8 Hz, 2H),
3.46(s, 3H), 4.0-4.1(m, 2H), 5.20(s, 2H), 6.75(d, J=8 Hz, 1H),
6.86(d, J=8 Hz, 1H), 6.94(s, 1H), 7.95(s, 2H)
EXAMPLE 176
3-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin
-8-yl]propionaldehyde
[2013] 1.3 g of ethyl
3-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzo-
thiazin-8-yl]propanoate was successively treated in the same
manners as those of Production Example 64 and Example 7 to thereby
give 0.5 g of the title compound as a yellow oily substance.
521
[2014] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2015] 2.79(t, J=8 Hz, 2H), 2.90(t, J=8 Hz, 2H), 3.54(s, 3H),
5.27(s, 2H), 6.80(d, J=8 Hz, 1H), 6.94(d, J=8 Hz, 1H), 7.00(s, 1H),
7.9-7.95(m, 2H), 9.83(s, 1H)
EXAMPLE 177
3-(10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)propyl
methanesulfonate
[2016] 3.0 g of ethyl
3-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-yl)propanoate was treated successively by the methods
described in Example 3 and Production Example 52 to thereby give
2.7 g of the title compound as a yellow oily substance. 522
[2017] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2018] 2.06(quint., J=7.2 Hz, 2H), 2.70(t, J=7.2 Hz, 2H), 2.88(s,
3H), 3.54(s, 3H), 4.23(t, J=7.2 Hz, 2H), 5.27(s, 2H), 6.82(d, J=8.6
Hz, 1H), 6.96(d, J=8.6 Hz, 1H), 6.99(s, 1H), 7.84(s, 2H)
EXAMPLE 178
10H-Pyrazino[2,3-b][1,4]benzothiazine-8-ethanol
[2019] Starting with 2.3 g of methyl
10H-pyrazino[2,3-b][1,4]benzothiazine- -8-acetate, the procedure of
Example 3 was repeated to thereby give 2.5 g of the title compound
as a brown oily substance. 523
[2020] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2021] 2.51(t, J=7 Hz, 2H), 3.33(br.s, 1H), 3.50(t, J=7 Hz, 2H),
6.62(s, 1H), 6.63(d, J=8 Hz, 1H), 6.78(d, J=8 Hz, 1H), 7.58-7.65(m,
2H), 9.44(m, 1H)
EXAMPLE 179
8-[(2-(tert-Butyldimethylsiloxy)ethyl]-10H-pyrazin[2,3-b][1,4]benzothiazin-
e
[2022] 500 mg of
2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)ethanol was dissolved
in 7 ml of N,N-dimethylformamide. After adding 369 mg of
tert-butyldimethylsilyl chloride,. 0.34 ml of triethylamine and a
catalytic amount of 4-dimethylaminopyridine, the resulting mixture
was stirred at room temperature for 14 hours. After adding water,
the reaction mixture was extracted with ethyl acetate. The ethyl
acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous sodium sulfate
and concentrated under reduced pressure. Then the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 671 mg of the title
compound as a yellow solid. 524
[2023] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2024] 0.00(s, 6H), 0.87(s, 9H), 2.66(t, J=6.8 Hz, 2H), 3.75(t,
J=6.8 Hz, 2H), 6.37(d, J=1.6 Hz, 1H), 6.57(br.s, 1H), 6.69(dd,
J=1.6, 7.9 Hz, 1H), 6.80(d, J=7.9 Hz, 1H), 7.56(d, J=2.9 Hz, 1H),
7.69(d, J=2.9 Hz, 1H)
EXAMPLE 180
8-[(2(tert-Butyldimethylsiloxy)ethyl]-10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazine
[2025] 603 mg of
8-[(2-(tert-butyldimethylsilyloxy)ethyl]-10H-pyrazino[2,3-
-b][1,4]benzothiazine was dissolved in 6 ml of tetrahydrofuran.
After adding 63 mg of 70% sodium hydride, the resulting mixture was
stirred under ice-cooling for 15 minutes. Then 0.14 ml of
chloromethyl methyl ether was added thereto and the resulting
mixture was stirred for 1 hour and for additional 18 hours at room
temperature. The reaction mixture was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
463 mg of the title compound as a brown oily substance. 525
[2026] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2027] 0.01(s, 6H), 0.88(s, 9H), 2.76(t, J=7.0 Hz, 2H), 3.53(s,
3H), 3.79(t, J=7.0 Hz, 2H), 5.27(s, 2H), 6.83(dd, J=1.6, 7.9 Hz,
1H), 6.93(d, J=7.9 Hz, 1H), 7.00(d, J=1.6 Hz, 1H), 7.82(d, J=2.7
Hz, 1H), 7.83(d, J=2.7 Hz, 1H)
EXAMPLE 181
10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine-8-ethanol
[2028] 463 mg of
8-[(2-(tert-butyldimethylsilyloxy)ethyl]-10-(methoxymethy-
l)-10H-pyrazino[2,3-b][1,4]benzothiazine was dissolved in 5 ml of
tetrahydrofuran. After adding 1.3 ml of n-tetrabutylammonium
fluoride (1.0 M solution in tetrahydrofuran), the resulting mixture
was stirred at room temperature for 1 hour and then at 4.degree. C.
for additional 13 hours. The reaction mixture was concentrated
under reduced pressure and the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 281 mg of the title compound as a pale orange solid.
526
[2029] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2030] 1.51(t, J=5.5 Hz, 1H), 2.82(t, J=6.6 Hz, 2H), 3.54(s, 3H),
3.85(dt, J=5.5, 6.6 Hz, 2H), 5.28(s, 2H), 6.86(dd, J=1.6, 7.9 Hz,
1H), 6.96(d, J=7.9 Hz, 1H), 7.03(d, J=1.6 Hz, 1H), 7.83(d, J=2.7
Hz, 1H), 7.84(d, J=2.7 Hz, 1H)
EXAMPLE 182
8-[2-(Methanesulfonyloxy)ethyl]-10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,- 4]benzothiazine
[2031] Starting with
10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiaz-
ine-8-ethanol, the title compound was obtained by the same method
as the one of Production Example 52. 527
[2032] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2033] 2.94(s, 3H), 3.00(t, J=6.8 Hz, 2H), 3.54(s, 3H), 4.40(t,
J=6.8 Hz, 2H), 5.28(s, 2H), 6.85(dd, J=1.6, 7.9 Hz, 1H), 6.97(d,
J=7.9 Hz, 1H), 7.04(d, J=1.6 Hz, 1H), 7.83(d, J=2.7 Hz, 1H),
7.85(d, J=2.7 Hz, 1H)
EXAMPLE 183
2-Benzyl-7-(methoxymethoxy)-2-azaspiro[3,5]nonane
[2034] 11.91 g of 4-(methoxymethoxy)cyclohexane -1,1-dimethyl
dimethanesulfonate was dissolved in 30 ml of diphenyl ether. After
adding 5.94 g of anhydrous potassium carbonate and 7.23 ml of
benzylamine, the resulting mixture was stirred at 180.degree. C.
for 21 hours. Then water was added to the reaction mixture followed
by extraction with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride, dried
over anhydrous sodium sulfate and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 5.15 g of the title compound as a pale yellow oily substance.
528
[2035] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2036] 1.32-1.43(m, 2H), 1.44-1.53(m, 2H), 1.74-1.82(m, 2H),
1.86-1.96(m, 2H), 3.00(s, 2H), 3.04(s, 2H), 3.36(s, 3H), 3.51(m,
1H), 3.65(s, 2H), 4.66(s, 2H), 7.21-7.34(m, 5H)
EXAMPLE 184
2-Benzyl-2-azaspiro[3,5]nonan-7-one
[2037] 900 mg of
2-benzyl-7-(methoxymethyloxy)-2-azaspiro-[3,5]nonane was dissolved
in 40 ml of acetone. After adding 10 ml of 6 N hydrochloric acid,
the resulting mixture was stirred at room temperature for 1.5
hours. Then the reaction mixture was concentrated under reduced
pressure and an aqueous solution of potassium hydrogencarbonate was
added thereto followed by extraction with ether. The organic layer
was washed with water and a saturated aqueous solution of sodium
chloride, dried over anhydrous sodium sulfate and concentrated
under reduced pressure. Thus, 794 mg of a pale yellow oily
substance was obtained.
[2038] 0.43 ml of oxalyl chloride was dissolved in 8 ml of
dichloromethane and stirred under cooling to -70.degree. C. 0.37 ml
of dimethyl sulfoxide was dissolved in 1 ml of dichloromethane and
dropped into the above solution while maintaining the inner
temperature at -50.degree. C. or below. 10 minutes thereafter, 794
mg of the oily substrate obtained above was dissolved in 2 ml of
dichloromethane and dropped into the mixture while maintaining the
bulk temperature at -50.degree. C. or below. 25 minutes thereafter,
2.3 ml of triethylamine was dropped thereinto. After 15 minutes,
the mixture was heated to room temperature and stirred for 1 hour.
After adding water, the reaction mixture was extracted with ethyl
acetate. The organic layer was washed with water and a saturated
aqueous solution of sodium chloride, dried over anhydrous sodium
sulfate and concentrated under reduced pressure. The residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 655 mg of the title
compound as a pale yellow oily substance. 529
[2039] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2040] 2.06(t, J=7.0 Hz, 4H), 2.31(t, J=7.0 Hz, 4H), 3.17(s, 4H),
3.69(s, 2H), 7.23-7.35(m, 5H)
EXAMPLE 185
8-Benzyl-8-azabicyclo[4.3.0]nonan-3-ol
[2041] 8.33 g of 8-benzyl-8-azabicyclo[4.3.0]-3-nonene was
dissolved in 100 ml of tetrahydrofuran and 167 ml of a 1 M solution
of borane in tetrahydrofuran was dropped thereinto in a nitrogen
atmosphere under ice-cooling. Then the resulting mixture was
brought back to room temperature and stirred for 1 hour and 15
minutes. To the reaction mixture were added 50 ml of a 4 N aqueous
solution of sodium hydroxide and 23 ml of a 30% aqueous solution of
hydrogen peroxide under ice-cooling and the resulting mixture was
stirred at the same temperature for 1 hour. The reaction mixture
was then concentrated under reduced pressure, extracted with ethyl
acetate and concentrated under reduced pressure. 6 N hydrochloric
acid was added to the residue and the resulting mixture was stirred
at 90.degree. C. for 20 minutes. The reaction mixture was
ice-cooled and made basic by adding sodium hydroxide pellets. Then
it was extracted with ethyl acetate and the organic layer was dried
over anhydrous potassium carbonate. After filtration, the solvent
was distilled off under reduced pressure to thereby give 8.29 g of
the title compound as a pale yellow oily substance. 530
[2042] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2043] 1.24-1.91(m, 7H), 2.02-2.36(m, 2H), 2.42-2.89(m, 4H),
3.63-3.91(m, 3H), 7.20-7.4(m, 5H)
EXAMPLE 186
8-(tert-Butoxycarbonyl)-8-azabicyclo[4.3.0]nonan-3-ol
[2044] 6.87 g of 8-benzyl-8-azabicyclo[4.3.0]nonan -3-ol was
dissolved in 100 ml of methanol and 500 mg of palladium-carbon and
4 ml of formic acid were added thereto. The resulting mixture was
stirred at 50.degree. C. for 20 minutes and then at 65.degree. C.
for 4 hours and 20 minutes. After further adding 500 mg of
palladium-carbon and 3 ml of formic acid, the resulting mixture was
heated under reflux for 3 hours. After filtering off the
palladium-carbon, the solvent was distilled off under reduced
pressure. The residue was then dissolved in 150 ml of methanol.
After adding 7 ml of triethylamine and 6.5 g of t-butyl
dicarbonate, the resulting mixture was stirred at room temperature
for 20 minutes. The reaction mixture was concentrated under reduced
pressure, diluted with ethyl acetate, washed successively with 1 N
hydrochloric acid, a saturated solution of sodium hydrogencarbonate
and a saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After filtration, the solvent was
concentrated under reduced pressure. The residue thus obtained was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 3.73 g of the title
compound as a colorless oily substance. 531
[2045] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2046] 1.30-1.43(m, 2H), 1.45(s, 9H), 1.50-1.59(m, 1H),
1.75-1.90(m, 3H), 2.07-2.21(m, 1H), 2.42-2.52(m, 1H), 3.11-3.22(m,
2H), 3.30-3.43(m, 3H), 3.85-3.93(m, 1H)
EXAMPLE 187
8-(tert-Butoxycarbonyl)-8-azabicyclo[4.3.0]nonan-3-one
[2047] 4.9 g of oxalyl chloride was dissolved in 250 ml of
dichloromethane and cooled to -78.degree. C. in a nitrogen
atmosphere. Then a solution of 4.83 g of dimethyl sulfoxide in
dichloromethane (20 ml) was dropped thereinto over 17 minutes.
Subsequently, a solution of 3.73 g of
8-(tert-butoxycarbonyl)-8-azabicyclo[4.3.0]nonan-3-ol in
dichloromethane (40 ml) was dropped thereinto over 10 minutes.
After stirring for,10 minutes, 7.82 g of triethylamine was dropped
thereinto over 10 minutes and stirring was continued for additional
1 hour. The reaction mixture was brought back to room temperature,
diluted with dichloromethane, washed with water and a saturated
aqueous solution of sodium chloride and then dried over anhydrous
magnesium sulfate. After filtration, the solvent was distilled off
under reduced pressure. The residue thus obtained was purified by
silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 3.21 g of the title compound as a
colorless oily substance. 532
[2048] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2049] 1.45(s, 9H), 1.81-1.93(m, 1H), 2.00-2.10(m, 1H),
2.30-2.55(m, 5H), 2.65-2.75(m, 1H), 3.05-3.14(m, 1H), 3.30-3.38(m,
1H), 3.48-3.55(m, 2H)
EXAMPLE 188 to 191
[2050] Appropriate known compounds were treated in the same manner
as those described in Production Example 14 and Example 16 to
thereby give the following compounds.
56 Ex. Structural formula NMR 188 5337-(tert- butoxycarbonyl)-7-
azaspiro[3.5]nonan-2- one .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.46(s, 9H), 1.69(t, J=6Hz, 4H), 2.81(s, 4H), 3.41(t, J=6Hz, 4H)
189 5343-(tert- butoxycarbonyl)-3- azabicyclo[3.3.0]octa
ne-7-spiro-(3'- cyclobutanone) .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.45(s, 9H), 1.75(dd, J=6.4, 13.2Hz, 2H), 2.11(dd, J=7.6, 13.2Hz,
2H, 2.67-2.99(m, 2H), 2.88(d, J=2.4Hz, 2H), 3.04(dd, J=3.2, 4.0Hz,
2H), # 3.23-3.36(m, 2H), 3.41-3.52(m, 2H) 190 5356-(tert-
butoxycarbonyl)-6- azaspiro[3.4]octan-2- one
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.46(s, 9H), 2.01-2.08(m, 2H),
2.90-3.14(m, 4H), 3.36-3.53(m, 4H), 191 5363-[1-(tert-
butoxycarbonyl)piperi din-4-yl]cyclobutan- 1-one
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.08-1.21(m, 2H), 1.34-1.50(m,
1H), 1.46(s, 9H), 1.67-1.77(m, 2H), 2.04-2.17(m, 1H), 2.60-2.80(m,
2H), 2.72-2.83(m, 2H), 3.03-3.14(m, 2H), 4.01- # 4.27(m, 2H)
EXAMPLE 192
1-Benzyl-2-methyl-4-piperidone
[2051] 6.97 g of 4-methoxy-2-methylpyridine was dissolved in 200 ml
of acetone and 13.5 g of benzyl bromide was added thereto. Then the
resulting mixture was heated under reflux for 2 hours and 30
minutes. The reaction mixture was cooled to room temperature and
diluted with diethyl ether. The precipitate was taken up by
filtration and the solid matter was dissolved in 60 ml of water.
Next, 5.35 g of sodium borohydride was added thereto in portions.
After stirring for 15 minutes, the reaction mixture was
concentrated under reduced pressure, diluted with ethyl acetate,
washed successively with water and a saturated aqueous solution of
sodium chloride and dried over anhydrous magnesium sulfate. After
filtration, the solvent was distilled off under reduced pressure.
To the obtained residue was added 5 N hydrochloric acid and the
resulting mixture was stirred at room temperature overnight. The
reaction mixture was made basic by adding potassium carbonate,
extracted with ethyl acetate, washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After filtration, the solvent was distilled off under
reduced pressure and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
6.84 g of the title compound as a colorless oily substance. 537
[2052] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2053] 1.18(d, J=6.4 Hz, 3H), 2.29(dd, J=7.6, 14.4 Hz, 1H),
2.34-2.42(m, 2H), 2.50-2.60(m, 2H), 2.94-3.06(m, 2H), 3.45(d,
J=12.8 Hz, 1H), 3.97(d, J=12.8 Hz, 1H), 7.25-7.40(m, 5H)
EXAMPLE 193
1-Benzyl-2-methyl-4-methylenepiperidine
[2054] 6.84 g of 1-benzyl-2-methyl-4-piperidone was treated in the
same manner as the one of Production Example 14 to thereby give
6.41 g of the title compound as a pale yellow oily substance.
538
[2055] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2056] 1.14(d, J=6.0 Hz, 3H), 2.00-2.38(m, 5H), 2.46-2.62(m, 1H),
2.70-2.82(m, 1H), 3.26-3.38(m, 1H), 3.87-4.00(m, 1H), 4.65(d,
J=10.4 Hz, 2H), 7.14-7.42(m, 5H)
EXAMPLE 194
1-(tert-Butoxycarbonyl)-2-methyl-4-methylenepiperidine
[2057] 6.41 g of 1-benzyl-2-methyl-4-methylenepiperidone was
dissolved in 70 ml of dichloroethane and 5.92 g of 1-chloroethyl
chloroformate was added thereto under ice-cooling. After heating
the mixture under reflux for 50 minutes, 100 ml of methanol was
added thereto and the resulting mixture was allowed to stand at
room temperature overnight. Then triethylamine was added to the
reaction mixture under ice-cooling until the pH value reached 9.
Further, 7.64 g of tert-butyl dicarbonate was added thereto and the
resulting mixture was stirred at room temperature for 1 hour. The
reaction mixture was concentrated under reduced pressure, diluted
with ethyl acetate, washed successively with water, 1 N
hydrochloric acid, a saturated aqueous solution of sodium chloride
and a saturated aqueous solution of sodium bicarbonate and dried
over anhydrous magnesium sulfate. After filtration, the solvent was
distilled off under reduced pressure and the obtained residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 7.2 g of the title compound
as a colorless oily substance. 539
[2058] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2059] 1.06(d, J=6.8 Hz, 3H), 1.47(s, 9H), 1.99-2.05(m, 1H),
2.08-2.23(m, 2H), 2.35-2.43(m, 1H), 2.81-2.90(m, 1H), 3.98-4.06(m,
1H), 4.45-4.55(m, 1H), 4.72-4.75(m, 1H), 4.83-4.86(m, 1H)
EXAMPLE 195
7-(tert-Butoxycarbonyl)-6-methyl-7-azaspiro[3.5]nonan-2-one
[2060] 7.2 g of
1-(tert-butoxycarbonyl)-2-methyl-4-methylenepiperidine was treated
in the same manner as the one described in Production Example 16 to
thereby give 2.98 g of the title compound as a yellow oily
substance. 540
[2061] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2062] 1.10-1.18(m, 3H), 1.47(s, 9H), 1.61-1.75(m, 3H), 2.00(dd,
J=6.4, 13.6 Hz, 1H), 2.72-3.04(m, 5H), 4.01-4.09(m, 1H),
4.42-4.52(m, 1H)
EXAMPLE 196
1-Benzyl-4-[4-[2-(methoxymethoxy)ethyl]phenyl]piperidin -4-ol
[2063] Into a solution of 10 g of 4-bromophenethyl methoxymethyl
ether in 200 ml of tetrahydrofuran was dropped 28 ml of a 1.6 M
solution of n-butyllithium in hexane at -78.degree. C. and the
resulting mixture was stirred at the same temperature for 30
minutes. After heating to -20.degree. C., a solution of 7.0 g of
1-benzyl-4-piperidone in tetrahydrofuran (10 ml) was added thereto.
The mixture was reacted at the same temperature for 2 hours. After
adding water, the resulting mixture was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, 7.6 g of the
title compound was obtained as a yellow oily substance. 541
[2064] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2065] 1.65(br.t, J=13 Hz, 2H), 2.0-2.18(m, 2H), 2.40(br.t, J=10
Hz, 2H), 2.6-2.75(m, 2H), 2.83(t, J=7 Hz, 2H), 3.23(s, 3H), 3.51(s,
2H), 3.69(t, J=7 Hz, 2H), 4, 54(s, 2H), 7.1-7.35(m, 7H), 7.35(d,
J=8 Hz, 2H)
EXAMPLE 197
4-(1-Benzyl-1,2,5,6-tetrahydropyrid-4-yl)phenethyl alcohol
[2066] To a solution of 1.0 g of
1-benzyl-4-[4-[2-(methoxymethoxy)ethyl]ph- enyl]piperidin-4-ol in
30 ml of toluene was added 2.0 g of p-toluenesulfonic acid. Then
the resulting mixture was heated under reflux for 1 hour while
eliminating the water thus formed with a Dean Stark trap. Then the
reaction mixture was brought back to room temperature and a
saturated aqueous solution of sodium bicarbonate was added thereto.
Then it was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.2 g of the title compound as a brown oily substance. 542
[2067] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2068] 2.55(m, 2H), 2.71(t, J=6 Hz, 2H), 2.85(t, J=6 Hz, 2H),
3.17(dd, J=2, 6 Hz, 2H), 3.64(s, 2H), 3.84(t, J=6 Hz, 2H), 6.04(m,
1H), 7.14-7.40(m, 9H)
EXAMPLE 198 to 202
[2069] The following compounds were obtained by the same methods as
those described in Examples 196 and 197.
57 Ex. Structural formula NMR 198 5434-(4-bromophenyl)-1-
benzyl-1,2,3,6- tetrahydropyridine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.43(br.s, 2H), 2.55-2.65(m, 2H), 3.03(br.s, 2H), 3.55(s, 2H),
6.18(s, 1H), 7.2-7.5(m, 9H) 199 5444-(4-benzyloxyphenyl)-
1-benxyl-1,2,3,6- tetrahydropyridine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.5-2.57(m, 2H), 2.70(t, J=6Hz, 2H), 3.15(d, J=3Hz,
2H), 3.63(s, 2H), 5.05(s, 2H), 5.97(s, 1H), 6.92(d, J=9Hz, 2H),
7.23-7.45(m, 12H) 200 5454-[3-[2- (benzyloxy)ethyl]phenyl
]-1-benzyl-1,2,3,6- tetrahydropyridine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.54(s, 2H), 2.71(t, J=5Hz, 2H), 2.93(t, J=5Hz, 2H),
3.16(s, 2H), 3.65(s, 2H), 3.69(t, J=5Hz, 2H), 4.52(s, 2H), 6.04(s,
1H), 7.10(s, 1H), 7.2-7.4(m, 13H) 201 5464-[4-methoxy-3-[2-
(benzyloxy)ethyl]phenyl ]-1-benzyl-1,2,3,6- tetrahydropyridine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.53(s, 2H), 2.70(t, J=6Hz,
2H), 2.95(t, J=6Hz, 2H), 3.15(s, 2H), 3.63(s, 2H), 3.6-3.7(m, 2H),
3.78(s, 3H), 4.53(s, 2H), 5.94(s, 1H), 7.2-7.4(m, 13H) 202
5474-[4,5-dimethoxy-3-[2- (benzyloxy)ethyl]phenyl
]-1-benzyl-1,2,3,6- tetrahydropyridine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.52(br.s, 2H), 2.70(t, J=6Hz, 2H), 2.95(t, J=8Hz,
2H), 3.16(dd, J=3, 6Hz, 2H), 3.64(s, 2H), 3.66(t, J=8Hz, 2H),
3.79(s, 3H), 3.85(s, 3H), 4.52(s, # 2H), 5.94-5.98(m, 1H), 6.81(d,
J=2Hz, 1H), 6.84(d, J=2Hz, 1H), 7.22-7.40(m, 10H)
EXAMPLE 203
4-[1-(Benzyloxycarbonyl)piperidin-4-yl]phenethyl alcohol
[2070] To a solution of 8.0 g of 4-(1-benzyl
-1,2,5,6-tetrahydropyrid-4-yl- )phenethyl alcohol in ethanol (200
ml) was added 15 g of 10% palladium-carbon (moisture content: 50%)
and hydrogenation was effected at ordinary temperature under
atmospheric pressure for 12 hours. After the completion of the
reaction, the palladium-carbon was filtered off and the filtrate
was distilled under reduced pressure to thereby give 4.0 g of crude
4-(piperidin-4-yl)phenethyl alcohol as a colorless oily substance.
To 4.0 g of this crude product and 3.3 ml of triethylamine
dissolved in dichloromethane (30 ml) was added 3.1 ml of benzyl
chloroformate at 0.degree. C. and the mixture was reacted at room
temperature for 1 hour. After adding water, the reaction mixture
was extracted with ethyl acetate, washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 4.0 g of the
title compound as a yellow oily substance. 548
[2071] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2072] 1.55-1.70(m, 2H), 1.77-1.90(m, 2H), 2.6-2.7(m, 1H), 2.84(t,
J=7 Hz, 2H), 2.8-3.0(m, 2H), 3.8-3.9(m, 2H), 4.2-4.4(m, 2H),
5.15(s, 2H), 7.14(d, J=8 Hz, 2H), 7.18(d, J=8 Hz, 2H), 7.30-7.40(m,
5H)
EXAMPLE 204 and 205
[2073] The following compounds were obtained by the same method as
that of Example 203.
58 Ex. Structural formula NMR 204 5494-[1- (benzyloxycarbonyl)
piperidin-4-yl]phenol .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.50-1.70(m, 2H), 1.77-1.85(m, 2H), 2.55-2.65(m, 1H), 2.8-3.0(m,
2H), 4.2-4.4(m, 2H), 5.15(s, 2H), 6.78(d, J=7Hz, 2H), 7.04(d,
J=7Hz, 2H), 7.3-7.4(m, 5H) 205 5503-[1- (benzyloxycarbonyl)
piperidin-4-yl]phenethyl alcohol .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.55-1.73(m, 2H), 1.8-1.9(m, 2H), 2.6-2.7(m, 1H) 2.85(t,
J=6Hz, 2H), 2.8-3.0(m, 2H), 3.86(t, J=6Hz, 2H), 4.2-4.4(m, 2H),
5.16(s, 2H), 7.04-7.12(m, 3H), 7.23- # 7.41(m 6H)
EXAMPLE 206
2-[1-(Benzyloxycarbonyl)piperidin-4-yl]phenethyl alcohol
[2074] The title compound was obtained by the same operations as
those described in Examples 196, 197 and 203. 551
[2075] .sup.1H-NMR(CDCl) .delta. ppm:
[2076] 1.5-1.8(m, 4H), 2.8-3.0(m, 2H), 2.95(t, J=7 Hz, 2H), 3.83(t,
J=7 Hz, 2H), 4.11(q, J=7 Hz, 2H), 4.2-4.4(m, 2H), 5.15(s, 2H),
7.1-7.3(m, 4H), 7.3-7.4(m, 5H)
EXAMPLE 207
4-[1-(Benzyloxycarbonyl)piperidin-4-yl]phenylacetaldehyde
[2077] 4.0 g of 4-[1-(benzyloxycarbonyl)piperidin -4-yl]phenethyl
alcohol was treated in the same manner as the one of Production
Example 7 to thereby give 1.7 g of the title compound as a yellow
oily substance. 552
[2078] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2079] 1.55-1.70(m, 2H), 1.77-1.90(m, 2H), 2.6-2.73(m, 1H),
2.7-3.0(m, 2H), 3.67(d, J=1 Hz, 2H), 4.2-4.43(m, 2H), 5.16(s, 2H),
7.16(d, J=8 Hz, 2H), 7.20(d, J=8 Hz, 2H), 7.3-7.4(m, 5H), 9.74(t,
J=2 Hz, 1H)
EXAMPLE 208 to 210
[2080] The following compounds were obtained by the same procedure
as the one of Production Example 7.
59 Ex. Structural formula NMR 208 5533-[1-(benzyloxycarbonyl)-
piperidin-4-yl]- phenylacetaldehyde .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 1.5-1.75(m, 2H), 1.75-1.9(m, 2H), 2.6-2.75(m, 1H),
2.8-3.0(m, 2H), 3.67(d, J=2Hz, 2H), 4.3-4.45(m, 2H), 5.16(s, 2H),
7.0-7.4(m, 9H), 9.74(t, J=2Hz, 1H) 209 5542-[1-(benzyloxycarbonyl)-
piperidin-4-yl]- phenylacetaldehyde .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 1.57-1.8(m, 4H), 2.65-2.8(m, 1H), 2.75-3.0(m, 2H),
3.77(s, 2H), 4.2-4.45(m, 2H), 5.16(s, 2H), 7.1-7.4(m, 9H), 9.75(s,
1H) 210 5552-methoxy-5-[1-(benzyloxy- carbonyl)piperidin-4-yl]-
phenylacetaldehyde .sup.1H-NMR(CDCl.sub.3) # .delta. ppm:
1.5-1.7(m, 2H), 1.7-1.9(m, 2H), 2.8-3.0(m, 2H), 3.0-3.2(m, 1H),
3.60(s, 2H), 3.83(s, 3H), 4.2-4.4(m, 2H), 5.15(s, 2H), 6.85(d,
J=8Hz, 1H), 6.95(s, 1H), 7.04(d, J=8Hz, 1H), 7.2-7.4(m, 5H), 9.7(s,
1H)
EXAMPLE 211
4-[1-(Benzyloxycarbonyl)piperidin-4-yl]phenylacetic acid
[2081] To a solution of 0.7 g of 4-[1-(benzyloxycarbonyl)-piperidin
-4-yl]phenylacetaldehyde and 0.5 g of sodium dihydrogenphosphate in
5 ml of water and 30 ml of dimethyl sulfoxide was added a solution
of 0.35 g of sodium chlorite in water (5 ml) and the resulting
mixture was reacted at room temperature for 20 minutes. After
adding water, the reaction mixture was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, 0.7 g of the
title compound was obtained as a colorless oily substance. 556
[2082] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2083] 1.5-1.7(m, 2H), 1.7-1.9(m, 2H), 2.6-2.7(m, 1H), 2.8-3.0(m,
2H), 3.62(s, 2H), 4.2-4.45(m, 2H), 5.15(s, 2H), 7.15(d, J=8 Hz,
2H), 7.23(d, J=8 Hz, 2H), 7.28-7.40(m, 5H)
EXAMPLE 212
Methyl 4-[1-(benzyloxycarbonyl)piperidin-4-yl]phenylacetate
[2084] To a solution of 1.55 g of
4-[1-(benzyloxycarbonyl)-piperidin -4-yl]phenylacetic acid in
methanol (20 ml) was added 13.2 ml of trimethylsilyldiazomethane (2
M solution in hexane) and the resulting mixture was reacted at room
temperature for 1 hour. After distilling off the reaction mixture
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 1.0 of the title compound as a colorless oily
substance. 557
[2085] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2086] 1.5-1.7(m, 2H), 1.75-1.88(m, 2H), 2.6-2.7(m, 1H),
2.8-2.95(m, 2H), 3.60(s, 2H), 3.69(s, 3H), 4.2-4.4(m, 2H), 5.15(s,
2H), 7.15(d, J=8 Hz, 2H), 7.22(d, J=8 Hz, 2H), 7.3-7.4(m, 5H)
EXAMPLE 213
Methyl 3-[1-(benzyloxycarbonyl)piperidin-4-yl]phenylacetate
[2087] To a solution of 2.0 g of 3-[1-(benzyloxycarbonyl)-piperidin
-4-yl]phenylacetaldehyde and 1.0 g of sodium dihydrogenphosphate in
10 ml of water and 50 ml of dimethyl sulfoxide was added a solution
of 2.0 g of sodium chlorite in water (10 ml) and the resulting
mixture was reacted at room temperature for 20 minutes. After
adding water, the reaction mixture was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, 2.0 g of crude
3-[1-(benzyloxycarbonyl)piperidin-4-yl]phenylacetic acid was
obtained as a colorless oily substance. To a solution of 2.0 g of
this oily substance in 50 ml of methanol was added 0.47 ml of
thionyl chloride at 0.degree. C. and the resulting mixture was
reacted at room temperature for 2 hours. The reaction mixture was
distilled off under reduced pressure and the residue was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 1.2 g of the title compound as a yellow
oily substance. 558
[2088] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2089] 1.5-1.7(m, 2H), 1.8-1.9(m, 2H), 2.6-2.7(m, 1H), 2.8-2.95(m,
2H), 3.61(s, 2H), 3.69(s, 3H), 4.25-4.40(m, 2H), 5.16(s, 2H),
7.13-7.16(m, 3H), 7.24-7.40(m, 6H)
EXAMPLE 214 to 216
[2090] The following compounds were obtained by the same procedure
as that of Example 213.
60 Ex. Structural formula NMR 214 559methyl
2-[1-(benzyloxycarbonyl)- piperidin-4-yl]phenylacetate
.sup.1H-NMR(CDCl.sub.3) 5 ppm: 1.55-1.8(m, 4H), 2.8-2.95(m, 3H),
3.68(s, 3H), 3.70(s, 2H), 4.2-4.4(m, 2H), 5.16(s, 2H), 7.14-7.40(m,
9H) 215 560methyl 2-methoxy-5-[1- (benzyloxycarbonyl)piperidin-4-
yl]phenylacetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.5-1.7(m,
2H), # 1.75-1.85(m, 2H), 2.8-3.0(m, 2H), 3.0-3.2(m, 1H), 3.55(s,
2H), 3.69(s, 3H), 3.81(s, 3H), 4.2-4.4(m, 2H), 5.16(s, 2H), 6.81(d,
J=8Hz, 1H), 7.03(d, J=2Hz, 1H), 7.10(dd, J=2, 8Hz, 1H), 7.3-7.4(m,
5H) 216 561methyl 2,3-dimethoxy-5-[1- (benzyloxycarbonyl)
piperidin- 4-yl]phenylacetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.5-1.7(m, 2H), 1.8-1.9(m, 2H), 2.55-2.65(m, # 1H), 2.75-2.95(m,
2H), 3.63(s, 2H), 3.70(s, 3H), 3.80(s, 3H), 3.95(s, 3H), 4.2-4.4(m,
2H), 5.15(s, 2H), 6.64(s, 1H), 6.66(s, 1H), 7.3-7.40(m, 5H)
EXAMPLE 217
Ethyl 4-[1-benzyl-1,2,3,6-tetrahydropyrid-4-yl]benzoate
[2091] To a solution of 11 g of 4-(4-bromophenyl)
-1-benzyl-1,2,3,6-tetrah- ydropyridine in 200 ml of tetrahydrofuran
was added 27 ml of a 2.5 M solution of n-butyllithium in hexane at
-78.degree. C. and the resulting mixture was stirred at the same
temperature for 15 minutes. Into the reaction mixture was dropped
42 ml of diethyl carbonate and the mixture was heated to room
temperature over 15 minutes. After adding water, the reaction
mixture was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
2.8 g of the title compound as a yellow oily substance. 562
[2092] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2093] 1.39(t, J=7 Hz, 3H), 2.5-2.62(m, 2H), 2.73(t, J=6 Hz, 2H),
3.07-3.11(m, 2H), 3.65(s, 2H), 4.37(q, J=7 Hz, 2H), 6.20(s, 1H),
7.24-7.42(m, 5H), 7.44(d, J=8 Hz, 2H), 7.98(d, J=8 Hz, 2H)
EXAMPLE 218
Ethyl 4-[1-(benzyloxycarbonyl)piperidin-4-yl]phenoxyacetate
[2094] To a solution of 0.5 g of [1-(benzyloxycarbonyl)piperidin
-4-yl]phenol in 20 ml of N,N-dimethylformamide was added 0.083 g of
sodium hydride (60% or more oily) and the resulting mixture was
stirred at room temperature for 10 minutes. Next, ethyl iodoacetate
was added thereto and the resulting mixture was reacted at
60.degree. C. for 1.5 hours. The reaction mixture was poured into
water, extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.4 g of the title compound as a colorless oily substance. 563
[2095] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2096] 1.30(t, J=7 Hz, 3H), 1.5-1.70(m, 2H), 1.75-1.90(m, 2H),
2.55-2.70(m, 1H), 2.8-2.95(m, 2H), 4.27(q, J=7 Hz, 2H), 4.2-4.4(m,
2H), 4.60(s, 2H), 5.15(s, 2H), 6.85(d, J=9 Hz, 2H), 7.11(d, J=9 Hz,
2H), 7.28-7.40(m, 5H)
EXAMPLE 219
Ethyl 4-(1-benzylpiperidin-4-yl)-2-methylpropanoate
[2097] To a solution of 40 g of ethyl 4-(1-benzylpiperidin
-4-yl)-2-methylpropanoate in ethanol (500 ml) were added 25 ml of
formic acid and 15 g of 10% palladium-carbon (moisture content:
50%) and hydrogenation was effected at ordinary temperature under
atmospheric pressure for 12 hours. Then the palladium-carbon was
filtered off and the solvent was distilled off. The residue was
poured into an aqueous solution of sodium bicarbonate and extracted
with ethyl acetate. The extract was washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
37.8 g of the title compound was obtained as a colorless oily
substance. 564
[2098] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2099] 1.10(t, J=7 Hz, 3H), 1.00-1.25(m, 6H), 1.50-1.80(m, 4H),
1.80-1.97(m, 2H), 2.43-2.62(m, 1H), 2.80-2.90(m, 2H), 3.46(s, 2H),
4.05-4.18(m, 2H), 7.20-7.30(m, 5H)
EXAMPLE 220
Ethyl 3-(1-benzylpiperidin-4-yl)-2,2-dimethylpropanoate
[2100] To a solution of 68 ml of diisopropylamine in
tetrahydrofuran (500 ml) was added 325 ml of a 1.6 M solution of
n-butyllithium in hexane and the resulting mixture was stirred at
0.degree. C. for 30 minutes. Then the reaction mixture was cooled
to -78.degree. C. and reacted with a solution of 30 g of ethyl
4-(1-benzylpiperidin-4-yl)-2-methylpropanoate in tetrahydrofuran
(50 ml) at 0.degree. C. for 30 minutes. After cooling to
-78.degree. C. again, 45.3 ml of methyl iodide was dropped
thereinto and the resulting mixture was brought back to room
temperature over 30 minutes. The reaction mixture was poured into
water, extracted with dichloromethane and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
21.5 g of the title compound as a yellow oily substance. 565
[2101] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2102] 1.15(s, 6H), 1.23(t, J=7 Hz, 3H), 1.1-1.4(m, 3H), 1.53(d,
J=7 Hz, 2H), 1.5-1.60(m, 2H), 1.90(br.t, J=10 Hz, 2H), 2.80(br.d,
J=10 Hz, 2H), 3.45(s, 2H), 4.08(q, J=7 Hz, 2H), 7.2-7.34(m, 5H)
EXAMPLE 221
Ethyl 2-(1-benzylpiperidin-4-yl)-2-methylpropanoate
[2103] Ethyl 2-(1-benzylpiperidin-4-yl)propanoate was treated in
the same manner as the one of Example 27 to thereby give the title
compound as an oily substance. 566
[2104] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2105] 1.10(s, 6H), 1.23(t, J=7 Hz, 3H), 1.39(dt, J=4, 12 Hz, 2H),
1.44-1.52(m, 2H), 1.52-1.62(m, 1H), 1.92(dt, J=2, 12 Hz, 2H),
2.93(br.d, J=12 Hz, 2H), 3.48(s, 2H), 4.11(q, J=7 Hz, 2H),
7.2-7.35(m, 5H)
EXAMPLE 222
3-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-2,2-dimethylpropanol
[2106] Into a solution of 2.7 g of lithium aluminum hydride in
tetrahydrofuran (200 ml) was slowly dropped at 0.degree. C. a
solution of 21.5 g of ethyl 3-(1-benzylpiperidin
-4-yl)-2,2-dimethylpropanoate in tetrahydrofuran (20 ml) and the
resulting mixture was stirred at room temperature for 30 minutes.
After adding water and a 10% aqueous solution of sodium hydroxide
to the reaction mixture, the insoluble matters were filtered off.
After distilling off the solvent under reduced pressure, 19 g of
crude 3-(1-benzylpiperidin-4-yl)-2,2-dimethylpropanol was obtained
as a yellow oily substance. This oily substance was dissolved in
300 ml of ethanol. After adding 20 ml of acetic acid, the mixture
was subjected to hydrogenation at ordinary temperature under
atmospheric pressure for 12 hours. After filtering off
palladium-carbon, the solvent was concentrated under reduced
pressure to thereby give 23 g of crude 3-(piperidin-4-yl)
-2,2-dimethylpropanol as a yellow oily substance. This crude
product was further dissolved in 200 ml of dichloromethane and 23
ml of pyridine was added thereto. Then 15.5 g of di-tert-butyl
dicarbonate was dropped thereinto at 0.degree. C. and the resulting
mixture was reacted at room temperature for 2 hours. After adding
water, the reaction mixture was extracted with ethyl acetate,
washed with a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 14.9 g of the title compound as colorless crystals.
567
[2107] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2108] 0.9(s, 6H), 1.1-1.2(m, 2H), 1.2(d, J=5 Hz, 2H), 1.3-1.4(m,
1H), 1.45(s, 9H), 1.6-1.7(m, 2H), 2.6-2.8(m, 2H), 3.31(s, 2H),
3.9-4.1(m, 2H)
EXAMPLE 223
4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-3,3-dimethyl-butyronitrile
[2109] To a solution of 14.9 g of
3-[1-(tert-butoxycarbonyl)-piperidin -4-yl]-2,2-dimethylpropanol in
100 ml of carbon tetrachloride was added 64 g of triphenylphosphine
and the resulting mixture was heated under reflux for 8 hours. The
reaction mixture was concentrated under reduced pressure and the
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 14.7 g of colorless
crystals. These crystals were dissolved in 200 ml of dimethyl
sulfoxide and 9.2 g of sodium iodide and 8.8 g of sodium cyanide
were added thereto. After stirring at 180.degree. C. for 6 hours,
water was added to the mixture at room temperature. Then the
reaction mixture was extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
6.7 g of the title compound as a colorless oily substance. 568
[2110] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2111] 1.09(s, 6H), 1.1-1.3(m, 2H), 1.33(d, J=5 Hz, 2H), 1.45(s,
9H), 1.45(m, 1H), 1.6-1.7(m, 2H), 2.24(s, 2H), 2.6-2.8(m, 2H),
3.9-4.1(m, 2H)
EXAMPLE 224
4-(1-Benzylpiperidin-4-yl)-3,3-dimethylbutyronitrile
[2112] To a solution of 6.7 g of
4-[1-(tert-butoxycarbonyl)-piperidin
-4-yl]-3,3-dimethylbutyronitrile in 50 ml of tetrahydrofuran was
added at room temperature 20 ml of conc. hydrochloric acid and the
resulting mixture was stirred for 2 hours. Then the reaction
mixture was concentrated under reduced pressure to thereby give
crude 4-(piperidin-4-yl)-3,3-dimethylbutyronitrile hydrochloride.
This crude product was dissolved in 100 ml of dichloromethane.
After adding 10.5 g of anhydrous potassium carbonate and 3.3 ml of
benzyl bromide, the reaction mixture was reacted at room
temperature for 12 hours. After adding water, the reaction mixture
was extracted with ethyl acetate, washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 4.7 g of the
title compound as a colorless oily substance. 569
[2113] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2114] 1.07(s, 6H), 1.3-1.4(m, 5H), 1.6-1.7(m, 2H), 1.96(br.t, J=12
Hz, 2H), 2.23(s, 2H), 2.83(br.d, J=12 Hz, 2H), 3.48(s, 2H),
7.2-7.4(m, 5H)
EXAMPLE 225
Methyl 4-(1-benzylpiperidin-4-yl)-3,3-dimethylbutanoate
[2115] To a solution of 4.7 g of 4-(1-benzylpiperidin
-4-yl)-3,3-dimethylbutyronitrile in ethylene glycol (20 ml) was
added 30 ml of an aqueous solution of 23 g of potassium hydroxide
and the resulting mixture was reacted at 200.degree. C. for 10
hours. After bringing back to room temperature, water was added to
the reaction mixture. Then the reaction mixture was made weakly
acidic with hydrochloric acid. After adding ethanol, the solvent
was distilled off under reduced pressure. The crude product thus
obtained was suspended in 500 ml of methanol and 6.3 ml of thionyl
chloride was dropped thereinto at 0.degree. C. After stirring at
room temperature for 72 hours, the solvent was distilled off under
reduced pressure. Then an aqueous solution of sodium hydroxide was
added to the residue followed by extraction with ethyl acetate. The
extract was washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 3.5 g of the title compound
as a colorless oily substance. 570
[2116] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2117] 1.0(s, 6H), 1.2-1.4(m, 5H), 1.55-1.8(m, 2H), 1.9-2.0(m, 2H),
2.21(s, 2H), 2.82(br.d, J=12 Hz, 2H), 3.47(s, 2H), 3.64(s, 3H),
7.2-7.35(m, 5H)
EXAMPLE 226
Methyl 3-[1-benzylpiperidin-4-yl]-3-methylbutanoate
[2118] Ethyl 2-(1-benzylpiperidin-4-yl)-2-methylpropanoate was
treated in the same manner as those of Examples 222, 223, 224 and
225 to thereby give the title compound as a yellow oily substance.
571
[2119] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2120] 0.96(s, 6H), 1.1-1.26(m, 1H), 1.25-1.44(m, 2H), 1.56-1.68(m,
2H), 1.84-1.96(m, 2H), 2.23(s, 2H), 2.96(br.d, J=12 Hz, 2H),
3.48(s, 2H), 3.64(s, 3H), 7.4-7.65(m, 5H)
EXAMPLE 227 to 236
[2121] The following compounds were obtained by treating known
compounds in the same manner as the one of Production Example
25.
61 Ex. Structural formula NMR 227 572ethyl
(E)-4-[1-(benzyloxycarbonyl)- piperidin-4-yl]-2-methyl-2-butenoa-
te .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.26(t, J=6Hz, 3H),
1.10-1.30(m, 2H), 1.50-1.60(m, 1H), 1.62-1.76(m, 2H), 1.82(s, 3H),
2.14(t, J=7Hz, 2H), 2.70-2.82(m, 2H), 4.10-4.23(m, 2H), 4.18(q,
J=6Hz, 2H), 5.12(s, 2H), 6.76(t, J=7Hz, 1H), 7.20-7.40(m, 5H) 228
573ethyl (E)-4-[1-(tert- butoxycarbonyl)-
piperidin-4-yl]-2-butenoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.04-2.20(m, 2H), 1.27(t, J=6Hz, 3H), 1.43(s, 9H), 1.58-1.70(m,
3H), 2.16(t, J=6Hz, 2H), 2.60-2.75(m, 2H), 4.00-4.18(m, 2H),
4.18(q, J=6Hz, 2H), 5.80(d, J=16Hz, 1H), 6.92(dt, J=6, 16Hz, 1H)
229 574ethyl 2-(1-benzylpiperidin-4-ylidene)pro- panoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.29(t, J=7Hz, 3H), 1.86(s,
3H), 2.36(t, J=6Hz, 2H), 2.42-2.52(m, 4H), 2.63(t, J=6Hz, 2H),
3.51(s, 2H), 4.18(q, J=7Hz, 2H), 7.2-7.4(m, 5H) 230 575ethyl
(E)-(1-benzylpyrrolidin-3-ylidene)acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.26(t, J=7Hz, 3H), 2.73(t, J=7Hz, 2H), 2.92-3.00(m,
2H), 3.26(d, J=1Hz, 2H), 3.65(s, 2H), 4.15(q, J=7Hz, 2H), 5.74(t,
J=2Hz, 1H), 7.2-7.4(m, 5H), 231 576ethyl
(Z)-(1-benzylpiperidin-3-yli- dene)acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.21(t, J=7Hz, 3H), 1.65-1.80(m, 2H), 2.23(t, J=6Hz,
2H), 2.50(t, J=6Hz, 2H), 3.61(s, 2H), 3.69(s, 2H), 4.10(q, J=7Hz,
2H), 5.67(s, 1H), 7.35(m, 5H) 232
577(E)-(1-benzylpiperidin-3-ylidene)acetic acid
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.26(t, J=7Hz, 3H),
1.68-1.76(m, 2H), 2.56(t, J=5Hz, 2H), 2.82-2.88(m, 2H), 2.95(s,
2H), 3.54(s, 2H), 4.14(q, J=7Hz, 2H), 5.63(s, 1H), 7.2-7.35(m, 5H)
233 578ethyl (E)-4-(1-benzylpiperidin-4-yl)-3-methyl-2-butenoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t, J=7Hz, 3H),
1.2-1.34(m, 2H), 1.4-1.7(m, 3H), 1.88-1.98(m, 2H), 2.05(d, J=7Hz,
2H), 2.13(d, J=1Hz, 3H), 2.87(br .multidot. d, J=12Hz, 2H), 3.49(s,
2H), 4.14(q, J=7Hz, 2H), 5.61-5.63(m, 1H), 7.2-7.35(m, 5H) 234
579ethyl (1,3,5-trimethylpiperidin-4-ylidene)acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.21(t, J=7Hz, 3H), 1.28(br
.multidot. s, 6H), 1.9-2.4(m, 2H), 2.21(br .multidot. s, 3H),
2.3-2.5(m, 1H), 2.5-2.7(m, 2H), 3.65-3.8(m, 1H), 4.08(q, J=7Hz,
2H), 5.58(s, 1H) 235 580ethyl
4-[(1-benzylpiperidin-4-ylidene)methyl]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.37(t, J=6Hz, 3H),
2.35-2.50(m, 4H), 2.50-2.60(m, 4H), 3.52(s, 2H), 4.35(q, J=6Hz,
2H), 6.30(br .multidot. s, 1H), 7.18-7.28(m, 3H), 7.28-7.40(m, 4H),
7.86(d, J=7Hz, 2H) 236 581ethyl 4-[1-(tert-
butoxycarbonyl)piperidin-4-yl]-2- -methyl-2-butenoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.00-1.20(m, 2H), 1.29(d,
J=7Hz, 3H), 1.20-1.4(m, 1H), 1.45(s, 9H), 1.6-1.7(m, 2H), 1.82(s,
3H), 2.13(t, J=8Hz, 2H), 2.60-2.75(m, 2H), 4.00-4.20(m, 2H),
4.19(q, J=7Hz, 2H), 6.76(t, J=8Hz, 1H)
EXAMPLE 237
Methyl 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-3-butenoate
[2122] 3.12 g of maleic acid and one drop of piperidine were added
to 50 ml of xylene and the resulting mixture was heated under
reflux for 30 minutes. After adding 2.27 g of
[1-(tert-butoxycarbonyl)piperidin -4-yl]acetaldehyde, the resulting
mixture was heated under reflux for 2 hours and 20 minutes while
eliminating water with a Dean Stark trap. Then the reaction mixture
was distributed into diethyl ether and water, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After filtration, the solvent was
distilled off under reduced pressure. The obtained residue was
dissolved in 150 ml of diethyl ether and treated with a solution of
diazomethane in diethyl ether. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.71 g of the title compound as an oily substance.
582
[2123] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2124] 1.03-1.25(m, 2H), 1.43(s, 9H), 1.60-1.70(m, 2H),
2.03-2.20(m, 2H), 2.55-2.80(m, 2H), 3.00-3.04(m, 1H),
3.67and3.73(s, 3H), 4.06(br.s, 2H), 5.43-5.58(m, 2H)
EXAMPLE 238
1-(tert-Butoxycarbonyl)piperidine-4-spiro-3'-(4'-butanolide)
[2125] To a solution of 0.856 g of 7-(tert-butoxycarbonyl)
-7-azaspiro[3.5]nonan-2-one in dichloromethane (30 ml) was added an
aqueous solution of 1.86 g of 3-chloroperbenzoic acid (purity:
50-60%) and 1.20 g of sodium hydrogencarbonate and the resulting
mixture was stirred for 18 hours. After adding 50 ml of water and
50 ml of dichloromethane, the organic layer was dried over
magnesium sulfate, filtered and concentrated under reduced
pressure. Then the residue was purified by silica gel column
chromatography (eluted with dichloromethane/ethyl acetate) to
thereby give 0.542 g of the title compound as white crystals.
583
[2126] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2127] 1.45(s, 9H), 1.58(m, 2H), 1.62(t, J=6 Hz, 2H), 2.44(s, 2H),
3.26(dt, J=6, 14 Hz, 2H), 3.57(dt, J=6, 14 Hz, 2H), 4.09(s, 2H)
EXAMPLE 239
8-(tert-Butoxycarbonyl)-2-oxa-8-azaspiro[4.5]decan -3-ol
[2128] Into a solution of 0.54 g of
1-(tert-butoxycarbonyl)-piperidine -4-spiro-3'-(4'-butanolide) in
dichloromethane (30 ml) was dropped in a nitrogen atmosphere 3.6 ml
of a 0.93 M solution of diisobutylaluminum hydride in hexane and
the reaction mixture was stirred at -70.degree. C. for 3 hours.
After adding 1 ml of methanol, water and dichloromethane were
further added thereto and the insoluble matters were filtered off.
The aqueous layer was extracted with dichloromethane. The organic
layers were combined, dried over magnesium sulfate, filtered and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 0.43 g of the title compound as a
colorless oily substance. 584
[2129] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2130] 1.45(s, 9H), 1.52(m, 2H), 1.66(m, 2H), 1.76(dd, J=2, 13 Hz,
1H), 1.99(dd, J=5, 13 Hz, 1H), 2.49(d, J=3 Hz, 1H), 3.29-3.48(m,
4H), 3.72(d, J=9 Hz, 1H), 3.84(d, J=9 Hz, 1H), 5.58(m, 1H)
EXAMPLE 240
Ethyl (E)-4-[1-(tert-butoxycarbonyl)-4-(hydroxymethyl)-piperidin
-4-yl]-2-methyl-2-butenoate
[2131] By using the same method as the one of Production Example
25, the title compound was obtained as an oily substance. 585
[2132] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2133] 1.29(t, J=7 Hz, 3H), 1.45(s, 9H), 1.44-1.51(m, 4H), 1.87(s,
3H), 2.30(d, J=7 Hz, 2H), 3.25(ddd, J=4, 7, 12 Hz, 2H), 3.46(ddd,
J=4, 7, 12 Hz, 2H), 3.49(d, J=6 Hz, 2H), 4.19(q, J=7 Hz, 2H),
6.81(tq, J=1, 7 Hz, 1H)
EXAMPLE 241 to 249
[2134] Appropriate ketones synthesized in Examples 188, 190, 189,
187, 184 and 195 and appropriate Wittig-Horner-Emons reagents were
treated in the same manner as the one of Production Example 25 to
thereby give the following compounds.
62 Ex. Structural formula NMR 241 586ethyl [7-(tert-
butoxycarbonyl)-7-azaspiro[3.5]non-2-ylidene]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t, J=7Hz, 3H), 1.46(s,
9H), 1.56-1.62(m, 4H), 2.55(br .multidot. s, 2H), 2.87(br
.multidot. s, 2H), 3.27-3.41(m, 4H), 4.15(q, J=7Hz, 2H),
5.69(quint, J=2Hz, 1H) 242 587ethyl 2-[7-(tert-
butoxycarbonyl)-7-azaspiro[3.5]non-2- ylidene]propanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t, J=7Hz, 3H), 1.45(s,
9H), 1.50-1.60(m, 4H), 1.71(t, J=1Hz, 3H), 2.50(br .multidot. s,
2H), 2.80(br .multidot. s, 2H), 3.35(m, 4H), 4.16(q, J=7Hz, 2H) 243
588ethyl [3-(tert- butoxycarbonyl)-3-azabicyclo[3- .3.0]oct-7-
ylidene]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t, J=7Hz,
3H), 1.44(s, 9H), 2.36-2.48(m, 1H), 2.64-2.83(m, 4H), 2.98-3.22(m,
3H), 3.48-3.60(m, 2H), 4.14(q, J=7.2Hz, 2H), 5.79-5.83(m, 1H) 244
589ethyl [6-(tert- butoxycarbonyl)-6-azaspiro[3.4]oct-2-
ylidene]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t,
J=7.2Hz, 3H), 1.45(s, 9H), 1.90(dt, J=2.4, 6.8Hz, 2H), 2.68-2.86(m,
2H), 2.99-3.19(m, 2H), 3.31-3.43(br .multidot. s, 4H), 4.08-4.22(m,
2H), 5.67-5.71(m, 1H) 245 590ethyl [3-(tert-
butoxycarbonyl)-3-azabicyclo[3.3.0]octane-7-
spirocyclobut-3'-ylidene]ace- tate .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 1.22-1.28(m, 3H), 1.45(s, 9H), 1.53-1.65(m, 2H),
1.96-2.06(m, 2H), 2.58-2.72(m, 3H), 2.78(d, J=1.6Hz, 1H), 2.93(dd,
J=2.4, 4.8Hz, 1H), 3.07(d, J=1.6Hz, 1H), 3.17-3.27(m, 2H),
3.38-3.50(m, 2H), 4.08-4.20(m, 2H), 5.61-5.67(m, 1H) 246 591ethyl
(E)-[8-(tert- butoxycarbonyl-8-azabicyclo[4.3.0- ]-non-3-
ylidene]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24-1.32(m,
3H), 1.49(s, 9H), 1.74-1.86(m, 1H), 2.10-2.58(m, 5H), 2.70-2.78(m,
1H), 3.02-3.46(m, 5H), 4.10-4.18(m, 2H), 5.66(s, 1/2H), 5.73(s,
1/2H) 247 592ethyl (2-benzyl-2- azaspiro[3.5]non-7-ylidene)acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t, J=7.1Hz, 3H),
1.78-1.87(m, 4H), 2.13-2.19(m, 2H), 2.77-2.82(m, 2H), 3.09(s, 4H),
3.68(s, 2H), 4.13(q, J=7.1Hz, 2H), 5.62(s, 1H), 7.23-7.27(m, 1H),
7.28-7.35(m, 4H) 248 593ethyl [7-(tert-
butoxycarbonyl)-6-methyl-7-azaspiro[3.- 5]-non-2- ylidene]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.08-1.18(m, 3H), 1.23-1.33(m,
3H), 1.45(s, 9H), 1.40-1.80(m, 3H), 2.43-3.26(m, 5H), 3.91-4.08(m,
1H), 4.10-4.24(m, 3H), 4.33-4.50(m, 1H), 5.65-5.69(m, 1H) 249
594ethyl (E)-3-[1-(tert- butoxycarbonylpiperidin-4-yl]-2-butenoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.28(t, J=6.8Hz, 3H),
1.35-1.48(m, 2H), 1.46(s, 9H), 1.64-1.73(m, 2H), 2.03-2.17(m, 1H),
2.15(s, 3H), 2.62-2.76(m, 2H), 4.04-4.25(m, 2H), 4.15(q, J=6.8Hz,
2H), 5.66(s, 1H)
EXAMPLE 250 to 257
[2135] The compounds obtained in Examples 241, 243, 244, 245, 246,
234, 248 and 236 were treated in the same manner as the one of
Example-20 to thereby give the following compounds.
63 Ex. Structural formula NMR 250 595ethyl [7-(tert-
butoxycarbonyl)-7-azaspiro[3.5]non-2-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25(t, J=7Hz, 3H), 1.45(s,
9H), 1.44-1.55(m, 6H), 2.04(m, 2H), 2.41(d, J=7Hz, 2H), 2.64(sept,
J=7Hz, 1H), 3.25(t, J=6Hz, 2H), 3.34(t, J=6Hz, 2H), 4.11(q, J=7Hz,
2H) 251 596ethyl [3-(tert-
butoxycarbonyl)-3-azabicyclo[3.3.0]oct-7-yl]aceta- te
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.00-1.13(m, 2H), 1.25(t,
J=7Hz, 3H), 1.45(s, 9H), 2.08-2.16(m, 2H), 2.24-2.40(m, 3H),
2.55-2.75(m, 2H), 3.00-3.62(m, 4H), 4.13(q, J=7.2Hz, 2H) 252
597ethyl [6-(tert- butoxycarbonyl)-6-azaspiro[3.5]non-2-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.21-1.28(m, 3H), 1.44 and
1.45(s, total 9H, 5:4), 1.64-1.79(m, 2H), 1.84-1.93(m, 1H),
2.05-2.21(m, 2H), 2.38-2.44(m, 2H), 2.58-2.69(m, 1H), 3.14-3.40(m,
5H), 4.07-4.15(m, 2H) 253 598ethyl [3-(tert-
butoxycarbonyl)-3-azabicyclo[3.3.0]oc- tane-7-
spirocyclobut-3'-yl]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.23(t, J=7.2Hz, 3H), 1.40-1.62(m, # 3H), 1.44(s, 9H), 1.74(dd,
J=9.2, 11.2Hz, 1H), 1.81(dd, J=7.6, 12.8Hz, 1H), 1.99-2.14(m, 3H),
2.36 and 2.37(s, total 2H, 2:3), 2.50-2.67(m, 3H), 3.06-3.26(m,
2H), 3.36-3.48(m, 2H), 4.09(q, J=7.2Hz, 2H) 254 599ethyl [8-(tert-
butoxycarbonyl)-8-azabicyclo[4.3.0]non-3-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.88-1.16(m, 2H), 1.24(t,
J=6.8Hz, 3H), 1.45(s, 9H), 1.50-1.84(m, 4H), 1.90-2.42(m, 5H),
3.08-3.38(m, 4H), 4.12(q, J=6.8Hz, 2H) 255 600ethyl
(1,3,5-trimethylpiperid- in-4-yl)acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 0.86(d, J=7Hz, 6H), 1.25(d, J=7Hz, 3H), 1.69(br
.multidot. t, J=12Hz, 2H), 1.95-2.05(m, 2H), 2.15(d, J=6Hz, 2H),
2.25(s, 3H), 2.2-2.3(m, 1H), 2.51(br .multidot. d, J=12Hz, 2H),
4.12(q, J=7Hz, 2H) 256 601ethyl [7-(tert-
butoxycarbonyl)-6-methyl-7- azaspiro[3.5]-non-2-yl]acetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.07 and 1.15(d, J=7.2Hz,
total 3H, # 1:1), 1.25(t, J=7.2Hz, 3H), 1.45(s, 9H), 1.34-2.00(m,
7H), 2.16-2.94(m, 5H), 3.78-3.94(m, 1H), 4.10(q, J=7.2Hz, 2H),
4.22-4.37(m, 1H) 257 602ethyl 4-[1-(tert-
butoxycarbonyl)piperidin-4-y- l]-2-methylbutanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.0-1.7(m, 7H), 1.15(d, J=7Hz,
3H), 1.25(t, J=7Hz, 3H), 1.44(s, 9H), 2.36(m, 3H), 2.0-2.7(m, 2H),
4.0-4.2(m, 2H), 4.12(q, J=7Hz, 2H)
EXAMPLE 258
Ethyl
3-[1-(tert-butoxycarbonyl)piperidin-4-yl]cyclobutylacetate
[2136] 3-[1-(Tert-butoxycarbonyl)piperidin-4-yl]cyclobutan -1-one
was treated in the same manner as those of Production Example 25
and Example 20 to thereby give the title compound. 603
[2137] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2138] 0.87-1.00(m, 2H), 1.24(t, J=7.0 Hz, 3H), 1.30-1.39(m, 1H),
1.45(s, 9H), 1.53-1.67(m, 4H), 1.73-1.84(m, 1H), 1.86-1.97(m, 1H),
2.17-2.26(m, 1H), 2.35(t, J=7.5 Hz, 1H), 2.48(t, J=7.5 Hz, 1H),
2.54-2.72(m, 3H), 4.00-4.19(m, 2H), 4.11(q, J=7.0 Hz, 2H)
EXAMPLE 259
Ethyl 3-[1-(tert-butoxycarbonyl)piperidin-4-yl]butanoate
[2139] 1-(tert-Butoxycarbonyl)piperidin-4-yl methyl ketone was
treated in the same manner as those of Production Example 25 and
Example 20 to thereby give the title compound. 604
[2140] .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.91(d, J=6.8 Hz, 3H),
1.13-1.27(m, 2H), 1.26(t, J=7.0 Hz, 3H), 1.27-1.48(m, 1H), 1.45(s,
9H), 1.53-1.62(m, 2H), 1.87-1.95(m, 1H), 2.10(dd, J=8.6, 14.9 Hz,
1H), 2.36(dd, J=4.7, 14.9 Hz, 1H), 2.57-2.69(m, 2H), 4.04-4.22(m,
2H), 4.13(q, J=7.0 Hz, 2H)
EXAMPLE 260
2-Trimethylsilylethyl
N-(1-benzylpiperidin-4-yl)sulfamoylacetate
[2141] Into a solution of 1.586 g of chlorosulfonylacetyl chloride
in diethyl ether (12 ml) was dropped in a nitrogen atmosphere at
-10.degree. C. a solution of 1.060 g of 2-trimethylsilylethanol in
diethyl ether (10 ml). After stirring at 0.degree. C. for 1 hour,
the reaction mixture was concentrated under reduced pressure and
the residue was dissolved in diethyl ether (15 ml) again. Into this
solution was dropped a solution of 3.41 g of
1-benzyl-4-aminopiperidine in diethyl ether (15 ml) and the
resulting mixture was stirred for 20 hours. After adding 50 ml of
water and 50 ml of ethyl acetate, the organic layer was dried over
magnesium sulfate, filtered and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 2.21 g of the title compound as a colorless oily substance.
605
[2142] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2143] 0.00(s, 9H), 0.95(m, 2H), 1.59(qd, J=3, 12 Hz, 2H),
1.94(br.d, J=12 Hz, 2H), 2.09(br.t, J=12 Hz, 2H), 2.77(br.d, J=12
Hz, 2H), 3.31(br.s, 1H), 3.46(s, 2H), 3.92(s, 2H), 4.22(m, 2H),
4.70(br.s, 1H), 7.25-7.30(m, 5H)
EXAMPLE 261
Ethyl
4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2,2-dimethylbutanoate
[2144] 4.792 g of ethyl 4-[1-(tert-butoxycarbonyl)piperidin
-4-yl]-2-methylbutanoate was treated in the same manner as the one
of Example 220 to thereby give 4.21 g of the title compound as a
colorless oily substance. 606
[2145] .sup.1H-HMR(CDCl.sub.3) .delta. ppm:
[2146] 1.00-1.20(m, 4H), 1.13(s, 6H), 1.20-1.38(m, 1H), 1.22(t, J=6
Hz, 3H), 1.42(s, 9H), 1.48-1.70(m, 4H), 2.58-2.70(m, 2H),
4.00-4.10(m, 2H), 4.12(q, J=6 Hz, 2H)
EXAMPLE 262 to 265
[2147] The ketones obtained in Examples 189, 190, 187 and 195 were
treated by the same method as the one of Production Example 14 to
thereby give the following compounds.
64 Ex. Structural formula NMR 262 6073-(tert-butoxycarbonyl)-3-
azabicyclo[3.3.0]octane-7-spiro-(3'- methylenecyclobutane)
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.45(s, 9H), 1.53(dd, J=6.4,
13.2Hz, 2H), 1.99(dd, J=8.0, 13.2Hz, 2H), 2.48-2.52(m, 2H),
2.57-2.69(m, 4H), 3.22(dd, J=3.2, 11.6Hz, 2H), 3.44(dd, J=8.0,
11.6Hz, 2H), 4.74-4.78(m, 2H) 263 6086-(tert-butoxycarbon-
yl)-2-methylene-6- azaspiro[3.4]octane .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.46(s, 9H), 1.88(t, J=6.8Hz, 2H), 2.54-2.61(m, 2H),
2.64-2.71(m, 2H), 3.32(s, 2H), 3.36(t, J=6.8Hz, 2H), 4.82-4.86(m,
2H) 264 6098-(tert-butoxycarbonyl)-3-methylene-8-
azabicyclo[4.3.0]nonane .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.46(s, 9H), 1.42-1.55(m, 1H), 1.67-1.76(m, 1H), 1.99-2.08(m, 1H),
2.10-2.38(m, 5H), 3.06-3.17(m, 1H), 3.18-3.27(m, 1H), 3.29-3.40(m,
2H), 4.67(s, 1H), 4.73(s, 1H) 265
6107-(tert-butoxycarbonyl)-6-methyl-2- methylene-7-azaspiro[3.5]
nonane .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.11(d, J=7.2Hz, 3H),
1.45(s, 9H), 1.39-1.49(m, 1H), 1.57-1.74(m, 3H), 2.28-2.36(m, 1H),
2.44-2.56(m, 2H), 2.60-2.67(m, 1H), 2.82-2.91(m, 1H), 3.89-3.96(m,
1H), 4.30-4.40(m, 1H), 4.77-4.82(m, 2H)
EXAMPLE 266 to 269
[2148] The compounds obtained in Examples 262, 263, 264 and 265
were treated in the same manner as the one of Production Example 72
to thereby give the following compounds.
65 Ex. Structural formula NMR 266
611[3-(tert-butoxycarbonyl)-3-azabicyclo[3.3.0]octane-
7-spiro-cyclobut-3'-yl]methanol .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.44(s, 9H), 1.45-1.62(m, 2H), 1.74-2.09(m, 6H), 2.34-2.47(m,
1H), 2.52-2.68(m, 2H), 3.14(dd, J=4.0, 11.2Hz, 1H), 3.22(dd, J=3.2,
11.2Hz, 1H), 3.43(dd, J=8.0, 11.2Hz, 2H), 3.58(d, J=9.2Hz, 2H) 267
612[6-(tert-butoxycarbonyl)-6-azaspiro[3.4]oct- 2-yl]-methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.45 and 1.46(s, total 9H,
1:1), 1.70-1.83(m, 3H), 1.89(t, J=6.8Hz, 1H), 1.96-2.10(m, 2H),
2.43-2.63(m, 1H), 3.21(s, 1H), 3.28-3.38(m, 2H), 3.34(s, 1H), 3.62
and 3.63(d, J=4.0Hz, total 2H, 1:I) 268
613[8-(tert-butoxycarbonyl)-8- -azabicyclo[4.3.0]non- 3-yl]methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.87-1.34(m, 2H), 1.44-1.83(m,
5H), 1.46(s, 9H), 1.97-2.13(m, 1H), 2.31-2.47(m, 1H), 3.15-3.23(m,
2H), 3.29-3.39(m, 2H), 3.47(d, J=3.2Hz, 1H), 3.48(d, J=2.8Hz, 1H)
269 614[7-(tert-butoxycarbonyl)- -6-methyl-7- azaspiro
[3.5]non-2-yl]methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.09(d,
J=7.2Hz, 1H), 1.16(d, J=7.2Hz, 2H), 1.36-1.90(m, 7H), 1.45(s, 9H),
2.03-2.23(m, 1H), 2.42-2.54(m, 1H), 2.81-2.97(m, 1H), 3.58-3.64(m,
2H), 3.80-3.95(m, 1H), 4.24-4.38(m, 1H)
EXAMPLE 270
4-Allyl-1-(tert-butoxycarbonyl)piperidin-4-ol
[2149] Into a solution of 4.98 g of 1-(tert-butoxycarbonyl)
-4-piperidone in diethyl ether (150 ml) was dropped at 0.degree. C.
in a nitrogen atmosphere 30 ml of a 1.0 M solution of
allylmagnesium bromide in diethyl ether and the resulting mixture
was stirred for 3 hours. Then the reaction mixture was poured into
an aqueous solution of sodium dihydrogenphosphate and extracted
with ethyl acetate. The organic layer was dried over anhydrous
magnesium sulfate, filtered and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
4.12 g of the title compound as a white solid. 615
[2150] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2151] 1.45(s, 9H), 1.54(m, 4H), 2.23(br.d, J=7 Hz, 2H), 3.15(br.s,
2H), 3.80(br.s, 2H), 5.15(ddt, J=1, 2, 16 Hz, 1H), 5.21(ddt, J=1,
2, 10 Hz, 1H), 5.86(ddt, J=7, 10, 16 Hz, 1H)
EXAMPLE 271
4-(2,3-Epoxypropan-1-yl)-1-(tert-butoxycarbonyl)piperidin -4-ol
[2152] To a solution of 4.115 g of
4-allyl-1-(tert-butoxycarbonyl)piperidi- n -4-ol in dichloromethane
(100 ml) were added 7.07 g of 3-chloroperbenzoic acid and 2.87 g of
sodium hydrogencarbonate and the resulting mixture was heated under
reflux for 24 hours. To the reaction mixture were added ethyl
acetate and an aqueous solution of sodium metabisulfite and the
resulting mixture was stirred for 1 hour. The organic layer was
dried over anhydrous magnesium sulfate, filtered and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluted with dichloromethane/ethyl acetate)
to thereby give 1.43 g of the title compound as a colorless solid.
616
[2153] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2154] 1.45(s, 9H), 1.40-1.56(m, 5H), 1.88(dd, J=3, 14 Hz, 1H),
2.00(br.s, 1H), 2.50(dd, J=3, 6 Hz, 1H), 2.82(t, J=3 Hz, 1H),
3.14-3.27(m, 3H), 3.91(br.s, 2H)
EXAMPLE 272
[7-(tert-Butoxycarbonyl)-1-oxa-7-azaspiro[3.5]non-2-yl]methanol
[2155] To a solution of 1.42 g of 4-(2,3-epoxypropan
-1-yl)-1-(tert-butoxycarbonyl)piperidin -4-ol in dimethyl sulfoxide
(20 ml) were added in a nitrogen atmosphere 5 ml of water and 2.32
g of lithium hydroxide and the resulting mixture was heated to
140.degree. C. for 30 minutes. After adding ethyl acetate, the
reaction mixture was washed with water thrice. The organic layer
was dried over anhydrous magnesium sulfate, filtered and
concentrated under reduced pressure. The residue was purified by
silica gel column chromatography (eluted with dichloromethane/ethyl
acetate) to thereby give 0.336 g of the title compound as colorless
crystals. 617
[2156] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:1.46(s, 9H),
1.72-1.85(m, 3H), 1.91(m, 1H), 1.97(dd, J=5, 8 Hz, 1H)2.26(dd, J=7,
10 Hz, 1H), 2.37(dd, J=8, 10 Hz, 1H), 3.32-3.52(m, 3H), 3.57(ddd,
J=4, 8, 11 Hz, 1H), 3.78(ddd, J=3, 4, 11 Hz, 1H), 4.75(m, 1H)
EXAMPLE 273 to 276
[2157] The compounds obtained in Examples 266, 267, 269 and 272
were treated in the same manner as the one of Production Example 73
to thereby give the following compounds.
66 Ex. Structural formula NMR 273 618[3-(tert-butoxycarbonyl)-3-
azabicyclo[3.3.0]octane-7-spiro- cyclobut-3'-yl]carbaldehyde
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.45(s, 9H), 1.44-1.50(m, 1H),
1.52-1.59(m, 1H), 1.84-1.92(m, 1H), 1.98-2.08(m, 4H), 2.25-2.31(m,
1H), 2.55-2.70(m, 2H), 3.04-3.28(m, 3H), 3.39-3.47(m, 2H), 9.71 and
9.72(s, total 1H, 1:1) 274
619[6-(tert-butoxycarbonyl)-6-azaspiro[3.5]non- 2-yl]carbaldehyde
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.45 and 1.46(s, total 9H,
1:1), 1.78 and 1.92(t, J=6.8Hz, total2H, 1:1), 2.06-2.35(m, 4H),
3.06-3.43(m, 5H), 9.74 and 9.77(d, J=2.0Hz, total 1H, 1:1) 275
620[7-(tert-butoxycarbonyl)-6-methyl-7-
azaspiro[3.5]non-2-yl]carbaldehyd- e .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.10 and 1.14(d, J=7.2Hz, total 3H, 1:2), 1.32-1.42(m,
1H), 1.45(s, 9H), 1.45-2.27(m, 7H), 2.80-2.96(m, 1H), 3.08-3.24(m,
1H), 3.81-4.00(m, 1H), 4.25-4.40(m, 1H), 9.73 and 9.78(d, J=1.6Hz,
total 1H, 1:2) 276 621[7-(tert-butoxycarbonyl)-1- -oxa-7-
azaspiro[3.5] non-2-yl]carbaldehyde .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.45(s, 9H), 1.66-2.01(m, 4H), 2.24-2.36(m, 2H), 3.47-3.51(m,
4H), 4.65(t, J=7Hz, 1H), 9.80(s, 1H)
EXAMPLE 277
[3-(tert-Butoxycarbonyl)-3-azabicyclo[3.3.0]oct-7-yl]-carbaldehyde
[2158] 3-tert-Butoxycarbonyl)-3-azabicyclo[3.3.0 octan-7-one was
successively treated by the procedures of Production Examples 71,
72 and 73 to thereby give the title compound. 622
[2159] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2160] 1.44(s,9H), 1.65-1.77(m, 2H), 2.06-2.18(m, 2H),
2.63-2.75(m,2H), 2.81-2.91 and 2.95-3.04(m, total 1H, 2:1),
3.12-3.23(m, 2H), 3.43-3.56(m, 2H), 9.62-9.64(m, 1H)
EXAMPLE 278 to 282
[2161] The aldehydes obtained in Examples 277, 273, 274, 276 and
275 were treated in the same manner as that of Production Example
74 to thereby give the following compounds.
67 Ex. Structural formula NMR 278 623methyl
[3-(tert-butoxycarbonyl)-3- azabicyclo[3.3.0]oct-7-yl]carboxyla- te
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.44(s, 9H), 1.65-1.84(m, 2H),
2.03-2.23(m, 2H), 2.56-3.02(m, 3H), 3.02-3.59(m, 4H), 3.67(s, 3H)
279 624methyl [3-(tert-butoxycarbonyl)-3- azabicyclo[3.3.0]-octan-
e-7-spiro-cyclobut-3'- yl]carboxylate .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 1.45(s, 9H), 1.46-1.56(m, 2H), 1.88-1.96(m, 1H),
2.01-2.19(m, 4H), 2.28-2.35(m, 1H), 2.53-2.69(m, 2H), 3.03(quint,
J=8.8Hz, 1H), 3.11-3.18(m, 1H), 3.20-3.28(m, 1H), 3.40-3.47(m, 2H),
3.67(s, 3H) 280 625methyl [6-(tert-butoxycarbonyl)-6-azas-
piro[3.4]- oct-2-yl]carboxylate .sup.1H-NMR(CDCl.sub.3) # .delta.
ppm: 1.42-1.52(m, 9H), 1.81-1.93(m, 2H), 2.10-2.38(m, 4H),
3.04-3.14(m, 1H), 3.22-3.46(m, 4H), 3.69(s, 3H) 281 626methyl
[7-(tert-butoxycarbonyl)-1-oxa-7- azaspiro
[3.5]-non-2-yl]carboxylate .sup.1H-NMR(CDCl.sub.3) # .delta. ppm:
1.46(s, 9H), 1.76(m, 2H), 1.95(m, 2H), 2.46(dd, J=7, 11Hz, 1H),
2.66(dd, J=9, 11Hz, 1H), 3.36-3.54(m, 4H), 3.80(s, 3H), 5.00(dd,
J=7, 9Hz, 1H) 282 627methyl [7-(tert-butoxycarbonyl)-6-methyl-7-
azaspiro[3.5]-non-2-yl]car- boxylate .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 1.08 and 1.14(d, J=7.2Hz, total 3H), 1.45(s, 9H),
1.56-1.83(m, 4H), 1.87-2.11(m, 2H), 2.17-2.37(m, 2H), 2.81-2.94(m,
1H), 3.04-3.16(m, 1H), 3.68 and 3.69(s, total 3H), 3.81-3.98(m,
1H), 4.24-4.38(m, 1H)
EXAMPLE 283
Methyl
[8-(tert-butoxycarbonyl)-8-azabicyclo[4.3.0]non-3-yl-carboxylate
[2162]
[8-(tert-Butoxycarbonyl)-8-azabicyclo[4.3.0]non-3-yl]methanol was
successively treated by the same methods as those of Production
Examples 73 and 74 to thereby give the title compound. 628
[2163] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2164] 1.46(s, 9H), 1.24-1.95(m, 6H), 2.03-2.14(m, 1H),
2.24-2.52(m, 2H), 3.14-3.25(m, 2H), 3.31-3.42(m, 2H), 3.67(s,
3H)
EXAMPLE 284
Methyl
(3-benzyloxycarbonyl-3-azabicyclo[4.1.0]hept-6-yl)acetate
[2165] 1.41 g of oxalyl chloride was dissolved in 70 ml of
dichloromethane and cooled to -78.degree. C. in a nitrogen
atmosphere. Then a solution of 1.38 g of dimethyl sulfoxide in
dichloromethane (3 ml) was dropped thereinto over 5 minutes.
Further, a solution of 1.22 g of
(3-benzyloxycarbonyl-3-azabicyclo[4.1.0]hept-6-yl)ethanol in
dichloromethane (10 ml) was dropped thereinto over 5 minutes. After
stirring the mixture for 15 minutes, 2.24 g of triethylamine was
dropped thereinto over 5 minutes and stirring was continued for
additional 30 minutes. Then the reaction mixture was diluted with
dichloromethane, washed with 1 N hydrochloric acid and a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After filtration, the solvent was distilled off
under reduced pressure and the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 450 mg of a product. This product was dissolved in 6
ml of dimethyl sulfoxide and 5 ml of an aqueous solution of 257 mg
of sodium dihydrogenphosphate was added thereto. Further, 5 ml of
an aqueous solution of 496 mg of sodium chlorite was added thereto
over 5 minutes and the resulting mixture was stirred at room
temperature for 10 minutes. Next, the reaction mixture was diluted
with ethyl acetate, washed successively with water and a saturated
aqueous solution of sodium chloride, dried over anhydrous magnesium
sulfate and filtered. After distilling off the solvent under
reduced pressure, the obtained residue was dissolved in 40 ml of
toluene. After adding 6 ml of a 2 M solution of
trimethylsilyldiazomethane in hexane and 10 ml of methanol, the
resulting mixture was stirred at room temperature for 50 minutes.
Then the reaction mixture was concentrated under reduced pressure
and the obtained residue was purified by silica gel column
chromatography (eluted with ethyl acetate/methanol) to thereby give
180 mg of the title compound as a colorless oily substance. 629
[2166] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2167] 0.41-0.48(m, 1H), 0.54-0.66(m, 1H), 0.88-1.04(m, 1H),
1.76-1.92(m, 2H.), 2.16-2.42(m, 2H), 3.15-3.24(m, 1H), 3.32-3.44(m,
1H), 3.60-3.68(m, 1H), 3.68(s, 3H), 3.80-3.88(m, 1H), 5.10(s, 2H),
7.28-7.40(m, 5H)
EXAMPLE 285
[7-(tert-Butoxycarbonyl)-7-azaspiro[3.5]non-2-yl]carbonitrile
[2168] 2.39 g of
[7-(tert-butoxycarbonyl)-7-azaspiro[3.5]nonan-2-one was treated in
the same manner as the one of Production Example 34 to thereby give
0.99 g of the title compound as colorless crystals. 630
[2169] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2170] 1.45(s, 9H), 1.55(dd, J=5, 6 Hz, 2H), 1.62(dd, J=5, 6 Hz,
2H), 2.18(m, 2H), 2.25(m, 2H), 3.17(m, 1H), 3.32(m, 4H)
EXAMPLE 286
(7-Benzyl-7-azaspiro[3.5]non-2-yl)carbonitrile
[2171] To a solution of 1.44 g of [7-(tert-butoxycarbonyl)
-7-azaspiro[3.5]non-2-yl]carbonitrile in dichloromethane (40 ml)
was added 10 ml of trifluoroacetic acid and the resulting mixture
was stirred at room temperature for 2.5 hours. Then an aqueous
solution of disodium hydrogenphosphate was added to the reaction
mixture followed by extraction with ethyl acetate and
dichloromethane. The extract was dried over anhydrous magnesium
sulfate and then the solvent was concentrated under reduced
pressure. Thus 0.935 g of crude (7-azaspiro[3.5]non-2-yl)ca-
rbonitrile was obtained. This crude product was dissolved in 40 ml
of dichloromethane. After adding at 0.degree. C. 0.94 g of
triethylamine and 1.27 g of benzyl bromide, the resulting mixture
was stirred at room temperature for 12 hours. To the reaction
mixture was added an aqueous solution of disodium
hydrogenphosphate. Then the resulting mixture was extracted with
ethyl acetate and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
methanol/dichloromethane) to thereby give 1.12 g of the title
compound as a colorless oily substance. 631
[2172] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2173] 1.60(t, J=5 Hz, 2H), 1.69(t, J=5 Hz, 2H), 2.13(dd, J=8, 12
Hz, 2H), 2.21(J=10, 12 Hz, 2H), 2.31(br.s, 4H), 3.02(m, 1H),
3.44(s, 2H), 7.22-7.33(m, 5H)
EXAMPLE 287
Methyl (7-benzyl-7-azaspiro[3.5]non-2-yl)carboxylate
[2174] (7-Benzyl-7-azaspiro[3.5]non-2-yl)carbonitrile was treated
in the same manner as the one of Production Example 35 to thereby
give the title compound. 632
[2175] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2176] 1.58(t, J=5 Hz, 2H), 1.64(t, J=5 Hz, 2H), 2.00(s, 2H),
2.02(s, 2H), 2.28(br.s, 2H), 2.34(br.s, 2H), 3.04(quint, J=9 Hz,
1H), 3.43(s, 2H), 3.67(s, 3H), 7.22-7.33(m, 5H)
EXAMPLE 288
Methyl 4-[1-(benzyloxycarbonyl)piperidin-4-yloxy]phenylacetate
[2177] 1-(Benzyloxycarbonyl)piperidin-4-ol and methyl
4-hydroxyphenylacetate were treated in the same manner as the one
of Production Example 65 to thereby give the title compound as a
pale green powder. 633
[2178] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2179] 1.73-1.83(m, 2H), 1.86-1.96(m, 2H), 3.42-3.50(m, 2H),
3.56(s, 2H), 3.69(s, 3H), 3.70-3.78(m, 2H), 4.47(m, 1H), 5.14(s,
2H), 6.83-6.88(m, 2H), 7.17-7.21(m, 2H), 7.29-7.38(m, 5H)
EXAMPLE 289
Methyl
4-[1-(benzyloxycarbonyl)piperidin-4-yl]methyloxy]-phenylacetate
[2180] [1-(Benzyloxycarbonyl)piperidin-4-yl]methanol and methyl
p-hydroxyphenylacetate were treated in the same manner as the one
of Production Example 65 to thereby give the title compound as a
pale green powder. 634
[2181] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2182] 1.22-1.35(m, 2H), 1.80-1.88(m, 2H), 1.98(m, 1H),
2.76-2.89(m, 2H), 3.56(s, 2H), 3.68(s, 3H), 3.78(d, J=6.4 Hz, 2H),
4.15-4.32(m, 2H), 5.14(s, 2H), 6.81-6.86(m, 2H), 7.16-7.21(m, 2H),
7.29-7.38(m, 5H)
EXAMPLE 290
Ethyl 1-(1-benzylpiperidin-4-yl)cyclopropane carboxylate
[2183] 13 ml of diisopropylamine was dissolved in a solvent mixture
of tetrahydrofuran (140 ml) with HMPA (15 ml) in a nitrogen
atmosphere and cooled to -78.degree. C. Into the obtained solution
was dropped 42 ml of a 2.5 M solution of n-butyllithium in hexane
and the resulting mixture was stirred at 0.degree. C. for 30
minutes. After cooling to -78.degree. C. again, 15 ml of a solution
of 5.8 g of ethyl (1-benzylpiperidin-4-yl)a- cetate in
tetrahydrofuran was dropped thereinto. The reaction mixture was
stirred at 0.degree. C. for 1 hour. Then 1,2-dibromoethane was
dropped thereinto at -78.degree. C. again. The reaction mixture was
stirred at 0.degree. C. for 30 minutes and then brought back to
room temperature. Next, it was distributed into water and ethyl
acetate. The organic layer was extracted, washed with water and
dried over magnesium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 1.40 g of ethyl 2-(1-benzyl-4-piperidyl)-4-bromo-
butanoate as a colorless oily substance. A solution of 1.40 g of
ethyl 2-(1-benzyl-4-piperidyl) -4-bromobutanoate in tetrahydrofuran
(20 ml) was stirred at room temperature and 1.0 g of
t-butoxypotassium was added thereto. The reaction mixture was
distributed into water and ethyl acetate. The organic layer was
extracted and washed with water. After distilling off the solvent
under reduced pressure, the obtained residue was purified by silica
gel column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 800 mg of the title compound as a colorless oily
substance. 635
[2184] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2185] 0.74(dd, J=3.9, 6.7 Hz, 2H), 1.08(dd, J=3.9, 6.7 Hz, 2H),
1.22(t, J=7.0 Hz, 3H), 1.32-1.44(m, 2H), 1.52-1.59(m, 2H),
1.70-1.79(m, 1H), 1.90-1.99(m, 2H), 2.87-2.93(m, 2H), 3.48(s, 2H),
4.19(q, J=7.0 Hz, 2H), 7.20-7.33(m, 5H)
EXAMPLE 291
Ethyl
[2-methyl-7-(tert-butoxycarbonyl)-7-azaspiro[3.5]non-2-yl]acetate
[2186] To a suspension of 2.85 g of cuprous iodide in diethyl ether
was added in a nitrogen atmosphere at 23.degree. C. 22 ml of a 1.4
M solution of methyllithium in diethyl ether. After stirring at
-23.degree. C. for 30 minutes, the mixture was cooled to
-75.degree. C. Into this solution was dropped 20 ml of a solution
of 0.927 g of ethyl
7-(tert-butoxycarbonyl)-7-azaspiro[3.5]non-2-ylidene]acetate and
trimethylsilyl chloride in diethyl ether. The bulk temperature was
elevated to room temperature and the reaction mixture was stirred
for 15 hours. After adding 100 ml of ethyl acetate and sodium
hydrogencarbonate thereto, the insoluble matters were filtered off,
dried over anhydrous magnesium sulfate, filtered and concentrated
under reduced pressure. The residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 0.609 g of the title compound as white crystals.
636
[2187] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2188] 1.22(s, 3H), 1.25(t, J=7 Hz, 3H), 1.44(s, 9H), 1.49(m, 2H),
1.56(m, 2H), 1.71(d, J=13 Hz, 2H), 1.88(d, J=13 Hz, 2H), 2.39(s,
2H), 3.29(m, 4H), 4.14(q, J=7 Hz, 2H)
EXAMPLE 292
1-Benzylpiperidin-4-ylideneethyl vinyl ether
[2189] To a solution of 1.08 g of (1-benzylpiperidin
-4-ylidene)ethanol in vinyl ethyl ether (30 ml) was added in a
nitrogen atmosphere 0.107 g of mercurous trifluoroacetate. After
stirring at room temperature for 18 hours, 10 ml of a 10% aqueous
solution of sodium hydroxide was added thereto and the resulting
mixture was extracted with n-hexane (50 ml). The organic layer was
washed with an aqueous solution of sodium chloride (3.times.10 ml),
dried over anhydrous magnesium sulfate and concentrated under
reduced pressure to thereby give 1.153 g of the title compound as a
colorless oily substance. 637
[2190] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2191] 2.24(t, J=5 Hz, 2H), 2.32(t, J=6 Hz, 2H), 2.45(tt, J=5, 6
Hz, 4H), 3.51(s, 2H), 4.01(d, J=5 Hz, 2H), 4.18-4.23(m, 2H),
5.38(t, J=5 Hz, 1H), 6.47(dd, J=9, 15 Hz, 1H), 7.34-7.36(m, 5H)
EXAMPLE 293
(1-Benzyl-4-vinylpiperidin-4-yl)acetaldehyde
[2192] A solution of 0.82 g of (1-benzylpiperidin -4-ylidene)-ethyl
vinyl ether in benzonitrile (30 ml) was degassed in a nitrogen
atmosphere and heated to 190.degree. C. for 1 hour. Then the
reaction mixture was concentrated under reduced pressure and the
residue was purified by silica gel column chromatography (eluted
with dichloromethane/methanol) to thereby give 0.67 g of the title
compound as a colorless oily substance. 638
[2193] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2194] 1.66-1.72(m, 2H), 1.78-1.83(m, 2H), 2.37-2.41(m, 2H),
2.40(s, 2H), 2.47-2.54(m, 2H), 3.48(s, 2H), 5.07(d, J=16 Hz, 1H),
5.24(d, J=10 Hz, 1H), 5.84(dd, J=10, 16 Hz, 1H), 7.31-7.35(m, 5H),
9.71(s, 1H)
EXAMPLE 294
Methyl (1-benzyl-4-vinylpiperidin-4-yl)acetate
[2195] To a solution of 0.486 g of (1-benzyl-4-vinylpiperidin
-4-yl)acetaldehyde in N,N-dimethylformamide (10 ml) were added 0.48
g of methanol and 4.50 g of pyridinium dichromate and the resulting
mixture was stirred at room temperature for 20 hours. After adding
100 ml of diethyl ether, the reaction mixture was filtered through
celite. After concentrating under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.321 g of the title
compound as a colorless oily substance. 639
[2196] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2197] 1.66(m, 2H), 1.78-1.84(m, 2H), 2.30-2.35(m, 2H), 2.37(s,
2H), 2.49-2.55(m, 2H), 3.48(s, 2H), 3.61(s, 3H), 5.01(d, J=17 Hz,
1H), 5.15(d, J=11 Hz, 1H), 5.76(dd, J=11, 17 Hz, 1H), 7.30-7.32(m,
5H)
EXAMPLE 295
4-(1-Benzyl-4-hydroxypiperidin-4-yl)benzaldehyde
[2198] Starting with 0.74 g of magnesium, 6.42 g of
4-bromobenzaldehyde dimethyl acetal and 50 ml of tetrahydrofuran, a
Grignard reagent was prepared in a conventional manner. Then it was
ice-cooled and 10 ml of a solution of 5.67 ml of
1-benzyl-4-piperidone in tetrahydrofuran was dropped thereinto in
such a manner that the bulk temperature did not exceed 20.degree.
C. After stirring at room temperature for 1 hour, 50 ml of a
saturated aqueous solution of ammonium chloride was added thereto
and then 1 N-hydrochloric acid was added until the pH value reached
about 2. After stirring for 1 hour, the reaction mixture was
concentrated under reduced pressure and the tetrahydrofuran was
distilled off. To the residue were added anhydrous potassium
carbonate and ethyl acetate and the resulting mixture was stirred
for 15 minutes. The organic layer was separated, washed with water
and a saturated aqueous solution of sodium chloride and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
4.27 g of the title compound as a slightly yellow solid. 640
[2199] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2200] 1.69-1.78(m, 3H), 2.18(dt, J=4.6, 13.3 Hz, 2H), 2.47(dt,
J=2.6, 13.3 Hz, 2H), 2.79-2.86(m, 2H), 3.59(s, 2H), 7.25-7.29(m,
1H), 7.31-7.38(m, 4H), 7.68-7.72(m, 2H), 7.85-7.89(m, 2H), 10.00(s,
1H)
EXAMPLE 296
4-(1-Benzyl-4-hydroxypiperidin-4-yl)-2-methoxybenzaldehyde dimethyl
acetal
[2201] 15.0 g of 4-bromo-2-methoxybenzaldehyde dimethyl acetal was
dissolved in 150 ml of ether and the obtained solution was cooled
to -50.degree. C. Then 25.3 ml of a 1.6 M solution of
n-butyllithium in hexane was dropped thereinto. 1 hour thereafter,
30 ml of a solution of 11.7 ml of 1-benzyl -4-piperidone in diethyl
ether was dropped thereinto in such a manner that the bulk
temperature did not exceed -35.degree. C.. After stirring at room
temperature for 50 minutes, water was added thereto followed by
extraction with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous sodium sulfate. After distilling off the solvent
under reduced pressure, 23.82 g of a pale yellow oily substance was
obtained. 13.82 g of this oily substance was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 6.31 g of the title compound as a pale yellow solid.
641
[2202] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2203] 1.59(s, 1H), 1.68-1.76(m, 2H), 2.11-2.22(m, 2H),
2.42-2.52(m, 2H), 2.77-2.84(m, 2H), 3.36(s, 6H), 3.59(s, 2H),
3.86(s, 3H), 5.64(s, 1H), 7.01-7.11(m, 2H), 7.24-7.29(m, 2H),
7.31-7.38(m, 3H), 7.48(dd, J=0.5, 7.7 Hz, 1H)
EXAMPLE 297
4-(1-Benzyl-4-hydroxypiperidin-4-yl)-2-methoxybenzaldehyde
[2204] To 10.0 g of 4-(1-benzyl-4-hydroxypiperidin
-4-yl)-2-methoxybenzald- ehyde dimethyl acetal were added 100 ml of
toluene and 6.15 g of p-toluenesulfonic acid monohydrate and the
resulting mixture was heated under reflux for 1 hour. To the
reaction mixture were added water and triethylamine followed by
extraction with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous sodium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 3.43 g of the title compound as a pale brown oily
substance. 642
[2205] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2206] 1.67-1.78(m, 3H), 2.13-2.22(m, 2H), 2.41-2.50(m, 2H),
2.79-2.87(m, 2H), 3.60(s, 2H), 3.94(s, 3H), 7.14(ddd, J=0.7, 1.6,
8.1 Hz, 1H), 7.22(d, J=1.6 Hz, 1H), 7.24-7.38(m, 5H), 7.80(d, J=8.1
Hz, 1H), 10.4(s, 1H)
EXAMPLE 298
4-[1-Benzyl-4-(3-methoxy-4-[2-methylthio-2-(methylsulfinyl)-vinyl]phenyl]p-
iperidin-4-ol
[2207] 3.43 g of 4-(1-benzyl-4-hydroxypiperidin-4-yl)
-2-methoxybenzaldehyde was dissolved in 30 ml of tetrahydrofuran.
To the resulting solution were added 2.42 ml of methyl
methylsulfinylmethyl sulfoxide and 2 ml of a 40% solution of
benzyltrimethylammonium hydroxide in methanol and the resulting
mixture was heated under reflux for 3 hours. After concentrating
the reaction mixture, water was added thereto followed by
extraction with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous sodium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 4.58 g of the title compound as a pale yellow oily
substance. 643
[2208] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2209] 1.71-1.78(m, 2H), 1.94(br.s, 1H), 2.13-2.23(m, 2H), 2.29(s,
3H), 2.44-2.53(m, 2H), 2.75(s, 3H), 2.79-2.85(m, 2H), 3.60(s, 2H),
3.85(s, 3H), 7.10-7.14(m, 2H), 7.24-7.39(m, 5H), 7.95(s, 1H),
8.12(d, J=8.6 Hz, 1H)
EXAMPLE 299
4-[1-Benzyl-4-[4-[2-methylthio-2-(methylsulfinyl)vinyl]phenyl-piperidin-4--
ol
[2210] The title compound was obtained as a pale yellow oily
substance by the same method as the one of Example 298. 644
[2211] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2212] 1.70-1.78(m, 3H), 2.13-2.23(m, 2H), 2.32(s, 3H),
2.44-2.52(m, 2H), 2.76(s, 3H), 2.78-2.84(m, 2H), 3.59(s, 2H),
7.30-7.38(m, 4H), 7.56-7.60(m, 2H), 7.60(s, 1H), 7.58-7.91(m,
2H)
EXAMPLE 300
Methyl
4-(1-benzyl-4-hydroxypiperidin-4-yl)-2-methoxyphenyl-acetate
[2213] 4.58 g of 4-[1-benzyl-4-[3-methoxy-4-[2-methylthio
-2-(methylsulfinyl)vinyl]phenyl]piperidin-4-ol was dissolved in 100
ml of a 10% solution of hydrogen chloride in methanol and the
solution was heated under reflux for 1 hour and 40 minutes. Then
the reaction mixture was concentrated under reduced pressure. After
adding an aqueous solution of sodium carbonate, the mixture was
extracted with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous sodium sulfate. After distilling off the solvent
under reduced pressure, 3.41 g of the title compound was obtained
as a slightly brown oily substance. 645
[2214] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2215] 1.58(br.s, 1H), 1.69-1.76(m, 2H), 2.11-2.21(m, 2H),
2.43-2.51(m, 2H), 2.77-2.83(m, 2H), 3.59(s, 2H), 3.61(s, 2H),
3.69(s, 3H), 3.82(s, 3H), 7.03(dd, J=1.8, 7.7 Hz, 1H), 7.07(d,
J=1.8 Hz, 1H), 7.15(d, J=7.7 Hz, 1H), 7.24-7.38(m, 5H)
EXAMPLE 301
Methyl 4-(1-benzyl-4-hydroxypiperidin-4-yl)phenylacetate
[2216] The title compound was obtained as a pale yellow oily
substance by the same method as the one of Example 300. 646
[2217] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2218] 1.54(br.s, 1H), 1.69-1.76(m, 2H), 2.15(dt, J=4.6, 13.2 Hz,
2H), 2.47(dt, J=2.6, 13.2 Hz, 2H), 2.75-2.82(m, 2H)3.58(s, 2H),
3.62(s, 2H), 3.69(s, 3H), 7.24-7.28(m, 3H), 7.30-7.38(m, 4H),
7.46-7.49(m, 2H)
EXAMPLE 302
Methyl
4-(1-benzyl-1,2,5,6-tetrahydropyrid-4-yl)-2-methoxy-phenylacetate
[2219] 3.41 g of methyl 4-(1-benzyl-4-hydroxypiperidin
-4-yl)-2-methoxyphenylacetate was dissolved in 50 ml of toluene.
After adding 3.5 g of p-toluenesulfonic acid monohydrate, the
mixture was heated under reflux for 1 hour and 45 minutes. After
adding water and triethylamine, the reaction mixture was extracted
with dichloromethane and the organic layer was dried over anhydrous
sodium sulfate. After distilling off the solvent under reduced
pressure, 3.6 g of a pale yellow oily substance was obtained.
[2220] This product was dissolved in 100 ml of a 10% solution of
hydrogen chloride in methanol and heated under reflux for 2 hours.
The reaction mixture was concentrated under reduced pressure. After
adding an aqueous solution of sodium hydrogencarbonate, the mixture
was extracted with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous sodium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 2.28 g of the title compound as a pale yellow oily
substance. 647
[2221] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2222] 2.52-2.58(m, 2H), 2.71(t, J=5.9 Hz, 2H), 3.17(dd, J=2.7, 5.9
Hz, 2H), 3.61(s, 2H), 3.64(s, 2H), 3.68(s, 3H), 3.81(s, 3H),
6.04(m, 1H), 6.88(d, J=1.6 Hz, 1H), 6.93(dd, J=1.6, 7.7 Hz, 1H),
7.11(d, J=7.7 Hz, 1H), 7.24-7.40(m, 5H)
EXAMPLE 303
[1-[1-tert-Butoxycarbonyl)piperidin-4-yl]butan-1-one oxime
[2223] 3.1 g of [1-[1-tert-butoxycarbonyl)piperidin
-4-yl]butan-1-one was dissolved in 20 ml of ethanol. After adding 1
g of hydroxylamine hydrochloride and 1.5 g of sodium acetate, the
resulting mixture was heated under reflux for 2.5 hours. The
reaction mixture was concentrated under reduced pressure and water
was added to the residue followed by extraction with ethyl acetate.
The organic layer was washed with water and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
2.3 g of the title compound as white crystals. 648
[2224] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2225] 0.96(t, J=7.2 Hz, 3H), 1.40-1.60(m, 5H), 1.45(s, 9H),
1.69-1.80(m, 2H), 2.22-2.33(m, 2H), 2.62-2.78(m, 2H), 4.03-4.25(m,
2H)
EXAMPLE 304
Ethyl
[(1-(tert-butoxycarbonyl)piperidin-4-yl]butan-1-yl]iminoxyacetate
[2226] 2.3 g of [1-[1-tert-butoxycarbonyl)piperidin
-4-yl]butan-1-one oxime was dissolved in 10 ml of
N,N-dimethylformamide and ice-cooled. After adding 0.41 g of 70%
sodium hydride, 1.1 ml of ethyl bromoacetate was further added and
the resulting mixture was stirred for 1 hour. After adding
ice-water, the reaction mixture was extracted with ethyl acetate.
The organic layer was washed with water and a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 2.47 g of the
title compound as a pale yellow oily substance. 649
[2227] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2228] 0.96(t, J=7.6 Hz, 3H), 1.27(t, J=7.2 Hz, 3H), 1.37-1.60(m,
5H), 1.46(s, 9H), 1.65-1.77(m, 2H), 2.23-2.31(m, 2H), 2.64-2.78(m,
2H), 4.04-4.26(m, 2H), 4.20(q, J=7.2 Hz, 2H), 4.55(s, 2H)
EXAMPLE 305
Ethyl [(1-(tert-butoxycarbonyl)piperidin-4-yl]-2-hydroxyacetate
[2229] To a solution of 6.1 g of diisopropylamine in
tetrahydrofuran (60 ml) was added a 1.6 M solution of 38 ml of
n-butyllithium in hexane and the resulting mixture was stirred at
0.degree. C. for 30 minutes. After cooling the reaction mixture to
-70.degree. C., a solution of 10.6 g of ethyl
[1-(tert-butoxycarbonyl)piperidin -4-yl]acetate in tetrahydrofuran
(40 ml) was dropped thereinto. After 1 hour, 26 g of MoPH
[peroxymolybdenum(pyridine)(hexamethylphosphorous triamide)] was
added thereto and the resulting mixture was slowly heated to room
temperature over 5 hours. After adding water, the reaction mixture
was extracted with ethyl acetate. The organic layer was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous magnesium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 3.9 g of the title compound as a pale yellow oily
substance. 650
[2230] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2231] 1.32(t, J=7.2 Hz, 3H), 1.39-1.45(m, 2H), 1.45(s, 9H),
1.60-1.67(m, 2H), 1.82-1.93(m, 1H), 2.59-2.74(m, 2H), 2.75(d, J=6.0
Hz, 1H), 4.05(dd, J=3.5, 6.0 Hz, 1H), 4.08-4.25(m, 2H), 4.27(q,
J=7.2 Hz, 2H)
EXAMPLE 306
Ethyl [(1-(tert-butoxycarbonyl)piperidin-4-yl]-2-oxoacetate
[2232] By the same method as the one of Production Example 73, the
title compound was obtained as a pale yellow oily substance.
651
[2233] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2234] 1.38(t, J=7.2 Hz, 3H), 1.45(s, 9H), 1.47-1.62(m, 2H),
1.84-1.93(m, 2H), 2.79-2.93(m, 2H), 3.16-3.25(m, 1H), 4.03-4.17(m,
2H), 4.33(q, J=7.2 Hz, 2H)
EXAMPLE 307
Ethyl [(1-benzylpiperidin-4-yl)carbamoyl]aminoacetate
[2235] 2 g of 4-amino-1-benzylpiperidine was dissolved in 15 ml of
tetrahydrofuran. After adding 1.6 g of ethyl isocyanatoacetate, the
resulting mixture was heated under reflux for 1 hour. Then the
reaction mixture was concentrated under reduced pressure to thereby
give 3.15 g of the title compound as white crystals. 652
[2236] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2237] 1.28(t, J=7.2 Hz, 3H), 1.41-1.52(m, 2H), 1.88-1.97(m, 2H),
2.07-2.17(m, 2H), 2.77-2.86(m, 2H), 3.51(s, 2H), 3.52-3.65(m, 1H),
3.97(d, J=5.2 Hz, 2H), 4.20(q, J=7.2 Hz, 2H), 4.52(br.d, J=8.5 Hz,
1H), 5.39(br.t, J=5.2 Hz, 1H), 7.22-7.35(m, 5H)
EXAMPLE 308
Ethyl [4-(tert-butoxycarbonyl)aminopiperidin-1-yl]acetate
[2238] 2 g of 4-(tert-butoxycarbonyl)aminopiperidine was dissolved
in 50 ml of dichloromethane. After adding 1.6 ml of triethylamine
and 1.2 ml of ethyl bromoacetate, the resulting mixture was stirred
at room temperature for 5 hours. The reaction mixture was washed
with water and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 3.0 g of the title
compound as pale yellow crystals. 653
[2239] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2240] 1.27(t, J=7.2 Hz, 3H), 1.44(s, 9H), 1.44-1.58(m, 2H),
1.88-1.97(m, 2H), 2.21-2.32(m, 2H), 2.85-2.95(m, 2H), 3.20(s, 2H),
3.42-3.53(m, 1H), 4.18(q, J=7.2 Hz, 2H), 4.39-4.49(m, 1H)
EXAMPLE 309 to 312
[2241] Similar to Example 308,
4-(tert-butoxycarbonyl)amino-piperidine was treated with a
halogenated fatty acid ester or an acid halide to thereby give the
following compounds.
68 Ex. Structural formula NMR 309 654ethyl
3-[4-(tert-butoxycarbonyl)amino- piperidin-1-yl]propanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25(t, J=7.2Hz, # 3H),
1.35-1.52(m, 2H), 1.45(s, 9H), 1.87-1.97(m, 2H), 2.08-2.18(m, 2H),
2.49(t, J=7.4Hz, 2H), 2.70(t, J=7.4Hz, 2H), 2.78-2.88(m, 2H),
3.41-3.52(m, 1H), 4.13(q, J=7.2Hz, 2H), 4.37-4.47(m, 1H) 310
655ethyl 4-[4-(tert-butoxycarbonyl) aminopiperidin-1-yl]butanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25(t, J=7.2Hz, # 3H),
1.37-1.49(m, 2H), 1.43(s, 9H), 1.81(quint, J=7.4Hz, 2H),
1.87-1.97(m, 2H), 2.05-2.14(m, 2H), 2.32(t, J=7.4Hz, 2H), 2.37(t,
J=7.4Hz, 2H), 2.80-2.89(m, 2H), 3.40-3.54(m, 1H), 4.11(q, J=7.2Hz,
2H), 4.39-4.49(m, 1H) 311 656ethyl 3-[4-(tert-butoxycarbonyl)amino-
piperidin-1-yl]-3-oxopropanoate .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.25-1.40(m, # 2H), 1.29(t, J=7.2Hz, 3H), 1.45(s, 9H),
1.93-2.07(m, 2H), 2.73-2.83(m, 1H), 3.12-3.20(m, 1H), 3.44(d,
J=14.7Hz, 1H), 3.48(d, J-14.7Hz, 1H), 3.62-3.76(m, 2H), 4.20(q,
J=7.2Hz, 2H), 4.43-4.57(m, 2H) 312 657ethyl
[4-(tert-butoxycarbonyl) aminopiperidin-1-yl]2-oxoacetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.33-1.42(m, # 2H), 1.36(t,
J=7.2Hz, 3H), 1.44(s, 9H), 1.97-2.07(m, 2H), 2.82-2.90(m, 1H),
3.12-3.20(m, 1H), 3.61-3.77(m, 2H), 4.32(q, J=7.2Hz, 2H),
4.36-4.52(m, 2H)
EXAMPLE 313
Ethyl
N-(methanesulfonyl)-N-(1-benzylpiperidin-4-yl)aminoacetate
[2242] By the same method as those of Examples 308 and 316, the
title compound was obtained as a pale yellow oily substance from
1-benzylpiperidine. 658
[2243] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2244] 1.28(t, J=7.2 Hz, 3H), 1.57-1.70(m, 2H), 1.77-1.84(m, 2H),
2.01-2.11(m, 2H), 2.91-2.98(m, 2H), 3.10(s, 3H), 3.49(br.s, 2H),
3.59-3.69(m, 1H), 4.01(s, 2H), 4.17(q, J=7.2 Hz, 2H), 7.23-7.35(m,
5H)
EXAMPLE 314
4-Aminomethyl-1-benzylpiperidine
[2245] To a solution of 2.2 g of 1-benzylisonipecotamide in 50 ml
of tetrahydrofuran was added 1.58 g of lithium aluminum hydride at
0.degree. C. and the resulting mixture was heated under reflux for
2 hours. Then the reaction mixture was cooled to 0.degree. C. After
adding water and a 10% aqueous solution of sodium hydroxide, the
insoluble matters were filtered off. After distilling off the
solvent under reduced pressure, 2.0 g of the title compound was
obtained as a brown oily substance. 659
[2246] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2247] 1.2-1.4(m, 3H), 1.4-1.8(m, 2H), 1.8-1.9(m, 2H), 1.94(br.t,
J=10 Hz, 2H), 2.56(d, J=5 Hz, 2H), 2.90(d, J=10 Hz, 2H), 3.49(s,
2H), 7.2-7.4(m, 5H)
EXAMPLE 315
2-(1-Benzylpiperidin-4-yl)ethylamine
[2248] By the same method of the one of Example 314, 0.5 g of
(1-benzylpiperidin-4-ylidene)acetonitrile was treated to thereby
give 0.5 g of the title compound as a brown oily substance. 660
[2249] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2250] 1.2-1.4(m, 6H), 1.5-1.7(m, 2H), 1.93(br.t, J=10 Hz, 2H),
2.71(t, J=8 Hz, 1H), 2.87(br.d, J=10 Hz, 2H), 3.46(s, 2H),
7.2-7.4(m, 5H)
EXAMPLE 316
N-(1-Benzylpiperidin-4-yl)methanesulfonamide
[2251] To a solution of 5.0 g of 4-amino-1-benzylpiperdine in 100
ml of dichloromethane were added 4.1 ml of pyridine and 2.2 ml of
methanesulfonyl chloride at 0.degree. C. Then the mixture was
reacted at the same temperature for 1 hour. The reaction mixture
was poured into water, extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the crystals thus precipitated were taken up by
filtration to thereby give 7.0 g of the title compound as colorless
crystals. 661
[2252] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2253] 1.36-1.48(m, 2H), 1.77(br.d, J=11 Hz, 2H), 1.96(t, J=12 Hz,
2H), 2.70(br.d, J=12 Hz, 2H), 2.88(s, 3H), 3.0-3.16(m, 1H), 3.40(s,
2H), 7.03(d, J=7 Hz, 1H), 7.18-7.34(m, 5H)
EXAMPLES 317 TO 325
[2254] The procedure of Example 316 was repeated by using known
acid chlorides or acid anhydrides as a substitute for the
methanesulfonyl chloride to thereby give the following
compounds.
69 Ex. Structural formula NMR 317 662N-(1-benzylpiperidin-4-
yl)trifluoromethanesulfonamide .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.5-1.63(m, 2H), 1.70-1.85(m, 2H), 2.75-2.95(m, 2H),
3.20-3.40(m, 3H), 3.43-3.65(m, 2H), 7.20-7.40(m, 5H), 9.45(s, 1H)
318 663N-(1-benzylpiperidin- 4-yl)-N,N'-dimethylsulfamide
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.7-2.2(m, 4H), 2.61(s, 6H),
2.9-3.4(m, 7H), 7.41(br .multidot. s, 4H), 7.58(br .multidot. s,
2H) 319 664N,N-(3-aza-3-benzylpenta- methylene)-
N,N'-dimethylsulfamide .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
2.46-2.56(m, 4H), 2.82(s, 6H), 3.24-3.32(m, 4H), 3.54(br .multidot.
s, 2H), 7.24-7.37(m, 5H) 320 665N-(1-benzylpiperidin-4-yl)-N-
'-methylsulfamide .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.34-1.50(m, 2H), 1.7-1.84(m, 2H), 1.84-1.96(m, 2H), 2.40(d, J=5Hz,
3H), 2.66-2.76(m, 2H), 2.84-2.96(m, 1H), 3.40(s, 2H), 6.58(d,
J=5Hz, 1H), 6.85(d, J=5Hz, 1H), 7.18-7.33(m, 5H) 321
666N-[(1-benzylpiperidin-4-yl)methyl- ]methanesulfonamide
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.2-1.35(m, 2H), 1.4-1.6(m,
1H), 1.71(d, J=13Hz, 2H), 1.95(t, J=13Hz, 2H), 2.90(d, J=10Hz, 2H),
2.94(s, 3H), 3.00(t, J=8Hz, 2H), 3.49(s, 2H), 4.4-4.6(m, 1H),
7.2-7.35(m, 5H) 322 667N-[(1-benzylpiperidin-4-yl)me-
thyl]acetamide .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.2-1.34(m,
2H), 1.4-1.56(m, 1H), 1.6-1.7(m, 2H), 1.88-1.98(m, 2H), 2.00(s,
3H), 2.84-2.94(m, 2H), 3.13(t, J=6Hz, 2H), 3.48(s, 2H), 5.5-5.6(m,
1H), 7.2-7.4(m, 5H) 323 668N-[2-(1-benzylpiperidin-4-yl)ethyl]-
methanesulfonamide .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.2-1.4(m, # 5H), 1.43-1.55(m, 2H), 1.64(br .multidot. d, J=10Hz,
2H), 1.93(br .multidot. t, J=10Hz, 2H), 2.86(br .multidot. d,
J=10Hz, 2H), 2.93(s, 3H), 3.15(t, J=5Hz, 1H), 3.46(s, 2H),
7.2-7.4(m, 5H) 324 669N-[2-(1-benzylpiperidin-4-yl)ethyl]acetamide
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.1-1.4(m, 5H), 1.4(m, 2H),
1.5-1.8(m, 2H), 1.8-2.2(m, 2H), 1.95(s, 3H), 2.87(br .multidot. d,
J=10Hz, 2H), 3.2-3.3(m, 1H), 3.48(s, 2H), 7.2-7.4(m, 5H) 325
670N-[1-(diphenylmethylazetidin-3- - yl)methyl]methane sulfonamide
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.59(m, 1H), 2.95(m, 2H),
2.98(s, 3H), 3.26(t, J=7Hz, 2H), 3.37(m, 2H), 4.34(s, 1H), 5.04(br
.multidot. s, 1H), 7.07-7.38(m, 10H)
EXAMPLE 326
N-(1-Benzylpiperidin-4-yl)sulfamide
[2255] To a solution of 3.0 g of 4-amino-1-benzylpiperidine in
dimethoxyethane (20 ml) was added 1.35 g of sulfamide. The
resulting mixture was stirred at 100.degree. C. for 10 minutes and
then reacted at 130.degree. C. for 1 hour. After distilling off the
solvent under reduced pressure, 4.0 g of the title compound was
obtained as a brown oily substance. 671
[2256] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2257] 1.35-1.50(m, 2H), 1.7-1.9(m, 2H), 1.9-2.1(m, 2H),
2.7-2.85(m, 2H), 3.0-3.1(m, 1H), 3.45(s, 2H), 6.46(s, 2H), 6.54(d,
J=6 Hz, 1H), 7.2-7.4(m, 5H)
EXAMPLE 327
N.sup.2-Methanesulfonyl-N.sup.1-(piperidin-4-yl)formamidine
[2258] Into a solution of 760 mg of ethyl
N-methanesulfonyl-formimidate in diethyl ether (20 ml) was dropped
0.95 g of 4-amino-1-benzylpiperidine at room temperature. After
stirring for 2 hours, the crystals thus precipitated were filtered
and washed with diethyl ether to thereby give 580 mg of
N.sup.2-methanesulfonyl-N.sup.1-(1-benzylpiperidin-4-yl)formami-
dine as colorless needles. These crystals were dissolved in 30 ml
of methanol and 500 mg of 10% palladium-carbon was added thereto.
Then the resulting mixture was stirred in a hydrogen atmosphere
under atmospheric pressure for 1 hour followed by filtration
through celite. After distilling off the solvent under reduced
pressure, the residue was recrystallized from acetone/ethyl acetate
to thereby give 310 mg of the title compound as colorless needles.
672
[2259] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2260] 1.26(dq, J=4.1, 12.5 Hz, 2H), 1.73(br.d, J=12.5 Hz, 2H),
2.44(br.t, J=12.5 Hz, 2H), 2.83(s, 3H), 2.85(br.d, J=12.5 Hz, 2H),
3.60-3.70(br.m, 1H), 7.84(s, 1H), 8.64-8.73(br.s, 1H)
EXAMPLE 328
N,N-(4-Benzylpiperazin-1-ylmethylene) methanesulfonamide
[2261] Into a solution of 1.51 g of ethyl
N-methanesulfonyl-formimidate in diethyl ether/tetrahydrofuran
(50%, 5 ml) was dropped a solution of 1.76 g of 1-benzylpiperazine
in diethyl ether/tetrahydrofuran (50%, 50 ml) and the resulting
mixture was reacted at 40.degree. C. for 1 hour. After allowing to
cool, the crystals thus precipitated were taken up by filtration
and washed with diethyl ether to thereby give 2.7 g of the title
compound as colorless crystals. 673
[2262] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2263] 2.48(t, J=5.0 Hz, 2H), 2.52(t, J=5.0 Hz, 2H), 2.95(s, 3H),
3.47(t, J=5.0 Hz, 2H), 3.55(s, 2H), 3.68(t, J=5.0 Hz, 2H),
7.27-7.38(m, 5H), 8.06(s, 1H)
EXAMPLE 329
N-(1-Benzylpiperidin-4-yl)amidinocarboxylic acid
[2264] A solution of 1.9 g of 4-amino-1-benzylpiperidine in
dichloromethane (40 ml) was stirred in a nitrogen atmosphere and 20
ml of a solution of benzyl 2-ethylthio-2-iminoacetate in
dichloromethane was dropped thereinto. Then the resulting mixture
was stirred for 30 minutes and the solvent was distilled off under
reduced pressure. To the obtained residue in the form of a
colorless oily substance were added 50 ml of methanol and 50 ml of
water. Then about 1 g of Dowex (HCO.sub.3-form) which had been
preliminarily conditioned was added thereto. After stirring for 1
hour, the resulting mixture was filtered and the Dowex-1 was well
washed with methanol. After distilling off the solvent under
reduced pressure, 2.3 g of the title compound was obtained as a
colorless powder. 674
[2265] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2266] 1.40-1.58(m, 1H), 1.60-1.70(m, 3H), 1.88-2.02(m, 2H),
2.71-2.83(m, 2H), 3.37-3.52(m, 1H), 3.43(s, 2H), 7.19-7.33(m, 5H),
8.62-8.69(br.s, 1H), 8.72-8.79(br.s, 1H), 8.88-8.96(br.s, 1H)
EXAMPLE 330
Methyl 1-benzylpiperidine-4-carboximidate dihydrochloride
[2267] A solution of 20 g of 1-benzylpiperidine-4-carbonitrile in a
mixture of dry dichlolomethane (200 ml) with methanol (30 ml) was
cooled and saturated with a hydrogen chloride gas while maintaining
the reaction system at 0.degree. C. or below. After allowing to
stand for 4 hours at 0.degree. C., the solvent was distilled off
under reduced pressure at room temperature or below and the residue
was diluted with ethyl acetate. The colorless crystals thus
obtained were ground, filtered and washed with ethyl acetate to
thereby give 23.6 g of the title compound. 675
[2268] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[2269] 2.12(br.q, J=13.1 Hz, 2H), 2.23(br.d, J=13.1 Hz, 2H),
3.07-3.16(br.m, 1H), 3.18(br.t, J=13.1 Hz, 2H), 3.58(br.d, J=13.1
Hz, 2H), 4.18(s, 3H), 4.36(s, 2H), 7.46-7.53(m, 3H), 7.55-7.63(m,
2H)
EXAMPLE 331
N.sup.2-methanesulfonyl(piperidin-4-yl)carboxamidine
[2270] 6.1 g of methyl 1-benzylpiperidine-4-carboximidate
dihydrochloride was distributed into an aqueous solution of
potassium carbonate and ethyl acetate under ice-cooling. The
organic layer was extracted and dried over anhydrous sodium
sulfate. After distilling off the solvent under reduced pressure,
4.7 g of free methyl 1-benzylpiperidine -4-carboximidate was
obtained as a colorless oily substance. A solution of 2.35 g of
methyl 1-benzylpiperidine-4-carboximidate and 0.95 g (10 mmol) of
methanesulfonamide in dry methanol was stirred at room temperature
for 3 days. Subsequently, 1.0 g of palladium-carbon was added to
the reaction mixture and the resulting mixture was stirred in a
hydrogen atmosphere under atmospheric pressure for 1 hour. The
inorganic matters were eliminated by filtering through celite.
After distilling off the solvent under reduced pressure, the
residue was recrystallized from methanol to thereby give 1.38 g of
the title compound as colorless needles. 676
[2271] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2272] 1.43(dq, J=4.1, 12.8 Hz, 2H), 1.56(br.d, J=12.8 Hz, 2H),
2.21-2.31(m, 1H), 2.38(br.t, J=12.8 Hz, 2H), 2.83(s, 3H),
2.91(br.d, J=12.8 Hz, 2H), 7.51-7.65(br.s, 1H), 8.27-8.39(br.s,
1H)
EXAMPLE 332
N.sup.2-Methanesulfonyl(4-benzylpiperazin-1-yl) carboxamidine
[2273] A solution of 2.52 g of
2-methyl-3-methanesulfonylisothiourea and 1.76 g of
1-benzylpeperazine in toluene (10 ml) and tetrahydrofuran (5 ml)
was heated under reflux in a nitrogen atmosphere for 5 days. (In
the course of this heating treatment, 2.52 g of
2-methyl-3-methanesulfonyliso- thiourea and 1.76 g of
1-benzylpiperazine were further added thereto). After distilling
off the solvent under reduced pressure from the reaction mixture,
the obtained residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol). After
recrystallizing from diisopropyl ether, 1.7 g of the title compound
was obtained as colorless crystals. 677
[2274] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2275] 2.46(t, J=5.0 Hz, 4H), 2.95(s, 3H), 3.48(t, J=5.0 Hz, 4H),
3.53(s, 2H), 6.02-6.16(br.s, 2H), 7.25-7.37(m, 5H)
EXAMPLE 333
N-(Piperidin-4-yl)benzenesulfonamide
[2276] 4-Amino-1-benzylpiperidine was treated successively by the
same methods as those of Examples 316 and 20 to thereby give 7.0 g
of the title compound as a pale yellow oily substance. 678
[2277] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2278] 1.43-1.60(m, 2H), 1.60-1.75(m, 2H), 2.78-2.90(m, 2H),
3.05-3.15(m, 2H), 3.2-3.4(m, 1H), 7.55-7.65(m, 3H), 7.81(d, J=8 Hz,
2H), 8.0(m, 1H)
EXAMPLE 334
4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-2-butenenitrile
[2279] The title compound was obtained as a pale yellow oily
substance by the same method as the one of Production Example 25.
679
[2280] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2281] 1.45(s, 9H), 1.62(m, 4H), 2.08(t, J=7 Hz, 2H), 2.39(m, 1H),
2.70(br.s, 2H), 4.05(br.s, 2H), 5.32 and 5.38(dt, J=2, 16 Hz and 2,
10 Hz, 1H trans/cis.apprxeq.2:1), 6.50 and 6.66(dt, J=7, 10 Hz
and7, 16 Hz, 1H cis/trans.apprxeq.1:2)
EXAMPLE 335
4-[1-(tert-Butoxycarbonyl)piperidin-4-yl]butyronitrile
[2282] The title compound was obtained as a pale yellow oily
substance by the same method as the one of Example 20. 680
[2283] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2284] 1.10(m, 2H), 1.41(m, 3H), 1.45(s, 9H), 1.56(m, 4H), 2.34(t,
J=7 Hz, 2H), 2.65(m, 2H), 4.08(br.s, 2H)
EXAMPLE 336
N-Methyl-2-(piperidin-4-yl)ethanesulfonamide acetate
[2285] 500 mg of N-methyl-2-(piperidin-4-yl)ethanesulfonamide was
dissolved in 15 ml of acetic acid. After adding 180 mg of platinum
oxide, the resulting mixture was subjected to catalytic reduction
at room temperature under a hydrogen pressure of 6 atm. After
filtering off the insoluble matters, the acetic acid was distilled
off under reduced pressure. The crystals thus precipitated were
well washed with diethyl ether and dried under reduced pressure.
Thus 664 mg of the title compound was obtained as white crystals
almost quantitatively. 681
[2286] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2287] 1.55(br.q, J=12 Hz, 2H), 1.72-1.78(m, 3H), 1.84(d, J=12 Hz,
2H),
1.88(s,3H),2.55(s,3H),2.62(br.s,2H),2.93-3.04(m,4H),6.89(br.s,1H)
EXAMPLE 337
N,N-Dimethyl-2-(piperidin-4-yl)ethanesulfonamide acetate
[2288] The title compound was obtained as white crystals by the
same method as the one of Example 336. 682
[2289] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2290] 1.18(q, J=12 Hz, 2H), 1.46-1.58(m, 3H), 1.71(br.d, J=12 Hz,
2H), 1.78(s, 3H), 2.58(br.t, J=12 Hz, 2H), 2.74(s, 6H), 3.01(m,
2H), 3.06(m, 2H)
EXAMPLE 338
[5-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-3-oxo-2-methyl
-4-penten-2-yl]acetate
[2291] The title compound was obtained as a colorless oily
substance by treating [1-(tert-butoxycarbonyl)piperidin
-4-yl]carbaldehyde and (4-diethylphosphono
-3-oxo-2-methylbutan-2-yl]acetate by the same method as the one of
Production Example 25. 683
[2292] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2293] 1.33(br.d, J=13 Hz, 2H), 1.46(s, 9H), 1.48(s, 6H),
1.72(br.d, J=13 Hz, 2H), 2.07(s, 3H), 2.29(m, 1H), 2.76(t, J=12 Hz,
2H), 4.11(br.s, 2H), 6.31(dd, J=2, 16 Hz, 1H), 6.97(dd, J=7, 16 Hz,
1H)
EXAMPLE 339
[5-[1-(tert-Butoxycarbonyl)piperidin-4-yl]-3-oxo-2-methyl-pentan
-2-yl]acetate
[2294] The title compound was obtained as a colorless oily
substance by treating [5-[1-(tert-butoxycarbonyl)piperidin
-4-yl]-3-oxo-2-methyl-4-pen- ten -2-yl]acetate by the same method
as the one of Example 20. 684
[2295] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2296] 1.08(qd, J=4, 12 Hz, 2H), 1.34-1.42(m, 1H), 1.45(s, 9H),
1.46(s, 6H), 1.51-1.56(m, 2H), 1.60-1.65(br.d, J=12 Hz, 2H),
2.08(s, 3H), 2.45(t, J=7 Hz, 2H), 2.66(t, J=11 Hz, 2H), 4.06(br.s,
2H)
EXAMPLE 340
(5-[1-(tert-Butoxycarbonyl)piperidin-4-yl)-2-hydroxy
-2-methyl]-3-pentanone
[2297] The title compound was obtained as a colorless oily
substance by treating [5-[1-(tert-butoxycarbonyl)piperidin
-4-yl]-3-oxo-2-methylpentan -2-yl]acetate by the same method as the
one of Production Example 96. 685
[2298] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2299] 1.10(qd, J=4, 12 Hz, 2H), 1.37(s, 6H), 1.45(s, 9H),
1.35-1.58(m, 3H)1.64(d, J=12 Hz, 2H), 2.67(t, J=8 Hz, 2H), 2.75(m,
2H), 3.74(s, 1H), 4.08(br.s, 2H)
EXAMPLE 341
3-(tert-Butoxycarbonyl)-3-azabicyclo[3.3.0]octan-7-ol
[2300] 386 mg of
3-(tert-butoxycarbonyl)-3-azabicyclo[3.3.0]-octan-7-one synthesized
in accordance with the method described in Tetrahedron, 49, 5047
(1993) was dissolved in 20 ml of ethanol. After adding 65 mg of
sodium borohydride, the resulting mixture was stirred at room
temperature for 30 minutes. Then the reaction mixture was
concentrated under reduced pressure, diluted with ethyl acetate,
washed with water and a saturated aqueous solution of sodium
chloride and then dried over anhydrous magnesium sulfate. After
filtering, the solvent was distilled off under reduced pressure and
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 319 mg of the
title compound as white crystals. 686
[2301] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2302] 1.42-1.55(m, 2H), 1.45(s, 9H), 1.69(s, 1H), 2.12-2.22(m,
2H), 2.54-2.66(m, 2H), 3.34(dd, J=3.6, 11.2 Hz, 2H), 3.49(dd,
J=8.0, 11.2 Hz, 2H), 4.29(q, J=6.4 Hz, 1H)
EXAMPLE 342
Methyl 1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydro
-4-pyridinecarboxylate
[2303] 4.62 g of methyl 1-benzyl-1,2,3,6-tetrahydro
-4-pyridinecarboxylate was dissolved in 30 ml of dichloromethane.
Under ice-cooling, 4.29 g of 1-chloroethyl chloroformate was added
thereto and the resulting mixture was heated under reflux for 2
hours. After adding 50 ml of methanol, the mixture was stirred at
70.degree. C. for 1 hour and 20 minutes. Then triethylamine was
added to the reaction mixture under ice-cooling until the pH value
of the mixture exceeded 7. After further adding 4.37 g of
tert-butyl dicarbonate, the resulting mixture was stirred at room
temperature for 10 minutes. Then the reaction mixture was
concentrated under reduced pressure, diluted with ethyl acetate,
washed successively with water and a saturated aqueous solution of
sodium chloride and dried over anhydrous magnesium sulfate. After
filtration, the solvent was distilled off under reduced pressure
and the obtained residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
4.46 g of the title compound as a yellow oily substance. 687
[2304] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2305] 1.47(s, 9H), 2.40(br.s, 2H), 3.51(t, J=5.6 Hz, 2H), 3.76(s,
3H), 4.07(d, J=2.4 Hz, 2H), 6.88(br.s, 1H)
EXAMPLE 343
1-(tert-Butoxycarbonyl)-1,2,3,6-tetrahydropyridine -4-methanol
[2306] 17.6 g of methyl 1-(tert-butoxycarbonyl)
-1,2,3,6-tetrahydro-4-pyri- dinecarboxylate was dissolved in 300 ml
of tetrahydrofuran. After adding 4.77 g of lithium tetrahydroborate
and then 20 ml of methanol, the resulting mixture was stirred at
room temperature for 20 minutes. Saturated ammonium chloride was
added to the reaction mixture under ice-cooling and the resulting
mixture was concentrated under reduced pressure. The residue was
diluted with ethyl acetate, washed successively with water and a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate followed by filtration. After
distilling off the solvent under reduced pressure, the obtained
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 10.7 g of the title
compound as a colorless oily substance. 688
[2307] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2308] 1.47(s, 9H), 1.64(br.s, 1H), 2.08-2.16(m, 2H), 3.47-3.58(m,
2H), 3.91(br.s, 2H), 4.06(br.s, 2H), 5.64(br.s, 1H)
EXAMPLE 344
[3-(tert-Butoxycarbonyl)-3-azabicyclo[4.1.0]hept-6-yl]methanol
[2309] Under ice-cooling, 15.3 ml of diethylzinc and 6.7 g of
dilodomethane were added to 130 ml of dichloromethane. After
further adding a solution of 1.07 g of
1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydro- pyridine -4-methanol in
dichloromethane (20 ml), the resulting mixture was stirred at room
temperature overnight. Then the reaction mixture was poured into
saturated ammonium chloride, extracted with ethyl acetate, washed
with a saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate followed by filtration. After
distilling off the solvent under reduced pressure, the obtained
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 90 mg of the title
compound as a colorless oily substance. 689
[2310] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2311] 0.38(t, J=5.2 Hz, 1H), 0.58and0.60(d, J=5.2 Hz, total1H),
0.92-1.00(m, 1H), 1.08-1.20(m, 1H), 1.44(s, 9H), 1.93and1.97(t,
J=5.6 Hz, total1H), 3.06and3.09(dd, J=5.2, 8.4 Hz, total1H),
3.37-3.43(m, 2H), 3.51and3.55(d, J=5.2 Hz, total1H), 3.58and3.72(d,
J=1.6 Hz, total1H), 4.08-4.17(m, 1H)
EXAMPLE 345
Ethyl[1-(tert-butoxycarbonyl)piperidin-4-ylidene]acetate
[2312] 51.0 g of ethyl (1-benzylpiperidin-4-ylidene]acetate was
dissolved in 200 ml of dichloroethane. After adding 36.5 g of
1-chloroethyl chloroformate under ice-cooling, the resulting
mixture was heated under reflux for 2 hours. After adding 100 ml of
methanol, the resulting mixture was further heated under reflux for
40 minutes and then allowed to stand at room temperature overnight.
Then 60 g of triethylamine was added to the reaction mixture under
ice-cooling. Further, 300 ml of methanol was added thereto and the
system was made homogeneous. Next, 47.2 g of tert-butyl dicarbonate
was added and the resulting mixture was stirred at room temperature
for 20 minutes. The reaction mixture was concentrated under reduced
pressure, diluted with ethyl acetate, washed successively with 1 N
hydrochloric acid, water, a saturated aqueous solution of sodium
chloride and saturated sodium hydrogencarbonate and dried over
anhydrous magnesium sulfate followed by filtration. After
distilling off the solvent under reduced pressure, the crude
crystals thus obtained were ground and washed with hexane to
thereby give 15.2 g of the title compound. The filtrate was
concentrated and the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
37.8 g of the additional title compound as colorless crystals.
690
[2313] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2314] 1.28(t, J=7.2 Hz, 3H), 1.47(s, 9H), 2.25-2.31(m, 2H),
2.91-2.96(m, 2H), 3.45-3.53(m, 4H), 4.15(q, J=7.2 Hz, 2H), 5.71(t,
J=1.2 Hz, 1H)
EXAMPLE 346
Ethyl[1-(tert-buxycarbonyl)-1,2,3,6-tetrahydro-pyridin
-4-yl]acetate
[2315] 53.0 g of ethyl[1-(tert-butoxycarbonyl)-piperidin
-4-ylidene]acetate was dissolved in 400 ml of toluene. After adding
3 g of 1,8-diazabicyclo[5.4.0]-7-undecene, the resulting mixture
was heated under reflux for 4 days. After concentrating the
reaction mixture under reduced pressure, the residue was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 31.9 g of the title compound as a
colorless oily substance. 691
[2316] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2317] 1.27(t, J=7.2 Hz, 3H), 1.46(s, 9H), 2.12-2.37(m, 2H),
3.02(s, 2H), 3.51(t, J=6.0 Hz, 2H), 3.88-3.92(m, 2H), 4.15(q, J=7.2
Hz, 2H)5.52(br.s, 1H)
EXAMPLE 347
2-[1-(tert-Butoxycarbonyl)-1,2,3,6-tetrahydropyridin
-4-yl]ethanol
[2318] The title compound was obtained as a colorless oily
substance by treating ethyl[1-(tert-butoxycarbonyl)
-1,2,3,6-tetrahydropyridin-4-yl]ac- etate by the same method as the
one of Example 343. 692
[2319] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2320] 1.47(s, 9H), 2.05-2.12(m, 2H), 2.24-2.32(m, 2H), 3.50(t,
J=6.0 Hz, 2H), 3.71(t, J=6.0 Hz, 2H), 3.86-3.90(m, 2H),
5.46-5.51(m, 1H)
EXAMPLE 348
2-[1-(Benzyloxycarbonyl)-1,2,3,6-tetrahydropyridin
-4-yl]ethanol
[2321] 11.76 g of 2-(1-benzyl-1,2,3,6-tetrahydropyridin
-4-yl)ethanol was dissolved in 100 ml of tetrahydrofuran. After
adding 100 ml of a 4 N solution of hydrogen chloride in dioxane,
the resulting mixture was stirred at room temperature for 8 hours
and 20 minutes. Then the reaction mixture was concentrated under
reduced pressure and the residue was dissolved in a mixture of
tetrahydrofuran (100 ml) with a 4 N solution of sodium hydroxide
(70 ml). Under ice-cooling, 9.7 g of benzyloxycarbonyl chloride was
dropped thereinto over 25 minutes and the resulting mixture was
stirred for 40 minutes. The reaction mixture was concentrated under
reduced pressure, diluted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate followed by filtration. After
distilling off the solvent under reduced pressure, the obtained
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 11.4 g of the title
compound as a colorless oily substance. 693
[2322] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2323] 1.62(s, 1H), 2.11(br.s, 2H), 2.29(t, J=6.0 Hz, 2H), 3.59(t,
J=6.0 Hz, 2H), 3.71(t, J=6.0 Hz, 2H), 3.95-4.00(m, 2H), 5.15(s,
2H), 5.49(br.s, 1H), 7.15-7.20(m, 5H)
EXAMPLE 349
2-[3-(Benzyloxycarbonyl)-3-azabicyclo[4.1.0]hept-6-yl]ethanol
[2324] Under ice-cooling, 75 ml of diethylzinc and 33.5 g of
diiodomethane were added to 500 ml of dichloroethane. After further
adding a solution of 6.53 g of
2-[1-(benzyloxycarbonyl)-1,2,3,6-tetrahydropyridin -4-yl]ethanol in
dichloroethane (20 ml), the resulting mixture was stirred at room
temperature for 6 days. Then the reaction mixture was poured into a
mixture of saturated ammonium chloride with 1 N hydrochloric acid,
washed with a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate followed by filtration.
After distilling off the solvent under reduced pressure, the
obtained residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 1.22 g of the
title compound as an oily substance. 694
[2325] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2326] 0.38-0.40(m, 1H), 0.50-0.54(m, 1H), 0.84-0.93(m, 1H),
1.60-1.83(m, 2H), 2.05-2.16(m, 1H), 2.06-2.12(m, 1H), 3.23-3.28(m,
1H), 3.57-3.62(m, 1H), 3.68-3.78(m, 3H), 3.98(s, 1H), 5.12(s, 1H),
5.15(s, 1H), 7.28-7.40(m, 5H)
EXAMPLE 350
6-(tert-Butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thienol[2,3-c]pyridine
[2327] The title compound was obtained as a yellow oily substance
by the same method as the one described in Journal of Heterocyclic
Chemistry, 27, 1169 (1990). 695
[2328] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2329] 1.49(s, 9H), 2.68-2.74(m, 2H), 3.65-3.71(m, 2H), 4.63(br.s,
2H), 6.79(d, J=5.2 Hz, 1H), 7.14(d, J=5.2 Hz, 1H)
EXAMPLE 351
[6-(tert-Butoxycarbonyl)-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridin-2-yl]c-
arbaldehyde
[2330] To a solution of 0.63 g of diisopropylamine in 10 ml of
tetrahydrofuran was added 3.7 ml of a 1.6 M solution of
n-butyllithium In hexane and the resulting mixture was stirred at
0.degree. C. for 30 minutes. After cooling the reaction mixture to
-70.degree. C., a solution of 1.0 g of 6-(tert-butoxycarbonyl)
-4,5,6,7-tetrahydro-6H-thieno[2,3-c]p- yridine in 10 ml of
tetrahydrofuran was dropped thereinto followed by the addition of
N,N,N,N-tetramethylethylenediamine. After stirring for 1 hour, 1.0
ml of N,N-dimethylformamide was added and stirring was continued
for additional 2 hours. After adding a saturated aqueous solution
of ammonium chloride, the reaction mixture was extracted with ethyl
acetate. The organic layer was washed with water and a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.35 g of the title compound as a yellow oily substance. 696
[2331] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2332] 1.49(s, 9H), 2.73-2.79(m, 2H), 3.67-3.73(m, 2H), 4.68(br.s,
2H), 7.48(s, 1H), 9.85(s, 1H)
EXAMPLE 352
2-[(1,3-Dithiacyclohexan-2-ylidene)methyl]-6-(tert-butoxycarbonyl)
-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine
[2333] The title compound was obtained as pale yellow crystals by
the same method as the one of Production Example 62. 697
[2334] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2335] 1.48(s, 9H), 2.21(quint, J=6.0 Hz, 2H), 2.60-2.69(m, 2H),
2.98(t, J=6.0 Hz, 2H), 3.01(t, J=6.0 Hz, 2H), 3.60-3.70(m, 2H),
4.59(br.s, 2H), 6.76(s, 1H), 6.93(s, 1H)
EXAMPLE 353
N-[8-Methyl-8-azabicyclo[3.2.1]oct-3-yl]-[7-(tert-butoxy-carbonyl)
-7-azaspiro[3.5]non-2-yl]acetamide
[2336] 1.7 g of
[7-(tert-butoxycarbonyl)-7-azaspiro[3.5]non-2-yl]acetic acid was
dissolved in 50 ml of dichloromethane. After adding 0.9 ml of
triethylamine, the resulting mixture was ice-cooled. After adding
0.95 ml of ethyl chloroformate, the resulting mixture was stirred
at room temperature for 30 minutes. Then 1.9 g of 3-amino
-8-methyl-8-azabicyclo[- 3.2.1]octane dihydrochloride and 2.5 ml of
triethylamine were added thereto and the resulting mixture was
stirred at room temperature for 6 hours. After adding water, the
reaction mixture was extracted with ethyl acetate. The organic
layer was washed with 1 N sodium hydroxide and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the obtained crystals were washed with ether to thereby
give 1.25 g of the title compound as white crystals. 698
[2337] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2338] 1.41-1.52(m, 4H), 1.45(s, 9H), 1.55-1.87(m, 4H),
1.67-1.74(m, 2H), 2.02-2.10(m, 2H), 2.12-2.18(m, 2H), 2.18-2.25(m,
2H), 2.27(d, J=9.0 Hz, 2H), 2.28(s, 3H), 2.56-2.68(m, 1H),
3.12-3.18(m, 2H), 3.22-3.28(m, 2H), 3.31-3.36(m, 2H), 4.02-4.10(m,
1H), 5.75(br.d, J=9.0 Hz, 1H)
EXAMPLE 354
[2-(Benzyloxycarbonyl)-2-azaspiro[4.5]dec-8-yl]methanol
[2339] 4.72 g of ethyl[4-(ethoxycarbonyl)-1-(nitromethyl)cyclohex
-1-yl]acetate was dissolved in 60 ml of ethanol. After adding 0.5 g
of 10% palladium-carbon (moisture content: 50%) and 5.93 g of
ammonium formate, the resulting mixture was heated to 60.degree. C.
for 1 hour. After allowing to cool, the reaction mixture was
filtered and concentrated under reduced pressure. After adding
tetrahydrofuran to the residue, the insoluble matters were filtered
off. After concentrating under reduced pressure, 4.06 g a slightly
pink oily substance was obtained.
[2340] This oily substance was heated to 180.degree. C. for 2 hours
and purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 2.19 g of a dark pinky
red solid. This product was dissolved in 10 ml of tetrahydrofuran
and dropped under ice-cooling into 40 ml of a suspension of 0.69 g
of lithium aluminum hydride in tetrahydrofuran. After stirring at
room temperature for 30 minutes, the reaction mixture was heated
under reflux for 4 hours. Then it was ice-cooled and 0.7 ml of
water, 15% sodium hydroxide and 2.1 ml of water were successively
added thereto. Further, celite was added thereto and the resulting
mixture was stirred at room temperature for 20 minutes. After
filtration, it was concentrated under reduced pressure to thereby
give 1.73 g of a slightly yellow oily substance.
[2341] This product was dissolved in 25 ml of methanol and 0.5 g of
10% palladium-carbon (moisture content: 50%) was added thereto. The
resulting mixture was stirred at room temperature under a hydrogen
pressure of 1 atm for 4 hours and then heated to 60.degree. C. for
3 hours and 20 minutes. After allowing to cool, the reaction
mixture was filtered and concentrated under reduced pressure to
thereby give 1.48 g of a colorless oily substance.
[2342] This product was dissolved in 14 ml of tetrahydrofuran and
added to 14 ml of an aqueous solution of 0.666 g of anhydrous
potassium carbonate. Then the mixture was cooled to -2.degree. C.
and 1.31 ml of benzyl chloroformate was dropped thereinto while
maintaining the bulk temperature at 0.degree. C. or below. After
the completion of the addition, the resulting mixture was stirred
under ice-cooling for 45 minutes. Then ice-water was added to the
reaction mixture followed by the extraction with ethyl acetate. The
organic layer was washed with water and a saturated aqueous
solution of sodium chloride and dried over anhydrous sodium
sulfate. After concentrating under reduced pressure, the residue
was purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 2.21 g of the title
compound as a colorless oily substance. 699
[2343] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2344] 0.97-1.17(m, 2H), 1.28-1.78(m, 10H), 3.15-3.28(m, 2H),
3.42-3.52(m, 4H), 5.12, 5.13(s, total 2H), 7.28-7.40(m, 5H)
EXAMPLE 355
Methyl[2-(benzyloxycarbonyl)-2-azaspiro[4.5]dec-8-yl]carboxylate
[2345] The following compound was obtained as a colorless oily
substance by the same method as those of Production Examples 73 and
74. 700
[2346] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2347] 1.28-1.46(m, 2H), 1.55-1.92(m, 8H), 2.25-2.38(m, 1H),
3.13-3.31(m, 2H), 3.42-3.51(m, 2H), 3.67, 3.68(s, total 3H), 5.12,
5.13(s, total 2H), 7.29-7.39(m, 5H)
EXAMPLE 356
2-Hydroxyphenyl (1-benzylpiperidin-4-yl)sulfamate
[2348] To a solution of 9.56 g of 1-benzyl-4-aminopiperidine in
N,N-dimethylformamide (125 ml) was added 5.56 g of triethylamine at
a temperature of 5.degree. C. or lower. Next, a solution of 9.45 g
of catechol sulfate [J. Org. Chem., 45 (26), 5371 (1980)] in
dichloromethane (20 ml) was dropped thereinto and the resulting
mixture was stirred for 2.5 hours. The reaction mixture was poured
into 500 ml of a 1% aqueous solution of sodium chloride and
extracted with diethyl ether thrice. The organic layer was washed
with water 6 times, dried over anhydrous magnesium sulfate and
filtered. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol) to thereby give 19.08 g of
the title compound as a colorless oily substance. 701
[2349] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2350] 1.58(dq, J=4, 12 Hz, 2H), 1.96(d, J=12 Hz, 2H), 2.08(t, J=12
Hz, 2H), 2.81(m, 2H), 3.44(m, 1H), 3.48(s, 2H), 4.95(br.s, 2H),
6.83(dt, J=2, 8 Hz, 1H), 6.91(dd, J=2, 8 Hz, 1H), 7.10(dt, J=2, 8
Hz, 1H), 7.22(dd, J=2, 8 Hz, 1H), 7.24-7.32(m, 5H)
EXAMPLE 357
N-(1-Benzylpiperidin-4-yl)-N,N'-pentamethylenesulfamide
[2351] To a solution of 1.81 g of 2-hydroxyphenyl
(1-benzylpiperidin-4-yl)- sulfamate in 1,4-dioxane (25 ml) was
added 0.47 g of piperidine and the resulting mixture was heated
under reflux for 4 hours. Then the reaction mixture was poured into
100 ml of water and extracted with ethyl acetate. The organic layer
was dried over anhydrous magnesium sulfate, filtered and distilled
off under reduced pressure. The residue thus obtained was purified
by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.701 g of the title
compound as a colorless oily substance. 702
[2352] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2353] 1.48(m, 4H), 1.58-1.66(m, 4H), 1.96(d, J=12 Hz, 2H), 2.10(t,
J=12 Hz, 2H), 2.78(d, J=12 Hz, 2H), 3.14(t, J=5 Hz, 4H), 3.21(m,
1H), 3.48(s, 2H), 3.94(d, J=7 Hz, 1H), 7.22-7.35(m, 5H)
EXAMPLES 358 to 361
[2354] The following compounds were obtained by the same method as
the one of Example 357.
70 Ex. Structural formula NMR 358
703N-(1-benzylpiperidin-4-yl)-N',N'-(3- oxapentamethylene)sulfamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.64(dq, J=2, # 12Hz, 2H),
1.96(br .multidot. d, J=12Hz, 2H), 2.09(t, J=12Hz, 2H), 2.80(br
.multidot. d, J=12Hz, 2H), 3.17(t, J=5Hz, 4H), 3.25(m, 1H), 3.48(s,
2H), 3.74(t, J=5Hz, 4H), 4.07(d, J=8Hz, 1H), 7.22-7.35(m, 5H) 359
704N-(1-benzylpiperidin-4-yl)-N',N'-[3-
(ethoxycarbonyl)pentamethylen- e]sulfamide .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.25(t, J=7Hz, 3H), # 1.52(dq, J=4, 11Hz, 2H),
1.75(qd, J=3, 11Hz, 2H), 1.95(br .multidot. dt, J=3, 11Hz, 4H),
2.08(t, J=11Hz, 2H), 2.38(tt, J=3, 11Hz, 1H), 2.76-2.82(m, 4H),
3.20(m, 1H), 3.48(s, 2H), 3.62(dt, J=3, 12Hz, 2H), 4.15(d, J=8Hz,
1H), 4.16(q, J=7Hz, 2H), 7.22-7.34(m, 5H) 360
705N-(1-benzylpiperidin-4-yl)-N'-(methoxycarbonyl)methylsulfamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.53(dq, J=3, # 12Hz, 2H),
1.97(br .multidot. d, J=12Hz, 2H), 2.09(t, J=12Hz, 2H), 2.79(br
.multidot. d, 12Hz, 2H), 3.27(m, 1H), 3.48(s, 2H), 3.77(s, 3H),
3.82(s, 2H), 4.31(d, J=8Hz, 1H), 4.89(br .multidot. s, 1H),
7.20-7.33(m, 5H) 361
706N-(1-benzylpiperidin-4-yl)-N'-(2-hydroxyethyl)sulfamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.55(dq, J=3, 12Hz, # 2H),
1.98(br .multidot. d, J=12Hz, 2H), 2.09(br .multidot. t, J=12Hz,
2H), 2.81(br .multidot. d, J=12Hz, 2H), 3.19(br .multidot. s, 2H),
3.25(m, 1H), 3.48(s, 2H), 3.75(t, J=5Hz, 2H), 4.46(br .multidot. s,
1H), 4.83(br .multidot. s, 1H), 7.25-7.34(m, 5H)
EXAMPLE 362
N-(Tetrazo-5-yl)-4-[1-(tert-butoxycarbonyl)
piperidin-4-yl]-butanamide
[2355] Into 20 ml of a solution of 0.883 g of
4-[1-(tert-butoxycarbonyl)pi- peridin -4-yl]butanoic acid in
tetrahydrofuran were successively added at 0.degree. C. in a
nitrogen atmosphere 0.67 g of triethylamine and 5 ml of a solution
of 1.19 g of diethyl chlorophosphate in tetrahydrofuran and the
resulting mixture was then stirred at 0.degree. C. for 2 hours. To
this reaction mixture were added 0.527 g of 5-aminotetrazole and 10
ml of a solution of 0.54 g of triethylamine in tetrahydrofuran and
the resulting mixture was stirred for additional 15 hours. After
distilling off the solvent under reduced pressure, ethyl acetate
and water were added to the residue and the pH value thereof was
adjusted to 4 with formic acid. Then the aqueous layer was
extracted with ethyl acetate. The organic layers were combined,
dried over anhydrous magnesium sulfate and filtered. After
concentrating under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.875 g of the title
compound as white crystals. 707
[2356] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2357] 1.10(dq, J=5, 12 Hz, 2H), 1.38(m, 3H), 1.45(s, 9H), 1.68(m,
2H), 1.85(m, 2H), 2.67(m, 2H), 2.71(t, J=6 Hz, 2H), 4.08(m, 2H),
12.45(s, 1H)
EXAMPLE 363
Methyl[3-(benzyloxycarbonyl)-3-azabicyclo
[4.1.0]hept-6-yl]-acetate
[2358] 1.41 g of oxalyl chloride was dissolved in 70 ml of
dichloromethane and cooled to -78.degree. C. in a nitrogen
atmosphere. Into the solution was dropped a solution of 1.38 g of
dimethyl sulfoxide in dichloromethane (3 ml) over 5 minutes.
Further, a solution of 1.22 g of
2-(3-(benzyloxycarbonyl)-3-azabicyclo[4.1.0]hept-6-yl]ethanol in
dichloromethane (10 ml) was dropped thereinto over 5 minutes. After
stirring for 15 minutes, 2.24 g of triethylamine was dropped
thereinto over 5 minutes and stirring was continued for additional
30 minutes. Then the reaction mixture was diluted with
dichloromethane, washed with 1 N hydrochloric acid and a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate followed by filtration. After distilling off the
solvent under reduced pressure, the obtained residue was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 450 mg of a product. Next, this compound
was dissolved in 6 ml of dimethyl sulfoxide and 5 ml of an aqueous
solution of 257 mg of sodium dihydrogenphosphate was added thereto.
After adding 5 ml of an aqueous solution of 496 mg of sodium
chlorite over 5 minutes, the resulting mixture was stirred at room
temperature for 10 minutes. Then the reaction mixture was diluted
with ethyl acetate, washed successively with water and a saturated
aqueous solution of sodium chloride, dried over anhydrous magnesium
sulfate and filtered. After distilling off the solvent under
reduced pressure, the obtained residue was dissolved in 40 ml of
toluene. After adding 6 ml of a 2 M solution of
trimethylsilyldiazomethane in hexane and 10 ml of methanol, the
resulting mixture was stirred at room temperature for 50 minutes.
After concentrating the reaction mixture under reduced pressure,
the obtained residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby-give
180 mg of the title compound as an oily substance. 708
[2359] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2360] 0.41-0.48(m, 1H), 0.54-0.66(m, 1H), 0.88-1.04(m, 1H),
1.76-1.92(m, 2H), 2.16-2.42(m, 2H), 3.15-3.24(m, 1H), 3.32-3.44(m,
1H), 3.60-3.68(m, 1H), 3.68(s, 3H), 3.80-3.88(m, 1H), 5.12(s, 2H),
7.28-7.40(m, 5H)
EXAMPLES 364 to 386
[2361] Starting with known compounds, the following compounds were
obtained by the same method as the one of Example 63.
71 Ex. Structural formula NMR 364
7098-[(piperidin-1-yl)methyl-10-(methoxymethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.34-1.48(br .multidot. s, 2H), 1.54-1.62(m, 4H), 2.30-2.45(br
.multidot. s, 4H), 3.41(s, 2H), 3.54(s, 3H), 5.26(s, 2H), 6.92(s,
2H), 7.12(s, 1H), 7.80(s, 2H) 365 710ethyl
[1-[10-(methoxymethyl)-10H-pyraz- ino[2,3-
b][1,4]benzothiazin-8-ylmethyl] piperidin-4-yl]carboxylate
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 1.23(t, J=6Hz, 3H),
1.60-1.80(m, 2H), 1.82-1.90(m, 2H), 1.92-2.08(m, 2H), 2.20-2.32(m,
1H), 2.75-2.85(m, 2H), 3.41(s, 2H), 3.52(s, 3H), 4.12(q, J=6Hz,
2H), 5.26(s, 2H), 6.92(d, J=8Hz, 1H), 6.94(d, J=8Hz, 1H), 7.10(s,
1H), 7.82(s, 2H) 366
711[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzoth-
iazin-8-ylmethyl]piperidin-4-ol .sup.1H-NMR(CDCl.sub.3) # .delta.
ppm: 1.50-1.62(m, 2H), 1.80-1.90(m, 2H), 2.05-2.16(m, 2H),
2.10-2.30(br .multidot. s, 1H), 2.68-2.80(m, 2H), 3.40(s, 2H),
3.52(s, 3H), 3.60-3.70(m, 1H), 5.26(s, 2H), 6.88(d, J=8Hz, 1H),
6.92(d, J=8Hz, 1Hz), 7.08(s, 1H), 7.80(s, 2H) 367
7128-[(4-methoxypiperidin-1-- yl)methyl]-10-
(metoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 1.50-1.62(m, 2H),
1.82-1.92(m, 2H), 2.06-2.17(m, 2H), 2.64-2.74(m, 2H), 3.16-3.24(m,
1H), 3.34(s, 3H), 3.42(s, 2H), 3.54(s, 3H), 5.26(s, 2H), 6.92(d,
J=8Hz, 1H), 6.94(d, J=8Hz, 1H), 7.10(s, 1H), 7.82(s, 2H) 368
713[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
)-4-methylpiperidin-4-ol .sup.1H-NMR(CDCl.sub.3) # .delta. ppm:
1.22(s, 3H), 1.23(s, 1H), 1.50-1.60(m, 2H), 1.60-1.70(m, 2H),
2.45-2.55(m, 2H), 2.32-2.43(m, 2H), 3.43(s, 2H), 3.54(s, 3H),
5.26(s, 2H), 6.94(s, 2H), 7.09(s, 1H), 7.80(s, 2H) 369
714[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
]piperidin-4-yl]carboxamide .sup.1H-NMR(CDCl.sub.3) # .delta. ppm:
1.68-1.82(m, 2H), 1.82-1.89(m, 2H), 1.90-2.30(m, 2H), 2.08-2.20(m,
1H), 2.86-2.95(m, 2H), 3.42(s, 2H), 3.54(s, 3H), 5.26(s, 2H),
5.50-5.62(br .multidot. s, 2H), 6.92(d, J=8Hz, 1H), 6.95(d, J=8Hz,
1H), 7.09(s, 1H), 7.80(s, 2H) 370
715[1-[10-(methoxymethyl)-10H-pyrazino[2,- 3-
b][1,4]benzothiazin-8-ylmethyl]piperidin-4-spiro-4'-(4'-butanolide)
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 1.69-1.80(m, 2H),
1.80-1.90(m, 2H), J=6Hz, 2H), 2.38-2.50(m, 2H), 2.52-2.62(m, 2H),
2.57(t, J=6Hz, 2H), 3.43(s, 2H), 3.52(s, 3H), 5.26(s, 2H), 6.92(d,
J=8Hz, 1H), 6.94(d, J=8Hz, 1H), 7.08(s, 1H), 7.80(s, 2H) 371
716[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl]piperidin-3-yl]carboxamide .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 1.50-1.68(m, 2H), 1.68-1.80(m, 1H), 1.78-1.90(m, 1H),
2.10-2.30(m, 1H), 2.30-2.42(m, 1H), 2.42-2.50(m, 1H), 2.58-2.70(m,
1H), 2.70-2.80(br .multidot. s, 1H), 3.35(d, J=13Hz, 1H), 3.41(d,
J=13Hz, 1H), 3.49(s, 3H), 5.26(s, 2H), 5.80(br .multidot. s, 2H),
6.82(d, J=8Hz, 1H), 6.93(d, J=8Hz, 1H), 7.06(s, 1H), 7.80(s, 2H)
372
717[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
]piperidin-2-yl]carboxamide .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.20-1.40(m, 2H), 1.50-1.70(m, 2H), 1.70-1.80(m, 1H), 1.97-2.08(m,
# 2H), 2.80-2.92(m, 1H), 2.92-2.97(m, 1H), 3.22(d, J=14Hz, 1H),
3.52(s, 3H), 3.82(d, J=14Hz, 1H), 5.26(s, 2H), 6.60-6.70(br
.multidot. s, 2H), 6.92(d, J=8Hz, 1H), 6.97(d, J=8Hz, 1H), 7.11(s,
1H), 7.82(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H) 373
718[1-[10-(methoxymethyl)-10H-pyra-
zino[2,3-b][1,4]benzothiazin-8-ylmethyl]pyrrolidin-2-yl]carboxamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.70-1.82(m, 2H), 1.82-2.00(m,
1H), 2.15-2.30(m, 1H), 2.30-2.40(m, # 1H), 3.00-3.10(m, 1H),
3.10-3.20(m, 1H), 3.42(d, J=14Hz, 1H), 3.50(s, 3H), 3.82(d, J=14Hz,
1H), 5.26(s, 2H), 5.95-6.15(br .multidot. s, 1H), 6.89(d, J=8Hz,
1H), 6.94(d, J=8Hz, 1H), 7.08(s, 1H), 7.10-7.20(br .multidot. s,
1H), 7.80(s, 2H) 374
7192-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-ylmethyl]piperidin-4-yl]ethanol .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.20-1.36(m, 2H), 1.35-1.45(m, 1H), 1.45-1.55(m, 2H),
# 1.60-1.70(m, 2H), 1.90-2.00(m, 2H), 2.70-2.80(br .multidot. s,
1H), 2.80-2.90(m, 2H), 3.42(s, 2H), 3.54(s, 3H), 3.66(t, J=6Hz,
2H), 5.25(s, 2H), 6.92(s, 2H), 7.08(s, 1H), 7.81(s, 2H) 375
7208-[(2,6-dimethylpiperidin-1-yl)methyl-10-
(methoxymethyl)-10H-pyrazino- [2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.02(d, J=7Hz, 3H), 1.04(d, #
J=7Hz, 3H), 1.20-1.40(m, 2H), 1.50-1.70(m, 4H), 2.40-2.50(m, 2H),
3.53(s, 3H), 3.72(s, 2H), 5.24(s, 2H), 6.92(d, J=8Hz, 1H), 6.97 (d,
J=8Hz, 1H), 7.24(s, 1H), 7.82(s, 2H) 376
721[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-
benzothiazin-8-ylmethyl]piperidin-4-yl carbamate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.62-1.76(m, 2H), 1.86-1.96(m,
2H), 2.18-2.30(m, 2H), 2.64-2.74(m, 2H), 3.42(s, 2H), 3.54(s, 3H),
4.50-4.70(m, 3H), 5.32(s, 2H), 6.92(d, J=8Hz, 1H), 6.94(d, J=8Hz,
1H), 7.12(s, 1H), 7.82(s, 2H) 377
7224-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1- ,4]-
benzothiazin-8-ylmethyl]piperidin-4-yl]butanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.16-1.30(m, 4H), 1.30-1.40(m,
# 2H), 1.50-1.60(m, 2H), 1.60-1.70(m, 2H), 1.70-1.90(m, 2H),
1.94(m, 2H), 2.82-2.90(m, 2H), 3.44(s, 2H), 3.54(s, 3H), 3.62(t,
J=6Hz, 2H) 5.28(s, 2H), 6.92(d, J=8Hz, 1H), 6.94(d, J=8Hz, 1H),
7.09(s, 1H), 7.82(s, 2H) 378
723[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4-
]benzothiazin-8-ylmethyl]-2-pyridone .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.49(s, 3H), 5.06(s, 2H), 5.22(s, 2H), 6.16(dt, J=2,
7Hz, 1H), 6.62(ddd, # J=1, 2, 9Hz, 1H), 6.87(dd, J=2, 8Hz, 1H),
6.97(d, J=8Hz, 1H), 7.08(d, J=2Hz, 1H), 7.28(ddd, J=1, 2, 7Hz, 1H),
7.34(ddd, J=2, 7, 9Hz, 1H), 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H)
379 724[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b]-
[1,4]benzo-thiazin-8-ylmet- hyl]-4-pyridone .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.48(s, 3H), 4.88(s, 2H), 5.22(s, 2H), # 6.45(d,
J=8Hz, 2H), 6.75(dd, J=1, 8Hz, 1H), 6.91(d, J=2Hz, 1H), 7.03(d,
J=8Hz, 1H), 7.33(d, J=8Hz, 2H), 7.85(d, J=3Hz, 1H), 7.87(d, J=3Hz,
1H) 380 7257-[(piperidin-1-yl)methyl]-5-(methoxy
methyl)-5H-pyrido[3,4-b][1,4]ben- zothiazine
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 1.44(m, 2H), 1.60(m, 4H),
2.41(br .multidot. s, 3.46(s, 2H), 3.53(s, 3H), 5.03(s, 2H),
6.87(d, J=6Hz, 1H), 6.93(d, J=8Hz, 1H), 7.03(d, J=8Hz, 1H), 7.07(s,
1H), 8.17(s, 1H), 8.25(d, J=6Hz, 1H) 381
726[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
]piperidin-4-yl]carbonitrile .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.81-1.98(m, 4H), # 2.26-2.38(m, 2H), 2.60-2.69(m, 3H), 3.43(s,
2H), 3.54(s, 3H), 5.27(s, 2H), 6.91(dd, J=1.5, 7.7Hz, 1H), 6.96(d,
J=7.7Hz, 1H), 7.83(d, J=2.7Hz, 1H), 7.84(d, J=2.7Hz, 1H) 382
727N,N-[3-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
ylmethyl]-3-azapentamethylene]methanesulfonamide
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 2.55(br .multidot. t,
J=4.8Hz, 4H), 2.78(s, 3H), 3.23(br .multidot. t, J=4.8Hz, 4H),
3.47(s, 2H), 3.53(s, 3H), 5.28(s, 2H), 6.92(dd, J=1.5, 7.9Hz, 1H),
6.96(d, J=7.9Hz, 1H), 7.09(d, J=1.5Hz, 1H), 7.82(d, J=2.8Hz, 1H),
7.83(d, J=2.8Hz, 1H) 383 7288-[(4-methylpiperazin-1-yl)methyl-10-
(methoxymethyl)-10H-pyrazino[2,3- -b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.96-2.23(m, 2H), 2.28(s, 3H),
# 2.30-2.65(m, 6H), 3.43(s, 2H), 3.53(s, 3H), 5.23(s, 2H), 6.93(dd,
J=1.4, 8.3Hz, 1H), 6.95(d, J=8.3Hz, 1H), 7.10(d, J=1.4Hz, 1H),
7.82(d, J=2.8Hz, 1H), 7.83(d, J=2.8Hz, 1H) 384
7298-(morpholinomethyl)-10-(methoxymethyl)-
10H-pyrazino[2,3-b][1,4]b- enzothiazine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.38-2.50(m, 4H), 3.43(s, 2H), 3.53(s, # 3H),
3.68-3.75(m, 4H), 5.28(s, 2H), 6.94(dd, J=1.1, 8.0Hz, 1H), 6.96(d,
J=8.0Hz, 1H), 7.12(d, J=1.1Hz, 1H), 7.83(d, J=2.8Hz, 1H), 7.84(d,
J=2.8Hz, 1H), 385 730[1-(10-methoxymethyl)-10H-pyrazino[2,3-
b][1,4]benzoxazin-8-ylmethyl)p- iperidin-4-yl]carboxamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.7-1.96(m, 4H), 1.96(m, 2H),
# 2.1-2.24(m, 1H), 2.93(br .multidot. d, J=12Hz, 2H), 3.38(s, 2H),
3.47(s, 3H), 5.32(s, 2H), 5.50(br .multidot. s, 1H), 5.60(br
.multidot. s, 1H), 6.77(s, 2H), 6.89(s, 1H), 7.42(d, J=3Hz, 1H),
7.57(d, J=3Hz, 1H) 386 731N-[1-(10-methoxymethyl)-10-
H-pyrazino[2,3-b][1,4]benzo-thiazin-8-ylmethyl]piperidin-4-ylacetamide
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.29-1.40(m, 2H),
1.63-1.73(m, 2H), 1.75(s, 3H), 1.92-2.01(m, 2H), 2.68-2.76(m, #
2H), 3.37(s, 2H), 3.38(s, 3H), 3.41-3.54(m, 1H), 5.23(s, 2H),
6.92(dd, J=1.2, 7.9Hz, 1H), 7.05(d, J=7.9Hz, 1H), 7.09(d, J=1.2Hz,
1H), 7.75(br .multidot. d, J=7.5Hz, 1H), 7.92(d, J=2.7Hz, 1H),
7.95(d, J=2.7Hz, 1H)
EXAMPLES 387 to 392
[2362] The following compounds were obtained by the same method as
the one of Example 64 by using anhydrous potassium carbonate,
sodium hydrogencarbonate or pyridine as a substitute for
N,N-diisopropylethylami- ne.
72 Ex. Structural formula NMR 387
732N-[1-[4-cyano-10-(methoxymethyl)-10H-pyrido[3,2-b][1,4]benzothiazin-8--
ylmethyl]piperidin-4-yl]-N',N'-dimethylsulfamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.57(m, 2H), 1.99(m, 4H),
2.21(m, # 2H), 2.78(s, 6H), 3.24(m, 1H), 3.37(s, 3H), 3.44(s, 2H),
3.96(d, J=4Hz, 1H), 5.24(s, 2H), 7.03(dd, J=2, 8Hz, 1H), 7.10(d,
J=8Hz, 1H), 7.11 (d, J=2Hz, 1H), 7.22(d, J=5Hz, 1H), 8.16(d, J=5Hz,
1H) 388
733N-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzoxazin-8-ylmethyl-
]piperidin-4-yl]methanesulfonamide .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.5-1.65(m, 2H), 1.9-2.05(m, 2H), # 2.13(t, J=7Hz, 2H),
2.75-2.85(m, 2H), 2.99(s, 3H), 3.30-3.40(m, 1H), 3.44(s, 2H),
3.53(s, 3H), 4.20-4.35(m, 1H), 5.30(s, 2H), 6.93(d, J=8Hz, 1H),
6.97(d, J=8Hz, 1H), 7.10(s, 1H), 7.82-7.87(m, 2H) 389
734N-[2-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylm-
ethyl]piperidin-4-yl]ethyl]acetamide .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.2-1.4(m, 3H), 1.4-1.5(m, 2H), 1.5-1.8(m, # 2H),
1.96(s, 3H), 1.9-2.1(m, 2H), 2.8-2.95(m, 2H), 3.22-3.3(m, 2H),
3.4-3.46(m, 2H), 3.53(s, 3H), 5.28(s, 2H), 5.3-5.4(m, 1H),
6.7-6.96(m, 1H), 6.96(d, J=8Hz, 1H), 7.08-7.12(m, 1H), 7.8-7.86(m,
2H) 390
735N-[2-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylm-
ethyl]piperidin-4-yl]ethyl]methanesulfamide .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.2-1.4(m, 3H), 1.44-1.54(m, 2H), # 1.56-1.68(m, 2H),
1.86-2.00(m, 2H), 2.8-2.9(m, 2H), 2.94(s, 3H), 3.08-3.20(m, 2H),
3.42(s, 2H), 3.53(s, 3H), 4.35(br .multidot. s, 1H), 5.28(s, 2H),
6.91(d, J=8Hz, 1H), 6.95(d, J=8Hz, 1H), 7.08(s, 1H), 7.76-7.86(m,
2H) 391
736N-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin--
8-ylmethyl]piperidin-4-yl]-N'-methylsulfamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.50-1.70(m, 2H), 1.90-2.05(m,
2H), 2.05-2.17(m, 2H), 2.71(d, # J=6Hz, 3H), 2.73-2.84(m, 2H),
3.17-3.30(m, 1H), 3.42(s, 2H), 3.53(s, 3H), 4.00-4.15(m, 2H),
5.28(s, 2H), 6.91(dd, J=1, 8Hz, 1H), 6.96(d, J=8Hz, 1H), 7.09(d,
J=1Hz, 1H), 7.83(d, J=2Hz, 1H), 7.84(d, J=2Hz, 1H) 392
737N-[1-[10-(methoxymethyl)-10H-pyrazino[2-
,3-b][1,4]benzothiazin-8-ylmethyl]piperidin-4-yl]sulfamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.5-1.63(m, 2H), 1.97-2.08(m,
2H), 2.05-2.18(m, 2H), # 2.73-2.85(m, 2H), 3.28-3.40(m, 1H),
3.42(s, 2H), 3.54(s, 3H), 4.34(d, J=10Hz, 1H), 4.6(br .multidot. s,
2H), 5.29(s, 2H), 6.91(dd, J=1, 8Hz, 1H), 6.96(d, J=8Hz, 1H),
7.08(d, J=1Hz, 1H), 7.83(d, J=2Hz, 1H), 7.84(J=2Hz, 1H)
EXAMPLE 393
N,N-[3-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzo-thiazin-8-ylmethy-
l]amiono]pentamethylene]methanesulfonamide
[2363] The title compound was obtained by the same method as the
one of Example 66. 738
[2364] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2365] 1.5-1.65(m, 2H), 1.95-2.05(m, 2H), 2.6-2.7(m, 1H), 2.77(s,
3H), 2.7-2.85(m, 2H), 3.53(s, 3H), 3.6-3.8(m, 2H), 3.77(s, 2H),
5.30(s, 3H), 6.92-7.0(m, 2H), 7.14(s, 1H), 7.83(d, J=3 Hz, 1H),
7.84(d, J=3 Hz, 1H)
EXAMPLE 394
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-2,-
3-dehydro-4-piperidone
[2366] Into a solution of 0.130 g of sodium aluminum hydride in
tetrahydrofuran (10 ml) was dropped in a nitrogen atmosphere a
solution of 0.858 g of
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-
-8-ylmethyl]-4-pyridone in tetrahydrofuran (20 ml). After reacting
for 16 hours, 0.13 ml of water, 0.13 ml of a 15% aqueous solution
of sodium hydroxide and 0.40 ml of water were successively added
thereto and the insoluble matters were filtered off. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.277 g of the title
compound as pale yellow crystals. 739
[2367] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2368] 2.48(t, J=8 Hz, 2H), 3.38(t, J=8 Hz, 2H), 3.53(s, 3H),
4.29(s, 2H), 5.04(d, J=8 Hz, 1H), 5.26(s, 2H), 6.68(dd, J=2, 8 Hz,
1H), 7.03(d, J=8 Hz, 1H), 7.05(d, J=2 Hz, 1H), 7.14(d, J=8 Hz, 1H),
7.85(d, J=3 Hz, 1H), 7.87(d, J=3 Hz, 1H)
EXAMPLE 395
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-3--
phthalimidomethylpyridinium chloride
[2369] 0.587 g of 8-chloromethyl-10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazine and a solution of 0.524 g of
N-(3-pyridylmethyl)phthalimide in 10 ml of dimethylforamide were
heated to 80.degree. C. in a nitrogen atmosphere for 4 hours. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.489 g of the title
compound as yellow crystals. 740
[2370] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2371] 3.53(s, 3H), 5.04(s, 2H), 5.32(s, 2H), 6.22(s, 2H), 7.02(d,
J=8 Hz, 1H), 7.22(dd, J=2, 8 Hz, 1H), 7.40(d, J=2 Hz, 1H), 7.76(dd,
J=3, 6 Hz, 2H), 7.84-7.87(m, 5H), 8.01(dd, J=6, 8 Hz, 1H), 8.30(dd,
J=1, 6 Hz, 1H), 9.26(d, J=1 Hz, 1H)
EXAMPLE 396
2-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
3,4-dehydropiperidin-3-ylmethyl]-3-hydroxyiso-indolin-1-one
[2372] To a solution of 0.486 g of [1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-3-phthalimido-methylpyr-
idinium chloride in methanol (10 ml) was added 0.086 g of sodium
borohydride and the resulting mixture was stirred for 30 minutes.
Next, 20 ml of tetrahydrofuran and 10 ml of water were further
added and the mixture was stirred for additional 1 hour. After
neutralizing with sodium dihydrogenphosphate, the mixture was
extracted with dichloromethane (50 ml) and the organic layer was
dried over anhydrous magnesium sulfate. After filtering and
distilling off the solvent under reduced pressure, 0.255 g of the
title compound was obtained as pale yellow crystals. 741
[2373] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2374] 2.16(br.s, 2H), 2.42(quint, J=6 Hz, 1H), 2.51-2.56(quint,
J=6 Hz, 1H), 2.54(d, J=15 Hz, 1H), 2.98(d, J=15 Hz, 1H), 3.44(d,
J=12 Hz, 1H), 3.46(s, 3H), 3.50(d, J=12 Hz, 1H), 3.94(d, J=15 Hz,
1H), 4.20(d, J=15 Hz, 1H), 5.22(d, J=10 Hz, 1H), 5.25(d, J=10 Hz,
1H)5.74(br.s, 1H), 5.78(s, 1H), 6.88(dd, J=1, 8 Hz, 1H), 6.91(d,
J=8 Hz, 1H), 7.05(d, J=1 Hz, 1H), 7.48(dt, J=1, 7 Hz, 1H), 7.56(dd,
J=1, 7 Hz, 1H), 7.59(dd, J=1, 7 Hz, 1H), 7.76(dt, J=1, 7 Hz, 1H),
7.81(d, J=3 Hz, 1H), 7.83(d, J=3 Hz, 1H)
EXAMPLE 397
N-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
3,4-dehydropiperidin-3-ylmethyl]-2-hydroxymethyl-benzamide
[2375] To a solution of 0.255 g of 2-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-3,4-dehydropiperidin
-3-ylmethyl]-3-hydroxyisoindolin-1-one in 2-propanol (7.7 ml) were
added 1.3 ml of water and 0.163 g of sodium borohydride and the
resulting mixture was stirred for 16 hours. Then the reaction
mixture was naturalized with sodium dihydrogenphosphate and
extracted with ethyl acetate. The organic layer was dried over
anhydrous magnesium sulfate and filtered. After distilling off the
solvent under reduced pressure, 0.235 g of the title compound was
obtained as pale yellow crystals. 742
[2376] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2377] 2.21(br.s, 1H), 2.58(t, J=6 Hz, 2H), 2.99(br.s, 2H), 3.48(s,
3H), 3.51(s, 3H), 3.99(d, J=5 Hz, 2H), 4.51(s, 2H), 5.26(s, 2H),
5.76(s, 1H), 6.68(br.s, 1H), 6.91(s, 2H), 7.11(s, 1H), 7.32-7.44(m,
3H), 7.52(d, J=8 Hz, 1H), 7.82(d, J=3 Hz, 1H), 7.84(d, J=3 Hz,
1H)
EXAMPLE 398
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-3--
aminomethyl-3,4-dehydropiperidine
[2378] To a solution of 0.235 g of N-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-3,4-dehydropiperidin-3--
ylmethyl]-2-hydroxymethylbenzamide in 2-propanol (8 ml) were added
1.5 ml of water and 0.9 ml of acetic acid and the resulting mixture
was stirred at 80.degree. C. for 2 hours. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 0.120 g of the title compound as a pale yellow oily
substance. 743
[2379] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2380] 2.16(br.s, 2H), 2.52(t, J=6 Hz, 2H), 2.94(br.s, 2H), 3.17(s,
2H), 3.53(s, 3H), 3.55(s, 2H), 5.29(s, 2H), 5.63(m, 1H), 6.96(d,
J=8 Hz, 1H), 6.99(dd, J=2, 8 Hz, 1H), 7.11(d, J=2 Hz, 1H), 7.83(d,
J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H)
EXAMPLE 399
N-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
3,4-dehydropiperidin-3-ylmethyl]methanesulfonamide
[2381] The title compound was obtained as pale yellow crystals by
the same method as the one of Example 316. 744
[2382] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2383] 2.38(m, 2H), 2.84(m, 2H), 2.96(s, 3H), 3.38(br.s, 2H),
3.54(s, 3H), 3.68(d, J=5 Hz, 2H), 3.88(br.s, 2H), 5.33(s, 2H),
5.49(br.s, 1H), 5.86(m, 1H), 7.00(d, J=8 Hz, 1H), 7.06(br.d, J=8
Hz, 1H), 7.26(br.s, 1H), 7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz,
1H)
EXAMPLE 400
Ethyl
N-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylme-
thyl]-2,3-dehydro-3-piperidinecarboxylate
[2384] To a solution of 0.506 g of diisopropylamine in
tetrahydrofuran (10 ml) was added at 0.degree. C. in a nitrogen
atmosphere a 1.6 M solution of n-butyllithium in hexane. Further a
solution of 0.776 g of ethyl 2,3-dehydro-3-piperidinecarboxylate in
tetrahydrofuran (2 ml) was added thereto. In another container,
1.00 g of 8-chloromethyl
-10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine was added
at 60.degree. C. in a nitrogen atmosphere to a solution of 1.53 g
of sodium iodide in N,N-dimethylformamide (10 ml). After heating
for 2 hours, the mixture was brought back to room temperature and
then added to the above-mentioned solution of the lithium salt.
After stirring at room temperature for 2 hours and concentrating
under reduced pressure, the residue was distributed into ethyl
acetate and water. The organic layer was concentrated and the
residue was purified by silica gel column chromatography (eluted
with dichloromethane/methanol) to thereby give 0.375 g of the title
compound as pale yellow crystals. 745
[2385] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2386] 1.26(t, J=7 Hz, 3H), 1.52(quint, J=6 Hz, 2H), 2.29(t, J=6
Hz, 2H), 2.98(t, J=6 Hz, 2H), 3.49(s, 3H), 4.15(q, J=7 Hz, 2H),
4.23(s, 2H), 5.22(s, 2H), 6.82(dd, J=2, 7 Hz, 1H), 6.97(d, J=2 Hz,
1H), 6.98(d, J=7 Hz, 1H), 7.51(s, 1H), 7.83(d, J=3 Hz, 1H), 7.84(d,
J=3 Hz, 1H)
EXAMPLE 401
[2387] The following compounds were obtained by the same method as
the one of Example 8.
73 Ex. Structural formula MS M.p. NMR 401
746N-[2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)
piperidin-4-yl]ethyl]methanesulfonamide ESI(+) 420(MH.sup.+)
168-170.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.0-1.2(m, 2H), 1.24-1.40(m, # 3H), 1.54-1.66(m, 2H), 1.74-1.90(m,
2H), 2.65-2.80(m, 2H), 2.85(s, 3H), 2.92(q, J=7Hz, 2H), 3.23(br
.multidot. s, 2H), 6.65-6.75(m, 1H), 6.74(s, 1H), 6.82(d, J=8Hz.
1H), 6.89(t, J=6Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H),
9.43(m, 1H) 402 747N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl]methanesulfonamide ESI(+) 390(MH.sup.+)
220-170.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.3-1.5(m, 2H), 1.70-1.80(m, # 2H), 1.85-2.00(m, 2H), 2.60-2.75(m,
2H), 2.88(s, 3H), 3.00-3.20(m, 1H), 3.23(s, 2H), 6.63-6.70(m, 1H),
6.73(s, 1H), 6.82(d, J=8Hz, 1H), 7.0-7.1(m, 1H), 7.62(d, J=3Hz,
1H), 7.63(d, J=3Hz, 1H), 9.44(s, 1H) 403
748N-[1-(10H-pyrazino[2,3-b][1,4]ben- zothiazin-8-
ylmethyl)piperidin-4-yl]-N'-methylsulfamide ESI(+) 407(MH.sup.+)
209-210.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.34-1.48(m, 2H), 1.72-1.80(m, 2H), 1.82-1.94(m, # 2H), 2.41(d,
J=4Hz, 3H), 2.64-2.74(m, 2H), 2.84-2.96(m, 1H), 3.22(s, 2H),
6.55-6.63(m, 1H), 6.67(d, J=8Hz, 1H), 6.73(s, 1H), 6.82(d, J=8Hz,
1H), 6.87(d, J=8Hz, 1H), 7.62(d, J=3Hz, 1H), 7.62(d, J=3Hz, 1H),
9.44(s, 1H) 404
749N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
piperidin-4-yl]sulfamide ESI(+) 393(MH.sup.+) 196-199.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.32-1.48(m, # 2H),
1.74-1.88(m, 2H), 1.82-1.98(m, 2H), 2.6-2.76(m, 2H), 2H), 6.53(d,
J=7Hz, 1H), 6.67(d, J=8Hz, 1H), 6.73(d, J=1Hz, 1H), 6.82(d, J=8Hz,
1H), 7.61(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.44(s, 1H) 405
750N-[2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)
piperidin-4-yl]ethyl]acetamide ESI(+) 384(MH.sup.+) 194-196.degree.
C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.0-1.36(m, 5H), #
1.5-1.66(m, 2H), 1.75(s, 3H), 1.7-1.9(m, 2H), 2.64-2.80(m, 2H),
2.94-3.06(m, 2H), 3.21(m, 2H), 6.6-6.75(m, 1H), 6.73(m, 1H),
6.7-6.88(m, 1H), 7.62(br .multidot. s, 2H), 7.75(br .multidot. s,
1H), 9.43(m, 1H) 406
751N,N-[3-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]pentamethylene]methanesulfonamide FAB(+)
392(MH.sup.+) 219-221.degree. C. .sup.1H-NMR(DMS0-d.sub.6) .delta.
ppm: 1.24-1.38(m, 2H), # 1.80-1.90(m, 2H), 2.06-2.20(m, 1H),
2.75(t, J=7.2Hz, 2H), 2.81(s, 3H), 3.38-3.48(m, 2H), 3.54(s, 2H),
6.75(d, J=8.0Hz, 1H), 6.77(s, 1H), 6.81(d, J=8.0Hz, 1H), 7.61(d,
J=2.8Hz, 1H), 7.62(d, J=2.8Hz, 1H), 9.45(s, 1H), 407
752N-[1-(10H-pyrazino[2,3-b][1,4]benzoth- iazin-8-yl-
methyl)piperidin-4-benzenesulfonamide ESI(+) 454(MH.sup.+)
157-158.degree. C. .sup.1H-NMR(DMS0-d.sub.6) .delta. ppm:
1.25-1.40(m, 2H), 1.40-1.55(m, # 2H), 1.70-1.90(m, 2H),
2.50-2.65(m, 2H), 2.85-2.95(m, 1H), 3.17(s, 2H), 6.60-6.68(m, 1H),
6.68(s, 1H), 6.80(br .multidot. d, J=8Hz, 1H), 7.50-7.65(m, 5H),
7.68-7.75(m, 1H), 7.75-7.82(m, 2H), 9.41(s, 1H) 408
753N-[1-(10H-pyrazino[2- ,3-b][1,4]benzothiazin-8-
ylmethyl)-3,4-dehydropiperidin-3-yl]methyl]metha- ne-Sulfonamide
FAB(+) 440(MH.sup.+) 110-112.degree. C. .sup.1H-NMR(DMS0-d.sub.6)
.delta. ppm: 2.07(br .multidot. s, 2H), 2.42(t, J=3Hz, 2H), 2.79(br
.multidot. s, # 2H), 2.83(s, 3H), 3.36(s, 2H), 3.43(br .multidot.
d, J=3Hz, 2H), 5.74(br .multidot. s, 1H), 6.71(dd, J=1, 8Hz, 1H),
6.77(d, J=1Hz, 1H), 6.84(d, J=8Hz, 1H), 7.24(t, J=3Hz, 1H), 7.63(s,
2H), 9.44(s, 1H) 409 754[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-
8-yl-methyl)]piperidin-4-yl]- carbamate FAB(+) 358(MH.sup.+)
139-142.degree. C. .sup.1H-NMR(DMS0-d.sub.6- ) .delta. ppm: 1.44(m,
2H), 1.70-1.85(m, # 2H), 2.50-2.70(m, 2H), 3.15(d, J=10Hz, 1H),
3.20-3.40(m, 2H), 3.25(d, J=10Hz, 1H), 4.30-4.50(br .multidot. s,
3H), 6.68(d, J=8Hz, 1H), 6.71(s, 1H), 6.85(d, J=8Hz, 1H), 7.62(s,
2H), 9.45(br .multidot. s, 1H) 410
7554-[N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl]- butanol FAB(+) 371(MH.sup.+)
132-135.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
0.95-1.30(m, 7H), 1.30-1.40(m, # 2H), 1.50-1.62(m, 2H),
1.70-1.90(m, 2H), 2.70-2.80(m, 2H), 3.21(s, 2H), 3.30-3.40(m, 2H),
4.31(t, J=5Hz, 1H), 6.65(d, J=8Hz, 1H), 6.74(s, 1H), 6.81(d, J=8Hz,
1H), 7.61(s, 2H), 9.42(br .multidot. s, 1H) 411
7561-(10H-pyrido[3,4-b][1,4]benzothiazin-7-ylmethyl)-4-pyridone
FAB(+) 308(MH.sup.+) 168.degree. C. (decompose)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.95(s, 2H), 6.09-6.15(m,
2H), # 6.46(d, J=1.5Hz, 1H), 6.52(d, J=5.5Hz, 1H), 6.75(dd, J=1.5,
7.9Hz, 1H), 6.96(d, J=7.9Hz, 1H), 7.66-7.72(m, 2H), 7.88(s, 1H),
7.97(d, J=5.5Hz, 1H), 9.20(s, 1H)
EXAMPLES 412 to 433
[2388] The following compounds were obtained by the same method as
that of Example 9.
74 Ex. Structural formula MS M.p. NMR 412
757N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperi-
din- 4-yl]acetamide FAB (+) 35 6 (MH.sup.+) 212-214.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.25-1.40 (m, 2H),
1.60-1.72 (m, 2H), 1.87-2.02 (m, 2H), 2.48 (s, 3H), 2.60-2.78 (m,
2H), 3.23 (s, 2H), 3.40-3.54 (m, 1H), 6.68 (d, J = 8.3Hz, 1H), 6.73
(s, 1H), 6.83 (d, J = 8.3 Hz, 1H), 7.62 (s, 2H), 7.73 (d, # J = 7.6
Hz, 1H), 9.44 (s, 1H) 413
758[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylm-
ethyl)-piperidin- 4-yl]carboxamide ESI (+) 32 6 (MH.sup.+)
287-288.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.40-1.58 (m, 2H), 1.58-1.68 (m,2H), 1.84 (br.t, J = 11Hz, 2H),
1.96-2.08 (m, 1H), 2.76 (br.d, J = 11 Hz, 2H), 3.22 (s, 2H), 6.57
(d, J = 8 Hz, 1H), 6.60 (s, 1H), 6.68 (d, J = 8 Hz, 1H), 6.66- #
6.74 (m, 1H), 7.19 (br.s, 1H), 7.22-7.26 (m, 1H), 7.43-7.46 (m,
1H), 9.57 (s, 1H) 414
7598-(piperidin-1-ylmethyl)-10H-pyrazino-[2,3-b][1,4]-benzothiazine
FAB (+) 29 9 (MH.sup.+) .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.30-1.27 (m, 2H), 1.50-1.63 (m, 4H), 2.20-2.50 (m, 4H), 3.30 (s,
2H), 6.57 (s, 1H), 6.55-6.60 (br.s, 1H), 6.67 (d, J = 8 Hz, 1H),
6.80 (d, J = 8 Hz, 1H), 7.56 (d, J = 3 Hz, 1H), 7.68 (s, 1H) 415
7601-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-2-pyridone
FAB (+) 30 8 (M.sup.+) 260-261.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 4.90 (s, 2H), 6.23 (t, J = 8 Hz, 1H),
6.40 (d, J = 10 Hz, 1H), 6.65 (s, 1H), 6.66 (d, J = 8 Hz, 1H), 6.86
(d, J = 8 Hz, 1H), 7.43 (ddd, J = 2, 8, 10Hz, 1H), 7.63 (s, 2H),
7.70 (dd, J = 2, 8Hz, 1H), 9.52 (s, 1H) 416
7611-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-piper-
idone FAB (+) 30 9 (MH.sup.+) >275.degree.C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 4.92 (s, 2H), 6.09 (d, J = 8 Hz, 2H),
6.58 (d, J = 1Hz, 1H), 6.66 (dd, J = 1, 8 Hz, 1H), 6.92 (d, J = 8
Hz, 1H), 7.64 (s, 2H), 7.64 (d, J = 8 Hz, 2H), 9.57 (s, 1H) 417
7621-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-2,3-
dehydro-4-piperidone 233-235.degree. C. .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 2.30 (t, J = 7 Hz, 2H), 3.22 (t, J = 7 Hz, 2H), 4.23
(s, 2H), 5.74 (s, 1H), 6.60 (dd, J = 1, 7 Hz, 1H), 6.68 (d, J = 1
Hz, 1H), 6.82 (d, J = 7 Hz, 1H), 7.21 (s, 1H), 7.62 (s, 2H), 9.43
(s, 1H) 418
7631-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-2'-piperidin-
1-ylmethyl)benzyl alcohol FAB (+) 40 5 (MH.sup.+) 219-221.degree.
C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.58 (m, 6H), 2.34 (m,
4H), 3.25 (d, J = 13 Hz, 1H), 3.31 (d, J = 13 Hz, 1H), 5.65 (s,
1H), 6.36 (s, 1H), 6.58 (s, 1H), 6.59 (d, J = 2 Hz, 1H), 6.80 (dd,
J = 2, 8 Hz, 1H), 6.84 (d, J = 8 Hz, 1H), # 7.15-7.32 (m, 4H), 7.54
(d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H) 419
7648-(4-methylpiperazin-1-yl)m-
ethyl-10H-pyrazino[2,3-b][1,4]benzothiazine ESI (+) 31 4 (MH.sup.+)
191-192.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
2.10-2.33 (m, 2H), 2.75 (s, 3H), 2.75-3.05 (m, 6H), 3.33 (s, 2H),
6.68 (s, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.87 (d, J = 8.1 Hz, 1H),
7.64 (s, 2H), 9.50 (s, 1H) 420
7658-[(morpholin-4-yl)methyl]-10H-pyrazino[2,3-b][1,4-
]benzothiazine hydrochloride .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 2.96-3.10 (m, 2H), 3.15-3.25 (m, 2H), 3.68-3.80 (m, 2H),
3.86-3.94 (m, 2H), 4.11 (d, J = 6.0 Hz, 2H), 6.80 (s, 1H), 7.00 (d,
J = 8.3 Hz, 1H), 7.05 (d, J = 8.3 Hz, 1H), 7.66 (s, 2H), 9.74 (s,
1H), 10.95-11.08 (m, 1H) 421
766ethyl[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl- methyl)
piperidin-4-yl]carboxylate FAB (+) 37 1 (MH.sup.+) .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.24 (t, J = 7 Hz, 3H), 1.70-1.82 (m,
2H), 1.83-1.95 (m, 2H), 1.95-2.10 (m, 2H), 2.25-2.35 (m, 1H),
2.75-2.84 (m, 2H), 3.34 (s, 2H), 4.14 (q, J = 7 Hz, 2H), 6.54 (s,
1H), 6.64 (d, J = 8 Hz, 1H), # 6.82 (d, J = 8 Hz, 1H), 6.95 (s,
1H), 7.58 (d, J = 3 Hz, 1H).7.68 (d, J = 3 Hz, 1H) 422
7671-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-ol
FAB (+) 31 5 (MH.sup.+) J .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.30-1.40 (m, 2H), 1.60-1.70 (m, 2H), 1.90-2.05 (m, 2H), 2.55-2.65
(m, 2H), 3.25 (s, 2H), 3.35-3.45 (m, 1H), 4.53 (m, 1H), 6.68 (d, J
= 8 Hz, 1H), 6.73 (s, 1H), 6.82 (d, J = 8 Hz, 1H), 7.62 (s, 2H),
9.42 (br.s, 1H) 423
7681-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-methoxy
piperidine FAB (+) 32 9 (MH.sup.+) 172-174.degree. C. .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.55-1.70 (m, 2H), 1.83-2.00 (m, 2H),
2.10-2.30 (m, 2H), 2.70-2.80 (m, 2H), 3.20-3.30 (m, 1H), 3.35 (s,
3H), 3.40 (s, 2H), 6.58 (s, 1H), 6.62 (s, 1H), 6.78 (d, J = 8 Hz,
1H), 6.82 (d, J = 8 Hz, 1H), 7.57 (s, 1H), 7.68 (s, 1H) 424
7691-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-methyl
piperidin-4-ol FAB (+) 32 9 (MH.sup.+) 176-180.degree. C.
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.26 (s, 3H), 1.50-1.80 (m,
4H), 2.10 (s, 1H), 2.30-2.45 (m, 2H), 2.50-2.58 (m, 2H), 3.43 (s,
2H), 6.77 (d, J = 8 Hz, 1H), 6.83 (d, J = 8 Hz, 1H), 7.25 (s, 1H),
7.26 (s, 1H), 7.57 (d, J = 3 Hz, 1H), 7.67 (d, J = 3 Hz, 1H) 425
7701-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-
yl]carboxamide FAB (+) 34 2 (MH.sup.+) 225-228.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.52 (m, 2H), 1.58-1.68 (m,
2H), 1.83 (m, 2H), 2.00-2.10 (m, 1H), 2.70-2.81 (m, 2H), 3.23 (s,
2H), 6.68 (d, J = 8 Hz, 1H), 6.65-6.73 (br.s, 1H), 6.76 (s, 1H),
6.81 (d, J = 8 Hz, 1H), 7.18 (br.s, 1H), 7.61 (d, J = 3 Hz, 2H), #
9.42 (br.s, 1H) 426
7711-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidine--
4- spiro-4'-(4'-butanolide) FAB (+) 36 9 (MH.sup.+) 225-228.degree.
C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.60-1.70 (m, 2H),
1.70-1.80 (m, 2H), 1.97 (t, J = 7 Hz, 2H), 2.30-2.38 (m, 2H),
2.38-2.43 (m, 2H), 2.53 (t, J = 7 Hz, 2H), 3.29 (s, 2H), 6.69 (d, J
= 8 Hz, 1H), 6.74 (s, 1H), 6.82 (d, J = 8 Hz, 1H), # 7.60 (s, 2H),
9.43 (br.s, 1H) 427
772[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperid-
in-3- yl]carboxamide FAB (+) 34 2 (MH.sup.+), 364 (MNa.sup.+)
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.50-1.64 (m, 2H),
1.64-1.80 (m, 1H), 1.80-1.90 (m, 1H), 2.10-2.30 (m, 1H), 2.30-2.42
(m, 1H), 2.42-2.50 (m, 1H), 2.48-2.70 (m, 1H), 2.70-2.82 (m, 1H),
3.18 (s, 2H), 5.23 (br.s, 1H), 5.80 (br.s, 1H), # 6.68 (d, J = 8
Hz, 1H), 6.73 (s, 1H), 6.81 (d, J = 8 Hz, 1H), 7.80 (s, 2H), 9.49
(br.s, 1H) 428
773[1-(10H-pyrazino[2.3-b][1,4]benzothiazin-8-ylmethyl)piperidin-2-
yl]carboxamide FAB (+) 34 2 (MH.sup.+) 209-211.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.20-1.55 (m, 2H),
1.64-1.80 (m, 1H), 1.96-2.08 (m, 2H), 2.60-2.70 (m, 2H), 2.70-2.80
(m, 2H), 2.90 (d, J = 12 Hz, 1H), 3.56 (d, J = 12 Hz, 1H), 6.77 (s,
1H), 6.78 (d, J = 8 Hz, 1H), 7.82 (d, J = 8 Hz, 1H), 7.00- # 7.05
(br.s, 1H), 7.05-7.12 (br.s, 1H), 7.62 (s, 2H), 9.40 (br.s, 1H) 429
774[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pyrrolidin-
2-yl]carboxamide FAB (+) 32 8 (MH.sup.+) 194-197.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.60-1.72 (m, 3H),
1.09-1.95 (m, 1H), 1.10-1.22 (m, 1H), 2.80-2.90 (m, 1H), 2.90-2.96
(m, 1H), 3.20 (d, J = 8 Hz, 1H), 3.63 (d, J = 8 Hz, 1H), 6.00-6.15
(br.s, 1H), 6.70 (d, J = 8 Hz, 1H), 6.78 (s, 1H), 6.83 (d, # J = 8
Hz, 1H), 7.10-7.20 (br.s, 1H), 7.62 (s, 2H), 9.40 (br.s, 1H) 430
7752-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-
4-yl]ethanol FAB (+) 34 3 (MH.sup.+) 148-152.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.0-1.15 (m, 3H), 1.28-1.35 (m, 2H),
1.50-1.62 (m, 2H), 1.75-1.90 (m, 2H), 2.70-2.80 (m, 2H), 3.15 (s,
2H), 3.30-3.45 (m, J = 6Hz, 2H), 4.32 (m, J = 6Hz, 1H), 6.66 (d, J
= 8Hz, 1H), 6.70 (s, 1H), 6.81 (d, # J = 8Hz, 1H), 7.62 (s, 2H),
9.45 (br.s, 1H) 431
7768-[(2,6-dimethylpiperidin-1-yl)methyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine FAB (+) 32 7 (MH.sup..degree.)
168-172.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.03 (d, J
= 8 Hz, 6H), 1.04 (s, 3H), 1.20-1.40 (m, 2H), 1.50-1.70 (m, 4H),
2.40-2.50 (m, 2H), 3.60 (s, 2H), 6.67 (d, J = 8 Hz, 1H), 6.72 (s,
1H), 6.85 (d, J = 8 Hz, 1H), 7.55 (d, J = 3 Hz, 1H), 7.70 (d, J = 3
Hz, 1H), 9.75 (s, 1H) 432
777methyl[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylm-
ethyl)-3,4- dehydropiperidin-3-yl]carboxylate FAB (+) 36 9
(MH.sup.+) 172-175.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
2.37 (m, 2H), 2.59 (t, J = 6 Hz, 2H), 3.24 (br.s, 2H), 3.54 (s,
2H), 3.73 (s, 3H), 6.58 (d, J = 2 Hz, 1H), 6.72 (br.s, 1H), 6.78
(dd, J = 2, 8 Hz, 1H), 6.84 (d, J = 8 Hz, 1H), 7.20 (m, 1H), 7.56
(d, J = 3 Hz, 1H), # 7.68 (d, J = 3 Hz, 1H) 433
7787-[(piperidin-1-yl)methyl]-5H-pyrido[3- ,4-b][1,4]benzothiazine
FAB (+) 29 8 (MH.sup.+) 163-166.degree. C. .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.46 (m, 2H), 1.62 (m, 4H), 2.42 (br.s, 4H), 3.39 (s,
2H), 6.20 (s, 1H), 6.38 (d, J = 5 Hz, 1H), 6.65 (s, 1H), 6.76 (dd,
J = 2, 8 Hz, 1H), 6.88 (d, J = 8 Hz, 1H), 7.98 (s, 1H), 8.05 (d, J
= 5 Hz, 1H)
EXAMPLE 434
N,N-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azapentamethylene]methanesulfonamide
[2389] 300 mg of
N,N-[3-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothi-
azin-8-ylmethyl)-3-azapentamethylene]-methanesulfonamide was
stirred in glacial acetic acid (20 ml) at 65.degree. C. for 3
hours. After distilling off the solvent under reduced pressure, the
residue was crystallized from ethyl acetate/ether to thereby give
240 mg of the title compound as yellow crystals. 779
[2390] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2391] 2.39-2.44(m, 4H), 2.85(s, 3H), 3.05-3.10(m, 4H), 3.32(s,
2H), 6.71(d, J=7.9 Hz, 1H), 6.74(d, J=1.2 Hz, 1H), 6.85(dd, J=1.2,
7.9 Hz, 1H), 7.61-7.64(m, 2H), 9.44(s, 1H)
[2392] m.p.: 221-222.degree. C.
[2393] MS: FAB(+)377(M.sup.+)
EXAMPLES 435 and 436
[2394] The following compounds were obtained by the same method as
the one of Example 434.
75 Ex. Structural formula MS M.p. NMR 435
7801-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-
e- 4-carbonitrile FAB (+) 32 3 (M.sup.+) 198-199.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.61-1.72 (m, 2H),
1.78-1,84 (m, 2H), 2.14-2.26 (m, 2H), 2.41-2.50 (m, 1H), 2.80-2.90
(m, 2H), 3.28 (s, 2H), 6.69 (d, J = 7.9 Hz, 1H), 6.74 (d, J = 1.0
Hz, 1H), 6.83 (dd, J = 1.0, 7.9 Hz, 1H), 7.61-7.64 (m, 2H), 9.44
(s, 1H) 436
781N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-7-ylmethyl)piperidin-
4-yl]-n',N'-dimethylsulfamide FAB (+) 42 1 (MH.sup.+) 443
(MNa.sup.+) 172-173.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.34-1.46 (m, 2H), 1.71-1.79 (m, 2H), 1.82-1.93 (m, 2H), 2.60
(s, 6H), 2.64-2.71 (m, 2H), 2.89-2.99 (m, 1H), 3.20 (s, 2H), 6.69
(d, J = 7.6 Hz, 1H), 6.77 (d, J = 1.4 Hz, 1H), 6.85 (dd, # J = 1.4,
7.6 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.61 (d, J = 2.5 Hz, 1H),
7.62 (d, J = 2.5Hz, 1H), 9.47 (s, 1H)
EXAMPLES 437 to 465
[2395] The following compounds were obtained by the same method as
the one of Example 64 by using anhydrous potassium carbonate as a
base as a substitute for N,N-diisopropylamine.
76 Ex. Structural formula MS M.p. NMR 437
782N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperid-
in-4-yl]-N',N'- pentamethylene sulfamide FAB (+) 46 1 (MH.sup.+)
56-57.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.47-1.58
(m, 4H), 1/58-1.65 (m, 4H), 1.97 (br.d, J = 10 Hz, 2H), 2.18 (br.t,
J = 10 Hz, 2H), 2.77 (br.d, J = 12 Hz, 2H), 3.15 (t, J = 6 Hz, 4H),
3.22 (m, 1H), 3.33 (s, 2H), 4.27 (d, J = 9 Hz, 1H), 6.52 (d, # J =
2 Hz, 1H), 6.73 (dd, J = s, 8 Hz, 1H), 6.74 (br.s, 1H), 6.82 (d, J
= 8 Hz, 1H), 7.56 (d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H) 438
783N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]1-
N',N'- (3-oxapentamethylene)sulfamide FAB (+) 46 3 (MH.sup.+)
189-190.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.54
(br.t, J = 10 Hz, 2H), 1.99 (br.d, J = Hz, 2H), 2.08 (br.t, J = 10
Hz, 2H), 2.69 (br.d, J = 10 Hz, 2H), 3.18 (t, J = 5 Hz, 4H), 3.25
(m, 1H), 3.33 (s, 2H), 3.74 (t, J = 5 Hz, 4H), # 4.35 (d, J = 9 Hz,
1H), 6.52 (d, J = 2 Hz, 1H), 6.69 (br.s, 1H), 6.73 (dd, J = 8 Hz,
1H), 7.56 (d, J = 3 Hz, 1H), 7.69 (d, J = 3 Hz, 1H) 439
784N-[(10H-pyrazino[2,3-b-
][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-N'-
(2-hydroxyethyl)sulfamid- e FAB (+) 43 7 (MH.sup.+) 164-166.degree.
C. .sup.1H-NMR (CD.sub.3OD) .delta. ppm: 1.56-1.66 (m, 2H),
1.98-2.04 (m, 2H), 2.24-2.33 (m, 2H), 2.94-2.98 (m, 2H), 3.25 (t, J
= 6 Hz, 2H), 3.14-3.23 (m, 1H), 3.49 (s, 2H), 3.62 (t, J = 6 Hz,
2H), 6.67 (d, J = 2 Hz, 1H), 6.79 (dd, J = 2, 8 # Hz, 1H), 6.84 (d,
J = 8 Hz, 1H), 7.57 (d, J = 3 Hz, 1H), 7.58 (d, J = 3 Hz, 1H) 440
7852-[1-(10H-pyrazino[2,3-b][1,4]be-
nzothiazin-8-ylmethyl)piperidin-4-yl]-2- methyl-2-propanol FAB (+)
37 1 (MH.sup.+) 187-188.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.05 (s, 6H), 1.05-1.18 (m, 2H), 1.25 (d, J = 6 Hz,
2H), 1.34-1.45 (m, 1H), 1.64-1.70 (m, 2H), 1.80-1.90 (m, 2H),
2.65-2.70 (m, 2H), 3.20 (s, 2H), 4.12 (s, 1H), 6.68 (dd, J = 1, 7
Hz, 1H), 6.74 (d, J = 1 Hz, 1H), 6.82 (d, # J = 7 Hz, 1H), 7.62 (d,
J = 3 Hz, 1H), 7.63 (d, J = 3 Hz, 1H), 9.43 (br.s, 1H) 441
7861-(10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl)piperidine-4- spiro-5'-hydantoin FAB (+)
38 3 (MH.sup.+) >275.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.49 (d, J = 11 Hz, 2H), 1.81 (t, J = 11 Hz, 2H), 2.24
(t, J = 11 Hz, 2H), 2.63 (d, J = 11 Hz, 2H), 3.29 (s, 2H), 6.69
(dd, J = 2, 8 Hz, 1H), 6.78 (d, J = 2 Hz, 1H), 6.83 (d, J = 8 Hz,
1H), 7.62 (d, J = 3 Hz, 1H), 7.63 (d, # J = 3 Hz, 1H), 8.44 (s,
1H), 9.45 (s, 1H), 10.62 (s, 1H) 442
787N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-y-
lmethyl)piperidin-4-yl]-N'- methoxycarbonyl methylsulfamide FAB (+)
46 5 (MH.sup.+) 194-14 196.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.32-1.42 (m, 2H), 1.73-1.78 (m, 2H), 1.86-1.92 (m,
2H), 2.64-2.72 (m, 2H), 2.95-3.00 (m, 1H), 3.22 (s, 2H), 3.61 (s,
3H), 3.62 (d, J = 7 Hz, 2H), 6.67 (dd, J = 1, 8 Hz, 1H), 6.73 (d, J
= 1 Hz, # 1H), 6.82 (d, J = 8 Hz, 1H), 6.95 (d, J = 7 Hz, 1H), 7.32
(t, J = 7 Hz, 1H), 7.62 (d, J = 3 Hz, 1H), 7.63 (d, J = 3 Hz, 1H),
9.44 (s, 1H) 443
788N-[1-(5H-pyrido[3,4-b][1,4]benzothiazin-7-ylmethyl)piperidin-4-
yl]-N',N'-dimethylsulfamide FAB (+) 42 0 (MH.sup.+) 198-199.degree.
C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.54 (dq, J = 3, 11 Hz,
2H), 1.97 (br.d, J = 11 Hz, 2H), 2.08 (t, J = 11 Hz, 2H), 2.75
(br.s, 2H), 2.78 (s, 6H), 3.22 (br.s, 1H), 3.34 (s, 2H), 4.02 (d, J
= 7 Hz, 1H), 6.05 (s, 1H), 6.38 (d, J = 5 Hz, 1H), # 6.56 (s, 1H),
6.77 (dd, J = 2, 8 Hz, 1H), 6.88 (d, J = 8 Hz, 1H), 8.00 (s, 1H),
8.24 (d, J = 5 Hz, 1H), 444
7891-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperi-
dine-4- spiro-3'-(4'-butanolide) FAB (+) 36 9 (MH.sup.+)
180-182.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.68 (m,
4H), 2.32 (m, 2H), 2.40 (s, 2H), 2.46 (m, 2H), 3.33 (s, 2H), 4.05
(s, 2H), 6.38 (s, 1H), 6.50 (s, 1H), 6.75 (d, J = 8 Hz, 1H), 6.84
(d, J = 8 Hz, 1H), 7.58 (d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H)
445 7901-(10H-pyrazino[2,3-b]-
[1,4]benzothiazin-8-ylmethyl)piperidine-4-
spiro-3'-(4'-butanelactam) FAB (+) 36 8 (MH.sup.+) 211-212.degree.
C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.67 (t, J = 6 Hz, 4H),
2.41 (s, 2H), 2.35 (br.s, 2H), 2.43 (br.s, 2H), 3.18 (s, 2H), 3.24
(s, 2H), 5.47 (br.s, 1H), 6.45 (br.s, 1H), 6.53 (d, J = 2 Hz, 1H),
6.75 (dd, J = 2, 8 Hz, 1H), 6.83 (d, J = 8 Hz, 1H), 7.57 (d, J = #
3 Hz, 1H), 7.69 (d, J = 3 Hz, 1H) 446
791N-[1-(10H-cyanopyrido[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-
-4- yl]-N',N'-dimethylsulfamide FAB (+) 44 4 (MH.sup.+)
155-157.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta.ppm: 1.57 (m,
2H), 2.0 (m, 4H), 2.2 (br.s, 2H), 2.79 (s, 6H), 3.25 (br.s, 1H),
3.35 (s, 2H), 6.64 (br.s, 1H), 6.78 (dd, J = 2, 8 Hz, 1H), 6.83 (d,
J = 8 Hz, 1H), 6.87 (d, J = 5 Hz, 1H), 7.81 (d, J = 5 Hz, 1H) 447
792N-[1-(10H-pyrazino[2,3-
-b]pyrido[2,3-e][1,4]thiazin-8-ylmethyl)-
piperidin-4-yl]-N',N'-dimethylsu- lfamide FAB (+) 42 2 (MH.sup.+)
205-210.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.36-1.48 (m, 2H), 1.73-1.80 (m, 2H), 1.89-1.98 (m, 3H), 2.61 (s,
6H), 2.64-2.74 (m, 2H), 3.24 (s, 2H), 6.93 (s, 1H), 7.19 (s, 1H),
7.64 (s, 1H), 7.67 (s, 1H), 9.54 (s, 1H) 448
793N.sup.2-methanesulfonyl-N.sup.1-[1-(10H-pyrazino[2,3-b][1,4-
]benzothiazin-8- ylmethyl)piperidin-4-yl]formamidine FAB (+) 41 9
(MH.sup.+) 119-122.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.46 (m, 2H), 1.86-1.96 (m, 1H), 1.96-2.03 (m, 2H), 2.05-2.16 (m,
2H), 2.76-2.87 (m, 2H), 2.96 (s, 3H), 3.33 (s, 2H), 5.89-5.96 (m,
1H), 6.52 (d, J = 1.7 Hz, 1H), 6.69-6.72 (br.s, 1H), # 6.74 (dd, J
= 1.7, 8.3 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 7.56 (d, J = 3.0 Hz,
1H), 7.69 (d, J = 3.0 Hz, 1H), 8.14 (d, J = 5.6 Hz, 1H) 449
794N,N-[[4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperazin-1-
ylmethylene]methylsulfonamide FAB (+) 40 4 (M.sup.+) 405 (MH.sup.+)
212-214.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
2.32-2.37 (m, 2H), 2.39-2.44 (m, 2H), 2.84 (s, 3H), 3.33 (s, 2H),
3.48-3.55 (m, 4H), 6.71 (dd, J = 1.6, 8.6 Hz, 1H), 6.75 (d, J = 1.6
Hz, 1H), 6.86 (d, J = 8.6 Hz, 1H), 7.61-7.64 (m, 2H), # 8.07 (s,
1H), 9.46 (s, 1H) 450
795N,N-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl- )-3-
azapentamethylene]-N'-methylsulfamide FAB (+) 39 2 (M.sup.+)
208-210.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
2.36-2.41 (m, 4H), 2.49 (d, J = 5.1 Hz, 3H), 2.99-3.05 (m, 4H),
3.30 (br.s, 2H), 6.70 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 2.2 Hz,
1H), 6.84 (dd, J = 2.2, 8.0 Hz, 1H), 7.10 (q, J = 5.1 Hz, 1H), 7.63
(s, 1H), # 9.45 (s, 1H) 451
796N,N-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)- -3-
azapentamethylene]sulfamide FAB (+) 37 8 (M.sup.+) 215-217.degree.
C. (decom- pose) .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.37-2.43
(m, 4H), 2.91-2.96 (m,4H), 3.30 (s, 2H), 6.70 (d, J = 8.4 Hz, 1H),
6.75-6.79 (m, 3H), 6.84 (dd, J = 2.0, 8.4 Hz, 1H), 7.61-7.64 (m,
2H), 9.47 (s, 1H) 452
797N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)p-
iperidin-4-yl]amidinocarboxylic acid FAB (+) 38 5 (MH.sup.+)
186-190.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.56-1.70 (m, 4H), 1.85-1.97 (m, 2H), 2.70-2.78 (m, 2H), 3.25 (s,
2H), 3.36-3.47 (m, 1H), 6.68 (d, J = 7.9 Hz, 1H), 6.73 (s, 1H),
6.83 (d, J = 7.9 Hz, 1H), 7.60-7.64 (m, 2H), 8.60-8.80 (br.s, 2H),
# 8.84-9.02 (br.s, 1H), 9.46 (s, 1H) 453
798[1-(10H-pyrazino[2,3-b][1,4]benzothia-
zin-8-ylmethyl)-4-piperidin-4-yl]- (N.sup.2-sulfamoyl)carboxamidine
FAB (+) 42 0 (MH.sup.+) 202-206.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta.ppm: 1.56-1.68 (m, 4H), 1.80-1.90 (m, 2H),
2.07-2.17 (m, 1H), 2.77-2.84 (m, 2H), 3.25 (br.s, 2H), 6.47 (br.s,
2H), 6.69 (d, J = 8.0 Hz, 1H), 6.76 (s, 1H), 6.83 (d, J = 8.0 Hz,
1H), 7.20 (br.s, 1H), # 7.62 (s, 2H), 8.13 (br.s, 1H), 9.45 (s, 1H)
454
799[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-
(N.sup.2-methane sulfonyl)carboxamidine FAB (+) 41 9 (MH.sup.+)
204-209.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.56-1.69 (m, 4H), 1.80-1.89 (m, 2H), 2.14-2.23 (m, 1H), 2.76-2.82
(m, 2H), 2.84 (s, 3H), 3.24 (br.s, 2H), 6.68 (dd, J = 1.3, 8.3 Hz,
1H), 6.76 (d, J = 1.3 Hz, 1H), 6.82 (d, J = 8.3 Hz, 1H), 7.62 (s, #
2H), 7.63 (br.s, 1H), 8.38 (br.s, 1H), 9.45 (s, 1H) 455
800N-[1-(10H-pyrimido[5,4-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-
N',N'-dimethylsulfamide FAB (+) 42 1 (MH.sup.+) 198-203.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.35-1.48 (m, 2H),
1.71-1.80 (m, 2H), 1.85-1.95 (m, 2H), 2.60 (s, 6H), 2.65-2.73 (m,
2H), 2.90-3.00 (m, 1H), 3.23 (s, 2H), 6.73 (dd, J = 1.3, 7.7 Hz,
1H), 6.78 (d, J = 1.3 Hz, 1H), 6.86 (d, J = 7.7 Hz, 1H), # 7.19 (d,
J = 7.4 Hz, 1H), 7.92 (s, 1H), 8.22 (s, 1H), 9.78 (s, 1H) 456
8018-[(2-isoindolin-2-yl)methyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
FAB (+) 33 3 (MH.sup.+) 219-220.degree. C. .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 3.76 (s, 2H), 3.92 (2, 4H), 6.58 (br.s, 1H), 6.64
(br.s, 1H), 6.83-6.88 (m, 2H), 7.19 (s, 4H), 7.56 (d, J = 2.9 Hz,
1H), 7.63 (d, J = 2.9 Hz, 1H) 457
802N-[1-(10H-pyrazino[2,3-b][1,4]benz-
oxazin-8-ylmethyl)piperidin-4-yl]methanesulfonamide ESI (+) 37 6
(MH.sup.+) 241-243.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.34-1.48 (m, 2H), 1.72-1.82 (m, 2H), 1.86-1.98 (m, 2H),
2.64-2.74 (m, 2H), 2.88 (s, 3H), 3.20-3.14 (m, 1H), 3.21 (s, 2H),
6.5-6.65 (m, 2H), 6.65-6.70 (m, 1H), 7.0-7.1 (m, 1H), 7.20-7.28 (m,
1H), 7.42- #7.48 (m, 1H), 9.57 (s, 1H) 458
803N-[1-(10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl)piperdin-4-yl]methylmethane sulfonamide
ESI (+) 40 6 (MH.sup.+) 218-221.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.0-1.16 (m, 2H), 1.30-1.42 (m, 1H),
1.58-1.68 (m, 2H), 1.78-1.88 (m, 2H), 2.7-2.8 (m, 2H), 2.78 (t, J =
7 Hz, 2H), 2.84 (s, 3H), 3.23 (s, 2H), 6.65-6.70 (m, 1H), 6.74 (s,
1H), 6.82 (d, J = 8 Hz, 1H), 6.96 (t, # J = 6 Hz, 1H), 7.60-7.65
(m, 2H), 9.43 (s, 1H) 459
804N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]m-
ethylacetamide ESI (+) 37 0 (MH.sup.+) 168-170.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.0-1.2 (m, 2H), 1.25-1.45
(m, 1H), 1.50-1.65 (m, 2H), 1.77 (s, 3H), 1.75-1.90 (m, 2H),
2.68-2.80 (m, 2H), 2.89 (t, J = 7Hz, 2H), 3.22 (br.s, 2H), 6.6-6.75
(m, 1H), 6.74 (s, 1H), 6.75-6.90 (m, 1H), 7.62 (d, # J = 3 Hz, 1H),
7.63 (d, J = 3 Hz, 1H), 7.79 (m, 1H), 9.43 (s, 1H) 460
805N-[1-(10H-pyrazino[2,3-b][1,4]be-
nzothiazin-8-ylmethyl)piperidin-4-yl]- N',N'-dimethylsulfamide ESI
(+) 42 1 (MH.sup.+) 202-203.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.35-1.50 (m, 2H), 1.7-1.8 (m, 2H), 1.80-1.98 (m, 2H),
2.60 (s, 6H), 2.6-2.75 (m, 2H), 2.9-3.0 (m, 1H), 3.21 (s, 2H), 6.66
(d, J = 8 Hz, 1H), 6.72 (s, 1H), 6.81 (d, J = 8 Hz, 1H), 7.18 (d, #
J = 8 Hz, 1H), 7.61 (d, J = 3 Hz, 1H), 7.62 (d, J = 3 Hz, 1H), 9.43
(s, 1H) 461 806 ESI (+) 40 6 (MH.sup.+) 216-218.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.32-1.48 (m, 2H),
1.70-1.80 (m, 2H), 1.82-1.94 (m, 2H), 2.41 (d, J = 5 Hz, 3H),
2.64-2.74 (m, 2H), 2.84-2.96 (m,1H), 3.23 (s, 2H), 6.59 (q, J = 5
Hz, 1H), 6.67 (dd, J = 1, 8 Hz, 1H), 6.70 (dd, J = 1, 8 Hz, 1H),
6.78 (d, J = 1 Hz, 1H), 6.83 (d, J = 8 Hz, 1H), 6.87 (d, J = 8 Hz,
# 1H), 7.25 (dd, J = 1, 8 Hz, 1H), 7.78 (dd, J = 1, 8 Hz, 1H), 9.14
(s, 1H) 462
807N-[1-(10H-pyrazino[2,3-b][1,4]benzoxazin-8-ylmethyl)piperidin-4-yl]-
N'-methylsulfamide ESI (+) 39 1 (MH.sup.+) 219-222.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.3-1.46 (m, 2H), 1.70-1.84
(m, 2H), 1.82-1.94 (m, 2H), 2.41 (d, J = 5 Hz, 3H), 2.64-2.78 (m,
2H), 2.78-2.96 (m, 1H), 3.21 (s, 2H), 6.5-6.65 (m, 3H), 6.68 (d, J
= 8 Hz, 1H), 6.87 (d, J = 7 Hz, # 1H), 7.24 (d, J = 3 Hz, 1H), 7.44
(d, J = 3 Hz, 1H), 9.57 (s, 1H) 463
808N-[1-(10H-pyrazino2,3-b][1,4]benzothi-
azin-8-ylmethyl)piperidin-4-yl]trifluoromethaneulfonamide ESI (+)
44 6 (MH.sup.+) 199-201.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. pm: 1.53-1.60 (m, 2H), 1.7-1.8 (m, 2H), 1.9-2.3 (m, 2H),
2.66-2.80 (m, 2H), 3.25 (s, 2H), 3.2-3.4 (m, 1H), 6.67 (d, J = 8
Hz, 1H), 6.73 (s, 1H), 6.83 (d, J = 8 Hz, 1H), 7.62 (s, 2H), 9.45
(s, 2H) 464
8092-[1-(10H-pyrazino2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-
ylidene]-4-butanolide FAB (+) 38 1 (MH.sup.+) 159-162.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. pm: 2.29 (m, 2H), 2.39 (m, 2H),
2.44 (m, 2H), 2.85 (t, J = 7 Hz, 2H), 2.94 (br.s, 2H), 3.32 (s,
2H), 4.22 (t, J = 7 Hz, 2H), 6.72 (d, J = 8 Hz, 1H), 6.76 (s, 1H),
6.85 (d, J = 8 Hz, 1H), 7.63 (m, 2H), 9.45 (s, 1H) 465
8101-[1-(10H-pyrazino2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-
1,2-ethanediol FAB (+) 35 9 MH.sup.+) 182-185.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. pm: 1.16-1.35 (m, 3H), 1.44 (m,
1H), 1.63 (br.d, J = 12 Hz, 1H), 1.78 (br.q, J = 8 Hz, 2H), 2.77
(m, 2H), 3.17-3.38 (m, 3H), 3.20 (s, 2H), 4.13 (d, J = 6 Hz, 1H),
4.37 (t, J = 6 Hz, 1H), 6.67 (d, J = 8 Hz, 1H), # 1H), 7.63 (m,
2H), 9.43 (s, 1H)
EXAMPLE 466
N,N-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-3-azapentamethylene]-N',N'-dimethylsulfamide
[2396] The title compound was obtained as yellow crystals by
treating 3-benzyl-3-azapentamethylene]-N',N'-dimethylsulfamide and
8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine by the same
method as the one of Example 17. 811
[2397] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2398] 2.46-2.55(m, 4H), 2.83(s, 6H), 3.25-3.35(m, 4H), 3.38(s,
2H), 6.44(br.s, 1H), 6.54(s, 1H), 6.76(d, J=8.0 Hz, 1H), 6.84(d,
J=8.0 Hz, 1H), 7.58(d, J=2.8 Hz, 1H), 7.70(d, J=2.8 Hz, 1H)
[2399] m.p.: 171-173.degree. C.
EXAMPLE 467
N-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-azetidin
-3-ylmethyl]methanesulfonamide
[2400] The title compound was obtained as yellow crystals by
treating N-[(1-diphenylmethylazetidin
-3-yl)methyl]methanesulfoamide and 8-chloromethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the
one of Example 64. 812
[2401] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2402] 2.52(br.s, 1H), 2.87(s, 3H), 2.88(br.s, 2H), 3.10(t, J=7 Hz,
2H), 3.23(br.s, 2H), 3.41(br.s, 2H), 6.68(d, J=8 Hz, 1H), 6.69(s,
1H), 6.82(d, J=8 Hz, 1H), 7.07(t, J=5 Hz, 1H), 7.62(d, J=3 Hz, 1H),
7.63(d, J=3 Hz, 1H), 9.44(s, 1H)
[2403] MS: FAB(+)378(MH.sup.+)
[2404] m.p.: 84-88.degree. C.
EXAMPLES 468 to 497
[2405] The following compound was obtained by the same method as
the one of Example 467.
77 Ex. Structural formula MS M.p. NMR 468
813N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)azetidi-
n-3- ylmethyl]-N'-methylsulfamide FAB (+) 39 3 (MH.sup.+)
173-176.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.41 (d,
J = 5 Hz, 3H), 2.60 (br.s, 3H), 2.96 (t, J = 6 Hz, 2H), 3.44 (br.s,
2H), 3.57 (br.s, 2H), 6.68 (d, J = 8 Hz, 1H), 6.69 (s, 1H), 6.84
(d, J = 8 Hz, 1H), 6.94 (s, 1H), 7.62 (d, J = 3 Hz, 1H), # 7.63 (d,
J = 3 Hz, 1H), 9.48 (s, 1H)
EXAMPLE
[2406] The following compounds were obtained by the same method as
the one of Example 66.
78 Ex. Structural formula MS M.p. NMR 469
814N-(tetrazol-5-yl)-4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin--
8-ylmethyl)- piperidin-4-yl]butanamide FAB (+) 45 2 (MH.sup.+)
19--191.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm:
1.10-1.24 (m, 6H), 1.54-1.66 (m, 4H), 2.0 (m, 1H), 2.36 (m, 2H),
2.82 (d, J = 10Hz, 2H), 3.30 (s, 2H), 6.72 (d, J = 8 Hz, 1H), 6.75
(d, J = 2 Hz, 1H), 6.,85 (dd, J = 2, 8 Hz, 1H), 7.63 (m, 2H), 9.48
(br.s, # 1H), 11.61 (br.s, 1H) 470
815N-[-methyl-8-azabicyclo[3.2.1]oct-3-yl]-
-[7-[(10H-pyrazino[2,3-8][1,4]benzothiazin-8-ylmethyl)-7-azaspiro[3.5]non--
2-yl]acetamide FAB (+) 51 9 (MH.sup.+) 181-184.degree. C.
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.40-1.80 (m, 12H), 1.90-2.40
(m, 9H), 2.27 (d, J = 6.8 Hz, 2H), 2.34 (s, 3H), 2.52-2.64 (m, 1H),
3.18-3.27 (m, 2H), 3.30 (s, 2H), 4.02-4.12 (m, 1H), 6.39 (br.s,
1H), 6.54 (s, # 1H), 6.74 (d, J = 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz,
1H), 7.57 (d, J = 2.8 Hz, 1H), 7.69 (d, J = 2.8 Hz, 1H) 471
8161-(10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl)-4-piperidone oxime O- methyl ether ESI
(+) 34 2 (MH.sup.+) 142-143.degree. C. .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 2.31-2.35 (m, 2H), 2.44-2.49 (m, 2H), 2.51-2.55 (m,
2H), 2.55-2.60 (m, 2H), 3.36 (s, 2H), 3.82 (s, 3H), 6.54 (d, J =
7.9 Hz, 1H), 6.65-6.69 (br.s, 1H), 6.77 (dd, J = 1.5, 7.9 Hz, 1H),
6.83 (d, J = 7.9 Hz, # 1H), 7.58 (d, J = 3.1 Hz, 1H), 7.69 (d, J =
3.1 Hz, 1H) 472
8174-amino-3-[4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pipe-
razino]- 3-cyclobutene-1,2-dione FAB (+) 39 4 (M.sup.+)
285-288.degree. C. (decom- pose) .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 2.46 (br.m, 4H), 3.37 (s, 2H), 3.68 (br.m, 4H), 6.74 (d, J =
7.9 Hz, 1H), 6.77 (s, 1H), 6.86 (d, J = 7.9 Hz, 1H), 7.64 (d, J =
2.9 Hz, 1H), 7.65 (d, J = 2.9 Hz, 1H), 7.70 (s, 2H), 9.48 (s, 1H)
473
8184-methylamino-3-[4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
piperazino]-3-cyclobutene-1,2-dione FAB (+) 40 9 (MH.sup.+)
>300.degree.C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.43 (m,
4H), 3.16 (d, J = 4.6 Hz, 3H), 3.35 (s, 2H), 3.64 (br.s, 4H), 6.73
(dd, J = 1.5, 7.9 Hz, 1H), 6.76 (d, J = 1.5 Hz, 1H), 6.86 (d, J =
7.9 Hz, 1H), 7.61 (m, 1H), 7.64 (d, J = 2.7 Hz, 1H), # 7.65 (d, J =
2.7 Hz, 1H), 9.48 (s, 1H) 474 8194-dimethylamino-3-[4-(10H-pyrazi-
no[2,3-b][1,4]benzothiazin-8-ylmethyl)
piperazino]-3-cyclobutene-1,2-dione FAB (+) 42 3 (MH.sup.+)
296-300.degree. C. (decom- pose) .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 2.45 (m, 4H), 3.15 (s, 6H), 3.34 (s, 2H), 3.61 (m, 4H), 6.73
(d, J = 7.9 Hz, 1H), 6.77 (br.s, 1H), 6.86 (d, J = 7.9 Hz, 1H),
7.64 (br.s, 2H), 9.47 (s, 1H) 475
8203-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo
[3.3.0]octan-7-ol ESI (+) 34 1 (MH.sup.+) 192-195.degree. C.
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.70 (s, 1H), 1.86-1.97 (m,
4H), 2.16-2.27 (m, 2H), 2.70-2.80 (m, 2H), 2.82-2.90 (m, 2H), 3.51
(s, 2H), 4.05-4.11 (m, 1H), 6.54 (br.s, 1H), 6.68 (dd, J = 2, 8 Hz,
1H), 6.79 (d, J = 8 Hz, 1H), 7.00 (br.s, 1H), # 7.55 (d, J = 2.8Hz,
1H), 7.65 (d, J = 2.8Hz, 1H) 476
821[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylm-
ethyl)-3-azabicyclo[4.1.0]hep t-6-yl]methanol .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 0.53-0.59 (m, 2H), 0.97-1.0 (m, 1H),
1.80-2.08 (m, 2H), 1.95 (br.s, 1H), 2.12-2.24 (m, 2H), 2.58-2.74
(m, 2H), 3.21-3.50 (m, 4H), 6.56 (s, 1H), 6.71-6.76 (m, 2H), 6.81
(d, J = 8.0 Hz, 1H), 7.56 (d, J = 2.4 Hz, 1H), 7.68 (d, J = 2.4 Hz,
1H) 477
8222-[3-(10H-pyrazino[2.3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[4.-
1.0]hep t-6-yl]ethanol ESI (+) 35 5 (MH.sup.+) 57-60.degree. C.
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.16-0.22 (m, 1H), 0.50-0.55
(m, 1H), 0.90-1.00 (m, 1H), 1.35-1.75 (m, 5H), 2.30-2.50 (m, 4H),
3.37 (s, 2H), 3.50-3.72 (m, 2H), 6.59 (s, 1H), 6.71 (br.s, 1H),
6.77 (dd, J = 1.6, 8.0 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), # 7.58
(d, J = 2.8 Hz, 1H), 7.69 (d, J = 2.8 Hz, 1H) 478
823[3-(10H-pyrazino[2,3-
-b][1,4]benzothiazin-8-ylmethyl)-8-azabicyclo[3.3.0]oct-
7-yl]methanol ESI (+) 35 5 (MH.sup.+) oil .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.20-1.32 (m, 1H), 1.35-1.64 (m, 1H), 1.82-1.88 (m,
1H), 2.00-2.16 (m, 3H), 2.31-2.40 (m, 2H), 2.57-2.86 (m, 4H),
3.40-3.78 (m, 4H), 6.60-6.86 (m, 4H), 7.56 (d, J = 2.8 Hz, 1H),
7.68-7.69 (m, 1H) 479
8248-[(4,5,6,7-tetrahydrothieno[2,3-c]pyridin-6-yl)methyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine FAB (+) 35 3 (MH.sup.+)
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 2.71-2.82 (m, 4H), 3.56 (s,
2H), 3.66 (s, 2H), 6.43 (s, 1H), 6.62 (s, 1H), 6.79 (d, J = 5.0 Hz,
1H), 6.81 (d, J = 8.0 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 7.09 (d, J
= 5.0 Hz, 1H), 7.57 (d, J = 2.8 Hz, 1H), 7.68 (d, J = 2.8 Hz, 1H)
480 8258-[(4,5,6,7-tetrahydrofuro[2,3-c]pyridin-6-yl)methyl]-10H-
pyrazino[2,3-b][1.4]benzothiazine FAB (+ ) 33 7 (MH.sup.+)
168-172.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 2.54 (t, J
= 5.6 Hz, 2H), 2.72 (t, J = 5.6 Hz, 2H), 3.50 (s, 2H), 3.56 (s,
2H), 6.24 (d, J = 2.0 Hz, 1H), 6.49 (br.s, 1H), 6.60 (s, 1H), 6.81
(d, J = 8.0 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 2.0 Hz,
# 1H), 7.57 (d, J = 2.8 Hz, 1H), 7.68 (d, J = 2.8 Hz, 1H)
EXAMPLES
[2407] Starting with known compounds, the following compounds were
obtained by the same method as the one of Example 63.
79 Ex. Structural formula MS M. p. NMR 481
826N,N-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-
azapentamethylene]acetamide FAB (+) 34 1 (M.sup.+) .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.95 (s, 3H), 2.22-2.27 (m, 2H),
2.29-2.34 (s, 2H), 3.29 (s, 2H), 3.36-3.43 (m, 4H), 6.70 (d, J =
8.2 Hz, 1H), 6.75 (s, 1H), 6.84 (d, J = 8.2 Hz, 1H), 7.61-7.64 (m,
2H), 9.45 (s, 1H) 482
827N.N-[4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-- 4-
azahexamethylene]methanesulfonamide FAB (+) 39 1 (M.sup.+) 392
(MH.sup.+) 158-160.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 1.71-1.80 (m, 2H), 2.54-2.59 (m, 2H), 2.59-2.63 (m, 2H), 2.87
(s, 3H), 3.29-3.34 (m, 4H), 3.43 (s, 2H), 6.71 (d, J = 8.3 Hz, 1H),
6.78 (s, 1H), 6.84 (d, J = 8.3 Hz, 1H), 7.61-7.64 (m, 2H), # 9.47
(s, 1H) 483
8288-(1-imidazolinylmethyl)-10H-pyrazino[2,3-b][1,4]benzoth- iazine
hydrochloride FAB (+) 29 8 (MH.sup.+) 238.degree. C. (decom- pose)
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.84-1.92 (m, 2H),
2.18-2.24 (m, 2H), 2.24-2.29 (m, 2H), 4.48 (s, 2H), 6.68 (d, J =
1.3 Hz, 1H), 6.76 (dd, J = 1.3, 8.6 Hz, 1H), 6.95 (d, J = 8.6 Hz,
1H), 7.64 (s, 2H), 8.43 (d, J = 6.5 Hz, 1H), 9.58 (s, # 1H),
10.08-10.14 (br.s, 1H) 484 829(R*,
R*)-1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
pyrrolidine-3,4-diol hydrochloride ESI (+) 31 7 (MH.sup.+)
241-242.degree. C. (decom- pose) .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 2.95-3.04 (m, 1H), 3.16-3.25 (m, 1H), 3.26-3.35 (m, 1H),
3.55-3.65 (m, 1H), 4.04-4.23 (m, 4H), 5.18-5.26 (m, 1H), 5.30-5.39
(m, 1H), 6.81 (s, 1H), 6.98 (d, J = 8.5 Hz, 1H), 7.02 (d, # J = 8.5
Hz, 1H), 7.66 (s, 2H), 9.68 (s, 1H), 10.67-10.80 (br.s, 1H) 485
830[4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
piperazin-1-yl]methylene aminocarbonitrile FAB (+) 35 2 (MH.sup.+)
238-241.degree. C. (decom- pose) .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 2.31-2.36 (m, 2H), 2.38-2.43 (m, 2H), 3.29 (s, 2H), 3.43-3.49
(m, 4H), 6.71 (d, J = 7.4 Hz, 1H), 6.75 (s, 1H), 6.85 (d, J = 7.4
Hz, 1H), 7.62 (d, J = 2.3 Hz, 1H), 7.63 (d, J = 2.3 Hz, # 1H), 8.40
(s, 1H), 9.46 (s, 1H) 486 8311-[4-(10H-pyrazino[2,3-b][1,4]benzoth-
iazin-8-ylmethyl) piperazin-1-yl]ethyleneamino carbonitrile ESI (+)
36 6 (MH.sup.+), 388 (MNa.sup.+) 234.degree. C. (decom- pose)
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.30-2.36 (m, 2H), 2.33 (s,
3H), 2.37-2.42 (m, 2H), 3.31 (s, 2H), 3.49-3.54 (m, 2H), 3.58-3.63
(m, 2H), 6.70 )dd, J = 1.8, 7.8 Hz, 1H), 6.74 (d, J = 1.8, Hz, 1H),
6.85 (d, J = #7.8 Hz, 1H), 7.62 (d, J = 2.7 Hz, 1H), 7.63 (d, J =
2.7 Hz, 1H), 9.39-9.53 (br.s, 1H) 487
8328-(heptamethyleneiminomethyl)-10H-pyraz-
ino[2,3-b][1,4]benzothiazine FAB (+) 32 7 (MH.sup.+)
133-135.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.50-1.75
(m, 10H), 2.48-2.60 (m, 4H), 3.44 (s, 2H), 6.49 (br.s, 1H), 6.59
(s, 1H), 6.80-6.84 (m, 2H), 7.56 (d, J = 2.8 Hz, 1H), 7.68 (d, J =
2.8 Hz, 1H) 488
8338-(hexamethyleneiminomethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
FAB (+) 31 3 (MH.sup.+) 161-163.degree. C. .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.58-1.80 (m, 8H), 2.60-2.70 (m, 4H), 3.53 (s, 2H),
6.57 (br.s, 1H), 6.80 (s, 1H), 6.77 (d, J = 8.0 Hz, 1H), 6.82 (d, J
= 8.0 Hz, 1H), 7.57 (d, J = 2.8 Hz, 1H), 7.68 (d, J = 2.8 Hz, 1H)
489
8348-[(azetidin-1-yl)methyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
FAB (+) 27 1 (MH.sup.+) 158-161.degree. C. .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 2.11 (quint, J = 6.8 Hz, 2H), 3.23 (t, J = 6.8 Hz,
4H), 3.44 (s, 2H), 6.49 (d, J = 1.6 Hz, 1H), 6.54 (br.s, 1H), 6.72
(dd, J = 1.6, 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 7.57 (d, J =
2.8 Hz, 1H), 7.68 (d, J = 2.8 Hz, 1H) 490
8351-(10H-pyrazino[2,3-b][1,4]benzothiazi- n-8-
ylmethyl)pyridiniumchloride FAB (+) 29 3 (M.sup.+) 230-232.degree.
C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 5.67 (s, 2H), 6.68 (d, J
= 1 Hz, 1H), 6.84 (dd, J = 1, 7 Hz, 1H), 6.98 (d, J = 7 Hz, 1H),
7.65 (s, 2H), 8.19 (dd, J = 6, 7 Hz, 2H), 8.64 (t, J = 7 Hz, 1H),
9.11 (d, J = 6 Hz, 2H), 9.61 (s, 1H) 491
8361-(10H-pyrazino[2,3-b][1,4]benzo- thiazin-8-
ylmethyl)-4-piperidone FAB (+) 31 2 (M.sup.+) 186-188.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.32 (t, J = 6 Hz, 4H),
2.64 (t, J = 6 Hz, 4H), 3.32 (s, 2H), 6.75 (d, J = 8 Hz, 1H), 6.80
(s, 1H), 6.86 (d, J = 8 Hz, 1H), 7.63 (m, 2H), 9.47 (s, 1H) 492
8374-methyl-4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)
morpholiniumchloride FAB (+) 31 5 (M.sup.+) 144-146.degree. C.
.sup.1H-NMR (CD.sub.3OD) .delta. ppm: 3.12 (s, 3H), 3.34-3.41
(br.s, 2H), 3.54-3.61 (ddd, J = 5, 8, 13 Hz, 2H), 4.01-4.07 (m,
4H), 4.49 (s, 2H), 6.78 (d, J = 2 Hz, 1H), 6.95 (dd, J = 2, 8 Hz,
1H), 7.01 (d, J = 8 Hz, 1H), 7.62 (s, 2H) 493
8381-(10H-pyrazino[2,3-b][1,4]benzo- thiazin-8-
ylmethyl)-4-(hydroxymethyl)piperidin-4-ol FAB (+) 345 (MH.sup.+)
170-173.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.29
(br.d, J = 12 Hz, 2H), 1.54 (br.t, J = 12 Hz, 2H), 2.22 (br.t, J =
10 Hz, 2H), 2.43 (m, 2H), 3.12 (s, 2H), 3.23 (s, 2H), 4.13 (br.s,
1H), 4.51 (br.s, 1H), 6.68 (d, J = 8 Hz, 1H), 6.75 (s, 1H), 6.82
(d, # J = 8 Hz, 1H), 7.62 (s, 2H), 9.43 (s, 1H) 494
8398-[(1,2,3,4-tetrahydroquinolin-1-yl)methyl]-
10H-pyrazino[2,3-b][1,4]b- enzothiazine FAB (+) 347 (MH.sup.+)
208-210.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.96-2.07
(m, 2H), 2.81 (t, J = 6.0 Hz, 2H), 3.30 (t, J = 6.0 Hz, 2H), 4.31
(s, 2H), 6.42 (br.s, 1H), 6.44 (s, 1H), 6.59 (d, J = 7.2 Hz, 1H),
6.61 (d, J = 7.2 Hz, 1H), 6.74 (d, J = 8.0 Hz, 1H), 6.84 (d, # J =
8.0 Hz, 1H), 6.96-7.20 (m, 2H), 7.50 (d, J = 2.8 Hz, 1H), 7.65 (d,
J = 2.8 Hz, 1H) 495 840[4-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperazin-1-yl]am- idine ESI (+) 342 (MH.sup.+)
265-271.degree. C. (decom- pose) .sup.1H-NMR (CD.sub.3OD) .delta.
ppm: 2.51 (br.t, J = 5.1 Hz, 4H), 3.41 (s, 2H), 3.47 (br.t, J = 5.1
Hz, 4H), 6.70 (d, J = 1.6 Hz, 1H), 6.79 (dd, J = 1.6, 7.9 Hz, 1H),
6.82 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 2.9 Hz, 1H), 7.58 (d, J =
2.9 Hz, 1H) 496 8418-](1,2,3,4-tetrahydroquinolin-2-yl)me-
thyl]-10H- pyrazino[2,3-b][1,4]benzothiazine FAB (+) 34 7
(MH.sup.+) 188-191.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
2.73 (t, J = 6.0 Hz, 2H), 2.91 (t, J = 6.0 Hz, 2H), 3.52 (s, 2H),
3.60 (s, 2H), 6.57 (br.s, 1H), 6.63 (s, 1H), 6.83 (d, J = 8.0 Hz,
1H), 6.85 (d, J = 8.0 Hz, 1H), 6.99 (d, J = 8.0 Hz, 1H), 7.08-7.17
(m, 3H), 7.55 (d, # J = 2.8 Hz, 1H), 7.63 (d, J = 2.8 Hz, 1H) 497
8428-[(4,5,6,7-tetrahydrothieno[3.2-c]pyridin-5-yl)
methyl]-10H-pyrazino[2,3-b][1,4]benzothiazine FAB (+) 35 3
(MH.sup.+) 182-184.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
2.79 (t, J = 6.0 Hz, 2H), 2.89 (t, J = 6.0 Hz, 2H), 3.54 (s, 2H),
3.55 (s, 2H), 6.45 (br.s, 1H), 6.62 (s, 1H), 6.70 (d, J = 4.8 Hz,
1H), 6.82 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 8.0 Hz, 1H), # 7.08 (d,
J = 4.8 Hz, 1H), 7.57 (d, J = 2.8 Hz, 1H), 7.67 (d, J = 2.8 Hz,
1H)
EXAMPLE 498
N-Methyl-2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-
-yl]ethanesulfonamide
[2408] The title compound was obtained as yellow crystals by
treating N-methyl-2-(piperidin-4-yl)ethanesulfonamide acetate and
8-chloromethyl -10H-pyrazino[2,3-b][1,4]benzothiazine by the same
method as the one of Example 131. 843
[2409] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2410] 1.28(dq, J=3, 11 Hz, 2H), 1.39(m, 1H), 1.67(m, 2H), 1.75(m,
2H), 1.94(dt, J=1, 11 Hz, 2H), 2.81(d, J=6 Hz, 3H), 2.95(br.d, J=11
Hz, 2H), 3.04(m, 2H), 3.32(s, 2H), 4.18(q, J=6 Hz, 1H), 6.51(br.s,
1H), 6.53(d, J=2 Hz, 1H), 6.75(dd, J=2, 8 Hz, 1H), 6.83(d, J=8 Hz,
1H), 7.57(d, J=3 Hz, 1H), 7.69(d, J=3 Hz, 1H)
[2411] MS: ESI 420.1(MH.sup.+)
[2412] m.p.: 195-198.degree. C.
EXAMPLES 499 AND 500
[2413] The following compounds were obtained by the same method as
the one of Example 498.
80 Ex. Structural formula MS M. p. NMR 499
844N,N-dimethyl-2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl]ethanesulfonamide FAB (+) 43 4 (MH.sup.+)
188-190.degree. C. .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.27 (dq,
J = 3, 11 Hz, 2H), 1.39 (m, 1H), 1.67 (m, 2H), 1.75 (m, 2H), 1.92
(dt, J = 1, 11 Hz, 2H), 2.85 (br.d, J = 11 Hz, 2H), 2.86 (s, 6H),
2.93 (m, 2H), 3.32 (s, 2H), 6.51 (d, J = 2 Hz, 1H), 6.60 (br.s, #
1H), 6.75 (dd, J = 2, 8 Hz, 1H), 6.83 (d, J = 8 Hz, 1H), 7.58 (d, J
= 3 Hz, 1H), 7.69 (d, J = 3 Hz, 1H) 500
845N,N-(3-oxapentamethylene)-[1-(10H-pyrazino-
[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl]ehtanesulfonamide FAB (+) 47 6 (MH.sup.+)
193-194.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.14 (m,
2H), 1.31 (m, 1H), 1.53-1.64 (m, 4H), 1.83 (m, 2H), 2.74 (br.d, J =
8 Hz, 2H), 3.03 (m, 2H), 3.12 (t, J = 6 Hz, 4H), 3.23 (s, 2H), 3.61
(t, J = 6 Hz, 4H), 6.67 (d, J = 8 Hz, 1H), # 6.74 (s, 1H), 6.83 (d,
J = 8 Hz, 1H), 7.63 (s, 2H), 9.44 (s, 1H)
EXAMPLE 501
[1-(10H-Pyrazino[2,3-b][1,4]-benzothiazin-8-ylmethyl)-piperidine-4-(N-cyan-
o)carboxamidine
[2414] To a solution of 450 mg of
methyl[1-(10H-pyrazino[2,3-b][1,4]-benzo-
thiazin-8-ylmethyl)-piperidine-4-carboximidate in dry
tetrahydrofuran (10 ml) were added 1.0 ml of triethylamine and 1.0
g of cyanamide and the resulting mixture was heated to 45.degree.
C. for 2 hours. Then the reaction mixture was distributed into
water and ethyl acetate. The organic layer was extracted, washed
successively with an aqueous solution of sodium bicarbonate and
water and dried over sodium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 115 mg of the title compound as yellow crystals.
846
[2415] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2416] 1.49-1.72(m, 4H), 1.79-1.91(m, 2H), 2.08-2.28(m, 1H),
2.74-2.85(m, 2H), 3.25(s, 2H), 6.68(d, J=7.6 Hz, 1H), 6.73(s, 1H),
6.82(d, J=7.6 Hz, 1H), 7.59-7.65(m, 2H), 8.10-8.30(br.s, 1H),
8.40-8.70(br.s, 1H), 9.45(s, 1H)
[2417] MS: FAB(+)365(M.sup.+), 366(MH.sup.+)
EXAMPLE 502
4-[1-(10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)p-
iperidin -4-yl]butyronitrile
[2418] The title compound was obtained as yellow crystals by
treating 4-[1-(tert-butoxycarbonyl) piperidin-4-yl]butyronitrile
and 8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine by the
same method as the one of Example 66. 847
[2419] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2420] 1.40(m, 2H), 1.65(m, 7H), 1.96(t, J=10 Hz, 2H), 2.34(t, J=7
Hz, 2H), 2.87(t, J=10 Hz, 2H), 3.43(s, 2H), 3.55(s, 3H), 5.31(s,
2H), 6.94(d, J=8 Hz, 1H), 6.96(d, J=8 Hz, 1H), 7.10(s, 1H), 7.83(d,
J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H)
EXAMPLE 503
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-[2-(tetrazol-5-yl)et-
hyl]piperidine
[2421] To a solution of 0.323 g of
4-[1-(10-methoxymethyl)-10H-pyrazino[2,-
3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]butyronitrile in
1-methyl-2-pyrrolidone (10 ml) were added in a nitrogen atmosphere
0.354 g of sodium azide and 0.376 g of ammonium chloride. Next, the
resulting mixture was stirred under heating to 150.degree. C. for
28 hours. After distilling off the solvent under reduced pressure,
the residue was purified by high-porous gel chromatography (CHP20P,
75-150.mu.; manufactured by Mitsubishi Chemical Industries) (eluted
with methanol/water) to thereby give 0.208 g of the title compound
as pale yellow crystals. 848
[2422] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2423] 1.10(m, 2H), 1.20(m, 1H), 1.59(br.d, J=11 Hz, 2H),
1.67(quint, J=6 Hz, 2H), 1.99(t, J=11 Hz, 2H), 2.76(br.d, J=11 Hz,
2H), 2.81(t, J=9 Hz, 2H), 3.27(s, 2H), 6.68(dd, J=2, 8 Hz, 1H),
6.74(d, J=2 Hz, 1H), 6.83(d, J=8 Hz, 1H), 7.62(d, J=3 Hz, 1H),
7.63(d, J=3 Hz, 1H), 9.44(s, 1H)
[2424] MS: FAB(+)409(MH.sup.+)
[2425] m.p.: 149-152.degree. C.
EXAMPLE 504
N-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]-5-m-
ethyl -1,2-oxazole-4-carboxamide
[2426] 50 ml of a solution of 5.7 g of 4-amino-1-benzyl-piperidine
in toluene was stirred and 2.5 ml of diketene was carefully dropped
thereinto. After the completion of the,reaction, the solvent was
distilled off under reduced pressure and the residue was allowed to
stand at a low temperature. To the crystals thus precipitated was
added diethyl ether/isopropyl ether followed by grinding and
filtration. Thus 4.95 g of
N-(1-benzylpiperidin-4-yl)-3-oxobutanamide was obtained as
colorless crystals. Next, this compound was dissolved in a solvent
mixture of tetrahydrofuran (25 ml) with methanol (25 ml). After
adding 1.0 g of 10% palladium-carbon, the resulting mixture was
stirred under atmospheric pressure in a hydrogen atmosphere for 2
hours. After filtering off inorganic matters through celite, the
solvent was distilled off under reduced pressure. The oily residue
thus obtained was dissolved in 50 ml of N,N-dimethylformamide and
4.1 g of 8-chloromethyl-10-(methoxymethyl)-1-
0H-pyrazino[2,3-b][1,4]benzothiazine and 2.1 g of potassium
carbonate were added thereto. The resulting mixture was heated to
100.degree. C. for 1 hour. Then the reaction mixture was brought
back to room temperature and distributed into water and ethyl
acetate. The organic layer was extracted, washed with water and
dried over sodium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 3.7 g of
N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]-3--
oxobutanamide as yellow crystals. Further, 3.7 g of this
N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]-3--
oxobutanamide was dissolved in toluene (10 ml). After adding 1.3 ml
of N,N-dimethylformamide dimethyl acetal, the mixture was heated to
90.degree. C. for 30 minutes. After distilling off the solvent
under reduced pressure, 10 ml of methanol and 800 mg of
hydroxylamine hydrochloride were added to the yellow oily residue
thus obtained. Then the resulting mixture was heated under reflux
for 30 minutes. The reaction mixture was brought back to room
temperature and distributed into water and ethyl acetate. The
organic layer was extracted, washed with water and dried over
sodium sulfate. After distilling off the solvent under reduced
pressure, 30 ml of glacial acetic acid was added to the yellow oily
residue thus obtained. Then the resulting mixture was heated to
80.degree. C. for 4 hours. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) and
recrystallized from diethyl ether/ethyl acetate to thereby give 1.6
g of the title compound as yellow crystals. 849
[2427] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2428] 1.45-1.57(m, 2H), 1.94-2.02(m, 2H), 2.07-2.17(m, 2H),
2.70(s, 3H), 2.78-2.87(m, 2H), 3.34(s, 2H), 3.88-4.00(m, 1H),
5.66(br.d, J=7.6 Hz, 1H), 6.53(d, J=1.3 Hz, 1H), 6.68-6.72(br.s,
1H), 6.75(dd, J=1.3, 7.6 Hz, 1H), 6.82(d, J=7.9 Hz, 1H), 7.57(d,
J=3.0 Hz, 1H), 7.69(d, J=3.0 Hz, 1H), 8.36(s, 1H)
[2429] MS: FAB(+)423(MH.sup.+)
EXAMPLE 505
N-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]-3-o-
xo-2-cyanobutanamide
[2430] To 10 ml of a solution of 500 mg of
N-[1-(10H-pyrazino[2,3-b][1,4]b-
enzothiazin-8-ylmethyl)-piperidin-4-yl]-5-methyl-1,2-oxazole-4-carboxamide
in tetrahydrofuran was added 400 .mu.l of N,N-dimethylformamide
dimethyl acetal and the resulting mixture was heated under reflux
for 4 hours. After distributing into water and ethyl acetate, the
aqueous layer was extracted and washed with diethyl ether. After
distilling off the organic solvent contained therein under reduced
pressure, the residue was acidified with dilute hydrochloric acid
and purified by high-porous gel chromatography (CHP20P, 75-150.mu.;
manufactured by Mitsubishi Chemical Industries) (eluted with
methanol/water) to thereby give 110 mg of the title compound as
pale yellow crystals. 850
[2431] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2432] 1.38-1.54(m, 2H), 1.77-2.04(m, 4H), 1.99(br.s, 3H),
2.87-3.07(m, 2H), 3.32(s, 2H), 4.01-4.10(m, 1H), 6.76(s, 1H),
6.77(br.d, J=7.7 Hz, 1H), 7.00(d, J=7.7 Hz, 1H), 7.66(s, 2H),
9.48-9.59(m, 1H), 9.70(br.s, 1H)
[2433] MS: FAB(+)423(MH.sup.+)
EXAMPLES 506 AND 507
[2434] Starting with known compounds, the following compounds were
obtained by the same method as the one of Example 63.
81 Ex. Structural formula NMR 506 851ethyl
[1-(10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzoxazin-8-ylme-
thyl)piperidin-4-yl]carboxylate .sup.1H-NMR (CDCl.sub.3) .delta.
ppm: 1.25 (t, J = 7 Hz, 3H), 1.7-1.82 (m, 2H), 1.83-1.93 (m, 2H),
1.95-2.05 (m, 2H), 2.2-2.35 (m, 1H), 2.8-2.9 (m, 2H), 3.36 (s, 2H),
3.46 (s, 3H), 4.13 (q, J = 7 Hz, 2H), 5.31 (s, 2H), 6.78 (s, 2H),
6.88 (s, 1H), 7.41 (d, J = 3 Hz, 1H), 7.57 (d, # J = 3 Hz, 1H) 507
852ethyl
[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pip-
eridin-3-yl]carboxylate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.23
(t, J = 6 Hz, 3H), 1.38-1.62 (m, 2H), 1.65-1.76 (m, 1H), 1.86-1.96
(m, 1H), 1.96-2.10 (m, 1H), 2.10-2.30 (m, 1H), 2.50-2.60 (m, 1H),
2.65-2.70 (m, 1H), 2.90-2.97 (m, 1H), 3.41 (d, J = 14 Hz, 1H), 3.45
(d, J = 14 Hz, 1H), 3.54 (s, # 3H), 4.10 (q, J = 6 Hz, 2H), 5.28
(s, 2H), 6.92 (d, J = 8 Hz, 1H), 6.94 (d, J = 8 Hz, 1H), 7.10 (s,
1H), 7.82 (s, 2H)
EXAMPLE 508
Ethyl
4-[1-(10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylme-
thyl)piperidin-4-yl]-2-butenoate
[2435] The title compound was obtained as yellow crystals by the
same method as the one of Example 66. 853
[2436] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2437] 1.24(t, J=6 Hz, 3H), 1.36-1.46(m, 1H), 1.64-1.70(m, 2H),
1.76(br.s, 2H), 1.89-1.94(m, 2H), 2.14(t, J=6 Hz, 2H), 2.80-2.90(m,
2H), 3.39(s, 2H), 3.54(s, 3H), 4.16(q, J=6 Hz, 2H), 5.26(s, 2H),
5.80(d, J=16 Hz, 1H), 6.90(dt, J=6, 16 Hz, 1H), 6.94(d, J=8 Hz,
1H), 6.96(d, J=8 Hz, 1H), 7.08(s, 1H), 7.81(s, 2H)
EXAMPLES 509 TO 516
[2438] The following compounds were obtained by the same method as
the one of Example 508.
82 Ex. Structural formula NMR 509 854ethyl
3-[4-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]piperidin-1-yl]propanoate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.25 (t, J = 7.2 Hz, 3H), 1.36-1.51 (m, 2H), 1.87-1.95
(m, 2H), 2.00-2.12 (m, 2H), 2.46-2.58 (m, 3H), 2.66-2.74 (m, 2H),
2.85-2.93 (m, 2H), 3.65 (s, 3H), 3.76 (s, 2H), 4.13 (q, J = 7.2 Hz,
2H), 5.29 (s, 2H), 6.94 (d, # J = 7.4 Hz, 1H), 6.97 (d, J = 7.4 Hz,
1H), 7.13 (s, 1H), 7.83 (s, 2H) 510 855ethyl
4-[4-[(10-methoxymethyl-10- H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]piperidin-1-yl]butano- ate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.25 (t, J = 7.2 Hz, 3H), 1.43-1.58 (m, 2H), 1.69-1.78
(m, 2H), 1.85-1.94 (m, 2H), 1.94-2.03 (m, 2H), 2.30-2.38 (m, 3H),
2.41-2.53 (m, 2H), 2.93-3.03 (m, 2H), 3.55 (s, 3H), 3.76 (s, 2H),
4.13 (q, J = 7.2 Hz, 2H), 5.29 (s, 2H), 6.93 (d, # J = 8.0 Hz, 1H),
6.96 (d, J = 8.0 Hz, 1H), 7.12 (s, 1H), 7.83 (s, 2H) 511 856ethyl
[4-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,- 4]benzothiazin-8-
ylmethyl)amino]piperidin-1-yl]acetate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.26 (t, J = 7 Hz, 3H), 1.42-1.60 (m, 2H), 1.84-1.94
(m, 2H), 2.16-2.26 (m, 2H), 2.44-2.56 (m, 1H), 2.84-2.94 (m, 2H),
3.20 (s, 2H), 3.53 (s, 3H), 3.76 (s, 2H), 4.17 (q, J = 7 Hz, 2H),
5.30 (s, 2H), 6.90-7.00 (m, 2H), 7.13 (s, 1H), 7.80- # 7.85 (m, 2H)
512 857ethyl 3-[4-[(10-methoxymethyl-10H-pyrazino[2,3-
-b][1,4]benzothiazin-8- ylmethyl)
amino]piperidin-1-yl]-3-oxopropanoate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.28 (t, J = 6.8 Hz, 3H), 1.33-1.43 (m, 2H), 1.89-1.97
(m, 2H), 2.72-2.81 (m, 1H), 2.81-2.89 (m, 1H), 3.07-3.15 (m, 1H),
3.46 (s, 2H), 3.53 (s, 3H), 3.69-3.79 (m, 1H), 3.77 (s, 2H), 4.20
(q, J = 6.8 Hz, 2H), 4.37-4.44 (m, 1H), # 5.29 (s, 2H), 6.94 (d, J
= 7.6 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 7.13 (s, 1H), 7.83 (d, J =
2.8 Hz, 1H), 7.84 (d, J = 2.8 Hz, 1H) 513 858ethyl
[4-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]enzothiazin-8-
ylmethyl)amino]piperidin-1-yl]-2-oxoacetate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.30-1.47 (m, 2H), 1.36 (t, J = 7.0 Hz,
3H), 1.90-2.00 (m, 2H), 2.77-2.85 (m, 1H), 2.92-3.00 (m, 1H),
3.08-3.17 (m, 1H), 3.53 (s, 3H), 3.63-3.71 (m, 1H), 3.78 (s, 2H),
4.24-4.34 (m, 1H), 4.32 (q, J = 7.0 Hz, 2H), 5.29 (s, # 2H), 6.93
(dd, J = 1.4, 7.6 Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 7.13 (d, J =
1.4 Hz, 1H), 7.83 (d, J = 2.6 Hz, 1H), 7.84 (d, J = 2.6 Hz, 1H) 514
859ethyl (E)-3-[1-(10-methoxymeth-
yl-10H-pyrazino[2,3-b][1,4]enzothiazin-8-
ylmethyl)amino]piperidin-4-yl]-2- -butenoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.28 (t, J = 7.2 Hz, 3H), 1.52-1.72 (m,
4H), 1.91-2.03 (m, 3H), 2.15 (s, 3H), 2.91-2.97 (m, 2H), 3.44 (s,
2H), 3.54 (s, 3H), 4.14 (q, J = 7.2 Hz, 2H), 5.29 (s, 2H), 5.68 (s,
1H), 6.94 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 7.11 (s, #
1H), 7.84 (s, 2H) 515 860ethyl
[1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]enzothiazin-8-
ylmethyl)piperidin-4-yl]-2-oxoacetate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.30-1.47 (m, 2H), 1.36 (t, J = 7.0 Hz, 3H), 1.90-2.00
(m, 2H), 2.77-2.85 (m, 1H), 2.92-3.00 (m, 1H), 3.08-3.17 (m, 1H),
3.53 (s, 3H), 3.63-3.71 (m, 1H), 3.78 (s, 2H), 4.24-4.34 (m, 1H),
4.32 (q, J = 7.0 Hz, 2H), 5.29 (s, 2H), 6.93 (dd, J = 1.4, # 7.6
Hz, 1H), 6.97 (d, J = 7.6 Hz, 1H), 7.13 (d, J = 1.4 Hz, 1H), 7.83
(d, J = 2.6 Hz, 1H), 7.84 (d, J = 2.6 Hz, 1H) 516 861ethyl
[1-(10-methoxymethyl-10H-pyr- azino[2,3-b][1,4]enzothiazin-8-
ylmethyl)piperidin-4-yl]butanoate .sup.1H-NMR (CDCl.sub.3) .delta.
ppm: 0.91 (d, J = 6.8 Hz, 3H), 1.13-1.40 (m, 3H), 1.25 (t, J = 7.2
Hz, 3H), 1.54-1.63 (m, 2H), 1.85-1.96 (m, 3H), 2.08 (dd, J = 8.4,
14.8 Hz, 1H), 2.38 (dd, J = 4.9, 14.8 Hz, 1H), 2.81-2.94 (m, 2H),
3.42 (s, 2H), 3.54 (s, 3H), 4.12 (q, J = 7.2 Hz, # 2H), 5.29 (s,
2H), 6.93 (d, J = 7.9 Hz, 1H), 6.96 (d, J = 7.9 Hz, 1H), 7.10
(br.s, 1H), 7.83 (s, 2H)
EXAMPLES 517 AND 518
[2439] The following compounds were obtained as yellow crystals by
the same method as the one of Example 66 by using trifluoroacetic
acid as a substitute for hydrochloric acid.
83 Ex. Structural formula NMR 517 862ethyl
5-[1-(10-methoxymethyl)-10H-pyrido[2,3-b][1,4]-benzothiazin-8-
ylmethyl]piperidin-4-yl]-2-methylpentanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.13 (d, J = 7 Hz, 3H), 1.25 (t, J = 7
Hz, 3H), 1.1-1.45 (m, 7H), 1.55-1.70 (m, 2H), 1.65-1.80 (m, 2H),
1.85-1.95 (m, 2H), 2.35-2.45 (m, 1H), 2.85 (br.d, J = 12 Hz, 2H),
3.43 (s, 2H), 3.55 (s, 3H), 4.12 (q, J = 7 Hz, 2H), # 5.36 (s, 2H),
6.80 (dd, J = 5, 8 Hz, 1H), 6.92 (dd, J = 2, 8 Hz, 1H), 6.97 (d, J
= 8 Hz, 1H), 7.11 (d, J = 2 Hz, 1H), 7.28 (dd, J = 2, 8 Hz, 1H),
8.05 (dd, J = 2, 5 Hz, 1H) 518 863ethyl
4-[(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8- -
ylmethyl]piperidin-4-yl]-2,2-dimethylbutanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.10-1.30 (m, 5H), 1.14 (s, 6H), 1.26 (t,
J = 6 Hz, 3H), 1.48-1.56 (m, 2H), 1.58-1.70 (m, 2H), 1.84-1.96 (m,
2H), 2.80-2.90 (m, 2H), 3.40 (s, 2H), 3.52 (s, 3H), 4.09 (q, J = 6
Hz, 2H), 5.29 (s, 2H), 6.93 (d, J = 8 Hz, 1H), 6.96 (d, # J = 8 Hz,
1H), 7.09 (s, 1H), 7.82 (s, 2H)
EXAMPLES 519 TO 521
[2440] The following compounds were obtained by the same method as
the one of Example 64 by using anhydrous potassium carbonate as a
substitute for N,N-diisopropylamine.
84 Ex. Structural formula NMR 519 864methyl
[1-(10-methoxymethyl)-10H-pyrido[2,3-b][1,4]benzothiazin-8-ylme-
thyl]- 4-(p-methoxyphenyl)piperidin-4-yl]carboxylate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.87-14 2.0 (m, 2H), 2.16 (br.t, J = 12
Hz, 2H), 2.53 (br.d, J = 12 Hz, 2H), 2.75-2.85 (m, 2H), 3.39 (s,
2H), 3.52 (s, 3H), 3.64 (s, 3H), 3.79 (s, 3H), 5.27 (s, 2H), 6.85
(d, J = 9 Hz, 2H), 6.9-6.96 (m, 1H), 6.95 (d, J = 8 Hz, 1H), 7.11
(s, 1H), # 7.29 (d, J = 9 Hz, 2H), 7.82 (d, J = 3 Hz, 1H), 7.83 (d,
J = 3 Hz, 1H) 520 865methyl
[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]- benzothiazin-8-
ylmethyl]-4-(p-methoxyphenyl)piperidin-4-yl]carboxylate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.88-2.0 (m, 2H), 2.15 (br.t, J = 12 Hz,
2H), 2.53 (br.d, J = 12 Hz, 2H), 2.75-2.84 (m, 2H), 3.39 (s, 2H),
3.47 (s, 3H), 3.52 (s, 3H), 3.64 (s, 3H), 5.15 (s, 2H), 5.27 (s,
2H), 6.9-6.96 (m, 1H), 6.95 (d, J = 8 Hz, 1H), 6.98 (d, # J = 9 Hz,
2H), 7.10 (s, 1H), 7.29 (d, J = 9 Hz, 2H), 7.82 (d, J = 3 Hz, 1H),
7.83 (d, J = 3 Hz, 1H) 521 866ethyl 4-[1-(10-methoxymethyl)-10-
H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]piperidin-4-yl]methylbenzoat-
e .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.22-1.35 (m, 2H), 1.36 (t,
J = 6 Hz, 3H), 1.42-1.60 (m, 3H), 1.83-1.93 (m, 2H), 2.58 (d, J = 6
Hz, 2H), 2.80-2.80 (m, 2H), 3.40 (s, 2H), 3.52 (s, 3H), 4.36 (q, J
= 6 Hz, 2H), 5.29 (s, 2H), 6.92 (d, J = 8 Hz, 1H), 6.94 (d, J = 8
Hz, 1H), # 7.09 (s, 1H), 7.19 (d, J = 9 Hz, 2H), 7.82 (s, 2H), 7.94
(d, J = 9 Hz, 2H)
EXAMPLE 522
Methyl[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmeth-
yl]-4-phenylpiperidin-4-yl]carboxylate
[2441] To a solution of 0.46 g of
methyl[(1-benzyl-4-phenylpiperidin)-4-yl- ]carboxylate in
1,2-dichloroethane (10 ml) was added 0.18 ml of 1-chloroethyl
chloroformate at 0.degree. C. After stirring for 15 minutes, the
resulting mixture was heated under reflux for additional 1 hour.
After distilling off the solvent under reduced pressure, 50 ml of
methanol was added to the residue and the resulting mixture was
heated under reflux for 1 hour. After distilling off the solvent
under reduced pressure, 0.4 g of
methyl(4-phenylpiperidin-4-yl)carboxylate was obtained as colorless
crystals. 0.4 g of these crystals were dissolved in 20 ml of
N,N-dimethylformamide and 0.44 g of
8-(chloromethyl)-10H-(methoxymethyl)--
10H-pyrazino[2,3-b][1,4]benzothiazine and 0.62 g of anhydrous
potassium carbonate were added thereto. After reacting at
60.degree. C. for 1 hour, water was added to the reaction mixture.
The mixture was extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.55 g of the title compound as a yellow oily substance. 867
[2442] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2443] 1.9-2.05(m, 2H), 2.1-2.25(m, 2H), 2.5-2.6(m, 2H),
2.75-2.85(m, 2H), 3.41(m, 2H), 3.52(s, 3H), 3.65(s, 3H), 5.28(s,
2H), 6.92-6.96(m, 1H), 6.95(s, 1H), 7.10-7.13(m, 1H), 7.2-7.4(m,
5H), 7.82(d, J=3 Hz, 1H), 7.83(d, J=3 Hz, 1H)
EXAMPLES 523 TO 525
[2444] The following compounds were obtained by the same method as
the one of Example 522.
85 Ex. Structural formula NMR 523 868ethyl
4-[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl]piperidin-4-ylidene]-4-cyanobutanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.26 (t, J = 7 Hz, 3H), 2.4-2.5 (m, 4H),
2.5-2.58 (m, 6H), 2.58-2.66 (m, 2H), 3.46 (s, 2H), 3.53 (s, 3H),
4.13 (q, J = 7 Hz, 2H), 5.29 (s, 2H), 6.90-6.96 (m, 1H), 6.97 (d, J
= 8 Hz, 1H), 7.12 (s, 1H), 7.83 (d, J = 3 Hz, # 1H), 7.84 (d, J = 3
Hz, 1H) 524 869methyl
2,2-dimethyl-4-[4-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl]piperazin-1-yl]pentanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.17 (s, 6H), 1.38-1.56 (m, 4H), 2.30 (m,
2H), 2.39-2.54 (br.s, 8H), 3.44 (s, 2H), 3.53 (s, 3H), 3.65 (s,
3H), 5.26 (s, 2H), 6.94 (s, 2H), 7.10 (s, 1H), 7.82 (m, 2H) 525
870ethyl
N-(methanesulfonyl)-N-[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][-
1,4]benzothiazin-8-ylmethyl]piperidin-4-yl]aminoacetate NMR
(CDCl.sub.3) 1.29 (t, J = 6.8 Hz, 3H), 1.56-1.70 (m, 2H), 1.77-1.85
(m, 2H), 2.02-2.11 (m, 2H), 2.87-2.98 (m, 2H), 3.10 (s, 3H), 3.42
(br.s, 2H), 3.54 (s, 3H), 3.58-3.69 (m, 1H), 4.06 (s, 2H), 4.18 (q,
J = 6.8 Hz, 2H), 5.29 (s, 2H), 6.92 (dd, J = 1.2, 7.6 Hz, # 1H),
6.97 (d, J = 7.6 Hz, 1H), 7.07 (br.d, J = 1.2 Hz, 1H), 7.84 (d, J =
2.8 Hz, 1H), 7.85 (d, J = 2.8 Hz, 1H)
EXAMPLE 526
Ethyl
4-[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylme-
thyl]piperidin-4-yl]-2-methylbutanoate
[2445] To a solution of 15.7 g of ethyl
4-[1-benzyloxycarbonyl]piperidin-4- -yl]-2-methyl-2-butenoate in
ethanol (200 ml) was added 3.1 g of 10% palladium-carbon (moisture
content: 50%) and hydrogenation reaction was effected at ordinary
temperature under atmospheric pressure for 8 hours and 40 minutes.
After filtering off the palladium-carbon, the solvent was
concentrated under reduced pressure to thereby give 10.06 g of
crude ethyl 4-(piperidin-4-yl)-2-methyl-2-butanoate as a pale
yellow oily substance. A 3.74 g portion of this product was
dissolved in 50 ml of N,N-dimethylformamide. After adding 4.06 g of
8-(chloromethyl)-10H-(metho-
xymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine and 20 ml of
pyridine, the resulting mixture was reacted at 70.degree. C. for 11
hours. After adding water, the reaction mixture was extracted with
ethyl acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
toluene/ethyl acetate) to thereby give 4.5 g of the title compound
as a yellow oily substance. 871
[2446] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2447] 1.07(d, J=7 Hz, 3H), 1.10-1.30(m, 4H), 1.13(t, J=6 Hz, 3H),
1.58-1.70(m, 3H), 1.70-1.82(m, 2H), 1.88-1.98(m, 2H), 2.32-2.41(m,
1H), 2.80-2.88(m, 2H), 3.42(s, 2H), 3.52(s, 3H), 4.11(q, J=6 Hz,
2H), 5.30(s, 2H), 6.90(d, J=8 Hz, 1H), 6.92(d, J=8 Hz, 1H), 7.09(s,
1H), 7.82(s, 2H)
EXAMPLES 527 TO 530
[2448] The following compounds were obtained by the same method as
the one of Example 526.
86 Ex. Structural formula NMR 527 872ethyl
4-[1-(10-methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzoxazin-8-
ylmethyl]piperidin-4-yl]-2-methylbutanoate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.13 (d, J = 7 Hz, 3H), 1.1-1.3 (m, 3H), 1.24 (t, J =
7 Hz, 3H), 1.3-1.5 (m, 1H), 1.6-1.7 (m, 3H), 1.7-1.85 (m, 2H),
1.85-1.95 (m, 2H), 2.3-2.43 (m, 1H), 2.83 (br.d, J = 9 Hz, 2H),
3.35 (s, 2H), 3.45 (s, 3H), 4.11 (q, J = 7 Hz, 2H), 5.29 (m, 2H), #
6.77 (s, 2H), 6.87 (s, 1H), 7.40 (d, J = 3 Hz, 1H), 7.55 (d, J = 3
Hz, 1H) 528 873ethyl
4-[1-[5-(methoxymethyl)-5H-pyrido[3.4-b][1,4]benzothiazin-7-
ylmethyl]-piperidin-4-yl]-2-methylbutanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.13 (d, J = 7 Hz, 3H), 1.21 (m, 4H),
1.24 (t, J = 7 Hz, 3H), 1.41 (m, 1H), 1.65 (m, 4H), 1.92 (t, J = 11
Hz, 2H), 2.37 (sext, J = 7 Hz, 1H), 2.83 (d, J = 11 Hz, 2H), 3.42
(s, 2H), 3.53 (s, 3H), 4.12 (q, J = 7 Hz, 2H), 5.03 (s, 2H), 6.87
(d, # J = 6 Hz, 1H), 6.96 (dd, J = 2, 8 Hz, 1H), 7.02 (d, J = 2 Hz,
1H), 7.04 (d, J = 8 Hz, 1H), 8.18 (s, 1H), 8.26 (d, J = 6 Hz, 1H)
529 874ethyl
[40[[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl]amino]piperidin-1-yl]acetate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 1.26 (t, J = 8 Hz, 3H), 1.42-1.60 (m, 2H), 1.84-1.94
(m, 2H), 2.16-2.26 (m, 2H), 2.44-2.56 (m, 1H), 2.84-2.94 (m, 2H),
3.20 (s, 2H), 3.53 (br.s, 3H), 3.76 (s, 2H), 4.17 (q, J = 8 Hz,
2H), 5.2-5.35 (m, 3H), 6.9-7.0 (m, 2H), # 7.13 (s, 1H), 7.8-7.85
(m, 2H) 530 875ethyl
4-[1-(10-methoxymethyl)-10H-pyrazino[2,3-b]pyrido[2,3-e][1,4-
]thiazin-8-ylmethyl]piperidin-4-yl]-2-methylbutanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.13 (d, J = 6.8 Hz, 3H), 1.15-1.30 (m,
5H), 1.25 (t, J = 7.2 Hz, 3H), 1.35-1.47 (m, 1H), 1.57-1.69 (m,
3H), 1.88-1.98 (m, 2H), 2.33-2.42 (m, 1H), 2.79-2.86 (m, 2H), 3.40
(s, 2H), 3.52 (s, 3H), 4.12 (q, J = 6.8 Hz, 2H), # 5.26 (s, 2H),
7.28 (br.d, J = 1.6 Hz, 1H), 7.80 (d, J = 2.8 Hz, 1H), 7.84 (d, J =
2.8 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H)
EXAMPLE 531
Ethyl[4-1-[10-(methoxymethyl)-7-methoxy-10H-pyrazino[2,3-b][1,4]benzothiaz-
in-8-ylmethyl]piperidin-4-yl]-2-methyl-butanoate
[2449] To a solution of 0.7 g of
7-methoxy-10-(methoxymethyl)-10H-pyrazino-
[2,3-b][1,4]benzothiazine-8-carboxaldehyde and 0.98 g of ethyl
4-(piperidin-4-yl)-2-methylbutanoate in acetonitrile (50 ml) was
added 0.29 g of sodium cyanoborohydride. After stirring at room
temperature for 10 minutes, 0.4 ml of acetic acid was dropped
thereinto and the resulting mixture was reacted for 12 hours. After
adding water, the reaction mixture was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 0.2 g of the title compound
as a pale yellow oily substance. 876
[2450] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2451] 1.15(d, J=7 Hz, 3H), 1.26(t, J=7 Hz, 3H), 1.2-1.3(m, 2H),
1.35-1.50(m, 3H), 1.55-1.80(m, 6H), 2.2-2.40(m, 2H), 2.3-2.43(m,
1H), 3.0-3.15(m, 2H), 3.56(s, 3H), 3.79(s, 3H), 4.13(q, J=7 Hz,
2H), 5.28(s, 2H), 6.55(s, 1H), 7.26(s, 1H), 7.83(d, J=3 Hz, 1H),
7.85(d, J=3 Hz, 1H)
EXAMPLE 532
10H-Pyrazino[2,3-b][1,4]benzothiazine-8-carboxylic acid
[2452] To 50 ml of a solution of 2 g of methyl
10H-pyrazino[2,3-b][1,4]ben- zothiazine-8-carboxylate in methanol
was added 0.8 g of sodium hydroxide and the resulting mixture was
heated under reflux for 1 hour. After distilling off the methanol
under reduced pressure, a 1 N aqueous solution of hydrochloric acid
was added thereto so as to adjust the pH value to 5 to 6. Then the
mixture was extracted with ethyl acetate/dichloromethane and the
organic layer was dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, 1.9 g of the
title compound was obtained as a yellow solid. 877
[2453] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2454] 3.40(s, 3H), 5.26(s, 2H), 7.22(d, J=8.1 Hz, 1H), 7.52(dd,
J=1.7, 8.1 Hz, 1H), 7.64(d, J=1.7 Hz, 1H), 7.94(d, J=2.6 Hz, 1H),
7.87(d, J=2.6 Hz, 1H), 13.05-13.25(br.s, 1H)
EXAMPLE 533
Ethyl
4-[1-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbonyl]piperidin--
4-yl]-2-methylbutanoate
[2455] To a solution of 1 g of
10H-pyrazino[2,3-b][1,4]-benzothiazine-8-ca- rboxylic acid in
tetrahydrofuran (50 ml) were added under ice-cooling 0.6 ml of
triethylamine and 0.55 ml of diethyl chlorophosphate. The resulting
mixture was reacted at room temperature for 0.5 hour. Next, 0.66 g
of ethyl 4-(piperidin-4-yl)-2-methylbutanoate was added thereto and
the resulting mixture was stirred at room temperature for 12 hours.
After adding ethyl acetate to the reaction mixture, the organic
layer was washed with water and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 1.0 g of the
title compound as a yellow oily substance. 878
[2456] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2457] 1.0-1.8(m, 9H), 1.15(d, J=7 Hz, 3H), 1.26(t, J=7 Hz, 3H),
2.3-2.45(m, 1H), 2.6-2.7(m, 1H), 2.9-3.3(m, 1H), 3.51(s, 3H),
3.6-3.8(m, 1H), 3.95-4.10(m, 1H), 4.13(q, J=7 Hz, 2H), 5.26(s, 2H),
6.99(dd, J=2, 8 Hz, 1H), 7.04(d, J=8 Hz, 1H), 7.18(d, J=2 Hz, 1H),
7.85(d, J=3 Hz, 1H), 7.87(d, J=3 Hz, 1H)
EXAMPLE 534
10H-Pyrazino[2,3-b][1,4]benzothiazine-8-acetonitrile
[2458] To 50 ml of a solution of 5 g of
8-(chloromethyl)-10H-pyrazino[2,3-- b][1,4]benzothiazine in
dimethyl sulfoxide was added 0.92 g of sodium cyanide and the
resulting mixture was reacted at 60.degree. C. for 1 hour. After
adding ethyl acetate, the organic layer was washed with water and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, 4.7 g of the title compound was
obtained as a yellow solid. 879
[2459] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2460] 3.38(s, 3H), 4.00(s, 2H), 5.24(s, 2H), 6.99(dd, J=1.8, 8.0
Hz, 1H), 7.09(d, J=1.8 Hz, 1H), 7.15(d, J=8.0 Hz, 1H), 7.94(d,
J=2.4 Hz, 1H), 7.97(d, J=2.4 Hz, 1H)
EXAMPLE 535
10H-Pyrazino[2,3-b][1,4]benzothiazine-8-acetic acid
[2461] 4.7 g of
10H-pyrazino[2,3-b][1,4]benzothiazine-8-acetonitrile was dissolved
in 100 ml of ethanol. After adding 2.8 g of potassium hydroxide,
the resulting mixture was heated under reflux for 16 hours. After
distilling off the ethanol, water was added and the mixture was
made weakly acidic with dilute hydrochloric acid followed by the
extraction with ethyl acetate and dichloromethane. The organic
layer was dried over anhydrous magnesium sulfate. After distilling
off the solvent under reduced pressure, 3.85 g of the title
compound was obtained as yellow crystals. 880
[2462] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2463] 3.53(s, 3H), 3.60(s, 2H), 5.27(s, 2H), 6.90(dd, J=2, 8 Hz,
1H), 6.98(d, J=8 Hz, 1H), 7.08(d, J=2 Hz, 1H), 7.83(d, J=3 Hz, 1H),
7.85(d, J=3 Hz, 1H)
EXAMPLE 536
Ethyl
4-[1-[(10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylm-
ethyl]carbamoyl]piperidin-4-yl]-2-methylbutanoate
[2464] To a solution of 0.7 g of
10H-pyrazino[2,3-b][1,4]benzothiazine-8-a- cetic acid in
tetrahydrofuran (50 ml) were added 0.35 ml of triethylamine and
0.55 ml of diphenyl phosphate azide and the resulting mixture was
stirred at room temperature for 3 hours. Next, it was heated under
reflux for 1.5 hours. After adding 0.55 g of ethyl
4-(piperidin-4-yl)-2-methylbu- anoate, the resulting mixture was
reacted at room temperature for 1 hour. After adding ethyl acetate,
the reaction mixture was washed with water and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.66 g of the title compound as a yellow oily substance.
881
[2465] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2466] 1.14(d, J=7 Hz, 3H), 1.1-1.2(m, 1H), 1.25(t, J=7 Hz, 3H),
1.25-1.35(m, 2H), 1.3-1.5(m, 2H), 1.6-1.75(m, 4H), 2.3-2.45(m, 1H),
2.7-2.8(m, 2H), 3.52(s, 3H), 3.85-3.95(m, 2H), 4.12(q, J=7 Hz, 2H),
4.35(d, J=6 Hz, 2H), 4.73(br.t, J=6 Hz, 1H), 5.26(s, 2H), 6.91(dd,
J=1, 8 Hz, 1H), 6.96(d, J=8 Hz, 1H), 7.08(d, J=1 Hz, 1H),
7.8-7.86(m, 2H)
EXAMPLE 537
Ethyl
1-[(10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmet-
hyl]-2,3-dehydro-3-piperidinecarboxylate
[2467] To a solution of 0.506 g of diisopropylamine in
tetrahydrofuran (10 ml) was added in a nitrogen atmosphere at
0.degree. C. 3.14 ml of a 1.6 M solution of n-butyllithium in
hexane. Further, a solution of 0.776 g of ethyl
2,3-dehydro-3-piperidinecarboxylate in tetrahydrofuran (2 ml) was
added thereto to thereby prepare a lithium salt. In another
container, 1.00 g of
8-(chloromethyl)-10-methoxymethyl-10H-pyrazino(2,3-b][1,4]benzo-
thiazine was added to a solution of 1.53 g of sodium iodide in
N,N-dimethylformamide (10 ml). After heating for 2 hours, the
mixture was brought back to room temperature. The solution thus
obtained was added to the solution of the lithium salt as described
above and the resulting mixture was stirred at room temperature for
2 hours. After concentrating under reduced pressure, the residue
was dissolved in ethyl acetate and water. The organic layer was
concentrated and the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.375 g of the title compound as pale yellow crystals. 882
[2468] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2469] 1.26(t, J=7 Hz, 3H), 1.52(quint, J=6 Hz, 2H), 2.29(t, J=6
Hz, 2H), 2.98(t, J=6 Hz, 2H), 3.49(s, 3H), 4.15(q, J=7 Hz, 2H),
4.23(s, 2H), 5.22(s, 2H), 6.82(dd, J=2, 7 Hz, 1H), 6.97(d, J=2 Hz,
1H), 6.98(d, J=1, 7 Hz, 1H), 7.51(s, 1H), 7.83(d, J=3 Hz, 1H),
7.84(d, J=3 Hz, 1H)
EXAMPLE 538
1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmethyl]-3--
(tert-butyldimethylsilyloxymethyl)pyridinium chloride
[2470] 883
[2471] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2472] 0.00(s, 6H), 0.75(s, 9H), 3.35(s, 3H), 4.84(s, 2H), 5.20(s,
2H), 5.75(s, 2H), 7.05(dd, J=2, 8 Hz, 1H), 7.16(d, J=8 Hz, 1H),
7.18(d, J=2 Hz, 1H), 7.88(d, J=3 Hz, 1H), 7.94(d, J=3 Hz, 1H),
8.20(t, J=7 Hz, 1H), 8.44(d, J=7 Hz, 1H), 8.80(s, 1H), 9.06(d, J=7
Hz, 1H)
EXAMPLE 539
1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmethyl]-3,-
4-dehydro-3-(tert-butyldimethylsilyloxymethyl)piperidine
[2473] To a solution of 0.326 g of
1-[10-(methoxymethyl)-10H-pyrazino[2,3--
b][1,4]benzothiazin-8-ylmethyl)-3-(tert-butyldimethylsilyloxymethyl)pyridi-
nium chloride in methanol (10 ml) was added at room temperature in
a nitrogen atmosphere 0.06 g of sodium borohydride. After stirring
for 18 hours, water and ethyl acetate were added thereto. The
organic layer was dried over anhydrous magnesium sulfate, filtered
and concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 0.176 g of the title compound as pale
yellow crystals. 884
[2474] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2475] 0.05(s, 6H), 0.83(s, 9H), 2.10-2.15(m, 2H), 2.46(t, J=6 Hz,
2H), 2.86(br.s, 2H), 3.41(s, 3H), 3.49(s, 2H), 3.90(br.s, 2H),
5.25(s, 2H), 5.65(m, 1H), 6.92(d, J=8 Hz, 1H), 6.95(dd, J=2, 8 Hz,
1H), 7.08(d, J=8 Hz, 1H), 7.79(d, J=3 Hz, 1H), 7.80(d, J=3 Hz,
1H)
EXAMPLE 540
1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmethyl]-3,-
4-dehydro-3-piperidinemethanol
[2476] To a solution of 0.176 g of
1-[10-(methoxymethyl)-10H-pyrazino[2,3--
b][1,4]-benzothiazin-8-ylmethyl]-3,4-dehydro-3-(tert-butyldimethylsilyloxy-
methyl)piperidine in tetrahydrofuran (5 ml) was added at 0.degree.
C. in a nitrogen atmosphere 1 ml of a 1 M solution of
tetra-n-butylammonium fluoride in tetrahydrofuran and the resulting
mixture was stirred at room temperature for 3 hours. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.100 g of the title
compound as pale yellow crystals. 885
[2477] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2478] 2.18(m, 2H), 2.54(t, J=6 Hz, 2H), 3.04(br.s, 2H), 3.53(s,
3H), 3.57(s, 2H), 4.00(s, 2H), 5.30(s, 2H), 5.64(br.s, 1H), 6.95(s,
2H), 7.13(s, 1H), 7.81(d, J=3 Hz, 1H), 7.83(d, J=3 Hz, 1H)
EXAMPLE 541
1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-3,4-
-dehydro-3-piperidinecarbaldehyde
[2479] To a solution of 0.150 g of
1-[10-(methoxymethyl)-10H-pyrazino[2,3--
b][1,4]benzothiazin-8-ylmethyl]-3,4-dehydro-3-piperidinemethanol in
dichloromethane (4 ml) was added 1.00 g of manganese dioxide. After
stirring for 3 hours, the mixture was filtered. After distilling
off the solvent under reduced pressure, 0.108 g of the title
compound was obtained as pale yellow crystals. 886
[2480] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2481] 2.47(m, 2H), 2.58(t, J=7 Hz, 2H), 3.20(m, 2H), 3.53(s, 3H),
3.59(s, 2H), 5.30(s, 2H), 6.86(m, 1H), 6.96(s, 2H), 7.11(s, 1H),
7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H), 9.42(s, 1H)
EXAMPLE 542
Methyl
1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl]-3,4-dehydro-3-piperidinecarboxylate
[2482] To a solution of 0.108 g of
1-[10-(methoxymethyl)-10H-pyrazino[2,3--
b][1,4]-benzothiazin-8-ylmethyl]-3,4-dehydro-3-piperidinecarbaldehyde
in methanol (5 ml) were added 0.096 g of potassium cyanide, 0.504 g
of manganese dioxide and 0.070 g of acetic acid and the resulting
mixture was stirred for 12 hours. Then the reaction mixture was
filtered through celite and the celite was extracted with
dichloromethane. The organic layer was washed with a dilute aqueous
solution of potassium hydroxide and concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.080 g of the title compound as pale yellow crystals. 887
[2483] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2484] 2.34(m, 2H), 2.54(t, J=7 Hz, 2H), 3.22(br.s, 2H), 3.53(s,
3H), 3.58(s, 2H), 3.73(s, 3H), 5.28(s, 2H), 6.96(s, 2H), 7.01(m,
1H), 7.12(s, 1H), 7.83(s, 2H)
EXAMPLE 543
Ethyl
N-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l]-N-(1-methanesulfonylpiperidin-4-yl)-aminoacetate
[2485] To a solution of 1.1 g of
N,N-[3-[[(10-(methoxymethyl)-10H-pyrazino-
[2,3-b][1,4]benzothiazin-8-ylmethyl]-amino]penta-methylene]methanesulfonam-
ide in 30 ml of N,N-dimethylformamide were added 0.42 g of
anhydrous potassium carbonate and 0.34 ml of ethyl bromoacetate.
Then the resulting mixture was reacted at 60.degree. C. for 2
hours. After adding ethyl acetate, the reaction mixture was washed
with water and a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with methanol/dichloromethane) to
thereby give 0.34 g of the title compound as a yellow oily
substance. 888
[2486] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2487] 1.25(t, J=7 Hz, 3H), 1.5-1.7(m, 2H), 1.9-2.0(m, 2H),
2.6-2.7(m, 2H), 2.75(s, 3H), 2.7-2.8(m, 1H), 3.35(s, 2H), 3.53(s,
3H), 3.78(s, 2H), 3.75-3.85(m, 2H), 4.13(q, J=7 Hz, 2H), 5.27(s,
2H), 6.9-7.0(m, 2H), 7.20(s, 1H), 7.8-7.9(m, 2H)
EXAMPLE 544
Ethyl[[4-[N-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl-
methyl]-N-acetyl]amino]piperidin-1-yl]-acetate
[2488] To a solution of 1.1 g of
ethyl[4-[[10-(methoxymethyl)-10H-pyrazino-
[2,3-b][1,4]benzothiazin-8-ylmethyl]amino]-piperidin-1-yl]acetate
in dichloromethane (30 ml) were added 0.4 ml of triethylamine and
0.2 ml of acetyl chloride and the resulting mixture was reacted at
room temperature for 0.5 hour. Then the reaction mixture was washed
with water, dried over anhydrous magnesium sulfate and
concentrated. The residue was purified by silica gel column
chromatography (eluted with methanol/dichloromethane) to thereby
give 1.0 g of the title compound as a yellow oily substance.
889
[2489] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2490] 1.2-1.3(m, 5H), 1.5-1.7(m, 2H), 1.8-1.9(m, 1H), 2.2-2.3(m,
1H), 2.25(s, 3H), 2.9-3.0(m, 2H), 3.15and3.89(s, total2H), 3.51(s,
3H), 4.16(q, J=7 Hz, 2H), 4.45and4.50(s, total2H), 4.40-4.60(m,
1H), 5.23(m, 2H), 6.78(d, J=8 Hz, 1H), 6.85-7.00(m, 2H), 7.8-7.9(m,
2H)
EXAMPLES 545 TO 551
[2491] The following compounds were obtained by the same method as
the one of Example 18.
87 Ex. Structural formula NMR 545
890[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzo-thiazin-8-ylmethy-
l]piperidin-4-yl]carboxylic acid .sup.1H-NMR (CDCl.sub.3) .delta.
ppm: 1.90-2.06 (br.s, 2H), 2.06-2.16 (br.s, 2H), 2.38-2.43 (br.s,
1H), 2.58-2.70 (br.s, 2H), 3.18-3.30 (br.s, 2H), 3.48 (s, 3H), 3.94
(s, 2H), 5.28 (s, 2H), 6.96 (d, J = 8 Hz, 1H), 6.98 (s, 1H), 7.02
(d, J = 8 Hz, 1H), 7.79 (d, J = 3 Hz, 1H), 7.80 (d, # J = 3 Hz, 1H)
546
8914-[4-[10-(methoxymethyl)-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
methyl]piperazin-1-yl]-2,2-dimethylpentanoic acid .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.01 (s, 6H), 1.38 (br.s, 4H), 2.44
(br.s, 2H), 2.31-2.50 (br.s, 8H), 3.38 (s, 2H), 3.51 (s, 3H), 5.25
(s, 2H), 6.89 (d, J = 8 Hz, 1H), 6.91 (d, J = 1, 8 Hz, 1H), 7.08
(s, 1H), 7.81 (d, J = 3 Hz, 1H), 7.83 (d, J = 3 Hz, 1H) 547
892[1-[10-(methoxymethyl)-10H--
pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-
4-(p-methoxyphenyl)piperidin- -4-yl]carboxylic acid .sup.1H-NMR
(CD.sub.3OD) .delta. ppm: 2.0-2.2 (m, 2H), 2.4-2.6 (m, 2H), 2.8-3.0
(m, 2H), 3.0-3.2 (m, 2H), 3.30 (s, 2H), 3.51 (s, 3H), 3.78 (s, 3H),
5.38 (s, 2H), 6.78-7.0 (m, 2H), 7.1-7.2 (m, 2H), 7.3-7.4 (m, 3H),
7.88 (s, 1H), 7.93 (s, 1H) 548
893[1-[10-(methoxymethyl)-10H-pyrazino[1,3-b][1,4]benzothiazin-8-ylmethyl-
]- 4-(p-methoxymethoxyphenyl)piperidin-4-yl]carboxylic acid
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.6-1.75 (m, 2H), 2.13
(br.t, J = 12 Hz, 2H), 2.38 (br.d, J = 12 Hz, 2H), 2.6-2.7 (m, 2H),
3.34 (s, 3H), 3.35 (s, 2H), 3.36 (s, 3H), 5.13 (s, 2H), 5.23 (s,
2H), 6.93 (d, J = 9 Hz, 3H), 7.04 (d, J = 8 Hz, 1H), 7.08-7.11 (m,
1H), # 7.28 (d, J = 8 Hz, 2H), 7.91 (d, J = 3 Hz, 1H), 7.95 (d, J =
3 Hz, 1H) 549
894[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
]- 4-phenylpiperidin-4-yl]carboxylic acid .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 1.65-1.80 (m, 2H), 2.08-2.20 (m, 2H),
2.35-2.45 (m, 2H), 2.6-2.75 (m, 2H), 3.36 (s, 5H), 5.23 (s, 2H),
6.94 (d, J = 8 Hz, 1H), 7.04 (d, J = 8 Hz, 1H), 7.09 (s, 1H), 7.20
(t, J = 8 Hz, 1H), 7.30 (t, J = 8 Hz, 2H), 7.37 (d, J = 8 Hz, 2H),
7.9- # 7.93 (m, 1H), 7.93-7.97 (m, 1H) 550
895[1-[10-(methoxymethyl)-10H-pyraz-
ino[2,3-b][1,4]benzothiazin-8-ylmethyl]piperidin-4-yl]acetic acid
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.50-1.80 (m, 5H), 2.00-2.30
(m, 4H), 3.10-3.20 (m, 2H), 3.49 (s, 3H), 3.64 (s, 2H), 5.23 (s,
2H), 6.91 (d, J = 8 Hz, 1H), 6.94 (d, J = 8 Hz, 1H), 7.09 (s, 1H),
7.81 (s, 2H) 551
8964-[1-[10-(methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-ylmethyl]piperidin-4-yl]butanoic acid .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.20-1.30 (m, 4H), 1.44-1.58 (m, 4H),
1.74-1.82 (m, 2H), 2.23-2.28 (m, 3H), 2.42-2.56 (m, 2H), 3.48 (s,
3H), 4.02 (s, 2H), 5.23 (s, 2H), 6.96 (d, J = 8 Hz, 1H), 6.98 (d, J
= 8 Hz, 1H), 7.16 (s, 1H), 7.82 (s, 2H), 10.20-11.00 (br.s, 1H)
EXAMPLE 552
[[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]pi-
peridin -4-yl]carbamoyl]aminoacetic acid
[2492] The title compound was obtained by treating ethyl
[(1-benzylpiperidin-4-yl)carbamoyl]aminoacetate by the same methods
as those of Examples 64 and 18. 897
[2493] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2494] 1.57-1.68(m, 2H), 2.00-2.10(m, 2H), 2.44-2.57(m, 2H),
2.93-2.99(m, 2H), 3.45(s, 2H), 3.56(s, 3H), 3.88-3.99(m, 1H),
3.91(s, 2H), 5.25-5.35(br.s, 1H), 5.28(s, 2H), 5.33(br.s, 1H),
6.96(s, 2H), 7.14(s, 1H), 7.83(s, 2H)
EXAMPLES 553 TO 574
[2495] The following compounds were obtained by the same method as
the one of Example 64 by using N,N-diisopropylethylamine or
anhydrous potassium carbonate as a base.
88 Ex. Structural formula NMR 553 898methyl
4-[[4-hydroxy-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-
piperidin]- 4-yl]phenylacetate .sup.1H-NMR (CDCl.sub.3) .delta.
ppm: 1.56 (br.s, 1H), 1.71-1.78 (m, 2H), 2.08-2.20 (m, 2H),
2.42-2.53 (m, 2H), 2.73-2.81 (m, 2H), 3.43 (br.s, 2H), 3.63 (s,
2H), 3.70 (s, 3H), 6.46 (br.s, 1H), 6.59 (br.s, 1H), 6.81 (dd, J =
1.5, 7.8 Hz, 1H), 6.85 (d, J = 7.8 Hz, 1H), 7.25-7.30 # (m, 2H),
7.45-7.49 (m, 2H), 7.58 (d, J = 2.9 Hz, 1H), 7.69 (d, J = 2.9 Hz,
1H) 554 899ethyl
[2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-2-azaspiro[3.5]non-7-
- yl]acetate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.91-1.03 (m,
2H), 1.25 (t, J= 7.1 Hz, 3H), 1.41-1.51 (m, 2H), 1.63-1.79 (m, 3H),
1.94-2.02 (m, 2H), 2.15 (d, J = 7.0 Hz, 2H), 3.12 (s, 2H), 3.15 (s,
2H), 3.61 (s, 2H), 4.12 (q, J = 7.1 Hz, 2H), 6.64 (br.s, 1H), 6.67
(br.s, 1H), 6.74 (dd, J = 1.6, 7.9 Hz, # 1H), 6.82 (d, J = 7.9 Hz,
1H), 7.57 (d, J = 2.7 Hz, 1H), 7.68 (d, J = 2.7 Hz, 1H) 555
900methyl
2-methoxy-4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-methyl)piperidi-
n-4- yl]phenylacetate .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.72-1.86 (m, 4H), 2.02-2.10 (m, 2H), 2.49 (m, 1H), 2.95-3.02 (m,
2H), 3.38 (s, 2H), 3.60 (s, 2H), 3.69 (s, 3H), 3.81 (s, 3H), 6.49
(br.s, 1H), 6.58 (d, J = 1.5 Hz, 1H), 6.74 (d, J = 1.5 Hz, 1H),
6.78 (dd, J = 1.5, 7.5 Hz, 1H), 6.79 (dd, J = 1.5, 7.9 Hz, # 1H),
6.85 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 7.5 Hz, 1H), 7.58 (d, J =
2.9 Hz, 1H), 7.70 (d, J = 2.9 Hz, 1H) 556 901methyl
1-[2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8--
ylmethyl)piperidin-4-yl]thioacetate and ethyl
1-[2-(10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl)piperidin-4-yl]thioacetate (mixture of
about 1:1) .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.28 (t, J = 7.1
Hz, 1.5H), 1.54-1.66 (m, 2H), 1.93-2.00 (m, 2H), 2.01-2.10 (m, 2H),
2.78-2.87 (m, 3H), 3.25 (s, 1H), 3.27 (s, 1H), 3.32 (s, 2H), 3.74
(s, # 1.5H), 4.19 (q, J = 7.1 Hz, 1H), 6.54 (d, J = 1.5 Hz, 1H),
6.73 (dd, J = 1.5, 7.9 Hz, 1H), 6.81 (d, J = 7.9 Hz, 1H), 7.18
(br.s, 1H), 7.59 (d, J = 2.9 Hz, 1H), 7.69 (d, J = 2.9 Hz, 1H) 557
902N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]-
-N',N'- [(3-ethoxycarbonyl)pentamethylene]sulfamide .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.26 (t, J = 7 Hz, 3H), 1.38 (dq, J = 3,
12 Hz, 2H), 1.76 (dq, J = 12 Hz, 2H), 1.99 (br.d, J = 12 Hz, 4H),
2.41 (m, 5H), 2.83 (m, 4H), 3.22 (m, 1H), 3.38 (s, 2H), 4.14 (q, J
= 7 Hz, 2H), 6.55 (d, J = 1 Hz, 1H), 6.74 (dd, # J = 1, 8 Hz, 1H),
6.82 (d, J = 8 Hz, 1H), 7.40 (br.s, 1H), 7.48 (d, J = 3 Hz, 1H),
7.67 (d, J = 3 Hz, 1H), 8.20 (s, 1H) 558 903methyl
4-oxo-4-[4-(10H-pyrazino[2,3-b-
][1,4]benzothiazin-8-ylmethyl]piperazin-1-yl]butanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 2.41 (m, 4H), 2.60-2.69 (m, 4H), 3.35 (s,
2H), 3.48 (t, J = 5 Hz, 2H), 3.61 (t, J = 5 Hz, 2H), 3.69 (s, 3H),
6.41 (s, 1H), 6.53 (d, J = 2 Hz, 1H), 6.77 (dd, J = 2, 8 Hz, 1H),
6.85 (d, J = 8 Hz, 1H), 7.58 (d, J = 3 Hz, 1H), 7.70 (d, J = 3 Hz,
1H) 559
904(2-trimethylsilylethyl)N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin--
8-ylmethyl]piperidin- 4-ylsulfamoylacetate .sup.1H-NMR (CDCl.sub.3)
.delta. ppm: 0.00 (s, 9H), 0.99 (m, 2H), 1.61 (br.s, 2H), 1.95
(br.d, J = 12 Hz, 2H), 2.07 (br.s, 2H), 2.73 (br.s, 2H), 3.29 (s,
2H), 3.33 (m, 1H), 3.93 (s, 2H), 4.22 (m, 2H), 6.46 (br.s, 1H),
6.58 (br.s, 1H), 6.69 (dd, J = 2, 8 Hz, 1H), 6.78 (d, J = 8 Hz,
1H), # 7.52 (d, J = 3 Hz, 1H), 7.64 (d, J = 3 Hz, 1H) 560 905methyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-ethylpiperidin-4-y-
l]acetate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.84 (t, J = 7 Hz,
3H), 1.44 (q, J = 7 Hz, 2H), 1.47-1.61 (m, 4H), 2.30 (s, 2H),
2.33-2.40 (m, 2H), 2.41-2.49 (m, 2H), 3.35 (s, 2H), 3.54 (s, 3H),
6.55 (d, J = 2 Hz, 1H), 6.72 (br.s, 1H), 6.74 (dd, J = 2, 8 Hz,
1H), 6.81 (d, J = 8 Hz, 1H), 7.57 (d, # J = 3 Hz, 1H), 7.68 (d, J =
3 Hz, 1H) 561 906ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidi-
n-3-yl]acetate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.22 (t, J = 7
Hz, 3H), 1.5-1.7 (m, 3H), 1.7-1.8 (m, 2H), 1.9-2.15 (m, 2H),
2.15-2.28 (m, 2H), 2.65-2.75 (m, 2H), 3.29 (d, J = 9 Hz, 1H), 3.33
(d, J = 9 Hz, 1H), 4.10 (q, J = 7 Hz, 2H), 6.51 (br.s, 1H), 6.54
(d, J = 2 Hz, 1H), 6.74 (dd, J = 2, 8 Hz, 1H), # 6.81 (d, J = 8 Hz,
1H), 7.57 (d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H) 562 907methyl
[7-(10H-pyrazino[2,3-b][1,4]enzothiazin-8-ylmethyl)-7-azaspiro[3.5]non-2-
yl]arboxylate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.58 (t, J = 5
Hz, 2H), 1.64 (t, J = 5 Hz, 2H), 2.01 (s, 2H), 2.03 (s, 2H), 2.25
(br.s, 2H), 2.23 (br.s, 2H), 3.05 (quint, J = 9 Hz, 1H), 3.28 (s,
2H), 3.67 (s, 3H), 6.39 (br.s, 1H), 6.53 (br.s, 1H), 6.74 (dd, J =
2, 8 Hz, 1H), 6.82 (d, J = 8 Hz, 1H), 7.57 (d, # J = 3 Hz, 1H),
7.68 (d, J = 3 Hz, 1H) 563 908ethyl
3-[1-(10H-pyrazino[2,3-b][1,4]enzothiazin-8-ylme-
thyl)piperidin-4-yl]-2,2,- dimethylpropanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.15 (s, 6H), 1.23 (t, J = 7 Hz, 3H),
1.1-1.4 (m, 3H), 1.52 (d, J = 6 Hz, 2H), 1.50-1.60 (m, 2H),
1.8-1.95 (m, 2H), 2.78 (br.d, J = 12 Hz, 2H), 3.28 (s, 2H), 4.08
(q, J = 7 Hz, 2H), 6.53 (d, J = 1 Hz, 1H), 6.68-6.76 (m, 2H), 6.81
(d, # J = 8 Hz, 1H), 7.57 (d, J = 3 Hz, 1H, 7.68 (d, J = 3 Hz, 1H)
564 909ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pyrrolidin-3-yl]aceta-
te .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.24 (t, J = 7 Hz, 3H),
1.4-1.6 (m, 1H), 2.02-2.14 (m, 1H), 2.14-2.24 (m, 1H), 2.4 (d, J =
8 Hz, 2H), 2.46-2.64 (m, 3H), 2.80 (t, J = 8 Hz, 1H), 3.44 (d, J =
13 Hz, 1H), 3.48 (d, J = 13 Hz, 1H), 4.11 (q, J = 7 Hz, 2H),
6.44-6.50 (m, 1H), 6.56 (br.s, 1H), # 6.74-6.78 (m, 1H), 6.82 (d, J
= 8 Hz, 1H), 7.57 (d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H) 565
910ethyl
2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]prop-
anoate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.12 (d, J = 7 Hz,
3H), 1.25 (t, J = 7 Hz, 3H), 1.2-1.45 (m, 2H), 1.48-1.60 (m, 2H),
1.60-1.75 (m, 1H), 1.92 (t, J = 10 Hz, 2H), 2.25 (quint, J = 7 Hz,
1H),2.8-2.93 (m, 2H), 3.31 (s, 2H), 4.12 (q, J = 7 Hz, 2H),
6.50-6.56 (m, 1H), 6.53 (d, J = 1 Hz, 1H), 6.75 # (dd, J = 1, 8 Hz,
1H), 6.82 (d, J = 8 Hz, 1H), 7.57 (d, J = 3 Hz, 1H), 7, 68 (d, J =
3 Hz, 1H) 566 911ethyl
2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin--
4-yl]-2- methylpropanoate .sup.1H-NMR (CDCl.sub.3) .delta. ppm:
1.11 (s, 6H), 1.24 (t, J = 7 Hz, 3H), 1.3-1.45 (m, 2H), 1.45-1.55
(m, 2H), 1.50-1.65 (m, 1H), 1.85-1.95 (m, 2H), 2.85-2.9 (m, 2H),
3.31 (m, 2H), 4.11 (q, J = 7 Hz, 2H), 6.38-6.44 (m, 1H), 6.52
(br.s, 1H), 6.75 (dd, J = 1, 8 Hz, 1H), 6.82 (d, # J = 8 Hz, 1H),
7.57 (d, J = 2 Hz, 1H), 7.69 (d, J = 2 Hz, 1H) 567 912ethyl
3-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]prop-
anoate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.25 (t, J = 7 Hz,
3H), 1.28-1.45 (m, 1H), 1.53-1.65 (m, 2H), 1.6-1.70 (m, 2H),
1.70-1.90 (m, 2H), 1.85-2.0 (m, 2H), 2.30 (t, J = 8 Hz, 2H),
2.8-2.9 (m, 2H), 3.23 (s, 2H), 4.12 (q, J = 7 Hz, 2H), 6.55 (br.s,
1H), 6.57 (br.s, 1H), 6.74 (dd, J = 1, 8 Hz, 1H), # 6.82 (d, J = 8
Hz, 1H), 7.57 (d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H) 568
913ethyl
N-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]amin-
oacetate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.25 (t, J = 7.2 Hz,
3H), 1.33-1.45 (m, 2H), 1.75-1.83 (m, 2H), 1.93-2.03 (m, 2H),
2.41-2.50 (m, 1H), 2.75-2.84 (m, 2H), 3.29 (s, 2H), 3.40 (s, 2H),
4.16 (q, J = 7.2 Hz, 2H), 6.53 (d, J = 1.6 Hz, 1H), 6.70 (dd, J =
1.6, 7.7 Hz, 1H), 6.77 (d, J = 7.7 Hz, 1H), # 7.37 (br.s, 1H), 7.55
(d, J = 2.8 Hz, 1H), 7.64 (d, J = 2.8 Hz, 1H) 569 914ethyl
1-[1-(10H-pyrazino[2,3-b-
][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]cyclopropanecarboxylate
.sup.1H-NMR (CDCl.sub.3) .delta. ppm: 0.73 (dd, J = 4.6, 6.5 Hz,
2H), 1.10 (dd, J = 4.6, 6.5 Hz, 2H), 1.22 (t, J = 7.1 Hz, 3H),
1.35-1.48 (m, 2H), 1.53-1.60 (m, 2H), 1.63-1.73 (m, 1H), 1.86-1.96
(m, 2H), 2.83-2.90 (m, 2H), 3.30 (s, 2H), 4.09 (q, J = 7.1 Hz, 2H),
6.48-6.53 (br.s, 1H), # 6.54 (d, J = 1.4 Hz, 1H), 6.75 (dd, J =
1.4, 8.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 7.57 (d, J = 2.7 Hz,
1H), 7.68 (d, J = 2.7 Hz, 1H) 570 915methyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl)piperidin-4-yl]methoxyacetate .sup.1H-NMR (CDCl.sub.3) .delta.
ppm: 1.21-1.35 (m, 2H), 1.60-1.70 (m, 1H), 1.70-1.77 (m, 2H),
1.88-1.98 (m, 2H), 2.82-2.88 (m, 2H), 3.31 (s, 2H), 3.37 (d, J =
6.7 Hz, 2H), 3.75 (s, 3H), 4.08 (s, 2H), 6.51-6.56 (br.s, 1H), 6.54
(d, J = 1.7 Hz, 1H), 6.75 (dd, J = 1.7, 7.8 Hz, 1H), 6.82 (d, J = #
7.8 Hz, 1H), 7.57 (d, J = 3.2 Hz, 1H), 7.68 (d, J = 3.2 Hz, 1H),
571 916ethyl
4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]phen-
oxyacetate .sup.1H-NMR (CDCl.sub.3) .delta. ppm: 1.30 (t, J = 7 Hz,
3H), 1.7-1,85 (m, 4H), 2.0-2.1 (m, 2H), 2.4-2.5 (m, 1H), 2.9-3.0
(m, 2H), 3.38 (s, 2H), 4.27 (q, J = 7 Hz, 2H), 4.60 (s, 2H), 6.59
(s, 1H), 6.56-6.66 (m, 1H), 6.79 (dd, J = 1, 8 Hz, 1H), 6.84 (d, J
= 8 Hz, 1H), 6.85 (d, J = 9 Hz, 2H), # 7.14 (d, J = 9 Hz, 2H), 7.58
(d, J = 3 Hz, 1H), 7.69 (d, J = 3 Hz, 1H) 572 917ethyl
4-[1-(10H-pyrazino[2,3-b][-
1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]benzoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.38 (t, J = 7 Hz, 3H), 1.7-1.88 (m, 4H),
2.07 (dt, J = 4, 12 Hz, 2H), 2.5-2.64 (m, 1H), 2.99 (br.d, J = 12
Hz, 2H), 3.39 (s, 2H), 4.36 (q, J = 7 Hz, 2H), 6.56 (s, 1H), 6.58
(d, J = 1 Hz, 1H), 6.79 (dd, 1, 8 Hz, 1H), 6.85 (d, J = 8 Hz, 1H),
7.29 (d, J = 8 # Hz, 2H), 7.58 (d, J = 3 Hz, 1H), 7.70 (d, J = 3
Hz, 1H), 7.98 (d, J = 8 Hz, 2H) 573 918ethyl
3-[1-(10H-pyrazino[2,3-b][1,4]benz-
othiazin-8-ylmethyl)azetidin-3-yl]-2- methylpropanoate .sup.1H-NMR
(CDCl.sub.3) .delta. ppm: 1.12 (d, J = 7 Hz, 3H), 1.24 (t, J = 7
Hz, 3H), 1.65 (m, 1H), 1.89 (dt, J = 7, 13 Hz, 1H), 2.35 (sex, J =
7 Hz, 1H), 2.52 (m, 1H), 2.75 (dt, J = 3, 7 Hz, 2H), 3.42 (s, 2H),
3.46 (m, 2H), 4.10 (q, J = 7 Hz, 2H), 6.43 (br.s, 1H), 6.46 (d, J =
2 Hz, 1H), # 6.71 (dd, J = 2, 8 Hz, 1H), 6.81 (d, J = 8 Hz, 1H),
7.56 (d, J = 3 Hz, 1H), 7.68 (d, J = 3 Hz, 1H) 574 919ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]carbam-
oylformate .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.25 (t, J = 7.2
Hz, 3H), 1.47-1.59 (m, 2H), 1.60-1.68 (m, 2H), 1.88-1.97 (m, 2H),
2.69-2.78 (m, 2H), 3.24 (s, 2H), 3.48-3.60 (m, 1H), 4.19 (q, J =
7.2 Hz, 2H), 6.69 (d, J = 7.8 Hz, 1H), 6.73 (s, 1H), 6.84 (d, J =
7.8 Hz, 1H), 7.63 (s, 2H), 8.80 (d, # J = 8.4 Hz, 1H), 9.45 (s,
1H)
EXAMPLE 575
Methyl
4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4--
yl]phenylacetate
[2496] To a solution of 1.0 g of methyl
4-[1-(benzyloxy-carbonyl)piperidin- -4-yl]phenylacetate in ethanol
(100 ml) was added 1.0 g of 10% palladium-carbon (moisture content:
50%) and a hydrogenation reaction was effected under atmospheric
pressure for 12 hours. Then the palladium-carbon was filtered off
and the solvent was concentrated under reduced pressure to thereby
give 0.5 g of crude methyl 4-(piperidin-4-yl)phenylacetate. To a
solution of 0.5 g of this crude product and 0.5 g of
8-(chloroethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin- e in
N,N-dimethylformamide (30 ml) was added 0.87 g of anhydrous
potassium carbonate and the resulting mixture was stirred under
heating to 60.degree. C. for 40 minutes. After adding water, the
reaction mixture was extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.6 g of the title compound as a yellow oily substance. 920
[2497] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2498] 1.7-1.85(m, 4H), 2.0-2.1(m, 2H), 2.4-2.54(m, 1H),
2.94-3.0(m, 2H), 3.37(s, 2H), 3.59(s, 2H), 3.69(s, 3H),
6.38-6.43(m, 1H), 6.55-6.58(m, 1H), 6.76-6.80(m, 1H), 6.84(d, J=8
Hz, 1H), 7.18(d, J=8 Hz, 2H), 7.21(d, J=8 Hz, 2H), 7.57(d, J=3 Hz,
1H), 7.69(d, J=3 Hz, 1H)
EXAMPLES 576 TO 582
[2499] The following compounds were obtained by the same method as
the one of Example 575.
89 Ex. Structural formula NMR 576 921 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.76-1.88(m, 2H), 1.92-2.04(m, 2H), 2.20-2.36(m, 2H),
2.65-2.76(m, 2H), 3.37(s, 2H), 3.56(s, 2H), 3.69(s, 3H), 4.31(m,
1H), 6.52(br.s, 1H), 6.56(br.s, 1H), 6.77(dd, J=1.6, 7.9Hz, 1H),
6.82-6.88(m, 3H), 7.15-7.20(m, 2H), 7.58(d, J=2.7Hz, 1H), 7.69(d,
J=2.7Hz, 1H) 577 922 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.32-1.46(m, 2H), 1.74-1.86(m, 2H), 1.93-2.04(m, 3H), 2.86-2.94(m,
2H), 3.35(s, 2H), 3.56(s, 2H), 3.68(s, 3H), 3.78(d, J=5.9Hz, 2H),
3.56(s, 2H), 3.68(s, 3H), 3.78(d, J=5.9Hz, 2H), 6.56(br.s, 1H),
6.64(br.s, 1H), 6.77(dd, J=1.5, 8.0Hz, 1H), 6.81-6.86(m, 3H),
7.15-7.20(m, 2H), 7.58(d, J=2.7Hz, 1H), 7.69(d, J=2.7Hz, 1H) 578
923 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24-1.88(m, 10H),
2.20-2.43(m, total2H), 2.58-2.69(m, 2H), 3.46, 3.49(m, total2H),
3.65, 3.67(s, total3H), 6.50(m, 1H), 6.62(m, 1H), 6.67, 6.78(dd,
J=1.6, 7.9Hz, total1H), 6.83, 6.40(d, J=7.9Hz, total1H), 7.57(d,
J=2.9Hz, 1H), 7.69(d, J=2.9Hz, 1H) 579 924 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.5-1.9(m, 4H), 2.0-2.1(m, 2H), 2.38-2.48(m, 1H),
2.9-3.0(m, 2H), 3.38(s, 2H), 3.63(s, 2H), 3.70(s, 3H), 3.80(s, 3H),
3.84(s, 3H), 6.42-6.46(m, 1H), 6.58(d, J=1Hz, 1H), 6.68(d, J=2Hz,
1H), 6.72(d, J=2Hz, 1H), 6.79(dd, J=2, 8Hz, 1H), 6.85(d, J=8Hz,
1H), 7.58(d, J=3Hz, 1H), 7.70(d, J=3Hz, 1H) 580 925
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.5-1.7(m, 4H), 1.9-2.0(m,
2H), 2.5-2.66(m, 1H), 2.86(br.d, J=12Hz, 2H), 3.30(s, 2H), 3.57(s,
3H), 3.72(s, 2H), 6.72(d, J=8Hz, 1H), 6.79(s, 1H), 6.84(d, J=8Hz,
1H), 7.06-7.18(m, 2H), 7.18-7.28(m, 2H), 7.56-7.66(m, 2H), 9.44(s,
1H) 581 926 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.7-1.86(m, 4H),
2.0-2.1(m, 2H), 2.44-2.56(m, 1H), 2.94-3.0(m, 2H), 3.38(s, 2H),
3.61(s, 2H), 3.69(s, 3H), 6.40-6.48(m, 1H), 6.58(d, J=1Hz, 1H),
6.80(dd, J=1, 8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.1-7.18(m, 3H),
7.22-7.3(m, 1H), 7.58(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H) 582 927
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.00-1.09(m, 5H), 1.03(d,
J=7.1Hz, 3H), 1.14(t, J=7.3Hz, 3H), 1.29-1.40(m, 1H), 1.55-1.60(m,
3H), 1.77-1.87(m, 2H), 2.28-2.37(m, 1H), 2.66-2.75(m, 2H), 3.23(s,
2H), 4.03(q, J=7.3Hz, 2H), 6.74(dd, J=1.6, 7.9Hz, 1H), 6.79(d,
J=1.6Hz, 1H), 6.85(d, J=7.9Hz, 1H), 7.93(s, 1H), 8.22(s, 1H),
9.76(s, 1H)
EXAMPLE 583
Ethyl
(E)-3-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin--
4-yl]propanoate
[2500] To a solution of 1.6 g of ethyl
3-(1-benzylpiperidin-4-yl)propenoat- e in 1,2-dichloroethane (30
ml) was added at 0.degree. C. 0.74 ml of 1-chloroethyl
chloroformate and the resulting mixture was stirred at the same
temperature for 15 minutes and then heated under reflux for 1 hour.
After distilling off the solvent under reduced pressure, 50 ml of
methanol was added to the residue and the resulting mixture was
heated under reflux for 1 hour. Then the mixture was made weakly
alkaline with a dilute aqueous solution of sodium hydroxide and the
solvent was distilled off under reduced pressure. To a solution of
1.0 g of ethyl 3-(piperidin-4-yl)propenoate thus obtained and 0.64
g of 8-(chloroethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine in
N,N-dimethylformamide (30 ml) was added 1.1 g of anhydrous
potassium carbonate and the resulting mixture was stirred by
heating to 60.degree. C. for 1 hour. After adding water, the
reaction mixture was extracted with ethyl acetate, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with methanol/dichloromethane) to thereby
give 0.6 g of the title compound as yellow crystals. 928
[2501] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2502] 1.29(t, J=3 Hz, 3H), 1.4-1.55(m, 2H), 1.65-1.78(m, 2H),
1.93-2.05(m, 2H), 2.07-2.2(m, 1H), 2.8-2.90(m, 2H), 3.33(s, 2H),
4.18(q, J=7 Hz, 2H), 5.79(dd, J=1, 16 Hz, 1H), 6.48(s, 1H), 6.52(d,
J=, 2 Hz, 1H), 6.75(dd, J=2, 8 Hz, 1H), 6.83(d, J=8 Hz, 1H),
6.91(dd, J=6, 16 Hz, 1H), 7.57(d, J=3 Hz, 1H), 7.69(d, J=3 Hz,
1H)
EXAMPLES 584 TO 601
[2503] The following compounds were obtained by the same method as
the one of Example 583.
90 Ex. Structural formula NMR 584 929 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.27(t, J=7Hz, 3H), 2.71(t, J=7Hz, 2H), 2.92-3.0(m,
2H), 3.24(d, J=1Hz, 2H), 3.49(s, 2H), 4.15(q, J=7Hz, 2H), 5.75(t,
J=2Hz, 1H), 6.47(s, 1H), 6.53(d, J=1Hz, 1H), 6.77(dd, J=1, 8Hz,
1H), 6.84(d, J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H) 585
930 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.29(t, J=7Hz, 3H, E),
1.30(t, J=7Hz, 3H, Z), 1.34-1.48(m, 2H, Z), 1.44-1.56(m, 2H, E),
1.56-1.63(m, 2H, E), 1.63-1.72(m, 2H, Z), 1.84(d, J=2Hz, 3H, E),
1.87(d, J=1Hz, 3H, Z), 1.94-2.06(m, 2H, Z+E), 2.24-2.36(m, 1H, E),
2.84-2.96(m, 2H, E+Z), 2.84-2.96(m, 1H, Z), 3.48(s, 3H, Z), 3.50(s,
3H, E), 4.18(q, J=7Hz, 2H, E), 4.18(q, J=7Hz, 2H, Z), 5.73(d, J=
#9Hz, 1H, Z), 6.59(d, J=9Hz, 1H, E), 7.2-7.38(m, 5H, E+Z) 586 931
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.13(d, J=7Hz, 3H), 1.24(t,.
J=7Hz, 3H), 1.1-1.3(m, 3H), 1.55-1.80(m, 4H), 1.89(br.t, J=13Hz,
2H), 2.45-2.55(m, 1H), 2.77-2.8(m, 2H), 3.30(s, 2H), 4.05-4.18(m,
2H), 6.53(d, J=1Hz, 1H), 6.64-6.72(m, 1H), 6.74(dd, J=1, 8Hz, 1H),
6.81(d, J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H) 587 932
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.0(s, 6H), 1.24-1.38(m, 5H),
1.6-1.7(m, 2H), 1.94(br.t, J=12Hz, 2H), 2.21(s, 2H), 2.78(br.d,
J=12Hz, 2H), 3.30(s, 2H), 3.64(s, 3H), 6.45(s, 1H), 6.53(d, J=1Hz,
1H), 6.75(dd, J=1, 8Hz, 1H), 6.83(d, J=8Hz, 1H), 7.57(d, J=3Hz,
1H), 7.69(d, J=3Hz, 1H) 588 933 .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.00(t, J=7Hz, 3H), 1.4-1.5(m, 2H), 2.28(t, J=6Hz, 2H),
2.59(t, J=6Hz, 2H), 2.66(s, 2H), 3.11(s, 2H), 3.88(q, J=7Hz, 2H),
5.38(s, 1H), 6.28(d, J=2Hz, 1H), 6.48(dd, J=2, 8Hz, 1H), 6.55(s,
1H), 6.56(d, J=8Hz, 1H), 7.32(d, J=3Hz, 1H), 7.41(d, J=3Hz, 1H) 589
934 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.23(t, J=7Hz, 3H),
1.67-1.8(m, 2H), 2.2-2.28(m, 2H), 2.49(t, J=5Hz, 2H), 3.43(s, 2H),
3.66(s, 2H), 4.11(q, J=7Hz, 2H), 5.68(s, 1H), 6.56(d, J=2Hz, 1H),
6.74(dd, J=2, 8Hz, 1H), 6.81(d, J=8Hz, 1H), 6.82-6.94(m, 1H),
7.66(d, J=3Hz, 1H) 590 935 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
0.96(s, 6H), 1.15-1.4(m, 3H), 1.6-1.72(m, 2H), 1.87(br.t, J=12Hz,
2H), 2.23(s, 2H), 2.92(br.d, J=12Hz, 2H), 3.31(s, 2H), 3.65(s, 3H),
6.53(d, J=1Hz, 1H), 6.55(m, 1H), 6.75(dd, J=2, 8Hz, 1H), 6.82(d,
J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H) 591 936
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.28(t, J=7Hz, 3H),
1.17-1.35(m, 2H), 1.47-1.70(m, 3H), 1.85-1.95(m, 2H), 2.06(d,
J=7Hz, 2H), 2.14(d, J=1Hz, 3H), 2.84(br.d, J=12Hz, 2H), 3.32(s,
2H), 4.14(q, J=7Hz, 2H), 5.63(d, J=1Hz, 1H), 6.43(s, 1H), 6.53(d,
J=1Hz, 1H), 6.75(dd, J=1, 8Hz, 1H), 6.83(d, J=8Hz, 1H), 7.57(d,
J=3Hz, 1H), 7.69(d, J=3Hz, 1H) 592 937 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 0.85(d, J=7Hz, 6H), 1.25(t, J=7Hz, 3H), 1.7-1.9(m,
1H), 2.0-2.15(m, 2H), 2.16(d, J=6Hz, 2H), 2.25-2.35(m, 2H),
2.50-2.60(m, 2H), 3.3-3.45(m, 2H), 4.12(q, J=7Hz, 2H), 6.4-6.5(m,
1H), 6.5-6.7(m, 1H), 6.73-6.78(m, 1H), 6.83(d, J=8Hz, 1H), 7.57(d,
J=3Hz, 1H), 7.69(d, J=3Hz, 1H) 593 938 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.21(t, J=7.1Hz, 3H), 2.35-2.45(m, 4H), 2.41(br.t,
J=5.1Hz, 2H), 2.78(br.t, J=5.1Hz, 2H), 3.29(s, 2H), 4.19(q,
J=7.1Hz, 2H), 6.71(d, J=7.5Hz, 1H), 6.76(s, 1H), 6.84(d, J=7.5Hz,
1H), 7.63(s, 2H), 9.44(s, 1H) 594 939 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.20(t, J=7.3Hz, 3H), 1.30-1.48(m, 3H), 1.56-1.64(m,
1H), 1.70-1.92(m, 3H), 2.74-2.84(m, 2H), 3.24(s, 2H), 4.16(q,
J=7.3Hz, 2H), 4.95(dd, J=4.7, 48.8Hz, 1H), 6.67(d, J=7.6Hz, 1H),
6.75(s, 1H), 6.82(d, J=7.6Hz, 1H), 7.62(s, 2H), 9.44(s, 1H)
EXAMPLES
[2504] The following compounds were obtained by the same method as
the one of Example 66 by using trifluoroacetic acid as a substitute
for hydrochloric acid.
91 Ex. Structural formula NMR 595 940 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.25(t, J=7Hz, 3H), 1.44(dd, J=8, 12Hz, 2H), 1.52(t,
J=3Hz, 2H), 1.64(t, J=3Hz, 2H), 2.00(dd, J=8, 12Hz, 2H), 2.22(br.s,
2H), 2.32(br.s, 2H), 2.39(d, J=8Hz, 2H), 2.59(sept, J=8Hz, 1H),
3.28(s, 2H), 4.10(q, J=7Hz, 2H), 6.51(br.s, 1H0, 6.56(d, J=2Hz,
1H), 6.74(dd, J=2, 8Hz, 1H0, 6.81(d, J=8Hz, 1H), 7.57(d, J=3Hz,
1H), 7.68(d, J=3Hz, 1H) 596 941 .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.27(t, J=7Hz, 3H), 1.65(t, J=5Hz, 4H), 2.32(br.s, 4H),
2.54(br.s, 2H), 2.84(d, J=2Hz, 2H), 3.31(s, 2H), 4.14(q, J=7Hz,
2H), 5.67(quint, J=2Hz, 1H), 6.42(br.s, 1H), 6.54(d, J=2Hz, 1H),
6.75(dd, J=2, 8Hz, 1H), 6.82(d, J=8Hz, 1H), 7.57(d, J=3Hz, 1H),
7.68(d, J=3Hz, 1H) 597 942 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.11(d, J=7Hz, 3H), 1.20(t, J=7Hz, 3H), 1.17-1.64(m, 8H),
2.25-2.42(m, 5H), 3.28(s, 2H), 3.38(d, J=11Hz, 1H0, 3.44(d, J=11Hz,
1H), 4.07(q, J=7Hz, 2H), 6.45(s, 1H), 6.50(br.s, 1H), 6.68(dd, J=2,
8Hz, 1H), 6.76(d, J=8Hz, 1H), 7.50(d, J=3Hz, 1H), 7.62(d, J=3Hz,
1H) 598 943 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.20(s, 3H),
1.25(t, J=7Hz, 3H), 1.62(m, 4H), 1.67(d, J=13Hz, 2H), 1.85(d,
J=13Hz, 2H), 2.31(br.s, 4H), 2.37(s, 2H), 3.30(s, 2H), 4.13(q,
J=7Hz, 2H), 6.42(br.s, 1H), 6.55(br.s, 1H), 6.74(dd, J=1, 8Hz, 1H),
6.82(d, J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H) 599 944
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.86(m, 2H), 2.01(m, 2H),
2.35(m, 2H), 2.44(dd, J=7, 11Hz, 1H), 2.52(m, 2H), 2.64(dd, J=9,
11Hz, 1H), 3.32(s, 2H), 3.79(s, 3H), 4.98(dd, J=7, 9Hz, 1H),
6.53(br.s, 1H), 6.58(br.s, 1H), 6.74(dd, J=2, 8Hz, 1H), 6.82(d,
J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H) 600 945
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27(t, J=7Hz, 3H), 1.61(m,
4H), 1.70(t, J=1Hz, 3H), 2.32(br.s, 4H), 2.47(s, 2H), 2.76(s, 2H),
3.31(s, 2H), 4.16(q, J=7Hz, 2H), 6.41(br.s, 1H), 6.54(d, J=2Hz,
1H), 6.76(dd, J=2, 8Hz, 1H), 6.83(d, J=8Hz, 1H), 7.57(d, J=3Hz,
1H), 7.69(d, J=3Hz, 1H) 601 946 .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.13(d, J=7Hz, 3H), 1.25(t, J=7Hz, 3H), 1.1-1.45(m, 7H),
1.57-1.70(m, 2H), 1.7-1.83(m, 1H), 1.83-1.95(m, 2H), 2.35-2.46(m,
1H), 2.83(br.d, J=12Hz, 2H), 3.31(s, 2H), 4.12(s, 1H), 6.6-6.74(m,
1H), 6.75(dd, J=1, 8Hz, 1H), 6.82(d, J=3Hz, 1H), 7.58(d, J=3Hz,
1H), 7.68(d, J=3Hz, 1H), 8.02(s, 1H)
EXAMPLES 602 TO 610
[2505] The following compounds were obtained by the same method as
the one of Example 66.
92 Ex. Structural formula NMR 602 947 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.20-1.48(m, 2H), 1.60-2.18(m, 6H), 2.78-2.88(m, 2H),
3.00-3.06(m, 1H), 3.28-3.34(m, 2H), 3.67(s, 2H), 3.72(s, 1H),
5.49-5.54(m, 1H), 6.50-6.56(m, 1H), 6.63-6.98(m, 4H), 7.57(d,
J=3Hz, 1H), 7.66-7.70(m, 1H) 603 948 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.21-1.28(m, 3H), 1.68-1.88(m, 6H), 2.11-2.24(m, 2H),
2.33-2.68(m, 5H), 3.46(s, 2H), 4.06-4.13(m, 2H), 6.57-6.61(m, 2H),
6.72-6.79(m, 1H), 6.79-6.84(m, 1H), 7.55-7.59(m, 1H), 7.67-7.69(m,
1H) 604 949 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24(t, J=7.2Hz,
3H), 1.37-1.53(m, 3H), 1.69-1.78(m, 2H), 1.93-2.10(m, 2H),
2.12-2.20(m, 1H), 2.29-2.61(m, 9H), 3.39(s, 2H), 4.11(q, J=7.2Hz,
2H), 6.56(d, J=1.2Hz, 1H), 6.65(s, 1H), 6.74(dd, J=1.2, 8.0Hz, 1H),
6.80(d, J=8.0Hz, 1H), 7.55-7.58(m, 1H), 7.66-7.69(m, 1H) 605 950
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.06-1.20(m, 2H), 1.22-1.30(m,
3H), 1.50-2.47(m, 10H), 2.56-2.72(m, 2H), 2.83-2.92(m, 1H),
3.51-3.63(m, 2H), 4.09-4.18(m, 2H), 6.58(s, 1H), 6.60(br.s, 1H),
6.77(dd, J=1.2, 8.0Hz, 1H), 6.82(d, J=8.0Hz, 1H), 7.57(d, J=3.2Hz,
1H), 7.67-7.70(m, 1H) 606 951 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.89(t, J=7.2Hz, 1H), 1.99(t, J=6.8Hz, 1H), 2.16-2.36(m, 4H),
2.54-2.68(m, 4H), 2.88-3.31(m, 1H), 3.48(s, 2H), 3.67(s, 3H),
6.45-6.51(m, 1H), 6.59(br.s, 1H), 6.73-6.80(m, 1H), 6.81-6.86(m,
1H), 7.56-7.59(m, 1H), 7.68-7.71(m, 1H) 607 952
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.52-0.58(m, 1H), 0.63(t,
J=4.8Hz, 1H), 0.92-1.00(m, 1H), 1.74-1.96(m, 2H), 2.02-2.12(m, 1H),
2.18-2.32(m, 3H), 2.55-2.73(m, 2H), 3.26(s, 2H), 3.68(s, 3H),
6.52(s, 1H), 6.62(s, 1H), 6.74(dd, J=2.8, 8.0Hz, 1H), 6.81(d,
J=8.0Hz, 1H), 7.57(d, J=2.8Hz, 1H), 7.69(d, J=2.8Hz, 1H) 608 953
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.05-1.20(m, 3H), 1.24(t,
J=7.2Hz, 3H), 1.26-2.13(m, 10H), 2.30-2.42(m, 2H), 2.45-2.70(m,
2H), 2.80-2.95(m, 1H), 3.70-4.00(m, 1H), 4.10(q, J=7.2Hz, 2H),
6.52-6.64(m, 2H), 6.72-6.77(m, 1H), 6.78-6.84(m, 1H), 7.56-7.60(m,
1H), 7.67-7.70(m, 1H) 609 954 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.10-1.24(m, 3H), 1.34-2.13(m, 10H), 2.56-2.72(m, 1H), 2.84-3.12(m,
2H), 3.67(s, 3H), 3.84-4.01(m, 1H), 6.50-6.64(m, 2H), 6.73-6.77(m,
1H), 6.79-6.84(m, 1H), 7.56-7.60(m, 1H), 7.67-7.70(m, 1H) 610 955
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.03-1.18(m, 2H), 1.21-1.36(m,
1H), 1.25(t, J=7.0Hz, 3H), 1.52-1.82(m, 5H), 1.82-2.07(m, 3H),
2.15-2.24(m, 1H), 2.35(t, J=7.5Hz, 1H), 2.40-2.60(m, 1H), 2.47(t,
J=7.5Hz, 1H), 2.80-2.90(m, 2H), 3.20(s, 2H), 4.12(q, J=7.0Hz, 2H),
6.51(br.s, 1H), 6.56(s, 1H), 6.75(d, J=8.4Hz, 1H), 6.82(d, J=8.4Hz,
1H), 7.57(d, J=2.4Hz, 1H), 7.68(d, J=2.4Hz, 1H)
EXAMPLES 611 AND 612
[2506] The following compounds were obtained by the same method as
the one of Example 8.
93 Ex. Structural formula NMR 611 956 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.14(d, J=7Hz, 3H), 1.25(t, J=7Hz, 3H), 1.3-1.7(m,
7H), 1.7-1.8(m, 2H), 2.2-2.4(m, 2H), 2.30-2.4(m, 1H), 3.08-3.2(m,
2H), 3.66-3.76(m, 2H), 3.75(s, 3H), 4.12(q, J=7Hz, 2H), 6.42(s,
1H), 6.76-6.86(m, 1H), 6.92-7.00(m, 1H), 7.57(d, J=3Hz, 1H),
7.65(d, J=3Hz, 1H) 612 957 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.14(d, J=7Hz, 3H), 1.26(t, J=7Hz, 2H), 1.0-1.45(m, 8H),
1.55-1.70(m, 2H), 1.65-1.80(m, 1H), 1.80-1.95(m, 2H), 2.35-2.45(m,
1H), 2.83(br.d, J=12Hz, 2H), 3.30(s, 2H), 4.13(q, J=7Hz, 2H),
6.58(s, 1H), 6.67(s, 1H), 6.71(dd, J=5, 8Hz, 1H), 6.77(d, J=8Hz,
1H), 6.87(d, J=8Hz, 1H), 7.18(dd, J=2, 8Hz, 1H), 7.84(dd, J=2, 5Hz,
1H)
EXAMPLE 613
Ethyl
3-[1-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)propyl]piperidin
-4-yl]-2-methylbutanoate
[2507] To a solution of 2.7 g of
3-[10-(methoxymethyl)-10H-pyrazino[2,3-b]- [1,4]benzothiazin
-8-yl]propyl methanesulfonate in methyl ethyl ketone (50 ml) was
added 1.6 g of sodium iodide and the resulting mixture was reacted
at 80.degree. C. for 2 hours. After adding ice-water, the reaction
mixture was extracted with ethyl acetate, washed with a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, a 0.5 g portion of the obtained brown oily substance was
dissolved in 20 ml of N,N-dimethylformamide. After adding 0.5 g of
ethyl 4-(piperidin-4-yl)-2-methylbutanoate and 0.44 g of anhydrous
potassium carbonate, the resulting mixture was reacted at
90.degree. C. for 3 hours. After adding water, the reaction mixture
was extracted with ethyl acetate, washed with a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with methanol/dichloromethane) to thereby give 0.1 g of the
title compound as a yellow oily substance. 958
[2508] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2509] 1.13(d, J=7 Hz, 3H), 1.25(t, J=7 Hz, 3H), 1.14-1.3(m, 6H),
1.36-1.46(m, 1H), 1.5-1.7(m, 2H), 1.72-1.84(m, 2H), 1.84-1.96(m,
2H), 2.28-2.42(m, 3H), 2.47(t, J=8 Hz, 2H), 2.86-2.96(m, 2H),
4.12(q, J=7 Hz, 2H), 6.35(s, 1H), 6.3-6.4(m, 1H), 6.63-6.68(m, 1H),
6.79(d, J=8 Hz, 1H), 7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz, 1H)
EXAMPLE 614
Ethyl
[1-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-propyl]piperidin-4-
-yl]carboxylate
[2510] To a solution of 0.6 g of
3-[10-(methoxymethyl)-10H-pyrazino[2,3-b]-
[1,4]benzothiazin-8-yl]propionaldehyde and 0.31 g of ethyl
isonipecotate in acetonitrile (50 ml) was added 0.2 g of sodium
borohydride cyanide. Further, acetic acid was added so as to
maintain the pH value at 4. Then the resulting mixture was reacted
at room temperature for 12 hours. After adding an aqueous solution
of sodium hydroxide, the reaction mixture was extracted with ethyl
acetate, washed with a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the crude
product thus obtained was dissolved in 30 ml of tetrahydrofuran.
After adding 1 ml of 6 N hydrochloric acid, the resulting mixture
was reacted for l hour. After adding an aqueous solution of sodium
bicarbonate, the reaction mixture was extracted with ethyl acetate,
washed with a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with methanol/dichloromethane) to
thereby give 0.39 g of the title compound as a brown oily
substance. 959
[2511] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2512] 1.25(t, J=7 Hz, 3H), 1.7-1.85(m, 4H), 1.88-2.0(m, 2H),
2.0-2.15(m, 2H), 2.25-2.4(m, 1H), 2.36(t, J=8 Hz, 2H), 2.49(t, J=8
Hz, 2H), 2.85-2.95(m, 2H), 4, 13(q, J=7 Hz, 2H), 6.34(d, J=2 Hz,
1H), 6.46-6.54(m, 1H), 6.56(dd, J=1, 8 Hz, 1H), 6.79(d, J=8 Hz,
1H), 7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz, 1H)
EXAMPLE 615
Ethyl
4-[1-[2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)ethyl]piperidin
-4-yl]-2-methylbutanoate
[2513] Starting with
2-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzoth-
iazin-8-yl]ethyl methanesulfonate and ethyl
4-(piperidin-4-yl)-2-methylbut- anoate, ethyl
4-[1-[2-10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothia- zin
-8-yl)-ethylpiperidin-4-yl]-2-methylbutanoate was obtained by the
same method as the one of Example 63. Next, this product was
treated by the same method as the one of Example 8 to thereby give
the title compound. 960
[2514] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2515] 1.14(t, J=7.0 Hz, 3H), 1.20-1.48(m, 9H), 1.61-1.77(m, 3H),
2.05-2.14(m; 2H), 2.39(m, 1H), 2.57-2.65(m, 2H), 2.69-2.76(m, 2H),
3.03-3.10(m, 2H), 4.13(q, J=7.0 Hz, 2H), 6.40(d, J=1.6 Hz, 1H),
6.66(dd, J=1.6, 8.1 Hz, 1H), 6.79(d, J=8.1 Hz, 1H), 6.80(br.s, 1H),
7.56(d, J=2.9 Hz, 1H), 7.68(d, J=2.9 Hz, 1H)
EXAMPLES 616 TO 619
[2516] The following compounds were obtained by the same method as
the one of Example 9.
94 Ex. Structural formula NMR 616 961 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.22(t, J=6Hz, 3H), 1.34-1.62(m, 2H), 1.64-1.76(m,
1H), 1.90-2.00(m, 1H), 1.98-2.06(m, 1H), 2.10-2.24(m, 1H),
2.50-2.60(m, 1H), 2.60-2.80(m, 1H), 2.86-2.96(m, 1H), 3.35(d,
J=12Hz, 1H), 3.38(d, J=12Hz, 1H), 4.10(q, J=6Hz, 2H), 4.05-4.15(m,
1H), 6.54(s, 1H), 6.76(d, J=8Hz, 1H), 6.93(d, J=8Hz, 1H), 7.55(s,
1H), 7.66(s, 1H) 617 962 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.09(t, J=6Hz, 3H), 1.30-1.40(m, 1H), 1.50-1.64(m, 2H),
1.60-1.80(m, 2H), 1.80-1.90(m, 2H), 2.08(t, J=6Hz, 2H),
2.70-2.82(m, 2H), 3.25(s, 2H), 4.08(q, J=6Hz, 2H), 5.73(d, J=16Hz,
1H), 6.46(s, 1H), 6.50(s, 1H), 6.68(d, J=8Hz, 1H), 7.76(d, J=8Hz,
1H), 6.83(dt, J=6, 16Hz, 1H), 7.49(s, 1H), 7.60(s, 1H) 618 963
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.37(m, 2H), 2.59(t, J=6Hz,
2H), 3.24(br.s, 2H), 3.54(s, 2H), 3.73(s, 3H), 6.58(d, J=2Hz, 1H),
6.72(br.s, 1H), 6.78(dd, J=2, 8Hz, 1H), 6.84(d, J=8Hz, 1H), 7.20(m,
1H), 7.56(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H) 619 964
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.13(d, J=7Hz, 3H), 1.24(t,
J=7Hz, 3H), 1.1-1.3(m, 6H), 1.35-1.45(m, 1H), 1.6-1.7(m, 2H),
1.85-2.00(m, 2H), 2.3-2.43(m, 1H), 2.86(br.d, J=11Hz, 2H), 3.32(s,
2H), 4.12(q, J=7Hz, 2H), 6.57(br.s, 1H), 6.65(dd, J=2, 8Hz, 1H),
6.73(d, J=8Hz, 1H), 6.9-7.06(m, 1H), 7.36(d, J=3Hz, 1H), 7.45(d,
J=3Hz, 1H)
EXAMPLE 620
Ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]p-
ropiolate
[2517] 200 ml of a solution of 19.7 g of triphenylphosphine and
12.4 g of carbon tetrabromide in dichloromethane was stirred under
ice-cooling and 20 ml of a solution of 4.0 g of
1-(tert-butoxycarbonyl)piperidine-4-carba- ldehyde in
dichloromethane was dropped thereinto. After stirring for 1 hour,
the reaction mixture was diluted with diethyl ether and filtered
through celite to thereby remove the insoluble residue. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 5.7 g of
4-(2,2-dibromovinyl)-1-(tert-butoxycarbonyl)piperid- ine as a
colorless oily component.. Next, 2.72 g of this product was
dissolved in 50 ml of dry tetrahydrofuran in a nitrogen atmosphere
and cooled to -78.degree. C. A 1.0 M solution of n-buthyllithium
(15 ml; 15 mmol) in hexane was dropped thereinto and the resulting
mixture was stirred for 1 hour and then at room temperature for
additional 1 hour. After cooling to -78.degree. C. again, ethyl
chloroformate was dropped into the reaction mixture. Then the
reaction mixture was brought back to room temperature and
distributed into water and ethyl acetate. The organic layer was
extracted, washed with water and dried over magnesium sulfate.
After distilling off the solvent under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with ethyl acetate/n-hexane) to thereby give 2.2 g of ethyl
(1-(tert-butoxycarbonyl)piperidin-4-yl)propionate as a colorless
oily component. A 1.1 g portion of this product was dissolved in a
mixture of anisole (5 ml) with dichloromethane (5 ml). To this
solution was added trifluoroacetic acid until the material
disappeared. The reaction mixture was distributed into an aqueous
solution of potassium carbonate and ethyl acetate. The organic
layer was extracted and dried over potassium carbonate. After
distilling off the solvent under reduced pressure, the residue was
dissolved in 20 ml of N,N-dimethylformamide. After adding 350 mg of
potassium carbonate and 630 mg of
8-chloromethyl-10H-pyrazino[2.3-b- ][1,4]benzothiazine, the
resulting mixture was heated to 80.degree. C. for 1 hour. Then the
reaction mixture was brought back to room temperature and
distributed into water and ethyl acetate. The organic layer was
extracted, washed with water and dried over sodium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 550 mg of yellow crystals
of ethyl [1-(10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)piperidin-4-yl- ]propiolate. 965
[2518] 1H-NMR(DMSO-d6):
[2519] 1.19(t, J=6.9 Hz, 3H), 1.48-1.60(m, 2H), 1.75-1.84(m, 2H),
2.03-2.13(m;. 2H), 2.51-2.68(m, 3H), 3.24(s, 2H), 4.12(q, J=6.9 Hz,
2H), 6.68(d, J=8.0 Hz, 1H), 6.74(d, J=1.8 Hz, 1H), 6.83(dd, J=1.8,
8.0 Hz, 1H), 7.62(s, 2H), 9.44(s, 1H)
EXAMPLE 621
Ethyl
[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicyclo[3.-
1.0]hex-6-yl]carboxylate
[2520] To a solution of 1.523 g of ethyl
(3-azabicyclo[3.1.0]hex-6-yl)carb- oxylate in N,N-dimethylformamide
(30 ml) were added 2.30 g of sodium hydrogencarbonate and 1.39 g of
8-chloromethyl-10H-pyrazino(2,3-b][1,4]be- nzothiazine and the
resulting mixture was heated to 80.degree. C. for 2 hours. After
adding water and ethyl acetate, the organic layer was washed with
water, dried over magnesium sulfate and concentrated under reduced
pressure. Then the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.574 g of the title compound as pale yellow crystals. 966
[2521] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2522] 1.27(t, J=7 Hz, 3H), 1.95(m, 2H), 2.07(t, J=3 Hz, 1H),
2.38(d, J=10 Hz, 2H), 3.03(d, J=10 Hz, 2H), 3.44(s, 2H), 4.14(q,
J=7 Hz, 2H), 6.41(br.s, 1H), 6.45(d, J=1 Hz, 1H), 6.71(dd, J=1, 8
Hz, 1H), 6.81(d, J=8 Hz, 1H), 7.57(d, J=3 Hz, 1H), 7.69(d, J=3 Hz,
1H)
EXAMPLE 622
N-(10-methoxymethyl-10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
chloro-acetamide
[2523] 1.25 g of
8-aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]be-
nzothiazine and 0.7 ml of triethylamine were dissolved in
N,N-dimethylformamide (15 ml). Under ice-cooling, 2 ml of a
solution of 0.4 ml of chloroacetyl chloride in dichloromethane was
dropped thereinto and the resulting mixture was stirred for 1 hour.
After adding water, the reaction mixture was extracted with ethyl
acetate. The ethyl acetate layer was washed with water and a
saturated aqueous solution of sodium chloride and dried over
anhydrous sodium sulfate. After concentrating under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate). The crystals
thus obtained were washed with n-hexane and thus 1.28 g of the
title compound was obtained as a yellow powder. 967
[2524] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2525] 3.54(s, 3H), 4.11(s, 2H), 4.43(d, J=5.9 Hz, 2H), 5.27(s,
2H), 6.89(br.s, 1H), 6.91(dd, J=1.6, 7.9 Hz, 1H), 7.00(d, J=7.9 Hz,
1H), 7.08(d, J=1.6 Hz, 1H), 7.84(d, J=2.7 Hz, 1H), 7.85(d, J=2.7
Hz, 1H)
EXAMPLE 623
Ethyl
[1-[[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-carbamoyl]met-
hyl]piperidin-4-yl]carboxylate
[2526] 0.6 g of
N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)chloroa-
cetamide was dissolved in 9 ml of N,N-dimethylformamide. After
adding 0.26 g of anhydrous sodium carbonate and 0.3 g of
isonipecotic acid, the resulting mixture was stirred at room
temperature for 13 hours. After adding water, the reaction mixture
was extracted with ethyl acetate. The ethyl acetate layer was
washed with water and a saturated aqueous solution of sodium
chloride, dried over anhydrous sodium sulfate and concentrated
under reduced pressure to thereby give a yellow oily substance.
[2527] This oily substance was dissolved in 10 ml of ethanol. After
adding 5 ml of 6 N hydrochloric acid, the resulting mixture was
stirred for 30 minutes. After adding an aqueous solution of sodium
carbonate, the reaction mixture was extracted with ethyl acetate.
The ethyl acetate layer was washed with water and a saturated
aqueous solution of sodium chloride, dried over anhydrous sodium
sulfate and concentrated under reduced pressure. The obtained
residue was purified by silica gel column chromatography (eluted
with dichloromethane/methanol). The crystals thus obtained were
washed with ether and thus 0.64 g of the title compound was
obtained as a yellow powder. 968
[2528] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2529] 1.25(t, J=7.1 Hz, 3H), 1.65-1.78(m, 2H), 1.87-1.95(m, 2H),
2.18-2.33(m, 3H), 2.78-2.85(m, 2H), 3.04(s, 2H), 4.14(q, J=7.1 Hz,
2H), 4.30(d, J=6.2 Hz, 2H), 6.45(d, J=1.6 Hz, 1H), 6.61(br.s, 1H),
6.72(dd, J=1.6, 8.1 Hz, 1H), 6.84(d, J=8.1 Hz, 1H), 7.51(m, 1H),
7.57(d, J=2.7 Hz, 1H), 7.69(d, J=2.7 Hz, 1H)
EXAMPLE 624
Ethyl
[1-[3-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetylamino]propyl-
]piperidin-4-yl]carboxylate
[2530] To 10 ml of N,N-dimethylformamide were added 0.6 g of
10H-pyrazino[2,3-b][1,4]benzothiazine-8-acetic acid, 0.8 g of ethyl
1-(3-aminopropyl)piperidine-4-carboxylate dihydrochloride, 0.38 g
of 1-hydroxybenzotriazole, 1.07 ml of triethylamine and 0.53 g of
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and the resulting
mixture was stirred at room temperature for 22 hours. After adding
water, the reaction mixture was extracted with ethyl acetate. The
ethyl acetate layer was washed with water and a saturated aqueous
solution of sodium chloride, dried over anhydrous sodium sulfate
and concentrated under reduced pressure. The obtained residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol). The crystals thus obtained were washed
with ether and thus 0.72 g of the title compound was obtained as a
pale brown powder. 969
[2531] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2532] 1.28(t, J=7.1 Hz, 3H), 1.60-1.77(m, 4H), 1.86-2.05(m, 4H),
2.34(m, 1H), 2.40-2.46(m, 2H), 2.87-2.96(m, 2H), 3.30-3.46(m, 2H),
3.34(s, 2H), 4.19(q, J=7.1 Hz, 2H), 6.58(d, J=1.6 Hz, 1H), 6.76(dd,
J=1.6, 7.9 Hz, 1H), 6.82(d, J=7.9 Hz, 1H), 7.13(br.s, 1H), 7.37(m,
1H), 7.55(d, J=2.9 Hz, 1H), 7.66(d, J=2.9 Hz, 1H)
EXAMPLE 625
[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]methyl
ketone
[2533] Into a solution of 16 g of
10-(methoxymethyl)-10H-pyrazino[2,3-b][1- ,4]benzothiazine
-8-carboxaldehyde in 200 ml of tetrahydrofuran was dropped at
-78.degree. C. 60 ml of a 1.4 M solution of methyllithium in
diethyl ether. Next, the resulting mixture was heated to room
temperature over 2 hours. The reaction mixture was poured into
ice-water and extracted with ethyl acetate. The organic layer was
washed with a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, 16 g of a yellow oily substance was
obtained. To a solution of 16 g of this oily substance in
dichloromethane (300 ml) was added 100 g of manganese dioxide and
the resulting mixture was stirred at room temperature for 17 hours.
After the completion of the reaction, the manganese dioxide was
filtered off. The filtrate was concentrated and the residue thus
obtained was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 9.4 of the title
compound as yellow crystals. 970
[2534] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2535] 2.55(s, 3H), 3.55(s, 3H), 5.31(s, 2H), 7.18(d, J=8 Hz, 1H),
7.53(d, J=8 Hz, 1H), 7.69(s, 1H), 7.85(s, 2H)
EXAMPLE 626
[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]bromomethyl
ketone
[2536] To a solution of 1.5 g of
[10-(methoxymethyl)-10H-pyrazino[2,3-b][1-
,4]benzothiazin-8-yl]methyl ketone in a mixture of methanol (50 ml)
with dichloromethane (100 ml) was added 3.0 of
tetra-n-butylammonium tribromide and the resulting mixture was
stirred at room temperature for 4 hours. After distilling off the
solvent, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.9 g of the title compound as a yellow oil substance. 971
[2537] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2538] 3.56(s, 3H), 4.38(s, 2H), 5.30(s, 2H), 7.10(d, J=8 Hz, 1H),
7.54(dd, J=2, 8 Hz, 1H), 7.72(d, J=2 Hz, 1H), 7.87(s, 2H)
EXAMPLE 627
Ethyl
4-[1-[2-oxo-2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]ethyl]piper-
idin-4-yl]-2-methylbutanoate
[2539] To a solution of 2.6 of
[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4-
]benzothiazin-8-yl]bromomethyl ketone and 3.0 g of ethyl
4-(piperidin-4-yl)-2-methylbutanoate in N,N-dimethylformamide (50
ml) was added 2.9 g of anhydrous potassium carbonate and the
resulting mixture was reacted at room temperature for 1.5 hours.
After the completion of the reaction, ethyl acetate was added
thereto. The reaction mixture was washed with water and a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After concentrating the solvent, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 2.7 g of ethyl
4-1-[2-oxo-2-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,41]benzothiazin-8--
yl]ethyl]piperidin-4-yl]-2-methylbutanoate as a brown oily
substance.
[2540] To a solution of 1.7 g of this oily substance in
tetrahydrofuran (50 ml) was added 4 ml of 6 N hydrochloric acid and
the resulting mixture was reacted for 1 hour. After adding ethyl
acetate, the reaction mixture was washed with water and a saturated
aqueous solution of sodium chloride and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
1.0 g of the title compound as a brown oily substance. 972
[2541] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2542] 1.14(d, J=7 Hz, 3H), 1.24(t, J=7 Hz, 3H), 1.0-1.4(m, 4H),
1.3-1.5(m, 1H), 1.5-1.8(m, 4H), 2.0-2.1(m, 2H), 2.3-2.43(m, 1H),
2.91(br.d, J=10 Hz, 2H), 3.63(s, 2H), 4.11(q, J=7 Hz, 2H),
6.52-6.60(m, 1H), 6.93(d, J=8 Hz, 1H), 7.15(d, J=2 Hz, 1H),
7.46(dd, J=2, 8 Hz, 1H), 7.60(d, J=3 Hz, 1H), 7.70(d, J=3 Hz,
1H)
EXAMPLE 628
Ethyl
4-[1-[2-hydroxy-2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]ethyl]p-
iperidin-4-yl]-2-methylbutanoate
[2543] To a solution of 0.8 g of ethyl
4-[1-[2-oxo-2-(10H-pyrazino[2,3-b][-
1,4]benzothiazin-8-yl]ethyl]piperidin-4-yl]-2-methylbutanoate in
ethanol (30 ml) was added 70 mg of sodium borohydride and the
resulting mixture was reacted at room temperature for 30 minutes.
After adding ethyl acetate, the reaction mixture was washed with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous magnesium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.53 g of the title compound as a yellow oily
substance. 973
[2544] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2545] 1.14(d, J=7 Hz, 3H), 1.25(t, J=7 Hz, 3H), 1.0-1.5(m, 6H),
1.5-1.8(m, 3H), 2.05-2.2(m, 1H), 2.3-2.6(m, 3H), 2.4-2.6(m, 2H),
2.9-3.0(m, 1H), 3.15-3.25(m, 1H), 4.13(q, J=7 Hz, 2H), 4.65-4.75(m,
1H), 6.63(s, 1H), 6.4-6.8(m, 1H), 6.7-6.8(m, 1H), 6.83(dd, J=2, 8
Hz, 1H), 7.55(d, J=3 Hz, 1H), 7.66-7.7(m, 1H)
EXAMPLE 629
Ethyl
[2-butyl-7-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-7-azasp-
iro[3.5]non-2-yl]acetate
[2546] Ethyl
[7-(tert-butoxycarbonyl)-7-azaspiro[3.5]non-2-ylidene]acetate was
treated successively by the same methods as those of Examples 66
and 9 to thereby give the title compound. 974
[2547] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2548] 0.75(t, J=7 Hz, 3H), 1.07(m, 2H), 1.1o(t, J=7 Hz, 3H),
1.35(m, 2H), 1.47(m, 6H), 1.54(d, J=13 Hz, 2H)1.65(d, J=13 Hz, 2H),
2.16(br.s, 4H), 2.25(s, 2H), 3.15(s, 2H), 3.95(q, J=7 Hz, 2H),
6.33(br.s, 1H), 6.41(br.s, 1H), 6.59(dd, J=1, 8 Hz, 1H), 6.65(d,
J=8 Hz, 1H), 7.42(d, J=3 Hz, 1H), 7.53(d, J=3 Hz, 1H)
EXAMPLE 630
Ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]b-
utan-1-yl]iminoxyacetate
[2549] 2.47 g of
ethyl[(1-(tert-butoxycarbonyl)piperidin-4-yl]butan-1-yl]i-
minoxyacetate was dissolved in 20 ml of dichloromethane and
ice-cooled. After adding 1.1 ml of iodotrimethylsilane, the
resulting mixture was stirred and then heated to room temperature
over 16 hours and 30 minutes. After adding 1.0 ml of
iodotrimethylsilane, stirring was continued for additional 1 hour.
The reaction mixture was concentrated under reduced pressure and
thus a pale brown oily substance was obtained.
[2550] The obtained product was dissolved in 20 ml of
N,N-dimethylformamide. After adding 1.7 g of
8-chloromethyl-10H-pyrazino[- 2,3-b][1,4]benzothiazine and 9.7 g of
anhydrous potassium carbonate, the resulting mixture was stirred at
80.degree. C. for 2 hours. After adding ethyl acetate, the reaction
mixture was washed with water and a saturated aqueous solution of
sodium chloride and dried over anhydrous magnesium sulfate. After
concentrating the solvent, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 2.8 g of the title compound as a yellow oily
substance. 975
[2551] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2552] 0.95(t, J=7.6 Hz, 3H), 1.27(t, J=7.2 Hz, 3H), 1.50-1.75(m,
8H), 2.06-2.20(m, 1H), 2.22-2.32(m, 2H), 2.86-2.93(m, 2H), 3.23(s,
2H), 4.20(q, J=7.2 Hz, 2H), 4.55(s, 2H), 6.48(br.s, 1H), 6.55(br.d,
J=1.6 Hz, 1H), 6.76(dd, J=1.6, 7.6 Hz, 1H), 6.83(d, J=7.6 Hz, 1H),
7.58(d, J=2.4 Hz, 1H), 7.69(d, J=2.4 Hz, 1H)
EXAMPLES 631 TO 734
[2553] The following compounds were obtained by the same method as
the one of Example 18.
95 Ex. Structural formula MS M.p. NMR 631 976[1-[2-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)amino-2- oxoethyl]piperidin-4-
yl]carboxylic acid FAB(+) 400(MH.sup.+) 226-230.degree. C.
(decompose) .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.58-1.72(m,
2H), 1.74-1.83(m, 2H), 2.07-2.23(m, 3H), 2.27-2.80(m, 2H), 2.94 (s,
2H), 4.11(d, J=6.0Hz, 2H), 6.66(d, J=1.3Hz, 1H), 6.68(dd, J=1.3,
7.9Hz, 1H), 6.85(d, J=7.9Hz, 1H), 7.63(d, J=2.7Hz, 1H), 7.65(d,
J=2.7Hz, 1H), 8.25(t, J=6.0Hz, 1H), 9.55(s, 1H) 632
9773-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin -8-
ylmethyl)piperidin-4- yl] cyclobutaneacetic acid FAB(+)
411(MH.sup.+) 215-220.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 0.90-1.34(m, 3H), 1.48-1.90(m, 8H), 2.02-2.14(m, 1H),
2.22-2.60(m, 3H), 2.70-2.82(m, 2H), 3.26(s, 2H), 6.67(d, J=8Hz,
1H), 6.74(s, 1H), 6.81(d, J=8Hz, 1H), 7.61(d, J=2.8Hz, 1H), 7.62(d,
J=2.8Hz, 1H), 9.34(s, 1H) 633 978[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin-
4-yl]butan-1-yl]iminoxyacetic acid FAB(+) 442(MH.sup.+)
193-195.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 0.86(t)
J=6.4Hz, 3H), 1.38-1.52(m, 4H), 1.60-1.70(m, 2H), 1.82-1.92(m, 2H),
1.95-2.10(m, 1H), 2.10-2.20(m, 2H), 2.75-2.82(m, 2H), 3.24(s, 2H),
4.00(s, 2H), 6.68(d, J=8.0Hz, 1H), 6.78(s, 1H), 6.81(d, J=8.0Hz,
1H), 7.61(d, J=2.8Hz, 1H), 7.62(d, J=2.8Hz, 1H), 9.47(s, 1H) 634
979(E)-3-[1-(10H- pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl)
piperidin-4-yl]-2- butenoic acid FAB(+) 383(MH.sup.+)
207-209.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.50-2.04(m, 7H), 2.05(s, 3H), 2.75-2.90(m, 2H), 3.18(s, 2H),
5.57(s, 1H), 6.70(d, J=8.0Hz, 1H), 6.75(s, 1H), 6.83(d, J=8.0Hz,
1H), 7.61(d, J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H), 9.45(s, 1H) 635
980[1-3-[(10H-pyrazino [2,3-b][1,4]benzothiazin-8-yl)
acetylaminopropyl]piperidin-4-yl]carboxylic acid FAB(+)
428(MH.sup.+) 143.degree. C. (decompose) .sup.1H-NMR(DMSO-d.sub.6)
# .delta. ppm: 1.45-1.58(m, 4H), 1.72-1.80(m, 2H), 1.86-1.95(m,
2H), 2.16(m, 1H), 2.20-2.27(m, 2H), 2.72-2.80(m, 2H), 3.00-3.07(m,
2H), 3.21(s, 2H), 6.65-6.70(m, 2H), 6.83(d, J=8.2Hz, 1H), 7.64(d,
J=2.7Hz, 1H), 7.65(d, J=2.7Hz, 1H), 8.00(t, J=5.0Hz, 1H), 9.52(s,
1H) 636 9813-[4-[(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]piperidin-1-yl]-3- oxopropanoic acid FAB(+)
400(MH.sup.+) 167-170.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 1.04-1.15(m, 1H), 1.18-1.30(m, 1H), 1.70-1.81(m, 2H),
2.50-2.62(m, 1H), 2.68(t, J=11.2Hz, 2H), 2.97(t, J=11.2Hz, 1H),
3.23(s, 2H), 3.55(s, 2H), 3.70(d, J=12Hz, 1H), 4.10(d, J=12Hz, 1H),
6.75(d, J=8.0Hz, 1H), 6.80(s, 1H), 6.81(d, J=8.0Hz, 1H),
7.60-7.66(m, 2H), 9.45(s, 1H) 637 982[4-[(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)amino]piperidin-1-yl]-2-
oxoacetic acid FAB(+) 371(MH.sup.+) 200-204.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.38-1.50(m, 3H),
1.65-1.78(m, 2H), 1.92-2.06(m, 2H), 2.70-2.80(m, 2H), 3.17(s, 2H),
6.69(d, J=8.0Hz, 1H), 6.76(s, 1H), 6.82(d, J=8.0Hz, 1H), 7.61(d,
J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H), 9.46(s, 1H) 638
9834-[4-[(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]piperidin-1-yl]butanoic acid FAB(+) 400(MH.sup.+)
121-124.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.20-1.35(m, 2H), 1.56-1.66(m, 2H), 1.72-1.82(m, 2H), 2.02-2.10(m,
2H), 2.23(t, J=6.8Hz, 2H), 2.37(t, J=6.8Hz, 2H), 2.42-2.50(m, 1H),
2.82-2.90(m, 2H), 3.15(s, 2H), 6.74(d, J=8.0Hz, 1H), 6.76(s, 1H),
6.81(d, J=8.0Hz, 1H), 7.61(d, J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H),
9.45(s, 1H) 639 9843-[4-[(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]piperidin-1-yl]propanoic acid FAB(+) 386(MH.sup.+)
130-134.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.20-1.34(m, 2H), 1.76-1.87(m, 2H), 2.04-2.14(m, 2H), 2.32(t,
J=6.8Hz, 2H), 2.40-2.50(m, 1H), 2.59(t, J=6.8Hz, 2H), 2.83-2.92(m,
2H), 3.15(s, 2H), 6.76(d, J=8.0Hz, 1H), 6.77(s, 1H), 6.83(d,
J=8.0Hz, 1H), 7.61(d, J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H), 9.48(s,
1H) 640 9852-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]propanoic acid ESI(+) 371(MH.sup.+)
240-243.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 0.99(d,
J=5Hz, 3H), 1.1-1.3(m, 2H), 1.3-1.6(m, 3H), 1.81(br .multidot. t,
J=10Hz, 2H), 2.1-2.2(m, 1H), 2.7-2.8(m, 2H), 3.23(s, 2H),
6.65-6.70(m, 1H), 6.74(s, 1H), 6.81(d, J=8Hz, 1H), 7.62(d, J=3Hz,
1H), 7.63(d, J=3Hz, 1H), 9.43(s, 1H) 641 9864-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin- 4-ylidene]-4-
cyanobutanoic acid ESI(+) 408(MH.sup.+) 114-116.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 2.34-2.60(m, 12H), 3.33(s,
2H), 6.71(dd, J=2, 8Hz, 1H), 6.76(d, J=2Hz, 1H), 6.84(d, J=8Hz,
1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.45(s, 1H) 650
987(E)-[1-(10H- pyrazino[2,3-b][1,4]benzothiazin-- 8-
ylmethyl)piperidin- 3-ylidene]acetic acid ESI(+) 355(MH.sup.+)
200-203.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.50-1.60(m, 2H), 2.42(br .multidot. t, J=5Hz, 2H), 2.72(br
.multidot. t, J=6Hz, 2H), 2.89(s, 2H), 3.30(s, 2H), 5.56(s, 1H),
6.68(d, J=8Hz, 1H), 6.74(s, 1H), 6, 83(d, J=8Hz, 1H), 7.61(d,
J=2Hz, 1H), 7.62(d, J=2Hz, 1H), 9.44(s, 1H), 12.2(br .multidot. s,
1H) 651 988(Z)-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 3-ylidene]acetic acid ESI(+) 355(MH.sup.+)
216-220.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.56-1.66(m, 2H), 2.19(t, J=6Hz, 2H), 2.36-2.44(m, 2H), 3.32(s,
2H), 3.51(s, 2H), 5.60(s, 1H), 6.68(dd, J=2, 8Hz, 1H), 6.74(d,
J=2Hz, 1H), 6.82(d, J=8Hz, 1H), 7.61(d, J=3Hz, 1H), 7.62(d, J=3Hz,
1H), 9.42(s, 1H) 652 989[1-(10H-pyrazino 2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 3-yl]acetic acid ESI(+) 357(MH.sup.+) amorphous
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 0.84-0.98(m, 1H),
1.36-1.48(m, 1H), 1.50-1.60(m, 1H), 1.60-1.70(m, 2H), 1.80-1.92(m,
2H), 2.06-2.12(m, 2H), 2.56-2.70(m, 2H), 3.23(s, 2H), 6.68(dd, J=1,
8Hz, 1H), 6.74(d, J=1Hz, 1H), 6.82(d, J=8Hz, 1H), 7.62(d, J=3Hz,
1H), 7.63(d, J=3Hz, 1H), 9.45(s, 1H) 653 9904-[1-(10H-pyrido
[3,2-b][1,4]benzothiazin-8- ylmethyl)piperidin- 4-yl]-2-
methylbutanoic acid ESI(+) 398(MH.sup.+) 113-115.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.01(d, J=7Hz, 3H),
0.94-1.22(m, 5H), 1.20-1.40(m, 1H), 1.46-1.62(m, 3H), 1.78-1.88(m,
2H), 2.24(q, J=7Hz, 1H), 2.72(br .multidot. d, J=12Hz, 2H), 3.23(s,
2H), 6.6-6.74(m, 2H), 6.72(s, 1H), 6.82(d, J=8Hz, 1H), 7.2-7.28(m,
1H), 7.78(dd, J=1, 4Hz, 1H), 9.12(s, 1H) 654 9914-[1-(10H-pyrazino
[2,3-b][1,4]benzoxazin-8- ylmethyl)piperidin- 4-yl]-2-
methylbutanoic acid ESI(+) 383(MH.sup.+) 238-240.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.01(d, J=7Hz, 3H), #
0.96-1.24(m, 5H), 1.24-1.38(m, 1H), 1.44-1.60(m, 1H), 1.57(br
.multidot. d, J=11Hz, 2H), 1.82(t, J=12Hz, 2H), 2.16-2.30(m, 1H),
2.72(br .multidot. d, J=11Hz, 2H), 3.20(s, 2H), 6.56(dd, J=2, 8Hz,
1H), 6.58(d, J=2Hz, 1H), 6.67(J=8Hz, 1H), 7.23(d, J=3Hz, 1H),
7.44(d, J=3Hz, 1H), 9.55(br .multidot. s, 1H) 655
9924-[1-(10H-pyrimido [5,4-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]-2- methylbutanoic acid FAB(+)
399(MH.sup.+) 219-220.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.01(d, # J=7.1Hz, 3H), 1.01-1.19(m, 5H), 1.25-1.36(m, 1H),
1.45-1.60(m, 3H), 1.77-1.86(m, 2H), 2.18-2.28(m, 1H), 2.67-2.75(m,
2H), 3.14(s, 2H), 6.73(dd, J=1.5, 7.9Hz, 1H), 6.79(d, J=7.9Hz, 1H),
6.85(d, J=1.5Hz, 1H), 7.95(s, 1H), 8.22(s, 1H), 9.76(s, 1H) 656
9934-[1-[2-hydroxy-2- (10H-pyrazino[2,3- b][1,4]benzothiazin-
8-yl)ethyl)]piperidin-4-yl]-2- methylbutanoic acid FAB(+)
429(MH.sup.+) 239-242.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 0.9-1.3(m, # 5H), 1.01(d, J=7Hz, 3H), 1.2-1.4(m, 1H),
1.4-1.75(m, 3H), 1.8-2.1(m, 2H), 2.1-2.4(m, 3H), 2.8-2.95(m, 2H),
4.2-4.35(m, 1H), 6.72(d, J=8Hz, 1H), 6.78(d, J=2Hz, 1H), 6.81(d,
J=8Hz, 1H), 7.60(d, J=3Hz, 1H), 7.62(d, J=3Hz, 1H), 9.44(s, 1H) 657
9944-[1-[3-(10H- pyrazino[2,3-b][1,4]benzothiazin-8-
yl)propyl]piperidin-4-yl]-2- methylbutanoic acid ESI(+)
427(MH.sup.+) 235-238.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.01(d, # J=7Hz, 3H), 1.0-1.2(m, 5H), 1.26-1.36(m, 1H),
1.46-1.60(m, 1H), 1.50-1.68(m, 4H), 1.74-1.90(m, 2H), 2.16-2.30(m,
3H), 2.37(t, J=9Hz, 2H), 2.76-2.86(m, 2H), 6.60(s, 1H), 6.61(d,
J=8Hz, 1H), 6.78(d, J=8Hz, 1H), 7.61(d, J=2Hz, 1H), 7.62(d, J=2Hz,
1H), 9.40(s, 1H) 658 995[1-(10H-pyrazino [2,3-b][1,4]benzoxazin-8-
ylmethyl)piperidin- 4-yl]carboxylic acid ESI(+) 327(MH.sup.+)
242-244.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.42-1.58(m, # 2H), 1.70-1.80(m, 2H), 1.84-2.0(m, 2H), 2.10-2.25(m,
1H), 2.64-2.76(m, 2H), 3.24(s, 2H), 6.57(dd, J=1, 8Hz, 1H), 6.60(s,
1H), 6.68(d, J=8Hz, 1H), 7.24(d, J=3Hz, 1H), 7.44(d, J=3Hz, 1H),
9.57(s, 1H) 659 9964-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]phenylacetic acid ESI(+) 432(MH.sup.+)
266-269.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.84-2.08(m, 4H), 2.68-2.80(m, 1H), 2.90-3.08(m, 2H), 3.28-3.42(m,
2H), 3.51(s, 2H), 4.06-4.16(m, 2H), 6.82(s, 1H), 7.00(d, J=8Hz,
1H), 7.0-7.1(m, 1H), 7.14(d, J=8Hz, 2H), 7.19(d, J=8Hz, 2H),
7.65(d, J=3Hz, 1H), 7.66(d, J=3Hz, 1H), 9.73(s, 1H) 660
9975-[1-(10H-pyrazino 2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]-2- methylpentanoic acid ESI(+)
413(MH.sup.+) Amorphous .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.01(d, J=7Hz, 3H), 0.98-1.38(m, 8H), 1.42-1.54(m, 1H), 1.58(br
.multidot. d, J=12Hz, 2H), 1.82-1.94(m, 2H), 2.22-2.34(m, 1H),
2.74(br .multidot. d, J=18Hz, 2H), 3.25(s, 2H), 6.68(d, J=8Hz, 1H),
6.74(s, 1H), 6.82(d, J=8Hz, 1H), 7.58-7.66(m, 2H), 9.44(s, 1H) 661
9985-[1-(10H-pyrido [3,2-b][1,4]benzothiazin-8- ylmethyl)piperidin-
4-yl]-2- methylpentanoic acid ESI(+) 412(MH.sup.+) oily substance
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 0.95-1.36(m, 8H), 1.01(d,
J=7Hz, 3H), 1.40-1.62(m, 3H), 1.80-1.90(m, 2H), 2.20-2.32(m, 1H),
2.70-2.80(m, 2H), 3.26(s, 2H), 6.66-6.72(m, 2H), 6.79(s, 1H),
6.83(d, J=8Hz, 1H), 7.25(d, J=7Hz, 1H), 7.78(d, J=5Hz, 1H), 9.13(s,
1H) 662 9994-[1-(10H-pyrazino 2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]benzoic acid ESI(+) 419(MH.sup.+)
265-268.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.9-2.1(m, # 4H), 2.85(br .multidot. s, 1H), 3.00(br .multidot. s,
2H), 3.39(br .multidot.s, 2H), 4.10(br .multidot. s, 2H), 6.82(br
.multidot. s, 1H), 6.97-7.06(m, 1H), 6.97-7.12(m, 1H), 7.33(d,
J=8Hz, 2H), 7.65(d, J=2Hz, 1H), 7.66(d, J=2Hz, 1H), 7.89(d, J=8Hz,
2H), 9.73(br .multidot. s, 1H), 12.9(br .multidot. s, 1H) 663
10004-[1-(10H-pyrazino [2-3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]phenoxyacetic acid ESI(+) 449(MH.sup.+)
258-262.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.50-1.75(m, # 4H), 1.95-2.10(m, 2H), 2.35-2.55(m, 2H), 2.87(br
.multidot. d, J=11Hz, 1H), 3.32(s, 2H), 4.53(s, 2H), 6.72(d, J=8Hz,
1H), 6.78(d, J=8Hz, 2H), 6.79(s, 1H), 6.84(d, J=8Hz, 1H), 7.11(d,
J=8Hz, 2H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.46(s, 1H) 664
10014-[1-(10H-methoxy pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl) piperidin-4-yl]-2- methylbutanoic acid ESI(+)
429(MH.sup.+) 155-160.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.02(d, J=7Hz, # 3H), 1.10-1.25(m, 5H), 1.45-1.65(m, 4H),
1.88-2.00(m, 2H), 2.20-2.32(m, 1H), 2.78(br .multidot. d, J=12Hz,
2H), 3.30(s, 2H), 3.65(s, 3H), 6.57(s, 1H), 6.83(s, 1H), 7.57(d,
J=3Hz, 1H), 7.60(d, J=3Hz, 1H), 9.28(s, 1H) 665
10023-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-yl-
methyl)piperidin-4- yl]phenylacetic acid ESI(+) 433(MH.sup.+)
130-132.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.50-1.76(m, # 4H), 1.96-2.08(m, 2H), 2.40-2.52(m, 1H), 2.88(br
.multidot. d, J=11Hz, 2H), 3.32(s, 2H), 3.51(s, 2H), 6.72(dd, J=1,
8Hz, 1H), 6.79(s, 1H), 6.84(d, J=8Hz, 1H), 7.05(d, J=8Hz, 1H),
7.09(d, J=8Hz, 1H), 7.10(s, 1H), 7.21(t, J=8Hz, 1H), 7.62(d, J=3Hz,
1H), 7.63(d, J=3Hz, 1H), 9.45(s, 1H) 666 10032-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- -yl- methyl)piperidin-4-
yl]phenylacetic acid ESI(+) 433(MH.sup.+) 152-154.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.56-1.80(m, 4H), #
1.96-2.20(m, 2H), 2.58-2.72(m, 1H), 2.84-2.96(m, 2H), 3.38(s, 2H),
3.61(s, 2H), 6.74(d, J=8Hz, 1H), 6.79(s, 1H), 6.86(d, J=8Hz, 1H),
7.10(t, J=7Hz, 1H), 7.15(d, J=7Hz, 1H), 7.21(t, J=7Hz, 1H), 7.24(d,
J=7Hz, 1H), 7.62(d, J=2Hz, 1H), 7.63(d, J=2Hz, 1H), 9.47(s, 1H) 667
10042-methoxy-5-[1-(10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]phenylacetic acid ESI(+) 463(MH.sup.+)
174-176.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.53-1.68(m, 4H), # 1.96-2.08(m, 2H), 2.80-2.92(m, 3H), 3.33(s,
2H), 3.45(s, 2H), 3.74(s, 3H), 6.72(dd, J=1, 8Hz, 1H), 6.80(d,
J=1Hz, 1H), 6.84(d, J=8Hz, 1H), 6.86(d, J=8Hz, 1H), 7.00-7.08(m,
1H), 7.04(s, 1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.45(s,
1H) 668 10052,3-dimethoxy-5-[1- (10H-pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl) piperidin-4-yl]phenylacetic acid
ESI(+) 493(MH.sup.+) 138-140.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.55-1.75(m, # 4H), 1.93-2.05(m, 2H), 2.35-2.48(m,
1H), 2.83-2.93(m, 2H), 3.29(s, 2H), 3.46(s, 2H), 3.63(s, 3H),
3.77(s, 3H), 6.64(d, J=2Hz, 1H), 6.72 (dd, J=2, 8Hz, 1H), 6.78(s,
1H), 6.79(s, 1H), 6.84(d, J=8Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d,
J=3Hz, 1H), 9.44(s, 1H) 669 10063-[1-(10H-pyrazino
[2,3-b][1,4]benzo thiazin-8-ylmethyl) piperidin-4-yl]-3-
methylbutanoic acid ESI(+) 399(MH.sup.+) 272-275.degree. C.
.sup.1H-NMR(CD.sub.3OD) # .delta. ppm: 1.02(s, 6H), 1.50-1.75(m,
3H), 1.95-2.05(m, 2H), 2.24(s, 2H), 2.85-2.98(m, 2H), 3.45-3.55(m,
2H), 4.09(s, 2H), 6.77(d, J=2Hz, 1H), 6.91(dd, J=2, 8Hz, 1H),
6.96(d, J=8Hz, 1H), 7.61(d, J=3Hz, 1H), 7.61(d, J=3Hz, 1H) 670
10074-[1-(10H-pyrazino [2,3-b][1,4]benzo thiazin-8-ylmethyl)
piperidin-4-yl]-3,3- dimethylbutanoic acid ESI(+) 413(MH.sup.+)
230-232.degree. C. .sup.1H-NMR(CD.sub.3OD) .delta. ppm: 1.04(s,
6H), # 1.38(d, J=5Hz, 2H), 1.45-1.60(m, 2H), 1.65-1.70(m, 1H),
1.92-2.03(m, 2H), 2.20(s, 2H), 2.78-3.00(m, 2H), 3.36(br .multidot.
d, J=8Hz, 2H), 4.05(s, 2H), 6.76(d, J=2Hz, 1H), 6.90(dd, J=2, 8Hz,
1H), 6.95(d, J=8Hz, 1H), 7.60(d, J=3Hz, 1H), 7.61(d, J=3Hz, 1H) 671
1008[1-[N-[1-(10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]sulfamoyl]piperidin-4-yl]carboxylic acid
FAB(+) 505(MH.sup.+) 54-55.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.41-1.56(m, # 4H), 1.75-1.89(m, 4H), 2.05-2.16(m,
2H), 2.31-2.38(m, 1H), 2.65-2.72(m, 2H), 2.74-2.82(m, 2H),
2.96-3.04(m, 1H), 3.30(s, 2H), 3.31-3.42(m, 2H), 6.71(s, 1H),
6.72(d, J=8Hz, 1H), 6.86(d, J=8Hz, 1H), 7.26(s, 1H), 7.64(s, 2H),
9.45(s, 1H) 672 1009[N-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8-yl- methyl)piperidin-4-
yl]sulfamoyl]aminoacetic acid FAB(+) 451(MH.sup.+) 195-196.degree.
C. .sup.1H-NMR(CD.sub.3OD) # .delta. ppm: 1.50-1.61(m, 2H),
1.82-1.98(m, 2H), 2.07-2.15(m, 2H), 2.79-2.85(m, 2H), 3.14-3.21(m,
1H), 3.35(s, 2H), 3.50(s, 2H), 6.66(d, J=2Hz, 1H), 6.76(dd, J=2,
8Hz, 1H), 6.80(d, J=8Hz, 1H), 7.55(d, J=3Hz, 1H), 7.57(d, J=3Hz,
1H) 673 10104-oxo-4-[4-(10H- pyrazino[2,3-b][1,4]benzothiazin- -8-
ylmethyl)piperazin- 1-yl]butanoic acid FAB(+) 399(M.sup.+)
240-242.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.95(dd,
# J=6, 7Hz, 2H), 2.22-2.26(br .multidot. s, 2H), 2.27-2.32(br
.multidot. s, 2H), 2.35(dd, J=7, 9Hz, 2H), 3.28(s, 2H),
3.34-3.42(m, 4H), 6.70(dd, J=1, 8Hz, 1H), 6.77(d, J=1Hz, 1H),
6.83(d, J=8Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.52(s,
1H) 674 10111-(10H-pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-3- azetidinecarboxylic acid FAB(+) 315(MH.sup.+)
181-183.degree. C. .sup.1H-NMR(CD.sub.3OD) .delta. ppm: 3.65-3,
72(m, 1H), 4.25-4.35(m, 6H), 6.71(s, 1H), 6.86(d, J=8Hz, 1H),
6.96(d, J=8Hz, 1H), 7.62(s, 2H) 675 10123-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)azetidin-3-
yl]-2-methylpropanoic acid FAB(+) 357(MH.sup.+) Amorphous
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 0.80(d, # J=7Hz, 3H),
1.24-1.31(m, 1H), 1.65-1.74(m, 2H), 2.38-2.45(m, 1H), 2.59(t,
J=7Hz, 2H), 3.20-3.27(m, 2H), 3.28(s, 2H), 6.64(dd, J=2, 7Hz, 1H),
6.71(d, J=2Hz, 1H), 6.78(d, J=7Hz, 1H), 7.61(d, J=3Hz, 1H), 7.62(d,
J=3Hz, 1H), 9.53(s, 1H) 676 1013[4-ethyl-1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin- 4-yl]acetic
acid FAB(+) 385(MH.sup.+) 225-226.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 0.80(t, J=7Hz, 3H),
1.43(br .multidot. s, 2H), 1.70(br .multidot. s, 4H), 2.25(br
.multidot. s, 2H), 2.80(br .multidot. s, 4H), 3.80(s, 2H), 6.84(s,
1H), 6.89(d, J=8Hz, 1H), 6.96(br .multidot. s, 1H), 7.63(s, 2H),
9.42(br .multidot. s, 1H) 677 1014[7-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-7-
azaspiro[3.5]non-2- yl]acetic acid FAB(+) 397(MH.sup.+)
207-209.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.36(dd,
J=10, # 11Hz, 2H), 1.42(t, J=5Hz, 2H), 1.52(m, 2H), 1.87(t, J=10Hz,
2H), 2.14(br .multidot. s, 2H), 2.22(br .multidot. s, 2H), 2.28(d,
J=8Hz, 2H), 2.46(m, 1H), 3.18(s, 2H), 6.67(dd, J=2, 8Hz, 1H),
6.74(d, J=2Hz, 1H), 6.81(d, J=8Hz, 1H), 7.61(d, J=3Hz, 1H), 7.62(d,
J=3Hz, 1H), 9.41(s, 1H) 678 10154-[1-(5H-pyrido[3,4-
b][1,4]benzothiazin- 7-ylmethyl) piperidin-4-yl]-2- methylbutanoic
acid FAB(+) 398(MH.sup.+) 210-215.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 0.95(d, # J=8Hz, 3H),
1.02-1.21(m, 5H), 1.44-1.58(m, 4H), 1.79(m, 2H), 2.09(m, 1H),
2.70(d, J=10Hz, 2H), 3.21(s, 2H), 6.51(d, J=5Hz, 1H), 6.65(s, 1H),
6.66(d, J=8Hz, 1H), 6.81(d, J=8Hz, 1H), 7.84(s, 1H), 7.94(d, J=5Hz,
1H), 9.10(s, 1H) 679 1016[7-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-7- azaspiro[3.5]non-2-
ylidene]acetic acid FAB(+) 395(MH.sup.+) 238-241.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.54(m, 4H), # 2.22(br
.multidot. s, 4H), 2.49(br .multidot. s, 2H), 2.71(br .multidot. s,
2H), 3.24(s, 2H), 5.57(br .multidot. s, 1H), 6.68(d, J=8Hz, 1H),
6.75(s, 1H), 6.82(d, J=8Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz,
1H), 9.44(s, 1H), 11.85(br .multidot. s, 1H) 680
1017[2-ethoxy-7-(10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-7-azaspiro [3.5]non-2-yl]acetic acid FAB(+) 441(MH.sup.+)
226-227.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.02(t,
J=7Hz, # 3H), 1.47(m, 2H), 1.54(m, 2H), 1.81(d, J=13Hz, 2H),
1.90(d, J=13Hz, 2H), 2.29(br .multidot. s, 4H), 2.46(s, 2H),
3.18(s, 2H), 3.30(q, J=7Hz, 2H), 6.67(dd, J=2, 8Hz, 1H), 6.73(d,
J=2Hz, 1H), 6.81(d, J=7Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz,
1H), 9.42(s, 1H) 681 10184-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-4-(hydroxy- methyl)piperidin-
4-yl]-2-methyl- butanoic acid FAB(+) 429(MH.sup.+) 105-110.degree.
C. .sup.1H-NMR(CD.sub.3OD) # .delta. ppm: 1.04(d, J=7Hz, 3H),
1.2-1.5(m, 8H), 2.21(m, 3H), 2.29(m, 2H), 3.16(s, 2H), 3.42(s, 2H),
5.74(s, 1H), 6.67(dd, J=2, 8Hz, 1H), 6.75(d, J=2Hz, 1H), 6.81(d,
J=8Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.43(br
.multidot. s, 1H) 682 1019sodium 2-[7-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-7-azaspiro
[3.5]non-2-yl]carboxylate FAB(+) 405(MH.sup.+) 230-232.degree. C.
.sup.1H-NMR(CD.sub.3OD) # .delta. ppm: 1.61(t, J=11Hz, 2H), 1.68(t,
11Hz, 2H), 1.96(s, 2H), 1.98(s, 2H), 2.4-2.8(br .multidot. m, 5H),
3.41(s, 2H), 6.66(d, J=2Hz, 1H), 6.78(dd, J=2, 8Hz, 1H), 6.83(d,
J=8Hz, 1H), 7.56(d, J=3Hz, 1H), 7.58(d, J=3Hz, 1H) 683
10202-[7-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)-7-azaspiro [3.5]non-2-ylidene]propanoic acid FAB(+)
409(MH.sup.+) 251-252.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.51(m, 4H), 1.58(s, 3H), 2.2(br .multidot. s, 4H), 2.43(s,
2H), 2.66(s, 2H), 3.22(s, 2H), 6.68(d, J=8Hz, 1H), 6.75(d, J=2Hz,
1H), 6.82(dd, J=2, 8Hz, 1H), 7.62(m, 2H), 9.42(br .multidot. s, 1H)
684 10212-[7-(10H-pyrazino 2,3-b][1,4]benzothiazin-8- ylmethyl)-7-
azaspiro3.5]non-2- yl]propanoic acid FAB(+) 410(M.sup.+)
169-172.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 0.92(d,
J=7Hz, 3H), 1.3-1.42(m, 5H), 1.52(br .multidot. s, 2H),
1.74-1.85(m, 2H), 2.10-2.26(m, 5H), 3.22(s, 2H), 6.69(d, J=8Hz,
1H), 6.75(s, 1H), 6.83(d, J=8Hz, 1H), 7.63(m, 2H), 9.43(br
.multidot. s, 1H) 685 1022[2-methyl-7-(10H-
pyrazino[2,3-b][1,4]enzothiazin-8- ylmethyl)-7- azaspiro[3.5]non-2-
yl]acetic acid FAB(+) 411(MH.sup.+) 149-151.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.25(s, 3H), 1.72(d,
J=13Hz, 2H), 1.78(br .multidot. s, 4H), 2.02(d, J=13Hz, 2H),
2.33(s, 2H), 2.88(br .multidot. s, 4H), 3.84(s, 2H), 6.69(d, J=2Hz,
1H), 6.85(dd, J=2, 8Hz, 1H), 6.92(d, J=8Hz, 1H), 7.60(d, J=3Hz,
1H), 7.61(d, J=3Hz, 1H), 9.42(s, 1H) 686 1023[7-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-7- azaspiro[3.5]non-2-
yl]carboxylic acid FAB(+) 383(MH.sup.+) 265-268.degree. C.
.sup.1H-NMR(CD.sub.3OD) # .delta. ppm: 1.71(m, 2H), 1.87(s, 2H),
2.05-2.15(m, 4H), 2.95-3.10(m, 5H), 3.97(s, 2H), 6.74(d, J=2Hz,
1H), 6.89(dd, J=2, 8Hz, 1H), 6.96(d, J=8Hz, 1H), 7.61(s, 2H) 687
1024[2-butyl-7-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-yl-methyl)-7- azaspiro[3.5]non-2- yl]acetic acid FAB(+)
453(MH.sup.+) 133-135.degree. C. .sup.1H-NMR(CD.sub.3OD) .delta.
ppm: 0.92(t, J=7Hz, 3H), # 1.21-1.33(m, 4H), 1.55(m, 2H), 1.67(d,
J=13Hz, 2H), 1.75(m, 4H), 1.95(d, J=13Hz, 2H), 2.32(s, 2H), 2.50(br
.multidot. s, 2H), 2.75(br .multidot. s, 2H), 3.68(s, 2H), 6.67(d,
J=2Hz, 1H), 6.82(dd, J=2, 8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.58(d,
J=3Hz, 1H), 7.59(d, J=3Hz, 1H) 688 10251-(10-pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl-1-
azoniabicyclo[2.2.2]octane-4-carboxylate FAB(+) 369(MH.sup.+)
229-230.degree. C. .sup.1H-NMR(CD.sub.3OD) # .delta. ppm: 2.19(t,
J=8Hz, 6H), 3.43(t, J=8Hz, 6H), 4.19(s, 2H), 6.71(d, J=2Hz, 1H),
6.88(dd, J=2, 8Hz, 1H), 6.99(d, J=8Hz, 1H), 7.62(s, 2H) 689
1026[3-(10H-pyrazino [2,3-b][1,4]benzo- thiazin-8-ylmethyl)-3-
azabicyclo[3.1.0]hexa-6-yl]carboxylic acid FAB(+) 341(MH.sup.+)
>275.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.83(s,
2H), 2.31(d, J=10Hz, 2H), 2.91(d, J=10Hz, 2H), 3.29(s, 2H), 3.38(s,
1H), 6.64(d, J=7Hz, 1H), 6.72(s, 1H), 6.81(d, J=7Hz, 1H), 7.62(d,
J=3Hz, 1H), 7.63(d, J=3Hz, 1H), 9.44(s, 1H) 690
1027[7-(10H-pyrazino [2,3-b][1,4]benzothiazin-8- ylmethyl)-1-oxa-7-
azaspiro[3,5]non-2- yl]carboxylic acid FAB(+) 385(MH.sup.+)
178-180.degree. C. 1H-NMR(CD.sub.3OD) .delta.: 1.81-1.95(m, # 3H),
2.00-2.09(m, 1H), 2.31(dd, J=7, 11Hz, 1H), 2.66(dd, J=9, 11Hz, 1H),
2.78(br .multidot. s, 2H), 3.31(s, 2H), 3.58(br .multidot. s, 2H),
4.74(dd, J=7, 9Hz, 1H), 6.68(d, J=2Hz, 1H), 6.81(dd, J=2, 8Hz, 1H),
6.86(d, J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.59(d, J=3Hz, 1H) 691
1028[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)-piperidin- 4-yl]aminoacetic acid ESI(+) 372(MH.sup.+)
206-208.degree. C. .sup.1H-NMR(CD.sub.3OD) # .delta.: 1.43-1.53(m,
2H), 1.80-1.92(m, 4H), 2.73-2.86(m, 3H), 3.11(s, 2H), 3.24(s, 2H),
6.67(dd, J=1.9, 7.4Hz, 1H), 6.72(d, J=1.9Hz, 1H), 6.83(d, J=7.4Hz,
1H), 7.62(s, 2H), 9.46(s, 1H) 692 1029[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-piperidin- 4-yl]methoxyacetic
acid ESI(+) 387(MH.sup.+) 146-148.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.59-1.72(m, 2H), #
1.43-1.57(m, 1H), 1.57-1.66(m, 2H), 1.82-1.92(m, 2H), 2.71-2.79(m,
2H), 3.14(s, 2H), 3.27(d, J=6.3Hz, 2H), 3.94(s, 2H), 6.68(dd,
J=2.0, 8.7Hz, 1H), 6.75(d, J=2.0Hz, 1H), 6.82(d, J=8.7Hz, 1H),
7.61(d, J=2.7Hz, 1H), 7.63(d, J=2.7Hz, 1H), 9.43(s, 1H) 693
1030[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]carbamoylacetic acid FAB(+) 400(MH.sup.+)
149-151.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.28-1.41(m, 2H), # 1.65-1.73(m, 2H), 1.93-2.02(m, 2H),
2.65-2.73(m, 2H), 3.07(s, 2H), 3.25(s, 2H), 3.43-3.55(m, 1H),
6.67(dd, J=1.3, 7.4Hz, 1H), 6.74(d, J=1.3Hz, 1H), 6.83(d, J=7.4Hz,
1H), 7.62(d, J=2.9Hz, 1H), 7.63(d, J=2.9Hz, 1H), 8.00(d, J=8.0Hz,
1H), 9.45(s, 1H) 694 1031[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin-
4-ylidene]fluoroacetic acid ESI(+) 373(MH.sup.+) 167-173.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 2.34-2.39(m, 2H),
2.39-2.45(m, 4H), 2.75-2.81(m, 2H), 3.32(s, 2H), 6.71(d, J=7.9Hz,
1H), 6.76(s, 1H), 6.85(d, J=7.9Hz, 1H), 7.62(s, 2H), 9.46(s, 1H)
695 1032[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]fluoroacetic acid ESI(+) 375(MH.sup.+)
163.degree. C. (decompose) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.35-1.52(m, # 3H), 1.59-1.67(m, 1H), 1.70-1.88(m, 1H),
1.92-2.07(m, 2H), 2.83-2.91(m, 2H), 3.34(s, 2H), 4.77(dd, J=4.5,
49.2Hz, 1H), 6.70(d, J=7.7Hz, 1H), 6.74(s, 1H), 6.83(d, J=7.7Hz,
1H), 7.61(d, J=2.8Hz, 1H), 7.62(d, J=2.8Hz, 1H), 9.46(s, 1H) 696
1033[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]propiolic acid ESI(+) 367(MH.sup.+)
155-156.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.50-1.61(m, 2H), 1.76-1.85(m, 2H), 2.15-2.25(m, 2H), 2.54-2.72(m,
3H), 3.14(s, 2H), 6.71(dd, J=1.2, 7.7Hz, 1H), 6.74(d, J=1.2Hz, 1H),
6.84(d, J=7.7Hz, 1H), 7.61(d, J=2.5Hz, 1H), 7.63(d, J=2.5Hz, 1H),
9.47(s, 1H) 697 10344-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-7-
ylmethyl)piperidin- 4-yl]-2- methylbutanoic acid ESI(+)
399(MH.sup.+) 221-222.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.01(d, J=6.5Hz, # 3H), 1.02-1.21(m, 5H), 1.24-1.38(m, 1H),
1.44-1.65(m, 3H), 1.79-1.99(m, 2H), 2.20-2.27(m, 1H), 2.69-2.82(m,
2H), 3.15(s, 2H), 6.69(d, J=7.9Hz, 1H), 6.80(br .multidot. s, 1H),
6.87(br .multidot. d, J=7.9Hz, 1H), 7.60(d, J=2.6Hz, 1H), 7.62(d,
J=2.6Hz, 1H), 9.48(s, 1H) 698 10351-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-7- ylmethyl)-4-
piperidin-4-yl]cyclopropane carboxylic acid ESI(+) 383(MH.sup.+)
228-231.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
0.63-0.69(m, # 2H), 0.90-0.95(m, 2H), 1.31-1.51(m, 5H)1.71-1.84(m,
2H), 2.71-2.81(m, 2H), 3.20(s, 2H), 6.67(dd, J=1.6, 8.7Hz, 1H),
6.74(d, J=1.6Hz, 1H), 6.81(d, J=8.7Hz, 1H), 7.61(d, J=2.5Hz, 1H),
7.62(d, J=2.5Hz, 1H), 9.43(s, 1H) 699 1036[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-7-yl-
methyl)piperidin-4-yl]carbamoylformic acid FAB(+) 386(MH.sup.+)
222-226.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.52-1.66(m, 2H), 1.66-1.76(m, 2H), 2.21-2.35(m, 2H), 2.85-2.96(m,
2H), 3.51(s, 2H), 3.55-3.65(m, 1H), 6.74(d, J=7.7Hz, 1H), 6.85(s,
1H), 6.87(d, J=7.7Hz, 1H), 7.63(s, 2H), 8.48(d, J=9.0Hz, 1H),
9.52(s, 1H) 700 1037(E)-4-[1-(10H- pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl) piperidin- 4-yl]-3-methyl-2-
butenoic acid ESI(+) 397(MH.sup.+) 126-130.degree. C.
.sup.1H-NMR(CD.sub.3OD) .delta. ppm: 1.30-1.45(m, 2H), #
1.70-1.88(m, 3H), 2.07(d, J=1Hz, 3H), 2.09(d, J=8Hz, 2H),
2.55-2.65(m, 2H), 3.20-3.30(m, 2H), 3.82(s, 2H), 5.66(d, J=1Hz,
1H), 6.70(d, J=2Hz, 1H), 6.85(dd, J=2, 8Hz, 1H), 6.90(d, J=8Hz,
1H), 7.59(d, J=3Hz, 1H), 7.60(d, J=3Hz, 1H) 701
1038[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8- ylmethyl)-3,5-
dimethylpiperidin-4- yl]acetic acid ESI(+) 385(MH.sup.+)
200.degree. C. (decompose) .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
0.77(d, J=7Hz, 6H), 1.69(m, 2H), 1.82(m, 2H), 2.01(m, 2H), 2.09(m,
1H), 2.34(d, J=10Hz, 2H), 3.20(s, 2H), 6.67(d, J=8Hz, 1H), 6.73(s,
1H), 6.81(d, J=8Hz, 1H), 7.55-7.70(m, 2H), 9.45(s, 1H) 702
10394-[4-hydroxy-1-(10H- - pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl) piperidin-4- yl]phenylacetic acid FAB(+) 449(MH.sup.+)
192.degree. C. (decompose) .sup.1H-NMR(CD.sub.3OD) # .delta. ppm:
1.81-1.89(m, 2H), 2.15-2.28(m, 2H), 3.30-3.40(m, 4H), 3.56(s, 2H0,
4.15(s 2H), 6.82(s, 1H), 6.95-6.98(m, 2H), 7.28-7.32(m, 2H),
7.36-7.40(m, 2H), 7.61(d, J=2.9Hz, 1H), 7.62(d, J=2.9Hz, 1H) 703
1040[2-(10H-pyrazino [2,3- b][1,4] benzothiazin-
8-ylmethyl)-2-azaspiro [3.5]non-7-yl]acetic acid FAB(+)
397(MH.sup.+) 145.degree. C. (decompose) .sup.1H-NMR(CD.sub.3OD)
.delta. ppm: 0.93-1.06(m, 2H), # 1.49-1.58(m, 2H), 1.64-1.77(m,
3H), 1.97-2.04(m, 2H), 2.08(d, J=6.8Hz, 2H), 3.67(s, 2H), 3.76(m,
2H), 4.07(s, 2H), 6.69(d, J=1.6Hz, 1H), 6.85(dd, J=1.6, 7.9Hz, 1H),
6.92(d, J=7.9Hz, 1H), 7.60(d, J=2.9Hz, 1H), 7.10(d, J=2.9Hz, 1H)
704 1041[2-(10H-pyrazino [2,3- b][1,4] benzothiazin-
8-ylmethyl)-2-azaspiro [4.5]dec-8-yl]carboxylic acid FAB(+)
397(MH.sup.+) 146.degree. C. (decompose) .sup.1H-NMR(CD.sub.3OD) #
.delta. ppm: 1.39-1.62(m, 4H), 1.68-1.94(m, 6H), 2.12-2.23(m, 1H),
2.90, 3.04(s, total2H), 3.16-3.24(m, 2H), 3.98, 4.02(s, total2H),
6.72-6.76(m, 1H), 6.86-6.94(m, 2H), 7.58-7.63(m, 2H) 705 1042sodium
4-[1-(10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4- yloxy]phenylacetate FAB(+) 471(MH.sup.+)
261-265.degree. C. (decompose) .sup.1H-NMR(DMSO-d.sub.6) # .delta.
ppm: 1.52-1.62(m, 2H), 1.83-1.92(m, 2H), 2.11-2.20(m, 2H),
2.56-2.66(m, 2H), 3.13(s, 2H), 3.27(s, 2H), 4.26(m, 1H), 6.69(d,
J=7.9Hz, 1H), 6.72-6.83(m, 4H), 7.05-7.11(m, 2H), 7.59-7.63(m, 2H),
9.49(br .multidot. s, 1H) 706 10434-[[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-piperidin-
4-yl]methyloxy]phenylacetic acid FAB(+) 463(MH.sup.+)
225-230.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.20-1.34(m, 2H), # 1.52-1.62(m, 3H), 1.83-1.92(m, 2H),
2.75-2.82(m, 2H), 3.25(s, 2H), 3.38(s, 2H), 3.76(d, J=5.9Hz, 2H),
6.69(dd, J=1.5, 7.9Hz, 1H), 6.76(d, J=1.5Hz, 1H), 6.78-6.83(m, 3H),
7.08-7.13(m, 2H), 7.61(d, J=2.7Hz, 1H), 7.62(d, J=2.7Hz, 1H),
9.49(br .multidot. s, 1H) 707 10442-methoxy-4-[[1-
(10H-pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl)
piperidin-4-yl]phenylacetic acid FAB(+) 463(MH.sup.+)
171-177.degree. C. (decompose) .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
1.86-2.00(m, # 4H), 2.76(m, 1H), 2.88-2.97(m, 2H), 3.41-3.48(m,
2H), 3.52(s, 2H), 3.76(s, 3H), 4.04(s, 2H), 6.71(dd, J=1.6, 7.7Hz,
1H), 6.77(d, J=1.6Hz, 1H), 6.81(m, 1H), 6.91-6.96(m, 2H), 7.12(d,
J=7.7Hz, 1H), 7.60(d, J=2.9Hz, 1H), 7.61(d, J=2.9Hz, 1H) 708
10454-[1-[2-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-yl)ethyl]piperidin-4-yl]-2- methylbutanoic acid FAB(+)
413(MH.sup.+) 229-230.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 0.95-1.21(m, # 8H), 1.33(m, (decompose) 1H), 1.48-1.64(m, 3H),
1.88(m, 2H), 2.26(m, 1H), 2.40(m, 2H), 2.46-2.56(m, 2H),
2.82-2.90(m, 2H), 6.24(s, 1H), 6.64(d, J=7.9Hz, 1H), 6.79(d,
J=7.9Hz, 1H), 7.62(d, J=2.9Hz, 1H), 7.63(d, J=2.9Hz, 1H), 9.43(s,
1H) 709 1046[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]thioacetic acid FAB(+) 389(MH.sup.+)
148-152.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.38-1.49(m, # 2H), 1.86-2.04(m, 4H), 2.67-2.84(m, 3H), 3.23(s,
2H), 3.27(s, 2H), 6.70(dd, J=1.5, 7.7Hz, 1H), 6.77(d, J=1.5Hz, 1H),
6.84(d, J=7.7Hz, 1H), 7.64(d, J=2.7Hz, 1H), 7.65(d, J=2.7Hz, 1H),
9.46(s, 1H) 710 1047(E)-4-[1-(10H- pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl) piperidin-4-yl]-3- butenoic acid
.sup.1H-NMR(CD.sub.3OD) .delta. ppm: 1.42-1.56(m, 2H), #
1.73-1.82(m, 2H), 2.00-2.20(m, 1H), 2.24-2.30(m, 2H), 2.84-2.88(m,
2H), 3.02-3.08(m, 2H), 3.58(s, 2H), 5.43(dd, J=6, 16Hz, 1H),
5.61-5.71(m, 1H), 6.68(s, 1H), 6.78-6.88(m, 2H), 7.56(d, J=3Hz,
1H), 7.58(d, J=3Hz, 1H) 711 1048[3-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-3- azabicyclo[3.3.0]oct-
7-yl]acetic acid ESI(+) 383(MH.sup.+) 112-117.degree. C.
1H-NMR(D.sub.2O) # .delta. ppm: 1.35-1.45(m, 2H), 1.90-2.10(m, 5H),
2.66-2.80(m, 2H), 2.92-3.03(m, 2H), 3.13-3.23(m, 2H), 3.80-3.90(m,
2H), 6.37-6.39(m, 1H), 6.50-6.59(m, 2H), 7.19-7.26(m, 2H) 712
1049[3-(10H-pyrazino [2,3-b][1,4]benzothiazin-8- ylmethyl)-3-
azabicyclo[3.3.0]oct- 7-yl]carboxylic acid .sup.1H-NMR(D.sub.2O)
.delta. ppm: 1.58-1.76(m, 4H), # 2.65-2.70(m, 3H), 2.74-2.82(m,
2H), 3.39-3.48(m, 2H), 3.84(s, 2H), 6.35(d, J=1.6Hz, 1H), 6.51(d,
J=8.0Hz, 1H), 6.56(dd, J=1.6, 8.0Hz, 1H), 7.18(d, J=2.0Hz, 1H),
7.22(d, J=2.0Hz, 1H) 713 1050[3-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-3- azabicyclo[3.3.0]oct-
7-yl]carboxylic acid .sup.1H-NMR(D.sub.2O) .delta. ppm:
1.44-1.54(m, 2H), # 2.06(dt, J=8.0, 13.6Hz, 2H), 2.59(quint,
J=7.2Hz, 1H), 2.84(br .multidot. s, 2H), 3.08(br .multidot. s, 4H),
3.80(s, 2H), 6.32(d, J=1.6Hz, 1H), 6.39(d, J=8.0Hz, 1H), 6.48(dd,
J=1.6, 8.0Hz, 1H), 7.11(d, J=3.2Hz, 1H), 7.16(d, J=3.2Hz, 1H) 714
1051[3-(10H-pyrazino [2,3-b][1,4]benzothiazin-8- ylmethyl)-3-
azabicyclo[3.3.0]oct- 7-yl]acetic acid ESI(+) 383(MH.sup.+)
110-115.degree. C. .sup.1H-NMR(D.sub.2O) .delta. ppm: 0.82-0.95(m,
# 2H), 1.86-2.10(m, 5H), 2.65-2.80(m, 2H), 2.88-3.03(m, 2H),
3.07-3.23(m, 2H), 3.85(s, 2H), 6.37(d, J=1.6Hz, 1H), 6.51(d,
J=8.0Hz, 1H), 6.56(dd, J=1.6, 8.0Hz, 1H), 7.17-7.21(m, 1H),
7.21-7.26(m, 1H) 715 1052sodium [6-(10H- pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl)-6- azaspiro[3.4]oct-2- yl]acetate
ESI(+) 383(M -Na+2H).sup.+ 203-214.degree. C. (decompose)
.sup.1H-NMR(D.sub.2O) # .delta. ppm: 1.60-1.72(m, 2H), 1.90-2.15(m,
6H), 2.25-2.48(m, 1H), 3.00-3.28(m, 4H), 3.85(s, 7/5H), 3.88(s,
3/5H), 6.34-6.39(m, 1H), 6.50-6.59(m, 2H), 7.17-7.20(m, 1H),
7.21-7.25(m, 1H) 716 1053sodium [3-(10H- pyrazino[2,3-
b][1,4]benzothiazin- 8-yl-methyl)-3- azabicyclo[3.3.0]octane-
7-spirocyclobut- 3'-yl]acetate ESI(+) 423(M -Na+2H).sup.+
231-235.degree. C. .sup.1H-NMR(D.sub.2O) # .delta. ppm:
1.02-1.28(m, 3H), 1.36-1.56(m, 2H), 1.62-1.84(m, 3H), 1.94-2.08(m,
2H), 2.12-2.48(m, 5H), 2.56-2.74(m, 2H), 3.35(s, 2H), 6.34(s,
1H),
6.39(s, 2H), 7.25(d, J=2.4Hz, 1H), 7.30(d, J=2.4Hz, 1H) 717
1054sodium [8-(10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-8- azabicyclo[4.3.0]non- 3-yl]acetate ESI(+) 397(M
-Na+2H).sup.+ 126-130.degree. C. .sup.1H-NMR(D.sub.2O) .delta. ppm:
0.63-0.90(m, # 2H), 1.25-1.55(m, 5H), 1.80-2.35(m, 4H), 2.68(d,
J=10.8Hz, 1H), 2.80-3.13(m, 2H), 2.88(d, J=10.4Hz, 1H), 3.68(dd,
J=13.2, 22.4Hz, 2H), 6.31(s, 1H), 6.38(d, J=8.0Hz, 1H), 6.48(d,
J=8.0Hz, 1H), 7.13-7.16(m, 1H), 7.16-7.21(m, 1H) 718 1055sodium
[3-(10H- pyrazino[2,3- b][1,4]benzothiazin- 8-ylmethyl)-3-
azabicyclo[3.3.0]oct ane-7-spirocyclobut- 3'-yl]carboxylate ESI(+)
409(M -Na+2H).sup.+ 232-243.degree. C. (decompose)
.sup.1H-NMR(D.sub.2O) # .delta. ppm: 1.08-1.10(m, 2H), 1.44-1.54(m,
1H), 1.60-2.02(m, 7H), 2.18-2.40(m, 4H), 2.66(quint, J=8.8Hz, 1H),
3.09(br .multidot. s, 2H), 6.28(s, 1H), 6.31(d, J=7.6Hz, 1H),
6.35(d, J=7.6Hz, 1H), 7.25(d, J=2.8Hz, 1H), 7.31(d, J=2.8Hz, 1H)
719 1056sodium [6-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-6- azaspiro[3.4]oct-2- yl]carboxylate
.sup.1H-NMR(D.sub.2O) .delta. ppm: 1.60-1.68(m, # 1H), 1.73-1.82(m,
1H), 1.88-2.03(m, 4H), 2.32-2.48(m, 4H), 2.58-2.82(m, 1H),
3.12-3.20(m, 2H), 6.21-6.26(m, 1H), 6.37-6.45(m, 2H), 7.14-7.20(m,
2H) 720 1057sodium [8-(10H- pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-8- azabicyclo[4.3.0]non- 3-yl]carboxylate
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.18-1.82(m, 8H),
2.10-2.20(m, 1H), 2.28(dd, J=2.4, 8.8Hz, 2/3H), 2.34(dd, J=2.4, #
8.8Hz, 1/3H), 2.44-2.57(m, 2H), 2.67(dd, J=6.0, 8.8Hz, 1/3H),
2.74(dd, J=6.0, 8.8Hz, 2/3H), 3.40-3.54(m, 2H), 6.70(dd, J=1.6,
8.0Hz, 1/3H), 6.71(dd, J=1.6, 8.0Hz, 2/3H), 6.78-6.81(m, 1H),
6.82(d, J=8.0Hz, 1/3H), 6.82(d, J=8.0Hz, 2/3H), 7.63(d, J=2.8Hz,
1H), 7.64(d, J=2.8Hz, 1H), 9.54(s, 1H) 721 1058sodium [3-(10H-
pyrazino[2,3- b][1,4]benzothiazin- 8-yl-methyl)-3-
azabicyclo[4.1.0]hept- 6-yl]acetate ESI(+) 369(M -Na+2H).sup.+
152-156.degree. C. (decompose) .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
0.50(t, J=4.8Hz, 1H), 0.60- 0.66(m, 1H), 0.96-1.04(m, 1H),
1.84-2.28(m, 6H), 2.52-2.59(m, 1H), 2.78(dd, J=6.0, 11.6Hz, 1H),
3.25(d, J=13.2Hz, 1H), 3.27(d, J=13.2Hz, 1H), 6.67(d, J=1.2Hz, 1H),
6.72-6.80(m, 2H), 7.54(d, J=2.8Hz, 1H), 7.57(d, J=2.8Hz, 1H) 722
1059sodium [7-(10H-pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-6-methyl- 7-azaspiro [5.3]non- 2-yl]acetate ESI(+)
411(M -Na+2H).sup.+ 226-234.degree. C. (decompose)
.sup.1H-NMR(CD.sub.3OD) .delta. ppm: 1.13-1.24(m, # 3H),
1.28-1.58(m, 5H), 1.66-2.10(m, 4H), 2.18-2.36(m, 3H), 2.51-2.72(m,
2H), 3.03(d, J=13.2Hz, 1/2H), 3.04(d, J=13.2Hz, 1/2H), 3.87(d,
J=13.2Hz, 1/2H), 3.89(d, J=13.2Hz, 1/2H), 6.64(m, 1H), 6.72-6.80(m,
2H), 7.53-7.58(m, 2H) 723 1060sodium [7-(10H- pyrazino[2,3-
b][1,4]benzothiazin- 8-ylmethyl)-6- methyl-7-azaspiro
[5.3]non-2-yl]carboxylate ESI(+) 397(M -Na+2H).sup.+
253-265.degree. C. (decompose) .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
1.15(d, # J=6.0Hz, 1H), 1.21(d, J=6.0Hz, 2H), 1.26-2.07(m, 9H),
2.18-2.33(m, 1H), 2.57-2.71(m, 1H), 2.82-2.94(m, 1H), 3.02(d,
J=13.2Hz, 1H), 3.86(d, J=13.6Hz, 1/3H), 3.87(d, J=13.2Hz, 2/3H),
6.64-6.67(m, 1H), 6.73-6.81(m, 2H), 7.53-7.58(m, 2H) 724
1061[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]carboxylic acid .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.00-1.20(m, 1H), # 1.30-1.40(m, 1H), 1.45-1.60(m,
1H), 1.60-1.85(m, 2H), 1.95-2.10(m, 1H), 2.30-2.50(m, 1H),
2.50-2.70(m, 1H), 2.70-2.90(m, 1H), 3.15(d, J=10Hz, 1H), 3.24(d,
J=10Hz, 1H), 6.65(d, J=8Hz, 1H), 6.70(s, 1H), 6.80(d, J=8Hz, 1H),
7.60(s, 2H), 9.47(s, 1H) 725 10624-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin- 4-yl]-2-butenoic
acid FAB(+) 383(MH.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.05-1.20(m, 2H), # 1.25-1.40(m, 1H), 1.50-1.60(m, 2H),
1.75-1.90(m, 4H), 2.00-2.10(m, 2H), 3.15(s, 2H), 5.70(d, J=16Hz,
1H), 6.65(d, J=8Hz, 1H), 6.75(s, 1H), 6.80(d, J=8Hz, 1H), 6.82(dt,
J=6, 16Hz, 1H), 7.60(s, 2H), 9.42(br .multidot. s, 1H) 726
10634-[N-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidine- 2,2-dimethylbutanoic acid FAB(+) 413(MH.sup.+)
180-185.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.10(s,
6H), # 1.00-1.30(m, 5H), 1.30-1.40(m, 2H), 1.45-1.60(m, 2H),
1.75-1.85(m, 2H), 3.20(s, 2H), 3.20-3.30(m, 2H), 6.67(d, J=8Hz,
1H), 6.72(s, 1H), 6.82(d, J=8Hz, 1H), 7.60(br .multidot. s, 2H),
9.42(br .multidot. s, 1H) 727 1064[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin- 4-ylidenle]acetic
acid FAB(+) 355(MH.sup.+) 214-216.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 2.24(br .multidot. m, 2H),
2.42(br .multidot. s, 4H), 2.83(br .multidot. s, 2H), 3.33(s, 2H),
5.59(s, 1H), 6.72(d, J=8Hz, 1H), 6.77(s, 1H0, 6.85(d, J=8Hz, 1H),
7.63(s, 2H), 9.45(s, 1H), 12.01(br .multidot. s, 1H) 728
10652-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-ylidene]propanoic acid FAB(+) 369(MH.sup.+
125-127.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.34(s,
3H), 2.26(m, 2H), 2.34(m, 4H), 2.53(m, 2H), 3.26(s, 2H), 6.70(d,
J=8Hz, 1H), 6.77(s, 1H), 6.84(d, J=8Hz, 1H), 7.63(s, 2H), 9.44(s,
1H) 729 10664-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin- 4-yl]-2-methylbutanoic acid FAB(+) 399
(MH.sup.+), 421 (M + Na.sup.+) 149-152.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.00-1.20(m, 4H), 1.14(d,
J=6Hz, 3H), 1.21-1.40(m, 1H), 1.42-1.60(m, 4H), 1.78-1.90(m, 2H),
2.20-2.30(m, 1H), 2.68-2.78(m, 2H), 3.22(s, 2H), 6.67(d, J=8Hz,
1H), 6.74(s, 1H), 6.80(d, J=8Hz, 1H), 7.62(s, 2H), 9.43(s, 1H) 730
1067N-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8- -
ylmethyl)piperidin- 4-ylidene] aminoxyacetic acid FAB(+)
368(MH.sup.+) 128-131.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 2.21(m, 2H), 2.38(m, 2H), 2.45(m, 2H), 2.50(m, 2H),
3.33(s, 2H), 4.43(s, 2H), 6.72(dd, J=1, 8Hz, 1H), 6.77(d, J=1Hz,
1H), 6.83(d, J=8Hz, 1H), 7.63(s, 2H), 9.45(br .multidot. s, 1H) 731
1068(E)-4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-
4-yl]-2-methyl-2-butenoic acid FAB(+) 397(MH.sup.+) 91-93.degree.
C. .sup.1H-NMR(CD.sub.3OD) .delta. ppm: 1.48(m, 1H), # 1.72(m, 1H),
1.81(s, 3H), 1.85-1.95(m, 3H), 2.21(m, 2H), 2.79(br .multidot. t,
J=12Hz, 2H), 3.35(m, 2H), 3.98(s, 2H), 6.70(t, J=7Hz, 1H), 6.74(d,
J=2Hz, 1H), 6.88(dd, J=2, 8Hz, 1H), 6.92(s, 1H), 6.93(d, J=8Hz,
1H), 7.60(s, 2H) 732 10692-hydroxy-[1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)piperidin- 4-yl]acetic
acid 98-99.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.26-1.59(m, 5H), 1.71-1.85(m, 2H), 2.77(m, 2H), 3.22(s, 2H),
3.46(m, 1H), 6.67(d, J=8Hz, 1H), 6.75(s, 1H), 6.81(d, J=8Hz, 1H),
7.61(s, 2H), 9.45(s, 1H) 733
1070[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3,4-
dehydropiperidin-4-yl]acetic acid 124-128.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.11(br .multidot. s, # 2H),
2.56(br .multidot. s, 1H), 2.91(s, 2H), 2.94(br .multidot. s, 1H),
3.32(br .multidot. s, 4H), 5.48(s, 1H), 6.77(d, J=8Hz, 1H), 6.78(s,
1H), 6.86(d, J=8Hz, 1H), 7.63(s, 2H), 9.49(br .multidot. s, 1H) 734
10711-(10H-pyrazino[2,3- b][1,4]benzothiazin-
8-ylmethyl)-3,4-dehydro-3- piperidinecarboxylic acid formate acid
FAB(+) 341(MH.sup.+) 178-180.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 2.24(br .multidot. m2H), 2.43(t, J=3Hz, 2H), 2.95(br
.multidot. s, 2H), 3.39(s, 2H), 6.72(d, J=4Hz, 1H), 6.78(s, 1H),
6.81(br .multidot. m, 1H), 6.84(d, J=4Hz, 1H), 7.63(s, 2H), 8.33(s,
1H), 9.46(s, 1H)
EXAMPLE 735
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-2,3-dehyrdo-3-piperidi-
necarboxylic acid
[2554] To a solution of 0.126 g of ethyl
1-(10H-pyrazino(2,3-b][1,4]benzot- hiazin-8-ylmethyl)
-2,3-dehydro-3-piperidine-carboxylate in dimethyl sulfoxide (6 ml)
were added in a nitrogen atmosphere 0.018 g of water and 0.448 g of
tert-butoxypotassium and the resulting mixture was reacted for 16
hours. After pouring into water, the solution was neutralized with
sodium dihyrogenphosphate. The precipitate thus formed was taken up
by filtration, washed successively with a small portion of water
and dichloromethane and dissolved in dichloromethane. The obtained
solution was dried over magnesium sulfate. After filtering off the
insoluble matters, the solution was concentrated to 5 ml under
reduced pressure. Then diethyl ether (10 ml) was added thereto and
the crystals thus precipitated were taken up by filtration to
thereby give 0.035 g of the title compound as pale yellow crystals.
1072
[2555] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[2556] 1.81(quint, J=6 Hz, 2H), 2.23(t, J=6 Hz, 2H), 3.19(t, J=6
Hz, 2H), 4.20(s, 2H), 6.59(d, J=1 Hz, 1H), 6.71(dd, J=1, 7 Hz, 1H),
6.85(d, J=7 Hz, 1H), 7.57(d, J=3 Hz, 1H), 7.57(d, J=3 Hz, 1H),
7.58(1H, s)
[2557] MS: FAB(+)340(MH.sup.+)
[2558] m.p.: 158-160.degree. C.
EXAMPLE 736
N-[l-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl)sulf-
amoylacetic acid
[2559] To a solution of (2-trimethylsilylethyl)
N-[1-(10H-pyrazino[2,3-b][-
1,4]benzothiazin-8-ylmethyl)piperidin-4-yl)sulfamoylacetate in
tetrahydrofuran (30 ml) was added in a nitrogen atmosphere at
0.degree. C. 5.4 ml of a 1 M solution of tetra-n-butylammonium
fluoride in tetrahydrofuran and the resulting mixture was stirred
at 0.degree. C. for 1 hour and then at room temperature for 2
hours. The reaction mixture was concentrated under reduced pressure
and the residue was purified by High-porous gel chromatography
(CHP20P, mfd. by Mitsubishi Chemical Industries, 45-150.mu.)
(eluted with methanol/water). The compound thus obtained was
dissolved again in a 5 N aqueous solution of sodium hydroxide (100
ml) and washed with dichloromethane. Then the aqueous layer was
neutralized with sodium dihydrogenphosphate and treated by
High-porous gel chromatography (CHP20P, mfd by Mitsubishi Chemical
Industries, 75-150.mu.) (eluted with methanol/water) again. Thus
0.190 g of the title compound was obtained as pale yellow crystals.
1073
[2560] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[2561] 1.55-1.62(m, 4H), 1.98(d, J=10 Hz, 2H), 2.15(d, J=10 Hz,
2H), 2.81(d, J=10 Hz, 1H), 3.2(m, 1H), 3.35(s, 2H), 3.85(s, 2H),
6.66(d, J=1 Hz, 1H), 6.76(dd, J=1, 8 Hz, 1H), 6.80(d, J=8 Hz, 1H),
7.55(d, J=3 Hz, 1H), 7.57(d, J=3 Hz, 1H)
[2562] MS: FAB(+)436(MH.sup.+)
[2563] m.p.: 200-210.degree. C.
EXAMPLES 737 TO
[2564] The following compounds were obtained by the same method as
the one of Example 8.
96 Ex. Structural formula MS M.p. NMR 737
10743-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperi-
din-4-yl]butanoic acid FAB(+) 385(MH+) 218-220.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 0.82(d, # J=6.8Hz, 3H),
1.48-1.55(m, 3H), 1.69-1.95(m, 5H), 2.24-2.30(m, 2H), 2.75-2.82(m,
2H), 3.22(s, 2H), 6.67(d, J=8.0Hz, 1H), 6.75(s, 1H), 6.81(d,
J=8.0Hz, 1H), 7.61(d, J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H), 9.43(s,
1H) 738 1075[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-
phenylpiperidin-4-yl]carboxylic acid ESI(+) 419(MH.sup.+)
>297.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.78-1.90(m, # 2H), 2.14-2.26(m, 2H), 2.36-2.46(m, 2H),
2.68-2.80(m, 2H), 3.30-3.40(m, 2H), 6.73(d, J=8Hz, 1H), 6.76(s,
1H), 6.84(d, J=8Hz, 1H), 7.24(t, J=7Hz, 1H), 7.33(t, J=7Hz, 2H),
7.37(d, J=7Hz, 2H), 7.62(d, J=2Hz, 1H), 7.63(d, J=2Hz, 1H), 9.46(s,
1H) 739 1076[1-(10H-pyrazino[2,3-b][1-
,4]benzothiazin-8-ylmethyl)-4-(p-methoxyphenyl)piperidin-
4-yl]carboxylic acid FAB(+) 499(MH.sup.+) >295.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.70-1.90(m, 2H), #
2.10-2.20(m, 2H), 2.30-2.45(m, 2H), 2.60-2.80(m, 2H), 3.30(m, 2H),
3.71(s, 3H), 6.68-6.74(m, 1H), 6.76(d, J=2Hz, 1H), 6.84(d, J=8Hz,
1H), 6.88(d, J=9Hz, 2H), 7.28(d, J=9Hz, 2H), 7.62(d, J=3Hz, 1H),
7.63(d, J=3Hz, 1H), 9.45(s, 1H) 740
1077[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-4-(p-hydroxyphenyl)piperidin-4-yl]carboxylic acid FAB(+)
435(MH.sup.+) 260-262.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.60-1.80(m, # 2H), 1.90-2.12(m, 2H), 2.20-2.40(m, 2H)
2.54-2.72(m, 2H), 3.23(m, 2H), 6.69(d, J=8Hz, 1H), 6.69(d, J=9Hz,
2H), 6.75(s, 1H), 6.82(d, J=8Hz, 1H), 7.15(d, J=9Hz, 2H), 7.62(s,
2H), 9.32(s, 1H), 9.42(s, 1H) 741
1078[1-[3-(10H-pyrazino[2,3-b][1,4]b- enzothiazin-8-
yl)propyl]piperidin-4-yl]carboxylic acid ESI(+) 371(MH.sup.+)
262-264.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.46-1.66(m, # 4H), 1.70-1.80(m, 2H), 1.84-1.96(m, 2H),
2.10-2.20(m, 1H), 2.21(t, J=7Hz, 2H), 2.38(t, J=8Hz, 2H),
2.7-2.8(m, 2H), 6.60(s, 1H), 6.62(d, J=8Hz, 1H), 6.78(d, J=8Hz,
1H), 7.60(d, J=3Hz, 1H), 7.62(d, J=3Hz, 1H), 9.41(s, 1H) 742
10794-[1-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)
carbonyl]piperidin-4-yl]-2-methylbutanoic acid FAB(+) 427(MH.sup.+)
275-280.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
0.93-1.08(m, 2H), # 1.02(d, J=8Hz, 3H), 1.13-1.23(m, 2H),
1.28-1.40(m, 1H), 1.40-1.76(m, 4H), 2.21-2.32(m, 1H), 2.58-2.73(m,
1H), 2.86-3.01(m, 1H), 3.50-3.65(m, 1H), 4.27-4.43(m, 1H), 6.71(d,
J=1.7Hz, 1H), 6.74(dd, J=1.7, 7.7Hz, 1H), 6.94(d, J=7.7Hz, 1H),
7.64(d, J=2.9Hz, 1H), 7.65(d, J=2.9Hz, 1H), 9.58(s, 1H) 743
10804-[1-(10H-pyrazino[2,3-b]pyrido[- 3,2-e][1,4]thiazin-8-
ylmethyl)piperidin-4-yl]-2-methylbutanoic acid FAB(+) 400(MH.sup.+)
115-118.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.01(d,
J=7.1Hz, # 3H), 1.03-1.22(m, 5H), 1.25-1.37(m, 1H), 1.44-1.55(m,
1H), 1.55-1.66(m, 2H), 1.78-2.01(m, 2H), 2.18-2.29(m, 1H),
2.68-2.83(m, 2H), 3.32(s, 2H), 6.94(br .multidot. d, J=1.9Hz, 1H),
7.63(s, 2H), 7.69(br .multidot. d, J=1.9Hz, 1H), 9.49-9.60(br
.multidot. s, 1H) 744
1081[4-[(10H-pyrazino[2,3-b][1,4]benzothiazin-- 8-
ylmethyl)amino]piperidin-1-yl]acetic acid FAB(+) 372(MH.sup.+)
148-152.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.38-1.54(m, # 2H), 1.80-1.90(m, 2H), 2.40-2.50(m, 1H),
2.60-2.70(m, 2H), 3.10-3.22(m, 2H), 3.14(s, 2H), 3.51(s, 2H),
6.74(d, J=8.0Hz, 1H), 6.75(s, 1H), 6.81(d, J=8.0Hz, 1H), 7.60(d,
J=2.8Hz, 1H), 7.62(d, J=2.8Hz, 1H), 9.45(s, 1H) 745
10821083[4-[(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)acetylamino]piperidin-1-yl]acetic acid (1:1 mixture)
FAB(+) 400(MH.sup.+) 185-191.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.45-1.53 and 1.53-1.61(m, total 2H), 1.63-1.79(m,
total 2H), 2.01 and 2.14 (s, # total 3H), 2.40-2.49(m, total 2H),
2.981-3.08(m, total 2H), 3.09 and 3.10(s, total 2H), # 3.68-3.82
and 4.24-4.38(m, total 1H), 4.28 and 4.35(s, 2H), 6.61 and 6.65(dd,
J=1.7, 8.0Hz, total 1H), 6.62 and 6.70(d, J=1.7Hz, total 1H), 6.80
and 6.88(d, J=8.0Hz, total 1H), 7.61 and 7.62(d, J=3.0Hz, total
1H), 7.62 and 7.63(d, J=3.0Hz, total 1H), 9.44 and 9.49(s, total
1H) 746 1084N-(methanesulfonyl)-N-[1-(10H-pyrazino[2,3-
b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]aminoacetic acid
FAB(+) 450(MH.sup.+) 210-215.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.52-1.70(m, # 4H), 1.86-1.98(m, 2H), 2.72-2.80(m,
2H), 3.08(s, 3H), 3.23(s, 2H), 3.38-3.48(m, 1H), 3.68(s, 2H),
6.66(d, J=8.0Hz, 1H), 6.75(s, 1H), 6.81(d, J=8.0Hz, 1H), 7.61(d,
J=2.8Hz, 1H), 7.62(d, J=2.8Hz, 1H), 9.44(s, 1H) 747
1085[1-(10H-pyrazino[2,3-b][1,4]benz- othiazin-8-
ylmethyl)piperidin-4-yl]carbamoyl]aminoacetic acid FAB(+)
415(MH.sup.+) 207-210.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.20-1.35(m, 3H), # 1.66-1.75(m, 2H), 1.94-2.04(m, 2H),
2.60-2.69(m, 2H), 3.24(s, 2H), 3.64(d, J=5.6Hz, 2H), 5.93(t,
J=5.6Hz, 1H), 6.10(d, J=7.2Hz, 1H), 6.68(d, J=8.0Hz, 1H), 6.74(s,
1H), 6.82(d, J=8.0Hz, 1H), 7.61(d, J=2.8Hz, 1H), 7.63(d, J=2.8Hz,
1H), 9.43(s, 1H) 748
10864-[1-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)carbamoyl]piperidin-4-yl]-2-butanoic acid FAB(+)
442(MH.sup.+) 94-98.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 0.85-1.00(m, 2H), 1.02(d, J=6.0Hz, 3H), # 1.10-1.22(m, 3H),
1.26-1.40(m, 2H), 1.50-1.62(m, 2H), 2.20-2.32(m, 1H), 2.55-2.65(m,
2H), 3.85-3.95(m, 2H), 4.02(d, J=5.2Hz, 2H), 6.62-6.68(m, 1H),
6.65(s, 1H), 6.81(d, J=8.0Hz, 1H), 6.93(d, J=8.0Hz, 1H), 7.61(d,
J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H), 9.51(s, 1H) 749
1087N-(10H-pyrazino[2,3-b][1,4]benzothiaz- in-8-
ylmethyl)-N-[1-(methanesulfonyl)piperidin-4-yl]aminoacetic acid
FAB(+) 450(MH.sup.+) 185-189.degree. C. (decompose)
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.32-1.45(m, 3H),
1.82-1.90(m, 2H), 2.57-2.70(m, 2H), 2.80(s, 3H), 3.15(s, 2H),
3.44-3.56(m, 2H), 3.62(s, 2H), 6.74(d, J=8.0Hz, 1H), 6.78(d,
J=8.0Hz, 1H), 6.79(s, 1H), 7.59(d, J=2.8Hz, 1H), 7.61(d, J=2.8Hz,
1H), 9.45(s, 1H) 750
10882,2-dimethyl-5-[4-(10H-pyrazino[2,3-b][1,4]benzot- hiazin-
8-ylmethyl)piperazin-1-yl]pentanoic acid FAB(+) 428(MH.sup.+)
240-242.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.05(s,
6H), 1.26-1.35(m, 2H), 1.38-1.42(m, 2H), 2.18(t, J=7Hz, 2H),
2.30(br .multidot. s, 8H), 3.23(s, 2H), 6.68(dd, J=1, 8Hz, 1H),
6.74(d, J=1Hz, 1H), 6.83(d, J=8Hz, 1H), 7.62(d, J=3Hz, 1H), 7.63(d,
J=3Hz, 1H), 9.44(s, 1H) 751
10892,2-dimethyl-4-[4-(10H-pyrazino[2,3-b- ][1,4]benzothiazin-8-
ylmethyl)piperazin-1-yl]pentanoic acid dihydrochloride FAB(+)
428(MH.sup.+) >275.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 1.06(s, 6H), 1.43(m. 2H), 1.65(m, 2H), 3.05(br
.multidot. s, 2H), 3.44(br .multidot. s, 4H), 3.50(br .multidot. s,
4H), 4.16(s, 2H), 6.86(br .multidot. s, 1H), 6.98(d, J=8Hz, 1H),
7.12(br .multidot. d, J=8Hz, 1H), 7.64(d, J=3Hz, 1H), 7.65(d,
J=3Hz, 1H), 9.70(s, 1H)
EXAMPLES
[2565] The following compounds were obtained by the same method as
the one of Example 9.
97 Ex. Structural formula MS M.p. NMR 752
1090[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl]acetic acid FAB(+) 357(MH.sup.+),
379(MNa.sup.+) 142-146.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 1.05-1.25(m, 2H), 1.50-1.65(m, 3H), 1.83-1.90(m, 2H),
2.03(d, J=6Hz, 2H), 2.70-2.75(m, 2H), 3.22(s, 2H), 6.66(d, J=8Hz,
1H), 6.74(s, 1H), 6.80(d, J=8Hz, 1H), 7.62(s, 2H), 9.40(s, 1H) 753
10914-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl- ]methylbenzoic acid FAB(+) 433(MH.sup.+)
158-161.degree. C. .sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm:
1.10-1.19(m, 2H), 1.19-1.30(m, 3H), 1.50-1.70(m, 2H), 2.40-2.52(m,
2H), 2.50-2.60(m, 2H), 3.30(s, 2H), 6.64(s, 2H), 6.83(s, 1H),
7.26(d, J=8Hz, 2H), 7.63(s, 2H), 7.82(d, J=8Hz, 2H), 9.50(d, 1H)
754 10924-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)piperidin-4-yl- ]butanoic acid FAB(+) 384(MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.00-1.30(m, 5H),
1.40-1.55(m, 2H), 1.55-1.62(m, 2H), 1.70-1.90(m, 2H), 2.12(t,
J=6Hz, 2H), 2.70-2.80(m, 2H), 3.22(s, 2H), 6.65(d, J=8Hz, 1H),
6.73(s, 1H), 6.80(d, J=8Hz, 1H), 7.60(s, 2H), 9.43(br .multidot. s,
1H) 755 1093[1-(10H-pyrazino[2,3-b][1,4]ben- zothiazin-8-
ylmethyl)piperidin-4-yl]carboxylic acid FAB(+) 343(MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 1.40-1.60(m, 2H),
1.65-1.80(m, 2H), 1.80-1.95(m, 2H), 2.0-2.13(m, 1H), 2.60-2.75(m,
2H), 3.20(s, 2H), 6.66(d, J=8Hz, 1H), 6.78(s, 1H), 6.82(d, J=8Hz,
1H), 7.62(s, 2H), 9.43(br .multidot. s, 1H)
EXAMPLE 756
[5-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]-2-h-
ydroxy-3-oxo-2-methyl-4-pentan-5-yl]thioacetic acid
[2566] To a solution of 0.240 g of
[5-[1-(10H-pyrazino[2,3-b][1,4]benzothi- azin-8-ylmethyl)
piperidin-4-yl]-2-hydroxy-2-methyl-4-penten-3-one in
tetrahydrofuran (20 ml) was added at 0.degree. C. a solution of
0.18 g of mercaptoacetic acid in water (10 ml). After adding 0.18 g
of sodium hydroxide, the resulting mixture was stirred at room
temperature for 30 minutes and then concentrated under reduced
pressure. Next, the residue was purified by High-porous gel
chromatography (CHP20P, mfd by Mitsubishi Chemical Industries,
75-150.mu.) (eluted with methanol/water) to thereby give 0.165 g of
the title compound as pale yellow crystals. 1094
[2567] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2568] 1.15(s, 6H), 1.18-1.23(m, 1H), 1.36-1.46(m, 2H), 1.53(br.d,
J=13 Hz, 1H), 1.61(br.d, J=13 Hz, 1H), 1.74-1.83(m, 2H), 2.78(d,
J=11 Hz, 2H), 2.87-2.98(m, 2H), 3.08(m, 1H), 3.17(d, J=4 Hz, 2H),
3.22(s, 2H), 6.67(d, J=8 Hz, 1H), 6.75(d, J=2 Hz, 1H), 6.82(dd,
J=2, 8 Hz, 1H), 7.62(m, 2H), 9.42(s, 1H)
[2569] MS: FAB(+)503(MH.sup.+)
[2570] m.p.: 130-132.degree. C.
EXAMPLE 757
[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-1-azoniabicyclo[2.2.2-
]octane-4-carboxylate
[2571] 0.620 g of 1-azabicyclo[2.2.2]octane-4-carboxylic acid was
dissolved in 40 ml of acetonitrile. After adding 3.98 g of
N-methyl-N-(trimethylsilyl)trifluoroacetamide, the resulting
mixture was stirred for 2 hours. Next, 0.998 g of
8-chloromethyl-10H-pyrazino[2,3-b][- 1,4]benzothiazine was added
thereto and the resulting mixture was heated under reflux for 4
hours. After distilling off the solvent under reduced pressure, the
residue was dissolved in methanol/dichloromethane. After adding
diethyl ether, the mixture was filtered and the residue was
purified by High-porous gel chromatography (CHP20P, mfd by
Mitsubishi Chemical Industries, 75-150.mu.) (eluted with
methanol/water) to thereby give 0.21 g of the title compound as a
yellow powder. 1095
[2572] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2573] 2.19(t, J=8 Hz, 6H), 3.43(t, J=8 Hz, 6H), 4.19(s, 2H),
6.71(d, J=2 Hz, 1H), 6.88(dd, J=2, 8 Hz, 1H), 6.99(d, J=8 Hz, 1H),
7.62(s, 2H)
[2574] MS: FAB(+)369(MH.sup.+)
[2575] m.p. : 229-230.degree. C.
EXAMPLE 758
[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin-4-yl]oxyacet-
ic acid
[2576] Ethyl (piperidin-4-yl)oxyacetate was treated by the same
methods as those of Examples 63 and 18 to thereby give the title
compound as yellow crystals. 1096
[2577] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2578] 1.35-1.47(m, 2H), 1.76-1.84(m, 2H), 1.95-2.06(m, 2H),
2.56-2.64(m, 2H), 3.24(s, 2H), 3.29-3.38(m, 1H), 3.98(s, 2H),
6.68(dd, J=1.8, 7.8 Hz, 1H), 6.74(d, J=1.8 Hz, 1H), 6.82(d, J=7.8
Hz, 1H), 7.61(d, J=2.8 Hz, 1H), 7.62(d, J=2.8 Hz, 1H), 9.43(s,
1H)
[2579] MS: ESI(+)373(MH+)
[2580] m.p.: 204-207.degree. C.
EXAMPLE 759
[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-piperidin-4-yl]methyl-
thioacetic acid
[2581] Ethyl
[1-(tert-butoxycarbonyl)piperidin-4-yl)methylthio-acetate was
treated successively by the same methods as those of Examples 66
and 18 to thereby give the title compound. 1097
[2582] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2583] 1.10-1.20(m, 2H), 1.36-1.48(m, 1H), 1.63-1.72(m, 2H),
1.82-1.91(m, 2H), 2.48(d, J=7.2 Hz, 2H), 2.71-2.78(m, 2H), 3.17(s,
2H), 3.24(s, 2H), 6.68(d, J=7.9 Hz, 1H), 6.74(s, 1H), 6.82(d, J=7.9
Hz, 1H), 7.62(s, 2H), 9.43(s, 1H)
[2584] MS: FAB(+)403(MH.sup.+)
[2585] m.p. : 110-113.degree. C.
EXAMPLE 760
8-[2-[(1,3-Dithiacyclohexan-2-ylidene)methyl]-4,5,6,7-tetrahydro-6H-thieno-
[2,3-c]pyridin-6-ylmethyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
[2586]
2-[(1,3-Dithiacyclohexan-2-ylidene)methyl]-6-(tert-butoxycarbonyl)
-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridine was treated by the
same method as the one of Example 66 to thereby give the title
compound as orange crystals. 1098
[2587] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2588] 2.20(quint, J=6.0 Hz, 2H), 2.72(br.t, J=5.4 Hz, 2H),
2.84(br.t, J=5.4 Hz, 2H), 2.98(t, J=6.0 Hz, 2H), 3.00(t, J=6.0 Hz,
2H), 3.60(s, 2H), 3.70(br.s, 2H), 6.51-6.58(br.s, 1H), 6.68(br.d,
J=1.6 Hz, 1H), 6.77(s, 1H), 6.79(dd, J=1.6, 8.0 Hz, 1H), 6.85(d,
J=8.0 Hz, 1H), 6.92(s, 1H), 7.57(d, J=2.8 Hz, 1H), 7.68(d, J=2.8
Hz, 1H)
EXAMPLE 761
[6-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-4,5,6,7-tetrahydro-6H-thieno[2,3-c]pyridin-2-yl]acetic acid
[2589] 8-[2-[(1,3-Dithiacyclohexan-2-ylidene)
methyl]-4,5,6,7-tetrahydro-6-
H-thieno[2,3-c]pyridin-6-ylmethyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
was treated successively by the same methods as those of Production
Example 63 and Example 18 to thereby give the title compound as
yellow crystals. 1099
[2590] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2591] 2.56(t, J=6.8 Hz, 2H), 2.65(t, J=6.8 Hz, 2H), 3.47(s, 4H),
3.64(s, 2H), 6.5-9(s, 1H), 6.73(d, J=8.0 Hz, 1H), 6.81(s, 1H),
6.84(d, J=8.0 Hz, 1H), 7.61(d, J=2.8 Hz, 1H), 7.62(d, J=2.8 Hz,
1H), 9.45(s, 1H)
[2592] MS: FAB(+)411(MH.sup.+)
[2593] m.p. : 98-105.degree. C.
EXAMPLE 762
4-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl]acetyl]-piperidin-4-yl]-2--
methylbutanoic acid
[2594]
10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine-8-acetic
acid was treated successively by the same methods as those of
Examples 362, 18 and 8 to thereby give the title compound as yellow
crystals. 1100
[2595] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2596] 0.82-0.94(m, 2H), 1.01(d, J=7.1 Hz, 3H), 1.10-1.19(m, 2H),
1.26-1.46(m, 2H), 1.46-1.56(m, 1H), 1.56-1.66(m, 2H), 2.19-2.30(m,
1H), 2.43-2.53(m, 1H), 2.86-2.96(m, 1H), 3.50(s, 2H), 3.82(br.d,
J=13.0 Hz, 1H), 4.33(br.d, J=13 Hz, 1H), 6.62(s, 1H), 6.63(d, J=8.3
Hz, 1H), 6.82(d, J=8.3 Hz, 1H), 7.62(d, J=2.7 Hz, 1H), 7.63(d,
J=2.7 Hz, 1H), 9.48(s, 1H)
[2597] MS: FAB(+)427(MH.sup.+)
[2598] m.p. : 84-89.degree. C.
PRODUCTION EXAMPLE 120
2-[N-Methyl-(2-nitrophenyl)amino]-3-chloropyrazine
[2599] To a solution of 1.52 g of N-methyl-2-nitroaniline in
N,N-dimethylformamide (50 ml) was added in a nitrogen atmosphere
0.44 g of sodium hydride. After stirring for 30 minutes, 1.75 g of
2,3-dichloropyrazine was added thereto and the resulting mixture
was stirred at room temperature for additional 6 hours. Then the
reaction mixture was distributed into ethyl acetate and a saturated
aqueous solution of sodium dihydrogenphosphate and the aqueous
layer was extracted with ethyl acetate. The organic layers were
combined, washed successively with water and a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 0.586 g of the
title compound as an oily substance. 1101
[2600] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2601] 3.45(s, 3H), 7.08(dd, J=1, 7 Hz, 1H), 7.39(dt, J=1, 7 Hz,
1H), 7.58(dt, J=1, 7 Hz, 1H), 7.89(d, J=2 Hz, 1H), 7.97(dd, J=1, 7
Hz, 1H), 8.17(d, J=2 Hz, 1H)
PRODUCTION EXAMPLE 121
2-[(2-Nitrophenyl)amino]-3-chloropyrazine
[2602] Starting with 41.4 g of 2-nitroaniline and 35.0 g of
2,3-dichloropyrazine, 39.8 g of the title compound was obtained by
the same method as the one described in Production Example 120.
1102
[2603] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2604] 7.13(dt, J=1, 7 Hz, 1H), 7.67(dt, J=1, 7 Hz, 1H), 7.96(d,
J=2 Hz, 1H), 8.18(d, J=2 Hz, 1H), 8.31(dd, J=1,7 Hz, 1H), 9.02(dd,
J=1, 7 Hz, 1H), 11.00(br.s, 1H)
PRODUCTION EXAMPLES
[2605] The following compounds were obtained from various anilines
and 2,3-dichloropyrazine by the same procedure as the one of
Production Example 121.
98 Prodn. Ex. Structural formula NMR 122
11032-[[2-nitro-4-(methoxymethoxy)- phenyl)amino]-3-chloropyrazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.50(s, 3H), # 5.22(s, 2H),
7.39(dd, J=3, 9Hz, 1H), 7.91(d, J=3Hz, 1H), 7.95(d, J=3Hz, 1H),
8.12(d, J=3Hz, 1H), 8.88(d, J=9Hz, 1H), 10.70(br .multidot. s, 1H)
123 11042-[(2-nitro-5-methoxyphenyl)- amino]-3-chloropyrazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.87(s, 3H), # 7.28(dd,
J=3.10Hz, 1H), 7.75(d, J=3Hz, 1H), 7.90(d, J=3Hz, 1H), 8.12(d,
J=3Hz, 1H), 8.88(d, J=10Hz, 1H), 10.70(br .multidot. s, 1H) 124
1105ethyl 3-nitro-4-[(3-chloropyrazin-2- yl)amino]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.42(t, J=7Hz, # 3H), 4.42(q,
J=7Hz, 2H), 8.14(d, J=3Hz, 1H), 8.24(d, J=3Hz, 1H), 8.29(dd, J=2,
8Hz, 1H), 8.98(d, J=2Hz, 1H), 9.16(d, J=8Hz, 1H), 11.30(s, 1H) 125
11063-nitro-4-[(3-chloropyrazin-2-yl) amino]benzonitrile
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 7.87(dd, J=2, 8Hz, 1H),
8.10(d, J=3Hz, 1H), 8.26(d, J=3Hz, 1H), 8.65(d, J=2Hz, 1H), 9.30(d,
J=8Hz, 1H), 11.34(s, 1H) 126 11072-[(4-iodo-2-nitrophenyl)amino]-
3-chloropyrazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 7.90(dd, J=2,
8Hz, 1H), 7.98(d, J=3Hz, 1H), 8.18(d, J=3Hz, 1H), 8.60(d, J=2Hz,
1H), 8.84(d, J=8Hz, 1H), 10.95(br .multidot. s, 1H)
PRODUCTION EXAMPLE 127
2-[(2-Aminophenyl)amino]-3-chloropyrazine
[2606] To a solution of 1.1 g of 2-[(2-nitrophenyl)
-1-amino)]-3-chloropyrazine in tetrahydrofuran (35 ml) was added an
aqueous solution (14 ml) of 7 g of sodium hydrosulfide. After
adding 14 ml of 50% aqueous ammonia thereto, the resulting mixture
was vigorously stirred at room temperature for 16 hours. Then the
reaction mixture was distributed into ethyl acetate and water and
the organic layer was dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 0.28 g of the title
compound as yellow crystals. 1108
[2607] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2608] 3.73(br.s, 2H), 6.79(br.s, 1H), 6.83-6.87(m, 2H), 7.10(t,
J=7 Hz, 1H), 7.38(d, J=7 Hz, 1H), 7.74(d, J=2 Hz, 1H), 8.00(d, J=2
Hz, 1H)
PRODUCTION EXAMPLES
[2609] The following compounds were obtained by reducing nitro
groups by the same procedure as the one of Production Example
127.
99 Prodn. Ex. Structural formula NMR 128
11092-[[2-amino-4-(methoxymethoxy)- phenyl]amino]-3-chloropyrazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.48(s, 3H), # 3.79(br
.multidot. s, 2H), 5.14(s, 2H), 6.51(dd, J=3, 8Hz, 1H), 6.54(br
.multidot. s, 1H), 6.56(d, J=3Hz, 1H), 7.14(d, J=8Hz, 1H), 7.70(d,
J=3Hz, 1H), 7.98(d, J=3Hz, 1H) 129 11102-[(2-amino-5-methoxyphen-
yl]amino]- 3-chloropyrazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.78(s, 3H), # 3.80(br .multidot. s, 2H), 6.37-6.40(m, 2H), 6.53(br
.multidot. s, 1H), 7.12(d, J=9Hz, 1H), 7.69(d, J=3Hz, 1H), 7.98(d,
J=3Hz, 1H) 130 1111ethyl 3-amino-4-[(3-chloropyrazin-2-
yl)amino]benzoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.39(t,
J=7Hz, # 3H), 3.69(br .multidot. s, 2H), 4.35(q, J=7Hz, 2H),
7.20(br .multidot. s, 1H), 7.58-7.62(m, 2H), 7.80(d, J=3Hz, 1H),
7.81(d, J=8Hz, 1H), 8.06(d, J=3Hz, 1H) 131
11123-amino-4-[(3-chloropyraz- in- 2-yl)amino]benzonitrile
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.75(br .multidot. s, 2H),
7.14(d, J=2Hz, 1H), 7.17(br .multidot. s, 1H), 7.20(dd, J=2, # 8Hz,
1H), 7.85(d, J=3Hz, 1H), 7.90(d, J=8Hz, 1H), 8.08(d, J=3Hz, 1H)
PRODUCTION EXAMPLE 132
2-[N-Allyl-(2-nitrophenyl)amino]-3-chloropyrazine
[2610] A solution of 5.01 g of 2-[(2-nitrophenyl)
amino]-3-chloropyrazine in N,N-dimethylformamide (200 ml) was
degassed in a nitrogen atmosphere and then 0.92 g of sodium hydride
(60% oily) was added thereto at 0.degree. C. After stirring for 30
minutes, 4.84 g of allyl bromide was added and the resulting
mixture was stirred at ordinary temperature for 16 hours. Then the
reaction mixture was distributed into ethyl acetate and water and
the aqueous layer was extracted with ethyl acetate. The organic
layers were combined, washed successively with water and a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
4.78 g of the title compound as a colorless oily substance.
1113
[2611] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2612] 4.54(d, J=7 Hz, 2H), 5.11-5.16(m, 2H), 5.99-6.09(m, 1H),
7..19(dd, J=1, 7 Hz, 1H), 7.38(dt, J=1, 7 Hz, 1H), 7.57(dt, J=1, 7
Hz, 1H), 7.91(d, J=3 Hz, 1H), 7.95(dd, J=1, 7 Hz, 1H), 8.16(d, J=3
Hz, 1H)
PRODUCTION EXAMPLES
[2613] The following compounds were obtained by treating
2-[(2-nitrophenyl)amino]-3-chloropyrazine with various halides by
the same procedure as the one of Production Example 132.
100 Prodn. Ex. Structural formula NMR 133 1114t-butyl
N-(3-chloropyrazin-2-yl)-N- (2-nitrophenyl)minoacetate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.45(s, 9H), # 4.40(s, 2H),
7.45(dt, J=2, 8Hz, 1H), 7.51(dd, J=2, 8Hz, 1H), 7.60(dt, J=2, 8Hz,
1H), 7.91(d, J=2Hz, 1H), 8.03(dd, J=2, 8Hz, 1H), 8.12(d, J=2Hz, 1H)
134 1115methyl 4-[N-(3-chloropyrazin-2- -yl)-
N-(2-nitrophenyl)minomethyl]- benzoate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.88(s, # 3H), 5.22(s, 2H), 7.11(dd, J=1, 7Hz, 1H),
7.37(dt, J=1, 7Hz, 1H), 7.42(d, J=8Hz, 2H), 7.51(dt, J=1, 7Hz, 1H),
7.91-7.94(m, 4H), 8.12(d, J=3Hz, 1H) 135 1116methyl
(E)-4-[N-(3-chloropyrazin-2- yl)-N-(2-nitrophenyl)amino]-
2-butenoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.71(s, 3H), #
4.66(d, J=6Hz, 2H), 5.93(d, J=16Hz, 1H), 7.10(td, J=6, 16Hz, 1H),
7.14(d, J=8Hz, 1H), 7.42(t, J=8Hz, 1H), 7.57(t, J=8Hz, 1H), 7.95(s,
1H), 7.97(d, J=8Hz, 1H), 8.17(s, 1H)
PRODUCTION EXAMPLES
[2614] The following compounds were obtained by the same method as
the one of Production Example 132 by replacing the allyl bromide by
methyl iodide.
101 Prodn. Ex. Structural formula NMR 136
11172-[N-(4-methoxymethoxy-2-nitrophenyl)- N-methylamino]-3-chloro-
pyrazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.42(s, 3H), 3.50(s,
3H), 5.23(s, 2H), 7.10(d, J=9Hz, 1H), 7.24(dd, J=3, 9Hz, 1H),
7.65(s, 1H), 7.85(s, 1H), 8.15(d, J=3Hz, 1H) 137
11182-[N-(5-methoxy-2-nitrophenyl)-N- methylamino]-3-chloropyrazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.42(s, 3H), 3.88(s, 3H),
7.05(m, 2H), 7.49(m, 1H), 7.84(d, J=3Hz, 1H), 8.15(d, J=3Hz, 1H)
138 1119ethyl 4-[N-methyl-N-(3-chloropyrazin-2-
yl)amino]-3-nitrobenzoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.41(t, # J=7Hz, 3H), 3.51(s, 3H), 4.42(q, J=7Hz, 2H), 7.25(d,
J=8Hz, 1H), 8.02(d, J=2Hz, 1H), 8.20(d, J=2Hz, 1H), 8.21(dd, J=2,
8Hz, 1H), 8.58(d, J=2Hz, 1H) 139
11203-nitro-4-[N-methyl-N-(3-chloropyrazin- 2-yl)amino]benzonitrile
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.53(s, 3H), 7.33(d, J=8Hz,
1H), 7.83(dd, J=2, 8Hz, 1H), 8.12(d, J=3Hz, 1H), 8.20(d, J=2Hz,
1H), 8.21(d, J=3Hz, 1H) 140 11212-[N-(4-iodo-2-nitrophenyl)-N-
methylamino]-3-chloropyrazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.37(s, 3H), 6.86(d, J=8Hz, 1H), 7.80(d, J=8Hz, 1H), 7.88(s, 1H),
8.12(s, 1H), 8.19(s, 1H)
PRODUCTION EXAMPLES
[2615] The following compounds were obtained by the same method as
the one of Production Example 132 by replacing the allyl bromide by
chloromethyl methyl ether.
102 Prodn. Ex. Structural formula NMR 141
11222-[N-(4-methoxymethoxy-2-nitrophenyl)-N-
(methoxymethyl)amino]-3-chloropyrazine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.38(s, 3H), 3.50(s, 3H), 5.23(s, 2H), 5.27(s, 2H),
7.26(d, J=9Hz, 1H), 7.32(d, J=9Hz, 1H), 7.62(s, 1H), 7.94(s, 1H),
8.18(s, 1H) 142 11232-[N-(4-methoxy-2-nitrophenyl)-N-
(methoxymethyl)amino]3-chl- oropyrazine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.39(s, 3H), 3.88(s, 3H), 5.27(s, 2H), 7.14(dd, J=3,
9Hz, 1H), 7.33(d, J=9Hz, 1H), 7.46(d, J=3Hz, 1H), 7.94(d, J=3Hz,
1H), 8.18(d, J=3Hz, 1H) 143
11244-[N-methoxymethyl-N-(3-chloropyrazin-2-yl)
amino]-3-nitrobenzonitril- e .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.35(s, 3H), 5.39(s, 2H), 7.75(d, J=8Hz, 1H), 7.87(d, J=2, 8Hz,
1H), 8.15(d, J=2Hz, 1H), 8.17(d, J=3Hz, 1H), 8.25(d, J=3Hz, 1H) 144
1125 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
2-[N-methoxymethyl-N-(2-nitrophenyl)amino]- 3.38(s, 3H), 5.32(s,
2H), 7.42(dt, J=1, 8Hz, 1H), 3-chloropyrazine 7.47(dd, J=1, 8Hz,
1H), 7.62(dt, J=1, 8Hz, 1H), 7.94(dd, J=1, 8Hz, 1H), 8.00(d, J=2Hz,
1H), 8.21(d, J=2Hz, 1H)
PRODUCTION EXAMPLE 145
(E)-2-[N-(4-Bromo-2-buten-1-yl)-N-(2-nitrophenyl)
amino]-3-chloropyrazine
[2616] Similar to Production Example 132, 5.04 g of
2-[(2-nitrophenyl)amino]-3-chloropyrazine was treated with
(E)-1,4-dibromo-2-butene to thereby give 0.34 g of the title
compound. 1126
[2617] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2618] 3.86(d, J=7 Hz, 2H), 4.51(d, J=6 Hz, 2H), 5.76(td, J=7, 14
Hz, 1H), 6.01(td, J=6, 14 Hz, 1H), 7.15(dd, J=1, 8 Hz, 1H),
7.41(dt, J=1, 8 Hz, 1H), 7.57(dt, J=1, 8 Hz, 1H), 7.92(d, J=2 Hz,
1H), 7.97(dd, J=1, 8 Hz, 1H), 8.17(d, J=2 Hz, 1H)
PRODUCTION EXAMPLE 146
(E)-2-[N-(4-Dimethylamino-2-buten-1-yl)-N-(2-nitrophenyl)amino]-3-chloropy-
razine
[2619] Similar to Example 1094, 0.34 g of
(E)-2-[N-(4-bromo-2-buten-1-yl)--
N-(2-nitrophenyl)amino]-3-chloropyrazine was treated with 20 ml of
a 0.86 M ethanol solution of dimethylamine in 5 ml of ethanol to
thereby give 0.17 g of the title compound as a yellow oily
substance. 1127
[2620] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2621] 2.65(s, 6H), 3.57(d, J=7 Hz, 2H), 4.53(d, J=6 Hz, 2H),
5.90(td, J=7, 16 Hz, 1H), 6.16(td, J=6, 16 Hz, 1H), 7.17(dd, J=1, 8
Hz, 1H), 7.41(dt, J=1, 8 Hz, 1H), 7.60(dt, J=1, 8 Hz, 1H), 7.92(dd,
J=1, 8 Hz, 1H), 7.93(d, J=2 Hz, 1H), 8.19(d, J=2 Hz, 1H)
PRODUCTION EXAMPLE 147
3-[[N-(3-Chloropyrazin-2-yl)-N-(2-nitrophenyl)]amino]-1,2-propanediol
[2622] 1.16 g of 2-[N-[allyl-N-(2-nitrophenyl)
amino]-3-chloropyrazine was treated in the same manner as that of
Example 1195 to thereby give 0.716 g of the title compound.
1128
[2623] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2624] 3.55-3.60(m, 1H), 3.62-3.68(m, 1H), 3.93(br.s, 1H),
3.98-4.03(m, 1H), 4.08-4.20(m, 2H), 4.43(br.s, 1H), 7.36(d, J=7 Hz,
1H), 7.45(t, J=7 Hz, 1H), 7.63(t, J=7 Hz, 1H), 7.98(d, J=2 Hz, 1H),
8.00(d, J=7 Hz, 1H), 8.14(d, J=2 Hz, 1H)
PRODUCTION EXAMPLE 148
2-(6-Methyl-2-nitrophenyl)thio-3-chloropyrazine
[2625] To a solution of 1.254 g of 6-methyl-2-nitrobenzenethiol in
tetrahydrofuran (10 ml) was added 0.326 g of sodium hydride under
ice-cooling in a nitrogen atmosphere. After stirring for 10
minutes, 1.67 g of dichloropyrazine was added thereto and the
resulting mixture was stirred at room temperature for 1 hour and
heated under reflux for 1.5 hour. Then the reaction mixture was
poured into a saturated aqueous solution of sodium
dihydrogenphosphate and extracted with ethyl acetate. The organic
layer was dried over anhydrous magnesium sulfate and distilled
under reduced pressure. Then the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.737 g of the title compound as a red oily substance.
1129
[2626] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2627] 2.46(s, 3H), 7.53(t, J=8 Hz, 1H), 7.58(dd, J=2, 8 Hz, 1H),
7.68(dd, J=2, 8 Hz, 1H), 8.06(d, J=3 Hz, 1H), 8.10(d, J=3 Hz,
1H)
PRODUCTION EXAMPLE 149
Diethyl 2-phenyl-2-(5-nitropyridin-2-yl)malonate
[2628] 14.9 g of diethyl phenylmalonate was dissolved in 50 ml of
N,N-dimethylformamide and 2.52 g of sodium hydride (60% oily) was
added thereto at room temperature. Next, 5.0 g of
2-chloro-5-nitropyridine was added thereto and the resulting
mixture was stirred at 80.degree. C. for 2 hours. After the
completion of the reaction, the reaction mixture was poured into
ice-water/ethyl acetate and neutralized with dilute hydrochloric
acid. After extracting with ethyl acetate, the extract was dried
over anhydrous sodium sulfate and filtered. The filtrate was
distilled under reduced pressure and the obtained residue was
purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 16.55 g of the title compound as
a reddish brown oily substance. 1130
[2629] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2630] 1.23(t, J=7 Hz, 6H), 4.15(q, J=7 Hz, 4H), 7.20-7.45(m, 6H),
8.25(d, J=7 Hz, 1H), 9.38(s, 1H)
PRODUCTION EXAMPLE 150
2-Benzyl-5-nitropyridine
[2631] 1.5 g of diethyl 2-phenyl-2-(5-nitropyridin-2-yl)malonate
was dissolved in 50 ml of ethanol. After adding 10 ml of water and
10 ml of conc. sulfuric acid, the mixture was heated under reflux
for 8 hours. After the completion of the reaction, the reaction
mixture was poured into a saturated aqueous solution of sodium
hydrogencarbonate and extracted with ethyl acetate. The extract was
dried over anhydrous sodium sulfate and filtered. The filtrate was
distilled under reduced pressure and the obtained residue was
purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 632 mg of the title compound as
reddish brown crystals. 1131
[2632] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2633] 4.28(s, 2H), 7.20-7.43(m, 6H), 8.33(d, J=7 Hz, 1H), 9.36(s,
1H)
PRODUCTION EXAMPLE 151
2-Benzyl-5-amlnopyridine
[2634] 389 mg of 2-benzyl-5-nitropyridine was dissolved in ethyl
acetate and 153 mg of 10% palladium carbon was added thereto. Then
the resulting mixture was stirred under a hydrogen gas stream at
room temperature under atmospheric pressure for 30 minutes. Then
the reaction mixture was filtered through celite. After distilling
off the solvent under reduced pressure, 333 mg of the title
compound was obtained as an amber oily substance. 1132
[2635] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2636] 3.65(br.s, 2H), 4.02(s, 2H), 6.82(d, J=7 Hz, 1H), 6.85(d,
J=7 Hz, 1H), 7.13-7.36(m, 5H), 7.97(s, 1H)
PRODUCTION EXAMPLES
[2637] The following compounds were obtained by successively
treating diethyl benzylmalonate and diethyl methylmalonate in the
same manner as those of Production Examples 149, 150 and 151.
103 Prodn. Ex. Structural formula NMR 152
11332-phenethyl-5-aminopyridine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.92(s, 4H), 3.90(br .multidot. s, 2H), 6.72-6.83(m, 2H),
7.08-7.20(m, 2H), 7.20-7.30(m, 3H), 7.96(br .multidot. s, 1H) 153
11342-ethyl-5-aminopyridine .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.23(t, J=7Hz, 3H), 2.72(q, J=7Hz, 2H), 3.58(br .multidot.s, 2H),
6.92(s, 2H), 8.00(s, 1H)
PRODUCTION EXAMPLE 154
Triethyl
5-methyl-1-(5-nitropyridin-2-yl)hexane-1,1,5-tricarboxylate
[2638] 5 g of diethyl malonate was dissolved in 30 ml of
N,N-dimethylformamide and 1.550 g of sodium hydride (60% oily) was
added thereto under ice-cooling. Next, 7.04 g of ethyl
2,2-dimethyl-5-bromopent- anoate was added to the reaction mixture
and the resulting mixture was stirred at 80.degree. C. for 2 hours.
After ice-cooling the reaction mixture again, 1.550 g of sodium
hydride (60% oily) was added thereto. After stirring for 25
minutes, 7.4 g of 2-chloro-5-nitropyridine was added and the
resulting mixture was stirred at 80.degree. C. for 1.5 hours. After
the completion of the reaction, the reaction mixture was poured
into a saturated aqueous solution of sodium chloride and repeatedly
extracted with ethyl acetate. The extracts were dried over
anhydrous sodium sulfate and filtered. The filtrate was distilled
under reduced pressure and the obtained residue was purified by
silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 9.71 g of the title compound as a
yellow oily substance. 1135
[2639] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2640] 1.12(s, 6H), 1.13(t, J=7 Hz, 3H), 1.14(t, J=7 Hz, 6H),
1.43-1.60(m, 2H), 2.25-2.38(m, 4H), 4.10(q, J=7 Hz, 2H), 4.21(q,
J=7 Hz, 2H), 4.23(q, J=7 Hz, 2H), 8.00(d, J=8 Hz, 1H), 8.49(d, J=8
Hz, 1H), 9.33(s, 1H)
PRODUCTION EXAMPLE 155
Ethyl 6-(5-nitropyridin-2-yl)-2,2-dimethylhexanoate
[2641] 9.71 g of triethyl
5-methyl-1-(5-nitropyridin-2-yl)hexane-1,1,5-tri- carboxylate was
treated in the same manner as the one of Production Example 149 to
thereby give 2.87 g of a yellow oily substance. A 1.82 g portion of
this product was dissolved in 30 ml of ethanol. After adding 3 ml
of conc. sulfuric acid, the resulting mixture was heated under
reflux for 7 hours. After the completion of the reaction, the
reaction mixture was poured into a saturated aqueous solution of
sodium chloride and extracted with ethyl acetate. The extract was
dried over anhydrous sodium sulfate and filtered. The filtrate was
distilled under reduced pressure and the obtained residue was
purified by silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 1.0 g of the title compound as a
yellow oily substance. 1136
[2642] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2643] 1.12(s, 6H), 1.22(t, J=7 Hz, 3H), 1.60-1.80(m, 4H), 2.30(t,
J=6 Hz, 2H), 2.60(t, J=6 Hz, 2H), 4.13(q, J=7 Hz, 2H), 7.35(d, J=8
Hz, 1H), 8.37(dd, J=2, 8 Hz, 1H), 9.28(d, J=2 Hz, 1H)
PRODUCTION EXAMPLE 156
6-(5-Nitropyridin-2-yl)-2,2-dimethylhexanamide
[2644] Ethyl 6-(5-nitropyridin-2-yl)-2,2-dimethylhexanoate was
treated in the same manner as the one of Example 18 and 661 mg of
6-(5-nitropyridin-2-yl)-2,2-dimethylhexanoic acid thus obtained was
dissolved in 15 ml of tetrahydrofuran. After adding 695 mg of
carbonyldiimidazole, the resulting mixture was heated under reflux
for 2 hours. Then the reaction mixture was cooled to room
temperature and 25 ml of saturated aqueous ammonia was added
thereto followed by stirring over day and night. After the
completion of the reaction, the reaction mixture was poured into a
saturated aqueous solution of sodium chloride and repeatedly
extracted with ethyl acetate. The extracts were dried over
anhydrous sodium sulfate and filtered. The filtrate was distilled
under reduced pressure and the residue was purified by silica gel
column chromatography (eluted with toluene/acetone) to thereby give
453 mg of the title compound as white crystals. 1137
[2645] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2646] 1.13(s, 6H), 1.30-1.40(m, 2H), 1.50-1.60(m, 2H),
1.7.0-1.80(m, 2H), 2.90(t, J=7 Hz, 2H), 5.55-5.80(br.s, 2H),
7.16(d, J=7 Hz, 1H), 8.37(d, J=7 Hz, 1H), 9.33(s, 1H)
PRODUCTION EXAMPLES
[2647] Ethyl 6-(5-nitropyridin-2-yl)-2,2-dimethylhexanoate and
6-(5-nitropyridin-2-yl)-2,2-dimethylhexanamide were hydrogenated in
the same manner as the one of Production Example 151 to thereby
give the following compounds.
104 Prodn. Ex. Structural formula NMR 157 1138ethyl
6-(5-aminopyridin-2-yl)-2,2-dimethylhexanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.13(s, 6H), 1.23(t, J=7Hz,
3H), 1.60-1.80(m, 4H), 2.32(t, J=6Hz, 2H), 2.60(t, J=6Hz, 2H),
3.40-3.60(br .multidot. s, 2H), 4.12(q, J=7Hz, 2H), 6.92(s, 2H),
8.01(s, 1H) 158 11396-(5-aminopyridin-2-yl)-2,2- dimethylhexanamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.13(s, 6H), 1.22-1.36(m, 2H),
1.50-1.58(m, 2H), 1.60-1.70(m, 2H), 2.63(t, J=7Hz, 2H), 3.60(br
.multidot. s, 2H), 5.62(br .multidot. s, 2H), 6.92(s, 2H), 7.99(s,
1H)
PRODUCTION EXAMPLE 159
Mixture of 2-methyl-5-aminopyridine with ethyl
(5-aminopyridin-2-yl)acetat- e.
[2648] 3.131 g of diethyl 2-(5-nitropyridin-2-yl)malonate, 476 mg
of lithium chloride and 0.2 ml of water were dissolved in 10 ml of
N,N-dimethylformamide and heated at 120.degree. C. for 3 hours.
Then the reaction mixture was distilled under reduced pressure and
the residue thus obtained was purified by silica gel column
chromatography (eluted with ethyl acetatein-hexane) to thereby give
803 mg of a mixture of 2-methyl-5-nitropyridine with ethyl
(5-nitropyridin-2-yl)acetate as a reddish brown crystalline
substance. 803 mg of these crystals were hydrogenated in the same
manner as the one of Production Example 151 to thereby give as a
pale yellow oily substance 614 mg of a mixture of the title
compounds which could be hardly separated.
2-methyl-5-aminopyridine- : 1140
[2649] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2650] 2.27(s, 3H), 3.70-3.90(br.s, 2H), 6.82(d, J=2 Hz, 1H),
6.98(d, J=7 Hz, 1H), 7.93(dd, J=2, 7 Hz, 1H) ethyl
(5-aminopyridin-2-yl)acetate 1141
[2651] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2652] 1.18(t, J=7 Hz, 3H), 3.65(s, 2H), 3.70-3.90(br.s, 2H),
4.10(q, J=7 Hz, 2H), 6.82(d, J=2 Hz, 1H), 6.98(d, J=7 Hz, 1H),
7.93(dd, J=2, 7 Hz, 1H)
PRODUCTION EXAMPLE 160
N-(Imidazol-2-ylmethyl)acetamide
[2653] 0.34 g of 2-aminomethylimidazole dihydrochloride was added
to 20 ml of N,N-dimethylformamide in a nitrogen atmosphere. Under
ice-cooling, 0.40 g of sodium hydride (60% oily) was added thereto
and the resulting mixture was subjected to ultrasonication for 30
minutes. To the reaction mixture were added 20 ml of pyridine and
10 ml of acetic anhydride and the obtained mixture was stirred at
room temperature for 2 days. After concentrating under reduced
pressure, the residue was distributed into water and ethyl acetate.
The organic layer was washed with water and dried over anhydrous
sodium sulfate. The extract was concentrated under reduced pressure
to thereby give 0.24 g of the title compound as a pale brown solid.
1142
[2654] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2655] 1.99(s, 3H), 4.44(d, J=7 Hz, 2H), 6.96(s, 2H), 8.25(br.s,
1H), 8.39(br.m, 1H)
PRODUCTION EXAMPLE 161
N-[1-[2-(Trimethylsilyl)ethoxymethyl]imidazol-2-ylmethyl]-acetamide
[2656] Under ice-cooling, 0.08 g of sodium hydride (60% oily) was
added to a solution of 0.31 g of N-(imidazol-2-ylmethyl)acetamide
in N,N-dimethylformamide (10 ml). After stirring for 15 minutes, a
solution of 0.35 ml of 2-(trimethylsilyl)ethoxymethyl chloride in
N,N-dimethylformamide (1 ml) was dropped thereinto and the
resulting mixture was stirred at room temperature for additional 16
hours. Then the reaction mixture was distributed into water and
ethyl acetate. The organic layer was washed with water and dried
over anhydrous magnesium sulfate. After concentrating under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.16 g of the title compound as a colorless oily substance.
1143
[2657] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2658] 0.01(s, 9H), 0.92(t, J=8 Hz, 2H), 2.05(s, 3H), 3.51(t, J=8
Hz, 2H), 4.54(d, J=7 Hz, 2H), 5.30(s, 2H), 6.53(br.s, 1H), 6.99(d,
J=1 Hz, 1H), 7.01(d, J=1 Hz, 1H)
PRODUCTION EXAMPLE 162
2-[N-(tert-Butoxycarbonyl)aminomethyl]imidazole
[2659] To an aqueous solution (10 ml) of 0.34 g of
2-aminomethylimidazole dihydrochloride were added 0.32 g of sodium
hydroxide and 0.34 g of sodium hydrogencarbonate. Then a
tetrahydrofuran solution (10 ml) of 1.05 g of di-tert-butyl
dicarbonate was added thereto and the resulting mixture was stirred
at room temperature for 16 hours. After adding an aqueous solution
of disodium hydrogenphosphate, the resulting mixture was extracted
with ethyl acetate. The organic layer was washed successively with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous magnesium sulfate. After concentrating under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.20 g of the title compound as a colorless powder. 1144
[2660] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2661] 1.43(s, 9H), 4.32(d, J=7 Hz, 2H), 5.43(br.s, 1H), 6.96(s,
2H)
PRODUCTION EXAMPLE 163
1-[2-(Trimethylsilyl)ethoxymethyl-2-[N-(tert-butoxycarbonyl)-aminomethyl]i-
midazole
[2662] Starting with
2-[N-(tert-butoxycarbonyl)aminomethyl]-imidazole, the title
compound was obtained by the same procedure as that of Production
Example 161. 1145
[2663] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2664] 0.01(s, 9H), 0.92(t, J=8 Hz, 2H), 1.46(s, 9H), 3.49(t, J=8
Hz, 2H), 4.46(d, J=5 Hz, 2H), 5.33(br.s, 2H), 7.00(br.s, 2H),
8.03(br.s, 1H)
PRODUCTION EXAMPLE 164
N,N-Dimethyl-[2-[(pyridin-2-yl)hydroxymethyl]imidazol-1-yl]-sulfonamide
[2665] To a solution of 4.37 g of 2-bromopyridine in diethyl ether
(40 ml) was added 16.5 ml of a 1.6 M hexane solution of
n-butyllithium at -78.degree. C. in a nitrogen atmosphere. After
stirring for 30 minutes, a tetrahydrofuran solution (20 ml) of 4.34
g of N,N-dimethyl-2-formylimidaz- ole-1-sulfonamide was added
thereto. Then the reaction mixture was brought back to room
temperature and distributed into ethyl acetate and an aqueous
solution of ammonium chloride. The organic layer was extracted and
washed successively with water and a saturated aqueous solution of
sodium chloride and dried over anhydrous sodium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 2.02 g of the title
compound as a pale yellow oily substance. 1146
[2666] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2667] 2.99(.s, 6H), 5.32(d, J=7 Hz, 1H), 6.30(d, J=7 Hz, 1H),
7.00(d, J=1 Hz, 1H), 7.29(d, J=1 Hz, 1H), 7.26-7.31(m, 2H),
7.71(dt, J=2, 8 Hz, 1H), 8.61(dt, J=1, 5 Hz, 1H
PRODUCTION EXAMPLE 165
[(Pyridin-2-yl)[1-(N,N-dimethylsulfonamido) imidazol-1-yl]methyl
acetate
[2668] 0.93 g of
N,N-dimethyl-[2-[(pyridin-2-yl)hydroxymethyl]-imidazol-1--
yl]-sulfonamide was dissolved in 20 ml of pyridine and 1.0 ml of
acetic anhydride and 0.44 g of 4-dimethylaminopyridine were added
thereto. After stirring at room temperature for 48 hours, the
solvent was distilled off under reduced pressure. Then the residue
was purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.976 g of the title
compound as an orange oily substance. 1147
[2669] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2670] 2.20(s, 3H), 3.00(s, 6H), 7.08(d, J=2 Hz, 1H), 7.22(s, 1H),
7.25(ddd, J=2, 5, 8 Hz, 1H), 7.30(d, J=2 Hz, 1H), 7.40(br.d, J=8
Hz, 1H), 7.73(dt, J=2, 8 Hz, 1H), 8.58(ddd, J=l, 2, 5 Hz, 1H)
PRODUCTION EXAMPLE 166
N,N-Dimethyl[2-(pyridin-2-ylmethyl)imidazol-1-yl]sulfonamide
[2671] A solution of 0.97 g of
[(pyridin-2-yl)[1-(N,N-dimethylsulfonamido)- imidazol-1-yl]methyl
acetate in ethanol (30 ml) was stirred in the presence of 0.20 g of
palladium carbon (containing 50% of moisture) in a hydrogen gas
stream at room temperature for 20 hours. After filtering off the
catalyst, the residue was concentrated under reduced pressure to
thereby give 0.21 g of the title compound as a colorless oily
substance. 1148
[2672] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2673] 2.81(s, 6H), 4.54(s, 2H), 7.03(d, J=2 Hz, 1H), 7.16(ddd,
J=1, 5, 8 Hz, 1H), 7.21(br.d, J=8 Hz, 1H), 7.28(d, J=2 Hz, 1H),
7.64(dt, J=2, 8 Hz, 1H), 8.54(ddd, J=l, 2, 5 Hz, 1H)
PRODUCTION EXAMPLE 167
2-(Pyridin-2-ylmethyl)imidazole
[2674] To a solution of 0.21 g of
N,N-dimethyl[2-(pyridin-2-ylmethyl)imida- zol-1-yl]sulfonamide in
ethanol (2 ml) was added a 2% aqueous solution (20 ml) of potassium
hydroxide and the resulting mixture was heated under reflux for 11
hours. After distilling off the solvent under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with dichloromethane/methanol) to thereby give 0.053 g of the title
compound as a colorless oily substance. 1149
[2675] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2676] 4.22(s, 2H), 7.02(s, 2H), 7.13(ddd, J=1, 5, 8 Hz, 1H),
7.25(br.d, J=8 Hz, 1H), 7.59(dt, J=2, 8 Hz, 1H), 8.51(ddd, J=l, 2,
5 Hz, 1H)
PRODUCTION EXAMPLE 168
2-Pyridyl 2-imidazolyl ketone
[2677] To an ethanol solution (5 ml) of 1.41 g of
N,N-dimethyl[2-(pyridin-- 2-yl)hydroxymethyl)
imidazol-1-yl]sulfonamide was added 50 ml of a 2% aqueous solution
of potassium hydroxide and the resulting mixture was heated under
reflux for 9 hours. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 0.441 g of the title compound as a colorless oily substance.
1150
[2678] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2679] 7.32(br.s, 1H), 7.47(br.s, 1H), 7.58(ddd, J=2, 5, 8 Hz, 1H),
7.98(dt, J=2, 8 Hz, 1H), 8.46(br.d, J=8 Hz, 1H), 8.76(br.d, J=5 Hz,
1H)
PRODUCTION EXAMPLE 169
N,N-Dimethyl-2-[[4-(4,4-dimethyl-2-oxazolin-2-yl)phenyl]hydroxymethyl]imid-
azole-1-sulfonamide
[2680] Similar to Production Example 164, 4.54 g of
N,N-dimethyl-2-formylimidazole-1-sulfonamide was treated with 7.0 g
of 2-(4-bromophenyl) -4,4-dimethyl-2-oxazoline to thereby give 3.41
g of the title compound. 1151
[2681] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2682] 1.36(s, 6H), 2.72(s, 6H),, 3.98(d, J=7 Hz, 1H), 4.08(s, 2H),
6.21(d, J=7 Hz, 1H), 7.08(d, J=2 Hz, 1H), 7.24(d, J=2 Hz, 1H),
7.41(d, J=8 Hz, 2H), 7.91(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 170
Methyl 4-[(imidazol-2-yl)carbonyl]benzoate and methyl
4-[(imidazol-2-yl)hydroxymethyl]benzoate
[2683] To a solution of 1.70 g of N,N-dimethyl
-2-[[4-(4,4-dimethyl-2-oxaz-
olin-2-yl)phenyl]hydroxymethyl]imidazole-1-sulfonamide in ethanol
was added 50 ml of a 2% aqueous solution of potassium hydroxide and
the resulting mixture was heated under reflux for 15 hours. After
distilling off the solvent under reduced pressure, 50 ml of
methanol and 5 ml of conc. sulfuric acid were added to the residue
and the resulting mixture was heated under reflux for 10 hours.
After distilling off methanol under reduced pressure, the residue
was distributed into ethyl acetate and an aqueous solution of
sodium bicarbonate. The organic layer was extracted, washed
successively with water and a saturated aqueous solution of sodium
chloride and dried over anhydrous sodium sulfate. After distilling
off the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.38 g of methyl
4-[(imidazol-2-yl)carbonyl]benzoate and 0.21 g of methyl
4-[(imidazol-2-yl)hydroxymethyl]benzoate each as a colorless oily
substance.
methyl 4-[(imidazol-2-yl)carbonyl]benzoate
[2684] 1152
[2685] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2686] 3.89(s, 3H), 7.27(d, J=1 Hz, 1H), 7.35(d, J=1 Hz, 1H),
8.11(d, J=8 Hz, 2H), 8.57(d, J=8 Hz, 2H)
methyl 4-[(imidazol-2-yl)hydroxymethyl]benzoate
[2687] 1153
[2688] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2689] 3.91(s, 3H), 5.98(s, 1H), 6.99(s, 2H), 7.50(d, J=8 Hz, 2H),
8.02(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 171
Methyl 4-[(1-acetylimidazol-2-yl) acetoxymethyl]benzoate
[2690] To a pyridine solution (16 ml) of 0.21 g of methyl
4-[(imidazol-2-yl)hydroxymethyl]benzoate was added 0.5 ml of acetic
anhydride and the resulting mixture was stirred at room temperature
for 20 hours. After distilling off the solvent under reduced
pressure, 0.25 g of the title compound was obtained as an orange
oily substance. 1154
[2691] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2692] 2.15(s, 3H), 2.54(s, 3H), 3.79(s, 3H), 7.06(s 1H), 7.23(s,
1H), 7.35(s, 1H), 7.56(d, J=8 Hz, 2H), 8.02(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 172
Methyl 4-[(imidazol-2-yl)methyl]benzoate
[2693] 0.25 g of methyl
4-[(1-acetylimidazol-2-yl)acetoxy-methyl]benzoate was treated in
the same manner as the one of Production Example 166 to thereby
give the title compound. 1155
[2694] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2695] 3.90(s, 3H), 4.17(s, 2H), 6.99(s, 2H), 7.32(d, J=8 Hz, 2H),
7.99(d, J=8 Hz, 2H)
PRODUCTION EXAMPLE 173
8-Trifluoromethyl-6-dimethylaminopurine
[2696] 0.306 g of 4,5-diamino-6-dimethylaminopyrimidine was
dissolved in 20 ml of trifluoroacetic anhydride. Then the reaction
mixture was introduced into a steel container. After sealing, it
was heated to 100.degree. C. for 14 hours. The reactor was opened
at room temperature and the solvent was distilled off under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.073 g of the title compound as white crystals. 1156
[2697] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2698] 3.47(br.s, 3H), 3.99(br.s, 3H), 8.39(s, 1H)
PRODUCTION EXAMPLE 174
6-Dimethylamino-8-oxo-7(H),8(H)-purine
[2699] To an acetonitrile solution (30 ml) of 0.306 g of
4,5-diamino-6-dimethylaminopyrimidine was added 30 ml of an
acetonitrile solution of 0.512 g of N,N'-disuccinimidyl carbonate
and the resulting mixture was stirred for 24 hours. Further, 0.256
g of N,N'-disuccinimidyl carbonate was added thereto and the
resulting mixture was stirred at room temperature for 24 hours.
Next, the reaction mixture was concentrated under reduced pressure
and the crystals thus precipitated were collected by filtration and
washed successively with water and methanol. Thus 0.128 g of the
title compound was obtained as brown crystals. 1157
[2700] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2701] 3.08(s, 6H), 7.99(s, 1H), 10.54(br.s, 1H), 11.34(br.s,
1H)
PRODUCTION EXAMPLE 175
(Purin-6-yl)ethanone
[2702] 1.04 g of 6-(ethoxyvinyl)purine was dissolved in 80 ml of 1
N hydrochloric acid and stirred at room temperature for 15 hours.
After neutralizing with a saturated aqueous solution of sodium
bicarbonate, it was extracted with dichloromethane and the organic
layer was dried over anhydrous sodium sulfate. After distilling off
the solvent under reduced pressure, 0.70 g of crude title compound
was obtained as a colorless oily substance. 1158
[2703] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2704] 2.75(s, 3H), 8.80(s, 1H), 9.14(s, 1H)
PRODUCTION EXAMPLE 176
1-(Purin-6-yl)ethanol
[2705] To an ethanol solution (80 ml) of 0.70 g of
(purin-6-yl)ethanone was added 0.70 g of sodium borohydride and the
resulting mixture was stirred at room temperature for 4 hours. The
excessive reagent was decomposed by adding water and 4 N
hydrochloric acid and distilled off under reduced pressure. The
residue was purified by silica gel column chromatography (eluted by
dichloromethane/methanol) to thereby give 0.57 g of the title
compound as a white solid. 1159
[2706] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2707] 1.48(d, J=7 Hz, 3H), 5.05(m, 1H), 5.78(br.s, 1H), 8.58(s,
1H), 8.82(s, 1H)
PRODUCTION EXAMPLE 177
6-[1-(tert-Butyldimethylsiloxy)ethyl]purine
[2708] To a solution of 0.543 g of 1-(purin-6-yl)ethanol in
N,N-dimethylformamide (10 ml) were added 0.27 g of imidazole and
0.598 g of tert-butyldimethylsilyl chloride and the resulting
mixture was stirred at room temperature for 15 hours. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.793 g of the title
compound as a white solid. 1160
[2709] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2710] 0.08(s, 3H), 0.01(s, 3H), 0.77(s, 9H), 1.53(d, J=7 Hz, 3H),
5.23(q, J=7 Hz, 1H), 8.37(s, 1H), 9.03(s, 1H)
EXAMPLE 763
5,10-Dihydro-5-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline
[2711] To a solution of 0.586 g of 2-[N-methyl
-N-(2-nitro-phenyl)amino]-3- -chloropyrazine in tetrahydrofuran (20
ml) was added 4 g of hydrosulfite sodium in water (8 ml). After
adding 8 ml of 50% aqueous ammonia/water, the resulting mixture was
vigorously stirred at room temperature for 6 hours. Then the
reaction mixture was distributed into ethyl acetate and water and
the organic layer was dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 0.32 g of the title
compound as yellow crystals. 1161
[2712] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2713] 2.93(s, 3H), 6.33(m, 1H), 6.42(m, 1H), 6.50-6.56(m, 2H),
6.83(d, J=3 Hz, 1H), 6.93(d, J=3 Hz, 1H), 9.04(s, 1H)
[2714] m.p. : 229-231.degree. C.
[2715] MS: FAB(+)198(M.sup.+)
EXAMPLE 764
5,10-Dihydro-10H-pyrazino[2,3-b][1,4]quinoxaline
[2716] A solution of 0.28 g of
2-[(2-aminophenyl)amino]-3-chloropyrazine in N,N-dimethylformamide
(15 ml) was degassed and then heated to 100.degree. C. for 30
minutes. Next, the reaction mixture was brought back to room
temperature and poured into water. The precipitate was taken up by
filtration and dissolved in 2 N hydrochloric acid. After filtering
off the insoluble matters, the hydrochloric acid solution was
neutralized with potassium hydroxide. The crystals thus
precipitated were taken up by filtration to thereby give 0.10 g of
the title compound as greenish yellow crystals. 1162
[2717] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2718] 6.23(dd, J=3, 6 Hz, 2H), 6.39(dd, J=3, 6 Hz, 2H), 6.75(s,
2H), 8.75(s, 2H)
[2719] m.p.: 215-217.degree. C.
[2720] MS: FAB(+)184(M.sup.+)
EXAMPLE 765
5,10-Dihydro-5-allyl-10H-pyrazino[2,3-b][1,4]quinoxaline
[2721] 2.91 g of 2-[N-allyl-N-(2-nitrophenyl)
amino]-3-chloropyrazine was treated by the same method as the one
of Example 985 to thereby give 1.26 g of the title compound as a
yellow powder. 1163
[2722] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2723] 4.28(d, J=5 Hz, 2H), 5.23(d, J=11 Hz, 1H), 5.30(d, J=16 Hz,
1H),, 5.79-5.91(tdd, J=5, 11, 16 Hz, 1H), 6.21(d, J=8 Hz, 1H),
6.36(d, J=8 Hz, 1H), 6.54-6.63(m, 2H), 6.91(d, J=3 Hz, 1H), 7.04(d,
J=3 Hz, 1H)
[2724] m.p.: 173-175.degree. C.
[2725] MS: ESI(+)225(MH.sup.+)
EXAMPLES
[2726] The following compounds were obtained by reacting analogs of
2-[(2-nitrophenyl)amino]-3-chloropyrazine by the same method as the
one of Example 763.
105 Ex. Structural formula MS M.p. NMR 766 1164tert-butyl
(5,10-dihydro-10H-pyrazino- [2,3-b] [1,4quinoxalin-5-yl)acetate
ESI(+) 299(MH.sup.+) 199-201.degree. C. .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.40(s, 9H), 4.25(s, 2H), 6.13-6.15(m, 1H),
6.17-6.19(m, 1H), 6.52-6.58(m, 2H), 6.91(d, J=3Hz, 1H), 6.99(d,
J=3Hz, 1H) 767 1165methyl 4-[(5,10-dihydro-10H-py- razino- [2,3-b]
[1,4]quinoxalin-5- yl)methyl]benzoate ESI(+) 333(MH.sup.+)
232-234.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.90(s,
3H), # 4.96(br .multidot. s, 2H), 6.15(dd, J=1, 8Hz, 1H), 6.24(dd,
J=1, 8Hz, 1H), 6.48(dt, J=1, 8Hz, 1H), 6.57(dt, J=1, 8Hz, 1H),
6.98(d, J=3Hz, 1H), 7.04(d, J=3Hz, 1H), 7.41(d, J=8Hz, 2H), 8.01(d,
J=8Hz, 2H) 768 1166methyl (E)-4-(5,10-dihydro-10H- pyrazino[2,3-b]
[1,4]quinoxalin-5- yl)-2-butenoate ESI(+) 287(MH.sup.+)
195-197.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.72(s,
3H), 4.44(m, 2H), 6.06(d, J=16Hz, 1H), 6.24(m, 2H), 6.60(m, 2H),
6.95-7.05(m, 3H) 769 11675,10-dihydro-5-methoxymethyl-10H-
pyrazino[2,3-b] [1,4]quinoxaline ESI(+) 229(MH.sup.+)
185-188.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.45(s,
3H), 5.13(s, 2H), 6.14(br .multidot. s, 1H), 6.26(m, 1H),
6.65-6.71(m, 3H), 7.05(d, J=3Hz, 1H), 7.13(d, J=3Hz, 1H) 770
11685,10-dihydro-5-benzyl-10H- pyrazino[2,3-b] [1,4]quinoxaline
ESI(+) 275(MH.sup.+) 194-196.degree. C. .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 4.85(s, 2H), 6.13-6.17(m, 2H), 6.41(dt, J=2, 8Hz, 1H),
6.48(dt, J=2, 8Hz, 1H), 6.87(d, J=3Hz, 1H), 6.97(d, J=3Hz, 1H),
7.16-7.28(m, 5H), 7.46(br .multidot. s, 1H) 771
11693-(5,10-dihydro-10H-pyrazino [2,3-b][1,4] quinoxalin-5-
yl)-1,2-propanediol ESI(+) 281 (MNa.sup.+) 191-194.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.34(m, # 2H), 3.53-3.64(m,
2H), 3.71-3.76(m, 1H), 4.64(t, J=6Hz, 1H), 4.90(d, J=6Hz, 1H),
6.29-6.31(m, 1H), 6.46-6.52(m, 2H), 6.55-6.59(m, 1H), 6.81(d,
J=3Hz, 1H), 6.87(d, J=3Hz, 1H), 9.02(s, 1H)
EXAMPLES
[2727] The following compounds were obtained by reacting analogs of
2-[1-(2-amino-4-substituted phenyl)amino]-3-chloropyrazine by the
same method as the one of Example 764.
106 Ex. Structural formula MS M.p. NMR 772
11705,10-dihydro-7-methoxymethoxy-
10H-pyrazino[2,3-b][1,4]quinoxaline FAB(+) 244(M.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.38(s, 3H), 4.94(s, 2H),
6.03(s, 1H), 6.07(d, J=8Hz, 1H), 6.15(d, J=8Hz, 1H), 6.74(m, 2H),
8.65(s, 1H), 8.79(s, 1H) 773 11715,10-dihydro-7-methoxy-10H-
pyrazino[2,3-b][1,4]quinoxaline .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.54(s, 3H), 5.92(d, J=2Hz, 1H), 5.99(dd, J=2, 8Hz, 1H),
6.17(d, J=8Hz, 1H), 6.74(d, J=3Hz, 1H), 6.76(d, J=3Hz, 1H), 8.64(s,
1H), 8.77(s, 1H) 774 1172ethyl
(5,10-dihydro-10H-pyrazino[2,3-b][1,4]quinoxali- n-7-yl)carboxylate
ESI(+) 257(MH.sup.+) >275.degree. C. .sup.1H-NMR(DMSO-d.sub.6) #
.delta. ppm: 1.21(t, J=7Hz, 3H), 4.16(q, J=7Hz, 2H), 6.26(d, J=8Hz,
1H), 6.79-6.85(m, 3H), 7.05(dd, J=1, 8Hz, 1H), 8.94(s, 1H), 9.23(s,
1H) 775
1173(5,10-dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)carbonitrile
EI(+) 209(M.sup.+) >275.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 6.26(d, J=8Hz, 1H), 6.37(d, J=1Hz, 1H), 6.83-6.88(m,
3H), 9.05(s, 1H), 9.30(s, 1H)
EXAMPLES
[2728] The following compounds were obtained by reacting analogs of
2-[(nitrophenyl)amino]-3-chloropyrazine by the same method as the
one of Example 763.
107 Ex. Structural formula MS M.p. NMR 776
11745,10-dihydro-8-methoxy-5-methyl-
10H-pyrazino[2,3-b][1,4]quinoxaline ESI(+) 228(M.sup.+)
198-201.degree. C. .sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 3.06(s,
3H), 3.68(s, 3H), 5.87(d, J=1Hz, 1H), 6.17(dd, J=1, 8Hz, 1H),
6.31(d, J=8Hz, 1H), 6.54(br .multidot. s, 1H), 6.89(d, J=3Hz, 1H),
7.08(d, J=3Hz, 1H) 777 11755,10-dihydro-8-methoxymet- hoxy-5-
methyl-10H-pyrazino[2,3-b][1,4]quinoxaline ESI(+) 259(MH.sup.+)
197-198.degree. C. .sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 2.92(s,
3H), 3.32(s, 3H), 4.98(s, 2H), 6.11(d, J=2Hz, 1H), 6.21(dd, J=2,
8Hz, 1H), 6.34(d, J=8Hz, 1H), 6.83(d, J=3Hz, 1H), 6.95(d, J=3Hz,
1H), 9.07(s, 1H) 778 1176(5,10-dihydro-5-methyl-10H-pyrazino-
[2,3-b][1,4]quinoxalin-8-yl)carbonitrile ESI(+) 224(MH.sup.+)
274-275.degree. C. .sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 2.94(s,
3H), 6.45(d, J=2Hz, 1H), 6.48(d, J=8Hz, 1H), 6.95(d, J=3Hz, 1H),
6.98(dd, J=2, 8Hz, 1H), 7.01(d, J=3Hz, 1H), 9.33(s, 1H) 779
1177ethyl (5,10-dihydro-5-methyl-10H-pyrazino-
[2,3-b][1,4]quinoxalin-8-y- l)carboxylate ESI(+) 271(MH.sup.+)
239-242.degree. C. .sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 1.23(t,
J=7Hz, 3H), 2.96(s, 3H), 4.18(q, J=7Hz, 2H), 6.47(d, J=8Hz, 1H),
6.86(d, J=2Hz, 1H), 6.91(d, J=3Hz, 1H), 6.99(d, J=3Hz, 1H),
7.16(dd, J=2, 8Hz, 1H), 9.20(s, 1H) 780
11785,10-dihydro-8-iodo-5-methyl-10H-
pyrazino[2,3-b][1,4]quinoxaline ESI(+) 325(MH.sup.+)
>275.degree. C. .sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 2.88(s,
3H), 6.20(d, J=8Hz, 1H), 6.58(d, J=2Hz, 1H), 6.83(dd, J=2, 8Hz,
1H), 6.87(d, J=3Hz, 1H), 6.96(d, J=3Hz, 1H), 9.13(s, 1H) 781
11795,10-dihydro-5-methoxymethyl-8-
methoxy-10H-pyrazino[2,3-b][1,4]quino- xaline ESI(+) 259(MH.sup.+)
244-251.degree. C. .sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 3.26(s,
3H), 3.59(s, 3H), 4.99(s, 3H), 6.06(d, J=3Hz, 1H), 6.14(dd, J=3,
9Hz, 1H), 6.48(d, J=9Hz, 1H), 6.99(d, J=3Hz, 1H), 7.12(d, J=3Hz,
1H) Ex. Structural formula NMR 782
11805,10-dihydro-8-methoxymethoxy-5-methoxymethyl-
10H-pyrazino[2,3-b][1,4]quinoxaline .sup.1H-NMR(CDCl.sub.3) #
.delta. ppm: 3.43(s, 3H), 3.45(s, 3H), 5.03(s, 2H), 5.11(s, 2H),
6.05(s, 1H), 6.33(d, J=8Hz, 1H), 6.60(d, J=8Hz, 1H), 6.79(br
.multidot. s, 1H), 7.05(d, J=3Hz, 1H), 7.13(d, J=3Hz, 1H) 783
1181(5,10-dihydro-5-methoxymethyl-10H-
pyrazino[2,3-b][1,4]quinoxalin-8-y- l)carbonitrile
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 3.38(s, 3H), 5.07(s, 2H),
6.36(s, 1H), 6.61(d, J=8Hz, 1H), 6.89(d, J=8Hz, 1H), 7.08(d, J=3Hz,
1H), 7.14(d, J=3Hz, 1H)
EXAMPLE 784
5,10-Dihydro-7-hydroxy-10H-pyrazino[2,3-b][1,4]quinoxaline
hydrochloride
[2729] 5,10-Dihydro-5-methoxymethyl-8-methoxymethoxy
-10H-pyrazino[2,3-b][1,4]quinoxaline was treated by the same method
as the one of Example 8 to thereby give the title compound.
1182
[2730] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm
[2731] 6.07(d, J=8 Hz, 1H), 6.11(s, 1H), 6.46(d, J=8 Hz, 1H),
6.49(br.s, 1H), 6.56(br.s, 1H)
[2732] m.p.: >275.degree. C.
[2733] MS: ESI(+)201(MH.sup.+)
EXAMPLES
[2734] The compounds obtained in Examples 767 and 779 were treated
by the same method as the one of Example 8 to thereby give the
following compounds.
108 Ex. Structural formula MS M.p. NMR 785
1183[4-(5,10-dihydro-10H-pyrazino[2,3- b][1,4]quinoxalin-5-yl)-
methyl]benzoic acid ESI(+) 319(MH.sup.+) 253-255.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 4.90(s, 2H), 6.15(d,
J=8Hz, 1H), 6.36(d, J=8Hz, 1H), 6.39(t, J=8Hz, 1H), 6.49(t, J=8Hz,
1H), 6.88(d, J=3Hz, 1H), 6.90(d, J=3Hz, 1H), 7.43(d, J=9Hz, 2H),
7.88(d, J=8Hz, 2H), 9.18(s, 1H) 786 11845,10-dihydro-10-methyl-10-
H- pyrazino[2,3-b][1,4]quinoxaline- 7-carboxylic acid
.sup.1H-NMR(DMSO-d.sub.6) # .delta. ppm: 2.96(s, 3H), 6.47(d,
J=8Hz, 1H), 6.85(d, J=2Hz, 1H), 6.91(d, J=3Hz, 1H), 6.98(d, J=3Hz,
1H), 7.15(dd, J=2, 8Hz, 1H), 9.23(s, 1H)
EXAMPLE 787
(5,10-Dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)acetic
acid
[2735] The title compound was obtained by treating tert-butyl
(5,10-dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)acetate by
the same method as the one of Example 9. 1185
[2736] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2737] 4.26(s, 2H), 6.33(dd, J=2, 8 Hz, 1H), 6.37(dd, J=2, 6 Hz,
1H), 6.51(dt, 2, 8 Hz, 1H), 6.54(dt, J=2, 8 Hz, 1H), 6.91(d, J=3
Hz, 1H), 6.93(d, J=3 Hz, 1H), 9.14(s, 1H)
[2738] m.p. :210-212.degree. C.
[2739] MS: ESI(+)243(MH.sup.+)
EXAMPLE 788
5,10-Dihydro-7-methoxy-5-methyl-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]- quinoxaline
[2740] 0.258 g of
5,10-dihydro-5-methoxymethyl-8-methoxy-10H-pyrazino[2,3--
b][1,4]quinoxaline in N,N-dimethylformamide (20 ml) was degassed at
0.degree. C. in a nitrogen atmosphere. After adding 0.050 g of
sodium hydride (60% or above), the resulting mixture was stirred
for 30 minutes. Then a solution of 0.13 ml of methyl iodide in
N,N-dimethylformamide (5 ml) was dropped thereinto at the same
temperature and the resulting mixture was stirred at room
temperature for 16 hours. The reaction mixture was distributed into
ethyl acetate and water and the aqueous layer was extracted with
ethyl acetate. Then the organic layers were combined, washed
successively with water and a saturated aqueous solution of sodium
chloride and dried over magnesium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.234 g of the title compound as a yellow solid.
1186
[2741] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2742] 3.13(s, 3H), 3.44(s, 3H.), 3.75(s, 3H), 5.16(s, 2H), 6.13(s,
1H), 6.21(d, J=8 Hz, 1H), 6.65(d, J=8 Hz, 1H), 7.14(s, 1H), 7.18(s,
1H)
EXAMPLES
[2743] The compounds obtained in Examples 783 and 782 were treated
by the same method as the one of Example 788 to thereby give the
following compounds.
109 Ex. Structural formula NMR 789
11875,10-dihydro-7-methoxymethoxy-10-
methoxymethyl-5-methyl-10H-pyrazino- [2,3- b][1,4]quinoxaline
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 3.13(s, 3H), 3.43(s, 3H),
3.47(s, 3H), 5.08(s, 2H), 5.13(s, 2H), 6.23(d, J=2Hz, 1H), 6.40(dd,
J=2, 8Hz, 1H), 6.63(d, J=8Hz, 1H), 7.10(d, J=3Hz, 1H), 7.17(d,
J=3Hz, 1H) 790 11885,10-dihydro-10-methoxyme- thyl-5-methyl-
10H-pyrazino[2,3-b][1,4]quinoxaline- 7-carbonitrile
.sup.1H-NMR(CDCl.sub.3) # .delta. ppm: 3.04(s, 3H), 3.38(s, 3H),
5.09(s, 2H), 6.49(s, 1H), 6.62(d, J=8Hz, 1H), 6.93(d, J=8Hz, 1H),
7.10(s, 1H), 7.19(s, 1H)
EXAMPLES
[2744] The compounds obtained in Examples 782, 790 and 788 were
treated by the same method as the one of Example 8 to thereby give
the following compounds.
110 Ex. Structural formula MS M.p. NMR 791
11895,10-dihydro-5-methyl-7-hydroxy- 10H-pyrazino[2,3-b][1,4]q-
uinoxaline ESI (+) 215 (MH.sup.+) >275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 3.02(s, 3H), 6.25(br.s, 2H),
6.59(br.s, 2H), 6.81(br.s, 1H) 5,10-dihydro-5-methyl-7-hydroxy-
10H-pyrazino[2,3-b][1,4]quinoxaline 792 11905,10-dihydro-5-methyl-
10H-pyrazino[2,3-b][1,4]quinoxaline- 7-carbonitrile FAB (+) 223
(M.sup.+) >275.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta. ppm:
2.92(s, 3H), 6.34(d, J=8Hz, 1H), 6.69(s, 1H), 6.94(d, J=3Hz, 1H),
6.98(d, J=8Hz, 1H), 7.05(d, J=3Hz, 1H), 9.58(s, 1H)
5,10-dihydro-5-methyl-10H-pyrazino[2,3-b][1,4]quinoxa-
line-7-carbonitrile 793 11915,10-dihydro-5-methyl-7-methox- y-
10H-pyrazino[2,3- b][1,4]quinoxaline ESI (+) 228 (M.sup.+)
195-197.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.95(s,
3H), 3.61(s, 3H), 6.07(br.s, 1H), 6.12(br.d, J=8Hz, 1H), 6.25(br.d,
J=8Hz, 1H), 684(br.s, 1H), 6.91(br.s, 1H), 8.92(br.s, 1H)
EXAMPLES
[2745] The following compounds were obtained by treating
5,10-dihydro-5-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxaline by
the same method as the one of Example 788 by using appropriate
halides as a substitute for methyl iodide.
111 Ex. Structural formula NMR 794 1192ethyl 3-(5,10-dihydro-
10-methoxymethyl-10H- pyrazino[2,3-b][1,4]quin-
oxalin-5-yl)propanoate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.20(t,
J=7Hz, 3H), 2.57(t, J=8Hz, 2H), 3.38(s, 3H), 3.95(t, J=8Hz, 2H),
4.09(q, J=7Hz, 2H), 5.07(s, 2H), 6.45(dd, J=2, 8Hz, 1H),
6.63-6.70(m, 3H), 7.04(d, J=2Hz, 1H), 7.10(d, J=2Hz, 1H) 795
1193methyl (E)-4-(5,10-dihydro-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]quinoxalin- -5-yl)-2-butenoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.47(s, 3H), 3.72(s, 3H),
4.50(br.m, 2H), 5.09(s, 2H), 6.02(br.d, J=16Hz, 1H), 6.28(br.d,
J=8Hz, 1H), 6.67-6.77(m, 3H), 6.92(td, J=6, 16Hz, 1H), 7.14(s,
2H)
EXAMPLE 796
Ethyl
3-(5,10-dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)propanoate
[2746] The title compound was obtained by treating ethyl
3-(5,10-dihydro-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl- )propanoate by the same
method as the one of Example 8. 1194
[2747] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2748] 1.20(t, J=7 Hz, 3H), 2.55(t, J=7 Hz, 2H), 3.88(t, J=7 Hz,
2H), 4.09(q, J=7 Hz, 2H), 6.14(d, J=8 Hz, 1H), 6.3.8(d, J=8 Hz,
1H), 6.42(t, J=8 Hz, 1H), 6.56(t, J=8 Hz, 1H), 6.84(d, J=3 Hz, 1H),
6.98(d, J=3 Hz, 1H)
[2749] MS: ESI(+)285(MH.sup.+)
[2750] m.p.:
EXAMPLE 797
5,10-Dihydro-5-[4-(N,N-dimethylamino)-2-buten
-1-yl)]-10H-pyrazino[2,3-b][- 1,4]quinoxaline
[2751] 0.0060 g of the title compound was obtained by treating
0.170 g of (E)-2-[N-(4-dimethylamino
-2-buten-1-yl)-N-(2-nitrophenyl)amino]-3-chloro- pyrazine by the
same method as the one of Example 763. 1195
[2752] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2753] 2.62(s, 6H), 3.65(m, 2H), 4.26(m, 2H), 5.72(td, J=8, 16 Hz,
1H), 5.93(td, J=5, 16 Hz, 1H), 6.35-6.39(m, 2H), 6.51-6.54(m, 2H),
6.87(d, J=3 Hz, 1H), 6.91(d, J=3 Hz, 1H), 9.20(s, 1H)
[2754] MS: ESI(+)282(MH.sup.+)
EXAMPLE 798
5,10-Dihydro-5-propyl-10H-pyrazino[2,3-b][1,4]quinoxaline
[2755] 0.188 g of the title compound was obtained as yellow
crystals by treating 0.224 g of
5,10-dihydro-5-allyl-10H-pyrazino[2,3-b][1,4]quinoxal- ine by the
same method as the one of Example 20. 1196
[2756] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2757] 0.98(t, J=7 Hz, 3H), 1.55-1.68(m, 2H), 3.56(t, J=8 Hz, 2H),
6.18(d, J=8 Hz, 1H), 6.35(d, J=8 Hz, 1H), 6.55(t, J=8 Hz, 1H),
6.62(t, J=8 Hz, 1H), 6.86(d, J=3 Hz, 1H), 7.03(d, J=3 Hz, 1H)
[2758] m.p. : 190-192.degree. C.
[2759] MS: ESI(+)227(MH.sup.+)
EXAMPLE 799
Methyl
4-(5,10-dihydro-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxalin-
-5-yl)butanoate
[2760] The title compound was obtained by treating methyl
4-(5,10-dihydro-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl- )-2-butenoate by the same
method as the one of Example 20. 1197
[2761] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2762] 1.87(quint, J=7 Hz, 2H), 2.38(t, J=7 Hz, 2H), 3.38(s, 3H),
3.63(s, 3H), 3.67(t, J=7 Hz, 2H), 5.06(s, 2H), 6.55(d, J=8 Hz, 1H),
6.61-6.65(m, 2H), 6.69(ddd, J=2, 6, 8 Hz, 1H), 7.00(d, J=3 Hz, 1H),
7.06(d, J=3 Hz, 1H)
EXAMPLE 800
Methyl
4-(5,10-dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)butanoate
[2763] The title compound was obtained by treating methyl
4-(5,10-dihydro-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)-
-2-butenoate by the same method as the one of Example 8. 1198
[2764] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2765] 1.92(quint, J=7 Hz, 2H), 2.44(t, J=7 Hz, 2H), 3.68(t, J=7
Hz, 2H), 3.70(s, 3H), 6.18(d, J=8 Hz, 1H), 6.53-6.59(m, 2H),
7.05(t, J=8 Hz, 1H), 6.87(d, J=3 Hz, 1H), 7.00(d, J=3 Hz, 1H)
[2766] m.p. 189-190.degree. C.
[2767] MS: ESI(+)285(MH.sup.+)
EXAMPLE 801
5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline-
-7-carbonitrile
[2768] 2.43 g of the title compound was obtained as yellow crystals
by reacting 3.14 g of
5,10-dihydro-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxa-
line-7-carbonitrile with chloromethyl methyl ether by the same
method as the one of Example 788. 1199
[2769] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2770] 3.16(s, 3H), 3.45(s, 3H), 5.11(s, 2H), 6.42(d, J=8 Hz, 1H),
6.86(d, J=2 Hz, 1H), 7.05(dd, J=2, 8 Hz, 1H), 7.21(d, J=3 Hz, 1H),
7.26(d, J=3 Hz, 1H)
EXAMPLE 802
5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline-
-7-carboxamide
[2771] 0.267 g of 5,10-dihydro-5-methoxymethyl
-10-methyl-10H-pyrazino[2,3- -b][1,4]quinoxaline -7-carbonitrile
was dissolved at 0.degree. C. in 20 ml of ethanol and 20 ml of
dimethyl sulfoxide. After adding 0.36 ml of a 30% aqueous solution
of hydrogen peroxide and 0.36 ml of 6 N sodium hydroxide, the
resulting mixture was stirred at room temperature for 16 hours.
Then the reaction mixture was poured into water. The precipitate
was taken up by filtration and washed with water to thereby give
0.271 g of the title compound as a yellow powder. 1200
[2772] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2773] 3.07(s, 3H), 3.31(s, 3H), 5.12(s, 2H), 6.61(d, J=8 Hz, 1H),
7.12(d, J=1 Hz, 1H), 7.15(d, J=3 Hz, 1H), 7.16(br.s, 1H), 7.22(d,
J=3 Hz, 1H) 7.29(dd, J=l, 8 Hz, 1H), 7.77(br.s, 1H)
EXAMPLE 803
5,10-Dihydro-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline-7-carboxamide
[2774] The title compound was obtained by treating
5,10-dihydro-5.-methoxy- methyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxaline-7-carboxamide by the same
method as the one of Example 8. 1201
[2775] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2776] 2.95(s, 3H), 6.43(d, J=8 Hz, 1H), 6.81(s, 1H), 6.89(d, J=3
Hz, 1H), 6.97(d, J=3 Hz, 1H), 7.06(br.s, 1H), 7.09(d, J=8 Hz, 1H),
7.65(br.s, 1H), 9.18(s, 1H)
[2777] MS: ESI(+)263.9(MNa.sup.+)
EXAMPLE 804
5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline-
-7-carbaldehyde
[2778] A solution of 1.068 g of 5,10-dihydro-5-methoxymethyl
-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline-7-carbonitrile in
toluene (100 ml) was degassed in a nitrogen atmosphere and cooled
to -78.degree. C. After dropping 9.6 ml of a 1.0 M solution of
diisobutylaluminum hydride in toluene thereinto, the resulting
mixture was heated to room temperature over 15 hours. Then the
reaction mixture was cooled to 0.degree. C. and the excessive
reagent was decomposed with methanol. The reaction mixture was
distributed into ethyl acetate and water. After filtering off the
insoluble matters, the aqueous layer was extracted with ethyl
acetate. The organic layers were combined, washed successively with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous magnesium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.519 g of the title compound as a yellow solid.
1202
[2779] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2780] 3.13(s, 3H), 3.33(s, 3H), 5.13(s, 2H), 6.75(d, J=8 Hz, 1H),
7.01(d, J=2 Hz, 1H), 7.24(d, J=3 Hz, 1H), 7.28(d, J=3 Hz, 1H),
7.35(dd, J=2, 8 Hz, 1H), 9.67(s, 1H)
EXAMPLE 805
Ethyl (E)-3-(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)propenoate
[2781] The title compound was obtained by treating
5,10-dihydro-10-methyl-- 5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline-7-carbaldehyde by the same
method as the one of Production Example 25. 1203
[2782] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2783] 1.26(t, J=7 Hz, 3H), 3.09(s, 3H), 3.40(s, 3H), 4.18(q, J=7
Hz, 2H), 5.11(s, 2H), 6.18(d, J=16 Hz, 1H), 6.38(d, J=8 Hz, 1H),
6.91(d, J=2 Hz, 1H), 6.86(dd, J=2, 8 Hz, 1H), 7.09(d, J=3 Hz1H),
7.16(d, J=3 Hz, 1H), 7.43(d, J=16 Hz, 1H)
EXAMPLES
[2784] The following compounds were obtained by hydrolyzing the
compounds obtained in Examples 805 and 799 by the same method as
the one of Example 18.
112 Ex. Structural formula NMR 806 1204(E)-3-(5,10-dihydro-5-
methoxymethyl-10-methyl10H-
pyrazino[2,3-b][1,4]quinoxalin-7-yl)propenoic acid
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.07(s, 3H), 3.42(s, 3H),
5.17(s, 2H), 6.26(d, J=16Hz, 1H),6.61(d, J=8Hz, 1H), 6.88(d, J=1Hz,
1H), 7.07(dd, J=1, 8Hz, 1H), 7.16(d, J=3Hz, 1H), 7.24(d, J=Hz, 1H),
7.38(d, J=16Hz, 1H), 12.20(br.s, 1H) 807 12054-(5,10-dihydro-10-
methoxymethyl-10H- pyrazino[2,3-b][1,4]quinoxalin-5-yl)butanoic
acid .sup.1H-NMR(CDCl.sub.3) .delta. ppm; 1.89(quint, J=7Hz, 2H),
2.42(t, J=7Hz, 2H), 3.38(s, 3H), 3.69(br.t, J=7Hz, 2H), 5.06(s,
2H), 6.52(d, J=8Hz, 1H), 6.60-6.71(m, 3H), 7.01-7.04(m, 2H)
EXAMPLES
[2785] The following compounds were obtained by treating the
compounds obtained in Examples 806 and 807 by the same method as
the one of Example 8.
113 Ex. Structural formula MS M.p. NMR 808 1206(E)-3-(5,10-
dihydro-5-methyl- 10H-pyrazino[2,3-b][1,4]qui-
noxalin-8-yl)propanoic acid ESI (+) 269 (MH.sup.+) >275.degree.
C. .sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.97(s, 3H), 6.05(d,
J=16Hz, 1H), 6.46(d, J=8Hz, 1H), 6.55(d, J=1Hz, 1H), 6.87(dd, J=1,
8Hz, 1H), 6.90(d, J=3Hz, 1H), 6.99(d, J=3Hz, 1H), 7.27(d, J=16Hz,
1H), 9.13(s, 1H) 809 12074-(5,10-dihydro- 10H-pyrazino[2,3-
b][1,4]quinoxalin- 5-yl)butanoic acid ESI (+) 271 (MH.sup.+)
273-274.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta. ppm:
1.66(quint, J=7Hz, 2H), 2.28(t, J=7Hz, 2H), 3.53(t, J=7Hz, 2H),
6.31(d, J=8Hz, 1H), 6.49-6.55(m, 3H), 6.81(d, J=3Hz, 1H), 6.90(d,
J=3Hz, 1H), 9.03(s, 1H)
EXAMPLE 810
5,10-Dihydro-5-methoxymethyl-10-methyl-7-(oxazol
-5-yl)-10H-pyrazino[2,3-b- ][1,4]quinoxaline
[2786] To 15 ml of methanol were added 0.166 g of
5,10-dihydro-10-methyl-5-
-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxaline-7-carbaldehyde,
0.120 g of p-toluenesulfonylmethyl isocyanide and 0.081 g of
potassium carbonate and the resulting mixture was heated under
reflux for 90 minutes. After distilling off the solvent under
reduced pressure, the residue was dissolved in ethyl acetate,
washed successively with a 1 N aqueous solution of sodium
hydroxide, water and a saturated aqueous solution of sodium
chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 0.134 g of the title
compound as a yellow solid. 1208
[2787] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2788] 3.16(s, 3H), 3.47(s, 3H), 5.22(s, 2H), 6.49(d, J=8 Hz, 1H),
6.97(d, J=2 Hz, 1H), 7.05(dd, J=2, 8 Hz, 1H), 7.15(d, J=3 Hz, 1H),
7.21(s, 1H), 7.22(d, J=3 Hz, 1H), 7.86(s, 1H)
EXAMPLE 811
5,10-Dihydro-10-methyl-5-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxaline-
-7-methanol
[2789] The title compound was obtained by treating
5,10-dihydro-10-methyl-- 5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline-7-carbaldehyde by the same
method as the one of Example 2. 1209
[2790] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2791] 3.12(s, 3H), 3.35(s, 3H), 3.46(s, 3H), 4.27(s, 2H), 5.17(s,
2H), 6.45(d, J=8 Hz, 1H), 6.70(s, 1H), 6.74(d, J=8 Hz, 1H), 7.10(d,
J=3 Hz, 1H), 7.18(d, J=3 Hz, 1H)
EXAMPLE 812
5,10-Dihydro-10-methyl-5,7-dimethoxymethyl-7-10H-pyrazino[2,3-b][1,4]quino-
xaline
[2792] The title compound was obtained by treating
5,10-dihydro-10-methyl--
5-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxaline-7-methanol by
the same method as the one of Example 788. 1210
[2793] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2794] 3.12(s, 3H), 3.45(s, 3H), 4.5.0(d, J=6 Hz, 2H), 5.17(s, 2H),
6.44(d, J=8 Hz, 1H), 6.72(d, J=2 Hz, 1H), 6.76(dd, J=2, 8 Hz, 1H),
7.11(d, J=3 Hz, 1H), 7.19(d, J=3 Hz, 1H)
EXAMPLES
[2795] The following compounds were obtained by treating the
compounds obtained in Examples 804, 805, 810, 811 and 812 by the
same method as the one of Example 8.
114 Ex. Structural formula MS M.p. NMR 813 12115,10-dihydro-5-
methyl-10H- pyrazine[2,3-b][1,4]quinoxalin- e-8- carbaldehyde ESI
(+) 227 (MH.sup.+) 215-219.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 3.00(s, 3H), 6.58(d, J=8Hz,
1H), 6.70(s, 1H), 6.97(d, J=3Hz, 1H), 7.02(d, J=3Hz, 1H), 7.15(d,
J=8Hz, 1H), 9.36(s, 1H), 9.55(s, 1H) 814 1212ethyl (E)-3-(5,10-
dihydro-5-methyl- 10H-pyrazino[2,3-b][1,4]quinoxalin-8-
yl)propenoate ESI (+) 297 (MH.sup.+) 190-191.degree. C.
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 1.33(t, J=7Hz, 3H), 3.20(s,
3H), 4.24(q, J=7Hz, 2H), 6.31(d, J=16Hz, 1H), 6.45(d, J=3Hz, 1H),
6.60(d, J=8Hz, 1H), 6.85(d, J=2Hz, 1H), 6.97(d, J=3Hz, 1H), #
7.04(dd, J=2, 8Hz, 1H), 7.45 d, J=16Hz, 1H) 815 12135,10-dihydro-5-
methyl-8-(oxazol- 5-yl)-10H-pyrazino [2,3-b][1,4]quinoxaline ESI
(+) 266 (MH.sup.+) 268-269.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 3H), 6.51(d, J=8Hz, 1H),
6.64(d, J=2Hz, 1H), 6.90(d, J=4Hz, 1H), 6.93(dd, J=2, 8Hz, 1H),
6.98(d, J=4Hz, 1H), 7.37(s, 1H), 8.33(s, 1H). 9.23(s, 1H) 816
12145,10-dihydro-5- methyl-10H-
pyrazino[2,3-b]1,4]uinoxaline-8-methanol ESI (+) 229 (MH.sup.+)
215-218.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta- . ppm: 2.93(s,
3H), 4.18(d, J=6Hz, 2H), 4.97(t, J=6Hz, 1H), 6.33(s. 1H), 6.37(d,
J=8Hz, 1H), 6.47(d, J=8Hz, 1H), 6.82(d, J=3Hz, 1H), 6.92(d, J=3Hz,
1H), 9.07(s, 1H) 817 12155,10-dihydro-5- methyl-8- methoxymethyl-7-
10H-pyrazino[2,3- b][1,4]uinoxaline ESI (+) 243 (MH.sup.+)
169-172.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta.ppm: 2.94(s,
3H), 3.19(s, 3H), 4.08(s, 2H), 6.30(s, 1H), 6.36(d, J=8Hz, 1H).
6.48(d, J=8Hz, 1H), 6.84(d, J=4Hz, 1H), 6.94(d, J=4Hz, 1H), 9.08(s,
1H)
EXAMPLE 818
(5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b]-[1,4]quinoxali-
n-7-yl)-(pyridin -3-yl)methanol
[2796] Into a solution of 0.22 g of 3-bromopyridine in dry diethyl
ether (10 ml) was dropped 0.7 ml of a 1.6 M solution of
n-butyllithium in hexane at -78.degree. C. in a nitrogen
atmosphere. After stirring for 1 hour, a solution of 0.126 g of
5,10-dihydro -5-methoxymethyl-10-methyl-10-
H-pyrazino[2,3-b][1,4]quinoxaline-7-carbaldehyde in tetrahydrofuran
(3 ml) was dropped into the reaction mixture and then the bulk
temperature was elevated to -20.degree. C. After adding a saturated
aqueous solution of sodium dihydrogenphosphate, the resulting
mixture was extracted with ethyl acetate. The organic layers were
combined, washed successively with water and a saturated aqueous
solution of sodium chloride and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with n-hexane/ethyl acetate) to thereby give 0.100 g of the
title compound as a yellow solid. 1216
[2797] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2798] 3.10(s, 3H), 3.41(s, 3H), 5.12(s, 2H), 5.70(s, 1H), 6.42(d,
J=8 Hz, 1H), 6.71(dd, J=2, 8 Hz, 1H), 6.72(d, J=2 Hz, 1H), 7.11(d,
J=3 Hz, 1H), 7.19(d, J=3 Hz, 1H), 7.27(dd, J=5, 8 Hz, 1H), 7.71(td,
J=2, 8 Hz, 1H), 8.51(dd, J=2, 5 Hz, 1H), 8.62(d, J=2 Hz, 1H)
EXAMPLES
[2799] The following compounds were obtained by treating
5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxali- ne-7-carbaldehyde with
appropriate alkyl-metals or arylmetals by the same method as the
one of Example 818.
115 Ex. Structural formula NMR 819 1217(5,10-dihydro-5-
methoxymethyl-10- methyl-10H-pyrazino [2,3-b][1,4]quinoxalin-7-yl)-
(thiazol-2-yl)methanol .sup.1H-NMR(CDCl.sub.3).delta. ppm: 3.11(s,
3H), 3.42(s, 3H), 3.43(br.s, 1H), 5.12(s, 2H), 5.88(s, 1H), 6.43(d,
J=8Hz, 1H), 6.80(d, J=2Hz, 1H), 6.83(dd, J=2, 8Hz, 1H), 7.11(d,
J=3Hz, 1H), 7.19(d, J=3Hz, 1H), 7.31(d, J=3Hz, 1H), 7.74(d, J=3Hz,
1H) 820 1218(5,10-dihydro-5- methoxymethyl-10- methyl-10H-pyrazino
[2,3-b][1,4]quinoxalin-7-yl)- (thiophen-2-yl)methanol
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 2.37(s, 1H), 3.12(s, 3H),
3.41(s, 3H), 5.11(d, J=11Hz, 1H), 5,15(d, J=11Hz, 1H), 5.89(s. 1H),
6.44(d, J=8Hz, 1H), 6.79(d, J=2Hz, 1H), 6.83(dd, J=2, 8Hz, 1H),
6.92-6.96(m, 2H), 7.11(d, J=3Hz, 1H), # 7.19(d, J=3Hz, 1H),
7.25--7.28(m, 1H) 821 1219(5,10-dihydro-5- methoxymethyl-10-
methyl-10H-pyrazino [2,3-b][1,4]quinoxalin-7-yl)-
(pyridin-2-yl)methanol .sup.1H-NMR(CDCl.sub.3).delta. ppm: 3.11(s,
3H), 3.40(s, 3H), 5.12(s, 2H), 5.15(d, J=4Hz, 1H), 5.59(d, J=4Hz,
1H), 6.42(d, J=8Hz, 1H), 6.73(d, J=2Hz, 1H), 6.75(dd, J=2, 8Hz,
1H), 7.09(d, J=3Hz, 1H), 7.16-7.24(m, # 3H), 7.65(dt, J=1, 8Hz,
1H), 8.56(ddd, J=1, 2, 6Hz, 1H) 822 1220.alpha.-(5,10-dihydro-5-
methoxymethyl-10- methyl-10H- pyrazino[2,3-b][1,4]quinoxalin-7-yl)
benzyl alcohol .sup.1H-NMR(CDCl.sub.3).delta. ppm: 2.21(s, 1H),
3.09(s, 3H), 3.39(s, 3H), 5.16(d, J=9Hz, 1H), 5.22(d, J=9Hz, 1H),
5.78(s, 1H), 6.41(d, J=8Hz, 1H), 6.73(d, J=8Hz, 1H), 6.74(s, 1H),
7.09(d, J=3Hz, 1H), 7.18(d, J=3Hz, 1H), 7.25-7.39(m, 5H) 823
12211-(5,10-dihydro-5- methoxymethyl-10- methyl-10H-
pyrazino[2,3-b][1,4]quinoxalin-7-yl)- 3-phenylpropynol
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 2.36(br.s, 1H), 3.13(s, 3H),
3.45(s, 3H), 5.18(s, 2H), 5.51(d, J=5Hz, 1H), 6.47(d, J=8Hz, 1H),
6.98(d, J=2Hz, 1H), 7.00(dd, J=2, 8Hz), 1H), 7.12(d, J=3Hz, 1H),
7.20(d, J=3Hz, 1H), 7.29-7.34(m, 3H), 7.45-7.48(m, 2H) 824
1222N,N-dimethyl-[2-(5,10- dihydro-5- methoxymethyl-10-
methyl-10H-pyrazino [2,3-b][1,4]quinoxalin-7-yl)hydroxy-
methyl]imidazole- 1-sulfonamide .sup.1H-NMR(CDCl.sub.3).delta. ppm:
2.79(s, 6H), 3.07(s, 3H), 3.38(s, 3H), 5.01(d, J=11Hz, 1H), 5.10(d,
J=11Hz, 1H), 6.04(s, 1H), 6.39(d, J=8Hz, 1H), 6.68(d, J=2Hz, 1H),
6.75(dd, J=2, 8Hz, 1H), 7.06(d, # J=2Hz, 1H), 7.09(d, J=3Hz, 1H),
7.16(d, J=3Hz, 1H), 7.23(d, J=2Hz, 1H)
EXAMPLE 825
(5,10-Dihydro-10-methyl-5-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxalin-
-7-yl)-(1,2,4-triazol -3-yl)methanol
[2800] To a solution of 0.404 g of 1-diethoxymethyl -1,2,4-triazole
in dry tetrahydrofuran (10 ml) was added at 0.degree. C. in a
nitrogen atmosphere 1.5 ml of a 1.5 M solution of n-butyllithium in
hexane. After stirring for 1 hour, the resulting mixture was cooled
to -78.degree. C. Then a solution of 0.270 g of 5,10-dihydro
-5-methoxymethyl-10-methyl-10H-
-pyrazino[2,3-b][1,4]quinoxaline-7-carbaldehyde in dry
tetrahydrofuran (10 ml) was dropped thereinto and the bulk
temperature was elevated to room temperature. After stirring for 16
hours, a saturated aqueous solution of sodium dihydrogenphosphate
was added and the resulting mixture was extracted with ethyl
acetate. The organic layers were combined, washed successively with
water and a saturated aqueous solution of sodium chloride and dried
over anhydrous magnesium sulfate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.170 g of the title compound as a yellow solid.
1223
[2801] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2802] 3.02(s, 3H), 3.29(s, 3H), 5.04(s, 2H), 5.53 and 5.64(s,
total 1H), 5.64(s, 1H), 6.55(d, J=8 Hz, 1H), 6.73-6.89(m, 2H),
7.10(d, J=3 Hz, 1H), 7.18(d, J=3 Hz, 1H), 7.79 and 8.43(s, total
1H), 13.90(s, 1H)
EXAMPLES
[2803] The following compounds were obtained by the same method as
the one of Example 8.
116 Ex. Structural formula MS M.p. NMR 826 1224(5,10-dihydro-5-
methyl-10H- pyrazino[2,3-b][1,4]quinoxali- n-8-yl)-
(pyridin-3-yl)methanol ESI (+) 306 (MH.sup.+) 131-134.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.91(s, 3H), 5.46(d, J=5Hz,
1H), 5.88(d, J=5Hz, 1H), 6.36(d, J=2Hz, 1H), 6.36(d, J=8Hz, 1H),
6.55(dd, J=2, 8Hz, 1H), 6.83(d, J=4Hz, 1H), 6.92(d, J=4Hz, 1H),
7.31(dd, J=6, # 8Hz, 1H), 8.40(dd, J=2, 6Hz, 1H), 8.50(d, J=2Hz,
1H), 9.01(s, 1H) 827 1225(5,10-dihydro-5- methyl-10H-
pyrazino[2,3-b][1,4]quinoxal- in-8-yl)- (thiazol-2-yl)methanol ESI
(+) 334 (MNa.sup.+) 203-204.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.92(s, 3H), 5.62(d, J=5Hz,
1H), 6.38(d, J=8Hz, 1H), 6.43(s, 1H), 6.57(d, J=5Hz, 1H), 6.60(d,
J=8Hz, 1H), 6.83(d, J=3Hz, 1H), 6.93(d, J=3Hz, 1H, 7.59(d, # J=4Hz,
1H), 7.66(d, J=4Hz, 1H), 9.05(s, 1H) 828 1226(5,10-dihydro-5-
methyl-10H- pyrazino[2,3-b][1,4]quinoxalin-8-yl)-
(thiophen-2-yl)methanol ESI (+) 311 (MH.sup.+) >275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta- . ppm: 2.93(s, 3H), 5.62(d, J=5Hz,
1H), 6.02(d, J=5Hz, 1H), 6.37(d, J=8Hz, 1H), 6.43(s, 1H), 6.56(d,
J=8Hz, 1H), 6.82(d, J=4Hz, 1H), 6.83(d, J=6Hz, 1H), 6.90(d, J=6Hz,
1H), 6.93(d, J=4Hz, # 1H), 9.05(s, 1H) 829 1227(5,10-dihydro-5-
methyl-10H- pyrazino[2,3-b][1,4]quinoxa- lin-8-yl)-
(pyridin-2-yl)methanol ESI (+) 328 (MH.sup.+) 171-173.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.90(s, 3H), 5.39(d, J=5Hz,
1H), 5.89(d, J=5Hz, 1H), 6.35(d, J=8Hz, 1H), 6.40(d, J=2Hz, 1H),
6.56(dd, J=2. 8Hz, 1H), 6.81(d, J=4Hz, 1H), 6.92(d, # J=4Hz, 1H),
7.21(dd, J=5, 8Hz, 1H), 7.45(d, J=8Hz, 1H), 7.75(t, J=8Hz, 1H),
8.42(d, J=5Hz, 1H), 9.00(s, 1H) 830 1228.alpha.-(5,10-dihydro-5-
methyl-10H- pyrazino[2,3-b][1,4]quinoxalin-8-yl) benzyl alcohol ESI
(+) 305 (MH.sup.+) 127-132.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.90(s, 3H), 5.38(d, J=5Hz,
1H), 5.69(d, J=5Hz, 1H), 6.35(d, J=8Hz, 1H), 6.37(s, 1H), 6.53(d,
J=8Hz, 1H), 6.82(d, J=4Hz, 1H), 6.92(d, J=4Hz, 1H), 7.15-7.21(m,
2H), # 7.23-7.28(m, 3H), 9.00(s, 1H) 831 12291-(5,10-dihydro-5-
methyl-10H- pyrazino-10H- pyrazino[2,3-b][1,4]quinoxalin-8-yl)-
3-phenylpropynol ESI (+) 329 (MH.sup.+) 204-208.degree. C.
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 3.11(s, 3H), 5.29(s, 1H),
5.30(d, J=6Hz, 1H), 5.95(d, J=6Hz, 1H), 6.42(d, J=8Hz, 1H), 6.58(d,
J=2Hz, 1H), 6.69(dd, J=2, 8Hz, 1H), 6.85(dd, # J=1, 3Hz, 1H),
6.95(dd, J=1, 3Hz, 1H), 7.37(m, 3H), 7.42(m, 2H) 832
1230N,N-dimethyl-[2- (5,10-dihydro-5- methyl-10H-
pyrazino[2,3-b][1,4]qui- noxalin-8-yl) hydroxymethyl]imidazole-
1-sulfonamide ESI (+) 424 (MNa.sup.+) 185-190.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.84(s, 6H), 2.93(s, 3H), 5,
83(s,1H), 5.89(br.s, 1H), 6.37(d, J=8Hz, 1H), 6.46(d, J=2Hz, 1H),
6.52(dd, J=2, 8Hz, 1H), 6.83(d, J=4Hz, 1H), # 6.94(d, J=4 Hz, 1H),
7.00(d, J=2Hz, 1H), 7.50(d, J=2Hz, 1H), 9.06(s, 1H) 833
1231(5,10-dihydro-5- methyl-10H-
pyrazino[2,3-b]]1,4]quinoxalin-8-yl)- (1,2,4-triazol-3- yl)methanol
FAB (+) 296 (MH.sup.+) >275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.92(s, 3H), 5.54(s, 1H),
6.37(m, 2H), 6.54(d, J=8Hz, 1H), 6.83(s, 1H), 6.93(s, 1H), 7.79(s,
1H), 9.09(br.s, 1H), 13.86(br.s, 1H)
EXAMPLE 834
(5,10-Dihydro-5-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-8-yl)-(imidazol--
2-yl)methanol
[2804] 0.084 g of N,N-dimethyl-[2-(5,10-dihydro
-5-methyl-10H-pyrazino[2,3- -b][1,4]quinoxalin-8-yl)
hydroxymethyl]imidazole-1-sulfonamide was dissolved in 4.5 ml of
35% hydrochloric acid in a nitrogen atmosphere and heated to
50.degree. C. for 30 hours. Then the reaction mixture was
neutralized with a saturated aqueous solution of sodium
hydrogencarbonate and the solid thus precipitated was taken up by
filtration. This solid was dissolved in 6 N hydrochloric acid.
After filtering off the insoluble matters, the solution was
neutralized again with a saturated aqueous solution of sodium
hydrogencarbonate. The crystals thus precipitated were taken up by
filtration to thereby give 0.060 g of the title compound as a
yellowish green solid. 1232
[2805] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2806] 2.92(s, 3H), 5.46(s, 1H), 6.10(br.s, 1H), 6.37(d, J=8 Hz,
1H), 6.38(s, 1H), 6.55(d, J=8 Hz, 1H), 6.83(d, J=3 Hz, 1H), 6.94(d,
J=3 Hz, 1H), 6.96(br.s, 2H), 9.08(br.s, 1H)
[2807] MS: ESI(+)295(MH.sup.+)
EXAMPLE 835
(5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-
-7-yl) (pyridin -2-yl) ketone
[2808] The title compound was obtained by oxidizing
(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxal- in-7-yl)-(pyridin -2-yl)methanol
with manganese dioxide by the same method as the one of Example
625. 1233
[2809] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2810] 3.19(s, 3H), 3.45(s, 3H), 5.20(s, 2H), 6.50(d, J=8 Hz, 1H),
7.20(d, J=3 Hz, 1H), 7.24(d, J=3 Hz, 1H), 7.46(ddd, J=1, 5, 8 Hz,
1H), 7.49(d, J=2 Hz, 1H), 7.61(dd, J=2, 8 Hz, 1H), 7.86(dt, J=2, 8
Hz, 1H), 7.77(td, J=1, 8 Hz, 1H), 8.69(ddd, J=1, 2, 5 Hz, 1H)
EXAMPLE 836
1-(5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxal-
in-7-yl)-1-(pyridin -2-yl)ethanol
[2811] The title compound was obtained by treating
(5,10-dihydro-5-methoxy- methyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl) (pyridin-2-yl) ketone
with methyllithium by the same method as the one of Example 818.
1234
[2812] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2813] 1.85(s, 3H), 3.08(s, 3H), 3.38(s, 3H), 5.09(s, 2H), 5.75(s,
1H), 6.49(d, J=8 Hz, 1H), 6.82(d, J=2 Hz, 1H), 6.86(dd, J=2, 8 Hz,
1H), 7.09(d, J=3 Hz, 1H), 7.16(d, J=3 Hz, 1H), 7.17(dd, J=5, 8 Hz,
1H), 7.31(d, J=8 Hz, 1H), 7.66(dt, J=1, 8 Hz, 1H), 8.52(dd, J=1, 5
Hz, 1H)
EXAMPLE 837
[(5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxali-
n-7-yl)-(pyridin -2-yl)methyl]acetate
[2814] 0.192 g of the title compound was obtained as a yellow solid
by treating 0.202 g of (5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-(pyridin -2-yl)methanol
with 0.5 ml of acetic anhydride in the presence of 5 ml of pyridine
by the same method as the one of Production Example 165. 1235
[2815] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2816] 2.19(s, 3H), 3.08(s, 3H), 3.40(s, 3H), 5.09(s, 2H), 6.40(d,
J=8 Hz, 1H), 6.68(s, 1H), 6.75(d, J=2 Hz, 1H), 6.80(dd, J=2, 8 Hz,
1H), 7.09(d, J=3 Hz, 1H), 7.17(d, J=3 Hz, 1H), 7.19(ddd, J=1, 5, 8
Hz, 1H), 7.40(br.t, J=8 Hz, 1H), 7.67(dt, J=2, 8 Hz, 1H), 8.58(ddd,
J=1,2,5 Hz, 1H)
EXAMPLE 838
5,10-Dihydro-5-methoxymethyl-10-methyl-7-[(piperidin-2-yl)methyl]-10H-pyra-
zino[2,3-b][1,4]quinoxaline
[2817] 0.019 g of the title compound was obtained as a yellow solid
by hydrogenating 0.096 g of
[(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-(pyridin -2-yl)methyl]
acetate in a solvent [ethanol (10 ml)/acetic acid (0.2 ml)] in the
presence of 0.12 g of a 10% palladium-carbon powder (moisture
content: 50%) by the same method as the one of Example 20. 1236
[2818] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2819] 1.30-1.41(m, 1H), 1.48-1.60(m, 1H), 1.74-1.87(m, 4H),
2.65(dd, J=9, 13 Hz, 1H), 2.79(dd, J=5, 13 Hz, 1H), 2.95-3.07(m,
3H), 3.07(s, 3H), 3.36-3.42(m, 1H), 3.44(s, 3H), 5.12(s, 2H),
6.36(d, J=8 Hz, 1H), 6.53(d, J=2 Hz, 1H), 6.60(dd, J=2, 8 Hz, 1H),
7.08(d, J=3 Hz, 1H), 7.17(d, J=3 Hz, 1H)
EXAMPLE 839
5,10-Dihydro-5-methoxymethyl-10-methyl-7-[(pyridin-2-yl)methyl]-10H-pyrazi-
no[2,3-b][1,4]quinoxaline
[2820] 0.160 g of the title compound was obtained as a yellow solid
by hydrogenating 0.194 g of
[(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-(pyridin -2-yl)methyl)
acetate in a mixture (15 ml) of tetrahydrofuran with ethanol (1:1)
in the presence of 0.12 g of a 10% palladium-carbon powder
(moisture content: 50%) by the same method as the one of Example
20. 1237
[2821] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2822] 3.03(s, 3H), 3.46(s, 3H), 4.05(s, 2H), 5.10(s, 2H), 6.37(d,
J=8 Hz, 1H), 6.61(m, 2H), 7.01(d, J=3 Hz, 1H), 7.09(d, J=3 Hz, 1H),
7.21(m, 1H), 7.62(dt, J=2, 8 Hz, 1H), 7.70(br.t, J=8 Hz, 1H),
8.51(m, 1H)
EXAMPLES
[2823] The following compounds were obtained by treating the
compounds obtained in Examples 835, 836, 838 and 839 by the same
method as the one of Example 8.
117 Ex. Structural formula MS M.p. NMR 840 1238(5,10-dihydro-5-
methyl-10H- pyrazino[2,3-b][1,4]quinoxali- n-8-yl)
(pyridin-2-yl)ketone ESI (+) 326 (MNa.sup.+) 261-262.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 3.01(s, 3H), 6.52(d, J=8Hz,
1H), 6.95(d, J=4Hz, 1H), 6.98(d, J=2Hz, 1H), 7.02(d, J=4Hz, 1H),
7.28(dd, J=2, 8Hz, 1H), 7.60(dd, J=5, 8Hz, 1H), 7.82(d, J=8Hz, 1H),
# 8.00(dt, J=1, 8Hz, 1H), 8.57(dd, J=1, 5Hz, 1H), 9.28(s, 1H) 841
12391-(5,10-dihydro-5- methyl-10H-
pyrazino[2,3-b][1,4]qyinoxalin-8-yl)- 1-(pyridin-2-yl)ethanol ESI
(+) 342 (MH.sup.+ 185-187.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 1.71(s, 3H), 2.89(s, 3H),
5.74(s, 1H), 6.32(d, J=8Hz, 1H), 6.53(d, J=2Hz, 1H), 6.62(dd, J=2,
8Hz, 1H), 6.80(d, J=4Hz, 1H), 6.90(d, J=4Hz, 1H), 7.18(dd, J=6, #
8Hz, 1H), 7.56(d, J=8Hz, 1H), 7.71(dt, J=2, 8Hz, 1H), 8.44(dd, J=2,
6Hz, 1H), 8.95(s, 1H) 842 12405,10-dihydro-5- methyl-8-
[(piperidin-2-yl) methyl]-10H- pyrazino[2,3-b][1,4]quinoxaline
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 0.84-0.88(m, 1H), 1.04-1.12(m,
1H), 1.16-1.28(m, 3H), 2.19-2.30(m, 1H), 2.36-2.50(m, 3H),
2.92-3.05(m, 2H), 3.00(s, 3H), 5.95(br.s, 1H), 6.01(d, J=2Hz, 1H),
6.25(d, J=8Hz, # 1H), 6.43(dd, J=2, 8Hz, 1H), 6.84(d, J=3Hz, 1H),
7.01(d, J=3Hz, 1H) 843 12415,10-dihydro-5- methyl-8- [(pyridin-2-
yl)methyl]-10H- pyrazino[2,3-b][1,4]quinoxaline ESI (+) 290
(MH.sup.+) .sup.1H-NMR(CDCl.sub.3).delta. ppm: 3.05(s, 3H), 3.88(s,
2H), 6.13(d, J=2Hz, 1H), 6.34(d, J=8Hz, 1H), 6.55(dd, J=2, 8Hz,
1H), 6.88(d, J=4Hz, 1H), 7.06(d, J=4Hz, 1H), 7.12(d, J=8Hz, 1H),
7.12(dd, J=6, 8Hz, 1H), 7.59(dt, J=2, # 8Hz, 1H), 8.54(dd, J=2,
6Hz, 1H)
EXAMPLE 844
Methyl
(5,10-dihydro-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]quinoxalin-5-
-yl)acetate
[2824] 1.71 g of the title compound was obtained by treating 2.28 g
of 5,10-dihydro-5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline with ethyl bromoacetate by the
same method as the one of Example 788. 1242
[2825] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2826] 3.46(s, 3H), 3.78(s, 3H), 4.49(s, 2H), 5.18(s, 2H), 6.26(m,
1H), 6.70-6.79(m, 3H), 7.16(s, 2H)
EXAMPLES
[2827] The following compounds were obtained by treating the
compounds obtained in Examples 844, 794 and 795 by the same method
as the one of EXAMPLE 2.
118 Ex. Structural formula NMR 845 12432-(5,10-dihydro-10-
methoxymethyl-10H- pyrazino[2,3-b][1,4]quinoxalin- -5-yl)ethanol
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 3.29(s, 3H), 3.52(q, J=7Hz,
2H), 3.74(t, J=7Hz, 2H), 4.84(t, J=7Hz, 1H), 5.05(s, 2H),
6.61-6.72(m, 4H), 7.08(s, 1H), 7.16(s, 1H) 846
12444-(5,10-dihydro-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]quinoxalin- -5-yl)-1-butanol
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 1.60-1.79(m, 4H), 2.64(br.s,
1H), 3.43(s, 3H), 3.68-3.78(m, 4H), 5.13(s, 2H), 6.48(d, J=8Hz,
1H), 6.66-6.76(m, 3H), 7.07(d, J=3Hz, 1H), 7.12(d, J=3Hz, 1H) 847
1245(E)-4-(5,10-dihydro-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]quinoxalin-5-yl)-2-buten-1-ol
.sup.1H-NMR(CDCl.sub.3)- .delta. ppm: 3.45(s, 3H), 4.15(br.m, 2H),
4.37(br.s, 2H), 5.13(s, 2H), 5.75(ttd, J=1, 4, 16Hz, 1H), 5.90(ttd,
J=1, 5, 16Hz, 1H), 6.43(m, 1H), 6.68(m, 3H), 7.11(d, J=3Hz, 1H),
7.16(d, J=3Hz, 1H)
EXAMPLES
[2828] The following compounds were obtained by treating the
compounds obtained in Examples 845, 846 and 847 by the same method
as the one of Example 8.
119 Ex. Structural formula MS M.p. NMR 848 12462-(5,10-dihydro-
10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)e- thanol ESI (+) 229
(MH.sup.+ 197-204.degree. C. .sup.1H-NMR(DMSO-d.sub.6).- delta.
ppm: 3.46(t, J=7Hz, 2H), 3.62(t, J=7Hz, 2H), 6.30(d, J=8Hz, 1H),
6.47-6.55(m, 3H), 6.83(d, J=3Hz, 1H), 6.90(d, J=3Hz, 1H), 9.03(s,
1H) 849 12474-(5,10-dihydro- 10H-pyrazino[2,3-b][1,4]quinoxalin-5-
-yl)-1-butanol ESI (+) 257 (MH.sup.+ 138-139.degree. C.
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 1.51-1.69(m, 4H), 2.58(br.s,
1H), 3.59(t, J=7Hz, 2H), 3.68(m, 2H), 6.14(d, J=8Hz, 1H), 6.35(d,
J=8Hz, 1H), 6.48-6.60(m, 2H), 6.80(s, 1H), 6.93(s, 1H) 850
12484-(5,10-dihydro-
10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)-2-buten-1-o- l ESI (+) 255
(MH.sup.+) 197-199.degree. C. .sup.1H-NMR(CDCl.sub.3).delta. ppm:
3.88(dd, J=5, 6Hz, 2H), 4.16(d, J=4Hz, 2H), 4.69(d, J=6Hz, 1H),
5.43(td, J=5, 16Hz, 1H), 5.77(td, J=4, 16Hz, 1H), 6.30-6.38(m, 2H),
6.47-6.52(m, 2H), 6.84(d, J=3Hz, 1H), 6.90(d, J=3Hz, 1H)
EXAMPLE 851
5,10-Dihydro-10-(3-chloropropan-1-yl)-5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline
[2829] 0.607 g of the title compound was obtained by treating 0.684
g of 5,10-dihydro
-5-methoxymethoxy-10H-pyrazino[2,3-b][1,4]quinoxaline with
3-bromo-1-chloropropane by the same method as the one of Example
788. 1249
[2830] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2831] 2.33(quint, J=7 Hz, 2H), 3.45(s, 3H), 3.67(t, J=7 Hz, 2H),
3.86(t, J=7 Hz, 2H), 5.13(s, 2H), 6.55(d, J=8 Hz, 1H), 6.70-6.78(m,
3H), 7.08-7.15(m, 2H)
EXAMPLE 852
5,10-Dihydro-10-(3-azidopropan-1-yl)-5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline
[2832] To a solution of 0.082 g of 5,10-dihydro
-10-(3-chloropropan-1-yl)-- 5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline in N,N-dimethylformamide (5
ml) was added in a nitrogen atmosphere 0.035 g of sodium azide and
the resulting mixture was heated to 80.degree. C. for 1 hour. Then
the reaction mixture was distributed into ethyl acetate and water
and the aqueous layer was extracted with ethyl acetate. The organic
layers were combined, washed with water and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.045 g of the title compound as a yellow solid. 1250
[2833] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2834] 1.83(quint, J=7 Hz, 2H), 3.38(s, 3H), 3.39(t, J=7 Hz, 2H),
3.73(t, J=7 Hz, 2H), 5.07(s, 2H), 6.43(d, J=8 Hz, 1H), 6.61(m, 3H),
7.02(s, 1H), 7.08(s, 1H)
EXAMPLE 853
5,10-Dihydro-10-(3-aminopropan-1-yl)-5-methoxymethyl
-10H-pyrazino[2,3-b][1,4]quinoxaline
[2835] 0.045 g of 5,10-dihydro-10-(3-azidopropan
-1-yl)-5-methoxymethyl-10- H-pyrazino[2,3-b][1,4]quinoxaline was
dissolved in ethanol (10 ml) and 0.020 g of 10% palladium-carbon
was added thereto. Then the mixture was subjected to a
hydrogenation reaction at room temperature under atmospheric
pressure for 24 hours. Next, the reaction mixture was filtered
through celite and concentrated under reduced pressure to thereby
give 0.018 g of the title compound as a yellow solid. 1251
[2836] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2837] 2.15(quint, J=7 Hz, 2H), 2.89(t, J=7 Hz, 2H), 3.44(s, 3H),
3.83(br.m, 2H), 5.13(s, 2H), 6.45(dd, J=2, 8 Hz, 1H), 6.90-6.97(m,
3H), 7.02(d, J=2 Hz, 1H), 7.10(d, J=2 Hz, 1H)
EXAMPLE 854
5,10-Dihydro-5-(3-aminopropan-1-yl)-10H-pyrazino
[2,3-b][1,4]quinoxaline
[2838] 0.011 g of the title compound was obtained as a yellowish
green solid by treating 0.018 g of 5,10-dihydro-5-methoxymethyl
-10-(3-aminopropan-1-yl)-10H-pyrazino[2,3-b][1,4]quinoxaline by the
same method as the one of Example 8. 1252
[2839] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2840] 1.51(quint, J=7 Hz, 2H), 2.58(t, J=7 Hz, 2H), 3.59(t, J=7
Hz, 2H), 6.30(d, J=8 Hz, 1H), 6.47-6.52(m, 3H), 6.80(d, J=3 Hz,
1H), 6.89(d, J=3 Hz, 1H), 9.00(s, 1H)
EXAMPLES
[2841] The following compounds were obtained by treating the
compounds obtained in Examples 811 and 845 by the same method as
the one of Example 1237.
120 Ex. Structural formula NMR 855 1253N-(5,10-dihydro-5-
methoxymethyl-10- methyl-10H- pyrazino[2,3-b][1,4]quinoxalin-7-yl)
methylphthalimide .sup.1H-NMR(CDCl.sub.3).delta. ppm: 3.05(s, 3H),
3.38(s, 3H), 4.60(s, 2H), 5.08(s, 2H), 6.32(d, J=8Hz, 1H),
6.74-6.77(m, 2H), 7.03(s, 1H), 7.10(s, 1H), 7.63-7.66(m, 2H),
7.75-7.79(m, 2H) 856 1254N-[2-(5,10-dihydro-5- methoxymethyl-10-
methyl-10H- pyrazino[2,3-b][1,4]quinoxalin-7-yl) ethyl]phthalimide
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 3.38(s, 3H), 3.92(m, 2H),
3.96(m, 2H), 5.07(s, 2H), 6.66-6.71(m, 4H), 6.95(d, J=3Hz, 1H),
6.97(d, J=3Hz, 1H), 7.64(dd, J=2, 5Hz, 2H), 7.75(dd, J=2, 5Hz,
2H)
EXAMPLES
[2842] The following compounds were obtained by treating the
compounds obtained in Examples 855 and 856 by the same method as
the one of Example 1239.
121 Ex. Structural formula NMR 857 12555,10-dihydro-7-
aminomethyl-5- methoxymethyl-10- methyl-10H-
pyrazino[2,3-b][1,4]quinoxaline .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.12(s, 3H), 3.46(s, 3H), 3.70(s, 2H), 5.17(s, 2H), 6.42(d,
J=8Hz, 1H), 6.68(d, J=2Hz, 1H), 6.71(dd, J=2, 8Hz, 1H), 7.09(d,
J=3Hz, 1H), 7.18(d, J=3Hz, 1H) 858 12565,10-dihydro-5-(2-
aminoethan-1-yl)-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]quinoxaline .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.15(quint, J=7Hz, 2H), 2.89(t, J=7Hz, 2H), 3.44(s, 3H),
3.83(br.m, 2H), 5.13(s, 2H), 6.45(dd, J=2, 8Hz, 1H), 6.90-6.97(m,
3H), 7.02(d, J=2Hz, 1H), 7.10(d, J=2Hz, 1H)
EXAMPLES
[2843] The following compounds were obtained by treating the
compounds obtained in Examples 857 and 858 by the same method as
the one of Example 8.
122 Ex. Structural formula MS M.p. NMR 859 12575,10-dihydro-10-
methyl-7- aminomethyl-10H- pyrazino[2,3-b][1,4]quinoxaline ESI (+)
228 (MH.sup.+) 117-122.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta.
ppm: 2.93(s, 3H), 3.54(s, 2H), 6.33(d, J=2Hz, 1H), 6.41(d, J=8Hz,
1H), 6.56(dd, J=2, 8Hz, 1H), 6.85(d, J=3Hz, 1H), 6.94(d, J=3Hz,
1H), 9.16(s, 1H) 860 12585,10-dihydro-5-(2- aminoethan-1-yl)-
10H-pyrazino[2,3-b][1,4]quinoxal- ine ESI (+) 228 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.86-2.94(m, 2H), 3.85(t,
J=7Hz, 2H), 6.42(dd, J=4, 7Hz, 1H), 6.56-6.60(m, 2H), 6.67(dd, J=4,
7Hz, 1H), 6.86(d, J=3Hz, 1H), 6.92(d, J=3Hz, 1H), 8.02(br.s, 2H),
9.47(br.s, 1H)
EXAMPLE 861
N-[(5,10-Dihydro-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-(piper-
idin-2-yl)methyl]phthalimide
[2844] The title compound was obtained by treating
(5,10-dihydro-5-methoxy- methyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-(pyridin -2-yl)methanol
with phthalimide by the same method as the one of Example 1237
followed by the same treatment as the one of Example 8. 1259
[2845] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2846] 2.93(s, 3H), 6.30(s, 1H), 6.42-6.45(m, 2H), 6.61(d, J=8 Hz,
1H), 6.84(d, J=3 Hz, 1H), 6.95(d, J=3 Hz, 1H), 7.23(d, J=8 Hz, 1H),
7.28(dd, J=5, 8 Hz, 1H), 7.52-7.63(m, 2H), 7.77(t, J=8 Hz, 1H),
7.87(m, 2H), 8.45(d, J=5 Hz, 1H), 9.02(s, 1H)
EXAMPLE 862
5,10-Dihydro-5-methyl-8-[(pyridin-2-yl)(amino)
methyl]-10H-pyrazino[2,3-b]- [1,4]quinoxaline
[2847] The title compound was obtained by treating
N-[(5,10-dihydro-10-met-
hyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-(pyridin
-2-yl)methyl]phthalimide with hydrazine by the same method as the
one of Example 1239. 1260
[2848] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2849] 2.22(br.s, 2H), 2.91(s, 3H), 4.81(s, 1H), 6.35(d, J=8 Hz,
1H), 6.40(s, 1H), 6.58(d, J=8 Hz, 1H), 6.81(d, J=4Hz, 1H), 6.91(d,
J=4Hz, 1H), 7.19(dd, J=6, 8 Hz, 1H), 7.38(d, J=8 Hz, 1H), 7.70(t,
J=8 Hz, 1H), 8.44(d, J=6Hz, 1H), 8.99(s, 1H)
[2850] MS: ESI(+)305(MH.sup.+)
[2851] m.p. : >275.degree. C.
EXAMPLE 863
N-[2-(5,10-Dihydro-10-methoxymethyl-10H-pyrazino[2,3-b]l[1,4]quinoxalin-5--
yl)ethyl]urea
[2852] To a solution of 0.081 g of 5,10-dihydro
-5-(2-aminoethan-1-yl)-10-- methoxymethyl -10H-pyrazino
[2,3-b][1,4]quinoxaline in dry tetrahydrofuran (10 ml) were added
in a nitrogen atmosphere 0.081 ml of triethylamine and 0.061 ml of
trimethylsilyl isocyanate and the resulting mixture was stirred at
room temperature for 16 hours. Next, the reaction mixture was
distributed into ethyl acetate and water. The organic layer was
washed with a saturated aqueous solution of sodium chloride and
dried over anhydrous magnesium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 0.057 g of the title compound as a yellow solid.
1261
[2853] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2854] 3.40(m, 2H), 3.46(s, 3H), 3.84(t, J=7 Hz, 2H), 5.14(s, 2H),
6.64-6.68(m, 1H), 6.73-6.80(m, 3H), 7.10(d, J=3 Hz, 1H), 7.14(d,
J=3 Hz, 1H)
EXAMPLE 864
N-[(5,10-Dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinox- alin-7-yl)methyl]urea
[2855] 0.034 g of the title compound was obtained by treating 0.041
g of 5,10-dihydro
-5-methoxymethyl-10-methyl-7-aminomethyl-10H-pyrazino[2,3-b]-
[1,4]quinoxaline by the same method as the one of Example 863.
1262
[2856] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2857] 3.02(s, 3H), 3.30(s, 3H), 3.96(d, J=6 Hz, 2H), 5.06(s, 2H),
5.48(s, 2H), 6.28(t, J=6 Hz, 1H), 6.54(d, J=8 Hz, 1H), 6.56(d, J=2
Hz, 1H), 6.65(dd, J=2, 8 Hz, 1H), 7.09(d, J=3 Hz, 1H), 7.18(d, J=3
Hz, 1H)
EXAMPLES
[2858] The following compounds were obtained by treating the
compounds obtained in Examples 863 and 864 by the same method as
the one of Example 8.
123 Ex. Structural formula MS M.p. NMR 865 1263N-[(5,10-dihydro-
10-methyl-10H- pyrazino[2,3-b][1,4]quino- xalin-7-yl) methyl]urea
ESI (+) 271 (MH.sup.+) >275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6).delta. ppm: 2.94(s, 3H), 3.85(d, J=6Hz,
2H), 5.46(s, 2H), 6.21(t, J=6Hz, 1H), 6.26(s, 1H), 6.35(d, J=8Hz,
1H), 6.43(d, J=8Hz, 1H), 6.83(d, J=4Hz, 1H), 6.93(d, J=4Hz, 1H),
9.08(s, 1H) 866 1264N-[2-(5,10- dihydro-10H-
pyrazino[2,3-b][1,4]quinoxalin-5- yl)ethyl]urea ESI (+) 293
(MNa.sup.+) 231-233.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta.
ppm: 3.04(q, J=7Hz, 2H), 3.54(t, J=7Hz, 2H), 5.49(s, 2H), 6.19(t,
J=7Hz, 1H), 6.32(m, 1H), 6.51(m, 2H), 6.72(m, 1H), 6.84(d, J=4Hz,
1H), 6.90(d, J=4Hz, 1H), 9.03(s, 1H)
EXAMPLE 867
N-[(5,10-Dihydro-5-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-8-yl)methyl]g-
uanidine
[2859] To a solution of 0.084 g of 5,10-dihydro
-5-methyl-8-aminomethyl- 10H-pyrazino[2,3-b][1,4]quinoxaline in
methanol (10 ml) was added 0.046 g of formamidinesulfonic acid and
the resulting mixture was stirred at room temperature for 40 hours.
After adding water, the precipitate thus formed was taken up by
filtration to thereby give 0.066 g of the title compound as a
yellow solid. 1265
[2860] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2861] 2.92(s, 3H), 4.03(s, 2H), 6.26(d, J=1 Hz, 1H), 6.40(d, J=8
Hz, 1H), 6.48(dd, J=1, 8 Hz, 1H), 6.85(d, J=3 Hz, 1H), 6.94(d, J=3
Hz, 1H)
[2862] m.p. : >275.degree. C.
[2863] MS: ESI(+)270(MH.sup.+)
EXAMPLE 868
N-[2-(5,10-Dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)ethyl]guanidine
[2864] Starting with 0.064 g of
5,10-dihydro-5-(2-aminoethan-1-yl)-10-meth-
oxymethyl-10H-pyrazino[2,3-b][1,4]quinoxaline, 0.030 g of the title
compound was obtained by the same method as the one of Example 867.
1266
[2865] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2866] 3.22(t, J=7 Hz, 2H), 3.66(t, J=7 Hz, 2H), 6.33(m, 1H),
6.50-6.62(m, 3H), 6.81(d, J=4 Hz, 1H), 6.92(d, J=4 Hz, 1H)
[2867] MS: ESI(+)270(MH.sup.+)
EXAMPLES
[2868] The following compounds were obtained by the same method as
the one of Production Example 165.
124 Ex. Structural formula NMR 869 1267N[(5,10-dihydro-5-
methoxymethyl-10- methyl-10H-pyrazino [2,3-b][1,4]quinoxalin-7-
yl)methyl]acetamide .sup.1H-NMR(CDCl.sub.3).del- ta. ppm: 1.83(s,
3H), 3.03(s, 3H), 3.31(s, 3H), 4.03(d, J=6Hz, 2H), 5.06(s, 2H),
6.54(d, J=8Hz, 1H), 6.56(d, J=2Hz, 1H), 6.63(dd, J=2, 8Hz, 1H),
7.10(d, J=3Hz, 1H), 7.18(d, J=3Hz, 1H), 8.24(br.s, 1H) 870
1268(E)-N-[4-(5,10- dihydro-5- methoxymethyl-10H-
pyrazin[2,3-b][1,4]quinoxalin-5-yl)-2- buten-1-yl]acetamide
.sup.1H-NMR(CDCl.sub.3).delta. ppm: 1.90(s, 3H), 3.39(s, 3H),
3.81(br.t, J=6Hz, 2H), 4.25(br.t, J=4Hz, 2H), 5.07(s, 2H),
5.55-5.67(m, 2H), 6.53(m, 1H), 6.61-6.66(m, 3H), 7.04(d, J=3Hz,
1H), 7.08(d, J=3Hz, 1H)
EXAMPLES
[2869] The following compounds were obtained by the same method as
the one of Example 8.
125 Ex. Structural formula MS M.p. NMR 871 1269N-[(5,10-dihydro-
5-methyl-10H- pyrazino[2,3- b][1,4]quinoxalin-8-yl)
methyl]acetamide ESI (+) 270 (MH.sup.+) 247-249.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.48(s, 3H), 2.93(s, 3H), #
3.93(d, J=6Hz, 2H), 6.25(s, 1H), 6.37(d, J=8Hz, 1H), 6.43(d, J=8Hz,
1H), 6.85(d, J=4Hz, 1H), 6.92(d, J=4Hz, 1H), 8.19(br.s, 1H),
9.05(s, 1H) 872 1270(E)-N-[4-(5,10- dihydro-10H- pyrazino[2,3-
b][1,4]quinoxalin-5-yl)- 2-buten-1- yl]acetamide ESI (+) 318
(MH.sup.+) 225-227.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: # 1.77(s, 3H), 3.63(t, J=6Hz, 2H), 4.16(d, J=3Hz, 2H),
5.49(td, J=3, 15Hz, 1H), 5.53(td, J=6, 15Hz, 1H), 6.31-6.36(m, 2H),
6.47-6.51(m, 2H), 6.85(d, J=3Hz, 1H), 6.91(d, J=3Hz, 1H), 7.96(t,
J=6Hz, 1H), 9.06(s, 1H)
EXAMPLE 873
N-[2-(5,10-Dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)ethyl]methylsul-
fonamide
[2870] The title compound was obtained by successively treating
5,10-dihydro-5-(2-aminoethan
-1-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][- 1,4]quinoxaline by
the same methods as those of Examples 316 and 8. 1271
[2871] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2872] 2.92(s, 3H), 3.06(q, J=7 Hz, 2H), 3.65(t, J=7 Hz, 2H),
6.34(m, 1H), 6.53(m, 3H), 6.86(d, J=3 Hz, 1H), 6.93(d, J=3 Hz, 1H),
7.26(t, J=7 Hz, 1H), 9.07(s, 1H)
[2873] MS: ESI(+)306(MH.sup.+)
[2874] m.p. : 218-222.degree. C.
EXAMPLE 874
[4-(5,10-Dihydro-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-quinoxalin-5-yl-
)butan-1-yl]methylsulfonate
[2875] Starting with 0.195 g of 4-(5,10-dihydro
-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]-quinoxalin-5-yl)butan-1-ol, 0.247 g of the title
compound was obtained as a yellow oily substance by the same method
as the one of Production Example 52. 1272
[2876] .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.62-1.71(m, 2H),
1.83-1.92(quint, J=7 Hz, 2H), 3.01(s, 3H), 3.45(s, 3H), 3.64(m,
2H), 4.30(t, J=7 Hz, 2H), 5.13(s, 2H), 6.43(d, J=8 Hz, 1H),
6.65-6.77(m, 3H), 7.08(d, J=3 Hz, 1H), 7.12(d, J=3 Hz, 1H)
EXAMPLE 875
N-[4-(5,10-Dihydro-10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]-quinoxalin-5- -yl)butyl]-p-toluenesulfonamide
[2877] A solution of 0.089 g of p-toluenesulfonamide in
N,N-dimethylformamide (5 ml) was cooled to 0.degree. C. in a
nitrogen atmosphere. After adding 0.023 g of sodium hydride (60%
oily), 0.131 g of [4-(5,10-dihydro-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]-quinoxalin
-5-yl)butan-1-yl]methanesulfonate was further added thereto and the
resulting mixture was heated to 60.degree. C. for 16 hours. Then
the reaction mixture was distributed into ethyl acetate and water.
The organic layer was washed with a saturated aqueous solution of
sodium chloride and dried over anhydrous magnesium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.094 g of the title
compound as a yellow solid. 1273
[2878] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2879] 2.41(s, 3H), 3.05(quint, J=7 Hz, 2H), 3.44(s, 3H), 3.55(m,
2H), 3.74(m, 1H), 4.71(br.s, 4H), 5.13(s, 2H), 6.41(d, J=8 Hz,
1H),6.68-6.75(m,3H),7.25-7.30(m,4H),7.64(d,J=8 Hz,2H)
EXAMPLE 876
N-[4-(5,10-Dihydro-10H-pyrazino[2,3-b][1,4]quinoxalin-5-yl)butyl]-p-toluen-
esulfonamide
[2880] 0.051 g of the title compound was obtained as a yellow solid
by treating 0.094 g of
N-[4-(5,10-dihydro-10-methoxymethyl-10H-pyrazino[2,3--
b][1,4]quinoxalin-5-yl)butyl]-p-toluenesulfonamide by the same
method as the one of Example 8. 1274
[2881] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2882] 1.39(m, 4H), 2.35(s, 3H), 2.71(m, 2H), 3.47(m, 2H), 6.32(m,
1H),. 6.41(m, 1H), 6.48-6.54(m, 2H), 6.80(d, J=3 Hz, 1H), 6.88(d,
J=3 Hz, 1H), 7.35(d, J=8 Hz, 2H), 7.52(t, J=6 Hz, 1H), 7.63(d, J=8
Hz, 2H), 9.10(br.s, 1H)
[2883] m.p. : 124-128.degree. C.
EXAMPLE 877
5-Methoxymethyl-5,10-dihydro-7-iodo-10-methyl
-10H-pyrazino-[2,3-b][1,4]qu- inoxaline
[2884] 7.3 g of the title compound was obtained as a yellow solid
by reacting 10.0 g of 5,10-dihydro
-7-iodo-10-methyl-10H-pyrazino[2,3-b][1,4- ]quinoxaline with
chloromethyl methyl ether by the same method as the one of Example
788. 1275
[2885] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2886] 3.08(s, 3H), 3.44(s, 3H), 5.10(s, 2H), 6.17(d, J=9 Hz, 1H),
6.95(d, J=2 Hz, 1H), 7.05(dd, J=2, 9 Hz, 1H), 7.12(d, J=3 Hz, 1H),
7.21(d, J=3 Hz, 1H)
EXAMPLE 878
5,10-Dihydro-5-methoxymethyl-10-methyl-7-(pyridin
-2-yl)-10H-pyrazino[2,3-- b][1,4]quinoxaline
[2887] To a solution of (pyridin-2-yl)copper in toluene (20 ml)
were added 0.423 g of 5,10-dihydro
-7-iodo-5-methoxymethyl-10-methyl-10H-pyrazino[2,-
3-b][1,4]quinoxaline and 1.68 g of triphenylphosphine and the
resulting mixture was heated to 100.degree. C. in a nitrogen
atmosphere for 14 hours. After cooling to room temperature, the
reaction mixture was filtered and distributed into ethyl acetate
and water. After filtering off the insoluble matters, the organic
layer was washed with aqueous ammonia and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.224 g of the title compound as a yellow solid. 1276
[2888] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2889] 3.18(s, 3H), 3.50(s, 3H), 5.28(s, 2H), 6.55(d, J=9 Hz, 1H),
7.14(d, J=3 Hz, 1H), 7.10(ddd, J=1, 4, 7 Hz, 1H), 7.14(d, J=3 Hz,
1H), 7.33-7.36(m, 2H), 7.54(d, J=8 Hz, 1H), 7.63(dt, J=2, 8 Hz,
1H), 8.56(ddd, J=1, 2, 8 Hz, 1H)
EXAMPLE 879
5,10-Dihydro-5-methyl-8-(pyridin-2-yl)-10H-pyrazino[2,3-b][1,4]quinoxaline
[2890] The title compound was obtained by treating
5,10-dihydro-5-methoxym- ethyl-10-methyl
-7-(pyridin-2-yl)-10H-pyrazino[2,3-b][1,4]quinoxaline by the same
method as the one of Example 8. 1277
[2891] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2892] 2.99(s,3H),6.53(d,J=8 Hz,1H),6.89(d,J=4 Hz,1H),6.98(d,J=4
Hz,1H),7.16(d,J=2 Hz,1H),7.24(dd,J=5,8 Hz,1H),7.28(dd,J=2,8
Hz,1H),7.69(d,J=8 Hz,1H),7.78(dt,J=2,8 Hz,1H),8.54(dd,J=2,5
Hz,1H),9.20(s,1H)
[2893] MS: FAB(+)275(M.sup.+)
EXAMPLE 880
5,10-Dihydro-5-methoxymethyl-10-methyl-7-trimethylsilyl-ethynyl
-10H-pyrazino[2,3-b][1,4]quinoxaline
[2894] To a solution of 1.445 g of 5,10-dihydro
-7-iodo-5-methoxymethyl-10-
-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline in
N,N-dimethylformamide (40 ml) were added 0.28 g of
dichlorobis(triphenylphosphine)palladium, 0.090 g of cuprous
iodide, 0.86 ml of triethylamine and 1.10 ml of
trimethylsilylacetylene. Then this mixture was treated by the same
method as the one of Example 1386-3 to thereby give 1.329 g of the
title compound as a yellow solid. 1278
[2895] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2896] 0.23(s, 9H), 3.12(s, 3H), 3.46(s, 3H), 5.15(s, 2H), 6.36(d,
J=8 Hz, 1H), 6.78(d, J=2 Hz, 1H), 6.89(dd, J=2, 8 Hz, 1H), 7.12(d,
J=3 Hz, 1H), 7.20(d, J=3 Hz, 1H)
EXAMPLE 881
5,10-Dihydro-7-ethynyl-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]- quinoxaline
[2897] Similar to Example 1418, a solution of 0.338 g of
5,10-dihydro-5-methoxymethyl-10-methyl
-7-trimethylsilylethynyl-10H-pyraz- ino[2,3-b][1,4]quinoxaline in
dry tetrahydrofuran was treated with 1.5 ml of a 1 M solution of
tetra-n-butylammonium fluoride in tetrahydrofuran. Thus 0.250 g of
the title compound was obtained as a yellow solid. 1279
[2898] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2899] 3.00(s, 1H), 3.12(s, 3H), 3.45(s, 3H), 5.12(s, 2H), 6.38(d,
J=8 Hz, 1H), 6.80(s, 1H), 6.91(d, J=8 Hz, 1H), 7.13(s, 1H), 7.20(s,
1H)
EXAMPLE 882
N,N-Dimethyl-3-(5,10-dihydro-5-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-8-
-yl)propynylamide
[2900] To 5 ml of triethylamine were added in a nitrogen atmosphere
0.115 g of 5,10-dihydro-7-ethynyl
-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b- ][1,4]quinoxaline,
0.020 g of dichlorobis (triphenylphosphine)palladium, 0.020 g of
cuprous iodide, 0.026 g of triphenylphosphine and 0.044 ml of
dimethylcarbamoyl chloride and the resulting mixture was heated to
90.degree. C. for 6 hours. After distilling off the solvent under
reduced pressure, the residue was distributed into ethyl acetate
and water and the insoluble matters were filtered off. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.081 g of the title
compound as a yellow solid. 1280
[2901] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2902] 2.86(s,3H),2.95(s,3H),3.15(s,3H),6.41(d,J=2
Hz,1H),6.45(d,J=8 Hz,1H),6.82(dd,J=2,8 Hz,1H),6.92(d,J=3 Hz,1H),
6.99(d,J=3 Hz,1H),9.25(s,1H)
[2903] m.p. : 203-205.degree. C.
[2904] MS: ESI(+)316(MNa.sup.+)
EXAMPLE 883
(5,10-Dihydro-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-
-7-yl)propynoic acid
[2905] Into a solution of 0.266 g of 5,10-dihydro
-7-ethynyl-5-methoxymeth-
yl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxaline in dry
tetrahydrofuran (15 ml) was dropped at -78.degree. C. in a nitrogen
atmosphere 1.6 ml of a 1.6 M solution of n-butyllithium in hexane.
After stirring for 1 hour, dry ice was added to the mixture. Then
the bulk temperature was elevated to room temperature and the
reaction mixture was distributed into 6 N potassium hydroxide and
ethyl acetate. The pH value of the aqueous layer was adjusted to 4
with hydrochloric acid followed by extraction with ethyl acetate.
The extractant was distilled off under reduced pressure to thereby
give 0.180 g of the title compound as a yellow solid. 1281
[2906] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2907] 3.06(s, 3H), 3.32(s, 3H), 5.11(s, 2H), 6.61(d, J=9 Hz, 1H),
6.73(d, J=2 Hz, 1H), 7.04(dd, J=2, 9 Hz, 1H), 7.19(d, J=3 Hz, 1H),
7.25(d, J=3 Hz, 1H)
EXAMPLE 884
(5,10-Dihydro-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)propynoic
acid
[2908] The title compound was obtained by treating
(5,10-dihydro-5-methoxy-
methyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)propynoic
acid by the same method as the one of Example 9. 1282
[2909] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2910] 2.95(s, 3H), 6.41(d, J=2 Hz, 1H), 6.45(d, J=8 Hz, 1H),
6.84(dd, J=2, 8 Hz, 1H), 6.93(d, J=3 Hz, 1H), 7.00(d, J=3 Hz,
1H)
[2911] MS: ESI(+)267(MH.sup.+)
[2912] m.p. : >275.degree. C.
EXAMPLES
[2913] The following compounds were synthesized by treating
5,10-dihydro-5-methoxymethyl-7-iodo-10-methyl
-10H-pyrazino[2,3-b][1,4]qu- inoxaline by the same method as the
one of Example 883.
126 Ex. Structural formula NMR 885 12833-(5,10-dihydro-5-
methoxymethyl-10-methyl- 10H-pyrazino[2,3-b][1,4]q-
uinoxalin-7-yl)-2- propyn-1-ol .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.06(s, 3H), 3.38(s, 3H), 4.40(s, 2H), 5.06(s, 2H), 6.38(d, J=8Hz,
1H), 6.77(d, J=2Hz, 1H), # 6.86(dd, J=2, 8Hz, 1H), 7.14(d, J = 3Hz,
1H), 7.21(d, J = 3Hz, 1H) 886 12845,10-dihydro-5-
methoxymethyl-10-methyl- 7-phenylethynyl-10H-
pyrazino[2,3-b][1,4]quinoxa- line .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.12(s, 3H), 3.48(s, 3H), 5.17(s, 2H), 6.42(d, J=8Hz, 1H),
6.86(d, J=2Hz, 1H), 6.96(dd, J=2, 8Hz, 1H), 7.14(d, J=3Hz, 1H), #
7.21(d, J=3Hz, 1H), 7.30-7.35(m, 3H), 7.49-7.52(m, 2H) 887
12855,10-dihydro-7-[3-(N,N- dimethylamino)-1-propyn-
1-yl]-5-methoxymethyl- 10-methyl-10H-pyrazino
[2,3-b][1,4]quinoxaline .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
2.37(s, 6H), 3.12(s, 3H), 3.42(s, 2H), 3.44(s, 3H), 5.13(s, 2H),
6.37(d, J=8Hz, # 1H), 6.77(d, J=2Hz, 1H), 6.86(dd, J=2, 8Hz, 1H),
7.12(d, J=3Hz, 1H), 7.20(d, J=3Hz, 1H) 888 1286ethyl
(5,10-dihydro-5- methoxymethyl-10-methyl-
10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl) propynoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25(t, J=7Hz, 3H), 3.13(s,
3H), 3.43(s, 3H), 4.09(q, J=7Hz, 2H), 5.10(s, 2H), 6.40(d, J=8Hz,
1H), # 6.66(s, 1H), 7.02(d, J=8Hz, 1H), 7.16(d, J=3Hz, 1H), 7.22(d,
J=3Hz, 1H)
EXAMPLES
[2914] The following compounds were obtained by treating the
compounds obtained in Examples 885, 886 and 887 by the same method
as the one of Example 8.
127 Ex. Structural formula MS M.p. NMR 889 12873-(5,10-dihydro-5-
methyl-10H-pyrazino [2,3-b][1,4]quinoxalin-8-yl)-2- propyn-1-ol ESI
(+) 253 (MH.sup.+) 241-243.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 2.93(s, 3H), 4.21(d, J=7Hz, 2H), 5.24(t, J=7Hz, 1H), #
6.31(d, J=2Hz, 1H), 6.38(d, J=8Hz, 1H), 6.61(dd, J=2, 8Hz, 1H),
6.88(d, J=3Hz, 1H), 6.97(d, J=3Hz, 1H), 9.16(s, 1H) 890
12885,10-dihydro-5- methyl-8- phenylethynyl-10H-
pyrazino[2,3-b][1,4]quinoxaline ESI (+) 299 (MH.sup.+)
245-247.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.09(s,
3H), 6.24(br.s, 1H), 6.35(d, J=2Hz, 1H), # 6.35(d, J=8Hz, 1H),
6.85(dd, J=2, 8Hz, 1H), 6.96(d, J=4Hz, 1H), 7.11(d, J=4Hz, 1H),
7.30-7.35(m, 3H), 7.46-7.49(m, 2H) 891 12895,10-dihydro-8-[3-
(N,N-dimethylamino)- 1-propyn-1-yl]-5- methyl-10H-
pyrazino[2,3-b][1,4]quinoxaline ESI (+) 280 (MH.sup.+)
188-189.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.19(s,
6H), 2.92(s, 3H), # 3.38(s, 2H), 6.32(s, 1H), 6.39(d, J=8Hz, 1H),
6.63(d, J=8Hz, 1H), 6.87(d, J=3Hz, 1H), 6.93(d, J=3Hz, 1H), 9.12(s,
1H)
EXAMPLE 892
Ethyl (5,10-dihydro-50-methyl-10H-pyrazino[2,3-b][1,
4]quinoxalin-8-yl)propynoate
[2915] The following compound was obtained by treating ethyl
(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinoxal- in-7-yl)propynoate by the same
method as the one of Example 9. 1290
[2916] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2917] 1.24(t, J=7 Hz, 3H), 2.95(s, 3H), 4.18(q, J=7 Hz, 2H),
6.41(d, J=2 Hz, 1H), 6.45(d, J=8 Hz, 1H), 6.87(dd, J=2, 8 Hz, 1H),
6.93(d, J=3 Hz, 1H), 7.00(d, J=3 Hz, 1H), 9.27(s, 1H)
[2918] MS: ESI(+)295(MH.sup.+)
[2919] m.p. : 232-235.degree. C.
EXAMPLE 893
Ethyl 3-(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]q- uinoxalin-7-yl)-3-oxopropanoate
[2920] 0.150 g of ethyl 3-(5,10-dihydro-5-methoxymethyl
-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)propynoate was
dissolved in a saturated solution of dimethylamine in ethanol (25
ml) and heated under reflux for 1 hour. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 0.080 g of the title compound as a yellow solid.
1291
[2921] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2922] 1.27(t, J=7 Hz, 3H), 3.18(s, 3H), 3.46(s, 3H), 3.86(s, 2H),
4.20(q, J=7 Hz, 2H), 5.17(s, 2H), 6.46(d, J=8 Hz, 1H), 7.21(d, J=3
Hz, 1H), 7.24-7.26(m, 2H), 7.37(dd, J=2, 8 Hz, 1H)
EXAMPLE 894
Ethyl 3-(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino-[2,3-b][1,4]-
quinoxalin-7-yl)-3-(methylthio)propenoate
[2923] To a solution of 0.205 g of ethyl 3-(5,10-dihydro
-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)propyn-
oate in N,N-dimethylformamide (10 ml) were added 1 ml of methanol
and 0.063 g of methylmercaptane sodium salt and the resulting
mixture was stirred at room temperature for 1 hour. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) to thereby give 0.136 g of the title
compound as a reddish oily substance. 1292
[2924] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2925] 1.12 and 1.29(t, J=7 Hz, total 3H), 2.13 and 2.37(s, total
3H), 3.07(s, 3H), 3.30 and 3.32(s, total 3H), 3.94 and 4.07(q, J=7
Hz, total 2H), 5.03 and 5.13(s, total 2H), 5.53 and 5.87(s, total
1H), 6.52-6.73(m, 3H), 7.15 and 7.16(d, J=3 Hz, total 1H), 7.23(d,
J=3 Hz, 1H)
EXAMPLE 895
Ethyl 3-(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino-[2,3-b][1,4]-
quinoxalin-7-yl)-3-(methylsulfinyl)propenoate
[2926] To a solution of 102 mg of ethyl 3-(5,10-dihydro
-5-methoxymethyl-10-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-7-yl)-3-(me-
thylthio)propenoate in dichloromethane (10 ml) were added 0.120 g
of m-chloroperbenzoic acid and 0.025 g of sodium hydrogencarbonate
and the resulting mixture was stirred at room temperature for 20
hours. Then the reaction mixture was distributed into ethyl acetate
and water. Next, the organic layer was dried over anhydrous
magnesium sulfate and distilled off under reduced pressure to
thereby give 0.150 g of the crude title compound as a red oily
substance. 1293
[2927] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2928] 1.18 and 1.26(t, J=7 Hz, total 3H), 2.42 and 2.80(s, total
3H), 3.06(s, 3H), 3.37 and 3.38(s, total 3H), 4.10 and 4.17(q, J=7
Hz, total 2H), 4.98-5.13(m, 2H), 6.21 and 6.22(s, total 1H), 6.40
and 6.41(d, J=8 Hz, total 1H), 6.57 and 6.73(d, J=2 Hz, total 1H),
6.67 and 6.85(dd, J=2, 8 Hz, total 1H), 7.08 and 7.10(d, J=3 Hz,
total 1H), 7.15 and 7.17(d, J=3 Hz, total 1H)
EXAMPLES
[2929] The following compounds were obtained by treating the
compounds obtained in Examples 893 and 895 by the same method as
the one of Example 9.
128 Ex. Structural formula MS M.p. NMR 896 1294ethyl
3-(5,10-dihydro- 5-methyl-10H- pyrazino[2,3-b][1,4]quinoxalin-8-yl)
-3-oxopropanoate 88-89.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.16(t, J=7Hz, 3H), 3.11(s, 3H), 3.80(s, 2H), 4.20(q, J=7Hz,
2H), 6.35(d, J=8Hz, 1H), 6.77(d, J=2Hz, 1H), # 7.01(d, J=3Hz, 1H),
7.11(d, J=3Hz, 1H), 7.21(dd, J=2, 8Hz, 1H), 7.25(br.s, 1H) 897
1295ethyl 3-(5,10-dihydro- 5-methyl-10H-pyrazino-
[2,3-b][1,4]quinoxalin-8-yl)-3- methylsulfinyl propenoate FAB (+)
359 (MH.sup.+) .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25and1.32(t,
J=7Hz, total 3H), 2.47 and 2.86(s, total 3H), 3.06 and 3.07(s,
total # 3H), 4.17 and 4.23(q, J=7Hz, total 2H), 6.16 and 6.24(s,
total 1H), 6.35-6.41(m, 2H), 6.62 and 6.71(m, 1H), 6.95 and 6.98(d,
J=3Hz, total 1H), 7.09 and 7.12(d, J=3Hz, total 1H)
EXAMPLE 898
Ethyl
3-(5,10-dihydro-5-methyl-10H-pyrazino[2,3-b][1,4]quinoxalin-8-yl)-3--
(methylthio)propenoate
[2930] The title compound was obtained by treating ethyl
3-(5,10-dihydro-5-methoxymethyl-10-methyl
-10H-pyrazino[2,3-b][1,4]quinox-
alin-7-yl)-3-(methylthio)propenoate by the same method as the one
of Example 8. 1296
[2931] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2932] 1.20 and 1.27(t, J=7 Hz, total 3H), 2.05 and 2.36(s, total
3H), 3.07 and 3.08(s, total 3H), 4.06 and 4.21(q, J=7 Hz, total
2H), 5.53 and 5.59(s, total 1H), 6.15 and 6.19(d, J=2 Hz, total
1H), 6.38(d, J=2 Hz, 1H), 6.59 and 6.64(dd, J=2, 8 Hz, total 1H),
6.91 and 6.95(d, J=3 Hz, total 1H), 7.07 and 7.11(d, J=3 Hz, total
1H)
EXAMPLE 899
6-Methyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[2933] To a solution of 0.737 g of 2-(6-methyl-2-nitrophenyl)thio
-3-chlotopyrazine in 15 ml of tetrahydrofuran was added a solution
of 4.2 g of hydrosulfite sodium in water (8.4 ml). Into the
reaction mixture was dropped a solution of 4.2 ml of aqueous
ammonia with 4.2 ml of water under ice-cooling. After stirring at
room temperature for 20 hours, the reaction mixture was distributed
into ethyl acetate and water and the organic layer was dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, 0.676 g of a crude amine was obtained. This amine
was dissolved in 10 ml of N,N-dimethylformamide. The reaction
mixture was degassed and heated to 80.degree. C. for 2 hours. Then
the reaction mixture was distributed into ethyl acetate and water.
The organic layer was washed with water and dried over anhydrous
magnesium sulfate. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.105 g of the title compound as a yellow solid. 1297
[2934] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2935] 2.07(s, 3H), 6.58(d, J=8 Hz, 1H), 6.65(d, J=8 Hz, 1H),
6.85(t, J=8 Hz, 1H), 7.60(d, J=3 Hz, 1H), 7.61(d, J=3 Hz, 1H),
9.40(s, 1H)
[2936] MS: FAB(+)215(M.sup.+)
[2937] m.p. 165-166.degree. C.
EXAMPLE 900
10-Methoxymethyl-8-[N-(pyridin-3-yl)aminomethyl]-10H-pyrazino-[2,3-b][1,4]-
benzothiazine
[2938] 3 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-
carbaldehyde and 3.4 g of 3-aminopyridine were dissolved in toluene
and heated under reflux for 2 hours. During this period, the water
formed in the reaction system was eliminated by using a Dean-Stark
tube. After the completion of the reaction, the toluene was
distilled off under reduced pressure and the residue was dissolved
in ethanol and tetrahydrofuran newly added thereto. After adding
4.06 g of sodium borohydride under ice-cooling, the resulting
mixture was stirred at room temperature. After the completion of
the reaction, the reaction mixture was poured into a saturated
aqueous solution of sodium chloride and repeatedly extracted with
ethyl acetate. The extract thus obtained was dried over anhydrous
sodium sulfate and filtered. The filtrate was distilled off under
reduced pressure and the residue was purified by silica gel column
chromatography (eluted with toluene/acetone) to thereby give 1.35 g
of the title compound as a yellow oily substance. 1298
[2939] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2940] 3.46(s, 3H), 4.28(s, 2H), 4.30(s, 2H), 5.22(s, 2H), 6.83(dd,
J=2, 5 Hz, 1H), 6.95(d, J=8 Hz, 1H), 6.97(d, J=8 Hz, 1H), 7.12(s,
1H), 7.83(d, J=3 Hz, 2H), 7.98(d, J=5 Hz, 1H), 8.04-8.09(m, 1H)
EXAMPLE 901
8-[N-(Pyridin-3-yl)aminomethyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
[2941] 0.99 g of the title compound was obtained as yellow crystals
by deblocking 1.35 g of
10-methoxymethyl-8-[N-(pyridin-3-yl)aminomethyl]-10H-
-pyrazino[2,3-b][1,4]benzothiazine obtained in Example 900 by the
same method as the one of Example 9. 1299
[2942] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2943] 4.08(d, J=6 Hz, 2H), 6.45(t, J=6 Hz, 1H), 6.74(s, 1H),
6.78(d, J=8 Hz, 1H), 6.80(d, J=8 Hz, 1H), 6.84(d, J=8 Hz, 1H),
7.02(dd, J=5, 8 Hz, 1H), 7.60(s, 2H), 7.70(d, J=5 Hz, 1H), 7.90(s,
1H), 9.49(br.s, 1H)
[2944] MS: FAB(+)308(MH.sup.+)
[2945] m.p.: 168-172.degree. C.
EXAMPLES
[2946] Similar to Example 900, (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]- -benzothiazin-8-yl) carbaldehyde was
treated with readily available various amines. Then, the products
thus obtained were deblocked by the same method as the one of
Example 9 to thereby give the following compounds.
129 Ex. Amine Structural formula MS M.p. NMR 902 1300
13018-[N-(pyridin-2-yl) aminomethyl]-10H-
pyrazino[2,3-b][1.4]benzothiazine ESI(+) 308 (MH.sup.+)
208-212.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.25(d,
J=6Hz, 2H), 6.42-6.48(m, 1H), 6.47(t, J=6Hz, 1H), # 6.74(d, J=8Hz,
1H), 6.76(s, 1H), 6.82(d, J=8Hz, 1H), 6.94-7.02(m, 1H), 7.34(d,
J=8Hz, 1H), 7.62(s, 2H), 7.90(d, J=5Hz, 1H), 9.50(br.s, 1H) 903
1302 13038-[N-(pyridin-4-yl) aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazi- ne ESI(+) 308 (MH.sup.+)
194-196.degree. C. .sup.1H-NI-IRCDMSO-d.sub.6) .delta. ppm: 4.13(d,
J=6Hz, 2H), 6.44(d, J=6Hz, 2H), 6.72(s, 1H), 6.74(d, # J=8Hz, 1H),
7.17(t, J=6Hz, 1H), 7.62(s, 2H), 7.87(d, J=8Hz, 1H), 7.98(d, J=5Hz,
2H), 9.52(br.s, 1H) 904 1304 13058-[N-(pyrazin-2-yl)
aminomethyl]-10H- pyrazino[2,3-b][1,4]benzothiazi- ne
.sup.1H-NMR(DMSO-d.sub.6) .delta.ppm: 4.28(d, J=5Hz, 2H), 6.72(s,
1H), 6.73(d, J=8Hz, 1H), 6.82(d, J=8Hz, 1H), 7.53(t, J=5Hz, 1H),
7.61(s, 1H), # 7.60(d, J=2Hz, 1H), 7.64(d, J=2Hz, 1H), 7.88(s, 1H),
7.92(s, 1H), 9.48(br.s, 1H) 905 1306 13078-[N-(pyrimidin-2-
yl)aminomethyl]-10H- pyrazino[2,3-b][1,4]benzothia- zine
232-235.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.48(d,
J=5Hz, 1H), 5.70(br.s, 1H), 6.52(s, 1H), 6.59(d, J=8Hz, 1H),
6.81(d, J=8Hz, 1H), # 6.82(d, J=8Hz, 1H), 7.25(d. J=4Hz, 1H),
7.50(d, J=3Hz, 1H), 7.65(d, J=3Hz, 1H), 8.30(d, J=4Hz, 2H),
8.75(br.s, 1H) 906 1308 13098-[N-(thiazol-2-yl) aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine FAB(+) 313(M.sup.+)
230-235.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.ppm: 4.22(d,
J=6Hz, 2H), 6.60(d, J=5Hz, 1H), 6.66(d, J=8Hz, 1H), # 6.67(s, 1H),
6.84(d, J=8Hz, 1H), 6.98(d, J=5Hz, 1H), 7.60(d, J=3Hz, 1H), 7.61(d,
J=3Hz, 1H), 7.99(t, J=6Hz, 1H), 9.50(br.s, 1H) 907 1310
13118-[N-(4-aminophenyl) aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiaz- ine ESI(+) 322 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.92(s, 2H), 4.20(br.s, 2H),
5.28-5.33(m, 1H), 6.32(d, J=8Hz, 2H), # 6.37(d, J=8Hz, 2H), 6.77(s,
1H), 6.73-6.82(m, 2H), 7.62(s, 2H), 9.46(s, 1H) 908 1312
13138-[N-(quinolin-3-yl) aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI(+) 358 (MH.sup.+)
160-164.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.21(d,
J=5Hz, 2H), 6.80(s, 1H), 6.82(d, J=8Hz, 1H), 6.87(s, # 1H), 6.88(d,
J=8Hz, 1H), 6.84-6.92(m, 1H), 7.26-7.40(m, 2H), 7.58(d, J=5Hz, 1H),
7.60(s, 2H), 7.77(d, J=5Hz, 1H), 8.50(br.s, 1H), 9.50(br.s, 1H) 909
1314 13158-[N-(isoquinolin-1- yl)aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI(+) 358 (MH.sup.+)
222-225.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.53(d,
J=5Hz, 2H), 6.75-6.80(m, 1H), 6.78(s, 1H), 6.79(d, J=8Hz, 1H),
6.88(d, # J=8Hz, 1H), 7.48(t, J=10Hz, 1H), 7.58(s, 2H),
7.55-7.63(m, 1H), 7.69(d, J=10Hz, 1H), 7.79(d, J=8Hz, 1H), 7.92(t,
J=8Hz, 1H), 8.24(d, J=10Hz, 1H), 9.45(br.s, 1H) 910 1316
13178-[N-(2-pyridyl methyl)aminomethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine ESI(+) 322 (MH.sup.+)
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.62(s, 2H), 3.82(s, 2H),
6.30(br.s, 1H), 6.53(s, 1H), 6.77(d, J=8Hz. 1H), 6.85(d, # J=8Hz,
1H), 7.12-7.15(m, 1H), 7.26(d, J=7Hz, 1H), 7.62(t, J=7Hz, 1H),
7.70(d, J=3Hz. 2H), 8.55(d, J=5Hz, 1H), 9.52(br.s, 1H) 911 1318
13198-[N-(3-pyridyl methyl)aminomethyl]- 10H-pyrazino[2,3-b][1,4-
]benzothiazine ESI (+) 322 (MH.sup.+) 104-106.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.68(s, 2H), 3.80(s, 2H),
6.52(br.s, 1H), # 6.54(s, 1H), 6.78(d, J=8Hz, 1H), 6.83(d, J=8Hz,
1H), 7.25-7.28(m, 2H), 7.57(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H),
7.66-7.70(m, 1H), 8.52-8.55(m, 1H), 8.59(br.s, 1H) 912 1320
13218-[N-(4-pyridyl methyl)aminomethyl)-
10H-pyrazino[2,3-b][1,4]benzothi- azine ESI (+) 322 (MH.sup.+)
174-176.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.65(s,
2H), 3.80(s, 2H), 6.54(s, 1H), 6.67(br.s, 1H), # 6.79(d, J=8Hz,
1H), 6.83(d, J=8Hz, 1H), 7.22-7.30(m, 3H), 7.55(d, J=3Hz, 1H),
7.68(d,J=3Hz, 1H), 8.58(d, J=5Hz, 2H) 913 1322
13238-[N-(piperidin-4- ylmethyl)aminomethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine ESI (+) 328 (MH.sup.+)
173-175.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
0.83-1.00(m, 2H), 1.30-1.50(m, 1H), # 1.60(d, J=8Hz, 2H), 2.28(d,
J=5Hz, 2H), 2.38(dt, J=2, 8Hz, 2H), 2.87(d, J=7Hz, 2H), 3.25(br.s,
2H), 3.44(s, 2H), 6.74(d, J=7Hz, 1H), 6.75(s, 1H), 6.80(d, J=7Hz,
1H), 7.60(d, J=2Hz, 1H), 7.61(d, J=2Hz, 1H), 9.48(br.s, 1H) 914
1324 13258-[N-[2-(2-pyridyl) ethyl]aminomethyl]-
10H-pyrazino[2,3-b][1,4]benzo- thiazine ESI (+) 336 (MH.sup.+)
179-182.degree. C. .sup.1H-NMR(DMSO-d.sub.- 6) .delta. ppm: 3.03(t,
J=7Hz, 2H), 3.10-3.20(m, 2H), # 3.30(br.s, 1H), 3.86(br.s, 2H),
6.78(s, 1H), 6.88(d, J=8Hz, 1H), 6.92(d, J=8Hz, 1H), 7.20-7.32(m,
2H), 7.63(s, 2H), 7.68-7.78(m, 1H), 8.50(d, J=5Hz, 1H), 9.63(br.s,
1H) 915 1326 13278-[N-(2,4-dimethyl aminopyridin-6-yl)
aminomethyl)-10H- pyrazino[2,3-b][1,4]benzothiazine ESI (+) 336
(MH.sup.+) 162-165.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.ppm:
2.08(s, 3H), 2.17(s, 3H), # 4.24(d, J=5Hz, 2H), 6.03(s, 1H),
6.18(s, 1H), 6.70(br.s, 1H), 6.73(d, J=8Hz, 1H), 6.75(s, 1H),
6.82(d, J=8Hz, 1H), 7.62(s, 2H), 9.48(br.s, 1H) 916 1328
13298-[N-(3-benzyloxy pyridin-2-yl)amino methyl]-10H-pyrazino
[2,3-b][1,4]benzothiazine ESI (+) 413 (M.sup.+) 180-184.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta.ppm: 4.35(d, J=5Hz, 2H), 5.12(s,
2H), 6.42- # 6.48(m, 1H), 6.53(t, J=5Hz, 1H), 6.72(d, J=8Hz, 1H),
6.74(s, 1H), 6.79(d, J=8Hz, 1H), 7.04(d, J=5Hz, 1H), 7.30-7.36(m,
1H), 7.38-7.42(m, 2H), 7.48-7.52(m, 3H), 7.60(s, 2H), 9.48(br.s,
1H) 917 1330 13318-[N-[3-chloro-5- (trifluoromethyl)pyrid
in-2-yl)axninomethyl]- 10H-pyrazino[2,3-b][1,4]benzothiazine FAB
(+) 409 (M.sup.+) 158-161.degree. C. .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 4.60(d, J=5Hz, 2H), # 5.64(t, J=5Hz, 1H), 6.50(s, 1H),
6.55(br.s, 1H), 6.80(d, J=8Hz,1H), 6.88(d, J=8Hz, 1H), 7.58(s, 1H),
7.67(s, 1H), 7.69(s, 1H), 8.30(s, 1H) 918 1332
13332-(10H-pyrazino[2,3-b][1,4]- benzothiazin-8- ylmethyl)amino
pyridine-5-carboxamide 245-250.degree. C. .sup.1H-NMR(CD.sub.3OD)
.delta. ppm: 4.52(s, 2H), 4.90(br.s, 2H), 6.55(d, J=8Hz, 1H),
6.92(d, J=8Hz, 1H), 6.95(s, 1H), # 6.96(s, 1H), 6.97(d, J=8Hz, 1H),
7.72(s, 1H), 7.82(d, J=3Hz, 1H), 7.86(d, J=3Hz, 1H), 7.87(d, J=8Hz,
1H), 8.53(s, 1H) 919 1334 1335methyl 2-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8-yl methylamino)pyridine-
5-carboxylate ESI (+) 366 (MH.sup.+) 140-148.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta.ppm: 3.73(s, 3H), 4.16(d, J=5Hz,
2H), # 6.71(d, J=8Hz, 1H), 6.74(s, 1H), 6.83(d, J=8Hz, 1H), 7.62(s,
2H), 7.82(d, J=8Hz, 2H), 7.85(t, J=5Hz, 1H), 8.55(s, 1H),
9.50(br.s, 1H) 920 1336 13378-[N-(2-ethylpyridin-4-
yl)aminomethyl-10H- pyrazino[2,3-b][1,4]benzothiazine ESI (+) 336
(MH.sup.+) 148-152.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.ppm:
1.14(t, J=6Hz, 3H), 2.55(q, J=6Hz, 2H), # 3.30(s, 2H), 4.20(d,
J=5Hz, 1H), 6.42(d, J=3Hz, 1H), 6.46(s, 1H), 6.72(s, 1H), 6.73(d,
J=8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.60(s, 2H), 7.94(d, J=3Hz, 1H),
9.53(s, 1H) 921 1338 1339[4-(10H-pyrazino[2,3-
b][1,4]benzothiazin-8- ylmethyl)aminopyridin-2- yl]methanol ESI (+)
338 (MH.sup.+) 156-160.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta.ppm: 3.30(t, J=5Hz, 1H), 4.15(d, J=5Hz, 2H), # 4.36(s, 2H),
6.34(m, 1H), 6.62(s, 1H) 6.65(s, 1H), 6.66(d, J=8Hz, 1H), 6.82(d,
J=8Hz, 1H), 7.31(m, 1H), 7.61(s, 2H), 7.92(d, J=5Hz, 1H), 9.52(s,
1H) 922 1340 13418-[N-(2,6- dimethylpyridin-4- yl)aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI (+) 336 (MH.sup.+)
230-235.degree. C. .sup.1H-NMR(DMSO-d.sub.6).delta- .ppm: 2.48(s,
6H), 4.05(d, J=6Hz, 2H), 6.14(s, 2H), # 6.68(s, 1H), 6.69(d, J=8Hz,
1H), 6.84(d, J=8Hz, 1H), 7.62(s, 2H), 7.85(br.s, 1H), 9.50(br.s,
1H)
EXAMPLES
[2947] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
with various aminopyridines by the same method as the one of
Example 900.
130 Amino Ex. pyridine Structural formula NMR 923 1342
134310-methoxymethyl-8-[N- (2-N',N'-dimethyl
amino)pyridin-5-yl]aminomethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.95(s, 6H), 3.43(s, 3H), 4.17(s, 2H), 5.18(s, 2H), 6.43(d,
J=8Hz, 1H), 6.85- # 6.90(m, 2H), 6.89(s, 2H), 7.08(s, 1H), 7.66(d,
J=2Hz, 1H), 7.77-7.82(m, 2H) 924 1344 134510-methoxymethyl-8-[N-
[2-N'-benzylamino) pyridin-5-yl]amino methyl-10H-pyrazino
[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.48(s, 3H), 4.18(s, 2H), 4.40(s, 1H), 4.50(br.s, 2H), 5.22(s, 2H),
6.28(d, J=8Hz, # 1H), 6.82(dd, J=2, 5Hz, 1H), 6.93(s, 2H), 7.10(s,
1H), 7.20-7.40(m, 6H), 7.60(d, J=2Hz, 1H), 7.81(d, J=3Hz, 1H),
7.83(d, J=3Hz, 1H)
EXAMPLES
[2948] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 9.
131 Ex. Structural formula MS M.p. NMR 925 13468-[N-[2-N',N'-
dimethylamino)pyridin- 5-yl]aminomethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI (+) 351 (MH.sup.+)
244-247.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.95(s,
6H), 4.13(s, 2H), # 6.45(d, J=7Hz, 1H), 6.45(br.s, 1H), 6.52(s,
1H), 6.80(d, J=8Hz, 1H), 6.83(d, J=8Hz, 1H), 6.92(dd, J=2, 7Hz,
1H), 755(d, J=2Hz, 1H), 7.71(d, J=2Hz, 1H), 7.72(d, J=2Hz, 1H),
9.50(s, 1H) 926 13478-[N-[2-N'-(benzyl amino)pyridin-5-
yl]aminomethyl-10H- pyrazino[2,3-b][1,4]benzothiazine FAB (+) 413
(MH.sup.+) 208-211.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
4.20(s, 2H), 4.42(s, 2H), # 4.55(br.s, 2H), 6.30(d, J=8Hz, 1H),
6.82(d, J=5Hz, 1H), 6.95(s, 2H), 7.12(s, 1H), 7.20-7.40(m, 5H),
7.62(d, J=2Hz, 1H), 7.81(d, J=3Hz, 1H), 7.83(d, J=3Hz, 1H), 9.50(s,
1H) 927 13488-[N-(2-aminopyridin- 3-yl]aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI (+) 323 (MH.sup.+)
225-228.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.09(d,
J=6Hz, 2H), 5.39(t, J=6Hz, 1H), 5.50(s, 2H), # 6.34-6.39(m, 2H),
6.75(s, 1H), 6.76(d, J=8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.24(br.d,
J=4Hz, 1H), 7.62(s, 2H), 9.52(s, 1H)
EXAMPLES
[2949] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino(2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
with various aminopyridines by the same method as the one of
Example 900.
132 Ex. Amine Structural formula NMR 928 1349
135010-methoxymethyl-8-[N- (2-methoxypyridin-5-yl]aminomethyl-
]-10H- pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.46(s, 3H). 3.87(s, 3H), 4.22(s, 2H), 5.22(s, 2H),
6.58(d, J=8Hz, 1H), 6.60(d, J=8Hz, 1H), 6.97(s, 1H), # 7.02(d,
J=8Hz, 1H), 7.03(d, J=8Hz, 1H), 7.12(s, 1H), 7.55(d, J=2Hz, 1H),
7.82(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H) 929 1351
135210-methoxymethyl-8-[N- (2,6-dimethoxypyridin-3-
yl)aminomethyl]-10H- pyrazino[2,3-b][1,4]benzoth- iazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.34(s, 3H), 3.85(s, 3H),
3.88(s, 3H), 4.10(s, 2H), 5.10(s, 2H), 6.03(d, J=8Hz, 1H), 6.05(d,
J=8Hz, 1H), # 6.62(d, J=8Hz, 1H), 6.82(d, J=8Hz, 1H), 6.83(s, 1H),
7.00(s, 1H), 7.52(s, 2H) 930 1353 13548-[N-(2-
isopropoxypyridin-5-yl) aminomethyl]-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.29(d, J=6Hz, 6H), 3.42(s, 3H), 3.90(br.s, 1H), 4.18(s, 2H),
5.02-5.17(m, 1H), 5.18(5, 2H), 6.52(d, J=8Hz, # 1H), 6.87(s, 2H),
6.88(d, J=8Hz, 1H), 7.06(s, 1H), 7.52(d, J=2Hz, 1H), 7.78(s, 2H)
931 1355 13568-[N-(2-phenoxypyridin- 5-yl)aminomethyl]-10-
methoxymethyl-10H- pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.47(s, 3H), 4.22(s, 2H),
5.22(s, 2H), 6.73(d, J=7Hz, 1H), 6.95(s, 1H), 6.97(d, J=7Hz, 1H),
7.09(s, 1H), # 6.90-7.12(m, 5H), 7.32(t, J=7Hz, 2H), 7.62(d, J=2Hz,
1H), 7.82(d, J=3Hz, 1H), 7.83(d, J=3Hz, 1H) 932 1357 1358ethyl
[5-[N-(10- methoxymethyl-10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)amino]pyridin 2-yloxy]acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.23(t, J=7Hz, 3H), 3.43(s, 3H), 3.90(br.s, 1H),
4.20(q, J=7Hz, 2H), 4.20(s, 2H), 4.77(s, 2H), 5.21(s, 2H), #
6.70(d, J=8Hz, 1H), 6.90(s, 2H), 6.92(dd, J=2, 8Hz, 1H), 7.08(s,
1H), 7.48(d, J=2Hz, 1H), 7.78(d, J=3Hz, 1H), 7.80(d, J=3Hz, 1H)
EXAMPLES
[2950] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 9.
133 Ex. Structural formula MS M.p. NMR 933
13598-[N-(2-methoxypyridin -5-yl]aminomethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine ESI (+) 338 (MH.sup.+)
168-172.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.67(s,
3H), 4.02(d, J=5Hz, 2H), 5.93(t, J=5Hz, 1H), 6.56(d, J=7Hz, 1H),
6.77(s, # 1H), 6.78(d, J=8Hz, 1H), 6.84(d, J=8Hz, 1H), 6.98(d,
J=8Hz, 1H), 7.38(s, 1H), 7.60(s, 2H), 9.48(br.s, 1H) 934
13608-(N-(2,6-dimethoxy pyridin-3-yl) aminomethyl]-10H-
pyrazino[2,3-b][1.4]benzothiazine ESI (+) 368 (MH.sup.+)
160-164.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.82(s,
3H), 3.98(s, 3H), 4.15(br.s, 1H), 4.18(s, 2H), 6.17(d, J=7Hz, 1H),
# 6.47(br.s, 1H), 6.52(s, 1H), 6.70(d, J=7Hz, 1H), 6.82(d, J=8Hz,
1H), 6.84(d, J=8Hz, 1H). 7.55(s, 1H), 7.68(s, 1H) 935 13618-[N-(2-
isopropoxypyridin-1- yl)aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazi- ne ESI (+) 366 (MH.sup.+)
145-148.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.30(d,
J=6Hz, 6H), 3.70-3.80(m, 1H), 4.18(s, 2H), 1H), 6.52(d, J=2Hz, 1H),
# 6.56(d, J=6Hz, 1H), 6.82(d, J=8Hz, 1H), 6.85(d, J=8Hz, 1H),
6.90-6.95(m, 1H), 7.54(d, J=3Hz, 1H), 7.58(d, J=3Hz, 1H), 7.69(s,
1H) 936 13628-[N-(2-phenoxypyridin -5-yl)aminomethyl]-
10H-pyrazino(2,3-b][1,4]benzothiazine ESI (+) 400 (MH.sup.+)
161-165.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.13(s,
2H), 6.48(br.s, 1H), 6.74(d, J=8Hz, 1H), 6.76(s, 1H), 6.80(d,
J=8Hz, # 1H), 6.90-7.10(m, 5H), 7.15(br.s, 1H), 7.30(t, J=6Hz, 2H),
7.48(d, J=3Hz, 1H), 7.60(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H) 937
1363ethyl [5-(10H-pyrazino [2,3b][1,4]benzothiazin-8-
ylmethyl)amino]pyridin -2-yloxy]acetate ESI (+) 410 (MH.sup.+)
230-235.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.25(t,
J=6Hz, 3H), 4.14(s, 2H), 4.21(q, J=6Hz, 2H), # 4.79(s, 2H).
6.44(brs, 1H), 6.51(s, 1H), 6.72(d, J=8Hz, 1H), 6.81(d, J=7Hz, 1H),
6.86(d, J=8Hz, 1H), 6.95(dd, J=3, 7Hz, 1H), 7.25-7.28(m, 1H),
7.42(d, J=3Hz, 1H), 7.55(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H)
EXAMPLES
[2951] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
with various aminopyridines by the same method as the one of
Example 900.
134 Amino- Ex. pyridine Structural formula NMR 938 1364
13658-[N-(2-benzylpyridin-5- yl)aminomethyl]-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3H), 4.00(s, 2H), 4.20(s, 2H), 4.23-4.37(br.s, 1H), 5.17(s,
1H), 6.77(d, J=8Hz, 1H), 6.87(d, J=8Hz, 1H), # 7.07(s, 1H),
7.10-7.30(m, 7H), 7.79(s, 2H), 7.88(d, J=8Hz 1H), 7.97(s, 1H) 939
1366 13678-[N-(2-phenethylpyridin- -5-yl)aminomethyl]-10-
methoxymethyl-10H- pyrazino[2,3-b][1,4]benzothiazi- ne
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.95(s, 4H), 3.42(s, 3H),
4.20(s, 2H), 4.36(br.s, 1H), 5.18(s, 2H), 6.75(dd, J=2, 8Hz, 1H),
6.85(d, J=8Hz, 1H), 6.85-7.00(m, # 2H), 7.07(s; 1H), 7.10-7.30(m,
5H), 7.78(s, 2H), 7.97(s, 1H) 940 1368 13698-[N-(2-ethylpyridin-5-
yl)aminomethyl]-10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.23(t, J=6Hz, 3H), 2.68(q, J=6Hz, 2H), 3.42(s, 3H), 4.20(s,
2H), 5.18(s, 2H), 6.78(d, J=8Hz, 1H), 6..82(d, J=8Hz, # 1H),
7.09(s, 1H), 7.16(d, J=8Hz, 1H), 7.22(d, J=8Hz, 1H), 7.78(s, 2H),
7.82(s, 1H), 7.95(s, 1H)
EXAMPLES
[2952] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 9.
135 Ex. Structural formula MS M.p. NMR 941
13708-[N-(2-benzylpyridin- 5-yl)aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI (+) 398 (MH.sup.+)
162-164.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.02(s,
2H), 4.18(d, J=5Hz, 2H), 6.75(d, J=8Hz, 1H), 6.86(d, J=8Hz, 1H),
6.89(s, # 1H), 6.90(d, J=8Hz, 1H), 7.08(s, 1H), 7.10-7.40(m, 7H),
7.56(s, 1H), 7.69(s, 1H), 7.96(s, 1H) 942 13718-[N-(2-phenethyl-
pyridin-5-yl)amino methyll-10H-pyrazino [2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.95(br.s, 4H), 4.13(s, 2H),
4.28(br.s, 1H), 6.46(s, 1H), 6.73(d, J=8Hz, 1H), 6.78(s, 1H),
6.70-6.80(m, 2H), 6.83(d, J=8Hz, 1H), 7.12-7.21(m, 3H), # 7.23(m,
2H), 7.37(s, 1H), 7.58(s, 1H), 7.73(s, 1H) 943
13728-[N-(2-ethylpyridin- 5-yl)aminomethyl]-10H-
pyrazino[2,3b][1,4]benzothiazine ESI (+) 336 (MH.sup.+)
202-204.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.10(t,
J=6Hz, 3H), 2.54(q, J=6Hz, 2H), 4.06(d, J=3Hz, 2H), 6.23(t, J=3Hz,
1H), # 6.72(s, 1H), 6.73(d, J=8Hz, 6.83(d, J=8Hz, 1H), 6.88(br.s,
1H), 7.62(s, 2H), 7.80(br.s, 1H), 9.50(s, 1H)
EXAMPLES
[2953] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
with various amines by the same method as the one of Example 900
and then treating the obtained products by the same method as the
one of Example 9.
136 Ex. Amine Structural formula MS M.p. NMR 944 1373 1374ethyl
6-[5-(10H- pyrazino[2,3-b][1,4]benzothiaz- in-8-
ylmethylamino)pyridin-2- yl]-2,2- dimethylhexanoate 160-164.degree.
C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.15(s, 6H), 1.21(t, J=6Hz,
3H), 1.20-1.30(m, 2H), 1.45- # 1.55(m, 2H), 1.60-1.70(m, 2H),
2.60-2.75(m, 2H), 3.62(s, 2H), 4.08(q, J=6Hz, 2H), 4.20(br.s, 1H),
6.54(br.s, 1H), 6.80(d, J=8Hz, 1H), 6.81(d, J=7Hz, 1H), 6.83(d,
J=8Hz, 1H), 6.83(s, 1H), 6.95(d, J=7Hz, 1H), 7.55(s, 1H), 7.70(d,
J=3Hz, # 2H) 945 1375 13766-[5-10H-pyrazino [2,3-
b][1,4]benzothiazin-8- ylmethylamino)pyridin-2- dimethylhexanamide
ESI (+) 449 (MH.sup.+) .sup.1H-NMR(CD.sub.3OD) .delta. ppm: 1.05(s,
6H), 1.25-1.35(m, 2H), 1.40-1.50(m, 2H), 1.50- # 1.62(m, 2H),
2.50-2.65(m, 2H), 4.13(s, 2H), 4.10(br.s, 2H), 4.25(br.s, 1H),
6.65(d, J=8Hz, 1H), 6.75(s, 1H),, 6.76(d, J=8Hz, 1H), 6.89(d,
J=7Hz, 1H), 6.95(d, J=7Hz, 1H), 7.50(s, 2H), 7.67(s, 1H), 9.50(s,
1H)
EXAMPLE 946
Ethyl
5-[5-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-methylamino)pyridin
-2-yl]pentanoate
[2954] The title compound was obtained by treating
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde with ethyl
5-(5-aminopyridin -2-yl)pentanoate by the same method as the one of
Example 900 and then treating the obtained product by the same
method as the one of Example 9. 1377
[2955] 1.23(t, J=6 Hz, 3H), 1.58-1.72(m, 4H), 2.30(t, J=6 Hz, 2H),
2.67(t, J=6 Hz, 2H), 4.09(q, J=6 Hz, 2H), 4.14(s, 2H), 4.24(br.s,
1H), 6.48(s, 1H), 6.73(d, J=8 Hz, 1H), 6.74(d, J=7 Hz, 1H), 6.90(d,
J=8 Hz, 1H), 7.40(s, 1H), 7.46(br.s, 1H), 7.59(s, 1H), 7.78(d, J=7
Hz, 1H), 7.90(m, 1H)
EXAMPLE 947
2-[5-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methylami-
no]pyridin-2-yl]ethanol and
8-[N-(2-methylpyridin-5-yl)aminomethyl]-10-met- hoxymethyl
-10H-pyrazino[2,3-b][1,4]-benzothiazine
[2956] By the same method as the one of Example 900,
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
was treated with 290 mg of a mixture of 2-methyl-5-aminopyridine
with ethyl (5-aminopyridin-2-yl)acetate and then the obtained
product was reduced with sodium borohydride by heating under reflux
to thereby give 230 mg of
2-[5-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
yl)methylamino]pyridin-2-yl]ethanol and 173 mg of
8-[N-(2-methylpyridin-5--
yl)aminomethyl]-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
each as a yellow oily substance.
2-[5-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methylam-
ino]pyridin-2-yl]ethanol:
[2957] 1378
[2958] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2959] 2.85(t, J=6 Hz, 2H), 3.45(br.s, 1H), 3.42(s, 3H), 3.92(t,
J=6 Hz, 2H), 4.20(s, 2H), 4.35(br.s, 1H), 5.20(s, 2H), 6.80(dd,
J=2, 5 Hz, 1H), 6.85-6.98(m, 3H), 7.07(s, 1H), 7.80(s, 2H), 7.90(d,
J=2 Hz, 1H)
8-[N-(2-methylpyridin-5-yl)aminomethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[2960] 1379
[2961] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2962] 2.37(5, 3H), 3.41(s, 3H), 4.21(s, 2H), 4.25(br.s, 1H),
5.17(s, 2H), 6.73(dd, J=2, 5 Hz, 1H), 6.88(d, J=5 Hz, 1H), 6.90(s,
2H), 7.08(s, 1H), 7.78(s, 2H), 7.92(d, J=2 Hz, 1H)
EXAMPLES
[2963] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
with aminopyridines by the same method as the one of Example
947.
137 Ex. Amine Structural formula NMR 948 1380
13812-[5-((10-methoxymethyl- 10H-pyrazino[2,3-b][1,4]benzothi-
azin-8-yl) methylamino]pyridin-2- ylthio]ethanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.70(br.s, 1H), 3.18(t, J=6Hz,
2H), 3.45(s, 3H), 3.90(t, J=6Hz, 2H), 4.25(s, 2H), 5.22(s, 2H), #
5.57(br.s, 1H), 6.50(dd, J=2, 5Hz, 1H), 6.92(d, J=8Hz, 1H), 6.97(d,
J=8Hz, 1H), 7.10(d, J=5Hz, 1H), 7.13(s, 1H), 7.22(s, 1H), 7.82(d,
J=3Hz, 1H), 7.84(d, J=3Hz, 1H) 949 1382
13836-[5-[(10-methoxymethyl- 10H-pyrazino[2,3-b][1,4-
]benzothiazin-8-yl) methylamino]pyridin-2- yl]hexan-1-ol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.30-1.48(m, 4H), 1.49-1.60(m,
2H), 1.60-1.80(m, 3.43(s, 3H), 3.58(t, J=6Hz, 2H), 4.13(t, J=6Hz, #
2H), 4.18(s, 2H), 4.19(s, 2H), 5.18(s, 2H), 6.57(d, J=8Hz, 1H),
6.91(s, 2H), 6.92(d, J=8Hz, 1H), 7.08(s, 1H), 7.50(d, J=2Hz, 1H),
7.78(s, 2H)
EXAMPLES
[2964] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
with various aminopyridines by the same method as the one of
Example 900.
138 Ex. Amine Structural formula NMR 950 1384 1385ethyl
[5-[(10-methoxy methyl-10H-pyrazino[2,3- [1,4]benzothiazin-8-
yl)methylaminolpyridin- 2-yl]acetate .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.23(t, J=6Hz, 3.42(s, 3H), 3.70(s, 2H), 4.13(q,
J=6Hz, 2H), 4.23(s, 2H), 4.30(br.s, 1H), 5.20(s, 2H), # 6.82(dd,
J=2, 5Hz, 1H), 6.92(d, J=8Hz, 1H), 6.95(d, J=8Hz, 1H), 7.05(d,
J=5Hz, 1H), 7.08(s, 1H), 7.79(d, J=3Hz, 1H), 7.81(d, J=3Hz, 1H),
7.98(d, J=2Hz, 1H) 951 1386 1387ethyl [5-[(10- methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazin-8-yl) methylamino]pyridin-2-
ylthio]acetate .sup.1H-NMR(CDCl.sub.3) .delta. ppm: J=6Hz, 3H),
3.42(s, 3H), 3.82(s, 2H), 4.22(s, 2H), 4.10(q, J=6Hz, 2H),
4.25(br.s, 1H), 5.18(s, # 2H), 6.75(dd, J=2, 5Hz, 1H), 6.90(d,
J=8Hz, 1H), 6.92(d, J=8Hz, 1H), 7.06(d, J=5Hz, 1H), 7.07(s, 1H),
7.80(d, J=3Hz, 1H), 7.82(d, J=3Hz, 1H), 7.88(d, J=2Hz, 1H) 952 1388
1389ethyl 6-[5-[(10- methoxymethyl-10H pyrazino[2,3-b][1,4]benz-
othiazin-8-yl) methylamino]pyridin-2- yloxyl]hexanoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.22(t, J=6Hz, 3H),
1.38-1.50(m, 2H), 1.60-1.70(m, 2H), 1.70-1.80(m, 2H), 2.28(t, #
J=6Hz, 2H), 3.42(s, 3H), 4.10(q, J=6Hz, 2H), 4.20(s, 2H), 4.13(t,
J=6Hz, 2H), 5.20(s, 2H), 6.57(d, J=8Hz, 1H), 6.90(s, 2H), 6.92(d,
J=8Hz, 1H), 7.08(s, 1H), 7.52(d, J=2Hz, 1H), 7.80(s, 2H)
EXAMPLES
[2965] The following compounds were obtained by treating the
compounds obtained in Examples 947, 950, 952, 949, 951 and 948 by
the same method as the one of Example 9.
139 Ex. Structural formula MS M.p. NMR 953 13902-[5-[(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- yl)methylamino]pyridin -2-yl]ethanol
ESI (+) 352 (MH.sup.+) 138-142.degree. C. .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.86(t, J=5Hz, 2H), 3.92(t, J=5Hz, 2H), # 4.18(s, 2H),
4.20(br.s, 1H), 6.52(s, 1H), 6.78(d, J=8Hz, 1H), 6.80-6.86(m, 2H),
6.96(s, 1H), 6.97(d, J=8Hz, 1H), 6.82(s, 1H), 7.52(d, J=2Hz, 1H),
7.63(d, J=2Hz, 1H), 7.90(d, J=2Hz, 1H) 954
13918-[N-(2-methylpyridin- 5-yl)aminomethyl]-10H-
pyrazino[2,3-b][1.4]benzothiazine ESI (+) 322 (MH.sup.+)
205-208.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.42(s,
3H), 3.97(br.s, 1H), 3.98(t, J=5Hz, 1H), 4.18(d, J=5Hz, 1H), #
6.48(br.s, 1H), 6.52(s, 1H), 6.75-7.82(m, 2H), 6.86(d, J=8Hz, 1H),
6.92(d, J=8Hz, 1H), 7.54(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H), 7.94(d,
J=3Hz, 1H) 955 1392ethyl [5-[(10H-
pyrazino[2,3-b][1,4]benzothiazin-8-yl) methylamino]pyridin-2-
yl]acetate FAB (+) 394 (MH.sup.+) amorphous .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.12(t, J=6Hz, 3H), 3.69(s, 2H), 4.10(q, J=6Hz, 2H),
4.13(s, 2H), # 4.30(br.s, 1H), 6.46(s, 1H), 6.72(d, J=8Hz, 1H),
6.76(s, 1H), 6.78(d, J=8Hz, 1H), 7.03(d, J=7Hz, 1H), 7.42(d, J=7Hz,
1H), 7.43(d, J=3Hz, 1H), 760(d, J=3Hz, 1H), 7.90(s, 1H) 956
1393ethyl 6-[5-[(10H- pyrazino[2,3-b][1,4]benzothiazin-8- -yl)-
methylamino]pyridin-2- yloxy]hexanoate ESI (+) 466 (MH.sup.+)
105-108.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.23(t,
J=6Hz, 3H), 1.40-1.50(m, 2H), 1.60-1.70(m, # 2H), 1.70-1.80(m, 2H),
2.30(t, J=6Hz, 2H), 4.10(br.s, 1H), 4.13(q, J=6Hz, 2H), 4.15(q,
J=6Hz, 2H), 4.18(s, 2H), 6.51(br.s, 1H), 6.60(d, J=8Hz, 1H),
6.65-6.70(m, 1H), 6.81(s, 1H), 6.82(s, 1H), 7.00(d, J=7Hz, 1H),
7.52(s, 1H), 7.58(br.s, 1H), 7.68(s, 1H) 957
13946-[5-[(10H-pyrazino- 2,3-b][1,4]benzohiazin
-8-yl)methylmino]yridin-2-yloxy]hexan- 1-ol ESI (+) 424 (MH.sup.+)
124-128.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.16(br.s,
1H), 1.30-1.42(m, 4H), 1.42-1.60(m, # 2H), 1.60-1.75(m, 2H),
3.58(t, J=6Hz, 2H), 4.10(t, J=6Hz, 2H), 4.12(s, 2H), 4.10(br.s,
1H), 6.45(s, 1H), 6.54(d, J=7Hz, 1H), 6.66(br.s, 1H), 6.72(d,
J=7Hz, 1H), 6.78(d, J=8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.48(d, J=3Hz,
2H), 7.60(s, 1H) 958 1395ethyl [5-[(10H-
pyrazino[2,3-b][1,4]enzothiazin-8-yl) methylamino]pyridin-2-
ylthio]acetate ESI (+) 426 (MH.sup.+) 118-122.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24(t, J=6Hz, 3H), 3.85(s,
2H), 4.19(q, # J=6Hz, 2H), 4.21(s, 2H), 6.47(d, J=8Hz, 1H), 6.49(s,
1H), 6.76-6.82(m, 1H), 6.80(br.s, 1H), 6.80(d, J=8Hz, 1H), 6.85(d,
J=6Hz, 1H), 7.09(d, J=6Hz, 1H), 7.58(d, J=3Hz, 1H), 7.71(dd, J=2,
6Hz, 1H), 7.90(s, 1H) 959 13962-[5-[(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- yl)methylamino]pyridin
-2-ylthio]ethanol ESI (+) 384 (MH.sup.+) 138-142.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: J=6Hz, 2H), 3.93(t, J=6Hz,
2H), 4.19(s, 2H), 6.48(s, # 1H), 6.50(s, 1H), 6.80(br.s, 1H),
6.80(d, J=8Hz, 2H), 6.86(d, J=8Hz, 1H), 7.15(d, J=8Hz, 1H), 7.57(s,
1H), 7.70(s, 1H), 7.83(s, 1H)
EXAMPLE 960
[5-[(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)amino]pyridin
-2-yloxy]acetic acid
[2966] The title compound was obtained by treating ethyl
[5-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)ami-
no]pyridin-2-yloxy]acetate successively by the same methods as
those of Examples 18 and 9. 1397
[2967] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2968] 4.14(s, 2H), 4.80(s, 2H), 6.49(br.s, 1H), 6.52(s, 1H),
6.75(d, J=8 Hz, 1H), 6.78(s, 1H), 6.80(d, J=8 Hz, 1H), 6.84(d, J=7
Hz, 1H), 7.12(d, J=7 Hz, 1H), 7.43(d, J=3 Hz, 1H), 7.56(d, J=3 Hz,
1H), 7.62((d, J=3 Hz, 1H), 9.50(br.s, 1H)
[2969] MS: FAB(+)382(MH.sup.+)
[2970] m.p.: 170.degree. C.
EXAMPLES
[2971] The following compounds were obtained by successively
treating by the same methods as those of Examples 18 and 9.
140 Ex. Structural formula MS M.p. NMR 961
1398[2-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methylamino-
]pyridin-5-yl]carboxylic acid ESI (+) 352 (MH.sup.+)
215-220.degree. C. .sup.1H NMR(DMSO-d.sub.6) .delta. ppm:
4.20(br.s, 1H), 4.35(d, J=5Hz, 2H), 6.50(d, J=8Hz, 1H),
6.70-6.72(m, 1H), 6.70(d, J=8Hz, 1H), 6.73(s, 1H), 6.82(d, # J=8Hz,
1H), 7.62(s, 2H), 7.80 (d, J=8Hz, 1H), 9.50(br.s, 1H) 962
1399[5-[(10H-pyrazino[2,3-b][1,4]benzo-
thiazin-8-yl)methylamino]pyridin-2-ylthio]acetic acid ESI (+) 398
(MH.sup.+) 114-116.degree. C. .sup.1H NMR(DMSO-d.sub.6) .delta.
ppm: 3.78(s, 2H), 4.10(s, 2H), 6.72(s, 1H), 6.75(d, J=8Hz,
6.90(br.s, 1H), 6.95(dd, J=2, 7Hz, 1H), 7.12(d, J=7Hz, 1H), 7.60(s,
2H), 7.80 # (d, J=2Hz, 1H), 9.50(s, 1H) 963
1400[5-[(10H-pyrazino[2,3-
-b][1,4]benzothiazin-8-yl)methylamino]pyridin-2-yl]acetic acid
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.50(s, 2H). 4.05(d, J=5Hz,
6.70-6.84(m, 2H), 6.78(s, 1H), 6.84(d, J=8Hz, 1H), 6.99 (d, J=8Hz,
1H), 7.62(s, 2H), 7.82(d, J=3Hz, 1H), 9.54 (br.s, 1H) 964
14016-[5-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methylamino]pyridin--
2-yloxy]hexanoic acid ESI (+) 438 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.20-1.23(m, 2H), 1.40-1.55
(m, 2H), 1.55-1.70(m, 2H), 2.18(t, J=6Hz, 2H), 3.97(br.s, 1H),
3.98(t, J=6Hz, 2H), 4.08 (s, 2H), 6.60(d, J=8Hz, 1H), # 1H),
6.76(d, J=7Hz, 1H), 6.81 (d, J=8Hz, 1H), 7.05(d, J=7Hz, 1H),
7.40(s, 1H), 7.60(s, 2H), 9.50(s, 1H) 965
14025-[5-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methylamino-
]pyridin-2-yl]pentanoic acid .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.40-1.50(m, 2H), 1.50-1.60 (m, 2H), 2.18(t, J=6Hz, 2H), 2.50(m,
2H), 4.08(d, J=5Hz, 2H), 6.28(t, J=5Hz, 1H), 6.68(m, 3H), 6.80(d,
J=8Hz, 1H), 6.83(d, J=8Hz, 1H), 7.60(s, 2H), 7.81(s, 1H), # 9.50(s,
1H) 966
14036-[5-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methyl-
amino]pyridin-2-yl]- 2,2-dimethylhexanoic acid ESI (+) 450
(MH.sup.+) 158-161.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.02(s, 6H), 1.10-1.20(m, 2H), 1.40-1.48(m, 2H), 1.48-1.55(m,
2H), 2.40-2.50(m, 6.23(t, J=5Hz, 1H), 6.70- # 6.80(m, 1H), 6.72(s,
1H), 6.73(d, J=8Hz, 1H), 6.74(d, J=7Hz, 1H), 6.85(d, J=8Hz, 1H),
6.89(d, 9.50(s, 1H)
EXAMPLE 967
8-[(2-Methylquinolin-4-yl)aminomethyl]-[(10H-pyrazino[2,3-b][1,4]benzothia-
zine
[2972] Similar to Example 1094, 307 mg of 8-chloromethyl
-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine was treated
with 354 mg of 2-methyl -4-aminoquinoline in the presence of 91 mg
of sodium hydride (60% oily) to thereby give 413 mg of
8-[(2-methylquinolin-4-yl)am- inomethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine as a yellow oily substance.
Then this product was deblocked by the same method as the one of
Example 9 to thereby give 114 mg of the title compound as yellow
crystals. 1404
[2973] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2974] 3.53(s, 3H), 4.22(s, 2H), 6.74(d, J=8 Hz, 1H), 6.79(s, 1H),
6.82(d, J=8 Hz, 1H), 6.82(s, 1H), 7.50(t, J=7 Hz, 1H), 7.60(s, 2H),
7.64(t, J=7 Hz, 1H), 7.84(d, J=7 Hz, 1H), 8.14(d, J=7 Hz, 1H),
9.48(br.s, 2H)
[2975] MS: ESI(+)372(MH.sup.+)
[2976] m.p. : 290-300.degree. C.
EXAMPLES
[2977] The following compounds were synthesized by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
with amines by the same method as the one of Example 967 and then
treating by the same method as the one of Example 9.
141 Ex. Amine Structural formula MS M.p. NMR 968 1405
14068-[N-(5-chloropyridin-2-yl)aminomethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI (+) 342 (MH.sup.+)
200-203.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.30(d,
J=5Hz, 2H), 6.50(d, J=8Hz, 1H), 6.70(d, J=8Hz, 1H), 6.72(s, 1H),
6.82 (d, J=8Hz, 1H), 7.25(t, J=5Hz, 1H), # 7.42(d, J=8Hz, 1H),
7.61(s, 2H), 7.92 (s, 1H), 9.50(br.s, 1H) 969 1407
14088-[N-(5-bromopyridin-2-yl)ami- nomethyl]-10H-
pyrazino[2,3-b][1,4] FAB(+) 386 (MH.sup.+), 388 (MH.sup.+)
265-268.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.52(d,
J=5Hz, 2H), 6.51(d, J=8Hz, 1H), 6.72(d, J=8Hz, 1H), 6.73(s, 1H),
6.85 (d, J=8Hz, 1H), 7.00(t, J=5Hz, 1H), # 7.45(d, J=8Hz, 1H),
7.62(s, 2H), 7.92 (s, 1H), 9.50(br.s, 1H)
EXAMPLES
[2978] Similar to Example 10947,
N-[1-(2-trimethylsilylethoxy-methyl)imida- zol
-2-ylmethyl]acetamide and 1- (2-trimethylsilyl-ethoxymethyl)
-2-(N-tert-butoxycarbonylaminomethyl) imidazole were treated with
8-chloromethyl-10-methoxy -10H-pyrazino[2,3-b][1,4]benzothiazine in
the presence of sodium hydride to thereby give the following
compounds.
142 Ex. Amino-pyridine Structural formula NMR 970 1409
1410N-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benz-
othiazin-8-ylmethyl)-N-[1-[2-(trimethylsilyl)ethoxymethyl]imidazol-2-ylmet-
hyl]acetamide .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.02(s, 9H),
0.93(t, J=9Hz, 2H), 2.16(s, 3H), 3.44(t, J=9Hz, 2H), 3.46(s, 3H),
4.64(s, 2H), 4.73(s, 2H), 5.29 (s, 2H), 5.44(s, 2H), 6.83(d, J=8Hz,
1H), # 7.01-7.05(m, 4H), 7.88-7.90 (m, 2H) 971 1411
1412N-[2-(trimethylsilyl)ethoxymethylimidazol-2-
ylmethyl]-N-(10-methoxym-
ethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-tert-butylcarbamate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.00(s, 9H), 0.92(m, 2H),
1.52(s, 9H), 3.49(m, 2H), 3.57(s, 3H), 4.41(s, 2H), 4.62(br.s, 2H),
5.31(s, 2H), 5.39(s, 2H), 6.90(d, J=8Hz, 1H), # 6.97-7.12(m, 4H),
7.86(m, 2H)
EXAMPLES
[2979] The following compounds were obtained by treating the
compounds obtained in Examples 970 and 971 by the same method as
the one of Example 9.
143 Ex. Structural formula MS M.p. NMR 972
1413N-(10H-pyrazino(2,3-b][1,4]benzothiazin-8-
ylmethyl)-N-(imidazol-2-ylmethyl)acetamide FAB(+) 353 (MH.sup.+)
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.10(s, 3H), 4.39(s, 2H),
4.43(s, 2H), 6.25(s, 1H), 6.57(d, J=8Hz, 1H), 6.79(d, J=8Hz, 1H),
6.92(s, 3H), 7.41(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H) 973
14148-[N-(imidazol-2-ylmethyl)aminomethyl]-10H-
pyrazino[2,3-b][1,4]benzo- thiazine .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 3.52(s, 2H), 3.66(s, 2H), 6.74(d, J=1Hz, 1H), 6.78(d,
J=1Hz, 1H), 6.85(d, J=8Hz, 1H), 6.91(s, 2H), 7.62(d, J=3Hz, 1H),
7.63(d, J=3Hz, 1H), 9.47 (s, 1H)
EXAMPLE 974
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N-(py-
ridin-3-yl)acetamide
[2980] The title compound was obtained by treating
10-methoxymethyl-8-[N-(-
pyridin-3-yl)aminomethyl]-10H-pyrazino[2,3-b][1,4]-benzothiazine by
the same method as the one of Production Example 85. 1415
[2981] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2982] 1.90(s, 3H), 3.42(s, 3H), 4.80(s, 2H), 5.19(s, 2H), 6.78(d,
J=8 Hz, 1H), 6.92(d, J=8 Hz, 1H), 6.97(s, 1H), 7.30-7.42(m, 2H),
7.83(d, J=3 Hz, 2H), 8.38(br.s, 1H), 8.58(br.s, 1H)
EXAMPLE 975
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-N-(3-pyridyl)acetamide
[2983] The title compound was obtained by treating
N-(10-methoxymethyl-10H-
-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N-(pyridin-3-yl)acetamide
by the same method as the one of Example 9. 1416
[2984] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[2985] 1.82(s, 3H), 4.88(s, 2H), 6.58(d, J=8 Hz, 1H), 6.63(s, 1H),
6.80(d, J=8 Hz, 1H), 7.45(br.s, 1H), 7.60(s, 2H), 7.68-7.70(m, 1H),
8.43-8.50(m, 2H), 9.41(s, 1H)
[2986] MS: ESI(+)350(MH.sup.+)
[2987] m.p.: 212-214.degree. C.
EXAMPLE 976
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N-(py-
ridin-3-yl)-N'-ethylurea
[2988] 341 mg of
10-methoxymethyl-8-[N-(pyridin-3-yl)aminomethyl]-10H-pyra-
zino[2,3-b][1,4]benzothiazine was dissolved in 5 ml of toluene.
After adding 3 ml of pyridine and 1.9 ml of ethyl isocyanate, the
reaction mixture was heated under reflux for 3 days. After the
completion of the reaction, the reaction mixture was poured into a
saturated aqueous solution of sodium chloride and extracted
repeatedly with ethyl acetate. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with toluene/acetone) to thereby give
350 mg of the title compound as a yellow oily substance. 1417
[2989] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[2990] 1.03(t, J=6 Hz, 3H), 3.17(q, J=6 Hz, 2H), 3.42(s, 3H),
4.29(br.s, 1H), 4.75(s, 2H), 5.14(s, 2H), 6.80(d, J=8 Hz, 1H),
6.86(d, J=8 Hz, 1H), 6.97(s, 1H), 7.18-7.23(m, 1H), 7.23(d, J=5 Hz,
1H), 7.42(d, J=5 Hz, 1H), 7.77(s, 2H), 8.40(s, 1H)
EXAMPLE 977
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N-(pyridin
-3-yl)-N'-ethylurea
[2991] The title compound was obtained by treating
N-(10-methoxymethyl-10H-
-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N-(pyridin-3-yl)-N'-ethylure-
a by the same method as the one of Example 9. 1418
[2992] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 0.96(t, J=6 Hz, 3H),
3.06(q, J=6 Hz, 2H), 4.68(s, 2H), 6.26(t, J=7 Hz, 1H), 6.58(d, J=8
Hz, 1H), 6.69(s, 1H), 6.79(d, J=8 Hz, 1H), 7.30-7.40(m, 1H),
7.53-7.62(m, 1H), 7.60(s, 2H), 8.16(m, 1H), 8.20(m, 1H), 9.48(s,
1H)
[2993] MS: ESI(+)379(MH.sup.+)
[2994] m.p. 210-212.degree. C.
EXAMPLES
[2995] The following compounds were obtained by treating
10-methoxymethyl-8-[N-(pyridin-3-yl)
aminomethyl]-10H-pyrazino[2,3-b][1,4- ]benzothiazine by the same
method as the one of Example 974 or 976 followed by the same
treatment as the one of Example 9.
144 Ex. Structural formula MS M.p. NMR 978
1419N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-N-(pyridin-3-yl)benzenesulfonamide ESI(+) 448 (MH.sup.+)
205-206.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.68(s,
2H), 6.60(d, J=8Hz, 1H), 6.77(d, J=8Hz, 1H), 6.79(s, 1H), 7.32(dd,
J=2, 5Hz, 1H), 7.47-7.56(m, 1H), 7.58-7.62(m, 6H), 7.70-7.76(m,
1H), 8.30(d, # J=3Hz, 1H), 8.42(d, J=3Hz, 1H), 9.50(br.s, 1H) 979
1420N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-N-(pyridyl)benza- mide FAB(+) 411(M.sup.+)
178-182.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.92(s,
2H), 6.60(d, J=8Hz, 1H), 6.61(s, 1H), 6.72(d, J=8Hz, 1H),
7.05-7.20(m, 3H), 7.20-7.40(m, 5H), 7.53(d, J=3Hz, 1H), 7.60(d,
J=3Hz, 1H), 8.24(s, 1H), 8.36(d, J=2Hz, 1H) 980
1421N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-N-(pyridin-3-yl)- methanesulfonamide FAB(+) 385 (M.sup.+)
208-210.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.14(s,
3H), 4.73(s, 2H), 6.62(d, J=8Hz, 1H), 6.73(s, 1H), 6.78(d, J=8Hz,
1H), 7.40(m, 1H), 7.60(m, 2H), 7.84(dd, J=2, 8Hz, 1H), 8.43 (d,
J=4Hz, 1H), 8.54(s, 1H), 9.50(s, 1H) 981
1422N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-N-(pyridin-3-yl)-N-phenylurea ESI(+) 427 (MH.sup.+)
208-210.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.78(s,
2H), 6.65(d, J=8Hz, 1H), 6.77(s, 1H), 6.81(d, J=8Hz, 1H), 6.95(t,
J=7Hz, 2H), 7.22(t, J=7Hz, 2H), 7.22(t, J=7Hz, 2H), 7.42(d, #
J=7Hz, 2H), 7.60(d, J=2Hz, 1H), 7.61(d, J=2Hz, 1H), 7.69(m, 1H),
8.38(d, J=2Hz, 1H), 8.42(s, 1H), 8.48(s, 1H), 9.52(s, 1H)
EXAMPLES
[2996] The following compounds were obtained by treating
10-methoxymethyl-8-chloromethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
with various imidazoles by the same method as the one of Example
1094.
145 Ex. Imidazole Structural formula NMR 982 1423
14248-(2-methylimidazol-1-ylmethyl)-10-methoxy-
methyl-10H-pyrazino[2,3-b][1,4]enzothiazine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.34 (s, 3H), 3.45(s, 3H), 4.98(s, 2H), 5.16(s, 2H),
6.64(dd, J=1, 8Hz, 1H), 6.77(d, J=1Hz, 1H), 6.84(d, J=1Hz, 1H),
6.96 (d, J=1Hz, 1H), 6.97(d, J=8Hz, 1H), 7.84(d, J=3Hz, 1H),
7.85(d, J= # 3Hz, 1H) 983 1425
14268-(2-ethylimidazol-1-ylmethyl)-10-m- ethoxy-
methyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27 (t, J=7Hz, 3H), 2.61(q,
J=7Hz, 2H), 3.42(s, 3H), 4.98(s, 2H), 5.12(s, 2H), 1H), 6.82(s,
1H), 6.94(d, J=8Hz, 1H), 6.98 (s, 1H), 7.82(m, 2H) 984 1427
14288-(2-isopropylimidazol-1-ylmethyl)-10-methoxy-
methyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.27 (d, J=7Hz, 6H),
2.93(sept, J=7Hz, 1H), 3.42(s, 3H), 5.03(s, 2H), 5.13(s, 2H),
6.63(d, J=8Hz, 1H), 6.70(s, 1H), 6.78(s, 1H), 6.96(d, J=8Hz, 1H),
7.02 (s, 1H), 7.83(m, 2H) 985 1429
14308-(2-chloroimidazol-1-ylmethyl)-10-methoxy-
methyl-10H-pyrazino[2,3-b- ][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.48 (s, 3H), 5.03(s, 2H),
5.19(s, 2H), 6.73(dd, J=2, 8Hz, 1H), 6.89(d, J=2Hz, 1H), 6.91(d,
J=1Hz, 1H), 6.99(d, J=1Hz, 1H), 7.00(d, J=8Hz, 1H), 7.84 (d, J=3Hz,
1H), 7.86(d, J=3Hz, 1H) 986 1431
14328-(2-bromoimidazol-1-ylmethyl)-10-methoxy-
methyl-10H-pyrazino[2,3-b]- [1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.47 (s, 3H), 5.05(s, 2H),
5.19(s, 2H), 6.74(dd, J=2, 8Hz, 1H), 6.89(d, J=2Hz, 6.99(d, J=8Hz,
1H), 7.06(d, J=1Hz, 1H), 7.84(d, J=3Hz, 1H), 7.86 (d, J=3Hz, 1H)
987 1433 14348-[2-(trifluoromethyl)imidazol-1-ylmethyl)-10-
10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.46 (s, 3H), 5.17(s, 2H),
5.18(s, 2H), 6.75(dd, J=1, 8Hz, 1H), 6.88(br.s, 1H), 6.98(s, 1H),
7.00(d, J=8Hz, 1H), 7.13(s, 1H), 7.83-7.88(m, 2H) 988 1435
14368-(2-aminoimidazol-1-ylmethyl)-10-methoxy-
methyl-10H-pyrazino[2,3-b]- [1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.46 (s, 3H), 4.86(s, 2H),
5.19(s, 2H), 6.59(d, J=2Hz, 1H), 6.70 (d, J=2Hz, 1H), 6.72(d,
J=2Hz, 1H), 6.87(d, J=2Hz, 1H), 7.00(d, J=8Hz, 1H), 7.84 (d, J=3Hz,
1H), 7.86(d, J=3Hz, 1H) 989 1437
14381-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)i-
midazole-2-carbaldehyde .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.48
(s, 3H), 5.19(s, 2H), 5.53(s, 2H), 6.78(d, J=8Hz, 1H), 6.97 (s,
2H), 7.17(s, 1H), 7.28(s, 1H), 7.83(m, 2H), 9.84(s, 1H) 990 1439
14401-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)i-
midazol-2-yl 2-pyridylketone .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.48 (s, 3H), 5.20(s, 2H), 5.64(s, 2H), 6.87(dd, J=2, 8Hz, 1H),
6.99(d, J=8Hz, 1H), 7.05(d, J=2Hz, 1H), 7.20(d, J=1Hz, 1H), 7.33(d,
J=1Hz, 1H), 7.47 (ddd, J=2, 5, 8Hz, 1H), 7.83- # 7.88(m, 3H),
8.26(dd, J=2, 8Hz, 1H), 8.81(dd, J=1, 5Hz, 1H) 991 1441
14428-[2-(pyridin-2-ylmethyl)imidazol-1-ylmethyl]-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.42 (s, 3H), 4.24(s, 2H),
5.08(s, 2H), 5.12(s, 2H), 6.54(dd, J=2, 8Hz, 1H), 6.69(d, J=2Hz,
1H), 6.85(d, J=1Hz, 1H), 6.88 (d, J=8Hz, 1H), 7.03(d, J=1Hz, 1H),
7.07(ddd, J=2, 5, # 8Hz, 1H), 7.19(br.d, J=8Hz, 1H), 7.54(dt, J=2,
8Hz, 1H), 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.42(ddd, J=1, 2,
5Hz, 1H) 992 1443
14448-(4-phenylimidazol-1-ylmethyl)-10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.43 (s, 3H), 5.08(s, 2H), 5.19(s, 2H), 6.79(dd, J=2, 8Hz,
1H), 6.92(d, J=2Hz, 1H), 7.00(d, J=8Hz, 1H), 7.19(d, J=2Hz, 1H),
7.23(t, J=8Hz, 1H), 7.36 (t, J=8Hz, 2H), 7.60(d, J=2Hz, 1H), 7.75 #
(d, J=8Hz, 2H), 7.83(d, J=3Hz, 1H), 7.85(d, J=3Hz, 1H), 993 1445
14468-[4-(pyridin-4-yl)imidazol-1-ylmethyl]-10-methoxymethyl-
10H-pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.43 (s, 3H), 5.10(s, 2H), 5.20(s, 2H), 6.80(dd, J=2,
8Hz, 1H), 6.94(d, J=2Hz, 1H), 7.02(d, J=8Hz, 1H), 7.35(d, J=1Hz,
1H), 7.62(dd, J=2, 5Hz, 2H), 7.64(d, J=1Hz, 1H), # 7.84(d, J=3Hz,
1H), 7.87(d, J=3Hz, 1H), 8.57(dd, J=2, 5Hz, 2H) 994 1447
1448[1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-
8-ylmethyl)imidazol-4(5)-yl]methanol .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: (4,5-mix) 3:4), 4.50 and 4.54 (s, total 2H, 3:4), 5.00
and 5.16(s, total 2H, 4:3), 5.16 and 5.20(s, total 2H, 4:3), 6.70
and 6.73(dd, J=1.8, 8.1Hz, total 1H, 3:4), 6.84 and 6.90(d,
J=1.8Hz, # total 1H, 3:4), 6.85 and 6.94 (s, total 1H, 4:3), 6.95
and 6.97(d, J=8.1Hz, total 1H, 3:4), 7.48(s, total 1H), 7.83 and
7.84(d, J=2.5Hz, total 1H, 3:4), 7.84 and 7.85(d, J=8.1Hz, total
1H, 3:4) 995 1449
14501-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-
8-ylmethyl)imidazole-4,5-dicarbonitrile .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.52 (s, 3H), 5.20(s, 2H), 5.26(s, 2H), 6.85(dd, J=2,
8Hz, 1H), 7.06(d, J=8Hz, 1H), 7.09(d, J=2Hz, 1H), 7.72(s, 1H), 7.86
(d, J=3Hz, 1H), 7.88(d, J=3Hz, 1H) 996 1451
14524-[1-(10-methoxymethyl-10- H-pyrazino[2,3-b][1,4]benzothiazin-
8-ylmethyl)imidazol-4-yl]benzonitrile .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.44 (s, 3H), 5.09(s, 2H), 5.21(s, 2H), 6.79(dd, J=2,
8Hz, 1H), 6.94(d, J=2Hz, 7.29(d, J=1Hz, 1H), 7.62-7.65(m, 3H),
7.83-7.87(m, 4H) 997 1453
14541-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-
8-ylmethyl)-5-methylimidazol-4-carbonitrile .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.30 (s, 3H), 3.46(s, 3H), 5.01(s, 2H), 5.17(s, 2H),
6.62-6.67 (m, 1H), 6.77(d, J=2Hz, 1H), 7.01(d, J=8Hz, 1H), 7.48(s,
1H), 7.84(d, J=3Hz, 1H), 7.87 (d, J=3Hz, 1H) 998 1455
1456N-[2-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
methylimidazol-4-yl]ethyl]benzenesulfonamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.68 (t, J=8Hz, 2H), 3.25(q,
J=8Hz, 2H), 5.20(s, 2H), 5.86 (br.s, J=8Hz, 1H), 6.88(s, 1H),
6.97(d, J=8Hz, 1H), 7.43 (s, 1H), 7.48(t, J=8Hz, 2H), 7.50-7.58(m,
1H), # 7.80-7.90(m, 4H) 999 1457
1458N-[2-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothi-
azin-8-ylmethyl]imidazol-4-yl]ethyl]benzamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.86 (t, J=6Hz, 2H), 3.45(s,
3H), 3.68-3.76(m, 2H), 5.00(s, 2H), 5.19(s, 2H), 6.73(s, 1H),
6.70-6.76(m, 1H), 6.89(s, 1H), 6.97(d, J=8Hz, 1H), 7.40 (t, J=8Hz,
2H), 7.44- # 7.49(m, 1H), 7.51(s, 1H), 7.52-7.60(m, 1H), 7.80(d,
J=8Hz, 2H), 7.80-7.88 (m, 2H)
EXAMPLES
[2997] The following compounds were obtained by the same method as
the one of Example 8.
146 Ex. Structural formula MS M.p. NMR 1000
14598-(2-methylimidazol-1-ylmethyl)-10H-pyrazino[2,3-b][1,4]b-
enzothiazine ESI(+) 296.2 (MH.sup.+) 244-246.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.27(s, 3H), 5.01(s, 2H),
6.53(s, 1H), 6.56(d, J=8Hz, 1H), 6.89(d, J=8Hz, 1H), 6.93(s, 1H),
7.16 (s, 1H), 7.63(s, 2H), 9.53(s, 1H) 1001
14608-(2-ethylimidazol-1-yl-
methyl)-10H-pyrazino[2,3-b][1,4]benzothiazine ESI(+) 310.2
(MH.sup.+) 230-231.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.27(t, J=7Hz, 3H), 2.61(q, J=7Hz, 2H), 4.90(s, 2H), 6.09 (d,
J=2Hz, 1H), 6.55(dd, J=2, 8Hz, 1H), 6.79(br.s, 1H), 6.82(d, J=1Hz,
1H), 6.85(d, J=8Hz, 1H), 6.99(d, J= # 1Hz, 1H), 7.56(d, J=3Hz, 1H),
7.69(d, J=3Hz, 1H) 1002
14618-(2-isopropylimidazol-1-ylmethyl)-10H-pyrazino[2,3-b][1,4]be-
nzothiazine ESI(+) 324.0 (MH.sup.+) 241-242.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.26(d, J=1Hz, 6H),
2.90(septet, J=7Hz, 1H), 4.94(s, 2H), 6.09(d, J=2Hz, 1H), 6.55(dd,
J=2, 8Hz, 1H), 6.76(d, J=1Hz, 1H), 6.85(d, J=8Hz, 1H), 6.98(d,
J=1Hz, 1H), 7.18 # (br.s, 1H), 7.52(d, J=3Hz, 1H), 7.68(d, J=3Hz,
1H) 1003
1462N-[2-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-4-
yl]ethyl]benzenesulfonamide ESI(+) 465 (MH.sup.+) 127-130.degree.
C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.70(t, J=6Hz, 2H), 3.27(q,
J=6Hz, 2H), 4.88(s, 2H), 6.21 (s, 1H), 6.64(s, 1H), 6.63(dd, J=2,
8Hz, 1H), 6.86(d, J=8Hz, 1H), 7.40(s, # 1H), 7.48(t, J=8Hz, 2H),
7.52-7.58(m, 2H), 7.68(d, J=3Hz, 1H), 7.85(d, J=8Hz, 2H) 1004
1463N-[2-[1-[10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl]imidazol-4-yl]ethyl]benzamide ESI(+) 429 (MH.sup.+)
231-233.degree. C. .sup.1H NMR(DMSO-d.sub.6) .delta. ppm: 2.97(t,
J=6Hz, 2H), 3.62(q, J=6Hz, 2H), 5.29(s, 2H), 6.75 (d, J=1Hz, 1H),
6.76(dd, J=1, 8Hz, 1H), 6.91(d, J=8Hz, 1H), 7.47(t, J=7Hz, 2H), #
7.53(t, J=7Hz, 1H), 7.55(s, 1H), 7.72(s, 2H), 7.85(d, J=7Hz, 2H),
8.78(t, J=6Hz, 1H), 9.27(s, 1H), 9.66(s, 1H)
EXAMPLES
[2998] The following compounds were obtained by the same method as
the one of Example 9.
147 Ex. Structural formula MS M.p. NMR 1005
14648-(2-chloroimidazol-1-ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine FAB(+) 316 (MH.sup.+) 231-232.degree. C.
.sup.1H NMR(DMSO-d.sub.6) .delta. ppm: 5.01(s, 2H), 6.55(d, J=1Hz,
1H), 6.59(dd, J=1, 8Hz, 1H), 6.90(d, J=8Hz, 1H), 6.92 (d, J=2Hz,
1H), 7.34(d, J=2Hz, 1H), 7.63(s, 2H), 9.55(s, 1H) 1006
14658-(2-bromoimidazol-1-ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine FAB(+) 361 (M.sup.+) 256-258.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.00(s, 2H), 6.54(s, 1H),
6.56(d, J=8Hz, 1H), 6.90(d, J=8Hz, 1H), 6.97(d, J=2Hz, 1H), 7.39(d,
J=2Hz, 1H), 7.63(s, 2H), 9.45(s, 1H) 1007
14668-[2-(trifluoromethyl)imidazol-1-ylmethyl]-10H-pyrazino[2-
,3-b][1,4]benzothiazine FAB(+) 350 (MH.sup.+) 231-233.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.20(s, 2H), 6.50(d, J=1Hz,
1H), 6.57(dd, J=1, 8Hz, 1H), 6.90(d, J=8Hz, 1H), 7.15(d, J=1Hz,
1H), 7.54(d, J=1Hz, 1H), 7.63(s, 2H), 9.55(s, 1H) 1008
14678-(2-aminoimidazol-1-ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine FAB(+) 297 (MH.sup.+) 286-287.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.87(s, 2H), 6.56(s, 1H),
6.59(d, J=8Hz, 1H), 6.74(s, 1H), 6.77(s, 1H), 6.90(d, J=8Hz, 1H),
6.92(br.s, 2H), 7.63(s, 2H), 9.57(s, 1H) 1009
14681-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-2-yl 2-pyridyl ketone FAB(+) 387 (MH.sup.+)
191-193.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 5.52(s,
2H), 6.43(s, 1H), 6.72(d, J=8Hz, 1H), 6.84(d, J=8Hz, 1H), 6.95(s,
1H), 7.19(s, 1H), 7.32(s, 1H), 7.47(dd, J=5, 8Hz, 1H), 7.53(d,
J=3Hz, 1H) J=3Hz, 1H), # 7.85(td, J=1, 8Hz, 1H), 8.15(d, J=8Hz,
1H), 8.78(d, J=5Hz, 1H) 1010
14698-[2-(pyridin-2-ylethyl)imidazol-1-ylmethyl]-10H-
pyrazino[2,3-b][1,4]-benzothiazine FAB(+) 373 (MH.sup.+)
216-219.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.10(s,
2H), 5.04(s, 2H), 6.45(d, J=8Hz, 1H), 6.48(s, 1H), 6.81(d, J=8Hz,
1H), 6.82(s, 1H), 7.09(s, 1H), 7.14(d, J=9Hz, 1H), 7.16(dd, J=6,
9Hz, 1H), # 7.63(s, 2H), 7.64(dt, J=2, 9Hz, 1H), 8.41(dd, J=2, 6Hz,
1H), 9.49(s, 1H) 1011
14708-(4-phenylimidazol-1-ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine FAB(+) 358 (MH.sup.+) 216-218.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.05(s, 2H), 6.62(d, J=1Hz,
6.68(dd, J=1, 8Hz, 1H), 6.90(d, J=8Hz, 1H), 7.16(t, J=8Hz, 1H),
7.31(t, J=8Hz, 2H), 7.59(s, 1H), 7.62(s, 2H), 7.73(d, J=8Hz, 2H),
7.75(s, 1H), # 9.53(s, 1H) 1012 14718-[4-(pyridin-4-yl)imidazol-1-
-ylmethyl]-10H- pyrazino[2,3-b][1,4]benzothiazine
bistrifluoroacetate FAB(+) 359 (MH.sup.+) 157-158.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.17(s, 2H), 6.63(d, J=1Hz,
1H), 6.73(dd, J=1, 7Hz, 1H), 6.94(d, J=7Hz, 1H), 7.64(s, 2H),
8.20(d, J=1Hz, 1H), 8.24(d, J=6Hz, 2H), # 8.38(d, J=1Hz, 1H),
8.75(d, J=6Hz, 2H), 9.54(s, 1H) 1013
14724-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-4-yl]benzonitrile FAB(+) 383 (M.sup.+)
262-264.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.09(s,
2H), 6.60(d, J=1Hz, 1H), 6.69(dd, J=1, 8Hz,1H), 6.91(d, J=8Hz, 1H),
7.62(s, 2H), 7.77(d, J=8Hz, 2H), 7.85(d, J=1Hz, 1H), 7.86(d, J=1Hz,
1H), 7.91 # (d, J=8Hz, 2H), 9.52(s, 1H)
EXAMPLES
[2999] The following compounds were obtained by the same treatment
as the one of Example 434.
148 Ex. Structural formula MS M.p. NMR 1014
14731-(10H-pyrazino[2,3-b][1,4]benzothiazin- 8-ylmethyl)
imidazole-2-carbaldehyde 218-219.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.41(s, 2H), 6.53(d, J=1Hz,
1H), 6.57(dd, J=1, 9Hz, 1H), 6.86(d, J=9Hz, 1H), 7.33(s, 1H),
7.63(s, 2H), 7.69(s, 1H), 9.49(s, 1H), 9.68(s, 1H) 1015
1474[1-(10H-pyrazino[2,3-b][1,4]benzothi- azin-
8-ylmethyl)imidazol-4(5)-yl]methanol ESI(+) 312.0 (MH.sup.+)
208-215.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.38(m,
2H), 4.79 and 5.08 (t, J=6Hz, 1H), 4.79 and 5.06(s, 2H), 6.54-6.65
(m, 2H), 6.85-6.90(m, 1H), 6.82 and 6.91(s, 1H), 7.59 and 7.63(s,
1H), 7.63-7.65(m, 2H), # 9.51 and 9.53(s, 1H) 1016
14751-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)
imidazole-4,5-dicarbonitrile .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
5.34(s, 2H), 6.56(d, J=2Hz, 1H), 6.73(dd, J=2, 8Hz, 1H), 6.96(d,
J=8Hz, 1H), 7.66 (s, 2H), 8.48(s, 1H), 9.54(s, 1H) 1017
14761-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-5-methylimidazol- e-4-carbonitrile
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.24(s, 3H), 5.12(s, 2H),
6.47(d, J=2Hz, 1H), 6.62(dd, J=2, 8Hz, 1H), 6.92(d, J=8Hz, 1H),
7.65(s, 2H), 7.90(s, 1H), 9.50(s, 1H)
EXAMPLES
[3000] 280 mg portions of the following compounds were obtained by
the same method as the one of Example 1094 by starting with 0.55 g
of ethyl (5-methylimidazol -4-yl)carboxylate and 0.7 g of
10-methoxymethyl
-8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine.
149 Ex. Structural formula NMR 1018 1477ethyl
[1-(10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiaz-
in-8-ylmethyl)-5-methylimidazol-4-yl]carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.40(t, J=7Hz, 2.47(s, 3H),
3.45(s, 3H), 4.37(q, J=7Hz, 2H), 5.02(s, 2H), 5.17(s, 2H), 6.62(dd,
J=2, 8Hz, 1H), 6.80(d, J=2Hz, 1H), 6.98 (d, J=8Hz, 1H), 7.48(s,
1H), 7.84(d, J=3Hz, 1H), 7.86 # (d, J=3Hz, 1H) 1019 1478ethyl
[1-(10-(methoxymethyl)-10H-pyra-
zino[2,3-b][1,4]benzothiazin-8-ylmethyl)-4-methylimidazol-5-yl]carboxylate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.33(t, J=7Hz, 3H), 2.51(s,
3H), 3.46(s, 3H), 4.28(q, J=7Hz, 2H), 5.18(s, 2H), 5.40(s, 2H),
6.73(dd, J=2, 8Hz, 1H), 6.87(d, J=2Hz, 1H), 6.96(d, J=8Hz, 1H),
7.53(s, 1H), 7.83(d, J=3Hz, # 1H), 7.85(d, J=3Hz, 1H)
EXAMPLES
[3001] The following compounds were obtained by the same method as
the one of Example 1094 by starting with
10-methoxymethyl-8-chloromethyl-10H-pyra- zino
[2,3-b][1,4]benzothiazine and various imidazoles.
150 Ex. Imidazole Structural formula NMR 1020 1479 1480methyl
(E)-3-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-
-b][1,4]benzothiazin-8-ylmethyl]imidazol-4-yl]propenoate
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.33(s, 3H), 3.65(s, 3H),
5.66(s, 2H), 5.70(s, 2H), 6.33 (d, J=15.5Hz, 1H), 6.88 (dd, J=1.7,
8.3Hz, 1H), 6.97(d, J=1.7Hz, 1H), 7.12(d, J=8.3Hz, 1H), 7.48(d,
J=15.5Hz, 1H), 7.62(s, 1H), # 7.86(s, 1H), 7.93(d, J=3.0Hz, 1H),
7.96(d, J=3.0Hz, 1H) 1021 1481 1482methyl 4-[1-(10-(methoxymethyl-
)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]imidazol-4-yl]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.42(s, 3H), 3.81(s, 3H),
5.09(s, 2H), 5.20(s, 2H), 6.80(dd, J=2, 8Hz, 1H), 6.93 (d, J=2Hz,
1H), 7.01(d, J=8Hz, 1H), 7.29(d, J=1Hz, 1H), 7.63(d, J=1Hz, 1H),
7.82(d, J=8Hz, 2H), 7.83(d, J=3Hz, 1H), # 7.86(d, J=3Hz, 1H),
8.03(d, J=8Hz, 2H) 1022 1483 1484methyl
4-[1-(10-(methoxymethyl)-10H-pyrazino[2,3-
-b][1,4]benzothiazin-8-ylmethyl]imidazol-2-yl]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.43(s, 3H), 3.87(s, 3H),
4.08(s, 2H), 4.83(s, 2H), 5.10(s, 2H), 6.63(s, 1H), 6.76(d, J=8Hz,
1H), 6.90(d, J=8Hz, 1H), 6.99(s, 1H), 7.16(d, J=8Hz, 2H), 7.78 (s,
1H), 7.82-7.93(m, 4H) 1023 1485 1486methyl
4-(1-[10-(methoxymethyl)-10H-pyr-
azino[2,3-b][1,4]benzothiazin-8-ylmethyl]imidazol-2-ylcarbonyl]benzoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.43(s, 3H), 3.94(s, 3H),
5.18(s, 2H) 5.63(s, 2H), 6.83(dd, J=2, 8Hz, 1H), 6.99(d, J=8Hz,
1H), 7.01(d, J=2Hz, 1H), 7.20(d, J=1Hz, 1H), 7.30(d, J=1Hz, 1H),
7.83(d, J=3Hz, 1H), 7.84(d, # J=3Hz, 1H), 8.13(d, J=8Hz, 2H),
8.30(d, J=8Hz, 2H)
EXAMPLES
[3002] The following compounds were obtained by treating the
starting compounds by the same method as the one of Example
434.
151 Ex. Structural formula MS M.p. NMR 1024 1487ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-5-methylimidazol-4-yl]carboxylate ESI(+) 368 (MH.sup.+)
222-224.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.25(q,
J=7Hz, 3H), 2.33(s, 3H), 4.19(q, J=7Hz, 2H), 5.09(s, 2H), 6.45(d,
J=2Hz, 1H), 6.56(dd, J=2, 8Hz, 1H), 6.89(d, J=8Hz, 1H), 7.62(s,
2H), # 7.84(s, 1H), 9.48(s, 1H) 1025 1488ethyl
[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-4-methylimidazol-5-- yl]carboxylate ESI(+) 368 (MH.sup.+)
194-196.degree. C. .sup.1H NMR(DMSO-d.sub.6) .delta. ppm: 1.23(t,
J=7Hz, 3H), 2.38(s, 3H), 4.18(q, J=7Hz, 2H), 5.30(s, 2H), 6.48(s,
1H), 6.45-6.54(m, 1H), 6.86(d, J=8Hz, 1H), 7.64(s, 2H), 7.94(s,
1H), # 9.52(s, 1H) 1026 1489methyl
(E)-3-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-4-yl]propenoate ESI(+) 366.1 (MH.sup.+)
248-250.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.65(s,
3H), 5.05(s, 2H), 6.33(d, J=15.6Hz, 1H), 6.56(s, 1H), 6.66(d,
J=7.9Hz, 1H), 6.90(d, J=7.9Hz, 1H), 7.49(d, J=15.6Hz, 1H), 7.56(s,
1H), # 7.63(s, 2H), 7.81(s, 1H), 9.52(s, 1H)
EXAMPLE 1027
Methyl 4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)imidazol-4-y- l]benzoate trifluoroacetate
[3003] The title compound was obtained by treating methyl
4-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-
imidazol-4-yl]benzoate by the same method as the one of Example 9.
1490
[3004] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3005] 3.83(s, 3H), 5.19(s, 2H), 6.64(d, J=1 Hz, 1H), 6.76(dd, J=1,
7 Hz, 1H), 6.95(d, J=7 Hz, 1H), 7.64(s, 2H), 7.90(d, J=8 Hz, 2H),
8.00(d, J=8 Hz, 2H), 8.06(s, 1H), 8.75(s, 1H), 9.54(s, 1H)
[3006] MS: FAB(+)416(MH.sup.+)
[3007] m.p. : 161-162.degree. C.
EXAMPLE 1028
(E)-3-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol
-4-yl]-2-propenoic acid
[3008] The title compound was obtained as yellow crystals by
treating methyl (E)-3-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-
-8-ylmethyl)imidazol-4-yl]propenoate successively by the same
methods as those of Examples 434 and 18. 1491
[3009] H-NMR(DMSO-d.sub.6) .delta. ppm:
[3010] 5.04(s, 2H), 6.26(d, J=15.4 Hz, 1H), 6.56(s, 1H), 6.65(d,
J=7.9 Hz, 1H), 6.90(d, J=7.9 Hz, 1H), 7.41(d, J=15.4 Hz, 1H),
7.52(s, 1H), 7.63(s, 2H), 7.89(s, 1H), 9.52(s, 1H)
[3011] MS: ESI(+)352.2(MH.sup.+)
[3012] m.p. : 275-276.degree. C.
EXAMPLES
[3013] The following compounds were obtained by treating the
compounds obtained in Examples 1021, 1022 and 1023 successively by
the same methods as those of Examples 9 and 18.
152 Ex. Structural formula MS M.p. NMR 1029
14924-[1-(10H-pyrazino-[2,3-b][1,4]benzothiazin-8-ylmethyl)-
imidazol-4-yl]benzoic acid trifluoroacetate FAB(+) 402 (M.sup.+)
264-266.degree. C. .sup.1H NMR(DMSO-d.sub.6) .delta. ppm: 5.20(s,
2H), 6.64(d, J=1Hz, 1H), 6.77(dd, J=1, 7Hz, 1H), 6.94(d, J=7Hz,
1H), 7.64(s, 2H), 7.86(d, J=8Hz, 2H), 7.97(d, J=8Hz, # 2H), 8.18(s,
1H), 8.65(s, 1H), 9.54(s, 1H) 1030 14934-[1-(10H-pyrazino[2,3--
b][1,4]benzothiazin-8- ylmethyl]imidazol-2-ylmethyl]benzoic acid
FAB(+) 416 (MH.sup.+) 185-188.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 4.03(s, 2H), 4.94(s, 2H), 6.42(s, 1H), 6.44(d, J=8Hz,
1H), 6.78(d, J=8Hz, 1H), 6.85(s, 1H), 7.11(s, 1H), 7.20(d, J=8Hz,
2H), 7.63(s, 2H), 7.78(d, J=8Hz, # 2H), 9.45(s, 1H), 13.50(br.s,
1H) 1031 14944-(1-[10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl]imidazol-2-ylc- arbonyl]benzoic acid FAB(+) 430 (MH.sup.+)
242-246.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.53(s,
2H), 6.55(d, J=1Hz, 1H), 6.62(dd, J=1, 8Hz, 1H),6.87(d, J=8Hz, 1H),
7.33(s,1H), 7.62(s, 2H), 7.75(s,1H), 8.04(d, J=8Hz, 2H), 8.25(d,
J=8Hz, # 2H), 9.51(s, 1H)
EXAMPLE 1032
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-5--
methylimidazol-4-yl]carboxamide
[3014] To a solution of 0.7 g of ethyl [1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-5-methylimidazol-4-yl]c-
arboxylate in tetrahydrofuran (10 ml) was added 50 ml of aqueous
ammonia. After sealing, the resulting mixture was heated to
100.degree. C. for 24 hours. Then the reaction mixture was
concentrated, extracted with dichloromethane, washed with a
saturated aqueous solution of sodium chloride and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with ethanol/dichloromethane) to thereby
give 0.31 g of the title compound as pale yellow crystals. 1495
[3015] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3016] 2.35(s, 3H), 3.29(s, 3H), 5.15(s, 4H), 6.73(dd, J=2, 8 Hz,
1H), 6.82(d, J=2 Hz, 1H), 6.92-6.97(m, 1H), 7.11(d, J=8 Hz, 1H),
7.16-7.22(m, 1H), 7.72(s, 1H), 7.92(d, J=3 Hz, 1H), 7.95(d, J=3 Hz,
1H)
EXAMPLE 1033
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4--
methylimidazol-5-yl]carboxylic acid
[3017] 0.4 g of the title compound was obtained as a yellow oily
substance by treating 0.5 g of ethyl
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4-
]benzothiazin-8-ylmethyl]-4-methylimidazol-5-yl]carboxylate by the
same method as the one of Example 1032 by conducting the reaction
for 60 hours. 1496
[3018] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3019] 2.34(s, 3H), 3.32(s, 3H), 5.13(s, 2H), 5.47(s, 2H), 6.73(dd,
J=2, 8 Hz, 1H), 6.88(d, J=2 Hz, 1H), 7.06(d, J=8 Hz, 1H), 7.73(s,
1H), 7.93(d, J=3 Hz, 1H), 7.97(d, J=3 Hz, 1H)
EXAMPLE 1034
(E)-3-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl]-5-methylimidazol-4-yl]-2-methylpropenamide
[3020] 0.9 g of ethyl (E)-3-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-ylmethyl]-5-methylimidazol
-4-yl]-2-methylpropenoate was treated by the same method as the one
of Example 18 to thereby give 0.9 g of (E)-3-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-y-
lmethyl]-5-methylimidazol -4-yl]-2-methylpropenoic acid as yellow
crystals. To a solution of 0.9 g of these crystals in
tetrahydrofuran (30 ml) were added at 0.degree. C. 0.83 ml of
triethylamine and 0.57 ml of diethyl chlorophosphate. After
stirring for 30 minutes, 5 ml of an ammonia-methanol solution was
added and the resulting mixture was reacted at room temperature for
2 hours. Then the reaction mixture was poured into water, extracted
with ethyl acetate, washed with a saturated aqueous solution of
sodium chloride and dried over anhydrous magnesium sulfate. After
concentrating under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
methanol/dichloromethane) to thereby give 0.27 of the title
compound as a yellow oily substance. 1497
[3021] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3022] 2.22(s, 3H), 2.51(d, J=1 Hz, 3H), 3.43(s, 3H), 5.02(s, 2H),
5.16(s, 2H), 6.62(dd, J=2, 8 Hz, 1H), 6.78(d, J=2 Hz, 1H), 6.98(d,
J=8 Hz, 1H), 7.40-7.43(m, 1H), 7.57(s, 1H), 7.84(d, J=3 Hz, 1H),
7.86(d, J=3 Hz, 1H)
EXAMPLES
[3023] The following compounds were obtained by treating the
compounds obtained in Examples 1032, 1033 and 1034 by the same
method as the one of Example 8.
153 Ex. Structural formula MS M.p. NMR 1035
1498[1-[10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-5-
methylimidazol-4-yl]carboxamide ESI(+) 339 (MH.sup.+)
>298.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.33(s,
3H), 5.03(s, 2H), 6.47(s, 1H), 6.54(d, J=8Hz, 1H), 6.89(d, J=8Hz,
1H), 6.96(br.s, 1H), 7.13-7.25(m, 1H), 7.62(s, 2H), 7.68 (br.s,
1H), 9.50(s, 1H) 1036
1499[1-[10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4-
methyl-imidazol-5-yl]-carboxylic acid ESI(+) 340 (MH.sup.+)
235.degree. C. (decom- pose) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
2.37(s, 3H), 5.32(s, 2H), 6.49(s, 1H), 6.47-6.52(m, 1H), 6.86(d,
J=8Hz, 1H), 7.64(s, 2H), 7.97(s, 1H), 9.51(s, 1H) 1037
1500(E)-3-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl]-5-methylimidazol-4-yl]-2-methylpropenamide ESI(+) 379
(MH.sup.+) >280.degree. C. (decomp- pose)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.11(s, 3H), 2.28(s, 5.03(s,
2H), 6.49(s, 1H), 6.53(d, J=8Hz, 1H), 6.75-6.90(m, 1H), 6.88(d,
J=8Hz, 1H), 7.06(s, 1H), 7.35- # 7.40(m, 1H), 7.62(s, 2H), 7.74(s,
1H), 9.51(s, 1H)
EXAMPLE 1038
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8
-ylmethyl]-5-methylimidazol-4 -yl]carbaldehyde
[3024] 0.22 g of the title compound was obtained as yellow crystals
by treating 0.68 g of [1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-ylmethyl]-5-methylimidazol-4-yl]methanol with manganese
dioxide by the same method as the one of Example 173. 1501
[3025] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3026] 2.49(s, 3H), 3.45(s, 3H), 5.04(s, 2H), 5.18(s, 2H),
6.63-6.69(m, 1H), 6.80.(m, 1H), 7.01(d, J=8 Hz, 1H), 7.53(s, 1H),
7.85(d, J=3 Hz, 1H), 7.87(d, J=3 Hz, 1H), 9.98(s, 1H)
EXAMPLES
[3027] The following compounds were obtained by the same method as
the one of Production Example 25 by starting with
[1-[10-(methoxymethyl)-10H-pyra- zino
[2,3-b][1,4]benzothiazin-8-ylmethyl]-5-methylimidazol
-4-yl]carbaldehyde and various Wittig-Horner-Emmons reagents.
154 Ex. Structural formula NMR 1039 1502ethyl
(E)-3-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzo-
thiazin-8- ylmethyl]-5-methylimidazol-4-yl]-2-methylpropenoate
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.33(t, J=7Hz, 3H), 2, 21(s,
3H), 2.49(d, J=1Hz, 3H), 3.43(s, 3H), 4.25(q, J=7Hz, 2H), 5.03(s,
2H), 5.15(s, 2H), 6.61-6.50 (m, 1H), 6.72-6.76(m, 1H), 6.98(d,
J=8Hz, 1H), # 7.48(m, 1H), 7.59(s, 1H), 7.85(d, J=3Hz, 1H), 7.86(d,
J=3Hz, 1H) 1040 1503ethyl
(E)-2-[[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1-
,4]ylmethyl]-5-methylimidazol-4-yl] .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 0.87(t, J=7Hz, 3H), 1.57 (m, 2H), 2.20(s, 3H), 3.0-3.1(m, 2H),
3.42(s, 3H), 4.24(q, J=7Hz, 2H), 5.01(s, 2H), 5.15(s, 2H), 6.63
(dd, J=1, 8Hz, 1H), 6.74(d, J=1Hz, 1H), 6.98(d, J=8Hz, 1H), 7.42(s,
1H), 7.54(s, 1H), 7.84(d, # J=3Hz, 1H), 7.86(d, J=3Hz, 1H)
EXAMPLES
[3028] 1.2 g of
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazi-
n-8-ylmethyl]-4-methylimidazol -5-yl]carbaldehyde was obtained from
1.6 g of
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
]-4-methylimidazol-5-yl ]methanol by the same method as the one of
Example 173. Next, the obtained product was treated with various
Wittig-Horner-Emmons reagents similar to Production Example 25 to
thereby give the following compounds.
155 Ex. Structural formula NMR 1041 1504ethyl (E)-3-[1-[10-
(methoxymethyl)-10H- pyrazino[2,3-b][1,4]ben- zothiazin-8-
ylmethyl]-4- methylimidazol-5-yl]- 2 -methylpropenoate
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.17(t, J=7Hz, 3H), 1.74(s,
3H), 1.99(s, 3H), 3.29(s, 3H), 4.10(q, # J=7Hz, 2H), 5.08(s, 2H),
5.12(s, 2H), 6.69(dd, J=1, 8Hz, 1H), 6.78(d, J=8Hz, 1H), 7.21(s,
1H), 7.83(s, 1H), 7.92(d, J=3Hz, 1H), 7.95(d, J=3Hz, 1H) 1042
1505ethyl (E)-2-[1-[10- (methoxymethyl)-10H-
pyrazino[2,3-b][1,4]benzothi- azin-8- ylmethyl]-4-
methylimidazol-5-yl]methylene]butanoate .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 0.73(t, J=7Hz, 3H), 1.18(t, J=8Hz, 3H), 1.99(s, 3H),
2.13(q, # J=8Hz, 2H), 3.30(s, 3H), 4.12(q, J=8Hz, 2H), 5.07(s, 2H).
5.13(s. 2H), 6.68(d, J=8Hz, 1H), 6.80(s, 1H), 7.07(dd, J=1, 8Hz,
1H), 7.11(s, 1H), 7.83(s, 1H), 7.90 7.94(m, 1H), 7.94-7.98(m,
1H)
EXAMPLE 1043
(E)-2-Hydroxy-5-[1-[10-(methoxymethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-ylmethyl]-5-methylimidazol
-4-yl]-2-methyl-4-penten-3-one
[3029] 0.7 g of the title compound was obtained as a yellow oily
substance by reacting 0.5 g of
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzo-
thiazin-8-ylmethyl]-5-methylimidazol-4-yl]carbaldehyde with 2.1 m 1
of 3-hydroxy-3-methyl-2-butanone in the presence of lithium
hydroxide by the same method as the one of Example 1203. 1506
[3030] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3031] 1.45(s, 6H), 2.25(s, 3H), 3.43(s, 3H), 5.01(s, 2H), 5.17(s,
2H), 6.60-6.65(m, 1H), 6.80(s, 1H), 6.98(d, J=8 Hz, 1H), 7.15(d,
J=16 Hz, 1H), 7.55(s, 1H), 7.77(d, J=16 Hz, 1H), 7.80-7.88(m,
2H),
EXAMPLE 1044
2-Hydroxy-5-[1-[10-(methoxymethyl)-10H-pyrazino
[2,3-b][1,4]-benzothiazin-- 8-ylmethyl]-5-methylimidazol
-4-yl]-2-methyl-4-penten-3-one
[3032] The title compound was obtained by hydrogenating
(E)-2-hydroxy-5-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothia-
zin-8-ylmethyl]-5-methylimidazol-4-yl]-2-methyl -4-penten-3-one by
the same method as the one of Example 20. 1507
[3033] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3034] 1.33(s, 6H), 2.04(s, 3H), 2.86(t, J=7 Hz, 2H), 2.99(t, J=7
Hz, 2H), 3.45(s, 3H), 3.49(s, 1H), 4.94(s, 2H), 5.17(s, 2H),
6.60(dd, J=2, 8 Hz, 1H), 6.78(d, J=2 Hz, 1H), 6.97(d, J=8 Hz, 1H),
7.39(s, 1H), 7.84(d, J=3 Hz, 1H), 7.86(d, J=3 Hz, 1H)
EXAMPLE 1045
Ethyl
(E)-3-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-methyl)imidazol--
2-yl]propenoate
[3035] The title compound was obtained by treating
1-(10-methoxymethyl-10H-
-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-2-carbaldehyde
successively by the same methods as those described in Production
Example 25 and Example 9. 1508
[3036] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3037] 1.20(t, J=7 Hz, 3H), 4.11(q, J=7 Hz, 2H), 5.25(s, 2H),
6.50(d, J=1 Hz, 1H), 6.52(dd, J=1, 8 Hz, 1H), 6.56(d, J=16 Hz, 1H),
6.87(d, J=8 Hz, 1H), 7.12(s, 1H), 7.34(s, 1H), 7.47(d, J=16 Hz,
1H), 7.63(s, 2H), 9.55(s, 1H)
[3038] MS: ESI(+)402.1(MNa.sup.+)
[3039] m.p. : 213-215.degree. C.
EXAMPLES
[3040] The following compounds were obtained by the same treatments
as those of Examples 18 and 8.
156 Ex. Structural formula MS M.p. NMR 1046 1509(E)-3-[1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-5-
methylimidazol-4-yl]- 2-methyl-2-propenoic acid ESI (+) 380
(MH.sup.+) >290.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 2.12(5, 3H), 2.27(s, 3H), # 5.04(s, 2H), 6.48(s, 1H),
6.50-6.60(m, 1H), 6.88(d, J=8Hz, 1H), 7.32(s, 1H), 7.62(s, 2H),
7.79(s, 1H), 9.49(s, 1H) 1047 1510(E)-2-[[1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-4-
methylimidazol-5-yl]meth- ylene]butanoic acid ESI (+) 394
(MH.sup.+) >288.degree. C. (decom- pose)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: # 0.99(t, J=8Hz, 3H),
2.13(s, 3H), 2.90(q, J=8Hz, 2H), 5.04(s, 2H), 6.50(s, 1H), 6.57(d,
J=8Hz, 1H), 6.89(dd, J=2, 8Hz, 1H), 7.28(d, J=2Hz, 1H),
7.60-7.64(m, 2H), 7.79(d, J=2Hz, 1H), 9.50(s, 1H) 1048
1511(E)-5-methoxy-5- methyl-2-[[1-(10H
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-5-
methylimidazol-4-yl]methylene]hexanoic acid ESI (+) 466 (MH.sup.+)
202-204.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: # 2H),
2.13(s, 3H), 2.8-2.93(m, 2H), 3.12(s, 3H), 5.03(s, 2H), 6.51(d,
J=2Hz, 1H), 6.58(dd, J=2, 8Hz, 1H), 6.89(d, J=8Hz, 1H), 7.30(s,
1H), 7.62(s, 2H), 7.77(s, 1H), 9.50(s, 1H) 1049 1512(E)-2-[[1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-5-
methylimidazol-4-yl]meth- ylene]undecanoic acid ESI (+) 492
(MH.sup.+) 194-197.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 0.81(t, J=8Hz, 3H), # 1.18(br.s, 13H), 1.3-1.43(m, 2H),
2.13(s, 3H), 2.6-2.78(m, 2H), 5.13(s, 2H), 6.53(d, J=1Hz, 1H),
6.61(d, J= 8Hz, 1H), 6.89(d, J=8Hz, 1H), 7.26(s, 1H), 7.62(s, 2H),
8.2-8.5(m, 1H), 9.52(s, 1H) 1050 1513(E)-3-[1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-4-
methylimidazol-5-yl]- 2-methylpropenoic acid ESI (+) 380 (MH.sup.+)
>298.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.71(d,
J=1Hz, 3H), 1.99(s, 3H), 4.96(s, 2H), # 6.41(s, 1H), 6.38-6.46(m,
1H), 6.84(d, J=8Hz, 1H), 7.12(s, 1H), 7.61(s, 2H), 7.75(s, 1H),
9.51(s, 1H) 1051 1514(E)-2-[[1-(10H-
pyrazino[2,3-b][1,4]benzothiazin-8- ylmethyl)-4-
methylimidazol-5-yl]methylene]butanoic acid ESI (+) 394 (MH.sup.+)
172.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.20(m, 2H),
2.13(s, 3H), 0.78(t. J=8Hz, 3H). 2.00- # 5.15(s, 2H), 6.40-6.45(m,
1H), 6.55-6.63(m, 1H), 6.88(d, J=8Hz, 1H), 7.00(s, 1H), 7.63(s,
2H), 8.90(m, 1H), 9.49(s, 1H)
EXAMPLE 1052
(E)-3-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazo
-2-yl]propenoic acid
[3041] The title compound was obtained by treating ethyl
(E)-3-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-2-yl]p-
ropenoate by the same method as the one of Example 18. 1515
[3042] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3043] 5.26(s, 2H), 6.46(d, J=1 Hz, 1H), 6.50(dd, J=1, 8 Hz, 1H),
6.52(d, J=16 Hz, 1H), 6.88(d, J=8 Hz, 1H), 7.12(s, 1H), 7.37(d,
J=16 Hz, 1H), 7.39(s, 1H), 7.62(s, 2H), 9.52(s, 1H)
[3044] MS: ESI(+)352.2(MH.sup.+)
[3045] m.p. : 243-244.degree. C.
EXAMPLE 1053
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
imidazol-2-carboxylic acid
[3046] To a solution of 177 mg of 1-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)imidazol-2-carbaldehyde in a mixture of tetrahydrofuran
(10 ml) with ethanol (10 ml) were added 0.5 ml of an aqueous
solution of 0.24 g of silver nitrate and 1.5 N sodium hydroxide (4
ml) and the resulting mixture was stirred at room temperature for
15 hours. After filtering off the insoluble matters, the solution
was concentrated under reduced pressure and the crystals of
1-(10-methoxymethyl -10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)imidazol-2-carboxylic acid thus precipitated were taken
up by filtration. Next, the crystals were treated by the same
method as the one of Example 9 to thereby give 55 mg of the title
compound as orange crystals. 1516
[3047] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3048] 5.61(s, 2H), 6.56(d, J=8 Hz, 1H), 6.65(s, 1H), 6.78(s, 1H),
6.81(d, J=8 Hz, 1H), 7.05(s, 1H), 7.61(s, 2H), 9.55(s, 1H)
[3049] MS: ESI(+)281(M.sup.+-CO.sub.2)
[3050] m.p.: 219-220.degree. C.
EXAMPLE 1054
N-[2-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-imidazol
-4-yl]ethyl]methanesulfonamide
[3051] 0.5 g of 10-methoxymethyl-8-chloromethyl
-10H-pyrazino-[2,3-b][1,4]- benzothiazine and 1.0 g of
4-(2-aminoethyl)imidazole dihydorchloride were treated by the same
method as the one of Example 1094 to thereby give 0.7 g of crude
8-[4-(2-aminoethyl)imidazol -1-yl]-10-methoxymethyl-10H-pyrazi-
no[2,3-b][1,4]benzothiazine as a brown solid. This crude product
was then treated by the same method as the one of Example 316 to
thereby give 0.1 g of N-[2-[1-(10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-yl-
methyl)imidazol-4-yl]ethyl]methanesulfonamide. Further, it was
treated by the same method as the one of Example 8 to thereby give
50 mg of the title compound as yellow crystals. 1517
[3052] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3053] 2.80(t, J=6 Hz, 2H), 2.94(s, 3H), 3.44(q, J=6 Hz, 2H),
4.92(s, 2H), 5.40-5.50(m, 1H), 6.20(d, J=2 Hz, 1H), 6.64(dd, J=2, 8
Hz, 1H), 6.73(d, J=1 Hz, 1H), 6.86(d, J=8 Hz, 1H), 6.90-6.98(m,
1H), 7.44(d, J-1 Hz, 1H), 7.56(d, J=3 Hz, 1H), 7.68(d, J=3 Hz,
1H)
[3054] MS: ESI(+)403(MH.sup.+)
[3055] m.p.: 173-176.degree. C.
EXAMPLE 1055
N-[2-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmeth-
yl]imidazol-4-yl]ethyl]sulfamide
[3056] 0.25 g of the title compound was obtained as yellow crystals
by treating 1.0 g of 8-[4-(2-aminoethyl)imidazol
-1-yl]-10-(methoxymethyl)-1- 0H-pyrazino[2,3-b][1,4]-benzothiazine
and 0.23 g of sulfamide by the same method as the one of Example
326. 1518
[3057] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3058] 2.62(t, J=8 Hz, 2H), 3.02-3.10(m, 2H), 3.33(s, 3H), 5.06(s,
2H), 5.19(s, 2H), 6.50(s, 3H), 6.85(dd, J=1, 8 Hz, 1H), 6.92(s,
1H), 6.95(m, 1H), 7.10(d, J=8 Hz, 1H), 7.63(s, 1H), 7.92(d, J=3 Hz,
1H), 7.95(d, J=3 Hz, 1H)
EXAMPLE 1056
[3059]
N-[2-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-imidazol
-4-yl]ethyl]sulfamide
[3060] The title compound was obtained as yellow crystals by
treating N-[2-[1-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylme-
thyl]imidazol-4-yl]ethyl]sulfamide by the same method as the one of
Example 8. 1519
[3061] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3062] 2.58-2.65(m, 3H), 3.02-3.10(m, 2H), 4.95(s, 2H), 6.50(br.s,
3H), 6.58(d, J=2 Hz, 1H), 6.60-6.65(m, 1H), 6.85(s, 1H), 6.88(d,
J=8 Hz, 1H), 7.59(s, 1H), 7.63(s, 2H)
[3063] MS: ESI(+)404(MH.sup.+)
[3064] m.p. : 187-189.degree. C.
EXAMPLE 1057
8-[4-(4-Nitrophenyl)imidazol-1-ylmethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3065] The title compound was synthesized by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
and 4-(4-nitrophenyl)imidazole by the same method as the one of
Example 1094. 1520
[3066] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3067] 3.43(s, 3H), 5.09(s, 2H), 5.22(s, 2H), 6.81(dd, J=2, 8 Hz,
1H), 6.96(d, J=2 Hz, 1H), 7.03(d, J=8 Hz, 1H), 7.34(d, J=1 Hz, 1H),
7.65(d, J=1 Hz, 1H), 7.84(d, J=3 Hz, 1H), 7.87(d, J=3 Hz, 1H),
7.89(m, 2H), 8.22(m, 2H)
EXAMPLE 1058
8-[4-(4-Aminophenyl)imidazol-1-ylmethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3068] The title compound was obtained by hydrogenating
8-[4-(4-nitrophenyl)imidazol-1-ylmethyl]-10-methoxymethyl-10H-pyrazino[2,-
3-b][1,4]benzothiazine by the same method as the one of Example 20.
1521
[3069] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3070] 3.42(s, 3H), 3.67(br.s, 2H), 5.05(s, 2H), 5.18(s, 2H),
6.69(m, 2H), 6.78(dd, J=2, 8 Hz, 1H), 6.89(d, J=2 Hz, 1H), 6.99(d,
J=8 Hz, 1H), 7.04(d, J=2 Hz, 1H), 7.54(d, J=2 Hz, 1H), 7.55(m, 2H),
7.83(d, J=3 Hz, 1H), 7.85(d, J=3 Hz, 1H)
EXAMPLES
[3071] The following compounds were obtained by treating
8-[4-(4-aminophenyl)imidazol-1-ylmethyl]-10-methoxymethyl-10H-pyrazino[2,-
3-b][1,4]benzothiazine by the same method as the one of Example
316.
157 Ex. Structural formula NMR 1059 1522N-[4-[1-(10-
methoxymethyl-10H- pyrazino[2,3-b][1,4]benzothiazin- -8-
ylmethyl)imidazol-4- yl]phenyl]methanesulfonamide
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.99(s, 3H), 3.43(s, 3H),
5.08(s, 2H), 5.20(s, 2H), 6.51(br.s, 1H), 6.79 (dd, J=2, 8Hz, 1H),
# 6.93(d, J=2Hz, 1H), 7.01(d, J=8Hz, 1H), 7.16(d, J=1Hz, 1H),
7.21(d, J=8Hz, 2H), 7.61(d, J=1Hz, 1H), 7.73(d, J=8Hz, 2H), 7.84(d,
J=3Hz, 1H), 7.86(d, J=3Hz, 1H) 1060 1523N-[4-[1-(10-
methoxymethyl-10H- pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-4- yl]phenyl]acetamide .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.18(s, 3H), 3.42(s, 3H), 5.07(s, 2H), 5.19(s, 2H),
6.80(dd, J=2, 8Hz, 1H), 6.92(d, J=2Hz, 1H), 7.02(d, # J=8Hz, 1H),
7.04(m, 2H), 7.19(d, J=1Hz, 1H), 7.62(d, J=1Hz, 1H), 7.76(m, 2H),
7.83-7.85(m, 2H)
EXAMPLE 1061
.sup.1N-[4-[1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl-
methyl)imidazol-4-yl]phenyl]-N.sup.2-methanesulfonyl-formamidine
[3072] The title compound was obtained by treating
8-[4-(4-aminophenyl)imi- dazol-1-ylmethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the
one of Example 328.. 1524
[3073] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3074] 3.03 and 3.05(s, total 3H), 3.43(s, 3H), 5.07(s, 2H),
5.20(s, 2H), 6.80(dd, J=2, 8 Hz, 1H), 6.84(d, J=2 Hz, 1H), 7.01(d,
J=8 Hz, 1H), 7.11 and 7.65(d, J=8 Hz, total2H), 7.18(d, J=1 Hz,
1H), 7.61(d, J=1 Hz, 1H), 7.75 and 7.77(d, J=8 Hz, total 2H),
7.84(d, J=3 Hz, 1H), 7.86(d, J=3 Hz, 1H), 7.98 and 8.01(.s, total
1H), 8.67 and 8.71(s, total 1H)
EXAMPLES
[3075] The following compounds were obtained by treating the
compounds obtained in Examples 1059, 1060 and 1061 by the same
method as the one of Example 9.
158 Ex. Structural formula MS M.p. NMR 1062
1525N-[4-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-4- yl]phenyl]methanesulfonamide ESI (+) 451.1
(MH.sup.+) 253-255.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 2.97(s, 3H), 5.05(s, 2H), 6.62(d, J=1Hz, 1H), # 6.90(d, J=7Hz,
1H), 7.16(d, J=8Hz, 2H), 7.53(d, J=1Hz, 1H), 7.63(s, 2H), 7.68(d,
J=8Hz, 2H), 7.74(d, J=1Hz, 1H), 9.53(s, 1H), 9.65(s, 1H) 1063
1526N-[4-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-4- yl]phenyl]acetamide FAB (+) 415 (M.sup.+)
261-263.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.02(s,
3H), 5.04(s, 2H), 6.62(d, J=1Hz, 1H), 6.68(dd, J=1, 7Hz, 1H), #
6.90(d, J=7Hz, 1H), 7.49(s, 1H), 7.53(d, J=8Hz, 2H), 7.63(s, 2H),
7.64(d, J=8Hz, 2H), 7.74(s, 1H), 9.53(s, 1H), 9.79(s, 1H) 1064
1527.sup.1N-[4-[1-(10H- pyrazino[2,3-b][1,4]- benzothiazin-8-
ylmethyl)imidazol-4- yl]phenyl]-N.sup.2- methanesulfonyl-
formamidine FAB (+) 478 (M.sup.+) 159-162.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.30(s, 3H), 5.06(s, 2H), #
6.61(d, J=1Hz, 1H), 6.69(dd, J=1, 7Hz, 1H), 6.91(d, J=7Hz, 1H),
7.24(d, J=8Hz, 1H), 7.57(s, 1H), 7.62(s, 2H), 7.65(d, J=8Hz, 2H),
7.74(d, J=8Hz, 2H), 7.75(d, J=8Hz, 1H), 8.08(s, 1H), 9.52(s,
1H)
EXAMPLE 1065
N-[4-[1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-
imidazol-4-yl]phenyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanami-
de
[3076] 104 mg of
8-[4-(4-aminophenyl)imidazol-1-ylmethyl]-10-methoxymethyl-
-10H-pyrazino[2,3-b][1,4]benzothiazine and 91 mg of
hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanoic acid were
treated by the same method as the one of Example 1294. Then the
obtained product was purified by using a preparative silica gel
plate to thereby give 72 mg of the title compound as yellow
crystals. 1528
[3077] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3078] 1.4-1.6(m, 6H), 2.28(t, J=6 Hz, 2H), 2.56(d, J=7 Hz, 1H),
2.80(dd, J=3, 7 Hz,, 1H), 3.10(m, 1H), 3.30(s, 3H), 4.12(m, 1H),
4.28(m, 1H), 5.15(s, 2H), 5.20(s, 2H), 6.35(s, 1H), 6.43(s, 1H),
6.91(dd, J=2, 8 Hz, 1H), 7.00(d, J=2 Hz, 1H), 7.12(d, J=8 Hz, 1H),
7.54(d, J=8 Hz, 2H), 7.55(d, J=1 Hz, 1H), 7.63(d, J=8 Hz, 2H),
7.77(d, J=1 Hz, 1H), 7.92(d, J=3 Hz, 1H), 7.98(d, J=3 Hz, 1H),
9.84(s, 1H)
EXAMPLE 1066
N-[4-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol
-4-yl]phenyl]-hexahydro-2-oxo-1H-thieno[3,4-d]-imidazole-4-pentanamide
[3079] The title compound was obtained by treating
N-[4-[1-(10-methoxymeth-
yl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-4-yl]phenyl]-h-
exahydro -2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide by the same
method as the one of Example 9. 1529
[3080] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3081] 1.4-1.6(m, 6H), 2.28(t, J=6 Hz, 2H), 2.46(d, J=7 Hz, 1H),
2.80(dd, J=3, 7 Hz, 1H), 3.10(m, 1H), 4.09(m, 1H), 4.28(m, 1H),
5.15(s, 2H), 6.35(s, 1H), 6.43(s, 1H), 6.91(dd, J=1, 6 Hz, 1H),
7.00(d, J=1 Hz, 1H), 7.12(d, J=6 Hz, 1H), 7.54(d, J=5 Hz, 2H),
7.54(s, 1H), 7.63(d, J=5 Hz, 2H), 7.77(d, J=1 Hz, 1H), 7.92(d, J=2
Hz, 1H), 7.95(d, J=2 Hz, 1H), 9.53(s, 1H), 9.85(s, 1H)
[3082] MS: FAB(+)599(M.sup.+)
EXAMPLE 1067
N-[2-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethy-
l)imidazol-4-yl]ethyl]-5-methyl-1,2-oxazole-4-carboxamide
[3083] 0.5 g of the title compound was obtained as a yellow oily
substance by dehydrating/condensing 1.5 g of
8-[4-(4-aminoethyl)imidazol-1-ylmethyl-
]-10H-pyrazino[2,3-b][1,4]benzothiazine with 1.5 g of
5-methyl-1,2-oxazole-4-carboxylic acid by the same method as the
one of Example 1294. 1530
[3084] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3085] 2.58(s, 3H), 2.64(t, J=6 Hz, 2H), 3.32(s, 3H), 3.34-3.42(m,
2H), 5.07(s, 2H), 5.19(s, 2H), 6.80-6.86(m, 1H), 6.90-6.96(m, 2H),
7.07(d, J=8 Hz, 1H), 7.62-7.66(m, 1H), 7.92(d, J=3 Hz, 1H), 7.95(d,
J=3 Hz, 1H), 8.33(t, J=6 Hz, 1H), 8.80(s, 1H)
EXAMPLE 1068
N-[2-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol
-4-yl]ethyl]-5-methyl-1,2-oxazole -4-carboxamide
[3086] The title compound was obtained by treating
N-[2-[1-[10-(methoxymet-
hyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-4-yl]ethyl]--
5-methyl-1,2-oxazole-4-carboxamide by the same method as the one of
Example 8. 1531
[3087] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3088] 2.59(s, 3H), 2.64(t, J=8 Hz, 2H), 3.3-3.45(m, 2H), 4.95(s,
2H), 6.56(m, 1H), 6.6-6.65(m, 1H), 6.85(d, J=8 Hz, 1H), 6.88(br.s,
1H), 7.63(s, 3H), 8.33(t, J=6 Hz, 1H), 8.90(s, 1H), 9.51(s, 1H)
[3089] MS: ESI(+)434(MH.sup.+)
[3090] m.p. : 165-167.degree. C.
EXAMPLE 1069
N-[2-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmeth-
yl]imidazol-4-yl]phenyl]-5-methyl-1,2-oxazole-4-carboxamide
[3091] The title compound was obtained as a yellow oily substance
by dehydrating/condensing 1.5 g of
8-[4-(4-aminophenyl)imidazol-1-ylmethyl]--
10H-pyrazino[2,3-b][1,4]benzothiazine with 5-methyl
-1,2-oxazole-4-carboxylic acid by the same method as the one of
Example 1294. 1532
[3092] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3093] 2.77(s, 3H), 3.43(s, 3H), 5.07(s, 2H), 5.19(s, 2H), 6.80(dd,
J=2, 8 Hz, 1H), 6.93(d, J=2 Hz, 1H), 7.01(d, J=8 Hz, 1H), 7.17(d,
J=1 Hz, 1H), 7.49(br.s, 1H), 7.56(br.d, J=8 Hz, 2H), 7.59(d, J=1
Hz, 1H), 7.75(d, J=8 Hz, 2H), 7.84(d, J=3 Hz, 1H), 7.86(d, J=3 Hz,
1H), 8.46(br.s, 1H)
EXAMPLE 1070
N-[2-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-imidazol
-4-yl]phenyl]-2-cyano-3-oxobutanamide
[3094] The title compound was obtained by treating
N-[2-[1-[10-(methoxymet-
hyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmethyl]imidazol-4-yl]phenyl-
]-5-methyl-1,2-oxazole-4-carboxamide successively by the same
methods as those of Examples 9 and 505. 1533
[3095] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3096] 2.66(s, 3H), 5.05(s, 2H), 6.62(d, J=1 Hz, 1H), 6.70(d, J=1,
7 Hz, 1H), 6.91(d, J=7 Hz, 1H), 7.54(d, J=1 Hz, 1H), 7.62(s, 2H),
7.64(d, J=8 Hz, 2H), 7.72(d, J=8 Hz, 2H), 7.75(d, J=1 Hz, 1H),
9.05(s, 1H), 9.52(s, 1H), 10.00(s, 1H)
[3097] MS: FAB(+)482(M.sup.+)
[3098] m.p. : 259-261.degree. C.
EXAMPLE 1071
[1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imida-
zol-2-yl]-(2-pyridyl) methanol
[3099] The title compound was obtained by treating
[1-(10-methoxymethyl-10-
H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-2-yl](2-pyridyl)
ketone by the same method as the one of Example 628. 1534
[3100] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3101] 3.43(s, 3H), 5.12(s, 4H), 5.40(br.s, 1H), 6.00(s, 1H),
6.64(dd, J=2, 8 Hz, 1H), 6.67(d, J=2 Hz, 1H), 6.85(d, J=8 Hz, 1H),
6.85(d, J=1 Hz, 1H), 7.04(d, J=1 Hz, 1H), 7.13(ddd, J=2, 5, 8 Hz,
1H), 7.23-7.25(m, 1H), 7.59(dt, J=2, 8 Hz, 1H), 7.84(d, J=3 Hz,
1H), 7.85(d, J=3 Hz, 1H), 8.45(ddd, J=1, 2, 5 Hz, 1H)
EXAMPLE 1072
[1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imida-
zol-2-yl]methanol
[3102] The title compound was obtained by treating
1-(10-methoxymethyl-10H-
-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazole-2-carbaldehyde
by the same method as the one of Example 628. 1535
[3103] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3104] 1.80(br.s, 1H), 3.48(s, 3H), 4.66(s, 2H), 5.14(s, 2H),
5.19(s, 2H), 6.73(dd, J=2, 8 Hz, 1H), 6.88(d, J=2 Hz, 1H), 6.89(s,
1H), 6.98(d, J=8 Hz, 1H), 6.99(s, 1H), 7.83(d, J=3 Hz, 1H), 7.85(d,
J=3 Hz, 1H)
EXAMPLE 1073
Methyl
4-[[1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylme-
thyl)imidazol-2-yl]hydroxymethyl]benzoate
[3105] The title compound was obtained by treating methyl
4-[1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)im-
idazol-2-ylcarbonyl]benzoate by the same method as the one of
Example 628. 1536
[3106] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3107] 3.43(s, 3H), 3.87(s, 3H), 4.80(d, J=16 Hz, 1H), 4.91(d, J=16
Hz, 1H), 5.09(d, J=10 Hz, 1H), 5.13(d, J=10 Hz, 1H), 5.90(s, 1H),
6.48(dd, J=2, 8 Hz, 1H), 6.61(d, J=2 Hz, 1H), 6.86(d, J=8 Hz, 1H),
6.87(d, J=1 Hz, 1H), 7.06(d, J=1 Hz, 1H), 7.36(d, J=8 Hz, 2H),
7.83(d, J=3 Hz, 1H), 7.85(d, J=3 Hz, 1H), 7.94(d, J=8 Hz, 2H)
EXAMPLE 1074
4-[[1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)im-
idazol-2-yl]hydroxymethyl]benzoic acid
[3108] The title compound was obtained by treating methyl
4-[[1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)i-
midazol-2-yl]hydroxymethyl]benzoate by the same method as the one
of Example 18. 1537
[3109] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3110] 3.48(s, 3H), 4.95(d, J=16 Hz, 1H), 5.04(d, J=16 Hz, 1H),
5.13(d, J=10 Hz, 1H), 5.17(d, J=10 Hz, 1H), 5.98(s, 1H), 6.58(dd,
J=2, 8 Hz, 1H), 6.72(s, 1H), 6.89-6.91(m, 2H), 7.13(s, 1H), 7.36(d,
J=8 Hz, 2H), 7.83(s, 2H), 7.89(d, J=8 Hz, 2H)
EXAMPLES
[3111] The following compounds were obtained by treating the
compounds obtained in Examples 1071, 1072 and 1074 by the same
method as the one of Example 9.
159 Ex. Structural formula MS M.p. NMR 1075
1538[1-(10H-pyrazino[2,3-b][1,4)benzothiazin-8-yl-
methyl)imidazol-2-yl]-(2-pyridyl)methanol FAB (+) 389 (MH.sup.+)
95-98.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.09(s,
2H), 5.78(d, J=6Hz, 1H), 6.26(d, J=6Hz, 1H), 6.46(dd, J=1, 8Hz,
1H), # 6.54(d, J=1Hz, 1H), 6.78(s, 1H), 6.82(d, J=8Hz, 1H), 7.04(s,
1H), 7.22(dd, J=6, 9Hz, 1H), 7.57(d, J=9Hz, 1H), 7.63(s, 2H),
7.75(dt, J=2, 9Hz, 1H), 8.48(dd, J=2, 6Hz, 1H), 9.51(s, 1H) 1076
1539[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-2-yl]me- thanol ESI (+) 312.2 (MH.sup.+)
247-250.degree. C. .sup.1H-NMR(DMSO-d.sub.- 6) .delta. ppm: 4.41(d,
J=6Hz, 2H), 5.06(s, 2H), 5.31(t, J=6Hz, 1H), 6.57(d, J=9Hz, 1H),
6.58(s, # 1H), 6.80(s, 1H), 6.87(d, J=9Hz, 1H), 7.07(s, 1H),
7.63(s, 2H), 9.51(s, 1H) 1077
15404-[[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)imidazol-2-yl]hydroxymethyl]benzoic acid FAB (+) 432
(MH.sup.+) 240-241.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 4.98(d, J=15Hz, 1H), 5.05(d, J=15Hz, 1H), # J=6Hz, 1H),
6.44(d, J=8Hz, 1H), 6.45(s, 1H), 6.78(d, J=8Hz. 1H), 6.84(s, 1H),
7.05(s, 1H), 7.35(d, J=9Hz, 2H), 7.63(s, 2H), 7.81(d, 2H, J=9Hz,
2H), 9.45(s, 1H)
EXAMPLE 1078
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-5--
methylimidazol-4-yl]methanol
[3112] The title compound was obtained by treating ethyl
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-5-
-methylimidazol-4-yl]carboxylate by the same method as the one of
Example 3. 1541
[3113] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3114] 2.13(s, 3H), 3.46(s, 3H), 4.58(s, 2H), 4.98(s, 2H), 5.18(s,
2H), 6.64(dd, J=2, 8 Hz, 1H), 6.77(d, J=2 Hz, 1H), 6.98(d, J=8 Hz,
1H), 7.45-7.51(m, 1H), 7.84(d, J=3 Hz, 1H), 7.86(d, J=3 Hz, 1H)
EXAMPLE 1079
[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4--
methylimidazol-5-yl]methanol
[3115] The title compound was obtained by treating ethyl
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4-
-methylimidazol-5-yl]carboxylate by the same method as the one of
Example 3. 1542
[3116] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3117] 2.25(s, 3H), 3.46(s, 3H), 4.51(s, 2H), 5.14(s, 2H), 5.19(s,
2H), 6.70-6.76(m, 1H), 6.84-6.87(m, 1H), 6.98-7.00(m, 2H), 7.84(d,
J=3 Hz, 1H), 7.86(d, J=3 Hz, 1H)
EXAMPLES
[3118] The following compounds were obtained by treating the
compounds obtained in Examples 1078 and 1079 by the same method as
the one of Example 434.
160 Ex. Structural formula MS M.p. NMR 1080
1543[1-(10H-pyrazino[2,3- b][1,4]benzothiazin-8- ylmethyl)-5-
methylimidazol-4-yl]methanol ESI (+) 326 (MH.sup.+) >270.degree.
C. (decom- pose) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.04(s,
3H), 4.28(s, 2H), 4.60(s, 1H), 4.96(s, 2H), 6.54(d, # J=8Hz, 1H),
6.55(s, 1H), 6.89(d, J=8Hz, 1H), 7.55(s, 1H), 7.64(s, 2H), 9.54(s,
1H) 1081 1544[1-(10H-pyrazino[2,3- b][1,4]benzothiazin-8-
ylmethyl)-4- methylimidazol-5-yl]methanol ESI (+) 326 (MH.sup.+)
188-192.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.08(s,
3H), 4.25(d, J=5Hz, 2H), 4.91(t, J=5Hz, 1H), 5.02(s, 2H), #
6.50-6.60(m, 2H), 6.88(d, J=8Hz, 1H), 7.53(s, 1H), 7.64(s, 2H),
9.57(s, 1H)
EXAMPLE 1082
2-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
5-methylimidazol-4-yl]-2-propanol
[3119] 0.49 g of the title compound was obtained as a yellow oily
substance by treating 0.7 g of ethyl
[1-[10-(methoxymethyl)-10H-pyrazino[-
2,3-b][1,4]benzothiazin-8-ylmethyl]-5-methylimidazol-4-yl]carboxylate
with methylmagnesium bromide by the same method as the one of
Production Example 86. 1545
[3120] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3121] 1.58(s, 6H), 2.21(s, 3H), 3.46(s, 3H), 4.97(s, 2H), 5.17(s,
2H), 6.64(d, J=8 Hz, 1H), 6.75(d, J=1 Hz, 1H), 6.98(dd, J=1, 8 Hz,
1H), 7.40(s, 1H), 7.84(dd, J=1, 3 Hz, 1H), 7.85(dd, J=1, 3 Hz,
1H)
EXAMPLE 1083
2-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
,4-methylimidazol-5-yl]-2-propanol and
[1-[10-(methoxymethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-ylmethyl]-4-methylimidazol -5-yl]methyl
ketone
[3122] 0.7 g of ethyl
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzo-
thiazin-8-ylmethyl]-4-methylimidazol -5-yl]-carboxylate was treated
with methylmagnesium bromide by the same method as the one of
Production Example 86. Thus, 0.4 g of
2-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1-
,4]benzothiazin-8-ylmethyl]-4-methylimidazol-5-yl]-2-propanol and
80 mg of
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4-
-methylimidazol -5-yl]methyl ketone were obtained each as yellow
crystals.
2-[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
4-methylimidazol-5-yl]-2-propanol
[3123] 1546
[3124] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3125] 1.59(s, 6H), 2.34(s, 3H), 3.48(s, 3H), 5.15(s, 2H), 5.39(s,
2H), 6.64(dd, J=2, 8 Hz, 1H), 6.69(d, J=2 Hz, 1H), 6.95(d, J=8 Hz,
1H), 7.30(s, 1H), 7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H)
[1-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4--
methylimidazol-5-yl]methyl ketone
[3126] 1547
[3127] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3128] 2.40(s, 3H), 2.48(s, 3H), 3.33(s, 3H), 5.13(s, 2H), 5.42(s,
2H), 6.73(dd, J=2, 8 Hz, 1H), 6.82(d, J=2 Hz, 1H), 7.06(d, J=8 Hz,
1H), 7.93(d, J=3 Hz, 1H), 7.97(d, J=3 Hz, 1H), 7.98(s, 1H)
EXAMPLE 1084
1-[1-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]--
4-methylimidazol-5-yl]ethanol
[3129] The title compound was obtained by treating
[1-[10-(methoxymethyl)--
10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl]-4-methylimidazol-5-yl]met-
hyl ketone by the same method as the one of Example 628. 1548
[3130] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3131] 1.46(d, J=7 Hz, 3H), 2.30(s, 3H), 3.44(s, 3H), 4.94(q, J=7
Hz, 1H), 5.1-5.25(m, 4H), 6.68-6.74(m, 1H), 6.72(s, 1H), 6.98(d,
J=8 Hz, 1H), 7.40(s, 1H), 7.82(d, J=3 Hz, 1H), 7.85(d, J=3 Hz,
1H)
EXAMPLES
[3132] The following compounds were obtained by treating the
compounds obtained in Examples 1082, 1083 and 1084 by the same
method as the one of Example 8.
161 Ex. Structural formula MS M.p. NMR 1085 15492-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-5- methylimidazol-4-yl]-
2-propanol ESI (+) 354 (MH.sup.+) 264-266.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.60(s, 1H), 4.93(s, 2H), #
6.54(d, J=7Hz, 1H), 6.57(s, 1H), 6.89(d, J=8Hz, 1H), 7.49(s, 1H),
7.65(s, 2H), 9.55(s, 1H) 1086 15502-[1-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8- ylmethyl)-4- methylimidazol-5-yl]-
2-propanol ESI (+) 354 (MH.sup.+) 199-202.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.41(s, 6H), 2.20(s, 3H), #
5.12(s, 1H), 5.30(s, 2H), 6.46(dd, J=2, 8Hz, 1H), 6.53(d, J=2Hz,
1H), 6.87(d, J=8Hz, 1H), 7.38(s, 1H), 7.64(s, 2H), 9.52(s, 1H) 1087
15511-[1-(10H-pyrazino [2,3-b][1,4]benzothiazin-8- ylmethyl)-4-
methylimidazol-5-yl]ethanol ESI (+) 340 (MH.sup.+) 178-182.degree.
C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.23(d, J=7Hz, 3H),
2.15(s, # 3H), 4.75(br.s, 1H), 5.00-2H), 6.84-6.92(m, 1H), 7.50(m,
1H), 7.64(s, 2H), 9.52(s, 1H)
EXAMPLE 1088
(E)-8-(3-Chloro-1-propen-1-yl)-10-methoxymethyl
-10H-pyrazino-[2,3-b][1,4]- benzothiazine
[3133] 2.9 g of ethyl (E)-3-[10-(methoxymethyl)
-10H-pyrazino-[2,3-b][1,4]- benzothiazin-8-ylmethyl]propenoate was
dissolved in 20 ml of dry dichloromethane in a nitrogen atmosphere
and ice-cooled. The reaction mixture was stirred and 5.8 ml of a
1.5 M solution of isobutylalminum hydride in toluene was dropped
thereinto. After stirring for 2 hours, the reaction mixture was
poured into ice-ethyl acetate and stirred for 30 minutes. The
insoluble matters were removed by filtering the reaction mixture
thorough celite. Then the organic layer was extracted, washed with
water and dried over anhydrous sodium sulfate. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 1.4 g of
3-[10-(methoxymethyl)-10H-pyrazino-[2,3-b][1,4]benzothiazin-
-8-ylmethyl]-2-propen-1-ol as a pale yellow oily substance. The
obtained compound was dissolved in 10 ml of hexachloroacetone and
1.34 g of triphenylphosphine was added in several portions thereto
under ice-cooling. After stirring at room temperature for 30
minutes, the reaction mixture was distributed into an aqueous
solution of sodium bicarbonate and diethyl ether and extracted with
ether. After drying over anhydrous sodium sulfate and distilling
off the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with ethyl
acetate/n-hexane) to thereby give 230 mg of the title compound as
yellow crystals. 1552
[3134] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3135] 3.53(s, 3H), 4.23(d, J=7.1 Hz, 2H), 5.27(s, 2H), 6.28(dt,
J=7.1, 15.6 Hz, 1H), 6.57(d, J=15.6 Hz, 1H), 6.95(d, J=8.1 Hz, 1H),
7.00(dd, J=1.7, 8.1 Hz, 1H), 7.15(d, J=1.7 Hz, 1H), 7.83(d, J=3.0
Hz, 1H), 7.84(d, J=3.0 Hz, 1H)
EXAMPLE 1089
(E)-8-[3-(1-Imidazolyl)-1-propen-1-yl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3136] 150 mg of the title compound was obtained as yellow crystals
by treating 200 mg of (E)-8-(3-chloro
-1-propen-1-yl)-10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazine with imidazole by the same method
as the one of Example 1094. 1553
[3137] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3138] 3.54(s, 3H), 4.72(d, J=6.1 Hz, 2H), 5.28(s, 2H), 6.25(dt,
J=6.1, 15.9 Hz, 1H), 6.43(d, J=15.9 Hz, 1H), 6.95(d, J=8.0 Hz, 1H),
6.97(s, 1H), 6.98(dd, J=1.6, 8.0 Hz, 1H), 7.11(s, 1H), 7.13(d,
J=1.6 Hz, 1H), 7.56(s, 1H), 7.83(d, J=2.6 Hz, 1H), 7.84(d, J=2.6
Hz, 1H)
EXAMPLE 1090
(E)-8-[3-(1-Imidazolyl)-1-propen-1-yl]-10H-pyrazino[2,3-b][1,4]benzothiazi-
ne
[3139] The following compound was obtained by treating
(E)-8-[3-imidazolyl)-1-propen-1-yl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the
one of Example 434. 1554
[3140] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3141] 4.73(d, J=5.3 Hz, 2H), 6.26(td, J=5.3, 15.8 Hz, 1H), 6.30(d,
J=15.8 Hz, 1H), 6.75(s, 1H), 6.85(d, J=7.8 Hz, 1H), 6.87(d, J=7.8
Hz, 1H), 6.91(s, 1H), 7.16(s, 1H), 7.61-7.63(m, 2H), 7.65(s, 1H),
9.45(s, 1H)
EXAMPLE 1091
8-[3-(1-Imidazolyl)-1-propyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
[3142] Similar to Example 1094, 3-[10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl]propyl methanesulfonate
was reacted with imidazole and then treated by the same method as
the one of Example 434 to thereby give the following compound.
1555
[3143] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3144] 2.06(quintet, J=7.0 Hz, 2H), 2.44(t, J=7.0 Hz, 2H), 3.93(t,
J=7.0 Hz, 2H), 6.30(d, J=1.8 Hz, 1H), 6.63(dd, J=1.8, 8.0 Hz, 1H),
6.82(d, J=8.0 Hz, 1H), 6.86-6.93(br.s, 1H), 6.91(s, 1H), 7.09(s,
1H), 7.50(s, 1H), 7.55(d, J=2.9 Hz, 1H), 7.69(d, J=2.9 Hz, 1H)
[3145] MS: ESI(+)310.2(MH.sup.+)
[3146] m.p.: 139-141.degree. C.
EXAMPLE 1092
8-(Imidazol-1-yl)-10H-pyrazino[2,3-b][1,4]benzoxazine
[3147] The following compound was obtained by reacting
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzoxazine
with imidazole and then treating by the same method as the one of
Example 8. 1556
[3148] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3149] 5.04(s, 2H), 6.46(d, J=2 Hz, 1H), 6.59(dd, J=2, 8 Hz, 1H),
6.75(d, J=8 Hz, 1H), 6.87-6.98(m, 1H), 7.10-7.20(m, 1H), 7.27(d,
J=3 Hz, 1H), 7.47(d, J=3 Hz, 1H), 7.65-7.78(m, 1H), 9.66(s, 1H)
[3150] MS: ESI(+)266(MH.sup.+)
[3151] m.p.: 252-255.degree. C.
EXAMPLE 1093
4-[1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol
-4-yl]benzamidine
[3152] 0.092 g of the title compound was obtained by treating 0.44
g of
4-[1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)imidazol-4-yl]benzo-
nitrile by the same method as the one of Example 1479. 1557
[3153] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3154] 5.10(s, 2H), 6.64(d, J=1 Hz, 1H), 6.72(dd, J=1, 7 Hz, 1H),
6.93(d, J=7 Hz, 1H), 7.60(d, J=8 Hz, 2H), 7.64(s, 2H), 7.87(s, 2H),
7.96(d, J=8 Hz, 2H), 9.51(s, 1H)
[3155] MS: FAB(+)399(M.sup.+)
EXAMPLE 1094
10-Methoxymethyl-8-(pyrazol-1-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiaz-
ine
[3156] To a solution of 100 mg of pyrazole in N,N-dimethylformamide
was added in a nitrogen atmosphere 60 mg of sodium hydride (oily
60%) under ice cooling and the resulting mixture was stirred for 10
minutes. Subsequently, 240 mg of
10-methoxymethyl-8-chloromethyl-10H-pyrazino[2,3--
b][1,4]benzothiazine was added to the reaction mixture, which was
then heated to 80.degree. C. for 10 minutes. Then the reaction
mixture was brought back to room temperature and distributed into
water and ethyl acetate. The organic layer was extracted, washed
with water and dried over anhydrous sodium sulfate. After
distilling off the solvent under reduced pressure, the residue thus
obtained was purified by silica gel column chromatography (eluted
with ethyl acetate/n-hexane) to thereby give 150 mg of the title
compound as a yellow powder. 1558
[3157] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3158] 3.47(s, 3H), 5.20(s, 2H), 5.27(s, 2H), 6.30(t, J=2.1 Hz,
1H), 6.79(dd, J=1.6, 7.8 Hz, 1H), 6.82(d, J=1.6 Hz, 1H), 6.97(d,
J=7.8 Hz, 1H), 7.42(d, J=2.1 Hz, 1H), 7.56(d, J=2.1 Hz, 1H),
7.83(d, J=2.9 Hz, 1H), 7.84(d, J=2.9 Hz, 1H)
EXAMPLE 1095
10-Methoxymethyl-8-(1H-tetrazol-1-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzot-
hiazine and 10-methoxymethyl
-8-(2H-tetrazol-2-ylmethyl)-10H-pyrazino[2,3--
b][1,4]benzothiazine
[3159] The title compounds were obtained by treating 1H-tetrazole
and 10-methoxymethyl-8-chloromethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the
one of Example 1094. 10-methoxymethyl-8-(1H-tetraz-
ol-1-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine: 1559
[3160] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3161] 3.51(s, 3H), 5.33(s, 2H), 5.53(s, 2H), 6.88(dd, J=1.5, 8.1
Hz, 1H), 7.04(d, J=8.1 Hz, 1H), 7.07(d, J=1.5 Hz, 1H), 7.85(d,
J=2.7 Hz, 1H), 7.88(d, J=2.7 Hz, 1H), 8.56(s, 1H)
10-methoxymethyl-8-(2H-tetrazol-2-ylme-
thyl)-10H-pyrazino[2,3-b][1,4]benzothiazine: 1560
[3162] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3163] 3.52(s, 3H), 5.23(s, 2H), 5.73(s, 2H), 6.97(dd, J=1.6, 7.8
Hz, 1H), 7.01(d, J=7.8 Hz, 1H), 7.15(d, J=1.6 Hz, 1H), 7.84(d,
J=3.0 Hz, 1H), 7.86(d, J=3.0 Hz, 1H), 8.53(s, 1H)
EXAMPLE 1096
10-Methoxymethyl-8-[1H-pyrrolo[2,3-b]pyridin-1-ylmethyl]-10H-pyrazino[2,3--
b][1,4]benzothiazine and
10-methoxymethyl-8-[1H-pyrrolo[2,3-b]pyridin-3-yl-
methyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
[3164] The title compounds were obtained by reacting
1H-pyrrolo[2,3-b]pyridine with 10-methoxymethyl
-8-chloromethyl-10H-pyraz- ino[2,3-b][1,4]benzothiazine by the same
method as the one of Example 1094.
10-methoxymethyl-8-[1H-pyrrolo[2,3-b]pyridin-1-ylmethyl]-10H-pyrazino[2,3--
b][1,4]benzothiazine
[3165] 1561
[3166] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3167] 3.31(s, 3H), 5.09(s, 2H), 5.44(s, 2H), 6.50(d, J=4 Hz, 1H),
6.78(dd, J=2, 8 Hz, 1H), 6.91(d, J=2 Hz, 1H), 6.93(d, J=8 Hz, 1H),
7.09(dd, J=5, 8 Hz, 1H), 7.20(d, J=4 Hz, 1H), 7.81(d, J=3 Hz, 1H),
7.82(d, J=3 Hz, 1H), 7.93(dd, J=1, 8 Hz, 1H), 8.34(dd, J=1, 5 Hz,
1H)
10-methoxymethyl-8-[1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-10H-pyrazino[2,3--
b][1,4]benzothiazine
[3168] 1562
[3169] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3170] 3.37(s, 3H), 5.13(s, 2H), 5, 84(s, 2H), 6.72(d, J=3 Hz, 1H),
6.91(dd, J=6, 8 Hz, 1H), 6.94(dd, J=2, 8 Hz, 1H), 6.98(d, J=8 Hz,
1H), 7.15(d, J=2 Hz, 1H), 7.60(d, J=6 Hz, 1H), 7.83(d, J=3 Hz, 1H),
7.84(d, J=3 Hz, 1H), 7.92(d, J=3 Hz, 1H), 8.13(d, J=8 Hz, 1H)
EXAMPLES
[3171] Starting with 10-methoxymethyl-8-chloromethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine, the following compounds
were obtained by the same method as the one of Example 1094.
162 Ex. Structural formula NMR 1097 156310-methoxymethyl-8-
[2,4(1H, 3H)- pyrimidinedion-1- ylmethyl]-10H-pyrazino
[2,3-b][1,4]benzothiazine .sup.1H-NMR(DMSO-d.sub.6- ) .delta. ppm:
3.33(s, 3H), 4.80(s, 5.60(d, J=8.2Hz, 1H), 2H), 5.19(s, 2H),
6.91(d, J=7.9Hz, 1H), # 7.02(s, 1H), 7.11(d, J=7.9Hz, 1H), 7.73(d,
J=8.2Hz, 1H), 7.93(d, J=3.0Hz, 1H), 7.96(d, J=3.0Hz, 1H),
11.34(br.s, 1H) 1098 156410-methoxymethyl-8- (benzimidazol-1-
ylmethyl)-10H-pyrazino [2,3-b][1,4]benzothiazine
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.30(s, 3H), 5.09(s, 2H),
5.31(s, 2H), 6.77(dd, J=1.7, 8.1Hz, 1H), 6.88(d, J=1.7Hz, 1H),
6.97(d, J=8.1Hz, # 1H), 7.25-7.33(m, 4H), 7.83(d, J=2.7Hz, 1H),
7.85(d, J=2.7Hz, 1H), 7.96(s, 1H) 1099 156510-methoxymethyl-8-(1H-
imidazo[4,5-b]pyridin- 1-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.23(s, 3H), 5.14(s, 2H), 5.49(s, 6.93(d, J=7.8Hz, 1H),
7.02(s, 1H), 7.09(d, J=7.8Hz, 1H), 7.24(dd, # 7.91(d, J=2.9Hz, 1H),
7.94(d, J=2.9Hz, 1H), 7.99(d J=8.1Hz, 1H), 8.40(d, J=5.1Hz, 1H),
8.64(s, 1H) 1100 156610-methoxymethyl-8-(3H- imidazo[4,5-b]pyridin-
3-ylmethyl)-10H- pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.23(s, 3H), 5.10(s, 2H),
5.44(s, 2H), 6.94(dd, J=1.2, 8.2Hz, 1H), 7.06(d, J=1.2Hz, 1H),
7.07(d, J=8.2Hz, # 1H), 7.28(dd, J=4.9, 8.6Hz, 1H), 7.91(d,
J=2.9Hz, 1H), 7.93(d, J=2.9Hz, 1H), 8.09(dd, J=1.2, 8.6Hz, 1H),
8.37(dd, J=1.2, 4.9Hz, 1H), 8.58(s, 1H) 1101
156710-methoxymethyl-8- (benztriazol-1- ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.38(s, 3H), 5.13(s, 2H), 5.79(s, 2H), 6.85(dd, J=2, 8Hz, 1H),
6.97(d, J=8Hz, 1H), 6.99(d, J=2Hz, 1H), # 7.35-7.47(m, 3H), 7.82(d,
J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.08(dt, J=1, 8Hz, 1H) 1102
156810-methoxymethyl-8-(3- indazolinon-2- ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.33(s, 3H), 5.12(s, 2H), 5.20(s, 2H), 6.84(dd, J=2, 8Hz, 1H),
6.93(d, J=8Hz, 1H), 6.96(d, J=2Hz, 1H), # 7.10(t, J=8Hz, 1H),
7.25(d, J=8Hz, 1H), 7.42(d, J=8Hz, 1H), 7.75(d, J=8Hz, 1H), 7.79(d,
J=3Hz, 1H), 7.81(d, J=3Hz, 1H)
EXAMPLES
[3172] The following compounds were obtained by treating the
compounds obtained in Examples 1095 and 1097 by the same method as
the one of Example 434.
163 Ex. Structural formula MS M.p. NMR 1103 15698-(1H-tetrazol-1-
ylmethyl)-10H- pyrazino(2,3-b][1,4]benz- othiazine 210-212.degree.
C. .sup.1H-NHR(DMSO-d.sub.6) .delta. ppm: 5.54(s, 2H), 6.62(d,
J=1.9Hz, 1H), 6.73(dd, J=1.9, 7.8Hz, 1H), 6.92(d, J=7.8Hz, 1H),
7.63(d, # J=3.1Hz, 1H), 7.64(d, J=3.1Hz, 1H), 9.48(s, 1H), 9.54(s,
1H) 1104 15708-(2H-tetrazol-2- ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine 206-208.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.78(s, 2H), 6.66(d,
J=1.7Hz, 1H), 6.77(dd, J=1.7, 7.8Hz, 1H), 6.91(d, J=7.8Hz, 1H),
7.63(d, # J=3.1Hz, 1H), 7.64(d, J=3.1Hz, 1H), 9.00(s, 1H), 9.55(s,
1H) 1105 15718-[2,4(1H, 3H)- pyrimidinedion-1- ylmethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine 269-271.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.69(s, 2H), 5.60(d,
J=8.4Hz, 1H), 6.62(d, J=1.8Hz, 1H), 6.68(dd, # J=1.8, 8.1Hz, 1H),
6.88(d, J=8.1Hz, 1H), 7.63(s, 2H), 7.67(d, J=8.4Hz, 1H),
11.34(br.s, 1H)
EXAMPLES
[3173] The following compounds were obtained by treating
methoxymethyl compounds by the same method as the one of Example
9.
164 Ex. Structural formula MS M.p. NMR 1106
15728-[1H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-
10H-pyrazino[2,3-b][1,4]benzothazine ESI (+) 332 (MH.sup.+)
202-204.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.28(s,
2H), 6.50(d, J=4Hz, # 1H), 6.60-6.63(m, 2H), 6.83(d, J=8Hz, 1H),
7.09(dd, J=5, 8Hz, 1H), 7.55(d, J=4Hz, 1H), 7.61(s, 2H), 7.97(dd,
J=1, 8Hz, 1H), 8.23(dd, J=1, 5Hz, 1H), 9.48(s, 1H) 1107
15738-[1H-pyrrolo[2,3-b]pyridin-7-ylmethyl]-
10H-pyrazino[2,3-b]1,4]benzo- thiazine FAB (+) 332 (MH.sup.+)
210-214.degree. C. .sup.1H-NMR(DMSO-d.sub.- 6) .delta. ppm: 5.73(s,
2H), 6.66(s, 1H), # 6.72(d, J=2Hz, 1H), 6.86(dd, J=2. 8Hz, 1H),
6.87(d, J=8Hz, 1H), 7.11(dd, J=6, 7Hz, 1H), 7.60(d, J=3Hz, 1H),
7.61(d, J=3Hz, 1H), 8.17(d, J=6Hz, 1H), 8.30(d, J=7Hz, 1H), 9.51(s,
1H) 1108 15748-(pyrazol-1-ylmethyl)-
10H-pyrazino[2,3-b][1,4]benzothazine ESI (+) 282 (MH.sup.+)
211-212.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.14(s,
1H), 6.61(d, J=1.5Hz, 1H), 6.61(d, # J=8.5Hz, 1H), 6.84(dd, J=1.5,
8.5Hz, 1H), 7.44(d, J=2.0Hz, 1H), 7.62(s, 2H), 7.76(d, J=2.0Hz,
1H), 9.52(s, 1H) 1109 15758-(benzimidazol-1- ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 5.33(s, 2H), 6.60(s, 1H), 6.70(d, J=8.1Hz, 1H), 6.87(d,
J=8.1Hz, 1H), 7.14-7.23(m, 2H), 7.43(d, J=6.7Hz, 1H), # 7.61(s,
1H), 7.65(d, J=6.7Hz, 1H), 8.32(s, 1H), 9.46(s, 1H) 1110
15768-(benzotriazol-1- ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine FAB (+) 332 (M.sup.+) 251-258.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.80(s, 2H), 6.63(d, J=2Hz,
1H), 6.67(dd, # J=2, 8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.40(ddd, J=1,
7, 8Hz, 1H), 7.54(ddd, J=1, 7, 8Hz, 1H), 7.61(s, 2H), 7.79(td, J=1,
8Hz, 1H), 8.25(td, J=1, 8Hz, 1H), 9.47(s, 1H) 1111
15778-(3-indazolinon-2- ylmethyl)-10H-pyrazino
[2,3-b][1,4]benzothiazine >275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.15(s, 2H), 6.61(s, 1H),
6.62(d, J=8Hz, 1H), 6.81(d, J=8Hz, 1H), 6.98(t, J=8Hz, 1H), #
7.31(t, J=8Hz, 1H), 7.43(d, J=8Hz, 1H), 7.60(s, 2H), 7.61(d, J=8Hz,
1H), 9.38(s, 1H) 1112 15788-(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-
10H-pyrazino[2,3-b][1,4]benzothiazine 265.degree. C. (decom- pose)
.sup.1H-NHR(DMSO-d.sub.6) .delta. ppm: 5.37(s, 2H), 6.57(t, J=1Hz,
1H), 6.76(dd, J=1, 8Hz, 1H), 6.91(dd, # J=1, 8Hz, 1H), 7.24(dd,
J=5, 8Hz, 1H), 7.61(m, 2H), 7.89(dd, J=2, 8Hz, 1H), 8.41(dd, J=2,
5Hz, 1H), 8.58(s, 1H), 9.44(s, 1H) 1113 15798-(3H-imidazo[4,5-
b]pyridin-3-ylmethyl)- 10H-pyrazino[2,3-b][1,4]benzothiazine
249-251.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.36(s,
2H), 6.64(t, J=1Hz, 1H), 6.73(dd, J=1. 8Hz, 1H), 6.87(dd, # J=1,
8Hz, 1H), 7.29(dd, J=5, 8Hz, 1H), 7.61(m, 2H), 8.10(dd, J=2, 8Hz,
1H), 8.35(dd, J=2, 5Hz, 1H), 8.54(s, 1H), 9.47(s, 1H)
EXAMPLES
[3174] The following compounds were obtained by treating
10-methoxymethyl-8-chloromethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
successively by the same methods as those of Examples 1094 and
434.
165 Ex. Structural formula MS M.p. NMR 1114
15808-(pyrrol-1-ylmethyl)- 10H-pyrazino[2,3-b][1,4]benzothiaz- ine
197-198.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.91(s,
2H), 6.00(t, J=7.9Hz, 1H), 6.58(s, 1H), J=2.0Hz, 2H), 6.55(d,
6.73(t, J=2.0Hz, 2H), # 6.86(d, J=7.9Hz, 1H), 7.62(s, 2H), 9.52(s,
1H) 1115 15818-(1H-1,2,4-triazol-1- ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine 223-226.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.23(s, 2H), 6.60(d,
J=7.8Hz, 1H), 7.62(s, 2H), 7.98(s, 1H), 8.61(s, 1H), # 9.53(s,
1H)
EXAMPLE 1116
10-Methoxymethyl-8-(thiazol-2-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiaz-
ine
[3175] 150 mg of the title compound was obtained as a yellow oily
substance by treating 380 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,- 4]benzothiazin -8-yl)thioacetamide with
chloroacetaldehyde by the same method as the one of Example 1125.
1582
[3176] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3177] 3.49(s, 3H), 4.29(s, 2H), 5.25(s, 2H), 6.91(dd, J=1.6, 7.9
Hz, 1H), 6.98(d, J=7.9 Hz, 1H), 7.09(dd, J=1.6 Hz, 1H), 7.24(d,
J=3.3 Hz, 1H), 7.72(d, J=3.3 Hz, 1H), 7.84(s, 2H)
EXAMPLE 1117
O-[[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]-[1-(N,N--
dimethylsulfamoyl) imidazol-2-yl]methyl]O-phenyl thiocarbonate
[3178] Into a solution of 0.317 g of N,N-dimethyl
-2-[[10-(methoxymethyl)--
10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]-hydroxymethyl]]imidazole-1-sulf-
onamide and 0.117 g of 4-dimethylaminopyridine in acetonitrile (15
ml) was dropped in a nitrogen atmosphere at 0.degree. C. a solution
of 0.146 g of phenyl chlorothioformate in acetonitrile (1 ml) and
the resulting mixture was stirred at room temperature for 16 hours.
Then the reaction mixture was distilled off under reduced pressure
and the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol) to thereby give 0.202 g of
the title compound as a yellow oily substance. 1583
[3179] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3180] 2.78(s, 6H), 3.48(s, 3H), 5.17(d, J=10 Hz, 1H), 5.22(d, J=10
Hz, 1H), 6.96(d, J=8 Hz, 1H), 7.10-7.41(m, 10H), 7.82(s, 2H)
EXAMPLE 1118
N,N-Dimethyl-[2-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-
-yl]methyl]imidazol-1-yl]sulfonamide
[3181] To a solution of 0.202 g of O-[[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]-[1-(N,N-dimethyl-sulfamoyl)im-
idazol -2-yl]methyl]O-phenyl thiocarbonate in toluene (15 ml) were
added 0.20 ml of tri-n-butyltin hydride and 0.02 g of
a,a'-azobis(isobutyronitr- ile). After degassing, the reaction
mixture was heated to 75.degree. C. in a nitrogen atmosphere for 3
hours. After further adding 0.10 ml of tri-n-butyltin hydride, the
reaction mixture was heated for 2 hours. After distilling off the
solvent under reduced pressure completely, the residue was purified
by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.064 g of the title
compound as a yellow solid. 1584
[3182] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3183] 2.75(s, 6H), 3.47(s, 3H), 4.38(s, 2H), 5.21(s, 2H), 6.89(dd,
J=2, 8 Hz, 1H), 6.94(d, J=8 Hz, 1H), 7.02(d, J=2 Hz, 1H), 7.03(d,
J=2 Hz, 1H), 7.24(d, J=2 Hz, 1H), 7.82(d, J=2 Hz, 1H), 7.83(d, J=2
Hz, 1H)
EXAMPLE 1119
10-(Methoxymethyl)-8-(imidazol-2-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzoth-
iazine
[3184] To 0.064 g of N,N-dimethyl-[2-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]methyl]imidazol-1-yl]sulfonami-
de was added 5 ml of a 10% aqueous solution of sodium hydroxide.
After degassing, the resulting mixture was heated under reflux in a
nitrogen atmosphere for 14 hours. After distilling off the solvent
under reduced pressure completely, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.020 g of the title
compound as a yellow solid. 1585
[3185] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3186] 3.47(s, 3H), 4.03(s, 2H), 5.20(s, 2H), 6.81(d, J=8 Hz, 1H),
6.92-6.97(m, 4H), 7.82(d, J=3 Hz, 1H), 7.83(d, J=3 Hz, 1H)
EXAMPLE 1120
8-[2-(Pyridin-4-yl)ethyl]-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoth-
iazine
[3187] Similar to Production Example 14, 0.82 g of
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde was treated with
(pyridin-4-ylmethyl)triphenylphosphonium bromide in the presence of
tert-butoxypotassium to thereby give 1.10 g of
8-[2-(pyridin-4-yl)vinyl]--
10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine as yellow
crystals. Subsequently, the obtained product was hydrogenated in a
solvent mixture of ethanol (20 ml) with tetrahydrofuran (20 ml) in
the presence of 0.2 g of 10% palladium-carbon (moisture content:
50%) at room temperature under atmospheric pressure for 5 hours to
thereby give 1.00 g of the title compound as yellow crystals.
1586
[3188] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3189] 2.98(s, 4H), 3.47(s, 3H), 5.19(s, 2H), 6.75(d, J=8 Hz, 1H),
6.87(s, 1H), 6.92(d, J=8 Hz, 1H), 7.54(d, J=8 Hz, 2H), 7.81(d, J=3
Hz, 1H), 7.83(d, J=3 Hz, 1H), 8.48(d, J=8 Hz, 2H)
EXAMPLE 1121
8-(Thiazol-2-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3190] The title compound was obtained by treating
10-methoxymethyl-8-(thi-
azol-2-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine by the same
method as the one of Example 434. 1587
[3191] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3192] 4.18(s, 2H), 6.45(d, J=1.7 Hz, 1H), 6.52(br.s, 1H), 6.79(dd,
J=1.7, 8.0 Hz, 1H), 6.86(d, J=8.0 Hz, 1H), 7.24(d, J=3.3 Hz, 1H),
7.56(d, J=2.9 Hz, 1H), 7.69(d, J=2.9 Hz, 1H), 7.72(d, J=3.3 Hz,
1H)
[3193] MS: ESI(+)298(M.sup.+)
[3194] m.p. : 160-161.degree. C.
EXAMPLE 1122
8-(Imidazol-2-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3195] The title compound was obtained as a yellow amorphous
product by treating 10-(methoxymethyl)-8-(imidazol
-2-ylmethyl)-10H-pyrazino[2,3-b][- 1,4]benzothiazine by the same
method as the one of Example 9. 1588
[3196] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[3197] 3.96(s, 2H), 6.54(s, 1H), 6.68(d, J=8 Hz, 1H), 6.81(d, J=8
Hz, 1H), 7.01-7.18(br.s, 2H), 7.55(d, J=3 Hz, 1H), 7.56(d, J=3 Hz,
1H)
[3198] MS: FAB(+)262(MH.sup.+)
EXAMPLES
[3199] The following compounds were obtained by treating
8-[2-(pyridin-4-yl)vinyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzo- thiazine and
8-[2-(pyridin-4-yl)ethyl]-10-methoxymethyl-10H-pyrazino[2,3-b-
][1,4]benzothiazine by the same method as the one of Example 8.
166 Ex. Structural formula MS M.p. NMR 1123
1589(E)-8-[2-(pyridin-4- yl)vinyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI(+) 305 (MH.sup.+)
>275.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 6.99(d,
J=1Hz, 1H), 7.02(d, 8Hz, 1H), 7.28(d, J=16Hz, # 1H), 7.64(d, J=3Hz,
1H), J=16Hz, 1H), 8.14(d, J=7Hz, 2H), 8.79(d, J=7Hz, 2H), 9.65(s,
1H) 1124 15908-[2-(pyridin-4-yl) ethyl]-10H-pyrazino
[2,3-b][1,4]benzothiazine ESI(+) 307 (MH.sup.+) 179-183.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.62(t, J=8Hz, 2H), 2.82(t,
J=8Hz, 2H), 6.59(d, J=2Hz, # 1H), 6.75(dd, J=2, 8Hz, 1H), 6.80(d,
J=8Hz, 1H), 7.22(d, J=5Hz, 2H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz,
1H), 8.43(d, J=5Hz, 2H), 9.43(s, 1H)
EXAMPLE 1125
8-[4-(2-Pyridyl)thiazol-2-ylmethyl]-10H-pyrazino[2,3-b][1,4]benzothiazine
[3200] To a solution of 550 mg of
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-- yl)thioacetamide in a
solvent mixture of ethanol (10 ml) with N,N-dimethylformamide (10
ml) was added 560 mg of (2-bromoacetyl)pyridine hydrobromide and
the resulting mixture was heated to 60 to 70.degree. C. for 2
hours. Then the reaction mixture was brought back to room
temperature and distributed into dichloromethane and an aqueous
solution of sodium bicarbonate. After extracting the organic layer,
the extract was washed with water and dried over anhydrous sodium
sulfate. After distilling off the solvent under reduced pressure,
the crystals thus precipitated were washed successively with ethyl
acetate and diethyl ether to thereby give 420 mg of the title
compound as yellow crystals. 1591
[3201] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3202] 4.21(s, 2H), 6.77(s, 1H), 6.81(d, J=8.6 Hz, 1H), 6.89(d,
J=8.6 Hz, 1H), 7.33(dd, J=5.4, 7.4 Hz, 1H), 7.62(s, 2H), 7.88(t,
J=7.4 Hz, 1H), 8.05(d, J=7.4 Hz, 1H), 8.14(s, 1H), 8.59(d, J=5.4
Hz, 1H), 9.52(s, 1H)
[3203] m.p. : 194-195.degree. C.
EXAMPLE 1126
8-(1,2,4-Triazol-3-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3204] 330 mg of
N-formyl-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)aceta-
midrazone was dissolved in N,N-dimethylformamide (5 ml) and heated
to 120.degree. C. for 2 hours. Then the reaction mixture was
brought back to room temperature. After distilling off the solvent
under reduced pressure, the obtained residue was crystallized from
ethyl acetate/diethyl ether to thereby give 287 mg of the title
compound as yellow crystals. 1592
[3205] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3206] 3.79 and 3.78(br.s, 2H), 6.59-6.69(m, 2H), 6.87-6.88(m, 1H),
7.62(s, 2H), 7.83 and 8.42(br.s, 1H), 9.42-9.51(br.s, 1H),
13.37(br.s, 1H)
[3207] MS: FAB(+)282(M.sup.+)
EXAMPLE 1127
8-(6-Methyl-1,4-dihydro-1,2,4,5-tetrazin-3-yl)-10H-pyrazino-[2,3-b][1,4]be-
nzothiazine
[3208] To a solution of 0.274 g of
(10H-pyrazino[2,3-b][1,4]benzothiazin-8- -yl)thioacetamide in
tetrahydrofuran (40 ml) was added 0.1 ml of hydrazine monohydrate
and the resulting mixture was stirred for 30 minutes. After further
adding 1.0 ml of hydrazine monohydrate, the mixture was stirred for
additional 1 hour. After distilling off the solvent under reduced
pressure, the residue was dissolved in ethanol (40 ml) and
tetrahydrofuran (20 ml). After adding 5 ml of triethyl
orthoacetate, the resulting mixture was heated under reflux for 4
hours. Then the reaction mixture was distilled off under reduced
pressure and the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 50 mg of the title compound as a pale yellow solid. 1593
[3209] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3210] 1.65(s, 3H), 3.12(s, 2H), 6.65(d, J=1 Hz, 1H), 6.70(dd, J=1,
8 Hz, 1H), 6.83(d, J=8 Hz, 1H), 7.63(d, J=3 Hz, 1H), 7.64(d, J=3
Hz, 1H), 7.76(s, 1H), 7.83(s, 1H), 9.50(s, 1H)
[3211] MS: FAB(+)311(MH.sup.+)
[3212] m.p.: 233-235.degree. C.
EXAMPLE 1128
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(pyridin-3-yl-
)methanol
[3213] Into a solution of 0.45 ml of 3-bromopyridine in dry ether
(20 ml) was dropped in a nitrogen atmosphere at -78.degree. C. 3.2
ml of a 1.6 M solution of n-butyllithium in hexane and the
resulting mixture was stirred for 30 minutes. Then 5 ml of a
solution of 450 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde in dry
tetrahydrofuran was dropped into the reaction mixture and the
resulting mixture was stirred at -45 to -20.degree. C. for 1 hour.
After adding water carefully, the reaction mixture was extracted
with ethyl acetate. The extract was washed with water, dried over
anhydrous sodium sulfate and filtered. After distilling off the
solvent under reduced pressure, the reside was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 500 mg of the title compound as a yellow oily
substance. 1594
[3214] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3215] 2.80-2.93(br.s, 1H), 3.48(s, 3H), 5.22(s, 2H), 5.80(s, 1H),
6.94(br.d, J=8.2 Hz, 1H), 6.99(br.d, J=8.2 Hz, 1H), 7.15(s, 1H),
7.27(dd, J=4.9, 8.2 Hz, 1H), 7.68(br.d, J=8.2 Hz, 1H), 7.83(d,
J=3.1 Hz, 1H), 7.84(d. J=3.1 Hz, 1H), 8.50(d, J=4.9 Hz, 1H),
8.61(br.s, 1H)
EXAMPLES
[3216] Similar to Example 1128, aromatic halides were reacted with
(10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde to thereby give the
following compounds. Two compounds were obtained by treating
1-bromo-2,4-difluorobenzene with n-butyllithium and then reacting
with (10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
)carbaldehyde.
167 Ex. Structural formula NMR 1129 1595(10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazin-8-yl)- (pyridin-2-yl)methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.46(s, 3H), 5.20-5.40(br.s,
1H), 5.22(s, 2H), 5.41(s, 1H), 6.96(s, 2H), 7.15(s, 1H), 7.18(d,
J=7.8Hz, # 1H), 7.20(dd, J=4.8, 7.8Hz, 1H), 7.63(dt, J=1.5, 7.8Hz,
1H), 7.81(s, 2H), 8.54(d, J=1.5, 4.8Hz, 1H) 1130
1596(10-methoxymethyl-10N- pyrazino[2,3-b][1,4]benzothiazin-8-yl)-
(pyrazin-2-yl)methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.49(s,
3H), 4.40(d, J=6Hz, 1H), 5.25(s, 2H), 5.80(d, J=6Hz, 1H), 6.97(dd,
J=2, 8Hz, 1H), 6.99(d, J=8Hz, 1H), # 7.20(d, J=2Hz, 1H), 7.82(d,
J=3Hz, 1H), 7.83(d, J=3Hz, 1H), 8.51(d, J=3Hz, 1H), 8.52(dd, J=2,
3Hz, 1H), 8.61(d, J=2Hz, 1H) 1131 1597(10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazin-8-yl)- (pyrlmidin-5-yl) methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.35(s, 3H), 5.24(s, 2H),
5.78(d, J=4Hz, 1H), 6.34(d, J=4Hz, 1H), 7.03(dd, J=2, 8Hz, 1H), #
7.08(d, J=8Hz, 1H), 7.20(d, J=2Hz, 1H), 7.93(d, J=3Hz, 1H), 7.96(d,
J=3Hz, 1H), 8.77(s, 2H), 9.07(s, 1H) 1132
1598(10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(2- bromopyridin-5-yl)
methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.52(s, 1H), 3.48(s,
3H), 5.23(s, 2H), 5.77(s, 1H), 6.91(dd, J=2, 8Hz, 1H), 6.99(d,
J=8Hz, 1H), 7.13(d, # J=2Hz, 1H), 7.42(d, J=8Hz, 1H), 7.53(dd, J=2,
8Hz, 1H), 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.40(d, J=2Hz,
1H) 1133 1599.alpha.-(10-methoxymethyl-
10H-pyrazino[2,3-b][1,4]benzothiazin-8- yl)benzyl alcohol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.76(br.s, 1H), 3.43(s, 3H),
5.18(d, J=9.0Hz, 1H), 5.22(d, J=9.0Hz, 1H), 5.72(br.s, 1H), 6.92(d,
J=7.8Hz, 1H), # 6.94(d, J=7.8Hz, 1H), 7.13(s, 1H), 7.23 7.29(m,
1H), 7.30-7.37(m, 4H), 7.79(d, J=2.9Hz, 1H) 1134
1600.alpha.-(10-methoxymethyl
10H-pyrazino[2,3-b][1,4]benzothiazin-8 yl)-3-bromo-2,6-
difluorobenzyl alcohol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.73(d,
J=8Hz, 1H), 3.47(s, 3H), 5.21(d, J=9Hz, 1H), 5.24(d, J=9Hz, 1H),
6J7(d, # J=8Hz, 1H), 6.86(dt, J=3, 9Hz, 1H), 6.56(br.d, J=8Hz, 1H),
6.99(d, J=8Hz, 1H), 7.20(br.s, 1H) 7.49(ddd, J=6, 8, 9Hz, 1H),
7.84(m, 2H) 1135 1601.alpha.-(10-methoxymethyl-
10H-pyrazino[2,3-b]E1,4]benzothiazin-8- yl)-2,4- difluorobenzyl
alcohol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.78(d, J=9Hz, 1H),
3.44(s, 3H), 5.21(s, 2H), 6.16(d, J=9Hz, 1H), 6.90-6.94(m, 2H), #
6.95-7.00(m, 2H), 7.20(s, 1H),7.24-7.31(m, 1H), 7.84(s, 2H) 1136
1602.alpha.-(10-methoxymethyl-
10H-pyrazinol[2,3-b]1,4]benzothiazin-8- yl) -5-bromo-2-
fluorobenzyl alcohol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.57(d,
J=6Hz, 1H), 3.48(s, 3H), 5.19(d, J=9Hz, 1H), 5.22(d, J=9Hz, 1H),
6.01(d, # J=6Hz, 1H), 6.90(t, J=9Hz, 1H), 6.96(m, 2H), 7.14(s, 1H),
7.36(ddd, J=3, 5, 9Hz, 1H), 7.69(dd, J=3, 6Hz, 1H), 7.83(s, 2H)
EXAMPLE 1137
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-[1-(triphenyl-
methyl)imidazol-2-yl]methanol
[3217] 50 ml of a solution of 1.32 g of
1-(triphenylmethyl)imidazole in dry tetrahydrofuran was ice-cooled
in a nitrogen atmosphere. After adding 2.8 ml of a 1.6 M solution
of n-butyllithium in hexane, the resulting mixture was stirred for
2 hours. Then the reaction mixture was cooled to -78.degree. C.
After adding 1.23 g of cerium (III) chloride, the reaction mixture
was stirred for 30 minutes. Further, 40 ml of a solution of 0.546 g
of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbalde-
hyde in dry tetrahydrofuran was dropped thereinto.. Then the
reaction mixture was brought back to room temperature and
distributed into an aqueous solution of sodium dihydrogenphosphate
and ethyl acetate. After filtering off the inorganic matters, the
aqueous layer was extracted with ethyl acetate, washed successively
with water and a saturated aqueous solution of sodium chloride and
dried over anhydrous sodium sulfate followed by filtration. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 716 mg of the title
compound as a yellow solid. 1603
[3218] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3219] 2.84(d, J=8 Hz, 1H), 3.44(s, 3H), 4.98(d, J=8 Hz, 1H),
5.07(d, J=9 Hz, 1H), 5..19(d, J=9 Hz, 1H), 6.40(dd, J=2, 8 Hz, 1H),
6.68(d, J=8 Hz, 1H), 6.77(d, J=2 Hz, 1H), 6.78(d, J=2 Hz, 1H),
7.09-7.12(m, 7H), 7.23-7.26(m, 9H), 7.82(s, 2H)
EXAMPLES
[3220] The following compounds were obtained by starting with
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
and each of 1-bromo-4-fluorobenzene, 4-bromoanisole and
2-bromothiazole.
168 Ex. Structural formula NMR 1138 1604.alpha.-(10-methoxymethyl-
10H-pyrazino[2,3- b][1,4]benzothiazin-8- yl)-4-fluorobenzyl alcohol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.23(s, 1H), 3.46(s, 3H),
5.21(d, J=9Hz, 1H), 5.24(d, J=9Hz, 1H), 5.76(s, 1H), 6.95(dd, #
J=2, 8Hz, 1H), 6.98(d, J=8Hz, 1H), 7.03(t, J=9Hz, 2H), 7.12(d,
J=2Hz, 1H), 7.34(dd, J=5, 9Hz, 2H), 7.83(d, J=3Hz, 1H), 7.84(d,
J=3Hz, 1H) 1139 1605.alpha.-(10-methoxymethyl-
10H-pyrazino[2,3-b][1,4]benzothiazin-8- yl) -4-methoxybenzyl
alcohol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3H), 4.63(s, 3.78(s,
5.29(s, 1H), 5.32(s, 2H), 6.78(d, J=8Hz, 2H), 7.08(d, J=8Hz, 1H), #
7.15(d, J=8Hz, 1H), 7.16(s, 1H), 7.36(d, J=8Hz, 2H), 7.87(s, 2H)
1140 1606.alpha.-(10-methoxymethyl-
10H-pyrazino[2,3-b][1,4]benzothiazin-8- yl)-(thiazol-2-yl) methanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.44(s, 1H), 3.50(s, 3H),
5.26(s, 2H), J=8Hz, 1H), 7.18(dd, J=2, 8Hz,1H), 7.26(d, # J=2Hz,
1H), 7.33(d, J=3Hz, 1H), 7.75(d, J=3Hz, 1H), 7.83(d, J=3Hz, 1H),
7.84(d, J=3Hz, 1H)
EXAMPLE 1141
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(pyrimidin-2--
yl)methanol
[3221] 10 ml of a solution of 1.85 g of
2-(tributylstannyl)pyrimidine in tetrahydrofuran was cooled to
-75.degree. C. in a nitrogen atmosphere. Then 3.1 ml of a 1.6 M
solution of n-butyllithium in hexane was dropped thereinto. After
stirring for 10 minutes, 1.23 g of cerium (III) chloride was added
thereto and the reaction mixture was stirred for 30 minutes.
Further, 40 ml of a solution of 0.54 g of
(10-methoxymethyl-10H-pyrazino[-
2,3-b][1,4]benzothiazin-8-yl)carbaldehyde in tetrahydrofuran was
dropped thereinto. After stirring at -75.degree. C. for 30 minutes,
the reaction mixture was brought back to room temperature and
distributed into water and ethyl acetate. After filtering off the
inorganic matters, the aqueous layer was extracted with ethyl
acetate, washed successively with water and a saturated aqueous
solution of sodium chloride and dried over anhydrous sodium sulfate
followed by filtration. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 532 mg of the title compound as a yellow solid. 1607
[3222] .sup.1H-NMR(CDCl) .delta. ppm:
[3223] 3.52(s, 3H), 4.98(d, J=6 Hz, 1H), 5.25(d, J=10 Hz, 1H),
5.29(d, J=10 Hz, 1H), 5.80(d, J=6 Hz, 1H), 6.97(d, J=8 Hz, 1H),
7.11(d, J=8 Hz, 1H), 7.23(t, J=5 Hz, 1H), 7.30(s, 1H), 7.81(s, 2H),
8.73(d, J=5 Hz, 2H)
EXAMPLE 1142
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(pyridin-4-yl-
)methanol
[3224] A solution of 609 mg of phenyl (pyridin-4-yl) sulfoxide in
tetrahydrofuran was cooled to -15.degree. C. in a nitrogen
atmosphere. Then 1.5 ml of a 2 M solution of phenylmagnesium
bromide in tetrahydrofuran was dropped thereinto. After stirring at
room temperature for 10 minutes, 3 ml of a solution of 819 mg of
(10-methoxymethyl-10H-pyr-
azino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde in tetrahydrofuran
was dropped into the reaction mixture. After stirring for 10
minutes, the reaction mixture was distributed into water and ethyl
acetate. Then the organic layer was extracted, washed with water
and dried over anhydrous sodium sulfate followed by filtration.
After distilling off the solvent under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with dichloromethane/methanol) and recrystallized from ethyl
acetate/n-hexane to thereby give 260 mg of the title compound as
yellow crystals. 1608
[3225] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3226] 3.45(s, 3H), 3.58-3.78(br.s, 1H), 5.20(s, 2H), 5.70(s, 1H),
6.91(dd, J=1.5, 8.6 Hz, 1H), 6.96(d, J=8.6 Hz, 1H), 7.15(d, J=1.5
Hz, 1H), 7.31(d, J=6.4 Hz, 2H), 7.83(s, 2H), 8.49(d, J=6.4 Hz,
2H)
EXAMPLE 1143
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(imidazo[1,2--
a]pyridin-5-yl) methanol
[3227] To 40 ml of a tetrahydrofuran solution were added 1.20 g of
magnesium and 0.1 ml of 1,2-dibromoethane in a nitrogen atmosphere.
Subsequently, 10 ml of a solution of 2.96 g of
5-bromoimidazo[1,2-a]pyrid- ine and 2.8 ml of 1,2-dibromoethane in
tetrahydrofuran were dropped into the reaction mixture while
heating under reflux. Further, 10 ml of a solution of 2.73 g of
(10-methoxymethyl -10H-pyrazino[2,3-b][1,4]benzothi- azin
-8-yl)carbaldehyde in tetrahydrofuran was dropped thereinto. After
heating to 50.degree. C. for 1 hour, the reaction mixture was
brought back to room temperature and distributed into an aqueous
solution of ammonium chloride and ethyl acetate. The organic layer
was extracted, washed with water and dried over anhydrous sodium
sulfate followed by filtration. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 260 mg of the title compound as a yellow oily
substance. 1609
[3228] .sup.1H-NMR(CDCl.sub.3) 8 ppm:
[3229] 3.45(s, 3H), 3.60-3.85(br.s, 1H), 5.23(s, 2H), 5.74(s, 1H),
6.95(dd, J=1.4, 7.7 Hz, 1H), 6.99(d, J=7.7 Hz, 1H), 7.02(dd, J=1.7,
9.4 Hz, 1H), 7.19(d, J=1.4 Hz, 1H), 7.44(d, J=9.4 Hz, 1H), 7.52(s,
1H), 7.57(d, J=1.7 Hz, 1H), 7.83(d, J=2.6 Hz, 1H), 7.85(d, J=2.6
Hz, 1H), 8.14(s, 1H)
EXAMPLES
[3230] The following compounds were obtained by the same method as
the one of Example 9.
169 Ex. Structural formula NMR 1144
1610(10H-pyrazino[2,3-b][1,4]benzothiazin-8- yl)-(pyridin-2-yl)
methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 5.20-5.40(br.s, 1H),
6.50(s, 1H), 6.78-6.83(br.s, 1H), 6.85(s, 2H), 7.18(d, J=7.8Hz,
1H), 7.23(dd, J=5.2, # 7.8Hz, 1H), 7.52(d, J=2.6Hz, 1H), 7.66(d,
J=2.6Hz, 1H), 7.66(dt, J=1.6, 7.8Hz, 1H), 8.55(dd, J=1.6, 5.2Hz,
1H) 1145 1611(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
yl)-(pyridin-3-yl) methanol .sup.1H-NMR(DMSOd.sub.6) .delta. ppm:
J=7.7Hz, 1H), 6.82(s, 5.79(s, 1H), 6.80(d, 1H), 6.89(d, J=7.7Hz,
1H), 7.62(s, 2H), 7.94(dd, J=5.2, 8.6Hz, # 1H), 8.35(d, J=8.6Hz,
1H), 8.77(d, J=5.2Hz, 1H), 8.82(s, 1H), 9.49(s, 1H) 1146
1612(10H-pyrazino[2,3-b][1,4]benzothiazi- n-8- yl)-(pyridin-4-yl)
methanol .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.51(d, J=4.0Hz,
1H), 6.11(d, J=4.0Hz, 1H), 6.78(d, J=7.6Hz, 1H), 6.79(s, 1H),
6.84(d, J=7.6Hz, 1H), 7.31(d, # J=5.8Hz, 2H), 7.61(5, 2H), 8.48(d,
J=5.8Hz, 2H), 9.43(s, 1H) Ex. Structural formula MS M.p. NMR 1147
1613(10H-pyrazino[2,3-b]1,4]benzothiazin-- 8- yl)-(pyrimidin-4-
yl)methanol ESI(+) 310 (MH.sup.+) 218-221.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.65(d, J=4Hz, 1H), 6.26(d,
J=4Hz, 1H), # 6.80(d, J=8Hz, 1H), 6.83(s, 1H), 6.87(d, J=8Hz, 1H),
7.63(s, 2H), 8.73(s, 2H), 9.07(s, 1H), 9.45(s, 1H) 1148
1614(10H-pyrazino[2,3-b]1,4]benzothiazin-8- yl)-(pyrimidin-2-yl)
methanol FAB(+) 310 (MH.sup.+) 105-107.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.65(d, J=5Hz, 1H), 6.25(d,
J=5Hz, 1H), # 6.82(s, 1H), 6.86(d, 6.80(d, J=8Hz, 1H), J=8Hz, 1H),
7.64(s, 2H), 8.72(s, 2H), 9.06(s, 1H), 9.45(s, 1H) 1149
1615(10H-pyrazino[2,3-b][1,- 4]benzothiazin-8- yl)-(pyrazin-2-yl)
methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 4.64(d, J=4Hz, 1H),
5.78(br.s, 1H), 6.55(br.s, 2H), 6.85(dd, J=1, 8Hz, 1H), 6.88(d,
J=8Hz, 1H), # 7.55(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H), 8.52(s, 2H),
8.60(s, 1H) 1150 1616(10H-pyrazino[2,3- b][1,4]benzothiazin-
8-yl)-(thiazol-2-yl) methanol FAB(+) 314 (M.sup.+) 110-114.degree.
C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.48(s, 1H), 5.95(s, 1H),
6.59(d, J=1Hz, 1H), # 6.82(d, J=8Hz, 1H), 6.91(dd, J=1, 8Hz, 1H),
7.13(s, 1H), 7.31(d, J=4Hz, 1H), 7.50(d, J=3Hz, 1H), 7.64(d, J=3Hz,
1H), 7.70(d, J=4Hz, 1H) 1151
1617(10H-pyrazino[2,3-b][1,4]benzothiazin-8- yl)-(imidazol-2-yl)
methanol ESI(+) 298 (MH.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 5.52(d, J=6Hz, 1H), 6.77(d, J=8Hz, 1H), 6.82(s, 1H), 6.83(d, #
J=8Hz, 1H), 6.87(br.s, 2H), 7.62(d, J=3Hz, 1H), 7.63(d, J=3Hz, 1H),
9.51(s, 1H) 1152 1618(10H-pyrazino[2,3-b][1,4]benzothiazi- n-8-
pyridin-5-yl) methanol .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
5.53(d, J=4.3Hz, 1H), 6.08(d, J=4.3Hz, 1H), 6.71(d, J=7.7Hz, 1H),
6.72(s, 1H), 6.86(d, # J=7.7Hz, 1H), 7.01(dd, J=1.3, 9.0Hz, 1H),
7.46(d, J=9.0Hz, 1H), 7.52(s, 1H), 8.50(d, J=1.3Hz, 1H), 9.44(s,
1H) 1153 1619(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
yl)-(phenyl)methanol .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
2.38-2.50(br.s, 1H), 5.68(br.s, 1H), 6.54(s, 1H), 6.66-6.72(br.s,
1H), 6.82(d, J=8.6Hz, 1H), # 6.83(d, J=8.6Hz, 1H), 7.27-7.32(m.
2H), 7.32-7.38(m, 3H), 7.49(d, J=2.9Hz, 1H), 7.65(d, J=2.9Hz, 1H)
1154 1620(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
yl)-(4-fluorophenyl) methanol FAB(+) 325 (MH.sup.+) 150-152.degree.
C. .sup.1H-NMR(DMSO-d.sub.- 6) .delta. ppm: 5.51(d, J=4Hz, 1H),
5.93(d, J=4Hz, 1H), # 6.74(dd, J=1, 8Hz, 1H), 6.80(d, J=1Hz, 1H),
6.82(d, J=8Hz, 1H), 7.12(t, J=9Hz, 2H), 7.33(dd, J=6, 9Hz, 2H),
7.61(d, J=3Hz, 1H), 7.62(d, J=3Hz, 1H), 9.44(s, 1H) 1155
1621(10H-pyrazino[2,3-b][1,4]benzothiazi- n-8- yl)-(5-bromo-2-
fluorophenyl) methanol FAB(+) 405 (M.sup.+) 202-203.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 5.94(s, 1H), 6.50(br.s, # 1H),
6.55(d, J=1Hz, 1H), 6.84(dd, J=1, 8Hz, 1H), 6.87(d, J=8Hz, 1H),
6.92(t, J=9Hz, 1H), 7.38(ddd, J=3, 5, 9Hz, 1H), 7.40(dd, J=3, 6Hz,
1H), 7.55(d, J=3Hz, 1H), 7.69(d, 33Hz, 1H) 1156
1622(10H-pyrazino[2,3-b][1,4]benzothiazin-8- yl)-(2,4-
difluorophenyl) methanol FAB(+) 387 (M.sup.+) 175-176.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.90(s, 1H), 6.15(br.s, #
1H), 6.71(d, J=8Hz, 1H), 6.83(d, J=8Hz, 1H), 6.88(s, 1H),
7.04(br.t, J=9Hz, 2H), 7.36(tt, J=7, 9Hz, 1H), 7.62(s, 2H), 9.45(s,
1H) 1157 1623(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
yl)-(3-bromo-2,6- difluorophenyl) methanol FAB(+) 467 (M.sup.+)
198-200.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 6.09(s,
1H), 6.60(br.s, # J=8Hz, 1H), 6.85(d, J=8Hz, 1H), 6.88(td, J=8,
11Hz, 1H), 7.51(ddd, J=5, 7, 8Hz, 1H), 7.65(d, J=3Hz, 1H), 7.69(d,
J=3Hz, 1H) 1158 1624(10H-pyrazino[2,3-b]yl)-(4- methoxyphenyl)
methanol FAB(+) 337 (M.sup.+) 84-86.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.79(s, 3H), 5.43(s, 1H),
6.54(d, J=1Hz, 1H), # 6.66(br.s, 1H), 6.81(dd, J=1, 8Hz, 1H),
6.84(d, J=8Hz, 1H), 6.88(d, J=9Hz, 2H), 7.25(d, J=9Hz, 2H), 7.50(d,
J=3Hz, 1H), 7.66(d, J=3Hz, 1H)
EXAMPLE 1159
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(2-bromopyridin -5-yl)
methanol
[3231] The title compound was obtained by treating
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)-(2-bromopyridin-5-yl(methanol
by the same method as the one of Example 434. 1625
[3232] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3233] 5.50(s, 1H), 6.20(br.s, 1H), 6.77(d, J=8 Hz, 1H), 6.78(s,
1H), 6.85(d, J=8 Hz, 1H), 7.60(d, J=8 Hz, 1H), 7.61(d, J=8 Hz, 1H),
7.62(d, J=3 Hz, 1H), 7.63(d, J=3 Hz; 1H), 8.36(s, 1H), 9.45(s,
1H)
[3234] MS: FAB(+)388(M.sup.+)
[3235] m.p. : 221-223.degree. C.
EXAMPLE 1160
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)
(pyridin-3-yl) ketone
[3236] 1.25 g of the title compound was obtained by oxidizing 1.48
g of (10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-yl)-(pyridin-3-- yl)methanol with
manganese dioxide by the same method as the one of Example 625.
1626
[3237] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3238] 3.48(s, 3H), 5.29(s, 2H), 7.13(d, J=8 Hz, 1H), 7.36(dd, J=2,
8 Hz, 1H), 7.45(ddd, J=1, 5, 8 Hz, 1H), 7.58(d, J=2 Hz, 1H),
7.88(d, J=3 Hz, 1H), 7.89(d, J=3 Hz, 1H), 8.10(td, J=2, 8 Hz, 1H),
8.82(dd, J=2, 5 Hz, 1H), 8.99(dd, J=1, 2 Hz, 1H)
EXAMPLE 1161
8-[(Pyridin-3-yl)difluoromethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4- ]benzothiazine
[3239] 350 mg of (10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazin-8- -yl) (pyridin-3-yl) ketone was added in
a nitrogen atmosphere to 3 ml of dimethylaminosulfur trifluoride
and the resulting mixture was stirred at room temperature for 16
hours and then at 50.degree. C. for additional 5 hours. The
reaction mixture was ice-cooled and diluted with ethyl acetate.
After adding water under ice-cooling, the extract was dried over
anhydrous magnesium sulfate and filtered. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/ethyl
acetate) to thereby give 287 mg of the title compound as a yellow
solid. 1627
[3240] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3241] 3.48(s, 3H), 5.24(s, 2H), 7.06(s, 2H), 7.25(s, 1H), 7.37(dd,
J5, 8 Hz, 1H), 7.80(d, J=8 Hz, 1H), 7.86(d, J=3 Hz, 1H), 7.87(d,
J=3 Hz, 1H), 8.70(d, J=5 Hz, 1H), 8.77(s, 1H)
EXAMPLE 1162
8-[(Pyridin-3-yl)fluoromethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]b- enzothiazine
[3242] 177 mg of the title compound was obtained by treating 352 mg
of (10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-yl)-(pyridin-3-- yl)methanol by the same
method as the one of Example 1161. 1628
[3243] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3244] 3.46(s, 3H), 5.21(d, J=9 Hz, 1H), 5.24(d, J=9 Hz, 1H),
6.44(d, J=45 Hz, 1H), 6.91(d, J=8 Hz, 1H), 7.04(d, J=8 Hz, 1H),
7.11(s, 1H), 7.32(dd, J=5, 8 Hz, 1H), 7.64(d, J=8 Hz, 1H),
7.83-7.85(m, 2H), 8.60-8.63(m, 2H)
EXAMPLE 1163
8-[1-(Pyridin-3-yl)-1-methoxymethyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3245] 504 mg of the title compound was obtained as yellow crystals
by treating 704 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]-benzothiaz- in
-8-yl)-(pyridin-3-yl)methanol with methyl iodide in the presence of
sodium hydride by the same method as the one of Example 788.
1629
[3246] .sup.1H-NMR(CDCl) .delta. ppm:
[3247] 3.39(s, 3H), 3.48(s, 3H), 5.20(s, 1H), 5.22(d, J=10 Hz, 1H),
5.25(d, J=10 Hz, 1H), 6.94(dd, J=2, 8 Hz, 1H), 7.00(d, J=8 Hz, 1H),
7.11(d, J=2 Hz, 1H), 7.26(dd, J=5, 8 Hz, 1H), 7.63(td, J=2, 8 Hz,
1H), 7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H), 8.52(dd, J=2, 5 Hz,
1H), 8.60(d, J=2 Hz, 1H)
EXAMPLE 1164
1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-1-(pyridin--
3-yl)ethanol
[3248] 303 mg of the title compound was obtained as yellow crystals
by treating 350 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazi- n-8-yl)
(pyridin-3-yl) ketone with methyllithium by the same method as the
one of Production Example 86. 1630
[3249] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3250] 1.95(s, 3H), 2.38(br.s, 1H), 3.43(s, 3H), 5.18(d, J=10 Hz,
1H), 5.21(d, J=10 Hz, 1H), 6.97(d, J=8 Hz, 1H), 6.99(dd, J=2, 8 Hz,
1H), 7.21(d, J=2 Hz, 1H), 7.25(dd, J=5, 8 Hz, 1H), 7.63(td, J=2, 8
Hz, 1H), 7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H), 8.50(dd, J=2, 5
Hz, 1H), 8.70(d, J=2 Hz, 1H)
EXAMPLE 1165
8-[1-(Pyridin-3-yl)vinyl]-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoth-
iazine
[3251] To a solution of 303 mg of 1-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-1-(pyridin-3-yl)ethanol in dichloromethane was added in a
nitrogen atmosphere 0.32 ml of methyl chlorosulfonate and the
resulting mixture was heated under reflux for 2 hours. Then the
reaction mixture was brought back to room temperature and
distributed into water and ethyl acetate. The extract was dried
over anhydrous magnesium sulfate and filtered. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 230 mg of the title
compound as a yellow solid. 1631
[3252] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3253] 3.39(s, 3H), 5.21(s, 2H), 5.50(s, 1H), 5.59(s, 1H), 6.91(dd,
J=2, 8 Hz, 1H), 7.00(d, J=8 Hz, 1H), 7.07(d, J=2 Hz, 1H),
7.29(br.s, 1H), 7.62(br.d, J=8 Hz, 1H), 7.85(d, J=3 Hz, 1H),
7.86(d, J=3 Hz, 1H), 8.59(br.m, 1H), 8.65(br.m, 1H)
EXAMPLE 1166
8-[1-(Pyridin-3-yl)ethyl]-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoth-
iazine
[3254] 0.23 g of 8-[1-(pyridin-3-yl)vinyl]-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine was dissolved in 10 ml of
ethanol and then hydrogenated in the presence of 0.056 g of 10%
palladium-carbon (moisture content: 50%) in a hydrogen gas stream
at room temperature for 26 hours. Thus 0.106 g of the title
compound was obtained as yellow crystals. 1632
[3255] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3256] 1.63(d, J=7 Hz, 3H), 3.45(s, 3H), 4.11(q, J=7 Hz, 1H),
5.20(s, 2H), 6.82(dd, J=2, 8 Hz, 1H), 6.96(d, J=8 Hz, 1H), 6.98(d,
J=2 Hz, 1H), 7.23(dd, J=5, 8 Hz, 1H), 7.50(td, J=2, 8 Hz, 1H),
7.85(m, 2H), 8.46(br.m, 1H), 8.53(br.m, 1H)
EXAMPLES
[3257] The following compounds were obtained by the same method as
the one of Example 9.
170 Ex. Structural formula MS M.p. NMR 1167 1633 FAB(+) 329
(MH.sup.+) 183-184.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
6.54(br.s, 1H), 6.61(d, J=1 Hz, 1H), 6.91(dd, J=1, 8 Hz, 1H),
6.95(d, J=8 Hz, 1H), 7.38(dd, J=5, 8 Hz, 1H), 7.59(d, J=3 Hz, 1H),
7.73(d, J=3 Hz, 1H), 8-[(pyridin-3-yl)difluo- romethyl]-10H-
7.80(d, J=8 Hz, 1H), pyrazino[2,3-b][1,4]benzothi- azine 8.71(d,
J=5 Hz, 1H), 8.75(s, 1H) 1168 1634 FAB(+) 311 (MH.sup.+)
157-159.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 6.63(d,
J=46 Hz, 1H), 6.77(s, 1H), 6.78(d, J=8 Hz, 1H), 6.95(d, J=8 Hz,
1H), 7.46(dd, J=5, 8 Hz, 1H), 8-[(pyridin-3-yl)fluoromethyl]-10H-
7.63(s, 2H), 7.74(d, J=8 Hz, 1H), pyrazino[2,3-b][1,4]benzothia-
zine 8.60(br.s, 2H), 9.53(s, 1H) 1169 1635 FAB(+) 323 (MH.sup.+)
156-188.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.37(s,
3H), 5.11(br.s, 1H), 6.40(br.s, 1H), 6.50(d, J=1 Hz, 1H), 6.78(dd,
J=1, 8 Hz, 1H), 7.27(dd, J=5, 8 Hz, 1H), 7.57(d, J=3 Hz, 1H),
7.61(td, J=2, 8 Hz, 1H), 7.70(d, J=3 Hz, 1H),
8-[1-(pyridin-3-yl)-1-methoxymethyl]-10H- 8.53(dd, J=2, 5 Hz, 1H),
pyrazino[2,3-b]-[1,4]benzothiazine 8.57(d, J=2 Hz, 1H) 1170 1636
FAB(+) 307 (MH.sup.+) 180-181.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.50(d, J=7 Hz, 3H), 4.03(q, J=7 Hz, 1H), 6.66(d, J=1
Hz, 1H), 6.71(dd, J=1, 8 Hz, 1H), 6.84(d, J=8 Hz, 1H), 7.31(dd,
J=5, # 8 Hz, 1H), 7.59(td, J=2, 8 Hz, 1H), 7.62(s, 2H),
8-[1-(pyridin-3-yl)ethyl]-10H-pyrazino 8.39(dd, J=2, 5 Hz, 1H),
[2,3-b][1,4]benzothiazine 8.46(d, J=2 Hz, 1H), 9.39(s, 1H)
EXAMPLE 1171
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-[2-[(trimethy-
lsilyl)ethynyl]pyridin-5-yl]methanol
[3258] 0.198 g of the title compound was obtained by treating 0.215
g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(2-bromopyri-
din -5-yl)methanol by the same method as the one of Example 1417.
1637
[3259] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3260] 0.27(s, 9H), 2.41(s, 1H), 3.40(s, 3H), 5.24(s, 2H), 5.82(s,
1H), 6.92(dd, J=2, 8 Hz, 1H), 7.00(d, J=8 Hz, 1H), 7.15(d, J=2 Hz,
1H), 7.40(d, J=8 Hz, 1H), 7.65(dd, J=2, 8 Hz, 1H), 7.85(d, J=3 Hz,
1H), 7.86(d, J=3 Hz, 1H), 8.51(d, J=2 Hz, 1H)
EXAMPLE 1172
(10-Methoxymethyl-10H-pyrazino(2,3-b][1,4]benzothiazin-8-yl)-(2-ethynylpyr-
idin-5-yl)methanol
[3261] 0.316 g of the title compound was obtained by treating 0.392
g of
(10-methoxymethyl-10H-pyrazin[2,3-b][1,4]benzothiazin-8-yl)-[2-[(trimethy-
lsilyl)ethynyl]pyridin-5-yl]methanol with tetra-n-butylammonium
fluoride by the same method as the one of Example 1418. 1638
[3262] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3263] 2.36(d, J=4 Hz, 1H), 3.15(s, 1H), 3.49(s, 3H), 5.23(s, 2H),
5.82(d, J=4 Hz, 1H), 6.93(dd, J=2, 8 Hz, 1H), 7.00(d, J=8 Hz, 1H),
7.14(d, J=2 Hz, 1H), 7.45(d, J=8 Hz, 1H), 7.66(dd, J=2, 8 Hz, 1H),
7.84(d, J=3 Hz, 1H), 7.85(d, J=3 Hz, 1H), 8.62(d, J=2 Hz, 1H)
EXAMPLE 1173
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(2-ethylpyrid-
in-5-yl)methanol
[3264] 0.262 g of the title compound was obtained by treating 0.316
g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(2-ethynylpy-
ridin -5-yl)methanol by the same method as the one of Example 20.
1639
[3265] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3266] 1.28(t, J=7 Hz, 3H), 2.39(s, 1H), 2.81(q, J=7 Hz, 2H),
3.47(s, 3H), 5.22(d, J=9 Hz, 1H), 5.26(d, J=9 Hz, 1H), 5.80(s, 1H),
6.96(dd, J=2, 8 Hz, 1H), 7.00(d, J=8 Hz, 1H), 7.14(d, J=8 Hz, 1H),
7.17(d, J=2 Hz, 1H), 7.58(dd, J=2, 8 Hz, 1H), 7.84(d, J=3 Hz, 1H),
7.85(d, J=3 Hz, 1H), 8.55(d, J=2 Hz, 1H)
EXAMPLE 1174
Methyl
[5-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl)hy-
droxymethyl]pyridin-2-ylthiol]acetate
[3267] To a solution of 0.106 g of methyl thioacetate in
N,N-dimethylformamide (8 ml) was added in a nitrogen atmosphere
0.040 g of sodium hydride (60% oily) and the resulting mixture was
stirred for 15 minutes. After adding 0.215 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-yl)-(2-bromopyridin-5-yl)methanol, the resulting
mixture was stirred at room temperature for 14 hours and heated to
60.degree. C. for 2 hours. Then the reaction mixture was
distributed into water and ethyl acetate and the aqueous layer was
extracted with ethyl acetate. The organic layer was washed with
water and dried over anhydrous sodium sulfate. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with n-hexane/ethyl
acetate) to thereby give 0.128 g of the title compound as a yellow
solid. 1640
[3268] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3269] 3.48(s, 3H), 3.74(s, 3H), 3.97(s, 2H), 5.23(s, 2H), 5.74(s,
1H), 6.92(dd, J=2, 8 Hz, 1H), 7.00(d, J=8 Hz, 1H), 7.05(d, J=2 Hz,
1H), 7.44(d, J=8 Hz, 1H), 7.54(d, J=8 Hz, 1H), 7.83(m, 2H),
8.40(br.s, 1H)
EXAMPLES
[3270] The following compounds were obtained by treating the
compounds obtained in Examples 1173 and 1174 by the same method as
the one of Example 9.
171 Ex. Structural formula MS M.p. NMR 1175 1641 FAB(+) 337
(MH.sup.+) 161-163.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.30(t, J=7 Hz, 3H), 2.82(q, J=7 Hz, 2H), 5.70(s, 1H), 6.55(s, 1H),
6.60(s, 1H), 6.81(d, J=8 Hz, 1H), 6.86(d, J=8 Hz, 1H), 7.17(d, J=9
Hz, 1H), 7.55(d, J=3 Hz, 1H), (10H-pyrazino[2,3-b] 7.58(dd, J=1, 9
Hz, 1H), [1,4]benzothiazin-8-yl)-(2- 7.68(d, J=3 Hz, 1H),
(ethylpyridin-5-yl)methanol 8.51(d, J=1 Hz, 1H) 1176 1642 FAB(+)
399 (MH.sup.+) 65-70.degree. C. solvent unknown 3.91(s, 2H),
5.53(d, J=4 Hz, 1H), 6.02(d, J=4 Hz, 1H), 6.75(dd, J=1, 8 Hz, 1H),
6.81(d, J=1 Hz, 1H), 6.84(d, J=8 Hz, 1H), 7.26(d, J=8 Hz, 1H),
7.50(dd, J=2, 8 Hz, 1H), methyl [5-[(10H-pyrazino[2,3-b][1,4]
7.62(d, J=3 Hz, 1H), benzothiazin-8-yl)hydroxymethyl]pyridin-
7.63(d, J=3 Hz, 1H), 2-ylthio]acetate 8.35(d, J=2 Hz, 1H), 9.44(s,
1H)
EXAMPLE 1177
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(6-bromopyrid-
in-2-yl)methanol
[3271] 30 ml of a solution of 2.84 g of 2,6-dibromopyridine in
diethyl ether was cooled in a nitrogen atmosphere in a
methanol/liquefied nitrogen bath to -85.degree. C. and 7.5 ml of a
1.6 M solution of n-butyllithium in hexane was dropped thereinto.
After stirring for 30 minutes, the reaction mixture was heated to
-78.degree. C. and 40 ml of a. solution of 1.05 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-yl)carbaldlehyde in dry tetrahydrofuran was dropped
thereinto. Then the reaction mixture was brought back to room
temperature and distributed into an aqueous solution of sodium
dihydrogenphosphate and ethyl acetate. The aqueous layer was
extracted with ethyl acetate, washed successively with water and a
saturated aqueous solution of sodium chloride and dried over
anhydrous sodium sulfate followed by filtration. After distilling
off the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 1.05 g of the title
compound as a yellow solid. 1643
[3272] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3273] 3.51(s, 3H), 4.40(d, J=5 Hz, 1H), 5.25(s, 2H), 5.66(d, J=5
Hz, 1H), 6.98(m, 2H), 7.16(d, J=8 Hz, 1H), 7.17(s, 1H), 7.40(d, J=8
Hz, 1H), 7.50(t, J=8 Hz, 1H), 7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz,
1H)
EXAMPLE 1178
8-[(6-Bromopyridin-2-yl)-(tert-butyldimethylsiloxy)methyl]-10-methoxymethy-
l-10H-pyrazino[2,3-b][1,4]benzothiazine
[3274] To a solution of 1.05 g of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-(6-bromopyridin-2-yl)methano- l in 15 ml of acetonitrile was
added in a nitrogen atmosphere 3.2 ml of
N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide and the
resulting mixture was stirred at room temperature for 22 hours.
After distilling off the solvent under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with n-hexane/ethyl acetate) to thereby give 0.72 g of the title
compound as a yellow solid. 1644
[3275] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3276] 0.01(s, 3H), 0.04(s, 3H), 0.93(s, 9H), 3.53(s, 3H), 5.23(s,
2H), 5.77(s, 1H), 6.93(d, J=8 Hz, 1H), 7.09(dd, J=2, 8 Hz, 1H),
7.31(dd, J=2, 7 Hz, 1H), 7.36(d, J=2 Hz, 1H), 7.48(dd, J=2, 7 Hz,
1H), 7.51(t, J=7 Hz, 1H), 7.82(m, 2H)
EXAMPLE 1179
Ethyl(E)-3-[6-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-y-
l)-(tert-butyldimethylsiloxy)methyl]pyridin -2-yl]-2-propenoate
[3277] To a solution of 0.72 g of 8-[(6-bromopyridin
-2-yl)-(tert-butyldimethylsiloxy)
methyl]-10-methoxymethyl-10H-pyrazino[2- ,3-b][1,4]benzothiazine in
N,N-dimethylformamide (8 ml) were added 0.17 ml of ethyl acrylate,
0.22 ml of triethylamine, 12 mg of palladium (II) acetate and 33 mg
of triphenylphosphine and the resulting mixture was heated to
90.degree. C. for 30 hours. Then the reaction mixture was brought
back to room temperature and distributed into water and ethyl
acetate. The organic layer was extracted, washed successively with
water and a saturated aqueous solution of sodium chloride, dried
over anhydrous magnesium sulfate and filtered. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (diluted with
dichloromethane/ethyl acetate) to thereby give 540 mg of the title
compound as a yellow oily substance. 1645
[3278] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3279] 0.01(s, 3H), 0.07(s, 3H), 0.96(s, 9H), 1.35(t, J=7 Hz, 3H),
3.53(s, 3H), 4.28(q, J=7 Hz, 2H), 5.23(s, 2H), 5.82(s, 1H), 6.84(d,
J=8 Hz, 1H), 6.94(d, J=16 Hz, 1H), 7.12(dd, J=2, 8 Hz, 1H), 7.25(d,
J=8 Hz, 1H), 7.42(d, J=2 Hz, 1H), 7.50(d, J=8 Hz, 1H), 7.65(d, J=16
Hz, 1H), 7.67(t, J=8 Hz, 1H), 7.82(s, 2H)
EXAMPLE 1180
Ethyl
3-[6-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl)--
(tert-butyldimethylsiloxy)methyl)pyridin -2-yl]propanoate
[3280] 201 mg of the title compound was obtained by treating 249 mg
of ethyl 3-[6-[(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl-
)-(tert-butyldimethylsiloxy)methyl]pyridin -2-yl]-2-propenoate by
the same method as the one of Example 20. 1646
[3281] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3282] 0.05(s, 3H), 0.03(s, 3H), 0.93(s, 9H), 1.20(t, J=7 Hz, 3H),
2.77(m, 2H), 3.06(m, 2H), 3.51(s, 3H), 4.11(q, J=7 Hz, 2H), 5.22(s,
2H), 5.74(s, 1H), 6.91(d, J=8 Hz, 1H), 7.00(d, J=8 Hz, 1H),
7.06(dd, J=2, 8 Hz, 1H), 7.30(d, J=8 Hz, 1H), 7.36(d, J=2 Hz, 1H),
7.53(t, J=8 Hz, 1H), 7.81(s, 2H)
EXAMPLES
[3283] The following compounds were obtained by treating the
compounds obtained in Examples 1179 and 1180 with
tetrabutylammonium fluoride by the same method as the one of
Example 1418 and followed by the same treatment as the one of
Example 9.
172 Ex. Structural formula MS M.p. NMR 1181 1647 ESI(+) 429
(MNa.sup.+) 160-170.degree. C. (decom- pose)
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.37(t, J=7 Hz, 3H), 4.30(q,
J=7 Hz, 2H), 5.59(s, 1H), 6.86(s, 2H), 6.99(d, J=16 Hz, 1H),
7.12(d, J=8 Hz, 1H), 7.12(d, J=8 Hz, 1H), ethyl
(E)-3-[6-[(10H-pyrazino[2,3-b- ] 7.35(d, J=8 Hz, 1H), 7.55(d, J=3
Hz, 1H), [1,4]benzothiazin-8-yl)hydroxymethyl]pyridin- 7.67(d, J=3
Hz, 1H), 7.69(t, J=8 Hz, 1H), 2-yl]-2-propenoate 7.69(d, J=16 Hz,
1H) 1182 1648 ESI(+) 431 (MNa.sup.+) .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.24(t, J=7 Hz, 3H), 2.83(t, J=6 Hz, 2H), 3.18(t, J=6
Hz, 2H), 4.14(q, J=7 Hz, 2H), 5.52(s, 1H), 6.51(s, 1H), 6.66(s,
1H), ethyl 3-[6-[(10H-pyrazino[2,3-b] 6.84(s, 2H), 6.94(d, J=8 Hz,
1H), [1,4]-benzothiazin-8-yl)hydroxymethyl] 7.12(d, J=8 Hz, 1H),
7.53(d, J=3 Hz, 1H), pyridin-2-yl]propanoate 7.55(t, J=8 Hz, 1H),
7.60(d, J=3 Hz, 1H)
EXAMPLE 1183
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)
(pyridin-2-yl) ketone
[3284] The title compound was synthesized by oxidizing
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-(pyridin-3-y-
l)methanol with manganese dioxide by the same method as the one of
Example 625. 1649
[3285] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3286] 3.47(s, 3H), 5.30(s, 2H), 7.10(d, J=8.2 Hz, 1H), 7.50(ddd,
J=1.3, 4.3, 7.6 Hz, 1H), 7.70(dd, J=1.5, 8.2 Hz, 1H), 7.85(s, 2H),
7.87(d, J=1.5 Hz, 1H), 7.91(dt, J=1.9, 7.6 Hz, 1H), 8.05(d, J=1.3,
7.6 Hz, 1H), 8.72(d, J=1.9, 4.3 Hz, 1H)
EXAMPLE 1184
1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-2-(pyridin-2-yl)ethanol
[3287] 90 mg of the title compound was obtained as a yellow oily
substance by treating 260 mg of 2-methylpyridine and
(10-methoxymethyl-10H-pyrazino-
[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde by the same method as
the one of Example 1128. 1650
[3288] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3289] 3.10(d, J=5.9 Hz, 2H), 3.52(s, 3H), 5.10(d, J=5.9 Hz, 1H),
5.25(s, 2H), 5.8-6.0(br.s, 1H), 6.97(d, J=7.9 Hz, 1H), 7.02(dd,
J=1.6, 7.9 Hz, 1H), 7.11(br.d, J=7.5 Hz, 1H), 7.19(br.dd, J=5.0,
7.5 Hz, 1H), 7.21(br.d, J=1.6 Hz, 1H), 7.62(dt, J=1.8, 7.5 Hz, 1H),
7.82(s, 2H), 8.52(br.d, J=5.0 Hz, 1H)
EXAMPLE 1185
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)(pyridin-2-yl)ketone
[3290] The title compound was obtained by treating
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)(pyridin-2-yl)ketone by the
same method as the one of Example 9. 1651
[3291] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3292] 7.05(d, J=8.6 Hz, 1H), 7.35(d, J=1.6 Hz, 1H), 7.37(dd,
J=1.6, 8.6 Hz, 1H), 7.65(d, J=3.2 Hz, 1H), 7.66(dd, J=4.3, 7.6 Hz,
1H), 7.67(d, J=3.2 Hz, 1H), 7.92(d, J=7.6 Hz, 1H), 8.04(dt, J=1.6,
7.6 Hz, 1H), 8.70(dd, J=1.6, 4.3 Hz, 1H), 9.64(s, 1H)
EXAMPLE 1186
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-2-(pyridin
-2-yl)ethanol
[3293] The following compound was obtained by treating
1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-2-(pyridin-
-2-yl)ethanol by the same method as the one of Example 434.
1652
[3294] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3295] 2.89(dd, J=5.5, 13.5 Hz, 1H), 2.95(dd, J=8.3, 13.5 Hz, 1H),
4.79(ddd, J=4.3, 5.5, 13.5 Hz, 1H), 5.37(d, J=4.3 Hz, 1H), 6.69(dd,
J=1.3, 8.3 Hz, 1H), 6.80(d, J=8.3 Hz, 1H), 6.81(d, J=1.3 Hz, 1H),
7.17(d, J=7.6 Hz, 1H), 7.18(t, J=4.3 Hz, 1H), 7.62(d, J=3.2 Hz,
1H), 7.63(d, J=3.2 Hz, 1H), 7.64(dt, J=1.7, 7.6 Hz, 1H), 8.47(d,
J=4.3 Hz, 1H), 9.46(s, 1H)
[3296] MS: FAB(+)325(MH.sup.30 )
EXAMPLE 1187
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)(pyridin
-2-ylmethyl)ketone
[3297] 0.15 ml of diisopropylamine in tetrahydrofuran (10 ml) was
ice-cooled and 1.0 ml of a 1.6 M solution of n-butyllithium in
hexane was added thereto. After stirring for 10 minutes, the
reaction mixture was cooled to -78.degree. C. After adding 0.15 ml
of 2-methylpyridine, the mixture was stirred for 30 minutes and
then a solution of 303 mg of methyl
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbox-
ylate in tetrahydrofuran (5 ml) was dropped thereinto. The reaction
mixture was brought back to room temperature and distributed into
an aqueous solution of ammonium chloride and ethyl acetate. The
organic layer was extracted, dried over anhydrous sodium sulfate
and filtered. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
30 mg of (10-methoxymethyl-10H-pyrazino[2,3-b][1-
,4]benzothiazin-8-yl)(pyridin-2-ylmethyl)ketone as yellow crystals.
This ketone was further treated by the same method as the one of
Example 119 to thereby give 13 mg of the title compound as yellow
crystals. 1653
[3298] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3299] 4.36(s, initial, 2H, keto), 6.68(s, initial 1H, enol), 6.94
and 7.04(d, J=8.8 Hz, total 1H, enol:keto=8:1), 7.12 and 7.25(t,
J=6.4 Hz, total 1H, 8:1), 7.25 and 7.33(d, J=8.8 Hz, total 1H,
8:1), 7.25 and 7.44(d, J=8.0 Hz, total 1H, 8:1), 7.26 and 7.28(s,
total 1H, 8:1), 7.53(d, J=2.4 Hz, total 1H), 7.54(d, J=2.4 Hz,
total 1H), 8.37 and 8.44(t, J=6.4 Hz, total 1H, 8:1), 8.73 and
8.78(t, J=8.0 Hz, total 1H, 1:8), 9.57 and 9.64(s, total 1H,
8:1)
[3300] MS: FAB(+)321(M.sup.+)
EXAMPLE 1188
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)hydroxyacetic acid
[3301] 5 ml of an aqueous solution of 780 mg of potassium hydroxide
and 300 mg of lithium chloride was ice-cooled. Into the mixture was
dropped 5 ml of a solution of 900 mg of bromoform and 960 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)carbaldehyde in dioxane. After stirring at 0.degree. C. to
room temperature over day and night, the reaction mixture was
distributed into dilute hydrochloric acid and ethyl acetate. The
organic layer was extracted with ethyl acetate, washed with water
and dried over anhydrous sodium sulfate and then the extract was
filtered. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol). After recrystallizing from
ethyl acetate, 260 mg of the title compound was obtained as yellow
crystals. 1654
[3302] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3303] 4.81(s, 1H), 6.81(dd, J=1.5, 8.2 Hz, 1H), 6.84(d, J=1.5 Hz,
1H), 6.86(d, J=8.2 Hz, 1H), 7.62(d, J=2.8 Hz, 1H), 7.63(d, J=2.8
Hz, 1H)
[3304] MS: FAB(+)275(M.sup.30 ), 276(MH.sup.30 )
EXAMPLE 1189
Methyl(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)hydroxyacetate
[3305] 150 mg of methyl iodide was added to a solution of 100 mg of
(10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)hydroxyacetic acid in
N,N-dimethylformamide (8 ml) in the presence of 260 mg of potassium
carbonate. After purifying by silica gel column chromatography
(eluted with dichloromethane/methanol) and recrystallizing from
ethyl acetate/diisopropyl ether, 68 mg of the title compound was
obtained as yellow crystals. 1655
[3306] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3307] 3.48-3.68(br.s, 1H), 3.77(s, 3H), 5.01(s, 1H), 6.58(s, 1H),
6.65-6.71(br.s, 1H), 6.88(s, 2H), 7.57(d, J=2.7 Hz, 1H), 7.69(d,
J=2.7 Hz, 1H)
EXAMPLE 1190
Methyl 3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)
-3-hydroxypropanoate
[3308] 820 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-
-yl)carbaldehyde was dissolved in tetrahydrofuran (5 ml)/trimethyl
borate (5 ml) in a nitrogen atmosphere and 195 mg of zinc dust
(400-mesh) was added thereto. After stirring, 460 mg of methyl
bromoacetate was further added to the reaction mixture. After
heating under reflux for 8 hours, the reaction mixture was brought
back to room temperature and distributed into an aqueous solution
of ammonium chloride and ethyl acetate. The organic layer was
extracted, washed with water and dried over anhydrous sodium
sulfate and the extract was filtered. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 300 mg of methyl
3-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoth-
iazin-8-yl)-3-hydroxypropanoate as a yellow oily substance. A 100
mg portion of this product was treated by the same method as the
one of Example 9 to thereby give 30 mg of the title compound as
yellow crystals. 1656
[3309] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3310] 2.68(d, J=9.2 Hz, 2H), 3.35(br.d, J=3.3 Hz, 1H), 3.73(s,
3H), 4.99(dt, J=3.3, 9.2 Hz, 1H), 6.50(br.s, 1H), 6.59(dd, J=1.3,
8.2 Hz, 1H), 6.87(d, J=8.2 Hz, 1H), 6.95(d, J=1.3 Hz, 1H)7.58(d,
J=2.6 Hz, 1H), 7.70(d, J=2.6 Hz, 1H)
EXAMPLE 1191
3-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-3-hydroxypropanoic acid
[3311] 80 mg of the title compound was obtained as yellow crystals
by treating 100 mg of methyl 3-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]be- nzothiazin -8-yl)-3-hydroxypropanoate
by the same method as the one of Example 18. 1657
[3312] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3313] 2.68(dd, J=3, 14 Hz, 1H), 2.74(dd, J=9, 14 Hz, 1H), 3.49(s,
3H), 5.03(dd, J=3, 9 Hz, 1H), 5.24(s, 2H), 6.90(d, J=8.5 Hz, 1H),
6.92(d, J=8.5 Hz, 1H), 7.10(s, 1H), 7.80(s, 2H)
EXAMPLE 1192
3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-3-hydroxypropanoic
acid
[3314] 40 mg of the title compound was obtained as yellow crystals
by treating 3-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-- 3-hydroxypropanoic
acid by the same method as the one of Example 434. 1658
[3315] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3316] 2.43(d, J=6.9 Hz, 2H), 4.72(t, J=6.9 Hz, 1H),
5.39-5.46(br.s, 1H), 6.73(d, J=7.8 Hz, 1H), 6.79(d, J=1.4 Hz, 1H),
6.83(dd, J=1.4, 7.8 Hz, 1H), 7.61(d, J=3.2 Hz, 1H), 7.62(d, J=3.2
Hz, 1H), 9.48(s, 1H), 12.06-12.17(br.s, 1H)
[3317] MS: FAB(+)289(M.sup.+)
EXAMPLE 1193
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-1,3-propanediol
[3318] 50 mg of the title compound was obtained as yellow crystals
by treating 100 mg of methyl 3-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]be- nzothiazin -8-yl)-3-hydroxypropanoate
by the same methods as those of Examples 2 and 434. 1659
[3319] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3320] 1.52-1.71(m, 2H), 3.30-3.41(m, 1H), 3.41-3.52(m, 1H),
4.41(t, J=5.2 Hz, 1H), 4.40-4.48(m, 1H), 5.12(d, J=4.3 Hz, 1H),
6.71(d, J=7.6 Hz, 1H), 6.77(s, 1H), 6.82(d, J=7.6 Hz, 1H), 7.61(d,
J=2.4 Hz, 1H), 7.63(d, J=2.4 Hz, 1H), 9.47(s, 1H)
[3321] MS: FAB(+)275(M.sup.+)
EXAMPLE 1194
8-Vinyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3322] To 2.94 g of methyltriphenylphosphonium bromide in
N,N-dimethylformamide (20 ml) was added at room temperature 360 mg
of sodium hydride (60% oily) and the resulting mixture was stirred
for 1 hour. Next, 1.50 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothia-
zin-8-yl)carbaldehyde was added thereto and the resulting mixture
was heated to 65.degree. C. for 1.5 hours. Then the reaction
mixture was brought back to room temperature and distributed into
water and ethyl acetate. The organic layer was extracted, washed
with water and dried over anhydrous sodium sulfate and the extract
was filtered. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
1.42 g of the title compound as a yellow oily substance. 1660
[3323] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3324] 3.53(s, 3H), 5.26(d, J=10.9 Hz, 1H), 5.30(s, 2H), 5.72(d,
J=17.5 Hz, 1H), 6.63(dd, J=10.9, 17.5 Hz, 1H), 6.96(d, J=7.9 Hz,
1H), 7.03(dd, J=1.7, 7.9 Hz, 1H), 7.18(d, J=1.7 Hz, 1H), 7.83(s,
2H)
EXAMPLE 1195
1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-1,2-ethanediol
[3325] To 30 ml of a solution of 2.6 g of 8-vinyl
-10-methoxymethyl-10H-py- razino[2,3-b][1,4]benzothiazine and 1.06
g of N-methylmorpholine oxide in acetone was added 4.2 ml of a 1%
solution of osmium tetraoxide in tert-butanol and the resulting
mixture was stirred at room temperature for 12 hours. Then it was
distributed into an aqueous solution of sodium hydrogenthiosulfate
and ethyl acetate. After filtering off the inorganic matters
through celite, the organic layer was extracted, washed with water
and dried over anhydrous sodium sulfate and the extract was
filtered. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol) to thereby give 0.35 g of
the title compound as yellow crystals. 1661
[3326] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3327] 3.50(s, 3H), 3.59(dd, J=8.1, 11.4 Hz, 1H), 3.71(dd, J=3.0,
11.4 Hz, 1H), 4.71(dd, J=3.0, 8.1 Hz, 1H), 5.24(s, 2H), 6.90(dd,
J=1.4, 7.9 Hz, 1H), 6.94(d, J=7.9 Hz, 1H), 7.10(d, J=1.4 Hz, 1H),
7.81(s, 2H)
EXAMPLE 1196
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-1,2-ethanediol
[3328] 100 mg of the title compound was obtained as yellow crystals
by treating 350 mg of 1-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothia- zin -8-yl)-1,2-ethanediol by
the same method as the one of Example 9. 1662
[3329] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3330] 3.24-3.43(m, 2H), 4.32(t, J=5.5 Hz, 1H), 6.73(d, J=8.4 Hz,
1H), 6.78(d, J=1.4 Hz, 1H), 6.82(dd, J=1.4, 8.4 Hz, 1H), 7.61(d,
J=3.4 Hz, 1H), 7.62(d, J=3.4 Hz, 1H), 9.46(s, 1H)
[3331] MS: FAB(+)261(M.sup.30 ), 262(MH.sup.30 )
EXAMPLES
[3332] The following compounds were obtained by treating
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
successively by the same methods as those of Examples 1128 and
9.
173 Ex. Structural formula MS M.p. NMR 1197 1663 192-194.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 5.54(br.s, 1H), 6.50(br.s,
1H), 6.77(s, 1H), 6.92(d, J=8 Hz, 1H), 7.05(d, J=8 Hz, 1H),
7.28-7.40(m, 4H), 1-(10H-pyrazino[2,3-b][1,4]benzothiazin-
7.43-7.48(m, 2H), 8-yl)-3-phenyl-2-propyn-1-ol 7.58(d, J=3 Hz, 1H),
7.67(d, J=3 Hz, 1H) 1198 1664 ESI 312 (MH.sup.+) 116-118.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.20(t, J=6 Hz, 3H),
1.34-1.48(m, 2H), 1.50-1.60(m, 2H), 2.15-2.20(br.s, 1H), 2.25(dt,
J=2, 6 Hz, 2H), 5.28-5.35(br.s, 1H), 6.43-6.50(br.s, 1H), 6.72(s,
1H), 1-(10H-pyrazino[2,3-b][1,4]benzothiazin- 6.88(d, J=8 Hz, 1H),
6.97(d, J=8 Hz, 1H), 8-yl)hept-2-yn-1-ol 7.57(d, J=3 Hz, 1H),
7.69(d, J=3 Hz, 1H)
EXAMPLE 1199
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-3-phenylpropan
-1-ol
[3333] The title compound was obtained by treating
1-(10H-pyrazino[2,3-b][- 1,4]benzothiazin-8-yl)-3-phenyl
-2-propyn-1-ol by the same method as the one of Example 20.
1665
[3334] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3335] 1.90-2.10(m, 2H), 2.60-2.80(m, 2H), 4.50-4.60(br.s, 1H),
6.40-6.46(br.s, 1H), 6.52(s, 1H), 6.78(d, J=8 Hz, 1H), 6.85(d, J=8
Hz, 1H), 7.15-7.23(m, 2H), 7.25-7.30(m, 4H), 7.58(d, J=3 Hz, 1H),
7.72(d, J=3 Hz, 1H)
[3336] MS: ESI(+)336(MH.sup.30 )
[3337] m.p.: 156-158.degree. C.
EXAMPLE 1200
(E)-3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)
-2-propen-1-ol
[3338] The title compound was obtained as yellow crystals by
treating
(E)-3-[10-(methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-2-pr-
open-1-ol by the same method as the one of Example 434. 1666
[3339] .sup.1H-NMR(D, O-d.sub.6) .delta. ppm:
[3340] 4.07(dd, J=4.9, 5.5 Hz, 2H), 4.87(t, J=5.5 Hz, 1H), 6.21(dt,
J=4.9, 16.2 Hz, 1H), 6.33(d, J=16.2 Hz, 1H), 6.79(s, 1H), 6.84(s,
2H), 7.61-7.65(m, 2H), 9.47(s, 1H)
EXAMPLE 1201
3-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-1-propanol
[3341] 6.0 g of the title compound was obtained as yellow crystals
by treating 7.5 g of ethyl 3-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benz- othiazin -8-yl)propanoate by the
same method as the one of Example 2 followed by purification by
silica gel column chromatography (eluted with
dichloromethane/methanol). 1667
[3342] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3343] 1.33-1.38(m, 1H), 1.87(dt, J=7.0, 14.9 Hz, 2H), 2.66(dd,
J=7.0, 9.3 Hz, 2H), 3.53(s, 3H), 3.65-3.72(m, 2H), 5.28(s, 2H),
6.83(dd, J=1.6, 7.7 Hz, 1H), 6.94(d, J=7.7 Hz, 1H), 7.00(d, J=1.6
Hz, 1H), 7.82(d, J=2.8 Hz, 1H), 7.84(d, J=2.8 Hz, 1H)
EXAMPLE 1202
3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-1-propanol
[3344] 120 mg of the title compound was obtained as yellow crystals
by treating 250 mg of 3-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothia- zin -8-yl)-1-propanol by the
same method as the one of Example 434. 1668
[3345] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3346] 1.33-1.45(br.s, 1H), 1.83(quint, J=7.1 Hz, 2H), 2.58(t,
J=7.1 Hz, 2H), 3.68(t, J=7.1 Hz, 2H), 6.36(d, J=1.9 Hz, 1H),
6.46-6.53(br.s, 1H), 6.69(dd, J=1.9, 7.9 Hz, 1H), 6.81(d, J=7.9 Hz,
1H), 7.57(d, J=2.8 Hz, 1H), 7.69(d, J=2.8 Hz, 1H)
EXAMPLE 1203
(E)-5-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-2-hydro-
xy-2-methyl-4-penten-3-one
[3347] 550 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
yl)carbaldehyde and 3-hydroxy -3-methyl-2-butanone was dissolved in
methanol (10 ml)/tetrahydrofuran (2 ml). After adding 250 mg of
lithium hydroxide, the reaction mixture was stirred at room
temperature over day and night. Then the reaction mixture was
distributed into an aqueous solution of ammonium chloride and ethyl
acetate. The organic layer was extracted, washed with water and
dried over anhydrous sodium sulfate. After filtering, the filtrate
was distilled off under reduced pressure and the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 420 mg of the title
compound as a yellow oily substance. 1669
[3348] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3349] 1.45(s, 6H), 3.55(s, 3H), 3.92(s, 1H), 5.29(s, 2H), 6.96(d,
J=15.7 Hz, 1H), 7.03(d, J=8.0 Hz, 1H), 7.23(dd, J=1.7, 8.0 Hz, 1H),
7.30(d, J=1.7 Hz, 1H), 7.75(d, J=15.7 Hz, 1H), 7.85(d, J=2.8 Hz,
1H), 7.86(d, J=2.8 Hz, 1H)
EXAMPLE 1204
(E)-5-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)
-2-hydroxy-2-methyl-4-pe- nten-3-one
[3350] 320 mg of the title compound was obtained as yellow crystals
by treating 420 mg of (E)-5-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzo- thiazin
-8-yl)-2-hydroxy-2-methyl-1-penten-3-one by the same method as the
one of Example 9. 1670
[3351] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3352] 1.23(s, 6H), 5.43(s, 1H), 6.97(d, J=8.2 Hz, 1H), 7.06(s,
1H), 7.12(d, J=8.2 Hz, 1H), 7.33(d, J=16.9 Hz, 1H), 7.37(d, J=16.9
Hz, 1H), 7.64(d, J=3.0 Hz, 1H), 7.65(d, J=3.0 Hz, 1H), 9.51(s,
1H)
EXAMPLE 1205
5-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-2-hydroxy-2-methylpentan-3-one
[3353] 320 mg of the title compound was obtained as yellow crystals
by treating 450 mg of (E)-5-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzo- thiazin
-8-yl)-2-hydroxy-2-methyl-4-penten-3-one successively by the same
methods as those of Examples 20 and 9. 1671
[3354] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3355] 1.14(s, 6H), 2.55(t, J=7 Hz, 2H), 2.88(t, J=7 Hz, 2H),
5.24(br.s, 1H), 6.61(t, J=1 Hz, 1H), 6.63(dd, J=1, 8 Hz, 1H),
6.79(dd, J=1, 8 Hz, 1H), 7.62(m, 2H), 9.43(s, 1H)
[3356] MS: FAB(+)315(M.sup.30 )
EXAMPLE 1206
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)ethanol
[3357] 5.0 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-y-
l)carbaldehyde was treated by the same method as the one of
Production Example 86 to thereby give 5.0 g of
1-(10-methoxymethyl-10H-pyrazino[2,3--
b][1,4]benzothiazin-8-yl)ethanol as a yellow oily substance. Next,
a 0.5 g portion of this product was treated by the same method as
the one of Example 9 to thereby give 0.1 g of the title compound as
yellow crystals. 1672
[3358] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3359] 1.43(d, J=4.0 Hz, 3H), 1.91(br.s, 1H), 4.78(q, J=4.0 Hz,
1H), 6.50-6.60(br.s, 1H), 6.57(d, J=1.6 Hz, 1H), 6.81(dd, J=1.6,
8.3 Hz, 1H), 6.86(d, J=8.3 Hz, 1H), 7.57(d, J=3.1 Hz, 1H), 7.69(d,
J=3.1 Hz, 1H)
EXAMPLE 1207
Diethyl (10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)phosphonate
[3360] To 2 ml of triethyl phosphite was added 0.374 g of
8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine and the
resulting mixture was heated to 160.degree. C. for 3 hours. Then
the reaction mixture was brought back to room temperature and
diethyl ether (10 ml) and n-hexane (20 ml) were added thereto. The
precipitate was taken up by filtration and washed several times
with n-hexane to thereby give 0.413 g of the title compound as a
yellow powder. 1673
[3361] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3362] 1.28(t, J=6 Hz, 6H), 2.94(d, J=23 Hz, 2H), 4.05(m, 4H),
6.50(s, 1H), 6.51(d, J=2 Hz, 1H), 6.73(dd, J=2, 8 Hz, 1H), 6.82(d,
J=8 Hz, 1H), 7.57(d, J=3 Hz, 1H), 7.69(d, J=3 Hz, 1H)
[3363] MS: FAB(+)352(MH.sup.30 )
[3364] m.p.: 164-165.degree. C.
EXAMPLE 1208
5-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-1,3-oxazole
[3365] To 10 ml of a solution of 560 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)carbaldehyde in
methanol were added 280 mg of potassium carbonate and 392 mg of
(p-toluenesulfonyl)meth- yl isocyanide and the resulting mixture
was heated under reflux for 1.5 hours. Then the reaction mixture
was brought back to room temperature and diluted with water. The
crystals thus precipitated were taken up by filtration and washed
successively with water and diethyl ether to thereby give 400 mg of
the title compound as yellow crystals. 1674
[3366] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3367] 3.41(s, 3H), 5.33(s, 2H), 7.22(d, J=8.2 Hz, 1H), 7.37(dd,
J=1.7, 8.2 Hz, 1H), 7.39(d, J=1.7 Hz, 1H), 7.68(s, 1H), 7.94(d,
J=2.8 Hz, 1H), 7.98(d, J=2.8 Hz, 1H), 8.45(s, 1H)
EXAMPLE 1209
1-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-1,3-butanedione
[3368] Into 20 ml of ice-cooled solution of 1.27 ml of
diisopropylamine in dry tetrahydrofuran was dropped in a nitrogen
atmosphere 5.5 m l of a 1.6 M solution of n-butyllithium in hexane.
After stirring for 10 minutes, the reaction mixture was cooled to
-78.degree. C. Next, 5 ml of a solution of 2.0 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiaz- in -8-yl)
methyl ketone in dry tetrahydrofuran was added thereto and the
mixture was stirred for 30 minutes. After further dropping 700 mg
of acetyl chloride thereinto, the reaction mixture was brought back
to room temperature. Then the reaction mixture was distributed into
water and ethyl acetate,and the organic layer was extracted, washed
with water, dried over anhydrous sodium sulfate and filtered. The
filtrate was distilled off under reduced pressure and the residue
was purified by silica gel column chromatography (eluted with
toluene/acetone) to thereby give 420 mg of the title compound as a
yellow oily substance. 1675
[3369] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3370] 2.20(s, 3H), 3.56(s, 3H), 5.33(s, 2H), 6.10(s, 1H), 7.06(d,
J=7.8 Hz, 1H), 7.43(dd, J=1.6, 7.8 Hz, 1H), 7.64(d, J=1.6 Hz, 1H),
7.86(s, 2H)
EXAMPLE 1210
8-(5-Methylpyrazol-3-yl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3371] To 10 ml of a solution of 180 mg of 1-(10-methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)-1,3-butanedione in
methanol was added 50 mg of hydrazine monohydrate and the resulting
mixture was heated under reflux for 30 minutes. Then the reaction
mixture was brought back to room temperature. After distilling off
the solvent under reduced pressure, the crystals thus precipitated
were taken up by filtration and washed with diethyl ether to
thereby give 150 mg of 8-(5-methylpyrazol
-3-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine as
yellow crystals. Further, this product was treated by the same
method as the one of Example 9 to thereby give 110 mg of the title
compound as yellow crystals. 1676
[3372] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3373] 2.22(br.s, 3H), 6.27(s, 1H), 6.89(br.d, J=8.0 Hz, 1H),
7.12(d, J=8.0 Hz, 1H), 7.23(br.s, 1H), 7.63(d, J=2.9 Hz, 1H),
7.64(d, J=2.9 Hz, 1H), 9.52(br.s, 1H), 12.50-12.60(br.s, 1H)
[3374] MS: FAB(+)285(M.sup.+)
EXAMPLE 1211
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-3-methylisoxazole
[3375] Similar to Example 1223,
1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,-
4]benzothiazin-8-yl)-1,3-butanedione was treated with hydroxylamine
to thereby give (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl- )-3-methylisoxazole.
Further, this product was treated by the same method as the one of
Example 9 to thereby give the title compound. 1677
[3376] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3377] 2.26(s, 3H), 6.72(s, 1H), 7.04(d, J=8.0 Hz, 1H), 7.15(d,
J=1.4 Hz, 1H), 7.21(dd, J=1.4, 8.0 Hz, 1H), 7.66(d, J=3.0 Hz, 1H),
7.67(d, J=3.0 Hz, 1H), 9.65(s, 1H)
EXAMPLE 1212
2-Amino-1-[N-[(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-
methylene]]aminobenzene
[3378] 820 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
yl)carbaldehyde and 360 mg of o-phenylenediamine were suspended in
2 ml of pyridine in a nitrogen atmosphere and heated under reflux
for 10 minutes. Then the reaction mixture was brought back to room
temperature and a small amount of ethyl acetate was added thereto.
The crystals thus precipitated were ground by ultrasonication and
filtered. Thus 610 mg of the title compound was obtained as yellow
crystals. 1678
[3379] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3380] 3.57(s, 3H), 4.26(br.s, 2H), 5.35(s, 2H), 6.75(dt, J=1.2,
7.4 Hz, 1H), 6.78(dd, J=1.2, 7.4 Hz, 1H), 7.07(d, J=7.4 Hz, 1H),
7.08(t, J=7.4 Hz, 1H), 7.09(d, J=8.3 Hz, 1H), 7.50(dd, J=1.5, 8.3
Hz, 1H), 7.66(d, J=1.5 Hz, 1H), 7.86(s, 2H), 8.46(s, 1H)
EXAMPLE 1213
8-(Benzimidazol-2-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazi-
ne
[3381] 610 mg of 2-amino-1-[N-[(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]-
benzothiazin-8-yl)methylene]]aminobenzene was heated under reflux
in 3 ml of pyridine for 8 hours. Then the reaction mixture was
brought back to room temperature and eluted with ethyl acetate. The
crystals thus precipitated were ground and filtered to thereby give
310 mg of the title compound as yellow crystals. 1679
[3382] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3383] 3.45(s, 3H), 5.39(s, 2H), 7.15-7.25(m, 2H), 7.31(d, J=8.3
Hz, 1H), 7.48-7.56(br.d, J=7.2 Hz, 1H), 7.63-7.70(br.d, J=7.2 Hz,
1H), 7.75(dd, J=1.7, 8.3 Hz, 1H), 7.94(d, J=1.7 Hz, 1H), 7.96(d,
J=2.6 Hz, 1H), 8.00(d, J=2.6 Hz, 1H), 12.93(br.s, 1H)
EXAMPLE 1214
8-(Benzothiazol-2-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazi-
ne
[3384] Similar to Example 1212, 2-aminobenzenethiol employed as a
substitute for o-phenylenediamine was heated under reflux in
pyridine for 30 minutes to thereby give 820 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b-
][1,4]benzothiazin-8-yl)carbaldehyde, from which 250 mg of the
title compound was obtained as yellow crystals. 1680
[3385] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3386] 3.61(s, 3H), 5.40(s, 2H), 7.13(t, J=8.1 Hz, 1H), 7.40(t,
J=8.3 Hz, 1H), 7.50(t, J=8.3 Hz, 1H), 7.68(dd, J=1.8, 8.1 Hz, 1H),
7.85(d, J=1.8 Hz, 1H), 7.88(s, 2H), 7.90(d, J=8.3 Hz, 1H), 8.07(d,
J=8.3 Hz, 1H)
EXAMPLES
[3387] The following compounds were obtained each as yellow
crystals by treating the compounds obtained in Examples 1213 and
1214 by the same method as the one of Example 434.
174 Ex. Structural formula NMR 1215 1681 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 7.09(d, J=7.7 Hz, 1H), 7.13-7.23(m, 2H), 7.45-7.52(m,
1H), 7.48(dd, J=1.7, 7.7 Hz, 1H), 7.59-7.65(m, 1H), 7.63(d, J=1.7
Hz, 1H), 8-(benzimidazol-2-yl)-10- H-pyrazino 7.66(d, J=2.7 Hz,
1H), 7.68(d, J=2.7 Hz, 1H), [2,3-b][1,4]benzothiazine 9.70(s, 1H),
12.83(br.s, 1H) 1216 1682 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
7.08(d, J=8.1 Hz, 1H), 7.44(dd, J=1.8, 8.1 Hz, 1H), 7.45(t, J=8.0
Hz, 1H), 7.52(d, J=1.8 Hz, 1H), 7.53(t, J=8.0 Hz, 1H), 7.67(d,
J=2.8 Hz, 1H), 8-(benzothiazol-2-yl)-10H-pyrazino 7.68(d, J=2.8 Hz,
1H), 8.01(d, J=8.0 Hz, 1H), [2,3-b][1,4]benzothiazine 8.13(d, J=8.0
Hz, 1H), 9.69(s, 1H)
EXAMPLE 1217
(E)-8-(Benzenesulfonylvinyl)-10-methoxymethyl-10H-pyrazino-[2,3-b][1,4]ben-
zothiazine
[3388] A solution of 1.40 g of diethyl
(benzenesulfonyl)-methylphosphonate in N,N-dimethylformamide (15
ml) was cooled to 0.degree. C. in a nitrogen atmosphere. After
adding 210 mg of sodium hydride, the resulting mixture was stirred
for 5 minutes. Into the reaction mixture was dropped a solution of
1.00 g of (10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothia-
zin-8-yl)carbaldehyde in N,N-dimethylformamide (5 ml). After
stirring for additional 10 minutes, the reaction mixture was
distributed into water and ethyl acetate. The organic layer was
extracted, washed with water and dried over magnesium sulfate.
After distilling off the solvent under reduced pressure, the
residue was diluted with diisopropyl ether and the crystals thus
precipitated were filtered to thereby give 1.38 g of the title
compound as yellow crystals. 1683
[3389] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3390] 3.36(s, 3H), 5.33(s, 2H), 7.18(d, J=8.0 Hz, 1H), 7.35(d,
J=1.7 Hz, 1H), 7.40(dd, J=1.7, 8.0 Hz, 1H), 7.58(s, 2H),
7.62-7.69(m, 2H), 7.70-7.75(m, 1H), 7.89-7.93(m, 2H), 7.95(d, J=2.9
Hz, 1H), 7.97(d, J=2.9 Hz, 1H)
EXAMPLE 1218
8-(1,2,3-Triazol-4(5)-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoth-
iazine
[3391] To a solution of 410 mg of 8-(2-benzenesulfonylvinyl)
-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine in a
mixture of N,N-dimethylformamide (3 ml) and dimethyl sulfoxide (7
ml) was added sodium azide (450 mg in total) and the resulting
mixture was heated to 120.degree. C. for 3 hours. Then the reaction
mixture was brought back to room temperature and distributed into 1
N hydrochloric acid and ethyl acetate. The organic layer was
extracted, washed with water and dried over anhydrous magnesium
sulfate. After distilling off the solvent under reduced pressure,
the crystals thus precipitated were filtered and washed with
diisopropyl ether. Thus 220 mg of the title compound was obtained.
1684
[3392] .sup.1H-NMR(DMSO-d.sub.6), .delta. ppm:
[3393] 3.41(s, 3H), 5.33(s, 2H), 7.19 and 7.21(d, J=7.7 Hz, total
1H, 1:2), 7.47 and 7.49(dd, J=1.4, 7.7 Hz, total 1H, 1:2), 7.62 and
7.69(d, J=1.4 Hz, total 1H, 2:1), 7.94(d, J=2.8 Hz, 1H), 7.98(d,
J=2.8 Hz, 1H), 8.23 and 8.57(d, J=1.2 Hz, initial 1H, and, br.s,
initial 1H, 2:1)
EXAMPLE 1219
8-(3-Trimethylsilylpyrazol-4-yl)-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4- ]benzothiazine
[3394] 1.5 ml of a 2.0 M solution of (trimethylsilyl)-diazomethane
in hexane was added to dry tetrahydrofuran (7 ml) in a nitrogen
atmosphere and cooled to -78.degree. C. After dropping 1.0 ml of a
1.6 M n-butyllithium solution in n-hexane thereinto, the resulting
mixture was stirred for 30 minutes. Into the reaction mixture was
dropped a solution of 410 mg of 8-(2-benzenesulfonylvinyl)
-10-methoxymethyl-10H-pyrazino[2,- 3-b][1,4]benzothiazine obtained
in Example 1080-1 in dry tetrahydrofuran (5 ml). Then the reaction
mixture was gradually heated to room temperature and an aqueous
solution of ammonium chloride was added thereto followed by
extraction with ethyl acetate. Then the mixture was dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the obtained residue was purified by silica gel
column chromatography (eluted with ethyl acetate/n-hexane) to
thereby give 130 mg of the title compound as yellow crystals.
1685
[3395] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3396] 0.00(s, 9H), 3.20(s, 3H), 4.96(s, 2H), 6.68(dd, J=1.5, 7.6
Hz, 1H), 6.72(d, J=7.6 Hz, 1H), 6.68(d, J=1.5 Hz, 1H), 7.38(s, 1H),
7.54(d, J=2.8 Hz, 1H), 7.55(d, J=2.8 Hz, 1H)
EXAMPLE 1220
8-(Pyrazol-4-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3397] 5 ml of a solution of 130 mg of 8-(3-trimethylsilyl-pyrazol
-4-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine in
tetrahydrofuran was stirred at room temperature and 1.1 ml of a 1M
solution of tetrabutylammonium fluoride in tetrahydrofuran was
added thereto. After stirring for 5 minutes, the reaction mixture
was distributed into ethyl acetate and 1 N hydrochloric acid. The
organic layer was extracted, washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the obtained residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 42 mg of the title compound as yellow crystals.
1686
[3398] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3399] 3.56(s, 3H), 5.33(s, 2H), 7.03(d, J=7.8 Hz, 1H), 7.12(dd,
J=1.6, 7.8 Hz, 1H), 7.32(d, J=1.6 Hz, 1H), 7.85(s, 2H), 7.85(d,
J=2.8 Hz, 1H), 7.86(d, J=2.8 Hz, 1H)
EXAMPLE 1221
8-(1,2,3-Triazol-4(5)-yl)-10H-pyrazino[2,3-b][1,4]-benzothiazine
[3400] The title compound was obtained by treating
8-(1,2,3-triazol-4(5)-y-
l)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine by the
same method as the one of Example 434. 1687
[3401] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3402] 6.69(d, J=8.6 Hz, 1H), 7.23(d, J=8.6 Hz, 1H),
7.27-7.35(br.s, 1H), 7.64(d, J=3.0 Hz, 1H), 7.65(d, J=3.0 Hz, 1H),
8.12-8.27(br.s, 1H), 9.61(s, 1H)
[3403] MS: FAB(+)269(MH.sup.30 )
EXAMPLE 1222
8-(Pyrazol-4-yl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3404] The title compound was obtained by treating
8-(pyrazol-4-yl)-10-met-
hoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method
as the one of Example 9. 1688
[3405] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3406] 6.88(d, J=7.6 Hz, 1H), 6.96(d, J=1.8 Hz, 1H), 7.02(dd,
J=1.8, 7.6 Hz, 1H), 7.63(d, J=2.9 Hz, 1H), 7.64(d, J=2.9 Hz, 1H),
7.87(br.s, 2H), 9.44(s, 1H)
[3407] MS: FAB(+)268(MH.sup.+)
EXAMPLE 1223
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)carbaldehyde oxime
[3408] To 10 ml of a solution of 820 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)carbaldehyde and 430 mg
of ammonium acetate in ethanol was added 1 ml of an aqueous
solution of 230 mg of hydroxylamine hydrochloride. Then the
resulting mixture was heated under reflux for 1 hour while adding
tetrahydrofuran if necessary. The reaction mixture was brought back
to room temperature and the solvent was distilled off under reduced
pressure. The crystals thus precipitated were taken up by
filtration and washed successively with water and diethyl ether to
thereby give 760 mg of the title compound as yellow crystals.
1689
[3409] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3410] 3.54(s, 3H), 5.30(s, 2H), 7.02(d, J=8.0 Hz, 1H), 7.14(dd,
J=1.6, 8.0 Hz, 1H), 8.38(d, J=1.6 Hz, 1H), 7.58(s, 1H),
7.85(d,.J=3.1 Hz, 1H), 7.86(d, J=3.1 Hz, 1H), 8.06(s, 1H)
EXAMPLE 1224
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)carbonitrile
[3411] 100 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
yl)carbaldehyde oxime was suspended in 2 ml of
trichloroacetonitrile in a nitrogen atmosphere and heated under
reflux for 30 minutes. After distilling off the low-boiling
fraction, the crystals thus precipitated were ground after adding
diethyl ether thereto and taken up by filtration to thereby give 90
mg of the title compound as colorless crystals. 1690
[3412] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3413] 3.54(s, 3H), 5.26(s, 2H), 7.08(d, J=7.8 Hz, 1H), 7.22(dd,
J=1.6, 7.8 Hz, 1H), 7.38(d, J=1.6 Hz, 1H), 7.88(d, J=2.7 Hz, 1H),
7.90(d, J=2.7 Hz, 1H)
EXAMPLE 1225
8-(Tetrazol-5-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3414] To a solution of 150 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)carbonitrile in
dimethyl sulfoxide were added 360 mg of sodium azide and 300 mg of
ammonium chloride and the resulting mixture was heated to
100.degree. C. for 4 hours. Then the reaction mixture was brought
back to room temperature and distributed into ethyl acetate and 1 N
hydrochloric acid. The organic layer was extracted, washed with
water and dried over anhydrous sodium sulfate. After distilling off
the solvent under reduced pressure, the obtained residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol/acetic acid) to thereby give 130 mg of the
title compound as yellow crystals. 1691
[3415] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3416] 3.43(s, 3H), 5.32(s, 2H), 7.35(d, J=7.9 Hz, 1H), 7.61(dd,
J=1.7, 7.9 Hz, 1H), 7.76(d, J=1.7 Hz, 1H), 7.96(d, J=2.6 Hz, 1H),
8.00(d, J=2.6 Hz, 1H)
EXAMPLE 1226
8-(Tetrazol-5-yl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3417] 40 mg of 8-(tetrazol-5-yl)-10-methoxymethyl
-10H-pyrazino[2,3-b][1,- 4]benzothiazine was heated in 5 ml of
glacial acetic acid to 60.degree. C. for 30 minutes. After the
completion of the reaction, silica gel was added thereto. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol/acetic acid) to thereby give 18 mg of the
title compound as yellow crystals. 1692
[3418] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3419] 7.13(d, J=8.2 Hz, 1H), 7.34(dd, J=1.7, 8.2 Hz, 1H), 7.45(d,
J=1.7 Hz, 1H), 7.67(d, J=3.0 Hz, 1H), 7.68(d, J=3.0 Hz, 1H),
9.77(s, 1H)
[3420] MS: FAB(+)270(MH.sup.30 )
EXAMPLE 1227
[N-(2-Pyridyl)aminometyl](10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoth-
iazin-8-yl) ketone
[3421] To 3 ml of a solution of 140 mg of 2-aminopyridine in
ethanol was added 130 mg of sodium hydrogencarbonate and the
resulting mixture was stirred at room temperature. Next, 2 ml of a
solution of 360 mg of bromomethyl (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl) ketone in
tetrahydrofuran was dropped thereinto and the resulting mixture was
heated under reflux for 2 hours. Then the reaction mixture was
brought back to room temperature and silica gel was added thereto.
After distilling off the solvent under reduced pressure, the
residue was purified by silica gel column chromatography (eluted
with dichloromethane/methanol) to thereby give 200 mg of the title
compound as yellow crystals. 1693
[3422] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3423] 3.47(s, 2H), 3.58(s, 3H), 5.41(s, 2H), 6.78(dt, J=0.9, 6.7
Hz, 1H), 7.06(d, J=8.3 Hz, 1H), 7.18(ddd, J=1.3, 6.7, 9.1 Hz, 1H),
7.55(dd, J=1.7, 8.3 Hz, 1H), 7.62(br.d, J=9.1 Hz, 1H), 7.72(d,
J=1.7 Hz, 1H), 7.83(s, 1H), 7.84(s, 2H), 8.11(br.d, J=6.7 Hz,
1H)
EXAMPLE 1228
8-(Imidazo[1,2-a]pyridin-3-yl)-10H-pyrazino[2,3-b][1,4]-benzothiazine
[3424] 10 ml of a solution of 200 mg of
[N-(2-pyridyl)aminometyl](10-metho-
xymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl) ketone in
carbon tetrachloride was stirred at room temperature and 240 mg of
thionyl chloride was dropped thereinto. The reaction mixture was
distributed into dichloromethane and an aqueous solution of sodium
bicarbonate and the organic layer was separated. To the organic
layer were added methanol and tetrahydrofuran to give a homogeneous
solution. After adding silica gel and distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 103 mg of the title compound as yellow crystals.
1694
[3425] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3426] 6.88(dt, J=1.1, 7.7 Hz, 1H), 6.95(d, J=7.7 Hz, 1H),
7.23(ddd, J=1.1, 7.0, 9.5 Hz, 1H), 7.37(dd, J=1.8, 7.7 Hz, 1H),
7.44(d, J=1.8 Hz, 1H), 7.53(d, J=9.5 Hz, 1H), 7.63(d, J=2.6 Hz,
1H), 7.65(d, J=2.6 Hz, 1H), 8.26(s, 1H), 8.52(dd, J=1.1, 7.0 Hz,
1H), 9.59(s, 1H)
[3427] MS: FAB(+)218(MH.sup.30 )
EXAMPLE 1229
8-(1,3-Thiazol-5-yl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-
e
[3428] To 3 ml of a solution of 180 mg of crude thioformamide in
ethanol was added 130 mg of sodium hydrogencarbonate and the
resulting mixture was stirred at room temperature. After dropping 2
ml of a solution of 360 mg of bromomethyl (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl) ketone in
tetrahydrofuran, the resulting mixture was stirred for 1 hour. Then
the reaction mixture was distributed into water and ethyl acetate.
The organic layer was extracted and dried over anhydrous sodium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with ethyl acetate/n-hexane) to thereby give 100 mg of the
title compound as yellow crystals. 1695
[3429] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3430] 3.42(s, 3H), 5.33(s, 2H), 7.20(d, J=8.3 Hz, 1H), 7.61(dd,
J=1.5, 8.3 Hz, 1H), 7.78(d, J=1.5 Hz, 1H), 7.94(d, J=2.4 Hz, 1H),
7.98(d, J=2.4 Hz, 1H), 8.17(d, J=2.0 Hz, 1H), 9.19(d, J=2.0 Hz,
1H)
EXAMPLE 1230
8-(Imidazo[2,1-b]benzothiazol-1-yl)-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3431] 180 mg of the title compound was obtained as yellow crystals
by the same method as the one of Example 1229 by starting with 550
mg of bromomethyl
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin -8-yl)
ketone and 300 mg of 2-aminobenzothiazole. 1696
[3432] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3433] 3.46(s, 3H), 5.35(s, 2H), 7.18(d, J=8.3 Hz, 1H), 7.42(t,
J=7.6 Hz, 1H), 7.48(dd, J=1.6, 8.3 Hz, 1H), 7.56(t, J=7.6 Hz, 1H),
7.68(d, J=1.6 Hz, 1H), 7.94(d, J=2.6 Hz, 1H), 7.98(d, J=2.6 Hz,
1H), 8.00(d, J=7.6 Hz, 1H), 8.03(d, J=7.6 Hz, 1H), 8.77(s, 1H)
EXAMPLES
[3434] The following compounds were obtained each as yellow
crystals by treating the compounds obtained in Examples 1229 and
1230.
175 Ex. Structural formula MS NMR 1231 1697 FAB(+) 284 (M.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 6.98(d, J=8.4 Hz, 1H),
7.16(dd, J=1.5, 8.4 Hz, 1H), 7.45(d, J=1.5 Hz, 1H), 7.62-7.65(m,
2H), 8-(thiazol-5-yl)-10H-pyrazino[2,3-b] 8.02(d, J=1.8 Hz, 1H),
9.16(d, J=1.8 Hz, 1H), [1,4]benzothiazine 9.59(s, 1H) 1232 1698
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 6.95(d, J=8.1 Hz, 1H),
7.23(dd, J=1.6, 8.1 Hz, 1H), 7.33(d, J=1.6 Hz, 1H), 7.42(t, J=7.7
Hz, 1H), 7.55(t, J=7.7 Hz, 1H), 7.64(d, J=3.1 Hz, 1H), 7.66(d,
J=3.1 Hz, 1H), 8.00(d, J=7.7 Hz, 1H),
8-(imidazo[2,1-b]benzothiazol-1-yl)- 8.02(d, J=7.7 Hz, 1H),
10H-pyrazino[2,3-b][1,4]enzothiazine 8.65(s, 1H), 9.63(s, 1H)
EXAMPLE 1233
2-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-yl)-4,5-dihydro-1,3-thiazol-4-ol
[3435] 450 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
yl)carbothioamide was dissolved in a solvent mixture of
tetrahydrofuran (5 ml) with 1,2-dimethoxyethane (5 ml). Under
stirring, 610 mg of potassium hydrogencarbonate and 2 ml of a 40%
chloroacetaldehyde solution were added thereto at room temperature
and the resulting mixture was stirred for half a day. Then the
reaction mixture was distributed into an aqueous solution of
ammonium chloride and ethyl acetate. The organic layer was
extracted and dried over anhydrous sodium sulfate. After distilling
off the solvent, the crystals thus precipitated were taken up by
filtration to thereby give 475 mg of the title compound as yellow
crystals. 1699
[3436] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3437] 3.41(dd, J=4.5, 11.8 Hz, 1H), 3.56(s, 3H), 3.63(dd, J=6.9,
11.8 Hz, 1H), 5.33(s, 2H), 6.28(dd, J=4.5, 6.9 Hz, 1H), 7.05(d,
J=8.2 Hz, 1H), 7.43(dd, J=1.5, 8.2 Hz, 1H), 7.64(d, J=1.5 Hz, 1H),
7.86(s, 2H)
EXAMPLE 1234
8-(Thiazol-2-yl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3438] 450 mg of
2-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin--
8-yl)-4,5-dihydro -1,3-thiazol-4-ol and 0.83 ml of pyridine were
dissolved in 15 ml of 1,2-dimethoxyethane. While stirring the
reaction mixture under ice-cooling, 300 mg of trifluoroacetic
anhydride was dropped thereinto and the resulting mixture was
stirred for 1 hour. Then the reaction mixture was distributed into
an aqueous solution of sodium bicarbonate and ethyl acetate. The
organic layer was extracted, washed with water and dried over
anhydrous magnesium sulfate. After distilling off the solvent under
reduced pressure, the oily residue thus obtained was treated in the
same manner as the one of Example 434 and purified by silica gel
column chromatography (eluted with dichloromethane/methanol). Thus
230 mg of the title compound was obtained as yellow crystals.
1700
[3439] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3440] 7.01(d, J=7.7 Hz, 1H), 7.31(dd, J=1.9, 7.7 Hz, 1H), 7.39(d,
J=1.9 Hz, 1H), 7.66(d, J=2.4 Hz, 1H), 7.67(d, J=2.4 Hz, 1H),
7.76(d, J=3.2 Hz, 1H), 7.89(d, J=3.2 Hz, 1H), 9.66(s, 1H)
EXAMPLE 1235
8-(3H,4H-Dihydrothiazol-2-ylmethyl)-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3441] 670 mg of 2-aminoethanethiol hydrochloride was suspended in
20 ml of methanol. Then 1.2 g of a 28% solution of sodium methoxide
in methanol was added thereto and the resulting mixture was
subjected to ultrasonication at room temperature for about 5
minutes. Next, 570 mg of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazin -8-yl)carbaldehyde was added
thereto and the resulting mixture was heated under reflux for 3
hours. The reaction mixture was then distributed into water and
ethyl acetate. The organic layer was extracted, washed with water
and dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 510 mg of the title compound as a yellow oily
substance. 1701
[3442] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3443] 3.29(t, J=8.5 Hz, 2H), 3.53(s, 3H), 3.76(s, 2H), 4.25(t,
J=8.5 Hz, 2H), 5.27(s, 2H), 6.90(dd, J=1.4, 8.0 Hz, 1H), 6.97(d,
J=8.0 Hz, 1H), 7.08(d, J=1.4 Hz, 1H), 7.83(d, J=2.7 Hz, 1H),
7.84(d, J=2.7 Hz, 1H)
EXAMPLE 1236
8-(3H,4H-Dihydrothiazol-2-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3444] 15 mg of the title compound was obtained as yellow crystals
by treating 400 mg of 8-(3H,4H-dihydrothiazol
-2-ylmethyl)-10-methoxymethyl--
10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the one
of Example 434. 1702
[3445] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3446] 3.25(t, J=8.6 Hz, 2H), 3.60(s, 2H), 4.12(t, J=8.6 Hz, 2H),
6.65(s, 1H), 6.67(d, J=7.8 Hz, 1H), 6.84(d, J=7.8 Hz, 1H), 7.63(s,
2H), 9.48(s, 1H)
EXAMPLE 1237
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)phthalimide
[3447] A solution of 3.32 g of (10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]- benzothiazin-8-yl)methanol, 2.12 g of
phthalimide and 3.77 g of triphenylphosphine in tetrahydrofuran (50
ml) was ice-cooled and 2.24 ml of diethyl azodicarboxylate was
dropped thereinto. After stirring at room temperature for 1 hour,
the solvent was distilled off under reduced pressure and diethyl
ether was added to the residue. Then it was subjected to
ultrasonication and the crystals thus precipitated were taken up by
filtration to thereby give 2.6 g of the title compound as pale
yellow crystals. 1703
[3448] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3449] 3.51(s, 3H), 4.76(s, 2H), 5.22(s, 2H), 6.95(d, J=7.9 Hz,
1H), 7.03(dd, J=1.7, 7.9 Hz, 1H), 7.21(d, J=1.7 Hz, 1H), 7.71(dd,
J=3.0, 5.4 Hz, 2H), 7.82(s, 2H), 7.84(dd, J=3.0, 5.4 Hz, 2H)
EXAMPLE 1238
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)phthalimide
[3450] 7.9 g of the title compound was obtained as yellow crystals
by treating 10.0 g of N-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothia- zin -8-ylmethyl)phthalimide by
the same method as the one of Example 434. 1704
[3451] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3452] 4.58(s, 2H), 6.68(s, 1H), 6.74(d, J=7.6 Hz, 1H), 6.86(d,
J=7.6 Hz, 1H), 7.61(s, 2H), 7.85(dd, J=2.9, 5.7 Hz, 2H), 7.90(dd,
J=2.9, 5.7 Hz, 2H), 9.42(s, 1H)
EXAMPLE 1239
8-(Aminomethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3453] 7.9 g of N-(10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)phthalimide was suspended in hydrazine monohydrate (10
ml)/ethanol (50 ml) and the reaction mixture was heated to
80.degree. C. for 20 minutes. Then the reaction mixture was brought
back to room temperature. After distilling off the solvent under
reduced pressure, the residue was distributed into an aqueous
solution of potassium carbonate and ethyl acetate. The organic
layer was extracted and dried over anhydrous sodium sulfate. After
distilling off the solvent under reduced pressure, the residue thus
obtained was purified by silica gel column chromatography (eluted
with dichloromethane/methanol/aqueous ammonia) to thereby give 5.0
g of the title compound as yellow orthorhombic crystals. 1705
[3454] .sup.1H-NMR(CDCl.sub.3) .delta..delta. ppm:
[3455] 3.72(s, 2H), 6.50(d, J=1.4 Hz, 1H), 6.74(dd, J=1.4, 7.9 Hz,
1H), 6.81(d, J=7.9 Hz, 1H), 7.09-7.20(br.s, 1H), 7.54(d, J=2.7 Hz,
1H), 7.66(d, J=2.7 Hz, 1H)
EXAMPLE 1240
N-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)propyl]phthalimide
[3456] The title compound was obtained as yellow crystals by
treating 3-(10H-pyrazino[2,3-b][1,4]-benzothiazin -8-yl)propanol
with phthalimide by the same method as the one of Example 1237
followed by the same treatment as the one of Example 434. 1706
[3457] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3458] 1.83(quint, J=7.2 Hz, 2H), 2.43(t, J=7.2 Hz, 2H), 3.58(t,
J=7.2 Hz, 2H), 6.56(s, 1H), 6.61(d, J=7.8 Hz, 1H), 6.72(d, J=7.8
Hz, 1H), 7.51(d, J=3.3 Hz, 1H), 7.53(d, J=3.3 Hz, 1H), 7.72-7.77(m,
2H), 7.77-7.82(m, 2H), 9.38(s, 1H)
EXAMPLE 1241
8-(Aminomethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
hydrochloride
[3459] To a solution of 5.0 g of 8-(aminomethyl)
-10H-pyrazino[2,3-b][1,4]- benzothiazine in a mixture of dry
methanol (5 ml)/ethyl acetate (30 ml) was added 10 ml of a solution
of 22 g of hydrogen chloride in 500 ml of ethyl acetate and the
resulting mixture was subjected to ultrasonication. To the crystals
thus precipitated was added diethyl ether followed by filtration.
Thus, the title compound was obtained as orange crystals almost
quantitatively. 1707
[3460] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3461] 3.79(br.q, J=5.7 Hz, 2H), 6.73(d, J=1.7 Hz, 1H), 6.90(dd,
J=1.7, 7.8 Hz, 1H), 6.95(d, J=7.8 Hz, 1H), 7.64(d, J=3.1 Hz, 1H),
7.66(d, J=3.1 Hz, 1H), 8.25-8.45(br.s, 3H), 9.70(s, 1H)
EXAMPLE 1242
8-(3-Aminopropyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
hydrochloride
[3462] The title compound was obtained by treating
N-[3-(10H-pyrazino[2,3--
b][1,4]benzothiazin-8-yl)-propyl]phthalimide successively by the
same methods as those of Examples 1239 and 1241. 1708
[3463] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3464] 1.73(quint, J=7.2 Hz, 2H), 2.45(t, J=7.2 Hz, 2H),
2.68-2.80(m, 2H), 6.60(d, J=1.5 Hz, 1H), 6.64(dd, J=1.5, 8.0 Hz,
1H), 6.83(d, J=8.0 Hz, 1H), 7.62(d, J=3.1 Hz, 1H), 7.63(d, J=3.1
Hz, 1H), 7.82-8.02(br.s, 3H), 9.50(s, 1H)
EXAMPLE 1243
.alpha.-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)benzylamine
[3465] The title compound was obtained by treating
.alpha.-(10H-pyrazino[2- ,3-b][1,4]benzothiazin-8-yl)benzyl alcohol
successively by the same methods as those of Examples 1237 and
1239. 1709
[3466] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3467] 5.03(s, 1H), 6.54(d, J=1.2 Hz, 1H), 6.78(d, J=7.8 Hz, 1H),
6.82(dd, J=1.2, 7.8 Hz, 1H), 7.09-7.18(br.s, 1H), 7.20-7.26(m, 2H),
7.28-.7.33(m, 3H), 7.40(d, J=3.0 Hz, 1H), 7.41-7.47(br.s, 2H),
7.60(d, J=3.0 Hz, 1H)
EXAMPLE 1244
8-(N-Methyl)aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothia-
zine
[3468]
8-Chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazi-
ne was stirred in a solution of methylamine in methanol at room
temperature over day and night. Then the reaction mixture was
distilled under reduced pressure and the residue was distributed
into sodium hydroxide and ethyl acetate. The organic layer was
extracted and dried over anhydrous sodium sulfate. After distilling
off the solvent under reduced pressure, the obtained residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give the title compound as a
yellow oily substance. 1710
[3469] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3470] 2.44(s, 3H), 3.53(s, 3H), 3.68(s, 2H), 5.29(s, 2H), 6.93(dd,
J=1.6, 7.8 Hz, 1H), 6.97(d, J=7.8 Hz, 1H), 7.10(d, J=1.6 Hz, 1H),
7.82(d, J=2.8 Hz, 1H), 7.83(d, J=2.8 Hz, 1H)
EXAMPLES
[3471] The following compounds were obtained by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
by the same method as the one of Example 1244.
176 Ex. Structural formula NMR 1245 1711 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.20(s, 6H), 3.33(s, 2H), 3.47(s, 3H), 5.25(s, 2H),
6.89(dd, J=1.5, 7.7 Hz, 1H),
8-(dimethylamino)ethyl-10-methoxymethyl- 6.92(d, J=7.7 Hz, 1H),
7.04(d, J=1.5 Hz, 1H), 10H-pyrazino[2,3-b][1,4]enzothiazine 7.77(d,
J=2.9 Hz, 1H), 7.78(d, J=2.9 Hz, 1H) 1246 1712
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.75(quint, J=8.1 Hz, 2H),
2.21(s, 6H), 1.28(t, J=8.1 Hz, 2H), 1.58(t, J=8.1 Hz, 2H), 3.51(s,
3H), 5.26(s, 2H), 8-[3-(dimethylamino)ropyl]-10- 6.81(dd, J=1.5,
7.9 Hz, 1H), methoxymethyl-10H-pyrazino[2,3-b][1,4] 6.92(d, J=7.9
Hz, 1H), 6.99(d, J=1.5 Hz, 1H), enzothiazine 7.81(d, J=2.9 Hz, 1H),
7.82(d, J=2.9 Hz, 1H) 1247 1713 .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.22(s, 6H), 3.30(s, 2H), 3.52(s, 3H), 5.26(s, 2H), 6.99(d,
J=2.0 Hz, 1H), 7.05(dd, J=2.0, 8.5 Hz, 1H),
7-(dimethylamino)ethyl-10-methoxymethyl- 7.08(d, J=8.5 Hz, 1H),
7.81(d, J=2.7 Hz, 1H), 10H-pyrazino[2,3-b][1,4]enzothiazine 7.82,
J=2.7 Hz, 1H)
EXAMPLE 1248
8-(Dimethylamino)methyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3472] The title compound was obtained by treating
8-(N-methyl)aminomethyl-
-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine by the same
method as the one of Example 9. 1714
[3473] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3474] 2.40(s, 3H), 3.57(s, 2H), 6.50(d, J=1.6 Hz, 1H), 6.73(dd,
J=1.6, 7.9 Hz, 1H), 6.79(d, J=7.9 Hz, 1H), 7.10-7.38(br.s, 1H),
7.53(d, J=2.6 Hz, 1H), 7.65(d, J=2.6 Hz, 1H)
EXAMPLE 1249
8-(N-Methylaminomethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
hydrochloride
[3475] The title compound was obtained by treating
8-(N-methylaminomethyl)- -10H-pyrazino[2,3-b][1,4]benzothiazine by
the same method as the one of Example 1241. 1715
[3476] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3477] 2.48(s, 3H), 3.89(t, J=5.5 Hz, 2H), 6.75(d, J=1.4 Hz, 1H),
6.93(dd, J=1.4, 7.8 Hz, 1H), 6.98(d, J=7.8 Hz, 1H), 7.64(d, J=3.2
Hz, 1H), 7.65(d, J=3.2 Hz, 1H), 8.93-9.10(m, 2H), 9.72(s, 1H)
EXAMPLES
[3478] The following compounds were obtained by treating
successively by the same methods as those of Examples 9 and
1241.
177 Ex. Structural formula NMR 1250 1716 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 2.65(d, J=5.1 Hz, 6H), 4.06(d, J=5.1 Hz, 2H),
8-(dimethylamino)methyl-10H-pyrazino 6.76(s, 1H), 6.98(d, J=8.1 Hz,
1H), [2,3-b][1,4]benzothiazine 6.99(d, J=8.1 Hz, 1H), 7.66(s, 2H),
hydrochloride 9.72(s, 1H), 10.38-10.50(m, 1H) 1251 1717
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.86(quint, J=7.8 Hz, 2H),
2.44(br.t, J=7.8 Hz, 2H), 2.68(d, J=5.0 Hz, 6H), 2.93-3.01(m, 2H),
6.62(s, 1H), 8-[3-(dimethylamino)propyl]- 6.67(d, J=8.3 Hz, 1H),
10H-pyrazino[2,3-b][1,4]benzothiazine 6.84(d, J=8.3 Hz, 1H),
7.63(s, 2H), hydrochloride 9.50(s, 1H), 10.53-10.64(br.s, 1H) 1252
1718 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.63(d, J=5.0 Hz, 6H),
4.03(d, J=5.0 Hz, 2H), 7-(dimethylamino)methyl-10H-pyrazino 6.78(d,
J=7.9 Hz, 1H), 7.10(d, J=1.7 Hz, 1H), [2,3-b][1,4]benzothiazine
7.12(dd, J=1.7, 7.9 Hz, 1H), 7.66(s, 2H), hydrochloride 9.69(s,
1H), 10.31-10.44(m, 1H) 1253 1719 .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.90(t, J=5.5 Hz, 2H), 4.10(t, J=5.5 Hz, 2H), 6.76(d, J=1.6
Hz, 1H), 6.97(d, J=8.0 Hz, 1H), 7.00(dd, J=1.6, 8.0 Hz, 1H)
7.38-7.45(m, 3H), 7.51(m, 2H), 7.65(d, J=2.9 Hz, 1H),
8-(benzylamino)methyl-10H-pyrazino[2,3-b] 7.66(d, J=2.9 Hz, 1H),
9.54-9.68(m, 2H), [1,4]benzothiazine hydrochloride 9.70(s, 1H)
EXAMPLES
[3479] The following compounds were obtained by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
by the same method as the one of Example 1244.
178 Ex. Structural formula NMR 1254 1720 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.44(s, 3H), 4.07(br.s, 1H), 4.29(d, J=5 Hz, 2H),
5.22(s, 2H), 6.62(d, J=8 Hz, 2H), 8-[(N-phenyl)aminomethyl]-10-
6.72(t, J=8 Hz, 1H), 6.98(s, 2H),
(methoxymethyl)-10H-pyrazino[2,3-b][1,4] 7.13(s, 1H), 7.18(t, J=8
Hz, 2H), benzothiazine 7.83(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H)
1255 1721 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.01(s, 3H), 3.35(s,
3H), 4.47(s, 2H), 5.14(s, 2H), 6.68-6.78(m, 3H), 6.82-6.86(m, 1H),
6.96(br.s, 1H), 6.95(d, J=7 Hz, 1H), 8-[(N-phenyl-N-methyl)a-
minomethyl]-10- 7.20-7.26(m, 2H), 7.82(d, J=3 Hz, 1H),
(methoxyethyl)-10H-pyrazino[2,3-b][1,4] 7.83(d, J=3 Hz, 1H)
benzothiazine
EXAMPLES
[3480] The following compounds were obtained by treating the
compounds given in the above table by the same method as the one of
Example 8.
179 Ex. Structural formula MS M.p. NMR 1256 1722 ESI(+) 307
(MH.sup.+) 183-186.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
4.0-4.2(m, 1H), 4.21(s, 2H), 6.52(s, 1H), 6.59(d, J=8 Hz, 2H),
6.68(br.s, 1H), 6.73(t, J=8 Hz, 1H), 6.82(d, J=8 Hz, 1H),
8-[(N-phenyl)aminomethyl]-10H- 6.86(d, J=8 Hz, 2H), 7.50(d, J=3 Hz,
1H), pyrazino[2,3-b][1,4]benzothiazine 7.66(d, J=3 Hz, 1H) 1257
1723 ESI(+) 321 (MH.sup.+) 172-174.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.99(s, 3H), 4.37(s, 2H),
6.37(s, 1H), 6.66-6.78(m, 4H), 6.84(d, J=8 Hz, 1H),
8-[(N-phenyl-N-methyl)aminomethyl]- 7.20-7.28(m, 2H), 7.46(d, J=3
Hz, 1H), 10H-pyrazino[2,3-b][1,4]benzothiazine 7.63(d, J=3 Hz,
1H)
EXAMPLE 1258
4-[N-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl]aminomethyl]benzenesulfonamide
[3481] The title compound was obtained by treating
8-chloromethyl-10-metho-
xymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine and
4-aminomethylbenzenesuf- lonamide by the same method as the one of
Example 1244. 1724
[3482] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3483] 3.38(s, 3H), 3.59(s, 2H), 3.71(s, 2H), 5.25(s, 2H),
6.96-7.02(m, 1H), 7.06(d, J=8 Hz, 1H), 7.14-7.16(m, 1H), 7.29(s,
2H), 7.52(d, J=8 Hz, 2H), 7.75(d, J=8 Hz, 2H), 7.92(d, J=3 Hz, 1H),
7.96(d, J=3 Hz, 1H)
EXAMPLES
[3484] The following compounds were obtained by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
successively by the same methods as those of Examples 1244 and
8.
180 Ex. Structural formula NMR 1259 1725 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.30(t, J=7 Hz, 3H), 3.48(s, 2H), 3.71(s, 2H), 4.28(q,
J=7 Hz, 2H), 6.75(dd, J=2, 8 Hz, 1H), 6.78(s, 1H), 6.83(d, J=8 Hz,
1H), 7.47(d, J=8 Hz, 2H), 7.61(d, J=3 Hz, 1H), ethyl
4-[N-(10H-pyrazino[2,3-b][1,4] 7.62(d, J=3 Hz, 1H), 7.89(d, J=8 Hz,
2H), benzothiazin-8-ylmethyl)aminomethyl]benzoate 9.47(s, 1H) 1260
1726 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 0.8-0.95(m, 2H),
1.14(t, J=7 Hz, 3H), 1.20-1.40(m, 3H), 1.70-1.90(m, 4H),
2.10-2.23(m, 1H), 2.20-2.33(m, 2H), 3.48(s, 2H), 4.0(q, J=7 Hz,
2H), ethyl 4-[N-(10H-pyrazino[2,3-b][1,4] 6.70-6.80(m, 1H), 6.75(s,
1H), benzothiazin-8-ylmethyl)aminomethyl) 6.81(d, J=8 Hz, 1H),
7.58-7.68(m, 2H), cyclohexanecarboxylate 9.46(s, 1H)
EXAMPLE 1261
4-[[N-[10-(Methoxymethyl)-10H-pyrazino[2,3-b][1,4]-benzothiazin
-8-ylmethyl]-N-methyl]aminomethyl]benzene-sulfonamide
[3485] To a solution of 0.25 g of 4-[[N-[10-(methoxymethyl)
-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl]aminomethyl]-benzenesul- fonamide and 0.45 ml of a 37%
aqueous solution of formalin in acetonitrile (20 ml) was added 57
mg of sodium borocyanohydride. After adjusting the pH value to 4 to
5 with acetic acid, the mixture was reacted at room temperature for
2 hours. After adding a 1 N aqueous solution of sodium hydroxide,
the reaction mixture was extracted with ethyl acetate, washed with
a saturated aqueous solution of sodium chloride and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 110 mg of the title compound as a yellow oily substance.
1727
[3486] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3487] 2.20(s, 3H), 3.48(s, 3H), 3.56(s, 4H), 4.90(s, 2H), 5.29(s,
2H), 6.96(s, 2H), 7.20(s, 1H), 7.52(d, J=8 Hz, 2H), 7.80-7.85(m,
2H), 7.86(d, J=8 Hz, 2H)
EXAMPLES
[3488] The following compounds were obtained by the same method as
the one of Example 1261.
181 Ex. Structural formula NMR 1262 1728 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.39(t, J=7 Hz, 3H), 2.20(s, 3H), 3.47(s, 2H), 3.55(s,
2H), 3.56(s, 3H), 4.37(q, J=7 Hz, 2H), ethyl
4-[[N-[10-(methoxymethyl)-10H- 5.29(s, 2H), 6.97(s, 2H), 7.22(s,
1H), pyrazino[2,3-b][1,4]benzothiazin-8- 7.45(d, J=8 Hz, 2H),
7.84(s, 2H), ylmethyl]-N-methyl]aminomethyl]benzoate 8.00(d, J=8
Hz, 2H) 1263 1729 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.8-1.0(m,
2H), 1.25(t, J=7 Hz, 3H), 1.3-1.6(m, 2H), 1.6-1.7(m, 1H),
1.9-2.05(m, 4H), 2.1-2.2(m, 3H), ethyl 4-[[N-[10-(methoxymethyl)--
10H- 2.16(s, 3H), 3.38(s, 2H), 3.52(s, 3H),
pyrazino[2,3-b][1,4]benzothiazin-8- 4.11(q, J=7 Hz, 2H), 5.26(s,
2H), ylmethyl]-N-methyl]aminomethyl] 6.91(dd, J=1, 8 Hz, 1H),
6.95(d, J=8 Hz, 1H), cyclohexanecarboxylate 7.14(d, J=1 Hz, 1H),
7.83(s, 2H)
EXAMPLES
[3489] The following compounds were obtained by the same method as
the one of Example 8.
182 Ex. Structural formula MS M.p. NMR 1264 1730 ESI(+) 400
(MH.sup.+) 210-212.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.47(s, 2H), 3.70(s, 2H), 6.76(dd, J=1, 8 Hz, 1H), 6.79(s,
1H), 6.83(d, J=8 Hz, 1H), 4-[N-(10H-pyrazino[2,3-b][1,4] 7.29(s,
2H), 7.57(d, J=8 Hz, 2H), benzothiazin-8-ylmethyl) 7.62(d, J=3 Hz,
1H), 7.63(d, J=3 Hz, 1H), aminomethyl]benzenesulfonamide 7.75(d,
J=8 Hz, 2H), 9.47(s, 1H) 1265 1731 ESI(+) 414 (MH.sup.+)
181-184.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.50(s,
3H), 3.31(s, 2H), 3.52(s, 2H), 6.74(d, J=8 Hz, 1H), 6.80-6.88(m,
2H), 7.31(s, 2H), 4-[[N-(10H-pyrazino[2,3-b][1,4] 7.53(d, J=8 Hz,
2H), 7.62(d, J=3 Hz, 1H), benzothiazin-8-ylmethyl)-N-methyl]
7.63(d, J=3 Hz, 1H), 7.77(d, J=8 Hz, 2H),
aminomethyl]benzenesulfonamide 9.50(s, 1H) 1266 1732 ESI(+) 379
(MH.sup.+) 241-244.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 2.05(s, 3H), 3.31(s, 2H), 3.51(s, 2H), 6.74(d, J=8 Hz),
6.80-6.90(m, 2H), 4-[[N-(10H-pyrazino[2,3-b- ][1,4] 7.45(d, J=8 Hz,
H), 7.62(d, J=2 Hz, 1H), benzothiazin-8-ylmethyl)-N-methyl] 7.63(d,
J=2 Hz, 1H), 7.89(d, J=8 Hz, 2H), aminomethyl]benzoic acid 9.50(s,
1H) 1267 1733 ESI(+) 385 (MH.sup.+) 203-204.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 0.7-0.87(m, 2H), 1.2-1.35(m,
2H), 1.35-1.50(m, 1H), 1.75-1.90(m, 4H), 2.04(s, 3H), 2.05(d, J=8
Hz, 2H), 4-[[N-(10H-pyrazino[2,3-b][1,4] 2.0-2.15(m, 1H), 3.21(s,
2H), benzothiazin-8-ylmethyl)-N-methyl] 6.67(dd, J=1, 8 Hz, 1H),
6.75(d, J=1 Hz, 1H), aminomethyl]cyclohexane- 6.81(d, J=8 Hz, 1H),
7.61(d, J=3 Hz, 1H), carboxylic acid 7.62(d, J=3 Hz, 1H), 9.48(s,
1H)
EXAMPLES
[3490] The following compounds were obtained by treating the
compounds obtained in Examples 1259 and 1260 by the same method as
the one of Example 18.
183 Ex. Structural formula MS M.p. NMR 1268 1734 ESI(+) 365
(MH.sup.+) 245-248.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.54(s, 2H), 3.75(s, 2H), 6.77(d, J=8 Hz, 1H), 6.78(s, 1H),
4-[N-(10H-pyrazino[2,3-b][1,4] 6.84(d, J=8 Hz, 1H), 7.46(d, J=8 Hz,
2H), benzothiazin-8-ylmethyl- ] 7.56-7.68(m, 2H), 7.88(d, J=8 Hz,
2H), aminomethyl]benzoic acid 9.50(s, 1H) 1269 1735 ESI(+) 371
(MH.sup.+) 217-220.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 0.8-0.96(m, 2H), 1.14-1.32(m, 2H), 1.32-1.48(m, 1H),
1.70-1.86(m, 2H), 1.74-1.92(m 2H), 2.02-2.16(m, 1H), 2.40(d, J=7
Hz, 2H), 4-[[N-(10H-pyrazino[2,3-b][1,4] 3.61(s, 2H), 6.75(s, 1H),
benzothiazin-8-ylmethyl]aminomethyl] 6.78(d, J=8 Hz, 1H), 6.85(d,
J=8 Hz, 1H), cyclohexane carboxylic acid 7.56-7.68(m, 2H), 9.53(s,
1H)
EXAMPLES
[3491] Similar to Example 1244, 8-(N-methyl)aminomethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine was treated with various
alkyl halides to thereby give the following compounds.
184 Ex. Structural formula NMR 1270 1736 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.25(t, J=7 Hz, 3H), 1.30-1.40(m, 2H), 1.45-1.60(m,
2H),1.60-1.75(m, 2H), 2.18(s, 3H), 2.30(t, J=7 Hz, 2H),
2.60-2.80(m, 2H), 3.41(s, 2H), 3.53(s, 3H), 4.12(q, J=7 Hz, 2H),
ethyl 6-[[N-[10-(methoxymethyl)-10H- 5.29(s, 2H), 6.90-6.96(m, 1H),
pyrazino[2,3-b][1,4]benzothiazin-8- 6.96(d, J=8 Hz, 1H), 7.10(s,
1H), ylmethyl]-N-methyl]amino]hexanoate 7.83(d, J=3 Hz, 1H),
7.84(d, J=3 Hz, 1H) 1271 1737 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.17(s, 6H), 1.36-1.48(m, 2H), 1.64-1.70(m, 2H), 2.15(s, 3H),
2.32(t, J=7 Hz, 2H), 3.39(s, 2H), 3.53(s, 3H), 3.64(s, 3H), 5.28(s,
2H), methyl 5-[N-[10-(methoxymethyl)-10- H- 6.92(dd, J=1, 8 Hz,
1H), pyrazino[2,3-b][1,4]benzothiazin-8- 6.96(d, J=8 Hz, 1H),
7.09(d, J=1 Hz, 1H), ylmethyl]-N-methyl]amin-
o-2,2-dimethylpentanoate 7.82(d, J=3 Hz, 1H), 7.83(d, J=3 Hz, 1H)
1272 1738 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.18(s, 6H), 1.77(t,
J=7 Hz, 2H), 2.16(s, 3H), 2.34(t, J=7 Hz, 2H), 3.40(s, 2H), 3.53(s,
3H), methyl 4-[N-[10-(methoxymethyl)-10H- 3.62(s, 3H), 5.31(s, 2H),
pyrazino[2,3b][1,4]benzothiazin-8- 6.90-6.96(m, 1H), 6.96(d, J=8
Hz, 1H), ylmethyl]-N-methyl]amino-2,2-dimethylbutanoa- te 7.07(s,
1H), 7.80-7.86(m, 2H)
EXAMPLES
[3492] The following compounds were obtained by treating the
compounds obtained in the above table successively by the same
methods as those of Examples 18 and 8.
185 Ex. Structural formula MS M.p. NMR 1273 1739 ESI(+) 359
(MH.sup.+) 191-193.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.20-1.30(m, 2H), 1.36-1.54(m, 4H), 2.06(s, 3H), 2.18(t, J=7
Hz, 2H), 2.26(t, J=7 Hz, 2H), 3.25(s, 2H), # 6.68(dd, J=2, 8 Hz,
1H), 6.74(d, J=2 Hz, 1H), 6.81(d, J=8 Hz, 1H), 7.61(d, J=3 Hz, 1H),
6-[[N-(10H-pyrazino[2,3-b][1,4]benzothi- azin-8- 7.62(d, J=3 Hz,
1H), ylmethyl)-N-methyl]amino]hexanoic acid 9.44(s, 1H) 1274 1740
ESI(+) 373 (MH.sup.+) 200-202.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.06(s, 6H), 1.3-1.46(m, 4H), 2.05(s, 3H),
2.24-2.32(m, 2H), 3.26(s, 2H), 6.69(d, J=8 Hz, 1H), 6.73(s, 1H),
6.83(d, J=8 # Hz, 1H), 7.61(d, J=3 Hz, 1H),
5-[N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.62(d, J=3 Hz, 1H),
ylmethyl)-N-methyl]amino-2,2-dimethylpentanoic acid 9.46(s, 1H)
1275 1741 FAB(+) 359 (MH.sup.+) .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.21(s, 6H), 1.72-1.84(m, 2H), 2.36(s, 3H), 2.68-2.84(m, 2H),
3.56(br.s, 2H), 6.65-6.82(m, 3H),
4-[N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.56(d, J=2.8 Hz,
1H), ylmethyl)-N-methyl]amino-2,2-dimethylbutanoic acid 7.65(d,
J=2.8 Hz, 1H)
EXAMPLE 1276
N-Methyl-2-[[N-(10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)-N-methyl]amino]ethanesulfonamide
[3493] The title compound was obtained as yellow crystals by
treating 8-chloromethyl-10H-pyrazino[2,3-b][1,4]benzothiazine with
N-methyl-2-aminoethanesulfonamide in the presence of sodium
bicarbonate by the same method as the one of Example 1244. 1742
[3494] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3495] 2.13(s, 3H), 2.54(d, J=5 Hz, 3H), 2.64-2.70(m, 2H),
3.14-3.20(m, 2H), 3.32(s, 2H), 6.71(d, J=8 Hz, 1H), 6.73(s, 1H),
6.84(d, J=8 Hz, 1H), 6.80-6.90(m, 1H), 7.56-7.66(m, 2H), 9.45(s,
1H)
[3496] MS: ESI(+)366(MH.sup.30 )
[3497] m.p. : 143-146.degree. C.
EXAMPLES
[3498] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
successively by the same methods as those of Examples 900 and
9.
186 Ex. Structural formula MS M.p. NMR 1277 1743
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.90(br.s, 1H), 2.66(t, J=7
Hz, 2H), 3.30(s, 2H), 3.50(t, J=7 Hz, 2H), 3.65(br.s, 1H), 6.75(s,
1H), 6.79(d, J=8 Hz, 1H),
2-[N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 6.87(d, J=8 Hz, 1H),
ylmethyl)amino]ethanol 7.62(s, 2H), 9.56(br.s, 1H) 1278 1744
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.42(m, 2H), 1.53(m, 2H),
2.73(t, J=6 Hz, 2H), 3.35(t, J=6 Hz, 2H), 3.35(br.s, 2H), 3.76(s,
2H), 6.75(s, 1H), 6.84(d, J=8 Hz, 1H), 6.92(d, J=8 Hz, 1H), 7.63(d,
J=3 Hz, 1H), 4-[N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.66(d,
J=3 Hz, 1H), ylmethyl)amino]butanol 9.63(s, 1H) 1279 1745 FAB(+)
302 (MH.sup.+) Hygro- scopic .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
2.78(s, 6H), 3.37(br.s, 2H), 3.50(br.s, 2H), 4.02(s, 2H), 6.81(s,
1H), 6.95(d, J=8 Hz, 1H), 7.08(d, J=8 Hz, 1H), 7.65(d, J=3 Hz, 1H),
7.66(d, J=3 Hz, 1H), 8-[N-[2-(N',N'-dimethyl)ethyl]aminometh-
yl]-10H- 9.78(s, 1H), 9.91(br.s, 2H), pyrazino[2,3-b][1,4]benzot-
hiazine dihydrochloride 11.14(br.s, 1H)
EXAMPLES
[3499] The following compounds were obtained from
(10-methoxymethyl-10H-py- razino[2,3-b][1,4]benzothiazin
-8-yl)carbaldehyde by the same method as the one of Example
900.
187 Ex. Structural formula NMR 1280 1746 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.24(t, J=7Hz, 3H), 3.44(s, 3H), 3.49(s, 2H),
4.0-4.1(m, 1H), 4.12(q, J=7 Hz, 2H), 4.27(s, 2H), 5.22(s, 2H),
6.55-6.60(m, 2H), 6.97(s, 2H), 7.04-7.12(m, 2H), 7.12(s, 1H), ethyl
4-[N-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4- ] 7.83(d, J=3 Hz,
1H), benzothiazin-8-ylmethyl)amino]phenylacetate 7.84(d, J=3 Hz,
1H) 1281 1747 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.44(d, J=7 Hz,
3H), 3.43(s, 3H), 3.55-3.70(m, 1H), 3.64(s, 3H), 4.00-4.10(m, 1H),
4.26(s, 2H), 5.22(s, 2H), 6.54-6.60(m, 2H), 6.97(s, 2H),
7.06-7.14(m, 2H), 7.12(s, 1H), methyl
2-[4-[N-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4] 7.82(d, J=3 Hz,
1H), benzothiazin-8-ylmethyl)amino]phenyl]propanoate 7.84(d, J=3
Hz, 1H)
EXAMPLES
[3500] The following compounds were obtained by treating the
compounds obtained in the above table successively by the same
methods as those of Examples 18 and 8.
188 Ex. Structural formula MS M.p. NMR 1282 1748 FAB(+) 365
(MH.sup.+) 252-256.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.21(s, 2H), 4.05(s, 2H), 6.44(d, J=8.4 Hz, 2H), 6.75(d, J=8.0
Hz, 1H), 6.76(s, 1H), 6.83(d, J=8.0 Hz, 1H),
4-[N-(10-pyrazino[2,3-b][1,4]benzothiazin-8- 6.91(d, J=8.4 Hz, 2H),
7.61(m, 2H), ylmethyl)amino]phenylacetic acid hydrochloride 9.49(s,
1H) 1283 1749 228-233.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.26(d, J=8.0 Hz, 3H), 3.40-3.60(m, 1H), 4.10(s, 2H),
6.58-6.70(m, 2H), 6.76(s, 1H), 6.77(d, J=8.0 Hz, 1H), 6.85(d, J=8.0
Hz, 1H), 7.02(d, J=8.0 Hz, 2H), 7.61(d, J=2.8 Hz, 1H),
2-[4-[N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.62(d, J=2.8 Hz,
1H), ylmethyl)amino]phenyl]propanoic acid hydrochloride 9.52(s,
1H)
EXAMPLE 1284
8-Aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3501] To a solution of 1.3 g of N-(10-methoxymethyl -10H-pyrazino
[2,3-b][1,4]benzothiazin -8-ylmethyl)phthalimide in 20 ml of
ethanol was added 5 ml of hydrazine monohydrate and the resulting
mixture was heated to 60.degree. C. for 10 minutes. After
distilling off the solvent under reduced pressure, the residue was
distributed into a 5% aqueous solution of sodium hydroxide and
ethyl acetate. The organic layer was extracted and the extract was
dried over potassium carbonate. After distilling off the solvent
under reduced pressure, the obtained residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol/aq-
ueous ammonia) to thereby give 890 mg of the title compound as a
yellow oily substance. 1750
[3502] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3503] 3.53(s, 3H), 3.80(s, 2H), 5.28(s, 2H), 6.92(dd, J=1.5, 8.0
Hz, 1H), 6.96(d, J=8.0 Hz, 1H), 7.10(d, J=1.5 Hz, 1H), 7.81(d,
J=2.8 Hz, 1H), 7.83(d, J=2.8 Hz, 1H)
EXAMPLE 1285
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)formamide
[3504] 250 mg of 8-aminomethyl-10-methoxymethyl
-10H-pyrazino-[2,3-b][1,4]- benzothiazine was heated under reflux
in 10 ml of ethyl formate for 3 hours. Then the reaction mixture
was brought back to room temperature and distributed into an
aqueous solution of ammonium chloride and ethyl acetate. The
organic layer was extracted, washed with water and then dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the crystals thus precipitated were filtered
after adding diisopropyl ether. Thus 230 mg of the title compound
was obtained as yellow crystals. 1751
[3505] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3506] 3.37(s, 3H), 4.22(d, J=6.0 Hz, 2H), 5.22(s, 2H), 6.91(dd,
J=1.4, 8.0 Hz, 1H), 7.03(d, J=1.4 Hz, 1H), 7.07(d, J=8.0 Hz, 1H),
7.92(d, J=2.8 Hz, 1H), 7.96(d, J=2.8 Hz, 1H), 8.12(s, 1H),
8.51(br.t, J=6.0 Hz, 1H)
EXAMPLE 1286
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)formamide
[3507] 75 mg of the title compound was obtained as yellow crystals
by treating 150 mg of N-(10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothia- zin -8-ylmethyl)formamide by
the same method as the one of Example 9. 1752
[3508] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3509] 4.10(d, J=6.0 Hz, 2H), 6.67(s, 1H), 6.68(d, J=7.7 Hz, 1H),
6.86(d, J=7.7 Hz, 1H), 7.63(br.s, 2H), 8.10(br.s, 1H),
8.73-8.53(br.t, J=6.0 Hz, 1H), 9.50(s, 1H)
EXAMPLE 1287
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)acetamide
[3510] 1 ml of acetic anhydride was added to 5 ml of a solution of
350 mg of 8-aminomethyl-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]benzothiazine in dichloromethane and the
resulting mixture was stirred at room temperature for 2 hours.
After adding diethyl ether, the precipitate thus formed was taken
up by filtration to thereby give 350 mg of the title compound as
yellow crystals. 1753
[3511] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3512] 1.86(s, 3H), 3.36(s, 3H), 4.16(d, J=5.9 Hz, 2H), 5.21(s,
2H), 6.89(dd, J=1.6, 7.9 Hz, 1H), 7.00(d, J=1.6 Hz, 1H), 7.06(d,
J=7.9 Hz, 1H), 7.92(d, J=2.6 Hz, 1H), 7.96(d, J=2.6 Hz, 1H),
8.36(t, J=5.9 Hz, 1H)
EXAMPLE 1288
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)acetamide
[3513] 150 mg of the title compound was obtained by treating 250 mg
of
N-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)aceta-
mide by the same method as the one of Example 9. 1754
[3514] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3515] 1.84(s, 3H), 4.04(d, J=6.2 Hz, 2H), 6.65(s, 1H), 6.66(d,
J=8.4 Hz, 1H), 6.84(d, J=8.4 Hz, 1H), 7.52(d, J=3.2 Hz, 1H),
7.53(d, J=3.2 Hz, 1H), 8.29(t, J=6.2 Hz, 1H), 9.49(s, 1H)
EXAMPLES
[3516] The following compounds were obtained by treating
8-aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
successively by the same methods as those of Examples 1287 and
434.
189 Ex. Structural formula MS M.p. NMR 1289 1755 ooi ooi
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.25(t, J=7.3 Hz, 3H),
4.12(d, J=6.3 Hz, 2H), 4.22(q, J=7.3 Hz, 2H), 6.67(s, 1H), 6.68(d,
J=7.4 Hz, 1H), 6.85(d, J=7.4 Hz, 1H), 7.62(d, J=3.1 Hz, 1H),
7.63(d, J=3.1 Hz, 1H), 9.40(t, J=6.3 Hz, 1H), 9.51(s, 1H) 1290 1756
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.28(d, J=6.0 Hz, 2H),
6.73(d, J=7.8 Hz, 1H), 6.74(s, 1H), 6.85(d, J=7.8 Hz, 1H), 7.45(t,
J=7.7 Hz, 2H), 7.52(t, J=7.7 Hz, 1H), 7.61(s, 2H), 7.87(t, J=7.7
Hz, 2H), N-(10H-pyrazino[2,3-b][1,4]benzothiazin- 8.97(t, J=6.0 Hz,
1H), 8-ylmethyl)benzamide 9.50(s, 1H)
EXAMPLES
[3517] The following compounds were obtained by treating
8-aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
successively by the same methods as those of Examples 1287 and
8.
190 Ex. Structural formula MS M.p. NMR 1291 1757 FAB(+) 336
(MH.sup.+) 249-253.degree. C. (decom- pose)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.33(d, J=5.9 Hz, 2H),
6.72-6.79(m, 2H), 6.88(d, J=8.8 Hz, 1H), 7.64(d, J=2.9 Hz, 1H),
7.65(d, J=2.9 Hz, 1H),
N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl- ) 7.80(m, 2H),
8.76(m, 2H), isonicotinamide 9.31(t, J=5.9 Hz, 1H), 9.53(s, 1H)
1292 1758 FAB(+) 336 (MH.sup.+) 243-245.degree. C. (decom- pose)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.33(d, J=5.9 Hz, 2H),
6.75-6.80(m, 2H), 6.88(d, J=8.4 Hz, 1H), 7.54(m, 1H), 7.64(d, J=2.9
Hz, 1H), 7.64(d, J=2.9 Hz, 1H),
N-(10H-pyrazino[2,3-b][1,4]benzothiazin- 8.23(m, 1H), 8.73(m, 1H),
9.06(m, 1H), 8-ylmethyl)nicotinamide 9.21(t, J=5.9 Hz, 1H), 9.53(s,
1H)
EXAMPLE 1293
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-1-methylpiperidine-4-carboxamide
[3518] The title compound was obtained as yellow crystals by
treating 8-aminomethyl-10-methoxymethyl
-10H-pyrazino[2,3-b][1,4]-benzothiazine and
1-methylpiperidine-4-carboxylic acid successively by the same
methods as those of Examples 1303 and 8. 1759
[3519] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3520] 1.71-1.98(m, 5H), 2.04-2.18(m, 2H), 2.26(s, 3H),
2.86-2.94(m, 2H), 4.26(d, J=5.9 Hz, 2H), 5.99(d, J=5.9 Hz, 1H),
6.43(d, J=1.6 Hz, 1H), 6.67(dd, J=1.6, 7.9 Hz, 1H), 6.79(d, J=7.9
Hz, 1H), 7.01(s, 1H), 7.56(d, J=2.9 Hz, 1H), 7.67(d, J=2.9 Hz,
1H)
[3521] MS: FAB(+)336(MH.sup.+)
[3522] m.p.: 230-232.degree. C. (decompose)
EXAMPLE 1294
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-5-methyl-1,2-oxazole-4-carboxamide
[3523] A solution of 520 mg of 5-methyl-1,2-oxazole -4-carboxylic
acid and 0.75 ml of triethylamine in tetrahydrofuran (10 ml) was
ice-cooled. After adding 0.8 ml of diethyl chlorophosphate, the
resulting mixture was stirred at room temperature for 30 minutes.
To the reaction mixture was added 5 ml of a solution of 750 mg of
8-aminomethyl-10-methoxymethyl-10H--
pyrazino[2,3-b][1,4]-benzothiazine in tetrahydrofuran and the
resulting mixture was stirred at room temperature for 1.5 hours.
Next, the reaction mixture was distributed into ethyl acetate and
an aqueous solution of ammonium chloride. The organic layer was
extracted, washed with water and dried over anhydrous sodium
sulfate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol) to thereby give 520 mg of
N-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)-5-methyl-1,2-oxazole-4-carboxamide. Further, the
product was treated by the same method as the one of Example 434 to
thereby give 310 mg of the title compound as yellow crystals.
1760
[3524] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3525] 2.63(s, 3H), 4.23(d, J=6.3 Hz, 2H), 6.71(s, 1H), 6.72(d,
J=7.5 Hz, 1H), 6.86(d, J=7.5 Hz, 1H), 7.62(s, 2H), 8.79(t, J=6.3
Hz, 1H), 8.89(s, 1H), 9.50(s, 1H)
EXAMPLE 1295
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)
-2-cyano-3-oxobutanamide
[3526] 120 mg of the title compound was obtained as yellow crystals
by treating 170 mg of
N-(10H-pyrazino[2,3-b][1,4]-benzothiazin-8-ylmethyl)-5- -methyl
-1,2-oxazole-4-carboxamide with 0.17 ml of dimethylformamide
dimethyl acetal by the same method as the one of Example 505.
1761
[3527] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3528] 2.05(s, 3H), 4.13(s, 2H), 6.64-6.68(m, 2H), 6.83(dd, J=2, 8
Hz, 1H), 7.61-7.63(m, 2H), 9.51(s, 1H)
[3529] MS: FAB(+)339(M.sup.30 )
EXAMPLE 1296
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin
-8-ylmethyl)acetamide
[3530] 200 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-
-ylmethyl)acetonitrile was dissolved in 5 ml of dimethyl sulfoxide.
After adding 200 mg of powdered potassium hydroxide, the resulting
mixture was heated to 40 to 60.degree. C. for 10 minutes. Then the
reaction mixture was distributed into 1 N hydrochloric acid and
ethyl acetate. The organic layer was extracted, washed successively
with a saturated aqueous solution of sodium bicarbonate and water
and dried over anhydrous magnesium sulfate. After distilling off
the solvent under reduced pressure, the residue was purified by
silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 35 mg of the title
compound as yellow crystals. 1762
[3531] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3532] 3.31(s, 2H), 3.38(s, 3H), 5.22(s, 2H), 6.87-6.95(br.s, 1H),
6.91(dd, J=1.7, 8.0 Hz, 1H), 7.03(d, J=1.7 Hz, 1H), 7.04(d, J=8.0
Hz, 1H), 7.42-7.50(br.s, 1H), 7.92(d, J=2.8 Hz, 1H), 7.96(d, J=2.8
Hz, 1H)
EXAMPLE 1297
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamide
[3533] The title compound was obtained by treating
(10-methoxymethyl-10H-p- yrazino[2,3-b][1,4]benzothiazin
-8-yl)acetamide by the same method as the one of Example 9.
1763
[3534] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3535] 3.18(s, 2H), 6.66(s, 1H), 6.67(d, J=7.6 Hz, 1H), 6.82(d,
J=7.6 Hz, 1H), 6.83-6.95(br.s, 1H), 7.37-7.48(br.s, 1H), 7.61(d,
J=2.6 Hz, 1H), 7.63(d, J=2.6 Hz, 1H), 9.50(s, 1H)
EXAMPLE 1298
3-[(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamido]propanoic
acid
[3536] The title compound was obtained by treating
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)acetic acid successively by
the same methods as those of Examples 1294, 18 and 8. 1764
[3537] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm
[3538] 2.36(t, 2H, J=6.8 Hz)3.20(s, 2H)3.21(t, 2H, J=6.8 Hz)6.64(s,
1H)6.65(d, 1H, J=8.0 Hz)6.80(d, 1H, J=8.0 Hz)7.61(d, 1H, J=2.8
Hz)7.63(d, 1H, J=2.8 Hz)9.48(s, 1H)
[3539] MS: FAB(+)331(MH.sup.30 )
[3540] m.p.: 220-225.degree. C.
EXAMPLE 1299
8-Amino-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3541] 10 ml of an aqueous solution of 720 mg of sodium hydroxide
was ice-cooled and 0.24 ml of bromine was dropped thereinto. After
stirring for 5 minutes, 900 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-yl)carboxamide was added thereto at once and the resulting
mixture was heated to 40 to 60.degree. C. for 15 minutes. Next, the
reaction mixture was distributed into water and ethyl acetate.
After filtering off the insoluble matters through celite, the
organic layer was extracted, washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) to thereby
give 400 mg of the title compound as yellow crystals. 1765
[3542] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3543] 3.37(s, 3H), 5.14(s, 2H), 5.31(br.s, 2H), 6.25(dd, J=1.9,
8.1 Hz, 1H), 6.46(d, J=1.9 Hz, 1H), 6.72(d, J=8.1 Hz, 1H), 7.88(d,
J=2.5 Hz, 1H), 7.91(d, J=2.5 Hz, 1H)
EXAMPLE 1300
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamide
[3544] 200 mg of
8-amino-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothi- azine
was suspended in 10 ml of ethyl acetate. After adding 1 ml of
acetic anhydride, the reaction mixture was subjected to
ultrasonication. The crystals thus precipitated were filtered and
washed with diethyl ether to thereby give 206 mg of the title
compound as yellow crystals. 1766
[3545] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3546] 2.01(s, 3H), 3.38(s, 3H), 5.17(s, 2H), 7.01(d, J=8.6 Hz,
1H), 7.31(d, J=1.8, 8.6 Hz, 1H), 7.44(d, J=1.8 Hz, 1H), 7.91(d,
J=2.6 Hz, 1H), 7.95(d, J=2.6 Hz, 1H), 10.02(s, 1H)
EXAMPLES
[3547] The following compounds were obtained by treating the
compounds obtained in Examples 1299 and 1300 by the same method as
the one of Example 8.
191 Ex. Structural formula MS NMR 1301 1767 FAB(+) 216(M.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.14(br.s, 2H), 6.04(dd,
J=1.9, 8.2 Hz, 1H), 6.07(d, J=1.9 Hz, 1H), 6.52(d, J=8.2 Hz, 1H),
8-amino-10H-pyrazino[2,3-b][1,4] 7.58(d, J=2.8 Hz, 1H),
benzothiazine 7.60(d, J=2.8 Hz, 1H), 9.31(s, 1H) 1302 1768
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.97(s, 3H), 6.80(d, J=8.5
Hz, 1H), 6.96(d, J=1.6, 8.5 Hz, 1H), 7.16(d, J=1.6 Hz, 1H), 7.62(d,
J=2.9 Hz, 1H), N-(10H-pyrazino[2,3-b][1,4]benzothiaz- in- 7.63(d,
J=2.9 Hz, 1H), 8-yl)acetamide 9.57(s, 1H), 9.88(s, 1H)
EXAMPLE 1303
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carboxamide
[3548] 1.04 g of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8--
yl)carboxylic acid was dissolved in a mixture of dichloromethane
(20 ml) with tetrahydrofuran (20 ml) in a nitrogen atmosphere.
Under ice-cooling, 1.04 g of
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 200
mg of 1-hydroxybenzotriazole were added thereto and the resulting
mixture was stirred at room temperature for 30 minutes. After
blowing ammonia gas thereinto, the reaction mixture was distributed
into an aqueous solution of sodium bicarbonate and ethyl acetate.
The organic layer was extracted, washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the crystals thus precipitated were filtered.
Further, the aqueous layer was acidified and the starting materials
were recovered. After repeating the above-mentioned procedures, the
title compound (620 mg in total) was obtained as yellow crystals.
1769
[3549] .sup.1H-NMR(DMSO-D.sub.6) .delta. ppm:
[3550] 3.38(s, 3H), 5.28(s, 2H), 7.19(d, J=8.4 Hz, 1H),
7.74-7.46(br.s, 1H), 7.47(dd, J=1.8, 8.4 Hz, 1H), 7.56(d, J=1.8 Hz,
1H), 7.93(d, J=2.8 Hz, 1H), 7.95-8.02(br.s, 1H), 7.79(d, J=2.8 Hz,
1H)
EXAMPLE 1304
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)carboxamide
[3551] The title compound was obtained by treating
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)carboxamide by the same method
as the one of Example 9. 1770
[3552] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3553] 6.96(d, J=7.8 Hz, 1H), 7.21(s, 1H), 7.23(d, J=7.8 Hz, 1H),
7.27-7.34(br.s, 1H), 7.64(d, J=2.7 Hz, 1H), 7.65(d, J=2.7 Hz, 1H),
7.80-7.87(br.s, 1H), 9.59(s, 1H)
EXAMPLES
[3554] The following compounds were obtained by the same method as
the one of Example 1303.
192 Ex. Structural formula NMR 1305 1771 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 3.40(s, 3H), 5.33(s, 2H), 7.09(t, J=8.4 Hz, 1H),
7.28(d, J=8.2 Hz, 1H), 7.34(t, J=8.4 Hz, 2H), 7.60(d, J=1.6 Hz,
1H), 7.60(dd, J=1.6, 8.2 Hz, 1H), 7.73(d, J=8.4 Hz, 2H),
N-phenyl-(10-methoxymethyl-10H- 7.95(d, J=2.5 Hz, 1H),
pyrazino[2,3-b][1,4]benzothiazin-8-yl) 7.99(d, J=2.5 Hz, 1H),
carboxamide 10.24(s, 1H) 1306 1772 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 3.41(s, 3H), 5.36(s, 2H), 7.28(d, J=8.8 Hz, 1H),
7.29(d, J=3.7 Hz, 1H), 7.55(d, J=3.7 Hz, 1H), 7.70(dd, J=1.7, 8.8
Hz, 1H), 7.71(d, J=1.7 Hz, 1H),
N-(thiazol-2-yl)-(10-methoxymethyl-10H- 7.94(d, J=2.8 Hz, 1H),
pyrazino[2,3-b][1,4]benzothiazin-8-yl) 7.99(d, J=2.8 Hz, 1H),
carboxamide 12.65-12.75(br.s, 1H) 1307 1773
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.09(t, J=6.5 Hz, 3H),
3.25(dt, J=5.5, 6.5 Hz, 2H), 3.38(s, 3H), 5.28(s, 2H), 7.19(d,
J=8.3 Hz, 1H), 7.44(dd, J=1.5, 8.3 Hz, 1H), 7.53(d, J=1.5 Hz, 1H),
7.93(d, J=2.7 Hz, 1H),
N-ethyl-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4] 7.97(d, J=2.7
Hz, 1H), benzothiazin-8-yl)carboxamide 8.48(t, J=5.5 Hz, 1H)
EXAMPLES
[3555] The following compounds were obtained by treating the
compounds obtained in the above table by the same method as the one
of Example 434.
193 Ex. Structural formula MS M.p. NMR 1308 1774 281-282.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 7.05(d, J=8.5 Hz, 1H),
7.07(t, J=8.1 Hz, 1H), 7.26(s, 1H), 7.31(d, J=8.5 Hz, 1H), 7.33(t,
J=8.1 Hz, 2H), 7.65(d, J=2.9 Hz, 1H), 7.66(d, J=2.9 Hz, 1H),
N-phenyl-(10H-pyrazino[2,3-b][1,4] 7.70(d, J=8.1 Hz, 2H), 9.66(s,
1H), benzothiazin-8-yl)carboxamide 10.16(s, 1H) 1309 1775
320-322.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 7.04(d,
J=8.4 Hz, 1H), 7.25(d, J=3.9 Hz, 1H), 7.32(d, J=1.6 Hz, 1H),
7.50(dd, J=1.6, 8.4 Hz, 1H), 7.53(d, J=3.9 Hz, 1H), 7.64(d, J=2.9
Hz, 1H), N-(thiazol-2-yl)-(10H-pyrazino[2,3-b] 7.67(d, J=2.9 Hz,
1H), 9.71(s, 1H), [1,4]benzothiazin-8-yl)carboxamide
12.47-12.60(br.s, 1H) 1310 1776 274-275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.06(t, J=7.0 Hz, 3H),
3.21(dq, J=5.7, 7.0 Hz, 2H), 6.96(d, J=8.3 Hz, 1H), 7.18(dd, J=1.6,
8.3 Hz, 1H), 7.19(d, J=1.6 Hz, 1H), 7.63(d, J=2.9 Hz, 1H), 7.64(d,
J=2.9 Hz, 1H), N-ethyl-(10H-pyrazino[2,3-b][1,4] 8.35(t, J=5.7 Hz,
1H), benzothiazin-8-yl)carboxamide 9.59(s, 1H)
EXAMPLES
[3556] The following compounds were obtained by effecting
dehydration/condensation with various amines by the same method as
the one of Example 1303 and treating the compounds thus obtained by
the same method as the one of Example 9.
194 Ex. Structural formula MS NMR 1311 1777 ESI(+) 328.0 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.80(s, 3H), 2.95-3.10(br.s,
4H), 3.22-3.33(br.s, 4H), 6.78(d, J=2 Hz, 1H), 6.84(dd, J=2, 8 Hz,
1H), N,N-(3-methyl-3-azapentamethylene)-(10H-pyrazino[2, 3-b]
7.00(d, J=8 Hz, 1H), [1,4]benzothiazin-8-yl)carboxamide 7.67(s,
2H), 9.66(s, 1H) 1312 1778 FAB(+) 314 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.40-3.65(m, 8H), 6.75(d,
J=1.7 Hz, 1H), 6.78(dd, J=1.7, 7.7 Hz, 1H),
N,N-(3-oxapentamethylene)-(10H-pyrazino[2,3-b][1,4] 6.96(d, J=7.7
Hz, 1H), benzothiazin-8-yl)carboxamide 7.65(s, 2H), 9.60(s, 1H)
1313 1779 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.17(t, J=7.4 Hz,
3H), 4.28(q, J=7.4 Hz, 2H), 7.07(d, J=8.1 Hz, 1H), 7.26(d, J=1.7
Hz, 1H), 7.37(dd, J=1.7, 8.1 Hz, 1H), 7.65(d, J=2.8 Hz, 1H),
7.88(d, J=8.7 Hz, 2H), ethyl
4-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl) 7.93(d, J=8.7 Hz,
2H), carboxamido]benzoate 9.68(s, 1H), 10.47(s, 1H)
EXAMPLE 1314
4-[(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl) carboxamido]-benzoic
acid
[3557] The title compound was obtained by treating ethyl
4-[(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carboxamido]benzoate
by the same method as the one of Example 18. 1780
[3558] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3559] 7.07(d, J=7.8 Hz, 1H), 7.26(d, J=1.8 Hz, 1H), 7.37(dd,
J=1.8, 7.8 Hz, 1H), 7.65(d, J=3.1 Hz, 1H), 7.67(d, J=3.1 Hz, 1H),
7.85(d, J=9.1 Hz, 2H), 7.91(d, J=9.1 Hz, 2H), 9.68(s, 1H), 10.45(s,
1H)
EXAMPLES
[3560] The following compounds were obtained by
dehydrating/condensing
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetic acid with various
amines by the same method as the one of Example 1303.
195 Ex. Structural formula MS M.p. NMR 1315 1781 FAB(+) 344
(MH.sup.+) 145 148.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.61(quint, J=6.0 Hz, 2H), 2.13(s, 6H), 2.34(t, J=6.0 Hz, 2H),
3.33(m, 2H), 3.38(s, 2H), 6.48(d, J=1.5 Hz, 1H), 6.69(dd, J=1.5,
7.9 Hz, 1H), 6.84(d, J=7.9 Hz, 1H), 7.01(br.s, 1H), 7.38(br.s, 1H),
N-[3-(dimethylamino)propyl]-(10H-pyrazino[2,3-b][- 1,4] 7.58(d,
J=2.9 Hz, 1H), benzothiazin-8-yl)acetamide 7.69(d, J=2.9 Hz, 1H)
1316 1782 FAB(+) 358 (MH.sup.+) .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.63-1.75(m, 2H), 2.20(s, 6H), 2.22, 2.26(t, J=7.1 Hz,
total2H), 2.94, 2.99(s, total3H), 3.34, 3.41(t, J=7.1 Hz, total2H),
3.54, 3.62(s, total2H), 6.51(d, J=1.8 Hz, 1H), 6.64(dd, J=1.8, 7.9
Hz, 1H), 6.76, # 6.77(d, J=7.9 Hz, total1H), 7.55(d, J=2.9 Hz, 1H),
7.58, 7.64(br.s, total1H), N-[3-(dimethylamino)pro-
pyl]-N-methyl-(10H-pyrazino[2,3-b] 7.63(d, J=2.9 Hz, 1H),
[1,4]benzothiazin-8-yl)acetamide 7.65(m, 1H) 1317 1783 FAB(+) 300
(M.sup.+) 212.degree. C. (decom- pose) .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 0.88(t, J=7.5 Hz, 3H), 1.49(m, 2H), 3.20(q, J=6.6 Hz,
2H), 3.39(s, 2H), 5.54(m, 1H), 6.45(d, J=1.5 Hz, 1H), 6.69(dd,
J=1.5, 7.7 Hz, 1H), 6.84(d, J=7.7 Hz, 1H), 6.93(s, 1H),
N-propyl-(10H-pyrazino[2- ,3-b][1,4] 7.57(d, J=2.9 Hz, 1H),
benzothiazin-8-yl)acetamide 7.69(d, J=2.9 Hz, 1H)
EXAMPLE 1318
(E)-N,N-Pentamethylene-3-(10-methoxymethyl-10OH-pyrazino[2,3-b][1,4]benzot-
hiazin-8-yl)propenamide
[3561] 140 mg of the title compound was obtained as yellow crystals
from 273 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)car-
boxamide by the same method as the one of Production Example 25.
1784
[3562] .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.56-1.66(m, 4H),
1.66-1.74(m, 2H), 3.52-3.63(m, 2H), 3.54(s, 3H), 3.63-3.72(m, 2H),
5.28(s, 2H), 6.85(d, J=15.3 Hz, 1H), 7.00(d, J=7.8 Hz, 1H),
7.16(dd, J=1.6, 7.8 Hz, 1H), 7.24(d, J=1.6 Hz, 1H), 7.55(d, J=15.3
Hz, 1H), 7.85(s, 2H)
EXAMPLE 1319
(E)-3-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]
benzothiazin-8-yl)propeno- ic acid
[3563] The title compound was obtained as yellow crystals by
treating ethyl
(E)-3-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)
propenoate by the same method as the one of Example 18. 1785
[3564] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3565] 3.38(s, 3H), 5.33(s, 2H), 6.48(d, J=15.8 Hz, 1H), 7.16(d,
J=7.9 Hz, 1H), 7.32(s, 1H), 7.34(d, J=7.9 Hz, 1H), 7.50(d, J=15.8
Hz, 1H), 7.93(d, J=2.4 Hz, 1H), 7.97(d, J=2.4 Hz, 1H),
12.4-12.5(br.s, 1H)
EXAMPLE 1320
3-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)propenamide
[3566] 950 mg of
(E)-3-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothia-
zin-8-yl)propenoic acid was dissolved in a solvent mixture of
tetrahydrofuran (10 ml) with N,N-dimethylformamide (10 ml) in a
nitrogen atmosphere. Under ice-cooling, 0.48 ml of diethyl
chlorophosphonate was dropped into the reaction mixture. After
stirring at room temperature for 30 minutes, ammonia gas was blown
into the system. Then the reaction mixture was distributed into an
aqueous solution of sodium carbonate and ethyl acetate and
extracted with ethyl acetate. The extract was washed with water and
dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the crystals thus precipitated were
recrystallized from diisopropyl ether/ethyl acetate to thereby give
400 mg of the title compound as yellow crystals. 1786
[3567] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3568] 3.41(s, 3H), 5.30(s, 2H), 6.54(d, J=16.0 Hz, 1H), 7.12(br.s,
1H), 7.15(d, J=7.9 Hz, 1H), 7.20(dd, J=1.3, 7.9 Hz, 1H), 7.26(d,
J=1.3 Hz, 1H), 7.33(d, J=16.0 Hz, 1H), 7.59(br.s, 1H), 7.93(d,
J=2.4 Hz, 1H), 7.97(d, J=2.4 Hz, 1H)
EXAMPLES
[3569] The following compounds were obtained by treating the
compounds obtained in Examples 1318 and 1320 by the same method as
the one of Example 9.
196 Ex. Structural formula NMR 1321 1787 .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.40-1.55(m, 4H), 1.55-1.64(m, 2H), 3.46-3.54(m, 2H),
3.54-3.63(m, 2H), 6.91(s, 1H), 6.93(d, J=8.3 Hz, 1H), 7.05(d,
J=15.1 Hz, 1H), 7.19(d, J=8.3 Hz, 1H), 7.21(d, J=15.1 Hz, 1H),
(E)-N,N-pentamethylene-3-(10H-pyrazino[2,- 3-b] 7.63(d, J=3.0 Hz,
1H), [1,4]benzothiazin-8-yl)propenamide 7.65(d, J=3.0 Hz, 1H),
9.46(s, 1H) 1322 1788 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
6.41(d, J=15.3 Hz, 1H), 6.89(s, 1H), 6.93(d, J=8.4 Hz, 1H), 6.96(d,
J=8.4 Hz, 1H), 7.12(br.s, 1H), (E)-3-(10H-pyrazino[2,3-b][1,4]
7.18(d, J=15.3 Hz, 1H), 7.60(br.s, 1H),
benzothiazin-8-yl)propenamide 7.63-7.67(m, 2H), 9.61(s, 1H)
EXAMPLE 1323
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)thioacetamide
[3570] The title compound was obtained by treating
(10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazin-8-yl)acetonitrile by the same
method as the one of Example 1533. 1789
[3571] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3572] 3.53(s, 3H), 4.01(s, 2H), 5.25(s, 2H), 6.86(br.s, 1H),
6.88(dd, J=1.7, 7.7 Hz, 1H), 7.00(d, J=7.7 Hz, 1H), 7.05(d, J=1.7
Hz, 1H), 7.73-7.85(br.s, 1H), 7.85(d, J=2.9 Hz, 1H), 7.86(d, J=2.9
Hz, 1H)
EXAMPLES
[3573] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbonitrile
successively by the same methods as those of Examples 1339-1 and
9.
197 Ex. Structural formula MS NMR 1324 1790 FAB(+) 274 (M.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.61(s, 2H), 6.73(d, J=1.7
Hz, 1H), 6.74(dd, J=1.7, 7.7 Hz, 1H), 6.83(d, J=7.7 Hz, 1H),
7.62(d, J=2.8 Hz, 1H), 7.63(d, J=2.8 Hz, 1H),
(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 9.29-9.35(br.s, 1H),
yl)thioacetamide 9.47-9.54(br.s, 1H), 9.53(s, 1H) 1325 1791 FAB(+)
260 (M.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 6.93(d, J=7.8
Hz, 1H), 7.13(d, J=7.8 Hz, 1H), 7.32(s, 1H), 7.64(br.s, 2H),
(10H-pyrazino[2, 3-b][1,4]benzothiazin-8- 9.40(br.s, 1H), 9.61(s,
1H), yl)carbothioamide 9.80(br.s, 1H)
EXAMPLES
[3574] The following compounds were obtained by treating
8-aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
by the same method as the one of Example 316.
198 Ex. Structural formula NMR 1326 1792 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 2.93(s, 3H), 3.54(s, 3H), 4.23(d, J=6.0 Hz, 2H),
4.76(br.t, J=6.0 Hz, 1H), 5.26(s, 2H), 6.95(dd, J=1.7, 7.6 Hz, 1H),
7.00(d, J=7.6 Hz, 1H), 7.13(d, J=1.7 Hz, 1H),
N-(10-methoxymethyl-10H-pyrazino[2,3-b] 7.84(d, J=2.7 Hz, 1H),
[1,4]benzothiazin-8-ylmethyl)methanesulfonamide 7.86(d, J=2.7 Hz,
1H) 1327 1793 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.53(s, 3H),
4.33(d, J=6.0 Hz, 2H), 5.22(s, 2H), 5.64-5.74(br.d, J=6.0 Hz, 1H),
6.78(dd, J=1.7, 8.0 Hz, 1H), 6.96(d, J=8.0 Hz, 1H),
N-(10-methoxymethyl-10H-pyrazino[2,3-b] 7.03(d, J=1.7 Hz, 1H),
[1,4]benzothiazin-8-ylmethyl) 7.87(d, J=3.0 Hz, 1H),
trifluoromethane-sulfonamide 7.88(d, J=3.0 Hz, 1H)
EXAMPLES
[3575] The following compounds were obtained by treating
8-aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
successively by the same methods as those of Examples 316 and
434.
199 Ex. Structural formula MS NMR 1328 1794 FAB(+) 370 (M+), 371
(MH.sup.+) .sup.1H-NMR(DMSO-d.sub.- 6) .delta. ppm: 3.76(d, J=6.4
Hz, 2H), 6.62(d, J=7.3 Hz, 1H), 6.69(s, 1H), 6.80(d, J=7.3 Hz, 1H),
7.57(t, J=8.0 Hz, 2H), 7.61(t, J=8.0 Hz, 1H), 7.53(s, 2H),
N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.77(d, J=8.0 Hz, 2H),
ylmethyl)benzenesulfonamide 8.11(d, J=6.4 Hz, 1H), 9.52 (s,1H) 1329
1795 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.86(s, 3H), 3.95(d,
J=6.2 Hz, 2H), 6.74(d, J=8.3 Hz, 1H), 6.75(s, 1H), 6.87(d, J=8.3
Hz, 1H), 7.50(t, J=6.2 Hz, 1H),
N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.62(d, J=2.8 Hz, 1H),
ylmethyl)methanesulfonamide 7.63(d, J=2.8 Hz, 1H), 9.54(s, 1H) 1330
1796 .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.15(s, 2H), 6.73(d,
J=8.6 Hz, 1H), 6.74(s, 1H), 6.91(d, J=8.6 Hz, 1H), 7.63(d, J=2.8
Hz, 1H), N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- 7.65(d, J=2.8
Hz, 1H), ylmethyl)trifluoromethanesulfonamide 9.62(s, 1H),
9.87-9.96(br.s, 1H)
EXAMPLE 1331
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl) sulfamide
[3576] 5 ml of a solution of 283 mg of chlorosulfonyl isocyanate in
tetrahydrofuran was ice-cooled and 92 mg of formic acid was added
thereto. After stirring at room temperature for 30 minutes, the
mixture was added to a solution of 276 mg of
8-aminomethyl-10H-pyrazino[2,3-b][1,- 4]benzothiazine in
tetrahydrofuran (5 ml) and the resulting mixture was stirred at
room temperature for 20 minutes. Next, it was distributed into an
aqueous solution of potassium carbonate and ethyl acetate and the
aqueous layer was extracted. The aqueous layer was well washed with
ethyl acetate and the organic solvent contained therein was
distilled off under reduced pressure. The residual aqueous solution
was purified by High-porous gel chromatography (CHP20P mfd. by
Mitsubishi Chemical Industries, Ltd., 75-150.mu.) (fluted with
water/methanol) to thereby give 45 mg of the title compound as
yellow crystals. 1797
[3577] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3578] 3.70(d. J=7.0 Hz, 2H), 4.57(t, J=7.0 Hz, 1H), 6.73(d, J=8.0
Hz, 1H), 6.74(s, 1H), 6.78(d, J=8.0 Hz, 1H), 7.57-7.64(m, 2H),
9.46(s, 1H)
[3579] MS: FAB(-)309(M.sup.-)
EXAMPLE 1332
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)phenylcarbamate
[3580] Into a solution of 350 mg of
8-aminomethyl-10H-pyrazino[2,3-b][1,4]- benzothiazine and 100 mg of
pyridine in tetrahydrofuran (8 ml) was dropped 270 mg of phenyl
chlorocarbonate and the resulting mixture was stirred for 5
minutes. Then the reaction mixture was distributed into water and
ethyl acetate. The organic layer was extracted, washed with water
and dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, diisopropyl ether was added to the
crystals thus precipitated followed by filtration. Thus, 230 mg of
the title compound was obtained as yellow crystals. 1798
[3581] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3582] 4.08(d, J=5.9 Hz, 2H), 6.72(d, J=8.6 Hz, 1H), 6.73(s, 1H),
6.88(d, J=8.6 Hz, 1H), 7.11(d, J=7.8 Hz, 2H), 7.19(t, J=7.8 Hz,
1H), 7.37(t, J=7.8 Hz, 2H), 7.62-7.65(m, 2H), 8.25(t, J=5.9 Hz,
1H), 9.57(s, 1H)
EXAMPLES
[3583] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methanol
successively by the same methods as those of Examples 1336 and
9.
200 Ex. Structural formula MS M.p. NMR 1333
1799N-butyl-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)carbamate FAB(+) 330(M.sup.+) 169-171.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.93(t, J=6Hz, 3H),
1.30-1,40(m, 2H), 1,40-1.50(m, 2H), 3.10-3.22(m, 2H),
4.70-4.80(br.s, 1H), 4.92(s, 2H). 6.40-6.50(br.s, 1H), 6.53(s, 1H),
6.82(d, J=8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.58(d, J=2Hz, 1H), 7.80(d,
J=2Hz, 1H) 1334
1800N-phenyl-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)carbamate FAB(+) 350(M.sup.+) 237- 240.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.93(s, 2H), 6.80(d, J=8Hz,
1H), 6.86(s, 1H), 6.92(d, J=8Hz, 1H), 6.93-6.99(m, 1H),
7.22-7.28(m, 2H), 7.41-7.48(m, 2H), 7.62(d, J=2Hz, 2H), 9.58(s,
1H), 9.77(br.s, 1H)
EXAMPLE 1335
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)urea
[3584] A solution of 420 mg of
8-aminomethyl-10H-pyrazino[2,3-b][1,4]benzo- thiazine in acetic
acid (2 ml)/water (4 ml) was heated to 70.degree. C. and potassium
cyanate (1 g in total) was added thereto over 2 hours. Then the
reaction mixture was brought back to room temperature and diluted
with water. The solid thus precipitated was filtered, washed well
with water and recrystallized from dimethyl sulfoxide/ethyl acetate
to thereby give 70 mg of the title compound as yellow crystals.
1801
[3585] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3586] 3.97(d, J=6.4 Hz, 2H), 5.52(s, 2H), 6.33(t, J=6.4 Hz, 1H),
6.66(d, J=8.7 Hz, 1H), 6.67(s, 1H), 6.83(d, J=8.7 Hz, 1H), 7.62(d,
J=2.5 Hz, 1H), 7.63(d, J=2.5 Hz, 1H), 9.52(s, 1H)
[3587] MS: FAB(+)273(M.sup.+)
EXAMPLE 1336
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N'-phenylurea
[3588] To 5 ml of a solution of 200 mg of
8-aminomethyl-10H-pyrazino[2,3-b- ][1,4]benzothiazine in
tetrahydrofuran was added 120 mg of phenyl isocyanate and the
resulting mixture was stirred at room temperature for 1 hour. The
crystals thus precipitated were filtered after adding diethyl ether
thereto and thus the title compound was obtained as yellow crystals
almost quantitatively. 1802
[3589] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3590] 4.10(d, J=5.8 Hz, 2H), 6.53(t, J=5.8 Hz, 1H), 6.70(d, J=7.9
Hz, 1H), 6.71(s, 1H), 6.85(d, J=7.9 Hz, 1H), 6.88(t, J=8.1 Hz, 1H),
7.20(t, J=8.1 Hz, 2H), 7.38(d, J=8.1 Hz, 2H), 7.62(s, 2H), 8.54(s,
1H), 9.53(s, 1H)
EXAMPLE 1337
N-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N'-be-
nzoylthiourea
[3591] To 5 ml of a solution of 350 mg of ammonium thiocyanate in
acetone was added in a nitrogen atmosphere 0.50 ml of benzoyl
chloride and the resulting mixture was heated under reflux for 5
minutes. Then 5 ml of a solution of 890 mg of
8-aminomethyl-10-methoxymethyl-10H-pyrazino[2,3-b][-
1,4]benzothiazine in acetone was added thereto and the resulting
mixture was heated under reflux for additional 1.5 hours. Next, the
reaction mixture was distributed into water and ethyl acetate,
washed with water and dried over anhydrous sodium sulfate. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
n-hexane/ethyl acetate) and recrystallized from diisopropyl ether
to thereby give 710 mg of the title compound as yellow crystals.
1803
[3592] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3593] 3.53(s, 3H), 4.85(d, J=6 Hz, 2H), 5.28(s, 2H), 7.01(s, 2H),
7.20(s, 1H), 7.52(t, J=8.0 Hz, 2H), 7.64(tt, J=1.3, 8.0 Hz, 1H),
7.83(dd, J=1.3, 8.0 Hz, 2H), 7.84(d, J=2.9 Hz, 1H), 7.85(d, J=2.9
Hz, 1H), 9.05(br.s, 1H), 10.98-11..07(br.s, 1H)
EXAMPLE 1338
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N'-benzoylthiourea
[3594] 250 mg of the title compound was obtained as yellow crystals
by treating 300 mg of
N-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiaz-
in-8-ylmethyl)-N'-benzoylthiourea by the same method as the one of
Example 434. 1804
[3595] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3596] 5.77(d, J=6 Hz, 2H), 6.58(d, J=1.5 Hz, 1H), 6.84(dd, J=1.5,
8.1 Hz, 1H), 6.87(d, J=8.1 Hz, 1H), 7.30-7.39(br.s, 1H), 7.49(d,
J=3.1 Hz, 1H), 7.53(t, J=7.7 Hz, 2H), 7.64(tt, J=1.0, 7.7 Hz, 1H),
7.67(d, J=3.1 Hz, 1H), 7.84(dd, J=1.0, 7.7 Hz, 2H), 9.10(br.s, 1H),
10.96-11.16(br.s, 1H)
EXAMPLE 1339
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)thiourea
[3597] 250 mg of
N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N'-be-
nzoylthiourea was added to a mixture of a 20% aqueous solution of
potassium hydroxide (5 ml) with methanol (5 ml). After further
adding a small portion of tetrahydrofuran, the resulting mixture
was heated to 50.degree. C. for 5 minutes. Then the reaction
mixture was brought back to room temperature and distributed into
water and ethyl acetate. The organic layer was extracted, washed
with water and dried over anhydrous sodium sulfate. After
distilling off the solvent under reduced pressure, the crystals
thus precipitated were suspended in ethyl acetate and filtered.
Thus, 140 mg of the title compound was obtained as yellow crystals.
1805
[3598] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3599] 4.36-4.48(br.s, 2H), 6.68(br.s, 1H), 6.69(br.d, J=7.8 Hz,
1H), 6.85(d, J=7.8 Hz, 1H), 6.97-7.22(br.s, 2H), 7.62(d, J=3.2 Hz,
1H), 7.64(d, J=3.2 Hz, 1H), 7.85-7.95(br.s, 1H), 9.50-9.60(br.s,
1H)
[3600] MS: FAB(+)289(M.sup.+)
EXAMPLES
[3601] The following compounds were obtained by treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)methano-
l successively by the same methods as those of Examples 788 and
9.
201 Ex. Structural formula MS M.p. NMR 1340
18068-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine ESI(+)
246 (MH.sup.+) 189-192.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.37(s, 3H), 4.30 (s, 2H), 6.51(s, 1H), 6.52(s, 1H), 6.78(d,
J=8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.68(d, J=3Hz,
1H) 1341
18078-benzyloxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine ESI(+)
322 (MH.sup.+) 118-120.degree. C. .sup.1H-NHR(CDCl.sub.3) .delta.
ppm: 4.40(s, 2H), 4.54 (s, 2H), 6.54(s, 1H), 6.60-6.70(br.s, 1H),
6.59 (d, J=8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.22-7.45 (m, 5H), 7.57(s,
1H), 7.67(s, 1H)
EXAMPLE 1342
(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbohydroxami-
c acid
[3602] To 2 ml of an aqueous solution of 280 mg of sodium hydroxide
and 210 mg of hydroxylamine hydrochloride was added 5 ml of a
solution of 303 mg of methyl
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-
carboxylate in tetrahydrofuran and the resulting mixture was
stirred at room temperature for 1 hour. Then the reaction mixture
was distributed into dilute hydrochloric acid and ethyl acetate.
The organic layer was extracted, washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, the residue was purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
240 mg of the title compound as yellow crystals. 1808
[3603] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3604] 3.38(s, 3H), 5.28(s, 2H), 7.18(d, J=8.0 Hz, 1H), 7.32(dd,
J=1.4, 8.0 Hz, 1H), 7.45(d, J=1.4 Hz, 1H), 7.93(d, J=3.1 Hz, 1H),
7.97(d, J=3.1 Hz, 1H), 9.06(s, 1H), 11.23(br.s, 1H)
EXAMPLE 1343
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl) carbohydroxamic
acid
[3605] 40 mg of the title compound was obtained as yellow crystals
by treating 240 mg of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-
-8-yl)carbohydroxamic acid by the same method as the one of Example
434. 1809
[3606] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3607] 6.95(d, J=8.2 Hz, 1H), 7.06(dd, J=1.6, 8.2 Hz, 1H), 7.14(d,
J=1.6 Hz, 1H), 7.63(d, J=3.2 Hz, 1H), 7.65(d, J=3.2 Hz, 1H),
9.00(br.s, 1H), 9.60(s, 1H), 11.05-11.17(br.s, 1H)
EXAMPLE 1344
N-(Methanesulfonyl)-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamide
[3608] To a solution of 0.259 g of (10H-pyrazino
[2,3-b][1,4]benzothiazin-- 8-yl)acetic acid in tetrahydrofuran (10
ml) was added in a nitrogen atmosphere 0.18 g of
carbonyldiimidazole and the resulting mixture was heated under
reflux for 30 minutes. Then the reaction mixture was brought back
to room temperature and 0.285 g of methanesulfonamide was added
thereto. After stirring at room temperature for 16 hours, the
solvent was distilled off under reduced pressure and the residue
was purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.163 g of the title
compound as a yellow solid. 1810
[3609] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3610] 3.10(s, 3H), 3.33(s, 2H), 6.65(s, 1H), 6.66(d, J=8 Hz, 1H),
6.83(d, J=8 Hz, 1H), 7.62(d, J=4 Hz, 1H), 7.63(d, J=4 Hz, 1H),
9.52(s, 1H)
[3611] m.p.: 236-238.degree. C.
[3612] MS: FAB(+)336(MH.sup.+)
EXAMPLE 1345
N-Cyano-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamide
[3613] 0.100 g of the title compound was obtained as a yellow solid
by treating 0.259 g of
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetic acid by the same
method as the one of Example 1344 by using 0.126 g of cyanamide as
a substitute for the methanesulfonamide. 1811
[3614] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3615] 3.37(s, 2H), 6.65(s, 1H), 6.67(d, J=8 Hz, 1H), 6.93(d, J=8
Hz, 1H), 7.62(d, J=3 Hz, 1H), 7.63(d, J=3 Hz, 1H), 9.51(s, 1H)
[3616] MS: FAB(+)263(M.sup.+)
[3617] m.p. : 197-198.degree. C.
EXAMPLE 1346
Sodium
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methane-
sulfonate
[3618] To a solution of 900 mg of
8-chloromethyl-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine in a mixture of water (8 ml)/methanol
(4 ml) was added 0.8 g of sodium sulfite and the resulting mixture
was heated to 90.degree. C. for 2 hours. Then the reaction mixture
was brought back to room temperature and diluted with ethanol.
After filtering off the inorganic salt, silica gel was added to the
filtrate. After distilling off the solvent under reduced pressure,
the residue was purified by silica gel column chromatography
(eluted with dichloromethane/methanol/ac- etic acid) to thereby
give 650 mg of the title compound as yellow crystals. 1812
[3619] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3620] 3.37(s, 3H), 3.62(s, 2H), 5.20(s, 2H), 6.95(dd, J=1.2, 7.8
Hz, 1H)6.99(d, J=7.8 Hz, 1H), 7.09(d, J=1.2 Hz, 1H), 7.90(d, J=2.5
Hz, 1H), 7.95(d, J=2.5 Hz, 1H)
EXAMPLE 1347
Sodium (10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)
methane-sulfonate
[3621] 200 mg of the title compound was obtained as yellow crystals
by treating 320 mg of sodium
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzo-
thiazin-8-yl)methanesulfonate by the same method as the one of
Example 434. 1813
[3622] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3623] 3.49(s, 2H), 6.69(dd, J=1.6, 7.7 Hz, 1H), 6.74(d, J=1.6 Hz,
1H), 6.77(d, J=7.7 Hz, 1H), 7.60(d, J=2.9 Hz, 1H), 7.62(d, J=2.9
Hz, 1H), 9.47(s, 1H)
[3624] MS: FAB(+)317(M.sup.+)
EXAMPLE 1348
8-(Purin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazi- ne and
8-(purin-7-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzo-
thiazine
[3625] In accordance with the procedure of Example 1094, 740 mg of
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
was reacted with 460 mg of purine in the presence of sodium hydride
(60% oily) in N,N-dimethylformamide (10 ml). The two isomers thus
obtained were purified by silica gel column chromatography (eluted
with dichloromethane/methanol) to thereby give 320 mg of
8-(purin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazi-
ne and 125 mg of
8-(purin-7-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b]-
[1,4]benzothiazine each as yellow crystals. 1814
[3626] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3627] 3.24(s, 3H), 5.12(s, 2H), 5.46(s, 2H), 6.96(d, J=7.8 Hz,
1H), 7.07(s, 1H), 7.09(d, J=7.8 Hz, 1H), 7.91(d, J=2.8 Hz, 1H),
7.94(d, J=2.8 Hz, 1H), 8.72(s, 1H), 8.94(s, 1H), 9.17(s, 1H)
1815
[3628] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3629] 3.26(s, 3H), 5.19(s, 2H), 5.56(s, 2H), 7.01(d, J=7.8 Hz,
1H), 7.09(s, 1H), 7.11(d, J=7.8 Hz, 1H), 7.91(d, J=2.8 Hz, 1H),
7.94(d, J=2.8 Hz, 1H), 8.87(s, 1H), 8.96(s, 1H), 9.14(s, 1H)
EXAMPLES
[3630] The following compounds having substituents at different
sites were obtained by reacting
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][-
1,4]benzothiazine with various purines by the same method as the
one of Example 1348.
202 Ex. Purine Structural formula NMR 1349 1816
18178-(6-methylpurin-9-ylmethyl)-10-methoxymethyl-10H- pyrazino[2,
3-b][1,4]benzothiazine .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
2.58(s, 3H), 3.12(s, 3H), 5.05(s, 2H), 5.68(s, 2H), 6.70-6.75(m,
2H), 7.11(d, J=8Hz, 1H), 7.91(d, J=3Hz, 1H), 7.94(d, J=3Hz, 1H),
8.75(s, 1H), 8.78(s, 1H) 1350
18188-(6-methylpurin-7-methoxymethyl-10- H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(DMSO-d.sub.6) 8 ppm:
2.70(s, 3H), 3.25(s, 3H), 5.11(s, 2H), 5.42(s, 2H), 6.93(dd, J=2,
8Hz, 1H), 7.06(d, J=2Hz, 1H), 7.07(d, J=8Hz, 1H), 7.90(d, J=3Hz,
1H), 7.94(d, J=3Hz, 1H), 8.62(s, 1H), 8.77(s, 1H) 1351 1819
18208-(6-dimethylaminopurin-9-ylmethyl)-10-
pyrazino[2,3-b][1,4]benzothia- zine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.43(s, 3H), 3.42-3.65(br.s, 6H), 5.17(s, 2H), 5.28(s, 2H),
6.82(dd, J=2, 8Hz, 1H), 6.96(d, J=8Hz, 1H), 7.08(d, J=2Hz, 1H),
7.72(s, 1H), 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.38(s, 1H)
1352 18218-(6-dimethylaminopurin-7-ylme- thyl)-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.33(br.s, 3H), 3.43(s, 3H),
3.92(br.s, 3H), 5.17(s, 2H), 5.44(s, 2H), 6.93(dd, J=2, 8Hz, 1H),
6.97(d, J=8Hz, 1H), 7.21(d, J=2Hz, 1H), 7.83(d, J=3Hz, 1H), 7.84(d,
J=3Hz, 1H), 7.95(s, 1H), 8.02(s, 1H) 1353 1822
18238-(6-chloropurin-9-ylmethyl)-10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.45(s, 3H), 5.20(s, 2H), 5.39(s, 2H), 6.88(dd, J=2, 8Hz, 1H),
7.00(d, J=8Hz, 7.83(d, J=3Hz, 1H), 7.85(d, J=3Hz, 1H), 8.13(s, 1H),
8.79(s, 1H) 1354 18248-(6-chloropurin-7-ylmethyl)-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.40(s, 3H), 5.15(s, 2H),
5.61(s, 2H), 6.75(dd, J=2, 8Hz, 1H), 6.96(d, J=2Hz, 1H), 7.01(d,
J=8Hz, 1H), 7.83(d, J=3Hz, 1H), 7.86(d, J=3Hz, 1H), 8.26(s, 1H),
8.91(s, 1H) 1355 1825 18269-(10-methoxymethyl-10H-benzothiazin-8-
ylmethyl)purine-6-carbonitrile .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.46(s, 3H), 5.21(s, 2H), 5.42(s, 2H), 6.90(dd, J=2, 8Hz, 1H),
7.00(d, J=8Hz, 1H), 7.15(d, J=2Hz, 1H), 7.83(d, J=3Hz, 1H), 7.86(d,
J=3Hz, 1H), 8.29(s, 1H), 9.01(s, 1H) 1356 1827
18288-(6-aminopurin-9-yl)-10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzo- thiazine .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 3.28(s, 3H), 5.13(s, 2H), 8Hz, 1H), 7.06(d, J=2Hz,
5.32(s, 2H), 6.93(dd, J=2, 1H), 7.10(d, J=8Hz, 1H), 7.27(s, 2H),
7.90-7.94(m, 1H), 7.95-7.98(m, 1H), 8.16(s, 1H), 8.24(s, 1H) 1357
1829 18308-(8-trifluoromethyl-6-dimethyl- aminopurin-9-yl)-
10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.34(s, 3H), 3.45(s, 3.92(s,
3H), 5.17(s, 2H), 5.43(s, 2H), 6.91-6.99(m, 3H), 7.82(m, 2H),
8.00(s, 1H) 1358 1831
18328-(8-methyl-6-dimethylaminopurin-9-ylmethyl)-
10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.47(s, 3H), 3.38(s, 3H),
2(br.s, 6H), 5.12(s, 2H), 5.26(s, 2H), 6.72(dd, J=2, 8Hz, 1H),
6.93(d, J=8Hz, 1H), 6.96(d, J=2Hz, 1H), 7.82(d, J=3Hz, 1H), 7.84(d,
J=3Hz, 1H), 8.32(s, 1H) 1359 1833
18348-(2,8-dimethylhypoxanthin-9-ylmethyl)-- 10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.35(s, 3H), 2.48(s, 3H),
3.24(s, 3H), 5.09(s, 2H), 5.24(s, 2H), 6.79(d, J=8Hz, 1H), 6.90(s,
1H), 7.09(d, J=8Hz, 1H), 7.92(d, J=3Hz, 1H), 7.95(d, J=3Hz, 1H),
12.14(s, 1H) 1360 1835
18369-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothi-
azin-8-ylmethyl)-6-dimethylamino-8-oxo- 7(H), 8(H)-purine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.24(s, 6H), 3.47(s, 3H),
4.99(s, 2H), 5.20(s, 2H), 6.93(d, J=8Hz, 1H), 7.00 (dd,J=2, 8Hz,
1H), 7.27(d, J=2Hz, 1H), 7.82(m, 2H), 8.24(s, 1H), 10.36(s, 1H)
1361 1837
18389-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmet-
hyl)-3,7-dihydro-1,3-dimethyl-1H- purine-2,6-dione
.sup.1H-NMR(DMSO-d.sub.- 6) .delta. ppm: 3.20(s, 3H), 3.31(s, 3H),
3.39(s, 3H), 5.14(s, 2H), 5.40(s, 2H), 6.95(dd, J=1,4, 8.2Hz, 1H),
7.08(d, J=1,4Hz, 1H), 7.09(d, J=2.8Hz, 1H), 7.95(d, J=2.8Hz, 1H),
8.26(s, 1H) 1362 1839 18408-(6-bromopurin-9-ylmethyl)-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4- ]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.39(s, 3H), 5.13(s, 2H),
5.32(s, 2H), 6.82(dd, J=2, 8Hz, 1H), 6.93(d, J=8Hz, 1H), 7.06(d,
J=2Hz, 1H), 7.73(d, J=3Hz, 1H), 7.79(d, J=3Hz, 1H), 8.08(s, 1H),
8.68(s, 1H) 1363 18418-(6-bromopurin-7-ylmethyl)-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.32(s, 3H), 5.08(s, 2H),
5.59(s, 2H), 6.67(dd, J=2, 8Hz, 1H), 6.87(d, J=2Hz, 1H), 6.95(d,
J=8Hz, 1H), 7.77(d, J=3Hz, 1H), 7.80(d, J=3Hz, 1H), 8.21(s, 1H),
8.80(s, 1H)
EXAMPLES
[3631] The following compounds were obtained each as yellow
crystals by treating the methoxymethyl compounds in the above table
by the same method as the one of Example 434.
203 Ex. Structural formula MS M.p. NMR 1364
18428-(purin-9-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazin- e
ESI(+) 334.1 (MH.sup.+) 264-265.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.34(s, 2H), 6.59(s, 1H),
6.74(d, J=8.6Hz, 1H), 6.88(d, J=8.6Hz, 1H), 7.61(s, 2H), 8.69(s,
1H), 8.93(s, 1H), 9.18(s, 1H), 9.44(br.s, 1H) 1365
18438-(purin-7-yl-methyl)-10H-pyrazin- o[2,3-b][1,4]benzothiazine
ESI(+) 334.2 (MH.sup.+) 277-280.degree. C. .sup.1H
NMR(DMSO-d.sub.6) .delta. ppm: 5.46(s, 2H), 6.60(s, 1H), 6.80(d,
J=8.0Hz, 1H), 6.91(d, J=8.0Hz, 1H), 7.61(s, 2H), 8.81(s, 1H),
8.97(s, 1H), 9.07(s, 1H), 9.43(br.s, 1H) 1366
18448-(6-aminopurin-9-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI(+) 349 (MH.sup.+) 290.degree.
C.< .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.20(s, 2H), 6.60(d,
J=2Hz, 1H), 6.72(dd, J=2, 8Hz, 1H), 6.89(d, J=8Hz, 1H), 7.27(s,
2H),7.63(s, 2H), 8.14(s, 1H), 8.20(s, 1H), 9.50(s, 1H)
EXAMPLES
[3632] The following compounds were obtained each as yellow
crystals by treating the methoxymethyl compounds in the above table
by the same method as the one of Example 9.
204 Ex. Structural formula MS M.p. NMR 1367
18458-(6-methylpurin-9-ylmethyl)-10H- pyrazino[2,3-b][1,4]ben-
zothiazine ESI(+) 348 (MH.sup.+) 276-278.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.57(s, 3H), 5.57(s, 2H),
6.32(s, 1H), 6.57(d, J=8Hz, 1H), 6.90(d, J=8Hz, 1H), 7.60(s, 2H),
8.71(s, 1H), 8.79(s, 1H), 9.38(s, 1H) 1368
18468-(6-methylpurin-7-ylme- thyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 2.71(s, 3H), 5.31(s, 2H), 6.57(s, 1H), 6.72(d, J=8Hz, 1H),
7.61(s, 2H), 8.59(s, 1H), 8.76(s, 1H), 9.43(s, 1H) 1369
18478-(6-dimethylaminopurin-9-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothi- azine FAB(+) 377 (MH.sup.+)
229-233.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.43(s,
6H), 5.20(s, 2H), 6.56(d, J=1Hz, 1H), 6.67(dd, J=1, 8Hz, 1H),
6.86(d, J=8Hz, 1H), 7.62(5, 2H), 8.19(s, 1H), 8.21(s, 1H), 9.46(s,
1H) 1370 18488-(6-dimethylaminopurin-9-ylmethyl)-- 10H-
pyrazino[2,3-b][1,4]benzothiazine FAB(+) 377 (MH.sup.+)
265-268.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.39(s,
3H), 3.83(s, 3H), 5.34(s, 2H), 6.69(d, J=1Hz, 1H), 6.78(dd, J=1,
8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.61(s, 2H), 7.71(s, 1H), 8.52(s,
1H), 9.40(s, 1H) 1371 18498-(6-chloropurin-9-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine FAB(+) 367 (M.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.36(s, 2H), 6.54(s, 1H),
6.75(d, J=8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.61(s, 2H), 8.78(s, 2H),
9.40(s, 1H) 1372 18508-(6-chloropurin-7-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine FAB(+) 367 (M.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.57(s, 2H), 6.39(d, J=1Hz,
1H), 6.65(dd, J=1, 8Hz, 1H), 6.89(d, J=8Hz, 1H), 7.60(d, J=3Hz,
1H), 7.61(d, J=3Hz, 1H), 8.83(s, 1H), 8.94(s, 1H), 9.35(s, 1H) 1373
18519-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)purine-6-carbonit- rile 272-274.degree.C.
.sup.1H-NNR(DMSO-d.sub.6) .delta. ppm: 5.42(s, 2H), 6.56(d, J=2Hz,
1H), 6.78(dd, J=2, 8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.62(s, 2H),
9.02(s, 1H), 9.39(S, 1H), 9.40(s, 1H) 1374
18528-(8-trifluoromethyl-6-dimethylaminopurin-
9-ylmethyl)-10H-pyrazino[2- ,3-b][1,4]benzothiazine FAB(+) 444
(M.sup.+) 231-233.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
3.37(s, 3H), 3.95(s, 3H), 5.35(s, 2H), 6.44(d, J=1Hz, 1H), 6.75(dd,
J=1, 8Hz, 1H), 6.78(br.s, 1H), 6.83(d, J=8Hz, 1H), 7.55(d, J=3Hz,
1H), 7.67(d, J=3Hz, 1H), 7.90(s, 1H) 1375
18538-(8-methyl-6-dimethylaminopurin-9-
ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.45(s, 3H), 3.54(s, 6H),
5.19(s, 2H), 6.22(d, J=1Hz, 1H), 6.42(br.s, 1H), 6.63(dd, J=1, 8Hz,
1H), 6.83(d, J=8Hz, 1H), 7.54(d, J=3Hz, 1H), 7.68(d, J=3Hz, 1H),
8.33(s, 1H) 1376 18548-(2,8-dimethylhypoxanthin-9-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzo- thiazine 206-211.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.30 and 2.31(s, total 3H),
2.34 and 2.35(s, total 3H), 5.13 and 5.49(s, total 2H), 6.43 and
6.46(s, total 1H), 6.59(d, J=8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.61(s,
2H), 9.44 and 9.46(s, total 1H), 12.13(br.s, 1H) 1377
18559-(10H-pyrazino[2,3-b[1,4]benzothiazin-8-
ylmethyl)-6-dimethylamino-1,7-dihydro- 8H-purin-8-one FAB(+)
392(M.sup.+) >280.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.20(s, 3H), 3.35(s, 3H), 4.75(s, 2H), 6.65(s, 1H), 6.72(d,
J=8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.60(s, 2H),8.09(s, 1H), 9.46(s,
1H), 10.95(s, 1H)
EXAMPLES
[3633] The following compounds were obtained by treating
8-(6-bromopurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benz-
othiazine by the same method as the one of Example 9 and separating
and purifying each of the two compounds thus formed.
205 Ex. Structural formula MS M.p. NMR 1378
18567-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)-6-oxo-1(H), 6(H)-purine FAB(+) 350 (MH.sup.+)
>275.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.38(s,
2H), 6.57 (d, J=1Hz, 1H), 6.68(dd, J=1, 8Hz, 1H), 6.87 (d, J=8Hz,
1H), 7.61(s, 2H), 7.97(d, J=4Hz, 1H), 8.30(s, 1H), 9.48(s, 1H),
12.30(s, 1H) 1379 18575-(6-bromopurin-7-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 5.21(s, 2H), 6.39(d, J=1Hz, 1H), 6.60(br.s, 1H), 6.74(dd, J=1,
8Hz, 7.55(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H), 7.90(s, 1H), 8.56(s,
1H)
EXAMPLES
[3634] The following compounds were obtained by treating
8-(6-bromopurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benz-
othiazine by the same method as the one of Example 9 and separating
and purifying each of the two compounds thus formed.
206 Ex. Structural formula MS M.p. NMR 1380
18588-(hypoxanthin-9-ylmethyl)-10H- pyrazino[2,3-b][1,4]benzo-
thiazine FAB(+) 349 (M.sup.+) >275.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 5.20(s, 2H), 6.53 (d, J=1Hz,
1H), 6.69(dd, J=1, 8Hz, 1H), 6.87 (d, J=8Hz, 1H), 7.62(s, 2H),
8.02(d, J=4Hz, 1H), 8.14(s, 1H), 9.45(s, 1H), 12.31(s, 1H) 1381
18598-(6-bromopurin-9-ylme- thyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 5.22(s, 2H), 6.36 (d, J=1Hz, 1H), 6.43(br.s, 1H), 6.70(dd,
J=1, 8Hz, 1H), 6.82(d, J=8Hz, 1H), 7.50(d, J=3Hz, 1H), 7.64(d,
J=3Hz, 1H), 8.06(s, 1H), 8.67(s, 1H)
EXAMPLE 1382
9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3,7-dihydro-1,3-dimeth-
yl-1H-purine-2,6-dione
[3635] The title compound was obtained by treating
9-(10-methoxymethyl-10H-
-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H--
purine-2,6-dione by the same method as the one of Example 9.
1860
[3636] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3637] 3.19(s, 3H), 3.43(s, 3H), 5.32(s, 2H), 6.59(d, J=2 Hz, 1H),
6.68(d, J=8 Hz, 1H), 6.87(dd, J=2, 8 Hz, 1H), 7.62(m, 2H), 8.20(s,
1H), 9.47(s, 1H)
[3638] m.p. : 264-266.degree. C.
EXAMPLE 1383
8-(2,6-Dichloropurin-9-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3639] The title compound was obtained by reacting
8-chloromethyl-10-metho-
xymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine with
2,6-dichloropurine by the same method as the one of Example 1348
followed by the same treatment as the one of Example 434. 1861
[3640] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3641] 5.44(s, 2H), 6.20(d, J=1 Hz, 1H), 6.55(dd, J=1, 8 Hz, 1H),
6.59(br.s, 1H), 6.83(d, J=8 Hz, 1H), 7.49(d, =3 Hz, 1H), 7.65(d,
J=3 Hz, 1H), 8.19(s, 1H) MS: FAB(+)401(M.sup.+)
EXAMPLES
[3642] The following compounds were obtained by reacting
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
with 8-methylpurine by the same method as the one of Example 1348
to thereby give
8-(8-methylpurin-9(7)-ylmethyl)-10-methoxymethyl-10H-pyrazin-
o[2,3-b][1,4]benzothiazine and then treating this product by the
same method as the one of Example 9.
207 Ex. Structural formula MS M.p. NMR 1384
18628-(8-methylpurin-9-ylmethyl)-10H- pyrazino[2,3-b][1,4]ben-
zothiazine ESI(+) 348 (MH.sup.+) 191-193.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.48(s, 3H), 5.31(s, 2H),
6.48(s, 1H), 6.68(d, J=8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.60(s, 2H),
8.86(d, J=1Hz, 1H), 9.01(d, J=1Hz, 1H), 9.39(br.s, 1H) 1385
18638-(8-methylpurin-7-ylmethyl)-10H-
pyrazino[2,3-b][1,4]benzothiazine ESI(+) 348 (MH.sup.+)
>275.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.59(s,
3H), 5.42(s, 2H), 6.47(d, J=2Hz, 1H), 6.70(dd, J=2, 8Hz, 1H),
6.89(d, J=8Hz, 1H), 7.59(s, 2H), 8.89(s, 1H), 9.00(s, 1H), 9.37(s,
1H)
EXAMPLE 1386
8-[6-(Morpholin-4-yl)purin-9-ylmethyl]-10-methoxymethyl-10H-pyrazino[2,3-b-
][1,4]benzothiazine
[3643] 0.222 g of the title compound was obtained as a yellow solid
by treating 0.21 g of
8-(6-chloropurin-9-ylmethyl)-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine with 0.5 ml of morpholine in
dichloromethane by the same method as the one of Example 1244.
1864
[3644] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3645] 3.44(s, 3H), 3.83(t, J=5 Hz, 4H), 4.26-4.35(br.s, 4H),
5.18(s, 2H), 5.29(s, 2H), 6.83(d, J=8 Hz, 1H), 6.97(d, J=8 Hz, 1H),
7.07(s, 1H), 7.62(s, 1H), 7.81-7.83(m, 2H), 8.38(s, 1H)
EXAMPLES
[3646] The following compounds were obtained by treating
8-(6-chloropurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]ben-
zothiazine with various amines by the same method as the one of
Example 1244.
208 Ex. Structural formula NMR 1387
18658-[6-(piperidin-1-yl)purin-9-ylmethyl]-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-MMR(CDCl.sub.3) .delta. ppm: 1.65-1.77(m, 6H), 3.43 (s,
3H), 4.24(br.s, 4H), 5.17(s, 2H), 5.28(s, 2H), 6.84(dd, J=2, 8Hz,
1H), 6.94(d, J=8Hz, 1H), 7.08(d, J=2Hz, 1H), 7.71(s, 1H), 7.83(d,
J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.36 (s, 1H) 1388
18668-[6-(2,6-dimethylmorph- olin-4-yl)purin-9-ylmethyl]-
10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benz- othiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.28(d, J=7Hz, 6H),
2.75-2.87(br.s, 2H), 3.44(s, 3H), 3.72(br.s, 5.29(s, 2H),
5.30(br.s, 2H), 6.83(dd, J=2, 8Hz, 1H), 6.96(d, J=8Hz, 1H), 7.73(s,
1H), 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.37(s, 1H), 1389
18678-[6-(4-methypiperazin-1-yl)purin-9-ylmethyl]-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.35(s, 3H), 2.55(m, 4H),
3.43(s, 3H), 4.33(br.s, 4H), 5.18(s, 2H), 5.29(s, 2H), 6.83(dd,
J=2, 8Hz, 1H), 6.94(d, J=8Hz, 1H), 7.08 (d, J=2Hz, 1H), 7.63(s,
1H), 7.83(d, J=3Hz, 1H), 7.84 (d, J=3Hz, 1H), 8.37(s, 1H) 1390
18681-(9-(10-methoxylmethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl)purin-6-yl]piperidin-4-ol .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.62(m, 2H), 2.03(m, 2H), 3.43(s, 3H), 3.72(br.s, 2H), 4.02(br.s,
2H), 4.91(br.m, 1H), 5.17(s, 2H), 5.28(s, 2H), 6.84(dd, J=2, 8Hz,
1H), 6.96(6, J=8Hz, 1H), 7.09(6, J=2Hz, 1H), 7.73(s, 1H), 7.83(6,
J=3Hz, 1H), 7.84(d, J=3Hz, 1H), 8.37(s, 1H) 1391
18691-[9-(10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]piperidine-4-
carboxylic acid .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.52(m, 2H),
1.91(m, 2H), 2.59(m, 1H), 3.2(m, 4H), 3.24(s, 3H), 5.11(s, 2H),
5.22(s, 2H), 6.91(dd, J=2, 8Hz, 1H), 7.02(6, J=2Hz, 1H), 7.07(d,
J=8Hz, 1H), 7.91(6, J=3Hz, 1H), 7.94 (d, J=3Hz, 1H), 8.23(s, 1H),
8.28(s, 1H) 1392
18708-[6-(3,5-dimethypiperidin-1-yl)purin-9-ylmethyl]-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.97 and 0.99(d, J=7Hz, total
6H), 1.50-1.92(m, 4H), 2.48(br.s, 2H), 3.43(s, 3H), 5.17(s, 2H),
5.28(s, 2H), 5.32(br.s, 2H), 6.83(dd, J=2, 8Hz, 1H), 6.94(6, J=8Hz,
1H), 7.08(d, J=2Hz, 1H), 7.71(s, 1H), 7.83(d, J=3Hz, 1H), 7.84(d,
J=3Hz, 1H), 8.36(s, 1H) 1393
18718-[6-(4-benzylpiperidin-1-yl)purin-9-ylmethy-
l]-10-methoxymethyl-10H- pyrazinol[2,3-b]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.32(dq, J=4, 11Hz, 2H), 1.81
(br.d, J=11Hz, 2H), 1.85-1.94(m, 1H), 2.56(d, J=8Hz, 2H), 3.02(m,
2H), 3.44(s, 3H), 5.18(s, 2H), 5.28(s, 2H), 5.43(m, 2H), 6.83(dd,
J=2, 8Hz, 1H), 6.96(d, J=8Hz, 1H), [1,4]7.08(a, J=2Hz, 1H),
7.13-7.31(m, 5H), 7.71(s, 1H), # 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz,
1H), 8.35(s, 1H) 1394
18728-]6-(4-benzylpiperazin-1-yl)purin-9-ylmethyl]-10-metho-
xymethyl-10H- pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.58(t, J=5Hz, 4H), 3.43(s,
3H), 3.57(s, 2H), 4.32(br.s, 4H), 5.17(s, 2H), 5.28 (s, 2H),
6.83(dd, J=2, 8Hz, 1H), 6.94(d, J=8Hz, 1H), 7.07 (d, J=2Hz, 1H),
7.26-7.35(m, 5H), 7.71(s, 1H), 7.83(d, J=3Hz, 1H), 7.84(d, J=3Hz,
1H), 8.36(s, 1H) 1395
18738-[6-(4-phenylpiperidin-1-yl)purin-9-ylmethyl]-10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.79(dq, J=4, 11Hz, 2H), 2.03(br.d, J=11Hz, 2H), 2.88(tt, J=1,
11Hz, 1H), 3.16 (br.t, J=11Hz, 2H), 3.45(s, 3H), 5.19(s, 2H),
5.30(s, 2H), 5.65(br.s, 2H), 6.85(dd, J=2, 8Hz, 1H), 6.97(d, J=8Hz,
1H), 7.10(d, J=2Hz, 1H), 7.21-7.32(m, 5H), 7.74(s, 1H), 7.83(d,
J=3Hz, # 1H), 8.39(s, 1H) 1396
18748-[[4-(2-aminoethyl)piperazin-1-yl]p- urin-9-ylmethyl]-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 2.32(t, J=6Hz, 2H), 2.45(m,
4H), 2.66(t, J=6Hz, 2H), 3.26(s, 3H), 4.39(m, 4H), 5.11(s, 2H),
5.30(s, 2H), 6.90(dd, J=2, 8Hz, 1H), 7.03(d, J=2Hz, 1H), 7.07(d,
J=8Hz, 1H), 7.91(d, J=3Hz, 1H), 7.94 (d, J=3Hz, 1H), 8.23(s, 1H),
8.28(s, 1H) 1397
18758-[6-(N-methylamino)purin-9-ylmethyl]-10-methoxymethyl-10H-
pyrazino[2,3-b][1,4]benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 3.21(br.s, 3H), 3.43(s, 3H), 5.18(s, 2H), 5.29(s, 2H), 6.84(d,
J=8Hz, 1H), 6.97(d, J=8Hz, 1H), 7.08(s, 1H), 7.62(s, 1H),
7.82-7.84(m, 2H), 8.44(s, 1H)
EXAMPLES
[3647] The following compounds were obtained by treating the
compounds obtained in the above table by the same method as the one
of Example 9.
209 Ex. Structural formula MS M.p. NMR 1398
18768-[6-(morpholin-4-yl)purin-9-ylmethyl]-10H-pyrazino[2,3-b-
][1,4]benzothiazine FAB (+) 419 (MH+) .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 3.84(t, J=5Hz, 4H), 4.30(br.s, 4H), 5.20(s, 2H), 6.37
(d, J=1Hz, 1H), 6.40(br.s, 1H), 6.73 (dd, J=4, 8Hz, 1H), 6.85(d,
J=8Hz, 1H), 7.55(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H), 7.72(s, 1H),
8.38(s, 1H) 1399
18778-(6-(piperidin-1-yl)purin-9-ylmethyl]-10H-pyrazino[2,3-b][1,4]b-
enzothiazine FAB (+) 417 (MH+) 228-229.degree. C.
.sup.1H-NMR(DMSO-d.sub.6- ) .delta. ppm: 1.56(br.s, 4H), 1.65(br.s,
2H), 4.17(br.s, 4H), 5.20(s, 2H), 6.58(d, J=1Hz, 1H), 6.70 (dd,
J=1, 8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.61(s, 2H), 8.19(s, 1H),
8.21(s, 1H), 9.45(s, 1H) 1400
18788-[6-(2,6-dimethylmorpholin-4-yl)purin-9-ylmethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine FAB (+) 447 (MH+)
227-229.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.29(d,
J=7Hz, 6H), 2.80(m, 2H), 3.74(m, 2H), 5.20(s, 2H), 5.30(br.s, 2H),
6.36(d, J=8Hz, 1H), 6.39(s, 1H), 6.73(dd, J=1, 8Hz, 1H), 6.85(d,
J=8Hz, 1H), 7.55(d, J=3Hz, 1H), 7.69(d, J=3Hz, 1H), 7.72(s, 1H),
8.36(s, 1H) 1401
1879methylpiperazin-1-yl)purin-9-ylmethyl]-10H-pyrazino[2,3-b][1,4
]benzothiazine FAB (+) 432 (MH.sup.+) 197-202.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.52(s, 3H), 2.80(br.s, 4H),
4.35(br.s, 4H), 5.23(s, 2H), 6.64(d, J=1Hz, 1H), 6.67 (d, J=1, 8Hz,
1H), 6.87(d, J=8Hz, 1H), 7.62(s, 2H), 8.33(s, 1H), 8.37(s, 1H),
9.49(s, 1H) 1402
18801-[9-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmeth-
yl)purin-6-yl]piperidin-4-ol .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.65(m, 2H), 2.05(m, 2H), 4.85(m, 1H), 5.20(s, 2H), 3.75(m, 2H),
4.05(m, 2H), 6.38(d, J=1Hz, 1H), 8Hz, 1H), 6.85(d, J=8Hz, 1H),
7.55(d, J=3Hz, 1H), 7.67(d, J=3Hz, 1H), 7.71(s, 1H), 8.36(s, 1H)
1403
18811-[9-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]pipe-
ridine-4-carboxylic acid FAB (+) 461 (MH.sup.+) 238-240.degree. C.
.sup.1H NMR(DMSO-d.sub.6) .delta. ppm: 1.53(t, J=10Hz, 2H), 1.93(d,
J=10Hz, 2H), 2.60(m, 1H), 3.2(br.s, 4H), 5.20(s, 2H), 6.57(d,
J=1Hz, 1H), 6.70(dd, J=1, 8Hz, 1H), 6.86(d, J=8Hz, 1H), 7.62(s,
2H), 8.22(s, 1H), 8.25(s, 1H), 9.45(s, 1H) 1404
18828-[6-(3,5-dimethylpiperidin-1-yl)pur- in-9-ylmethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine FAB (+) 445 (MH.sup.+)
237-238.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: total 6H),
1.5 and 1.6(m, 0.87 and 0.91(d, J=7Hz, total 2H), 1.8 and 1.9(m,
total 2H), 3.2 (m, 4H), 5.20(s, 2H), 6.58 and 6.61(d, J=1Hz, total
1H), 6.70(dd, J=1, 8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.62(s, 2H), #
8.17 and 8.20(s, total 1H), 8.20 and 8.22(s, total 1H), 9.47 and
9.48(s, total 1H) 1405
18838-[6-(4-benzylpiperidin-1-yl)purin-9-ylmethy- l]-
10H-pyrazino[2,3-b][1,4]benzothiazine FAB (+) 507 (MH.sup.+)
186-188.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.2(m,
4H), 1.65(m, 1H), 2.50(d, J=7Hz, 2H), 3.2(br.s, 4H), 5.20(s,
6.70(dd, J=1, 8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.15 7.18(m, 3H),
7.27(dd, J=7, 8Hz, 2H), 7.62(s, 2H), 8.19(s, 1H), 8.21(s, 1H),
9.47(s, 1H) 1406
18848-[6-(4-benzylpiperazin-1-yl)purin-9-ylmethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine FAB (+) 508 (MH.sup.+)
213-214.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
2.45(br.t, J=7Hz, 4H), 3.50(s, 2H), 4.20(br.s, 4H), 5.21(s, 2H),
6.56(d, J=1Hz, 1H), 6.69(dd, J=1, 7Hz, 1H), 6.86(d, J=7Hz, 1H),
7.25(m, 1H), 7.30-7.36(m, 4H), 7.61(s, 2H), 8.21(s, 1H), 8.23(s,
1H), 9.45(s, 1H) 1407
18858-[6-(4-phenylpiperidin-1-yl)purin-9-ylmethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine FAB (+) 493 (MH.sup.+)
239-241.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.63(dq,
J=4, 12Hz, 2H) 1.99(br.d, J=12Hz, 2H), 2.89(tt, J=2, 12Hz, 1H),
3.1(br.s, 2H), 3.3(br.s, 2H), 5.22(s, 2H), 6.60(d, J=1Hz, 1H),
6.72(dd, J=1, 8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.16(tt, J=1, 7Hz, 1H),
7.22-7.29 # (m, 4H), 7.62(s, 2H), 8.23(s, 1H), 8.25 (s, 1H),
9.47(s, 1H) 1408
18868-[[4-(2-aminoethyl)piperazin-1-yl]purin-9-ylmethyl]-10H-
pyrazino[2,3-b][1,4]benzothiazine FAB (+) 461 (MH.sup.+)
226-229.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.37(t,
J=7Hz, 2H), 2.49(br.s, 4H), 2.72(t, J=7Hz, 2H), 4.2(br.s, 4H),
5.21(s, 2H), 6.60(d, J=1Hz, 1H), 6.69(dd, J=1, 8Hz, 1H), 6.87(d,
J=8Hz, 1H), 7.62 (s, 2H), 7.63(br.s, 2H), 8.23(s, 1H), 1H), 8.26(s,
1H), 9.47(s, 1H) 1409
18878-[6-(N-methylamino)purin-9-ylmethyl]-10H-pyrazino[2,3-b][1,4]benzoth-
iazine FAB (+) 363 (MH.sup.+) 279 281.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.95(br.s, 3H), 5.20(s, 2H),
6.57(d, J=1Hz, 1H), 6.79(dd, J=1, 8Hz, 1H), 6.86(d, J=8Hz, 1H),
7.61(s, 2H), 7.63(br.s, 8.21(br.s, 1H), 9.47(s, 1H)
EXAMPLES
[3648] The following compounds were obtained by reacting
8-(6-chloropurin-7-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]ben-
zothiazine with various amines by the same method as the one of
Example 1244.
210 Ex. Structural formula NMR 1410
18888-[6-(morpholin-4-yl)purin-7-ylmethyl)-10-
methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.39(s, 3H), 3.40(t, J=5Hz,
4H), 3.85(t, J=5Hz, 4H), 5.13(s, 2H), 5.41(s, 2H), 6.69(dd, J=2,
8Hz, 1H), 6.82(d, J=2Hz, 1H), 6.97(d, J=8Hz, 1H), 7.82(d, J=3Hz,
1H), 7.85(d, 8.75(s, 1H) 1411
18898-[6-(N-methylamino)methoxymethyl-10- H-
methoxymethyl-10H-benzothiazine .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 2.98(d, J=5Hz, 3H), 3.34(s, 3H), 4.61(q, J=5Hz, 1H), 5.12(s,
2H), 540(s, 2H), 6.72(dd, J=2, 8Hz, 1H), 6.83(d, J=2Hz, 1H),
7.05(d, J=8Hz, 1H), 7.85(d, J=3Hz, 1H), 7.97(s, 1H), 8.56(s,
1H)
EXAMPLES
[3649] The following compounds were obtained by treating the
compounds obtained in the above table by the same method as the one
of Example 9.
211 Ex. Structural formula MS M.p. NMR 1412
18908-[6-(morpholin-4-yl)purin-7-ylmethyl]-
10H-pyrazino[2,3-b][1,4]benzothiazine FAB(+) 419 (MH.sup.+)
269-273.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.40(t,
J=4Hz, 4H), 3.82(t, J=4Hz, 4H), 5.35(s, 2H), 6.27(d, J=1Hz, 1H),
6.62(dd, J=1, 8Hz, 1H), 6.86(d, J=8Hz, 1H), 7.23(s, 1H), 7.56(d,
J=3Hz, 1H), 7.68(d, J=3Hz, 1H), 8.01 (s, 1H), 8.71(s, 1H) 1413
18918-[6-(N-methylamino)purin-7-ylmethyl]-10H-
pyrazino[2,3-b][1,4]benzot- hiazine FAB(+) 363 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.89(d, J=4Hz, 3H), 5.54(s,
2H), 6.38(s, 1H), 6.55(d, J=8Hz, 1H), 6.72(q, J=4Hz, 1H), 6.86(d,
J=8Hz, 1H), 7.60(s, 2H), 8.28(s, 1H), 8.29(s, 1H), 9.50(s, 1H)
EXAMPLE 1414
8-(6-Dimethylamino-2-chloropurin-9-yl)-10-methoxymethyl-10H-pyrazino(2,3-b-
][1,4]benzothiazine
[3650] 1.1 g of the title compound was obtained as a yellow solid
by reacting 0.81 g of
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,-
4]benzothiazine with 6-dimethylamino-2-chloropurine by the same
method as the one of Example 1348. 1892
[3651] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3652] 3.22-3.35(br.s, 3H), 3.48(s, 3H), 3.71(br.s, 3H), 5.20(s,
2H), 5.23(s, 2H), 6.83(dd, J=2, 8 Hz, 1H), 6.97(d, J=8 Hz, 1H),
7.11(d, J=2 Hz, 1H), 7.65(s, 1H), 7.83(d, J=3 Hz, 1H), 7.84(d, J=3
Hz, 1H)
EXAMPLE 1415
8-[2,6-Bis(dimethylamino)purin-9-ylmethyl]-10-methoxymethyl-10H-pyrazino[2-
,3-b][1,4]benzothiazine
[3653] To a solution of 0.27 g of
8-(6-dimethylamino-2-chloropurin-9-yl)-1-
0-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine in
tetrahydrofuran (10 ml) was added a 50% solution of dimethylamine
in methanol. Then the resulting mixture was heated to 110.degree.
C. for 50 hours in a sealed tube. After distilling off the solvent
under reduced pressure, the residue was purified by silica gel
column chromatography (eluted with dichloromethane/methanol) to
thereby give 0.23 g of the title compound as a yellow solid.
1893
[3654] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3655] 3.16(s, 6H), 3.42(s, 3H), 3.46(br.s, 6H), 5.14(s, 2H),
5.17(s, 2H), 6.87(dd, J=2, 8 Hz, 1H), 6.94(d, J=8 Hz, 1H), 7.06(d,
J=2 Hz, 1H), 7.42(s, 1H), 7.82(d, J=3 Hz, 1H), 7.83(d, J=3 Hz,
1H)
EXAMPLE 1416
8-[2,6-Bis(dimethylamino)purin-9-ylmethyl]-10H-pyrazino[2,3-b][1,4]benzoth-
iazine
[3656] The title compound was obtained by treating
8-[2,6-bis(dimethylamin-
o)purin-9-ylmethyl]-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
by the same method as the one of Example 9. 1894
[3657] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3658] 3.07(s, 6H), 3.60(br.s, 6H), 5.03(s, 2H), 6.62(d, J=1 Hz,
1H), 6.71(dd, J=1, 8 Hz, 1H), 6.85(d, J=8 Hz, 1H), 7.61(s, 2H),
7.77(s, 1H), 9.50(s, 1H)
[3659] MS: FAB(+)419(M.sup.+)
[3660] m.p. : 239-240.degree. C.
EXAMPLE 1417
8-[6-(Trimethylsilyl)ethynylpurin-9-ylmethyl]-10-methoxymethyl-10H-pyrazin-
o[2,3-b][1,4]benzothiazine
[3661] To a solution of 2.05 g of
8-(6-bromopurin-9-ylmethyl)-10-methoxyme-
thyl-10H-pyrazino[2,3-b][1,4]benzothiazine in N,N-dimethylformamide
(20 ml) were added in a nitrogen atmosphere 0.32 g of
bis(triphenylphosphine) palladium (II) chloride, 0.10 g of cuprous
iodide, 1.23 ml of (tirmethylsilyl)acetylene and 0.97 ml of
triethylamine and the resulting mixture was stirred for 16 hours.
After further adding bis(triphenylphosphine) palladium (II)
chloride, cuprous iodide, (tirmethylsilyl)acetylene and
triethylamine each in the same amount as the one defined above, the
resulting mixture was stirred at room temperature for 24 hours and
heated to 55.degree. C. for 6 hours. Then the reaction mixture was
distributed into ethyl acetate and water and filtered through
celite. The organic layer was washed with aqueous ammonia several
times, dried over anhydrous magnesium sulfate and concentrated
under reduced pressure. Then the residue was purified by silica gel
column chromatography (eluted with n-hexane/ethyl acetate) to
thereby give 1.22 g of the title compound as a yellow solid.
1895
[3662] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3663] 0.33(s, 9H), 3.44(s, 3H), 5.17(s, 2H), 5.45(s, 2H), 6.84(dd,
J=2, 8 Hz, 1H), 6.98(d, J=8 Hz, 1H), 7.10(d, J=2 Hz, 1H), 7.83(d,
J=3 Hz, 1H), 7.85(d, J=3 Hz, 1H), 8.12(s, 1H), 8.95(s, 1H)
EXAMPLE 1418
8-(6-Ethynylpurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4[ben-
zothiazine
[3664] To a solution of 0.194 g of 8-
6-(tirmehtylsilyl)-ethynylpurin-9-yl-
methyl]-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine in
tetrahydrofuran (15 ml) was added in a nitrogen atmosphere 0.8 ml
of a 1 M solution of tetra-n-butylammonium fluoride in
tetrahydrofuran and the resulting mixture was stirred for 16 hours.
After adding ethyl acetate and water, the organic layer was dried
over anhydrous magnesium sulfate and concentrated under reduced
pressure. The residue was then purified by silica gel column
chromatography (eluted with n-hexane/ethyl acetate) to thereby give
0.076 g of the title compound as a yellow solid. 1896
[3665] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3666] 3.44(s, 3H), 3.72(s, 1H), 5.19(s, 2H), 5.38(s, 2H), 6.88(dd,
J=2, 8 Hz, 1H), 6.99(d, J=8 Hz, 1H), 7.12(d, J=2 Hz, 1H), 7.83(d,
J=3 Hz, 1H), 7.85(d, J=3 Hz, 1H), 8.14(s, 1H), 8.99(s, 1H)
EXAMPLE 1419
8-(6-Ethylpurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzo-
thiazine
[3667] 0.070 g of the title compound was obtained as a yellow solid
by treating 0.076 g of
8-(6-ethynylpurin-9-ylmethyl)-10-methoxymethyl-10H-py-
razino[2,3-b][1,4]benzothiazine by the same method as the one of
Example 20. 1897
[3668] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3669] 1.44(t, J=7 Hz, 3H), 3.23(q, J=7 Hz, 2H), 3.43(s, 3H),
5.19(s, 2H), 5.37(s, 2H), 6.88(d, J=8 Hz, 1H), 6.97(d, J=8 Hz, 1H),
7.12(s, 1H), 7.83(m, 2H), 8.09(s, 1H), 8.94(s, 1H)
EXAMPLE 1420
3-[9-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pur-
in-6-yl]-2-propyn-1-ol
[3670] The title compound was obtained by reacting
8-(6-bromopurin-9-ylmet-
hyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine with
propargyl alcohol by the same method as the one of Example 1417.
1898
[3671] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3672] 3.44(s, 3H), 4.63(s, 2H), 5.19(s, 2H), 5.38(s, 2H), 6.86(dd,
J=2, 8 Hz, 1H), 6.98(d, J=8 Hz, 1H), 7.12(d, J=2 Hz, 1H), 7.84(m,
2H), 8.14(s, 1H), 8.97(s, 1H)
EXAMPLE 1421
[3673]
3-[9-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmet-
hyl)purin-6-yl]-1-propanol
[3674] 0.028 g of the title compound was obtained as yellow
crystals by treating 0.088 g of
3-[9-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-ylmethyl)purin-6-yl]-2-propyn-1-ol by the same method as
the one of Example 20. 1899
[3675] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3676] 2.11(quint, J=7 Hz, 2H), 3.38(d, J=7 Hz, 2H), 3.44(s, 3H),
3.65(t, J=7 Hz, 2H), 5.19(s, 2H), 5.37(s, 2H), 6.89(dd, J=2, 8 Hz,
1H), 6.98(d, J=8 Hz, 1H), 7.03(d, J=2 Hz, 1H), 7.83(d, J=3 Hz, 1H),
7.84(d, J=3 Hz, 1H), 8.05(s, 1H), 8.91(s, 1H)
EXAMPLES
[3677] The following compounds were obtained by treating
8-(6-ethylpurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino(2,3-b][1,4]benz-
othiazine,
3-[9-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-y-
lmethyl)purin-6-yl]-1-propanol and
3-[9-(10-methoxymethyl-10H-pyrazino[2,3-
-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]-2-propyn-1-ol by the
same method as the one of Example 9.
212 Ex. Structural formula MS M.p. NMR 1422
19008-(6-ethylpurin-9-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzo-
thiazine FAB(+) 361(M.sup.+) 215-217.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1,45(t, J=7Hz, 38), 3.22(q,
J=7Hz, 2H), 5.26(s, 28), 6.43(d, J=1Hz, 1H), 6.68(br.s, 1H),
6.77(dd, J=1, 8Hz, 1H), 6.87(d, J=8Hz, 1H), 7.54(d, J=3Hz, 1H),
7.69(d, J=3Hz, 1H), 8.01(s, 1H), 8.90(s, 1H) 1423
19013-[9-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)purin-6-yl]-1-propanol FAB(+) 392 (MH.sup.+)
174-177.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.95(quint, J=7Hz, 2H), 3.10(t, J=7Hz, 2H), 3.47(q, J=7Hz, 2H),
4.55(t, J=7Hz, 1H), 5.21(s, 2H), 6.60(d, J=1Hz, 1H), 6.75(dd, J=1,
9Hz, 1H), 6.87(d, J=9Hz, 1H), 7.61(s, 2H), 8.57(s, 1H), 8.78(s, #
1H), 9.45(s, 1H) 1424
19023-[9-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)purin-6-yl]-2-- propyn-1-ol 152-154.degree. C. (decom-
pose) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 4.46(d, J=6Hz, 2H),
5.34(s, 2H), 5.61(t, J=6Hz, 1H), 6.54(s, 1H), 6.76(d, J=8Hz, 1H),
6.88(d, J=8Hz, 1H), 7.61 (s, 2H), 8.72(s, 1H), 8.87(s, 1H), 9.42(s,
1H)
EXAMPLE 1425
8-(6-Iodopurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazine
[3678] The title compound was obtained by treating
8-chloromethyl-10-metho-
xymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine with 6-iodopurine by
the same method as the one of Example 1094. 1903
[3679] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3680] 3.46(s, 3H), 5.20(s, 2H), 5.36(s, 2H), 6.88(dd, J=2, 8 Hz,
1H), 6.99(d, J=8 Hz, 1H), 7.12(d, J=2 Hz, 1H), 7.84(d, J=3 Hz, 1H),
7.86(d, J=3 Hz, 1H), 8.14(s, 1H), 8.68(s, 1H)
EXAMPLE 1426
4-[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]-2-methyl-
-3-butyn-2-ol
[3681]
8-(6-Iodopurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4-
]benzothiazine was treated by the same method as the one of Example
9 to thereby give
8-(6-iodopurin-9-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothia- zine.
Next, this product was treated with 2-methyl-3-butyn-2-ol by the
same method as the one of Example 1417 to thereby give the title
compound. 1904
[3682] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3683] 1.52(s, 6H), 5.32(s, 2H), 5.78(s, 1H), 6.51(d, J=1 Hz, 1H),
6.73(dd, J=1, 8 Hz, 1H), 6.87(d, J=8 Hz, 1H), 7.60(s, 2H), 8.71(s,
1H), 8.85(s, 1H), 9.40(s, 1H)
EXAMPLE 1427
4-[[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]-2-hydro-
xymethyl-3-butyne-1,2-diol
[3684]
8-(6-Iodopurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4-
]benzothiazine was treated by the same method as the one of Example
9 to thereby give
8-(6-iodopurin-9-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothia- zine.
Next, this product was treated with
bis(tert-butyldimethylsiloxymeth- yl)-2-propyn-1-ol by the same
method as the one of Example 1417. The compound thus obtained was
further treated with tetrabutylammonium fluoride in accordance with
the method of Example 1386-3 to thereby give the title compound.
1905
[3685] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3686] 3.53-3.61(m, 4H), 4.94(t, J=6 Hz, 2H), 5.34(s, 2H), 5.62(s,
1H), 6.51(s, 1H), 6.73(d, J=8 Hz, 1H), 6.87(d, J=8 Hz, 1H), 7.61(s,
2H), 8.70(s, 1H), 8.85(s, 1H), 9.40(s, 1H)
[3687] m.p. : 79-84.degree. C.
EXAMPLE 1428
10-Methoxymethyl-8-(6-ethylpurin-7-ylmethl)-10H-pyrazino[2,3-b][1,4]benzot-
hiazine
[3688] To a solution of 0.30 g of
8-(6-chloropurin-7-ylmethyl)-10-methoxym-
ethyl-10H-pyrazino[2,3-b][1,4]benzothiazine in
N,N-dimethylformamide (10 ml) were added in a nitrogen atmosphere
0.312 g of vinyl-tri-n-butyltin (IV) and 0.050 g of
bis(triphenylphosphine) palladium (II) chloride. After degassing,
the mixture was heated to 80.degree. C. for 20 hours. Then the
insoluble matters were removed by filtering through celite. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.19 g of
10-methoxymethyl-8-(6-vinylpurin-7-ylmethl)-10H-pyrazino[2,3-b][1,4]benzo-
thiazine as a yellow solid. To a solution of 190 mg of the obtained
compound in methanol (20 ml) was added 0.018 g of palladium/carbon
and hydrogenation was effected in a hydrogen gas stream for 2
hours. Thus, 0.10 g of the title compound was obtained as a yellow
solid. 1906
[3689] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3690] 1.28(t, J=7 Hz, 3H), 2.97(q, J=7 Hz, 2H), 3.31(s, 3H),
5.08(s, 2H), 5.50(s, 2H), 6.62(dd, J=2, 8 Hz, 1H), 6.74(d, J=2 Hz,
1H), 6.99(d, J=8 Hz, 1H), 7.83(d, J=3 Hz, 1H), 7.86(d, J=3 Hz, 1H),
8.20(s, 1H), 9.05(s, 1H)
EXAMPLE 1429
8-[6-(1-Ethoxyvinyl)purin-7-ylmethyl]-10-methoxymethyl-10H-pyrazino[2,3-b]-
[1,4]benzothiazine
[3691] To a solution of 0.9 g of
8-(6-chloropurin-7-ylmethyl)-10-methoxyme-
thyl-10H-pyrazino[2,3-b][1,4]benzothiazine in N,N-dimethylformamide
(15 ml) were added in a nitrogen atmosphere 1.03 g of
1-ethoxyvinyl-tri-n-but- yltin (IV) and 0.015 g of
bis(triphenylphosphine) palladium (II) chloride. After degassing,
the mixture was heated to 80.degree. C. for 20 hours. Then the
insoluble matters were removed by filtering through celite. After
distilling off the solvent under reduced pressure, the residue was
purified by silica gel column chromatography (eluted with
dichloromethane/methanol) to thereby give 0.77 g of the title
compound as yellow crystals. 1907
[3692] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3693] 1.34(t, J=7 Hz, 3H), 3.32(s, 3H), 3.93(q, J=7 Hz, 2H),
4.54(d, J=3 Hz, 1H), 4.94(d, J=3 Hz, 1H), 5.09(s, 2H), 5.54(s, 2H),
6.60(dd, J=2, 8 Hz, 1H), 6.77(d, J=2 Hz, 1H), 6.94(d, J=8 Hz, 1H),
7.82(d, J=3 Hz, 1H), 7.85(d, J=3 Hz, 1H), 8.23(s, 1H), 9.09(s,
1H)
EXAMPLE 1430
8-(6-(Ethylpurin-7-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3694] The title compound was obtained by treating
10-methoxymethyl-8-(6-e-
thylpurin-7-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine by the
same method as the one of Example 9. 1908
[3695] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3696] 1.45(t, J=7 Hz, 3H), 3.24(q, J=7 Hz, 2H), 5.26(s, 2H),
6.44(s, 1H), 6.62(br.s, 1H), 6.75(d, J=8 Hz, 1H), 6.87(d, J=8 Hz,
1H), 7.55(s, 1H), 7.69(s, 1H), 8.02(s, 1H), 8.90(s, 1H)
[3697] MS: FAB(+)362(MH.sup.+)
[3698] m.p.: >275.degree. C.
EXAMPLE 1431
8-(6-Acetylpurin-7-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3699] The title compound was obtained by treating
8-[6-(1-ethoxyvinyl)pur- in-7-ylmethyl]-10H-pyrazino
(2,3-b][1,4]benzothiazine by the same method as the one of Example
8. 1909
[3700] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3701] 2.59(s, 3,H), 5.58(s, 2H), 6.25(s, 1H), 6.47(d, J=8 Hz, 1H),
6.84(d, J=8 Hz, 1H)., 7.59(d, J=3 Hz, 1H), 7.60(d, J=3 Hz, 1H),
8.98(s, 1H), 9.15(s, 1H), 9.34(s, 1H)
[3702] MS: FAB(+)375(M.sup.+)
[3703] m.p. : 266-268.degree. C.
EXAMPLE 1432
8-(6-Acetylpurin-7-ylmethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benz-
othiazine
[3704] 0.21 g of the title compound was obtained as yellow crystals
by treating 0.316 g of
8-(6-acetylpurin-7-ylmethyl)-10H-pyrazino[2,3-b][1,4]-
benzothiazine by the same method as the one of Example 5. 1910
[3705] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3706] 2.71(s, 3H), 3.36(s, 3H), 5.09(s, 2H), 5.72(s, 2H), 6.62(dd,
J=2, 8 Hz, 1H), 6.92(d, J=2 Hz, 1H), 6.94(d, J=8 Hz, 1H), 7.81(d,
J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H), 8.40(s, 1H), 9.21(s, 1H)
EXAMPLE 1433
1-[7-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pur-
in-6-yl]ethanol
[3707] 0.08 g of the title compound was obtained as yellow crystals
by treating 0.13 g of
8-(6-acetylpurin-7-ylmethyl)-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine with diisobutylaluminum hydride by
the same method as the one of Example 6. 1911
[3708] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3709] 1.46(d, J=7 Hz, 3H), 1.93(br.s, 1H), 3.32(s, 3H),
5.07-5.14(m, 3H), 5.50(d, J=15 Hz, 1H), 5.64(d, J=15 Hz, 1H),
6.62(dd, J=2, 8 Hz, 1H), 6.77(d, J=2 Hz, 1H), 6.97(d, J=8 Hz, 1H),
7.81(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H), 8.21(s, 1H), 9.03(s,
1H)
EXAMPLE 1434
2-[7-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pur-
in-6-yl]-2-propanol
[3710] 0.148 g of the title compound was obtained as yellow
crystals by treating 0.21 g of
8-(6-acetylpurin-7-ylmethyl)-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine with methylmagnesium bromide by the
same method as the one of Production Example 86. 1912
[3711] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3712] 1.66(s, 6H), 2.64(br.s, 1H), 3.30(s, 3H), 5.07(s, 2H),
5.90(s, 2H), 6.60(d, J=8 Hz, 1H), 6.65(s, 1H), 6.96(d, J=8 Hz, 1H),
7.81-7.84(m, 2H), 8.18(s, 1H), 9.01(s, 1H)
EXAMPLES
[3713] The following compounds were obtained by treating
1-[7-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pu-
rin-6-yl]ethanol and
2-[7-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-ylmethyl)purin-6-yl]-2-propanol by the same method as the
one of Example 9.
213 Ex. Structural formula MS M.p. NMR 1435
19131-[7-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
ylmethyl)purin-6-yl]ethanol FAB(+) 377 (M.sup.+) 205-208.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.37(d, J=6Hz, 3H),
4.89(quint, J=6Hz, 1H), 5.70(s, 2H), 5.78(d, J=6Hz, 1H), 6.30(d,
J=1Hz, 1H), 6.52(dd, J=1, 9Hz, 1H), 6.68(d, J=9Hz, 1H), 7.60(s,
2H), 8.73(s, 1H), 8.90(s, 1H), 9.35(s, 1H) 1436
19142-[7-(10H-pyrazino[2,3-b][1,4]benzot- hiazin-8-
ylmethyl)purin-6-yl]-2-propanol FAB(+) 391 (M.sup.+)
268-271.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1,42(s,
6H), 5.90(s, 1H), 5.96(s, 2H), 6.25(d, J=1Hz, 1H), 6.39(dd, J=1,
8Hz, 1H), 6.85(d, J=8Hz, 1H), 7.61(s,2H), 8.67(s, 1H), 8.85(s, 1H),
9.38(s, 1H)
EXAMPLES
[3714] The following compounds were obtained by reacting
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzoxazine
and
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
with 2-(purin-6-yl)-2-propanol by the same method as the one of
Example 1094.
214 Ex. Structural formula NMR 1437
19152-[9-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin--
8-ylmethyl)purin-6-yl]-2-propanol .sup.1H-NMR(CDCl.sub.3) .delta.
ppm: 1.75(s, 6H), 3.40(s, 3H), 5.16(s, 2H), 5.36(s, 2H), 6.88(dd,
J=2, 8Hz, 1H), 6.96(d, J=8Hz, 1H), 7.10(d, J=2Hz, 1H), 7.80(d,
J=3Hz, 1H), 8.07(s, 1H), 8.91(s, 1H) 1438
19162-[9-(10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzoxazin-8-ylmethyl)purin-6-yl]-2-propanol
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.78(s, 6H), 3.42(s, 3H),
5.26(s, 2H), 5.34(s, 2H), 5.42(br.s, 1H), 6.79(d, J=8Hz, 1H),
6.97(s, 1H), 7.44(6, J=3Hz, 1H), 7.59(6, J=3Hz, 1H), 8.08(s, 1H),
8.94(s, 1H)
EXAMPLES
[3715] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 9.
215 Ex. Structural formula MS M.p. NMR 1439 1917 ESI (+) 392
(MH.sup.+) 178-179.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.79(s, 6H), 5.31(s, 2H), 6.47(d, J=2Hz, 1H), 6.59(br.s, 1H),
6.79(dd, J=2, 8Hz, 1H), 6.88(d, J=8Hz, 1H), 7.56(d, J=3Hz, 1H),
7.70(d, J=3Hz, 1H), 8.07(s, 1H), 8.95(s, 1H) 2-[9-(10H-pyrazino
[2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-yl]- 2-propanol 1440
1918 ESI (+) 376 (MH.sup.+) 143-145.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.79(s, 6H), 5.29(s, 2H),
6.52(s, 1H), 6.76(d, J=8Hz, 1H), 6.80(d, J=8Hz, 1H), 7.38(d, J=3Hz,
1H), 7.44(d, J=3Hz, 1H), 8.10(s, 1H), 8.96(s, 1H)
2-[9-(10H-pyrazino [2,3-b][1,4] benzoxazin-8- ylmethyl)purin-6-yl]-
2-propanol
EXAMPLES
[3716] The following compounds were obtained by reacting
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
with 2-(benzimidazol-5-yl)-2-propanol by the same method as the one
of Example 1094 followed by the same treatment as the one of
Example 9.
216 Ex. Structural formula MS M.p. NNR 1441 1919
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.43(s, 6H), 5.00(s, 1H),
5.32(s, 2H), 6.59(d, J=1 Hz, 1H), 6.67(dd, J=1, 8 Hz, 1H), 6.88(d,
J=8 Hz, 1H), 7.29(d, J=8 Hz, 1H), 7.53(s, 1H), 7.55(d, J=8 Hz, 1H),
7.61(s, 2H), 8.27(s, 1H), 9.50(s, 1H) 2-[1-(10H-pyrazino
[2,3-b][1,4] benzothiazin-8- ylmethyl)benzimidazol-
5-yl]-2-propanol 1442 1920 .sup.1H-NMR(DMSO-d.sub.6- ) .delta. ppm:
1.44(s, 6H), 4.97(s, 1H), 5.29(s, 2H), 6.60(s, 1H), 6.69(d, J=8 Hz,
1H), 6.87(d, J=8 Hz, 1H), 7.30-7.33(m, 2H), 7.60(s, 2H), 7.71(s,
1H), 8.27(s, 1H), 9.46(s, 1H) 2-[1-(10H- pyrazino[2,3-b][1,4]
benzothiazin-8- ylmethyl)benzimidazol- 6-yl)-2-propanol
EXAMPLE 1443
8-[6-(1-Ethoxyvinyl)purin-9-ylmethyl]-10-methoxymethyl-10H-pyrazino[2,3-b]-
[1,4]benzothiazine
[3717] 1.0 g of the title compound was obtained as a yellow solid
by treating 1.33 g of
8-(6-chloropurin-7-ylmethyl)-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine by the same method as the one of
Example 1429. 1921
[3718] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3719] 1.52(t, J=7 Hz, 3H), 3.43(s, 3H), 4.12(q, J=7 Hz, 2H),
4.98(d, J=4 Hz, 1H), 5.18(s, 2H), 5.39(s, 2H), 6.15(d, J=4 Hz, 1H),
6.87(d, J=8 Hz, 1H), 6.98(d, J=8 Hz, 1H), 7.12(s, 1H), 7.83(d, J=3
Hz, 1H), 7.84(d, J=3 Hz, 1H), 8.09(s, 1H), 9.10(s, 1H)
EXAMPLE 1444
8-(6-Acetylpurin-9-ylmethyl)-10-methoxymethyl-10H-pyrazino-[2,3-b][1,4]ben-
zothiazine
[3720] 0.2 g of the title compound was obtained as a yellow solid
by treating 0.66 g of
8-[6-(1-ethoxyvinyl)purin-9-ylmethyl)-10-methoxymethyl-
-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the
one of Example 8. 1922
[3721] H-NMR(DMSO-d.sub.6) .delta. ppm:
[3722] 2.79(s, 3H), 5.39(s, 2H), 6.57(d, J=1 Hz, 1H), 6.75(dd, J=1,
8 Hz, 1H), 6.88(d, J=8 Hz, 1H), 7.61(s, 2H), 8.86(s, 1H), 9.07(s,
1H), 9.43(s, 1H)
[3723] MS: FAB(+)376(MH.sup.+)
EXAMPLE 1445
8-[6-[1-(tert-Butyldimethylsiloxy)ethyl]purin-9-ylmethyl]-10-methoxymethyl-
-10H-pyrazino[2,3-b][1,4]benzothiazine
[3724] 1.63 g of the title compound was obtained as a yellow solid
by reacting 1.78 g of
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,-
4]benzothiazine with 1.26 g of
6-[1-(tert-butyldimethylsiloxy)ethyl]purine by the same method as
the one of Example 1094. 1923
[3725] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3726] 0.01(s, 3H), 0.04(s, 3H), 0.86(s, 9H), 1.64(d, J=7 Hz, 3H),
3.41(s, 3H), 5.17(s, 2H), 5.34(d, J=15 Hz, 1H), 5.38(d, J=15 Hz,
1H), 5.60(q, J=7 Hz, 1H), 6.89(dd, J=2, 8 Hz, 1H), 6.99(d, J=8 Hz,
1H), 7.12(d, J=2 Hz, 1H), 7.82(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H),
8.03(s, 1H), 8.98(s, 1H)
EXAMPLE 1446
8-[6-[1-(tert-Butyldimethylsiloxy)ethyl]purin-7-ylmethyl]-10H-pyrazino[2,3-
-b][1,4]benzothiazine
[3727] 1.35 g of the title compound was obtained by treating 1.55 g
of
8-[6-[1-(tert-butyldimethylsiloxy)ethyl]purin-9-ylmethyl]-10-methoxymethy-
l-10H-pyrazino[2,3-b][1,4]benzothiazine by the same method as the
one of Example 9. 1924
[3728] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3729] 0.01(s, 3H), 0.04(s, 3H), 0.87(s, 9H), 1.63(d, J=7 Hz, 3H),
5.26(m, 2H), 5.59(q, J=7 Hz, 1H), 6.43(br.s, 1H), 6.45(d, J=2 Hz,
1H), 6.77(dd, J=2, 8 Hz, 1H), 6.86(d, J=8 Hz, 1H), 7.53(d, J=3 Hz,
1H), 7.68(d, J=3 Hz, 1H), 8.01(s, 1H), 8.97(s, 1H)
EXAMPLE 1447
1-[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]ethanol
[3730] 0.52 g of the title compound was obtained by treating
8-[6-[1-(tert-butyldimethylsiloxy)ethyl]purin-9-ylmethyl]-10H-pyrazino[2,-
3-b][1,4]benzothiazine with tetrabutylammonium fluoride by the same
method as the one of Example 1418. 1925
[3731] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3732] 1.50(d, J=6 Hz, 3H), 5.29(quint, J=6 Hz, 1H), 5.34(s, 2H),
5.35(d, J=6 Hz, 1H), 6.63(d, J=1 Hz, 1H), 6.75(dd, J=1, 8 Hz, 1H),
6.87(d, J=8 Hz, 1H), 7.61(s, 2H), 8.64(s, 1H), 8.86(s, 1H).9.46(s,
1H)
[3733] m.p. : 210-212.degree. C.
[3734] MS: FAB(+)378(MH.sup.+)
EXAMPLES
[3735] The following compounds were obtained by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
with ethyl 4-(purin-6-ylthio)butanoate by the same method as the
one of EXAMPLE 1094.
217 Ex. Structural formula NMR 1448 1926 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.25(t, J=7 Hz, 3H), 2.13(quint, J=7 Hz, 2H), 2.51(t,
J=7 Hz, 2H), 3.43(s, 3H), 3.44(t, J=7 Hz, 2H), 4.13(q, J=7 Hz, 2H),
5.18(s, 2H), 5.33(s, 2H), 6.85(dd, J=2, 8 Hz, 1H), 6.98(d, J=8 Hz,
1H), 7.11(d, J=2 Hz, 1H), 7.83(d, J=3 Hz, 1H), 7.85(d, J=3 Hz,
#1H), 9.95(s, 1H), 8.62(s, 1H) ethyl 4-[9-(10- methoxymethyl-10H-
pyrazino[2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-
ylthio]butanoate 1449 1927 .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
1.24(t, J=7 Hz, 3H), 2.08(quint, J=7 Hz, 2H), 2.44(t, J=7 Hz, 2H),
3.37(s, 3H), 3.44(t, J=7 Hz, 2H), 4.13(q, J=7 Hz, 2H), 5.12(s, 2H),
5.57(s, 2H), 6.73(dd, J=2, 8 Hz, 1H), 6.87(d, J=2 Hz, 1H), 7.00(d,
J=8 Hz, 1H), 7.83(d, J=3 Hz, 1H), 7.85(d, J=3 Hz, #1H), 8.07(s,
1H), 8.84(s, 1H) ethyl 4-[7-(10- methoxymethyl-10H-
pyrazino[2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-
ylthio]butanoate
EXAMPLE 1450
4-[7-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-ylthio]butan-
oic acid
[3736] To 15 ml of a solution of 0.109 g of ethyl
4-[7-(10-methoxymethyl-1-
0H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-ylthio]butanoate
in dichloromethane was added in a nitrogen atmosphere 0.84 ml of a
1 M solution of boron tribromide in dichloromethane and the
resulting mixture was heated under reflux for 2 hours. Then the
reaction mixture was distributed into dichloromethane and water.
The organic layer was extracted and dried over anhydrous sodium
sulfate. After distilling off the solvent under reduced pressure,
the obtained residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol) and
recrystallized from diethyl ether to thereby give 40 mg of the
title compound as yellow crystals. 1928
[3737] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3738] 1.95(quint, J=7 Hz, 2H), 2.17(t, J=7 Hz, 2H), 3.35(t, J=7
Hz, 2H), 5.55(s, 2H), 6.35(d, J=1 Hz, 1H), 6.58(dd, J=1, 8 Hz, 1H),
6.87(d, J=8 Hz, 1H), 7.60(d, J=3 Hz, 1H), 7.61(d, J=3 Hz, 1H),
8.67(s, 1H), 8.75(s, 1H), 9.41(s, 1H)
[3739] m.p.: 120-130.degree. C. (decompose)
EXAMPLE 1451
4-[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-ylthio]butan-
oic acid
[3740] The title compound was obtained by treating ethyl
4-[9-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pu-
rin-6-ylthio]butanoate by the same method as the one of Example
1450. 1929
[3741] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3742] 1.91(quint, J=8 Hz, 2H), 2.30(t, J=8 Hz, 2H), 3.36(t, J=8
Hz, 2H), 5.30(s, 2H), 6.55(d, J=1 Hz, 1H), 6.72(dd, J=1, 8 Hz, 1H),
6.88(d, J=8 Hz, 1H), 7.60(s, 2H), 8.53(s, 1H), 8.70(s, 1H), 9.42(s,
1H)
[3743] m.p.: >180.degree. C. (decompose)
EXAMPLES
[3744] The following compounds were obtained by reacting ethyl
5-(purin-6-ylthio)pentanoate with
8-chloromethyl-10-methoxymethyl-10H-pyr-
azino[2,3-b][1,4]benzothiazine by the same method as the one of
Example 1094.
218 Ex. Structural formula NMR 1452 1930 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.24(t, J=7 Hz, 3H), 1.82(m, 4H), 2.37(t, J=7 Hz, 2H),
3.40(t, J=7 Hz, 2H), 3.44(s, 3H), 4.12(q, J=7 Hz, 2H), 5.18(s, 2H),
5.33(s, 2H), 6.84(d, J=8 Hz, 1H), 6.97(d, J=8 Hz, 1H), 7.09(s, 1H),
7.82(d, J=3 Hz, 1H), 7.84(d, J=3 Hz, 1H), 7.94(s, 1H), 8.73(s, 1H)
ethyl 5-[9-(10- methoxymethyl-10H- pyrazino[2,3-b][1,4]
benzothiazin-8-ylmethyl) purin-6-ylthio] pentanoate 1453 1931
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.23(t, J=7 Hz, 3H), 1.79(m,
4H), 2.33(m, 2H), 3.35(s, 3H), 3.39(t, J=7 Hz, 2H), 4.11(q, J=7 Hz,
2H), 5.11(s, 2H), 5.57(s, 2H), 6.72(d, J=8 Hz, 1H), 6.86(s, 1H),
6.98(d, J=8 Hz, 1H), 7.82(m, 2H), 8.07(s, 1H), 8.83(s, 1H) ethyl
5-[7-(10- methoxymethyl-10H- pyrazino[2,3-b][1,4] benzothiazin-8-
ylmethyl)purin-6-ylthio] pentanoate
EXAMPLES
[3745] The following compounds were obtained by treating ethyl
5-[9-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)pu-
rin-6-ylthio]pentanoate and ethyl
5-[7-(10-methoxymethyl-10H-pyrazino[2,3--
b][1,4]benzothiazin-8-ylmethyl)purin-6-ylthio]pentanoate by the
same method as the one of Example 1450.
219 Ex. Structural formula MS M.p. NMR 1454 19325-[9-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8-ylmethyl)pu- rin-6-ylthio]pentanoic acid
FAB (+) 466 (MH.sup.+) 243-244.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.40-1.55(m, 4H), 2.14(t, J=8 Hz, 2H), 3.35(t, J=8 Hz,
2H), 5.30(s, 2H), 6.55(s, 1H), 6.74(d, J=8 Hz, 1H), 6.87(d, # J=8
Hz, 1H), 7.61(s, 2H), 8.53(s, 1H), 8.70(s, 1H), 9.43(s, 1H),
12.15(s, 1H) 1455 19335-[7-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-ylthio]pentanoic acid
FAB (+) 488 (MNa.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.56(m, 2H), 1.63(m, 2H), 2.17(t, J=7 Hz, 2H), # 3.40(t, J=7 Hz,
2H), 5.55(s, 2H), 6.35(d, J=1 Hz, 1H), 6.58(dd, J=1, 8 Hz, 1H),
6.87(d, J=8 Hz, 1H), 7.60(d, J=2 Hz, 1H), 7.61(d, J=2 Hz, 1H),
8.67(s, 1H), 8.75(s, 1H), 9.42(s, 1H) 1456 1934ethyl
5-[7-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-ylthio]pentanoate FAB
(+) 494 (MH.sup.+) 175-178.degree. C. .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.25(t, J=7 Hz, 3H), 1.78(m, 2H), 1.85(m, 2H), 2.38(m,
2H), 3.12(t, J=8 Hz, 2H), 4.14(q, J=7 Hz, 2H), # 5.48(s, 2H),
6.35(s, 1H), 6.65(d, J=8 Hz, 1H), 6.86(d, J=8 Hz, 1H), 7.12(s, 1H),
7.53(s, 1H), 7.67(s, 1H), 8.06(s, 1H), 8.85(s, 1H)
EXAMPLES
[3746] The following compounds were obtained by treating ethyl
2-(purin-6-ylthio)hexanoate with
8-chloromethyl-10-methoxymethyl-10H-pyra-
zino[2,3-b][1,4]benzothiazine by the same method as the one of
Example 1094.
220 Ex. Structural formula NMR 1457 1935 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 0.90(t, J=7 Hz, 3H), 1.26(t, J=7 Hz, 3H), 1.37(m, 2H),
1.48(m, 2H), 1.97(m, 1H), 2.06(m, 1H), 3.43(s, 3H), 4.20(q, J=7 Hz,
2H), 4.88(t, J=7 Hz, 1H), 5.17(s, 2H), 5.33(s, 2H), 6.83(d, J=8 Hz,
1H), 6.94(s, 1H), 6.97(d, J=8 Hz, 1H), 7.83(m, 2H), 7.95(s, 1H),
8.75(s, 1H) ethyl 2-[9-(10- methoxymethyl-10H- pyrazino[2,3-b][1,4]
benzothiazin-8- ylmethyl)purin-6- ylthio]hexanoate 1458 1936
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 0.89(m, 3H), 1.25(t, J=7 Hz,
3H), 1.35-1.46(m, 4H), 1.97-2.06(m, 2H), 3.38(s, 3H), 4.15-4.27(m,
1H), 4.86(t, J=7 Hz, 2H), 5.17(m, 2H), 5.45(d, J=10 Hz, 1H),
5.59(d, J=10 Hz, 1H), 6.75(d, J=8 Hz, 1H), 6.99(m, 2H), 7.84(m,
2H), 8.07(s, 1H), 8.82(s, 1H) ethyl 2-[7-(10- methoxymethyl-10H-
pyrazino[2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-
ylthio]hexanoate
EXAMPLES
[3747] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 1450.
221 Ex. Structural formula MS M.p. NNR 1459 1937 FAB (+) 480
(MH.sup.+) 110-120.degree. C. (dec) .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 0.84(t, J=7 Hz, 3H), 1.19-1.41(m, 4H), 1.80-2.00(m,
2H), 4.80(t, J=7 Hz, 1H), 5.30(s, 2H), 6.55(s, 1H), 6.74(d, J=8 Hz,
1H), 6.87(d, J=8 Hz, 1H), 7.60(s, 2H), 8.56(s, 1H), 8.70(s, 1H),
9.42(s, 1H) 2-[9-(10H-pyrazino [2,3-b][1,4] benzothiazin-8-
ylmethyl)purin-6- ylthio]hexanoic acid 1460 1938 FAB (+) 506
(MH.sup.+) 152-156.degree. C. .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
0.91(t, J=7 Hz, 3H), 1.10(t, J=7 Hz, 3H), 1.13-1.32(m, 4H),
1.72-1.95(m, 2H), 4.10(q, J=7 Hz, 2H), 4.79(t, J=8 Hz, 1H), 5.25(d,
J=16 Hz, 1H), 5.37(d, J=16 Hz, 1H), 6.42(s, 1H), 6.53(d, J=8 Hz,
1H), 6.69(d, #J=8 Hz, 1H), 7.37(s, 1H), 7.48(s, 1H), 7.95(s, 1H),
8.67(s, 1H) ethyl 2-[7-(10H- pyrazino[2,3-b][1,4] benzothiazin-8-
ylmethyl)purin-6- ylthio]hexanoate
EXAMPLES
[3748] The following compounds were obtained by treating methyl
11-(purin-6-ylthio)undecanoate with
8-chloromethyl-10-methoxymethyl-10H-p-
yrazino[2,3-b][1,4]benzothiazine by the same method as the one of
Example 1094.
222 Ex. Structural formula NMR 1461 1939 .sup.1H-NMR(CDCl.sub.3)
.delta. ppm: 1.23-1.35(m, 12H), 1.47(quint, J=7 Hz, 2H),
1.78(quint, J=7 Hz, 2H), 2.30(t, J=7 Hz, 2H), 3.38(t, J=7 Hz, 2H),
3.43(s, 3H), 3.66(s, 3H), 5.17(s, 2H), 5.34(s, 2H), 6.84(d, J=8 Hz,
1H), 6.97(d, J=8 Hz, 1H), 7.08(s, 1H), 7.82(d, J=3 Hz, 1H), 7.83(d,
J=3 Hz, 1H), #7.94(s, 1H), 8.73(s, 1H) methyl 11-[9-(10-
methoxymethyl-10H- pyrazino[2,3-b][1,4] benzothiazin-8-
ylmethyl)purin-6- ylthio]undecanoate 1462 1940
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24-1.36(m, 12H), 1.41(m,
2H), 1.71(quint, J=7 Hz, 2H), 2.39(t, J=7 Hz, 2H), 3.35(s, 3H),
3.37(t, J=7 Hz, 2H), 3.66(s, 3H), 5.12(s, 2H), 5.58(s, 2H), 6.73(d,
J=8 Hz, 1H), 6.87(s, 1H), 6.99(d, J=8 Hz, 1H), 7.82-7.84(m, 2H),
8.06(s, 1H), 8.85(s, 1H) methyl 11-[7-(10- methoxymethyl-10H-
pyrazino[2,3-b][1,4] benzothiazin-8-ylmethyl) purin-6-ylthio]
undecanoate
EXAMPLES
[3749] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 1450.
223 Ex. Structural formula MS M.p. NMR 1463 1941 FAB (+) 550
(MH.sup.+) 154-156.degree. C. .sup.1H-NMR(DMSO- d.sub.6) .delta.
ppm: 1.20-1.30(m, 10H), 1.35-1.50(m, 4H), 1.70(m, 2H), 2.16(t, J=7
Hz, 2H), 3.37(t, J=7 Hz, 2H), 5.30(s, 2H), 6.55(d, J=1 Hz, 1H),
6.73(dd, J=1, 8 Hz, 1H), 6.87(d, J=8 Hz, 1H), 7.61
11-[9-(10H-pyrazino [2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-
ylthio]undecanoic acid 1464 1942 FAB (+) 549 (M.sup.+)
166-170.degree. C. .sup.1H-NMR(DMSO- d.sub.6) .delta. ppm:
1.02-1.30(m, 12H), 1.42(quint, J=7 Hz, 2H), 1.57(quint, J=7 Hz,
2H), #2.13(t, J=7 Hz, 2H), 3.35(t, J=7 Hz, 2H), 5.55(s, 2H),
6.30(s, 1H), 6.55(d, J=8 Hz, 1H), 6.76(d, J=8 Hz, 1H), 7.58(d,
11-[7-(10H-pyrazino [2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-
ylthio]undecanoic acid
EXAMPLES
[3750] The following compounds were obtained by treating
8-chloromethyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine
with various purine compounds by the same method as the one of
Example 1094.
224 Purine Ex. derivative Structural formula NMR 1465 1943 1944
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.26(t, J=7 Hz, 3H), 2.87(t,
J=7Hz, 2H), 2.87(t, J=7 Hz, 2H), 3.43(s, 3H), 3.64(t, J=7 Hz, 2H),
4.17(t, J=7 Hz, 2H), 5.23(s, 2H), 5.32 (s, 2H), 6.82(d, J=8 Hz,
1H), 6.96(d, J=8 Hz, 1H), 7.27(s, 1H), 7.82(m, 2H), 7.95(s, 1H),
8.76(s, 1H) ethyl 3-[9-(10- methoxymethyl-10H- pyrazino[2,3-b][1,4]
ylmethyl)purin-6-ylthio] propanoate 1466 1945 1946
.sup.1H-NMR(CDCl.sub.3) .delta. ppm; 3.41(s, 3H), 3.89(s, 3H),
4.68(s, 2H), 5.17(s, 2H), 5.34(s, 2H), 6.85(dd, J=2, 8Hz, 1H),
6.97(d, J=8 Hz, 1H), 7.08(d, J=2 Hz, 1H), 7.37(t, J=8 Hz, 1H),
7.68(td, J=1, 8 Hz, 1H), 7.83(d, J=3 Hz, 1H), 7,85(d, J=3 Hz, 1H),
7.91(td, J=1, 8 Hz, 1H), 7.96(s, 1H), 8.16(t, J=1 Hz, 1H), 8.78(s,
1H) methyl 3-[[9-(10- methoxymethyl-10H- pyrazino[2,3-b][1,4]
benzothiazin-8-ylmethyl) purin-6-ylthiomethyl] benzoate 1467 1947
1948 .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.24(t, J=7 Hz, 3H),
1.53(m, 2H), 1.68(quint, J=7 Hz, 2H), 1.81(quint, J=7 Hz, 2H),
2.32(t, J=7 Hz, 2H), 3.39(t, J=7 Hz, 2H), 3.43(s, 3H), 4.12(q, J=7
Hz, 2H), 5.23(s, 2H), 5.34(s, 2H), 6.86(dd, J=2, 8 Hz, 1H), 6.96(d,
J=8 Hz, 1H), 7.10(d, J=2 Hz, 1H), 7.80(d, J=3 Hz, 1H), 7.82(d, J=3
Hz, 1H), 7.94(s, 1H), 8.72(s, #1H) ethyl 6-[9-(10-
methoxymethyl-10H- pyrazino[2,3-b][1,4] benzothiazin-8-ylmethyl)
purin-6-ylthio]hexanoate
EXAMPLES
[3751] The following compounds were obtained by treating the
compounds in the above table by the same method as the one of
Example 1450.
225 Ex. Structural formula MS M.p. NMR 1468 1949
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.55(t, J=7 Hz, 2H), 3.35(t,
J=7 Hz, 2H), 5.74(s, 2H), 6.55(d, J=1 Hz, 1H), 6.73(dd, J=1, 8 Hz,
1H), 6.87(d, J=8 Hz, 1H), 7.61(s, 2H), 8.54(s, 1H), 8.72(s, 1H),
9.43(s, 1H) 3-[9-(10H-pyrazino [2,3-b][1,4] benzothiazin-8-
ylmethyl)purin-6- ylthio]propanoic acid 1469 1950 FAB (+) 514
(MH.sup.+) .sup.1H-NMR(CDCl.sub.3) .delta. ppm: 3.90(s, 3H),
4.70(s, 2H), 5.25(s, 2H), 6.38(d, J=1 Hz, 1H), 6.40(br, s, 1H),
6.76(dd, J=1, 8 Hz, 1H), 6.86(d, J=8 Hz, 1H), 7.37(t, J=8 Hz, 1H),
7.57(d, J=3 Hz, 1H), 7.68(td, J=1, 8 Hz, 1H), 7.70(d, J=3 Hz, 1H),
7.91(td, J=1, #8 Hz, 1H), 7.94(s, 1H), 8.15(t, J=1 Hz, 1H), 8.77(s,
1H) methyl 3-[[9-(10H- pyrazino[2,3-b][1,4] benzothiazin-8-
ylmethyl)purin-6- ylthiomethyl]benzoate 1470 1951 FAB (+) 480
(MH.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.41(quint, J=7
Hz, 2H), 1.52(quint, J=7 Hz, 2H), 1.69(quint, J=7 Hz, 2H), 2.20(t,
J=7 Hz, 2H), 3.35(t, J=7 Hz, 2H), 5.30(s, 2H), 6.55(d, J=1 Hz, 1H),
6.74(dd, J=1, 8 Hz, 1H), 6.87(d, J=8 Hz, 1H), 7.61(s, 2H), 8.53(s,
1H), #8.69(s, 1H), 9.43(s, 1H), 11.9(s, 1H) 6-[9-(10H-pyrazino
[2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6- ylthio]hexanoic acid
1471 1952 FAB (+) 508 (MH.sup.+) 78-79.degree. C.
.sup.1H-NMR(CDCl.sub.3) .delta. ppm: 1.16(t, J=7 Hz, 3H),
1.35(quint, J=7 Hz, 2H), 1.65(quint, J=7 Hz, 2H), 1.81(quint, J=7
Hz, 2H), 2.31(t, J=7 Hz, 2H), 3.40(t, J=7 Hz, 2H), 4.12(q, J=7 Hz,
2H), 5.25(s, 2H), 6.39(s, 2H), 6.74(d, J=8 Hz, 1H), # 6.85(d, J=8
Hz, 1H), 7.55(s, 1H), 7.70(s, 1H), 7.94(s, 1H), 8.73(s, 1H) ethyl
6-[9-(10H- pyrazino[2,3-b][1,4] benzothiazin-8- ylmethyl)purin-6-
ylthio]hexanoate
EXAMPLE 1472
[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]carbothioam-
ide
[3752] In a steel container, 2.75 g of
9-(10H-pyrazino[2,3-b][1,4]benzothi-
azin-8-ylmethyl)purine-6-carbonitrile and 6.5 g of powdery sodium
hydrogensulfide were suspended in 150 ml of methanol. Next,
hydrogen sulfide was blown into the system at -30.degree. C. to
ensure saturation thereof and then the container was hermetically
sealed. After heating the reactor to 80 to 90.degree. C. for 4
hours, the reaction mixture was poured into an aqueous solution of
potassium hydrogensulfate. The crystals thus precipitated were
taken up by filtration and washed with water. Thus, 3.1 g of the
title compound was obtained as yellow crystals. 1953
[3753] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3754] 5.48(s, 2H), 6.66(s, 1H), 6.75(d, J=8.3 Hz, 1H), 6.88(d,
J=8.3 Hz, 1H), 7.61(s, 2H), 8.75(s, 1H), 8.92(s, 1H), 9.47(s, 1H),
9.90-10.03(br.s, 1H), 10.38-10.51(br.s, 1H)
EXAMPLE 1473
[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-yl]-N.sup.2-cy-
anocarboxamidine
[3755] 500 mg of
[9-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-
-6-yl]carbothioamide was dissolved in a solvent mixture of acetone
(200 ml) with N,N-dimethylformamide (10 ml). Under ice-cooling, 300
mg of methyl iodide was added thereto and the resulting mixture was
stirred at 0.degree. C. to room temperature for 3 hours. Then the
reaction mixture was distributed into an aqueous solution of
potassium carbonate and ethyl acetate and the organic layer was
extracted. After distilling off the solvent under reduced pressure,
the residue was dissolved in dry methanol (5 ml) and
tetrahydrofuran (10 ml). After adding 1.0 g of cyanamide, the
reaction mixture was stirred at 30 to 40.degree. C. for 3 hours.
Then the reaction mixture was distributed into water and ethyl
acetate. The organic layer was extracted, washed with water and
dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the residue was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 78 mg of the title compound as yellow crystals.
1954
[3756] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3757] 5.40(s, 2H), 6.53-6.70(br.s, 1H), 6.76(d, J=7.9 Hz, 1H),
6.88(d, J=7.9 Hz, 1H), 7.61(s, 2H), 8.89(s,, 1H), 9.03-9.10(br.s,
1H), 9.30-9.50(m, 3H)
[3758] MS: FAB(+)400(M.sup.+)
[3759] m.p. : >290.degree. C.
EXAMPLE 1474
[3760]
N.sup.2-(9-(10H-Pyrazino[2,3-b](1,4]benzothiazin-8-ylmethyl)purin-6-
-yl]-N.sup.1,N.sup.1-dimethylformamidine
[3761] The title compound was obtained by treating
8-(6-aminopurin-9-yl)-1- 0H-pyrazino[2,3-b][1,4]benzothiazine with
N,N-dimethylformamide dimethyl acetal by the same method as the one
of Example 1540. 1955
[3762] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3763] 3.11(s, 3H), 3.17(s, 3H), 3.24(s, 2H), 6.58(s, 1H), 6.70(d,
J=8 Hz, 1H), 6.86(d, J=8 Hz, 1H), 7.61(s, 2H), 8.31(s, 1H), 8.39(s,
1H), 8.90(s, 1H), 9.47(s, 1H)
EXAMPLE 1475
8-(6-Aminopurin-9-yl)-10H-pyrazino[2,3-b][1,4]benzothiazine
hemioxalate
[3764] The title compound was obtained by hydrogenating
9-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purine-6-carbonitrile
by the same method as the one of Example 16. 1956
[3765] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3766] 4.58(br.s, 2H), 5.37(s, 2H), 6.68(s, 1H), 6.71(d, J=8 Hz,
1H), 6.88(d, J=8 Hz, 1H), 7.62(s, 2H), 8.61(br.s, 3H), 8.79(s, 1H),
8.99(s, 1H), 9.50(s, 1H)
[3767] MS: ESI(+)363(MH.sup.+)
[3768] m.p.: 97-104.degree. C. (dec)
EXAMPLE 1476
N.sup.1-[9-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)purin-6-ylmeth-
yl]-N.sup.2-cyanoformamidine
[3769] The title compound was obtained by treating
8-(6-aminomethylpurin-9- -yl)-10H-pyrazino[2,3-b][1,4]benzothiazine
with ethyl N-cyanoformimidate by the same method as the one of
Example 1534. 1957
[3770] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3771] 5.24(s, 2H), 6.30(s, 2H), 6.60(s, 1H), 6.74(d, J=8 Hz, 2H),
6.87(d, J=8 Hz, 1H), 7.62(s, 2H), 8.48(s, 1H), 8.69(s, 1H), 8.88(s,
1H), 9.46(s, 1H)
EXAMPLE 1477
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl) carbonitrile
[3772] 150 mg of the title compound was obtained by treating 300 mg
of
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbonitrile
by the same method as the one of Example 434. 1958
[3773] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3774] 6.96(d, J=1.8 Hz, 1H), 7.10(dd, J=1.8, 8.2 Hz, 1H), 7.18(d,
J=8.2 Hz, 1H), 7.67(d, J=3.3 Hz, 1H), 7.68(d, J=3.3 Hz, 1H),
9.74(s, 1H)
[3775] MS: FAB(+)227(MH.sup.+)
[3776] m.p.: 263-264.degree. C.
EXAMPLE 1478
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl) carboxamidine
hydrochloride
[3777] Into a metallic pressure container (50 ml) were fed 300 mg
of (10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbonitrile and 450
mg of ammonium chloride. After adding about 20 ml of liquefied
ammonia at -78.degree. C., the container was sealed and heated to
120.degree. C. for 15 hours. Then it was opened under ice-cooling
and the ammonia was released. The obtained residue was distributed
into dilute hydrochloric acid and ethyl acetate. The aqueous layer
was washed with ethyl acetate several times. Then the pH value of
the aqueous layer was adjusted to about 10 with potassium
hydroxide. Next, it was extracted with ethyl acetate and dried over
anhydrous potassium carbonate. After distilling off the solvent
under reduced pressure, the obtained residue was dissolved in a
small amount of methanol. After adding hydrogen chloride and ethyl
acetate, crystallization was effected to thereby give 45 mg of the
title compound as orange crystals. 1959
[3778] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3779] 6.99(s, 1H), 7.09(d, J=8.0 Hz, 1H), 7.14(d, J=8.0 Hz, 1H),
7.70(d, J=2.8 Hz, 1H), 7.71(d, J=2.8 Hz, 1H), 9.10(br.s, 2H),
9.31(br.s, 2H), 9.82(br.s, 1H)
[3780] MS: FAB(+)244(MH.sup.+)
[3781] m.p.: >280.degree. C.
EXAMPLE 1479
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl) acetamidine
[3782] 2.68 g of ammonium chloride was added to 20 ml of dry
toluene in a nitrogen atmosphere. Then 36.5 ml of a 15% solution of
trimethylaluminum in n-hexane was added thereto under stirring and
ice-cooling. The reaction mixture was brought back to room
temperature and 70 ml of dry toluene was further added. The
resulting mixture was subjected to ultrasonication until the
ammonium chloride disappeared completely. A 60 ml portion of the
solution thus obtained was taken and 1.5 g of
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetonitrile was added
thereto. The obtained mixture was heated under reflux for 18 hours.
After bringing back to room temperature, the reaction mixture was
distributed into ethyl acetate and dilute hydrochloric acid and
repeatedly extracted with water. The aqueous layer was washed with
methylene chloride and the solvent contained in the solution was
eliminated under reduced pressure. The obtained residue was
purified by High-porous gel column chromatography (CHP20, mfd. by
Mitsubishi Chemical Industries, Ltd., 75-15[) (eluted with
water/methanol) to thereby give 620 mg of the title compound as
yellow crystals. 1960
[3783] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3784] 3.52(br.s, 2H), 6.70(br.s, 1H), 6.75(br.d, J=8.0 Hz, 1H),
6.91(br.d, J=8.0 Hz, 1H), 7.64(br.s, 2H)
EXAMPLE 1480
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamidine
hydrochloride
[3785] (10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamidine was
dissolved in a small amount of methanol and a solution of hydrogen
chloride in ethyl acetate was added thereto under ultrasonication.
Thus, the title compound was obtained almost quantitatively as the
precipitated orange crystals. 1961
[3786] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3787] 3.56(s, 2H), 6.71(s, 1H), 6.79(d, J=8.2Hz, 1H), 6.91(d,
J=8.2Hz, 1H), 7.64(s, 2H), 8.76(br.s, 2H), 9.18(br.s, 2H), 9.65(s,
1H)
[3788] MS: FAB(+)258(MH.sup.+)
[3789] m.p.: >280.degree. C.
EXAMPLES
[3790] The following compounds were obtained by the same method as
the one of Example 1479 by using methylamine hydrochloride and
dimethylamine hydrochloride each as a substitute for the ammonium
chloride followed by the same treatment as the one of Example
1399.
226 Ex. Structural formula MS M.p. NNR 1481 1962 FAB (+) 272
(MH.sup.+) 244-247.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 2.81(s, 3H), 3.59(s, 2H), 6.69(s, 1H), 6.78(d, J=8.1 Hz, 1H),
6.91(d, J=8.1 Hz, 1H), 7.64(s, 2H), 8.72-8.83(br.s, 1H),
9.26-9.37(br.s, 1H), 9.62(s, 1H), 9.76-9.86(br.s, 1H)
N.sup.1-methyl-(10H- pyrazino[2,3-b][1,4] benzothiazin-8-yl)
acetamidine hydrochloride 1482 1963 FAB (+) 286 (MH.sup.+)
>280.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.05(s,
3H), 3.07(s, 3H), 3.84(s, 2H), 6.66(s, 1H), 6.71(d, J=8.2 Hz, 1H),
6.92(d, J=8.2 Hz, 1H), 7.64(s, 2H), 8.79-8.87(br.s, 1H),
9.43-9.50(br.s, 1H), 9.60(s, 1H) N.sup.1,N.sup.1-dimethyl-(10H-
pyrazino[2,3-b][1,4] benzothiazin-8-yl) acetamidine
hydrochloride
EXAMPLE 1483
Methyl(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetothi-
oimidate
[3791] Into 15 ml of a solution of 318 mg of
(10-methoxymethyl-10H-pyrazin-
o[2,3-b][1,4]benzothiazin-8-yl)thioacetamide in acetone was dropped
1.5 m of methyl iodide. After stirring at room temperature for 2
hours, the reaction mixture was distributed into ethyl acetate and
an aqueous solution of potassium carbonate. The organic layer was
extracted and the extract was washed with water and dried over
anhydrous sodium sulfate. After distilling off the solvent under
reduced pressure, 350 mg of the title compound was obtained as a
yellow oily substance. 1964
[3792] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3793] 2.29(br.s, 3H), 3.53(s, 3H), 3.68(s, 2H), 5.27(s, 2H),
6.88(br.d, J=7.7Hz, 1H), 6.98(d, J=7.7Hz, 1H), 7.04(br.s, 1H),
7.83(d, J=2.8Hz, 1H), 7.84(d, J=2.8Hz, 1H)
EXAMPLE 1484
N-Phenyl-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl)acet-
amidine
[3794] 350 mg of
methyl(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothia-
zin-8-yl)acetothioimidate was dissolved in a solvent mixture of
tetrahydrofuran (7 ml) with methanol (15 ml). After adding 0.5 ml
of aniline, the resulting mixture was heated under reflux for 5
hours. Then the reaction mixture was brought back to room
temperature. After distilling off the solvent under reduced
pressure, the residue was purified by silica gel column
chromatography (eluted with dichloromethane/methanol/aqueous
ammonia) to thereby give 250 mg of the title compound as yellow
crystals. 1965
[3795] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3796] 3.53(s, 3H), 3.60(s, 2H), 3.6-4.1(br.s, 2H), 5.24(s, 2H),
6.92(d, =7.3Hz, 2H), 6.94(br.d, J=7.7Hz, 1H), 6.98(d, J=7.7Hz, 1H),
7.04(t, J=7.3Hz, 1H), 7.17(br.s, 1H), 7.31(t, J=7.3Hz, 2H), 7.83(d,
J=2.7Hz, 1H), 7.84(d, J=2.7Hz, 1H)
EXAMPLE 1485
N-Phenyl-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamidine
hydrochloride
[3797] 250 mg of
N-phenyl-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzot-
hiazin-8-yl)acetamidine was treated by the same method as the one
of Example 434 and then crystallized from ethyl acetate containing
hydrogen chloride. Thus, 130 mg of the title compound was obtained
as orange crystals. 1966
[3798] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3799] 3.78(s, 2H), 6.81(s, 1H), 6.86(d, J=8.2Hz, 1H), 6.95(d,
J=8.2Hz, 1H), 7.32(d, J=7.4Hz, 2H), 7.44(t, J=7.4Hz, 1H), 7.53(t,
J=7.4Hz, 2H), 7.64(d, J=2.2Hz, 1H), 7.65(d, J=2.2Hz, 1H), 8.76(s,
1H), 9.67-9.75(br.s, 1H), 9.70(s, 1H), 11.66(s, 1H)
[3800] MS: FAB(+)334(MH.sup.+)
[3801] m.p.: 245-249.degree. C.(decompose)
EXAMPLE 1486
Methyl(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetothioimidate
[3802] The title compound was obtained as a yellow oily substance
quantitatively by treating
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)thi- oacetamide with
methyl iodide by the same method as the one of Example 1483.
1967
[3803] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3804] 2.61(s, 3H), 4.00(s, 2H), 6.68(s, 1H), 6.77(d, J=8.1Hz, 1H),
6.94(d, J=8.1Hz, 1H), 7.65(s, 2H), 9.62(s, 1H)
EXAMPLE 1487
N.sup.2-Cyano-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamidine
[3805] To 15 ml of a solution of 410 mg of
methyl(10H-pyrazino[2,3-b][1,4]- benzothiazin-8-yl)acetothioimidate
in methanol was added 250 mg of cyanamide and the resulting mixture
was heated to 60.degree. C. or below for 1 hour. Then the reaction
mixture was brought back to room temperature and the solvent was
distilled off under reduced pressure to reduce its amount. The
crystals thus precipitated were taken up by filtration and washed
successively with methanol and ethyl acetate. Thus, 295 mg of the
title compound was obtained as yellow crystals. 1968
[3806] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[3807] 3.62(br.s, 2H), 6.67(br.s, 1H), 6.78(d, J=8Hz, 1H), 6.84(d,
J=8Hz, 1H), 7.57(d, J=3Hz, 1H), 7.58(d, J=3Hz, 1H)
[3808] MS: FAB(+)286(MH.sup.+)
[3809] m.p.: 230-232.degree. C.
EXAMPLES
[3810] The following compounds were synthesized by treating
methyl(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetothioimidate
with various amines by the same method as the one of Example
1487.
227 Ex. Structural formula MS M.p. NMR 1488 1969 FAB (+) 336
(MH.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.83(s, 3H),
3.33(s, 2H), 6.70(s, 1H), 6.71(d, J=7.8 Hz, 1H), 6.85(d, J=7.8 Hz,
1H), 7.60-7.65(m, 2H), 7.79(s, 1H), 8.58(s, 1H), 9.57(s, 1H)
N.sup.2-(methanesulfonyl)- (10H-pyrazino[2,3-b]
[1,4]benzothiazin-8- yl)acetamidine 1489 1970 FAB (+) 390
(MH.sup.+), 389 (M.sup.+) 200-202.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.57(s, 2H), 6.67(s, 1H),
6.70(d, J=7.5 Hz, 1H), 6.89(d, J=7.5 Hz, 1H), 7.61-7.66(m, 2H),
9.00-9.10(br.s, 1H), 9.58(s, 1H), 9.63-9.72(br.s, 1H)
N.sup.2-(trifluoromethane- sulfonyl)-(10H- pyrazinol[2,3-b][1,4]
benzothiazin-8-yl) acetamidine 1490 1971 FAB (+) 398 (MH.sup.+),
397 (M.sup.+) 206-207.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.34(s, 2H), 6.62(d, J=7.8 Hz, 1H), 6.66(s, 1H), 6.79(d, J=7.8
Hz, 1H), 7.43-7.57(m, 3H), 7.61-7.69(m, 2H), 7.70-7.78(m, 2H),
8.00-8.10(br.s, 1H), 8.73-8.84(br.s, 1H), 9.53(s, 1H)
N.sup.2-(benzenesulfonyl)- (10H-pyrazino[2,3-b]
[1,4]benzothiazin-8- yl)acetamidine 1491 1972 FAB (+) 296
(MH.sup.+) 222-223.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.48(t, J=2.5 Hz, 1H), 3.62(s, 2H), 4.15(dd, J=2.5, 5.4 Hz,
2H), 6.71(s, 1H), 6.78(d, J=8.2 Hz, 1H), 6.91(d, J=8.2 Hz, 1H),
7.64(s, 2H), 9.11(s, 1H), 9.66(d, J=2.4 Hz, 2H), 10.25(t, J=5.4 Hz,
1H) N.sup.2-(2-propynyl)-(10H- pyrazino[2,3-b][1,4]
benzothiazin-8-yl) acetamidine hydrochloride 1492 1973 FAB (+) 336
(M.sup.+) >260.degree.C. (de- com- pose)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.51(s, 2H), 4.3-4.5(br.s,
1H), 5.1-5.3(br.s, 1H), 6.70(br.s, 1H), 6.76(br.d, J=7.9 Hz, 1H),
6.91(br.d, J=7.9 Hz, 1H), 7.65(br.s, 2H) N.sup.2-sulfamoyl-(10H-
pyrazino[2,3-b][1,4] benzothiazin-8-yl) acetamidine 1493 1974 FAB
(+) 413 (MH.sup.+) 226-227.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 3.03-3.10(br.s, 2H), 6.09-6.12(br.s, 1H),
6.50-6.62(br.d, J=7.6 Hz, 1H), 6.58(s, 1H), 6.74(d, J=7.6 Hz, 1H),
7.27-7.42(br.s, 1H), 7.47-7.59(m, 3H), 7.60-7.66(m, 2H),
7.70-7.80(m, 2H), 8.82- #8.92(br.s, 1H), 9.43-9.55(br.s, 1H)
N-(benzenesulfonyl)- (10H-pyrazino[2,3-b] [1,4]benzothiazin-8-
yl)acetamidrazone 1494 1975 FAB (+) 301 (MH.sup.+)
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 3.13 and 3.17(s, total 2H),
6.03 and 6.10(s, total 1H), 6.67-6.77(m, 2H), 7.60-7.63(m, 1H),
7.80(s, initial 1H), 8.33(d, J=9.8 Hz, initial 1H), 9.47(s, 2H),
9.51(s, initial 1H), 9.34(d, J=9.8 Hz, initial 1H) N-formyl-(10H-
pyrazino[2,3-b][1,4] benzothiazin-8-yl) acetamidrazone 1495 1976
FAB (+) 329 (MH.sup.+) 158-161.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 2.76(s, 3H), 2.96(s, 3H), 3.23(s, 2H), 6.73(s, 1H),
6.74(d, J=7.9 Hz, 1H), 6.82(d, J=7.9 Hz, 1H), 7.61(d, J=2.3 Hz,
1H), 7.62(d, J=2.3 Hz, 1H), 7.82-8.00(br.s, 1H), 8.82-9.04(br.s,
1H), 9.53(s, 1H) N.sup.2-(dimethylamino- carbonyl)-(10H-
pyrazino[2,3-b][1,4] benzothiazin-8-yl) acetamidine 1496 1977 FAB
(+) 287 (M.sup.+) 217-218.degree. C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 3.04(s, 2H), 3.57(s, 3H), 5.57-5.63(br.s, 2H), 6.68(d,
J=1.5 Hz, 1H), 6.72(d, J=7.7 Hz, 1H), 6.82(dd, J=1.5, 7.7 Hz, 1H),
7.61-7.64(m, 2H), 9.50(s, 1H) (10H-pyrazino[2,3-b]
[1,4]benzothiazin-8- yl)acetamide O-methyl oxime 1497 1978 FAB (+)
273 (M.sup.+) 252-254.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.06(s, 2H), 5.30-5.36(br.s, 2H), 6.66(d, J=1.0 Hz, 1H),
6.70(dd, J=1.0, 7.5 Hz, 1H), 6.81(d, J=7.5 Hz, 1H), 7.61(d, J=2.3
Hz, 1H), 7.62(d, J=2.3 Hz, 1H), 8.89(s, 1H), 9.49(s, 1H)
(10H-pyrazino[2,3-b] [1,4]benzothiazin-8- yl)acetamide oxime
EXAMPLE 1498
N.sup.2-Cyano-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamidine
[3811] 500 mg of
7-chloromethyl-10-methoxymethyhl-10H-pyrazino[2,3-b][1,4]-
benzothiazine was treated by the same method as the one of Example
1513 to thereby give
(10-methoxymethyhl-10H-pyrazino[2,3-b][1,4]benzothiazin-7-yl-
)acetonitrile. Next, this product was converted into
methyl(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-7-yl)acetimi-
date by the same method as the one of Example 1518. After treating
with cyanamide by the same method as the one of Example 1487, 110
mg of the title compound was obtained as yellow crystals. 1979
[3812] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[3813] 3.63(br.s, 2H), 6.62 and 6.64(d, J=8Hz, 1H), 6.81(d, J=2Hz)
and 6.86(br.s)(total 1H), 6.91(dd, J=2, 8Hz) and 6.97(d,
J=8Hz)(total 1H), 7.55 and 7.57(d, J=3Hz, 1H), 7.56 and 7.58(d,
J=3Hz, 1H)
[3814] MS: FAB(+)283(MH.sup.+)
[3815] m.p.: 218-219.degree. C.
EXAMPLE 1499
N.sup.2-Cyano-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetamidine
S-oxide
[3816] To a solution of 150 mg of
N.sup.2-cyano-(10H-pyrazino[2,3-b][1,4]b-
enzothiazin-8-yl)acetamidine in acetic acid (10 ml) was added 1.0
ml of 30% hydrogen peroxide and the resulting mixture was heated to
40 to 45.degree. C. for 30 minutes. Then 5 ml of an aqueous
solution of 3 g of sodium thiosulfate was added to the reaction
mixture. After distilling off the solvent under reduced pressure,
the obtained residue was extracted by decantation with
dichloromethane/methanol (20%). The extract was distilled under
reduced pressure. The residue thus obtained was purified by silica
gel column chromatography (eluted with dichloromethane/methanol) to
thereby give 110 mg of the title compound as colorless crystals.
1980
[3817] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3818] 3.90(br.s, 2H), 7.22-7.30(m, 1H), 7.47-7.56(m, 1H),
7.97-8.06(m, 1H), 8.50(d, J=2.1Hz, 1H), 8.69(d, J=2.1Hz, 1H)
[3819] MS: FAB(+)299(MH.sup.+)
[3820] m.p.: >280.degree. C.
EXAMPLES
[3821] The following compounds were obtained by treating
methyl(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetimidate
hydrochloride with various amines.
228 Ex. Amine Structural formula MS M.p. NMR 1500 1981 1982 FAB (+)
298 (MH.sup.+) .sup.1H-NMR(DMSO-d.sub.6) .delta.ppm: 1.76-1.90(m,
2H), 3.23-3.40(m, 4H), 3.58(s, 2H), 6.69(d, J=1.5 Hz, 1H), 6.78(dd,
J=1.5, 8.4 Hz, 1H), 6.91(d, J=8.4 Hz, 1H), 7.63(d, J=2.4 Hz, 1H),
7.65(d, J=2.4 Hz, 1H), 9.61(s, 1H), 9.82-9.90(br.s, 2H) 8-(1,4,5,6-
tetrahydropyrimidin-2- ylmethyl)-10H- pyrazino[2,3-b][1,4]
benzothiazine hydrochloride 1501 1983 1984 FAB (+) 302 (MH.sup.+)
174-175.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
3.26-3.33(m, 2H), 3.53-3.59(m, 2H), 3.60(s, 2H), 5.07(t, J=5.0 Hz,
1H), 6.69(d, J=1.5 Hz, 1H), 6.77(dd, J=1.5, 8.0 Hz, 1H), 6.80(d,
J=8.0 Hz, 1H), 7.63(d, J=2.4 Hz, 1H), 7.64(d, J=2.4 Hz, 1H),
8.74-8.81(br.s, # 1H), 9.16-9.23(br.s, 1H), 9.62(s, 1H),
9.74-9.82(br.s, 1H) N.sup.1-(2-hydroxyethyl)- (10H-pyrazino[2,3-b]
[1,4]-benzothiazin-8- yl)acetamidine hydrochloride 1502 1985 1986
FAB (+) 312 (MH.sup.+) >280.degree.C. .sup.1H-NMR(DMSO-d.sub.6)
.delta. ppm: 1.91-2.00(m, 2H), 2.99(s, 3H), 3.29-3.36(m, 2H),
3.39-3.46(m, 2H), 3.84(s, 2H), 6.68(d, J=1.2 Hz, 1H), 6.73(dd,
J=1.2, 8.1 Hz, 1H), 6.92(d, J=8.1 Hz, 1H), 7.65(s, 2H), 9.59(s,
1H), 10.07-10.12(br.s, 1H) 8-(1-methyl-1,4,5,6-
tetrahydropyrimidin-2- ylmethyl)-10H- pyrazino[2,3-b][1,4]
benzothiazine hydrochloride 1503 1987 1988 FAB (+) 388 (MH.sup.+)
153-155.degree. C. (decompose) .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm,: 1.90-2.00(m, 2H), 3.26-3.32(m, 2H), 3.36-3.43(m, 2H), 3.96(s,
2H), 4.57(s, 2H), 6.72(s, 1H), 6.77(d, J=7.8 Hz, 1H), 6.89(d, J=7.8
Hz, 1H), 7.12-7.18(m, 2H), 7.25-7.37(m, 3H), 7.65(s, 2H), 9.56(s,
1H), #10.38-10.43(br.s, 1H) 8-(1-benzyl-1,4,5,6-
tetrahydropyrimidin-2- ylmethyl)-10H-pyrazino [2,3-b][1,4]
benzothiazine hydrochloride 1504 1989 1990 FAB (+) 314 (MH.sup.+)
156-163.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
3.15-3.22(m, 2H), 3.31-3.38(m, 2H), 3.60(s, 2H), 4.08-4.13(m, 1H),
5.51(d, J=3.7 Hz, 1H), 6.71(d, J=1.4 Hz, 1H), 6.78(dd, J=1.4, 8.4
Hz, 1H), 6.90(d, J=8.4 Hz, 1H), 7.63(d, J=2.0 Hz, 1H), 7.65(d,
J=2.0 Hz, 1H), 9.62(s, 1H), #9.78-9.88(br.s, 2H)
2-(10H-pyrazino[2,3-b] [1,4]benzothiazin-8- ylmethyl)-1,4,5,6-
tetrahydropyrimidin-4- ol hydrochloride 1505 1991 1992 FAB (+) 391
(MH.sup.+) 275-277.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 3.20(s, 3H), 3.24-3.31(m, 2H), 3.45-3.52(m, 2H), 3.60(s, 2H),
3.85-3.91(m, 1H), 6.72(s, 1H), 6.80(d, J=7.5 Hz, 1H), 6.91(d, J=7.5
Hz, 1H), 7.58-7.69(m, 1H), 7.64(d, J=2.5 Hz, 1H), 7.65(d, J=2.5 Hz,
1H), 9.59(s, 1H) N-[2-(10H-pyrazino [2,3-b][1,4] benzothiazin-8-
ylmethyl)-1,4,5,6- tetrahydropyrimidin-4- yl]methanesulfonomide
hydrochloride 1506 1993 1994 FAB (+) 420 (MH.sup.+) 251-254.degree.
C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.66(s, 6H), 3.25-3.33(m,
3H), 3.42-3.49(m, 2H), 3.56-3.60(br.s, 2H), 3.70-3.76(m, 1H),
6.71(d, J=1.4 Hz, 1H), 6.80(dd, J=1.4, 7.8 Hz, 1H), 6.91(d, J=7.8
Hz, 1H), 7.65(s, 2H), 9.59(s, 1H) N-[2-(10H-pyrazino [2,3-b][1,4]
benzothiazin-8- ylmethyl)-1,4,5,6- tetrahydropyrimidin-4-
yl]-N',N'- dimethylsulfamide 1507 1995 1996 FAB (+) 342 (MH.sup.+)
265-267.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
1.18-1.43(m, 2H), 1.55-1.85(m, 2H), 3.24-3.47(m, 2H), 3.57-3.82(m,
3H), 3.88(s, 2H), 3.93(d, J=4.1 Hz, 1H), 6.64(s, 1H), 6.71(d, J=7.8
Hz, 1H), 6.91(d, J=7.8 Hz, 1H), 7.64(s, 2H), 9.61(s, 1H) N.sup.1,
N.sup.1-(3- hydroxypenta- methylene)-(10H- pyrazino[2,3-b][1,4]
benzothiazin-8-yl) acetamidine 1508 1997 1998 FAB (+) 454
(MH.sup.+) 219-220.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 0.76-0.90(m, 1H), 1.01(d, J=7.0 Hz, 3H), 1.06-1.20(m, 2H),
1.13(t, J=6.8 Hz, 3H), 1.26-1.39(m, 1H), 1.43-1.55(m, 2H),
1.55-1.66(m, 1H), 1.69-1.81(m, 1H), 2.27-2.38(m, 1H), 3.00-3.12(m,
2H), 3.24-3.36(m, 1H), #3.71-3.82(m, 1H), 3.83-3.88(br.s, 2H),
4.01(q, J=6.8 Hz, 2H), 4.08-4.19(m, 1H), 6.63(d, J=1.3 Hz, 1H),
6.71(dd, J=1.3, 8.3 Hz, 1H), 6.92(d, J=8.3 Hz, 1H), 7.64(s, 2H),
8.93-9.03(br.s, 1H), 9.43-9.52(br.s, 1H), 9.61(s, 1H) ethyl
4-[1-[1-imino- 2-(10H-pyrazino[2,3- b][1,4]benzothiazin-
8-yl)ethyl] piperidin-4-yl]-2- methylbutanoate hydrochloride 1509
1999 2000 FAB (+) 448 (MH.sup.+) 215-218.degree. C.
.sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 1.20(m, 1H), 1.38(m, 1H),
1.53-1.72(m, 1H), 1.72-1.83(m, 1H), 1.86-2.00(m, 1H), 2.50-2.70(m,
1H), 2.62(s, 6H), 3.17-3.43(m, 2H), 3.67-3.80(m, 1H), 3.87(br.s,
2H), 6.66(d, J=2.0 Hz, 1H), 6.71(dd, J=2.0, 7.8 Hz, 1H), 6.92(d, #
J=7.8 Hz, 1H), 7.34(d, J=7.4 Hz, 1H), 7.65(s, 2H), 9.00-9.13(br.s,
1H), 9.50-9.58(br.s, 1H), 9.60(s, 1H) N-[1-[1-imino-2-
(10H-pyrazino[2,3- b][1,4]benzothiazin- 8-yl)ethyl] piperidin-4-yl-
N',N'- dimethylsulfamide hydrochloride 1510 2001 2002 FAB (+) 369
(MH.sup.+) 268-269.degree. C. .sup.1H-NMR(DMSO-d.sub.6) .delta.
ppm: 1.93-2.03(br.s, 3H), 3.35-3.74(m, 8H), 3.87-3.96(br.s, 2H),
6.64(d, J=1.1 Hz, 1H), 6.73(dd, J=1.1, 8.4 Hz, 1H), 6.93(d, J=8.4
Hz, 1H), 7.65(s, 2H), 9.11-9.26(br.s, 1H), 9.59(s, 1H),
9.60-9.74(br.s, 1H) N,N-[3-[1-imino-2- (10H-pyrazino[2,3-
b][1,4]benzothiazin- 8-yl)ethyl]-3- azapentamethylene] acetamide
hydrochloride 1511 2003 2004 FAB (+) 432 (MH.sup.+) 215-218.degree.
C. .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm: 2.85 and 2.86(s, total
3H), 3.28-3.31 and 3.46-3.52(m, total 2H), 3.54-3.65(m, 4H),
3.65-3.71 and 3.72-3.79(m, total 2H), 6.66(s, 1H), 6.73(d, J=7.5
Hz, 1H), 6.93(d, J=7.5 Hz, 1H), 7.64(s, 2H), 8.13 and #8.17(bs.s,
total 1H), 9.22-9.28 and 9.28-9.36(br.s, total 1H), 9.59(s, 1H),
9.73-9.83(br.s, 1H) N.sup.1, N.sup.1-[3-[1-imino-2-
(10H-pyrazino[2,3- b][1,4]benzothiazin- 8-yl)ethyl]
piperidin-4-yl]-3- azapentamethylene]- N.sup.2-(methanesulfonyl)
formamidine hydrochloride
EXAMPLE 1512
4-[1-[1-Imino-2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-ethyl]piperidi-
n-4-yl]-2-methylbutanoic acid hydrochloride
[3822] The title compound was obtained by hydrolyzing ethyl
4-[1-[1-imino-2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)ethyl]piperidi-
n-4-yl]-2-methylbutanoate hydrochloride by the same method as the
one of Example 18. 2005
[3823] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3824] 0.83-1.01(m, 2H), 0.90(d, J=6.9Hz, 3H), 1.03-1.22(m, 3H),
1.33-1.51(m, 2H), 1.54-1.65(m, 2H), 1.94-2.05(m, 1H), 2.80-2.94(m,
2H), 3.70-3.77(br.s, 2H), 3.94-4.09(m, 2H), 6.65(d, J=8.0Hz, 1H),
6.66(s, 1H), 6.86(d, J=8.0Hz, 1H), 7.62(s, 2H), 9.60-9.76(br.s,
1H)
[3825] MS: FAB(+)426(MH.sup.+)
[3826] m.p.: 166-171.degree. C.
EXAMPLE 1513
(5H-Pyrido[3,4-b][1,4]benzothiazin-7-yl)acetonitrile
[3827] The title compound was obtained by treating
5-methoxymethyl-7-(chlo-
romethyl)-5H-pyrido[3,4-b][1,4]benzothiazine by the same method as
the one of Example 53 and then deblocking by the same method as the
one of Example 8. 2006
[3828] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3829] 3.61(s, 2H), 6.18(br.s, 1H), 6.39(d, J=6Hz, 1H), 6.56(br.s,
1H), 6.78(d, J=8Hz, 1H), 6.95(d, J=8Hz, 1H), 7.98(s, 1H), 8.08(d,
J=6Hz, 1H)
EXAMPLES
[3830] The following compounds were obtained by treating
(5H-pyrido[3,4-b][1,4]benzothiazin-7-yl)acetonitrile by the same
method as the one of Example 1518 and treating the corresponding
imidates thus obtained with various amines by the same method as
the one of Example 1520.
229 Ex. Amine Structural formula NMR 1514 H.sub.2N--CN 2007
.sup.1H-NMR(D.sub.2O) .delta. ppm: 3.51(s, 2H), 6.40(d, J=6 hz,
1H), 6.44(d, J=2 Hz, 1H), 6.63(d, J=8 Hz, 1H), 6.70(dd, J=2, 8 Hz,
1H), 7.52(d, J=1 Hz, 1H), 7.63(dd, J=1, 6 Hz, 1H)
N.sup.2-cyano-(5H-pyrido[3,4- b][1,4]benzothiazin-7- yl)acetamidine
dihydrochloride 1515 2008 2009 .sup.1H-NMR(D.sub.2O) .delta. ppm:
3.44-3.53(m, 6H), 6.38(t, J=5 Hz, 2H), 3.75(s, 2H), 6.44-6.48(m,
2H), 6.70(d, J=9 Hz, 1H), 6.75(d, J=9 Hz, 1H), 7.56(s, 2H), 7.70(d,
J=6 Hz, 1H) N.sup.1, N.sup.1-(3- oxopentamethylene)-(5H-
pyrido[3,4-b][1,4] benzothiazin-7-yl) acetamidine 1516 2010 2011
.sup.1H-NMR(D.sub.2O) .delta. ppm: 1.72-2.34(m, 3H), 3.40-3.78(m,
6H), 6.38-6.48(m, 2H), 6.63-6.77(m, 2H), 7.52-7.57(m, 1H),
7.63-7.70(m, 1H) [1-[1-imino-2-(5H- pyrido[3,4-b][1,4]
benzothiazin-7-yl) ethyl]pyrrolidin-2-yl] carboxamide
EXAMPLE 1517
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetonitrile
[3831] The title compound was obtained from
8-chloromethyl-10H-pyrazino[2,- 3-b][1,4]benzothiazine by the same
method as the one of Example 53. 2012
[3832] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3833] 3.88(s, 2H), 6.73(d, J=7.6Hz, 1H), 6.74(s, 1H), 6.91(d,
J=7.6Hz, 1H), 7.65(s, 2H), 9.60(s, 1H)
EXAMPLE 1518
Methyl(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetimidate
hydrochloride
[3834] 480 mg of
(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetonitrile was
suspended in a solution of dry methanol (20 ml)/dry dichloromethane
and cooled to -20.degree. C. Then dry hydrogen chloride gas was
blown thereinto until saturation was attained while paying
attention lest the bulk temperature exceed 0.degree. C. Then the
reaction mixture was hermetically sealed and allowed to stand under
ice-cooling over day and night. Next, the solvent was distilled off
under reduced pressure while maintaining the bulk temperature at
room temperature or below. Then a small amount of dry methanol was
added to the residue and ethyl acetate was gradually added thereto
under ultrasonication. The orange crystals thus precipitated were
taken up by filtration, washed with diethyl ether and dried under
reduced pressure. Thus, 570 mg of the title compound was obtained.
2013
[3835] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3836] 3.85(s, 2H), 4.05(s, 3H), 6.69(s, 1H), 6.77(d, J=7.9Hz, 1H),
6.90(d, J=7.9Hz, 1H), 7.00-7.25(br.s, 2H), 7.53(s, 2H), 9.61(s,
1H)
EXAMPLE 1519
Methyl
N.sup.2-cyano(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetimidate
[3837] To 40 ml of an aqueous solution of 1.4 g of monosodium
dihydrogenphosphate, 3.2 g of disodium monohydrogenphosphate and 5
g of cyanamide was added 20 ml of acetonitrile. To the obtained
solution was gradually added 30 ml of a suspension of 1.2 g of
methyl(10H-pyrazino[2,3- -b][1,4]benzothiazin-8-yl)acetimidate
hydrochloride in acetonitrile. The pH value of the reaction mixture
was strictly adjusted to 6.0 to 6.5 by adding aqueous solutions of
monosodium dihydrogenphosphate and disodium monohydrogenphosphate
respectively. After further adding about 100 ml of acetonitrile,
the reaction mixture was stirred at room temperature for 30 minutes
and then distributed into an aqueous solution of ammonium chloride
and ethyl acetate. The organic layer was extracted, washed with
water and dried over anhydrous sodium sulfate. After distilling off
the solvent under reduced pressure, 1.2 g of the title compound was
obtained as a yellow oily substance almost quantitatively. 2014
[3838] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3839] 3.77(s, 2H), 3.87(s, 3H), 6.50(d, J=1.8Hz, 1H), 6.75(dd,
J=1.8, 8.2Hz, 1H), 6.81(d, J=8.2Hz, 1H), 7.09(br.s, 1H), 7.57(d,
J=3.2Hz, 1H), 7.68(d, J=3.2Hz, 1H)
EXAMPLE 1520
N.sup.1-Methyl-N.sup.2-cyano(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)ace-
tamidine
[3840] To 10 ml of a solution of 420 mg of methyl
N.sup.2-cyano(10H-pyrazi-
no[2,3-b][1,4]benzothiazin-8-yl)acetimidate in tetrahydrofuran was
added 1 ml of a 40% aqueous solution of methylamine and the
resulting mixture was stirred at room temperature for 5 minutes.
Then the reaction mixture was distributed into water and ethyl
acetate. The organic layer was extracted, washed with water and
dried over anhydrous sodium sulfate. After adding 3 g of silica
gel, the solvent was distilled off under reduced pressure. The
residue thus obtained was purified by silica gel column
chromatography (eluted with dichloromethane/methanol/aqueous
ammonia) to thereby give 340 mg of the title compound as yellow
crystals. 2015
[3841] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3842] 2.72(s, 3H), 3.64(s, 2H), 6.68(s, 1H), 6.71(d, J=7.3Hz, 1H),
6.88(d, J=7.3Hz, 1H), 7.64(s, 2H), 8.86-8.93(br.s, 1H), 9.58(s,
1H)
[3843] MS: FAB(+)297(MH.sup.+)
[3844] m.p.: 233-234.degree. C.(decompose)
EXAMPLES
[3845] The following compounds were obtained by reacting methyl
N.sup.2-cyano(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)acetimidate
with various amines by the same method as the one of Example
1520.
230 Ex. Amine Structural formula MS M.p. NMR 1521 2016 2017 FAB (+)
311 (MH.sup.+) 247-249.degree.C. (de- compose) .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 3.02 (s, 3H), 3.04 (s, 3H), 3.95 (s,
2H), 6.62 (d, J=1.7 Hz, 1H), 6.65 (d, J=7.9 Hz, 1H), 6.91 (dd,
J=1.7, 7.9 Hz, 1H), 7.64 (s, 2H), 9.54 (s, 1H) 1522 2018 2019 FAB
(+) 325 (MH.sup.+) 266-268.degree.C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 1.12 (d, J=6.8 Hz, 6H), 3.60 (s. 2H), 3.87-3.99 (m,
1H), 6.67 (d, J=1.7 Hz, 1H), 6.69 (dd, J-1.7, 7.5 Hz, 1H), 6.88 (d,
J=7.5 Hz, 1H), 7.63 (d, J=2.4 Hz, 1H), 7.64 (d, J=2.4 Hz, 1H), 8.93
(d, # J=7.98 Hz, 1H), 9.66 (s, 1H) 1523 2020 2021 FAB (+) 374
(MH.sup.+) 195-196.degree.C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 3.75 (s, 2H), 4.50 (s, 2H), 6.75 (s, 1H), 6.78 (d, J=7.9 Hz,
1H), 6.90 (d, J=7.9 Hz, 1H), 7.27-7.32 (m, 1H), 7.29 (d, J=7.8 Hz,
1H), 7.63-7.66 (m, 2H), 7.77 (d, J=7.8 Hz, 1H), 8.52 (d, J=6.0 Hz,
# 1H), 9.45-9.55 (m, 1H), 9.62 (s, 1H) 1524 2022 2023 FAB (+) 327
(MH.sup.+) 268-270.degree.C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 3.23-3.29 (m, 2H), 3.46-3.52 (m, 2H), 3.66 (s, 2H), 4.83 (t,
J=5.4 Hz, 1H), 6.69 (d, J=1.0 Hz, 1H), 6.72 (dd, J=1.0, 8.4 Hz,
1H), 6.88 (d, J=8.4 Hz, 1H), 7.63 (d, J=2.6 Hz, 1H), 7.64 (d, J=2.6
Hz, 1H), # 9.05 (t, J=5.1 Hz, 1H), 9.59 (s, 1H) 1525 2024 2025 FAB
(+) 413 (MH.sup.+), 435 (MNa+) 213-215.degree.C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 2.65 (t, J=7.4 Hz, 2H), 3.39-3.46 (m,
2H), 3.62 (s, 2H), 6.69 (s, 1H), 6.71 (d, J=7.7 Hz, 1H), 6.86 (d,
J=7.7 Hz, 1H), 7.60-7.65 (m, 2H), 8.96 (t, J=5.6 Hz, 1H), 9.54 (s,
1H) 1526 2026 2027 FAB (+) 396 (M.sup.+) 154-155.degree.C.
.sup.1H-NNR (DMSO-d.sub.6) .delta. ppm: 1.16 (t, J=6.9 Hz, 3H),
1.68-1.78 (m, 2H), 2.31 (t, J=7.6 Hz, 2H), 3.16-3.24 (m, 2H), 3.63
(s, 2H), 4.03 (q, J=6.9 Hz, 2H), 6.69 (d, J=1.6 Hz, 1H), 6.71 (dd,
J=1.6, 7.8 Hz, 1H), 6.89 (d, J=7.8 Hz, 1H), # 7.63 (d, J=2.4 Hz,
1H), 7.64 (d, J=2.4 Hz, 1H), 8.97 (t, J=5.0 Hz, 1H), 9.62 (s, 1H)
1527 2028 2029 FAB (+) 452 (MH.sup.+) 241-245.degree.C. .sup.1H-NNR
(DMSO-d.sub.6) .delta. ppm: 3.72 (s, 2H), 4.47 (d, J=5.6 Hz, 2H),
6.74 (d, J=8.1 Hz, 1H), 6.75 (s, 1H), 6.91 (d, J=8.1 Hz, 1H),
7.28-7.36 (br.s, 2H), 7.43 (d, J=7.8 Hz, 2H), 7.64 (d, J=2.4 Hz,
1H), 7.66 (d, J=2.4 Hz, 7.78 # (d, J=7.8 Hz, 2H), 9.46 (t, J=5.6
Hz, 1H), 9.66 (s, 1H) 1528 H.sub.2N--OH 2030 FAB (+) 298 (M.sup.+)
253-256.degree.C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 3.58 (s,
2H), 6.64 (d, J=1.1 Hz, 1H), 6.68 (dd, J=1.1, 8.4 Hz, 1H), 6.82 (d,
J=8.4 Hz, 1H), 7.61 (d, J=2.2 Hz, 1H), 7.63 (d, J=2.2 Hz, 1H),
7.66-7.71 (br.m, 2H), 9.47 (s, 1H) 1529 H.sub.2N--OMe 2031 FAB (+)
312 (M.sup.+) 172-174.degree.C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 3.43-3.46 (br.s, 2H), 3.73 (s, 3H), 6.13-6.25 (br.s, 1H), 6.67
(d, J=8.0 Hz, 1H), 6.68 (s, 1H), 6.87 (d, J=8.0 Hz, 1H), 7.63 (d,
J=2.0 Hz, 1H), 7.64 (d, J=2.0 Hz, 1H), 9.57 (s, 1H) 1530
H.sub.2N--NH.sub.2 2032 FAB (+) 297 (M.sup.+) .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 3.53 (s, 2H), 5.50-5.80 (br.s. 2H),
6.63 (s, 1H), 6.65 (d, J=8.5 Hz, 1H), 6.78 (d, J=8.5 Hz, 1H), 7.60
(d, J=2.2 Hz, 1H), 7.61 (d, J=2.2 Hz, 1H), 9.36-9.55 (br.s, 1H)
1531 2033 2034 FAB (+) 410 (MH.sup.+) >280.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 0.91 (d, J=6.7 Hz, 12H),
2.43-2.49 (m, 2H), 2.90 (sept, J=6.7 Hz, 2H), 3.09-3.17 (m, 2H),
3.65 (s, 2H), 6.69 (d, J=1.1 Hz, 1H), 6.72 (dd, J=1.1, 8.2 Hz, 1H),
6.89 (d, J=8.2 Hz, 1H), 7.63 (d, J=2.4 Hz, # 1H), 7.65 (d, J=2.4
Hz, 1H), 8.63 (br.t, J=5.7 Hz, 1H), 9.57-9.64 (br.s, 1H) 1532 2035
2036 FAB (+) 391 (MH.sup.+) 205-208.degree.C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 186-198 (m, 2H), 3.10-3.16 (m, 2H),
3.64 (s, 2H), 3.97 (t, J=7.1 Hz, 2H), 6.69 (s, 1H), 6.72 (d, J=8.6
Hz, 1H), 6.87 (s, 1H), 6.89 (d, J=8.6 Hz, 1H), 7.14 (s, 1H), 7.56
(s, 1H), 7.62-7.65 (m, 2H), 9.00 (t, J=5.4 # Hz, 1H), 9.63 (s,
1H)
EXAMPLE 1533
4-[[1-(N-Cyanoimino)-2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)ethyl]am-
ino]butanoic acid
[3846] The title compound was obtained by hydrolyzing ethyl
4-[N.sup.1-[1-(N.sup.2-cyanoimino)-2-(10H-pyrazino[2,3-b][1,4]benzothiazi-
n-8-yl)ethyl]amino]butanoate by the same method as the one of
Example 18. 2037
[3847] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3848] 1.65-1.76(m, 2H), 2.24(t, J=7.5Hz, 2H), 3.16-3.23(m, 2H),
3.63(s, 2H), 6.69(d, J=7.8Hz, 1H), 6.71(dd, J=1.7, 7.8Hz, 1H),
6.89(d, J=1.7Hz, 1H), 7.62(d, J=2.5Hz, 1H), 7.64(d, J=2.5Hz, 1H),
8.99(t, J=5.4Hz, 1H), 9.62(s, 1H), 12.11(s, 1H)
[3849] MS: FAB(+)369(MH.sup.+)
[3850] m.p.: 217-218.degree. C.(decompose)
EXAMPLE 1534
N.sup.2-Cyano-N.sup.1-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)for-
mamidine
[3851] 500 mg of
8-aminomethyl-10H-pyrazino[2,3-b][1,4]benzothiazine and 400 mg of
ethyl N.sup.2-cyanocarboxyimidate were dissolved in a solvent
mixture of tetrahydrofuran (5 ml) with methanol (5 ml) and stirred
at 40.degree. C. for 1.5 hours. Then the reaction mixture was
distributed into an aqueous solution of potassium carbonate and
ethyl acetate. The organic layer was extracted, washed with water
and dried over anhydrous sodium sulfate. After distilling off the
solvent under reduced pressure, the obtained residue was purified
by silica gel column chromatography (eluted with
dichloromethane/methanol) and recrystallized from methanol/ethyl
acetate. Thus, 170 mg of the title compound was obtained as yellow
crystals. 2038
[3852] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3853] 4.20(d, J=5Hz, 2H), 6.66(s, 1H), 6.68(d, J=8.0Hz, 1H),
6.87(d, J=8.0Hz, 1H), 7.63(s, 2H), 8.41(d, J=4.4Hz, 1H),
9.30-9.38(m, 1H), 9.54(s, 1H)
[3854] MS: FAB(+)282(M.sup.+)
[3855] m.p.: 224-226.degree. C.
EXAMPLES
[3856] The following compounds were obtained by treating
8-(aminomethyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine
with various imidates by the same method as the one of Example 1534
followed by deblocking in accordance with Example 9.
231 Ex. Imidate Structural formula MS M.p. NMR 1535 2039 2040 FAB
(+) 296 (M.sup.+) 275-277.degree. C. .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm: 2.22 (s, 3H), 4.18 (d, J=5.8 Hz, 2H), 6.66 (s, 1H),
6.68 (d, J=7.7 Hz, 1H), 6.87 (d, J=7.7 Hz, 1H), 7.59-7.66 (m, 2H),
9.19 (t, J=5.8 Hz, 1H), 9.52 (s, 1H) 1536 2041 2042 FAB (+) 335
(M.sup.+) 175-176.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 2.86 (s, 3H), 4.24 (s, 2H), 6.68 (s, 1H), 6.71 (d, J=7.6 Hz.
1H), 6.88 (d, J=7.6 Hz, 1H), 7.63 (s, 2H), 8.06 (d, J=4.0 Hz, 1H),
9.02 (br.d, J=4.0 Hz, 1H), 9.56 (s, 1H) 1537 2043 2044 FAB (+) 335
(MH.sup.+) 137-142.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm: 4.61 and 4.74 (s, total 2H), 6.75 (d, J=8 Hz, 1H), 6.84 (m,
1H), 6.94 (d, J=8 Hz, 1H), 7.28-7.41 and 7.55-7.59 (m, total 2H),
7.91-8.02 (m, 1H). 8.37-8.45 (m, 1H), 9.58-9.63 (m, 1H) 1538 2045
2046 FAB (+) 296 (M.sup.+) 197-198.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 2.73 and 2.98 (s, 3H), 4.37 and 4.41
(s, total 2H), 6.63 and 6.68 (s, total 1H), 6.69 and 6.71 (d, J=7.8
Hz, total 1H), 6.89 and 6.92 (d, J=7.8 Hz, total 1H), 7.63 (s, 2H),
8.53 and 8.67 (s, total 1H), 9.51 and 9.53 (s, total 1H) 1539 2047
2048 FAB (+) 373 (M.sup.+) 208-210.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 4.28 and 4.58 (s, total 2H), 4.48 (s,
2H), 6.61 and 6.72 (d, J=7.8 Hz, total 1H), 6.64 and 6.67 (s, total
1H), 6.83 and 6.90 (d, J=7.8 Hz, total 1H), 7.26 and 7.36 (d, J=8.8
Hz, total 1H), 7.28-7.32 and 7.32-7.35 (m, total 1H), 7.62-7.66 #
(m, 2H), 7.55-7.80 (d, =8.8 Hz. 1H), 8.51 and 8.56 (d, J=5.3 Hz,
total 1H), 8.83 and 8.85 (s, total 1H), 9.50 (s, 1H)
EXAMPLE 1540
N.sup.1,N.sup.1-Dimethyl-N.sup.2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-y-
lmethyl)formamidine
[3857] 400 mg of
8-(aminomethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine was dissolved
in tetrahydrofuran (5 ml)/methanol (5 ml). After adding 250 mg of
N,N-dimethylformamide dimethyl acetal, the resulting mixture was
heated to 40.degree. C. for 1.5 hours. After distilling off the
solvent under reduced pressure, the crystals thus precipitated were
taken up by filtration and washed successively with diethyl ether
and diisopropyl ether. Thus 400 mg of the title compound was
obtained as yellow crystals. 2049
[3858] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3859] 2.77(s, 6H), 4.15(s, 2H), 6.64(dd, J=1.4, 7.9Hz, 1H),
6.68(d, J=1.4Hz, 1H), 6.79(d, J=7.9Hz, 1H), 7.42(s, 1H), 7.61(d,
J=2.4Hz, 1H), 7.62(d, J=2.4Hz, 1H), 9.44(s, 1H)
[3860] MS: ESI(+)286(MH.sup.+)
[3861] m.p.: 218-219.degree. C.
EXAMPLE 1541
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-S-methylisothiourea
[3862] To a solution of 1.0 g of
N-(10H-pyrazino[2,3-b][1,4]benzothiazin-8- -ylmethyl)thiourea in
acetone (10 ml)/N,N-dimethylformamide (10 ml) was added 1.0 ml of
methyl iodide and the resulting mixture was stirred at room
temperature for 0.5 hour. Next, the reaction mixture was
distributed into an aqueous solution of potassium carbonate and
ethyl acetate. The organic layer was extracted and washed with
water. After distilling off the solvent under reduced pressure, the
crystals thus precipitated were taken up by filtration and washed
with ethyl acetate to thereby give 0.900 g of the title compound as
yellow crystals. 2050
[3863] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3864] 2.25(s, 3H), 4.02and4.14(s, total2H), 6.21and6.67(br.s,
total2H), 6.68and6.69(s, total1H), 6.75and6.80(d, J=8.2Hz,
total1H), 6.79and6.85(s, total1H), 7.58-7.63(m, 2H), 9.51(s,
1H)
EXAMPLE 1542
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-2-cyanoguanidine
[3865] 450 mg of
N-(10H-pyrazino(2,3-b][1,4]benzothiazin-8-ylmethyl)-S-met-
hylisothiourea and 500 mg of cyanamide were heated in 30 ml of
N,N-dimethylformamide to 70.degree. C. for 12 hours. Then the
reaction mixture was brought back to room temperature and
distributed into water and ethyl acetate. The organic layer was
extracted and washed with water. After adding 5 g of silica gel,
the solvent was distilled off under reduced pressure. The residue
was purified by silica gel column chromatography (eluted with
dichloromethane/methanol/aqueous ammonia) to thereby give 340 mg of
the title compound as yellow crystals. 2051
[3866] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3867] 4.08(d, J=5.0Hz, 2H), 6.65(d, J=8.4Hz, 1H), 6.66(d, J=1.7Hz,
1H), 6.68-6.82(br.s, 2H), 6.86(dd, J=1.7, 8.4Hz, 1H),
7.06-7.25(br.s, 1H), 7.62(d, J=2.8Hz, 1H), 7.63(d, J=2.8Hz, 1H),
9.55(s, 1H)
[3868] MS: FAB(+)298(MH.sup.+), 297(M.sup.+)
[3869] m.p.: 246-248.degree. C.
EXAMPLE 1543
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)guanidine
hydrochloride
[3870] 330 mg of
8-aminomethyl-10H-pyrazino[2,3-b][1,4]benzothiazine and 400 mg of
methylisothiourea hemi- sulfate were heated under reflux in 10 ml
of ethanol for 3 hours. The crystals thus precipitated were taken
up by filtration and washed with ethyl acetate. Then these crystals
were dissolved in ethyl acetate containing hydrochloric acid and
recrystallized from methanol/ethyl acetate to thereby give 30 mg of
the title compound as yellow crystals. 2052
[3871] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3872] 4.20(d, J=6.0Hz, 2H), 6.67(s, 1H), 6.69(d, J=8.2Hz, 1H),
6.92(d, J=8.2Hz, 1H), 7.65(s, 2H), (t, J=6.0Hz, 1H), 9.63(s,
1H)
[3873] MS: FAB(+)273(MH.sup.+)
[3874] m.p.: 279-282.degree. C.
EXAMPLES
[3875] The following compounds were obtained by treating
8-aminomethyl-10H-pyrazino[2,3-b][1,4]benzothiazine with various
isothiourea compounds by the same method as the one of Example
1543.
232 Ex. Isothiourea Structural formula MS M.p. NMR 1544 2053 2054
FAB (+) 318 (MH.sup.+) 317 (M.sup.+) 226-228.degree. C. .sup.1H-NMR
(DMSO-d.sub.6) .delta. ppm: 4.11-4.33 (br.s, 2H), 6.67 (s, 1H),
6.68 (d, J=7.5 Hz, 1H), 6.88 (d, J=7.5 Hz, 1H), 7.62 (d, J=2.5 Hz,
1H), 7.64 (d, J=2.5 Hz, 1H), 7.70-8.10 (br.s, 2H), 8.85-900 (br.s,
1H), 9.57 (s, 1H) 1545 2055 2056 FAB (+) 350 (M.sup.+)
244-245.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.78 (s,
3H), 4.11 (d, J=6.0 Hz, 2H), 6.54-6.78 (br.s, 2H), 6.65 (s, 1H),
6.68 (d, J=7.9 Hz, 1H), 6.85 (d, J=7.9 Hz, 1H), 7.02-7.15 (br.s,
1H), 7.61-7.64 (m, 2H), 9.38 (s, 1H)
EXAMPLE 1546
8-(1,4,5,6-Tetrahydropyrimidin-1-ylmethyl)-10H-pyrazino[2,3-b][1,4]benzoth-
iazine hydrochloride
[3876] The title compound was obtained by reacting
8-(chloromethyl)-10H-py- razino[2,3-b][1,4]benzothiazine by the
same method as the one of Example 14 by using potassium carbonate
as a base. 2057
[3877] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3878] 1.84-1.92(m, 2H), 2.18-2.24(m, 2H), 2.24-2.29(m, 2H),
4.48(s, 2H), 6.68(d, J=1.3Hz, 1H), 6.76(dd, J=1.3, 8.6Hz, 1H),
6.95(d, J=8.6Hz, 1H), 7.64(s, 2H), 8.43(d, J=6.5Hz, 1H), 9.58(s,
1H), 10.08-10.14(br.s, 1H)
[3879] MS: FAB(+)298(MH.sup.+)
[3880] m.p.: 238.about..degree. C.(decompose)
EXAMPLE 1547
N-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-N.sup.1-methyl-2-nitro-
-1,1-ethenediamine
[3881] 0.7 g of
8-aminomethyl-10H-pyrazino[2,3-b][1,4]-benzothiazine and 1.35 g of
N-methyl-1-methylthio-2-nitro-1-ethenamine were dissolved in a
solvent mixture of tetrahydrofuran (50 ml) with water (3 ml) and
stirred at 60.degree. C. for 8 hours. After filtering off the
insoluble matters, the filtrate was concentrated under reduced
pressure. The residue was purified by silica gel column
chromatography (eluted with methanol/dichloromethane) to thereby
give 0.14 g of the title compound as yellow crystals. 2058
[3882] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[3883] 2.95(br.s, 3H), 4.31(s, 2H), 6.63(s, 2H), 6.74(d, J=8Hz,
1H), 6.86(d, J=8Hz, 1H), 7.58(s, 2H)
[3884] MS: ESI(+)331(MH.sup.+)
[3885] m.p.: >265.degree. C.(decompose)
EXAMPLE 1548
4-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-3-imino-1,2,5-thiazolidine
1,1-dioxide
[3886] To 50 ml of a 70% solution of 0.573 g of
10H-pyrazino[2,3-b][1,4]be- nzothiazine-8-carbaldehyde in ethanol
were added 0.48 g of sulfamide and 0.135 g of sodium cyanide and
the resulting mixture was heated under reflux for 6 hours. After
distilling off the solvent under reduced pressure, the residue was
dissolved in 50 ml of a 10% aqueous solution of sodium hydroxide.
After filtering off the insoluble matters, the filtrate was
ice-cooled and the pH value thereof was adjusted to 2 with 1 N
hydrochloric acid. The precipitate thus formed was taken up by
filtration and washed with water to thereby give 0.90 g of the
title compound as a yellow solid. 2059
[3887] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3888] 5.12(d, J=6Hz, 1H), 6.76(s, 1H), 6.77(d, J=8Hz, 1H), 6.93(d,
J=8Hz, 1H), 7.54(s, 1H), 7.60(d, J=6Hz, 1H), 7.65(s, 2H), 8.38(s,
1H), 9.65(s, 1H)
[3889] MS: FAB(+)357(M.sup.+)
EXAMPLE 1549
(5H-Pyrido(3,4-b][1,4]benzothiazin-2-yl)carboxamidine
hydrochloride
[3890] The title compound was obtained by treating
(5H-pyrido[3,4-b][1,4]b- enzothiazin-2-yl)carboxamide successively
by the same methods as those of Examples 1518 and 1520. 2060
[3891] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3892] 6.84(t, J=7.5Hz, 1H), 6.89(d, J=7.5Hz, 1H), 6.92(d, J=4.8Hz,
1H), 7.01(d, J=7.5Hz, 1H), 7.06(t, J=7.5Hz, 1H), 7.97(d, J=4.8Hz,
1H), 9.4-9.5(br.s, 2H), 9.5-9.6(br.s, 2H), 9.63(s, 1H)
[3893] MS: FAB(+)243(MH.sup.+)
[3894] m.p.: >280.degree. C.
EXAMPLE 1550
Ethyl(E)-3-[10-(tert-butoxycarbonyl)-10H-pyrazino[2,3-b][1,4]benzothiazin--
8-yl]propenoate
[3895] The title compound was obtained by treating
3-[10-(tert-butoxycarbo-
nyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]carbaldehyde by the
same method as the one of Production Example 25. 2061
[3896] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3897] 1.31(t, J=7.1Hz, 3H), 1.47(s, 9H), 4.25(q, J=7.1Hz, 2H),
6.44(d, J=15.8Hz, 1H), 7.36(s, 2H), 7.64(d, J=15.8Hz, 1H), 7.82(s,
1H), 8.29(d, J=2.8Hz, 1H), 8.35(d, J=2.8Hz, 1H)
EXAMPLE 1551
Ethyl 3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]propanoate
[3898] The title compound was obtained by treating
ethyl(E)-3-(10H-pyrazin- o[2,3-b][1,4]benzothiazin-8-yl)propenoate
by the same method as the one of Example 20. 2062
[3899] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3900] 1.23(t, J=7.1Hz, 3H), 2.56(t, J=8.0Hz, 2H), 2.80(t, J=8.0Hz,
2H), 4.12(q, J=7.1Hz, 2H), 6.36(d, J=1.4Hz, 1H), 6.40-6.48(br.s,
1H), 6.36(d, J=1.4Hz, 1H), 6.68(dd, J=1.4, 8.1Hz, 1H), 6.81(d,
J=8.1Hz, 1H), 7.57(d, J=3.0Hz, 1H), 7.69(d, J=3.0Hz, 1H)
[3901] m.p.: 95-97.degree. C.
EXAMPLE 1552
Ethyl(E)-3-[10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]propenoate
[3902] The title compound was obtained by treating
ethyl(E)-3-[10-(tert-bu-
toxycarbonyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]propenoate
by the same method as the one of Example 9. 2063
[3903] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3904] 1.23(t, J=6.8Hz, 3H), 4.16(q, J=6.8Hz, 2H), 6.37(d,
J=15.8Hz, 1H), 6.93(d, J=1.7Hz, 1H), 6.95(d, J=7.5Hz, 1H), 7.14(dd,
J=1.7, 7.5Hz, 1H), 7.40(d, J=15.8Hz, 1H), 7.64(d, J=2.8Hz, 1H),
7.65(d, J=2.8Hz, 1H), 9.54(s, 1H)
[3905] m.p.: 177-178.degree. C.
EXAMPLE 1553
(E)-3-[10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl]propenoic acid
[3906] The title compound was obtained as yellow crystals by
hydrolyzing
ethyl(E)-3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)propenoate by
the same method as the one of Example 18. 2064
[3907] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3908] 6.28(d, J=16.3Hz, 1H), 6.93(d, J=1.5Hz, 1H), 6.95(d,
J=8.1Hz, 1H), 7.09(dd, J=1.5, 8.1Hz, 1H), 7.35(d, J=16.3Hz, 1H),
7.64(d, J=2.9Hz, 1H), 7.65(d, J=2.9Hz, 1H), 9.54(s, 1H),
12.34-12.52(br.s, 1H)
[3909] m.p.: 280-281.degree. C.
EXAMPLE 1554
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl]carbaldehyde
[3910] The title compound was obtained as yellow crystals by
treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]carbaldehyde
by the same method as the one of Example 9. 2065
[3911] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3912] 7.13(d, J=8.1Hz, 1H), 7.14(d, J=1.5Hz, 1H), 7.19(dd, J=1.5,
8.1Hz, 1H), 7.65(d, J=2.7Hz, 1H), 7.67(d, J=2.7Hz, 1H), 9.73(s,
1H), 9.74(s, 1H) m.p.: 248-252.degree. C.
EXAMPLE 1555
(E)-3-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)propenen-
itrile
[3913] The title compound was obtained as yellow crystals by
treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
by the same method as the one of Production Example 25. 2066
[3914] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3915] 3.55(s, 3H), 5.28(s, 2H), 5.84(d, J=17.3Hz, 1H), 7.02(d,
J=7.9Hz, 1H), 7.04(dd, J=1.5, 7.9Hz, 1H), 7.19(d, J=1.5Hz, 1H),
7.30(d, J=17.3Hz, 1H), 7.85(d, J=2.9Hz, 1H), 7.86(d, J=2.9Hz,
1H)
EXAMPLE 1556
(E)-4-(10-Methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-3-prope-
n-2-one
[3916] The title compound was obtained as yellow crystals by
treating
(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde
by the same method as the one of Production Example 25. 2067
[3917] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3918] 2.39(s, 3H), 3.56(s, 3H), 5.30(s, 2H), 6.66(d, J=16.2Hz,
1H), 7.03(d, J=8.3Hz, 1H), 7.15(dd, J=1.6, 8.3Hz, 1H), 7.30(d,
J=1.6Hz, 1H), 7.42(d, J=16.2Hz, 1H), 7.85(d, J=2.9Hz, 1H), 7.86(d,
J=2.9Hz, 1H)
EXAMPLE 1557
Ethyl(E)-4-[2-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]-benzothiazin-8-yl-
)vinyl]benzoate
[3919] The title compound was obtained as yellow crystals by
treating (10-methoxymethyl-10H-pyrazino
[2,3-b][1,4]benzothiazin-8-yl)carbaldehyde by the same method as
the one of Production Example 25. 2068
[3920] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3921] 1.41(t, J=6.7Hz, 3H), 3.59(s, 3H), 4.38(q, J=6.7Hz, 2H),
5.34(s, 2H), 7.01(d, J=7.9Hz, 1H), 7.08(d, J=7.9Hz, 1H), 7.08(d,
J=15.3Hz, 1H), 7.13(d, J=15.3Hz, 1H), 7.17(dd, J=1.6, 7.9Hz, 1H),
7.29(d, J=1.6Hz, 1H), 7.56(d, J=8.4Hz, 2H), 7.84(d, J=2.9Hz, 1H),
7.85(d, J=7.9Hz, 2H), 8.03(d, J=8.4Hz, 2H)
EXAMPLES
[3922] The following compounds were obtained by treating
(E)-3-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)propene-
nitrile,
(E)-4-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
)-3-propen-2-one and
ethyl(E)-4-[2-(10-methoxymethyl-10H-pyrazino[2,3-b][1-
,4]benzothiazin-8-yl)vinyl]benzoate by the same method as the one
of Example 9.
233 Ex. Structural formula MS NMR 1558 2069 296-299.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 6.21 (d, J=16.8 Hz, 1H),
6.84 (d, J=1.6 Hz, 1H), 6.98 (d, J=8.0 Hz, 1H), 7.08 (d, J=1.6, 8.0
Hz, 1H), 7.46 (d, J=16.8 Hz, 1H), 7.64 (d, J=2.8 Hz, 1H), 7.65 (d,
J=2.8 Hz, 1H), 9.63 (s, 1H) 1559 2070 214-215.degree. C.
.sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 2.31 (s, 3H), 6.54 (d,
J=16.3 Hz, 1H), 6.96 (d, J=1.4 Hz, 1H), 6.97 (d, J=8.4 Hz, 1H),
7.11 (dd, J=1.4, 8.4 Hz, 1H), 7.40 (d, J=16.3 Hz, 1H), 7.64 (d,
J=2.7 Hz, 1H), 7.66 (d, J=2.7 Hz, 1H), 9.58 (s, 1H) 1560 2071
235-236.degree. C. .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm: 1.31 (t,
J=6.5 Hz, 3H), 4.29 (q, J=6.5 Hz, 2H), 6.94 (d, J=8.3 Hz, 1H), 6.95
(d, J=1.4 Hz, 1H), 7.09 (dd, J=1.4, 8.3 Hz, 1H), 7.12 (d, J=16.7
Hz, 1H), 7.23 (d, J=16.7 Hz, 1H), 7.64 (d, J=2.2 Hz, 1H), 7.65 (d,
J=2.2 Hz, 1H), 7.71 (d, J=8.5 Hz, 2H), J=8.5 Hz, 2H), 9.57 (s,
1H)
EXAMPLE 1561
(E)-4-[2-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)vinyl]-benzoic
acid
[3923] The title compound was obtained as yellow crystals by
hydrolyzing
ethyl(E)-4-[2-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)vinyl]benzoate
by the same method as the one of Example 18. 2072
[3924] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3925] 6.93(dd, J=1.6, 8.1Hz, 1H), 6.95(d, J=1.6Hz, 1H), 7.08(d,
J=8.1Hz, 1H), 7.12(d, J=16.6Hz, 1H), 7.21(d, J=16.6Hz, 1H),
7.62-7.67(m, 2H), 7.62-7.67(m, 2H), 7.69(d, J=8.1Hz, 2H), 7.90(d,
J=8.1Hz, 2H), 9.58(s, 1H)
[3926] m.p.: 322-325.degree. C.
EXAMPLE 1562
(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)carboxylic acid
[3927] The title compound was obtained as yellow crystals by
hydrolyzing
methyl(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carboxylate by the
same method as the one of Example 18. 2073
[3928] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3929] 6.99(d, J=8.5Hz, 1H), 7.28(dd, J=1.6, 8.5Hz, 1H), 7.30(d,
J=1.6Hz, 1H), 7.63(d, J=2.5Hz, 1H), 7.65(d, J=2.5Hz, 1H), 9.63(s,
1H)
[3930] m.p.: 321-323.degree. C.(decmpose)
EXAMPLE 1563
(E)-8-(2-Benzenesulfonylvinyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3931] The title compound was obtained as yellow crystals by
treating
(E)-8-(2-benzenesulfonylvinyl)-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]b-
enzothiazine by the same method as the one of Example 9. 2074
[3932] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3933] 6.87(d, J=1.7Hz, 1H), 6.97(d, J=8.1Hz, 1H), 7.17(dd, J=1.7,
8.1Hz, 1H), 7.35(d, J=15.4Hz, 1H), 7.40(d, J=15.4Hz, 1H),
7.61-7.67(m, 2H), 7.63(d, J=2.9Hz, 1H), 7.65(d, J=2.9Hz, 1H),
7.69-7.74(m, 1H), 7.88-7.92(m, 2H), 9.57(s, 1H)
[3934] m.p.: 201-202.degree. C.
EXAMPLE 1564
8-Vinyl-10H-pyrazino[2,3-b][1,4]benzothiazine
[3935] The title compound was obtained as yellow crystals by
treating
8-vinyl-10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazine by
the same method as the one of Example 9. 2075
[3936] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3937] 5.30(d, J=10.7Hz, 1H), 5.37(d, J=17.6Hz, 1H), 6.55(dd,
J=10.7, 17.6Hz, 1H), 6.79(d, J=1.6Hz, 1H), 6.82(d, J=8.5Hz, 1H),
6.99(dd, J=1.6, 8.5Hz, 1H), 7.16(d, J=3.5Hz, 1H), 7.59(d, J=3.5Hz,
1H), 11.05-11.15(br.s, 1H)
[3938] m.p.: 140-142.degree. C.
EXAMPLE 1565
1-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-yl)-1,3-butadione
[3939] The title compound was obtained as yellow crystals by
treating
1-(10-methoxymethyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)-1,3-butadi-
one by the same method as the one of Example 9. 2076
[3940] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3941] 2.14 and 2.19(s, total 3H, enol:keto=4:1), 4.11(s, initial
2H, keto), 6.34(s, initial 1H, enol), 7.03 and 7.05(d, J=8.1Hz,
total 1H, 4:1), 7.19 and 7.27(d, J=1.8Hz, total 1H, 1:4), 7.32 and
7.33(dd, J=1.8, 8.1Hz, total 1H, 1:4), 7.64(d, J=3.2Hz, total 1H),
7.66(d, J=3.2Hz, total 1H), 9.52 and 9.54(br.s, total 1H, 4:1)
[3942] m.p.: 218-220.degree. C.
EXAMPLE 1566
Methyl(anti)-(3-azabicyclo[3.3.1]non-9-yl)acetate hydrochloride
[3943] 25.6 g of
ethyl(anti)-(3-methyl-3-azabicyclo[3.3.1]non-9-yl)acetate was
cooled to 0.degree. C. and 25 ml of 1-chloroethyl chloroformate was
dropped thereinto. After stirring at the same temperature for 15
minutes, the mixture was reacted for an additional 1 hour. Then it
was brought back to room temperature and the 1-chloroethyl
chloroformate was distilled off under reduced pressure. 400 ml of
methanol was added to the residue and the resulting mixture was
heated under reflux for 2 hours. After distilling off the solvent
under reduced pressure, 20 ml of methanol and 200 ml of ethyl
acetate were added to the residue. The crystals thus precipitated
were collected by filtration to thereby give 20 g of
methyl(anti)-(3-azabicyclo[3.3.1]non-9-yl)acetate hydrochloride.
2077
[3944] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3945] 1.62-1.90(m, 5H), 1.91(br.s, 2H), 2.16-2.34(m, 2H), 2.51(d,
J=8Hz, 2H), 3.20-3.32(m, 2H), 3.47(dd, J=4, 13Hz, 2H), 3.66(d,
J=1Hz, 3H), 8.51(br.s, 1H), 10.08(br.s, 1H)
EXAMPLE 1567
Methyl(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabic-
yclo[3.3.1]non-9-yl]acetate
[3946] To 12 ml of a solution of 1.00 g of
8-chloromethyl-10H-pyrazino[2,3- -b][1,4]benzothiazine in
1,2-dichloroethane were added 1.59 g of
methyl(anti)-(3-azabicyclo[3.3.1]non-9-yl)acetate hydrochloride and
2.1 ml of diisopropylamine and the resulting mixture was heated
under reflux for 1 hour. Then the reaction mixture was brought back
to room temperature and purified as it was by silica gel column
chromatography (eluting with hexane/ethyl acetate) to thereby give
1.24 g of the title compound as a yellow powder. 2078
[3947] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3948] 1.34-1.48(m, 3H), 1.57(br.s, 2H), 1.60-1.76(m, 2H),
1.82-1.92(m, 1H), 2.15(br.d, J=10Hz, 2H), 2.46(d, J=8Hz, 2H),
2.44-2.6(m, 1H), 2.86(br.d, J=10Hz, 2H), 3.15(s, 2H), 3.56(s, 3H),
6.68(dd, J=1, 8Hz, 1H), 6.71(d, J=1Hz, 1H), 6.83(d, J=8Hz, 1H),
7.61(d, J=3Hz, 1H), 7.62(d, J=3Hz, 1H), 9.55(s, 1H)
[3949] m.p.: 127-129.degree. C.
[3950] MS: ESI(+)411(MH.sup.+)
EXAMPLE 1568
(endo,anti)-[3-(10H-Pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)-3-azabicy-
clo[3.3.1]non-9-yl]acetic acid
[3951] 0.45 g of the title compound was obtained as a yellow powder
by treating 0.5 g of
methyl(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-
-methyl)-3-azabicyclo[3.3.1]non-9-yl]acetate by the same method as
described in Example 18. 2079
[3952] .sup.1H-NMR(DMSO-d.sub.6) .delta. ppm:
[3953] 1.34-1.48(m, 3H), 1.58(br.s, 2H), 1.60-1.76(m, 2H),
1.80-1.90(m, 1H), 2.14(br.d, J=10Hz, 2H), 2.33(d, J=8Hz, 2H),
2.44-2.60(m, 1H), 2.85(br.d, J=10Hz, 2H), 3.15(s, 2H), 6.67(d,
J=8Hz, 1H), 6.72(s, 1H), 6.82(d, J=8Hz, 1H), 7.60(d, J=3Hz, 1H),
7.62(d, J=3Hz, 1H), 9.54(s, 1H)
[3954] m.p.: 215-217.degree. C.
[3955] MS: FAB(+)397(MH.sup.+)
EXAMPLE 1569
8-(tert-Butyldimethylsiloxymethyl)-10H-pyrazino[2,3-b][1,4]benzothiazine
[3956] 10 g of (10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methanol
was subjected to the procedure described in Example 179 to thereby
give 13 g of the title compound as a yellow solid. 2080
[3957] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3958] 0.63(s, 6H), 0.88(s, 9H), 4.54(s, 2H), 6.48(s, 1H), 6.71(d,
J=8Hz, 1H), 6.80(d, J=8Hz, 1H), 7.53(s, 1H), 7.64(s, 1H)
EXAMPLE 1570
10-Acetyl-8-(tert-butyldimethylsiloxymethyl)-10H-pyrazino[2,3-b][1,4]benzo-
thiazine
[3959] To a solution of 4.0 g of
8-(tert-butyldimethylsiloxymethyl)-10H-py-
razino[2,3-b][1,4]benzothiazine in 50 ml of N,N-dimethylformamide
was added 0.73 g of sodium hydride (60%) and the resulting mixture
was stirred for 10 minutes. After adding 1.4 ml of acetyl chloride
thereto, the resulting mixture was reacted at room temperature for
10 minutes. After adding water followed by extraction with ethyl
acetate, the extract was washed with a saturated aqueous solution
of sodium chloride and dried over anhydrous magnesium sulfate.
After distilling off the solvent under reduced pressure, the
residue was purified by silica gel column chromatography (eluting
with ethyl acetate/hexane) to thereby give 2.5 g of the title
compound as a yellow oily substance. 2081
[3960] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3961] 0.1(s, 6H), 0.93(s, 9H), 2.28(s, 3H), 4.76(s, 2H),
7.24-7.28(m, 1H), 7.38(d, J=8Hz, 1H), 7.66(d, J=2Hz, 1H), 8.32(d,
J=3Hz, 1H), 8.35(d, J=3Hz, 1H)
EXAMPLE 1571
(10-Acetyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methanol
[3962] 2.5 g of
10-acetyl-8-(tert-butyldimethylsiloxymethyl)-10H-pyrazino[-
2,3-b][1,4]benzothiazine was subjected to the procedure described
in Example 181 to thereby give 1.0 g of the title compound as an
oily substance. 2082
[3963] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3964] 2.29(s, 3H), 4.73(s, 2H), 7.29(dd, J=2, 8Hz, 1H), 7.33(d,
J=8Hz, 1H), 7.74(m, 1H), 8.25(d, J=3Hz, 1H), 8.28(d, J=3Hz, 1H)
EXAMPLE 1572
(10-Acetyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)carboxaldehyde
[3965] 1.0 g of
(10-acetyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)metha- nol was
subjected to the procedure described in Example 174 to thereby give
0.6 g of the title compound as a pale brown solid. 2083
[3966] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3967] 2.34(s, 3H), 7.57(d, J=8Hz, 1H), 7.80(dd, J=2, 8Hz, 1H),
8.22(d, J=2Hz, 1H), 8.38(d, J=3Hz, 1H), 8.41(d, J=3Hz, 1H), 10.2(s,
1H)
EXAMPLE 1573
4-[1-(10-Acetyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl)piperidin--
4-yl]-2-methylbutanoic acid
[3968] To a solution of 0.13 g of
(10-acetyl-10H-pyrazino[2,3-b][1,4]benzo-
thiazin-8-yl)carboxaldehyde and 0.13 g of
4-(piperidin-4-yl)-2-methylbutan- oic acid in 20 ml of acetonitrile
were added 51 mg of sodium cyanoborohydride and 0.1 ml of acetic
acid and the resulting mixture was reacted at room temperature for
12 hours. The reaction mixture was concentrated under reduced
pressure and the residue was purified by silica gel column
chromatography (eluted with methanol/dichloromethane) to thereby
give 70 mg of the title compound as a colorless oily substance.
2084
[3969] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[3970] 1.14(d, J=7Hz, 3H), 1.25-1.40(m, 2H), 1.35-1.50(m, 3H),
1.50-1.73(m, 2H), 1.93-2.05(m, 2H), 2.30(s, 3H), 2.33-2.45(m, 1H),
2.97-3.10(m, 2H), 3.45-3.55(m, 2H), 4.35(s, 2H), 7.46(dd, J=2, 8Hz,
1H), 7.64(d, J=8Hz, 1H), 7.84(d, J=2Hz, 1H), 8.45(s, 2H)
[3971] MS: FAB(+)441(MH.sup.+)
EXAMPLE 1574
10-(Methoxycarbonyl)-8-(tert-butyldimethylsiloxymethyl)-10H-pyrazino[2,3-b-
][1,4]benzothiazine
[3972] 4.0 g of
8-(tert-butyldimethylsiloxymethyl)-10H-pyrazino[2,3-b][1,4-
]benzothiazine was subjected to the procedure described in Example
1570 but using methyl chlorocarbonate instead of acetyl chloride to
thereby give 2.5 g of the title compound as a yellow oily
substance. 2085
[3973] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3974] 0.1(s, 6H), 0.94(s, 9H), 3.83(s, 3H), 4.75(s, 2H),
7.18-7.24(m, 1H), 7.34(d, J=8Hz, 1H), 7.63(d, J=2Hz, 1H),
8.3-8.34(m, 1H), 8.34-8.38(m, 1H)
EXAMPLE 1575
[10-(Methoxycarbonyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl)methanol
[3975] 2.5 g of
10-(methoxycarbonyl)-8-(tert-butyldimethylsilyloxymethyl)--
10H-pyrazino[2,3-b][1,4]benzothiazine was subjected to the
procedure described in Example 181 to thereby give 1.0 g of the
title compound as a yellow oily substance. 2086
[3976] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3977] 3.84(s, 3H), 4.72-4.76(m, 2H), 7.28(dd, J=2, 8Hz, 1H),
7.39(d, J=8Hz, 1H), 7.67-7.70(m, 1H), 8.33(d, J=3Hz, 1H), 8.37(d,
J=3Hz, 1H)
EXAMPLE 1576
[10-(Methoxycarbonyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl]carboxalde-
hyde
[3978] 1.8 g of
[10-(methoxycarbonyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-
-8-yl]methanol was subjected to the procedure described in Example
174 to thereby give 0.8 g of the title compound as pale brown
crystals. 2087
[3979] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3980] 3.87(s, 3H), 7.54(d, J=8Hz, 1H), 7.78(dd, J=2, 8Hz, 1H),
8.16(d, J=2Hz, 1H), 8.36(d, J=3Hz, 1H), 8.41(d, J=3Hz, 1H),
10.01(s, 1H)
EXAMPLE 1577
4-[1-(10-(Methoxycarbonyl)-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
)piperidin-4-yl]-2-methylbutanoic acid
[3981] 0.8 g of [10-(methoxycarbonyl)-10H-pyrazino
[2,3-b][1,4]benzothiazi- n-8-yl]carboxaldehyde was subjected to the
procedure described in Example 1573 to thereby give 0.29 g of the
title compound as a yellow amorphous substance. 2088
[3982] .sup.1H-NMR(CD.sub.3OD) .delta. ppm:
[3983] 1.09(d, J=7Hz, 3H), 1.20-1.45(m, 5H), 1.45-1.70(m, 2H),
1.85-2.0(m, 2H), 2.28-2.40(m, 1H), 2.90-3.0(m, 2H), 3.35-3.50(m,
2H), 3.77(s, 3H), 4.29(s, 2H), 7.40(dd, J=2, 8Hz, 1H), 7.56(d,
J=8Hz, 1H), 7.81(d, J=2Hz, 1H), 8.37(d, J=3Hz, 1H), 8.38(d, J=3Hz,
1H)
EXAMPLE 1578
Methyl(anti)-[3-[10-(methoxycarbonyl)-10H-pyrazino
[2,3-b][1,4]benzothiazi- n-8-ylmethyl]-3-azabicyclo
[3.3.1]non-9-yl]acetate
[3984] 1.0 g of methyl(anti)-[3-(10H-pyrazino
[2,3-b][1,4]benzothiazin-8-y- lmethyl)-3-azabicyclo
[3.3.1]non-9-yl]acetate was treated in the same manner as the one
of Example 1574 to thereby give 0.14 g of the title compound as a
pale yellow solid. 2089
[3985] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3986] 1.4-1.6(m, 3H), 1.62-1.68(m, 2H), 1.68-1.84(m, 2H),
2.00-2.08(m, 1H), 2.31(br.d, J=11Hz, 2H), 2.50(d, J=8Hz, 2H),
2.52-2.68(m, 1H), 2.9-2.98(m, 2H), 3.41(s, 2H), 3.66(s, 3H),
3.83(s, 3H), 7.21(dd, J=2, 8Hz, 1H), 7.32(d, J=8Hz, 1H), 7.63(d,
J=2Hz, 1H), 8.32(d, J=3Hz, 1H), 8.36(d, J=3Hz, 1H)
[3987] m.p.: 106-108.degree. C.
[3988] MS: ESI(+)469(MH.sup.+)
EXAMPLE 1579
Methyl(anti)-[3-(10-acetyl-10H-pyrazino[2,3-b][1,4]benzothiazin-8-ylmethyl-
)-3-azabicyclo[3.3.1]non-9-yl]acetate
[3989] 1.0 g of
methyl(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzothiazin-8-yl-
methyl)-3-azabicyclo[3.3.1]non-9-yl]acetate was subjected to the
procedure described in Example 1570 to thereby give 0.4 g of the
title compound as a pale yellow solid. 2090
[3990] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3991] 1.44-1.60(m, 3H), 1.60-1.68(m, 2H), 1.68-1.82(m, 2H),
1.96-2.08(m, 1H), 2.28(s, 3H), 2.31(br.d, J=11Hz, 2H), 2.49(d,
J=8Hz, 2H), 2.50-2.70(m, 1H), 2.90-2.98(m, 2H), 3.41(s, 2H),
3.66(s, 3H), 7.23(dd, J=1, 8Hz, 1H), 7.36(d, J=8Hz, 1H), 7.66(s,
1H), 8.3-8.38(m, 2H)
[3992] m.p.: 160-162.degree. C.
[3993] MS: ESI(+)453(MH.sup.+)
EXAMPLE 1580
Methyl(anti)-[3-[10-(benzyloxycarbonyl)-10H-pyrazino[2,
3-b][1,4]benzothiazin-8-ylmethyl]-3-azabicyclo[3.3.1]non-9-yl]acetate
[3994] 1.0 g of
methyl(anti)-[3-(10H-pyrazino[2,3-b][1,4]benzotiazin-8-ylm-
ethyl)-3-azabicyclo[3.3.1]non-9-yl]acetate was subjected to the
procedure described in Example 1570 but using benzyl
chlorocarbonate instead of acetyl chloride to thereby give 0.4 g of
the title compound as a pale brown oily substance. 2091
[3995] .sup.1H-NMR(CDCl.sub.3) .delta. ppm:
[3996] 1.4-1.6(m, 3H), 1.56-1.66(m, 2H), 1.66-1.80(m, 2H),
1.96-2.24(m, 1H), 2.27(br.d, J=11Hz, 2H), 2.49(d, J=8Hz, 2H),
2.46-2.68(m, 1H), 2.86-2.94(m, 2H), 3.37(s, 2H), 3.67(s, 3H),
5.28(s, 2H), 7.10-7.40(m, 7H), 7.61(d, J=1Hz, 1H), 8.31(d, J=2Hz,
1H), 8.36(d, J=2Hz, 1H)
[3997] MS: ESI(+)545(MH.sup.+)
* * * * *